Isth2015 Book Complete Jun 0

In Memoriam:
Final Program
XXV Congress of the International Society
on Thrombosis and Haemostasis
and 61st Annual SSC Meeting
June 20 25, 2015

Toronto, Canada
www.isth2015.org
1
Final Program
Table of Contents
3 Venue and Contacts
5 Invitation and Welcome Message
12 ISTH 2015 Committees
24 Congress Support
25 Sponsors and Exhibitors
27 ISTH Awards
32 ISTH Society Information
37 Program Overview
41 Program Day by Day
55 SSC and Educational Program
83 Master Classes and Career Mentorship Sessions
87 Nurses Forum
93 Scientific Program, Monday, June 22
94 Oral Communications 1
102 Plenary Lecture
103 State of the Art Lectures
112 Abstract Symposia
120 Poster Session
189 Scientific Program, Tuesday, June 23
198 Plenary Lecture
208 Plenary Lecture
216 Poster Session
285 Scientific Program, Wednesday, June 24
294 Plenary Lecture
311 Poster Session
381 Scientific Program, Thursday, June 25
390 Plenary Lecture
397 Highlights of ISTH
399 Exhibition Floor Plan
402 Exhibitor List
405 Congress Information
406 Venue Plan
407 Congress Information
417 Social Program
418 Toronto & Canada Information
421 Transportation in Toronto
423 Future ISTH Meetings and Congresses
427 Authors Index
2 1
Thank You to Everyone
Who Supported the Venue and Contacts
2014 World Thrombosis Day
Campaign!
Venue
Metro Toronto Convention Center (MTCC)
MTCC South Building
222 Bremner Boulevard
Toronto, Ontario M5V 2W6
Canada
T: +1 (416) 585-8000
E : info@mtccc.com
W: http://www.mtccc.com
Contacts Membership Questions or any

ISTH Headquarters: General Inquiries about the ISTH:
610 Jones Ferry Road, Suite 205 ISTH Membership Staff
Carrboro, NC 27510
T: +1 919 929-3807
USA
membership@isth.org
T: +1 919 929-3807
F: +1 919 929-3935
headquarters@isth.org ISTH 2015 Organizing
www.isth.org Secretariat:
(Registration, Logistics, Exhibition, Hotel
Together, weve elevated Executive Meeting Matters: Accommodations)
the global conversation about Lisa Astorga c/o MCI Suisse SA

potentially deadly blood clots. ISTH Director of Meetings
lisa_astorga@isth.org
MCI Suisse SA
Rue de Lyon 75
1211 Geneva 13
Sponsorship and Exhibition: Switzerland
T: +41 22 33 99 728
Thomas Reiser isth.reg@mci-group.com
Executive Director
T: +1 919 929-3807 Abstract Questions:
tom_reiser@isth.org
isth2015abs@mci-group.com
Marketing and Media:

Louise M. Bannon
WWW.WORLDTHROMBOSISDAY.ORG Director of Marketing and Membership
Visit us at Booth 1036 T: +1 919 929-3807

louise_bannon@isth.org
FOUNDING
GLOBAL PARTNER GLOBAL PARTNERs GLOBAL PATRON
2 3
Invitation and Welcome Message
Dear ISTH Congress attendees,
We are happy to welcome you to Toronto, which in the Iroquois language means place
where trees stand in the water, and this was likely the initial native local name. From 1795
to 1834 it was the town of York, then becoming the City of Toronto with a population of
9,000. The population of the Toronto metropolitan area has grown to just over six million in
2015. Toronto is known for its multi-ethnicity and diverse neighbourhoods, where culture
and food from many parts of the world can be enjoyed. Similarly, delegates from a large
number of countries will convene at this congress to exchange new research data, ideas,
opinions and suggestions for future collaboration.
The ISTH Congress, now counting as the 25th since the first congress in Montreux, Swit-
The zerland, in 1970, is the largest and most important event every two years for all scientists
and clinicians with an interest in thrombosis and hemostasis. The ISTH Congress has ex-
panded - from the previous one in Toronto in 1981 of about 2,000 attendees to more than
NUMBER 8,000 today. Different from many other large meetings, the ISTH Congress takes much of
its features from the Local Organizing Committee, which with logistic support from ISTH
Headquarters and the professional congress organizer has substantial liberty to decide on
ONE the format of the sessions as well as the social components. For those established in the
field of thrombosis and hemostasis, attending consecutive congresses in different countries
and continents generates fond memories and stimulates comparisons. Those joining the
international ISTH Congress for the first time will hopefully get a very positive impression, encouraging
further contributions to science and a return to future meetings.
specialty Saturday and the first half of Sunday are, in keeping with tradition, devoted to the annual
meeting (the 61st) of the Scientific and Standardization Committee (SSC) of the ISTH.
Work in progress, preliminary or final reports from the multitude of projects of the SSC will
journal in be mixed with a wide variety of educational lectures. The latter have been carefully chosen
not to duplicate presentations of invited speakers during the following congress. At the end
of the SSC meeting, on Sunday at lunch, we extend a warm welcome to the recipients of the
your field! Young Investigator and the Reach-The-World awards and invite them to a special reception.
Last year was the exciting premier for World Thrombosis Day (WTD), in which more than
175 organizations were involved and spread important educational messages to millions of
people. On Sunday afternoon, you can enjoy a special presentation of the experiences and
highlights from this inaugural WTD.
The actual ISTH Congress kicks off with the Opening Ceremony on Sunday evening and we
are excited to give you a taste of Canadian music and culture from coast to coast. It will be
followed by a networking reception in the Exhibition Hall.
The scientific congress is composed of a variety of sessions five plenary lectures by

front-line scientists, 53 state-of-the-art lectures by leaders in the respective fields and
accompanied by corresponding articles in the educational book, 52 abstract symposia with
an introductory review lecture followed by oral presentations of top-scoring abstracts on
the topic, two late-breaking-sessions on Monday and Wednesday, respectively, with piping
hot results from 10 clinical trials, 89 oral communication sessions, and from Monday to
Wednesday poster sessions as well. For those that have reserved tickets, there are Master
Classes covering 40 different topics in the early morning of Sunday to Wednesday. As a new
feature we also have Career Mentorship sessions for small groups at lunch time.
13 - 5 5 3 8 5
wileyonlinelibrary.com/journal/jth
We are grateful to the industry for their generous support to the congress and we hope you
will take time to visit the exhibition and exchange ideas with the representatives from the
diagnostic and pharmaceutical industry. And dont forget the ISTH booth! During the lunch
break, after grabbing a complimentary lunch box, you may attend a satellite symposium, JOIN US! WEDNESDAY, JUNE 24, 2015 | 12:15 hrs 13:45 hrs | CONFERENCE ROOM: Room 717, Level 700
stroll through the poster area or just sit and network with colleagues.
The All Congress Party on Wednesday evening will be a social highlight for you and your
friends. You will taste the food of the ethnic neighbourhoods of Toronto while listening to
Emerging Trends and Strategies in Thrombosis Medicine
different music bands, culminating with a performance by the rock band the Barenaked
Ladies. Make sure you have tickets! Practical Dimensions of NOAC-Based Management
The congress ends on Thursday at noon with a novelty the Highlights of ISTH session.
Here you will get a recap of selected, top-scoring presentations both from basic and from
clinical science. Since there are many simultaneous sessions during the congress and you
therefore cannot possibly attend everything in your interest, this is the perfect chance to
Acute and Extended Treatment of
Venous Thromboembolism
catch up on the important presentations you may have missed.
The congress app, available for download on your mobile device, will help you stay orga-
nized, select your sessions and find your way. It will also provide you with the daily news
from the congress. In this Program Book the trainees can follow special tracks, identified
by symbols, if they have specific interest in Platelets-basic science, Coagulation-basic sci- Focus on the Role of Factor Xa Inhibition for Acute and
ence, Bleeding-clinical, Thrombosis-clinical, Pediatric thrombosis and hemostasis, or Car- Extended Duration Treatment of PE and DVT
diovascular-basic and clinical science.
Principles of Practice at the Front
Lines of Thrombosis Care
Practical Clinical and

Cased-Based Approaches for
Sam Schulman, M.D., Ph.D. Nigel Key, M.D., Ch.B. Sabine Eichinger, M.D. Oral Factor Xa Inhibition Across
ISTH XXV Congress ISTH Council Chair ISTH SSC Chair the Spectrum of VTE Care
2015 President
PRO G R A M CO - CH A I RS a n d D IST I N G U ISH E D FAC U LT Y
Professor Samuel Z. Goldhaber, MD Professor The Lord Ajay Kakkar, MD Professor Stavros V. Konstantinides,
Program Chairman Program Chairman MD, PhD, FESC
Professor of Medicine | Harvard Medical Professor of Surgery | University College Distinguished Faculty
School | Director, Thrombosis Research Group | London | Director, Thrombosis Research Professor, Clinical Trials, and Medical Director | Center
Cardiovascular Division | Brigham and Womens Institute | London, UK for Thrombosis and Hemostasis (CTH) | Johannes
Hospital | President, North American Thrombosis Gutenberg University Mainz | Mainz, Germany
Forum (NATF) | Boston, Massachusetts
Save the Date: Wednesday, June 24, 2015 CME Lunch Symposium
Registration and Boxed Lunch: 11:45 hrs 12:15 hrs (11:45 AM 12:15 PM) | Scientific Program: 12:15 hrs 13:45 hrs (12:15 PM 1:45 PM)
City: Toronto, Ontario | Location: Metro Toronto Convention Centre | Conference Room: Room 717, Level 700
NO PRE-REGISTRATION REQUIRED TO ATTEND!
Funded by an independent educational grant from Bayer Healthcare CMEducation Resources, LLC
Jointly Sponsored by the University of Massachusetts Medical School, Office of CME and CMEducation Resources, LLC
A Medical Education Company
This Satellite Program is not part of the official scientific program of the ISTH 2015 Congress
I am pleased to extend my warmest greetings to everyone attending the 25th Congress of
the International Society on Thrombosis and Haemostasis (ISTH) and 61st Annual Meeting
of ISTHs Scientific and Standardization Committee (SSC). On behalf of the Government of Ontario, I am delighted to extend warm greetings to ev-
Kathleen Wynne
eryone attending The International Society on Thrombosis and Haemostasis (ISTH) XXV
The Rt. Hon. Congress and 61st Annual Scientific and Standardization Committee (SSC) Meeting. I Premier
These events will provide an excellent opportunity for clinicians and researchers to ex-
Stephen Harper change ideas, best practices, and information about the latest developments in thrombosis, would like to take this opportunity to commend the ISTH for its commitment to supporting
P.C., M.P. haemostasis, and vascular biology, as well as their application to patient care. members in the ongoing advancement of the understanding, prevention, diagnosis and
treatment of thrombotic and bleeding disorders.
Over the years, ISTH has worked diligently to improve global health. I commend your ef-
forts to provide the best outcomes for patients through your commitment to the highest As Premier, I am proud that Ontario has the opportunity to host an event that facilitates
standards of excellence in the prevention, diagnosis, and treatment of thrombotic and fruitful discourse between clinicians, researchers, educators and practitioners with the no-
bleeding disorders. ble aim to improve patients lives. With an impressive array of lectures, educational ses-
sions and workshops, this conference is sure to both enlighten and inform.
On behalf of the Government of Canada, I offer my best wishes for a memorable and pro-
ductive gathering in Toronto. I would like to thank the ISTH for choosing our province to host this wonderful event. I am
confident that all the delegates and guests will enjoy their time in Toronto, our vibrant and
diverse capital city.
Please accept my best wishes for an informative and memorable congress.
The Rt. Hon. Stephen Harper, P.C., M.P.
OTTAWA Kathleen Wynne

2015 Premier
8 9
Pfizer Satellite Symposium at the XXV Congress of the
International Society on Thrombosis and Haemostasis
Managing Hemophilia for Life Managing Hemophilia for Life

Optimizing responses to The role of ultrasound in
therapy in hemophilia B: hemophilia joint health:
treatment individualization in progress and perspectives
It is my esteemed pleasure to extend greetings and a warm welcome to everyone attending an era of expanding options from clinical practice
the International Society on Thrombosis & Haemostasis (ISTH) XXV Congress and 61st
Annual Scientific and Standardization Committee Meeting.
Mayor John Tory
A global non-profit organization, the International Society on Thrombosis & Haemostasis is Monday 22nd June 2015, 12:1513:45 Tuesday 23rd June 2015, 12:1513:45
City of Toronto
dedicated to advancing the understanding, prevention, diagnosis and treatment of throm- Room 716, Level 700, Metro Toronto Room 716, Level 700, Metro Toronto
botic and bleeding disorders. Convention Centre, Toronto, Canada Convention Centre, Toronto, Canada
This convention will host thousands of delegates consisting of leading experts on thrombo- Chair: Alfonso Iorio (Canada) Chair: Giovanni DiMinno (Italy)
sis, haemostasis and vascular biology from around the world. They will gather together for
a productive exchange on the latest in science and clinical applications and to present the
most recent advances, in a setting designed for professional development.
I wish to welcome everyone to our city and encourage you to enjoy Toronto at this time of
the year as well as learn about vibrant neighborhoods.
On behalf of Toronto City Council, please accept my best wishes for an informative and
enjoyable event.
Yours truly,
Toronto Waterfront Royal Ontario Museum
Mayor John Tory 12:15 Welcome and introduction 12:15 Welcome and introduction
City of Toronto Chair: Alfonso Iorio (Canada) Chair: Giovanni DiMinno (Italy)
12:20 Review of new Phase III data for BeneFix: once-weekly 12:20 Innovative approaches to hemophilia joint assessment:
prophylactic dosing in hemophilia B insights from the European Ultrasound Program
Michael Tarantino (USA) Giovanni DiMinno (Italy)
12:40 Review of new Phase III data for BeneFix: 12:35 Optimizing joint health outcomes with ultrasound:
additional analysis practical application of the Hemophilia Early
Bartholomew Tortella (Pfizer) Arthropathy Detection with UltraSound (HEAD-US)
technique for joint assessment
12:50 Investigating the science behind FIX in Carlo Martinoli (Italy)
the extravascular space
Darrel Stafford (USA) 13:05 Practical approaches to the implementation of
ultrasound in hemophilia practice: case studies
13:10 Patient-centered approaches to dosing: treatment from Canada
individualization with PK modeling Shannon Jackson (Canada)
Alfonso Iorio (Canada) Karen Strike (Canada)
13:30 Panel discussion 13:25 Panel discussion

Moderated by Chair Moderated by Chair
13:40 Meeting summary and close 13:40 Meeting summary and close
10 11
Information based on approved Canadian product information for BeneFix This symposium is sponsored
Date of preparation: April 2015 by funding from Pfizer
ISTH 2015 Committees ISTH 2015 Committees
ISTH Organizing Committee
Local Organizing Committee Scientific and Standardization Scientific Program

Sam Schulman President
Committee Liaison Subcommittees
Philip Wells Vice President
Sabine Eichinger, Austria, SSC Chair
Victor Blanchette Treasurer
Lori Linkins, Canada, SSC Liaison Platelets Basic
Jeffrey Weitz Scientific Chair
Educational Program Margaret Rand, Canada, Chair

State-of-the-Art Book Editors Patrick Provost, Canada
Shannon Bates, Canada, Co-chair Lawrence (Skip) Brass, United States
David Lillicrap Editor Agnes Lee, Canada, Co-chair Sara Israels, Canada
James Douketis Co-Editor Archie McNicol, Canada
Heyu Ni, Canada
Social Events Committee
Scientific Program Subcommittee Chairs Rita Selby, Canada, Chair Platelets Clinical
Laurie Sardo Allied Health Professionals Program
Geoff Werstuck Atherothrombosis Trainee Program Committee Peter Gross, Canada, Chair
John Eikelboom Clinical Cardiovascular Walter Kahr, Canada
Paula James Coagulation Factors and Inhibitors Carol Gonsalves, Canada, Chair John Freedman, Canada
Jeffrey Weitz Fibrinolysis and Proteolysis Mandy Lauw, The Netherlands Ted Warkentin, Canada
Jerry Teitel Hemorrhagic Disorders Alan Michelson, United States
John Semple Inflammation and Immunology Jean-Francois Tanguay, Canada
Mark Crowther Innovation and Technology
ISTH 2015 Senior Advisory
Patti Massicotte Pediatric Hemostasis and Thrombosis Board Coagulation Factors and
Margaret Rand Platelets - Basic
Peter Gross Platelets - Clinical Morris Blajchman, Canada Inhibitors
Donald M. Arnold Transfusion Cedric Carter, Canada
Ed Conway Vascular Biology Bernadette Garvey, Canada Paula James, Canada, Chair
Marc Rodger Venous Thrombotic Disorders Jeff Ginsberg, Canada Ed Pryzdial, Canada
Jack Hirsh, Canada Patricia Liaw, Canada
John Kelton, Canada Rodney Camire, United States
Raelene Kinlough-Rathbone, Canada Alfonso Iorio, Canada
Michael Mant, Canada
Marian Packham, Canada
Graham Pineo, Canada Fibrinolysis and Proteolysis
Georges Rivard, Canada
Alexander G. Turpie, Canada Jeffrey Weitz, Canada, Chair
Jim Fredenburgh, Canada
Paul Kim, Canada
Katherine Hajjar, United States
12 13
ISTH 2015 Committees
Vascular Biology Inflammation and Immunology
Ed Conway, Canada, Chair John Semple, Canada, Chair

Mark Blostein, Canada Andy Weyrich, United States
William Aird, United States Dave Kuter, United States
Nigel Mackman, United States Jane Freedman, United States
Eric Boilard, Canada
Hemorrhagic Disorders
Innovation and Technology
Jerry Teitel, Canada, Chair
Mark Crowther, Canada, Chair
Leonard Valentino, United States
Cathy Hayward, Canada
Craig Kessler, United States
Adam Cuker, United States
Man-Chiu Poon, Canada
Karen Moffatt, Canada
Steven Pipe, United States
Scott Diamond, United States
James Zehnder, United States
Venous Thrombotic Disorders
Transfusion
Marc Rodger, Canada, Chair
Susan Kahn, Canada Donnie Arnold, Canada, Chair
Clive Kearon, Canada Sunny Dzik, United States
Bill Geerts, Canada Richard Kaufman, United States
Mary Cushman, United States Yulia Lin, Canada
David Garcia, United States Charles Quinn, United States
Atherothrombosis Pediatric Hemostasis and

Geoff Werstuck, Canada, Chair
Thrombosis
Dino Trigatti, Canada
Patti Massicotte Canada, Chair
Murray Huff, Canada
Michele David, Canada
Myron Cybulsky, Canada
Manuel Carcao, Canada
Avrum Gotlieb, Canada
Lynette Bowes, United States
Neil Goldenberg, Canada
Clinical Cardiovascular Leslie Raffini, United States
John Eikelboom, Canada, Chair

Robert Hart, Canada
Chris Granger, United States
William Hiatt, United States
14 15
International Advisory Board ISTH 2015 Abstract Reviewers
Walter Ageno Andreas Greinacher Doyeun Oh Rezan Abdul-Kadir, United Kingdom Paul Bray, United States
Italy Germany South Korea Thomas Abshire, United States Benjamin Brenner, Israel
Yolanda Adamczuk, Argentina George Broze, United States
Pantep Angchaisuksiri John-Bjarne Hansen Bjarne sterud Murray Adams, Australia Kathleen Brummel-Ziedins, United States
Dorothy Adcock, United States Harry Bller, The Netherlands
Thailand Norway Norway Walter Ageno, Italy Saulius Butenas, United States
Giancarlo Agnelli, Italy Suzanne Cannegieter, The Netherlands
Yujiro Asada Paul Harrison Yukio Ozaki Josefin Ahnstrm, United Kingdom Manuel Carcao, Canada
Japan United Kingdom Japan Ingo Ahrens, Germany Anders Carlsson, Sweden
Ramzi Ajjan, United Kingdom Marc Carrier, Canada
Patricia Casais Beverley Hunt Flora Peyvandi Nadine Ajzenberg, France Cedric Carter, Canada
Argentina United Kingdom Italy Lorenzo Alberio, Switzerland Patricia Casais, Argentina
Marie-Christine Alessi, France Elisabetta Castoldi, The Netherlands
Barry Coller James Huntington Margaret Ragni Julia Anderson, Scotland Spero Cataland, United States
Robert Andrews, Australia Marco Cattaneo, Italy
United States United Kingdom United States Pantep Angchaisuksiri, Thailand Elizabeth Chalmers, United Kingdom
Dominick Angiolillo, United States Howard Chan, Canada
Javier Corral Ral Izaguirre Francesco Rodeghiero Gail Annich, Canada Douglas Cines, United States
Spain Mexico Italy Jack Ansell, United States Kenneth Clemetson, Switzerland
Jovan Antovic, Sweden Christine Cockhill, Canada
Shaun Coughlin Barry Jacobson Wolfram Ruf Morio Arai, Japan Barry Coller, United States
United States South Africa United States Robert Arins, United Kingdom Ed Conway, Canada
Donald Arnold, Canada Michiel Coppens, The Netherlands
Bjrn Dahlbck Sriram Krishnaswamy Evan Sadler Valder Arruda, United States Ramn Corbalan, Chile
Roopen Arya, United Kingdom Javier Corral, Spain
Sweden United States United States Yujiro Asada, Japan Judith Cosemans, The Netherlands
Tatsuya Atsumi, Japan Benilde Cosmi, Italy
Hans Deckmyn Paul Kyrle Uri Seligsohn Simona Avram, Romania Jonathan Coutinho, The Netherlands
Belgium Austria Israel Cihan Ay, Austria Jim Crawley, United Kingdom
Lina Badimon, Spain Adam Cuker, United States
Ccile Denis Bernhard Lmmle Simon Stanworth Caroline Baglin, United Kingdom Armando DAngelo, Italy
France Switzerland United Kingdom Trevor Baglin, United Kingdom Bjrn Dahlbck, Sweden
Wadie Bahou, United States Martina Daly, United Kingdom
Donna DiMichele Nigel Mackman Scott Stevens Tamam Bakhoul, Germany Simon Davidson, United Kingdom
Alessandra Balduini, Italy Raimondo De Cristofaro, Italy
United States United States United States Carlo Balduini, Italy Philip de Groot, The Netherlands
Shannon Bates, Canada Moniek de Maat, The Netherlands
Sabine Eichinger Diego Mezzano Yoshiyuki Tomiyama Angelika Batorova, Slovakia Philippe de Moerloose, Switzerland
Austria Chile Japan Kenneth Bauer, United States Valerio De Stefano, Italy
Cecilia Becattini, Italy Najet Debili, France
Anna Falanga Toshiyuki Miyata Tetsumei Urano Richard Becker, United States Hans Deckmyn, Belgium
Italy Japan Joel Bennett, United States Paul Declerck, Belgium
Japan
Wolfgang Bergmeier, United States Herve Decousus, France
Bruce Furie Stephan Moll David Bergqvist, Sweden Ccile Denis, France
Christopher Ward
Francesco Bernardi, Italy Francesco Dentali, Italy
United States United States Australia Erik Berntorp, Sweden Scott Diamond, United States
Victor Blanchette, Canada Ludovic Drouet, France
Christian Gachet Laurent Mosnier Steve Watson Alicia Blanco, Argentina Sabine Eichinger, Austria
France United States United Kingdom Mark Blostein, Canada Jeroen Eikenboom, The Netherlands
Paul Bock, United States Petra Elfvinge, Sweden
Shinya Goto Bernhard Nieswandt Alisa Wolberg Michael Boffa, Canada Jessica Emed, Canada
Vladimir Bogdanov, United States Joseph Emmerich, France
Japan Germany United States
Eric Boilard, Canada Miguel Escobar, Spain
Mariana Bonduel, Argentina Koji Eto, Japan
Nuala Booth, United Kingdom Anna Falanga, Italy
Federico Bottaro, Argentina Emmanuel Favaloro, Australia
Henri Bounameaux, Switzerland Augusto Federici, Italy
Lynette Bowes, Canada Karin Fijnvandraat, The Netherlands
Leonardo Brandao, Canada Kathelijn Fischer, The Netherlands
16 17
ISTH 2015 Abstract Reviewers ISTH 2015 Abstract Reviewers
Garret Fitzgerald, United States Beverley Hunt, United Kingdom Wendy Lim, Canada Jim Munn, United States
Robert Flaumenhaft, United States Jim Huntington, United Kingdom Shu-Wha Lin, Taiwan Lszl Muszbek, Hungary
Veronica Flood, United States Akitada Ichinose, Italy Yulia Lin, Canada Nicola Mutch, United Kingdom
Georgina Floros, Canada Aida Inbal, Israel Ton Lisman, The Netherlands Khalid Naseem, United Kingdom
Jonathan Foley, United Kingdom Alfonso Iorio, Canada Rolf Ljung, Sweden Marguerite Neerman-Arbez, Switzerland
Charles Francis, United States Sara Israels, Canada Colin Longstaff, United Kingdom Claude Negrier, France
Jim Fredenburgh, Canada Ral Izaguirre, Mexico Marie Lordkipanidz, United Kingdom Fiona Newall, Australia
Jane Freedman, United States Marc Jacquemin, Belgium Gordon Lowe, United Kingdom Heyu Ni, Canada
John Freedman, Canada Joseph Jakubowski, United States Aharon Lubetsky, Israel Timothy Nichols, United States
Al Frelinger III, United States Andra James, United States Christopher Ludlam, United Kingdom Rienk Nieuwland, The Netherlands
Satoshi Fujii, Japan Paula James, Canada Brenda Luken, United Kingdom Marina Noris, Italy
Christian Gachet, France Martine Jandrot-Perrus, France Florea Lupu, United States Agata Nowak, United Kingdom
David Gailani, United States Bernd Jilma, Austria Jeanne Lusher, United States Alan Nurden, France
Monica Galli, Italy Gerhard Johnson, United States Ian Mackie, United Kingdom Paquita Nurden, France
Alex Gallus, Australia Scott Kaatz, United States Nigel Mackman, United States Doyeun Oh, South-Korea
Sophie Gandrille, France Susan Kahn, Canada Maria Magnusson, Sweden Tsukasa Ohmori, Japan
David Garcia, United States Michael Kalafatis, United States Mike Makris, United Kingdom Johannes Oldenburg, Germany
Chris Gardiner, United Kingdom Farhad Kamali, United Kingdom Asrar Malik, United States Pall nundarson, Iceland
Bernadette Garvey, Canada Pieter Willem Kamphuisen, The Netherlands Maura Malone Dumas, United States Bjarne sterud, Norway
Pascale Gaussem, France Carol Kasper, United States Naveen Manchanda, United States Hans-Martin Otten, The Netherlands
William Geerts, Canada Nevine Kassim, Egypt Maria Mancuso, Italy Yukio Ozaki, Japan
Jonathan Gibbins, United Kingdom Clive Kearon, Canada Marina Marchetti, Italy Bunis Packham, United Kingdom
Hollie Gilmore, Australia David Keeling, United Kingdom Ida Martinelli, Italy Joseph Palumbo, United States
David Ginsburg, United States Christine Kempton, United States Steffen Massberg, Germany Guillaume Par, Canada
Neil Goldenberg, United States Dermot Kenny, Ireland Patti Massicotte, Canada Paola Patrignani, Italy
Samuel Goldhaber, United States Steven Kerrigan, Ireland Alan Mast, United States Carlo Patrono, Italy
Rebecca Goldsmith, Canada Nigel Key, United States Yumiko Matsubara, Japan Rafal Pawlinski, United States
Anne Goodeve, United Kingdom Kate Khair, United Kingdom Osamu Matsuo, Japan Bernard Payrastre, France
Shinya Goto, Japan Paul Kim, Canada Tadashi Matsushita, Japan Ian Peake, United Kingdom
Jenny Goudemand, France Manjunatha Kini, Singapore Owen McCarty, United States Kathelijne Peerlinck, Belgium
Chris Granger, United States Steve Kitchen, United Kingdom Keith McCrae, United States Vanessa Pellegrinelli, United Kingdom
Andreas Greinacher, Germany Erik Klok, The Netherlands Brian McCrindle, Canada Vittorio Pengo, Italy
Paolo Gresele, Italy Tetsuhito Kojima, Japan Archie McNicol, Canada Jaime Pereira, Chile
John Griffin, United States Koichi Kokame, Japan Simon McRae, Australia Egon Persson, Sweden
Jean-Christophe Gris, France Krasimir Kolev, Hungary John McVey, United Kingdom Marjolein Peters, The Netherlands
Peter Gross, Canada Barbara Konkle, United States Robert Medcalf, Australia Flora Peyvandi, Italy
Yves Gruel, France Timo Korhonen, Finland Leonid Medved, United States Helen Philippou, United Kingdom
Chris Guelcher, United States Johanna Kremer, Switzerland Shannon Meeks, United States Gregory Piazza, United States
Sylvia Haas, Germany Steven Krilis, Australia Karina Meijer, The Netherlands Graham Pineo, Canada
Tilman Hackeng, The Netherlands Marieke Kruip, The Netherlands Joost Meijers, The Netherlands Steven Pipe, United States
Margaret Hall, United States Thomas Kuehne, Switzerland Koen Mertens, The Netherlands Ed Plow, United States
John-Bjarne Hansen, Norway Satya Kunapuli, United States Guy Meyer, France Mortimer Poncz, United States
Job Harenberg, Germany Shinichiro Kurosawa, United States Saskia Middeldorp, The Netherlands Man-Chiu Poon, Canada
Paul Harrison, United Kingdom Paul Kyrle, Austria Lindsey Miles, United States Paolo Prandoni, Italy
Robert Hart, Canada David Lane, United Kingdom Jonathan Miller, United States Kathleen Pratt, United States
Tatsuya Hayashi, Japan Francois Lanza, France Toshiyuki Miyata, Japan Patrick Provost, Canada
Cathy Hayward, Canada Sarah Lapner, Canada Jun Mizuguchi, Japan Charles Quinn, United States
Mary Heeb, United States Riitta Lassila, Finland Karen Moffat, Canada Leslie Raffini, United States
Johan Heemskerk, The Netherlands Daniel Lawrence, United States Stephan Moll, United States Margaret Ragni, United States
John Heit, United States Alan Lazarus, Canada Paul Monahan, United States Janusz Rak, Canada
Stan Heptinstall, United Kingdom Alejandro Lazo-Langner, Canada Manuel Monreal, Spain Jacob Rand, United States
William Hiatt, United States Bernard Le Bonniec, France Dougald Monroe, United States Margaret Rand, Canada
Karin Hoffmeister, United States Grgoire Le Gal, Canada Robert Montgomery, United States Anna Randi, United Kingdom
Philip Hogg, Australia Ramn Lecumberri, Spain Pierre-Emmanuel Morange, France A. Koneti Rao, United States
Keith Hoots, United States Agnes Lee, Canada Massimo Morfini, Italy Gary Raskob, United States
Marie Horellou, France Peter Lenting, France James Morrissey, United States Pieter Reitsma, The Netherlands
Hisanori Horiuchi, Japan Marcel Levi, The Netherlands John Morser, United States Thomas Renn, Sweden
Marc Hoylaerts, Belgium Willem Lijfering, The Netherlands Per Morten Sandset, Norway Alireza Rezaie, United States
Menno Huisman, The Netherlands Roger Lijnen, Belgium Laurent Mosnier, United States Suely Rezende, Brazil
David Motto, United States Frederick Rickles, United States
18 19
ISTH 2015 Abstract Reviewers ISTH Council
Dick Rijken, The Netherlands Arina ten Cate-Hoek, The Netherlands Nigel Key, United States
Georges Rivard, Canada Andreas Tiede, Germany Chair of Council (2014 2016)
Francesco Rodeghiero, Italy Cheng-Hock Toh, United Kingdom
Marc Rodger, Canada Yoshiyuki Tomiyama, Japan Ingrid Pabinger, Austria
Mark Roest, The Netherlands Mauro Torti, Italy
Secretary / Chair-Elect (2014 2016)
Frits Rosendaal, The Netherlands Alberto Tosetto, Italy
Jan Rosing, The Netherlands Paula Tracy, United States
Changgeng Ruan, China David Trgout, France Bjrn Dahlbck, Sweden
Wolfram Ruf, United States Bernardo Trigatti, Canada Treasurer (2015 2018)
Evan Sadler, United States Hiroko Tsuda, Japan
Jean-Marie Saint-Remy, Belgium Alexander G. Turpie, Canada
Marc Samama, France Shirley Uitte de Willige, The Netherlands
Per Morten Sandset, Norway Anetta Undas, Poland
Elena Santagostino, Italy Tetsumei Urano, Japan
Sentot Santoso, Germany Rolf Urbanus, The Netherlands
Class of 2016 Ex-Officio Council Members
Laurie Sardo, Canada Elizabeth Van Cott, United States
Ravi Sarode, United States Ton van den Besselaar, The Netherlands Marco Cattaneo, Italy J. Evan Sadler, United States
Anna Savoia, Italy Anske van der Bom, The Netherlands Bjrn Dahlbck, Sweden Secretary General
Rdiger Scharf, Germany Felix van der Meer, The Netherlands Andreas Greinacher, Germany
Inge Scharrer, Germany Chris van Greet, Belgium Yukio Ozaki, Japan Michael Berndt, Australia
Alvin Schmaier, United States Waander van Heerde, The Netherlands Paula Tracy, United States Immediate Past Chair, ISTH Council
Simone Schoenwaelder, Australia Victor van Hinsbergh, The Netherlands
Sam Schulman, Canada Astrid van Hylckama Vlieg, The Netherlands
Sam Schulman, Canada
Jean-Franois Schved, France Heleen van Ommen, The Netherlands Class of 2018 President, XXV ISTH Congress,
Marie Scully, United Kingdom Suresh Vedantham, United States
Rita Selby, Canada Peter Verhamme, Belgium Toronto, 2015
Peter Lenting, France
Uri Seligsohn, Israel Henri Versteeg, The Netherlands Claire McLintock, New Zealand
John Semple, Canada Sara Vesely, United States Philip Wells, Canada
James Morrissey, United States
Yotis Senis, United Kingdom Vicente Vicente, Spain Vice-President, XXV ISTH Congress
Amy Shapiro, United States Shoshana Vilk, Israel Ingrid Pabinger, Austria
Toronto, 2015
Midori Shima, Japan Jan Voorberg, The Netherlands Jeffrey Weitz, Canada
Robyn Shoemark, Australia Hideo Wada, Japan Pieter Reitsma, The Netherlands
Pierre Sie, France Theodore Warkentin, Canada Class of 2020
Deborah Siegal, Canada Henry Watson, United Kingdom Editor-in-Chief, Journal of Thrombosis
Bob Siegerink, The Netherlands Steve Watson, United Kingdom and Haemostasis
Wolfgang Siess, Germany Hartmut Weiler, United States Anna Falanga, Italy
Angela Silveira, Sweden Jeffrey Weitz, Canada David Lillicrap, Canada Frits Rosendaal, The Netherlands
Robert Silver, United States Philip Wells, Canada Jose Lopez, United States Past President, XXIV ISTH
Roy Silverstein, United States Geoff Werstuck, Canada Suely Rezende, Brazil Congress Amsterdam, 2013 and
Sergio Siragusa, Italy Randal Westrick, United States Steve Watson, United Kingdom Editor-in-Chief, Journal of Thrombosis
Nicholas Smith, United States Gilbert White, United States and Haemostasis
Kenji Soejima, Japan Richard White, United States
Henrik Toft Srensen, Denmark David Wilcox, United States
Arnold Spek, The Netherlands Suzan Williams, Canada Sabine Eichinger, Austria
Catherine Sperlich, Canada Alisa Wolberg, United States Chair, Scientific and Standardization
Henri Spronk, The Netherlands Tim Woods, United Kingdom Committee
Alex Spyropoulos, United States Renchi Yang, China
Deborah Stearns-Kurosawa, United States Masahiro Yasaka, Japan
Dana Stephens, United States Irene York, Canada
Scott Stevens, United States Neil Zakai, United States
Guus Sturk, The Netherlands Susan Zappa, United States
Peter Svensson, Sweden James Zehnder, United States
Campbell Tait, United Kingdom Ying Zheng, United States
Jerome Teitel, Canada Michelle Zondag, Canada
Hugo ten Cate, The Netherlands
20 21
SAVE THE DATES
ISTH Scientific and Standardization Committee
Haemophilia A: Individualised
solutions to global challenges
Tuesday, June 23, 2015
SSC Executive Committee Factor VIII, Factor IX and Rare 12:15 - 13:45
Coagulation Disorders
2014-2016 Guy Young, United States
Symposium Room 801
Sabine Eichinger, Austria This symposium will focus on the future of haemophilia A
Factor XI and the Contact System
Chair treatment including major challenges - the development of
Jonas Emsley, United Kingdom
inhibitors and the need for frequent venous access for FVIII
Walter Ageno, Italy injections. Importance of individually tailored prophylaxis
Factor XIII and Fibrinogen
Secretary/Chair-elect and the final results of personalised prophylaxis study,
Helen Philippou, United Kingdom
NuPreviq, will be presented.
David Lillicrap, Canada
Immediate Past Chair
Fibrinolysis Symposium
Nicola Mutch, United Kingdom Symposium chaired by Craig Kessler
Jean-Franois Schved, France New generation rFVIII concentrates: where do we stand?
Hemostasis and Malignancy
Ex-Officio: President, SSC 2016 Craig Kessler, USA
Alok Khorana, United States
NuProtect: update on human cell-line derived rFVIII in PUPs
Lupus Anticoagulant/Phospholipid- Anthony Chan, Canada
Standing Committees Dependent Antibodies
Bas de Laat, The Netherlands Every patient is unique: the need for a personalised
Bleeding Assessment Tool approach to treatment
Francesco Rodeghiero, Italy Pediatric and Neonatal Hemostasis and Massimo Morfini, Italy
Thrombosis
Coagulation Standards Anthony Chan, Canada NuPreviq: update on human cell-line derived rFVIII
Anthony Hubbard, United Kingdom in personalised prophylaxis
Plasma Coagulation Inhibitors John Pasi, UK
WHO-ISTH Standards Liaison Group Richard Marlar, United States Lunch will be served
Peter Lenting, France
Platelet Immunology
Yves Gruel, France
Subcommittees Addressing complex issues in
Animal, Cellular and Molecular Models
Platelet Physiology VWD & haemophilia care
Paolo Gresele, Italy
Susan Smyth, United States Wednesday, June 24, 2015
Predictive Hemostatic Variables 12:15 - 13:45
Biorheology Symposium Room 801
Paul Kyrle, Austria
Keith Neeves, United States
Vascular Biology This symposium aims to provide a platform for sharing
Control of Anticoagulation experiences on critical questions in the management of
Rienk Nieuwland, The Netherlands
Walter Ageno, Italy von Willebrand disease (VWD) and haemophilia A.
von Willebrand Factor
Disseminated Intravascular Coagulation
Jorge DiPaola, United States Symposium chaired by Jerry Teitel
Jecko Thachil, United Kingdom
Womens Health Issues in Thrombosis and Should prophylaxis be the standard of care for
Exogenous Hemostatic Factors severe VWD?
Hemostasis
Ivo Francischetti, United States Ulrike Nowak Gttl, Germany
Rezan Abdul-Kadir, United Kingdom
How to manage labour & delivery in VWD

Paula James, Canada
Management of surgeries in VWD: final results

of a clinical study
Alok Srivastava, India
Canadian experience with 1:1 VWF/FVIII concentrate

Mark Belletrutti, Canada
22
Symposium 23
Lunch will be served

Congress Support Sponsors and Exhibitors
ISTH wishes to recognize the following companies and organizations for 3i - Intelligent Imaging Innovations HYPHEN BioMed
their support of ISTH 2015 Accriva Diagnostics Immucor
Affinity Biologicals, Inc. Instrumentation Laboratory
Alexion Pharmaceuticals, Inc. International Initiative on Thrombosis and
PLATINUM SPONSORS Cancer (ITAC-CME)
ALNYLAM PHARMACEUTICALS
Baxalta International Society on Thrombosis and
Aniara Diagnostica & CoaChrom Diagnostica Haemostasis (ISTH)
Bayer HealthCare
Biogen and Sobi Answering T.T.P. (Thrombotic ISTH SSC 2016 - Montpellier, France
Novo Nordisk Health Care AG Thrombocytopenic Purpura) Foundation
Octapharma AG ISTH 2017 - Berlin, Germany
Aspen Pharma
Journal of Thrombosis and Haemostatis (JTH)
Baxalta
GOLD SPONSORS Bayer HealthCare
Kedrion Biopharma
LABTEK Science & Development Co., Ltd
Bio Products Laboratory USA, Inc.
Boehringer Ingelheim GmbH LEO Pharma
Biogen and Sobi
CSL Behring GmbH LFB BIOMEDICAMENTS
Pfizer bioMrieux
Pfizer Canada Inc. / Bristol-Myers Squibb Canada MediRox
Biotest AG
Novo Nordisk Haemophilia Foundation
Boehringer Ingelheim GmbH (NNHF)
SILVER SPONSORS Canadian Hemophilia Society (CHS) Novo Nordisk Health Care AG
CEDARLANE Octapharma AG
Daiichi Sankyo, Inc.
Chrono-log Corp. Pfizer
Kedrion Biopharma
Siemens Healthcare and Sysmex Corporation CMEology Pfizer Canada Inc./Bristol-Myers Squibb
STAGO Canada
Covidien
CSL Behring GmbH Portola Pharmaceuticals, Inc.
BRONZE SPONSORS Daiichi Sankyo, Inc. Precision BioLogic
Diapharma Group Roche Diagnostics International Ltd
Alexion Pharmaceuticals, Inc. Sanofi Canada
DSM Nutritional Products Ltd Branch
GRIFOLS
Pentapharm Schattauer Publishers
HYPHEN BioMed
Instrumentation Laboratory Enzyme Research / r2 Diagnostics Sekisui Diagnostics
LEO Pharma
European and Mediterranean League Against Siemens Healthcare
Portola Pharmaceuticals, Inc.
Thrombotic Diseases (EMLTD)
Roche Diagnostics International Ltd. STAGO
Ferrer inCode
Sysmex Corporation
Foundation for Women & Girls with Blood
Disorders (FWGBD) TECHNOCLONE
George King Bio-Medical, Inc. Thrombosis.TV
GRIFOLS Wiley
Haematologic Technologies, Inc. World Federation of Hemophilia
Hemostasis Reference Laboratory Inc. World Thrombosis Day (WTD) - 13 October
Please see the ISTH 2015 Show Guide for more detailed information
about our corporate supporters, exhibitors and sponsored programs.
24 25
Reach-the-World Fellowships ISTH Awards
ISTH 2015 Awards opinion of their peers, have made significant

contributions to research and education in
blood coagulation.
Robert P. Grant Medal
The Investigator Recognition Awards recognize
The Robert P. Grant Medal is the ISTHs high- ISTH members whose accomplishments are
est award. It is presented during the biennial internationally regarded as exemplary models
ISTH Congress in honor of research achieve- of excellence in research and teaching.
ments, organizational activities, support of
ISTH Reach-the-World Fellowship Program

research activities, facilitation of institution- The Distinguished Career Awards recognize
al cooperation and communication, unusual ISTH members whose career contributions
teaching or educational initiatives and/or the have significantly advanced the scientific
development of concepts that result in a clear- communitys understanding of the diseases
The ISTH Reach-the-World Fellowship Program, er understanding of research data. and disorders affecting hemostasis.
for early-career professionals from developing* The medal is named after Robert P. Grant, a The ISTH BACH Awards will be presented at
renowned cardiologist who spent many years the Presidents Dinner on Monday, June 22.
countries, promotes advanced knowledge and as a representative of the National Institutes
expertise in one or all of the following areas of Health in Europe, traveling extensively and
facilitating American-European collaboration 2015 Recipients of the
related to thrombosis and hemostasis: in medical research and education. Biennial Awards for
Medical care The ISTH Grant Medal will be presented at the Contributions to Hemostasis
Opening Ceremony on Sunday, June 21. (BACH) Award
Laboratory methods
Harold R. Roberts Award Distinguished Career
Research Harry Bller, The Netherlands
The ISTH Harold R. Roberts Award honors Nigel Mackman, United States
Deadlines for submission of applications are
mentorious service to the Scientific and Stan- Wolfram Ruf, United States, Germany
June 1 and January 1 of each year. dardisation Committee of the ISTH, beyond Ulla Hedner, Sweden
expectations and over a significant period of Gilbert White, United States
For more information on the Fellowship Program time.
and ISTH Reach-the-World Membership, please The ISTH Reach-the-World Fellowship Investigator Recognition
The Roberts Award will be presented at the Pres-
Program is supported thanks to an Steffen Massberg, Germany
visit www.isth.org or contact the ISTH via email idents Dinner on Monday, June 22.
Tim Springer, United States
unrestricted educational grant from Bayer.
at headquarters@isth.org. Sriram Krishnaswamy, United States
Biennial Awards for Willem Ouwehand, United Kingdom
Contributions to Hemostasis Alisa Wolberg, United States
*Countries designated as developing by the
classification of the World Bank Mission The ISTHs Biennial Awards for Contributions
to Hemostasis (BACH) are presented during
the ISTH Congress to individuals who, in the
Call for
The ISTH is a global not-for-profit
organization advancing the understanding,
Applications!
prevention, diagnosis and treatment of
thrombotic and bleeding disorders.
Join the conversation online!

Visit us at Booth 1036! www.isth.org
26 27
Congress Travel Stipends Congress Travel Stipends
Young Investigator Travel Stipends Oscar A Marcos-Contreras, United States Lucia Stefanini, United Kingdom
Simone Merlin, Italy David Stegner, Germany
The Young Investigators Travel Stipends were provided in the form of travel grants to medical Kahia Messaoudi, France Saravanan Subramaniam, Germany
trainees and young scientists (under 35 years of age as of June 21, 2015) who submitted Soraya Mezouar, France Pierre Suchon, France
highly rated abstracts. Kristina Modjeski, United States Laura Swystun, Canada
J.E. Molhoek, The Netherlands Maria Talmon, Italy
We hope that you will find attendance at ISTH 2015 fruitful in your continued research, clinical Samantha Moore, United Kingdom Chaojun Tang, China
and educational activities. Vincent Muczynski, France Claudia Tersteeg, Belgium
Ahmad Mufti, United Kingdom Cheng-Hock Toh, United Kingdom
Patrick Mnzer, Germany Nagaharu Tsukiji, Japan
Recipients of an ISTH 2015 Young Investigator Travel Stipend Moe Murata, Japan Robert Turnbull, United Kingdom
Giang Nguyen, United States Kristin Utne, Norway
Gregory Adams, United States Xuemei Fan, China Agata Anna Nowak, United Kingdom Bart van den Eshof, The Netherlands
Sonia Aguila, Spain Hendrik Feys, Belgium Kaisa Otteby, Sweden Tom Van Der Hulle, The Netherlands
Huda Omar Ali, Norway Dborah Franois, France Marta Palomo De Udaeta, Spain Judith Van Eeuwijk, Germany
Ashley Ambrose, United Kingdom Florian Gaertner, Germany Leonie Pelkmans, The Netherlands Nick van Es, The Netherlands
Ana Beln Arroyo Rodrguez, Spain Maxime Gauberti, France Behnaz Pezeshkpoor, Germany Nienke Van Rein, The Netherlands
Dario Balestra, Italy Xiaomei Ge, United States Raymond Piatt, United States Christophe Vandenbriele, Belgium
Elena Barbon, Italy Johanna Gebhart, Austria Tom Plug, The Netherlands Imre Varj, Hungary
Anthony Battram, United Kingdom Mitchell Geer, United Kingdom Irina Portier, Belgium Sebastien Verhenne, Belgium
Paul Batty, United Kingdom Maria Georgescu, Canada Cristina Puy, United States Danil Verhoef, The Netherlands
Roelof Bekendam, United States Ewelina Golebiewska, Japan Julia Riedl, Austria Britta Walker, Germany
Suzanne Bleker, The Netherlands Sanjeev Kiran Gotru, Germany Ludvig Balteskard Rinde, Norway Simon James Webster, United Kingdom
Johan Boender, The Netherlands Lindsey Greene, United States Rachel Roach, The Netherlands John Welsh, United States
Luca Bologna, Switzerland Angle Gros, France Ina Rye-Holmboe, Norway Anouck Wijgaerts, Belgium
Oliver Borst, Germany Kamlesh Gupta, United States Daniela Scalet, Italy Christopher Williams, United Kingdom
Yacine Boulaftali, France Elizabeth Haining, Germany Sarah Schiel, Germany Gary Woods, United States
Tara Bracken, United States Hendrika Hazendonk, The Netherlands Maaike Schillemans, The Netherlands Binggang Xiang, United States
Sigrid Braekkan, Norway Sara Henderson, Canada Shana Aadl Shaya, Canada Aizhen Yang, China
Alessio Branchini, Italy Christoph Hofbauer, Austria Birgit Smbrekke, Norway Jonathan Wai-hon Yau, Canada
Katherine Bridge, United Kingdom Lars Daae Horvei, Norway Bryn Smith, United States Patricia Young, United States
Tomasz Brzoska, Japan Craig Hughes, United Kingdom Michelle Alida Helena Sonneveld, The Netherlands Diego Zanolini, Italy
Loredana Bury, Italy James Lawrence Hutchinson, United Kingdom Erin Soule, United States Xiaohua Zhou, Belgium
James Byrnes, United States Ivan Ivanov, United States Erica Sparkenbaugh, United States
Elena Campello, Italy Iqbal Jaffer, Canada
Naadiya Carrim, Canada Ben Johnson, United Kingdom
Caterina Casari, France Lining Ju, Australia
Lara Casey, Canada Alev Karasu, The Netherlands
Elizabeth Chappell, United States Noah Kastelowitz, United States Reach-the-World Travel Stipends
Jorien Claes, Belgium Alexandre Kauskot, France
Theodora Claushuis, The Netherlands Avinash Khandagale, Germany In recognition of the expanding educational format of the ISTH meetings and congresses,
Audrey Cleuren, United States Hilde Kooistra, The Netherlands the Society is extending its Reach-the-World initiative by providing travel stipends to enable
Jagmanpreet Dang, Canada Colin Andrew Kretz, United States participation by scientists from all areas of the world in ISTH 2015.
Esterina DAsti, Canada Jesse Lai, Canada
Karen De Ceunynck, United States Jostein Lappegrd, Norway We hope that you will find attendance at ISTH 2015 fruitful in your continued research, clinical
Hugoline de Haan, The Netherlands Mandy Lauw, The Netherlands and educational activities.
Maria Eugenia De La Morena-Barrio, Spain Vincenzo Leo, United Kingdom
Louis Deforche, Belgium Rong Li, China
Celine Delierneux, Belgium Laurens Liesenborghs, Belgium
Recipients of an ISTH 2015 Reach-the-World Travel Stipend
Paul den Exter, The Netherlands Ruzica Livaja-Koshiar, Sweden
Carsten Deppermann, Germany Viola Lorenz, Germany Salma Abdel Ghany Shawkat, Egypt Nadia Arshad, Pakistan
Marco Domingues, United Kingdom Kate Lowe, United Kingdom Al-Zamzam Abubakar, Philippines Yanyan Bai, China
Sebastian Dtting, Germany Christopher John Lynch, United Kingdom Yolanda Adamczuk, Argentina Xia Bai, China
Eduard Ebberink, The Netherlands Kellie Machlus, United States Mukul Aggarwal, India Ergul Berber, Turkey
John Eicher, United States Bhanukanth Manne, United States Hebe Agustina Mena, Argentina Luis Bittar, Brazil
Laura Elbers, The Netherlands Giorgia Manni, Italy Jos Antonio Alvarado-Moreno, Mexico Jelena Bodrozic, Serbia
28 29
Congress Travel Stipends
Munira Borhany, Pakistan Lyu Mingen, China

Daniela Calderaro, Brazil Pravas Mishra, India
Jose Manuel Ceresetto, Argentina Daniella Mizurini, Brazil
Yao-Wen Chang, Taiwan, China Bushra Moiz, Pakistan
Zhenping Chen, China Robson Monteiro, Brazil
Yingyong Chinthammitr, Thailand Katia Morais, Brazil
Dorathy Chioma Okpokam, Nigeria Lakshmi Mundkur, India
Andra Costache, Romania Bla Nagy, Hungary
Lv Cuicui, China Nida Najmi, Pakistan
Jing Dai, China Hannah Omunakwe, Nigeria
Maria das Garas Carvalho, Brazil Fernanda Orsi, Brazil
Zelda De Lange, South Africa Juvenal Paiva, Argentina
Maria De Lourdes Herrera, Argentina Krisztina Pnzes-Daku, Hungary
Ernesto De Meis, Brazil Benedito Prezoto, Brazil
Las De Paula, Brazil Alessandra Prezotti, Brazil
Chang-Qing Deng, China Lucia Remotti, Argentina
Vrushali Deshpande, India Daniel Ribeiro, Brazil
Pratibha Dhiman, India Theera Ruchutrakool, Thailand
Zhongren Ding, China Emelyn Salazar, Venezuela, Bolivarian Republic Of
Valentina Djordjevic, Serbia Analia Sanchez-Luceros, Argentina
Luci Dusse, Brazil Priyanka Saxena, India
Fernanda Dutra Santiago Bassora, Brazil Mirta Schattner, Argentina
Yi Fang, China Tanusree Sengupta, India
Miguel Farfan, Colombia Yanyan Shao, China
Mariane Flores-Nascimento, Brazil Ankit Sharma, India
Juan Pablo Frontroth, Argentina Weihong Shen, China
Rongfeng Fu, China Shrimati Shetty, India
Tain Gomes, Brazil Nongnuch Sirachainan, Thailand
Marcelo Luide Goncalves, Brazil Samuel Souza Medina, Brazil
Lallindra Gooneratne, Sri Lanka Tiantian Sun, China
Hugo Guglielmone, Argentina Vikas Suri, India
Yang He, China Bundarika Suwanawiboon, Thailand
Mirta Hepner, Argentina Anna Tanka-Salamon, Hungary
Diego Higuera, Venezuela, Bolivarian Noemi Klara Toth, Hungary
Republic Of Fernando Vazquez, Argentina
Hu Hu, China Biljana Vuckovic, Serbia
Khon Huynh, Vietnam Anyou Wang, China
Obinna Iheanacho, Nigeria Yao Wang, China
Leticia Jardim, Brazil Luciana Wermelinger Serro, Brazil
Anjali Jaydeep Kelkar, India Adriana Ines Woods, Argentina
Peipei Jin, China Jianbo Wu, China
Sornsith Jirungda, Thailand Xiaolin Wu, China
Bat-Erdene Jugder, Mongolia Xiaodong Xi, China
Rajani Kanth Vangala, India Zhang Xian, China
Patcharee Komvilaisak, Thailand Shilong Xiong, China
Huiyuan Li, China Jingyi Yang, China
Junling Li, China Hao Yating, China
Qian Liang, China Ziqiang Yu, China
Wenjie Liu, China Han Yue, China
Liu Liu, China Donglei Zhang, China
Yeling Lu, China Bo Zhang, China
Rita Marchi, Venezuela, Bolivarian Zeping Zhou, China
Republic Of Jingyi Zhou, China
Marta Martinuzzo, Argentina Hu Zhou, China
Muriel Meiring, South Africa
30 31
ISTH Society Information ISTH Society Information
The International Society on Thrombosis and Haemostasis (ISTH) is a global not-for-profit orga-
nization advancing the understanding, prevention, diagnosis and treatment of thrombotic and
ISTH membership categories include:
bleeding disorders.
Regular: for active researches, educators and clinicians in the field
As a professional membership organization, the ISTH is dedicated to transformative scientific
Associate: for students, trainees, research staff, post-doctoral fellows as well as
discoveries and clinical practices as well as the development of next generation and the educa-
allied health professionals
tion of physicians, scientists and allied health professionals wherever they may live.
Reach-the-World: for researchers, educators and clinicians in non-industrialized countries
With over 3,700 members in more than 90 countries, the ISTH supports a community of spe-
cialists in bleeding and clotting disorders through the creation and promotion of education and
Nurse: registered nurses
outreach initiatives, scientific meetings, research activities, peer reviewed publications, expert
committees and the development of standards allowing a common language and approach to
Allied Health: laboratory and radiological technicians, occupational and physical
basic and clinical science all over the world.
therapists, pharmacists, and other health professions distinct from
medicine and nursing
A highly regarded Society poised on the leading edge of science, the ISTH offers a comprehen-
sive membership offering that includes the following benefits:
For more information, or to join the Society, please contact:
ISTH membership benefits:
ISTH Headquarters Office
- A
n international professional network of 3,700 members spanning more than 90 610 Jones Ferry Road, Suite 205
countries. Carrboro, NC 27510
United States
- Priority registration and discounted fees for ISTH meetings and congresses. T: +1 919 929-3807
F: +1 919 929-3935
- C
omplimentary print (for regular members only) and online subscriptions to ISTHs headquarters@isth.org
Journal of Thrombosis and Haemostasis (JTH) as well as subscription to the ISTH www.isth.org
monthly e-newsletter.
- F
ull access to the ISTH Academy, featuring webinars, webcasts, online courses and more. Join the Conversation Online!
The ISTH also offers a free ISTH Academy membership, with limited access to online
educational resources at academy.isth.org. www.facebook.com/internationalsocietythrombosisandhaemostasis
- A
ccess to ISTH member-only resources, including an increasing array of educational www.twitter.com/isth
materials, communication and membership directory.
www.linkedin.com/company/international-society-on-thrombosis-and-haemostasis-isth-
- E
xclusive access and reduced fees for other educational activities, programs and
www.instagram.com/isthofficeteam
publications.
- E
ngagement opportunities, such as World Thrombosis Day each year on 13 October.
Learn more at www.worldthrombosisday.org. Learn more about World Thrombosis Day, an ISTH-lead yearly campaign
at www.worldthrombosisday.org.
- ISTH Career Center.
Visit us at our booth (# 1036) in the Exhibition Area on Level 800.
- T
he right to nominate, elect, vote and serve on ISTH committees and working groups.
32 33
A GLOBAL FIRST Notes
Join us and our eminent faculty at two
symposia to hear exclusive real-world
experience with prolonged half-life
Fc Fusion Factors in the clinic
AFTERNOON SYMPOSIUM EVENING TECHNICAL SESSION
Monday 22 June Monday 22 June

12:15 13:45 18:30 19:30
Chaired by Chaired by
Dr Manuel Carcao Dr Shannon Jackson
Room 801, Level 800 Room 717, Level 700
Real-world experiences Sharing real-world

with prolonged half-life experience with Fc Fusion
rFVIIIFc in hemophilia A: Factors in hemophilia B:
New data and New data for rFIXFc
future prospects
Come and visit us at Booth 922 to hear more about the

work we are doing to move hemophilia treatment forward
Use the QR Code with your smartphone, or visit http://medical-congress.info/isth
for more information and to add these exciting symposia to your calendar
Date of preparation April 2015

026EOL-INT-2015
34 35
Program Overview
From Baxters BioScience

to Baxalta
Baxters BioScience is expected
to become Baxalta in mid-2015.
At Baxters BioScience, we see a world of endless
possibilities for our patients. And although our name
may be changing to Baxalta, our commitment to you
is as strong as ever. At our foundation is an enduring
heritage of innovation and advocacy. Your life is our
inspiration to make a meaningful difference, so you
can dream big, and experience life. We are excited
about the future and hope you are too!
Visit the Baxalta booth #1602 to learn more.
Baxalta is a trademark of Baxalta Incorporated

36 USBS/MG1/15-0266 May 2015 37
Program at a Glance Program at a Glance
From Saturday, June 20 Thursday, June 25, 2015 From Saturday, June 20 Thursday, June 25, 2015
Friday, Saturday, June 20 Sunday, June 21 Monday, June 22 Tuesday, June 23 Wednesday, June 24 Thursday, June 25
Jun, 19
Master Classes Master Classes

Master Classes (ticket needed) Master Classes (ticket needed) (ticket needed) (ticket needed)
07:00 - 07:50 07:00 - 07:50 07:00 - 07:50 07:00 - 07:50
Oral Oral Oral
Registration 7:30-13:00
Oral
Communications Communications Communications Communications
08:00 - 09:15 08:00 - 09:15 08:00 - 09:15
Subcommittee 08:00 - 09:15
Meetings and Plenary Session Plenary Session Plenary Session Plenary Session
Educational 09:45 - 10:30 09:45 - 10:30 09:30 - 10:15
09:45 - 10:30
Nurse Forum 08:00 - 16:30

Subcommittee Programme
Meetings and State of the Art State of the Art State of the Art Abstract Symposia
08:00 - 12:20
Educational 10:45 - 11:45 10:45 - 11:45 10:45 - 11:45 10:30 - 11:45
Nurse Forum 09:00 - 18:00
Programme
Highlights of ISTH
Exhibition 09:00 - 18:30

09:00 - 13:20 Lunch Symposia Lunch Symposia 12:00 - 13:00

Lunch Symposia

12:15 - 13:45 12:15 - 13:45
12:15 - 13:45
WHF/ World
Oral Oral
Bayer Thrombosis Oral Communications Communications
Day Communications 14:00 - 15:15 14:00 - 15:15
14:00 - 15:15
Plenary Session
Subcommittee 15:45 - 16:30
Special Industry Abstract Symposia
Meetings and Symposia Abstract Symposia
Abstract Symposia 15:45 - 17:15
Educational 15:30 - 17:30 15:45 - 17:15
15:30-20:00
Registration
16:45 - 18:00
Programme
14:30 - 18:50 Posters with Refreshments Posters with Posters with
17:15 - 18:30 Refreshments Refreshments
Opening Session 18:00 - 19:30 17:15 - 18:30
Technical Sessions
18:15 - 19:15
18:30 - 20:00
Presidents All Congress

Dinner Party
Welcome Reception invitation (ticket needed)
19:30 - 22:00 only
19:30 -
22:00
From Monday, June 22 Wednesday, June 24 On Thursday, June 25

On Saturday, June 20 On Sunday, June 21
Break: 09:15 09:45 (Coffee) Break: 09:15 09:30 (Coffee)
Break 11:00 11:30 (Coffee) Break: 10:00 10:30 (Coffee) Break: 10:30 10:45
Break: 13:30 14:30 (Lunch) Break: 12:15 13:00 (Lunch) Break: 11:45 12:15 (Lunch) Coffee will be served in the Foyers of the session
Break: 16:30 - 17:00 (Coffee) Break: 15:00 - 15:30 (Coffee) Lunch boxes available in the Exhibition Hall on Level rooms on Levels 700 and 800.
800 as well as in the Foyers of rooms on Levels 700
Coffee and lunches will be served in the Foyers of Coffee and lunches will be served in the Foyers of and 800
the session rooms on Levels 700 and 800. the session rooms on Levels 700 and 800. Break: (Exhibition): 15:15 - 15:45 (Coffee)
38 39
Notes
Program Day by Day
40 41
Saturday, June 20, 2015 Saturday, June 20, 2015
Room 701 Room 713 Room 714 Room 715 Room 716 Room 717 Room 718 Room 801
Womens Issues in Predictive and diagnostic Factor VIII, IX and Rare

Thrombosis and Fibrinolysis Vascular Biology variables in thrombotic Lupus Anticoagulants Coagulation Disorders, Platelet Immunology
Haemostasis 09:00 - 11:00 09:00 - 11:00 disease 09:00 - 11:00 Part I 09:00 - 11:00
09:00 - 11:00 09:00 - 11:00 09:00 - 11:00
Coffee Break Coffee Break
Womens Issues in T&H Fibrinolysis Education Vascular Biology Predictive Variables Lupus Anticoagulants Factor VIII, IX and Rare Platelet Immunology
Education Session Session Education Session Education Session Education Session Coagulation Disorders, Education Session
11:20 - 12:20 11:20 - 12:20 11:20 - 12:20 11:20 - 12:20 11:20 - 12:20 Part I Education Session 11:20 - 12:20
11:20 - 12:20
Womens Issues in Lupus Anticoagulants Factor VIII, IX and Rare Platelet Immunology
Thrombosis and Fibrinolysis (contd) Vascular Biology (contd) Predictive Variables Coagulation Disorders,
12:20 - 13:20 12:20 - 13:20 (contd) (contd) (contd)
Haemostasis (contd) 12:20 - 13:20 Part I (contd) 12:20 - 13:20
12:20 - 13:20 12:20 - 13:30 12:20 - 13:20
Lunch Lunch
Exogenous Factors Factor XIII and Fibrinogen Plasma Coag Inhibitors Biorheology Education Pediatric/Neonatal T&H VWF Education Sessions Hemostasis & Malignancy
Education Sessions Education Sessions Education Sessions Sessions Education Session 14:30 - 15:30 Education Sessions
14:30 - 15:30 14:30 - 15:30 14:30 - 15:30 14:30 - 15:30 14:30-15:30 14:30 - 15:30
Exogenous Factors Factor XIII and Fibrinogen Plasma Coag Inhibitors Biorheology Session Pediatric/Neonatal T&H VWF Session Hemostasis & Malignancy
Session Session Sessions 15:30 - 16:30 Session 15:30 - 16:30 Session
15:30 - 16:30 15:30 - 16:30 15:30 - 16:30 15:30 - 16:30 15:30 - 16:30
Coffee Break Coffee Break
Pediatric/Neonatal T&H
Exogenous Factors Factor XIII and Fibrinogen Plasma Coag Inhibitors Biorheology Session Session (contd) VWF Session (contd) Hemostasis & Malignancy
Session (contd) Session (contd) Sessions (contd) (contd) 16:50 - 18:30
16:50 - 18:50 Session (contd)
16:50 - 18:15 16:50 - 18:50 16:50 - 18:50 16:50 - 18:50 16:50 - 18:50
42 43
Sunday, June 21, 2015 Sunday, June 21, 2015
Exhibit Plenary Room 701 Room 707 Room 713 Room 714 Room 715 Room 716 Room 717 Room 718 Room 801 Room 803A Room 803B Intercontinental
Hall D & E Hall G&F
Master
Class
7:00-7:50
Working Factor XI and Control of Factor VIII and Platelet

Group on Animal DIC the contact Anticoagulation IX, part 2 Physiology
Perioperative Models 08:00 - 10:00 system
T&H 08:00 - 10:00 08:00 - 10:00 08:00 - 10:00 08:00 - 10:00
08:00 - 10:00
08:00 - 10:00
Genomics
08:00 - 12:20 Coffee Break
10:00-10:20 Coffee Break 10:00-10:20 Coffee Break 10:00-10:20
Animal Models F XI & Contact Control of Anticoag Plt Physiology
BAT Standing DIC Education Education
Education Education Session Education
Committee Session Session Session
Session 10:20 - 11:20 10:20-11:20 Factor VIII and
10:30 - 11:30 10:20 - 11:20 10:20 - 11:20 IX, part 2 10:20 - 11:20
(contd) Plt Physiology
Animal Models F XI & Contact Control of Anticoag
DIC (contd) 10:20 - 12:20
(contd) (contd) (contd) (contd)
11:20 - 12:20 Career
11:20 - 12:20 11:20 - 12:20 11:20-12:20 11:20-12:20
Mentorship
Lunch Lunch 12:20 - 13:00 Lunch 12:20 - 13:00 Sessions
12:20 - 13:00 12:00-13:00
RtW/YIA
Reception
and Session WFH / Bayer WDT
13:00 - 15:00 13:00 - 15:00
Nurse
Forum
Coffee Break Coffee Break 15:00-15:30 Coffee Break 15:00-15:30
15:00-15:30
Special Special Special Special

Industry Industry Industry Industry
Symposia Symposia Symposia Symposia
15:30-17:30 15:30-17:30 15:30-17:30 15:30-17:30
Opening
Ceremony
18:15 - 19:15
WELCOME
RECEPTION
19:30 - 22:00
44 45
Monday, June 22, 2015 Monday, June 22, 2015
Exhibit Plenary Room 701 Room 705 Room 707 Room 709 Room 711 Room 713 Room 714 Room 715 Room 716 Room 717 Room 718 Room 801 Room Room Intercontinental
Hall D & E Hall G&F 803 A 803 B
Master
Class
7:00-7:50
OC OC OC OC
Late breaking OC OC OC OC Mechanical Acquired OC OC VWD OC OC OC
abstract session Atherosclerosis Endothelium Tissue factor Heparin-induced circulatory Disorders
Anti-platelets Reproductive
classification, Animal models Platelet Disorders Hemophilia
- Thrombosis and 08:00-09:15
and vessel wall factor VII I thrombocytopenia support and treatment I basic Issues subtypes I 08:00-09:15 08:00-09:15
clinical
Anticoagulation 08:00-09:15 08:00-09:15 08:00-09:15 devices 08:00-09:15
08:00-09:15 08:00-09:15
08:00-09:15
08:00-09:15
08:00-09:15 08:00-09:15
Coffee Break 09:15 - 09:45 Coffee Break 09:15 - 09:45

Presidential
Plenary
9:45-10:30
Break
SOA Hemophilia SOA SOA SOA Hijacking SOA Platelet SOA
SOA of proteolytic Perioperative
gene therapy; A Controversies in Extracorporeal Mechanisms of function and
Joint ISTH-WFH circulation in thrombosis mechanisms by dysfunction cardiovascular
VTE management pathogens complications
Symposium children
10:45 - 11:45 10:45 - 11:45 10:45 - 11:45 10:45 - 11:45
10:45 - 11:45 10:45 - 11:45 10:45 - 11:45
Lunch
Lunch 11:45 - 12:15 11:45 - 12:15 Lunch 11:45 - 12:15
Career
EXHIBITION Nurse Forum Mentorship
09:00 - 18:30 08:00 - 16:30 Sessions
Lunch 12:00-13:00
Symposia Lunch Symposia
12:15-13:45
12:15-13:45
OC
OC
OC NOACs in Venous OC OC OC Innate OC Megakaryocytes OC OC OC OC OC
clinical practice thromboembolism Factor VIII I Platelets OC Stroke and acquired Antiphospholipid Vitamin K Von Willebrand Hemophilia Management of Thrombophilia
kinases-I 14:00 - 15:15 Immunity antibodies I and antagonists Disease prophylaxis bleeding
14:00 - 15:15 epidemiology I 14:00 - 15:15 thrombopoiesis I 14:00 - 15:15
14:00 - 15:15 14:00 - 15:15 14:00 - 15:15 14:00 - 15:15 14:00 - 15:15 14:00 - 15:15 14:00 - 15:15
14:00 - 15:15 14:00 - 15:15
AS New AS AS AS AS AS
AS AS AS AS AS Coagulation,
alternatives for Antiphospholipid Modulation of Sickle cell Innovation and Platelets and Protease Genetic basis AS Obesity AS Womens issue
treating bleeding activated fibrinolysis, of platelet Fibrinogen bench to Microparticles in venous
disorders antibodies atherothrombosis disease Technology bacteria receptors immunity and disorders 15:45 - 17:15 bedside 15:45 - 17:15 thrombosis
15:45 - 17:15 15:45 - 17:15 15:45 - 17:15 15:45 - 17:15 15:45 - 17:15 inflammation
15:45 - 17:15 15:45 - 17:15 15:45 - 17:15 15:45 - 17:15 15:45 - 17:15
15:45 - 17:15
Posters with
refreshments
17:15 - 18:30
Technical Technical Technical Technical Technical

Sessions Sessions Sessions Sessions Sessions
18:30-20:00 18:30-20:00 18:30-20:00 18:30-20:00 18:30-20:00
46 47
Tuesday, June 23, 2015 Tuesday, June 23, 2015
Exhibit Plenary Room 701 Room 705 Room 707 Room 709 Room 711 Room 713 Room 714 Room 715 Room 716 Room 717 Room 718 Room 801 Intercontinental
Hall D & E Hall G & F
Master
Class
7:00-7:50
OC OC OC OC OC OC OC OC OC
Cancer and Immune Platelets OC Risk factors OC OC OC VTE
Microparticles Rare bleeding Antiphospholipid Pediatric Hemophilia
thrombosis thrombocytopenia Signal thrombosis for venous Factor VIII II TTP and PNH Inflammation epidemiology inhibitors
Basic I disorders antibodies II thrombosis I II
clinical I 08:00-09:15 08:00-09:15
Transduction I 08:00-09:15
08:00-09:15 08:00-09:15 08:00-09:15
08:00-09:15
08:00-09:15 08:00-09:15 08:00-09:15 08:00-09:15
08:00-09:15 08:00-09:15
Plenary
9:45-10:30
Break
SOA SOA SOA Evolving role SOA Opening SOA
SOA Thrombotic SOA vessels: From Genetics of
Longer-acting Making Platelets of the intrinsic
clotting factor Thrombocytopenic pathway
Atherothrombosis fibrinolysis to megakaryocytes
for Transfusion Purpura 10:45 - 11:45 interventions and platelets
concentrates 10:45 - 11:45 10:45 - 11:45
10:45 - 11:45 10:45 - 11:45 10:45 - 11:45 10:45 - 11:45
Lunch 11:45 - 12:15 Lunch 11:45 - 12:15

Career
EXHIBITION Mentorship
09:00 - 18:30 Sessions
Lunch 12:00-13:00
Symposia Lunch Symposia
12:15-13:45
12:15-13:45
OC OC OC OC OC OC OC
OC OC Tissue factor Platelets signal Coagulation Arterial vascular
OC OC Cancer and OC Megakaryocytes NOAC bleeding OC
VTE diagnosis VWD clinical Pediatric Hemophilia Acquired Disorders
thrombosis and risk factors and Platelets I
factor VII II transduction II factors, V, X, XIII disease hemostasis novel treatments clinical II Clinical II thrombopoiesis II management 14:00 - 15:15
14:00 - 15:15 14:00 - 15:15 14:00 - 15:15 14:00 - 15:15 14:00 - 15:15
14:00 - 15:15 14:00 - 15:15 14:00 - 15:15 14:00 - 15:15 14:00 - 15:15 14:00 - 15:15 14:00 - 15:15
Plenary
15:45-16:30
Break Break
AS AS Vascular AS Vessel AS Alloimmune AS AS
AS AS AS AS and AS
Cancer and AS progenitor cells Hemostasis and wall in health Tools for Non-vitamin K AS
thrombosis - Inhibitors - basic Mechanisms and vascular Developmental Endothelial cell autoimmune Platelet
of ITP hemostasis wall + signaling infection and disease evaluation of antagonist oral VWF
basic disease annexins platelet bleeding
signalling
anticoagulants
16:45 - 18:00 16:45 - 18:00 disorders 16:45 - 18:00
16:45 - 18:00 16:45 - 18:00 16:45 - 18:00 16:45 - 18:00
16:45 - 18:00 16:45 - 18:00 16:45 - 18:00 16:45 - 18:00 16:45 - 18:00
16:45 - 18:00
Posters with
refreshments
18:00 - 19:30
48 49
Wednesday, June 24, 2015 Wednesday, June 24, 2015
Exhibit Plenary Room 701 Room 705 Room 707 Room 709 Room 711 Room 713 Room 714 Room 715 Room 716 Room 717 Room 718 Room 801 Room Room Intercontinental
Hall D & E Hall G&F 803A 803B
Master
Class
7:00-7:50
OC OC
OC Late breaking OC OC OC OC OC
abstract session - OC Factor VIII
Blood
Heparin and Microparticles OC Non-vitamin OC OC Cancer and OC Risk Factors
K oral Platelets
Bleeding disorders, ITP Clinical and IX
coagulation
heparinoids II Platelets II anticoagulants
Contact system I
kinases II thrombosis VTE treatment I for venous
08:00-09:15 clinical III 08:00-09:15 thrombosis II
TTP 08:00-09:15 tests I 08:00-09:15 and surgery 08:00-09:15
08:00-09:15 08:00-09:15 08:00-09:15 08:00-09:15 08:00-09:15
08:00-09:15 08:00-09:15
08:00-09:15
Plenary
9:45-10:30
Break
SOA Controversies
SOA Treatment SOA Transplantation SOA SOA SOA in antiplatelet
of anticoagulant- Small thrombosis medicine in Platelets and Innovations Trauma-induced therapy for
associated a big deal? childhood Inflammation and Technology coagulopathy coronary artery
bleeding 10:45 - 11:45 10:45 - 11:45 disease
10:45 - 11:45 10:45 - 11:45 10:45 - 11:45 10:45 - 11:45
10:45 - 11:45
Lunch 11:45 - 12:15 Lunch Lunch 11:45 - 12:15

11:45 - 12:15 Career
EXHIBITION Mentorship
09:00 - 18:30 Sessions
Lunch Lunch Lunch 12:00-13:00
Symposia Symposia Lunch Symposia Symposia
12:15-13:45
12:15-13:45 12:15-13:45 12:15-13:45
OC Non- OC
Postthrombotic OC OC OC
vitamin K oral OC ADAMTS OC Natural OC Fibrinogen OC Fibrinolytic OC Platelet Contact OC Cancer and OC OC
anticoagulants syndrome, 13 anticoagulants and fibrin I system I Hemophilia B disorders system II Platelets and
thrombosis
VTE VWF I
thrombophilia bleeding cancer Epidemiology III
and reversal 14:00 - 15:15 14:00 - 15:15 14:00 - 15:15 14:00 - 15:15 14:00 - 15:15
14:00 -
14:00 - 15:15
basic I 14:00 - 15:15
14:00 - 15:15
14:00 - 15:15 14:00 - 15:15 15:15 14:00 - 15:15
14:00 - 15:15

AS AS
AS AS Determinants AS AS AS
Therapeutic of thrombus AS AS AS Pregnancy AS AS
Modulators Platelet Prevention of Platelet
management AS structure and Assay Membrane Platelet structure and related Factor V and Vascular thrombosis in function
of venous Factor VIII of fibrinolytic susceptibility challenges scrambling activation function bleeding regulation remodeling children testing assays
thrombosis activity complications 15:45 - 17:15 15:45 - 17:15
15:45 - 17:15 to lysis 15:45 - 17:15 15:45 - 17:15 15:45 - 17:15 15:45 - 17:15 15:45 - 17:15 15:45 - 17:15
15:45 - 17:15 15:45 - 17:15
15:45 - 17:15 15:45 - 17:15
Posters with
refreshments
17:15 - 18:30
50 51
Thursday, June 25, 2015 Thursday, June 25, 2015
Plenary Room 701 Room 705 Room 707 Room 709 Room 711 Room 713 Room 714 Room 715 Room 716 Room 717 Room 718 Room 801
Hall G&F
OC OC
Venous Risk factors OC OC OC Cancer and OC OC OC OC OC
Blood coagulation Fibrinogen and thrombosis Fibrinolytic OC Megakaryocytes and OC OC Regulation of Hemophilia joint Anti-platelet agents
thromboembolism for venous Factor VIII III Platelets III VWF II coagulation and
therapy II thrombosis - III tests II fibrin II basic II system II 08:00-09:15
thrombopoiesis III 08:00-09:15 08:00-09:15 fibrinolysis disease and clinical - clinical
08:00-09:15 08:00-09:15 08:00-09:15 08:00-09:15 08:00-09:15 08:00-09:15 08:00-09:15
08:00-09:15
08:00-09:15 08:00-09:15

Plenary
9:30-10:15
AS AS AS AS AS
AS AS AS AS Cancer and AS
Atherosclerosis, Chronic kidney Atherosclerosis: AS AS AS Unusual Inhibitors -
Novel anti-platelet Fibrinolysis in Protein C and Endothelial cell- thrombosis site venous
agents inflammation and disease and health and disease progression and Glycobiology Stroke
sepsis VTE models
ADAMTS13 clinical
cancer coagulation development 10:30-11:45 10:30-11:45 clinical 10:30-11:45 thrombosis
10:30-11:45 10:30-11:45 10:30-11:45 10:30-11:45 10:30-11:45 10:30-11:45
10:30-11:45 10:30-11:45 10:30-11:45 10:30-11:45
Highlights of ISTH
12:00 - 13:00
52 53
Notes
SSC and Educational Program
54 55
SSC PROGRAM SSC PROGRAM
RARE BLEEDING DISORDERS
Saturday, June 20, 2015 9:00-13:20 Moderator: Elena Santagostino (Italy)
Factor VIII and IX, part 1 Room 718

12:20 - 12:40 Update on afibrinogenemia and dysfibrinogenemia
Chairman: Guy Young (United States)
Philippe de Moerloose (Switzerland), Alessandro Casini (Switzerland)
12:40 - 13:00
PRO-RBDD project: Prospective evaluation of the intensity of bleeding
Co-chairs: Manuel Carcao (Canada), Danijela Mikovic (Serbia), Flora Peyvandi (Italy)
Steve Pipe (United States), Elena Santagostino (Italy), Mike Makris (United Kingdom)
episodes in patients with fibrinogen and FXIII deficiency
Flora Peyvandi (Italy)
09:00 - 09:15 Welcome and introduction 13:00 - 13:20 Discussion
Guy Young (United States)
Lupus anticoagulant/Phospholipid-dependent antibodies Room 716

PROJECT UPDATES
Moderators: Flora Peyvandi (Italy), Mike Makris (United Kingdom) Chairman: Bas de Laat (The Netherlands)
09:15 - 09:30 Standardization of post-registration surveillance Co-chairs: Tatsuay Atsumi (Japan), Maria Laura Bertolaccini (United Kingdom)
Katrien M. Devreese (Belgium), Rolf T. Urbanus (The Netherlands)
Flora Peyvandi (Italy)
Denis G. Wahl (France)
09:30 - 09:40 Prophylaxis in patients without inhibitors
Victor Blanchette (Canada), Kathelijn Fischer (The Netherlands) 09:00 - 09:01 Opening
09:40 - 09:50 Prophylaxis in patients with inhibitors 09:01 - 09:10 The effect of different types of reagents on LAC detection
Carmen Escuriola (Germany) Osamu Kumano (Japan)
09:50 - 10:00 Bleeding score in hemophilia 09:10 - 09:25 Multicenter study on cut-off values for solid phase assays
Maria Elisa Mancuso (Italy) Katrien M. Devreese (Belgium)
10:00 - 10:10 ITI definitions 09:25 - 09:35 Conformation of beta2GPI
Elena Santagostino (Italy) Leonie Pelkmans (The Netherlands)
10:10 - 10:20 Mild hemophilia definitions 09:35 - 09:55 Anti-beta2GPI IgA antibodies & anti-PT/PS antibodies
Mike Makris (United Kingdom) Maria Laura Bertolaccini (United Kingdom)
10:20 - 10:30 Inhibitor reporting standardization in previously treated patients
SATURDAY
09:55 - 10:10 Thrombin generation in APS
Alfonso Iorio (Canada)
10:30 - 10:40 Standardization of genetic assays for diagnosis of hemophilia
10:10 - 10:25 Unravelling the mechanism behind LAC
Vince Jenkins (Ireland)
Rolf T. Urbanus (The Netherlands)
10:40 - 11:00 Discussion
10:25 - 10:45 esistance to Annexin A5 anticoagulant activity is a biomarker for adverse
R
clinical outcomes
COFFEE BREAK Jacob H. Rand (United States), Lucia R. Wolgast (United States)
SSC PROGRAM
10:45 - 11:00 Domain I and risk stratification
EDUCATION SESSION Vittorio Pengo (Italy)
Moderators: Guy Young (United States), Manuel Carcao (Canada)
COFFEE BREAK
11:20 - 11:50 From Alexie Romanov to Stephen Christmas to 2015: What is different
about factor IX deficiency?
Elena Santagostino (Italy)
EDUCATION SESSION
11:50 - 12:20 What is the true incidence of inhibitors in haemophilia? 11:20 - 11:50 The activity of antiphospholipid antibodies in vitro and in vivo
Michael Soucie (United States) Philip G. de Groot (The Netherlands)
56 57
11:50 - 12:20
The antiphospholipid syndrome (APS), a clinicians perspective 10:30 - 10:45 Protamine-induced thrombocytopenia
Vittorio Pengo (Italy) Ted Warkentin (Canada)

SUBCOMMITTEE CONTINUES
COFFEE BREAK
12:20 - 12:35 Global anti-phospholipid syndrome score (GAPSS)
EDUCATION SESSION
12:35 - 12:50 APS scoring
Tatsuya Atsumi (Japan) 11:20 - 11:50 Platelet alloantigens in other tissues, and implications in immunohematology
Sentot Santoso (Germany)
12:50 - 13:05 LAC in APS patients on rivaroxaban
Deepa Arachchillage (United Kingdom) 11:50 - 12:20
New insights explaining the variability in platelet response to HIT antibodies
Yves Gruel (France)
13:05 - 13:19 Rivaroxaban in antiphospholipid syndrome
Hannah Cohen (United Kingdom)
ALLOIMMUNE THROMBOCYTOPENIA
13:19 - 13:20 Closing remarks
Moderators: Tamam Bakchoul (Germany), Sentot Santoso (Germany)
Bas de Laat (The Netherlands)
12:20 - 12:35
NAIT- Should surface plasmon resonance (SPR) and antibody titre be part
Platelet immunology Room 801 of routine investigations and reporting?
Gerald Bertrand (France)
Chairman: Yves Gruel (France)
12:35 - 12:50
A new alloantigen (Cab 4) carried by GPIbIX in a context of severe neonatal
Co-chairs: Donald Arnold (Canada), Tamam Bakchoul (Germany), Francois Mullier (Belgium) alloimmune thrombocytopenia
Sentot Santoso (Germany), Yoshiaki Tomiyama (Japan), Chris Ward (Australia)
Rachel Petermann (France)
09:00 - 09:10
Welcome 12:50 - 13:20 Re-cap of ongoing and new proposals
Donald Arnold (Canada) Donald Arnold (Canada)
AUTOIMMUNE AND DRUG-INDUCED ITP Vascular biology Room 714

Moderators: Donald Arnold (Canada), Yoshiaki Tomiyama (Japan)
Chairman: Rienk Nieuwland (The Netherlands)
SATURDAY
09:10 - 09:25 Recommendations for platelet autoantibody testing in ITP
Co-Chairs: Alexander Brill (United Kingdom), Elizabeth E. Gardiner (Australia)
Donald Arnold (Canada) Chris Gardiner (United Kingdom), Anna Randi (United Kingdom)
09:25 - 09:40 Immature platelet fraction measurement for the diagnosis of ITP Florance Sabatier (France), Pia Siljander (Finland)
Yoshiaki Tomiyama (Japan)
CIRCULATING ENDOTHELIAL PROGENITOR CELLS
09:40 - 09:55
Recommendations for cutoff values for positive results of DITP testing and
Moderators: Anna Randi (United Kingdom), Florence Sabatier (France)
sample materials
Tamam Bakchoul (Germany), Brian Curtis (United States)
09:00 - 09:20
From VSELs to endothelial progenitor cells: What is the perfect
SSC PROGRAM
vasculogenic cell?
HEPARIN-INDUCED THROMBOCYTOPENIA David Smadja (France)
Moderators: Chris Ward (Australia), Yves Gruel (France)
09:20 - 09:40
Blood outgrowth endothelial cells offer novel insights into von Willebrand
disease
09:55 - 10:15 tandardized protocol of Multiplate assay for HIT diagnosis; and results of a
S Richard Starke (United Kingdom)
national survey of functional testing
Chris Ward (Australia), Tamam Bakchoul (Germany) 09:40 - 10:00
Derivation of endothelial colony forming cells from pluripotent stem cells
Nuttan Prasain (United States)
10:15 - 10:30 5B9, a potential standard for HIT laboratory assays?
Yves Gruel (France)
58 59
RECEPTOR SHEDDING FROM PLATELETS IN THE INFLAMED VASCULATURE PREDICTIVE AND DIAGNOSTIC VARIABLES IN THROMBOTIC DISEASE
Moderators: Elizabeth E. Gardiner (Australia), Alexander Brill (United Kingdom) Moderators: Paul A. Kyrle (Austria), Gregoire Le Gal (Canada)
10:00 - 10:20 Platelets and the inflamed vasculature 09:05 - 09:20

Decision rules in suspected DVT and PE; towards personalized strategies
Paul Kubes (Canada) Geert-Jan Geersing (The Netherlands)
10:20 - 10:40
Mechanistic insights into platelet receptor shedding 09:20 - 09:35 Diagnosis of recurrent VTE
Yotis Senis (United Kingdom) Frederikus A. Klok (The Netherlands)
10:40 - 11:00
Glycoprotein Ib-alpha shedding and platelet clearance 09:35- 09:50 Diagnosing small clots: Subsegmental pulmonary embolism
Renhao Li (United States) Marc Carrier (Canada)
09:50- 10:15 Diagnosing small clots: Distal deep vein thrombosis

Marc Righini (Switzerland)
COFFEE BREAK
10:15- 11:00
On-going studies (ADJUST-DVT, THEIA, CLOT 3, D-dimer and pre-test
clinical probability score in cancer patients with suspected deep vein
EDUCATION SESSION thrombosis of the legs, 4D, PEGED)
Moderators: Rienk Nieuwland (The Netherlands)
arc Righini (Switzerland), Frederikus A. Klok (The Netherlands), Scott Stevens
M
(United States), Marcello Di Nisio (Italy), Clive Kearon (Canada)
11:20 - 11:50
Multiple applications of endothelial colony forming cells
Juan Melero-Martin (United States) COFFEE BREAK
11:50 - 12:20 Measurement of tissue factor in clinical samples
Nigel Mackman (United States) EDUCATION SESSION
Moderators: Marc C. Samama (France), Alexander C. Spyropoulos (United States)
MICROPARTICLES AND STANDARDIZATION

11:20- 11:50 Etiology in clinical research: Possibilities and limitations
Moderators: Pia Siljander (Finland), Chris Gardiner (United Kingdom)
Suzanne Cannegieter (The Netherlands)
12:20 - 12:40
Vesicle size approximation enables interlaboratory comparison of vesicle 11:50 - 12:20 Clinical prediction modelling: Dos and donts
measurements by flow cytometry Karel Moons (The Netherlands)
Rienk Nieuwland (The Netherlands)
12:40 - 13:00 Studies of the microparticle cargo and its functional components
Eric Boilard (Canada)
PREDICTIVE VARIABLES IN THROMBOTIC DISEASE
SATURDAY
Moderators: Suzanne Cannegieter (The Netherlands), Shinya Goto (Japan)
13:00 - 13:20
Progress of endothelial microparticle detection and characterization by flow
cytometry 12:20 - 12:40
Extracellular nucleic acids as potential biomarkers of thrombosis and
Romaric Lacroix (France) cardiovascular disease
Hector Cabrera-Fuentes (Germany)
Predictive and diagnostic variables in thrombotic disease Room 715 12:40 - 13:00 he use of a bivariate model of thrombosis and bleeding in antithrombotic
T
trials
SSC PROGRAM
Chairman: Paul A. Kyrle (Austria) Alexander C. Spyropoulos (United States)
Co-chairs: Suzanne Cannegieter (The Netherlands), Shinya Goto (Japan) 13:00 - 13:20
Should we shorten or even skip VTE prophylaxis after day case surgery
Karel Moons (The Netherlands), Marc C. Samama (France) and/or surgery with enhanced recovery?
Alexander C. Spyropoulos (United States) Marc C. Samama (France)
13:20 - 13:30 Closing remarks

09:00 - 09:05 Welcome, information on the new scope of the subcommittee

60 61
10:40 - 11:00
Management of thrombotic thrombocytopenic purpura in pregnancy
Womens issues in thrombosis and haemostasis Room 701
Marie Scully (United Kingdom)
Chairman: Rezan Abdul-Kadir (United Kingdom)

COFFEE BREAK
Co-chairs: Claudia Chi (Singapore), Hannah Cohen (United Kingdom)
Ida Martinelli (Italy), Saskia Middeldorp (The Netherlands)
Maha Othman (Canada), Rochelle Winikoff (Canada) EDUCATION SESSION
Moderators: Rezan Abdul-Kadir (United Kingdom), Andra James (United States)
WELCOME AND INTRODUCTION

Moderator: Rezan Abdul-Kadir (United Kingdom) 11:20 - 11:45
Preeclampsia the role of haemostasis in its pathophysiology
Chris Gardiner (United Kingdom)
09:00 - 09:05 Outline of the SSC and overview of activities 11:45 - 12:20
Women and bleeding disorders the role of bleeding assessment tools
Rezan Abdul-Kadir (United Kingdom) Paula James (Canada)
09:05 - 09:10 Report on the Womens Health Issues in Thrombosis and Hemostasis
Symposium 2015 HEMOSTATSIS ISSUES
Benjamin Brenner (Israel) Moderators: Rochelle Winikoff (Canada), Peter Kouides (United States)
UPDATES ON REGISTRIES AND PROJECTS 12:20 - 12:30

Women and platelet function defects
Moderators: Saskia Middeldorp (The Netherlands), Maha Othman (Canada)
Sarah OBrien (United States)
12:30 - 12:45
Can carriers of hemophilia with normal factor levels bleed?
09:10 - 09:15 NOAC and pregnancy: Registry Robert Sidonio (United States)
Saskia Middeldorp (The Netherlands)
12:45 - 13:00 Postpartum hemorrhage in carriers of hemophilia and women with VWD
09:15 - 09:20 hrombophilia screening after recurrent failures in assisted reproductive
T Jeroen Eikenboom (The Netherlands)
techniques: Registry
Elvira Grandone (Italy) 13:00 - 13:15
Abnormal uterine bleeding in adolescents: Patterns, diagnoses and clinical
outcomes
09:20 - 09:25
Thrombophilia and outcomes of assisted reproduction technologies: Sum- Ayesha Zia (United States)
mary of systematic review and meta-analysis
Marcello Di Nisio (Italy) 13:15 - 13:20
Foundation for women and girls with blood disorders (FWGBD)
Ann-Marie Nazzaro (United States)
09:25 - 09:35 YEARS diagnostic study in PE
SATURDAY
Menno Huisman (The Netherlands)
09:35 - 09:45
The use of thrombo-elastography in pregnancy: Registry Fibrinolysis Room 713
Maha Othman (Canada)
Chairman: Nicola J. Mutch (United Kingdom)
09:45 - 09:55
Obstetric issues in mothers of children with severe protein C deficiency
Adrian Minford (United Kingdom) Co-chairs: Jonathan H. Foley (United Kingdom), Krasimir Kolev (Hungary)
Craig Thelwell (United Kingdom), Shirley Uitte de Willige (The Netherlands)
09:55 - 10:00 Discussion Waander van Heerde (The Netherlands), Paul Y. Kim (Canada)
SSC PROGRAM
THROMBOSIS ISSUES 09:00 - 09:05 Opening remarks & announcements
Moderators: Hannah Cohen (United Kingdom), Ida Martinelli (Italy) Nicola J. Mutch (United Kingdom)

10:00 - 10:20 Management of non-vitamin K oral anticoagulants (NOAC) in women of
childbearing age
STANDARDIZATION OF FIBRINOLYTIC PROTEINS
Deepa Arachchillage (United Kingdom)
09:05 - 09:15 Standardization of D-dimer
10:20 - 10:40
Management of obstetric antiphospholipid syndrome: New developments Colin Longstaff (United Kingdom)
Beverley Hunt (United Kingdom)
62 63
09:15 - 09:25
Development of standards for plasmin, streptokinase, ancrod and batroxoban Pediatric and neonatal thrombosis and hemostasis Room 717
Craig Thelwell (United Kingdom)
09:25 - 09:40 Standardization of TAFI (CPU) Chairman: Anthony K. Chan (Canada)

Craig Thelwell (United Kingdom)
Co-Chairs: Mariana Bonduel (Argentina), Leonardo R. Brandao (Canada)
Elizabeth A. Chalmers (United Kingdom), Neil Goldenberg (United States)
DIVERSE ROLES OF PLASMIN Shoshana Revel-Vilk (Israel), Heleen van Ommen (The Netherlands)
09:40 - 10:00 Plasmin and von Willebrand factor in thrombotic thrombocytopenic purpura EDUCATION SESSION
Claudia Tersteeg (The Netherlands)
Moderators: Anthony Chan (Canada), Elizabeth Chalmers (United Kingdom)
10:00 - 10:20
Plasmin generation by staphylokinase during skin infections with
Staphylococcus aureus 14:30-15:00 Direct oral anticoagulants: Current status in pediatric trials
Marijke Peetermans (Belgium) Heleen van Ommen (The Netherlands)
15:00-15:30 Antithrombin concentrate: What is the evidence on its use?

IMPACT OF CELLS ON FIBRINOLYSIS Paul Monagle (Australia)
10:20 - 10:40
Effect of hematocrit on clot structure and resistance to lysis
SUBCOMMITTEE SESSION 1
Paraskevi Untiveros (United Kingdom)
Moderators: Anthony Chan (Canada), Heleen van Ommen (The Netherlands)
10:40 - 11:00
Neutrophils as key modulators of fibrin structure and lysis in thrombi
Imre Varj (Hungary) 15:30-15:50 Report from catheter-related arterial thrombosis working group
Manuela Albisetti (Switzerland)
COFFEE BREAK 15:50-16:10 Report from radiological diagnosis working group
Leonardo Brandao (Canada)
EDUCATION SESSION
16:10-16:30 Report from pulmonary embolism working group
11:20 - 11:50 Influence of alpha-2AP on the pathogenesis of stroke Neil Goldenberg (United States)
Guy Reed (United States)
11:50 - 12:20 Plasminogen activation in the brain

Moderators: Leonardo Brandao (Canada), Neil Goldenberg (United States)
Manuel Yepes (United States)
SATURDAY
16:50-17:05 Report from VTE prevention working group
INHIBITORS OF FIBRINOLYSIS IN DISEASE Brian Branchford (United States), Julie Jaffray (United States)
12:20 - 12:40 Thrombolysis induced by a diabody against PAI-1 and TAFI 17:05-17:20 RCT: Do we need anti-Xa monitoring for use of enoxaparin?
Paul Declerck (Belgium) Mihir Bhatt (Canada)
12:40 - 13:00 Cell-free DNA modulates clot structure and impairs fibrinolysis in sepsis 17:20-17:35 Management of coagulopathy in children with liver disease
Travis Gould (Canada) Maria Magnusson (Sweden)
SSC PROGRAM
13:00 - 13:20
Measurement of active CPU (TAFIa) in samples from patients with acute 17:35-17:50 Purpura fulminans registry
coronary syndrome Victoria Price (Canada)
Dorien Leenaerts (Belgium) 17:50-18:00 DIC registry
Jecko Thachil (United Kingdom)
18:00-18:10 Management guide: CVL related thrombosis

Ketan Kulkarni (Canada)
18:10-18:20 Antithrombin registry

Riten Kumar (United States)
64 65
18:20-18:25 Menorrhagia in adolescence 18:00 - 18:15
Assessment of platelet-dependent coagulation and fibrinolysis under flow
Ayesha Zia (United States) Paola van der Meijden (The Netherlands)
18:25-18:30 Conclusion 18:15-18:30

Platelet adhesion and aggregation under disturbed blood flow: A focus on
Anthony Chan (Canada) the role of pulsatility
Pierre Mangin (France)
Biorheology Room 716 18:30 - 18:50 Discussion: Challenges and needs for standardization of flow assays
Chairman: Keith Neeves (United States)

Exogenous hemostatic factors Room 713
Co-chairs: Judith Cosemans (The Netherlands), David N. Ku (United States)
Pierre Mangin (France), Owen J. Mccarty (United States) Chairman: Ivo Francishetti (United States)
Mitsuhiko Sugimoto (Japan), Erik Westein (Australia)
Co-Chairs: Tur-Fu Huang (Taiwan), Manjunatha R. Kini (Singapore)
Francis Markland Jr. (United States), Robson Monteiro (Brazil)
JOINT BIORHEOLOGY AND PLATELET PHYSIOLOGY EDUCATION SESSION Kenneth J. Clemetson (Switzerland)

14:30 - 15:00
Bioreactors for the study of the biophysical mechanisms that regulate EDUCATION SESSION
platelet function?
Jos Lopez (United States) 14:30 - 15:00 Exogenous factor XIa inhibitors from snake venoms
Manjunatha R. Kini (Singapore)
15:00 - 15:30
Bioreactors for the study of the biophysical mechanisms that regulate
platelet function? 15:00 - 15:30 Hematophagy, neutrophils and contact pathway
Shaun Jackson (Australia) Ivo Francischetti (United States)
15:30 - 16:30
Joint Biorheology & VWF session on acquired von Willebrand syndrome in
room 718 SUBCOMMITTEE SESSION
Jorge A. Di Paola (United States), Keith Neeves (United States)
15:30 - 15:50 Structure of Pseutarin-C, a snake venom prothrombin activator
COFFEE BREAK Jim Huntington (United Kingdom)
VWF-MEDIATED MECHANISMS IN COMPLEX AND PATHOLOGICAL FLOWS 15:50 - 16:10

Rational strategy applied to a tick salivary FXa inhibitor in order to develop
Moderators: Mitsuhiko Sugimoto (Japan), Pierre Mangin (France) a potential antitumor drug candidate

SATURDAY
Ana Marisa Chudzinski-Tavassi (Brazil)
16:50 - 17:05
Biomechanical regulation of VWF and thrombus formation under complex 16:10 - 16:30
Exogenous inhibitors as tools for the study of new players in haemostasis
flow conditions and thrombosis
Erik Westein (Australia) Robson D. Monteiro (Brazil)
17:05 - 17:20
From single VWF molecules to collective aggregates: Towards an
understanding of thrombus formation COFFEE BREAK
Matthias Schneider (United States)
16:50 - 17:10 Exogenous hemostatic factors as tools in platelet research
SSC PROGRAM
17:20 - 17:35
Relative roles of VWF and platelets in formation of occlusive arterial Kenneth J. Clemetson (Switzerland)
thrombosis 17:10 - 17:30 Anfibatide and other exogenous platelet GPIb antagonists
David N. Ku (United States)
Heyu Ni (Canada)
17:30 - 17:50
The second generation of platelet GPIIb/IIIa antagonists derived from snake
NOVEL FLOW-DEPENDENT MECHANISMS OF PLATELET FUNCTION, venom disintegrins
COAGULATION AND FIBRINOLYSIS Tur-Fu Huang (Taiwan)
Moderators: Erik Westein (Australia), Judith Cosemans (The Netherlands)
17:50 - 18:10
Towards an understanding of the cellular and molecular events that underlie
17:45 - 18:00 Shear effects on platelet surface receptor shedding quick wound healing in salamanders
Ren Lai (China)
66 Elizabeth E. Gardiner (Australia) 67
18:10 - 18:15 Closing remarks 18:10 - 18:30
New guidance proposals: Pediatric VTE and intracranial hemorrhage
Ivo Francischetti (United States) Joseph S. Palumbo (United States), Jeffrey Zwicker (United States)
18:30 - 18:50 Update on new studies: Longheva registry; Prophylaxis

Hemostasis and malignancy Room 801 Pieter W. Kamphuisen (The Netherlands), Marc Carrier (Canada)
Chairman: Alok A. Khorana (United States) Plasma coagulation inhibitors Room 715
Co-Chairs: Marc Carrier (Canada), Howard Liebman (United States)
Chairman: Richard Marlar (United States)
Nigel Mackman (United States), Simon I. Noble (United Kingdom)
Ingrid Pabinger (Austria) Joseph S. Palumbo (United States)
Co-chairs: Ian Jennings (United Kingdom), Jun Teruya (United States)
Hiroko Tsuda (Japan)
EDUCATION SESSION
Moderators: Marc Carrier (Canada), Alok A. Khorana (United States) PLASMA COAGULATION INHIBITORS: RELATIONSHIP OF PHENOTYPE,
PLASMA LEVELS AND CLINICAL PHENOTYPE (THROMBOSIS)
14:30 - 15:00 Occult VTE: Do new trial results change practice?
Moderator: Richard Marlar (United States)
Marc Carrier (Canada)
15:00 - 15:30
Qualitative research into cancer associated thrombosis: Who needs it? 14:30 - 15:00 Molecular defects in protein S
Simon I. Noble (United Kingdom) Pieter H. Reitsma (The Netherlands)
15:00 - 15:30 Comparison of phenotype and genotype for AT, PC and PS

SUBCOMMITTEE SESSION 1 Anna Pavlova (Germany)
Moderators: Nigel Mackman (United States), Ingrid Pabinger (Austria)
15:30 - 16:10 Platelets, hemostatic factors and malignancy Moderators: Jun Teruya (United States), Richard Marlar (United States)
Ingrid Pabinger (Austria), Nigel Mackman (United States), Joseph S. Palumbo (United
States)
15:30 - 15:45 Current project: Mutation repository
16:10 - 16:30
Predicting recurrent VTE: New biomarkers and risk factor analyses from Richard Marlar (United States)
CATCH
15:45 - 16:00 Current project: Protein S testing
Alok A. Khorana (United States)
Ian Jennings (United Kingdom)
16:00 - 16:10 Current project: Racial differences
SATURDAY
COFFEE BREAK Hiroko Tsuda (Japan)
SUBCOMMITTEE SESSION 2 16:10 - 16:15

Manuscript progress for clinical testing for AT, PC, PS and APC-R: Protein C
Moderators: Jeffrey Zwicker (United States), Cihan Ay (Austria) Steve Kitchen (United Kingdom)
16:15 - 16:20
Manuscript progress for clinical testing for AT, PC, PS and APC-R: Protein S
16:50 - 17:10 Hypercoagulation screening as a marker of thrombosis and poor disease Richard Marlar (United States)
prognosis in cancer patients: The HYPERCAN prospective study
SSC PROGRAM
Marina Marchetti (Italy), Anna Falanga (Italy) 16:20 - 16:25
Manuscript progress for clinical testing for AT, PC, PS and APC-R:
Antithrombin
17:10 - 17:25 Incidental VTE: Emerging data TBD
Casey OConnell (United States)
16:25 - 16:30
Manuscript progress for clinical testing for AT, PC, PS and APC-R: APC
17:25 - 17:40 Incidental VTE: SSC guidance statement resistance
Marcello Di Nisio (Italy) Richard Marlar (United States)
17:40 - 18:00 Treating CAT: Indirect comparison of anticoagulants
Cihan Ay (Austria), Florian Posch (Australia)
18:00 - 18:10 Coagulopathy and prostate cancer

68 69
COFFEE BREAK JOINT BIORHEOLOGY & VWF SESSION ON ACQUIRED VON WILLEBRAND
SYNDROME
16:50 - 17:10 Other plasma Inhibitors: Review of other inhibitors Moderators: Jorge A. Di Paola (United States), Keith Neeves (United States)
Jun Teruya (United States)
17:10 - 17:25 Other plasma Inhibitors: Clinical work on heparin cofactor II 15:30 - 15:45 Flow mediated interactions of VWF and ADAMTS13: Shear ecstasy
Jun Teruya (United States) David Lillicrap (Canada)
15:45 - 16:00 Acquired von Willebrand syndrome in patients with VAD or ECMO
17:25 - 17:40 Other plasma Inhibitors: Clincal work on TFPI
Barbara Zieger (Germany)
17:40 - 17:50 Comparative schemes for thrombophilia testing by region-country: UK 16:00 - 16:15 Effects of high shear millisecond exposure on platelets
Steve Kitchen (United Kingdom) David Schmidtke (United States)
17:50 - 18:00
Comparative schemes for thrombophilia testing by region-country: Europe 16:15 - 16:30 Discussion for speakers and proposed AWS working group
Piet Meijer (The Netherlands)
18:00 - 18:10
Comparative schemes for thrombophilia testing by region-country: Japan COFFEE BREAK
Hiroko Tsuda (Japan)
18:10 - 18:20 Comparative schemes for thrombophilia testing by region-country: India

LABORATORY AND CLINICAL UPDATES
Moderators: Frank W. Leebeek (The Netherlands), Alberto Tosetto (Italy)
TBD
18:20 - 18:30
Comparative schemes for thrombophilia testing by region-country: Australia 16:50 - 17:05 Update of VWF functional assays
TBD Sandra Haberichter (United States)
18:30 - 18:40
Comparative schemes for thrombophilia testing by region-country: United 17:05 - 17:20 ADAMTS13 assays, the need for multicenter studies
States Johanna A. Kremer Hovinga (Switzerland), Koichi Kokame (Japan)
Dorothy Adcock (United States)
17:20 - 17:35
Development and validation of assessment tools for clinical trials in VWD
18:40 - 18:45 Summary of schemes Paula James (Canada), Alberto Tosetto (Italy)
Richard Marlar (United States)
18:45 - 18:50 Conclusions STUDYING VWF AND VWD UNDER FLOW

Moderators: Johanna A. Kremer Hovinga (Switzerland), Daniel J. Hampshire (United Kingdom)
Von Willebrand factor Room 718
SATURDAY
17:35 - 17:50 Studying VWF mutations under flow
Chairman: Jorge A. Di Paola (United States)
Maria Brehm (Germany)
17:50 - 18:05 Studying VWD with microfluidic devices

Co-chairs: Sandra Haberichter (United States), Daniel J. Hampshire (United Kingdom)
Chris Ng (United States)
Koichi Kokame (Japan), Johanna A. Kremer Hovinga (Switzerland)
Frank W. Leebeek (The Netherlands), Alberto Tosetto (Italy)
VISUALIZING VWF
EDUCATION SESSON Moderators: Koichi Kokame (Japan), Sandra Haberichter (United States)
SSC PROGRAM
Moderators: Jorge A. Di Paola (United States)
18:05 - 18:20 VWF in megakaryocytes
14:30 - 15:00 Factor VIII and VWF, rekindling a longstanding relationship Walter Kahr (Canada)
Peter Lenting (France) 18:20 - 18:35
Optimization of immunocytochemical staining and high resolution imaging
15:00 - 15:30 ADAMTS13 deficiency, TTP and beyond of VWF in HEK293 cells
Johanna A. Kremer Hovinga (Switzerland) Simon Webster (United Kingdom)
18:35 - 18:50 Visualizing VWF exocytosis

Jeroen C. Eikenboom (The Netherlands)
70 71
Factor XIII and fibrinogen Room 714

Sunday, June 21, 2015 8:00-12:20
Chairman: Helen Philippou (United Kingdom) Disseminated Intravascular Coagulation (DIC) Room 715
Co-Chairs: Zsuzsa Bagoly (Hungary), Matthew J. Flick (United States) Chairman: Jecko Thachil (United Kingdom)
Vytautas Ivaskevicius (Germany), Marlien Pieters (South Africa)
Verena Schroeder (Switzerland), Alisa S. Wolberg (United States) Co-Chairs: Marcello Di Nisio (Italy), Satoshi Gando (Japan)
Takashi Ito (Japan), Bernd Jilma (Austria)
Shinichiro Kurosawa (United States), Sacha Zeerleder (The Netherlands)
EDUCATION SESSON
14:30 - 15:00 Roles of the alpha chains of fibrinogen SUBCOMMITTEE SESSION 1

Leonid Medved (United States)
08:00 - 08:20 DIC in obstetrical disorders
15:00 - 15:30 A historic recollection of factor XIII research
Offer Erez (Israel)
Aki Ichinose (Japan)
08:20 - 08:40 DAMPS and DIC in sepsis
Patricia Liaw (Canada)
SUBCOMMITTEE SESSION
08:40 - 09:00 Sepsis, thrombosis and organ injury
15:30 - 15:50 Standardisation of turbidity and fibrinolysis measurements Hala Chabaan (United States)
Marlien Pieters (South Africa)
09:00 - 09:20
Hyperfibrinolytic afibrinogenemia in overt DIC
15:50 - 16:10 FXIII-B standardisation update Bernd Jilma (Austria)
va Katona (Hungary), Verena Schroeder (Switzerland)
09:20 - 09:40 Where to use thrombomodulin and antithrombin in DIC?
16:10 - 16:30 New insights into automated fibrinogen Clauss assays Toshiaki Iba (Japan)
Sanj Raut (United Kingdom)
COFFEE BREAK COFFEE BREAK

16:50 - 17:15 Fibrinogen and factor XIII in chronic inflammation
Matthew J. Flick (United States) EDUCATION SESSION
SATURDAY
17:15 - 17:40
Fibrinogen density decreases slightly and fiber stiffness decreases strongly 10:20 - 10:50 Zebrafish modelling in DIC
with increasing fibrin fiber diameter Jordan Shavit (United States)
Martin Guthold (United States)
10:50 - 11:20 Management of DIC in a critical care unit
17:40 - 18:05 Novel functions of fibrin(ogen) in liver repair and fibrosis Jerrold Levy (United States)
James P. Luyendyk (United States)
18:05 - 18:30 The role of crosslinking in fibrin structure and function SUBCOMMITTEE SESSION 2
Robert Arins (United Kingdom)
SSC PROGRAM
18:30 - 18:50
A ten year genotype-clinical phenotype assessment of fibrinogen disorders 11:20 - 11:40 DIC in trauma
from Bonn Satoshi Gando (Japan)
Vytautas Ivaskevicius (Germany)
11:40 - 12:00
Fibrin-related markers - current status and further prospects in the detec-
tion of in vivo fibrin formation and dissolution
Carl-Eric E. Dempfle (Germany)
12:00 - 12:20 International DIC survey and call for DIC registry
Marcello Di Nisio (Italy)
72 73
11:30 - 11:45 Overview of chromogenic assay basics
Factor VIII and IX, part 2 Room 718
Kenneth Friedman (United States)
Chairman: Guy Young (United States) 11:45 - 12:00 Implementation of the chromogenic assay into the clinical lab
Richard Ko (United States)
Co-chairs: Manuel Carcao (Canada), Danijela Mikovic (Serbia), Flora Peyvandi (Italy)
Steven Pipe (United States), Elena Santagostino (Italy) 12:00 - 12:20 Discussion
Mike Makris (United Kingdom)
Factor XI and the contact system Room 716

LABORATORY ISSUES 1
Chairman: Jonas Emsley (United Kingdom)
Moderators: Steven Pipe (United States), Elena Santagostino (Italy)
Co-Chairs: Jose W. Govers-Riemslag (The Netherlands), Christine Mannhalter (Austria)
08:00 - 08:15 Update on Nijmegen groups high sensitivity inhibitor assay Joost Meijers (The Netherlands), James Morrissey (United States)
Bert Verbruggen (The Netherlands) Ophira Salomon (Israel), Evi X. Stavrou (United States)
08:15 - 08:30
Inhibitor measurement using SMIA: A new approach in inhibitor measurement
Sanj Raut (United Kingdom) ACTIVATORS AND BASIC SCIENCE OF FXI AND THE CONTACT SYSTEM
08:00 - 08:30
Propagation of blood coagulation by extracellular nucleosomes/neutrophil
08:40 - 08:55 Establishment of the 5th International Standard for FIX extracellular traps
Elaine Gray (United Kingdom) Bernd Engelmann (Germany)
08:30 - 08:50
Structure of contact factors
08:55 - 09:10 Update on EAHAD coagulation factor variant genotype database
Keith Gomez (United Kingdom) Jonas Emsley (United Kingdom)
08:50 - 09:00
The factor XII registry database
Ammar Majeed (Sweden)
09:20 - 09:40 IU vs %: Clearing up the confusion and a proposal for a position paper 09:00 - 09:30 Driving plasminogen activation by factor XIIa
Steve Kitchen (United Kingdom) Nicola J. Mutch (United Kingdom)
09:40 - 09:50
WAPPS Project (Web-accessible population pharmacokinetics service) 09:30 - 10:00 Kininogen, overlooked but not forgotten
Alfonso Iorio (Canada) Keith McCrae (United States)
SATURDAY
COFFEE BREAK
COFFEE BREAK
EDUCATION SESSON
CLINICAL ISSUES
Moderators: Manuel Carcao (Canada), Mike Makris (United Kingdom) 10:20 - 10:50
Autoantibodies to factor XII and kininogens in patients with recurrent
pregnancy loss
10:20 - 10:45 Moderate hemophilia update Toshitaka Sugi (Japan)
SSC PROGRAM
Kathelijn Fischer (The Netherlands)
10:50 - 11:20
Effect of plant inhibitors of the contact system on a mouse thrombosis
10:45 - 11:10 Clinical use of extended half-life factor products model
Guy Young (United States) Maria Luiza Vilela Oliva (Brazil)
LABORATORY ISSUES 2 INHIBITORS OF FXI AND THE CONTACT SYSTEM: SAFER

Moderators: Steven Pipe (United States), Guy Young (United States) ANTICOAGULATION
11:10 - 11:30
Extended half-life factors and laboratory assays--overview of the problem 11:20 - 11:40 An update on factor XI structure function relationships
Steven Pipe (United States) David Gailani (United States)
74 75
11:40 - 12:00
Antisense reduction of FXI for thromboprophylaxis: A novel therapeutic 08:20 - 08:40
Position statement on the methods for the study of platelet secretion
approach Diego Mezzano (Chile)
Sanjay Bhanot (United States)
08:40 - 09:00 Position statement on the laboratory monitoring of P2Y12 inhibitors
Andrew L. Frelinger III (United States)
12:00 - 12:20
Open discussion on topics of factor XI and the contact system that are now
09:00 - 09:10
Prospective evaluation of the bleeding phenotype in PT-VWD to support
very current and relevant
evidence-based diagnosis and management
Joost Meijers (The Netherlands)
Working Group on Perioperative Thrombosis and Hemostasis Room 707 09:10 - 09:30 The measurement of platelet dimensions: Methods and clinical use
Patrizia Noris (Italy)
Chairman: James Douketis (Canada)
09:30 - 10:00 RNA signatures in platelets from cancer patients
Thomas Wurdinger (The Netherlands)
Moderators: Jim Douketis (Canada), Jerrold Levy (United States)
08:00 - 08:10 Working group on perioperative thrombosis and hemostasis COFFEE BREAK
James Douketis (Canada)
JOINT PLATELET PHYSIOLOGY AND BIORHEOLOGY EDUCATIONAL SESSION
08:10 - 08:30 Management of patients on DAPT who need urgent or elective surgery
Pierre Albaladejo (France) Moderators: Paolo Gresele (Italy), Owen McCarty (United States)
08:30 - 08:50 Management of patients on NOACs who need urgent reversal for surgery 10:20 - 10:50
Bioreactors for megakaryocyte studies and platelet formation: Where do we
Jerrold Levy (United States)
stand?
08:50 - 09:00 Discussion Jonathan Thon (United States)
10:50 - 11:20 ioreactors for megakaryocyte studies and platelet formation: Where do we
B
09:00 - 09:20 Management of perioperative bleeding
stand?
Marc C. Samama (France)
Alessandra Balduini (Italy)
09:20 - 09:40
What are the landmark studies (completed and planned) in perioperative
anticoagulant management? SUBCOMMITTEE CONTINUED
Alexander C. Spyropoulos (United States)
Moderators: Paul Harrison (United States), Diego Mezzano (Chile)
09:40 - 10:00 Panel discussion
11:20 - 11:50
The use of platelets in regenerative medicine: Contribution of platelets to
SATURDAY
vascular and tissue remodelling
Platelet physiology Room 801
Harald Langer (Germany)
Chairman: Paolo Gresele (Italy) 11:50 - 12:20 he use of platelets in regenerative medicine: Use of PRP for Achilles ten-
T
Co-Chairs: Hans Deckman (Belgium), Andrew L. Frelinger III (United States)
don rupture and burn injuries
Paul Harrison (United Kingdom), Diego Mezzano (Chile) Paul Harrison (United Kingdom)
Andrew D. Mumford (United Kingdom), Patrizia Noris (Italy)
SSC PROGRAM
Animal, cellular and molecular models of thrombosis Room 714
Moderators: Jim Douketis (Canada), Jerrold Levy (United States)
Chairman: Susan Smyth (United States)
SUBCOMMITTEE SESSION
Moderators: Paolo Gresele (Italy), Hans Deckmyn (Belgium) Co-Chairs: Cecile V. Denis (France), Jose A. Diaz (United States)
Tom Knudsen (Denmark), Leslie Parise (United States)
08:00 - 08:10 Overview of platelet physiology SSC and projects Denise Sabatino (United States), David Motto (United States)
Paolo Gresele (Italy)
08:00 - 08:20 Session introduction
08:10 - 08:20 BAT in IPFD study Susan Smyth (United States), Jose A. Diaz (United States)
Paolo Gresele (Italy), Paul Harrison (United Kingdom)
08:20 - 08:40 Animal Model of VT: Where we are
Jose A. Diaz (United States)
76 77
08:40 - 09:00 The use of IVC stenosis model in VT PART 2: NGS IN DIAGNOSTICS
Steve Grover (United States) Moderators: Anne Goodeve (United Kingdom), Walter Kahr (Canada)
09:00 - 09:20 The use of femoral vein electrolytic model in VT 09:15 - 09:30 Coagulation factor variant database - an update
Brian Cooley (United States) Daniel J. Hampshire (United Kingdom)
09:20 - 09:40 The use of IVC models in VT (Ligation - EIM - RVT) 09:30 - 09:45 Challenges in the interpretation of variants from next generation sequencing
Jose A. Diaz (United States) Andrew Paterson (Canada)
09:40 - 10:00 Open Discussion 09:45 - 10:00 Discussion: Sharing sequencing data All
COFFEE BREAK COFFEE BREAK
EDUCATION SESSON EDUCATION SESSION

Moderators: Pieter H. Reitsma (The Netherlands), Paul Bray (United States)
10:20 - 11:00 VWF and NETs in venous thrombosis

Denisa Wagner (United States) 10:20 - 10:50
Statistical and methodological challenges for gene discovery by NGS
Ernest Turro (United Kingdom)
11:00 - 11:30 Role of P-selectin in venous thrombosis
Tom Wakefield (United States) 10:50 - 11:20 Inherited platelet disorders
Walter Kahr (Canada)
11:30 - 11:50 Insight into the role of fibrin in VT animal models
Alisa Wolberg (United States)
REPORTING OF CLINICAL VARIANTS
11:50 - 12:20 Insight into the role of tissue factor in VT animal models Moderators: Kathleen Freson (Belgium), Daniel Bellissimo (United States)
Nigel Mackman (United States)
11:40 - 12:00 International guidelines to annotate pathogenic variants
Genomics in thrombosis and hemostasis Room 701 Kathleen Freson (Belgium), Daniel Bellissimo (United States)
12:00 - 12:20 New large control data: Opportunities & pitfalls

Chairman: Willem H. Ouwehand (United Kingdom)
Karyn Megy (United Kingdom), Daniel J. Hampshire (United Kingdom)
Co-Chairs: Paul Bray (United States), Kathleen Freson (Belgium)
Anne Goodeve (United Kingdom), Michele P. Lambert (United States)
Control of anticoagulation Room 717
SATURDAY
Pieter H. Reitsma (The Netherlands)
Chairman: Walter Ageno (Italy)
PART 1: NGS IN DIAGNOSTICS Co-Chairs: Rebecca Beyth (United States), Benilde Cosmi (Italy)
Moderators: Willem H. Ouwehand (United Kingdom), Michele Lambert (United States) Mark Crowther (Canada), Ismail Elalamy (France)
Elanie Hylek (United States), Peter Verhamme (Belgium)
Henry G. Watson (United Kingdom),
08:00 - 08:15 Welcome
Pieter W. Kamphuisen (The Netherlands)
Willem H. Ouwehand (United Kingdom)
SSC PROGRAM
08:15 - 08:30 Inherited bleeding/coagulation disorder 08:00 - 08:05 Introduction
Char Witmer (United States) Walter Ageno (Italy)
08:30 - 08:45 Hemostasis NGS panel in routine diagnostic use

Anne Goodeve (United Kingdom) UPDATE ON CURRENT SSC PROJECTS: REGISTRIES
Moderators: Benilde Cosmi (Italy), Rebecca Beyth (United States)
08:45 - 09:00 ThromboGenomics platform
Ilenia Simeoni (United Kingdom)
08:05 - 08:25 Perioperative management of NOACs
Alexander C. Spyropoulos (United States)
78 79
08:25 - 08:45 START-EVENTS SSC register Bleeding Assessment Tool (BAT) Standing Committee Room 707
Walter Ageno (Italy)
Chairman: Francesco Rodeghiero (Italy)
08:45 - 09:05
Pregnancy outcomes in patients who become pregnant while on NOACs
Saskia Middeldorp (The Netherlands) Secretary: Alberto Tosetto (Italy)
10:30 - 10:35 Introduction

UPDATE ON CURRENT SSC PROJECTS: STANDARDIZATION Francesco Rodeghiero (Italy)
Moderators: Henry G. Watson (United Kingdom), Pieter W. Kamphuisen (The Netherlands)
09:05 - 09:25 Non-major bleeding

REPORT OF NEW AND ONGOING STUDIES
Moderator: Barry Coller (United States)
Scott Kaatz (United States)
09:25 - 09:45
Clinical outcome for patients treated for a major oral anticoagulant-related 10:35 - 10:45 Bleeding phenotype in children with moderate/severe VWD
bleed Yvonne Sanders (The Netherlands), Frank Leebeek (The Netherlands)
Nakisa Khorsand (The Netherlands)
10:45 - 10:55 The Vienna Bleeding Biobank
09:45 - 10:05 Nomenclature of the novel oral anticoagulants Johanna Gebhart (Austria)
Geoffrey Barnes (United States)
10:55 - 11:05 The REBEL Study
10:05 10:15 rogress report on replacement of international standards for
P Alberto Tosetto (Italy)
thromboplastin
nton van den Besselar (The Netherlands), Veena Chantarangkul (Italy),
A
Armando Tripodi (Italy) FUTURE DEVELOPMENTS IN BLEEDING ASSESSMENT TOOLS
Moderator: Francesco Rodeghiero (Italy)
COFFEE BREAK
11:05 - 11:20 Integrating genotypic and phenotypic data: the perspective of the Subcom-
mitee on Genomics in Thrombosis and Hemostasis
EDUCATION SESSION: THE CONTRIBUTION OF PROF. MM SAMAMA TO Willem H. Ouwehand (United Kingdom)
CONTROL OF ANTICOAGULATION 11:20 - 11:30 Update on BAT and beyond
Moderators: Marc C. Samama (France), Jacqueline Conard (France) Francesco Rodeghiero (Italy)
10:30 - 11:00 Clinical: Risk assessment models, VTE prophylaxis, thrombophilia

RTW and Young Investigator Networking Reception
SATURDAY
Jacqueline Conard (France)
11:00 - 11:30
Biological: Pharmacology analysis, mechanisms of action of This will take place on on Sunday, June 21, from 12:00 13:00 in room 713 at the Metro Toronto Convention
antithrombotics, global assays Center
Grigoris Gerotziafas (France)
If you have been awarded a RtW or Young Investigator Grant from the 2015 ISTH congress we cordially invite you
to attend RtW and Young Investigator Networking Reception.
A LOOK INTO FUTURE INITIATIVES OF THE SSC ON CONTROL OF
ANTICOAGULATION WFH/RTW symposia:
SSC PROGRAM
Moderators: Mark Crowther (Canada), Elaine Hylek (United States) This will take place on Sunday, June 21 from 13:00 15:00 in room 715 of the Metro Toronto Convention Center.
11:30 - 11:55
Update on the clinical experience of the direct oral anticoagulants in real Building Capacity and Empowering Future Leaders: Lessons from the ISTH and WFH Fellowship Programs
life. What have we learned and what can we learn from registries? This session will focus on the ISTH Reach the World (RtW) fellowship program and the World Federation of Hemo-
Jan Beyer (Germany) philia (WFH) International Hemophilia Training Center (IHTC) fellowship program. The event will discuss the need
for capacity building programs in hemophilia, hematology and thrombosis. Past fellows and mentors will share
11:55 - 12:20 he white book: Proposal for a position paper on the role of the laboratory
T experiences and stories from both programs. Future applicants will be able to ask questions and connect with
with the direct oral anticoagulants leaders in both programs.
Ismail Elalamy (France)
80 81
SSC PROGRAM
World Thrombosis Day: From Global Conversation to Global Catalyst

Sunday, June 21
13:00 15:00
Master Classes and
Now in its second year, World Thrombosis Day (WTD) launched on October 13, 2014, with an important message
of awareness and action on a major contributor to the global burden of disease thrombosis. With one in four peo-
ple worldwide dying from causes related to thrombosis, the International Society on Thrombosis and Haemostasis
Career Mentorship Sessions
(ISTH) launched WTD to help reduce death and disability due to venous thromboembolism (VTE). Highlighting the
campaigns traction in its first year and focused on hospital-associated VTE in year two, this session will include
members of the WTD Steering Committee, including Chairman Dr. Gary Raskob, representatives from some of the
more than 200 partner organizations and comments and support from the WTD Sponsors. In addition to stories
from the first day, attendees will be invited to participate going forward as we continue our work to build awareness
of potentially deadly blood clots through educational activities, media outreach and communication with the public
and health care professionals around the world.
Special Industry Symposia

15:30 - 17:30
Special Industry Symposia Programs are available in the Show Guide. Please consult the different options to attend
the symposium of your choice.
Opening Ceremony
Welcome Reception
82 83
MASTER CLASSES MASTER CLASSES
The Master Class sessions are a recently introduced educational feature for the ISTH Congress. Young Investigators
and Reach-the-World participants are specifically invited for one-hour sessions with a senior, well-known and estab-
lished investigator. In small groups (20-25 per class), the session leader will give a short introduction (5-10 min-
Tuesday, June 23, 2015 07:00-07:50
utes), after which there will be an interactive exchange of questions and a discussion, which will last for 50 minutes
in total. Attendance had to be pre-booked. Master Classes are held daily between 7:00 and 07:50 am from Sunday, Room Haliburton: Shannon Bates (Canada) Assisted reproduction, pregnancy, and thrombosis
WEDNESDAY
June 21 to Wednesday, June 24. Continental breakfast will be provided during these early morning sessions.
Room Wellington: John Eikelboom (Canada) Atrial fibrillation: anticoagulant choice and monitoring
Rooms for the Master Classes are located at the Intercontinental Hotel, which is connected to the Metro Toronto Room High Park: Anthony Chan (Canada) Management issues in pediatric thrombosis
Convention Centre. You can find the room names on the vouchers you will receive as part of your registration pack.
Room Halton: Ed Pryzdial (Canada) Links between viruses and heart disease
The following Master Classes have been organized: Room Kingway: Sara Vesely (United States) TTP with an emphasis on registries
Room Caledon: Patrick Provost (Canada) Platelet microRNAs
Sunday, June 21, 2015 07:00-07:50 Room Oakville: David Lillicrap (Canada) VWD - biology, diagnosis, therapy
TUESDAY
Room Humber: Ken Bauer (United States) Coagulation system: mechanisms and big unanswered
questions
Room Grenadier: Cathy Hayward (Canada) Platelet function testing and diagnosis of platelet function
disorders Room Grenadier: Mitchell Cohen (United States) Trauma-induced coagulopathy
Room High Park: Susan Kahn (Canada) Post-thrombotic syndrome
Room Wentworth: Fred Spencer (Canada) Understanding and using guidelines to care for your patients
Room Wellington: Agnes Lee (Canada) Cancer and thrombosis: Prevention and treatment where do
the new direct acting anticoagulants fit in?
MONDAY
Room Haliburton: Jeff Weitz (Canada) Mechanisms of clotting on blood-contacting medical devices
Room Oakville: Donnie Arnold (Canada) ITP: clinical aspects and laboratory testing Wednesday, June 24, 2015 07:00-07:50
Room Wentworth: Margaret Rand (Canada) The procoagulant platelet
Room Oakville: Mark Crowther (Canada) Antiphospholipid antibodies: testing, treatment, prognosis
Room Halton: Steve Watson (United Kingdom) Platelet signaling
Room High Park: Martin ODonnell (Ireland) Antithrombotic and antiplatelet therapy in the elderly
Room Humber: Manuel Carcao (Canada) Hemophilia (adults, pediatric): prophylaxis, treatment (in-
cluding use and monitoring of long-acting formulations), and Room Caledon: Rita Selby (Canada) Laboratory measurements and the direct oral anticoagulants
Inhibitors
Room Wellington:
Room Caledon: Barbara Konkle (United States) Laboratory investigations for bleeding disorders Charles Chuck Esmon (United States) The ups and downs of thrombin generation
Room Kingsway: Phil Wells (Canada) How to get your paper published Room Halton: Ted Warkentin (Canada) HIT: clinical and laboratory testing pitfalls
Room Haliburton: Eric Boilard (Canada) Platelet microparticles
Room Wentworth: Heyu Ni (Canada) Platelet integrins and their ligands in thrombosis and
Monday, June 22, 2015
SATURDAY
07:00-07:50 hemostasis
Room Kingsway: Lawrence Brass (United States) Platelet thrombus formation
Room Haliburton: Walter Ageno (Italy) Treatment of thrombosis in unusual sites Room Humber: Paula James (Canada) Bleeding scores
Room High Park: James Douketis (Canada) Practical issues of antithrombotic therapy: bleeding and
Room Grenadier: Ed Conway (Canada) Coagulation and the complement system
reversal, perioperative management and drug interactions
Room Humber: Alex Spyropoulos (United States) Perioperative anticoagulant management
MASTER CLASSES
Room Oakville: Paul Cubes (Canada) NETs
Room Wentworth: Maintaining vascular flow: from liquid to solid to liquid again:
Shirley Uitte de Willige (The Netherlands) the dynamics of clot formation and lysis
Room Grenadier: Sara Israels (Canada) Platelet disorders in children and newborns
Room Kingsway: Bernhard Nieswandt (Germany) Targeting platelet receptors by antibodies
Room Halton: Flora Peyvandi (Italy) Rare bleeding disorders
Room Caledon: Thomas Ortel (United States) Tests of global hemostasis: What do they mean and why would
we use them?
Room Humber: Harry Bller (The Netherlands) Tips for preparing successful grant applications
84 85
CAREER MENTORSHIP SESSIONS
These session are a novelty for the ISTH congress. The intention is to provide mentorship in a truly interactive ses-
sion, which therefore will be limited to 10 participants. The Career Mentorship Sessions are dedicated to the young
investigators and recipients of the Reach The World awards. There are a total of 16 sessions and thus maximum
160 attendees, which is less than the total number of eligible attendees at the congress. Therefore, participation is
strictly limited to one session per attendee. There are different themes aiming at 3 target groups basic scientists,
Nurses Forum
clinical investigators, and clinician educators. We have also endeavoured to provide female and male mentors
within each subset.
Attendance had to be pre-booked. Career Mentorship Sessions are held daily between 12:00 and 13:00 from Sun-
day, June 21 to Wednesday, June 24. A lunch will be provided during these sessions.
Rooms for the Career Mentorship Sessions are located at the Intercontinental Hotel, main floor, which is connected
to the Metro Toronto Convention Centre. You can find the room names on the vouchers you will receive as part of
your registration pack.
The following Career Mentorship Sessions have been organized:
Sunday, June 21, 2015 12:00-13:00
Room Humber: Agnes Lee (Canada) Clinical Investigators

Room Halton: Nigel Mackman (United States) Basic Scientists
Room Wellington: Paula James (Canada) Clinical Investigators
Room Haliburton: Walter Kahr (Canada) Basic Scientists
Monday, June 22, 2015 12:00-13:00
Room Humber: Elaine Hylek (United States) Clinical Investigators

Room Halton: Marcel Levi (The Netherlands) Clinician Educators
Room Wellington: Donnie Arnold (Canada) Clinical Investigators
Room Haliburton:
Charles Chuck Esmon (United States) Basic Scientists
Tuesday, June 23, 2015 12:00-13:00
Room Humber: Phil Wells (Canada) Clinical Investigators

Room Halton:
Saskia Middeldorp (The Netherlands) Clinical Investigators
Room Wellington: Cathy Hayward (Canada) Basic Scientists
Room Haliburton: Shannon Bates (Canada) Clinician Educators
Wednesday, June 24, 2015 12:00-13:00
Room Humber: Susan Kahn (Canada) Clinical Investigators

Room Halton: Margaret Rand (Canada) Basic Scientists
Room Wellington: Jeff Weitz (Canada) Basic Scientists
86 87
NURSES FORUM NURSES FORUM
12:00 - 12:20
Cardiology thrombosis project collaboration between 2 services and nurse
Sunday, June 21, 2015 9:00-13:20 practitioners
Marilyn Blumenstein (United States)
Nurses Forum Room 803 A & B
12:20 - 12:30 Questions and Answers
The Nurses Forum takes place Sunday and Monday, June 21-22, 2015, during the Congress. On the morning of
Monday, June 22, a scientific session with oral presentation of peer-reviewed abstracts will be held. Nurses and 12:30 - 13:30 LUNCH
allied health professionals that have ongoing projects, or who can perform and complete a study by the end of
2014, have been encouraged to strongly consider submitting their results as an abstract to the ISTH Congress. Concurrent Sessions 13:30 15:15 Room 803 A & B
Moderator: Maura Malone (United States)

EDUCATION, ADHERENCE, QOL
09:00-09:15 Welcome and overview of Nursing Forum Moderators: Marilyn Blumenstein (United States), Erica Crilly (Canada)
Maura Malone (United States)
13:30-13:45
Thrombosis and anticoagulation program; Home INR monitoring and neona-
Host nurses perspective
on managing patient populations tal prophylatic enoxaparin dosing
with thrombosic and haemostatic disorders Kathy Harney (United States)
Moderator: Maura Malone (United States)
13:45-14:00 Adherence with DOACs - Application to clinical practice
09:15 - 09:30 Thrombosis management in Canada Bunis Packham (United Kingdom)
Laurie Sardo (Canada)
14:00-14:15 Thrombosis and Cancer ; Education and QOL considerations
09:30 - 09:45 The Structure of Hemophilia Care and HTC in Canada Annie Young (United Kingdom)
Rebecca Goldsmith (Canada)
14:15-14:35 Carrier Testing, genetics, education, ethics, age, etc
09:45-11:00 Selected oral communications and posters Robyn Shoemark, (Australia)
Moderator: Ann OSullivan (Ireland)
14:35-14:50
National Patient Needs Assessment
SUNDAY
Regina Butler (United States)
09:45 - 10:00 ow participating in a clinical trial has had a far reaching effect-A case
H 14:50-15.05 Mild hemophilia A: a manageable condition?
study Daryl Pollock (New Zealand)
Claire McGregor (Australia)
15:05-15.15 Questions and Answer Period
10:00 - 10:15 Barriers to inform hemophilic carriers of the possibility in Japan
Tomie Fujii (Japan)
NURSES FORUM
Literature Review Workshop preregistration required (Room 709)
10:15 - 10:30 Review of HTC needs assessment Facilitator: Fiona Newall (Australia)
Ann Forsberg (United States)
13:30 15:15 This interactive workshop aims to confirm the processes supporting development of a
10:30 - 10:45
Hemophilia and aging: Promoting healthy aging through proactive engage-
collaborative literature review suitable for publication on behalf of the ISTH Nursing
ment with general practitioners Forum.
Olivia Hollingdrake (Australia)
The specific objectives or this session are:
10:45 - 11:00 Review of research on hematuria disorders
Greta Mulders (The Netherlands) - Workshop attendees will be provided with a brief education session regarding the process
of preparing a Literature Review for publication in a peer reviewed journal
11:00 11:20 Coffee Break - Identification of topics for literature review (1 hemophilia and 1 thrombosis)
- Authorship panel will be decided and confirmed during the workshop
- Each working group will brainstorm key words, appropriate limits of the literature search,
Innovation
11:20 12:30 in nursing practice and a possible structure
11:20 - 11:40
Epidemiology of asymptomatic thrombosis and PTS following the use of 15:15 15:30 Break
central lines
Fiona Newall (Australia)
88 89
NURSES FORUM NURSES FORUM
Challenges in delivering care in resource-limited countries 15:30 16:00 Nurses and Allied Health Session Thrombosis and Anticoagulation 09:45 12:00
Moderators: Caroline Baglin (United Kingdom), Regina Butler (United States) Moderators: Jennifer Lowerison (Canada), Michelle Zondag (Canada)
15:30 15:45
Serbia: Inhibitors and CVL - lessons learned NUR006 DEVELOPING A NURSE LED ULTRASOUND SCANNING SERVICE TO
Ljiljiana Rakic (Serbia) 09:45 10:00 CONFIRM OR EXCLUDE THE DIAGNOSIS OF LOWER LIMB DEEP VEIN
THROMBOSIS - IMPROVING PATIENT CARE AND REDUCING THE RISK
15:45 16:00
Thrombosis - barriers to care OF UNECESSARY ANTICOAGULANTS IN A UNITED KINGDOM PRIMARY
Elizabeth Dotse (Ghana) CARE SETTING.
Jo Boyd (United Kingdom)
16.00 18:00 Nurses Network Reception Location TBD
NUR007
OVERWEIGHT IS A RISK FACTOR FOR VENOUS THROMBOEMBOLISM
10:00 10:15
AFTER TOTAL KNEE ARTHROPLASTY DESPITE RIVAROXABAN
THROMBOPROPHYLAXIS
Monday, June 22, 2015 08:00-16:30
Christine Cockhill, Owais Mian, MaryAnne Rizzo, Deborah Siegal, Howard Chan, Ellen
Nursing and Allied Health Professionals Research Session 09:00 12:00 Room 803 A&B McDonald (Canada)
NUR008
MANAGING ANTICOAGULATION THERAPY RISK THROUGH THE
Peer-reviewed abstracts from Nurses and Allied Health Professionals 10:15 10:30
MULTIDISCIPLINARY TEAM (MDT) WARD ROUND AT KINGS COLLEGE
HOSPITAL
MONDAY
Jignesh Patel, Lara Roberts, Emma Gee, Rosalind Byrne, Julia Czuprynska, Kwesi
Nurses and Allied Health Session - Bleeding 08:00 09:15 Kittoe, Alison Brown, Raj Patel, Lynda Bonner, Roopen Arya (United Kingdom)
Moderators: Laurie Sardo (Canada), Jim Munn (United States) NUR009 SAFE DISCHARGE PLANNING FOR PATIENTS ON ANTICOAGULANTS:
10:30 10:45
LAUNCH OF A NEW QUALITY IMPROVEMENT TOOL FOR NURSES
NUR001
WHEN 2N VWD SHOULD BE CONSIDERED A DIFFERENTIAL DIAGNOSIS Suzette Chung, Carla Strulovitch, Jessica Emed, Hetal Patel (Canada)
08:00 08:15 Claire Mcgregor, Natalie Gamble-Williams (Australia)
NUR010
DIRECT-ACTING ORAL ANTICOAGULANTS IN THE REAL WORLD: INSIGHTS
NURSES FORUM
NUR002 HE DDAVP CHALLENGE AN AUDIT TO ASSESS PRACTICE IN A UK
T 10:45 11:00
INTO APPROPRIATE PRESCRIBING AND MEDICATION USE
08:15 08:30 HAEMOPHILIA CENTRE
Jennifer Delaney, Sam Schulman, Mary Salib, Mohamed Panju, Menaka Pai (Canada)
D W George, James Uprichard, Anne Wareing (United Kingdom)
NUR011
NOVEL ORAL ANTICOAGULANT CHECKLISTS FOR FRONT LINE CLINICIANS
NUR003 CLOSING THE GAP: A MULTIDISCIPLINARY APPROACH DEVELOPING 11:00 11:15 Jennifer Lowerison, Jennifer Bolt, Tammy Bungard, Darcy Lamb (Canada)
08:30 08:45 LOCAL SERVICES FOR RURAL AND REMOTE PATIENTS WITH BLEEDING
DISORDERS. NUR012 A CROSS-SECTIONAL REGISTRY ON THE INCIDENCE OF
James Slade (Australia) 11:15 11:30 ASTROINTESTINAL ASSOCIATED SYMPTOMS WITH PRADAXA USE
G
(GASP REGISTRY)
NUR004
NON-ADHERENCE TO PROPHYLAXIS IN HAEMOPHILIA: EXTENT AND Michelle M. Zondag, Laurie Sardo, Sam Schulman (Canada)
08:45 09:00
UNDERLYING REASON

Marlies Schrijvers, Marlene Beijlevelt - van der Zande, Marjolein Peters, Janske Lock, NUR013 ASSESSING ORAL ANTICOAGULANT USE IN LONG-TERM CARE
Marjon Cnossen, Marieke Schuurmans, Kathelijn Fischer (The Netherlands) 11:30 11:45
RESIDENTS: EVIDENCE FOR ONGOING SUBOPTIMAL USE IN 2014
Carlos Rojas-Fernandez, Aein Zarrin, Melissa Warkentin, Jennifer Bonneau, Jennifer
NUR005
EXPANDING THE KNOWLEDGE BASE: OPPORTUNITIES AND CHALLENGES Hartwick, Susan Brown (Canada)
09:00 09:15
FOR ALLIED PROFESSIONALS IN BLEEDING DISORDER RESEARCH IN
CANADA NUR014 POST-THROMBOTIC PANIC: PANIC, POSITIVE OUTCOMES AND
Neale Smith, Claude Bartholomew (Canada) 11:45 12:00
THE PARADOXICAL IMPACT OF VENOUS THROMBOEMBOLISM (VTE)
Rachael Hunter, Paul Bennett, Sarah Lewis, Jaynie Rance, Simon Noble (United
Kingdom)
COFFEE BREAK 12:00-13:45 LUNCH and Poster viewing
12:15-13:45 Satellite symposia
90 91
NURSES FORUM
Practice guidelines for optimal health: Section 1 14:00 14:45
Moderators: Caroline Baglin (United Kingdom), Maura Malone (United States)
14:00 14:15 Review of VWD guidelines/compare/contrast/diagnostic

Vanessa Bouskill (Canada)
Scientific Program
14:15-14:30 Anticoagulation management for ventricular assist devices: A review
Hollie Gilmore (Australia) Monday, June 22
14:30-14:45 Cochrane Report and UKHCDO Guidelines
Kate Khair (United Kingdom)
14:45 15:00 BREAK
Practice guidelines for optimal health: Section 2 15:00 -16:30 Trainee Tracks (oral sessions only):
Moderators: Kim Schafer (United States), Bunis Packham (United Kingdom) Platelets track
15:00 - 15:15 Impact of footwear on ankle arthropathy in patients with hemophilia Basic thrombosis and hemostasis track
Karen Strike (Canada) Clinical bleeding track
15:15 - 15:30 Innovative treatment for managing PTS Clinical thrombosis track
Charlene Gates, PT ((United States)
Pediatric thrombosis and hemostasis track
15:30 - 15:45 Prophylaxis and impact on pain Cardiovascular and arterial diseases track
Anne OSullivan (Ireland)
15:45 - 16:00 Compression hosiery and PTS An asterisk (*) after a name denotes the presenting author
Grace Hughes (United Kingdom)
16:00 - 16:15
First experience with the hemoassist: An electronic substitution diary that
works on the basis of a personal digital assistant
Manuela Siebert (Germany)
16:15 - 16:30
Questions and Answers. Wrap-up
92 93
SCIENTIFIC PROGRAM SCIENTIFIC PROGRAM
08:30 08:45 TOLERANCE TO MULTIANTIGENIC MOLECULE EXPRESSING PEPTIDES
Monday, June 22, 2015 OR008 FROM APOB100, HSP60 AND OUTER MEMBRANE PROTEIN OF
CHLAMYDIA PNEUMONIA REDUCES MARKERS OF PLAQUE INSTABILITY
ORAL COMMUNICATIONS 1 08:00-09:15 AND STABILIZES ADVANCED ATHEROSCLEROSIS IN
APOBTM2SGY/LDLRTM1HER/J MICE.
Sheena Philip, Thiruvelselvan Ponnusamy, Lakshmi Narasimha Rao, Rameshkumar
Platelet Disorders Room 718
Krishnan, Xinjie Lu, Vrushali Deshpande, Vijay Kakkar, Lakshmi Mundkur* (India)
Moderators: David Wilcox (United States), Paquita Nurden (France)
08:45 09:00 MODULATION OF CLINICALLY RELEVANT PATHWAYS BY POST
08:00 08:15 JAK2 V617F MUTATION AND CARDIOVASCULAR RISK FACTORS OR009 TRANSLATION MODIFICATION REGULATORY SYSTEM IN CORONARY
OR001 DISCRIMINATE YOUNG PATIENTS WITH HIGH RISK OF THROMBOSIS ARTERY DISEASE.
IN ESSENTIAL THROMBOCYTHEMIA Rajani Kanth Vangala*, Ankit Sharma, Madankumar Ghatge (India)
ongfeng Fu*, Lei Zhang, Huiyuan Li, Liyan Zhang, Mingen Lv, Yating Hao, Renchi
R
09:00 09:15 GENE CENTRIC ANALYSIS COMBINED WITH NETWORK ANALYSIS TO
Yang (China)
OR010 IDENTIFY GENES ASSOCIATED WITH CORONARY ARTERY DISEASE
08:15 08:30 FIRST REPORT OF A NEW HOMOZYGOUS FLI1 MUTATION UNRAVELED Jiny Nair*, Madan Ghatge, Jayashree Shaker, Vijay Kakkar (India)
OR002 BY INCREASED MYH10 EXPRESSION IN AN INHERITED PLATELET
DISORDER Hemophilia clinical Room 801
Marie-Christine Morel-Kopp*, David Rabbolini, Sara Gabrielli, Qiang Chen, William
Stevenson, Christopher Ward (Australia) Moderators: Manuel Carcao (Canada), Peter Collins (United Kingdom)
MONDAY
08:30 08:45 A GAIN-OF-FUNCTION MUTATION IN FILAMIN-A POTENTIATES 08:00 08:15 LEOPOLD TRIAL RESULTS: CORRELATION OF VON WILLEBRAND FACTOR
OR003 PLATELET INTEGRIN ALPHA-IIB/BETA-3 ACTIVATION OR011 ANTIGEN LEVEL WITH BAY 81-8973 PHARMACOKINETIC PARAMETERS
liane Berrou, Frdric Adam, Virginie Planche, Marilyne Lebret, Patricia Fergelot,
E OF PATIENTS WITH SEVERE HEMOPHILIA A
Isabelle Coupry, Paquita Nurden, Dominique Bonneau, Estelle Colin, Cyril Goizet, hadan Lalezari, Teruhisa Fujii, YL Kwong, Heinz Delesen, Anita Shah, Claudia Tck-
S
Jean-Philippe Rosa, Marijke Bryckaert* (France) mantel, Waander van Heerde*, Monika Maas Enriquez (Germany)
08:45 09:00 HISTONE-ASSOCIATED THROMBOCYTOPENIA: A NEW CAUSE OF 08:15 08:30 IN HAEMOPHILIC PATIENTS TFPI LEVELS INFLUENCE THROMBIN
OR004 THROMBOCYTOPENIA IN CRITICALLY ILL PATIENTS
ORALS
OR012 GENERATION PROFILE AND TFPI NEUTRALIZATION NORMALIZES
asir Alhamdi, Simon Abrams, Ingeborg Welters, Guozheng Wang, Cheng-Hock Toh*
Y THROMBIN GENERATION POTENTIAL
(United Kingdom)
rigitte Tardy* , Fabienne Volot, Michle Piot, Cline Chapelle, Herv Chambost,
B
Anne Lienhart, Fabienne Dutrillaux, Yesim Dargaud, Pierre Morange, Patrick Mismetti,
09:00 09:15 PLATELET MITOCHONDRIAL DYSFUNCTION IN PATIENTS WITH SEPSIS Bernard Tardy (France)
OR005 OR CARDIOGENIC SHOCK
ndrea Artoni*, Alessandro Protti, Silvia La Marca, Anna Lecchi, Francesco Fortunato,
A 08:30 08:45 DDAVP IN MODERATE HEMOPHILIA A PATIENTS: A TREATMENT
Giacomo Comi, Flora Peyvandi (Italy) OR013 STRATEGY WORTH CONSIDERING
J anneke I. Loomans*, Alice Van Velzen, Marjolein Peters, Marieke Kruip, Simon
Atherosclerosis Room 701 McRae, Manuel Carcao, Kathelijne Peerlinck, Shannon Jackson, Robert Klamroth, Mar-
ten Nijziel, Russell Keenan, Maria Mancuso, Johanna Van der Bom, Karin Fijnvandraat
Moderators: Lina Badimon (Spain), Vi Dong (Canada) (The Netherlands)
08:00 08:15 SWAPPING OVER TWO PEPTIDE EPITOPES DERIVED FROM APOB AND 08:45 09:00 THE IMPACT OF PATIENT ADHERENCE ON FVIII LEVELS:
OR006 C5AR LOCATED AT TERMINUSES OF RECOMBINANT PROTEINS OR014 A COMPARISON OF RFVIII AND RFVIII-FC REGIMENS
MAINTAINS THE SIMILAR EFFECTIVE REDUCTION ON J osh Epstein, Elizabeth Schwartz*, Yan Xiong, Armin Reininger, Alessandro Gringeri
(United States)
ATHEROSCLEROTIC LESION IN B6;129S-LDLR(TM1HER)APOB
(TM2SGY)/J MICE 09:00 09:15 FUNCTIONAL EFFECTS OF F8 MISSENSE MUTATIONS ON DDAVP
in Xia, Valeria Endresz, Ildiko Lantos, Andrea Szabo, Lakshmi Mundkur, Vijay Kak-
M OR015 RESPONSE IN NONSEVERE HEMOPHILIA A BROTHERS
kar, Xinjie Lu* (United Kingdom)
J anneke I. Loomans*, Alice Van Velzen, Michael Tanck, Marjolein Peters, Elena
Santagostino, Cristina Santoro, Karina Meijer, Erik Beckers, Savita Rangarajan, Thynn
08:15 08:30 EXAMINING THE HEXOSAMINE BIOSYNTHESIS PATHWAY IN Yee, Pia Petrini, Giancarlo Castaman, Johanna Van der Bom, Karin Fijnvandraat (The
OR007 HYPERGLYCEMIA-INDUCED ACCELERATED ATHEROSCLEROSIS. Netherlands)
Vi T. Dang*, Christina Petlura, Daniel Beriault, Yuanyuan Shi, Geoff Werstuck (Canada)
94 95
08:30 08:45 ABNORMAL ANGIOGENESIS IN TYPE 2A AND 2B VON WILLEBRAND
Anti-platelet agents basic Room 714
OR023 DISEASE (VWD): COMPARATIVE STUDIES OF QUANTITATIVE AND
Moderators: Joseph Jakubowski (United States), Reheman Adili (Canada) QUALITATIVE VWD USING BLOOD OUTGROWTH ENDOTHELIAL CELLS
Lara Casey*, Mackenzie Bowman, Soundarya Selvam, Paula James (Canada)
TICAGRELOR AND CLOPIDOGREL ATTENUATE THE PROTHROMBOTIC
08:00 08:15
OR016 STATE INDUCED BY BACTERIAL ENDOTOXEMIA 08:45 09:00 TYPE 2N VON WILLEBRAND DISEASE: ONE VARIANT BUT MORE THAN
Mark R. Thomas*, Ramzi Ajjan, Fladia Phoenix, Samuel Outteridge, Heather Judge, OR024 ONE DISEASE
David Dockrell, Ian Sabroe, Robert Storey (United Kingdom) Jenny Goudemand, Christophe Zawadzki, Pierre Boisseau, Catherine Ternisien, Clau-
dine Caron, Fabienne Volot, Katia Pouymayou, Brigitte Pan-Petesch, Sabine Castet,
08:15 08:30 PLATELET SIGNALING AND ENDOTHELIAL FC GAMMA RECEPTOR IIB Agns Veyradier, Edith Fressinaud, Sophie Susen* (France)
OR017 ARE BOTH REQUIRED FOR ANTIBODY-INDUCED GLYCOPROTEIN VI
ECTODOMAIN SHEDDING IN VIVO 09:00 09:15 HETEROGENEITY OF VON WILLEBRAND DISEASE TYPE 3 IN A FRENCH
avid Stegner*, Michael Popp, Viola Lorenz, Sebastian Dtting, J. Engelbert Gessner,
D OR025 COHORT OF 75 PATIENTS
Bernhard Nieswandt (Germany) Pierre Boisseau, Edith Fressinaud, Catherine Ternisien, Claudine Caron, Annie
Borel-Derlon, Marc Trossaert, Cecile Lavenu-Blombed, Chantal Rothschild, Stephane
SMALL MOLECULE DCDBS84 REGULATES PLATELET THROMBUS
08:30 08:45 Beziau, Sophie Susen, Agns Veyradier, Jenny Goudemand* (France)
OR018 FORMATION BY TARGETING C-SRC SH3 DOMAIN
Zhangbiao Long, Kongkai Zhu, Jiansong Huang, Xiaofeng Shi, Jingqiu Liu, Jichun Acquired disorders treatment I Room 713
Yang, Bing Xiao, Lianchun Li, Hong Ding, Yi Wen, Naixia Zhang, Hualiang Jiang, Zhen
Ruan, Cheng Luo, Xiaodong Xi* (China) Moderators: Jean St Louis (Canada), Meera Chitlur (United States)
MONDAY
08:45 09:00 CONGENITAL SEVERE DEFICIENCY OR PHARMACOLOGICAL INHIBITION 08:00 08:15 ACQUIRED VON WILLEBRAND SYNDROME AND RESPONSE TO
OR019 OF THE PLATELET P2Y12 RECEPTOR FOR ADENOSINE DIPHOSPHATE OR026 DESMOPRESSIN
DOES NOT IMPAIR THE CAPACITY OF PLATELET TO SYNTHESIZE Eugenia Biguzzi*, Franca Franchi, Simona Siboni, Flora Peyvandi (Italy)
THROMBOXANE A2
Mariangela Scavone*, Eti A. Femia, Vera Caroppo, Marco Cattaneo (Italy) 08:15 08:30 ACTIVATED PROTHROMBIN COMPLEX CONCENTRATE IN ACQUIRED
OR027 HEMOPHILIA A: AN ITALIAN REGISTRY-THE F.A.I.R. STUDY
09:00 09:15 THE P2Y12 ANTAGONIST ACT-246475 CAUSES LESS BLOOD LOSS Ezio Zanon*, Marta Milan, Gabriella Gamba, Gaetano Giuffrida, Anna Falanga, Augus-
OR020 THAN TICAGRELOR AT COMPARABLE ANTITHROMBOTIC EFFICACY IN A
ORALS
to Federici, Isabella Cantori, Sergio Siragusa, Maria Mazzucconi (Italy)
RAT THROMBOSIS MODEL.
Markus Rey, Patrick Hess, Keith Morrison, Edgar Weber, Martine Clozel, Markus Rie- 08:30 08:45 PERIOPERATIVE MANAGEMENT OF BLEEDS WITH RECOMBINANT
derer, Beat Steiner* (Switzerland) OR028 PORCINE FVIII IN PATIENTS WITH ACQUIRED HEMOPHILIA A
Aaron Novack, Jean St-Louis*, Anne Greist, Amy Shapiro, Hedy Smith, Pratima Chow-
dary, Anja Drebes, Jay Lozier, Christelle Bourgeois, Min Mo, Heinrich Farin (United
VWD classification, subtypes I Room 716 States)
Moderators: Shannon Jackson (Canada), Anne Goodeve (United Kingdom)
08:45 09:00 REAL WORLD DATA ON TREATMENT WITH FEIBA IN PATIENTS WITH
OR029 CLOTTING FACTOR INHIBITORS
08:00 08:15 GENOTYPING OF VWD PATIENTS IN THE NETHERLANDS:
Claude Negrier*, Sophie Voisin, Fariba Baghaei, Aaron Novack, Jennifer Doralt, Rober-
OR021 PHENOTYPE-GENOTYPE DISCREPANCIES AND 27 NOVEL VWF GENE to Crea, Alessandro Gringeri (France)
MUTATIONS
Johan Boender*, Yvonne Sanders, Waander van Heerde, Marjon Cnossen, Britta Laros- 09:00 09:15 SHORT-TERM PROPHYLAXIS REGIMEN WITH ACTIVATED
van Gorkom, Karin Fijnvandraat, Selene Schoormans, Natasja Dors, Johanna van der OR030 PROTHROMBIN COMPLEX CONCENTRATE IN THE PREVENTION OF
Bom, Karina Meijer, Evelien Mauser-Bunschoten, Jeroen Eikenboom, Frank Leebeek
BLEEDING RELAPSE IN ACQUIRED HEMOPHILIA
(The Netherlands)
zio Zanon*, Marta Milan, Chiara Ambaglio, Graziella Saggiorato, Nadia Montani,
E
CASE STUDY OF TWO CONSANGUINEOUS BROTHERS WITH TYPE 3 VON
08:15 08:30 Gabriella Gamba (Italy)
OR022 WILLEBRAND DISEASE (VWD), INHIBITORS AND ANAPHYLACTOID
REACTION TO VWF
Loren Dangelo*, Craig Platt, A Dioun Broyles, Ellis Neufeld, Stacy Croteau (United
States)
96 97
Reproductive Issues Room 715 09:00 09:15 ANTIBODY RESPONSE TO HUMAN RECOMBINANT FACTOR VIII IN A
OR040 NEW RAT MODEL OF HEMOPHILIA A
Moderators: Margaret Ragni (Canada), Anna gren (Sweden) arin M. Lvgren*, Henrik Soendergaard, Sren Skov, Karin Weldingh, Bo Wiinberg
K
(Denmark)
08:00 08:15 PATHOLOGY OF PLACENTA IN FETAL AND NEONATAL IMMUNE
OR031 THROMBOCYTOPENIA: ROLES OF TH17 IMMUNE RESPONSES,
Endothelium and vessel wall Room 705
ANTI-PLATELET ANTIBODIES AND ANGIOGENIC FACTORS.
Issaka Yougbare*, Wei-She Tai, Darko Zdravic, Brian Vadasz, Alexandra Marshall, Moderators: Cormack McDonnell (Ireland), David Lane (United Kingdom)
Pingguo Chen, Guangheng Zhu, Howard x Howard Leong-Poi, Dawei Qu, Lisa X. Yu,
Lee Adamson, John Sled, John Freedman, Heyu Ni (Canada)
08:00 08:15 AUTOPHAGY REGULATES THROMBUS FORMATION IN MICE
08:15 08:30 CHARACTERISTICS OF VENOUS THROMBOEMBOLISM IN 3072 FRENCH OR041 Jonathan W.-H. Yau*, Yan Hou, Xi Lei, Krishna Singh, Subodh Verma (Canada)
OR032 WOMEN USING COMBINED OR PROGESTIN-ONLY CONTRACEPTION. 08:15 08:30 PLATELET ACTIVATION AND PLATELET-ENDOTHELIAL INTERACTIONS
J ustine Hugon-Rodin*, Marie-Hlne Horellou, Jacqueline Conard, Claire Flaujac,
OR042 IN THE SIV-INFECTED PIGTAIL MACAQUE MODEL OF HIV-ASSOCIATED
Pierre-Yves Scarabin, Genevive Plu-Bureau (France)
CNS DISEASE
08:30 08:45 CHARACTERISING FIBRIN MONOMER COMPLEX AND D-DIMER Claire Lyons, Hannah Schneider, Elizabeth Engle, Kevin Najarro, Suzanne Queen, Craig
Morrell, Joseph Mankowski, Kelly Metcalf Pate* (United States)
OR033 PROFILES IN PREGNANCY
Karin Lautmann*, Ranjit Akolekar, Roopen Arya (United Kingdom)
08:30 08:45 VASCULAR ENDOTHELIUM DYSREGULATION FOLLOWING
PRE-PREGNANCY BMI AND DELIVERY BMI AS RISK FACTORS FOR
08:45 09:00
OR043 STAPHYLOCOCCUS AUREUS INFECTION : NEW INSIGHTS FOR SEPSIS
MONDAY
OR034 POSTPARTUM VTE: A POPULATION-BASED, CASE-CONTROL STUDY Cormac McDonnell*, Elena Bojenov, Alisha McLoughlin, Phil Cummins, Steve Kerrigan
(Ireland)
Marc Blondon*, Laura Harrington, Franoise Boehlen, Helia Robert-Ebadi, Marc Righi-
ni, Nicholas Smith (Switzerland, United States)
08:45 09:00 ENDOTHELIAL BAMBI (BMP AND ACTIVIN MEMBRANE BOUND
09:00 09:15 HIGHER FREQUENCY OF LEFT-SIDED DEEP VEIN THROMBOSIS IN OR044 INHIBITOR) IS IMPORTANT FOR FIBRIN GENERATION AND THROMBUS
OR035 POSTPARTUM PERIOD STABILITY
nnemarie Venemans-Jellema, Laura Elbers*, Saskia Middeldorp, Victor Gerdes,
A
Isabelle Salles-Crawley*, James Monkman, David Lane, James Crawley (United King-
dom)
Suzanne Cannegieter (The Netherlands)
ORALS
09:00 09:15 VALIDATING A 3D TISSUE-ENGINEERED HUMAN BLOOD VESSEL MODEL
Animal models Room 717 OR045 FOR USE AS A NOVEL MODEL SYSTEM FOR THE ASSESSMENT OF
THROMBUS FORMATION
Moderators: Hartmut Weiler (United States), John Welsh (United States) F I. Musa*, Alan Harper, Ying Yang (United Kingdom)
08:00 08:15 ADVANCED IMAGING TECHNIQUES SHOW PROGRESSIVE ARTHROPATHY

OR036 FOLLOWING EXPERIMENTALLY INDUCED KNEE BLEEDING IN A FACTOR Tissue factor factor VII I Room 707
VIII-/- RAT MODEL
Moderators: Tara Bracken (United States), Wolfram Ruf (United States)
Kristine Rothaus Srensen*, Kirstine Roepstorff, Maj Petersen, Bo Wiinberg, Axel
Hansen, Sren Skov, Lise Nielsen (Denmark)
08:00 08:15 CROSS-TALK BETWEEN TISSUE FACTOR AND EPHA2 IN CANCER:
08:15 08:30 DEVELOPMENT OF A MOUSE CAROTID ARTERY THROMBOLYSIS MODEL OR046 POTENTIATION OF LIGAND-DEPENDENT EPHA2-SIGNALING IN VITRO
OR037 FOR THE EVALUATION OF THERAPEUTIC APPROACHES FOR STROKE AND CO-EXPRESSION IN HUMAN COLORECTAL CANCER SPECIMENS
imone M. Schoenwaelder*, Andre Samson, Sharelle Sturgeon, Jessica Lee, Arnold
S skar Eriksson, sa Thulin*, Anna Asplund, Geeta Hedge, Sanjay Navani, Agneta
O
Ju, Shaun Jackson (Australia) Siegbahn (Sweden)
08:30 08:45 REAL TIME INTRAVITAL IMAGING OF THROMBUS FORMATION IN THE 08:15 08:30 ANTIBODY-BASED TARGETING OF ALTERNATIVELY SPLICED TISSUE
OR038 MOUSE FEMORAL ARTERY REVEALS CRITICAL DIFFERENCES FROM OR047 FACTOR IMPEDES THE GROWTH AND AGGRESSIVENESS OF
EVENTS IN THE MICROVASCULATURE PANCREATIC DUCTAL ADENOCARCINOMA
John Welsh*, Timothy Stalker, Scott Diamond, Lawrence Brass (United States) Dusten Unruh, Xiaoyang Qi, Zhengtao Chu, Robert Sturm, Ryan Keil, Syed Ahmad,
Timofey Sovershaev, Mariette Adam, Patrick Van Dreden, Barry Woodhams, Janusz
08:45 09:00 GENOME EDITING OF FACTOR X IN ZEBRAFISH REVEALS UNEXPECTED Rak, Nigel Mackman, Henri Versteeg, Vladimir Bogdanov* (United States)
OR039 EARLY SURVIVAL AND LATE ONSET HEMORRHAGE
08:30 08:45 TISSUE FACTOR INHIBITION ATTENUATES NEURONAL DAMAGE AND
hilian Hu, Michael Huarng, Marzia Menegatti, Deepak Reyon, Yang Liu, Catherine
Z
Richter, J. Keith Joung, Flora Peyvandi, Jordan Shavit* (United States)
OR048 BEHAVIORAL DEFICIT IN A MOUSE MODEL OF ISCHEMIC STROKE
Shaobin Wang, Brandi Reeves, Daniel Kirchhofer, Rafal Pawlinski* (United States)
98 99
08:45 09:00 LOW FACTOR VII LEVELS FAIL TO REDUCE VASCULAR GRAFT Mechanical circulatory support and devices Room 711
OR049 THROMBUS PROPAGATION IN A BABOON MODEL
Michael Wallisch*, Jeffrey Crosby, Jennifer Greisel, Sue Murray, Erik Tucker, Owen Moderators: Michelle K. Brenner (United States), Paul Dobesh (United States)
McCarty, Monica Hinds, Brett Monia, Andrs Gruber (United States)
08:00 08:15 ACQUIRED VON WILLEBRAND SYNDROME IS A COMMON AND
OR056 PROGRESSIVE CONDITION AMONG PEDIATRIC ECMO PATIENTS
09:00 09:15 GENETIC DETERMINANTS OF ACTIVATED FACTOR VII-ANTITHROMBIN hiu-Ki R. Hui*, Gregory Pelkey, Vadim Kostousov, Trung Nguyen, Laura Loftis, James
S
OR050 COMPLEX PLASMA CONCENTRATION INCLUDE TISSUE FACTOR, FACTOR Thomas, Jun Teruya (United States)
VII AND ENDOTHELIAL PROTEIN C RECEPTOR GENE VARIANTS.
ilippo Sartori*, Barbara Lunghi, Federica Tosi, Patrizia Guarini, Daniela Scalet, Mar-
F 08:15 08:30 COMPARISON OF THE EFFECT OF DABIGATRAN AND WARFARIN ON
cello Baroni, Giovanna Marchetti, Barry Woodhams, Domenico Girelli, Oliviero Olivieri, OR057 MECHANICAL HEART VALVE-INDUCED THROMBIN GENERATION
Francesco Bernardi, Nicola Martinelli (Italy) Iqbal Jaffer*, Alan Stafford, Jim Fredenburgh, Richard Whitlock, Jeffrey Weitz (Canada)
08:30 08:45 ASSESSMENT OF PLATELET FUNCTION AND HEMOSTASIS IN

Heparin-induced thrombocytopenia Room 709 OR058 NEONATES UNDERGOING CARDIOPULMONARY BYPASS
Moderators: Lori Linkins (Canada), Yves Gruel (France) ichelle K. Brenner*, Rachel Bercovitz, Regina Cole, Robert Niebler, Jake Scott, Ecke-
M
hard Stuth, Michael Mitchell, James Tweddell, Ronald Woods, D. Woodrow Benson,
Debra Newman (United States)
08:00 08:15 DYNAMIC MECHANICAL THROMBOPROPHYLAXIS IS A MAJOR
OR051 HEPARIN-INDEPENDENT RISK FACTOR FOR THE FORMATION OF 08:45 09:00 USE OF FIBINOLYTIC THERAPY IN TREATMENT OF VENTRICULAR
ANTI-PLATELET FACTOR 4/HEPARIN ANTIBODIES IN PATIENTS OR059 ASSIST DEVICE THROMBOSIS
MONDAY
UNDERGOING TOTAL KNEE OR HIP ARTHROPLASTY Paul Dobesh*, Brian Trevarrow, Sara Varnado, Ashley Schenk, Eric Rome (United States)
Shigeki Miyata*, Seiji Bito, Kiyoshi Migita, Mashio Nakamura, Kazuhito Shinohara,
Tomotaro Sato, Takeharu Tonai, Motoyuki Shimizu, Yasuhiro Shibata, Kazuhiko Kishi, 09:00 09:15 APPLICATION OF A MICROFLUIDIC FLOW-BASED THROMBOSIS ASSAY
Chikara Kubota, Shinnosuke Nakahara, Toshihito Mori, Kazuo Ikeda, Shusuke Ota,
OR060 FOR POST-OPERATIVE PEDIATRIC CARDIOVASCULAR SURGERY
Takeshi Minamizaki, Shigeru Yamada, Naofumi Shiota, Masataka Kamei, Satoru Moto-
kawa (Japan)
PATIENTS
Nabil Othman*, Xiufeng Gao, Henry Walters, Patrick Hines (United States)
08:15 08:30 IS THE INCIDENCE TREND OF HEPARIN-INDUCED THROMBOCYTOPENIA
ORALS
OR052 DECREASED BY THE INCREASED USE OF
Late breaking abstract session - Thrombosis and Anticoagulation Plenary Hall F&G
LOW-MOLECULAR-WEIGHT-HEPARIN?
Fahad Aleidan* (Saudi Arabia) Moderators: Charles Francis (United States), Frits Rosendaal (The Netherlands)
08:30 08:45 THE IMPACT OF OPTICAL DENSITY CUT-OFF ON SENSITIVITY AND 08:00 08:15 SCREENING FOR OCCULT MALIGNANCY IN PATIENTS WITH
OR053 SPECIFICITY FOR THE DIAGNOSIS OF HEPARIN INDUCED LB001 UNPROVOKED VENOUS THROMBOEMBOLISM: AN OPEN RANDOMIZED
THROMBOCYTOPENIA: A SYSTEMATIC REVIEW AND META-ANALYSIS CONTROLLED TRIAL USING A COMPREHENSIVE ABDOMEN/PELVIS
Lisa D. Duffett*, Marc Carrier, Grgoire Le Gal, Marc Rodger, Esteban Gndara (Canada) COMPUTED TOMOGRAPHY (SOME TRIAL).
Marc Carrier*, Alejandro Lazo-Langner, Sudeep Shivakumar, Vicky Tagalakis, Ryan
08:45 09:00 HIT OR PIT- CLINICAL RELEVANCE OF THE ZYMUTEST HIA IGG Zarychanski, Susan Solymoss, Nathalie Routhier, James Douketis, Kim Danovitch,
OR054 (HYPHEN BIOMED) IN A ROUTINE LABORATORY SETTING Agnes Lee, Gregoire Le Gal, Phil Wells, Tim Ramsay, Doug Coyle, Isabelle Chagnon,
ndreas Czwalinna, Brbel Steggewentz, Burghard Arndt, Arndt Grning, Frauke Berg-
A Zahra Kassam, Donald Taves, Marc Rodger, Hardy Tao (Canada)
mann* (Germany)
08:15 08:30 BRIDGING ANTICOAGULATION IN PATIENTS WHO REQUIRE TEMPORARY
EVALUATION OF FLOW CYTOMETRIC ASSAY IN THE DIAGNOSIS OF HIT
09:00 09:15 LB002 INTERRUPTION OF WARFARIN THERAPY FOR AN ELECTIVE INVASIVE
OR055
Brigitte Tardy*, Aurlie Montmartin, Michele Piot, Cline Chapelle, Madjid Akrour, PROCEDURE OR SURGERY (THE BRIDGE TRIAL)
Martine Alhenc-Gelas, Emmanuel De Maistre, Ismal Elalamy, Pierre Fontana, Andreas James Douketis, Alex Spyropoulos, Scott Kaatz, Joseph Caprini, Andrew Dunn,
Greinacher, Marie-Hlne Horellou, Dominique Lasne, Thomas Lecompte, Gregoire David Garcia, Alan Jacobson, Amir Jaffer, Andrei Kindzelski, Sam Schulman,
Legal, Agnes Lillo-LeLouet, Franois Mullier, Philippe Nguyen, Claire Pouplard, Marie Alexander Turpie, Richard Becker, Nathan Clark, Barbara Conti, Stacey Ellsworth,
Toussaint-Hacquard, Aaron Tomer, Bernard Tardy (France) Robert Harrison, David Kong, Gerhard Johnson, Arun Krishnamoorthy, Sebastian
Palmeri, Wanda Parker, Jorge Saucedo, Patricia Schoch, Debbie Tallman, Dan Witt,
Vic Hasselblad, Thomas L. Ortel* (United States)
100 101
08:30 08:45 RAPS (RIVAROXABAN IN ANTIPHOSPHOLIPID SYNDROME):
LB003 A PROSPECTIVE RANDOMISED CONTROLLED PHASE II/III CLINICAL Monday, June 22, 2015
TRIAL OF RIVAROXABAN VERSUS WARFARIN IN PATIENTS WITH
THROMBOTIC ANTIPHOSPHOLIPID SYNDROME, WITH OR WITHOUT SLE STATE-OF-THE-ART LECTURES 10:45-11:45
Hannah Cohen*, Beverley Hunt, Maria Efythymiou, Deepa Arachchillage, Maria Ruiz,
Simon Clawson, Nicola Muirhead, Yvonne Sylvestre, Samuel Machin, Maria Bertolacci-
ni, Caroline Dore, Ian Mackie, David Isenberg, Munther Khamashta (United Kingdom) J. Fraser Mustard SoA: Platelet function and dysfunction Room 718
ANNEXA-A PART 2: A PHASE 3 RANDOMIZED, DOUBLE-BLIND,

08:45 09:00 Moderator: Peter Gross (Canada)
LB004 PLACEBO-CONTROLLED TRIAL DEMONSTRATING SUSTAINED
10:45 - 11:05 Inherited disorders of platelet function
REVERSAL OF APIXABAN-INDUCED ANTICOAGULATION IN OLDER
Alan Nurden (France)
SUBJECTS BY ANDEXANET ALFA (PRT064445), A UNIVERSAL ANTIDOTE
FOR FACTOR XA (FXA) INHIBITORS 11:05 - 11:25 The P2Y12 ADP receptor: Structure and function
Mark Crowther*, Alex Gold, Genmin Lu, Janet Leeds, Brian Wiens, Vandana Mathur, Marco Cattaneo (Italy)
Janice Castillo, Pamela Conley, Stuart Connolly, John Curnutte (Canada)
11:25 - 11:45 IIb3: structure and function
09:00 09:15 INITIAL RESULTS OF THE RE-VERSE AD TRIAL: IDARUCIZUMAB Barry Coller (United States)
LB005 REVERSES THE ANTICOAGULANT EFFECTS OF DABIGATRAN IN
PATIENTS IN AN EMERGENCY SETTING OF MAJOR BLEEDING,
URGENT SURGERY, OR INTERVENTIONS Hijacking of proteolytic mechanisms by pathogens Room 716
harles Pollack*, Paul Reilly, Peter Verhamme, Richard Bernstein, Robert Dubiel,
C
MONDAY
John Eikelboom, Menno Huisman, Elaine Hylek, Chak-Wah Kam, Pieter Kamphuisen, Moderator: Jim Fredenburg (Canada)
Joerg Kreuzer, Jerrold Levy, Frank Sellke, Thorsten Steiner, Bushi Wang, Jeffrey Weitz
(United States) Fibrinolytic and procoagulant activities of Yersinia pestis and Salmonella
10:45 - 11:15
enterica
Timo K. Korhonen (Finland)
Coffee break time in the exhibition (Level 800)
From 09:15 to 09:45 11:15 - 11:45 Pathogen activators of plasminogen
STATE OF THE ART

Paul Bock (United States)

Mechanisms of thrombosis Room 714
PLENARY SESSION 09:45-10:30
Moderator: Uri Seligsohn (Israel)
Frank Schofield Plenary Lecture Hall F&G 10:45 - 11:05 Thrombosis as a key regulator of innate immunity
Steffen Massberg (Germany)
Moderator: Jeffrey Weitz (Canada)
11:05 - 11:25 Fibrinogen, factor XIII, and red blood cells: novel mechanisms in thrombosis
09:45 - 10:30 75 years of progress in antithrombotic therapy for cardiovascular disease Alisa Wolberg (United States)
Eugene Braunwald (United States)
11:25 - 11:45 New insights into the biology of tissue factor pathway inhibitor
Alan Mast (United States)
Hemophilia gene therapy; A Joint ISTH-WFH Symposium Plenary Hall F&G

Moderators: Marijke van den Berg (The Netherlands); Alok Srivastava (India)
10:45 - 11:05 New approaches to gene and cell therapy for hemophilia
Tsukasa Ohmori (Japan)
Platelet directed gene therapy

11:05 - 11:25
Mortimer Poncz (United States)
Frank Schofield, 1889-1970

102 103
11:25 - 11:45 Gene therapy for hemophilia B ORAL COMMUNICATIONS 2 14:00-15:15
Paul Monahan (United States)
Controversies in VTE management Room 701 NOACs in clinical practice Plenary Hall F&G
Moderators: Henri Bounameaux (Switzerland); Alexander S. Gallus (Australia) Moderators: Deepa Suryanarayan (Canada), Pantep Angchaisuksiri (Thailand)
10:45 - 11:15 Pulmonary embolism Whom to thrombolyse? Whom to discharge? 14:00 14:15 ADHERENCE TO ANTICOAGULANT TREATMENT WITH DABIGATRAN AND
Guy Meyer (France) OR061 RIVAROXABAN IN A REAL-WORLD SETTING
Faris Al Khalili*, Deepa Suryanarayan, Catrine Lindstrm, Sam Schulman, Ammar
11:15 - 11:45 Controversies in VTE diagnosis Majeed (Sweden)
Gregoire Le Gal (Canada)
14:15 14:30 THE IMPACT OF THE INTRODUCTION OF DABIGATRAN ON
OR062 ANTICOAGULANT MANAGEMENT IN NEW ZEALAND
Burden, prevention and management of periop cardiovascular complications Room 801 Paul L. Harper*, Daryl Pollock, Laura Chen, Su Chen Fong (New Zealand)
Moderators: Giancarlo Agnelli (Italy); James Douketis (Canada) 14:30 14:45 REAL-WORLD RIVAROXABAN LEVELS FROM KINGS COLLEGE HOSPITAL
OR063 Kathryn Lan*, Jignesh Patel, Paradzai Chitongo, Julia Czuprynska, Lara Roberts, Raj
10:45 - 11:05 Perioperative myocardial injury Patel, Roopen Arya (United Kingdom)
Dan Sessler (United States) 14:45 15:00 PROSPECTIVE SURVEY OF ADVERSE EFFECTS OF NON-VITAMIN K ORAL
MONDAY
OR064 ANTICOAGULANTS IN TWO UK HOSPITAL TRUSTS
What is the role of aspirin for prevention and treatment of perioperative
11:05 - 11:25
Owain Myers, Sue Pavord, Marissa Hagan, Bethan Myers* (United Kingdom)
cardiovascular events?
Philip J. Devereaux (Canada) 15:00 15:15 DABIGATRAN BUT NOT RIVAROXABAN OR APIXABAN REDUCES
New paroxysmal perioperative atrial fibrillation: how important is it for
11:25 - 11:45
OR065 FIBRINOLYTIC RESISTANCE IN PATIENTS WITH ATRIAL FIBRILLATION
Concetta T. Ammollo*, Fabrizio Semeraro, Francesca Incampo, Claudia Dellanoce,
patients and what should I do about it?
Oriana Paoletti, Sophie Testa, Mario Colucci (Italy)
Pablo Alonso Coello (Spain)
ORALS
Extracorporeal circulation in children: can we restore normal hemostasis? Room 713 Management of bleeding? Room 718
Moderators: Ravindra Sarode (United States), Peter Kouides (United States)

Moderators: Leonardo Brandao (Canada); Ulrike Nowak-Gttl (Germany)
14:00 14:15 ROLE OF TRANEXAMIC ACID IN REDUCING BLEEDING EPISODES AND

10:45 - 11:15 ECMO: The precarious balance of hemostasis OR066 REQUIREMENT OF PLATELET SUPPORT IN PATIENTS WITH APLASTIC
Gail Annich (United States) ANEMIA
Pravas Mishra*, Sudhir Kumar, Manoranjan Mahapatra, Tulika Seth (India)
Ventricular assist devices and antithrombotic therapy: Do we really know
11:15 - 11:45
what to do? 14:15 14:30 EFFECTS OF IDARUCIZUMAB, GIVEN AS A SPLIT DOSE, IN A BLUNT
Patti Massicotte (Canada) OR067 LIVER DOUBLE TRAUMA MODEL IN PIGS RECEIVING DABIGATRAN
Markus Honickel, Joanne van Ryn, Rolf Rossaint, Hugo ten Cate, Henri Spronk, Oliver
Grottke* (Germany)
Lunch in the exhibition (Level 800)
14:30 14:45 HEMODIALYSIS FOR THE TREATMENT OF DABIGATRAN-ASSOCIATED
From 11:45 to 12:15 OR068 BLEEDING: A SYSTEMATIC REVIEW OF THE LITERATURE
Chatree Chai-Adisaksopha*, Christopher Hillis, Wendy Lim, Kochawan Boonyawat,
Lunch Symposia Mark Crowther (Canada)
From 12:15 to 13:45 14:45 15:00 OPTIMAL TIMING OF WARFARIN RESUMPTION AFTER WARFARIN
unch Symposia Programs are available in the Show Guide.
L OR069 RELATED UPPER GASTROINTESTINAL BLEEDING
Please consult the different options to attend the symposium of your choice. Ammar Majeed*, Joakim Eriksson, Niklas Wallvik, Sam Schulman (Sweden)

104 105
15:00 15:15 FIBRINOGEN CONCENTRATE IMPROVES FIBRIN NETWORK STRUCTURE 14:30 14:45 THE INCIDENCE OF VTE IN ASYMPTOMATIC CARRIERS OF A
OR070 DURING ORTHOTOPIC LIVER TRANSPLANTATION. OR078 DEFICIENCY OF AT, PC OR PS: A PROSPECTIVE COHORT STUDY
afna Groeneveld*, Jelle Adelmeijer, Greg Hugenholtz, Robert Porte, Ton Lisman (The
D Daniela Tormene*, Laura Guerra, Sabrina Gavasso, Cristiana Bulato, Francesca Sar-
Netherlands) torello, Elena Campello, Fabio Dalla Valle, Luca Spiezia, Paolo Simioni (Italy)
14:45 15:00 ANTITHROMBIN HEPARIN BINDING SITE DEFICIENCY: A CHALLENGING

Venous thromboembolism epidemiology I Room 701 OR079 DIAGNOSIS OF A NOT SO BENIGN THROMBOPHILIA
Christelle Orlando*, Olivier Heylen, Willy Lissens, Kristin Jochmans (Belgium)
Moderators: Ophira Salomon (Israel), Marco Donadini (Italy)
15:00 15:15 HIGH NEUTROPHIL AND BASOPHIL BLOOD COUNTS ARE ASSOCIATED
14:00 14:15 IMPACT OF INCIDENT MYOCARDIAL INFARCTION ON FUTURE RISK OF OR080 WITH INCREASED FACTOR II PLASMA COAGULANT ACTIVITY AND MAY
OR071 VENOUS THROMBOEMBOLISM BE PREDICTORS OF MORTALITY IN PATIENTS WITH STABLE CORONARY
udvig B. Rinde*, Birgit Smbrekke, Caroline Lind, Inger Njlstad, Ellisiv Mathiesen,
L ARTERY DISEASE.
Erin Hald, Sigrid Brkkan, John-Bjarne Hansen (Norway) icola Martinelli*, Domenico Girelli, Federica Tosi, Filippo Sartori, Giovanna Marchet-
N
ti, Roberto Corrocher, Francesco Bernardi, Oliviero Olivieri (Italy)
14:15 14:30 DEVELOPMENT AND VALIDATION OF A PATIENT SELF-ADMINISTERED
OR072 VILLALTA SCALE FOR PATIENT SELF-ASSESSMENT OF THE
POST-THROMBOTIC SYNDROME Megakaryocytes and thrombopoiesis I Room 714
Kristin Utne*, Waleed Ghanima, Per Sandset, Susan Kahn, Hilde Wik (Norway)
Moderators: Koji Eto (Japan), Rochelle Winikoff (Canada)
OUTCOMES FROM THE NATIONAL VENOUS THROMBOEMBOLISM
14:30 14:45
MONDAY
OR073 PREVENTION PROGRAMME IN ENGLAND 14:00 - 14:15 GENETIC ABLATION OF TRPM7 ALTERS MAGNESIUM HOMEOSTASIS
Lara Roberts, Helen Morrison, Tim Abbott, Frances Healey, Mike Durkin, Roopen Arya* OR081 AND INDUCES MACROTHROMBOCYTOPENIA IN MICE
(United Kingdom) Simon Stritt, Sanjeev Gotru, Vladimir Chubanov, Thomas Gudermann, Harald Schulze,
Paquita Nurden, Bernhard Nieswandt, Attila Braun* (Germany)
14:45 15:00 RISK STRATIFICATION OF PATIENTS WITH ACUTE SYMPTOMATIC
OR074 PULMONARY EMBOLISM BASED ON PRESENCE OR ABSENCE OF DEEP 14:15 - 14:30 OF MEN AND MICE: DIVERGENCE EFFECT OF HDAC6 ON PROPLATELET
VEIN THROMBOSIS: SYSTEMATIC REVIEW AND META-ANALYSIS OR082 FORMATION
ecilia Becattini, Alexander Cohen, Giancarlo Agnelli, Luke Howard, Borja Castejon,
C Kahia Messaoudi*, Ali Ashfaq, Alberta Palazzo, Olivier Bluteau, Philippe Rameau,
ORALS
Javier Trujillo-Santos, Manuel Monreal, Arnaud Perrier, Roger Yusen, David Jimenez* Hana Raslova, Isabelle Plo, William Vainchenker, Najet Debili (France)
(Spain)
14:30 - 14:45 GLYCOPROTEIN VI INTERACTIONS WITH COLLAGEN TYPE I SELECTIVELY
REGULAR PHYSICAL ACTIVITY AND FUTURE RISK OF MYOCARDIAL
15:00 15:15 OR083 INHIBIT PROPLATELET FORMATION
OR075 INFARCTION AND VENOUS THROMBOSIS THE TROMS STUDY Harald Schulze*, David Stegner, Daniela Semeniak, Beate Eckes, Bernhard Nieswandt,
Sigrid Braekkan*, Ellen Brodin, Anders Vik, Tom Wilsgaard, Inger Njlstad, Ellisiv Rebecca Kulawig (Germany)
Mathiesen, John-Bjarne Hansen (Norway)
14:45 - 15:00 RAPID RUPTURE-TYPE THROMBOPOIESIS PROCESSES FROM BONE
OR084 MARROW MEGAKARYOCYTE IN RESPONSE TO ACUTE PLATELET NEEDS
Thrombophilia Room 801 IS REGULATED BY IL-1ALPHA
Satoshi Nishimura*, Asuka Sakata, Kinya Seo, Tsukasa Ohmori, Koji Eto (Japan)
Moderators: Cynthia Wu (Canada), Ken Bauer (United States)
15:00 - 15:15 SYNTHESIS OF MARCKS IN THE LATE STAGES OF MEGAKARYOCYTE
14:00 14:15 ANTITHROMBIN DUBLIN (P.VAL30GLU): A POLYMORPHISM WITH OR085 MATURATION DRIVES PROPLATELET FORMATION
OR076 MODERATE RISK OF THROMBOSIS THAT CAUSES A TRANSIENT Kellie Machlus*, Stephen Wu, Debbie Stumpo, Robert Campbell, Andrew Weyrich,
ANTITHROMBIN DEFICIENCY BY INTRACELLULAR FOLDING INTO THE Perry Blackshear, Joseph Italiano (United States)
LATENT CONFORMATION
J os Navarro-Fernndez*, Mara de la Morena-Barrio, Jos Padilla, Antonia Miano, Von Willebrand Disease Room 716
Nataliya Bohdan, Sonia guila, Irene Martnez-Martnez, Teresa Sevivas, Carmen de
Cos, Nuria Fernndez-Mosteirin, Pilar Llamas, Susana Asenjo, Pilar Medina, Juan Moderators: Ian Peake (United Kingdom), Jordan Shavit (United States)
Souto, Kim Overvad, Sren Kristensen, Vicente Vicente, Javier Corral (Spain)
14:00 14:15 DETECTION OF LARGE EXONIC AND INTERGENIC DELETIONS IN THE
14:15 14:30 AGE-DEPENDENT FACTOR IX ACTIVITY IN ASSOCIATION WITH THE
OR086 VWF LOCUS OF VWD PATIENTS USING ARRAY COMPARATIVE GENOMIC
OR077 A/A-GENOTYPE OF F9 G32023A -POLYMORPHISM (RS440051) AND
HYBRIDISATION (ACGH)
CONSEQUENT RISK OF VENOUS THROMBOEMBOLISM (VTE)
Simon J. Webster*, Daniel Hampshire, Reinhard Schneppenheim, Daniel Bellissimo,
Rainer B. Zotz*, Daniel Szafarczyk, Ruediger Scharf, Andrea Gerhardt (Germany)
106 Paula James, Bimal Theophilus, Ian Peake, Anne Goodeve (United Kingdom) 107
14:15 14:30 LONG-TERM EXPRESSION OF VON WILLEBRAND FACTOR VIA SLEEPING Vitamin K antagonists Room 715
OR087 BEAUTY SANDWICH TRANSPOSON-MEDIATED GENE THERAPY
Irina Portier*, Karen Vanhoorelbeke, Sebastien Verhenne, Inge Pareyn, Hans Deckmyn, Moderators: Karina Meijer (The Netherlands), Jack Ansell (United States)
Zsuzsanna Izsvk, Simon De Meyer (Belgium)
14:00 14:15 QUALITY OF VITAMIN K ANTAGONIST CONTROL AND 1-YEAR
SAFETY, EFFICACY AND PHARMACOKINETICS OF A RECOMBINANT
14:30 14:45
OR096 OUTCOMES: A GLOBAL PERSPECTIVE FROM THE GARFIELD-AF
OR088 VON WILLEBRAND FACTOR IN PATIENTS WITH SEVERE VON
REGISTRY
WILLEBRAND DISEASE: A PROSPECTIVE CLINICAL TRIAL
Hugo ten Cate*, Sylvia Haas, Gabriele Accetta, Pantep Angchaisuksiri, John Camm,
Joan Gill, Giancarlo Castaman, Jerzy Windyga, Peter Kouides, Margaret Ragni*, Frank
Ramon Corbalan, John Eikelboom, David Fitzmaurice, Samuel Goldhaber, Shinya Goto,
Leebeek, Ortrun Obermann-Slupetzky, Miranda Chapman, Sandor Fritsch, Borislava
Barry Jacobson, Gloria Kayani, Alexander Turpie, Ajay Kakkar (The Netherlands)
Pavlova, Isabella Presch, Bruce Ewenstein (Austria)
14:15 14:30 INDEPENDENT PREDICTORS OF POOR VITAMIN K ANTAGONIST
14:45 15:00 NO DIFFERENCE IN VWF LEVELS NOR VWF SURVIVAL IN INDEX CASES
OR097 CONTROL IN VENOUS THROMBOEMBOLISM PATIENTS: DATA FROM THE
OR089 AND FAMILY MEMBERS WITH AND WITHOUT P.Y1584C ENROLLED IN
EINSTEIN-DVT AND PE STUDIES.
ZIMMERMAN PROGRAM FOR THE MOLECULAR AND CLINICAL BIOLOGY
Hilde A. Kooistra*, Martin Gebel, Kurtulus Sahin, Anthonie Lensing, Karina Meijer
OF VWD (ZPMCB-VWD) (The Netherlands)
Pamela A. Christopherson, Daniel Bellissimo, Veronica Flood, Kenneth Friedman, Joan
Gill, Robert Montgomery, Sandra Haberichter* (United States) 14:30 14:45 BLEEDING RISKS ARE HIGH IN ELDERLY PERSONS WHO USE VITAMIN K
OR098 ANTAGONISTS COMBINED WITH PLATELET AGGREGATION INHIBITORS
15:00 15:15 PREVALENCE AND RISK FACTORS ASSOCIATED WITH HYPERTENSION
Nienke Van Rein*, Uffe Heide-Jrgensen, Willem Lijfering, Lars Pedersen, Olaf Dek-
OR090 IN VON WILLEBRAND DISEASE
MONDAY
kers, Henrik Srensen, Suzanne Cannegieter (Denmark, The Netherlands)
Mariya Apostolova*, Craig Seaman, Diane Comer, Jonathan Yabes, Margaret Ragni
(United States) 14:45 15:00 THE EFFECT OF CYP2C9 POLYMORPHISM ON INR DECLINE IN PATIENTS
OR099 STOPPING WARFARIN BEFORE SURGERY
Antiphospholipid antibodies I Room 713 Salah Abohelaika*, Hilary Wynne, Peter Avery, Farhad Kamali (United Kingdom)
Moderators: Wendy Lim (Canada), Thomas Ortel (United States)

15:00 15:15 IMPACT OF VITAMIN K ANTAGONISTS (VKA) ON QUALITY OF LIFE (QOL)
OR100 IN A PROSPECTIVE COHORT OF 807 ATRIAL FIBRILLATION (AF) PATIENTS

ORALS
ilde A. Kooistra*, Margriet Piersma-Wichers, Hanneke Kluin-Nelemans, Nic Veeger,
H
14:00 14:15 EFFECTS OF ANTIPHOSPHOLIPID ANTIBODIES ON VASCULAR SMOOTH
Karina Meijer (The Netherlands)
OR091 MUSCLE CELLS
Camille Rouillon*, Stphanie Makhoul, Patrick Lacolley, Vronique Regnault, Denis
Wahl (France) Hemophilia prophylaxis Room 717
IMPACT OF HYDROXYCHLOROQUINE TREATMENT ON PREGNANCY
14:15 14:30 Moderators: Victor Blanchette (Canada), Kathelijn Fischer (The Netherlands)
OR092 OUTCOME IN PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES
Savino Sciascia*, Beverley Hunt, Eva Talavera, Gloria Lliso, Munther Khamashta, 14:00 14:15 SPINART TRIAL 3-YEAR RESULTS WITH BAYERS SUCROSE-FORMULATED
Maria Cuadrado (United Kingdom)
OR101 RECOMBINANT FACTOR VIII: RELATIONSHIP BETWEEN BLEEDING
14:30 14:45 THROMBIN GENERATION IN PATIENTS WITH ANTIPHOSPHOLIPID FREQUENCY AND JOINT HEALTH IN ADULTS WITH SEVERE
OR093 ANTIBODIES HEMOPHILIA A USING PROPHYLAXIS
Patrizia Della Valle, Chiara Novelli*, Paola Pradella, Benedetto Morelli, Armando DAn- Mark T. Reding*, Christine Kempton, Sharon Funk, Sylvia Engelen, Dale Walker, Walter
gelo (Italy) Hong (United States)
14:45 15:00 INFLAMMATION AND CARDIOVASCULAR RISK FACTORS ARE 14:15 14:30 DISCONTINUING EARLY PROPHYLAXIS IN YOUNG ADULTS WITH
OR094 ASSOCIATED WITH RECURRENT THROMBOSIS IN ANTIPHOSPHOLIPID OR102 SEVERE HAEMOPHILIA A: DETERIORATION OF JOINT STATUS AFTER 10
SYNDROME YEARS DESPITE LOW BLEEDING RATES
Sabrina Saraiva*, Isadora Custdio, Bruna Mazzeto, Marina Collela, Erich de Paula, Annelies Nijdam, Wouter Foppen, Piet de Kleijn, Evelien Mauser-Bunschoten, Goris
Simone Appenzeller, Joyce Annichino-Bizzacchi, Fernanda A. Orsi (Brazil) Roosendaal, Karin van Galen, Roger Schutgens, Kathelijn Fischer* (The Netherlands)
15:00 15:15 OBSTETRIC ANTIPHOSPHOLIPID SYNDROME: HIGH COMPARATIVE 14:30 14:45 RETROSPECTIVE 28-YEAR LONG TERM FOLLOW-UP OF PROPHYLAXIS IN
OR095 PREVALENCE OF COMMON MENTAL DISORDERS DURING FOLLOW-UP. OR103 A COHORT OF 49 PATIENTS WITH SEVERE HAEMOPHILIA A
J ean-Christophe R. Gris*, Graldine Lavigne, Sylvie Bouvier, Eva Nouvellon, Erick Mer- J ohannes Oldenburg*, Lemonia Krmer, Georg Goldmann, Natascha Marquardt,
cier, Cline Chauleur, Jean-Philippe Galanaud, Isabelle Qur, Pierre Mars (France) Hans-Hermann Brackmann (Germany)
108 109
14:45 15:00 PROPHYLAXIS IN CHILDREN WITH SEVERE AND MODERATE 14:30 14:45 MEKK3 CONTROLS THE ERK1/2- AND JNK2-MEDIATED PLATELET
OR104 HAEMOPHILIA: A SURVEY OF UK PRACTICE. OR113 ACTIVATION AND ARTERIAL THROMBOSIS
yan Rodgers*, Jay Alamelu, Peter Collins, Mary Mathias, Jeanette Payne, Mike Rich-
R uemei Fan*, Conghui Wang, Xue Chen, Jing Dai, Xiaolin Wu, Kemin Wang, Junling
X
ards, Oliver Tunstall, Mike Williams, David Young, Tina Biss, Angela Thomas, Elizabeth Liu (China)
Chalmers (United Kingdom)
14:45 15:00 CASEIN KINASE 2 IS CRITICAL PLAYER IN PLATELET ACTIVATION,
15:00 15:15 PROPHYLAXIS IN ADULT PATIENTS WITH SEVERE HEMOPHILIA A OR OR114 ARTERIAL THROMBOSIS AND ISCHEMIC STROKE
OR105 B WITHOUT INHIBITORS Oliver Borst*, Patrick Mnzer, Britta Walker, Friederike Langhauser, Mita Chatterjee,
Louis Aledort*, Laura Avila, Victor Blanchette, Thierry Lambert (United States) Anna Fotinos, Christoph Kleinschnitz, Florian Lang, Meinrad Gawaz (Germany)
15:00 15:15 THE FOCAL ADHESION KINASE PYK2 MEDIATES CA2+-DEPENDENT

Factor VIII I Room 705 OR115 ACTIVATION OF THE SRC FAMILY KINASES FYN AND LYN IN
THROMBIN-STIMULATED PLATELETS
Moderators: Paul Moorehead (Canada), Roland Herzog (United States) Ilaria Canobbio*, Lina Cipolla, Gianni Guidetti, Daria Manganaro, Soochong Kim,
Mitsuhiko Okigaki, Marco Falasca, Satya Kunapuli, Mauro Torti (Italy)
14:00 14:15 TRANSGENE EXPRESSION UNDER THE CONTROL OF FVIII PROMOTER
OR106 FOR HEMOPHILIA A TARGETED THERAPY
Diego Zanolini*, Simone Merlin, Valentina Bruscaggin, Antonia Follenzi (Italy) Stroke Room 709
14:15 14:30 ROLE OF THE IGG BACKBONE IN B CELL DEPLETION AND INHIBITOR Moderators: Alessandro Squizzato (Italy), Ajay Kakkar (United Kingdom)
OR107 REVERSAL IN HEMOPHILIA A WITH ANTI-CD20 ANTIBODIES
MONDAY
Geoffrey L. Rogers*, Alexandra Sherman, David Markusic, Haiyan Jiang, Roland Herzog 14:00 14:15 CM352, A NEW ANTIFIBRINOLYTIC, REDUCES HEMATOMA GROWTH
(United States) OR116 AND IMPROVES FUNCTIONAL RECOVERY IN A COLLAGENASE-INDUCED
RAT MODEL OF INTRACEREBRAL HEMORRHAGE
14:30 14:45 HIGH THROUGHPUT AMINO ACID SEQUENCE EPITOPE MAPPING OF J osune Orbe*, Tomas Sobrino, Jose Rodriguez, Francisco Campos, Julen Oyarzabal,
OR108 INHIBITORY ANTIBODIES IN SEVERE HEMOPHILIA A Jose Castillo, Jose A. Paramo (Spain)
aul Batty*, Stuart Skelton, Adrian Shepherd, Maria Mancuso, Elena Santagostino,
P
Flora Peyvandi, Daniel Hart (United Kingdom) 14:15 14:30 ASSESSMENT OF THE DIAGNOSTIC VALUE OF PLASMA LEVELS,
OR117 ACTIVITIES AND THEIR RATIOS OF VON WILLEBRAND FACTOR AND
ORALS
14:45 15:00 ADOPTIVE TRANSFER OF IN VITRO EXPANDED FVIII-SPECIFIC ADAMTS13 IN PATIENTS WITH CEREBRAL INFARCTION
OR109 REGULATORY T CELLS TO MEDIATE TOLERANCE IN HEMOPHILIA Yiming Zhao, Le Qu*, Miao Jiang, Changgeng Ruan (China)
A MICE
Bryn Smith*, Meghan Lyle, Carol Miao (United States) 14:30 14:45 IS ANEMIA A RISK FACTOR FOR CEREBRAL VENOUS THROMBOSIS?
OR118 Jonathan M. Coutinho*, Susanna Zuurbier, Jan Stam, Saskia Middeldorp, Suzanne
15:00 15:15 HEPATOCELLULAR DISTRIBUTION OF FVIII IN EX VIVO PERFUSED RAT Cannegieter (The Netherlands)
OR110 LIVER: LIVER SINUSOIDAL ENDOTHELIAL CELLS ARE THE CELLS
PRIMARILY RESPONSIBLE FOR UPTAKE OF FVIII 14:45 15:00 RISK PROFILES AND 1-YEAR OUTCOMES OF PATIENTS WITH NEWLY
irstine Roepstorff*, Mette Loftager, Jes Clausen, Marianne Kjalke, Frederik Rode,
K OR119 DIAGNOSED ATRIAL FIBRILLATION: RESULTS FROM GARFIELD-AF
Jesper Haaning, Rupa Appa (Denmark) Ajay K. Kakkar*, Gabriele Accetta, Giancarlo Agnelli, Pantep Angchaisuksiri, Jean-
Pierre Bassand, Karen Chiswell, Frank Cools, David Fitzmaurice, Harry Gibbs, Samuel
Goldhaber, Shinya Goto, Sylvia Haas, Barry Jacobson, Carlos Jerjes-Sanchez, Gloria
Platelets kinases-I Room 707 Kayani, Lorenzo Mantovani, Frank Misselwitz, Hugo ten Cate, Alexander Turpie, Martin
van Eickels, Freek Verheugt, John Camm (United Kingdom)
Moderators: Diego Mezzano (Chile), Satya Kunapuli (United States)
RED CELL DISTRIBUTION WIDTH IS ASSOCIATED WITH FUTURE RISK
15:00 15:15
DISTINCT PATHWAYS REGULATE SYK ACTIVATION DOWNSTREAM OF
14:00 14:15 OR120 OF INCIDENT STROKE. THE TROMS STUDY
OR111 ITAM AND HEMI-ITAM RECEPTORS IN PLATELETS Jostein Lappegrd*, Trygve Ellingsen, Tove Skjelbakken, Ellisiv Mathiesen, Inger Njls-
Bhanukanth Manne*, Rachit Badolia, Carol Dangelmaier, Wilfried Ellmeier, Mark tad, Tom Wilsgaard, Jan Brox, Sigrid Brkkan, John-Bjarne Hansen (Norway)
Kahn, Satua P Kunapuli (United States)
14:15 14:30 GLYCOGEN SYNTHASE KINASE-3 PHOSPHORYLATION PREVENTS

OR112 PATHOLOGICAL GPVI-MEDIATED PLATELET ACTIVATION AND
THROMBOSIS
Samantha F. Moore*, Thomas Blair, Ingeborg Hers (United Kingdom)
110 111
Innate and acquired Immunity Room 711 16:35 16:55 CHARACTERISATION OF CELLULAR FIBRINOGEN PHOSPHORYLATION
AS003 AND ITS FUNCTIONAL IMPLICATIONS IN CLOT FORMATION
Moderators: Anne Zufferey Bakos (Canada), Craig Morrell (United States) errie A. Smith*, Esther Cooke, Paul Cordell, Richard Pease, Jane Brown, Cora Beck-
K
ers, Kingsley Simpson, Peter Grant (United Kingdom)
14:00 14:15 NEUTROPHIL EXTRACELLULAR TRAP (NET) FORMATION IN PATIENTS
16:55 17:15 MECHANISMS BY WHICH DNA, HISTONES AND NEUTROPHIL
OR121 WITH POST-BURN SEPSIS
AS004 EXTRACELLULAR TRAPS STABILISE CLOTS TOWARDS MECHANICAL
Robert J. Dinsdale*, Peter Hampson, Chris Wearn, Jon Hazeldine, Alexander Brill,
AND FIBRINOLYTIC BREAKDOWN
Janet Lord, Naiem Moiemen, Paul Harrison (United Kingdom)
Imre Varj*, Colin Longstaff, Lszl Szab, Veronika Judit Varga-Szab, dm Zoltn
14:15 14:30 COMPARED TO B220/CD45R+ B LYMPHOCYTES, SPLENIC DENDRITIC Farkas, Erzsbet Komorowicz, Krasimir Kolev (Hungary)
OR122 CELLS AND MACROPHAGES HAVE LIMITED PROPENSITY TO BIND
FACTOR VIII AND DEMONSTRATE DOWN-REGULATION OF
CO-STIMULATORY MOLECULES. Platelets and bacteria Room 711
Jesse Lai*, Dominique Cartier, Alice van Velzen, Christine Hough, David Lillicrap
(Canada) Moderators: John Semple (Canada), Archie McNichol (Canada)
14:30 14:45 MITOCHONDRIAL DNA AND TOLL-LIKE RECEPTOR 9 ARE ASSOCIATED 15:45 - 16:15 THROMBUS FORMATION CAUSED BY INVADING PATHOGENS: THE ROL
OR123 WITH MORTALITY IN CRITICALLY ILL PATIENTS AS005 OF PLATELETS
Sarah Ruhittel, Konstantin Krychtiuk*, Philipp Hohensinner, Lorenz Koller, Christoph Steven Kerrigan (Ireland)
Kaun, Max Lenz, Benedikt Bauer, Lisa Wutzelhofer, Dominik Draxler, Gerald Maurer,
MONDAY
Kurt Huber, Johann Wojta, Gottfried Heinz, Alexander Niessner, Walter Speidl (Austria) 16:15 16:30 CLEC-2 IS REQUIRED FOR THE ACTIVATION OF MOUSE PLATELETS B
AS006 BACTERIAL DNA MIMETICS
14:45 15:00 AKI DEVELOPMENT UPON SIRS IS ASSOCIATED WITH PLATELET eline Delierneux*, Alexandre Hego, Christelle Lecut, Maud Vandereyken, Lucia Musu-
C
OR124 ACTIVATION, POSSIBLY TRIGGERED BY MITOCHONDRIAL DNA DERIVED meci, Souad Rahmouni, Vincent Bours, Patrizio Lancellotti, Ccile Oury (Belgium)
FROM DAMAGED CELLS
Marcel P. B. Jansen*, Wilco Pulskens, Loes Butter, Nike Claessen, Diba Emal, San- 16:30 16:45 PLATELET MYD88 ENHANCES CYTOKINE PRODUCTION INDUCED BY
drine Florquin, Nicole Juffermans, Joris Roelofs, Jaklien Leemans (The Netherlands) AS007 TLR AGONISTS AND KLEBSIELLA PNEUMONIAE
SYMPOSIA
heodora A. Claushuis*, Sacha de Stoppelaar, Cornelis van t Veer, Tom van der Poll
T
15:00 15:15 DIPHOSPHORYLATED LIPID A TRIGGERS TISSUE FACTOR MRNA (The Netherlands)
OR125 SPLICING IN HUMAN PLATELETS
Krystin Krauel*, Ulrike Thorack, Anne Schumacher, Hansjrg Schwertz (Germany) 16:45 17:00 POLYPHOSPHATE CHAIN LENGTH DETERMINES ANTIGENICITY OF
AS008 COMPLEXES FORMED WITH PLATELET FACTOR 4 (PF4) AND
PF4-BINDING TO BACTERIA
Coffee break time in the exhibition (Level 800) ihaela Delcea*, Sven Brandt, Krystin Krauel, Miriam Jaax, Thomas Renn, Christiane
M
From 15:15 to 15:45 Helm, Sven Hammerschmidt, Andreas Greinacher (Germany)
17:00 17:15 SHEAR-RESISTANT BINDING TO VON WILLEBRAND FACTOR ALLOWS

Monday, June 22, 2015 AS009 STAPHYLOCOCCUS LUGDUNENSIS TO ADHERE TO THE CARDIAC
VALVES AND INITIATE ENDOCARDITIS
ABSTRACT SYMPOSIA 15:45-17:15 aurens Liesenborghs*, Marijke Peetermans, Jorien Claes, Marleen Lox, Christophe
L
Vandenbriele, Maarten Criel, Thomas Vanassche, Marc Hoylaerts, Peter Verhamme
(Belgium)
Fibrinogen Room 716
Moderators: Matthew Flick (United States), Kellie Machlus (United States) Genetic basis of platelet disorders Room 715
Moderators: Kathleen Freson (Belgium), Matthew Rondina (United States)

15:45 - 16:15 REGULATORS OF STRUCTURE IN THE FIBRIN CLOT
AS001 Helen Philippou (United Kingdom)
15:45 - 16:15 PLATELET GRANULE BIOGENESIS
TRANSCRIPTOME ANALYSIS REVEALS HNF4A AS A MIR-29C TARGET
16:15 16:35 AS010 Walter Kahr (Canada)
AS002 LINKED TO REDUCED FIBRINOGEN EXPRESSION
Samuel Lukowski, Richard J. Fish*, Marguerite Neerman-Arbez (Switzerland)
112 113
16:15 16:30 CONSECUTIVE SLFN14 MUTATIONS IN 3 UNRELATED FAMILIES WITH 17:00 17:15 THROMBIN GENERATION IS INCREASED IN PLASMA FROM HEALTHY
AS011 AN INHERITED BLEEDING DISORDER, THROMBOCYTOPENIA AND AS019 MALES WHO HAVE RECEIVED CONCIZUMAB, AN ANTIBODY AGAINST
SECRETION DEFECTS TISSUE FACTOR PATHWAY INHIBITOR (EXPLORERTM2)
Sarah Fletcher, Ben Johnson, Gill Lowe, Danai Bem, Sian Drake, Marie Lordkipanid- Emily K. Waters*, Jens Sigh, Mirella Ezban, Ida Hilden (Denmark)
z, Isabel Snchez Gui, Ban Dawood, Jos Rivera, Michael Simpson, Martina Daly,
Jayashree Motwani, Peter Collins, Steve Watson, Neil V. Morgan* (United Kingdom)
Womens issues in venous thrombosis Room 801
16:30 16:45 UNRAVELLING RARE BLEEDING AND PLATELET DISORDERS (BPD)
AS012 USING COMPREHENSIVE PHENOTYPING AND GENOME SEQUENCING Moderators: Shannon Bates (Canada), Lisa Baumann-Kreuziger (United States)
Claire Lentaigne* (United Kingdom)
15:45 - 16:15 ANTITHROMBOTIC THERAPY TO PREVENT PLACENTA MEDIATED
A DOMINANT GAIN-OF-FUNCTION MUTATION IN A TYROSINE KINASE
16:45 17:00 AS020 COMPLICATIONS
AS013 GENE CAUSES A NEW GRAY PLATELET-LIKE SYNDROME WITH BONE Robert M. Silver (United States)
PATHOLOGIES
Anouck Wijgaerts* (Belgium) 16:15 16:35 TIME TO LIVE BIRTH IN WOMEN WITH RECURRENT MISCARRIAGE AND
AS021 INHERITED THROMBOPHILIA
17:00 17:15 MUTATION IN ETS VARIANT GENE 6 ASSOCIATES WITH AUTOSOMAL Paulien G. de Jong*, Stef Kaandorp, Remi Kool, Barbara Hutten, Saskia Middeldorp,
AS014 DOMINANT THROMBOCYTOPENIA AND RAISED LEVELS OF Maritte Goddijn (The Netherlands)
CIRCULATING CD34+ CELLS
Marjorie Poggi, Vronique Baccini, Marie Favier, Matthias Canault*, Anna Mezzapesa, 16:35 16:55 HORMONAL THERAPY AND THE RISK OF RECURRENT VENOUS
Dorsaf Ghalloussi, Nadjim Chelghoum, Badreddine Mohand-Oumoussa, Cline Falaise, AS022 THROMBOEMBOLISM IN WOMEN RECEIVING ANTICOAGULANT
MONDAY
Franck Peiretti, Pierre Morange, Nomie Saut, Jacques Ghysdael, Alan Nurden, Fabien TREATMENT
Guidez, Denis Bernot, Paquita Nurden, Hana Raslova, David-Alexandre Tregouet, Ida Martinelli*, Anthonie Lensing, Jan Beyer-Westendorf, Mila Trajanovic, Martin
Marie-Chrisitne Alessi (France) Gebel, Phuong Lam, Martin Prins (Italy)
16:55 17:15 THE PROPORTION OF NONDIAGNOSTIC COMPUTED TOMOGRAPHIC

New alternatives for treating bleeding disorders Plenary Hall F&G AS023 PULMONARY ANGIOGRAPHY AND VENTILATION/PERFUSION LUNG
SCANS IN PREGNANT WOMEN WITH SUSPECTED PULMONARY
SYMPOSIA
Moderators: Jerry Teitel (Canada), Jerzy Windyga (Poland)
EMBOLISM: A SYSTEMATIC REVIEW.
Arabesque Parker*, Ghazi Alotaibi, Cynthia Wu, Sarah Takach Lapner (Canada)
THE POTENTIAL OF BISPECIFIC ANTIBODIES FOR TREATMENT OF
15:45 - 16:15
AS015 HEMOPHILIA
Craig Kessler (United States) Modulation of atherothrombosis Room 705
16:15 16:30 A RECOMBINANT FUSION PROTEIN LINKING COAGULATION FACTOR Moderators: Xinjie Lu (United Kingdom), Ed Plow (United States)
AS016 VIIA WITH ALBUMIN (RVIIA-FP) BINDS TO NEONATAL FC RECEPTOR
AND TISSUE FACTOR IN VITRO
15:45 - 16:15 THE HEMOSTATIC SYSTEM AS A MODULATOR OF ATHEROSCLEROSIS
Susann Cattepoel, Annette Gaida, Marlies Illi, Rolf Spirig, Eva Herzog, Jenny Chia,
AS024 Hugo Ten Cate (The Netherlands)
Anne Verhagen, Ineke Muir, Hal Braley, Sabine Zollner* (Switzerland)
16:15 16:30 ADOPTIVE TRANSFER OF ANTIGEN-INDUCED SPECIFIC REGULATORY
LONG-TERM SAFETY AND PROPHYLACTIC EFFICACY OF ONCE-WEEKLY
16:30 16:45
AS025 T CELLS (TREG) PROTECTS AGAINST ATHEROSCLEROTIC LESION
AS017 SUBCUTANEOUS ADMINISTRATION OF ACE910, IN JAPANESE
FORMATION IN B6;129S-LDLR(TM1HER)APOB(TM2SGY)/J MICE
HEMOPHILIA A PATIENTS WITH AND WITHOUT FVIII INHIBITORS:
in Xia, Valeria Endresz, Ildiko Lantos, Andrea Szabo, Lakshmi Mundkur, Vijay
M
INTERIM RESULTS OF THE EXTENSION STUDY OF A PHASE 1 STUDY
Kakkar, Xinjie Lu* (United Kingdom)
Midori Shima, Hideji Hanabusa, Masashi Taki, Tadashi Matsushita, Tetsuji Sato,
Katsuyuki Fukutake, Naoki Fukazawa, Koichiro Yoneyama, Hiroki Yoshida, Hoyu Taka- 16:30 16:45 DISRUPTION OF SEMAPHORIN 7A DECREASES PLAQUE SIZE INDUCED
hashi, Keiji Nogami* (Japan)
AS026 BY DISTURBED FLOW AND CONFERS PROTECTION AGAINST THE
16:45 17:00 PHARMACODYNAMICS AND PHARMACOKINETICS OF TFPI- DEVELOPMENT OF ATHEROSCLEROSIS
AS018 NEUTRALIZING ANTIBODY (BAY1093884) IN CYNOMOLGUS MONKEYS Chaojun Tang*, Shuhong Hu, Fei Yang, Li Zhu (China)
AND PREDICTION OF HUMAN DOSE
16:45 17:00 CHANGES IN PERIPHERAL IMMUNE MARKERS IN RESPONSE TO
J ian-Ming Gu*, Elena Ho, Xiao-yan Zhao, Thomas Schwarz, Joachim Schuhmacher,
AS027 IMMUNE TOLERANCE AND ITS CORRELATION WITH PROGRESSION OF
Babu Subramanyan, Kathy Tran, Chandra Patel, Maria Koellnberger (United States)
ATHEROSCLEROSIS IN APOBTM2SGY LDLRTM1HER MICE
Thota Lakshmi narasimha Rao, Sheena Philip, Thiruvelselvan Ponnusamy, Xinjie Lu,
114 Vijay Kakkar, Lakshmi Mundkur* (India) 115
17:00 17:15 BONE MORPHOGENETIC PROTEIN (BMP)-7 UPREGULATES ADHESIVE ANNEXIN A5 RESISTANCE CORRELATES WITH MULTIPOSITIVITY FOR
17:00 17:15
AS028 AND MIGRATORY PROPERTIES OF HUMAN MONOCYTIC CELLS VIA AS037 ANTIPHOSPHOLIPID ASSAYS AND IS A PROSPECTIVE BIOMARKER FOR
BETA2 INTEGRIN-BMP RECEPTOR TYPE II (BMPRII) CROSSTALK ADVERSE EVENTS
Timofey Sovershaev*, Dusten Unruh, John-Bjarne Hansen, Vladimir Bogdanov, Mikhail Lucia Wolgast*, Xiao Wu, Vittorio Pengo, Jacob Rand (United States)
Sovershaev (Norway, United States)
Microparticles Room 718

Coagulation, fibrinolysis, immunity and inflammation Room 714
Moderators: Ashley Ambrose (United Kingdom), Nigel Mackman (United States)
Moderators: Paul Kim (Canada), Lawrence Leung (United States)
15:45 - 16:15 MICROPARTICLES IN HEALTH AND DISEASE
15:45 - 16:15 CROSS-TALK BETWEEN COAGULATION AND FIBRINOLYSIS AS038 Rienk Nieuwland (The Netherlands)
AS029 John Morser (United States)
MICROPARTICLES FROM PATIENTS WITH ACUTE CORONARY SYNDROME
16:15 16:30
IMAGING ANALYSES OF COAGULATION-DEPENDENT INITIATION OF
16:15 16:35 AS039 AND HEART TRANSPLANTED PATIENTS INDUCE PREMATURE
AS030 FIBRINOLYSIS ON ACTIVATED PLATELETS AND ITS MODIFICATION BY TAFI ENDOTHELIAL SENESCENCE AND THROMBOGENICITY: ROLE OF
Tomasz Brzoska*, Yuko Suzuki, Hideto Sano, Martyna Tomczyk, Tetsumei Urano (Japan) OXIDATIVE STRESS AND OF THE LOCAL ANGIOTENSIN SYSTEM
alak Abbas*, Laurence Jesel, Phuong Nga Nguyen, Cyril Auger, Nathan Messas,
M
ACTIVATION OF PROCHEMERIN BY FACTOR XIA REPRESENTS A NEW
16:35 16:55 Thais Ribeiro, Grazielle C Silva, Patrick Ohlman, Olivier Morel, Valerie Schini-Kerth,
AS031 MOLECULAR LINK BETWEEN INNATE IMMUNITY AND BLOOD Florence Toti (France)
COAGULATION
MONDAY
Xiaomei Ge*, Yasuto Yamaguchi, Lei Zhao, Shwu Shin Chang, John Morser, Lawrence THE GAS6-AXL INTERACTION MEDIATES ENDOTHELIAL UPTAKE OF
16:30 16:45
Leung (United States) AS040 PLATELET MICROPARTICLES
Kaisa Otteby*, Sinh Tran, Matthias Mrgelin, Bjrn Dahlbck (Sweden)
INTRAVENOUS THROMBOLYSIS GENERATES LARGE AMOUNTS OF
16:55 17:15
AS032 BRADYKININ IN STROKE PATIENTS: NEUROTOXIC IMPACT. PLATELETS RELEASE EXTRACELLULAR VESICLES IN AN AGONIST
16:45 17:00
Maxime Gauberti*, Sara Martinez de Lizarrondo, Oscar Marcos-Contreras, Denis Vivien AS041 DEPENDENT MANNER BUT RELEASE A CONSISTENT PROFILE OF
(France) MICRORNA
SYMPOSIA
Ashley R. Ambrose*, J Pringle, Alison Goodall (United Kingdom)
Antiphospholipid antibodies Room 701 A PROSPECTIVE EVALUATION OF THE PROTHROMBOTIC AND

17:00 17:15
AS042 PROGNOSTIC POTENTIAL OF CIRCULATING MICROPARTICLES IN
Moderators: Bas de Laat (The Netherlands), Philip de Groot (The Netherlands)
GLIOBLASTOMA MULTIFORME (GBM), PANCREATIC ADENOCARCINOMA
(PAC) AND ESOPHAGEAL-GASTRIC CANCER (EGC).
15:45 - 16:15 UNRAVELLING THE ANTIPHOSPHOLIPID SYNDROME: FROM EMPIRIC Elena Campello*, Claudia Radu, Luca Spiezia, Sabrina Gavasso, Barry Woodhams,
AS033 DESCRIPTION TO PATHOGENIC MECHANISMS Paolo Simioni (Italy)
Jacob Rand (United States)
INCREASED MORTALITY IN PATIENTS WITH THE LUPUS

16:15 16:30 Obesity bench to bedside Room 717
AS034 ANTICOAGULANT: THE VIENNA LUPUS ANTICOAGULANT AND
THROMBOSIS STUDY (LATS) Moderators: Michele David (Canada), Brian McCrindle (Canada)
J ohanna Gebhart*, Florian Posch, Silvia Koder, Thomas Perkmann, Peter Quehenberg-
er, Claudia Zoghlami, Cihan Ay, Ingrid Pabinger (Austria) ROLE OF ENDOTHELIAL CELLS IN ADIPOSE TISSUE INFLAMMATION
15:45 - 16:15
AS043 AND ADIPOCYTE ALTERATIONS DURING OBESITY
LUPUS ANTICOAGULANT ACTIVITY CAN BE EXPLAINED BY
16:30 16:45 Vanessa Pellegrinelli (United Kingdom)
AS035 INTERFERENCE OF ANTI-2GPI ANTIBODIES WITH THE
PROTHROMBINASE COMPLEX SILENCING OF SEC23A AND FLOTILIN PROTECTS ENDOTHELIAL CELLS
16:15 16:30
J.E. Molhoek*, Ph.G. de Groot, J.C.M. Meijers, R.T. Urbanus (The Netherlands) AS044 FROM DEVELOPING A PROINFLAMMATORY / PROTHROMBOTIC
PHENOTYPE IN OBESITY
CIRCULATING ENDOTHELIAL CELLS IDENTIFY PATIENTS WITH
16:45 17:00 arta Palomo De Udaeta*, Rebeca Fernandez-Ruiz, Sergi Torramad, Gins Escolar,
M
AS036 ANTIPHOSPHOLIPID-ANTIBODIES AND ASSOCIATED AUTO-IMMUNE Ramn Gomis, Felicia Hanzu, Maribel Daz-Ricart (Spain)
DISEASES AT RISK FOR THROMBOSIS.
Stphane Zuily*, Marie Heymonet, Qian Tu, Marcelo De Carvalho Bittencourt, Gilbert
Faure, Denis Wahl (France)
116 117
DNA METHYLATION PROFILING IDENTIFIES A LOCUS NEAR A
16:30 16:45 WHOLE EXOME SEQUENCING IN PATIENTS WITH INHERITED
16:15 16:35
AS045 HMG-COA SYNTHASE GENE ASSOCIATED WITH TRIGLYCERIDE LEVELS AS054 THROMBOCYTOPENIA AND EXCESSIVE BLEEDING IS AN EFFICIENT WAY
AND MODIFIED BY BMI TO IDENTIFY GENETIC VARIANTS IN KNOWN AND NOVEL GENES
inh Truong*, Nora Zwingerman, Irfahan Kassam, Dylan Assi, Jessica Dennis, Michael
V Ben Johnson*, Gillian Lowe, Michael Simpson, Isabel Snchez Gui, Sian Drake,
Wilson, Philip Wells, Pierre-Emmanuel Morange, David-Alexandre Trgout, France David MacDonald, Danai Bem, Sarah Fletcher, Jane Ftterer, Vincenzo Leo, Marie
Gagnon (Canada) Lordkipanidz, Ban Dawood, Tina Biss, Paula Bolton-Maggs, Peter Collins, Nicola
Curry, Mike Makris, Jayashree Motwani, Sue Pavord, Katherine Talks, Jecko Thacil,
OBESITY MEASURES, CRP AND RISK OF VENOUS THROMBOEMBOLISM
16:45 17:00 Jonathan Wilde, Mike Williams, Paul Harrison, Paul Gissen, Stuart Mundell, Andrew
AS046 AND MYOCARDIAL INFARCTION Mumford, Martina Daly, Steve Watson, Neil Morgan (United Kingdom)
Lars Daae Horvei*, Sigrid Brkkan, Ellisiv Mathiesen, Inger Njlstad, Tom Wilsgaard,
Jan Brox, John-Bjarne Hansen (Norway) A NOVEL PLATFORM TO STUDY THE MECHANO-SENSING MECHANISM
16:35 16:55
AS055 ON A SINGLE ASPIRED PLATELET
VISCERAL ADIPOSITY INDEPENDENTLY DETERMINES THROMBIN
17:00 17:15 Lining Ju*, Yunfeng Chen, Shaun Jackson, Cheng Zhu (United States, Australia)
AS047 GENERATION LAG TIME AND PEAK THROMBIN IN MORBID OBESITY
Paradzai Chitongo*, Lara Roberts, Lyall Rebecca, Raj Patel, Simon Aylwin, Roopen FACTOR XA OVERCOMES INHIBITION BY THE DIRECT FACTOR
16:55 17:15
Arya (United Kingdom) AS056 XA-INHIBITORS FOLLOWING INSERTION OF A STRUCTURAL ELEMENT
FROM THE SERINE PROTEASE DOMAIN OF SNAKE VENOM FACTOR XA
Danil Verhoef*, Mark Schreuder, Carlijn van der Sluijs, Ka Lei Cheung, Xiaoxun Yang,
Sickle cell disease Room 707 Pieter Reitsma, Mettine Bos (The Netherlands)
Moderators: Michael DeBaun (United States), Madeleine Verhovsek (Canada)
MONDAY
Protease activated receptors Room 713
15:45 - 16:15 THE OPPORTUNITIES FOR PRIMARY AND SECONDARY STROKE
AS048 PREVENTION IN SICKLE CELL DISEASE Moderators: Marc Hoylaerts (Belgium), Katherine Hajjar (United States)
Michael DeBaun (United States)
COAGULATION PROTEINASES, PROTEINASE-ACTIVATED RECEPTORS
15:45 - 16:15
KININOGEN DEFICIENCY ATTENUATES THROMBIN GENERATION IN A
16:15 16:30 AS057 (PARs) AND INFLAMMATION
AS049 MOUSE MODEL OF SICKLE CELL DISEASE Morley Hollenberg (Canada)
SYMPOSIA
Erica Sparkenbaugh*, Nigel Key, Kasemsiri Chandarajoti, Andras Gruber, Nigel Mack-
man, Keith McCrae, Rafal Pawlinski (United States) UNRAVELLING PAR1 SIGNALING IN ENDOTHELIAL CELLS USING
16:15 16:35
AS058 QUANTITATIVE PHOSPHOPROTEOMICS
MICROPARTICLES GENERATED DURING STORAGE OF PACKED RED
16:30 16:45 Bart L. van den Eshof*, Floris van Alphen, Koen Mertens, Alexander Meijer, Maartje
AS050 BLOOD CELL UNITS SUPPORT THROMBIN GENERATION van den Biggelaar (The Netherlands)
eth A. Bouchard*, Hollis Keith, Elizabeth Lavoie, Thomas Orfeo, Kenneth Mann
B
(United States) THROMBIN, STROMAL CELL-ASSOCIATED PAR-1, AND FIBRIN(OGEN)
16:35 16:55
AS059 PROMOTE COLON CANCER PROGRESSION
16:45 17:00 SPECIFIC INHIBITION OF GPIB SHEDDING IMPROVES POST- Gregory Adams*, Leah Rosenfeldt, Malinda Frederick, Whitney Miller, Dusty Waltz,
AS051 TRANSFUSION RECOVERY AND ADHESIVE FUNCTION OF OUTDATED Keith Kombrinck, Brett Monia, Alexey Revenko, Joseph Palumbo (United States)
HUMAN APHERESIS PLATELETS
Xin Liang, Yue Tao, Anum Syed, Paula Jessup, William Church, Cassandra Josephson, TUMOR-DERIVED TISSUE FACTOR-EXPRESSING MICROVESICLES
16:55 17:15
Xi Mo, Renhao Li* (United States) AS060 PROMOTE A PROADHESIVE PHENOTYPE IN ENDOTHELIAL CELLS
Sara Che*, Tracy Stokol (United States)
17:00 17:15 THE GLOBAL IMPACT OF PATHOGEN REDUCTION SYSTEMS ON THE
AS052 PLATELET MRNA TRANSCRIPTOME, ANALYSED BY DIFFERENTIAL
EXPRESSION OF RNA-SEQ DATA Poster with refreshments
Abdimajid Osman*, Walter Hitzler, Patrick Provost (Sweden)
17:15 - 18:30 in the Exhibition on Level 800
Innovation and Technology Room 709 Technical Sessions

Moderators: Deborah Siegal (Canada), Benjamin Brenner (Israel) The Technical Session Programs are in the Show Guide. Please consult the
different options to attend the session of your choice.
15:45 - 16:15 HIGH THROUGHPUT MICROFLUIDICS
AS053 Shaun Jackson (Australia)
118 119
PO005-MON
CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP)
Monday, June 22, 2015 CAUSED BY COMPOUND HETEROZYGOSITY OF C.1225C>T AND A NOV-
EL C.2321DELG ADAMTS13 GENE MUTATIONS
POSTER SESSION 17:15-18:30 Ana Kempfer, Juvenal Paiva*, Adriana Woods, Anala Sanchez-Luceros, Mara Lazzari
(Argentina)
Posters will be presented on different days during the Congress and are accessible at the same times as the
PO006-MON
QUALITY ASSESSMENT FOR ADAMTS-13 TESTING: A CANADIAN
exhibition opening hours. The official poster sessions with refreshments will take place as follows:
Monday, June 22, 2015, from 17.15-18.30 EXPERIENCE
Tuesday, June 23, 2015, from 18.00-19.30 Arnaud Bonnefoy*, Michael Keeney (Canada)
Wednesday, June 24, 2015, from 17.15-18.30
PO007-MON
PORTAL VEIN THROMBOSIS IN LIVER CIRRHOSIS: THE ROLE OF
The Poster Area is located inside the Exhibition on Level 800. ADAMTS13
Raimondo De Cristofaro*, Maria Basso, Vito Veca, Stefano Lancellotti, Laura Riccardi,
Poster setup times are as follows: Maurizio Pompili (Italy)
Monday, June 22, 2015, from 07.30 - 09.15
Tuesday, June 23, 2015, from 07.30 - 09.15 IMPORTANCE OF MONITORING ACTIVITY AND ANTI-ADAMTS-13
PO008-MON
Wednesday, June 24, 2015, from 07.30 - 09.15
ANTIBODIES LEVELS IN PREGNANCY WITH SEVERE PREECLAMPSIA
Poster dismantling times are as follows: HISTORY
Monday, June 22, 2015, from 18.30 - 19.00 Victoria Bitsadze*, Svetlana Akinshina, Ekaterina Zhuravleva, Alexander Makatsaria
Tuesday, June 23, 2015, from 19.30 - 20.00 (Russian Federation)
MONDAY
Posters not taken down after the dismantling time will be discarded. Angiogenesis/vasculogenesis
If you have sent your poster to the poster printing service, kindly note that you will be able to pick it up at the
Poster Booth located in the Swing Space on Level 800. PO009-MON
PAR1-STIMULATED PLATELETS ENHANCE ANGIOGENIC ACTIVITIES OF
ENDOTHELIAL PROGENITOR CELLS MORE POTENTLY THAN PAR4-STIM-
Poster Booth opening times are:
ULATED PLATELETS
Monday, June 22, 2015, from 07.30 - 19.00
Tuesday, June 23, 2015, from 19.30 - 20.00 Zhangsen Huang, Xinyan Miao, Yun Luan, Feng Kong, Nailin Li* (Sweden)
POSTERS
PO010-MON
DEVELOPMENT OF AN EX OVO CHICKEN EMBRYO MODEL FOR MEASUR-
Pins are provided on the poster boards directly ING TRACTION FORCES DURING IN VIVO ANGIOGENESIS
Sandra Baker-Groberg*, Dobryna Zalvidea, Arlyng Gonzlez, Xavier Trepat, Owen McCa-
ADAMTS13 I rty (United States)
PO011-MON
MICRORNA-126 REDUCES BLOOD-RETINAL BARRIER BREAKDOWN IN
PO001-MON
PROTECTIVE EFFECT OF ADAMTS13 HAPLOTYPE ON CORONARY AR- OXYGEN-INDUCED RETINOPATHY MOUSE MODEL
TERY DISEASE Yanyan Bai*, Xia Bai, Zhaoyue Wang (China)
Supakanya Lasom*, Nantarat Komanasin, Nongnuch Settasatian, Chatri Settasatian,
Upa Kukongviriyapan, Vichai Senthong, Pongsak Intharapetch (Thailand) PO012-MON
STIMULATION OF PAR-1 OR PAR-4 PROMOTES A SIMILAR PATTERN OF
PLATELET-MEDIATED ANGIOGENESIS
PO002-MON
AN UNBALANCE BETWEEN VON WILLEBRAND FACTOR AND ADAMTS13 Julia Etulain, Agustina Mena, Soledad Negrotto, Mirta Schattner* (Argentina)
FOLLOWING A MAJOR PARTIAL HEPATECTOMY
Dafna Groeneveld*, Edris Alkozai, Jelle Adelmeijer, Robert Porte, Ton Lisman (The PO013-MON
PLATELET MEMBRANE GLYCOPROTEIN CD151 PROMOTES ENDOTHELI-
Netherlands) AL PROGENITOR CELL ANGIOGENESIS
Zhangsen Huang*, Gunnar Nilsson, John Pernow, Xinyan Miao, Nailin Li (Sweden)
PO003-MON
THE NOVEL C.774_775 INS CCGCGCC MUTATION COMBINED WITH
C.4085 T>A IN THE ADAMTS13 GENE CONTRIBUTES TO THROMBOTIC PO014-MON
PROANGIOGENIC PROPERTIES OF FUCOIDAN IS ASSOCIATED WITH
THROMBOCYTOPENIC PURPURA (TTP) RECRUITMENT AND MODULATION OF MACROPHAGE POLARIZATION
Juvenal Paiva*, Ana Kempfer, Adriana Woods, Mara Casinelli, Anala Sanchez-Luceros, Elene Sapharikas*, Amel Mohamadi, Blandine Dizier, Anna Lokajczyk, Isabelle Ga-
Mara Lazzari (Argentina) ly-fauroux, Dominique Helley, Anne-Marie Fischer, Catherine Boisson-Vidal (France)
PO004-MON
THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) IN A MEMBER OF PO015-MON
UNALTERED ANGIOGENESIS-REGULATORY ACTIVITIES OF PLATELETS
A FAMILY WITH ADAMTS13 GENE ABNORMALITIES FROM MILD TYPE 2 DM PATIENTS DESPITE A MARKED PLATELET HY-
Juvenal Paiva*, Ana Kempfer, Adriana Woods, Mara Casinelli, Fabiana Alberto, Alicia PERREACTIVITY
Blanco, Mara Lazzari, Anala Sanchez-Luceros (Argentina) Xinyan Miao, Wei Zhang, Zhangsen Huang, Nailin Li* (Sweden)
120 121
PO016-MON
HUMAN PLATELET LYSATE GEL (HPLG) SUPPORTS AND STIMULATES PO029-MON
DISSECTION OF THE THERAPEUTIC EFFICACY OF FIX-TRIPLE FOR
ENDOTHELIAL PROGENITOR CELL-DRIVEN VASCULOGENESIS REDUCING HAEMOPHILIC ARTHROPATHY IN HEMOPHILIA B USING A
Giordano Pula*, Tiago Fortunato, Paul DeBank (United Kingdom) BLOOD-INDUCED JOINT INJURY MURINE MODEL
Guan-Ying Zheng*, Shu-Jhu Yang, Chun-Yu Chen, Mi-Hua Tao, Yu-Chen Hsu,
PO017-MON
TF-MEDIATED POSITIVE FEEDBACK CROSSTALK BETWEEN ENDOTHE- I-Shing Yu, Sh-Feng Yang, Shu-Wha Lin (Taiwan)
LIAL CELLS AND PATROLLING CD14+/CD16+ MONOCYTES STIMULATES
ANGIOGENESIS PO030-MON
STANDARDIZING ENOXAPARIN DOSING IN MOUSE MODELS OF DEEP
Sonia Espinosa, Gemma Arderiu, Esther Pena, Vladimir Bogdanov, Javier Crespo, Lina VEIN THROMBOSIS
Badimon* (Spain) Joshua Rainey, Kelsey Krus, Daniel Myers, Shirley Wrobleski, Diana Farris, Angela
Hawley, Thomas Wakefield, Jos A. A. Dia* (United States)
PO019-MON
PAR2-DEPENDENT SIGNALING VIA SMAD3 IN TF-INDUCED ANGIOGENESIS
Gemma Arderiu, Esther Pena, Sonia Espinosa, Lina Badimon* (Spain) PO031-MON
GENERATION OF HEMOPHILIA B MICE IN NSG BACKGROUND USING
CRISPR/CAS9 TECHNOLOGY
PO020-MON
INCREASE OF REACTIVE OXYGEN SPECIES AND SENESCENCE DOWN Meng-Ni Fan*, I-Shing Yu, Sheng-Kai Chang, Sheng-Chieh Chou, Ching-tzu Yen,
THE PROLIFERATIVE RATE OF ENDOTHELIAL PROGENITOR CELLS FROM Hsien-Wei Hsieh, Shu-Wha Lin, Yung-Li Yang (Taiwan)
PATIENTS WITH VENOUS THROMBOEMBOLIC DISEASE
Jos Antonio Alvarado-Moreno*, Jos Rubicel Hernandez-Lpez, Mara Antonieta PO032-MON
ACUTE BONE LOSS IN FVIII AND FIX BUT NOT VWF DEFICIENT MICE
Chvez-Gonzlez, Mervin C. Yoder, Irma Isordia-Salas, Jess Hernndez-Jurez, Abra- FROM JOINT INJURY
ham Majluf-Cruz (Mexico) Ted Bateman*, William Hanna, Anthony Lau, Eric Livingston, Junjiang Sun, Dominique
Heymann, Paul Monahan (United States)
MONDAY
Animal models I PO033-MON
ENOXAPARIN ACUTELY WORSENS HEMODYNAMIC MEASUREMENTS
COMPARED WITH TPA IN A LARGE ANIMAL MODEL OF SUBMASSIVE
PULMONARY EMBOLISM
PO021-MON
PLASMIN, NOT THROMBIN, ACTIVATES COMPLEMENT IN ARTERIAL AND
Daren M. Beam*, Jeffrey Kline, Evandro Neto-Neves (United States)
VENOUS THROMBOSIS
Jonathan H. Foley*, Bethany Walton, Alice OByrne, Victor Lei, Kimberley Foley, Jay PO034-MON
GENOME-WIDE KNOCKDOWNS IN ZEBRAFISH TO STUDY THROMBO-
Degen, Alisa Wolberg, Edward Conway (Canada, United Kingdom) CYTE FUNCTION
POSTERS
Pudur Jagadeeswaran, Hemalatha Sundaramoorthi*, Gauri Khandekar (United States)
PO022-MON
ESTABLISHMENT OF A VASCULAR INJURY MODEL DEMONSTRATING
DIFFERENT EFFICACIES OF ANTITHROMBOTIC AGENTS ON THROMBUS
FORMATION IN MICE Antiphospholipid syndrome I
Chaojun Tang*, Daoxi Lei, Lu Huang, Guixue Wang, Li Zhu (China)
PO023-MON
FERRIC CHLORIDE-INDUCED VENOUS THROMBOSIS MODEL IN RATS:
FINDING THE OPTIMAL CONCENTRATION OF FERRIC CHLORIDE PO035-MON
BRAIN WHITE MATTER MICROSCRUTURE IS ALTERED IN OBSTETRIC
Polina Alekseeva*, Natalia Pitukhina (Russian Federation) ANTIPHOSPHOLIPID SYNDROME: EVIDENCES FROM DIFFUSION-TEN-
SOR MRI IN ASYMPTOMATIC NEUROLOGICAL PATIENTS
PO025-MON THROMBIN GENERATION IN ZEBRAFISH Jean-Christophe R. Gris*, Graldine Lavigne, Sylvie Bouvier, Eva Nouvellon, Erick Mer-
Evelien Schurgers, Martijn Moorlag, Hilde Kelchtermans*, Coenraad Hemker, Bas de cier, Fabricio Pereira, Francesco Macri, Marcel Jackowski, Jean-Paul Beregi, Choukri
Laat (The Netherlands) Mekkaoui (France)
PO026-MON
CLOT CONTRACTION AND POLYHEDROCYTES IN CLOTS FORMED AFTER PO036-MON
THROMBOTIC RISK OF REDUCED ADAMTS13 ACTIVITY IN PATIENTS
SAPHENOUS VEIN PUNCTURE IN THE MOUSE WITH ANTIPHOSPHOLIPID ANTIBODIES
John W. Weisel*, Chandrasekaran Nagaswami, Yifan Xu, Irina Chernysh, Zelda de Hyun Kyung Kim* (Korea, Republic Of)
Lange, Sofia Kosolapova, Lilley Leong, Katalin Kauser, Derek Sim (United States)
PO037-MON
MIXING TEST SPECIFIC CUT-OFF IS MORE SENSITIVE AT DETECTING
PO027-MON
BENEFICIAL THERAPEUTIC PROPERTIES OF DIETARY ALPHA-LINOLE- IN VITRO LUPUS ANTICOAGULANT INHIBITION THAN THE INDEX OF
NIC ACID (ALA) IN A MOUSE MODEL OF SICKLE CELL DISEASE CIRCULATING ANTICOAGULANT
Simona Stivala*, Sara Gobbato, Martin Reiner, Thomas Lscher, Jrg Beer (Switzerland) Gary W. Moore*, Aidan Culhane, Christopher Daw, Charlotte Noronha, Osamu Kumano
(United Kingdom)
PO028-MON
RABBIT MODEL OF FERRIC CHLORIDE-INDUCED CAROTID ARTERIAL
THROMBOSIS OPTIMIZED FOR TRANSLATIONAL DRUG DISCOVERY
Xinkang Wang*, Stan Kurowski, Xueping Zhou, Weizhen Wu, Michael Wismer, Lin Chu,
Dietmar Seiffert (United States)
122 123
PO038-MON
A MULTICONTROL KIT FOR ANTIPHOSPHOLIPID AND ANTI-PLATELET PO050-MON
FREQUENCY OF CLINICALLY SIGNIFICANT ANTIPHOSPHOLIPID ANTI-
FACTOR 4-HEPARIN ANTIBODIES: NINE DIFFERENT ANALYTES IN A BODIES PROFILE IN PATIENTS WITH VENOUS THROMBOEMBOLISM,
SINGLE VIAL STROKE, MYOCARDIAL INFARCTION, PERIPHERAL ARTERIAL DISEASE
Josep Puig*, Fernando Cavalcanti, Raquel Torres, Sandra Matilla, Josep Serra (Spain) AND PREGANCY MORBIDITY
Benilde Cosmi*, Cristina Legnani, Michela Cini, Gualtiero Palareti (Italy)
PO039-MON
PERSISTENT LUPUS ANTICOAGULANT IN CLINICAL SETTINGS OTHER
THAN ANTIPHOSPHOLIPID SYNDROME PO051-MON
CLINICAL ASSESSMENT OF ANTIPHOSPHOLIPID ANTIBODIES AGAINST
Lucia Remotti*, Silvia Grosso, Marcelo Ingratti, Maria Vera Morandini, Emilse Bermejo, 2-GLYCOPROTEIN DOMAIN I IN ANTIPHOSPHOLIPID SYNDROME.
Analia Sanchez Luceros, Susana Meschengieser, Maria Lazzari, Alicia Blanco (Argentina) Pascual Marco*, Ana Marco, Virgilio Cabrera, Vanessa Gonzlez (Spain)
PO040-MON
HOW APPROPRIATE IS THE ANTIPHOSPHOLIPID ANTIBODIES TESTING PO052-MON
MULTIPLE POSITIVITY AND APA PROFILE IN WOMEN WITH FETAL LOSS
AT SIRIRAJ HOSPITAL? SYNDROME
Yingyong Chinthammitr*, Thanitsak Thaweekhot, Panutsaya Tientadakul, Chaicharoen Natalya Makatsariya, Nadezhda Stuleva, Jamilya Khizroeva* (Russian Federation)
Tantanate (Thailand)
PO041-MON
THROMBOMODULIN DOWN-REGULATION IS RELATED TO THE THROM- Antiplatelet agents I
BOSIS RISK IN ANTIPHOSPHOLIPID SYNDROME PATIENTS
Osamu Kumano*, Masahiro Ieko, Sumiyoshi Naito, Mika Yoshida, Nobuhiko Takahashi,
Takeshi Suzuki, Takashi Aoki (Japan) PO054-MON
IMPACT OF PREANALYTICAL DELAY ON RESULTS OF LIGHT TRANSMIT-
TANCE AGGREGOMETRY IN STEMI PATIENTS
PO042-MON USE OF D DIMER IN BIOLOGICAL CONTROL OF PREGNANCY Anna Vybivantseva*, Olga Demkova, Natalia Saraeva, Larisa Koryakina, Elena Andree-
MONDAY
na Otero, Ana M. Lena*, Elena De Lisa, Datevig Attarian, Enrique Pons, Ricardo
A va, Galina Lifshits, Konstantin Apartsin (Russian Federation)
Pou, Nora Mota, Gabriela Domnguez, Sebastin De Los Santos, Cecilia Carrizo (Uru-
guay) PO055-MON
ASSOCIATION OF PLATELET RESPONSE TO CILOSTAZOL WITH CLINICAL
OUTCOME AND CYP GENOTYPES IN PATIENTS WITH CEREBRAL INFARC-
PO043-MON
ANTI-ANNEXIN V ANTIBODIES IN PATIENTS WITH OBSTETRIC MORBIDITY TION
Alberto Maneyro*, Susana Ouvia, Laila Noya, Luis Palmer (Argentina) Jun Yamanouchi*, Takaaki Hato, Masaki Yasukawa (Japan)
PO044-MON
INTERACTIONS BETWEEN RIVAROXABAN AND ANTIPHOSPHOLIPID PO056-MON
PLATELET REACTIVITY BASED RISK ASSESSMENT FOR PATIENTS WITH
POSTERS
ANTIBODIES IN THROMBOTIC ANTIPHOSPHOLIPID SYNDROME CORONARY ARTERY DISEASE ON P2Y12 INHIBITORS IS NOT CONSIS-
Deepa Jayakody Arachchillage*, Ian Mackie, Maria Efthymiou, David Isenberg, Samuel TENT BETWEEN DIFFERENT PLATELET FUNCTION TESTS
Machin, Hannah Cohen (United Kingdom) M.J.A. Vries*, R.H. Olie, L.F. Veenstra, J.C.A. Hoorntje, A.J. Ten Cate-Hoek, H.M.H.
Spronk, P.E.J. van der Meijden, Y.M.C. Henskens, H. Ten Cate (The Netherlands)
PO045-MON
PROPOSED TRIAL: HYPATIA - A PROSPECTIVE RANDOMISED CON-
TROLLED TRIAL OF HYDROXYCHOROQUINE VERSUS PLACEBO DURING PO057-MON
PLATELET FUNCTION TESTING IN ACS PATIENTS USING MEASURE-
PREGNANCY IN WOMEN WITH ANTIPHOSPHOLIPID ANTIBODIES MENT OF PLATELET P-SELECTIN: COMPARISON WITH OTHER COMMER-
Karen Schreiber*, Savino Sciascia, Karen Breen, Soren Jacobsen, Roy Farquharson, CIAL TESTS
Saskia Middeldorp, Lesley Regan, Beverley Hunt (United Kingdom, Denmark) Jane May*, Natalia Dovlatova, Ashwin Radhakrishnan, Stan Heptinstall, Sue Fox (Unit-
ed Kingdom)
PO046-MON
RIVAROXABAN LIMITS COMPLEMENT ACTIVATION IN PATIENTS WITH
THROMBOTIC ANTIPHOSPHOLIPID SYNDROME PO058-MON
EFFICACY OF PRASUGREL ADMINISTRATION IMMEDIATELY AFTER
Deepa Jayakody Arachchillage, Ian Mackie, Maria Efthymiou, Andrew Chitolie, Beverly PERCUTANEOUS CORONARY INTERVENTION IN ACUTE MYOCARDIAL
Hunt, David Isenberg, Munther Khamashta, Samuel Machin, Hannah Cohen (United INFARCTION
Kingdom)
Andreas Schfer*, Ulrike Flierl, Johann Bauersachs (Germany)
PO048-MON
ANALYTICAL AND CLINICAL PERFORMANCE OF A NEW AUTOMATED
PO059-MON
THE ANTITHROMBOTIC EFFECTS OF SYNTHETIC POLYPEPTIDES DE-
CHEMILUMINESCENT ASSAY (CIA)
RIVED FROM SNACLECS: INVOLVEMENT OF PLATELET GLYCOPROTEIN
Teresa Iwaniec*, Marcin Kaczor, Magdalena Celinska-Lwenhoff, Stanisaw Polanski,
VI ANTAGONISM
Jacek Musia (Poland)
Chien-Hsin Chang*, Ching-Hu Chung, Chun-Chieh Hsu, Tur-Fu Huang (Taiwan)
PO049-MON
FALSE POSITIVE RESULTS OF PLATELET NEUTRALIZATION PROCEDURE
PO060-MON
CORRELATION BETWEEN PLATELET MRP4 EXPRESSION AND PLATELET
(PNP) IN LUPUS ANTICOAGULANT (LA) TESTING OF PATIENTS WITH
FUNCTION IN PATIENTS UNDER CHRONIC ASPIRIN TREATMENT
COAGULATION FACTOR DEFICIENCIES
Isabella Massimi*, Flavia Temperilli, Maria Luisa Guarino, Teresa Maltese, Lavinia
Geoffrey D. Wool*, Krzysztof Mikrut, Jonathan Miller (United States)
Vittoria Lotti, Luigi Frati, Fabio Maria Pulcinelli (Italy)
124 125
PO061-MON
PLATELET FUNCTION MONITORING IN PATIENTS ON DUAL ANTIPLATE- PO070-MON
DIVERSE EFFECTS OF PAI-1 ON VASCULAR SMOOTH MUSCLE CELLS
LET THERAPY UNDERGOING URGENT HIP SURGERY: PRELIMINARY PHENOTYPE SWITCH
RESULTS. Xin Deng*, Mao Luo, Rong Li, Meiping Ren, Ni Chen, Kai Yan, Min Zeng, Jianbo Wu
Luca Spiezia*, Francesco Vasques, Astrid Behr, Elena Campello, Sara Maggiolo, Paolo (China)
Simioni (Italy)
PO071-MON
RETINAL VESSEL CALIBERS AND HAEMOSTASIS IN BLACK AND WHITE
PO062-MON
PLATELET REACTIVITY IN PATIENTS WITH ACUTE MYOCARDIAL IN- SOUTH AFRICANS: THE SABPA STUDY
FARCTION CHRONICALLY TREATED WITH BETA-BLOCKERS BEFORE THE Leandi Lammertyn*, Aletta Schutte, Wayne Smith, Marlien Pieters, Rudolph Schutte
ONSET OF THE ACUTE EVENT. (South Africa)
Maria T. Santos*, Antonio Moscard, Ana Latorre, Isabel Madrid, Maria Paz Fuset,
Juana Valles (Spain) PO072-MON
PROGNOSTIC VALUE OF THE CHA2DS2VASC SCORE IN PATIENTS EXPE-
RIENCING A MYOCARDIAL INFARCTION
PO063-MON
PROTEOMIC PROFILING OF PLATELET RESPONSE TO ANTIPLATELET Serenella Conti*, Maria Cristina Vedovati, Roberta Molle, Giorgio Maragoni (Italy)
AGENTS REVEALS A WIDE INTER-INDIVIDUAL VARIABILITY AND DIS-
TINCT SIGNATURES OF DRUGS ALONE AND IN COMBINATION PO073-MON
GENETIC RISK FACTORS ON ATHEROTHROMBOTIC DISEASE: COMPARI-
Simone Marcone*, Desmond Fitzgerald (Ireland) SON BETWEEN TWO TERRITORIES.
Irma Isordia-Salas*, Lorena Mendoza-Valz, Jos Antonio Alvarado-Moreno, David San-
PO064-MON
DUAL ANTIPLATELET THERAPY COMBINING ASPIRIN AND TICAGRELOR tiago-Germn, Mara Guadalupe Valades-Meja, Jess Hernndez-Jurez, Rosa Mara
IN INTRACRANIAL ANEURYSMAL EMBOLIZATION. A 13-MONTH FRENCH Jimnez-Alvarado, Abraham Majluf-Cruz (Mexico)
EXPERIENCE.
Ana Paula Narata, Yves Gruel*, Denis Angoulvant, Denis Herbreteau (France)
PO074-MON
CARDIOLOGICAL AND THROMBOPHILIC RISK PROFILE IN PATIENTS
MONDAY
WITH OCULAR ARTERIAL OCCLUSION
PO065-MON
INHIBITION OF THIOREDOXIN INHIBITS GPVI-MEDIATED PLATELET Jerzy Dropinski, Agnieszka Kubicka-Trzaska, Teresa Domagala, Marek Sanak, Teresa
ACTIVATION Iwaniec, Jacek Musial (Poland)
Clive Metcalfe, Anjana Ramasubramoni, Giordana Pula, Matthew Harper, Stuart Mun-
dell, Carmen Coxon* (United Kingdom)
PO075-MON
A NOVEL ASSAY DEMONSTRATES PROCOAGULANT PLATELETS ARE
INCREASED IN PATIENT UNDERGOING CORONARY ANGIOGRAPHY WITH
PO066-MON
PREDICTION OF HIGH ON-TREATMENT PLATELET REACTIVITY IN CLOPI- DIFFERENTIAL EFFECTS BY ANTI-PLATELET AND ANTI-COAGULANT
THERAPY
POSTERS
DOGREL-TREATED PATIENTS WITH ACUTE CORONARY SYNDROMES,
USING ADVANCED ARTIFICIAL NEURAL NETWORKS Leonardo Pasalic*, Heather Campbell, Edwina Wing-Lun, Philip Hogg, David Connor,
Gian Marco Podda*, Enzo Grossi, Tullio Palmerini, Massimo Buscema, Eti A. Femia, David Muller, Vivien Chen (Australia)
Andrea Mariani, Diego Della Riva, Marco Cattaneo (Italy)
PO076-MON
RELATION BETWEEN INVASIVE CENTRAL PULSE PRESSURE AND
PO067-MON
ASPIRIN RESISTANCE IN MEDICAL INPATIENTS ON CHRONIC ASPIRIN THROMBOGENICITY
TREATMENT Gailing Chen, Kevin Bliden, Fang Liu, Udaya Tantry, Paul Gurbel* (United States)
Alessia Fabbri, Elisa Grifoni, Maddalena Pazzi, Rita Paniccia, Anna Maria Gori*, Sara
Bucherelli, Alessandro Morettini, Rossella Marcucci, Rosanna Abbate (Italy) PO077-MON
DRUG-ELUTING CORONARY STENTS GENERATE LOWER LEVEL OF
CELLULAR ACTIVATION COMPARED TO BARE METAL STENTS IN STABLE
PO068-MON
TXA2-BINDING PROTEINS, DIPETALODIPIN AND TRIPLATIN, BLOCK ANGINA PATIENTS
PLATELET-MEDIATED NETS FORMATION IN VITRO AND INHIBIT THROM- Bla Nagy Jr*, Tibor Szk, Ildik Debreceni, Zsolt Fejes, Adrienne Kernyi, Istvn
BOSIS IN VIVO WITHOUT IMPAIRING HEMOSTASIS des, Jnos Kappelmayer (Hungary)
Daniella Mizurini*, Jorgeane Aslan, Taina Gomes, Dongying Ma, Ivo Francischetti,
Robson Monteiro (Brazil) PO078-MON
NEUTROPHIL EXTRACELLULAR TRAPS IN CORONARY ARTERY THROMBI
IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION
Anouchska Autar*, Mie Kurata, Danielle Mensink, Evelyn Regar, Marco Valgimigli, Frank
Arterial vascular disorders - clinical I Leebeek, Felix Zijlstra, Moniek De Maat, Heleen Van Beusekom (The Netherlands)
PO079-MON
ASSOCIATION BETWEEN GLUCOMETABOLIC CONTROL AND DEGREE OF
PO069-MON
ADAMTS13 AND THE RISK OF MYOCARDIAL INFARCTION: AN INDIVIDU- HYPERCOAGULABILITY IN PATIENTS WITH COMBINED TYPE 2 DIABE-
AL PATIENT DATA META-ANALYSIS TES MELLITUS AND CORONARY HEART DISEASE.
Alberto Maino*, Bob Siegerink, Luca Lotta, James Crawley, Saskia le Cessie, Frank Vibeke Bratset*, Rune Byrkjeland, Svein Solheim, Harald Arnesen, Ingebjrg Seljeflot
Leebeek, David Lane, Gordon Lowe, Flora Peyvandi, Frits Rosendaal (Italy) (Norway)
126 127
PO079.1-MON
THE COBALT-CHROMIUM ALLOY COMPOSING STENT IS PO088-MON
ACCURATE RECOVERY OF PEGYLATED AND NON-PEGYLATED THERA-
THROMBOGENIC PEUTIC FVIII, USING A SPECIFIC APTT REAGENT, AND APPLICATION ON
Veronique Ollivier*, Caroline Roques, Elmina Mammadova-Bach, Matthias Gratz, Chris- AN AUTOMATED COAGULATION ANALYZER
tian Gachet, Didier Letourneur, Pierre Mangin, Martine Jandrot-Perrus (France) Mary J. Doyle*, Anuja Khan, Karen DiStasio, Alexandra Sullivan, Mark Triscott (United
States)
Atherosclerosis I PO089-MON
THROMBIN GENERATION CAPACITY AND PHENOTYPIC ASSOCIATION IN
ABO BLOOD GROUPS
PO080-MON
ASSOCIATION OF ABCB1 C3435T POLYMORPHISM WITH BLOOD GLU- Romy Kremers*, Abdulrahman Mohamed, Leonie Pelkmans, Salwa Hindawi, Coenraad
Hemker, Bas de Laat, Dana Huskens, Raed Al Dieri (The Netherlands)
COSE LEVELS AND RISK OF CORONARY ARTERY DISEASE IN THAIS
Sornsith Jirungda*, Nantarat Komanasin, Nongnuch Settasatian, Chatri Settasatian, PO090-MON
HAEMOSTASIS IN CARDIAC ARREST PATIENTS TREATED WITH THERA-
Upa Kukongwiriyapan, Pongsak Intharapetch, Vichai Senthong (Thailand)
PEUTIC HYPOTHERMIA
PO081-MON
UNDERSTANDING GENE EXPRESSION IN CORONARY ARTERY DISEASE Anne Katrine Wulff Nielsen*, Anni Jeppesen, Hans Kirkegaard, Anne-Mette Hvas
(Denmark)
THROUGH GLOBAL PROFILING, NETWORK ANALYSIS AND INDEPEN-
DENT VALIDATION OF KEY CANDIDATE GENES PO091-MON
IS TGA ABLE TO DISCRIMINATE A DIFFERENT COAGULATION PROFILE
Prathima Arvind* (India) IN INHIBITOR PATIENTS WITH SEVERE HEMOPHILIA A AS COMPARED
TO NON-INHIBITOR PATIENTS?
PO082-MON
INSIGHTS INTO THE GENETIC ARCHITECTURE OF CORONARY ARTERY
Maria Elisa Mancuso*, Veena Chantarangkul, Marigrazia Clerici, Maria Fasulo, Lidia
DISEASE IN ASIAN INDIANS Padovan, Erica Scalambrino, Flora Peyvandi, Armando Tripodi, Elena Santagostino
MONDAY
Jiny Nair*, Prathima Aravind, Jayashree Shanker, Vijay Kakkar (India) (Italy)
PO083-MON
CIRCULATING LYMPHOCYTES AND MONOCYTES AS RISK FACTORS FOR PO092-MON
IMPACT OF EDOXABAN ON A LARGE PANEL OF ROUTINE OR MORE
CORONARY ARTERY DISEASE IN INDIAN POPULATION SPECIFIC COAGULATION ASSAYS
Thiruvelselvan Ponnusamy, Srikanth Venkatachala, Manjunatha Ramanjappa, Vijay Jonathan Douxfils*, Tania Del Bianco, Justine Baudar, Sarah Lessire, Bernard Chate-
Kakkar, Lakshmi Mundkur* (India) lain, Jean-Michel Dogn, Franois Mullier (Belgium)
PO084-MON
TRANSLATIONAL INFORMATICS APPROACH LINKING RISK OF CORO- PO093-MON
MODIFICATION OF A THROMBIN GENERATION TEST TO IDENTIFY NEW
POSTERS
NARY ARTERY DISEASE, INFECTION AND INFLAMMATION COFACTORS OF THE PROTEIN C PATHWAY IN PLASMA
Rajani Kanth Vangala, Ankit Sharma*, Madankumar Ghatge (India) Laura Martos, Hiroshi Deguchi, Elena Bonet, Pilar Medina, Luis A Ramon, Saturnino
Haya, Ana R Cid, Santiago Bonanad, John H Griffin, Francisco Espaa, Silvia Navarro*
PO085-MON
IDENTIFICATION OF NOVEL GENETIC MUTATIONS IN LOW-DENSITY (Spain)
LIPOPROTEIN RECEPTOR (LDLR) GENE CAUSING FAMILIAL HYPERCHO-
LESTEROLEMIA IN SAUDI ARAB HOMOZYGOUS CHILDREN PO094-MON
PRELIMINARY PERFORMANCE DATA OF A NEW ASSAY FOR THE QUAN-
Faisal A. Al-Allaf*, Mohammad Athar, Zainularifeen Abduljaleel, Mohiuddin Taher, TITATIVE DETERMINATION OF THE ACTIVITY OF UNFRACTIONATED HEP-
Abdellatif Bouazzaoui, Halah Abalkhail, Rakan Own, Ahmad Al-Allaf, Iman ARIN (UFH) AND LOW MOLECULAR WEIGHT HEPARIN (LMWH) USING A
AboMansoor, Zohor Azhar, Faisal Ba-hammam, Abdullah Alashwal (Saudi Arabia) SINGLE CALIBRATION CURVE FOR BOTH TYPES OF HEPARIN*
Matthias Wilkens*, Beate Becker-Scheidemann, Anja Borchert, Sabine Halilovic, Anja
PO086-MON
ROLE OF RS4988300 AND RS3781590 LRP5 GENE AND RS1466535 Hecker, Regina Hoffmann, Irene Jennemann-Watzka, Markus Muth, Ruth Neunziger,
LRP1 GENE POLYMORPHISMS IN THE COHORT OF THE PROSPECTIVE Juergen Patzke, Andr Scheidler, Stephanie Schmidt, Bettina Wecht, Andrea Lichte
MONTIGNOSO STUDY (Germany)
Alice Sereni*, Betti Giusti, Francesco Sofi, Claudia Saracini, Silvia Galora, Rosina De
Cario, Daniele Della Latta, Dante Chiappino, Rosanna Abbate, Gian Franco Gensini PO095-MON
PROVISION OF EXTERNAL QUALITY ASSURANCE FOR THROMBOELAS-
(Italy) TOGRAPHY (TEG) AND THROMBOELASTOMETRY (ROTEM)
Dianne P. Kitchen*, Shelene Munroe-Peart, Ian Jennings, Steve Kitchen, Tim Woods,
Isobel Walker (United Kingdom)
Blood coagulation tests I
PO096-MON
ANTICOAGULATION ASSESSMENT WITH PROTHROMBIN TIME AND
PO087-MON
ACTIVE THROMBIN ASSAY FOR IMPROVED TREATMENT OF THROMBOSIS ANTI-XA ASSAYS IN REAL-WORLD PATIENTS ON TREATMENT WITH
Vera Ignjatovic, Leslie Berry, Anthony Chan, Paul Monagle* (Australia)
RIVAROXABAN
Oliver Knigsbrgge*, Peter Quehenberger, Sabine Belik, Gnter Weigel, Christoph
Seger, Andrea Griesmacher, Ingrid Pabinger, Cihan Ay (Austria)
128 129
PO097-MON
GLOBAL HEMOSTASIS ASSAYS THROMBOELASTOGRAPHY AND THROM- PO108-MON
MODELISATION OF THE PROCOAGULANT PROPERTIES OF ADENOCAR-
BODYNAMICS EVALUATE HYPERCOAGULATION IN CHILDREN WITH CINOMA PANCREATIC CELLS (BXPC3) AND BREAST CANCER CELLS
HEMOLYTIC ANEMIA (MCF7) AND ANALYSIS OF THEIR SPECIFIC INTERACTIONS WITH THE
Elena A. Seregina*, Janna Kuzminova, Alexander Poletaev, Asmik Sepoyan, Fazoil COAGULATION SYSTEM
Ataullakhanov, Natalya Smetanina, Anna Balandina (Russian Federation) Aurlie Rousseau, Patrick Van Dreden*, Grigoris Gerotziafas (France)
PO098-MON
CLINICALLY IMPORTANT DIFFERENCES IN PHARMACODYNAMIC EF- PO109-MON
EFFECT OF HYPOXIA ON TISSUE FACTOR PATHWAY INHIBITOR EXPRES-
FECTS OF RIVAROXABAN AND APIXABAN SION IN BREAST CANCER CELLS
Ross I. Baker*, Roza Szollosi, Scott McGregor (Australia) Cui Xue Yan, Benedicte Stavik, Grethe Skretting, Anders Erik Astrup Dahm, Nina
Iversen, Sebastian Seidl, Sandip Kanse, Per Morten Sandset (Norway)
PO099-MON
MONITORING NEW ORAL ANTICOAGULANTS (NOACS) USING NEW-GEN-
ERATION THROMBELASTOGRAPHY TEG6S SYSTEM PO110-MON THE THROMBOTIC POTENTIAL OF CIRCULATING TUMOR MICROEMBOLI
Kevin Bliden, Adina Muresan, Gabriel Raviv, Eli Cohen, Fowzia Zaman, Katayoon nnachiara Mitrugno*, Kevin Phillips, Michael King, Siddarth Chandrasekaran, Paul
A
Saadin, Nafees Mohammed, Rahul Chaudhary, Rahil Rafeedheen, Udaya Tantry, Paul Newton, Peter Kuhn, Craig Williams, Owen McCarty (United States)
Gurbel* (United States)
PO111-MON
FIBRIN DEGRADATION BY RTPA IMPROVES NANOPARTICLE DRUG DE-
PO100-MON
IN VITRO MODELS OF THROMBOSIS USING HUMAN WHOLE BLOOD LIVERY FOR TUMORS
UNDER FLOW CONDITIONS Bo Zhang*, Yu Hu (China)
Lewis Hardy*, Emma Hethershaw, Amy La Corte, Helen Philippou (United Kingdom)
PO112-MON
HUMAN ANGIOSARCOMA CELLS EXPRESS TISSUE FACTOR AND GENER-
PO101-MON
FXII618, A NEW FACTOR XII INHIBITOR: VALIDATION FOR THROMBIN ATE THROMBIN IN A TISSUE FACTOR-DEPENDENT MANNER
MONDAY
GENERATION ASSAY Lauren Witter, Tracy Stokol* (United States)
Sara Calzavarini*, Vanessa Baeriswyl, Claudia Quarroz, Christian Heinis, Anne Angelil-
lo-Scherrer (Switzerland) PO113-MON
ROLE OF AUTOANTIBODIES TO PLASMINOGEN AT ONCOLOGIC DISEASES
Roza Aisina*, E Goufman, V Yakovlev V.N., L Mukhametova, N Tikhonova, K Gershkov-
PO102-MON
PF4-R, A NOVEL HEPARIN NEUTRALIZING REAGENT SUITABLE FOR ich K.B., D Gulin (Russian Federation)
AUTOMATED COAGULOMETERS: COMPARISON WITH HEPARINASE IN
ROUTINE COAGULATION TESTS PO115-MON
PROTHROMBOTIC RISK ASSOCIATED WITH INTRAVENOUSLY GIVEN
POSTERS
Steven Raynard*, Ali Sadeghi-Khomami, Zhou Hui (Canada) HIGH DOSE VITAMIN C: ANOTHER EVIDENCE WARNING AGAINST THE
BLIND FAITH IN VITAMINS?
PO103-MON
GLOBAL ASSAYS DO NOT PREDICT BLEEDING PHENOTYPE IN HEMO- Keunyoung Kim*, Ok-Nam Bae, Sung-Hee Koh, Seojin Kang, Kyung-Min Lim, Ji-Yoon
PHILIA A. Noh, Sue Shin, Inho Kim, Jin-Ho Chung (Korea, Republic Of)
Marilyn J. Manco-Johnson*, Taylor Blades, John Kittelson, Elizabeth Vil-
lalobos-Menuey, Linda Jacobson (United States) PO116-MON
DOXORUBICIN-INDUCED MDR1/P-GP IN MCF-7 BREAST CANCER CELLS
WAS ASSOCIATED WITH TISSUE FACTOR OVEREXPRESSION AND
PO104-MON
TESTING AN IN VITRO MODEL OF LAMINAR FLOW FOR USE IN LARGE- THROMBIN GENERATION
SCALE APTAMER SCREENING Amir Khaterchi*, asmae Karroum, Elisabeth Mbemba, Aurelie Rousseau, Patrick Van
Laura Sommerville*, George Pitoc, Bruce Sullenger, Maureane Hoffman (United States)
Dreden, Vasiliki Gkalea, Ismail Elalamy, Mohamed Hatmi, Grigoris Gerotziafas (France)
PO105-MON
POLYHEDROCYTES IN WHOLE BLOOD CLOTS OF PATIENTS WITH TYPE 2 PO117-MON
ACTIVATED PROTEIN C UP-REGULATES THE OVARIAN CANCER CELL
DIABETES MIGRATION AND PROMOTES UNCLOTTABILITY OF CANCER PERITONEAL
Jakub Siudut*, Micha Zabczyk, Anetta Undas (Poland)
FLUID
Hamda Althawadi*, Halema Alfarsi, Shahsoltan Mirshahi, Jean Chidiac, Samaher Bes-
Cancer and thrombosis/hemostasis I bes, Amu Therwath, Marc Pocard, Jeannette Soria, Massoud Mirshahi (France, Qatar)
PO118-MON
ESTROGENS UPREGULATE TFPI-2 EXPRESSION IN MCF-7 CELLS PROB-
PO106-MON
ACTIVATION OF COAGULATION BY ANTINEOPLASTIC DRUGS FOR LYM- ABLY BY PROMOTER DEMETHYLATION
PHOID TUMORS Marianne Andresen, Huda Ali, Nina Iversen, Benedicte Stavik, Christiane Myklebust,
Misae Tsunaka*, Reina Arai, Ayaka Ohashi, Takatoshi Koyama (Japan) Per Morten Sandset, Grethe Skretting* (Norway)
PO107-MON
PROCOAGULANT TUMOR MICROENVIRONMENT AS TARGET FOR A PO119-MON
ENDOTHELIAL PROTEIN C RECEPTOR IN BREAST CANCER CELLS,
TFPI-LIKE MOLECULE CO-EXPRESSED WITH MULTIDRUG RESISTANCE PROTEIN, INHIBITS
Katia Morais*, Mrio Pacheco, Kerly Pasqualoto, Carolina Berra, Juliana Sciani, FIBRIN FORMATION IN TUMOR MICRO ENVIRONMENT
Mariana Schmidt, Maria Teresa Lamy, Evandro Duarte, Ana Marisa Chudzinski-Tavassi Halema Alfarsi*, Hamda Althawadi, Shahsoltan Mirshahi, Elodie Ducros, Amu
(Brazil) Therwath, Marc Pocard, Jeannette Soria, Massoud Mirshahi (France, Qatar)
130 131
PO120-MON CHANGES IN COAGULATION IN ACUTE PROMYELOCYTIC LEUKAEMIA PO132-MON
THE PHOTODYNAMIC THROMBI-SPECIFIC NANOPARTICLES STARVE
Richard Dillon, Kiran Parmar, David Grimwade, Beverley Hunt* (United Kingdom) SOLID LYMPHOMA TO DEATH
Yao Wang*, Wei Shi, Bo Zhang, Yu Hu (China)
PO121-MON FIBRINOLYTIC ACTIVATION IN ACUTE PROMYELOCYTIC LEUKAEMIA
Richard Dillon, Kiran Parmar, David Grimwade, Beverley Hunt* (United Kingdom) PO133-MON
NEUTROPHIL EXTRACELLULAR TRAPS MEDIATE ARTERIAL AND VE-
NOUS THROMBUS FORMATION IN A MURINE BREAST CANCER MODEL
PO122-MON
CONDITIONAL INACTIVATION OF INTEGRIN AV SUBUNIT IN VASCULAR Robson Q. Monteiro*, Ana Carolina Leal, Natalia Rochael, Susana Ortiz-Costa, Claudio
SMOOTH MUSCLE CELLS DECREASES THROMBIN GENERATION IN Wernek, Elvira Saraiva, Cristina Vicente, Daniella Mizurini (Brazil)
VESSELS AND BLOOD.
Amel Mohamadi*, Zhenlin Li, Huguette Louis, Mustapha Bourhim, Patrick Lacolley*,
Vronique Regnault (France) Coagulation factor V, X, II, XIII - I
PO123-MON
OESTROGENS REGULATE TFPI EXPRESSION THROUGH OESTROGEN
RESPONSE ELEMENTS IN TFPI 5 FLANKING REGION PO135-MON
PROTEOLYTIC INACTIVATION OF COAGULATION FACTOR V BY OMPT
Huda O. Ali*, Benedicte Stavik, Christiane Myklebust, Elisabeth Drum, Nina Iversen, FROM ENTEROHEMORRHAGIC ESCHERICHIA COLI.
Per Morten Sandset, Grethe Skretting (Norway) John A. Samis*, Derek Tilley, Veena Premjani, Samantha Gruenheid, Herve Le Moual,
Jeffrey Weitz (Canada)
PO124-MON
MONOCYTIC LEUKEMIA CELL LINES POSSESS ENHANCED PROCOAGU-
LANT ACTIVITY, THE ROLE OF FLT3-ITD MUTATION PO136-MON
COMBINED FV AND FVIII DEFICIENCY (F5F8D) IN A CHINESE FAMILY
Renta Hudk*, Ildik Debreceni, Gabriella Gl, Pter Antal-Szalms, Jnos Kappel- WITH A NOVEL MISSENSE MUTATION IN MCFD2 GENE
mayer (Hungary) Anyou Wang*, Xin Liu, Jingsheng Wu (China)
MONDAY
PO125-MON
THROMBIN DRIVES PANCREATIC DUCTAL ADENOCARCINOMA GROWTH PO137-MON
SUCCESSFUL ABDOMINAL OPERATION WITHOUT REPLACEMENT THER-
AND DISSEMINATION THROUGH MECHANISMS LINKED TO FIBRINOGEN APY IN A PATIENT WITH COMBINED FV AND FVIII DEFICIENCY DUE TO
AND PROTEASE-ACTIVATED RECEPTOR-1 NOVEL HOMOZYGOUS MUTATION IN LMAN1
Cheryl Rewerts, Carolina Cruz, Joseph Palumbo, James Luyendyk, Yi Yang, Stephen Anyou Wang*, Qiaohong Duan, Xin Liu, Jingsheng Wu (China)
Konieczny, Matthew Flick* (United States)
PO138-MON
ENGAGEMENT OF THE ACTIVE SITE OF THROMBIN BY DABIGATRAN
PO126-MON
MICROCIRCULATION THROMBOSIS IN BONE: A POSSIBLE MECHANISM OR ARGATROBAN MODULATES ITS EXOSITE-MEDIATED INTERACTIONS
POSTERS
FOR BONE PAIN WITH FIBRIN AND FACTOR VA
Eli Peled*, Mai Assalia, Elena Axelman, Doron Norman, Benjamin Brenner, Yona Nadir Calvin Yeh*, Alan Stafford, Beverly Leslie, James Fredenburgh, Jeffrey Weitz (Canada)
(Israel)
PO139-MON
FACTOR VA IN SYNERGY WITH PROTEIN S ENHANCES ACTIVATED PRO-
PO127-MON
PROCOAGULANT EFFECTS OF LUNG CANCER CHEMOTHERAPY TEIN C BINDING TO PHOSPHOLIPIDS
THROUGH RELEASE OF MICROPARTICLES AND CELL-FREE DNA. Magdalena Gierula*, Isabelle I. Salles-Crawley, James T.B. Crawley, David A. Lane*,
Zakhar Lysov*, Dhruva Dwivedi, Patricia Liaw (Canada) Josefin Ahnstrm (United Kingdom)
PO128-MON THE REED STERNBERG CELL COAGULOME PO140-MON

MEMBRANE CHOLESTEROL IS A CRITICAL REGULATOR OF PLATE-
Gabriela N. Cesarman-Maus*, Jonathan Reichel, Mikhail Roshal, Esteban Braggio, LET-ASSOCIATED PROTHROMBINASE COMPLEX ASSEMBLY
Rafael Fonseca, Ethel Cesarman (Mexico) Laura M. Haynes*, Paula Tracy (United States)
PO129-MON FACTOR VII DERIVED PROTEIN EGFP-EGF1 MEDIATE DRUG DELIVERY PO141-MON REFERENCE VALUE AND STABILITY OF FACTOR V
SYSTEM FOR HUMAN TUMOR Rahajuningsih Dharma*, Rudianto Rudianto (Indonesia)
Shi Wei*, Zhang Bo, Hu Yu (China)
PO143-MON
ACTIVATED FACTOR V INHIBITS THE ACTIVATION OF FACTOR IX BY TIS-
PO130-MON
THE ROLE OF M-COMPONENTS AND IMMUNOGLOBULINS IN PATIENTS SUE FACTOR/FACTOR VIIA COMPLEX
WITH MULTIPLE MYELOMA - PROCOAGULANT AND PROGNOSTIC? Dana Huskens*, Minka Vries, Joke Konings, Rob Wagenvoord, Saartje Bloemen, Raed
Thger Nielsen*, Henrik Gregersen, Anna-Marie Bloch Mnster, Ann Katharina Staush- Al Dieri, Mark Roest, H. Hemker, Marcus Lance, Henri Spronk, Hugo Ten Cate, Yvonne
Henkens, Bas de Laat (The Netherlands)
olm-Mller, Sren Risom Kristensen Risom Kristensen, Shona Pedersen (Denmark)
PO144-MON
THE C-DOMAINS OF PSEUDONAJA TEXTILIS VENOM FACTOR V CON-
PO131-MON
HYPOXIA-INDEPENDENT TUMOR PROGRESSION: ACTIVATION OF TRAN-
TRIBUTE TO COFACTOR STABILITY BUT ARE DISPENSABLE FOR LIP-
SCRIPTION FACTOR HIF 1 VIA PAR1 AND PAR2 RECEPTORS IN BREAST
ID-INDEPENDENT PROTHROMBINASE FUNCTION
CANCER.
Danil Verhoef*, Rodney Camire, Pieter Reitsma, Mettine Bos (The Netherlands)
Tain Gomes*, Robson de Queiroz Monteiro, Sandra Konig (Brazil)
132 133
PO145-MON
ASSESSING THE ROLE OF COMPLEX N-LINKED GLYCANS ON THE FAC- PO155-MON PROTEIN S, A NEW AGENT IN ADJUNCT THERAPY OF HEMOPHILIA B
TOR V LIGHT CHAIN IN ENDOCYTOSIS BY MEGAKARYOCYTES Rinku Majumder*, Howard Fried, Valder Arruda (United States)
Jacqueline M. Gertz*, Mark Jennings, Cody Couperus, Jay Silveira, Paula Tracy, Beth
Bouchard (United States) PO156-MON
IN VIVO EFFICACY OF HUMAN RECOMBINANT FACTOR IX PRODUCED BY
THE HUMAN HEPATOMA CELL LINE HUH-7
Nathalie Enjolras*, Eloise Perot, Sandra Le Quellec, Alice Indalecio, Jonathan Girard,
Coagulation factor VIII and IX - I Claude Negrier, Yesim Dargaud (France)
PO157-MON
INCORPORATION OF MUTATIONS AT E410 OF FACTOR IX IMPROVES
PO146-MON
N9-GP OVERESTIMATION IN ONE-STAGE CLOT METHOD DUE TO SILI- CLOTTING ACTIVITY IN VITRO AND IN VIVO
CA-MEDIATED CONVERSION TO FIXA DURING CONTACT ACTIVATION Eloise Perot, Nathalie Enjolras*, Sandra Le Quellec, Jonathan Girard, Alice Indalecio,
Per Rosn*, Steffen Rosn, Mirella Ezban, Egon Persson (Denmark) Claude Negrier, Yesim Dargaud (France)
PO147-MON
IN VIVO EFFECT OF RECOMBINANT FVIIA (NOVOSEVEN) AND RFIX IN PO158-MON
THE SLEEPING-BEAUTY TRANSPOSON TECHNOLOGY FOR THE GENER-
A REFINED TAIL VEIN TRANSECTION BLEEDING MODEL IN MICE WITH ATION OF CELLULAR AND ANIMAL MODELS OF HAEMOPHILIA B AND
HAEMOPHILIA A AND B THE ASSESSMENT OF RNA-BASED THERAPEUTIC APPROACH
Peter B. Johansen, Mikael Tranholm, Carsten Ley*, Torben Elm, Jesper Haaning, Mire- Elena Barbon*, Mattia Ferrarese, Giuseppe Ronzitti, Fanny Collaud, Mirko Pinotti,
lla Ezban, Tom Knudsen (Denmark) Federico Mingozzi (Italy)
PO148-MON
EARLY IMMUNOLOGICAL EVENTS IN AAV-F9 MEDIATED ITI FOR HEMO- PO159-MON
COMPARISON OF FACTOR IX GLYCOSYLATION IN DIFFERENT AGE
PHILIA B MICE WITH PATHOGENIC FIX INHIBITORS GROUPS
MONDAY
David Markusic*, Geoffrey Rogers (United States) Helen M. Atkinson*, Leslie Berry, Anthony Chan (Canada)
PO149-MON
RECOMBINANT LONG-ACTING GLYCOPEGYLATED FACTOR IX (NONACOG PO160-MON
INVESTIGATIONS INTO ANTICOAGULANT RESISTANCE AND ENHANCED
BETA PEGOL) IN HEMOPHILIA B: ASSESSMENT OF TARGET JOINTS IN ACTIVATION AS PUTATIVE MOLECULAR MECHANISMS OF THE HYPER-
THE MULTINATIONAL RANDOMIZED PHASE 3 CLINICAL TRIAL ACTIVITY OF FACTOR IX PADUA
Claude Negrier*, Faraizah Abdul Karim, Hideji Hanabusa, Peter Collins, Torben Col- Ben Samelson-Jones*, Jonathan Finn, Rodney Camire, Valder Arruda (United States)
berg, Bryan Goldman, Christopher Walsh (France)
PO161-MON
VARIETY OF F9 MUTATION IDENTIFIED IN 43 JAPANESE HEMOPHILIA B
POSTERS
PO150-MON
ASSESSMENT OF RECOMBINANT FACTOR IX-FC FUSION PROTEIN (RFIX- PATIENTS
FC) CLOTTING ACTIVITY IN PLASMA SAMPLES AT CANADIAN HAEMO- Keiko Shinozawa*, Hiroshi Inaba, Takashi Suzuki, Masato Bingo, Ikuo Seita, Takeshi
PHILIA TREATMENT CENTRES Hagiwara, Kagehiro Amano, Katsuyuki Fukutake (Japan)
F. Jon Geske*, Ali Sadeghi-Khomami, Hina Chaudhry, Michelle Sholzberg, Jerry Teitel
(Canada)
PO162-MON
LOCATION OF TWO NOVEL LARGE GENE DELETIONS IN CHINESE HAE-
PO151-MON
A CASE OF SEVERE HEMOPHILIA B ASSOCIATED WITH A LARGE INSER- MOPHILIA B PATIENTS
TION OF SVA RETROTRANSPOSON IN THE COAGULATION FACTOR IX Qingyun Wang*, Hui Liu, Liang Tang, Bei Hu, Yu Hu (China)
GENE
Naoki Mizutani*, Yuki Nakamura, Moe Murata, Yuki Takagi, Ryo Hasebe, Toshihiro Ko- PO163-MON
QUANTITATION AND VISUALISATION OF NANOSIZE PROTEIN AGGRE-
zuka, Yukiko Nakata, Akira Takagi, Jun-ichi Kitazawa, Midori Shima, Tetsuhito Kojima GATES IN RFIX AND PDFIX CONCENTRATES
(Japan) Martin Brodde*, Martin Wiemann, Anja Mller, Beate Kehrel (Germany)
PO152-MON
TISSUE DISTRIBUTION OF RIX-FP AFTER INTRAVENOUS APPLICATION PO164-MON
INHIBITOR DEVELOPMENT IN RELATION TO TREATMENT DURATION
TO RODENTS IN SEVERE HEMOPHILIA A IN PREVIOUSLY UNTREATED PATIENTS:
Sabrina Schenk, Brbel Doerr, Frauke May, Eva Herzog, Gerhard Dickneite, Marc W. RESULTS FROM THE SIPPET TRIAL
Nolte* (Germany)
Flora Peyvandi*, Pier Mannuccio Mannucci, Isabella Garagiola, Massimo Boscolo
Anzoletti, Amal El-Beshlawy, Mohsen El-Alfy, Vijay Ramanan Madatha, Peyman Eshghi,
PO153-MON
THE EFFECTS OF A NOVEL LONG-ACTING FACTOR IX PRODUCT (N9-GP)
Ramabadran Varadarajan, Suresh Hanagavadi, Mehran Karimi, Mamta Vijay Manglani,
ON WOUND HEALING Cecil Ross, Guy Young, Tulika Seth, Shashikant Apte, Dinesh Nayak, Elena Santagos-
Elizabeth Chappell*, Mirella Ezban, Maureane Hoffman, Dougald Monroe (United States) tino, Elisa Mancuso, Adriana Carolina Sandoval Gonzalez, M. Tarek Owaidah, Frits
Rosendaal (Italy)
PO154-MON
INHERITED FACTOR VIII AND IX DEFICIENCY IN PATIENTS REPORTED
TO A TERTIARY CARE UNIVERSITY HOSPITAL IN INDIA: A RETROSPEC-
TIVE COHORT ANALYSIS
Benson Babu* (India)
134 135
PO165-MON
USING HPSEC TO QUANTIFY THE EFFECT OF GAMMA-CARBOXYLATION PO174-MON
MOYAMOYA SYNDROME IN A HEMOPHILIA A PATIENT WITH A HIGH-TI-
ON DIVALENT METAL-INDUCED COMPACTION OF VKD-PROTEINS AND TRE FVIII INHIBITOR
BIOLOGICAL FUNCTION Wolf A. Hassenpflug*, Johanna Schrum, Manuela Albisetti, Nadia Khan, Reinhard
Nicholas Vanderslice*, Amanda Messer, Kanagasabai Vadivel, S. Paul Bajaj, Martin Schneppenheim (Germany)
Phillips, Mostafa Fatemi, Weijie Xu, William Velander (United States)
PO175-MON
OPTIMIZING PROCOAGULANT ACTIVITY FOR MUTANT RECOMBINANT
PO166-MON
INCREASED IMMUNOGENICITY OF FACTOR IX ADMINISTERED SUBCU- FACTOR IX WITH RESISTANCE TO HEPARIN- AND ANTITHROMBIN
TANEOUSLY VERSUS INTRAVENOUSLY DEMONSTRATED IN HEMOPHILIA John P. Sheehan*, Pamela Westmark (United States)
B MICE EXPRESSING A HUMAN MAJOR HISTOCOMPATIBILITY COMPLEX
II HAPLOTYPE
Yasmina Abajas*, Junjiang Sun, Genlin Hu, Paul Monahan (United States)
Disseminated intravascular coagulation
PO167-MON
PHARMACOKINETIC (PK) AND CLINICAL DATA SUPPORT FOR EFFEC-
PO176-MON
TO EVALUATE THE UTILITY OF ISTH SCORING SYSTEM, APTT AND
TIVENESS OF ONCE-WEEKLY RECOMBINANT COAGULATION FACTOR
SCHISTOCYTES AS MARKERS OF SEVERITY IN CASES OF DISSEMINAT-
IX (RFIX) DOSING FOR PROPHYLAXIS IN PATIENTS WITH MODERATELY
ED INTRAVASCULAR COAGULATION.
SEVERE OR SEVERE HEMOPHILIA B
Anjali J. Kelkar*, Amit Nisal, Parineeta Shelke, Ravindra Nimbargi (India)
Joan Korth-Bradley, Lynne Smith, Joanne Fuiman, Pablo Rendo* (United States)
PO177-MON
ROLE OF PLASMA HIGH MOBILITY GROUP BOX 1 IN DISSEMINATED
PO168-MON
EVALUATION OF HOST CELL PROTEIN IMMUNOGENICITY OF A POL-
INTRAVASCULAR COAGULATION WITH LEUKEMIA.
ISHED RECOMBINANT FACTOR IX INVESTIGATIONAL PRODUCT, IB1001
Manzhi Wang, Heng Mei*, Haiming Kou, Jun Deng, Yu Hu (China)
IN PREVIOUSLY TREATED PATIENTS WITH HEMOPHILIA B
MONDAY
Bojan Drobic*, Yi Hua, Tim Babinchak, Edward Gomperts, Christine Hall (Canada) PO178-MON
ROLE OF ACTIVATED PROTEIN C AND SOLUBLE FIBRIN IN THE EARLY
PHASE OF TRAUMA WITH DISSEMINATED INTRAVASCULAR COAGULA-
PO169-MON
FACTOR IX IMMUNOGENICITY IN HEMOPHILIA B PATIENTS ON RE-
TION: COMPARISON WITH ACUTE COAGULOPATHY OF TRAUMA-SHOCK
PLACEMENT THERAPY WITH A RECOMBINANT FACTOR IX INVESTIGA-
Satoshi Gando*, Atsushi Sawamura, Mineji Hayakawa, Takeshi Wada, Yuichiro Yan-
TIONAL PRODUCT (IB1001) agida, Daisuke Miyamoto, Kunihiko Maekawa, Yuichi Ono, Asumi Mizugaki, Subrina
Bojan Drobic, Yi Hua, Tim Babinchak*, Edward Gomperts, Christine Hall (United Jesmin (Japan)
States)
POSTERS
PO179-MON
EVALUATION OF NEW CHINESE DIAGNOSTIC SCORING SYSTEM FOR
PO170-MON
INDIRECT COMPARISONS OF FACTOR CONSUMPTION, BLEEDING DISSEMINATED INTRAVASCULAR COAGULATION.
RATES, AND INFUSION FREQUENCIES DURING ROUTINE PROPHYLAXIS Manzhi Wang, Heng Mei*, Haiming Kou, Jun Deng, Huafang Wang, Yu Hu (China)
WITH RECOMBINANT FACTOR VIII FC FUSION PROTEIN AND OTHER
RECOMBINANT FACTOR VIII PRODUCTS PO180-MON
A NOVEL MURINE MODEL OF DISSEMINATED INTRAVASCULAR COAGU-
Alfonso Iorio*, Sangeeta Krishnan, Karl-Johan Myrn, Stefan Lethagen, Nora McCor- LATION (DIC) TO AID THE DEVELOPMENT OF NOVEL THERAPEUTICS TO
mick, Paul Karner (Canada) TREAT DIC
Majid Ali*, Keith Norman, Helen Philippou (United Kingdom)
PO171-MON
INDIRECT COMPARISONS OF FACTOR CONSUMPTION, BLEEDING
RATES, AND INFUSION FREQUENCIES DURING ROUTINE PROPHYLAX- PO181-MON
THE PRESENCE OF OVERT DISSEMINATED INTRAVASCULAR COAG-
IS WITH RECOMBINANT FACTOR IX FC FUSION PROTEIN AND OTHER ULATION AT DIAGNOSIS OF ADULT PATIENTS WITH ACUTE MYLEOID
RECOMBINANT FACTOR IX PRODUCTS LEUKEMIA
Alfonso Iorio*, Sangeeta Krishnan, Karl-Johan Myrn, Stefan Lethagen, Nora McCor- Tadej Pajic*, Irena Zupan, Helena Podgornik, Uro Mlakar, Peter Cernelc (Slovenia)
mick, Paul Karner (Canada)
PO182-MON
BIOMARKER PROFILE OF SEPSIS-ASSOCIATED COAGULOPATHY USING
PO172-MON
SAFETY AND EFFICACY OF A NOVEL AAV VECTOR FOR TREATMENT OF BIOCHIP ASSAYS FOR INFLAMMATORY CYTOKINES
HEMOPHILIA B Amanda Walborn*, Debra Hoppensteadt, Daneyal Syed, Schuharazad Abro, Michael
Xavier Anguela*, Raffaella Toso, Linda Couto, Yifeng Chen, Daniel Hui, Martha DiPi- Mosier, Jawed Fareed (United States)
etro, Benjamin Lee, Guang Qu, Bernd Hauck, Romu Corbau, Fraser Wright, Katherine
High (United States)
Endothelium/vessel wall I
PO173-MON
COMPARISON OF FIX ACTIVITY OF SELECT NOVEL RECOMBINANT FIX
REPLACEMENT PRODUCTS IN COMMONLY USED FDA APPROVED ONE-
STAGE CLOT ASSAY SYSTEMS PO183-MON
HYPOXIA INDUCES DYSREGULATION OF MIR-126 AND AFFECTS VEGF
Mary M. Robinson*, Stefan Tiefenbacher, Erika Ross, Patrick Williams, Caroline Cog- AND MMP-9 EXPRESSION IN ENDOTHELIAL CELLS
swell, Tyrelle Wham, Dorothy Adcock (United States) Satoshi Fujii*, Misa Ogasawara, Soichiro Iwaki (Japan)
136 137
PO184-MON
ANTIOXIDANT PHARMACOLOGICAL STRATEGIES FOR THE PREVENTION Fibrinogen/fibrin/D-dimer I
OF ENDOTHELIAL DYSFUNCTION IN UREMIA
Susana Martin-Rodriguez*, Manel Vera, Enrique Mir, Jose Rivera, Josep Cruzado, Aleix
Cases, Gins Escolar, Maribel Diaz-Ricart (Spain) PO195-MON
EVALUATION OF DIFFERENT ASSAYS OF D-DIMER AND SOLUBLE FIBRIN
IN EMERGENCY DEPARTMENT PATIENTS WITH SUSPECTED VENOUS
PO185-MON
ANTI-THROMBOTIC AND PRO-FIBRINOLYTIC EFFECTS OF LEVOSIMEN- THROMBOEMBOLISM
DAN IN HUMAN ENDOTHELIAL CELLS IN VITRO Maria Farm*, Anwar Siddiqui, Liselotte Onelv, Ingela Jrnberg, Jaak Eintrei, Anders
Konstantin Krychtiuk*, Christoph Kaun, Stefan Stojkovic, Stefan Kastl, Andreas Kallner, Jovan Antovic (Sweden)
Zuckermann, Wolfgang Eppel, Gerald Maurer, Kurt Huber, Johann Wojta, Walter Speidl
(Austria) PO196-MON
PERFORMANCE OF AGE ADJUSTED D-DIMER CUT OFF VALUE: A STEP
TOWARDS IMPROVING CLINICAL UTILITY IN DIAGNOSIS OF ASYMPTOM-
PO186-MON
RNA-SEQ ANALYSIS OF HUMAN MAJOR LIVER CELL TYPES REVEALS
ATIC VENOUS THROMBOEMBOLISM
DIFFERENTIAL EXPRESSION PROFILE OF SINUSOIDAL VERSUS OTHER
Salma A. Shawkat*, Shaimaa Pessar, Tamer Farid, Nevine Kassim (Egypt)
HEPATIC VASCULAR ENDOTHELIAL CELLS
Tina Shahani*, Peyman Zarrineh, Kris Covens, Majid Ashtiani, Renaud LavendHomme, PO197-MON
EVALUATION OF THE RATIOS OF HIGH MOLECULAR WEIGHT FIBRIN
Hassan Rokni Zadeh, Kathelijne Peerlinck, Marc Jacquemin (Iran, Islamic Republic DEGRADATION PRODUCTS (HMW FDP) TO D-DIMER IN PATIENTS
Of)
BLOOD BY THE IMMUNOASSAY EQUALLY RECOGNIZING D-DIMER AND
PO187-MON
ENDOTHELIAL FIBRINOLYTIC RESPONSE ONTO AN EVOLVING MATRIX HMW FDP
OF FIBRIN Alexander Kogan*, Kadriya Mukharyamova, Anastasia Bereznikova, Ekaterina Koshkina,
Andrei Kara, Alexey Katrukha (Finland)
Rita Marchi*, Oscar Castillo, Hctor Rojas, Zury Dominguez, Eduardo Angls-Cano
MONDAY
(Venezuela, Bolivarian Republic Of)
PO198-MON
ISOCHRONOUS DESIGN TO STUDY THE STABILITY OF LIQUID D-DIMER
PO188-MON
A MICROFLUIDIC VASCULAR INJURY MODEL USING HEAT-ACTIVATED CONTROLS
ENDOTHELIAL CELLS Miquel Sales*, Begoa Arza, Susana Perez-Alvarez, Lidia del Toro (Spain)
Joanna L. Sylman*, Dylan Artzer, Keith Neeves (United States)
PO199-MON
THE FACTORS ASSOCIATED WITH ELEVATED D-DIMER LEVEL IN PA-
PO189-MON
EVIDENCE OF DEFIBROTIDE INTERNALIZATION AND ITS ENDOTHELIAL TIENTS WITH ACUTE VENOUS THROMBOEMBOLISM
PROTECTIVE EFFECT IN HEPATIC ENDOTHELIAL IN VITRO MODEL Natalya Vorobyeva*, Anatoly Dobrovolsky, Elena Titaeva, Olga Ermolina, Tatyana Balak-
POSTERS
honova, Alexandr Kirienko, Elizaveta Panchenko (Russian Federation)
Marta Palomo De Udaeta*, Enrique Mir, Montse Rovira, Gins Escolar, Enric Carreras,
Maribel Daz-Ricart (Spain)
PO200-MON
BASELINE D-DIMER LEVELS AS A PREDICTOR FOR RECANALISATION IN
PATIENTS WITH FIRST EPISODE OF DEEP VENOUS THROMBOSIS(DVT)
PO190-MON
CIRCULATING ENDOTHELIAL CELLS ARE INCREASED IN POST-THROM- OF THE LOWER LIMB
BOTIC SYNDROME PATIENTS Vikas Suri*, Nikhil P, Mukesh Yadav, Jaismina Ahluwalia, Narender Kumar, Pankaj
Malhotra, Gaurav Prakash, Alka Khadwal, Savita Kumari, Sanjay Jain, Neelam Varma,
Mariane Flores-Nascimento*, Bruna Mazetto, Fernanda Orsi, Joyce Annichino-Bizzac-
Subhash Varma (India)
chi (Brazil)
PO201-MON
AN EVALUATION OF THE TOSOH BIOSCIENCE ST AIA-PACK DDIMER
PO191-MON
ENDOTHELIAL DYSFUNCTION AFTER HEMATOPOIETIC CELL TRANS-
PERFORMED WITH THE AIA-360 AUTOMATE
PLANTATION (HCT) IS ENHANCED IN ACUTE GRAFT-VERSUS-HOST
Julie M Smith*, Steve Kitchen (United Kingdom)
DISEASE (GVHD)
Enrique Mir*, Marta Palomo, Montse Rovira, Gins Escolar, Enric Carreras, Maribel PO202-MON
EVALUATION OF DIAGNOSTIC ACCURACY OF TWO D-DIMER ASSAYS IN
Diaz-Ricart (Spain)
PULMONARY EMBOLISM
PO192-MON
EFFECT OF MATERNAL ANTI-HPA-1A ANTIBODIES ON ENDOTHELIAL Wallace Feese, James Dunnington, Jeffrey Kline* (United States)
CELLS
Rima Dardik*, Nurit Rosenberg, Ron Loewenthal, Ophira Salomon (Israel)
Fibrinolytic system
PO193-MON ENDOTHELIAL DYSFUNCTIONS IN CIRRHOSIS PATIENTS
laudia Maria Radu*, Cristiana Bulato, Kryssia Rodriguez-Castro, Patrizia Zerbinati,
C PO203-MON
DS-1040: A NOVEL SELECTIVE INHIBITOR OF ACTIVATED FORM OF
Graziella Saggiorato, Marco Senzolo, Paolo Simioni (Italy)
THROMBIN-ACTIVATABLE FIBRINOLYSIS INHIBITOR
PO194-MON KINDLINS ARE ACTIN BINDING PROTEINS Kengo Noguchi*, Naoko Edo, Yusuke Ito, Takanori Maejima, Kyoji Yamaguchi (Japan)
atarzyna Bialkowska*, Kamila Bledzka, Elzbieta Pluskota, Jun Qin, Edward Plow
K
PO204-MON
THE STATE OF FIBRINOLYTIC SYSTEM IN ATHLETES AT RUSSIAN NORTH
(United States)
Nadezda Vorobyeva*, Natalia Bushueva (Russian Federation)
138 139
PO205-MON
MIR-30C REGULATES THROMBUS FORMATION IN TYPE 2 DIABETIC PO217-MON
GLOBAL FIBRINOLYTIC PROFILE IN PATIENTS WITH CHRONIC THROM-
MELLITUS BOEMBOLIC PULMONARY HYPERTENSION
Mao Luo*, Fei Liu, Rong Li, Ni Chen, Ming Zeng, Xin Deng, Yan Yang, Qin Wan, Jianbo Aurlien Lebreton,* Alessandro Casini, Frdric Lador, Philippe de Moerloose, Margue-
Wu (China) rite Neerman-Arbez (France)
PO206-MON
THE INFLUENCE OF THE PEPTIDE PRO-ARG-GLY ON THE REGULATION PO218-MON
MEASUREMENT OF IN VIVO GENERATED CARBOXYPEPTIDASE U (CPU,
OF THE FIBRINOLYTIC AND INSULAR SYSTEMS OF THE BODY ON THE CPB2, TAFIA) IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION
MODEL OF DIABETES MELLITUS TYPE 2 Dorien Leenaerts*, Johan Bosmans, Pieter Van Der Veken, Yani Sim, Anne-Marie Lam-
Tatiana Shubina*, Tomara Obergan, Ludmila Lyapina (Russian Federation) beir, Dirk Hendriks (Belgium)
PO207-MON
EXPERIMENTAL VALIDATION OF A STOCHASTIC MULTISCALE MODEL OF PO219-MON
CHARACTERISTICS OF CARBOXYPEPTIDASE U (CPU, CPB2 OR TAFIA)
FIBRINOLYSIS GENERATION DURING IN VITRO CLOT LYSIS
Brittany Bannish*, Krasimir Kolev, Colin Longstaff (United States) Dorien Leenaerts*, Jef Aernouts, Yani Sim, Anne-Marie Lambeir, Dirk Hendriks (Bel-
gium)
PO208-MON
THROMBOLYTIC PREPARATION LONGOLYTIN FROM LOW FUNGUS RE-
SOLVES SUPERFICIAL HAEMATOMAS PO220-MON
CELL-FREE DNA MODULATES CLOT STRUCTURE AND IMPAIRS FIBRI-
Podorolskaya Lidya*, Sharkova Tamara (Russian Federation)
NOLYSIS IN SEPSIS.
Travis J. Gould*, Trang Vu, Dhruva Dwivedi, Jeffrey Weitz, Patricia Liaw (Canada)
PO209-MON
THE ANTIFIBRINOLYTIC EFFECT OF FACTOR XIII STRONGLY DEPENDS
ON CLOT COMPACTION/RETRACTION PO221-MON
IDENTIFICATION OF FUNCTIONAL PROCARBOXYPEPTIDASE U (PROCPU,
Dick C. Rijken*, Joyce Malfliet, Shiraaz Abdul, Frank Leebeek, Shirley Uitte de Willige
TAFI) IN CEREBROSPINAL FLUID AND ITS ENHANCEMENT IN THE
MONDAY
(The Netherlands) ACUTE PHASE OF BRAIN INJURY
Dorien Leenaerts*, Bart Feyen, Sleyman Sener, Andrew Maas, Yani Sim, Margareta
PO210-MON
THE ASSOCIATION OF PAI-1 AND CLOT LYSIS TIME WITH BODY COMPO- Ieven, Anne-Marie Lambeir, Dirk Hendriks (Belgium)
SITION IN AFRICANS IS SEX DEPENDENT
Zelda De Lange*, Philna Eksteen, Marlien Pieters, H. Salome Kruger (South Africa)
PO222-MON
IN-VITRO IMAGING OF PLATELET/FIBRIN CLOT FORMATION AND LYSIS
IN FLOW CONDITION
PO211-MON
FIBRINOLYTIC DYSREGULATION IN ARTHROPLASTY PATIENTS MAY Stphane Loyau*, Yacine Boulaftali, Benoit Ho Tin Noe, Martine Jandrot-Perrus (France)
POSTERS
CONTRIBUTE TO POSTOPERATIVE HEMOSTATIC COMPLICATIONS.
Nil Guler*, Drew Burleson, Debra Hoppensteadt, Harold Rees, Jawed Fareed, William
PO223-MON PAI-1 REGULATES FIBRIN CLOT STABILITY AND LYSIS
Hopkinson (United States) arhel Dassi*, Sylviane Fontaine, Olivier Mathieu, Landry Seyve, Raphal Marlu, Beno-
C
t Polack, Franois Caton, Genevive Contant (France)
PO212-MON
PRE AND PERIOPERATIVE FACTORS MODULATE FIBRINOLYSIS IN AR-
THROPLASTY PATIENTS PO224-MON
THE EFFECT OF ALPHA-2 PLASMIN INHIBITOR ARG6TRP POLYMOR-
Drew Burleson*, Nil Guler, Jennifer Saluk, Andrew Banos, Debra Hoppensteadt, Harold
PHISM ON THE RISK OF CORONARY ARTERY DISEASE
Rees, Jawed Fareed, William Hopkinson (United States) va Katona*, Adrienn Orosz, Zoltn Mezei, Lszl Balogh, Istvn Czuriga, Istvn des,
Lszl Muszbek (Hungary)
PO213-MON
KINETIC AND THROMBOLYTIC PROPERTIES OF PROUROKINASE-PAMAM
CONJUGATES PO225-MON
THROMBI FORMED AT LOW HAEMATOCRIT ARE RESISTANT TO FIBRI-
Liliya Mukhametova*, E. Ivanova, E. Zaharyan, R. Aisina, S. Varfolomeyev (Russian
NOLYSIS VIA A FACTOR XIIIA-MEDIATED MECHANISM
Federation)
Paraskevi Untiveros*, Ausra Lionikiene, Michael Greaves, Henry Watson, Nicola Mutch
(United Kingdom)
PO214-MON THE INFLUENCE OF RESIDUAL PLATELETS ON PLASMA PAI-1 ASSAYS
PO226-MON
IMPAIRED FIBRINOLYSIS IN BEHET SYNDROME
Sunelle Barnard*, Marlien Pieters, Du Toit Loots, Dingeman Rijken (South Africa)
Elena Silvestri, Giacomo Emmi, Anna Cellai, Emilia Antonucci, Danilo Squatrito, Lucia
Ciucciarelli, Caterina Cenci, Rosanna Abbate, Lorenzo Emmi, Domenico Prisco* (Italy)
PO215-MON
CLOT LYSIS PARAMETERS ARE HIGHER IN INFLAMMATORY BOWEL
DISEASE PATIENTS WITH A HISTORY OF THROMBOEMBOLISM PO227-MON
VARIABLE RESISTANCE TO PLASMINOGEN ACTIVATOR INITIATED FIBRI-
Lize Bollen*, Niels Vande Casteele, Miet Peeters, Sverine Vermeire, Ann Gils (Belgium)
NOLYSIS FOR INTERMEDIATE-RISK PULMONARY EMBOLISM
PO216-MON
TISSUE PLASMINOGEN ACTIVATOR (T-PA) RELEASED FROM HUMAN William Stubblefield*, Jeff Kline, Matt Rondina (United States)
CELLS BY SOFT RUSH [JUNCUS EFFUSUS L. VAR. DECIPENS]
Hiroyuki Sumi*, Masatoshi Imai, Hisaya Mizote (Japan)
140 141
Hemophilia clinical I PO238-MON
BURDEN OF ILLNESS AMONG PERSONS WITH HEMOPHILIA B: DIRECT
AND INDIRECT COSTS
Christina X. Chen*, Judith Baker, Barbara Konkle, Megan Ullman, Roshni Kulkarni,
PO228-MON
CARRIER AND PRENATAL DIAGNOSIS OF CHINESE HAEMOPHILIA A Jeffrey Hord, Mimi Lou, Michael Nichol (United States)
FAMILIES IN ONE CENTER FROM 2007 TO 2014
Yeling Lu*, Jin Dai, Qiulan Ding, Xuefeng Wang (China) PO239-MON
TREATMENT OF BLEEDING WITH RECOMBINANT FACTOR VIII FC FU-
SION PROTEIN IN PREVIOUSLY-TREATED PEDIATRIC SUBJECTS WITH
PO229-MON
GENETIC ALTERATIONS IN HEMOPHILIAC PATIENTS WITH INHIBITOR IN HEMOPHILIA A IN THE PHASE 3 KIDS A-LONG STUDY
THE REGION OF MURCIA, SPAIN Elizabeth Chalmers*, Guy Young, Johnny Mahlangu, Michael Recht, Amy Geddis,
Faustino Garca-Candel*, Antonia Melero-Amor, Noemi Marn-Atucha, Paola Romecn Jayanthi Alamelu, Giulia Gambino, Glenn Pierce, Geoffrey Allen (United Kingdom)
(Spain)
PO240-MON
ACUTE EFFECTS OF EXERCISE ON SPECIFIC AND GLOBAL COAGULA-
PO230-MON
A RETROSPECTIVE EVALUATION OF BLEEDING EPISODES IN PATIENTS TION PARAMETERS IN SEVERE HEMOPHILIA A
WITH HAEMOPHILIA A, B AND VON WILLEBRANDS DISEASE Eva Zetterberg, Henric Ek Olsson*, Lvdahl Susanna, Ola Thorsson, Erik Berntorp
Aylin Canbolat Ayhan*, Cetin Timur, Enise Avc, Ayse Ulusoy, Asm Yoruk (Turkey) (Sweden)
PO231-MON
ANTIBODIES OF HIGH AVIDITY IS THE HALLMARK OF SEVERE HEMO- PO241-MON
FIRST PROSPECTIVE RESULTS OF JOINT DISTRACTION IN HAEMOPHIL-
PHILIA A PATIENTS WITH FVIII INHIBITORS IC ANKLE ARTHROPATHY
Daniel Chaves*, Amanda Silveira, Hayama Arajo, Mariana Ruckert, Olindo Martins-Fil- L.F.D. van Vulpen, H.Ch. Vogely, G. Roosendaal, P. de Kleijn, P.M. van Roermund, S.C.
ho (Brazil) Mastbergen, F.P.J.G. Lafeber, R.E.G. Schutgens* (The Netherlands)
MONDAY
PO232-MON
THE ROLE OF LARGE POPULATION-BASED DATABASES IN THE EVALU- PO242-MON
INITIAL RESULTS OF A CLINICAL TRIAL EVALUATING A FULL-LENGTH
ATION OF SAFETY OF BYPASSING AGENTS IN HEMOPHILIA PATIENTS PEGYLATED RECOMBINANT FACTOR VIII WITH EXTENDED HALF-LIFE
WITH INHIBITORS FOR THE PERIOPERATIVE CONTROL OF HEMOSTASIS IN HEMOPHILIA A
Katsiaryna Bykov*, Rhonda Bohn, Bruce Ewenstein, Jerry Avorn, John Seeger (United Brigitte Brand, Ralph Gruppo, Tung Wynn, Laimonas Griskevicius, Maria Fernanda Lo-
States) pez Fernandez, Feriandas Greblikas*, Thomas Dvorak, Lisa Patrone, Monika Fuerlinger,
Brigitt Abbuehl (United States)
PO233-MON
EFFICACY OF SECONDARY PROPHYLAXIS ON ANNUAL BLEEDING RATIO
PO243-MON
EVALUATION OF JOINT DAMAGE IN BOYS WITH HEMOPHILIC AR-
POSTERS
(ABR) IN ADULT PATIENTS WITH HEMOPHILIA: A SINGLE CENTER OB-
SERVATION STUDY IN JAPAN. THROPATHTY BY ULTRASONOGRAPHY AND BIOMARKER OF CARTILAGE
Teruhisa Fujii*, Seiji Saito, Naoya Yamasaki, Tomie Fujii (Japan) TURNOVER URINARY C TERMINAL TELOPEPTIDE OF TYPE II COLLAGEN
(U-CTX-II)
PO234-MON
IMPACT OF THE INTRINSIC PATHWAY IN INDIVIDUAL THROMBIN GEN- Hoda Hassab*, Wessam El-Gendy, Khaled EL-Noueam, Hayam Abd EL Ghani, Nirmeen
ERATION AMONG HEMOPHILIA B PATIENTS Abdallah (Egypt)
Vuokko H. Jokela*, Annukka Jouppila, Riitta Lassila (Finland)
PO244-MON
SYSTEMATIC MONITORING OF HEMOSTATIC MANAGEMENT IN HEMO-
PO235-MON
SAFETY AND EFFICACY OF RECOMBINANT FACTOR VIII FC FUSION PRO- PHILIA A PATIENTS WITH INHIBITOR IN THE PERIOPERATIVE PERIOD
TEIN (RFVIIIFC) FOR THE PREVENTION AND TREATMENT OF BLEEDING USING ROTATIONAL THROMBOELASTOMETRY
IN PREVIOUSLY-TREATED ADULT AND ADOLESCENT SUBJECTS WITH Shoko Furukawa*, Keiji Nogami, Kenichi Ogiwara, Hiroaki Minami, Midori Shima (Japan)
HEMOPHILIA A: INTERIM ANALYSIS OF THE ASPIRE STUDY
Shannon Jackson*, David Perry, Doris Quon, Pratima Chowdary, Amy Shapiro, Ingrid PO245-MON SYMPTOMATIC FEMALE HEMOPHILIA SEEN IN TAIWAN
Pabinger, Elena Santagostino, Xiaoxi Li, Desilu Glazebrook, Geoffrey Allen (Canada) ing-Ching Shen*, Ming Chen, Shun-Ping Chang, Woei Tsai, Ching-Yeh Lin, Shyu-
M
ann-Yuh Lin (Taiwan)
PO236-MON
NEW ANTIVIRAL TREATMENT OF HCV INFECTED YOUNG HAEMOPHILI-
ACS EXPECTATIONS TO CURE HEPATITIS C PO246-MON
NO RELATION BETWEEN PLATELET ACTIVITY AND HEMOPHILIA B PHE-
Katalin Koehler-Vajta*, Gerald Denk, Matthias Wettstein (Germany) NOTYPE
Roger EG Schutgens*, Esther R van Bladel, Kathelijn Fischer, Mark Roest, Rolf T
PO237-MON
ANALYSIS OF BLEEDING RATES IN PEDIATRIC SUBJECTS WITH TARGET Urbanus (The Netherlands)
JOINTS AND SEVERE HEMOPHILIA A RECEIVING PROPHYLAXIS WITH
RECOMBINANT FACTOR VIII FC FUSION PROTEIN (RFVIIIFC) IN KIDS PO247-MON
OUTCOME OF LONG TERM PLASMA DERIVED FVIII CONCENTRATE FAN-
A-LONG HDI USE IN THE MATURE HAEMOPHILIA POPULATION.
Beatrice Nolan*, Guy Young, Savita Rangarajan, Michael Wang, Bryce Kerlin, Alex
Pu-Lin Luo*, Savita Rangarajan, Ruth Pink, Steve Austin (United Kingdom)
Leung, Elisa Tsao, Desilu Glazebrook, Glenn Pierce, Geoffrey Allen (Ireland)
142 143
PO248-MON
RACE AND THE IMMUNE RESPONSE TO FACTOR VIII REPLACEMENT PO258-MON
RESULTS FROM THE PUP-GCP CLINICAL TRIAL: LOW INHIBITOR RATE
THERAPY IN PREVIOUSLY UNTREATED PATIENTS WITH SEVERE HAEMOPHILIA A
Kenneth G. Mann*, Saulius Butenas, Glenn Pierce, Robert Peters, Siyuan Tan, Jeanne TREATED WITH A PLASMA DERIVED FVIII CONCENTRATE
Lusher, David Lillicrap, Christine Kempton, Johnny Mahlangu, Afshin Ameri, Nigel Key, Anna Klukowska, Sigurd Knaub, Vladimir Komrska, Pawel Laguna, Vladimir Vdovin,
Raymond Watts, Alexis Thompson, Cindy Leissinger, Kevin McRedmond, Christoper Martina Jansen* (Austria)
Walsh, Craig Kessler, Neil Josephson, Dana Matthews, Kathleen Pratt (United States)
PO259-MON
DESIGNING A STUDY FOR REAL-WORLD DATA ON SAFETY AND EFFEC-
PO249-MON
ANTIBODIES AGAINST POLYETHYLENE GLYCOL (PEG) IN HEALTHY SUB- TIVENESS OF RIXUBIS (NONACOG GAMMA) IN PEOPLE WITH HEMO-
JECTS MYTH OR REALITY? PHILIA B
Christian Lubich, Peter Allacher, Alexander Bauer, Thomas Prenninger, Frank Horling, Andreas Tiede*, Robert Klamroth, Carmen Escuriola-Ettingshausen, Karin Kurnik, Flo-
Jrgen Siekmann, Friedrich Scheiflinger, Birgit Reipert* (Austria) rian Langer, Cornelia Wermes, Nirjhar Chatterjee, Ingrid Rauter, Alessandro Gringeri
(Germany)
PO250-MON
CORRELATION BETWEEN ABR AND PK PARAMETERS IN PATIENTS
WITH SEVERE HAEMOPHILIA A RECEIVING TUROCTOCOG ALFA PO260-MON
BLEEDING PATTERNS EVALUATED DURING PROPHYLAXIS WITH A
(NOVO-EIGHT) FOR PROPHYLAXIS FULL-LENGTH PEGYLATED RECOMBINANT FACTOR VIII (BAX 855) WITH
Victor Jimnez-Yuste*, Sandra Lejniece, Anders Rosholm, Nikola Tripkovic, Elena EXTENDED HALF-LIFE IN HEMOPHILIA A
Santagostino (Spain) Barbara Konkle, Oleksandra Stasyshn, Tung Wynn, Marilyn Manco-Johnson, Ralph
Gruppo, Pratima Chowdary, Vladimir Komrska, Laimonas Griskevicius, M. Eyster,
PO251-MON
EXPRESSION OF PLATELET PROTEIN DISULFIDE ISOMERASE (PDI) IS Krzysztof Chojnowski, Werner Engl, Lisa Patrone, Brigitt E. Abbuehl* (Austria)
INCREASED IN PATIENTS WITH HEMOPHILIA OR VON WILLEBRAND DIS-
EASE PO261-MON
BAYESIAN APPROACH TO THE ASSESSMENT OF THE POPULATION
MONDAY
Minna Voigtlnder*, Katharina Holstein, Christina Dicke, Brigitte Spath, Carsten Boke- SPECIFIC RISK OF INHIBITORS
meyer, Florian Langer (Germany) Alfonso Iorio*, Ji Cheng, Maura Marcucci, Vadim Romanov, Lehana Thabane (Canada)
PO252-MON
ALTERNATIONS OF OXIDATIVE STRESS MARKERS IN PATIENTS WITH PO262-MON
PHARMACOKINETIC CHARACTERISTICS OF FACTOR VIII AND IX CON-
SEVERE HAEMOPHILIA TREATED BY DIFFERENT PROPHYLAXIS REGI- CENTRATES A SYSTEMATIC REVIEW
MENS Mengchen Xi, Victor Blanchette, Jan Blatny, Peter Collins, Amy Dunn, Kathleen
Irena Djunic*, Violeta Dopsaj, Predrag Miljic, Aleksandra Novkovic, Nada Suvajdzic-Vu- Fischer, Cedric Hermans, Tamara Navarro-Ruan, Kaan Kavakli, Shannon Jackson,
POSTERS
kovic, Dragica Tomin, Ivo Elezovic (Serbia) Paula James, Sunil Mammen, Massimo Morfini, Ellis Neufeld, Margarete Ozelo, Paolo
Radossi, Savita Rangarajan, Arlette Ruiz-Sez, Jerry Teitel, Lehana Thabane, Guy
PO253-MON
HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH HEMOFILIA A Young, Alfonso Iorio* (Canada)
AND B IN BRAZIL
Tassila Salomon, Daniel Chaves*, Stela Brener, Srgio Peixoto (Brazil) PO263-MON
IMMUNE TOLERANCE INDUCTION WITH HAEMATE P IN HEMOPHILIA
A: EXPERIENCE FROM A SINGLE CENTER.
PO254-MON
COMPARISON OF PROPHYLAXIS AND EPISODIC TREATMENT IN CHIL- Ralf Knfler*, Gabriele Siegert, Julia Stchele, Judith Lohse (Germany)
DREN WITH MODERATE TO SEVERE HEMOPHILIA A
Darintr Sosothikul*, Rachaneekorn Songnuy, Panya Seksarn (Thailand) PO264-MON
2003-2014 TWELVE YEAR RESULTS OF INHERITED BLEEDING DISOR-
DERS REGISTRY OF THE EMILIA ROMAGNA REGION IN ITALY
PO255-MON
USING MINUTE DOSES OF APTT REAGENT AND TISSUE FACTOR AS THE Gianna Franca Rivolta, Caterina Di Perna, Federica Riccardi, Gabriele Quintavalle,
COAGULATION TRIGGER TO QUANTIFY THE COAGULATION PROFILE IN Giuseppina Rodorigo, Lelia Valdr, Chiara Biasoli, Attilia Pizzini, Maria Luisa Serino,
HEMOPHILIA A Mariacristina Arbasi, Silvia Macchi, Paola Pedrazzi, Annarita Tagliaferri* (Italy)
Shu He*, Anna Eelde, Pia Petrini, Margareta Blombck (Sweden)
PO265-MON CONGENITAL FACTOR DEFICIENCIES: TWENTY-FIVE-YEAR FOLLOW-UP
PO256-MON
USER EXPERIENCE ASSESSMENT OF THE THERAPY MANAGEMENT Zafer Salcioglu*, Hulya Sayilan Sen, Deniz Tugcu, Tugce Kalayci, Gonul Aydogan,
SYSTEM HAEMOASSIST 2 Ferhan Akici, Zafer Baslar (Turkey)
Charlotte Bttger, Jrg Grimm, Susan Halimeh, Michael Sigl-Kraetzig, Johannes Olden-
burg, Andreas Tiede, Ian Winburn*, Martin Schulz (Germany) PO266-MON
THERE IS A DIRECT RELATIONSHIP BETWEEN THE PHYSICAL ACTIVITY
SCORE AND HDL CHOLESTEROL LEVEL IN HEMOPHILIA PATIENTS
PO257-MON
ONCE WEEKLY NONACOG ALFA IN HEMOPHILIA B (HEMB): A TIME Fahri Sahin*, Miray Bozgul Kilincer, Ugur Turk, Gunes Basol, Burcu Barutcuoglu, Kaan
COURSE PROFILE OF SPONTANEOUS BLEEDS IN PATIENTS FROM A Kavakli, Guray Saydam (Turkey)
PIVOTAL TRIAL
Bartholomew J. Tortella*, Marcus Carr, Pablo Rendo, Lynne Smith, Kaan Kavakli (Unit- PO267-MON
MEASUREMENT OF GAIT VARIABILITY IN PATIENTS WITH AND WITHOUT
ed States) HEMOPHILIC ARTHROPATHY: MOVE-STUDY (NTR 4561)
Sara C. Stoof*, Diana Hodgins, Frank Leebeek, Marjon Cnossen, Herwin Horemans,
Stephan Praet, Marieke Kruip (The Netherlands)
144 145
PO268-MON
THE EFFECTIVENESS OF EXERCISE PROGRAMME AND RADIOISOTOPE PO279-MON
RESULTS OF RADIOSYNOVECTOMY IN CHILDREN WITH SEVERE HEMO-
SYNOVECTOMY IN HEMOPHILIC PATIENTS PHILIA AND FACTOR VIII OR IX INHIBITOR
Melike Sezgin Evim, Ufuk Sekir, Birol Baytan, Adalet Meral Gnes* (Turkey) Pawel Laguna*, Jaroslaw Cwikla, Piotr Zbikowski, Anna Klukowska, Michal Matysiak
(Poland)
PO269-MON
ADHERENCE TO TREATMENT IN PATIENTS WITH HAEMOPHILIA IN GER-
MANY PO280-MON
F8 MUTATION AND INHIBITOR DEVELOPMENT IN SEVERE FACTOR VIII
Wolfgang Miesbach*, Werner Kalnins (Germany) DEFICIENCY: RESULTS FROM THE IRISH NATIONAL DATABASE
Vince Jenkins*, Catriona Keenan, Barry White, James ODonnell, Kevin Ryan, Beatrice
PO270-MON
PROPHYLAXIS PRACTICES IN CHILDREN AND ADULTS WITH HEMOPHIL- Nolan, Niamh OConnell (Ireland)
IA A OR B AND INHIBITORS
Manuel Carcao*, Laura Avila, Louis Aledort, Cindy Leissinger (Canada) PO281-MON
PATIENT PREFERENCES FOR FVIII AND BAX 855: RESULTS FROM THE
BAX 855 PIVOTAL TRIAL
PO271-MON
CURRENT STATUS OF OLDER PATIENTS WITH HEMOPHILIA: INSIGHTS Josh Epstein, Elizabeth Schwartz*, Brigit Abbuehl, Bruce Ewenstein (United States)
FROM A CROSS-SECTIONAL PAN-EUROPEAN STUDY
Pl Andre Holme*, Robert Tait, Christophe Combescure, Erik Berntorp, Stephan PO282-MON
RECURRENT HEMATURIA IN HEMOPHILIA PATIENTS IS NOT INDICATIVE
Rauchensteiner, Philippe de Moerloose (Norway) OF THE PRESENCE OF AN UNDERLYING CAUSE
Greta Mulders*, Sara Stoof, Frank Leebeek, Martijn Busstra, Marieke Kruip (The Neth-
PO272-MON
COMPARING THROMBIN GENERATION IN PATIENTS WITH HAEMOPHIL- erlands)
IA A AND PATIENTS ON VITAMIN K ANTAGONISTS
Marie-Sophie L. Y. De Koning, Kathelijn Fischer, Bas De Laat, Albert Huisman, Marisa PO283-MON
SPONTANEOUS INTRACRANIAL BLEEDING IS A MAJOR CAUSE OF
Ninivaggi, Roger Schutgens* (The Netherlands) DEATH IN NONSEVERE HEMOPHILIA A PATIENTS
MONDAY
Janneke I. Loomans*, Corien Eckhardt, Alice Van Velzen, Marjolein Peters, Evelien
PO273-MON
COATED PLATELET LEVELS IN SEVERE HEMOPHILIA DO NOT COR- Mauser-Bunschoten, Rainer Schwaab, Maria Mazzucconi, Annarita Tagliaferri, Berthold
RELATE TO BLEEDING PHENOTYPE Siegmund, Sylvia Reitter-Pfoertner, Johanna Van der Bom, Karin Fijnvandraat (The
Kelly L. Lastrapes*, Bassem Mohammed, Erika Martin, Dougald Monroe, Maureane Netherlands)
Hoffman, Melinda Nolte, Janice Kuhn, John Barrett, Donald Brophy (United States)
PO284-MON
RELIABLE RNA RETRIEVAL FROM LOW-VOLUME PAXGENE TUBES IN
PO274-MON
SUCCESSFUL IMMUNE TOLERANCE INDUCTION IN AN ADULT WITH SIMULATED REAL WORLD NEXT GENERATION SEQUENCING (RNA-
HEMOPHILIA A AND CHRONIC INHIBITOR A CASE STUDY SEQ): GENA-05 SUBSTUDY PILOT
POSTERS
Michelle Sholzberg*, Georgina Floros, Jerry Teitel (Canada) Paul Batty*, Charles Mein, Eva Wozniak, Daniel Hart (United Kingdom)
PO275-MON
PROPHYLACTIC APPROACH TO RECCURRENT BLEEDING IN HEMOPHIL- PO285-MON
U.S. SURVEILLANCE OF PROPHYLAXIS USE AMONG PERSONS WITH HE-
IA WITH INHIBITORS MOPHILIA A RECEIVING CARE AT HEMOPHILIA TREATMENT CENTERS
Bulent Zulfikar*, Basak Koc, Nihal Ozdemir (Turkey) (HTCS)
Marilyn J. Manco-Johnson*, Vanessa Byams, Brandi Cooke, Michael Recht, Diane
PO276-MON
UTILIZATION OF ANTI-INHIBITORS PRODUCTS AND INHIBITORS Aschman, Becky Dudley, Mariam Voutsis, Meredith Oakley (United States)
STATUS OF SEVERE HEMOPHILIA PATIENTS: 5 YEARS NATIONAL DATA
FROM THE CANADIAN HEMOPHILIA ASSESSMENT AND RESOURCE PO286-MON
ASSESSMENT OF INHIBITOR RISK AFTER SWITCHING FROM PLAS-
MANAGEMENT SYSTEM MA-DERIVED FACTOR VIII CONCENTRATE TO RECOMBINANT FACTOR
Aicha N. Traore*, Anthony Chan, Alfonso Iorio, Nancy Heddle, Irwin Walker (Canada) VIII (BRASIL-RFVIII: BRAZILIAN STUDY OF INHIBITOR LINKED TO
RECOMBINANT FACTOR VIII)
PO277-MON
RELIABILITY OF PATIENT-REPORTED OUTCOME (PRO) INSTRUMENTS IN Alessandra Prezotti*, Silmara Aparecida Montalvo, Ana Paula Marques, Clarissa
US ADULT PEOPLE WITH HEMOPHILIA (PWH): THE PAIN FUNCTIONAL Ferreira, Luciana Oliveira, Paula Villaa, Luiz Ivando Ferreira Filho, Cludia Lorenzato,
IMPAIRMENT AND QUALITY OF LIFE (P-FIQ) STUDY Samuel Medina, Fatima Araujo, Margareth Ozelo (Brazil)
Michael Wang*, Anne Neff, Amy Shapiro, Roshni Kulkarni, Mark Reding, Philip Kuria-
PO287-MON
PHENOTYPIC PROFILE OF A CHILD WITH SEVERE HEMOPHILIA B AND
kose, Craig Kessler, Michelle Witkop, Christine Kempton, David Cooper (United States)
INHIBITORS WITH NOVEL MUTATION IN THE FIX (F9) GENE
PO278-MON
ACQUIRED HEMOPHILIA IN PATIENT WITH CHRONIC MYELOMONOCYTIC Zorica Trajkova Antevska*, Sofijanka Glamocanin, Biljana Coneska, Violeta Dejanova
Ilijevska, Emilija Sukarova Stefanovska (Macedonia, The Former Yugoslav Republic Of)
LEUKEMIA (CMML1)-A CASE REPORT.
Bernadeta Ceglarek, Robert Wasilewski, Ksenia Bykowska, Anna Sikorska, Beata Baran,
PO288-MON
MILD HEMOPHILIA A COMPLICATED BY INHIBITOR AFTER SURGERY
Edyta Odnoczko, Adam Wiszniewski*, Jerzy Windyga (Poland)
AND FACTOR REPLACEMENT THERAPY
Miguel Escobar*, Shivika Chandra, Eric Wilson, Keneth Chong (United States)
146 147
Heparin and heparinoids PO299-MON
MEASUREMENT OF HEPARANASE ACTIVITY IN PLASMA REQUIRES THE
USE OF SAMPLE ANTITHROMBIN-DEPLETION
Shahsoltan Mirshahi*, Marc Pocard, Massoud Mirshahi, Soria Jeannette (France)
PO290-MON
DISTURBANCE OF THE HEMOSTATIC BALANCE BY CARDIOPULMONARY
BYPASS SURGERY PO300-MON
NOVEL SYNTHETIC COPOLYMERS ABLE TO BIND UNFRACTIONATED
Romy Kremers*, Yvonne Bosch, Edwin Mannens, Saartje Bloemen, Rob Wagenvoord, AND LOW MOLECULAR WEIGHT HEPARINS.
Raed Al Dieri, Coenraad Hemker (The Netherlands) Bartlomiej Kalaska, Kamil Kaminski, Emilia Sokolowska, Joanna Miklosz, Shin-ichi
Yusa, Krzysztof Szczubialka, Dariusz Pawlak, Maria Nowakowska, Andrzej Mogielnicki*
PO291-MON
BOVINE AND PORCINE MUCOSAL HEPARINS EXHIBIT SIMILAR BIOLOG- (Poland)
IC PROFILES
Jawed Fareed*, Helena Nader, Marcelo Lima, Debra Hoppensteadt, Jeanine Walenga, PO301-MON
DIFFERENCES BETWEEN NORMAL AND CANCER CELLS IN THE BIO-RE-
Walter Jeske, Mary Lewis, Emmanuele Kumar, Wolfram Raake, Mamdouh Bakhos SPONSE TO HEPARIN
(United States) Yunliang Chen*, Michael Scully, Christopher Goodwin, Ajay Kakkar (United Kingdom)
PO292-MON
CHARACTERIZATION OF THE ANTITHROMBOTIC FINGERPRINT OF THE PO302-MON
MONITORING UNFRACTIONATED HEPARIN IN CHILDREN APTT, AN-
BRANDED AND COPIES OF THE LOW MOLECULAR WEIGHT ENOXAPARIN TI-XA AND ACT IN A RANDOMIZED CONTROLLED TRIAL OF COMPARING
USING THROMBIN GENERATION ASSAY. TWO DOSE PROTOCOLS
Grigoris Gerotziafas*, Patrick Van Dreden, Elisabeth Mbemba, Amir Khartechi, Jeanine Katharina Ellen Thom*, Andreas Hanslik (Austria)
Walenga, Jawed Fareed, Ismail Elalamy (France)
PO303-MON
OVINE MUCOSAL HEPARIN AND ENOXAPARIN ARE BIOSIMILAR TO
PO293-MON
COMPARATIVE STUDIES ON THE MOLECULAR AND FUNCTIONAL THEIR PORCINE COUNTERPARTS
MONDAY
PROFILE OF SHEEP MUCOSAL DERIVED ENOXAPARIN WITH VARYING Emmanuel Kumar*, Yiming Yao, Daniel Kahn, Debra Hoppensteadt, Omer Iqbal, Walter
ANHYDRO-MANNO GROUPS Jeske, Jawed Fareed (United States)
Schuharazad Abro*, Emmanuel Kumar, Omer Iqbal, Daniel Kahn, Daneyal Syed, Debra
Hoppensteadt, Jawed Fareed (United States) PO304-MON
THE EFFICACY AND SAFETY OF LOW-MOLECULAR-WEIGHT HEPARIN
THROMBOPROPHYLAXIS IN CRITICALLY ILL ADULT PATIENTS: A SYS-
PO294-MON
SEVUPARIN; EFFECTS ON HEMOSTASIS OF A NOVEL POLYSACCHARIDE TEMATIC REVIEW AND META-ANALYSIS
DRUG DERIVED FROM HEPARIN Annukka Ylnen*, Anne Kuitunen, Suvi Vaara, Ville Pettil, Heini Huhtala (Finland)
POSTERS
Maria Lindgren*, Joost Meijers, Bart Biemond, Sofia Ramstrm, Tomas Lindahl, Per-
Olov Eriksson, Anna Leitgeb, Mats Wahlgren, John Hogwood, Elaine Gray, Erik Holmer PO305-MON
COMPARATIVE ANTICOAGULANT AND ANTI-INFLAMMATORY EFFECTS
(Sweden) OF SULODEXIDE AND ENOXAPARIN IN CITRATED WHOLE BLOOD
Schuharazad Abro*, Cafer Adiguzel, Daneyal Syed, Debra Hoppensteadt, Walter Jeske,
PO295-MON
REVERSAL OF THE HEPARINOID EFFECT WITH PROTHROMBIN COM- Jeanine Walenga, Jawed Fareed (United States)
PLEX CONCENTRATE AN IN VITRO STUDY USING THE THROMBIN
GENERATION ASSAY PO306-MON
IN VITRO EVALUATION OF NOVEL SYNTHETIC HEPARAN SULFATES
Emma L. Fosbury*, Colleen Hamid, Anne Riddell, Pratima Chowdary (United Kingdom) MIMETICS TO PREVENT XENOGENEIC RELATED-THROMBOSIS
Prabhjot Benipal, Hayato Iwase, Rami Al-Horani, Akul Mehta, Rajesh Karuturi, Lars
PO296-MON
PERFORMANCE EVALUATION OF A NEW ASSAY FOR THE QUANTITATIVE Burdorf, Xiangfei Cheng, Donald Harris, Richard Pierson, Simon Robson, David Cooper,
DETERMINATION OF BOTH UNFRACTIONATED HEPARIN (UFH) AND LOW Umesh Desai, Agnes M. Azimzadeh* (United States)
MOLECULAR WEIGHT HEPARIN (LMWH) USING A HYBRID CALIBRATION
CURVE. PO307-MON
ARGATROBAN VS FONDAPARINUX IN HEPARIN-INDUCED THROMBOCY-
Mechthild Merz, Sascha Lange*, Katharina Madlener (Germany) TOPENIA PATIENTS: A RESPONSE COMPARATIVE STUDY
Fahad Aleidan*, Saud Alrokan (Saudi Arabia)
PO297-MON
STRATEGIES AND OUTCOMES OF PERIPROCEDURAL BRIDGING THER-
APY WITH LOW-MOLECULAR-WEIGHT- HEPARIN IN PATIENTS WITH PO308-MON
ANTICOAGULANT AND FIBRINOLYTIC EFFECTS OF COMPLEXES OF DI-
MECHANICAL HEART VALVES PEPTIDE PRO-GLY WITH LOW-MOLECULAR-WEIGHT HEPARINS ANIMAL
Jacqueline Schulman*, Ammar Majeed, Eva Mattsson, Sam Schulman, Margareta AND PLANT ORIGIN
Holmstrm, Anna gren (Sweden) Tamara Obergan*, Tatiana Shubina (Russian Federation)
PO298-MON
BIOPHYSICAL CHARACTERIZATION OF THE INTERACTION BETWEEN
PLATELET FACTOR 4 AND SYNTHETIC LOW MOLECULAR WEIGHT HEPA-
RINS
Mihaela Delcea*, Thi-Huong Nguyen, Sven Brandt, Martin Kreimann, Wen Zhou, Jian
Liu, Andreas Greinacher (Germany)
148 149
Immune thrombocytopenia (ITP) I PO320-MON
AN INCREASED MAJOR LIPID RAFT PROTEIN RAFTLIN ASSOCIATED
WITH B CELLS SIGNALING IN PATIENTS WITH IMMUNE THROMBOCYTO-
PENIA
PO309-MON
USAGE OF ELTHROMBOPAG IN A 9 YEAR OLD SYRIAN PATIENT WITH Zhang Xian*, Yang Li, Zhang Donglei, Li Huiyuan, Fu Rongfeng, Yang Renchi (China)
IMMUNE THROMBOCYTOPENIC PURPURA AND FAMILIAL DEAF-
NESS-FIRST PEDIATRIC EXPERIENCE IN TURKEY
Fatma Burcu Belen*, Meltem Polat, Ulker Kocak, Shinji Kunishima (Turkey) Inflammation II
PO310-MON
ACUTE IMMUNE THROMBOCYTOPENIC PURPURA FOLLOWING COM-
BINED VACCINE PO321-MON
NEUTROPHIL ELASTASE IS NOT REQUIRED FOR NEUTROPHIL EXTRA-
Sinan Akbayram*, Kamuran Karaman, Hatice Akbayram, Mesut Garipardic, Ahmet
CELLULAR TRAP OR DEEP VEIN THROMBUS FORMATION IN MICE
Oner (Turkey) Kimberly Martinod*, Maureen Gallant, Denisa Wagner (United States)
PO311-MON
THROMBOPOIETIN RECEPTOR AGONISTS DO NO NOT CAUSE COAGULA- PO322-MON
TISSUE FACTOR-DEPENDENT PLATELET ACTIVATION SUPPORTS NEU-
TION ACTIVATION IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA TROPHIL RECRUITMENT, ROLLING AND TRANSMIGRATION DURING
Lamya Garabet*, Waleed Ghanima, Soo Lee, Marie-Christine Mowinckel, Howard Lieb- INFLAMMATION
man, Christine Jonassen, James Bussel, Per Morten Sandset (Norway) Soraya Mezouar*, Roxane Darbousset, Peter Lenting, Ccile Denis, Jean-louis Mege,
Nigel Mackman, Francoise Dignat-George, Laurence Panicot-Dubois, Christophe Du-
PO312-MON
TREATMENT-RELATED ADVERSE EVENT BURDEN IN IMMUNE THROM- bois (France)
BOCYTOPENIC PURPURA (ITP)
Prina Donga*, S. Pinar Bilir, Julie Munakata, Gregg Little, Tim Babinchak (United
PO323-MON
EFFECT OF GLUCOSE LEVELS IN INCREASED NEUTROPHIL EXTRACEL-
MONDAY
States) LULAR TRAP FORMATION (NETS) IN TYPE 2 DIABETES PATIENTS AT
DIAGNOSIS AND AFTER 6 AND 12 MONTHS OF METABOLIC CONTROL.
PO313-MON
HASHIMOTOS THYROIDITIS IN CHILDREN WITH CHRONIC IDIOPATHIC Mirta A. Schattner*, Agostina Carestia, Gustavo Frechtel, Gloria Cerrone, Claudio
THROMBOCYTOPENIA Gonzalez, Maria Linari, Patricia Casais (Argentina)
Muge Gokce*, Tubanur Tahtakesen, Cengiz Bayram, Deniz Tugcu, Zafer Salcoglu,
Gonul Aydogan, Gonca Keskndemirci, Ferhan Akc (Turkey) PO324-MON IMPACT OF PCSK9 IN A MURINE MOUSE MODEL OF SEPSIS.
hruva J. Dwivedi*, Momina Khan, Zakhar Lysov, Annik Prat, Alison Fox-Robichaud,
D
POSTERS
PO314-MON SERIAL MEAN PLATELET VOLUMES IN IMMUNE THROMBOCYTOPENIA Nabil Seidah, Patricia Liaw (Canada)
Mala Varma* (United States)
PO325-MON
PLASMA CELL-FREE DNA LEVELS ARE ELEVATED IN PATIENTS WITH
PO315-MON
RITUXIMAB EXPERIENCE IN CHILDHOOD IMMUNE THROMBOCYTOPE- ACUTE ISCHEMIC HEART FAILURE PARTIALLY DUE TO NEUTROPHIL
NIC PURPURA FROM A TERTIARY CENTER IN TURKEY EXTRACELLULAR TRAP FORMATION
Gonca Keskindemirci, Muge Gokce*, Deniz Tugcu, Sevin Gen, Arzu Akcay, Gonul Alexander Brill*, Eduard Shantsila, Tatyana Ponomaryov, Robert Dinsdale, Paul Harri-
Aydogan (Turkey) son, Gregory Lip (United Kingdom)
PO316-MON
ITP WITH THYROID DYSFUNCTION: NOT MERELY AN ASSOCIATION- PO326-MON
THE HISTONE-CLEAVING FACTOR SEVEN ACTIVATING PROTEASE DOES
PROSPECTIVE ANALYSIS NOT PROMOTE DEGRADATION OF NEUTROPHIL EXTRACELLULAR TRAPS
Mukul Aggarwal*, Manoranjan Mahapatra, Renu Saxena (India) Brenda M. Luken*, Ingrid Bulder, Melissa Stunnenberg, Gerben Marsman, Marein
Schimmel, Sacha Zeerleder (The Netherlands)
PO317-MON
LEVELS OF CYTOKINES SECRETED BY T LYMPHOCYTE AND THE RELA-
TIONSHIP WITH PROGNOSIS IN CHILDREN IMMUNE THROMBOCYTOPE- PO327-MON
MECHANISM OF E- VINIFERIN INHIBITS SUPEROXIDE GENERATION IN
NIA HUMAN NEUTROPHIL
Jingyao Ma*, Zhenping Chen, Runhui Wu (China) Chin-Hsuan Lin, Hsiang Ruei Liao*, Jih-Jung Chen (Taiwan)
PO318-MON
ELEVATED EXPRESSION OF IL-37 IN PATIENTS WITH IMMUNE THROM- PO328-MON
INHIBITORY EFFECT OF NKSE-5A ON SUPEROXIDE ANION GENERATION
BOCYTOPENIA IN HUMAN NEUTROPHILS
Liu Liu*, Ke Feng, Hu Zhou (China) Tzu-Chi Tseng*, Ih-Sheng Chen, Hsiang-Ruei Liao (Taiwan)
PO319-MON
ANALYSIS OF HISTOCOMPATIBILITY LOCUS ANTIGEN (HLA)-G AND PO329-MON
DIABETES PRIMES NEUTROPHILS TO UNDERGO NETOSIS WHICH SE-
IMMUNOGLOBULIN-LIKE TRANSCRIPTS (ILTS) ON PATIENTS WITH VERELY IMPAIRS WOUND HEALING
IMMUNE THROMBOCYTOPENIA Siu Ling Wong*, Melanie Demers, Kimberly Martinod, Maureen Gallant, Yanming
Wang, Allison Goldfine, C. Ronald Kahn, Denisa Wagner (United States)
Qi Feng*, Ji Ma, Miao Xu, Yu Hou, Yingyi Yu, Jun Peng (China)
150 151
PO330-MON
DETERMINANTS OF THE REGULATORY ACTION OF PLATELETS TO- PO340-MON
TF- AND UPA-BEARING MICROPARTICLES MODULATE FIBRIN NANO-
WARDS NEUTROPHIL ACTIVITIES STRUCTURE
Angle Gros*, Vronique Ollivier, Varouna Syvannarath, Martine Jandrot-Perrus, Benot Genevieve Contant, Olivier Mathieu, Sylvie Cointe, Tarik Bouriche, Jeremie Bez, Carhel
Ho-Tin-No (France) Dassi, Benoit Polack, Franois Caton, Romaric Lacroix, Philippe Poncelet* (France)
THE LEUKOCYTE INTEGRIN 2 PRIMES NEUTROPHILS FOR NETOSIS IN

PO331-MON PO341-MON
MODULATING THROMBOTIC DIATHESIS IN HEREDITARY THROMBO-
SICKLE CELL DISEASE PHILIA: A ROLE FOR CIRCULATING MICROPARTICLES?
Laila Elsherif*, Jessica Shen, Dell Strayhorn, Kenneth Ataga, Claire Doerschuk, Leslie Elena Campello*, Luca Spiezia, Claudia Radu, Cristiana Bulato, Sabrina Gavasso,
Parise (United States) Daniela Tormene, Barry Woodhams, Paolo Simioni (Italy)
PO332-MON
NEUTROPHIL INCORPORATION OF MEMBRANE FRAGMENTS FROM PO342-MON
CIRCULATING EXTRACELLULAR VESICLE (EV) AFTER ACUTE HINDLIMB
DYING PLATELETS ISCHEMIA
Shaun Jackson, Yuping Yuan*, David Bark Jr (Australia) Violeta Gomez-Rodriguez, Anita Bing, Josune Orbe, Rienk Nieuwland, Jos A. Para-
mo, Carmen Roncal* (Spain)
Microparticles I PO343-MON
COMPARISON OF INTRACARDIAC AND VENOUS BLOOD LEVELS OF MI-
CROVESICLES, TISSUE FACTOR AND PROCOAGULANT PHOSPHOLIPIDS
IN PATIENTS WITH AND WITHOUT ATRIAL FIBRILLATION
PO333-MON
GENERAL DECREASE OF CIRCULATING MICROPARTICLES IS RELATED
Morten Mrk*, Shona Pedersen, Lars Rasmussen, Jan Andreasen, Sren Risom Kris-
TO THE PRESENCE OF FVIII INHIBITORS IN HEMOPHILIA A PATIENTS tensen (Denmark)
Daniel Chaves*, Amanda Silveira, Marcela Moreira, Samantha Bla, Hayama Arajo,
MONDAY
Andrea Teixeira-Carvalho, Fernanda Campos-Nunes, Olindo Martins-Filho (Brazil)
Non-vitamin K antagonist oral anticoagulants I
PO334-MON
PRO-COAGULANT ACTIONS OF CIRCULATING MICROPARTICLES IN SICK-
LE CELL ANEMIA AND SEPSIS ASSOCIATED COAGULOPATHY AND THEIR
MODULATION BY A TRIBLOCK POLYMER MST 1-88. PO344-MON ANTICOAGULATION IN PATIENTS UNDERGOING CARDIOVERSION
Jawed Fareed*, Debra Hoppensteadt, Marty Emanuele, Daneyal Syed, Schuharazad Sufyan Benamer*, Kandiah Chandrakumaran, Debbie Lusty, Tamara Everington (United
Abro, Walter Jeske, Rakesh Wahi (United States) Kingdom)
POSTERS
PO335-MON
THE ROLE OF MICROVESICLES DERIVED FROM MYELOMA CELLS IN PO345-MON
EVALUATION OF DABIGATRAN, RIVAROXABAN AND APIXABAN TAR-
THROMBOGENICITY AND ANGIOGENESIS GET-SPECIFIC ASSAYS IN A MULTICENTER FRENCH STUDY.
Moran Zarfati, Tami Katz, Irit Avivi, Anat Aharon* (Israel) Isabelle Gouin-Thibault*, Emmanuel de Maistre, Sophie Susen, Genevive Freyburger,
Jean-Louis Golmard, Yves Gruel, Pierre Si (France)
PO336-MON
ANTITHROMBIN IS INCORPORATED INTO EXOSOMES AND ITS PRES-
ENCE IN THESE VESICLES IS MODULATED BY LOW MOLECULAR PO346-MON
VALIDATION STUDIES ON COAGULATION LABORATORY ASSAYS USEFUL
WEIGHT HEPARIN FOR ASSESSING THE PLASMA LEVELS OF APIXABAN
Irene Martnez-Martnez*, Patricia Carrasco, Ester Martn-Villar, Antonio Garca-Andreo, Debra Hoppensteadt*, Daneyal Syed, Marc Goldford, Anne Bisset, Leon Zuckerman,
Nataliya Bohdan, Salvador Espn, Javier Corral, Vicente Vicente, Miguel Quintanilla (Spain) Walter Jeske, Job Harenberg, Jawed Fareed (United States)
PO337-MON
SINGLE CASE REPORT: MONITORING THE BALANCE OF MICROPARTI- PO347-MON
HOW DO REAL-WORLD APIXABAN CONCENTRATIONS COMPARE TO
CLE-ASSOCIATED PROCOAGULANT AND FIBRINOLYTIC POTENTIALS EXPECTED CONCENTRATIONS?
AFTER ORTHOPEDIC SURGERY. Hawre Yones, Jignesh Patel*, Paradzai Chitongo, Rosalind Byrne, Alison Brown, Mag-
Philippe Poncelet*, Coralie Judicone, Jrmie Bez, Tarik Bouriche, Benjamin Franois, Eti- dalena Watras, Kathryn Lang, Julia Czuprynska, Lara Roberts, Raj Patel, Roopen Arya
enne Forestier, Olivier Brziat, Jos Sampol, Romaric Lacroix, Franoise George (France) (United Kingdom)
PO338-MON
PATIENTS WITH UNPROVOKED VENOUS THROMBOEMBOLISM HAVE PO348-MON THE DAILY PRACTICE OF NOACS; AN OBSERVATIONAL COHORT STUDY
HIGHER CONCENTRATION OF LARGE EXTRACELLULAR VESICLES WITH rina Ten Cate-Hoek*, Yvonne Henskens, Ren van Oerle, Rick Wetzels, Henri Spronk,
A
AUGMENTED POTENTIAL TO INITIATE COAGULATION ACTIVATION Simon Schalla, Harry Crijns, Hugo ten Cate (The Netherlands)
Simin Jamaly*, Irina Starikova, Vladimir Tichelaar, Cathrine Ramberg, Nadezhda Laty-
PO349-MON
POTENT ANTITHROMBOTIC EFFECT OF A NOVEL, SMALL-MOLECULE
sheva, John-Bjarne Hansen (Norway)
AND DIRECT INHIBITOR OF FACTOR XIA IN PREVENTION AND TREAT-
PO339-MON
INFLUENCE OF CALR AND JAK2 MUTATIONS ON PROCOAGULANT MENT OF THROMBOSIS IN RABBIT MODEL OF ARTERIAL THROMBOSIS
POTENTIAL OF PLATELET-DERIVED MICROPARTICLES IN ESSENTIAL AT DOSES THAT PRESERVE HAEMOSTASIS
THROMBOCYTHEMIA (ET) Pancras C. Wong*, Mimi Quan, Carol Watson, Earl Crain, Alan Rendina, Joseph Luett-
Marina Marchetti*, Sara Gamba, Alfonso Vignoli, Laura Russo, Carmen Tartari, Guido gen, Ruth Wexler, Dietmar Seiffert (United States)
152 Finazzi, Anna Falanga (Italy) 153

PO350-MON
COMPARING FEIBA WITH RECOMBINANT FVIIA FOR REVERSAL OF RI- PO361-MON
A CHROMOGENIC FACTOR XA INHIBITOR ASSAY FOR QUANTIFYING
VAROXABAN WITH A MODIFIED ANTI-XA ASSAY IN UNDILUTED PLASMA RIVAROXABAN LEVELS: OPTIMIZATION AND VALIDATION ON THE ACL
Jorell Gantioqui*, Ivan Stevic, Frank Lee, Anthony Chan, Howard Chan (Canada) TOP 700
Paula M. Jacobi*, Sharniece Covill, Kenneth Friedman, Sandra Haberichter (United
PO351-MON
DISCOVERY OF ONO-7750512, AN ORALLY BIOAVAILABLE SMALL MOL- States)
ECULE FACTOR XIA INHIBITOR: THE PHARMACOKINETIC AND PHARMA-
COLOGICAL PROFILES PO362-MON
BLEEDING AND THROMBOEMBOLIC OUTCOMES IN WARFARIN- AND
Sho Koyama*, Takehiro Ono, Kazutsune Harada, Aiko Fujioka, Keiko Tsukamoto, DABIGATRAN-TREATED PATIENTS IN THE RE-LY TRIAL WHO REQUIRED
Shinya Sakimoto, Masashi Gohda, Tetsuya Hagio, Tomoyuki Koda, Naoya Matsumura, AN URGENT SURGERY OR PROCEDURE
Yoshiyuki Yamaura, Ai Hashimoto, Motoyuki Tanaka, Takashi Kondo, Masaru Sakai, James Douketis*, Jeff Healey, Martina Brueckmann, Mandy Fraessdorf, Alex Spyro-
Kenji Tanaka, Hidekazu Matsuya, Akira Imagawa, Yasushi Hirota, Kazuhito Kawabata poulos, Lars Wallentin, Jonas Oldgren, Paul Reilly, Michael Ezekowitz, Stuart Connolly,
(Japan) Salim Yusuf (Canada)
PO352-MON
MONITORING NOVEL ANTICOAGULANTS DABIGATRAN, RIVAROXABAN PO363-MON
FROM LABORATORY TO CLINICAL PRACTICE: DABIGATRAN EFFECTS ON
AND APIXABAN USING THE NEW FULLY AUTOMATED THROMBELASTOG- THROMBIN GENERATION AND COAGULATION IN PATIENT SAMPLES
RAPHY TECHNIQUE TEG6S Tuukka Helin*, Marja Lemponen, Paul Hjemdahl, Yuko Rnquist-Nii, Riitta Lassila,
Ramin Artang*, Gregg Galloway, Jean Amiral, Jorn Dalsgaard Nielsen (United States) Lotta Joutsi-Korhonen (Finland)
PO353-MON
ENHANCEMENT OF FIBRINOLYSIS BY A FACTOR XA INHIBITOR EDOX- PO364-MON
THE ADDITION OF IDARUCIZUMAB TO PLASMA SAMPLES CONTAINING
ABAN AND COMBINATION WITH AN INHIBITOR OF ACTIVATED THROM- DABIGATRAN ALLOWS THE USE OF ROUTINE COAGULATION ASSAYS
BIN-ACTIVATABLE FIBRINOLYSIS INHIBITOR IN VITRO FOR THE DIAGNOSIS OF HEMOSTASIS DISORDERS
MONDAY
Yoshiyuki Morishima*, Chikako Kamisato, Taketoshi Furugohri (Japan) Marc Jacquemin*, Jelle Toelen, Joke Schoeters, Marijke Peetermans, Kathelijne Peer-
linck, Joanne van Ryn, Peter Verhamme (Belgium)
PO354-MON
NOVEL ORAL ANTICOAGULANTS: INCIDENCE AND MANAGEMENT OF
MAJOR BLEEDING. RETROSPECTIVE REVIEW AT A SINGLE CENTER. PO365-MON
IMPACT OF DABIGATRAN, RIVAROXABAN AND APIXABAN TREATMENT
Juan Peris*, Queralt Salas, Miren Gabilondo, Elena Pina, Elena Rossell, Pere Dome- ON HEMOSTASIS POINT-OF-CARE TESTING IN PATIENTS WITH ATRIAL
nech (Spain) FIBRILLATION.
Rita Paniccia*, Rossella Marcucci, Raffaella Priora, Daniela Poli, Yusuf Ahmed, Carlo
PO355-MON
INITIATING THROMBOPROPHYLAXIS WITH RIVAROXABAN UP TO 26
POSTERS
Fanciullacci, Agatina Alessandrello Liotta, Rosanna Abbate (Italy)
HOURS AFTER ELECTIVE KNEE ARTHROPLASTY DOES NOT INCREASE
THE INCIDENCE OF VENOUS THROMBOEMBOLISM PO366-MON
ANTICOAGULANT EFFECT OF DABIGATRAN, RIVAROXABAN AND APIX-
Owais Mian*, Christine Cockhill, Mary Ann Rizzo, Deborah Siegal, Howard Chan, Ellen ABAN TREATMENT ON DIFFERENT LABORATORY HEMOSTASIS TESTS IN
McDonald (Canada) PATIENTS WITH ATRIAL FIBRILLATION.
Rita Paniccia*, Rossella Marcucci, Raffaella Priora, Daniela Poli, Gaia Lembo, Carlo
PO356-MON
EVALUATION OF THE SAFETY AND TOLERABILITY OF TARGET SPECIFIC Fanciullacci, Elisa Grifoni, Maddalena Pazzi, Agatina Alessandrello Liotta, Rosanna
ORAL ANTICOAGULANTS AT A LARGE UNIVERSITY SETTING Abbate (Italy)
Gina Woodhouse, Patrick Klem*, Renjbar Zebari, Kathyrn Hassell, Toby Trujillo (United
States) PO367-MON
A NOVEL PROTHROMBIN TIME (PT) METHOD TO MEASURE ALL NON-VI-
TAMIN K DEPENDENT ORAL ANTICOAGULANTS (NOACS)
PO357-MON
EVALUATION OF ANTICOAGULANT THERAPY WITH DABIGATRAN BASED Tomas L. Lindahl*, Maria Wallstedt, Marie Danielsson-Rnby, Kerstin Arbring, Mats
ON ECARIN CLOTTING TIME Rnby (Sweden)
Takeshi Suzuki*, Masahiro Ieko, Ichiro Sakuma, Sumiyoshi Naito, Mika Yoshida,
Osamu Kumano, Nobuhiko Takahashi (Japan) PO368-MON
EFFECTS OF NEW ORAL ANTICOAGULANTS ON FIBRIN-NETWORK PER-
MEABILITY AND THROMBIN GENERATION
PO358-MON
SWITCH FROM VITAMIN K ANTAGONISTS (VKAS) TO DIRECT ORAL ANTI- Mika Skeppholm, Michal Zabczyk, Faris Al-Khalili, Rickard Malmstrm, Anna gren,
COAGULANTS (DOACS): A PRATICAL APPROACH Margareta Blombck, Shu He, Hkan Walln* (Sweden)
Samantha Pasca, Ugo Venturelli, Antonella Bertone, Giovanni Barillari* (Italy)
PO369-MON
KNOWLEDGE OF THE NEW ORAL ANTICOAGULANTS (NOACS) AMONGST
PO359-MON
WARFARIN AND MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE UNIVERSITY TEACHING HOSPITAL DOCTORS
REAL WORLD OF PATIENTS WITH ATRIAL FIBRILLATION Mahin Ahmad*, Manish Gautam, Tina Dutt (United Kingdom)
Pasquale Pignatelli, Daniele Pastori*, Gregory Lip, Francesco Violi (Italy)
PO360-MON GLOBAL ANTICOAGULANT SCREENING USING A DILUTE RVV REAGENT

Zhenghua Cao*, Ralph Bottenus, Mark Triscott (United States)
154 155
PO370-MON
REAL-LIFE USE OF NON-VITAMIN K ANTAGONIST ORAL ANTICOAGU- PO381-MON
DEVELOPMENT OF INPATIENT PEDIATRIC ANTICOAGULATION MAN-
LANTS IN COMPARISON WITH VITAMIN K ANTAGONISTS FOR NON-VAL- AGEMENT SERVICE: THE ADVANCED PRACTICE NURSE PRACTITIONER
VULAR ATRIAL FIBRILLATION: DATA FROM A PROSPECTIVE COHORT SERVICE MODEL
Michela Giustozzi*, Maria Cristina Vedovati, Federica Cianella, Paolo Verdecchia, Jennifer Meldau*, Christine Guelcher, Carole Hennessey, Deepika Darbari, Michael
Melina Verso, Serenella Conti, Esmeralda Filippucci, Emanuela Marchesini, Giancarlo Guerrera, Yaser Diab (United States)
Agnelli, Cecilia Becattini (Italy)
PO382-MON
FIRST EXPERIENCE WITH THE HAEMOASSIST, AN ELECTRONIC SUBSTI-
PO371-MON THE MODULATION OF PROTHROMBINASE LIFETIME BY RIVAROXABAN TUTION DIARY THAT WORKS ON THE BASIS OF A PERSONAL DIGITAL
aria Cristina Bravo*, Tom Orfeo, Matthew Gissel, Elizabeth Lavoie, Laura Haynes,
M ASSISTANT (PDA)
Kenneth Mann (United States) Manuela Siebert*, Michaela Bicker, Anja Brtz, Britta Lachmann (Germany)
PO372-MON
PHARMACOKINETICS AND -DYNAMICS OF DABIGATRAN ETEXILATE AND PO383-MON
AN EVALUATION OF A MYELOPROLIFERATIVE NEOPLASM SPECIALIST
RIVAROXABAN IN PATIENTS REQUIRING PARENTERAL NUTRITION FOR NURSE LED CLINIC
SHORT BOWEL SYNDROME (THE PDER PAN STUDY) Vashti Ragoonanan* (United Kingdom)
Stefano L. Barco*, Yuk Cheung, Michiel Coppens, Mireille Serlie, Ron Mathot, Saskia
Middeldorp (The Netherlands) PO384-MON
PHARMACIST SUPPORTED ANTICOAGULATION MANAGEMENT CLINIC -
IMPROVING PATIENT CARE IN AN EMERGING COUNTRY
PO373-MON
IS IT POSSIBLE TO ASSES RIVAROXABAN ACTIVITY WITHOUT SPECIFIC Nida Najmi*, Bushra Moiz, Sumaira Khan (Pakistan)
CALIBRATORS?
Maria De Lourdes Herrera*, Alicia Grinspon, Silvina Pons, Carolina Mahuad, Alejandra PO385-MON
NURSING MANAGEMENT OF VENOUS THROMBOEMBOLISM (VTE)
Scazziota (Argentina) TREATMENT WITH RIVAROXABAN AT THE UNIVERSITY HOSPITAL OF
MONDAY
PADUA: A 6-MONTH EXPERIENCE
PO374-MON
A NEW ASSAY FOR THE MEASUREMENT OF RIVAROXABAN CONCENTRA-
Chiara Tonello*, Elisabetta Baracco, Marianna Bettella, Lorenza Cacco, Nicola Griggio,
TIONS IN HUMAN PLASMA Stefano Morandin, Fabiana Nalin, Alessandra Noventa, Ornella Scarpazza, Paolo
Valeri Krougliak*, Zhenghua Cao, Hency Patel, Jessy Mathew, Asley Belanger, Chun Zulian, Giampiero Avruscio (Italy)
Kung, Ralph Bottenus (United States)
PO386-MON
RESPONSE OF LEUCOCYTE COUNT, LEUCOCYTE DIFFERENTIAL COUNT
PO375-MON MONITORING VITAMIN K ANTAGONIST TREATMENT : INTERESTS OF AND THROMBOCYTE COUNT ON FREQUENT BLOOD DONATIONS AMONG
GOOD THERAPEUTIC EDUCATION
POSTERS
MALE SUBJECTS IN UNIVERSITY OF CALABAR TEACHING HOSPITAL
Dalila Atchafa Tadlaoui*, Amina Taboukouyout, Zhor Guechi (Algeria)
DONOR CLINIC, CALABAR, NIGERIA
Dorathy C. Okpokam*, Ifeyinwa Okafor, Josephine Akpotuzor, Eme Osim, Esien Usan-
Nursing and Allied Health ga, Ogha Okpokam (Nigeria)
PO387-MON
PARTICIPATION OF NURSES IN PREPARATION OF PATIENTS WITH HE-
PO376-MON
HOW PARTICIPATING IN A CLINICAL TRIAL HAS HAD A FAR REACHING MOPHILIA FOR SURGERY OF COLON CANCER
EFFECT A CASE STUDY. Ljiljana Rakic* (Serbia)
Claire Mcgregor*, Marina Goruppi (Australia)
PO388-MON MILD HAEMOPHILIA A: A MANAGEABLE CONDITION?
PO377-MON
BARRIERS TO INFORM HEMOPHILIC CARRIERS OF THAT POSSIBILITY Daryl Pollock* (New Zealand)
IN JAPAN
Tomie Fujii*, Ayana Murakami, Teruhisa Fujii, Yukiko Miyakoshi (Japan) PO389-MON
SOURCE DATA VERIFICATION PILOT: USING CENTRAL MONITORING IN
AN OBSERVATIONAL CRITICAL CARE BIOMARKER STUDY
PO378-MON MECHANICAL THROMBOPROPHYLAXIS SOLVING DILEMMAS Ellen McDonald*, Davinder Jain, Roxanne Ward, Patricia Liaw, Alison Fox-Robichaud
Cara Doyle*, Emma Gee (United Kingdom) (Canada)
PO379-MON THE NURSES ROLE IN IDIOPATHIC THROMBOCYTOPENIA PO390-MON

RAISING AWARENESS OF VENOUS THROMBOEMBOLISM PREVENTION:
Vashti Ragoonanan* (United Kingdom) HOW THE JEWISH GENERAL HOSPITAL IS MEETING THE REQUIRE-
MENTS FOR HOSPITAL ACCREDITATION
PO380-MON
THE IMPACT OF FOOTWEAR ON ANKLE ARTHROPATHY IN PATIENTS Jessica Emed*, Carla Strulovitch, Suzette Chung, Hetal Patel (Canada)
WITH HEMOPHILIA.
Karen Strike*, Jherica Irwin (Canada) PO391-MON
HAEMOPHILIA AND AGEING. PROMOTING HEALTHY AGEING THROUGH
PROACTIVE ENGAGEMENT WITH GENERAL PRACTITIONERS LITERA-
TURE REVIEW AND PILOT SURVEY.
Olivia Hollingdrake*, Beryl Zeissink (Australia)
156 157
PO392-MON
A SURVEY OF CLINICAL RESEARCH COORDINATORS TO MANAGE THE PO403-MON
LOCALIZATION OF ZN2+ IN DENSE GRANULES OF HUMAN PLATELETS
CLINICAL RESEARCH PAPERWORK MOUNTAIN AND THE EXTENT OF ITS RELEASE UPON PLATELET ACTIVATION
Terri Schnurr*, Susan Cooke, Dori Kazimer, Mary Jane Sayles, Ellen McDonald (Canada) Sara J. Henderson*, Fred Pluthero, Alan Stafford, Ji Zhou, Nima Vaezzadeh, Ran Ni,
James Fredenburgh, Walter Kahr, Jeffrey Weitz (Canada)
PO393-MON
THE JEWISH GENERAL EXPERIENCE IN DEVELOPING PATIENT TEACH-
ING MATERIALS ON WARFARIN AND VENOUS THROMBOEMBOLISM PO404-MON
NEUTROPHILS CONTRIBUTE TO THE GENERATION OF PROCOAGULANT
Carla Strulovitch*, Jessica Emed, Suzette Chung, Hetal Patel (Canada) PLATELETS BY A MYELOPEROXIDASE INDEPENDENT MECHANISM
Leonardo Pasalic*, Latasha Abeynaike, Elias Glaros, Shane Thomas, Philip Hogg,
Vivien Chen (Australia)
Platelet activation/adhesion/aggregation I
PO405-MON
IMPAIRED RESPONSE TO COLLAGEN OF PLATELETS FROM HYPERLIPID-
EMIC MICE
THE IMPACT OF 3 CYTOPLASMIC TAIL MIMETIC PEPTIDES ON PLATE-
PO394-MON Marco van der Stoep*, Inge Snoeren, Menno Hoekstra, Philip de Groot, Miranda Van
LET AGGREGATION AND IIB3 ACTIVATION Eck, Suzanne Korporaal (The Netherlands)
Huong T. T. Nguyen*, Khon Huynh, Rudiger Scharf, Volker Stoldt (Germany)
PO406-MON
IMPROVING THE QUANTIFICATION OF IN VITRO THROMBUS FORMATION
PO395-MON
BILE SALT CHENODEOXYCHOLATE SUPPRESSES NORMAL PLATELET Kjersti Claesson*, Lars Faxlv, Tomas Lindahl (Sweden)
FUNCTIONS THROUGH CYCLIC AMP ACTIVATION PATHWAY
Pat Metharom*, Fergal OGara, Michael Berndt (Australia) PO407-MON
RS6929846-DEPENDENT REGULATION OF BTN2A1 EXPRESSION IN
INNATE AND ADAPTIVE IMMUNE CELLS AFFECTS PLATELET REACTIVITY
PO396-MON
THE ROLE OF HETEROTRIMERIC G PROTEINS IN REGULATION OF TO THROMBIN
MONDAY
GPIIB-IIIA ACTIVATION AND PLATELET CONTRACTILITY Ann-Stephan Gori, Christelle Lecut, Julia Dmitrieva, Cline Delierneux, Emilie Thtre,
Ivan Budnik, Boris Shenkman, Naphtali Savion* (Israel) Patrizio Lancellotti, Michel Georges, Ccile Oury* (Belgium)
PO397-MON
THE GUT MICROBIOTA REGULATES VON WILLEBRAND FACTOR EX- PO408-MON
MOUSE CLEC-2 CAN SUPPORT PLATELET ADHESION TO MOUSE PODO-
PRESSION AND PLATELET PROTHROMBOTIC FUNCTION VIA TOLL-LIKE PLANIN UNDER ARTERIAL FLOW
RECEPTOR-2 Stephanie Lombard*, Matthew Harrison, Marie Lordkipanidz, Alice Pollitt, G Rainger,
Sven Jckel*, Maren Lillich, Klytaimnistra Kiouptsi, Nives Hrmann, Cora Reiss, Kath- Steve Watson (United Kingdom)
POSTERS
arina Alber, Kerstin Jurk, Ulrich Walter, Wolfram Ruf, Christoph Reinhardt (Germany)
PO409-MON
AKT TRANSLOCATION AND PHOSPHORYLATION REGULATES PLATELET
PO398-MON
NUCLEAR RECEPTOR DEPENDENT FORMATION OF COATED PLATELETS AGGREGATION DOWNSTREAM OF G12/13 AND GI PATHWAYS
INHIBITS PLATELET RESPONSES TO STIMULI. Zhongren Ding*, Yan Zhang, Leilei Chen, Shuang Zheng, Lin Chang, Liang Hu, Si
Amanda J. Unsworth*, Tanya Sage, Neline Kriek, Michael Schenk, Christopher Jones, Zhang (China)
Leonardo Moraes, Jonathan Gibbins (United Kingdom)
PO410-MON
EFFECTS OF CYCLIC NUCLEOTIDES ON PLATELET AGGREGATION AND
PO399-MON
CONSIDERABLE VARIABILITY OF PLATELET RESPONSE TO TISSUE FAC- BIOLOGICAL RESPONSE MODIFIER RELEASE INDUCED BY STREPTO-
TOR IN HEALTHY INDIVIDUALS AND POTENTIAL ROLE OF FXA INHIBI- COCCUS SANGUINIS STRAIN 2017-78
TOR AS AN ANTI-PLATELET AGENT Archie McNicol*, Ahmed Abdulrehman, Elke Jackson, Sara Israels, Hind Hamzeh-Co-
Kagari M. Murasaki*, Kaori Ishigaki, Nobuhisa Hagiwara (Japan) gnasse, Fabrice Cognasse (Canada)
PO400-MON
PHYSIOLOGICAL REGULATION OF PLATELET AGGREGATION BY THE PO411-MON
COMBINED ROLES OF FACTOR XIIIA AND GLYCOPROTEIN IIB/IIIA IN
GASOTRANSMITTER HYDROGEN SULFIDE PLATELET-DRIVEN FIBRIN FORMATION
Michael Emerson*, Oumid Ahmad, Francesca Rauzi, Erica Smyth, Mark Wood, Mat- Nadine Mattheij*, Frauke Swieringa, Michelle Berny-Lang, Frauke May, Paola van
thew Whiteman (United Kingdom) der Meijden,* Dennis Suylen, Marc Nolte, Tilman Hackeng, Owen McCarty, Johan
Heemskerk, Judith M. Cosemans (The Netherlands)
PO401-MON
PLATELET-SPECIFIC GARP DEFICIENCY DOES NOT AFFECT THROMBO-
SIS AND HEMOSTASIS IN MICE PO412-MON
PIVOTAL ROLE OF SGK1 IN THE REGULATION OF PLATELET SECRETORY
Elien Vermeersch*, Karen Vanhoorelbeke, Simon De Meyer, Hans Deckmyn, Claudia PROTEOME, DENSE GRANULE BIOGENESIS AND SECRETION
Tersteeg (Belgium) Britta Walker*, Evi Schmid, Antonella Russo, Patrick Mnzer, Eva-Maria Schmidt, Oli-
ver Burk, Ana Velic, Boris Macek, Martin Schaller, Matthias Schwab, Miguel C. Seabra,
PO402-MON
CONSTRUCTION OF EXPRESSION SYSTEM FOR BIOLOGICALLY FUNC- Meinrad Gawaz, Florian Lang, Oliver Borst (Germany)
TIONAL RECOMBINANT RHODOCYTIN
Tomoyuki Sasaki*, Shogo Tamura, Toshiaki Shirai, Nagaharu Tsukiji, Kaneo Satoh, PO413-MON
IMPACT OF ELEVATED SHEAR STRESS ON INTEGRIN ALPHAIIB ETA3
Katsue Suzuki-Inoue, Yukio Ozaki (Japan) LIGAND INTERACTION
Marianna Gyenes*, Volker R. Stoldt, Rudiger E. Scharf (Germany)
158 159
PO414-MON
PLATELET FUNCTION IS REGULATED BY ACETYLATION AND DEACETYL- PO425-MON
REVERSAL OF THE ANTITHROMBOTIC PROPERTIES OF QUERCE-
ATION MECHANISMS CONTROLLED BY SIRTUINS. TIN-3-RUTINOSIDE WITH THE B DOMAIN OF PDI IN A MOUSE THROM-
Ana M. Latorre*, Maria Santos, Juana Valles, Maria Angeles Dasi, Antonio Moscardo BOSIS MODEL
(Spain) Lin Lin*, Srila Gopal, Anish Sharda, Freda Passam, Sheryl Bowley, Jack Stopa, Robert
Flaumenhaft, Mingdong Huang, Bruce Furie (United States)
PO415-MON
FIBRIN STIMULATES SPREADING AND ACTIVATION OF PLATELETS
THROUGH GPVI PO426-MON
PLATELET IN RATS WITH ACUTE RENAL FAILURE PRESENT HYPERRE-
Osama M. Alshehri*, Craig Hughes, Samantha Montague, Jon Frampton, Steve Watson ACTIVITY IN VITRO
(United Kingdom) Zhang-Yin Ming*, Guang-qiang Yao, Ming-lu Liang, Ao-di He, Xin-Wen Da, Wen Xie (China)
PO416-MON KINDLIN-2 IN MEGAKARYOCYTE AND PLATELET FUNCTIONS PO427-MON

FACTOR XI-DEPENDENT PLATELET THROMBIN GENERATION INDUCED
orsaf Ghalloussi, Pierre Dillard, Gatan Chicanne, Bernard Payrastre, Alan Nurden,
D BY THROMBIN IS REGULATED BY CD36
Vronique Baccini, Laurent Limozin, Marie-Christine Alessi, Matthias Canault* (France) Mareike Dhrmann*, Kathrin Schwierczek, Ivo Volf, Ulrich Walter, Kerstin Jurk (Germa-
ny)
PO417-MON
THE PRO33 (HPA-1B) ISOFORM OF INTEGRIN ALPHAIIB ETA3 IS IN-
DEED A PROTHROMBOTIC RECEPTOR VARIANT PO428-MON
DELETION OF PI3K P110A RESULTS IN ENHANCED PRIMER-MEDIATED
Rudiger. E Scharf*, Marianna Gyenes, Volker R. Stoldt (Germany) REGULATION OF PLATELET FUNCTION AND THROMBOSIS.
Thomas Blair*, Samantha Moore, Ingeborg Hers (United Kingdom)
PO418-MON
THE PRO33 VARIANT OF PLATELET ALPHAIIB ETA3: ALLOSTERIC
CHANGES RESULTING FROM A POINT MUTATION IN THE INTEGRIN PO429-MON
PROFILING OXYLIPINS RELEASED BY GPVI-ACTIVATED PLATELETS AND
ECTODOMAIN ARE ASSOCIATED WITH A PROTHROMBOTIC RECEPTOR THE EFFECT OF INHIBITORS OF CYCLOOXYGENASE-1 AND 12-LIPOXY-
MONDAY
PHENOTYPE GENASE
Giulia Pagani*, Joana Ventura Pereira, Nadine Homeyer, Volker R. Stoldt, Holger Gohl- Robert E. Turnbull*, Katrin Sander, David Barrett, Alison Goodall (United Kingdom)
ke, Rdiger E. Scharf (Germany)
PO430-MON
ROLE OF HYDRODYNAMIC SHEAR MEDIATED PLATELET DEFORMATION
PO419-MON
VASCULAR SMOOTH MUSCLE CELLS STIMULATE PLATELETS VIA CLEC- ON CELL TETHERING, TRANSLOCATION AND ACTIVATION
2: INVOLVEMENT OF INTRACELLULAR AND EXTRACELLULAR LIGANDS Changjie Zhang*, Sriram Neelamegham (United States)
OF CLEC-2
POSTERS
Katsue Suzuki-Inoue*, Osamu Inoue, Nagaharu Tsukiji, Yukio Ozaki (Japan) PO431-MON
THE ACTIVATING EFFECTS OF SHEAR STRESS GRADIENTS ON THROM-
BUS FORMATION
PO420-MON
PLATELET-FIBRIN THROMBI CAN KILL STENOTROPHOMONAS MALTO- Thomas Hoefer*, Elizabeth Gardiner, Robert Andrews, Karlheinz Peter, Erik Westein
PHILI (Australia)
Volker R. Stoldt*, Rudiger E. Scharf (Germany)
PO432-MON
MEMBRANE ESTROGEN RECEPTOR (MER) PROTEASE ACTIVATED
PO421-MON ENGINEERING PLATELETS FOR THE DELIVERY OF RNA RECEPTOR (PAR) CROSS TALK MODULATES PLATELET FUNCTION
Stefanie Novakowski*, Vivienne Chan, Simon Law, Christian Kastrup (Canada) Joseph E. Aslan*, Ishan Patel, Peizhong Mao, Fuchun Xie, Xiangshu Xiao, Oline Rn-
nekleiv, Martin Kelly, Owen McCarty (United States)
PO422-MON
INHIBITION OF SORBITOL DEHYDROGENASE INCREASES PLATELETS
ADHESION IN MICE TREATED WITH FIDARESTAT
Mariane Flores-Nascimento*, Kiara Zapponi, Regiane Ferreira, Lcia Helena Siqueira, Platelet disorders I
Thas Fornari, Bruna Mazetto, Fernanda Orsi, Erich De Paula, Joyce Annichino-Bizzac-
chi (Brazil)
PO433-MON
PLATELET CD34 EXPRESSION IS INCREASED IN FAMILIES WITH DIS-
PO423-MON
THE RAP1-GAP RASA3 PREVENTS CLEARANCE OF CIRCULATING PLATE- TINCT GFI1B MUTATIONS: UTILITY AS A SCREENING TEST
LETS Marie-Christine Morel-Kopp*, David Rabbolini, Sara Gabrielli, Qiang Chen, Christopher
Caterina Casari*, David Paul, Lucia Stefanini, Yacine Boulaftali, Robert Campbell, Ward*, William Stevenson (Australia)
Daniel Kechele, Kathleen Caron, Andrew Weyrich, Dale Cowley, Matthew Parrott,
Luanne Peters, Wolfgang Bergmeier (United States) PO434-MON
A CASE OF MYH9 DISORDERS CAUSED BY A NOVEL MUTATION (P.K74E)
Takeshi Kanematsu*, Nobuaki Suzuki, Mayuko Kishimoto, Tomohiro Aoki, Mika Ogawa,
PO424-MON BIOMECHANICS OF BLOOD CLOT CONTRACTION Yoshitoyo Kagami, Shinji Kunishima, Hitoshi Kiyoi, Tadashi Matsushita (Japan)
Valerie Tutwiler*, Hailong Wang, Rustem Litvinov, John Weisel, Vivek Shenoy (United
States)
160 161
PO435-MON
CALR MUTATIONS ARE ASSOCIATED WITH LOWER PLATELET AND Pediatric thrombosis and hemostasis
ENDOTHELIAL ACTIVATION THAN THE JAK2 MUTATION IN ESSENTIAL
THROMBOCYTHEMIA
Eduardo Arellano-Rodrigo*, Alberto Alvarez-Larrn, Juan-Carlos Reverter, Dolors Co- PO445-MON
RISK FACTORS AND CO-MORBIDITIES IN ADOLESCENT THROMBOEM-
lomer, Beatriz Bellosillo, Francisco Cervantes (Spain) BOLISM ARE DIFFERENT THAN THOSE IN YOUNGER CHILDREN
Susan Kirk, Titilope Ishola*, Katherine Voigt, Mona Shah, Lakshmi Srivaths (United States)
PO436-MON
DIFFERENT MICROTUBULE ABNORMALITIES IN TWO CASES OF MACRO-
THROMBOCYTOPENIA ASSOCIATED WITH TUBB1 VARIANTS PO446-MON
DO PRETERM INFANTS WITH PATENT DUCTUS ARTERIOSUS (PDA) WHO
Simon Stritt, Ernest Turro, Nomie Saut, Marie-Christine Alessi, Nicole Schlegel, Alan FAIL INDOMETHACIN TREATMENT HAVE LOWER PLATELET COUNTS?:
Nurden, Willem Ouwehand, Bernhard Nieswandt, Paquita Nurden* (Germany) A SYSTEMATIC REVIEW AND META-ANALYSIS
Souvik Mitra*, Bosco Paes, Anthony Chan (Canada)
PO437-MON
SOLUBLE GLYCOPROTEIN VI: A POTENTIAL BIOMARKER FOR DISEASE
ACTIVITY AND PLATELET REACTIVITY IN ACUTE GOUT. PO447-MON
CATHETER DIRECTED THROMBOLYSIS AS SAFE AND EFFECTIVE THER-
Geraldine Mccarthy*, Claire Louise Murphy, Anne Madigan, Paul MacMullan, Laura APY FOR PROXIMAL LOWER LIMB DEEP VEIN THROMBOSIS IN ADOLES-
Durcan, Eimear Dunne (Ireland) CENTS
Kathryn Musgrave*, Adriano Tenna, Tina Biss (United Kingdom)
PO438-MON
PERSONALIZED REFERENCE INTERVALS FOR PLATELET COUNT RE-
DUCE THE PREVALENCE OF UNEXPLAINED THROMBOCYTOPENIA AND PO448-MON
AGE-DEPENDENCY OF COAGULATION PARAMETERS DURING CHILD-
INCREASE THAT OF REACTIVE THROMBOCYTOSIS IN ELDERLY PEOPLE HOOD. RESULTS OF A MULTICENTER STUDY.
Patrizia Noris*, Carlo Zaninetti, Ginevra Biino, Elisa Civaschi, Federica Melazzini, Carlo Pierre Toulon*, Micheline Berruyer, Franois Grand, Marie Brionne-Franois, Domi-
Balduini (Italy) nique Lasne, Neila DePooter (France)
MONDAY
PO439-MON
MYH9 DISEASE: IDENTIFICATION OF TWO MUTATIONS ASSOCIATED PO449-MON
CLINICAL FEATURES IN CHILDREN PRESENTING FROM THE COMMUNI-
WITH UNCOMMON CLINICAL PHENOTYPE TY WITH PULMONARY EMBOLISM
Mara Isabel Snchez Guiu*, Begoa Muia, Adela Periago, Daniel Jaimes Albornoz, Charlie Y. Wang*, Peter Francis, Timothy Cain, Vera Ignjatovic, Fiona Newall, Ed Oak-
Mara Soler, Vicente Vicente, Mara Luisa Lozano, Jos Rivera (Spain) ley, Paul Monagle (Australia)
PO440-MON
ACTN1-RELATED THROMBOCYTOPENIAS (ACTN1-RT): PHENOTYPE/GEN- PO450-MON
EFFECTS OF MATERNAL HYPERTENSION ON NEONATAL HEMOGRAM IN
OTYPE OF A SERIES OF 13 NEW CASES
POSTERS
SOUTH-SOUTH NIGERIA
Anne Vincenot*, Olivier Rene, Sylvie Binard, Marie-Christine Alessi, Eric Durot, Paul Helen Okoye*, Lisa Eweputanna, Kaladada Korubo, Oseikhuemen Ejele (Nigeria)
Gueguen, Felipe Guerrero, Vronique Le Cam-Duchez, Elisabeth Mazoyer, Stphanie
Muller, Bndicte Neven, Catherine Pouymayou, Bruno Royer, Pierre Sie, Catherine PO451-MON
TREATMENT WITH ROMIPLOSTIM IN CHILDREN. INCIDENCE AND QUAL-
Trichet, Nathalie Trillot, Nicole Schlegel (France)
ITY OF THE RESPONSE.
PO441-MON
ROCK1 OR FLI1 MUTATIONS IN PATIENTS WITH MILD THROMBOCYTO- Maria Del Carmen Gmez Del Castillo* (Spain)
PENIA PO452-MON
OFF-LABEL USE OF RECOMBINANT FACTOR VIIA FOR DIFFUSE PULMO-
Marjorie Poggi, Matthias Canault*, Pauline Lucca, Catherine Pouymayou, Dorsaf Ghal-
NARY HEMORRHAGE IN CHILDREN
loussi, Nomie Saut, Pierre Morange, Davd-Alexandre Tregouet, Marie-Chrisitne Alessi
(France) Te-Fu Weng*, Kang-Hsi Wu Wu, Ching-Tien Peng (Taiwan)
PO442-MON
CONGENITAL THROMBOCYTOPENIAS AND IMMUNE THROMBOCYTOPE- PO453-MON
INVESTIGATING THE ROLE OF POLYPHOSPHATES IN NEONATAL HEMO-
NIC PURPURA : A MISLEADING DIAGNOSIS STASIS
Maria Coutinho, Ana Spnola, Catarina Lau, Sara Morais*, Mnica Pereira, Rui Matos, Axel Schlagenhauf*, Andrea Ehammer-Rosenkranz, Harald Haidl, Bettina Leschnik,
Manuel Campos (Portugal) Siegfried Gallistl, Wolfgang Muntean (Austria)
PO443-MON
FIVE NEW HETEROZYGOUS MUTATIONS IN THE GPIB AND GPIX ARE PO454-MON
RATIONALE AND DESIGN OF AESOP: APIXABAN FOR PREVENTION OF
ASSOCIATED WITH THE BOLZANO PHENOTYPE DEEP VEIN THROMBOSIS IN PEDIATRIC PATIENTS WITH ACUTE LYMPHO
Vronique Baccini*, Nomie Saut, Catherine Pouymayou, Matthias Canault, Dorsaf BLASTIC LEUKEMIA OR LYMPHOMA TREATED WITH L-ASPARAGINASE
Ghalloussi, Cline Falaise, Xavier Pillois, Franois Lanza, Pierre Morange, Ma- Vilmarie Rodriguez*, Sarah OBrien, Lillian Sung, Luz Ramirez, Danshi Li, Lesley
rie-Chrisitne Alessi (France) Mitchell (United States)
PO444-MON
INCREASE THE NUMBER OF GP IIB-IIIA AND P2Y12 RECEPTORS IN AC- PO455-MON
USE OF PROTHROMBIN COMPLEX CONCENTRATES (PCC) IN PAEDIAT-
TIVATED PLATELETS POSSIBLE EVIDENCE FOR PROTEINS SYNTHESIS RIC EXTRACORPOREAL LIFE SUPPORT PATIENTS
DE NOVO Tom Noga, Susan Nahirniak, Jennifer Conway, Holger Buchholz, Mary Bauman, Patti
Olga Sirotkina*, Pavel Andoskin, Anton Emelyanov, Tatiana Vavilova (Russian Federation) Massicotte, Aisha Bruce* (Canada)
162 163
PO456-MON
ANTITHROMBIN PLASMA LEVELS AND FIBTEM DETERMINATION IN
Post-thrombotic syndrome
CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA UNDERGOING
ASPARAGINASE TREATMENT
Luca Spiezia*, Maria Putti, Elena Campello, Sara Maggiolo, Maria Sartori, Alessandra PO466-MON DENSER CLOTS PREDISPOSE TO POST THROMBOTIC SYNDROME
Todesco, Maria Petris, Laura Sainati, Giuseppe Basso, Paolo Simioni (Italy) nnemieke C. Bouman*, Helen McPherson, Yuk Cheung, Marije ten Wolde, Hugo ten
A
Cate, Robert Arins, Arina ten Cate-Hoek (The Netherlands)
PO457-MON
WARFARIN THERAPY IN CHILDREN: CAN FAMILIES SAFELY AND EFFI-
CIENTLY MONITOR INRS AT HOME? PO467-MON
PRACTICE VARIATION IN THE TREATMENT OF DVT AND PREVENTION OF
Kathy Harney*, Juliann Duzan, Jenna Murray, Peter Forbes, Kathleen ONeil, Karen POST THROMBOTIC SYNDROME BETWEEN INTERNISTS AND VASCULAR
Mittler, Rosemary Galvin, Ellis Neufeld, Alan Michelson, Christopher Almond (United SURGEONS: A CANADIAN SURVEY OF PHYSICIAN PRACTICES.
States) Rick T. Ikesaka*, Susan Kahn, Jean-Philippe Galanaud, Fernando Vazquez, Graham
Roche-Nagle, Marc Carrier, Gregoire Le Gal, Marc Rodger, Esteban Gandara (Canada)
PO458-MON
PROPHYLACTIC ENOXAPARIN IN YOUNG INFANTS ARE THE CURRENT-
LY RECOMMENDED DOSES TOO LOW? PO468-MON
TWO WEEKS OF LOW MOLECULAR WEIGHT HEPARIN FOR ISOLATED
Kathy M. Harney*, Juliann Duzan, Stacy Croteau, Rachael Grace, Kathleen Houlahan*, SYMPTOMATIC DISTAL VEIN THROMBOSIS (TWISTER STUDY): INTERIM
Ellis Neufeld, Alan Michelson, Cameron Trenor (United States) ANALYSIS OF FIRST 100 PATIENTS POST THROMBOTIC SYNDROME
SUB-STUDY
PO459-MON THROMBOEMBOLIC EVENTS IN CHILDREN
Eileen Merriman*, Sanjeev Chunilal, Simon McRae, Tim Brighton, Huyen Tran (New
afer Salcioglu*, Hulya Sayilan Sen, Deniz Tugcu, Gonul Aydogan, Muge Gokce, Cengiz
Z
Zealand)
Bayram, Ali Aycicek, Ferhan Akici (Turkey)
PO469-MON
TITLE: FREQUENCY OF PERSISTENTLY ABNORMAL ECHOCARDIOGRA-
MONDAY
PO460-MON
BIVALIRUDIN USE IN CHILDREN ON ECMO FOLLOWING HEPARIN FAIL-
PHY AFTER ACUTE PULMONARY EMBOLISM
URE
Emily Gundert*, Jeffrey Kline, David Jimenez, Llorenc Font, Manuel Lorente, Barbara
Mary Bauman, Patti Massicotte, Aisha Bruce*, Don Granoski, Laurance Lequier, Lind-
Pagan, Radovan Maly, Peter Vehamme, Manuel Monreal (United States)
say Ryerson (Canada)
PO470-MON
TOLL-LIKE 9 GENE EXPRESSION IN THE POST THROMBOTIC SYN-
PO461-MON
THROMBOEMBOLIC EVENTS IN PEDIATRIC PATIENTS WITH CYANOTIC
DROME, RESIDUAL THROMBOSIS AND RECURRENT DEEP VENOUS
CONGENITAL HEART DISEASES IN SRINAGARIND HOSPITAL
THROMBOSIS: A CASE-CONTROL STUDY
Patcharee Komvilaisak*, Yuttapong Wongswadiwat, Arnkisa Chaikitpinyo (Thailand)
POSTERS
Whitney Cheung*, Annemieke Bouman, Elisabetta Castoldi, Simone Wielders, Henri
PO462-MON
PHENOMENON OF HYPERCOAGULABILITY IN CHILDREN WITH DEEP Spronk, Hugo ten Cate, Arina ten Cate-Hoek, Marije ten Wolde (The Netherlands)
VEIN THROMBOSIS PO471-MON
PATIENTS PREFERENCES REGARDING ELASTIC COMPRESSION STOCK-
Marina Gracheva*, Pavel Zharkov, Elena Seregina, Hasmik Sepoyan, Alexandr Poletaev,
ING THERAPY FOR THE PREVENTION OF POST THROMBOTIC SYN-
Fazoil Ataullakhanov (Russian Federation)
DROME
PO463-MON
IMPACT OF INHERITED AND ACQUIRED PROTHROMBOTIC DEFECTS (PD) Annemieke C. Bouman*, Arina ten Cate-Hoek, Carmen Dirksen, Manuela Joore (The
ON THE DEVELOPMENT OF SYMPTOMATIC THROMBOEMBOLISM (STE) Netherlands)
IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) TREATED PO472-MON
COMPARISON OF SELF-RATED AND PROFESSIONAL-RATED SCORES
ACCORDING TO THE DANA-FARBER CANCER INSTITUTE (DFCI) 05-01 OF THE VILLALTA SCALE FOR EVALUATION OF THE POST-THROMBOTIC
ALL-THERAPY PROTOCOL SYNDROME IN PATIENTS WITH PROXIMAL DEEP VEIN THROMBOSIS
Uma Athale*, Caroline Laverdiere, Trishana Nayiager, Yves-Line Delva, Gary Foster,
Trond Isaksen*, Vladimir Tichelaar, Finn Egil Skjeldestad, Ellen Brodin, Anders Vik,
Lehana Thabane, Anthony Chan (Canada)
Kulbir Singh, John-Bjarne Hansen (Norway)
PO464-MON
EXAMINING THE FEASIBILITY OF RECOMBINANT FACTOR VIIA TO COM- PO473-MON
IS POST THROMBOTIC SYNDROME PERCEIVED TO BE A CLINICALLY
PENSATE FOR PHYSIOLOGICAL OR DRUG-INDUCED IMPAIRMENT OF RELEVANT OUTCOME?: A SURVEY OF PHYSICIAN PRIORITIES
PLATELET FUNCTION: AN IN-VITRO STUDY. Rick T. Ikesaka*, Susan Kahn, Jean-Philippe Galanaud, Fernando Vazquez, Graham
Harald Haidl*, Axel Schlagenhauf, Gernot Grangl, Gerhard Cvrin, Siegfried Gallistl, Roche-Nagle, Marc Carrier, Gregoire Le Gal, Marc Rodger, Esteban Gandara (Canada)
Wolfgang Muntean (Austria)
PO474-MON
EXERCISE LIMITATION IN CHRONIC POST-THROMBOTIC ILIOFEMORAL
PO465-MON
ASSESSING THE ASSOCIATION OF FVIII AND ABO BLOOD GROUP WITH VEIN OBSTRUCTION
DEEP VEIN THROMBOSIS IN PEDIATRIC ONCOLOGY PATIENTS. Jacob Luboshitz*, Michael Segal, Ronen Reuveny, Issachar Ben Dov (Israel)
Jackie Halton, Maria Spavor, Kevin Dietrich, Sarah Israels, Leonardo Brandao, Qi Liu,
Yutaka Yasui, Lesley G. Mitchell* (Canada)
164 165
PO475-MON
ADVANCING THE DIAGNOSIS OF PEDIATRIC POST-THROMBOTIC SYN- PO484-MON
EFFICACY OF FGTW FIBRINOGEN CONCENTRATE IN THE TREATMENT
DROME: A FOUNDATION FOR THE IMPROVEMENT AND STANDARDIZA- OF BLEEDING EPISODES AND PREVENTION OF EXCESSIVE BLEEDING
TION OF ITS MEASUREMENT TOOLS DURING SURGERY IN PATIENTS WITH CONGENITAL FIBRINOGEN DEFI-
Laura Avila*, Leonardo Brandao, Suzan Williams, Madeline Montoya, Jennifer Stinson, CIENCY
Alex Kiss, Leigh Ward, Irene Lara Corrales, Brian Feldman (Canada) Claudia Djambas Khayat*, Mohamed El Khorassani, Valrie Gay, Malika Barthez-Toul-
lec, Cline Henriet, Franoise Bridey, Luis Carreras, Claude Ngrier, Philippe de
PO476-MON
FIBRINOGEN CHARACTERISTICS HELP PREDICT CHRONIC THROMBOTIC Moerloose (Lebanon)
VENOUS DISEASE AFTER ACUTE DEEP VEIN THROMBOSIS
Timothy Fernandes, James Marsh, Peter Chiles, Anthony Gamst, Tanya Wolfson, Roger PO485-MON
A NEW SWISS FAMILY WITH CONSTITUTIONAL HYPOFIBRINOGENEMIA
Moore, Gabriel Gugiu, Terry Lee, Timothy A. Morris* (United States) AND LIVER DISEASE
Alessandro Casini*, Christiane Sokollik, Samuel Lukowski, Eberhard Lurz, Claudine
PO477-MON
RESIDUAL THROMBUS MASS AND INCIDENCE OF POST THROMBOTIC Rieubland, Philippe de Moerloose, Marguerite Neerman-Arbez (Switzerland)
SYNDROME IN PATIENTS TREATED WITH VKA OR NON-VKA ORAL ANTI-
COAGULANTS IN PHASE-III DVT TREATMENT TRIALS PO486-MON
SAFE USE OF FXI CONCENTRATE IN A SINGLE CENTRE EXPERIENCE
Sebastian Werth*, Ines Paternoga, Luise Tittl, Norbert Weiss, Jan Beyer-Westendorf OVER 19 YEARS
(Germany) Gavin Ling*, Huseini Kagdi, Pratima Chowdary, Keith Gomez (United Kingdom)
PO478-MON
THE ROLE OF INFLAMMATION IN POST-THROMBOTIC SYNDROME AF- PO487-MON
THE EPIDEMIOLOGY OF INHERITED BLEEDING DISORDERS IN NEW-
TER PREGNANCY-RELATED VENOUS THROMBOSIS FOUNDLAND AND LABRADOR, CANADA
Hilde Skuterud Wik*, Anne Jacobsen, Per Sandset (Norway) Aaron Wiseman*, Sarah Boyd, Mary-Frances Scully (Canada)
MONDAY
PO479-MON
MOM, WHY SHOULD I WEAR THESE SOCKS? TAKING THE FIRST STEP PO488-MON
PHARMACOKINETIC AND PHARMACODYNAMIC RESULTS OF A MUL-
IN THE JOURNEY TO UNDERSTANDING THE ROLE OF COMPRESSION TICENTER, OPEN-LABEL, SINGLE ARM STUDY WITH A FIBRINOGEN
GARMENTS IN THE TREATMENT OF PEDIATRIC POST-THROMBOTIC CONCENTRATE (FGTW) IN SUBJECTS WITH AFIBRINOGENEMIA
SYNDROME Claudia Djambas Khayat*, Mohamed El Khorassani, Thierry Lambert, Anne Bellon,
Madeline I. Montoya*, Maria Laura Avila, Jennifer Vincelli, Leonardo Brando (Canada) Malika Barthez-Toullec, Francoise Bridey, Luis Carreras, Claude Negrier, Philippe de
Moerloose (Lebanon)
PO480-MON
INADEQUATE ANTICOAGULATION IS THE ONLY RISK FACTOR FOR DE-
PO489-MON
ALTERNATIVE STRATEGY TO TREAT HEMOPHILIA TROUGH PROTEIN S
POSTERS
VELOPMENT OF POST THROMBOTIC SYNDROME IN UNPROVOKED DEEP
VEIN THROMBOSIS INACTIVATION: INSIGHT FROM A MOUSE MODEL
Pravas Mishra*, Kamal Kishor, Tulika Seth, Manoranjan Mahapatra, Renu Saxena Luca Bologna*, Sara Calzavarini, Raja Prince, Natacha Dewarrat, Francois Saller, Anne
(India) Angelillo-Scherrer (Switzerland)
PO481-MON PATIENT COMPRESSION HOSIERY CONCORDANCE PO490-MON

GENOTYPE AND PHENOTYPE REPORT ON PATIENTS WITH CONGENITAL
Gary Benson*, Rosemary Lavery, Hilary Speers (United Kingdom) FIBRINOGEN DEFICIENCY IN SOUTH OF IRAN
Mehran Karimi*, Mohammad Mostafa Safarpour, Sezaneh Haghpanah, Aidin Meshk-
sar*, Abdolreza Afrasiabi, Javad Gerdabi, Rezvan Ardeshiri (Iran, Islamic Republic Of)
Rare bleeding disorders I
PO491-MON
FVIIIA MIMICKING BISPECIFIC ANTIBODY, ACE910 IMPROVES IN VITRO
COAGULATION FUNCTION OF FXI DEFICIENCY PATIENTS PLASMA
PO482-MON
THE UTILITY OF THROMBELASTOGRAPHY AND MULTIPLATE AS Hiroaki Minami*, Keiji Nogami, Takehisa Kitazawa, Kunihiro Hattori, Midori Shima
SCREENING TOOLS FOR RARE INHERITED BLEEDING DISORDERS NOT (Japan)
ASSOCIATED WITH A COAGULATION FACTOR DEFICIENCY
PO492-MON
SPECTRUM OF FACTOR XI MUTATIONS IN THE CHINESE POPULATION
Eva B. Leinoe*, Jakob Stensballe, Peter Kampmann, Jens P Goetze (Denmark) Yanyan Shao*, Qiulan Ding, Yelin Lu, Jing Dai, Xiaodong Xi, Xuefeng Wang, Hongli
Wang (China)
PO483-MON
BLEEDING SCORE AND CLOTTING SCREENING TEST PERFORMED
BEFORE ELECTIVE SURGERY TO DIAGNOSE UNKNOWN HEMORRHAGIC PO493-MON
CHARACTERIZING MECHANISMS OF FACTOR VIII BINDING TO THE
DISEASES. LOW-DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN 1
Federica Zane, Catherine Klersy, Luigia Scudeller, Chiara Ambaglio, Mariaconcetta Patricia Young*, Molly Migliorini, Joni Prasad, Andrey Sarafanov, Dudley Strickland
Russo, Nicola Ghidelli, Nicol Allorto, Gabriella Gamba* (Italy) (United States)
166 167
PO494-MON
RARE BLEEDING DISORDERS : 17 YEARS OF DIAGNOSIS IN THE PO502-MON
FIBRINOGEN DEFICIENCY: PRELIMINARY RESULTS OF THE PRO-RBDD
HEMOSTATSIS LABORATORY OF THE HEMOSTASIS LABORATORY OF PROJECT
THE DEPARTMENT OF HEMATOLOGY OF THE UNIVERSITY HOSPITAL OF Flora Peyvandi*, Marzia Menegatti, Roberta Palla, Simona Siboni, Marco Boscarino,
BENI MESSOUS, ALGIERS, ALGERIA Helen Pergantou, Helen Platokouki, Britta Lachmann, Susan Halimeh, Marlies van
Karima W. Chennoukh*, Meriem Bensadok, Mylade Aribi, Nadia Zidani, Mohamed Lent, Paul Brons, Britta Laros-van Gorkom, Naveena Fatima, Munira Borhany, Ay
Ramaoun, Meriem Belhani, Salim Nekkal (Algeria) Ylmaz, Adrianna Williamson, Amy Shapiro, Alessandro Casini, Nihal Ozdemir, Ondrej
Zapletal, Jan Blanty, Fraustina Hsu, John Chapin, Muriel Giansily-Blaizot, Jean Fran-
PO495-MON
THE THROMBIN GENERATION ASSAY IS SUPERIOR TO THROMBOELAS- cois Schved, Andrew Harvey, Andrew Mumford, Pearl Quartey, Steve Austin, Marko
Saracevic, Danijela Mikovic, Philippe de Moerloose (Italy)
TOGRAPHY AT DETERMINING BLEEDING PHENOTYPE IN CONGENITAL
FXI DEFICIENCY. PO503-MON
DECREASED FIBRINOLYTIC RESISTANCE IN FXI-DEFICIENCY IS INDE-
Gillian N. Pike*, Anthony Cumming, Charles Hay, John Burthem, Paula Bolton-Maggs
PENDENT OF CLOTTING IMPAIRMENT
(United Kingdom)
Francesca Incampo*, Antonio Cannav, Marzia Menegatti, Eugenia Biguzzi, Nicola
Semeraro, Mario Colucci, Flora Peyvandi (Italy)
PO496-MON
A NEW MUTATION IN THE SVIL GENE IS ASSOCIATED WITH AUTOSO-
MAL DOMINANT FAMILIAL GRAY PLATELET SYNDROME PO504-MON
IMPACT OF ASSAY METHOD ON CLINICAL DOSING OF A PURIFIED FAC-
Irina Demina*, Maria Kumskova, Artem Artemov, Sofya Lushchekina, Alyona Ivanova,
TOR X CONCENTRATE
Maria Suntsova, Sergey Vasiliev, Anton Buzdin, Alexey Maschan, Galina Novichkova,
Mikhail Panteleev (Russian Federation)
Joanne Lloyd*, Miranda Norton (United Kingdom)
PO497-MON
ACQUIRED GPVI DEFICIENCY IN TWO UNRELATED PATIENTS WITH MILD
THROMBOCYTOPENIA Regulation of gene expression in vascular cells
MONDAY
Marta Romera*, Eva Caparrs-Prez, Jos Vicente Snchez-Mndez, Mara Isabel
Snchez Guiu, Irene Martnez Martnez, Jos Padilla, Francisca Ferrer-Marin, Ral PO506-MON
BIOGENESIS, SUBCELLULAR LOCALIZATION AND MOBILIZATION OF
Teruel-Montoya, Vicente Vicente, Steve P Watson, Robert Andrews, Elizabeth Gardiner,
TWO ABUNDANT PLATELET THIOL ISOMERASES
Mara Luisa Lozano, Jos Rivera (Spain)
Marilena Crescente, Fred Pluthero, Michael Schenk, Ling Li, Richard Lo, Marfoua Ali,
PO498-MON
IDENTIFICATION OF THE PATHOPHYSIOLOGICAL MECHANISM OF THE Sakthivel Vaiyapuri, Lisa-marie Holbrook, Herve Falet, Walter Kahr, Jonathan Gibbins*
(United Kingdom)
VKCFD2 CAUSING MUTATION P.ARG98TRP IN HUMAN VKORC1 GENE
Katrin Czogalla*, Arijit Biswas, Matthias Watzka, Johannes Oldenburg (Germany)
POSTERS
Reproductive issues I
PO499-MON
SCOTT SYNDROME PLATELETS SHOW ALTERATIONS IN PROTEIN
EXPRESSION LEVELS, CALCIUM-DEPENDENT PHOSPHORYLATION AND
CLEAVAGE AS REVEALED BY PROTEOMICS
Nadine Mattheij, Fiorella Solari, Julia Burkhart, Frauke Swieringa, Peter Collins, Judith PO507-MON
RISK FACTORS FOR OBSTETRIC BLEEDING IN VON WILLEBRAND DIS-
Cosemans, Albert Sickmann, Ren Zahedi, Johan W. Heemskerk* (The Netherlands) EASE (VWD)
Gavin D. Roach*, David Elashoff, Judith Baker (United States)
PO500-MON
A FAILURE TO DIAGNOSE DYSFIBRINOGENAEMIA: DATA FROM MUL-
TICENTRE STUDIES AMONGST UK NEQAS AND PRO-RBDD PROJECT PO508-MON
PLACENTAL INSUFFICIENCY RESOLUTION WITH FULL ANTICOAGU-
LABORATORIES. LATION IN PATIENTS WITH PRIOR BAD OBSTETRIC OUTCOME AND
Ian Jennings*, Flora Peyvandi, Steve Kitchen, Marzia Menegatti, Roberta Palla, Isobel DYSLIPIDAEMIA DURING PREGNANCY.
Walker, Mike Makris (United Kingdom) Roberta Santos*, Venina Barros, Ana Igai, Rossana Pulcinelli, Marcelo Zugaib (Brazil)
PO501-MON
POST AUTHORIZATION SAFETY STUDY OF A TRIPLY SECURED FIBRINO- PO509-MON
D-DIMER MEASUREMENT HAS NO DIAGNOSTIC VALUE DURING
GEN CONCENTRATE IN CONGENITAL AFIBRINOGENEMIA. A PROSPEC- PREGNANCY A LONGITUDINAL STUDY OF 4314 SAMPLES FROM 791
TIVE OBSERVATIONAL STUDY. HEALTHY WOMEN
Zra Tellier*, Claude Ngrier, Chantal Rothschild, Jeanne-Yvonne Borg, Thierry Katrine Hedengran*, Malene Andersen, Steen Stender, Pal Szecsi (Denmark)
Lambert, Natalie Stieltjes, Sgolne Claeyssens, Laurence Sanhes, Arnaud Bertrand,
Marie-Hlne Andr, Pierre Si, Yves Gruel (France) PO510-MON MEN WITH FACTOR V LEIDEN HAVE INCREASED SPERM COUNTS
hijs E. Van Mens*, Cindy Korver, Danny Cohn, Joost Meijers, Saskia Middeldorp,
T
Sjoerd Repping (The Netherlands)
168 169
PO511-MON
INCIDENCE OF VENOUS THROMBOSIS IN PREGNANCIES AFTER SPON- PO521-MON
ALL CAUSE MORTALITY AND USE OF ANTITHROMBOTICS WITHIN 90
TANEOUS AND ART CONCEPTION - AN ITALIAN COHORT STUDY - DAYS OF DISCHARGE IN ACUTELY ILL MEDICAL PATIENTS
Michela Villani*, Francesco Dentali, Donatella Colaizzo, Giovanni Tiscia, Patrizia Ver- Charles E. Mahan*, Larry Fields, Roger Mills, Judith Stephenson, An-Chen Fu, Maxine
gura, Tiziana Petruccelli, Francesco Petruzzelli, Walter Ageno, Maurizio Margaglione, Fisher, Alex Spyropoulos (United States)
Elvira Grandone (Italy)
PO522-MON
RISK OF VENOUS THROMBOSIS AND COAGULATION PROFILE IN DUTCH
PO512-MON POST-PARTUM PROPHYLAXIS IN PRACTICE. NATIVES AND IMMIGRANTS IN THE NETHERLANDS: RESULTS FROM
mmanuelle Le Moigne*, Pascal Nicolas, Aurelien Delluc, Karine Lacut, Michel Collet,
E THE MEGA STUDY
Dominique Mottier, Brigitte Pan-Petesch (France) Suely Rezende*, Willem Lijfering, Mettine Bos, Joost Meijers, Frits Rosendaal, Su-
zanne Cannegieter (Brazil)
PO513-MON THE M2 HAPLOTYPE WITHIN THE ANNEXIN A5 GENE AND
ANTIPHOSPHOLIPID ANTIBODIES IN UNSELECTED PREGNANT PO523-MON
IMPACT OF TORNADOES ON HOSPITAL ADMISSIONS FOR VENOUS
WOMEN- A PROSPECTIVE HOSPITAL- BASED STUDY- THROMBOEMBOLISM AND CARDIOVASCULAR EVENTS
ichela Villani*, Elena Chinni, Filomena Cappucci, Pasquale Martinelli, Giuseppe
M Ana I. Casanegra*, Federico Silva, Alan Shapiro, Minh Phan, Beau Hawkins, Ji Li, Julie
Maruotti, Giovanni Tiscia, Donatella Colaizzo, Lucia Fischetti, Maurizio Margaglione, Stoner, Alfonso Tafur (United States)
Elvira Grandone (Italy)
PO524-MON
JOINT EFFECTS OF F5 GENE VARIANTS AND TALL STATURE ON VTE RISK
PO514-MON
AGE OF MENARCHE AND RISK OF VENOUS THROMBOEMBOLISM Tine S. Lnneberg*, Erin Smith, Sigrid Brkkan, Lars Horvei, Terry Solomon, Tom
Luuk Scheres*, Saskia Middeldorp, Frits Rosendaal, Suzanne Cannegieter (The Nether- Wilsgaard, Frits Rosendaal, Kelly Frazer, John-Bjarne Hansen (Norway)
lands)
PO525-MON
JOINT EFFECT OF OBESITY AND RISK ALLELES IN THE KNG1 GENE ON
MONDAY
PO515-MON
EFFECT OF PROPHYLAXIS WITH LMWH ON IMPLANTATION IN WOMEN RISK OF VENOUS THROMBOEMBOLISM.
UNDERGOING ASSISTED REPRODUCTIVE PROCEDURES (IVF OR ICSI): Tine Lnneberg*, Erin Smith, Sigrid Brkkan, Lars Horvei, Terry Solomon, Tom Wils-
A PROSPECTIVE RANDOMIZED STUDY gaard, Frits Rosendaal, Kelly Frazer, John-Bjarne Hansen (Norway)
Daniela Tormene*, Federica Esposito, Libera Falcone, Francesca Vigan, Michele
Gangemi, Giovanni Battista Nardelli, Paolo Simioni (Italy) PO526-MON
JOINT EFFECT OF CANCER AND THE GP6 RS1613662 SINGLE NUCLEO-
TIDE POLYMORPHISM ON VTE RISK
PO516-MON
PREDICTION OF VENOUS THROMBOEMBOLIC RELATED FETAL LOSSES Olga Dziewiecka*, Erin Smith, Sigrid Brkkan, Hilde Jensvoll, Kristine Blix, Terry
BY A NEW GENETIC RISK SCORE Solomon, Tom Wilsgaard, Frits Rosendaal, Kelly Frazer, John-Bjarne Hansen (Norway)
POSTERS
Eduardo Salas, Jose A. Paramo*, Ramon Lecumberri, Ana Alfonso, Kevin Guillen, Sara
Pich, Oriol Casagran, Ana Ferro, Jose Soria (Spain) PO527-MON
SEX HORMONE-BINDING GLOBULIN AND HEMOSTATIC VARIABLES IN
WOMEN USING COMBINED OR PROGESTIN-ONLY PILLS.
PO517-MON
MONITORING OF COAGULATION ACTIVATION MARKER AND APPLICA- Justine Hugon-Rodin*, Marianne Canonico, Martine Alhenc-Gelas, H.Coenraad Hem-
TION OF LMWH IN PREGNANCY ker, Sylvie Brailly-Tabard, Anne Guiochon-Mantel, Genevive Plu-Bureau, Pierre-Yves
Annelie Siegemund*, Ute Scholz, Thomas Siegemund (Germany) Scarabin (France)
PO518-MON
MECHANISM OF THE INCREASED THROMBOSIS RISK INDUCED BY PO528-MON
INVOLVEMENT OF HEREDITARY THROMBOPHILIA IN CEREBRAL VE-
BLOOD LOSS DURING CAESARIAN SECTION NOUS THROMBOSIS OCCURRING IN YOUNG PATIENTS
Victoria Kuhnt*, Maria Thomassen, Tilman Hackeng, Ana Zenclussen, Serban-Dan Hla Baccouche*, Eya Chakroun, Sonia Mahjoub, Montaha Ben Jemaa, Samia Ben
Costa, Svetlana Tchaikovski (Germany) Sassi, Zeineb Manai, Neila Ben Romdhane (Tunisia)
PO529-MON
CHRONIC LIVER DISEASE IS A SIGNIFICANT RISK FACTOR FOR VENOUS
Risk factors in thrombosis I THROMBOEMBOLISM AMONG MEDICAL PATIENTS IN SINGAPORE GEN-
ERAL HOSPITAL
Lai Heng Lee*, Xiao Zhu Zhang, Han Seong Ng, Jeffrey Hui, Yong Yang (Singapore)
PO519-MON
IDENTIFYING COMMON AND RARE GENETIC VARIANTS ASSOCIATED
WITH SERUM LEVELS OF ATHEROSCLEROTIC BIOMARKER PROTEINS PO530-MON
THE EFFECT OF HEMODIAFILTRATION AND HEMODIALYSIS ON COAGU-
Terry Solomon*, Erin Smith, Sigrid Braekkan, Tom Wilsgaard, John-Bjarne Hansen, LATION PARAMETERS IN PATIENTS WITH END-STAGE RENAL DISEASE
Kelly Frazer (United States) Krisztina Pnzes-Daku*, Gergely Becs, Boglrka Hurjk, va Molnr, Judit Csap, va
Katona, Jzsef Balla, Lszl Muszbek (Hungary)
PO520-MON
COMPARISON OF THROMBIN GENERATION TEST AND MARKERS OF
COAGULATION ACTIVATION IN UNCOMPLICATED PREGNANCY AND
PREGNANCY-RELATED VENOUS THROMBOEMBOLISM
Berangere Joly, Virginie Barbay, Jeanne-Yvonne Borg, Veronique Le Cam-Duchez*
(France)
170 171
PO531-MON
MIR-15A, MIR-96, MIR-144, MIR-150, MIR-155, MI210, MIR-212, PO540-MON
THROMBOPHILIC PROFILE IN EXTRAHEPATIC PORTAL VEIN OBSTRUC-
MIR-223, MIR-424 AND MIR-451 ARE DIFFERENTLY EXPRESSED IN TION- EXPERIENCE FROM A TERTIARY CENTRE IN INDIA
PLATELETS FROM DVT PATIENTS Pratibha Dhiman*, Priyanka Saxena, Chhagan Bihari, Archana Rastogi, Sk Sarin (India)
Mariane Flores-Nascimento*, Regiane Ferreira, Thas Fornari, Lcia Helena Siqueira,
Bruna Mazetto, Fernanda Orsi, Erich De Paula, Marina Collela, Joyce Annichino-Biz- PO541-MON
ISTHS CLARION CALL: TO RAISE THE AWARENESS OF THROMBOSIS
zacchi (Brazil) WORLDWIDE - A GLOBAL DISEASE BURDEN
Thiruchelvam Ayadurai*, Afandi Faridah, Faraizah Karim (Malaysia)
PO532-MON
PREVENTION OF VENOUS THROMBOSIS AFTER AN ANTERIOR CRUCI-
ATE LIGAMENT RECONSTRUCTION: COMPRESSION STOCKINGS ALONE PO542-MON RISK FACTORS OF THROMBOSIS AND SICKLE CELL ANEMIA
VERSUS ITS COMBINATION WITH LOW MOLECULAR WEIGHT HEPARIN. oure Awa Oumar*, Sall Abibatou, Fall Seynabou, Cisse Samba, Seck Moussa, Faye
T
Raymond A. Van Adrichem*, Nicole Tolen, Lucas Goldman, Anna Boef, Nienke van Blaise, Gadji Macoura, Ndiaye Fatou Samba, Dieye Tandakha, Diop Saliou (Senegal)
Rein, Marcel Driessen, Manfred Vischjager, Inger Schipper, Rob Nelissen, Frits
Rosendaal, Suzanne Cannegieter (The Netherlands) PO543-MON
GENETIC VARIABILITY OF KNG1 AND F11 GENES USING NEXT GENERA-
TION SEQUENCING
PO533-MON
EFFECT OF N-HOMOCYSTEINYLATION PROCESS ON TISSUE PLASMINO- Laura Martin-Fernandez*, Irene Corrales, Lorena Ramrez, Angel Martinez-Perez, Hele-
GEN ACTIVATOR. na Brunel, Juan Carlos Souto, Francisco Vidal, Jos Manuel Soria (Spain)
Heliana Hernndez Herrera, Luca Kordich, Irene Quintana*, Ana Mara Lauricella
(Argentina) PO544-MON LABORATORY MARKERS OF THROMBOPHILIA
Violeta Neceva*, Dejanova Violeta (Macedonia, The Former Yugoslav Republic Of)
PO534-MON
INCREASED CIRCULATING DNA, CALPROTECTIN AND MIELOPEROXI-
DASE, AS NEUTROPHIL EXTRACELLULAR TRAP MARKERS, ARE RISK PO545-MON
EVALUATION OF PROTEIN S SPECIFIC ACTIVITY PERMITS ACCURATE
MONDAY
FACTORS FOR DEEP VEIN THROMBOSIS DIAGNOSIS OF PROTEIN S TOKUSHIMA, A MISSENSE MUTATION WITH
Laura Martos, Silvia Navarro, Lus Ramn, Fernando Ferrando, Ana Cid, Santiago TYPE II PROTEIN S DEFICIENCY
Bonanad, Francisco Espaa, Pilar Medina* (Spain) Hiroko Tsuda*, Kenta Noguchi, Eri Nakazono, Tomohide Tsuda, Xiuri Jin (Japan)
PO535-MON
IN-HOSPITAL COSTS AND CLINICAL DETERMINANTS OF COSTS OF PO546-MON
HYPOXIA INDUCES A PROTHROMBOTIC STATE INDEPENDENTLY OF THE
ACUTE PULMONARY EMBOLISM: A PROSPECTIVE STUDY PHYSICAL ACTIVITY
Jean-Philippe Galanaud*, Aurelie Ternissien, Vera Georgescu, Daniel Pontal, Isabelle Marisa Ninivaggi, Marieke de Laat, Marcus Lanc, Ccile Kicken, Tessa Peters, Saartje
Quere, Pierre Aubas, Gregoire Mercier (France) Bloemen*, Marlou Dirks, Luc van Loon, Jos Govers-Riemslag, Ganeshram Krishna-
POSTERS
moorthy, Theo Lindhout, Joke Konings, Bas de Laat (The Netherlands)
PO536-MON
IDENTIFICATION AND VALIDATION OF PLASMA MICRORNAS INVOLVED
IN VENOUS AND ARTERIAL THROMBOSIS. PO547-MON
THE POSSIBLE ROLE OF C.1824C>T PROTHROMBIN GENE VARIANT IN
Luis A Ramon, Laura Martos, Joaquin Rueda, Miguel A Arnau, Esther Zorio, Fernando PATHOGENESIS OF THROMBOPHILIA
Ferrando, Yolanda Mira, Santiago Bonanad, Pilar Medina, Francisco Espaa, Silvia Valentina Djordjevic*, Iva Pruner, Maja Gvozdenov, Branko Tomi, Mira Kovac, Predrag
Navarro* (Spain) Miljic, Dragica Radojkovic (Serbia)
PO537-MON
THE INCIDENCE OF CATHETER-RELATED THROMBOSIS IN PATIENTS PO548-MON
PATHOGENETIC PROPHYLAXIS PRE-ECLAMPSIA IN PATIENTS WITH
ON LONG-TERM PARENTERAL NUTRITION: A SYSTEMATIC REVIEW AND THROMBOPHILIA AND THE HISTORY OF PRE-ECLAMPSIA
META-ANALYSIS. Alexander Makatsaria*, Victoria Bitsadze, Ekaterina Zhuravleva (Russian Federation)
Stefano L. Barco*, Bram Salman, Mireille Serlie, Saskia Middeldorp, Michiel Coppens
(The Netherlands) PO549-MON
THE CLINICAL AND LABORATORY ANALYSIS OF HOMOZYGOUS CARRI-
ERS FACTOR V LEIDEN MUTATION.
PO538-MON
VENA CAVA THROMBOSIS IN ADULTHOOD VS PEDIATRICS PATIENTS: Bernadeta Ceglarek, Ksenia Bykowska, Anna Sikorska, Paulina Adamczyk-Wojciech-
DIFFERENT PHENOTYPES AND RISK FACTORS FOR THE SAME ENTITY. owska, Magdalena Marchewka, Adam Wiszniewski*, Jerzy Windyga (Poland)
Georgina Daher*, Vernica Pons, Ins Valcarce, Gonzalo Artaza, Pavel Olivera, Laura
Lpez, Amparo Santamara, Francesc Bosch (Spain) PO550-MON MOLECULAR CHARACTERIZATION OF NEW ANTITHROMBIN MUTATIONS
Zsuzsanna Bereczky*, Rka Gindele, Marianna Speker, gnes Udvari, Zsolt Olh, Anna
Selmeczi, gota Schlammadinger, Helga Brdos, Istvn Komromi, Gizella Haramura,
Thrombophilia I Lszl Muszbek (Hungary)
PO551-MON
A REASON TO INCLUDE HOMOCYSTEINE IN THE HYPERCOAGULABLE
PO539-MON
A CLINICAL AUDIT OF HERITABLE THROMBOPHILIA TEST PROFILE IN A WORKUP
TERTIARY HEALTH CARE FACILITY, PAKISTAN. Mala Varma* (United States)
Anila Rashid, Bushra Moiz*, Humaira Perveen, Bushra Rizvi (Pakistan)
172 173
Tissue factor - Factor VII - I PO561-MON
NATURALLY OCCURRING NEISSERIA MENINGITIDIS WITH MUTATED
LIPID A MOIETY IS A WEAKER INDUCER OF TISSUE FACTOR EXPRES-
SION AND -ACTIVITY IN HUMAN MONOCYTES AND MONOCYTE-DERIVED
PO552-MON
PATHOLOGICAL DETERMINANTS OF HUMAN CORONARY THROMBUS MICROVESICLES THAN THE WILDTYPE MENINGOCOCCI
FORMATION: DISTINCT PROCOAGULANT ACTIVITY AND LACTATE PRO- Marit Hellum, Anne Marie Siebke Troseid, Jens Petter Berg, Petter Brandtzaeg, Reidun
DUCTION OF M1/M2 POLARIZED MACROPHAGES. Ovstebo, Carola Henriksson* (Norway)
Shuntaro Matsuda, Atsushi Yamashita*, Sayaka Moriguchi-Goto, Naoki Sameshima,
Takashi Iwakiri, Yunosuke Matsuura, Yuichiro Sato, Yujiro Asada (Japan) PO562-MON
DO ELEVATED COAGULATION FACTOR LEVELS AFFECT THE TISSUE
FACTOR-THRESHOLD IN THROMBIN GENERATION?
PO553-MON
SINGLE PHOSPHORYLATION OF THE CYTOPLASMIC DOMAIN OF TISSUE Inge M. Rietveld*, Pieter Reitsma, Mettine Bos (The Netherlands)
FACTOR AT SERINE 253 IS SUFFICIENT FOR THE BINDING OF TISSUE
FACTOR TO FILAMIN-A PO563-MON
TISSUE FACTOR/FACTOR VIIA SIGNALING PROMOTES CYTOKINE-IN-
Mary E. W. Collier*, Ben Goult, Anthony Maraveyas, Camille Ettelaie, Alison Goodall DUCED BETA CELL DEATH AND IMPAIRS GLUCOSE STIMULATED INSU-
(United Kingdom) LIN SECRETION FROM HUMAN PANCREATIC ISLETS.
Desire Edn*, Agneta Siegbahn, Dariush Mokhtari (Sweden)
PO554-MON
THE INTERPLAY BETWEEN TISSUE FACTOR AND ALTERNATIVELY
SPLICED TISSUE FACTOR AND ITS EFFECT ON THROMBOSIS AND HE- PO564-MON TISSUE FACTOR ACTIVATION IN PREGNANCY COMPLICATIONS
MOSTASIS. artin Prochazka*, Ludek Slavik, Jana Prochzkov, Jana lehlov, Martin Novk,
M
Betul Unlu*, Henri Versteeg (The Netherlands) Eliska Hostinska, Petr Polk (Czech Republic)
PO555-MON
K63-LINKED POLYUBIQUITINATION OF LYSINE 255 WITHIN TF PRO- PO565-MON
ACTIVATED PLATELETS REGULATE MONOCYTE TFPI GENE EXPRESSION
MONDAY
MOTES SELECTIVE TF-DEPHOSPHORYLATION, TRIGGERS TF-ENDOCY- THROUGH THE NUCLEAR TRANSCRIPTION FACTOR PPAR
TOSIS AND TERMINATES TF ACTIVITY Robert E. Turnbull*, Katrin Sander, Peter Watson, David Barrett, John Schwabe, Alison
Camille Ettelaie*, Anthony Maraveyas, Mary Collier (United Kingdom) Goodall (United Kingdom)
PO556-MON
CHARACTERISATION OF TF UBIQUITINATION: INVOLVEMENT OF MDM2 PO566-MON
TISSUE FACTOR AND TISSUE FACTOR PATHWAY INHIBITOR ASSESS-
AND THE UBE2D FAMILY OF E2 ENZYMES MENT IN EARLY AND LATE SEVERE PREECLAMPSIA
Camille Ettelaie*, Mary Collier, Sohpie Featherby, Anthony Maraveyas (United King- Lara C. Godoi*, Patrcia Alpoim, Karina Borges, Maria das Graas Carvalho, Melina
POSTERS
Pinheiro, Luci Dusse (Brazil)
dom)
PO557-MON
HIGH LEVEL OF TISSUE FACTOR INDUCES CELL APOPTOSIS IN ENDO-
Transfusion I
THELIAL CELLS, MEDIATED THROUGH ACTIVATION OF P38 AND P53
Azza ElKeeb, Mary Collier, Anthony Maraveyas, Camille Ettelaie* (United Kingdom)
PO567-MON
LEVONORGESTREL-RELEASING INTRA-UTERINE DEVICE USE IN ADO-
PO558-MON
THE POTENTIAL OF CANCER CELL LINES TO RELEASE TISSUE FAC- LESCENT FEMALES WITH HEAVY MENSTRUAL BLEEDING AND BLEED-
TOR-CONTAINING MICROVESICLES CORRELATES WITH TISSUE FACTOR ING DISORDERS: SINGLE INSTITUTION REVIEW
AND PAR2 MRNA LEVELS BUT NOT TISSUE FACTOR PROTEIN OR SUR- Oluyemisi A. Adeyemi, Xiomara Santos, Jennifer Dietrich, Lakshmi Srivaths* (United
FACE ACTIVITY States)
Camille Ettelaie*, Mary Collier, Sophie Featherby, John Greenman, Anthony Maraveyas
(United Kingdom) PO568-MON
A NEW ALLOANTIGEN (CAB4) CARRIED BY GPIX IDENTIFIED IN A CON-
TEXT OF SEVERE NEONATAL ALLOIMMUNE THROMBOCYTOPENIA.
PO559-MON
TISSUE FACTOR IS INDUCED BY INTERLEUKIN-33 IN HUMAN ENDOTHE- Vincent Jallu, Thomas Beranger, Frederic Bianchi, Cecile Casale, Christophe Chenet,
LIAL CELLS: A NEW LINK BETWEEN COAGULATION AND INFLAMMATION Nicolas Ferre, Sebastien Philippe, Jeannine Quesne, Corinne Martageix, Rachel Peter-
Stefan Stojkovic*, Christoph Kaun, Jos Basilio, Sabine Rauscher, Lena Hell, Konstan- mann* (France)
tin Krychtiuk, Wolfgang Holnthoner, Christoph Neumayer, Cihan Ay, Wolfgang Eppel,
Ihor Huk, Rainer De Martin, Kurt Huber, Svitlana Demyanets, Johann Wojta (Austria) PO569-MON
ASSESSMENT OF QUALITY AND CLINICAL EFFECTIVENESS OF APHER-
ESIS PLATELET CONCENTRATES TREATED WITH MIRASOL PATHOGEN
PO560-MON
SOLUBLE TISSUE FACTOR IMPROVES DETECTION OF THROMBIN GEN- REDUCTION SYSTEM IN PLASMA OR IN PLATELET ADDITIVE SOLUTION
ERATION RESPONSES TO WIDE RANGE OF FACTOR VIIA DOSES SSP+
Alexey Shibeko, Alireza Rezaie, Timothy Lee, Mikhail V. Ovanesov* (United States)
Anastasia Ignatova*, Oksana Karpova, Pavel Trahtman, Sergey Rumyantsev, Mikhail
Panteleev (Russian Federation)
174 175
PO570-MON
QUANTIFICATION OF CELL FREE DNA IN RED BLOOD CELL CONCEN- PO579-MON
PHASE II STUDY OF DANAZOL WITH PLASMA EXCHANGE AND CORTICO-
TRATES PRODUCED VIA BUFFY COAT (B1) OR WHOLE BLOOD (B2) STEROIDS FOR THE TREATMENT OF THROMBOTIC THROMBOCYTOPE-
METHODS NIC PURPURA
Andrew Shih*, Vinai Bhagirath, Patricia Liaw, Jason Acker, John Eikelboom, Nancy Vamsee Torri*, Mark Friedman, Ilan Shapira, Amit Patel, Joseph Yoe, Vijay Shah, Tahir
Heddle (Canada) Mirzoyev*, Maria Machuca, Mala Varma (United States)
PO571-MON
RESPONSIVENESS OF PLATELETS DURING STORAGE STUDIED WITH PO580-MON
DENSE GENOTYPING OF IMMUNE-RELATED DISEASE REGIONS FOR
FLOW CYTOMETRY FORMATION OF PLATELET SUBPOPULATIONS AND THE IDENTIFICATION OF GENETIC RISK FACTORS IN ACQUIRED
LAMP-1 AS NEW MARKERS FOR THE PLATELET STORAGE LESION THROMBOTIC THROMBOCYTOPENIC PURPURA.
Anna L. Sdergren*, Nahreen Tynngrd, Gsta Berlin, Sofia Ramstrm (Sweden) Ilaria Mancini*, Emanuela Pappalardo, Andrea Cairo, Marcin Gorski, Barbara Ferrari,
Isis Ricao-Ponce, Cisca Wijmenga, Flora Peyvandi (Italy)
PO572-MON
PRESERVED ULTRASTRUCTURE AND BIOCHEMICAL CHARACTERISTICS
OF PLATELET COMPONENTS PREPARED WITH AMOTOSALEN AND UVA PO581-MON
CHARACTERIZATION OF SINGLE SORTED ANTI-ADAMTS13 SPECIFIC B
FOR PATHOGEN INACTIVATION CELLS FROM THE SPLEEN OF ACQUIRED THROMBOTIC THROMBOCYTO-
Beatrice Hechler*, Catherine Ravanat, Philippe Ohlmann, Anita Eckly, Marjorie Leduc, PENIC PURPURA (ATTP) PATIENTS
Franois Guillonneau, Herv Isola, Christian Gachet (France) Magdalena Skowronska*, Monica Schaller, Johanna Kremer Hovinga (Switzerland)
PO573-MON
PLATELET TRANSFUSIONS AT THE CLINIC OF CHEMOTHERAPY: A HOS- PO582-MON
THE NATURAL MUTATION ASP173GLY IN THE CATALYTIC SITE OF THE
PITAL-BASED COHORT STUDY ADAMTS-13 GENE CAUSES A SEVERE UPSHAW-SCHULMAN SYN-
Gevorg Tamamyan*, Samvel Danielyan, Liana Safaryan, Davit Zohrabyan, Lilit DROME: CLINICAL COURSE, BIOCHEMISTRY AND MOLECULAR DYNAM-
Sargsyan, Astghik Voskanyan, Lusine Hakobyan, Lilit Harutyunyan, Armen Avagyan, ICS INVESTIGATION
MONDAY
Samvel Bardakchyan (Armenia) Stefano Lancellotti*, Flora Peyvandi, Maria Teresa Pagliari, Andrea Cairo, Safwat
Abdel-Azeim, Edrisse Chermak, Ilaria Lazzareschi, Stefano Mastrangelo, Luigi Cavallo,
PO574-MON
RELATIVE EFFECTS OF FRESH FROZEN PLASMA, FIBRINOGEN CON- Romina Oliva, Raimondo De Cristofaro (Italy)
CENTRATE, AND FACTOR XIII IN MASSIVE TRANSFUSION REGIMENS: A
LABORATORY STUDY PO583-MON
DEFECTIVE DEGRADATION OF NEUTROPHIL EXTRACELLULAR TRAPS IS
David Schmidt*, Agneta Wikman, Anna gren, Anders stlund (Sweden, Netherlands) ASSOCIATED WITH ACUTE THROMBOTIC MICROANGIOPATHIES
Miguel Jimnez-Alczar*, Markus Napirei, Rachita Panda, Elodie Khler, Johanna
POSTERS
PO575-MON
HPA BEADCHIP GENOTYPING STUDY: COMPARISON BETWEEN DNA Kremer Hovinga, Hans Mannherz, Sven Peine, Thormas Renn, Bernhard Lmmle,
EXTRACTED FROM BLOOD SAMPLES AND BUCCAL SWABS Tobias Fuchs (Germany)
Rachel Petermann*, Christophe Chenet, Thomas Beranger, Frederic Bianchi, Cecile Ca-
sale, Nicolas Ferre, Sebastien Philippe, Quesne Jeannine, Corinne Martageix, Vincent PO584-MON PLATELET INHIBITION IN TTP: A MECHANISM TO ESCAPE THROMBOSIS
Jallu, Olivier Garraud (France) ark Roest*, Rob Fijnheer, Loes Cornelissen, Judith Zandstra, Silvie Sebastian, Rolf
M
Urbanus (The Netherlands)
PO576-MON
PROTHROMBIN ACTIVATION IN PACKED RED BLOOD CELL UNITS OVER
THEIR STORAGE LIFETIME PO585-MON
TREATMENT OF A JEHOVAHS WITNESS WITH RECURRENT THROMBOT-
Thomas Orfeo*, Hollis Keith, Elizabeth Lavoie, Beth Bouchard, Matthew Gissel, Mark IC THROMBOCYTOPENIC PURPURA WITH RITUXIMAB
Fung, Kenneth Mann (United States) Fnu Kirti*, Gabriel Ibarra, Alejandro Calvo (United States)
PO577-MON
EXPLORING THE CHALLENGES OF EFFECTIVE FACTOR DISTRIBUTION PO586-MON
PATHOGENICITY OF ANTI-ADAMTS13 AUTOANTIBODIES IN ACQUIRED
AND MANAGEMENT IN THE PROVINCE OF SASKATCHEWAN TTP
Karen L. Dallas*, Roona Sinha (Canada) Mari Thomas*, Rens De Groot, James Crawley, Marie Scully (United Kingdom)
PO587-MON
MAJOR CLINICAL OUTCOMES ARE SIMILAR BETWEEN INITIAL AND RE-
TTP/thrombotic microangiopathies I LAPSED EPISODES OF THROMBOTIC THROMBOCYTOPENIC PURPURA
Shangbin Yang*, Susan Geyer, Elizabeth Biller, Haiwa Wu, Spero Cataland, Haifeng Wu
(United States)
PO578-MON
NEURO-IMAGING DOES NOT CORRELATE WITH DISEASE SEVERITY IN
ACUTE THROMBOTIC THROMBOCYTOPENIA PURPURA (TTP), BUT MAY PO588-MON
ACTIVATION OF THE COMPLEMENT SYSTEM AND REDUCTION OF
PREDICT LONG TERM SEQUELAE. ADAMTS13 ACTIVITY BOTH PRECEDE CLINICAL EVENTS OF TTP RE-
Indrani Karpha*, Clare Kay-Jones, Jennifer Burgiss, Vanessa Martlew, Cheng Toh, Paul LAPSE
Fitzsimmons*, Tina Dutt (United Kingdom) Shangbin Yang*, Spero Cataland, Haiwa Wu, Ming Jin, Yi Wang, Ante Lundberg, Hai-
feng Wu (United States)
176 177
PO589-MON
BASELINE DEMOGRAPHICS AND CHARACTERISTICS OF 570 PATIENTS PO598-MON
ACCURACY OF X-RAY WITH PERFUSION SCAN IN YOUNG PATIENTS
WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME IN THE GLOBAL AHUS WITH SUSPECTED PULMONARY EMBOLISM
REGISTRY Josien Van Es*, Renee Douma, Rachel Hezemans, Andrea Penaloza, Serge Motte, Pe-
Christoph Licht*, Gianluigi Ardissino, Gema Ariceta, David Cohen, Christoph Gasteyger, tra Erkens, Marc Durian, Berthe van Eck-Smit, Pieter Kamphuisen (The Netherlands)
Larry Greenbaum, Sally Johnson, Masayo Ogawa, Varant Kupelian, Franz Schaefer,
Johan Vande Walle, Veronique Fremeaux-Bacchi (Canada) PO599-MON
DEVELOPMENT OF ELISA SYSTEM FOR DETECTION OF PROTEIN S
K196E MUTATION, A GENETIC RISK FACTOR FOR VENOUS THROMBO-
PO590-MON
A CASE OF THROMBOTIC MICROANGIOPATHY WITH CFH GENE AL- EMBOLISM
TERATIONS THAT ARE NOT ASSOCIATED WITH ATYPICAL HEMOLYTIC Keiko Maruyama*, Masashi Akiyama, Koichi Kokame, Akiko Sekiya, Eriko Morishita,
UREMIC SYNDROME Toshiyuki Miyata (Japan)
Yesim Oymak*, Tuba Karapinar, Yilmaz Ay, Erkin Serdaroglu, Neryal Muminoglu, Canan
Vergin (Turkey) PO600-MON
MODIFIED COMPUTER-ASSISTED STRAIN GAUGE PLETHYSMOGRAPHY
AS A SIMPLE SCREENING TEST FOR PATIENTS WITH SUSPECTED DEEP
PO591-MON SEVERE FIRST MANIFESTATION OF TTP IN A 96-YEAR-OLD FEMALE VEIN THROMBOSIS: A COHORT STUDY.
Markus Munder, Lothar van den Abeelen, Roland Hardt, Charis von Auer, Ina Pretzell, Andrew S. Hughes*, Benjamin Hall, Kate Jennings, Victoria Webb, Georgia Page,
Annette Shresthna, Inge Scharrer* (Germany) Christine Smith, Florence Charova (United Kingdom)
PO592-MON
GENOTYPE AND PHENOTYPE FEATURES OF CONGENITAL THROMBOTIC PO601-MON
MODIFIED STRAIN GAUGE PLETHYSMOGRAPHY CAN DECREASE THE
THROMBOCYTOPENIC PURPURA PATIENTS (MILAN TTP REGISTRY). NEED FOR COMPRESSION ULTRASONOGRAPHY IN PATIENTS WITH
Andrea Cairo, Ilaria Mancini*, Gloria Casoli, Andrea Artoni, Barbara Ferrari, Haifeng SUSPECTED DEEP VEIN THROMBOSIS: A RETROSPECTIVE MULTI-
Wu, Flora Peyvandi (Italy) CENTRE COHORT STUDY.
MONDAY
Andrew S. Hughes*, Benjamin Hall, Jane Strong, Rachel Clarke-Drury, Mark Bennett,
PO593-MON
NEUROLOGICAL AND PSYCHOLOGICAL CONSEQUENCES AFTER RECOV- Lyn Hooton, Nimal Muttucumaru, Tracy Muttucumaru (United Kingdom)
ERY FROM THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP)
Veronique Schmitt, Stephanie Herold, Veronika Weyer, Charis Von Auer, Heidi Ross- PO602-MON
ULTRASOUND DIAGNOSTIC CRITERIA AND CLOT DIAMETERS OF ISO-
mann, Karl Lackner, Inge Scharrer, Bernhard Lmmle, Tanja Falter* (Germany) LATED DISTAL DEEP VENOUS THROMBOSIS
Michelangelo Sartori*, Gianfranco Lessiani, Elisabetta Favaretto, Ludovica Migliaccio,
Matteo Iotti, Angelo Ghirarduzzi, Benilde Cosmi (Italy)
Venous thromboembolism - diagnosis I
POSTERS
PO603-MON
OUTCOME OF SCREENING FOR OCCULT MALIGNANCY IN PATIENTS
PRESENTING WITH UNPROVOKED VENOUS THROMBOEMBOLISM AT A
PO594-MON
THE NEW CLINICAL PREDICTION SCORE FOR DIAGNOSIS OF LOWER
LARGE TERTIARY HOSPITAL IN CENTRAL LONDON
LIMB DEEP VEIN THROMBOSIS IN UNSELECTED POPULATION OF OUT-
Anne Mwirigi*, Vickie McDonald, Richard Glaves, Johanna Young, Susie Shapiro,
PATIENTS AND INPATIENTS
Beverley Hunt, Karen Breen (United Kingdom)
Nuttawut Sermsathanasawadi* (Thailand)
PO595-MON
OVER-REPRESENTATION OF SEVERE SUBCLAVIAN VEIN OCCLUSION IN
Venous thromboembolism - epidemiology I
THE AFFECTED ARM, COMPARED WITH THE CONTRALATERAL ARM, IN
PATIENTS WITH UNPROVOKED UNILATERAL UPPER EXTREMITY DEEP
VEIN THROMBOSIS PO604-MON
A PROSPECTIVE STUDY OF VENOUS THROMBOEMBOLISM INCIDENCE
Shuoyan Ning*, Ryan Rebello, Anthony Chan, Howard Chan (Canada) AND RISK FACTORS IN SEVERE SEPSIS AND SEPTIC SHOCK
David Kaplan*, Charles Casper, Larry Kraiss, Andrew Weyrich, Colin Grissom, Shaohua
PO596-MON
THE PERFORMANCE OF THE AGE-ADJUSTED D-DIMER THRESHOLD FOR Men, Robert Pendleton, Guy Zimmerman, Matthew Rondina (United States)
SUSPECTED PULMONARY EMBOLISM IN RELEVANT SUBGROUPS : AN
INDIVIDUAL PATIENT DATA META-ANALYSIS OF 7,000 PATIENTS PO605-MON
VENOUS THROMBOEMBOLISM IN NORTHEAST MELBOURNE, AUSTRA-
Nick van Es*, Tom van der Hulle, Josien van Es, Paul den Exter, Rene Douma, LIA: EVALUATION OF EPIDEMIOLOGY, RISK FACTORS AND TREATMENT
Robbert Goekoop, Inge Mos, Pieter Kamphuisen, Patrick Bossuyt, Menno Huisman, STRATEGIES IN THE WARFARIN ERA.
Frederikus Klok, Harry Bller (The Netherlands) Prahlad Ho*, Hui Yin Lim, Chyn Chua, Matthew Sleeman, Lachlan Hayes (Australia)
PO597-MON
A SIMPLE DECISION RULE INCLUDING THE D-DIMER TEST TO REDUCE PO606-MON
LOW INCIDENCE OF DEEP VEIN THROMBOSIS AFTER TOTAL KNEE
THE NEED FOR CT-SCANNING IN PATIENTS WITH SUSPECTED PULMO- ARTHROPLASTY IN AN ASIAN POPULATION
NARY EMBOLISM Stephrene S. W. Chan*, Jing Loong Moses Loh, Sanjay De Mel, Deborah Chew, Keng
Josien Van Es*, Ludo Beenen, Renee Douma, Paul den Exter, Inge Mos, Karin Kaas- Lin Wong, Eng Soo Yap (Singapore)
jager, Menno Huisman, Pieter Kamphuisen, Patrick Bossuyt (The Netherlands)
178 179
PO607-MON
ASYMPTOMATIC THROMBOSIS FOLLOWING THE USE OF CENTRAL PO617-MON
THROMBIN GENERATION AND THE RISK OF VENOUS THROMBOSIS:
VENOUS LINES IN CHILDREN RESULTS FROM A LARGE POPULATION-BASED CASE-CONTROL STUDY
Sophie E. Jones*, Fiona Newall, Warwick Butt, Paul Monagle (Australia) Kristien Winckers*, Astrid van Hylckama Vlieg, Stella Thomassen, Tilman Hackeng,
Frits Rosendaal (The Netherlands)
PO608-MON
DOES DIABETES INFLUENCE OUTCOME WITHIN THREE MONTHS
AFTER VENOUS THROMBOEMBOLISM? FINDINGS FROM 4,011 CASES
ENROLLED IN THE WORLDWIDE RIETE REGISTRY Venous thromboembolism - therapy I
Stefania Frasson, Gualberto Gussoni, Pierpaolo Di Micco, Laurent Bertoletti, Alicia Lo-
renzo, Olga Madridano, Javier Trujillo-Santos, Antonio Ceriello, Paolo Prandoni, Manuel PO618-MON
TWO WEEKS OF LOW MOLECULAR WEIGHT HEPARIN FOR ISOLATED
Monreal* (Italy)
SYMPTOMATIC DISTAL VEIN THROMBOSIS (TWISTER STUDY): INTERIM
PO609-MON
TIME TRENDS IN INCIDENCE RATES OF VENOUS THROMBOEMBOLISM ANALYSIS OF FIRST 100 PATIENTS
IN A LARGE COHORT RECRUITED FROM THE GENERAL POPULATION Eileen Merriman*, Sanjeev Chunilal, Simon McRae, Tim Brighton, Huyen Tran (New
Zealand)
Nadia Arshad*, Trond Isaksen, John-Bjarne Hansen, Sigrid Brkkan (Norway)
PO619-MON
A CANADIAN CONSENSUS ON VENOUS THROMBOEMBOLISM (VTE) PRO-
PO610-MON
POOR SELF-RATED HEALTH IS ASSOCIATED WITH FUTURE RISK OF
PHYLAXIS PREVENTION IN THORACIC SURGERY, A NATIONAL DELPHI
VENOUS THROMBOEMBOLISM IN WOMEN. THE TROMS STUDY.
CONSENSUS SURVEY
Sigrid Braekkan*, Trond Isaksen, John-Bjarne Hansen (Norway)
Yaron Shargall*, Lori-Ann Linkins, Laura Schneider, Mark Crowther, Marc De Perrot,
PO611-MON
ORAL AND INHALED CORTICOSTEROID USE HAS A TIME-DEPENDENT Christian Finley, Wael Hanna, Colin Schieman (Canada)
ASSOCIATION WITH RECURRENT PULMONARY EMBOLISM PO620-MON
ADHERENCE TO INTERNATIONAL GUIDELINES IN TREATMENT OF
MONDAY
Marlous Sneeboer, Barbara Hutten, Christof Majoor, Pieter-Willem Kamphuisen*,
THROMBOEMBOLIC EVENTS IN CANCER PATIENTS: A HOSPITAL-BASED
Elisabeth Bel (The Netherlands)
COHORT STUDY IN PARIS, FRANCE
PO612-MON
CASE FATALITY AND RECURRENCE RATES AFTER FIRST VENOUS Isabelle Mah*, Hortense Puget, Jean Chidiac, Andrey Strukov, Jean-Claude Buzzi,
THROMBOEMBOLISM IN A LARGE POPULATION-BASED COHORT Helene Helfer, Michele Lamuraglia, Anne Perozziello (France)
Nadia Arshad*, Trond Isaksen, John-Bjarne Hansen, Sigrid Brkkan (Norway)
PO621-MON
A FIRST-IN-HUMAN, SINGLE ASCENDING DOSE STUDY OF DS-1040,
PO613-MON
TIME TRENDS AND CASE FATALITY RATE OF PULMONARY EMBOLISM AN INHIBITOR OF THE ACTIVATED FORM OF THROMBIN-ACTIVATABLE
POSTERS
DURING 11 YEARS OF OBSERVATION IN NORTHWESTERN ITALY FIBRINOLYSIS INHIBITOR (TAFIA), IN HEALTHY SUBJECTS
Francesco Dentali*, Walter Ageno, Fulvio Pomero, Luigi Fenoglio, Alessandro Squizza- Jin Zhou*, Cynthia Zamora, George Atiee, Vance Warren, Ophelia Yin, Jarema Kochan,
to, Matteo Bonzini (Italy) Joseph Pav, Yasushi Orihashi, Vijay Kumar Vashi, Victor Dishy (United States)
PO614-MON
NATURAL HISTORY AND ANTITHROMBOTIC TREATMENT OF INCIDEN- PO622-MON
A RETROSPECTIVE MEDICATION USE EVALUATION OF ANTITHROM-
TALLY DETECTED SPLANCHNIC VEIN THROMBOSIS: FINDINGS FROM BOTIC THERAPY AFTER TOTAL HIP ARTHROPLASTY OR TOTAL KNEE
THE ISTH REGISTRY ARTHROPLASTY AT UNIVERSITY OF COLORADO HEALTH.
Nicoletta Riva*, Walter Ageno, Sam Schulman, Jan Beyer-Westendorf, Soo-Mee Bang, Patrick Klem*, Toby Trujillo, Larry Golightly, Megan Wong, Craig Hogan (United States)
Samantha Pasca, Daniela Poli, Peter Verhamme, Adriano Alatri, Donatella Colaizzo,
Elena Rancan, Suely Meireles Rezende, Antonietta Piana, Mario Bazzan, Maria T. De PO623-MON
PLATELET REACTIVITY IN PATIENTS WITH A HISTORY OF VENOUS
Sancho, Etienne Ciantar, Elena Elli, Krystyna Zawilska, Francesco Dentali, IRSVT study THROMBOSIS WHO USE ROSUVASTATIN: RANDOMIZED CLINICAL TRIAL
investigators (Italy) Joseph Biedermann*, Suzanne Cannegieter, Felix van der Meer, Marieke Kruip, Pieter
Reitsma, Willem Lijfering (The Netherlands)
PO615-MON
DEEP VEIN THROMBOSIS IN SEPTIC PATIENTS IN THE INTENSIVE CARE
UNIT PO624-MON
LONG-TERM USE OF LOW-MOLECULAR-WEIGHT HEPARINS (LMWH)
Vaia Florou*, Gregoris Komodikis, Damodar Penigalapati, Paris Charilaou, Haris Rana FOR THE TREATMENT OF CANCER-ASSOCIATED THROMBOSIS (CAT):
(United States) FACTORS ASSOCIATED WITH NON-COMPLIANCE WITH TREATMENT
RECOMMENDATIONS (NCTR) IN CLINICAL PRACTICE.
PO616-MON
FACTOR V IS ASSOCIATED WITH A MODERATELY INCREASED RISK OF Francis Cajfinger*, Philippe Debourdeau, Anne Lamblin, Dominique Farge-Bancel (France)
VENOUS THROMBOSIS
Inge M. Rietveld*, Mettine Bos, Frits Rosendaal, Pieter Reitsma, Suzanne Cannegieter PO625-MON
HOSPITAL LENGTH OF STAY FOR DEEP VEIN THROMBOSIS OR PULMONARY
(The Netherlands) EMBOLISM AMONG PATIENTS RECEIVING RIVAROXABAN OR WARFARIN
Steven Deitelzweig*, Monika Raut, Jay Margolis, Oth Tran, David Smith, Brahim
Bookhart, Jeff Schein, William Olson (United States)
180 181
PO626-MON
ACUTE PULMONARY EMBOLISM: EXTERNAL VALIDATION OF THE 2014 PO636-MON
SELECTION, MANAGEMENT AND OUTCOME OF VKA PATIENTS
RISK STRATIFICATION MODEL OF THE EUROPEAN SOCIETY OF CARDI- WITH ATRIAL FIBRILLATION NOT SWITCHED TO NOVEL ORAL AN-
OLOGY TICOAGULANTS RESULTS FROM THE DRESDEN NOAC REGISTRY
Cecilia Becattini*, Giancarlo Agnelli, Mareike Lankeit, Luca Masotti, Piotr Pruszczyk, (NCT01588119)
Franco Casazza, Simone Vanni, Cinzia Nitti, Pieter Kamphuisen, Maria Vedovati, Maria Franziska Michalski, Sebastian Werth, Luise Tittl, Sandra Marten, Norbert Weiss, Jan
De Natale, Stavros Konstantinides (Italy) Beyer-Westendorf* (Germany)
PO627-MON
RISK FACTORS FOR RECURRENCE AND THROMBOEMBOLIC EVENTS PO637-MON
ANTAGONIZATION OF WARFARIN IN CELLS: WARFARIN BINDING ON
AFTER ISOLATED SUPERFICIAL VEIN THROMBOSIS OF LOWER LIMBS HUMAN VKORC1 IS REVERSIBLE
Michelangelo Sartori*, Elisabetta Favaretto, Ludovica Migliaccio, Giuseppina Rodorigo, Katrin Czogalla*, Arijit Biswas, Matthias Watzka, Klara Hning, Veit Hornung, Johannes
Gualtiero Palareti, Benilde Cosmi (Italy) Oldenburg (Germany)
PO628-MON
EFFICACY AND SAFETY OF TREATMENT WITH ANTICOAGULANTS IN PO638-MON
RELATIONSHIP BETWEEN VITAMIN K ANTAGONISTS AND RECURRENT
PATIENTS WITH VENOUS THROMBOEMBOLISM IN KOREA BLEEDING EVENTS IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRIL-
Hun Gyu Hwang*, Myung Shin Kim, Gune-Il Lim, Eunju Sim, Won-Il Choi (Korea, LATION: REAL-WORLD FINDINGS FROM ENGLAND
Republic Of) Raza Alikhan*, Cinira Lefevre, Ian Menown, Steven Lister, Laure Lacoin, Alex Bird, Min
You, Essra Ridha, David Evans (United Kingdom)
Vitamin K antagonists I PO639-MON

RISK FACTORS FOR GASTRO-INTESTINAL BLEEDING IN ATRIAL FIBRIL-
LATION PATIENTS ON VKA TREATMENT: PROSPECTIVE ANALYSIS OF
TWO COHORTS OF PATIENTS
PO629-MON
PREVALENCE OF VKORC-1 POLYMORPHISMS ACROSS CAUCASIANS AND
MONDAY
Daniela Poli*, Emilia Antonucci, Sophie Testa, Alberto Tosetto, Walter Ageno, Gualtiero
AMERINDIANS
Palareti (Italy)
Maria Paula Vera Morandini, Lucia Remotti, Silvia Grosso, Marcelo Ingratti, Fabiana
Alberto, Vanesa Caruso, Analia Sanchez Luceros, Susana Sara Meschengieser, Maria PO640-MON
PREDICTORS OF ICH RECURRENCE ON VKA: SEVERITY OF THE FIRST
Lazzari, Alicia Blanco* (Argentina)
EPISODE AND HASBLED SCORE FAIL TO IDENTIFY HIGH RISK PATIENTS
PO630-MON
INFLUENCE VITAMIN K ANTAGONISTS ON THE THROMBINEMIA AND FROM THE CHIRONE STUDY
HOMOCYSTEINE LEVELS Daniela Poli*, Emilia Antonucci, Francesco Dentali, Sophie Testa, Gualtiero Palareti
POSTERS
(Italy)
Nadezda Vorobyeva*, Alexsandra Rogozina (Russian Federation)
PO641-MON PERIOPERATIVE INTERRUPTION OF WARFARIN ANTICOAGULATION
PO631-MON
SUSCEPTIBILITY OF VKORC1 AND ITS PARALOG VKORC1L1 TOWARDS
Joseph Shaw*, Dimitri Scarvelis, Lana Castellucci, Esteban Gandara, Wendy Riches,
DIFFERENT 4-HYDROXYCOUMARINS
Kerstin Hogg, Philip Wells (Canada)
Kerstin Liphardt*, Katrin Czogalla, Klara Hning, Veit Hornung, Matthias Watzka,
Johannes Oldenburg (Germany)
Von Willebrand disease I
PO632-MON
ZYMOGEN-LIKE FXA VARIANT AS NOVEL WARFARIN REVERSAL STRATE-
GY: PRE-CLINICAL EVALUATION AND MECHANISM OF ACTION
Lindsey A. Greene*, Nabil Thalji, Rodney Camire (United States) PO642-MON
COST OF TREATING THROMBOTIC EVENTS IN A US POPULATION OF
VON WILLEBRAND DISEASE PATIENTS
PO633-MON
CLINICAL AUDIT OF ANTICOAGULATION REVERSAL AND OUTCOME IN Alexandra Khachatryan*, Yan Xiong (United States)
WARFARIN-ASSOCIATED INTRACRANIAL HAEMORRHAGE (WAICH)
Danielle Blunt*, Safoorah Sagheer, Simon McRae (Australia) PO643-MON
AN OPEN-LABEL, MULTI-CENTER EXTENSION STUDY TO ASSESS THE
EFFICACY AND SAFETY OF A PLASMA-DERIVED VON WILLEBRAND
PO634-MON
EFFECT OF INR PRECISION AND ACCURACY ON THERAPEUTIC QUALITY FACTOR/FACTOR VIII (VWF/FVIII)CONCENTRATE IN PEDIATRIC, ADOLES-
CONTROL IN PATIENTS RECEIVING VITAMIN K-ANTAGONISTS CENT, AND ADULT SUBJECTS WITH VON WILLEBRAND DISEASE
Anton Van Den Besselaar*, Felix van der Meer (The Netherlands) Toshko Lissitchkov, Anna Klukowska, Kazimierz Kuliczkowski, Evgeny Buevich, Guent-
er Auerswald, Olexandra Stasyshyn, Wilfried Seifert* (Germany)
PO635-MON
HEMIZYGOUS DELETION OF 7Q11.21-Q11.23 ELIMINATING VKORC1L1
DOES NOT IMPAIR BLOOD COAGULATION BUT REVEALS ACCUMULA- PO644-MON
THROMBOCYTOPENIA DURING DDAVP TEST IN TWO CHILDREN WITH
TION OF MENAQUINONE-4 TYPE 2A VON WILLEBRAND DISEASE
Sol Schulman*, Xueyan Fu, Sarah Booth, Benno Rothlisberger, Barbara Furie, Bruce Juan P. Frontroth*, Carolina Pepe, Mirta Hepner, Gabriela Sciuccati, Graciela Pieroni,
Furie (United States) Silvina Annetta, Carolina Cervio, Aurora Feliu-Torres, Mariana Bonduel (Argentina)
182 183
PO645-MON
RULING OUT VON WILLEBRAND DISEASE IN PREOPERATIVE PATIENTS PO655-MON IDENTIFICATION OF LARGE VWF GENE DELETIONS AND DUPLICATIONS
WITH BLEEDING SYMPTOMS BY MLPA IN THE SOUTH MORAVIAN (CZECH REPUBLIC) VWD COHORT
M.J.A. Vries*, M.D. Lance, C.G.M. Van Oerle, R.J.H. Wetzels, E.A.M. Beckers, P.J. IN THE BRNO-VWD STUDY
Nelemans, H. Ten Cate, Y.M.C. Henskens (The Netherlands) Inge Vangenechten*, Petr Smejkal, O Zapletal, J Zavrelova, J Blatny, M Penka, Jan
Jacques Michiels, Alain Gadisseur (Belgium)
PO646-MON
HEALTH-RELATED QUALITY OF LIFE AMONG VON WILLEBRAND DIS-
EASE PATIENTS IS NOT RELATED TO DISEASE SEVERITY. PO656-MON
BASELINE FACTOR VIII PLASMA LEVELS AND AGE AT FIRST BLEEDING
Yan Xu*, Meghan Deforest, Julie Grabell, Wilma Hopman, Paula James (Canada) IN PATIENTS WITH SEVERE FORMS OF VON WILLEBRAND DISEASE
Simona Maria Siboni, Eugenia Biguzzi*, Valeria Caiani, Claudia Mistretta, Paolo Bucc-
PO647-MON
PLASMA-DERIVED, PURIFIED, PASTEURISED VON WILLEBRAND iarelli, Flora Peyvandi (Italy)
FACTOR/FACTOR VIII CONCENTRATE IN THE TREATMENT OF PATIENTS
WITH VON WILLEBRAND DISEASE AND HAEMOPHILIA A: UPDATE OF A PO657-MON TYPE 1 VWD DOES NOT LEAD TO INCREASED GINGIVAL BLEEDING
LONG-TERM OBSERVATIONAL STUDY isa Weickert, Peter Eickholz, Katrin Nickles, Stefanie Krekeler, Wolfgang Miesbac*
L
Cornelia Wermes*, Susanne Holzhauer, Susan Halimeh, Bettina Kemkes-Matthes, (Germany)
Patrick Sommerer, Ivonne Wieland, Manuela Krause (Germany)
PO658-MON JOINT SURGERY IN MODERATE AND SEVERE VON WILLEBRAND
PO648-MON
EVALUATION OF AN ELISA BASED ASSAY FOR DETECTION OF TYPE 2N DISEASE: A CROSS-SECTIONAL STUDY.
VON WILLEBRAND DISEASE arin van Galen, Frank Leebeek, Roger Schutgens*, Marjon Cnossen, Jeroen Eiken-
K
Rachel R. Leger*, Adam Tricker, Julie Tange, Dong Chen, Rajiv Pruthi (United States) boom, Charles Vogely, Karin Fijnvandraat, Karina Meijer, Evelien Mauser-Bunschoten
(The Netherlands)
PO649-MON
NEW INSIGHTS INTO TYPE 3 VON WILLEBRAND DISEASE: THE TYPE 3
MONDAY
VON WILLEBRAND DISEASE INTERNATIONAL REGISTRIES AND INHIBI- PO659-MON ETHNIC AND RACIAL VARIATION OF PLASMA VWF IN HEALTHY
TOR PROSPECTIVE STUDY (3WINTERS-IPS) PROJECT UPDATE CONTROLS
Augusto B Federici*, Flora Peyvandi, Ulrich Budde, Giancarlo Castaman, Jeroen Eiken- Robert R. Montgomery*, Joan Gill, Pamela Christopherson, Veronica Flood, Sandra
boom, Peyman Eshghi, Anne Goodeve, Jenny Goodemand, Hamid Hoorfar, Mehran Haberichter, Thomas Abshire (United States)
Karimi, Ian Peake, Reinhard Schneppenheim, Alberto Tosetto, Pier M Mannucci (Italy)
PO660-MON A COMPARATIVE STUDY OF MICROFLUIDIC FLOW ASSAYS AND CLINICAL
PO650-MON
EFFICACY AND SAFETY OF VON WILLEBRAND FACTOR CONCENTRATE ASSAYS IN TYPE I VON WILLEBRANDS DISEASE
Marcus Lehmann*, Christopher Ng, Jorge Di Paola, Keith Neeves (United States)
POSTERS
WITH A LOW FVIII CONTENT IN SEVERE VWD CHILDREN LESS THAN 6
YEARS OF AGE
Emna Gouider*, Anna Klukowska, Philippe Maes, Helen Platokouki, Wanda Badowska,
PO661-MON TOTAL THROMBUS-FORMATION ANALYSIS SYSTEM (T-TAS) FOR THE
Nathalie Knuchel, Cline Henriet, Franoise Bridey, Claudine Caron, Annie Borel-Der- MONITORING OF VON WILLEBRAND FACTOR-FVIII CONCENTRATE
lon, Balkis Meddeb, Christel Van Geet (Tunisia) TREATMENT IN PATIENTS WITH VON WILLEBRAND DISEASE TYPE 3.
Anna gren*, Paul Hjemdahl, Margareta Blombck, Kazuya Hosokawa, Margareta
PO651-MON
OVERDOSING OF REPLACEMENT THERAPY IN PERIOPERATIVE VON Holmstrm (Sweden)
WILLEBRAND PATIENTS: A LOT TO WIN
Hilde C. Veerman*, Hendrika C.A.M. Hazendonk, Yvonne V. Sanders, Karina Meijer,
PO662-MON SURVEILLANCE STUDY OF SAFETY AND EFFICACY OF A VWF/FVIII
Frank W.G. Leebeek, Marjon H. Cnossen (The Netherlands) CONCENTRATE IN PATIENTS WITH VON WILLEBRAND DISEASE (WIL-20)
A PLANNED INTERIM ANALYSIS
PO652-MON A MICROCHIP FLOW-CHAMBER SYSTEM (T-TAS) REFLECTS THE Kate Khair, Maria Sol Cruz*, Sylvia Werner, Sigurd Knaub, Alfonso Iorio (United Kingdom)
CLINICAL PHENOTYPES IN PATIENTS WITH TYPE 1 VON WILLEBRAND
DISEASE PO663-MON PREDICTORS OF COMPLETE RESPONSE TO DDAVP IN PATIENTS WITH
Keiji Nogami*, Koji Yada, Yasuaki Shida, Kenichi Ogiwara, Shoko Furukawa, Hiroaki VON WILLEBRAND DISEASE
Minami, Hiroaki Yaoi, Tomoko Matsumoto, Midori Shima (Japan) ugenia Biguzzi*, Paolo Bucciarelli, Franca Franchi, Francesca Stufano, Simona Sibo-
E
ni, Luciano Baronciani, Flora Peyvandi (Italy)
PO653-MON THE USE OF NEXT-GENERATION SEQUENCING TO SCREEN FOR
DISORDERS OF COAGULATION USING A 24 GENE PANEL. PO664-MON MAJOR SURGERIES IN CHILDREN AND ADULTS WITH VON WILLEBRAND
Patricia Bignell*, Nicola Curry, Joanne Mason, Pamela Wright, David Keeling, Paul DISEASE MANAGED WITH A HIGH-PURITY HUMAN VWF/FVIII
Giangrande, Shirley Henderson, Anna Schuh (United Kingdom) CONCENTRATE IN A PHYSIOLOGICAL 1:1 RATIO
lok Srivastava, Sylvia Werner, Margit Serban, Bruce Schwartz, Sigurd Knaub, Craig
A
PO654-MON COURSE OF VON WILLEBRAND FACTOR (VWF) DURING PREGNANCY IN Kessler* (United States)
WOMEN WITH VON WILLEBRAND DISEASE (VWD)
ario von Depka*, Carsten Detering, Anja Henkel-Klene, Stefanie Dpke, Emilie von
M
Depka, Mahnaz Ekhlasi-Hundrieser (Germany)
184 185
PO665-MON THE INFLUENCE OF PAI-1 LEVELS ON BLEEDING PHENOTYPE IN PO675-MON ASSESSMENT OF VON WILLEBRAND FACTOR PANEL AND PLATELET
THURSDSAY
MODERATE AND SEVERE VON WILLEBRAND DISEASE FUNCTION IN PATIENTS WITH MODERATE TO SEVERE RENAL
S Abdul*, J Boender, JMC Malfliet, HCJ Eikenboom, K Fijnvandraat, EP Mauser-Bun- INSUFFICIENCY UNDERGOING RENAL BIOPSY
schoten, K Meijer, FWG Leebeek, DC Rijken, S Uitte de Willige (The Netherlands) undarika Suwanawiboon*, Aksara Kajornkijaroen, Yupa Nakkinkun, Tasneem Binha-
B
ma, Ratana Chawanasuntorapoj (Thailand)
PO666-MON DYNAMIC THROMBUS FORMATION IN THE WHOLE BLOOD UNDER THE
SHEAR STRESS RAPIDLY REFLECTS CLINICAL SEVERITY IN TYPE 2N PO676-MON MISSENSE MUTATIONS LOCATED IN THE VON WILLEBRAND FACTOR
VON WILLEBRAND DISEASE (VWF) D1 DOMAIN CAUSE QUANTITATIVE VWF DEFICIENCY THROUGH
oji Yada*, Keiji Nogami, Yasuaki Shida, Masahiro Takeyama, Tomoko Matsumoto,
K IMPAIRMENT OF VWF PACKAGING INTO STORAGE ORGANELLES
WEDNESDAY
Kazuya Hosokawa, Midori Shima (Japan) Mellita Dsouza, Simon Webster, Jessica McMaster, Ashley Cartwright, Ulrich Budde,
Ian Peake, Anne Goodeve, Daniel J. Hampshire* (United Kingdom)
PO667-MON FUNCTIONAL CHARACTERISATION OF A NOVEL SPLICE MUTATION,
C.7887+2T>A, ASSOCIATED WITH TYPE 1 VON WILLEBRAND DISEASE PO677-MON MINIMUM LEVELS OF VON WILLEBRAND FACTOR AND PLATELETS TO
shley Cartwright, Simon Webster, Paula Jacobi, Nicholas Hickson, Ulrich Budde, Ian
A CREATE OCCLUSIVE HIGH SHEAR THROMBOSIS
Peake, Anne Goodeve, Sandra Haberichter, Daniel J. Hampshire* (United Kingdom) Lauren D. C. Casa*, Scott Gillespie, David Ku (United States)
PO668-MON DYNAMIC THROMBUS FORMATION IN THE WHOLE BLOOD UNDER THE PO678-MON AGING AND ABO BLOOD TYPE REGULATE VON WILLEBRAND FACTOR
SHEAR STRESS RAPIDLY REFLECTS THE HEMOSTATIC POTENTIAL(S) OF AND FACTOR VIII LEVELS THROUGH DISTINCT PATTERNS OF BOTH
TYPE 2A VON WILLEBRAND DISEASE UNEVALUATABLE BY SECRETION AND CLEARANCE
TUESDAY
PLASMA-BASED STATIC ASSAY. Silvia Albnez*, Kenichi Ogiwara, Julie Grabell, Paula James, David Lillicrap (Canada)
oji Yada*, Keiji Nogami, Yasuaki Shida, Masahiro Takeyama, Tomoko Matsumoto,
K
MONDAY
Kazuya Hosokawa, Midori Shima (Japan)
PO669-MON CO-OCCURRENCE OF V.WILLEBRAND DISEASE AND BERNARD

SOULIER-SYNDROME
Carl-Erik Dempfle*, Parviz Ahmad-Nejad, Thomas Alef, Andrea Dornbach, Bernhard
Thiele (Germany)
MONDAY
POSTERS
Von Willebrand Factor I
PO670-MON IDENTIFICATION AND CHARACTERIZATION OF ABERRANT SPLICING

FROM A NOVEL BRANCH SITE MUTATION IN VON WILLEBRAND FACTOR
Lindsey Hawke*, Georges Rivard, Paula James (Canada)
PO671-MON FUNCTIONAL LINK BETWEEN VON WILLEBRAND FACTOR (VWF) AND
SUNDAY
TISSUE FACTOR (TF) IN FLOW-DEPENDENT THROMBUS FORMATION:
AUGMENTATION OF INTRA-THROMBUS FIBRIN GENERATION BY
CATHEPSIN G ON VWF-TF COMPLEX
Yasunori Matsunari*, Hideto Matsui, Masahiko Kawaguchi, Mitsuhiko Sugimoto (Japan)
PO672-MON THROMBIN-DEPENDENT INCORPORATION OF VON WILLEBRAND

FACTOR INTO A FIBRIN NETWORK
Adam Miszta, Leonie Pelkmans*, Theo Lindhout, Philip de Groot, Coenraad Hemker,
SATURDAY
Johan Heemskerk, Hilde Kelchtermans, Bas de Laat (The Netherlands)
PO673-MON MIR-24 REGULATES VON WILLEBRAND FACTOR IN DIABETES

Yaozu Xiang*, Jijun Cheng, Jun Lu, Kathleen Martin, John Hwa (United States)
PO674-MON THE FIRST CASE OF AN INTRON RETENTION RESULTING FROM A

SILENT MUTATION IN THE VWF WHICH EXERTS A STRUCTURAL IMPACT
ON THE 5` SPLICE SITE
amideh Yadegari Baharanchi*, Arijit Biswas, Julia Diesen, Vytautas Ivaskevicius,
H
Natascha Marquardt, Johannes Oldenburg (Germany)
186 187
Notes
Scientific Program
Tuesday, June 23
Trainee Tracks (oral sessions only):
Platelets track
Basic thrombosis and hemostasis track
Clinical bleeding track
Clinical thrombosis track
Cardiovascular and arterial diseases track
An asterisk (*) after a name denotes the presenting author
188 189
08:30 08:45 CROSS-SECTIONAL ASSOCIATIONS OF 25-HYDROXYVITAMIN D WITH
THURSDSAY
8:00-09:15 OR133 HEMOSTATIC AND INFLAMMATORY BIOMARKERS IN THE MULTI-ETHNIC
STUDY OF ATHEROSCLEROSIS
ORAL COMMUNICATIONS 3 08:00-09:15 arc Blondon, Mary Cushman, Nancy Jenny, Erin Michos, Nicholas Smith, Bryan
M
Kestenbaum, Ian de Boer (Switzerland)
Cancer and thrombosis clinical I Plenary Hall F&G 08:45 09:00 UNPROVOKED DEEP VEIN THROMBOSIS IS ASSOCIATED WITH FUTURE
Moderators: Simon Noble (United Kingdom), Howard Liebman (United States) OR134 RISK OF DISABILITY PENSION
igrid Braekkan, Scott Grosse, Ekwutosi Okoroh, James Tsai, Suzanne Cannegieter, In-
S
WEDNESDAY
ger Anne Naess, Steinar Krokstad, John-Bjarne Hansen, Finn-Egil Skjeldestad (Norway)
08:00 08:15 RISK OF CARDIOVASCULAR EVENTS ASSOCIATED WITH BCR-ABL TKIS:
OR126 A SYSTEMATIC REVIEW AND META-ANALYSIS 09:00 09:15 SEX DIFFERENCE IN THE RISK OF VENOUS THROMBOSIS: A DETAILED
J onathan Douxfils*, Hlne Haguet, Franois Mullier, Christian Chatelain, Carlos OR135 ANALYSIS IN FOUR EUROPEAN COHORTS
Graux, Jean-Michel Dogn (Belgium)
TUESDAY
achel Roach*, Willem Lijfering, R. Tait, Trevor Baglin, Paul Kyrle, Suzanne Cannegi-
R
eter, Frits Rosendaal (The Netherlands)
08:15 08:30 DIFFERENCES IN VENOUS THROMBOEMBOLIC EVENTS IN SUBJECTS
OR127 ENROLLED IN STANDARD PHASE I CLINICAL TRIALS AND THOSE ON
PHASE I HEPATIC DYSFUNCTION CLINICAL TRIALS Immune thrombocytopenia basic Room 701
aron Mansfield*, Alfonso Tafur, Diana Vulih, Gary Smith, Pamela Jo Harris, S. Percy
A
Moderators: Alan Lazarus (Canada), Michelle Lambert (United States)
TUESDAY
Ivy (United States)
08:30 08:45 RISK FACTORS FOR INCIDENT VENOUS THROMBOEMBOLISM IN ACTIVE 08:00 08:15 THE DEFECTIVE IL-21/IL-21R PATHWAY IN THE B LYMPHOCYTES OF
ORALS
OR128 CANCER PATIENTS: A POPULATION BASED CASE-CONTROL STUDY OR136 PATIENTS WITH IMMUNE THROMBOCYTOPENIA
neel A. Ashrani*, Rachel Gullerud, Tanya Petterson, Randolph Marks, Kent Bailey,
A Donglei Zhang*, Liu Wenjie, Li Huiyuan, Zhang Xian, Xue Feng, Yang Renchi (China)
John Heit (United States)
08:15 08:30 SOLUBLE COSTIMULATORY FACTORS SB7-H2, SB7-H3 IN RELATION TO
08:45 09:00
COHORT PROFILE: THE SCANDINAVIAN THROMBOSIS AND CANCER OR137 PLATELET AUTOANTIBODIES IN PATIENTS WITH IMMUNE
OR129 (STAC) STUDY THROMBOCYTOPENIC PURPURA
MONDAY
Hilde Jensvoll*, Marianne Severinsen, Jens Hammerstrm, Sigrid Brkkan, Sren Weihong Shen*, Yang He (China)
Kristensen, Suzanne Cannegieter, Kristine Blix, Anne Tjnneland, Frits Rosendaal,
Olga Dziewiecka, Kim Overvad, Inger Anne Nss, John-Bjarne Hansen (Norway) 08:30 08:45 HIGH-DOSE DEXAMETHASONE CORRECTS IMPAIRED MYELOID-DERIVED
OR138 SUPPRESSOR CELL FUNCTIONS VIA POSITIVE CROSSTALK BETWEEN
09:00 09:15 PREDICTION OF VENOUS THROMBOEMBOLISM IN LUNG CANCER GLUCOCORTICOID RECEPTOR AND ETS1 IN IMMUNE
OR130 PATIENTS RECEIVING CHEMOTHERAPY THROMBOCYTOPENIA
Simon Noble*, Andrew Robbins, Raza Alikhan, Kerenza Hood, Fergus Macbeth (United Yu Hou*, Miao Xu, Qi Feng, Yingyi Yu, Xuena Liu, Ming Hou, Jun Peng (China)
Kingdom)
08:45 09:00 SUPPRESSION OF CELL-MEDIATED IMMUNE THROMBOCYTOPENIA (ITP)
SUNDAY
Venous thromboembolism epidemiology II Room 718 OR139 BY B CELL DEPLETION THERAPY IN A MURINE MODEL.
Li Guo*, Edwin Speck, Rukhsana Aslam, Rick Kapur, Heyu Ni, John Semple (Canada)
Moderators: Sarah Lapner (Canada), Daniel Witt (United States)
09:00 09:15 STAT1 SINGLE NUCLEOTIDE POLYMORPHISMS AND SUSCEPTIBILITY TO
08:00 08:15 RISK OF VENOUS THROMBOSIS IN INDIVIDUALS USING VITAMIN OR140 IMMUNE THROMBOCYTOPENIA
OR131 SUPPLEMENTS: A CASE-CONTROL STUDY Zhenping Chen*, Zhenxing Guo, Jingyao Ma, Chao Gao, Runhui Wu (China)
iljana Vuckovic*, Nienke van Rein, Suzanne Cannegieter, Frits Rosendaal, Willem
B
Lijfering (Serbia)
SATURDAY
Hemophilia inhibitors Room 801

08:15 08:30 THE INCIDENCE OF CHRONIC THROMBOEMBOLIC PULMONARY
Moderators: Georges Rivard (Canada), Pl Andre Holme (Norway)
OR132 HYPERTENSION AND THE PREDICTIVE VALUE OF RESIDUAL ARTERIAL
PULMONARY OBSTRUCTION: RESULTS FROM A LARGE, MULTICENTRE,
08:00 08:15 DO VACCINATIONS INFLUENCE THE RISK OF INHIBITOR DEVELOPMENT
PROSPECTIVE COHORT STUDY
OR141 IN PATIENTS WITH SEVERE HEMOPHILIA A?
affaele Pesavento*, Lucia Filippi, Antonio Palla, Annachiara Frigo, Adriana Vison,
R
SM Hashemi*, K Fischer, SC Gouw, A Rafowicz, M Carcao, H Platokouki, G Kenet, R
Carlo Bova, Stefano Cuppini, Fernando Porro, Sabina Villalta, Maurizio Ciammaichella,
Liesner, K Kurnik, G Rivard, HM van den Berg (The Netherlands)
Eugenio Bucherini, Giovanni Nante, Sandra Battistelli, Giampietro Beltramello, Dome-
nico Prisco, Paolo Prandoni (Italy)
190 191
08:30 08:45 PLASMA-DERIVED FACTOR VIII PRODUCTS AND INHIBITOR 09:00 09:15 LIPID LEVELS AND RISK OF VENOUS THROMBOSIS: RESULTS FROM
THURSDSAY
OR143 DEVELOPMENT IN PREVIOUSLY UNTREATED BOYS WITH SEVERE OR150 THE MEGA STUDY
HEMOPHILIA A : REPORT OF THE FRANCECOAG NETWORK Vnia M. Morelli*, Willem Lijfering, Frits Rosendaal, Suzanne Cannegieter (Brazil,
Jenny Goudemand*, Chantal Rothschild, Roseline dOiron, Virginie Demiguel, Vincent Netherlands)
Dalibard, Marguerite Micheau, Patrick Lutz, Yves Gruel, Christine Vinciguerra, Herv
Chambost, Thierry Calvez (France)
TTP and PNH from basic science to clinical practice Room 716
08:45 09:00
DETERMINANTS OF INHIBITOR DEVELOPMENT IN PREVIOUSLY
Moderators: Ian J. Mackie (United Kingdom), Karen Vanhoorelbeke (Belgium)
OR144 TREATED HEMOPHILIA A PATIENTS
Alfonso Iorio*, Angela Barbara, Giancarlo Castaman, Katheleijn Fischer, Estelle Gil-
WEDNESDAY
08:00 08:15 RECOMBINANT ADAMTS13 AS AN EFFECTIVE THERAPY FOR ACQUIRED
man, Jenny Goudemand, Khan Kavakli, Cornelia Kubicek-Hofmann, Thierry Lambert,
T Lissitchkov, Michael Makris, Prasad Matthew, Maria Eva Mingot Castelano, Nahil
OR151 THROMBOTIC THROMBOCYTOPENIC PURPURA IN RATS
Ozdemir, R Parra, Kathelijne Peerlinck, G Rivolta, Vadim Romanov, Valrie Rous- laudia Tersteeg*, Alexandra Schiviz, Barbara Plaimauer, Simon De Meyer, Friedrich
C
sel-Robert, Annarita Tagliaferri, Jerzy Windyga, Ezio Zanon (Canada) Scheiflinger, Karen Vanhoorelbeke, Hanspeter Rottensteiner (Belgium)
TUESDAY
09:00 09:15 ITI FOR INHIBITORY ANTIBODIES IN BOYS WITH SEVERE HAEMOPHILIA 08:15 08:30 HEREDITARY TTP A YOUNG PATIENT POPULATION WITH HIGH
OR145 A AT EIGHT UK CHILDRENS CENTRES 2003-2013 OR152 PREVALENCE OF ARTERIAL THROMBOEMBOLIC EVENTS. FIRST
ary Mathias*, Jayanthi Alamelu, Peter Collins, Jeanette Payne, Mike Richards, Oliver
M RESULTS FROM THE HEREDITARY TTP REGISTRY
Tunstall, Mike Williams, Tina Biss, Elizabeth Chalmers (United Kingdom) Magnus Mansouri, Masanori Matsumoto, Zuzana Cermakova, Kenneth Friedman,
James George, Ingrid Hrachovinova, Paul Knbl, Koichi Kokame, Anne Sophie von
TUESDAY
Krogh, Reinhard Schneppenheim, Sara Vesley, Yoshihiro Fujimura, Bernhard Lmmle,
Risk factors for venous thrombosis I Room 714 Johanna A. Kremer Hovinga* (Switzerland)
ORALS
Moderators: Scott Stevens (United States), Stephan Moll (United States) 08:30 08:45 ENDOGENOUS PLASMIN LEVELS CONTROL THE DEVELOPMENT OF
OR153 ACUTE EPISODES OF THROMBOTIC THROMBOCYTOPENIC PURPURA IN
08:00 08:15 RISK FACTORS OF RESIDUAL PERFUSION DEFECTS AFTER A FIRST MICE
OR146 EPISODE OF UNPROVOKED PE: RESULTS FROM THE PADIS PE Claudia Tersteeg*, Louis Deforche, Ann Gils, Hans Deckmyn, Paul Declerck, Hans-
MULTICENTER, DOUBLE-BLIND, RANDOMIZED TRIAL peter Rottensteiner, Coen Maas, Simon De Meyer, Karen Vanhoorelbeke (Belgium)
Olivier Sanchez*, Ccile Tromeur, Pierre Yves Leroux, Emilie Presles, Patrick Mismetti,
MONDAY
Patrick Jego, Gilles Pernod, Elisabeth Duhamel, Karine Provost, Philippe Castellant, 08:45 09:00 COVERSIN, A NOVEL COMPLEMENT C5 INHIBITOR AND POTENTIAL
Florence Parent, Pierre Yves Salaun, Michel Nonent, Philippe Girard, Karine Lacut, OR154 THERAPEUTIC AGENT, PREVENTS C5 ACTIVATION IN PATIENTS WITH C5
Solen Mlac, Marie Gugan, Gisle Marhic, Silvy Laporte, Christophe Leroyer, Herv POLYMORPHISMS
Dcousus, Dominique Mottier, Guy Meyer, Francis Couturaud (France)
Ian J. Mackie*, Andrew Chitolie, Miles Nunn, Wynne Weston-Davies, Samuel Machin
(United Kingdom)
08:15 08:30 EVOLUTIONARY CONSERVATION OF AUTOINHIBITORY B-DOMAIN
OR147 REGIONS IN BLOOD COAGULATION FACTOR V OF THE SUBORDER 09:00 09:15 LONG-TERM GENE THERAPY FOR THROMBOTIC THROMBOCYTOPENIC
SERPENTES OR155 PURPURA USING THE SLEEPING BEAUTY TRANSPOSON SYSTEM
Danil Verhoef*, Ka Lei Cheung, Hans Vos, Ryan McCleary, Manjunatha Kini, Pieter
SUNDAY
Sebastien Verhenne*, Nele Vandeputte, Inge Pareyn, Zsuzsanna Izsvak, Hanspeter
Reitsma, Mettine Bos (The Netherlands) Rottensteiner, Hans Deckmyn, Simon F De Meyer, Karen Vanhoorelbeke (Belgium)
08:30 08:45 IDENTIFICATION OF NEW GENETIC RISK FACTORS FOR RECURRENT

OR148 VENOUS THROMBOSIS Pediatric thrombosis Room 713
ugoline G. de Haan*, Marine Germain, Trevor Baglin, Jean-Francois Deleuze, Da-
H
vid-Alexandre Trgout, Frits Rosendaal, Astrid van Hylckama Vlieg (The Netherlands) Moderators: Laura Avila (Canada), Brian Branchford (United States)
08:45 09:00 RISK FACTORS OF RECURRENT VENOUS THROMBOEMBOLISM IN 08:00 08:15 CHILDRENS HOSPITAL-ACQUIRED THROMBOSIS DATABASE (CHAT):
SATURDAY
OR149 PATIENTS WITH A FIRST EPISODE OF UNPROVOKED PULMONARY OR156 A MULTI-INSTITUTIONAL DATABASE FOR PROSPECTIVE
EMBOLISM: RESULTS FROM THE PADIS PE MULTICENTER, IDENTIFICATION OF INDEPENDENT RISK FACTORS
DOUBLE-BLIND, RANDOMIZED TRIAL Brian R. Branchford*, Julie Jaffray, Arash Mahajerin, Neil Goldenberg, Guy Young
Francis Couturaud*, Olivier Sanchez, Emilie Presles, Pierre Yves Salaun, Gilles Pernod, (United States)
Patrick Mismetti, Patrick Jego, Elisabeth Duhamel, Karine Provost, Claire Bal Dit
Solier, Philippe Castellant, Florence Parent, Luc Bressollette, Philippe Girard, Karine 08:15 08:30 CORRELATION BETWEEN ACTIVATED PARTIAL THROMBOPLASTIN TIME
Lacut, Solen Mlac, Marie Gugan, Silvy Laporte, Christophe Leroyer, Herv Dcousus, OR157 (APTT) AND ANTI-FXA ASSAY IN CHILDREN ON UNFRACTIONATED
Guy Meyer, Dominique Mottier (France) HEPARIN (UFH) THERAPY: AN INSTITUTIONAL EXPERIENCE
Gary Woods*, Sheilah Harrison, Karen Texter, Joseph Stanek, Amy Dunn, Bryce Kerlin,
Riten Kumar (United States)
192 193
08:30 08:45 AGE IS MAIN CLINICAL RISK FACTOR FOR VENOUS
Inflammation Room 717
THURSDSAY
OR158 THROMBOEMBOLISM WITHIN A LARGE COHORT OF CHILDREN WITH
ACUTE LYMPHOBLASTIC LEUKEMIA Moderators: Ed Conway (Canada), Emilie Lameignere (Canada)
Mandy N. Lauw*, Irene Klaassen, Marianne Van de Wetering, Inge Van der Sluis, Rob
Pieters, C. Heleen Van Ommen (The Netherlands) 08:00 08:15 PLATELET FACTOR 4 REGULATES B CELL DIFFERENTIATION
OR166 Craig Morrell*, David Field, Sara Ture (United States)
08:45 09:00 OUTCOMES OF LOWER LIMB DEEP VEIN THROMBOSIS AND
OR159 PREDICTORS OF LOWER LIMB POST-THROMBOTIC SYNDROME IN 08:15 08:30 EXTRACELLULAR RNA INDUCES VENOUS THROMBOSIS THROUGH TLR3
PEDIATRIC PATIENTS OR167 atherine A. Lemarie*, Manraj Sidhu, Le Angela, Sandrine Laurance, Francois-Rene
C

WEDNESDAY
aura L. Avila*, Aida Gordanpour, Hosay Said, Heather Rotz, Suzan Williams, Walter
L Bertin, Mark Blostein (Canada)
Kahr, Leonardo Brandao (Canada)
08:30 08:45 CIRCULATING HISTONES DISTURB INTRACELLULAR CALCIUM
09:00 09:15 DIAGNOSIS AND MANAGEMENT OF VENOUS THROMBOEMBOLISM (VTE) OR168 HOMEOSTASIS AND CAUSE CALCIUM OVERLOAD TO INDUCE
OR160 IN CHILDREN: A PROSPECTIVE 22-YEAR REGISTRY FROM A SINGLE CARDIOVASCULAR ABNORMALITIES IN SEPSIS
TUESDAY
TERTIARY CENTER IN ARGENTINA asir Alhamdi, Simon Abrams, Min Zi, Ingeborg Welters, Elizabeth Cartwright,
Y
abriela Sciuccati, Mirta Hepner, Carolina Cervio*, Graciela Pieroni, Eliana Annetta, Au-
G Guozheng Wang, Cheng-Hock Toh* (United Kingdom)
rora Feliu Torres, Nicols Fernndez Ponce, Juan Frontroth, Mariana Bonduel (Argentina)
08:45 09:00 PLATELET GRANULE RELEASE IS CRUCIAL FOR VASCULAR
OR169 INTEGRITY IN THE ISCHEMIC BRAIN BUT NOT IN THE INFLAMED SKIN
Factor VIII II Room 715
TUESDAY
OR LUNG
Moderators: Antonia Follenzi (Italy), Juan Souto (Spain) arsten Deppermann*, Peter Kraft, Karen Wolf, Paquita Nurden, Guido Stoll, David
C
ORALS
Stegner, Bernhard Nieswandt (Germany)
08:00 08:15 HEMATOPOIETIC CELLS A NOVEL TARGET FOR HEMOPHILIA A CELL
09:00 09:15 DUAL ACTION OF PLATELETS AND GLYCOPROTEIN-VI IN IMMUNE
OR161 THERAPY
OR170 COMPLEX-MEDIATED INFLAMMATION
Diego Zanolini*, Simone Merlin, Alessio Stevano, Mauro Zaffaroni, Guido Valente,
Maria Prat, Antonia Follenzi (Italy)
ngle Gros*, Lamia Lamrani, Vronique Ollivier, Varouna Syvannarath, Stphane
A
Loyau, Tobias Goerge, Bernhard Nieswandt, Martine Jandrot-Perrus, Benot Ho-Tin-No
(France)
08:15 08:30 RELATIONS BETWEEN FACTOR ACTIVITY LEVEL AND JOINT BLEEDING
MONDAY
OR162 IN A LARGE COHORT OF MALES WITH MILD AND MODERATE
HEMOPHILIA IN THE UNITED STATES Microparticles I Room 705
ike Soucie*, Paul Monahan, Marshall Mazepa, Roshni Kulkarni, Barbara Konkle
M
(United States) Moderators: Eric Boilard (Canada), Rafal Pawlinski (United States)
08:30 08:45 CHARACTERIZATION OF INTERACTIVE SITES OF ACTIVATED 08:00 08:15 THE ROLE OF BREAST CANCER CELL MICROVESICLES IN
OR163 COAGULATION FACTOR VIII AND LOW-DENSITY LIPOPROTEIN OR171 THROMBOGENICITY, ANGIOGENESIS AND APOPTOSIS FOLLOWING
RECEPTOR-RELATED PROTEIN 1 CHEMOTHERAPY
SUNDAY
James Kurasawa, Svetlana Shestopal, Timothy Lee, Andrey G. Sarafanov* (United Anat Aharon*, Gil Barsela, David Loven, Benjamin Brenner (Israel)
States)
08:15 08:30 CIRCULATING MICROPARTICLES IN DEFICIENCY OF THE NATURAL
08:45 09:00 ACCUCOPY QUANTIFICATION COMBINED WITH PRE-AMPLIFICATION OF OR172 ANTICOAGULANTS
OR164 LONG-DISTANCE PCR FOR FAST GENOTYPING OF INT22H-RELATED Elena Campello*, Luca Spiezia, Claudia Radu, Cristiana Bulato, Sabrina Gavasso,
INVERSIONS IN HEMOPHILIA A Daniela Tormene, Barry Woodhams, Paolo Simioni (Italy)
Qian Liang*, Qiulan Ding, Xi Wu, Zhengwen Jiang, Xuefeng Wang (China)
08:30 08:45 CELLULAR MICROPARTICLES AS PREDICTIVE MARKERS FOR
SATURDAY
09:00 09:15 IN VIVO STUDIES OF EFFICACY AND POTENTIAL IMMUNOGENICITY OF OR173 THROMBOSIS AND OTHER CLINICAL EVENTS IN PATIENTS WITH
OR165 HUMAN FACTOR VIII PACE-FURIN DELETION VARIANTS IMPLANTED LVADS
Giang N. Nguyen*, Lindsey Greene, Robert Davidson, Denise Sabatino (United States) J eanine M. Walenga*, Bryan Menapace, Walter Jeske, Erin Coglianese, Vicki Escalante,
Emmanuel Kumar, Jeffrey Schwartz, Alain Heroux, Mamdouh Bakhos (United States)
08:45 09:00 ANALYSIS OF EXOSOME-LIKE MEMBRANE MICROPARTICLES RELEASED

OR174 FROM TRAP-ACTIVATED PLATELETS
Silvia De Paoli, Tseday Tegegn, Michael Strader, Ivan Tarandovskiy, Martina
Orecna, Oumsalama Elhelu, Mikhail Ovanesov, Abdu Alayash, Jan Simak* (United
States)
194 195
09:00 09:15 PEPTIDYL-PROLYL ISOMERASE 1 (PIN1) PRESERVES THE 08:45 09:00 G PROTEIN-COUPLED RECEPTOR KINASE 6 REGULATES PLATELET
THURSDSAY
OR175 PHOSPHORYLATION STATE OF TISSUE FACTOR AND PROLONGS THE OR184 ACTIVATION AND THROMBUS FORMATION THROUGH SELECTIVE GPCR
RELEASE OF TF WITHIN MICROVESICLES DESENSITIZATION
Camille Ettelaie*, Anthony Maraveyas, Mary Collier (United Kingdom) Dheeraj Bhavanasi, Rachit Badolia, Soochong Kim* (United States)
09:00 09:15 PROCOAGULANT PLATELETS ARE UNDERGOING CYCLOPHILIN D

Rare bleeding disorders Room 707 OR185 MEDIATED NECROSIS WITH DIFFERENTIAL INVOLVEMENT IN
Moderators: John Wu (Canada), David Ginsburg (United States) OCCLUSIVE VERSUS NON-OCCLUSIVE MODELS OF THROMBOSIS.
Minh Hua*, Latasha Abeynaike, Robert Lindeman, Philip Hogg, Vivien Chen (Australia)
WEDNESDAY
08:00 08:15 DIAGNOSIS OF INHERITED BLEEDING, THROMBOTIC AND PLATELET
OR176 DISEASES BY NEXT GENERATION SEQUENCING Antiphospholipid antibodies II Room 711
Ilenia Simeoni* (United Kingdom)
Moderators: Jacob Rand (United States), Stphane Zuily (France)
TUESDAY
08:15 08:30 ANTITHROMBIN REDUCTION IMPROVES COAGULATION IN RARE
OR177 BLEEDING DISORDER PLASMA 08:00 08:15 ACTIVATED PROTEIN C RESISTANCE DETERMINED BY THROMBIN
Alfica Sehgal*, Kun Qian, Julia Hettinger, Benny Sorensen, Akin Akinc (United States) OR186 GENERATION IS PREDICTIVE OF THROMBOSIS IN
ANTIPHOSPHOLIPID-POSITIVE PATIENTS AND ASSOCIATED
08:30 08:45 LONG-TERM CORRECTION OF CANINE FVII DEFICIENCY USING AUTO-IMMUNE DISEASES. A MULTICENTER PROSPECTIVE COHORT
OR178 AAV-MEDIATED EXPRESSION OF ZYMOGEN FVII
TUESDAY
STUDY
Oscar A Marcos-Contreras*, Shannon Smith, Dwight A Bellinger, Elizabeth Merricks, Stphane Zuily*, Veronique Regnault, Shirine Mohamed, Claire Lamboux-Matthieu,
Armida Faella, Giulia Pavani, Shangzhen Zhou, Timothy Nichols, Katherine High, Paris
ORALS
Anne-Christine Rat, Jacques Ninet, Nadine Magy-Bertrand, Jean-Louis Pasquali, Marc
Margaritis (United States) Lambert, Bernard Lorcerie, Pierre Kaminsky, Francis Guillemin, Denis Wahl (France)
08:45 09:00 ENGINEERED TRANSCRIPTION FACTORS (TALE-TF) AS POTENTIAL 08:15 08:30 EFFECTS OF NEW (DIRECT) ORAL ANTICOAGULANTS ON LUPUS
OR179 THERAPEUTIC STRATEGY FOR COAGULATION FACTOR DEFICIENCIES OR187 ANTICOAGULANT ASSAYS
CAUSED BY PROMOTER MUTATIONS J ovan Antovic*, Aleksandra Antovic, Eva-Marie Norberg, Maria Berndtsson, Mika
Elena Barbon*, Silvia Pignani, Alessio Branchini, Francesco Bernardi, Mirko Pinotti, Skeppholm (Sweden)
MONDAY
Matteo Bovolenta (Italy)
08:30 08:45 OBSTETRIC ANTIPHOSPHOLIPID SYNDROME: EARLY LMWH-INDUCED
09:00 09:15 STUDIES OF MCFD2 KNOCKOUT MICE SUGGEST ALTERNATIVE OR188 VARIATIONS OF ANGIOGENIC FACTORS PREDICT PLACENTA-MEDIATED
OR180 PATHWAYS FOR FV, FVIII AND ALPHA-1-ANTITRYPSIN SECRETION PREGNANCY COMPLICATIONS.
Bin Zhang*, Chunlei Zheng, Min Zhu, Lesley Everret, David Ginsburg (United States) J ean-Christophe R. Gris*, Sylvie Bouvier, Graldine Lavigne, Eva Nouvellon, Erick Mer-
cier, Jean-Philippe Galanaud, Isabelle Qur, Cline Chauleur, Pierre Mars (France)
Platelets Signal Transduction I Room 709
08:45 09:00 INCREASED RISK FOR PULMONARY HYPERTENSION ASSOCIATED WITH
Moderators: Stephen Watson (United Kingdom), Jos Lopez (United States) OR189 ANTIPHOSPHOLIPID ANTIBODIES IN PATIENTS WITH SYSTEMIC LUPUS
SUNDAY
ERYTHEMATOSUS. A META-ANALYSIS OF ECHOCARDIOGRAPHIC STUDIES
08:00 08:15 A NOVEL KNOCK-IN MOUSE REVEALS AN ESSENTIAL ROLE FOR THE- Stphane Zuily*, Vinicius Domingues, Denis Wahl (France)
OR181 CLEC-2 HEMITAM IN DEVELOPMENT
Elizabeth Haining*, David Stegner, Bernhard Nieswandt (Germany) 09:00 09:15 OBSTETRIC ANTIPHOSPHOLIPID SYNDROME: EARLY LMWH-INDUCED
OR190 VARIATIONS OF ANGIOGENIC FACTORS PREDICT PREGNANCY LOSS.
08:15 08:30 APOLIPOPROTEIN A-I ENHANCES PROTEASE-ACTIVATED RECEPTOR J ean-Christophe R. Gris*, Sylvie Bouvier, Graldine Lavigne, Eva Nouvellon, Erick
OR182 1-DEPENDENT CYTOPROTECTIVE SIGNALING BY ACTIVATED PROTEIN C Mercier, Jean-Philippe Galanaud, Isabelle Qur, Pierre Mars (France)

SATURDAY
Eimear Gleeson, Owen Smith, James ODonnell, Roger J. Preston* (Ireland)
08:30 08:45 REGULATION OF INTEGRIN ALPHAIIBBETA3-MEDIATED PLATELET Coffee break time in the exhibition (Level 800)
OR183 SPREADING BY THE RECEPTOR-LIKE TYROSINE PHOSPHATASES From 09:15 to 09:45
PTPRA AND PTPRE
Jun Mori, Luke Boothman*, Craig Hughes, Joao Correia, Silke Heising, Jeroen Den Her-
tog, Ilaria Canobbio, Mauro Torti, Jan Sap, David Varon, Ari Elson, Yotis Senis (United
Kingdom)
196 197
Evolving role of the intrinsic pathway Room 714
THURSDSAY
Moderator: Harry R. Bller (The Netherlands)
10:45 - 11:05 Medical device-induced thrombosis: What causes it and how can we prevent
it?
J. Fraser Mustard Plenary Lecture Hall F&G Jeff Weitz (Canada)
Moderator: Margaret Rand (Canada)
11:05 - 11:25 Extracellular DNA and histones: Double-edged swords in immunothrombosis
WEDNESDAY
Patricia Liaw (Canada)
09:45 -10:30 Platelets, NETs and Immunity
Paul Kubes (Canada) 11:25 - 11:45 Polyphosphate as modulator of hemostasis and thrombosis
Jim Morrissey (United States)
TUESDAY
Opening vessels: From fibrinolysis to interventions Room 718
Moderator: Robert Medcalf (Australia)
TUESDAY
STATE OF THE ART

10:45 - 11:05 Basic mechanisms and regulation of fibrinolysis
Colin Longstaff (United Kingdom)
11:05 - 11:25 Interventional therapy for VTE

J. Fraser Mustard, 1927-2011 Suresh Vedantham (United States)
11:25 - 11:45 Treatment of acute ischemic stroke: From fibrinolysis to neurointervention

Tuesday, June 23, 2015 Brian van Adel (Canada)
MONDAY
STATE-OF-THE-ART LECTURES 10:45-11:45
Longer-acting clotting factor concentrates Plenary Hall F&G
Moderators: Rita Lassila (Finland); Alfonso Iorio (Canada)
Genetics of megakaryocytes and platelets Room 801
Moderator: Jane Freedman (United States) 10:45 - 11:05 FVIII-Fc fusion protein for the treatment of hemophilia A
Jerry Powell (United States)
10:45 -11:15 Genetic regulation of megakaryocyte and platelet function
SUNDAY
Andy Weyrich (United States) 11:05 - 11:25 Half-life extended factor VIII for the treatment of hemophilia A
Andreas Tiede (Germany)
11:15 - 11:45 The formation of platelets: Lessons learned from population and rare dis-
ease cases genomics 11:25 - 11:45 Hepatic stem cells and related microparticles as treatment for hemophilia
Willem Ouwehand (United Kingdom) Etienne Sokal (Belgium)
Making Platelets for Transfusion Room 701 Atherothrombosis Room 716

SATURDAY
Moderator: Erik Yeo (Canada) Moderator: Per Morten Sandset (Norway)
10:45 - 11:15 Towards a self-renewing megakaryocyte 10:45 -11:15 Genetics and genomics of coronary artery disease
Koji Eto (Japan) Tim Assimes (United States)
11:15 - 11:45 Road blocks in making platelets for transfusion 11:15 - 11:45 Persistent platelet activation and coagulant activity in atherothrombosis
Jonathan Thon (United States) Judith Cosemans (The Netherlands)
198 199
Thrombotic Thrombocytopenic Purpura Room 713 15:00 15:15 A PROSPECTIVE ALGORITHM INCORPORATING LIMITED AND
THURSDSAY
OR195 WHOLE-LEG ASSESSMENT OF THE DEEP VENOUS SYSTEM IN
Moderator: Kenneth Clemetson (Switzerland) SYMPTOMATIC OUTPATIENTS (THE PALLADIO STUDY)
Walter Ageno*, Giuseppe Camporese, Nicoletta Riva, Angelo Ghirarduzzi, Eugenio
10:45 -11:15 Long-term outcomes and pregnancy outcomes in TTP Bucherini, Marc Righini, Pieter Kamphuisen, Peter Verhamme, James Douketis, Chiara
Sara Vesely (United States) Tonello, Paolo Prandoni (Italy)
11:15 - 11:45 ADAMTS13, thrombotic microangiopathies, and eculizumab NOAC bleeding risk factors and management Room 718
Spero Cataland (United States)
WEDNESDAY
Moderators: Steen Husted (Denmark), Kerstin de Wit (Canada)
Lunch in the exhibition (Level 800) 14:00 14:15 INFLUENCE OF ABCB1 GENOTYPE AND OF A P-GP DRUG INHIBITOR,
OR196 CLARITHROMYCIN, ON DABIGATRAN AND RIVAROXABAN
From 11:45 to 12:15
TUESDAY
PHARMACOKINETIC PROFILES IN HEALTHY VOLUNTEERS
Isabelle Gouin-Thibault*, Xavier Delavenne, Anne Blanchard, Virginie Siguret, Pascale
Lunch Symposia Gaussem, Christian Funck-Brentano, Michel Azizi, Patrick Mismetti, Marie-Anne Loriot
(France)
From 12:15 to 13:45
14:15 14:30 NEW ORAL ANTICOAGULANTS IN PATIENTS AFFECTED BY HIGH RISK
TUESDAY
Lunch Symposia Programs are available in the Show Guide. Please consult the different options to OR197 ATRIAL FIBRILLATION WITH HISTORY OF INTRACRANIAL HEMORRHAGE
attend the symposium of your choice. Dimitriy Arioli*, Elisa Romagnoli, Valentina Cocchi, Monica Casella, Angela Muoio,
ORALS
Maria Del Mar, Jordana Sanchez, Attilia Pizzini, Annamaria Casali, Ido Iori (Italy)

ORAL COMMUNICATIONS 4 14:00-15:15 14:30 14:45 INTRACRANIAL BLEEDING WITH THE NEW ORAL ANTICOAGULANT
OR198 DRUGS
Kerstin Hogg*, Bharat Bahl, Lana Castellucci, Ian Stiell (Canada)
Venous thromboembolism diagnosis Plenary Hall F&G
14:45 15:00 CLINICAL IMPACT AND COURSE OF MAJOR BLEEDING WITH EDOXABAN
MONDAY
Moderators: Clive Kearon (Canada), Nakisa Khorsand (The Netherlands)
OR199 VERSUS VITAMIN K ANTAGONISTS
Marjolein P. Brekelmans*, Suzanne Bleker, Rupert Bauersachs, Zoltn Boda, Harry
14:00 14:15 WITHHOLDING ANTICOAGULATION AFTER NORMAL CTPA IS SAFE IN Bller, Youngsook Choi, Alex Gallus, Michael Grosso, Michele Mercuri, Saskia Middel-
OR191 PATIENTS WITH A HIGH CLINICAL PROBABILITY OF PE IN THE dorp, Doyeun Oh, Gary Raskob, Lee Schwocho, Ander Cohen (The Netherlands)
ABSENCE OF A PRIOR EPISODE OF VTE
Tom van der Hulle*, Nick van Es, Paul den Exter, Josien van Es, Inge Mos, Rene 15:00 15:15 CHARACTERISTICS AND REVERSAL STRATEGIES OF REAL-WORLD
Douma, Pieter Kamphuisen, Harry Bller, Menno Huisman, Frederikus Klok (The Neth- OR200 ANTICOAGULATION-RELATED HEMORRHAGE IN THE NON-VITAMIN K
erlands) ANTAGONIST ORAL ANTICOAGULANT ERA: PRELIMINARY DATA FROM A
MULTICENTRE CHART REVIEW.
SUNDAY
14:15 14:30 REPRODUCIBILITY OF CLINICAL EVENTS ADJUDICATIONS IN A TRIAL
Yan Xu*, Sam Schulman, Dar Dowlatshahi, Anne Holbrook, Chris Simpson, Lois Shep-
OR192 OF VENOUS THROMBOEMBOLISM PREVENTION herd, Philip Wells, Antonio Giulivi, Eliot Frymire, Ana Johnson (Canada)
Philippe Girard*, Florence Parent, Beatrice Gable, Olivier Sanchez, Pierre Durieux,
Pierre Hausfater, Andrea Penaloza, Sophie Dambrine, Aurore Armand-Perroux, Marie
Beziaud, Jean-Pierre Nguyen, Guy Meyer, Pierre-Marie Roy (France) Von Willebrand disease clinical Room 701
14:30 14:45 DNA IN PLASMA INDICATES DISEASE EXTENT AND PREDICTS Moderators: Karl Desch (United States), Jeroen Eikenboom (The Netherlands)
OR193 MORTALITY IN PATIENTS WITH VENOUS THROMBOEMBOLISM
SATURDAY
14:00 14:15 VON WILLEBRAND DISEASE: DOES VON WILLEBRAND FACTOR

obias A. Fuchs*, Miguel Jimnez-Alczar, Andreas Limacher, Marie Man, Thomas
T
Renn, Drahomir Aujesky, Bernhard Lmmle (Sweden, Germany) OR201 DEFICIENCY DECREASE THE RISK OF CARDIOVASCULAR DISEASE?
Craig Seaman*, Margaret Ragni, Jonathan Yabes, Diane Comer (United States)
14:45 15:00 LOW END-TIDAL CO2 SIGNIFICANTLY INCREASES PRETEST
OR194 PROBABILITY OF PULMONARY EMBOLISM 14:15 14:30 QUALITATIVE AND QUANTITATIVE MODIFICATIONS OF VON
J effrey Kline*, Franck Verschuren, Kerstin Hogg, Pierre-Marie Roy, Andrea Penaloza, OR202 WILLEBRAND FACTOR IN ESSENTIAL THROMBOCYTHEMIA: THE ROLE
Donna Prentice (United States) OF PLATELETS AND NON-ADAMTS13-DEPENDENT PROTEOLYTIC
ROCESSING
Stefano Lancellotti*, Alfredo Dragani, Paola Ranalli, Giovanna Petrucci, Maria Basso,
Raffaele Tartaglione, Bianca Rocca, Raimondo De Cristofaro (Italy)
200 201
14:30 14:45 IMPACT OF ANNEXIN A2 SNP ON VON WILLEBRAND FACTOR LEVELS IN Hemophilia novel treatments Room 714
THURSDSAY
OR203 PATIENTS WITH MODERATE AND SEVERE VON WILLEBRAND DISEASE
aander Van Heerde*, Jelmer van Puffelen, Iris Kloots, Johan Boender, Yvonne Sand-
W Moderators: Johnny Mahlangu (South Africa), Craig Kessler (United States)
ers, Marjon Cnossen, Britta Laros-van Gorkom, Karin Fijnvandraat, Selene Schoormans,
Johanna van der Bom, Karina Meijer, Evelien Mauser-Bunschoten, Jeroen Eikenboom, 14:00 14:15 PERSONALIZATION OF TREATMENT REGIMENS FOR ACTIVE PATIENTS:
Lambertus Kiemeney, Frank Leebeek (The Netherlands) OR211 A COMPARISON OF FACTOR VIII AND EXTENDED HALF-LIFE TREATMENT
REGIMENS
14:45 15:00 VARIABILITY IN VON WILLEBRAND FACTOR ANTIGEN (VWF:AG) LEVELS
Elizabeth Schwartz*, Yan Xiong, Josh Epstein, Bruce Ewenstein, Leonard Valentino
OR204 IN PROSPECTIVE STUDIES OF THE ZIMMERMAN PROGRAM FOR THE (United States)
MOLECULAR AND CLINICAL BIOLOGY OF VON WILLEBRAND DISEASE
WEDNESDAY
(ZPMCB-VWD) SUBJECTS 14:15 14:30 CLINICAL EVALUATION OF NOVEL RECOMBINANT GLYCOPEGYLATED
Kenneth D. Friedman*, Pamela Christopherson, Veronica Flood, Joan Gill, Sandra OR212 FVIII (TUROCTOCOG ALFA PEGOL, N8-GP): EFFICACY AND SAFETY IN
Haberichter, Robert Montgomery (United States) PREVIOUSLY TREATED PATIENTS WITH SEVERE HEMOPHILIA A
TUESDAY
RESULTS OF PATHFINDER2 INTERNATIONAL TRIAL
15:00 15:15 CHARACTERIZATION OF A NEW GENETICALLY-ENGINEERED VON
Paul Giangrande*, Pratima Chowdary, Silke Enhrenforth, Hideji Hanabusa, Frank Lee-
OR205 WILLEBRAND DISEASE TYPE 2B MOUSE MODEL. beek, Steven Lentz, Laszlo Nemes, Lone Poulsen, Elena Santagostino, Chur You, Wan
Frdric Adam*, Caterina Casari, Alexandre Kauskot, Ccile Loubire, Paulette Legen- Hui Clausen, Johannes Oldenburg (United Kingdom)
dre, Christelle Reperant, Dominique Baruch, Jean-Philippe Rosa, Marijke Bryckaert,
Olivier Christophe, Peter Lenting, Ccile Denis (France) 14:30 14:45 A SUBCUTANEOUSLY ADMINISTERED INVESTIGATIONAL RNA
TUESDAY
OR213 THERAPEUTIC (ALN-AT3) TARGETING ANTITHROMBIN FOR TREATMENT
Platelets I Room 801 OF HEMOPHILIA: INTERIM PHASE 1 STUDY RESULTS IN PATIENTS
ORALS
WITH HEMOPHILIA A OR B
Moderators: Alan Nurden (France), Steffen Massberg (Germany) Benny Sorensen*, Tim Mant, Pencho Georgiev, Savita Rangarajan, K. John Pasi, Des-
mond Creagh, David H. Bevan, Steve Austin, Charles Hay, Brigitte Brand, Amy Simon,
14:00 14:15 SINGLE CELL TRACKING REVEALS AUTONOMOUS LOCOMOTION AS A Lauren Melton, Christian Lynam, Andrew Strahs, Alfica Sehgal, Renta Hutabarat,
OR206 PLATELET FUNCTION FACILITATING THROMBUS REORGANIZATION Prasoon Chaturvedi, Scott Barros, Pushkal Garg, Askhay Vaishnaw, Akin Akinc (United
States)
Florian Gaertner* (Germany)
MONDAY
14:45 15:00 BAY 81-8973 PROPHYLAXIS EFFICACY IN PATIENTS WITH SEVERE
14:15 14:30
MORE THAN JUST RED CELLS: HOW DO HEMOSTATIC THROMBI
OR214 HEMOPHILIA A: ANALYSES OF ANNUALIZED BLEEDING RATE
OR207 PREVENT THE LOSS OF PLASMA-BORNE MOLECULES?
OUTCOMES IN THE LEOPOLD I TRIAL
John D. Welsh*, Ryan Muthard, Timothy Stalker, Joshua Taliaferro, Scott Diamond,
Lawrence Brass (United States) Maria Elisa Mancuso*, Horst Beckmann, Monika Maas Enriquez (Germany)
14:30 14:45 DICER, THE KEY ENZYME OF RNA INTERFERENCE, IS REGULATED BY 15:00 15:15 FACTORS INFLUENCING THE PHARMACOKINETICS OF PEGYLATED
OR208 THROMBIN STIMULATION IN HUMAN PLATELETS. OR215 RECOMBINANT FACTOR VIII (BAX 855) ADMINISTERED FOR
Giorgia Manni*, Loredana Bury, Elisa Piselli, Paolo Gresele (Italy) PROPHYLAXIS IN PREVIOUSLY TREATED PATIENTS WITH SEVERE
SUNDAY
HEMOPHILIA A
14:45 15:00 REPLICATION OF PLATELET REACTIVITY GENOME-WIDE ASSOCIATION leksandra Stasyshyn, Werner Engl, Brigitt E. Abbuehl*, Victoria Empson, Bruce
O
OR209 SINGLE NUCLEOTIDE POLYMORPHISMS IN THE CAERPHILLY Ewenstein (Austria)
PROSPECTIVE STUDY
Acquired disorders clinical II Room 716
John D. Eicher*, Luting Xue, Yoav Ben-Shlomo, Andrew Beswick, Andrew Johnson
(United States)
Moderators: Claude Negrier (France), Elena Santagostino (Italy)
15:00 15:15
VPS33B REGULATES VWF POSITIVE VESICLES TRANSPORTATION TO
14:00 14:15 COMPARATIVE ANALYSIS OF VON WILLEBRAND FACTOR PROFILES IN
SATURDAY
OR210 PROPLATELET
OR216 LEFT VENTRICULAR ASSIST DEVICE AND TOTAL ARTIFICIAL HEART
Jing Dai*, Yeling Lu, Conghui Wang, Xue Chen, Panlai Shi, Xuemei Fan, Xiaolin Wu,
Kemin Wang, Xuefeng Wang, Junling Liu (China) RECIPIENTS
Heidi Reich, Francisco Arabia, Lawrence Czer, Jaime Moriguchi, Danny Ramzy, Fardad
Esmailian, Lee Lam, Julie Dunhill, Oxana Tcherniantchouk* (United States)
14:15 14:30 RELAPSE PATTERN AND LONG TERM OUTCOMES IN 111 SUBJECTS
OR217 WITH ACQUIRED HEMOPHILIA A
Terry Mizrahi*, Karine Doyon, Arnaud Bonnefoy, Margaret Warner, Christine Demers,
Stphanie Cloutier, Jean-Franois Castilloux, Georges-Etienne Rivard, Jean St-Louis
(Canada)
202 203
14:30 14:45 THROMBIN GENERATION VARIES WITH FIBROSIS SCORE IN PATIENTS Cancer and thrombosis clinical II Room 715
THURSDSAY
OR218 WITH WELL-COMPENSATED LIVER CIRRHOSIS OF MIXED AETIOLOGY.
Karl Egan*, Audrey Dillon, Zita Galvin, Barry Kevane, Elaine Neary, Stephen Stewart, Moderators: Huyen Tran (Australia), Rupert Bauersachs (Germany)
Fionnuala Ni Ainle (Ireland)
14:00 14:15 LONG-TERM CANCER RISK AFTER VENOUS THROMBOEMBOLISM
14:45 15:00 EARLY VON WILLEBRAND FACTOR DEGRADATION UPON ACUTE OR226 Lisbeth Eischer*, Paul Kyrle, Michael Kammer, Sabine Eichinger (Austria)
OR219 EXPOSURE TO HIGH SHEAR STRESS UNDER CONTINUOUS-FLOW
CIRCULATORY ASSIST DEVICES 14:15 14:30 HYPERCOAGULABILITY, VENOUS THROMBOEMBOLISM AND DEATH IN
ntoine Rauch*, Eric Van Belle, Andr Vincentelli, Emmanuelle Jeanpierre, Paulette
A OR227 PATIENTS WITH CANCER: A MULTI-STATE MODEL
WEDNESDAY
Legendre, Francis Juthier, Natacha Rousse, Carlo Banfi, Anne Godier, Claudine Caron, Florian Posch*, Eva-Maria Reitter, Julia Riedl, Ingrid Pabinger, Cihan Ay (Austria)
Dupont Annabelle, Christophe Zawadski, Delphine Corseaux, Bart Staels, Jenny Goude-
mand, Brigitte Jude, Peter Lenting, Sophie Susen (France) 14:30 14:45 CHARACTERISTICS AND RISK FACTORS OF MAJOR AND
OR228 CLINICALLY RELEVANT NON-MAJOR BLEEDING IN CANCER PATIENTS
15:00 15:15 HEMOSTATIC DISORDER OF UREMIA: PATIENTS WITH TERMINAL
TUESDAY
RECEIVING ANTICOAGULANT TREATMENT FOR ACUTE VENOUS
OR220 CHRONIC RENAL FAILURE (CRF) HAVE INCREASED PLATELET TISSUE THROMBOEMBOLISM THE CATCH STUDY
FACTOR DERIVED INTRAVASCULAR CLOTTING ACTIVATION WITH ieter W. Kamphuisen*, Agnes Y.Y. Lee, Guy Meyer, Rupert Bauersachs, Mette S.
P
DELAYED CLOT LYSIS TIME IN PLATELET RICH PLASMA (CLT-PRP) Janas, Mikala F. Jarner, Alok A. Khorana (The Netherlands)
lga Panes*, Csar Gonzlez, M. Macarena Ruiz, Camila Sandoval, Marcela Cayuleo,
O
Alejandro Rojas, Mariana Soto, Melan Peralta, Jaime Pereira, Mireya Ortiz, Diego 14:45 15:00 THROMBIN GENERATION AND VENOUS THROMBOEMBOLISM AMONG
TUESDAY
Mezzano (Chile) OR229 MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE AND
PREDNISOLONE MAINTENANCE FOLLOWING AUTOLOGOUS STEM CELL
ORALS
TRANSPLANTATION
Pediatric hemostasis Room 713
Huyen Tran*, James McFadyen, Anna Kalff, Andrew Spencer (Australia)
Moderators: Lesley Raffini (United States), Veerle Labarque (Belgium)
15:00 15:15 INCIDENTAL VENOUS THROMBOEMBOLISM AT THORACOABDOMINAL
14:00 14:15
ROLE OF THE G PROTEINS AND SYNTAXIN-11 IN THE DIFFERENCES OF OR230 STAGING CT IN COLORECTAL CANCER
OR221 PLATELET REACTIVITY AND SECRETION BETWEEN NEONATES AND Andreas Nordholm-Carstensen, Morten S. Rasmussen*, Hanne Hansen, Henrik Harling,
MONDAY
Lars Jorgensen (Denmark)
ADULTS.
Eva Caparrs-Prez*, Jos Miguel Torregrosa, Ral Teruel-Montoya, Jos Eliseo Blan-
co, Jos Rivera, Vicente Vicente, Constantino Martnez, Francisca Ferrer-Marn (Spain)
Megakaryocytes and thrombopoiesis II Room 717
14:15 14:30 DISSEMINATED INTRAVASCULAR COAGULATION CONTRIBUTES AN
Moderators: Li Guo (Canada), A. Koneti Rao (United States)
OR222 INDEPENDENT MORTALITY RISK IN CRITICALLY ILL CHILDREN.
James B. Ford, John Kittelson, Marilyn Manco-Johnson (United States) 14:00 14:15 SYNDROMES WITH GRAY PLATELETS: NBEAL2 EXPRESSION IS
OR231 REGULATED BY TRANSCRIPTION FACTOR GATA1
14:30 14:45 IMPAIRED COLLAGEN RESPONSE IN NEONATAL PLATELETS:
SUNDAY
Anouck Wijgaerts*, Marie-Christin Wittevrongel, Timothy Devos, Marloes Tijssen, Kath-
OR223 THE BALANCE BETWEEN ACTIVATION AND INHIBITION PATHWAYS elijne Peerlinck, Chris Van Geet, Kathleen Freson (Belgium)
Sara J. Israels*, Eileen McMillan-Ward, Archie McNicol (Canada)
14:15 14:30 DYNEIN-DEPENDENT MICROTUBULE SLIDING DRIVES PROPLATELET
14:45 15:00
THE CONTRIBUTION OF PRO- AND ANTICOAGULANT PROCESSES TO OR232 ELONGATION
OR224 THROMBIN GENERATION IN THE COURSE OF MATURATION Markus Bender,* Jonathan Thon, Allen Ehrlicher, Stephen Wu, Linas Mazutis, Emoke
Romy Kremers*, Rob Wagenvoord, Bas de Laat, Paul Monagle, Coenraad Hemker, Vera Deschmann, Martha Sola-Visner, Joseph Italiano, John Hartwig (United States)
Ignjatovic (The Netherlands)
14:30 14:45 4GALACTOSYLTRANSFERASE 1 (4GALT1) IS A KEY REGULATOR OF
SATURDAY
15:00 15:15 PEDIATRIC REFERENCE VALUES OF THROMBIN GENERATION OR233 HEMATOPOIETIC STEM CELL FUNCTION AND THROMBOPOIESIS.
OR225 MEASURED BY THE CALIBRATED AUTOMATED THROMBOGRAM (CAT) Silvia Giannini*, Max Adelman, Antonija Jurak Begonja, Karin Hoffmeister (United
Inge Appel*, Tineke Henniphof, Rene van Oerle, Marjon Cnossen, Auke Beishuizen, States)
Henri Spronk (The Netherlands)
14:45 15:00 TYPE 2B VON WILLEBRAND DISEASE (VWD) IS CHARACTERIZED BY A
OR234 CYTOSKELETAL DESORGANIZATION IN MEGAKARYOCYTES LEADING TO
MACROTHROMBOCYTOPENIA.
Alexandre Kauskot*, Sonia Poirault-Chassac, Caterina Casari, Frdric Adam, Audrey
Pietrzyk-Nivau, Eliane Berrou, Marijke Bryckaert, Jean-Philippe Rosa, Olivier D. Chris-
tophe, Peter J. Lenting, Ccile V. Denis, Dominique Baruch (France)
204 205
15:00 15:15 RECEPTOR-MEDIATED ENDOCYTOSIS IS REQUIRED FOR NORMAL 15:00 15:15 CALPAIN-CONTROLLED DETACHMENT OF MAJOR GLYCOPROTEINS
THURSDSAY
OR234 MEGAKARYOCYTE DEMARCATION MEMBRANE SYSTEM FORMATION OR245 FROM CYTOSKELETON REGULATES ADHESIVE PROPERTIES OF
AND PLATELET PRODUCTION PHOSPHATIDYLSERINE-POSITIVE ACTIVATED PLATELETS
Silvia Giannini, Fred Pluthero, Hilary Christensen, Richard Leung, Richard Lo, Jan Kor- Elena Artemenko, Alena Yakimenko, Alexey Pichugin, Fazly Ataullakhanov, Mikhail
mann, Markus Plomann, Walter Kahr, Karin Hoffmeister, Herv Falet* (United States) Panteleev* (Russian Federation)
Tissue factor and factor VII II Room 705 Coagulation factors V, X, and XIII Room 709
WEDNESDAY
Moderators: Nima Vaezzadeh (Canada), Bjarne sterud (Norway) Moderators: Cathy Hayward (Canada), Sriram Krishnaswamy (United States)
14:00 14:15 GENOME-WIDE SERINE PROTEASE KNOCKDOWNS IN ZEBRAFISH: 14:00 14:15 MACROPHAGE-SPECIFIC RECEPTOR SR-AI PLAYS A CRUCIAL
OR236 IDENTIFICATION OF PROSTASIN IN FACTOR VII ACTIVATION PATHWAY OR246 PROTECTIVE ROLE IN THE REGULATION OF COAGULATION FACTOR X
TUESDAY
Pudur Jagadeeswaran*, Gauri Khandekar (United States) PLASMA LEVELS
Vincent Muczynski*, Amine Bazaa, Amlie Harel, Ccile Loubire, Ghislaine Cherel,
14:15 14:30 TISSUE-FACTOR INDUCED ALLOSTERIC ENHANCEMENT OF FACTOR VIIA Peter Lenting, Ccile Denis, Olivier Christophe (France)
OR237 ACTIVITY BY STABILIZATION OF SEGMENT 215-219 AND TAMING OF
14:15 14:30 CB-FXA: AN IMPROVED SECOND GENERATION FXA VARIANT
W215 FLEXIBILITY
OR247 dwin Madison*, Christopher Thanos, Mark Fox, Kerryn McCluskie, Jodi Gureasko,
E
TUESDAY
Anders Sorensen, Jesper Madsen, Anders Svensson, Henning Stennicke, Henrik ster-
Tony Byun, David Sloane (United States)
gaard, Michael Overgaard, Ole Olsen, Prafull S. Gandhi* (Denmark)
ORALS
14:30 14:45 CHARACTERIZATION OF A NOVEL FV MUTATION (A512V, FV BONN)
14:30 14:45 RELATIONSHIPS OF CIRCULATING COAGULATION FACTOR VIIA (FVIIA)
OR238 WITH COMMON SINGLE NUCLEOTIDE POLYMORPHISMS AND RISK OF OR248 ASSOCIATED WITH DEEP VEIN THROMBOSIS AND APC RESISTANCE
INCIDENT ISCHEMIC STROKE: THE CARDIOVASCULAR HEALTH STUDY ehnaz Pezeshkpoor*, Elisabetta Castoldi, Nasim Hamedani, Arijit Biswas, Johannes
B
Oldenburg, Anna Pavlova (Germany)
Nels C. Olson*, Leslie Lange, Alex Reiner, Russell Tracy (United States)
14:45 15:00 PLATELET-DERIVED FACTOR V REGULATES ARTERIAL THROMBOSIS
14:45 15:00
EPIDERMAL TISSUE FACTOR IN WOUND HEALING
OR249 Jianbo Wu*, Meiping Ren, Yongjie Li, Ningbo Pang, Ni Chen, Xin Deng, Yan Yang,
MONDAY
OR239
Elizabeth Chappell*, Dougald Monroe, Maureane Hoffman, Nigel Mackman (United
Namei Xiao, Hongmin Sun (China)
States)
15:00 15:15 DEVELOPMENT OF A NOVEL ASSAY METHOD OF COAGULATION FACTOR
Platelets signal transduction II Room 707 OR250 XIII ACTIVITY FOR THE DETECTION OF ITS INHIBITOR IN PLASMA
Masayoshi Souri*, Tsukasa Osaki, Akitada Ichinose (Japan)
Moderators: Katsue Suzuki-Inoue (Japan), Kristina Modjeski (United States)
14:00 14:15 GLUTAMATE RECEPTOR INTERACTING PROTEIN 1 MEDIATES PLATELET Arterial vascular disease Room 711
OR241 ADHESION AND THROMBUS FORMATION
SUNDAY
Kristina Modjeski*, Sara Ture, David Field, Scott Cameron, Craig Morrell (United Moderators: John Eikelboom (Canada), Michiel Coppens (The Netherlands)
States)
14:00 14:15 THE EFFECT OF INTRACORONARY STEM CELL INJECTION ON MARKERS
14:15 14:30 UNEXPECTED ROLE OF PLATELETS IN LUNG DEVELOPMENT
OR251 OF LEUKOCYTE ACTIVATION IN ACUTE MYOCARDIAL INFARCTION
OR242 DEPENDING ON A PLATELET ACTIVATION RECEPTOR, CLEC-2 Ragnhild Helseth*, Trine Opstad, Svein Solheim, Ketil Lunde, Harald Arnesen, Ingeb-
Nagaharu Tsukiji*, Osamu Inoue, Shogo Tamura, Toshiaki Shirai, Tomoyuki Sasaki, jrg Seljeflot (Norway)
Kaneo Satoh, Katsue Suzuki-Inoue, Yukio Ozaki (Japan)
14:15 14:30 PLATELET NEUTROPHIL COMPLEX FORMATION AND INFILTRATION IS
SATURDAY
14:30 14:45
NON-GENOMIC ACTIVITIES OF RETINOIC ACID RECEPTOR ALPHA OR252 REGULATED BY PERIPHERAL SEROTONIN IN A MOUSE MODEL OF
OR243 CONTROL ACTIN CYTOSKELETAL EVENTS IN HUMAN PLATELETS MYOCARDIAL INFARCTION
Hansjorg Schwertz*, Martin Freitag, Jesse Rowley, Larry Kraiss, Zechariah Franks, Guy
aximilian Mauler*, Thilo Witsch, Ludwig Dorner, Kelly Blanz, Christoph Koentges,
M
Zimmerman, Andrew Weyrich, Matthew Rondina (Germany, United States)
Daniela Stallmann, Christoph Bode, Heiko Bugger, Daniel Duerschmied (Germany)
14:45 15:00 LEUKEMIA-ASSOCIATED RHOGEF (LARG) PLAYS A MINOR ROLE IN 14:30 14:45 POST- PCI THROMBIN GENERATION AND CARDIOVASCULAR MORTALITY
OR244 RHOA ACTIVATION, YET IS CRITICAL FOR PLATELET ACTIVATION IN OR253 IN ACUTE CORONARY SYNDROME PATIENTS.
MICE Monica Attanasio, Rossella Marcucci, Annamaria Gori*, Rita Paniccia, Raffaella Priora,
Christopher M. Williams*, Matthew Harper, Robert Goggs, Tony Walsh, Stefan Offer- Serafina Valente, Daniela Balzi, Alessandro Barchielli, Rosanna Abbate, Gian Franco
manns, Alastair Poole (United Kingdom) Gensini (Italy)
206 207
14:45 15:00 REPEATED MEASURES OF MODIFIABLE ATHEROSCLEROTIC RISK
THURSDSAY
OR254 FACTORS OVER TIME AND RISK OF MYOCARDIAL INFARCTION AND
VENOUS THROMBOSIS
irgit Smbrekke*, Ludvig Rinde, Erin Hald, Anders Vik, Tom Wilsgaard, Inger Njls-
B ABSTRACT SYMPOSIA 16:45-18:00
tad, Ellisiv Mathiesen, Sigrid Brkkan, John-Bjarne Hansen (Norway)
15:00 15:15 RECURRENCE AND MORTALITY IN YOUNG WOMEN WITH Von Willebrand factor Room 801
OR255 MYOCARDIAL INFARCTION OR ISCHEMIC STROKE: 19-YEAR FOLLOW-UP
OF THE RISK OF ARTERIAL THROMBOSIS IN RELATION TO ORAL Moderators: Laura Swystun (Canada), Jorge di Paola (United States)
WEDNESDAY
CONTRACEPTIVES (RATIO) STUDY.
Alberto Maino*, Bob Siegerink, Ale Algra, Flora Peyvandi, Frits Rosendaal (Italy) 16:45-17:05
THE MULTIPLE ROLES OF VON WILLEBRAND FACTOR: REGULATION OF
AS061 ANGIOGENESIS
Anna Randi (United Kingdom)
TUESDAY
Coffee break time in the exhibition (Level 800) 17:05 - 17:19 VON WILLEBRAND FACTOR IS INDISPENSABLE FOR VENOUS
From 15:15 to 15:45 AS062 HEMOSTASIS IN A NOVEL MURINE BLEEDING MODEL
Amine Bazaa*, Vincent Muczynski, Amlie Harel, Tom Knudsen, Ccile V. Denis, Olivi-
Tuesday, June 23, 2015 er D. Christophe, Peter J. Lenting (France)
TUESDAY
17:19 - 17:33 THE INTRODUCTION OF A MUCIN INSERT AT THE N-TERMINUS OF
SYMPOSIA
AS063 VWF-A1, BUT NOT THE C-TERMINUS, ENHANCES PLATELET GPIB
BINDING TO VWF
Maureen Andrew Plenary Lecture Hall F&G Anju Kelkar, Changjie Zhang*, Daniel Swartz, Sriram Neelamegham (United States)
Moderator: Patti Massicotte (Canada) 17:33 - 17:47 HIGH RESOLUTION MICROSCOPIC CHARACTERISATION OF VWF
AS064 BIOSYNTHESIS, STORAGE AND SECRETION IN TYPE 1 VWD PATIENTS
15:45 -16:30 hy do we miss the mark on preventing cardiovascular disease? Is it too
W WITH LARGE IN-FRAME VWF DELETIONS
little, too late or just futile? Simon J. Webster*, Ashley Cartwright, Daniel Hampshire, Ian Peake, Anne Goodeve
MONDAY
Brian McCrindle (Canada) (United Kingdom)
17:47 - 18.00 THE RECOGNITION OF COLLAGEN BY THE VWF A DOMAINS

AS065 amir W. Hamaia*, Kirsty Ferguson, Emma Hunter, Dominique Bihan, Richard Farn-
S
dale (United Kingdom)
Platelet signaling Room 717
Moderators: Attila Braun (Germany), Wolfgang Bergmeier (United States)
SUNDAY 16:45-17:05 TYROSINE PHOSPHATASES IN PLATELET SIGNAL TRANSDUCTION

AS066 Yotis Senis (United Kingdom)
17:05 - 17:19 RUNX1 REGULATES MEGAKARYOCYTIC/PLATELET RAS-RELATED SMALL

Maureen Andrew, 1952-2001 AS067 GTPASE RAB1B: POTENTIAL ROLE IN PLATELET DYSFUNCTION WITH
RUNX1 HAPLODEFICIENCY.
SATURDAY
Gauthami S. Jalagadugula*, A. Koneti Rao (United States)
17:19 - 17:33 TRPM7 KINASE REGULATES ITAM-SIGNALING AND PLAYS A CRITICAL

AS068 ROLE IN THROMBOSIS AND ISCHEMIC STROKE
Attila Braun*, Wenchun Chen, Carsten Schmitz, Rene Zahedi, Sanjeev Gotru, Peter
Kraft, Karen Wolf, Simon Stritt, Heike Hermanns, Masayuki Matsushita, Susanna
Zierler, Vladimir Chubanov, Thomas Gudermann, Guido Stoll, Bernhard Nieswandt
(Germany)
208 209
17:33 - 17:47 TYROSINE PHOSPHORYLATION OF THE ITIM-CONTAINING RECEPTOR 17:30 17:45 UTILITY OF BLEEDING SCORES AND A STANDARDIZED LABORATORY
THURSDSAY
AS069 G6B-B IS ESSENTIAL FOR PLATELET HOMEOSTASIS AS078 EVALUATION IN IDENTIFYING DEFECTS IN PRIMARY HEMOSTASIS IN
itchell Geer*, Silke Heising, Louise Tee, Ralph Gareus, Steve Watson, Alexandra
M CHILDREN REFERRED TO A TERTIARY-CARE PEDIATRIC CENTRE
Mazharian, Yotis Senis (United Kingdom) Veerle Labarque*, Victor Blanchette, Dewi Clark, Ann Marie Stain, Cindy Wakefield,
Vanessa Bouskill, William Brien, Leonardo Brandao, Walter Kahr, Manuel Carcao,
17:47 - 18:00 RASA3 IS A CRITICAL INHIBITOR OF PLATELET ACTIVATION AND THE Margaret Rand (Belgium)
AS070 MISSING LINK IN THE P2Y12/RAP1 SIGNALING PATHWAY.
ucia Stefanini*, David Paul, Raymond Robledo, Todd Getz, Caterina Casari, Raymond
L 17:45 18:00 ASSESSING BLEEDING PHENOTYPE IN CHILDREN WITH MODERATE OR
Piatt, Yacine Boulaftali, Luanne Peters, Wolfgang Bergmeier (United Kingdom) AS079 SEVERE VON WILLEBRAND DISEASE USING THE ISTH-BAT AND THE
RELEVANCE OF PEDIATRIC-SPECIFIC BLEEDING SYMPTOMS
WEDNESDAY
Yvonne Sanders, Karin Fijnvandraat, Johan Boender*, Evelien Mauser-Bunschoten,
Mechanisms of ITP Room 705 Johanna van der Bom, Joke de Meris, Frans Smiers, Bernd Granzen, Paul Brons, Rienk
Tamminga, Marjon Cnossen, Frank Leebeek (The Netherlands)
Moderators: Rick Kapour (Canada), Barbara Konkle (United States)
TUESDAY
16:45-17:05
THE ROLE OF T CELLS IN THE PATHOGENESIS OF IMMUNE Vascular progenitor cells and vascular disease Room 707
AS071 THROMBOCYTOPENIA
Moderators: David Smadja (France), Joyce Bischoff (United States)
John Semple (Canada)
TUESDAY
17:05 - 17:19 ALTERED PLASMA MICRORNA LEVELS IN PATIENTS WITH IMMUNE 16:45-17:15 ENDOTHELIAL PROGENITORS CELLS: FROM PATHOPHYSIOLOGY TO
SYMPOSIA
AS072 THROMBOCYTOPENIC PURPURA AS085 EMERGENT THERAPY OF VASCULAR DISORDERS
Yang He*, Bin Zuo, Yunxiao Zhao, Qingyu Wu (China) Franoise Dignat-George (France)
17:19 - 17:33 CD40L AND ITS DNA METHYLATION IN PRIMARY IMMUNE 17:15 17:30 CD34+ HEMATOPOIETIC STEM CELL COUNT IS PREDICTIVE FOR
AS073 THROMBOCYTOPENIA AS086 VASCULAR EVENT OCCURRENCE IN SICKLE CELL DISEASE CHILDREN
Huiyuan Li*, Donglei zhang, Renchi Yang (China) anoelle Kossorotoff, Marianne de Montalembert, Dominique Lasne, Valentine
M
Brousse, Emmanuel Curis, David Smadja, Romaric Lacroix, Sebastien Bertil, Isabelle
17:33 - 17:47 CYCLOSPORINE ENHANCES IMMUNOSUPPRESSIVE FUNCTIONS OF Desguerre, Damien Bonnet, Pascale Gaussem* (France)
MONDAY
AS074 MYELOID-DERIVED SUPPRESSOR CELLS IN IMMUNE
17:30 17:45 TREPROSTINIL INDIRECTLY REGULATES ENDOTHELIAL COLONY
THROMBOCYTOPENIA
AS087 FORMING CELL ANGIOGENIC PROPERTIES BY INCREASING VEGF-A
Yu Hou*, Miao Xu, Qi Feng, Yingyi Yu, Xuena Liu, Ming Hou, Jun Peng (China)
PRODUCED BY MESENCHYMAL STEM CELLS
17:47 - 18:00 ELEVATED SEMA5A IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA David Smadja*, Marilyne Levy, Lan Huang, Elisa rossi, Dominique Israel-Biet, Pascale
Gaussem, Joyce Bischoff (France)
AS075 yu Mingen*, Li yang, Hao Yating, Sun Tiantian, Liu wenjie, lyu Cuicui, Li Huiyuan,
L
Xue Feng, Liu Xiaofan, Zhang Lei, Yang Renchi (China)
17:45 18:00 INDUCED PLURIPOTENT STEM CELL- (IPSC) BASED STRATEGY TO
AS088 CORRECT THE BLEEDING PHENOTYPE IN HEMOPHILIA A
SUNDAY
Maria Talmon*, Cristina Olgasi, Simone Merlin, Gabriella Ranaldo, Angelo Lombardo,
Tools for evaluation of bleeding Room 716 Donato Colangelo, Giovanni Berta, Luigi Naldini, Angel Raya, Federica Valeri, Piercarla
Schinco, Maria Messina, Antonia Follenzi (Italy)
Moderators: Flora Peyvandi (Italy), Samantha Gouw (The Netherlands)
16:45-17:15 THE CLINICAL UTILITY OF BLEEDING SCORES Vessel wall in health and disease, annexins Room 714
AS076 Paula James (Canada)
Moderators: Colin Kretz (Canada), Robert Flaumenhaft (United States)
SATURDAY
17:15 17:30 ACCURACY OF THREE CLINICAL PREDICTION TOOLS FOR MAJOR

AS077 BLEEDING IN PATIENTS ON EXTENDED ORAL ANTICOAGULANT FOR 16:45-17:15 ANNEXIN A2 IN HEALTH AND DISEASE
VENOUS THROMBOEMBOLISM AS089 Katherine Hajjar (United States)
hil Wells*, Parvaneh Fallah, Michael Kovacs, David Anderson, Susan Kahn, Vinay
P
Shah, Scott Kaatz, Clive Kearon, Susan Solymoss, David Keeling, Russell Zide, Sam 17:15 17:30 THE ENDOTHELIAL CELL TRANSCRIPTOME IS HIGHLY
Schulman, Isabelle Chagnon, Rosendo Rodriguez, Daniel Corsi, Marc Rodger (Canada) AS090 HETEROGENEOUS ACROSS DIFFERENT VASCULAR BEDS
Audrey Cleuren*, Hui Jiang, Kristina Hunker, Andrew Yee, Santhi Ganesh, David Gins-
burg (United States)
210 211
17:30 17:45 A CLASS OF BIASED PAR1 AGONISTS THAT STIMULATE 17:33 - 17:47 DABIGATRAN PERSISTENCE AND ADHERENCE IN NEW ZEALAND
THURSDSAY
AS091 CYTOPROTECTIVE SIGNALING IN ENDOTHELIAL CELLS AS100 Paul L. Harper*, Su Chen Fong, Laura Chen (New Zealand)
Omozuanvbo R. Aisiku*, Christian Peters, Karen De Ceunyck, Jennifer Fitch-Tewfik,
James Dilks, Susanna Fustulo-Gunnink, Christopher Dockendorff, Robert Flaumenhaft 17:47 - 18:00 INCREASED RISK OF THROMBOTIC EVENTS IN PATIENTS WITH ATRIAL
(United States) AS101 FIBRILLATION SHORTLY AFTER DABIGATRAN OR RIVAROXABAN
DISCONTINUATION
17:45 18:00 PODOPLANIN AND CLEC-2 DRIVE CEREBROVASCULAR PATTERNING Nina Vene, Alenka Mavri, Mirjam Gubensek, Gregor Tratar, Tjasa Vizintin Cuderman,
AS092 AND INTEGRITY DURING DEVELOPMENT Maja Pohar Perme, Ales Blinc* (Slovenia)
Kate Lowe*, Brenda Finney, Ren Hgerling, Carsten Deppermann, Jon Frampton,
Bernhard Nieswandt, Christopher Buckley, Friedemann Kiefer, Steve Watson (United
WEDNESDAY
Kingdom) Developmental hemostasis Room 709
Moderators: Paul Monagle (Australia), Aisha Bruce (Canada)

Cancer and thrombosis basic Plenary Hall F&G
TUESDAY
16:45-17:15
DEVELOPMENTAL HEMOSTASIS: CONSEQUENCES FOR CLINICAL
Moderators: Esterina dAsti (Canada), Gary Lyman (United States)
AS102 PRACTICE
Heleen van Ommen (The Netherlands)
16:45-17:15 THROMBOSIS, INFLAMMATION AND CANCER
AS093 Tatiana V. Byzova (United States) 17:15 17:30 REDUCED DOSING OF ENOXAPARIN TO TREAT DEEP VEIN THROMBOSIS
TUESDAY
AS103 (DVT) OR PULMONARY EMBOLI (PE) IN OVERWEIGHT AND OBESE
SYMPOSIA
17:15 17:30 GPV IS A CENTRAL REGULATOR OF HEMOSTASIS, THROMBOSIS AND PEDIATRIC PATIENTS
AS094 THROMBO-INFLAMMATORY BRAIN INFARCTION IN MICE Stephanie Hoffman, Chi L. Braunreiter* (United States)
arah Schiel*, David Stegner, Ina Hagedorn, Peter Kraft, Ina Thielmann, Guido Stoll,
S
Bernhard Nieswandt (Germany) 17:30 17:45 DEVELOPMENT OF A RIVAROXABAN DOSING REGIMEN FOR TREATMENT
AS104 OF VTE IN CHILDREN AGED 12 TO 18 YEARS
17:30 17:45 PLATELET INTEGRIN ALPHA 6 BETA 1 PROMOTES METASTATIC uy Young*, Dagmar Kubitza, Anthony Chan, Gili Kenet, Christoph Male, Patti Massi-
G
AS095 DISSEMINATION cotte, Angelo Claudio Molinari, Paul Monagle, Ulrike Nowak-Goettl, Rolf Burghaus, Jan
Elmina Mammadova-Bach*, Monique Freund, Dominique Bagnard, Christian Gachet, Stampfuss, Anthonie Lensing (United States)
MONDAY
Pierre Mangin (France)
17:45 18:00 DEVELOPMENTAL DIFFERENCES IN FIBRIN CLOT FORMATION UNDER
17:45 18:00 PEPTIDES INHIBITING HEPARANASE PROCOAGULANT ACTIVITY AS105 VENOUS AND ARTERIAL LAMINAR FLOW
AS096 SIGNIFICANTLY REDUCE TUMOR GROWTH AND VASCULARIZATION IN A Hilde Kelchtermans*, Leonie Pelkmans, Paul Monagle, Bas deLaat, Vera Ignjatovic
MOUSE MODEL (Australia)
Yonatan Crispel, Elena Axelman, Mifleh Tatour, Inna Kogan, Yona Nadir* (Israel)
Alloimmune and autoimmune platelet disorders Room 715

Non-vitamin K antagonist oral anticoagulants Room 718
SUNDAY
Moderators: Ted Warkentin (Canada), Cindy Neunert (United States)
Moderators: Mark Crowther (Canada), Paul Harper (New Zealand)
16:45-17:05 UPDATE ON CURRENT ATTEMPTS TO PREVENT NEONATAL
16:45-17:05 NOACs IN VENOUS THROMBOEMBOLISM STRENGTHS AND CAVEATS AS106 ALLOIMMUNE THROMBOCYTOPENIA
AS097 Sam Schulman (Canada) Tamam Bakchoul (Germany)
17:05 - 17:19 REAL LIFE EFFICACY AND SAFETY OF APIXABAN FOR STROKE 17:05 - 17:19 IMPACT OF PLATELET ACTIVATION DETECTED BY THE WASHED
AS098 PREVENTION IN ATRIAL FIBRILLATION RESULTS OF THE AS107 PLATELET ACTIVATION ASSAY ON THROMBOTIC OUTCOMES IN
SATURDAY
PROSPECTIVE NOAC REGISTRY (NCT01588119) PATIENTS CLINICALLY SUSPECTED OF HAVING HEPARIN-INDUCED

J an Beyer-Westendorf*, Sebastian Werth, Luise Tittl, Franziska Michalski, Sandra THROMBOCYTOPENIA.
Marten, Norbert Weiss (Germany) Takuma Maeda*, Yoshiaki Kanaumi, Shiori Kawamura, Shu Seguchi, Mayumi Kodama,
Takeshi Kawai, Toshimitsu Hamasaki, Hitoshi Okazaki, Shigeki Miyata (Japan)
17:19 - 17:33 FIXED-DOSE RIVAROXABAN IS NOT ASSOCIATED WITH INCREASED
AS099 RECURRENT VENOUS THROMBOEMBOLISM OR MAJOR BLEEDING IN 17:19 - 17:33 DEVELOPMENT AND CHARACTERIZATION OF 5B9, A POTENTIAL
PATIENTS WITH A HIGH OR LOW BODY WEIGHT AS108 INTERNATIONAL STANDARD FOR THE DIAGNOSIS OF
artin H. Prins*, Marcello Di Nisio, Maria Cristina Vedovati, Antoni Riera-Mestre,
M HEPARIN-INDUCED THROMBOCYTOPENIA
Katharina Mueller, Alexander Cohen, Philip Wells, Jan Beyer-Westendorf, Timothy J rme Rollin*, Claire Pouplard, Claire Kizlik-Masson, Gal Champier, Steven McKen-
Brighton, Henri Bounameaux, Jonas Schneider, Anthonie Lensing (The Netherlands) zie, Yves Gruel (France)
212 213
17:33 - 17:47 DIFFERENT DOSAGES OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) IN 17:30 17:45 MAPPING ENDOTHELIAL CELL ACTIVATION IN THE CARDIOVASCULAR
THURSDSAY
AS109 TREATING ADULT IMMUNE THROMBOCYTOPENIA WITH LONG-TERM AS117 TARGET ORGANS USING ULTRA-SENSITIVE MOLECULAR MAGNETIC
FOLLOW-UP OF THREE YEARS: RESULTS OF A CASE-CONTROL STUDY RESONANCE IMAGING
INCLUDING 91 CASES. Maxime Gauberti*, Julie Bellire, Sara Martinez de Lizarrondo, Denis Vivien (France)
Zeping Zhou*, Zhuoqing Qiao, Huiyuan Li, Xian Zhang, Feng Xue, Renchi Yang (China)
17:45 18:00 REGULATION OF STIMULATED AND BASAL RELEASE OF
17:47 - 18:00 HIGHER OR LOWER DOSE CORTICOSTEROIDS FOR PRIMARY IMMUNE AS118 WEIBEL-PALADE BODIES BY SYNTAXIN-3 CONTAINING
AS110 THROMBOCYTOPENIA: SYSTEMATIC REVIEW AND META-ANALYSIS SNARE-COMPLEXES.
iraj Mithoowani*, Kathleen Gregory-Miller, Jennifer Goy, Matthew Miller, Nastaran
S Maaike Schillemans*, Dorothee van Breevoort, Maryam Wahedi, Stephan Huveneers,
WEDNESDAY
Noroozi, Donald Arnold (Canada) Maartje van den Biggelaar, Jan Voorberg, Ruben Bierings (The Netherlands)
Hemostasis and infection Room 713 Inhibitors - basic Room 701
TUESDAY
Moderators: Ed Pryzdial (Canada), Travis Gould (Canada) Moderators: Steven Pipe (United States), Paul Monahan (United States)
16:45-17:15 HEMOSTASIS-PATHOGEN INTERPLAY: THE VIRUS ENVELOPE 16:45-17:15 THE IMMUNOGENICITY OF FACTOR VIII
AS111 Ed Pryzdial (Canada) AS190 Shannon Meeks (United States)
TUESDAY
17:15 17:30 MUTATIONS IN THE CONTROL OF VIRULENCE SENSOR GENE FROM 17:15 17:30 CHEMOTACTIC ANTIGEN COMPETITION DECREASES THE INCIDENCE OF
SYMPOSIA
AS112 STREPTOCOCCUS PYOGENES AFTER INFECTION IN MICE LEAD TO AS191 FACTOR VIII INHIBITORS IN HEMOPHILIA A MICE IMMUNIZED WITH
CLONAL BACTERIAL VARIANTS WITH INCREASED VIRULENCE INFLUENZA, WITH AND WITHOUT THE ADJUVANT MF59C.1.
Jeff Mayfield*, Zhong Liang, Victoria Ploplis, Francis Castellino (United States) Jesse Lai*, Paul Moorehead, Kate Sponagle, Katharina Steinitz, Birgit Reipert, Chris-
tine Hough, David Lillicrap (Canada)
17:30 17:45
SECRETED STAPHYLOCOCCAL VON WILLEBRAND FACTOR-BINDING
AS113 PROTEIN BINDS TO A SORTASE A-DEPENDENT FACTOR TO ENABLE S. 17:30 17:45 FACTOR VIII TOLERANCE INDUCTION IN HAEMOPHILIA A MICE VIA
AUREUS BINDING TO VON WILLEBRAND FACTOR AS192 TRANSPLACENTAL TRANSFER OF RECOMBINANT FACTOR VIII FC
Jorien Claes*, Thomas Vanassche, Marijke Peetermans, Laurens Liesenborghs, Dom- aria Georgescu*, Tongyao Liu, Kate Sponagle, Kassandra Hebert, Douglas Drager,
M
MONDAY
inique Missiakas, Olaf Schneewind, Ruth Heying, Marc Hoylaerts, Peter Verhamme Susannah Patarroyo-White, Christine Hough, Haiyan Jiang, David Lillicrap (Canada)
(Belgium)
17:45 18:00 CAN A CENTER EFFECT BE THE REASON FOR THE HIGHER
17:45 18:00
MINIMAL TISSUE FACTOR EXPRESSION REDUCES BLOOD BRAIN AS193 FREQUENCY INHIBITORS FOR A SECOND GENERATION RECOMBINANT
AS114 BARRIER PERMEABILITY AND SUSCEPTIBILITY TO NEUROLOGICAL FACTOR VIII PRODUCT?
SYMPTOMS IN EXPERIMENTAL CEREBRAL MALARIA H.Marijke Van den Berg*, Rolf Ljung (The Netherlands)
Tara Bracken*, Catherine Smith, Caitlin Cooper, Demba Sarr, Julie Moore (United
States)
SUNDAY
Poster with refreshments
Endothelial cell wall and signaling Room 711 From 18:00 19:30 in the Exhibition on Level 800
Moderators: Maxime Gauberti (France), Bill Aird (United States)

16:45-17:15 ENGINEERING THE VASCULATURE
AS115 Ying Zheng (United States)
SATURDAY
17:15 17:30 INHIBITION OF RHOA-RHO KINASE PATHWAY ATTENUATES

AS116 COCAINE-INDUCED MICROVASCULAR ENDOTHELIAL CELL
DYSFUNCTION: STUDIES UNDER STATIC AND SHEAR FLOW
CONDITIONS
Jaime Pereira*, Claudia Sez, Karla Pereira-Flores, Alberto Leguina, Eduardo Fuentes,
Marcelo Alarcn, Ivn Palomo, Diego Mezzano (Chile)
214 215
PO005-TUE MODIFICATION OF THE BDNF GENE THAT INDUCES DEPRESSION-LIKE
THURSDSAY
STATES IS ASSOCIATED TO PRO-INFLAMMATORY AND PRO-THROMBOT-
IC PHENOTYPE IN MICE.
POSTER SESSION 17:15-18:15 Silvia S. Barbieri*, Patrizia Amadio, Sara Gianellini, Eva Tarantino, Alessandro Ieraci,
Maura Brioschi, Cristina Banfi, Francis Lee, Elena Tremoli (Italy)
Posters will be presented on different days during the Congress and are accessible at the same times as the
exhibition opening hours. The official poster sessions with refreshments will take place as follows: PO006-TUE FAMILIAL FELINE HYPERTROPHIC CARDIOMYOPATHY: A MODEL FOR
Monday, June 22, 2015, from 17.15-18.30
EVALUATING PLATELET ACTIVATION AND CLOPIDOGREL THERAPY
Tuesday, June 23, 2015, from 18.00-19.30
Wednesday, June 24, 2015, from 17.15-18.30 Ronald Li*, Joshua Stern, Fern Tablin (United States)
WEDNESDAY
The Poster Area is located inside the Exhibition on Level 800. PO007-TUE PLATELET EFFECTS OF EPISODIC OZONE AND PM EXPOSURE DURING
POSTNATAL DEVELOPMENT
Poster setup times are as follows: Fern Tablin*, Monica Pombo (United States)
Monday, June 22, 2015, from 07.30 - 09.15
TUESDAY
Tuesday, June 23, 2015, from 07.30 - 09.15 PO008-TUE EVALUATION OF FACTOR XIA PHARMACOKINETICS IN MICE WITH A
Wednesday, June 24, 2015, from 07.30 - 09.15 THROMBIN GENERATION ASSAY
Yideng Liang, Evi Struble, William Chang, Dorothy Scott, Mikhail Ovanesov* (United
Poster dismantling times are as follows:
States)
Monday, June 22, 2015, from 18.30 - 19.00
Tuesday, June 23, 2015, from 19.30 - 20.00
TUESDAY
Antiplatelets agents II
POSTERS
Posters not taken down after the dismantling time will be discarded.
If you have sent your poster to the poster printing service, kindly note that you will be able to pick it up at the
PO009-TUE RESISTANCE TO ANTI-PLATELET AGENTS IN PATIENTS WITH ISCHEMIC
Poster Booth located in the Swing Space on Level 800. STROKE
Anil Pathare*, Karima Al Falahi, Arun Gujjar, Badriya Al-Belushi, Nandagopal R, Jacob
Poster Booth opening times are: PC, Abdullah Al Asmi (Oman)
Monday, June 22, 2015, from 07.30 - 19.00
MONDAY
Tuesday, June 23, 2015, from 19.30 - 20.00 PO010-TUE MECHANISM OF ANTIPLATELET ACTION INDUCED BY GUANOSINE VIA
Wednesday, June 24, 2015, from 18.30 - 19.00 INCREASE IN CAMP LEVELS AND ITS ANTITHROMBOTIC ACTIVITY
Eduardo Fuentes*, Marcelo Alarcon, Julio Caballero, Ivn Palomo (Chile)
Pins are provided on the poster boards directly
PO011-TUE IMPACT OF NON-INHIBITED PLATELET SUPPLEMENTATION ON PLATE-
Animal models II LET REACTIVITY IN PATIENTS TREATED WITH PRASUGREL OR TICAGRE-
LOR FOR AN ACUTE CORONARY SYNDROME: AN EX-VIVO STUDY
Fanny Bonhomme, Robert Bonvini, Jean-Luc Reny, Antoine Poncet, Pierre Fontana*
PO001-TUE POLYPHOSPHATE AS A NOVEL THERAPEUTIC FOR AGE-RELATED MACU- (Switzerland)
SUNDAY
LAR DEGENERATION
Linnette M. Ocariza*, Alice OByrne, Stephanie Smith, James Morrissey, Jing Cui, PO012-TUE THE EFFECTS OF TWO COMMONLY USED HERBAL PRODUCTS ON HAE-
Joanne Matsubara, Edward Conway (Canada) MOSTATIC SYSTEM AND THEIR INTERACTIONS WITH ASPIRIN
Wan Hui Wong*, Seng Kok Ang, Foon Yin Fung, Hwee Ling Koh, Mei Ching Kun, Lai
PO002-TUE ANTI-OXIDANT TREATMENT IMPROVES CARDIAC DYSFUNCTION IN Heng Lee, Xiaomei Li, Heng Joo Ng, Chuen Wen Tan, Yan Zhao, Yeh Ching Linn (Singa-
BMAL1 DEFICIENT MICE pore)
Bianca Hemmeryckx*, Philipp Hohensinner, Melissa Swinnen, Ward Heggermont,
Johann Wojta, Henri Lijnen (Belgium) PO013-TUE EFFICACY OF PLATELET INHIBITION WITH PRASUGREL IN PATIENTS
SATURDAY
WITH ACUTE MYOCARDIAL INFARCTION UNDERGOING THERAPEUTIC

PO003-TUE NOVEL MOUSE HEMOSTASIS MODEL FOR REAL-TIME DETERMINATION HYPOTHERMIA AFTER CARDIOPULMONARY RESUSCITATION
OF BLEEDING TIME AND HEMOSTATIC PLUG COMPOSITION. Andreas Schfer*, Ulrike Flierl, Johann Bauersachs (Germany)
Raymond Piatt*, Todd Getz, Wolfgang Bergmeier (United States)
PO014-TUE ANTIBODY TARGETED, THROMBIN-SENSITIVE POLYMER CAPSULES FOR
PO004-TUE TARGETING EXTRACELLULAR CYCLOPHILIN A-MEDIATED NEUROVASCU- UROKINASE DELIVERY
LAR DYSFUNCTION Sylvia Gunawan, Kristian Kempe, Thomas Bonnard, Jiwei Cui, Karen Alt, Xiaowei
Georgette Suidan*, Marissa Ilardi, Andrew Cameron, Natasha Kablaoui, Kari Fonseca, Wang, Lok Law, Georgina Such, Karlheinz Peter, Frank Caruso, Christoph E. Hagemey-
Robert Bell (United States) er* (Australia)
216 217
PO015-TUE PLATELET TRANSFUSION MIGHT BE A POTENT ANTIDOTE FOR THIENO-
Arterial vascular disorders - clinical II
THURSDSAY
PYRIDINES, BUT NOT FOR TICAGRELOR
Anne Bertling*, Kira Mergemeier, Georg Georg Geissler, Walter Sibrowski, Reinhard
Kelsch, Johannes Waltenberger, Joseph Jakubowski, Beate Kehrel (Germany) PO025-TUE ASSOCIATION OF THE MEAN PLATELET VOLUME (MPV) WITH THE
DIAGNOSIS OF ACUTE CORONARY SYNDROMES (ACS) AMONG PATIENTS
PO016-TUE TICAGRELOR REVERSAL: IN VITRO ASSESSMENT OF VARIOUS HEMO- WHO PRESENT WITH CHEST PAIN AT THE EMERGENCY ROOM (ER)
STATIC AGENTS Al-Zamzam Abubakar* (Philippines)
Leyla Calmette, Anne-Cline Martin, Bernard Le Bonniec, Isabelle Gouin-Thibault,
Christilla Bachelot-Loza, Pascale Gaussem, Anne Godier* (France) PO026-TUE RESIDUAL PLATELET FUNCTION IN ACS PATIENTS TREATED WITH PRA-
WEDNESDAY
SUGREL IS LOWER THAN IN PATIENTS TREATED WITH CLOPIDOGREL
PO017-TUE TWO DISINTEGRINS, TFV-1 AND TFV-3, PURIFIED FROM TRIMERE-
BUT NOT IN PATIENTS WITH HYPERTENSION
SURUS FLAVOVIRIDIS SNAKE VENOM, EXHIBIT DISTINCT EFFECTS ON
Phakwan Laohathai*, Rashi Joshi, Ashwin Radhakrishnan, Jane May, Natalia Dovlato-
PLATELET ACTIVATION va, Stan Heptinstall, Sue Fox (Thailand, United Kingdom)

TUESDAY
Tzu Yu Pan*, Chun-Chieh Hsu, Tur-Fu Huang (Taiwan)
PO027-TUE PREDICTORS OF NEW ONSET ATRIAL FIBRILLATION AFTER MYOCARDI-
PO018-TUE PLATELET INHIBITION MONITORING WITH THROMBOELASTOGRAPHY AL INFARCTION
(TEG) PLATELET MAPPING IN PEDIATRIC PATIENTS WITH VENTRICULAR Serenella Conti*, Maria Cristina Vedovati, Roberta Molle, Giorgio Maragoni (Italy)
ASSIST DEVICE
Tiphaine Belleville, Chiara Giorni, Christilla Bachelot-Loza, Philippe Pouard, Tiffany PO028-TUE EFFECTS OF MINERALOCORTICOID RECEPTOR ANTAGONISTS ON THE
TUESDAY
Pascreau, Vanessa Lopez, Camilla Biselli, Claudio Barbanti, Delphine Borgel, Domi- RISK OF MORTALITY, THROMBOSIS AND BLEEDING IN PATIENTS WITH
nique Lasne* (France)
POSTERS
SECONDARY HYPERALDOSTERONISM: A META-ANALYSIS OF RANDOM-
PO019-TUE THE PROGNOSTIC UTILITY OF PLATELET FUNCTION TESTING FOR THE IZED CONTROLLED TRIALS
DETECTION OF ASPIRIN RESISTANCE IN PATIENTS WITH ESTAB- Laura Elbers*, Barbara Sjouke, Victor Gerdes, Alessandro Squizzato (The Netherlands)
LISHED CARDIOVASCULAR DISEASE PO029-TUE URINARY 11-DEHYDRO-THROMBOXANE B2 IS ASSOCIATED WITH
Marie Lordkipanidze*, Janine Dretzke, Richard Riley, Sue Jowett, Jennifer ODonnell,
CARDIOVASCULAR EVENTS AND MORTALITY IN ATRIAL FIBRILLATION
Joie Ensor, Eoin Moloney, Malcolm Price, Smriti Raichand, James Hodgkinson, Sue
Bayliss, David Moore, David Fitzmaurice (Canada) PATIENTS.
MONDAY
Pasquale Pignatelli*, Daniele Pastori, William Hiatt, Gregory Lip, Francesco Violi (Italy)
PO020-TUE A TIME COURSE STUDY OF HIGH ON TREATMENT PLATELET REACTIVI-
TY IN ACS PATIENTS ON DUAL ANTIPLATELET THERAPY PO030-TUE ASSOCIATION BETWEEN CIRCULATING PROTEINS AND CORRESPOND-
Alessia Fabbri, Rossella Marcucci, Anna Maria Gori*, Betti Giusti, Rita Paniccia, Dan- ING GENES EXPRESSED IN CORONARY THROMBI IN PATIENTS WITH
iela Balzi, Alessandro Barchielli, Serafina Valente, Cristina Giglioli, Rosanna Abbate, ACUTE MYOCARDIAL INFARCTION
Gian Franco Gensini (Italy) Ragnhild Helseth*, Thomas Weiss, Trine Opstad, Svein Solheim, Matthias Freynhofer,
Kurt Huber, Harald Arnesen, Ingebjrg Seljeflot (Norway)
PO021-TUE INHIBITION OF PLATELET AGGREGATION BY GLS-409, AN ANTAGONIST
OF BOTH P2Y1 AND P2Y12, IS DISTINCT FROM INHIBITION BY SELEC- PO031-TUE VASCULAR SMOOTH MUSCLE CELLS ARE RESPONSIBLE FOR A PRO-
SUNDAY
TIVE P2Y1 AND P2Y12 ANTAGONISTS THROMBOTIC PHENOTYPE OF SPONTANEOUSLY HYPERTENSIVE RAT
Thomas Gremmel*, Ivan Yanachkov, George Wright, Alan Michelson, Andrew Frelinger ARTERIES
(Austria, United States) Amel Mohamadi*, Karima Ait Aissa, Jrmy Lagrange, Huguette Louis, Bndicte
Houppert, Pascal Challande, Denis Wahl, Patrick Lacolley, Vronique Regnault
PO022-TUE P2Y12 IS NOT INVOLVED IN THE INITIATION AND STABILIZATION OF (France)
MURAL THROMBI AFTER LASER INJURY OF AN ARTERY.
Roxane Darbousset*, Eva Caroff, Francis Hubler, Markus Riederer, Laurence Pani- PO032-TUE PLATELET ERK5 REGULATES THROMBOSIS AND MYOCARDIAL INFARCT
cot-Dubois, Christophe Dubois (France) EXTENSION VIA MATRIX METALLOPROTEINASES
SATURDAY
Scott J. Cameron*, Sara Ture, Kristina Modjeski, Deanne Mickelsen, Enakshi

PO023-TUE SAFETY OF RIVAROXABAN: EFFECTS ON PLATELET FUNCTION Chakrabarti, David Field, Jun-ichi Abe, Craig Morrell (United States)
J esus Hernandez*, Hugo Espejo, Manuel Moreno, Jose Hernandez, Irma Isordia, Abra-
ham Majluf (Mexico) PO033-TUE ELEVATED ARTERIAL STIFFNESS AND THROMBIN GENERATION IN
PATIENTS WITH END-STAGE RENAL DISEASE UNDERGOING HEMODIAL-
PO024-TUE THE START-ANTIPLATELETS REGISTER: A MULTICENTER OBSERVATION- YSIS
AL PROSPECTIVE STUDY TO ASSESS THE RISK-BENEFITS OF ANTI- Lucie Tran, Tomas Serrato, Yvonnick Bezie, Sylvain Marchais, Patrick Lacolley, Bruno
THROMBOTIC THERAPY IN ACS PATIENTS. Pannier, Vronique Regnault* (France)
Rossella Marcucci, Vittorio Pengo*, Giuseppe Patti, Paolo Gresele, Emilia Antonucci,
Serafina Valente, Alessia Bracco, Tiziana Fierro, Ilaria Cavallari, Gian Franco Gensini,
218 Gualtiero Palareti (Italy) 219
PO034-TUE THROMBOGENIC STATE AFTER VASCULAR SURGERY AND PERIOPERA- PO043-TUE ATHEROSCLEROTIC CARDIOVASCULAR MORTALITY IN GOUTY ARTHRI-
THURSDSAY
TIVE CARDIOVASCULAR EVENTS TIS AND RHEUMATOID ARTHRITIS: IS IT ASSOCIATED WITH MEAN
Daniela Calderaro*, Tania Rubia Rocha, Adriana Pastana, Fernanda Justo, Danielle PLATELET VOLUME AND NEUTROPHIL/LYMPHOCYTE RATIO
Gualandro, Pai Yu, Mariana Matheus, Elbio DÀmico, Bruno Caramelli (Brazil) Gulsum Pamuk*, Muhammet Maden, Mehmet Uyanik, Omer PAMUK (Turkey)
PO035-TUE CLINICAL FEATURES OF VASCULAR EVENTS IN PATIENTS WITH AL

AMYLOIDOSIS Blood coagulation tests II
Hyunkyung Park*, Ji-Won Kim, Youngil Koh, Jeong-Ok Lee, Ki Hwan Kim, Soo-Mee
Bang, Inho Kim, Junglim Lee, Sung-Soo Yoon, Jeong-Wook Seo, Dae-Won Sohn, Seon-
yang Park (Korea, Republic Of) PO044-TUE EVALUATION OF THE LABORATORY METHOD IN PREGNANT WOMEN
WEDNESDAY
WITH COMPLICATED OBSTETRIC HISTORY FOR HAEMOSTASIS MONI-
TORING
Atherosclerosis II Nadezda Vorobyeva*, Yulia Pavlovskaia (Russian Federation)
TUESDAY
PO045-TUE EFFECTS OF LOW AND HIGH LEVELS OF NON VKA ORAL ANTICOAGU-
PO036-TUE SIMULTANEOUS OBSERVATION OF PERIPHERAL MONONUCLEAR CELL LANTS ON A COMPREHENSIVE PANEL OF ROUTINE AND SPECIALTY
AND PLASMA TFS EXPRESSION FOR PREVENTION AND TREATMENT OF COAGULATION TESTS
ISCHEMIC CARDIOCEREBROVASCULAR DISEASES Sverine Perroche, Nathalie Barat, Franois Depasse*, Franois Nicham, Anne Magde-
Rui Wang*, Tong Ma (China) laine, David Courtois, Tristan Herv, Jrme Beltran (France)
TUESDAY
PO037-TUE TOTAL CHEMICAL SYNTHESIS OF COVALENT RANTES-PF4 HETERODI- PO046-TUE FVIII SENSITIVE AUTOMATED THROMBIN GENERATION TEST OF CA-
POSTERS
MERS TO STUDY INITIATION AND PROGRESSION OF ATHEROSCLERO- NINE PLASMA
SIS Daniel Elenius Madsen*, Timothy Nichols, Emily Waters, Pernille Holm, Elizabeth
Stijn Agten, Dennis Suylen*, Hans Ippel, Kevin Mayo, Rory Koenen, Christian Weber, Merricks, Alisa Wolberg, Bo Wiinberg (Denmark)
Tilman Hackeng (The Netherlands)
PO047-TUE DIFFERENT CENTRIFUGATION CONDITIONS DO NOT INTERFERE WITH
PO038-TUE ENDOTHELIAL DELETION OF THIOREDOXIN-INTERACTING PROTEIN D-DIMER RESULTS
PRESERVES MOUSE ARTERIES FROM AGING INDUCED BY METABOLIC Carlos Aguilar*, Sylvaine Savigny (Spain)
MONDAY
DISORDERS
Tatiana Bedarida, Elise Dreano*, Franoise Vibert, Charles-Henry Cottart, Christilla PO048-TUE THROMBIN GENERATION IN THE NORMAL POPULATION FLATTENED
Bachelot-Loza, Pascale Gaussem, Stephanie Baron, Valerie Nivet-Antoine (France) THROMBIN GENERATION CURVES ASSOCIATED WITH POOR LIPID PRO-
FILE AND MALE SEX.
PO039-TUE HIGH LIPOPROTEIN(A) LEVELS ARE ASSOCIATED WITH CORONARY Prahlad Ho*, Carole Smith, Joseph Rigano, Geoffrey Donnan (Australia)
CALCIUM SCORE IN THE MONTIGNOSO STUDY POPULATION
Alice Sereni, Anna Maria Gori*, Rossella Marcucci, Betti Giusti, Francesco Sofi, Dante PO049-TUE THE RIVAROXABAN-CALIBRATED ANTI-FXA ASSAY CAN RELIABLY IDEN-
Chiappino, Daniele Della Latta, Rosanna Abbate, Gian Franco Gensini (Italy) TIFY PRESENCE OF RIVAROXABAN IN PLASMA
Jerzy Windyga*, Beata Baran, Miroslaw Lis, Edyta Odnoczko, Ewa Stefanska-Windyga
SUNDAY
PO040-TUE ASSOCIATION OF GAMMA-GLUTAMYL TRANSFERASE TO THE PREMA- (Poland)
TURE CORONARY ARTERY DISEASE IN YOUNG ASIAN INDIANS
Madankumar Ghatge*, Ankit Sharma, Rajani kanth Vangala (India) PO050-TUE A FULLY AUTOMATED AID FOR THE IMPROVEMENT OF HIL INTER-
FERENCE MANAGEMENT IN THE HEMOSTASIS LABORATORY: TEST
PO041-TUE CORONARY ARTERY DISEASE SEVERITY IS A MARKER OF THE ANTI-IN- ASSAY-SPECIFIC FLAGGING OF LABORATORY RESULTS FOR HEMOLYSIS,
FLAMMATORY RESPONSE TO STATIN THERAPY ICTERUS AND LIPEMIA/TURBIDITY
Rahil Rafeedheen, Kevin Bliden, Anand Singla, Martin Gesheff, Shachi Pandya, Rohit
Janos Polgar*, Hui-Feng Lin, Jack Havelick, Mary Doyle, Mark Triscott (United States)
Gosain, Udaya Tantry, Paul A. Gurbel* (United States)
SATURDAY
PO051-TUE HANDLING OF THE HEMOCLOT THROMBIN INHIBITOR ASSAY RE-

PO042-TUE EFFECTS OF 12 MONTHS EXERCISE INTERVENTION ON ADIPOSE
AGENTS ON SYSMEX CS-2100I WHEN MONITORING DABIGATRAN IN
TISSUE EXPRESSION OF CHEMOKINES IN PATIENTS WITH TYPE 2
ACUTE CLINICAL SITUATIONS
DIABETES AND STABLE CORONARY ARTERY DISEASE: A SUBSTUDY OF
Louise Faaborg*, Willemijn Comuth, Anna-Marie Bloch-Mnster, Linda Henriksen,
A RANDOMIZED CONTROLLED TRIAL (RCT). Steen Husted (Denmark)
Ida Unhammer Njerve*, Rune Byrkjeland, Harald Arnesen, Sissel kra, Svein Solheim,
Ingebjrg Seljeflot (Norway) PO052-TUE TIME IN THERAPEUTIC RANGE AND COMPLICATIONS OF ANTITHROM-
BOTIC TREATMENT
Milena Scekic* (Serbia)
220 221
PO053-TUE USEFULNESS OF DILUTE RUSSELLS VIPER VENOM CLOTTING TIME PO064-TUE INTRODUCTION OF A LIQUID ANTI-XA METHOD FOR QUANTIFICATION
THURSDSAY
(DRVVT) FOR THE ROUTINE MONITORING OF NEW ORAL ANTICOAGU- OF CURRENT THERAPEUTIC XA INHIBITORS
LANTS Helen Lewis*, Jane Needham, Nina Harrison, Savita Rangarajan (United Kingdom)
Debra Hoppensteadt*, Jake Kola, Mark Brayne, Omer Iqbal, Jawed Fareed (United
States) PO065-TUE PRELIMINARY PERFORMANCE DATA OF A NEW CHROMOGENIC DIRECT
ANTI-XA ASSAY EVALUATED FOR THE QUANTIFICATION OF RIVAROX-
PO054-TUE PERFORMANCE OF HEMOSIL DIRECT THROMIN INHIBITOR (DTI) ASSAY ABAN
ON THE ACL TOP FAMILY INSTRUMENTS Sabine Pilgrim*, Viktoria Esch, Karin Kolbe-Scheu, Barbara Krumpholz, Matthias
Judith Hammelburger*, Zhenghua Cao, Ralph Bottenus, Mark Triscott (United States) Schleifer, Andrea Lichte (Germany)
WEDNESDAY
PO055-TUE IN VITRO CORRECTION OF IMPAIRED BLOOD COAGULATION IN A MOD- PO066-TUE PRELIMINARY EVALUATION OF A NEW CHROMOGENIC ASSAY FOR THE
EL OF SEVERE THROMBOCYTOPENIA BY FIBRINOGEN AND ACTIVATED QUANTITATIVE DETERMINATION OF DABIGATRAN IN HUMAN PLASMA
PROTHROMBIN COMPLEX CONCENTRATE Julia Mueller*, Sabine Halilovic, Isabell Kieper-Rupp, Dieter Koch, Juergen Kurz,
TUESDAY
Boris Shenkman* (Israel) Andrea Lichte (Germany)
PO056-TUE NEW IMMUNODEPLETED PLASMA FOR DETERMINATION OF FACTOR XI PO067-TUE PREDICTION OF BLEEDING TENDENCY IN HEMOPHILIA A AND B USING
ACTIVITY THROMBODYNAMICS ASSAY
Vicente Cortina*, Carmen Altisent, Anna Castro, Rafael Parra, Vernica Pons, Laura Natalia M. Dashkevich*, Mikhail Panteleev, Fazoil Ataullakhanov, Claude Negrier
Lpez Andreoni, Pavel Olivera, Ana Marn, Francesc Bosch, Amparo Santamara (France, Russian Federation)
TUESDAY
(Spain)
PO068-TUE DO PT AND APTT SENSITIVITIES TO FACTOR DEFICIENCIES CALCULAT-
POSTERS
PO057-TUE ASSESSMENT OF THROMBIN GENERATION TEST FOR BYPASSING ED BY THE H47-A2 2008 CLSI GUIDELINE REFLECT THE DEFICIENCIES
THERAPY MONITORING IN HAEMOPHILIA PATIENT WITH INHIBITOR FOUND IN PLASMA FROM PATIENTS?
Olga Smirnova*, Yuriy Namestnikov, Inna Markova, Olga Golovina, Ludmila Papayan Marta Martinuzzo*, Luis Barrera, Marcos Rodriguez, Azogaray Viviana, Mara DÀda-
(Russian Federation) mo, Marina Lpez, Juan Otaso (Argentina)
PO058-TUE EVALUATION OF A NEW ASSAY FOR THE MEASUREMENT OF THE PO069-TUE MARKERS OF HEMOSTASIS ACTIVATION AFTER EARLY DISCONTINUA-
DIRECT FXA INHIBITOR RIVAROXABAN (DG-CHROM ANTI-XA) ON THE Q TION OF FONDAPARINUX IN LOW-RISK PATIENTS HOSPITALIZED WITH
MONDAY
HEMOSTASIS ANALYZER (GRIFOLS) NON-ST-ELEVATION ACUTE CORONARY SYNDROME
Kieron Hickey*, Steve Kitchen (United Kingdom) Igor S. Yavelov*, Anatoly Knyazev, Anatoly Dobrovolsky, Nikolay Gratsiansky (Russian
Federation)
PO059-TUE HOW THE DIRECT ORAL ANTICOAGULANT APIXABAN AFFECTS THROM-
BIN GENERATION PARAMETERS PO070-TUE NEW INSIGHTS FOR FACTOR ANALYSIS WITH APTT AND PT FOR FAC-
Erica Scalambrino*, Lidia Padovan, Veena Chantarangkul, Sophie Testa, Flora Pey- TORS IX, VIII, XI AND FACTOR V.
vandi, Armando Tripodi (Italy) Cornelis Kluft*, Cornelis van Leuven (The Netherlands)
PO060-TUE THE CORRELATION OF ATYPICAL APTT CURVES WITH TYPE OF COAGU- PO071-TUE RELIABILITY OF A NEW POINT-OF-CARE PORTABLE COAGULOMETER
SUNDAY
LATION DEFECT FOR PT-INR TEST PERFORMED IN THE HOSPITAL ANTICOAGULATION
Ludek Slavik*, Jana Ulehlova, Antonin Hlusi, Jana Prochazkova, Vera Krcova (Czech CLINIC.
Republic) Rita Paniccia*, Raffaella Priora, Rossella Marcucci, Lucia Mannini, Daniela Poli, Ele-
onora Tafuro, Fanny Attinasi, Laura Gori, Agatina Alessandrello Liotta, Rosanna Abbate
PO061-TUE EFFICACY OF NOVEL ORAL ANTICOAGULANTS (NOACS) USING DILUTED (Italy)
RUSSELLS VIPER VENOM TEST (DRVVT)
Makoto Kaneko*, Nobuko Kanno, Yutaka Yatomi (Japan) PO072-TUE STRENUOUS EXERCISE INDUCES A PROTHROMBOTIC STATE THAT IS
MORE PRONOUNCED IN MEN THAN IN WOMEN
SATURDAY
PO062-TUE EX-VIVO AND IN-VITRO COMPARATIVE ASSESSMENT OF MOD-5014 Dana Huskens*, Mark Roest, Jasper Remijn, Saartje Bloemen, Joke Konings, Evelien
(FACTOR VIIA-CTP), A NOVEL LONG-ACTING COAGULATION FACTOR TO Schurgers, Romy Kremers, Hilde Kelchtermans, Rinaldo van Meel, Rolf Urbanus,
RECOMBINANT FVIIA Marisa Ninivaggi, Bas de Laat (The Netherlands)
Gili Hart, Tami Livnat*, Boris Shenkman, Ahuva Bar -Ilan, Lior Binder, Malka Hoff-
man, Gili Kenet (Israel) PO073-TUE WHOLE BLOOD PLATELET ACTIVITY MEASUREMENTS MULTIPLEXED
WITH QUANTITATIVE FIBRINOGEN, CLOT TIME AND FIBRINOLYSIS MEA-
PO063-TUE IMPACT OF EDOXABAN ON HAEMOSTASIS DIAGNOSIS ASSAYS: PRACTI- SUREMENTS BY T2MR
CAL RECOMMENDATIONS Roger Smith*, Vyacheslav Papkov, Pierrette Andre, Oleg Yerov, Chuck Ritterhaus,
Jonathan Douxfils*, Tania Del Bianco, Justine Baudar, Sarah Lessire, Bernard Chate- Thomas Lowery (United States)
lain, Jean-Michel Dogn, Franois Mullier (Belgium)
222 223
PO074-TUE VARIABILITY IN NORMAL RANGES OF THROMBIN GENERATION BE- PO085-TUE TEST SPECIFIC ASSESSMENT OF EFFECTS OF HAEMOLYSIS ON CITRAT-
THURSDSAY
TWEEN LABORATORIES IS WIDE AND DEPENDENT ON TEST METHOD- ED BLOOD SAMPLES USING SYSMEX CS SERIES ANALYSERS
OLOGY Anita Woolley*, Yuka Tabuchi, Steve Kitchen (United Kingdom)
Hartirathpal Kaur*, Chuen Wen Tan, Wan Hui Wong, Yeh Ching Linn, Heng Joo Ng
(Singapore) PO086-TUE PROVINCE WIDE IMPLEMENTATION OF THE THROMBIN TIME FOR
QUALITATIVE ASSESSMENT OF DABIGATRAN CLEARANCE
PO075-TUE RESISTANCE TO THROMBOMODULIN BUT NOT TO ACTIVATED PROTEIN Artur Szkotak*, Gwen Clarke, Lisa Vandergouwe, Linda Stang (Canada)
C IN CIRRHOTIC PATIENTS
Thomas Sinegre*, Cedric Duron, Alain Marques-Verdier, Graldine Lamblin, Anne- PO087-TUE EFFECTS OF RIVAROXABAN ON PT AND APTT AS DETERMINED WITH A
Franoise Sapin, Armand Abergel, Aurelien Lebreton (France) FULL RANGE OF REAGENTS: RESULTS OF A UK NEQAS BLOOD COAGU-
WEDNESDAY
LATION EXERCISE
PO076-TUE HYPERCOAGULABILITY AND HIGH RESIDUAL PLATELET REACTIVITY IN Stephen Kitchen*, Ian Jennings, Rob Jones, Dianne Kitchen, Tim Woods, Isobel Walker
ACS PATIENTS ON DUAL ANTIPLATELET THERAPY. (United Kingdom)

TUESDAY
Rita Paniccia*, Rossella Marcucci, Monica Attanasio, Elisa Grifoni, Raffaella Priora,
Yusuf Ahmed, Cristina Giglioli, Rosanna Abbate, Gian Franco Gensini (Italy) PO088-TUE A NOVEL PLASMA-BASED FACTOR XA GENERATION ASSAY DEFINES
INTERACTION BETWEEN FVIIIA AND EACH COMPONENT OF XASE COM-
PO077-TUE EMERGENCY ASSESSEMENT OF PATIENTS IN DOACS: THE ROLE OF PLEX IN MILD HEMOPHILIA A.
POINT-OF-CARE TESTING. Nao Kamiya*, Koji Yada, Midori Shima, Keiji Nogami (Japan)
Paolo Carraro*, Haleh Afshar, Seena Padayattil Jose, Giacomo Zoppellaro, Gentian
TUESDAY
Denas, Manuela Miolo, Giovanni Nante, Mario Plebani, Vittorio Pengo (Italy) PO089-TUE THE FVIII PLASMA ACTIVITY OF RVIII-SINGLE CHAIN CAN BE MEA-
SURED IN BOTH THE ONE-STAGE AND CHROMOGENIC SUBSTRATE
POSTERS
PO078-TUE EVALUATING DABIGATRAN AND ITS SPECIFIC REVERSAL WITH IDARU- ASSAYS
CIZUMAB USING A FULLY AUTOMATED THROMBELASTOGRAPH TEG6S Katie St.Ledger*, Annette Feussner, Uwe Kalina, Carsten Horn, Hubert Metzner,
Fowzia Zaman*, Marc Doubleday, Oliver Grottke, Joanne Van Ryn (United States) Anthony Stowers, Debbie Bensen Kennedy (United States)
PO079-TUE EFFECT OF THE RESIDUAL PLATELET COUNT ON DIFFERENT COAGULA- PO090-TUE USEFULNESS OF COAGULATION SCREENING TESTS FOR DIAGNOSIS OF
TION PARAMETERS IN FREEZE-THAW PLASMA SAMPLES AT -20C COAGULOPATHY
Yolanda Adamczuk*, Sebastin de Vega, Marcela Pagano, Mabel Viola, Mara Lamas, Maria Rosaria Fasulo*, Eugenia Biguzzi, Simona Siboni, Antonino Cannav, Claudia
MONDAY
Gilda Lumelsky, Mara Brizuela, Ana Zerdiew (Argentina) Mistretta, Maria Elisa Mancuso, Elena Santagostino, Flora Peyvandi (Italy)
PO080-TUE CORRELATION TO FVIII:C IN TWO THROMBIN GENERATION ASSAYS: PO091-TUE BLEEDING SYMPTOMS OR BLEEDING DISORDER? THAT IS THE QUES-
TGA CAT AND INNOVANCE ETP TION
Marcus Ljungqvist*, Maria Berndtsson, Margareta Holmstrm, Jovan Antovic, Erik Maria Rosaria Fasulo*, Eugenia Biguzzi, Simona Siboni, Antonino Cannav, Claudia
Berntorp, Danijela Micovic, Ivo Elezovic, Eva Zetterberg (Sweden) Mistretta, Maria Elisa Mancuso, Elena Santagostino, Flora Peyvandi (Italy)
PO081-TUE INFLUENCE OF VARIOUS CONCENTRATIONS OF ANTICOAGULANTS ON PO092-TUE EVALUATION OF AN AUTOMATED COAGULOMETER IN A NEW HAEMO-
THE THROMBODYNAMICS ASSAY: AN IN VITRO STUDY PHILIA CARE CENTER
SUNDAY
Gaetan Flament, Laurence Rozen, Sara Derdabi, Anne Demulder* (Belgium) Mirta Arias, Emanuel Sueldo, Beatriz Erramouspe, Rodrigo Porsella, Gabriela Guerrero,
Patricia Do Nascimento*, Alejandra Baques (Argentina)
PO082-TUE OVERALL HEMOSTATIC POTENTIAL ASSAY IS SENSITIVE TO DIFFERENT
PLASMA FREEZING TECHNIQUES PO093-TUE FACTOR VIII INHIBITORS QUANTIFIED USING CLOT WAVEFORM ANALYSIS
Mojca Bozic-Mijovski*, Blanka Ulaga (Slovenia) Thomas Siegemund*, Rosemarie Schobess, Ute Scholz, Annelie Siegemund (Germany)
PO083-TUE DEFINING THE REFERENCE RANGE FOR BLOOD CLOT GEL POINT AND
FRACTAL DIMENSION Cancer and thrombosis/hemostasis II
SATURDAY
Lindsay Dsilva, Raza Alikhan*, Sophia Stanford, Ahmed Sabraa, Matthew Lawrence,
Rhodri Williams, Phillip Evans (United Kingdom)
PO094-TUE TISSUE FACTOR DOWNREGULATION BY THE PUTATIVE ONCOGENIC
PO084-TUE EFFECT OF HYPOTHERMIA AND HEMODILUTION ON CLOTTING ACTIVA- MICRORNA, MIR-520G, IN EMBRYONAL BRAIN TUMOUR CELLS
TION: ROTATIONAL THROMBOELASTOMETRY ANALYSIS IN AN ARTIFI- Esterina DAsti*, Annie Huang, Marcel Kool, Andrey Korshunov, Stefan Pfister, Janusz
CIAL ENVIRONMENT FROM HEALTHY SUBJECTS. Rak (Canada)
Sabrina Boraso*, Giuseppe Gagliardi, Alessandro Agnoli, Cinzia Bettin, Paolo Carraro,
Haleh Afshar, Gaia Lembo, Domenico Prisco, Rita Paniccia (Italy) PO095-TUE VTE RECURRENCE AND BLEEDING IN PATIENTS WITH CANCER. RE-
SULTS OF THE OPTIMEV STUDY
Marie Sevestre*, Celine Genty, Carole Rolland, Gilles Pernod, Jean-Luc Bosson (France)
224 225
PO096-TUE COLLABORATIVE EFFORTS OF THE NATIONAL HEART, LUNG, AND PO105-TUE MANAGEMENT OF CANCER ASSOCIATED THROMBOSIS IN FRANCE :
THURSDSAY
BLOOD INSTITUTE AND THE NATIONAL CANCER INSTITUTE IN CANCER A NATIONAL SURVEY IN VASCULAR DISEASE AND SUPPORTIVE CARE
AND THROMBOSIS SPECIALISTS
Michelle A. Berny-Lang*, Andrei Kindzelski, Traci Mondoro, Emily Greenspan (United Isabelle Mah*, Jean-Baptiste Rey, Ismail Elalamy, Anne Lamblin, Didier Mayeur,
States) Gilles Pernod (France)
PO097-TUE PATIENTS EXPERIENCES OF LIVING WITH CANCER ASSOCIATED PO106-TUE VENOUS THROMBOEMBOLISM AFTER SURGICAL TREATMENT OF SKEL-
THROMBOSIS: THE PELICAN STUDY ETAL METASTASES AN UNDERDIAGNOSED COMPLICATION
Simon Noble*, Hayley Prout, Annmarie Nelson (United Kingdom) Riitta Lassila*, Maire Ratasvuori, Minna Laitinen (Finland)
WEDNESDAY
PO098-TUE CANCER ASSOCIATED THROMBOSIS: DEVELOPING CONSENSUS GUID- PO107-TUE MAJOR AND NON-MAJOR CLINICALLY RELEVANT BLEEDING IN PA-
ANCE TO IMPROVE PATIENT CARE AND OUTCOMES TIENTS HOSPITALIZED IN PALLIATIVE CARE UNITS: RESULTS OF A
Simon Gwynn, Roopen Arya*, John McPhelim, Toby Talbot, John Pasi, Gail Fortes-May- FRENCH MULTICENTRE OBSERVATIONAL STUDY.
TUESDAY
er, Nitil Kedia, Stefan Kokiet, Malgosia King (United Kingdom) Bernard Tardy*, Cline Chapelle, Stphane Picard, Didier De Broucker, Marie Delerue,
Thomas Celarier, Pascale Vassal, Jean-Franois Ciais, Sbastien Salas, Elise Perceau,
PO099-TUE REDUCING CLOT RISK IN POST-OPERATIVE CANCER PATIENTS: WHAT Marilne Filbet, Frdric Guirimand, Jean-Marie Gomas, Christine Decherf, Laurent
IS THE COMMON GROUND AMONG INTERNATIONAL VTE PREVENTION Bertoletti, Aline Guillot, Jean-Baptiste Gaultier, Madjid Akrour, Florence Rancon, Adel
GUIDELINES? Merah, Silvy Laporte (France)
Carol Jackson* (United States)
TUESDAY
PO108-TUE HEALTHCARE RELATED COST OF THROMBOTIC EVENTS IN ELDERLY
PO100-TUE AGE-ADJUSTED D-DIMER CUT-OFF LEVEL INCREASES THE NUMBER OF PATIENTS: A RETROSPECTIVE DATABASE ANALYSIS
POSTERS
CANCER PATIENTS IN WHOM PULMONARY EMBOLISM CAN BE SAFELY Abiola Oladapo*, Yan Xiong, Aaron Novack, Joshua Epstein (United States)
EXCLUDED WITHOUT CTPA IMAGING: THE ADJUST-PE CANCER SUB-
STUDY PO109-TUE THE UTILITY OF PEMB-QOL AND VEINES-QOL/SYM QUESTIONNAIRES IN
Dorienke Wilts*, Grgoire Le Gal, Paul den Exter, Josien van Es, Marc Carrier, Benja-
EVALUATING QUALITY OF LIFE IN THE CANCER ASSOCIATED THROMBO-
min Planquette, Harry Bller, Marc Righini, Menno Huisman, Pieter Kamphuisen (The SIS PATIENT.
Netherlands) Hayley Prout, Annmarie Nelson, Simon Noble* (United Kingdom)
MONDAY
PO101-TUE RATES OF VENOUS THROMBOEMBOLISM DESPITE THROMBOPROPHY- PO110-TUE PATIENTS PREFERENCES FOR THE TREATMENT OF CANCER ASSOCIAT-
LAXIS IN MULTIPLE MYELOMA PATIENTS RECEIVING LENALIDOMIDE OR ED THROMBOSIS
POMALIDOMIDE: A SYSTEMATIC REVIEW AND META-ANALYSIS Simon Noble, Anthony Maraveyas, Axel Matzdorff, Majbrit Vindt Holm, Giovanni Pisa
Miriam Kimpton*, Marc Carrier, Jason Tay, Alexandra Davis, Gregoire Le Gal (Canada) (United Kingdom)
PO102-TUE PROSPECTIVE EVALUATION OF RISK ASSESSMENT MODELS AND PO111-TUE AGE SHOULD NOT BE CONSIDERED A RISK FACTOR FOR CANCER-RE-
BIOLOGICAL MARKERS OF HYPERCOAGULABILITY FOR THE IDENTIFI- LATED VENOUS THROMBOEMBOLISM: RESULTS FROM THE SCANDINA-
CATION OF HIGH VTE RISK PATIENTS WITH LUNG ADENOCARCINOMA. VIAN THROMBOSIS AND CANCER STUDY
Kristine Blix*, Marianne Severinsen, Sigrid Brkkan, Hilde Jensvoll, Olga Dziewiec-
SUNDAY
THE ROADMAP STUDY.
ka, Sren Kristensen, Kim Overvad, Anne Tjnneland, Inger Anne Nss, Jens Hammer-
Ilias Evmorfiadis, Boura Paraskevi, Aurlie Rousseau, Ariadni Charpidou, Patrick Van
strm, Frits Rosendaal, Suzanne Cannegieter, John-Bjarne Hansen (Norway)
Dreden, Giannis Giozos, Konstantinos Syrigos, Anastasia Spanoudaki, Matthieu Grusse,
Ismail Elalamy, Grigoris Gerotziafas* (France)
PO112-TUE CANCER-RELATED VENOUS THROMBOEMBOLISM IN THE GENERAL
PO103-TUE UNSUSPECTED PULMONARY EMBOLISM IN CANCER PATIENTS: AN POPULATION: RESULTS FROM THE SCANDINAVIAN THROMBOSIS AND
INTERNATIONAL, ONGOING, PROSPECTIVE, OBSERVATIONAL STUDY CANCER (STAC) STUDY
Suzanne M. Bleker*, Nick van Es, Ankie Kleinjan, Harry Bller, Joke Baars, Laurent Kristine Blix*, Marianne Severinsen, Sigrid Brkkan, Hilde Jensvoll, Olga Dziewiec-
ka, Sren Kristensen, Kim Overvad, Anne Tjnneland, Inger Anne Nss, Jens Hammer-
SATURDAY
Bertoletti, Jan Beyer - Westendorf, Joel Constans, Francis Couturaud, Anna Falanga,
Diana Iosub, Isabelle Mah, Guy Meyer, Andrs Munoz Martn, Ettore Porreca, Sebas- strm, Frits Rosendaal, Suzanne Cannegieter, John-Bjarne Hansen (Norway)
tian Werth, Marcello Di Nisio (The Netherlands)
PO113-TUE INCIDENCE, RISK FACTORS, AND OUTCOME OF EARLY HEMOSTATIC
PO104-TUE RISK OF SUBSEQUENT CANCER AFTER A VENOUS THROMBOEMBOLISM COMPLICATIONS IN PATIENTS AFTER ALLOGENEIC HEMATOPOIETIC
- THE SCANDINAVIAN THROMBOSIS AND CANCER (STAC) STUDY STEM CELL TRANSPLANTATION: A RETROSPECTIVE MULTICENTER
Hilde Jensvoll*, Marianne Severinsen, Jens Hammerstrm, Sigrid Brkkan, Sren STUDY OF 551 PATIENTS
Kristensen, Suzanne Cannegieter, Kristine Blix, Anne Tjnneland, Frits Rosendaal, HAN Yue*, Wu Depei, HAN Wei, Wang Jie, WANG Zhaoyue, RUAN Changgeng (China)
Olga Dziewiecka, Kim Overvad, Inger Anne Nss, John-Bjarne Hansen (Norway)
226 227
PO114-TUE DETECTION OF HYPERCOAGULABILITY IN HEPATOCELLULAR CARCINO- PO125-TUE EVALUATION OF MEAN PLATELET VOLUME AS A PREDICTIVE MARK-
THURSDSAY
MA (HCC). ER FOR VENOUS THROMBOEMBOLISM AND MORTALITY IN PATIENTS
Luca Spiezia*, Kryssia Rodriguez-Castro, Elena Campello, Alberto Zanetto, Sabrina TREATED FOR DIFFUSED LARGE B-CELL LYMPHOMA
Gavasso, Barry Woodhams, Marco Senzolo, Patrizia Burra, Paolo Simioni (Italy) Joanna Rupa-Matysek*, Lidia Gil, Mieczysaw Komarnicki (Poland)
PO115-TUE ROLE OF ARTERIAL CARDIOVASCULAR RISK FACTORS IN THE PATHO- PO126-TUE A NEW GENERIC RISK SCORE FOR PREDICTING VENOUS THROMBOEM-
GENESIS OF CANCER RELATED VTE. BOLIC EVENTS IN CANCER PATIENTS RECEIVING CHEMOTHERAPY
Francesco Dentali*, Graziella Pinotti, Mara Mantiero, Alessia Pastore, Walter Ageno Andres Muoz*, Andrey Ziyatdinov, Juan Carlos Souto, Jose Manuel Soria (Spain)
(Italy)
PO127-TUE THROMBOPROPHYLAXIS OF AMBULANT PANCREATIC CANCER PA-
WEDNESDAY
PO116-TUE FACTORS INFLUENCING THE USE OF THROMBOPROPHYLAXIS IN AM- TIENTS: SINGLE CENTRE EXPERIENCE UTILIZING THE LESSONS FROM
BULATORY CANCER PATIENTS IN THE REAL WORLD CLINICAL PRAC- FRAGEM AND CONKO-04.
TICE Iqtedar Ahmed Muazzam*, Anthony Maraveyas (United Kingdom)

TUESDAY
Elena Panizo, Ana Alfonso, Alberto Garca-Mouriz, Jos Lpez-Picazo, Ignacio Gil-Bazo,
Jos Hermida, Jos Pramo, Ramn Lecumberri* (Spain) PO128-TUE TREATMENT OF CANCER ASSOCIATED THROMBOSIS AFTER THE INITIAL
6 MONTH PERIOD.
PO117-TUE RESIDUAL VEIN THROMBOSIS TO ASSES THE DURATION OF LOW MO- Petr Kessler*, Hynek Poul, Michaela Harudova (Czech Republic)
LECULAR WEIGHT HEPARIN (THE EXTENDED CANCER-DACUS)
Mariasanta Napolitano*, Giorgia Saccullo, Simona Raso, Salvatrice Mancuso, Alessan-
TUESDAY
dra Casuccio, Sergio Siragusa (Italy) Coagulation factor V, X, II, XIII - II
POSTERS
PO118-TUE BETWEEN A ROCK AND A HARD PLACE: CONUNDRUMS IN THE MAN-
AGEMENT OF CEREBRAL SINOVENOUS THROMBOSIS (CSVT) IN CHIL- PO129-TUE DEFINING THE DIFFERENTIAL EFFECTS OF NOVEL ANTICOAGULANTS:
DREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)/LYMPHOMA. FXA VERSUS FIIA INHIBITION ON COAGULATION AND INFLAMMATION
Uma Athale*, Jeremy Robertson, Martha Rolland, Mahendranath Moharir, Suzan Khurrum Shahzad*, Fabian Bock, Dong Wei, Wang Hongjie, Ina Thielmann, Bernhard
Williams, Anthony Chan, Leonardo Brandao (Canada) Nieswandt, Madhusudhan Thati, Berend Isermann (Pakistan, Germany)
PO119-TUE A PROSPECTIVE STUDY ON THE INCIDENCE OF POSTOPERATIVE PO130-TUE RIVAROXABAN ASSOCIATES WITH FACTOR XA FASTER THAN APIXABAN:
MONDAY
VENOUS THROMBOEMBOLISM IN KOREAN COLORECTAL CANCER PA- A POTENTIAL EXPLANATION FOR THEIR DIFFERENT EFFECTS ON TESTS
TIENTS OF COAGULATION
Eunyoung Lee*, Sung-Bum Kang, Sang Il Choi, Eun Ju Chun, Soo-Mee Bang, Duck- Calvin Yeh*, Brian Dale, Beverly Leslie, Paul Kim, James Fredenburgh, Jack Hirsh,
Woo Kim, Heung-Kwon Oh, Jeong-Ok Lee, Jin Won Kim, Yu Jung Kim, Jee Hyun John Eikelboom, Jeffrey Weitz (Canada)
Kim, Jong Seok Lee, Keun-Wook Lee (Korea, Republic Of)
PO131-TUE GENERATION OF A RECOMBINANT TRUNCATED ACTIVATED FACTOR X
PO120-TUE THROMBOEMBOLIC EVENTS IN CHILDREN WITH CANCER IN SRI- AS ANTI-HEMOPHILIC AGENT
NAGARIND HOSPITAL Toufik Abache, Anne-Sophie Dezetter, Alain Longue, Dominique Grenier, Cline Bour-
Patcharee Komvilaisak*, Arunee Jetsrisuparb, Surapon Wiangnon, Paiporn Sripraya don, Marie-Claire Dagher, Raphael Marlu, Alexandre Fontayne, Benoit Polack, Jean-Luc
SUNDAY
(Thailand) Plantier* (France)
PO121-TUE THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH LYMPHOMA PO132-TUE PHENOTYPIC AND GENOTYPIC CHARACTERIZATION OF SEVERE FACTOR
Darko Antic*, Srdjan Nikolovski, Natasa Milic, Vladislava Djurasinovic, Vojin Vukovic, VII DEFICIENCY PATIENTS IN CENTRAL CHINA
Biljana Mihaljevic (Serbia) Hui Liu*, Huafang Wang, Liang Tang, Zhipeng Cheng, Qingyun Wang, Bei Hu, Yu Hu,
Wei Zeng, Yingying Wu (China)
PO122-TUE SELECTION OF ANTICOAGULATION THERAPY IN CANCER PATIENTS
Alexander Vorobev*, Alexander Makatsaria (Russian Federation) PO133-TUE FRAGMENT-2 INHIBITION OF PROTHROMBINASE REVEALS A UNIQUE
SATURDAY
ENZYME-SUBSTRATE INTERFACE FOR THE PLATELET-BOUND ENZYME

PO123-TUE DIC AND THROMBOPHILIA DURING CHEMOTHERAPY AND ITS PREVEN- Francis Ayombil*, Laura Haynes, Paula Tracy (United States)
TION APPROACHES IN OVARIAN CANCER PATIENTS
Alexander Vorobev* (Russian Federation) PO134-TUE NOVEL F10: P. CYS57ARG MUTATION IN A PAKISTANI SEVERE FX-DEFI-
CIENT PROBAND
PO124-TUE MORTALITY FOLLOWING VENOUS THROMBOEMBOLISM: A POPULA- Munira Borhany*, Olivier Guillot, Florence Rousseau, Christelle Delbes, Naveena Fati-
TION-BASED COHORT STUDY IN PATIENTS WITH ACTIVE CANCER ma, Tahir Shamsi, Muriel Giansily-Giansily-Blaizot (Pakistan)
Carlos Martinez*, Anja Katholing, Stephan Rietbrock, Alexander Cohen (Germany)
228 229
PO146-TUE PHYSICOCHEMICAL CHARACTERIZATION OF RECOMBINANT SIN-
Coagulation factor VIII and IX - II
THURSDSAY
GLE-CHAIN FACTOR VIII (RVIII-SINGLECHAIN)
Stefan Schmidbauer*, Lars Robbel, Petra Sebastian, Reinhild Witzel, Nicolas Gram-
PO135-TUE THE IL-10 POLARIZED CYTOKINE PATTERN IN INNATE AND ADAPTIVE mel, Hubert Metzner, Stefan Schulte (Germany)
IMMUNITY CELLS CONTRIBUTE TO THE DEVELOPMENT OF FVIII INHIBI-
TORS PO147-TUE FVIII ACTIVITY OF LONG-ACTING TUROCTOCOG ALFA PEGOL (N8-GP)
Daniel Chaves*, Amanda Silveira, Mrcio Santana, Olindo Martins-Filho (Brazil)
CAN BE ACCURATELY AND PRECISELY MEASURED BY DIFFERENT COM-
MERCIAL CHROMOGENIC ASSAYS
PO136-TUE EVALUATION OF N8-GP LONG TERM SAFETY IN IMMUNE DEFICIENT William Pickering*, Martin Hansen, Mirella Ezban, Marianne Kjalke (Denmark)
WEDNESDAY
RATS
Hanne Offenberg*, Julie Larsen, Jette Nowak, Caroline Rasmussen (Denmark)
PO148-TUE MOLECULAR GENOTYPING OF HAEMOPHILIA A IN SAUDI ARABIAN
POPULATION: REPORT OF NOVEL MUTATIONS.
PO137-TUE ASSOCIATION OF ARTERIAL AND VENOUS THROMBOSIS WITH CLOT- Faisal A. Al-Allaf*, Mohiuddin Taher, Zainularifeen Abduljaleel, Mohammed Athar,
TUESDAY
TING FACTOR USED IN PATIENTS WITH HEMOPHILIA Faisal Ba-hammam, Munir Abdulla, Abdellatif Bouazzaoui, Halah Abalkhail, Tarek
Owaidah (Saudi Arabia)
Jiaan-Der Wang* (Taiwan)
PO138-TUE ASSESSING THE INDICATION AND SUCCESS OF TREATMENT FOR HAE- PO149-TUE DIFFERENT STRATEGIES FOR TREATMENT ON HEMOPHILIA PATIENTS
MOPHILIA PATIENTS: RESULTS FROM A DELPHI PANEL WITH INHIBITOR, COSTS VERSUS BENEFITS
Alfonso Iorio*, Anne Rentz, Zaneta Balantac, Christina Hoxer (Canada)
Mohammad Reza Baghaipour* (Iran, Islamic Republic Of)
TUESDAY
PO150-TUE A PLASMA- AND CELL-BASED THROMBIN GENERATION ASSAY TO
POSTERS
PO139-TUE ASSESSING THE BURDEN OF DISEASE IN HAEMOPHILIA PATIENTS: A
QUALITATIVE STUDY ASSESS THE ANTICOAGULANT EFFECT OF TISSUE FACTOR PATHWAY
Ulla Slothuus*, Michelle Field, Christina Hoxer (Denmark)
INHIBITOR ON ENDOTHELIAL CELLS
Gabriele Gerstenbauer, Sabine Knappe, Erwin Panholzer, Katerina Prohaska, Fabian
PO140-TUE COMPARISON OF RECOMBINANT FACTOR VIII PRODUCTS WITH RE- Knofl, Nadja Ullrich, Robert Pachlinger, Friedrich Scheiflinger, Michael Dockal* (Austria)
SPECT TO HMWP CONTENT AND GENERAL HETEROGENEITY
PO151-TUE LETHALITY OF MOUSE TISSUE FACTOR PATHWAY INHIBITOR GENE
Per Nielsen*, Anders Nielsen (Denmark)
DISRUPTION IS RESCUED BY TRANSGENIC HUMAN TISSUE FACTOR
MONDAY
PO141-TUE DEVELOPMENT OF AN ELISA FOR THE DETECTION OF BINDING ANTI- PATHWAY INHIBITOR KNOCK IN
BODIES AGAINST HUMAN COAGULATION FACTOR VIII IN RAT PLASMA Robert Pachlinger, Rudolf Hartmann, Andrea Kolm, Erwin Panholzer, Nadja Ullrich,
Fabian Knofl, Maria Schuster, Werner Hoellriegl, Friedrich Scheiflinger, Michael Dock-
Karin M. Lvgren*, Karin Weldingh, Kristina Larsson, Mads Kjelgaard-Hansen, Bo
al* (Austria)
Wiinberg (Denmark)
PO152-TUE LONGITUDINAL MONITORING OF TFPI LEVELS AND THEIR CORRELA-
PO142-TUE THE TYPE OF REAGENTS DETERMINES THE ACCURACY OF CALIBRA-
TION WITH COAGULATION PARAMETERS IN HEALTHY SUBJECTS: A
TION WITH A PRODUCT SPECIFIC STANDARD FOR THE MEASUREMENT
ONE-YEAR OBSERVATION
OF THE B-DOMAIN DELETED RFVIII MOROCTOCOG ALFA-AF ACTIVITY.
Rudolf Hartmann, Jadranka Koehn, Erwin Panholzer, Bianca Marchula, Elisabeth
SUNDAY
Marc Jacquemin*, Alexandra Vodolazkaia, Evelien Heylen, Jelle Toelen, Joke Schoet- Schoenegger, Birgit Reipert, Friedrich Scheiflinger, Michael Dockal* (Austria)
ers, Kathelijne Peerlinck (Belgium)
PO153-TUE COMPARATIVE STUDY OF FULL-LENGTH AND B-DOMAIN MODIFIED
PO143-TUE HEALTH-RELATED QUALITY OF LIFE IN CHILDREN WITH HAEMOPHILIA
RFVIII PRODUCTS SHOWS NO RELATION BETWEEN B-DOMAIN MODIFI-
FROM TURKEY
CATION AND THE CONTENT OF SUBVISIBLE PARTICLES
Yasemin Isik Balci*, Onder Ozturk, Burge Kabukcu Basay, Omer Basay, Aziz Polat, Elif
Kazanc, Omer Faruk Tuncbilek, Funda Akpinar (Turkey)
Dorrit Baunsgaard*, Anette Henriksen, Heidi Bagger, Mirella Ezban (Denmark)
PO154-TUE THROMBIN GENERATION IN HUMAN HEMOPHILIA PLASMA AT RE-

SATURDAY
PO144-TUE STRUCTURAL CHARACTERISATION OF RECOMBINANT FACTOR IX FU-

SION PROTEIN LINKED WITH HUMAN ALBUMIN DUCED ANTITHROMBIN LEVELS AND CONCOMITANT FACTOR OR
Andreas Meister*, Nicholas Grammel, Matthias Pelzing (Australia)
BYPASS AGENT ADDITION
Akin Akinc*, Alfica Sehgal, Kun Qian, Harsha Prabhala, Ole Larsen, Benny Sorensen
PO145-TUE TISSUE FACTOR EXERTS FACTOR XA-CATALYZED FACTOR VIII ACTIVA- (United States)
TION IN THE PRESENCE OF VON WILLEBRAND FACTOR IN A FACTOR
PO155-TUE RATE-LIMITING ROLES OF TENASE COMPLEX OF FACTORS VIII AND IX
VIIA-INDEPENDENT MECHANISM
IN PLATELET PROCOAGULANT ACTIVITY AND FORMATION OF PLATE-
Shoko Furukawa*, Keiji Nogami, Kenichi Ogiwara, Midori Shima (Japan)
LET-FIBRIN THROMBI UNDER FLOW
Frauke Swieringa, Marijke Kuijpers, Moniek Lamers, Paola van der Meijden, Johan W.
Heemskerk* (The Netherlands)
230 231
PO156-TUE TREATMENT OF SEVERE BLEEDING AND PROPHYLAXIS WITH RFVIIA IN PO167-TUE MOST OF LUPUS ANTICOAGULANT IN RECURRENT PREGNANCY LOSS
THURSDSAY
A CHILD WITH FVIII INHIBITOR PATIENTS RECOGNIZE HIGH MOLECULAR WEIGHT KININOGEN AND/OR
Adalet Meral Gunes*, Melike Sezgin Evim, Birol Baytan (Turkey) FACTOR XII.
Yoshihiro Sato*, Toshitaka Sugi, Rie Sakai (Japan)
PO157-TUE MISFOLDED PROTEINS IN PLASMA-DERIVED FVIII CONCENTRATES AC-
TIVATE PLATELETS AND INHIBIT HEME OXYGENASE-1 UPREGULATION PO168-TUE FACTOR XIA, FACTOR IXA AND TISSUE FACTOR ACTIVITY IN BLUNT
IN MACROPHAGES BY SECRETED PLATELET FACTOR 4 (CXCL4) TRAUMA PATIENTS
Anne Bertling*, Martin Brodde, Mayken Visser, Lisa Smits, Janina Treffon, Michelle Saulius Butenas*, Chelsea Manning, Kalev Freeman (United States)
Fennen, Beate Kehrel (Germany)
PO169-TUE COAGULATION MONITORING OF VENTRICULAR ASSIST DEVICE RECIPI-
WEDNESDAY
PO158-TUE CIRCUMCISION IN TURKISH PATIENTS WITH BLEEDING DISORDERS: A ENTS REVEALS NEW INSIGHTS IN DISTURBED HAEMOSTASIS
SOCIOCULTURAL PERSPECTIVE Thomas Siegemund*, Stefan Feder, Andreas Oberbach, Annelie Siegemund, Friedrich
Yasemin Isik Balci*, nder ztrk, Burke Kabukcu Basay, Omer Basay, Mehmet Akin, Mohr (Germany)
TUESDAY
Funda Ozgurler Akpinar, Nazli Kapubagli, Aziz Polat (Turkey)
PO170-TUE HISTIDINE-RICH GLYCOPROTEIN BINDS DNA AND RNA AND ATTEN-
PO159-TUE INTRA-LABORATORY VARIATION IN FVIII:C INHIBITOR ASSAY: RESULTS UATES THEIR CAPACITY TO ACTIVATE THE INTRINSIC PATHWAY OF
OF A STUDY IN THREE FRENCH CENTERS COAGULATION
Christophe Nougier*, Camille Seignovert, Carine Crampe, Raphal Marlu (France) Trang T. Vu*, Beverly Leslie, Alan Stafford, Ji Zhou, James Fredenburgh, Jeffrey Weitz
(Canada)
TUESDAY
PO160-TUE STABILITY OF FVIII PRODUCTS - FORMATION OF SUBVISIBLE PARTI-
CLES UPON PHYSICAL STRESS PO171-TUE LOCALIZATION OF FACTOR XI IN PLATELETS IS NOT RESTRICTED TO
POSTERS
Mantas Malisauskas*, Christian Lubich, Thomas Prenninger, Friedrich Scheiflinger, ALPHA GRANULES.
Birgit Reipert (Austria) Michal Zucker*, Uri Seligsohn, Hagit Hauschner, Nurit Rosenberg (Israel)
PO161-TUE COMPARISON OF FVIII ACTIVITY OF SELECT NOVEL RECOMBINANT FVIII PO172-TUE THE 2,5-DICHLOROPHENYL FRAGMENT AS STARTING POINT IN THE
REPLACEMENT PRODUCTS IN COMMONLY USED FDA APPROVED ONE- DESIGN OF NEW FXIIA INHIBITORS
STAGE CLOT ASSAY SYSTEMS Charlotte Bouckaert*, Silvia Serra, Jean-Michel Dogn, Raphal Frdrick, Lionel
Stefan Tiefenbacher*, Mary Robinson, Erika Ross, Patrick Williams, Caroline Cogswell, Pochet (Belgium)
MONDAY
Tyrelle Wham, Geoff Chow, Dorothy Adcock (United States)
PO173-TUE DSR-130787, A NOVEL ORALLY-ACTIVE FACTOR XIA INHIBITOR WITH
PO162-TUE INVESTIGATING POTENTIAL DETERMINANTS OF ITI SUCCESS USING LOW RISK OF BLEEDING
IMMUNE GENE EXPRESSION PROFILING: A PRELIMINARY STUDY Masaya Mori*, Toshihiro Goto, Masakazu Shintome, Masako Toda, Shiori Taga, Keizo
Davide Matino*, Marco Gargaro, Cristina Santoro, Giancarlo Castaman, Francesca Matsushita, Katsuya Fujita, Yohei Ikuma, Masato Iwata, Kuniko Suzuki, Nobuhisa
Fallarino, Alfonso Iorio (Canada) Fukuda, Hiroshi Kato, Isao Shimizu (Japan)
PO163-TUE FACTOR VIII DEFICIENCY: INHIBITION OR ABNORMAL CONTACT? PO174-TUE EVALUATION OF THE EFFECTS OF A NOVEL CONTACT PATHWAY INHIBI-
Ana Azevedo*, Isabel Freire, Teresa Gago (Portugal) TOR, IR-CPI, ON IN VITRO PLATELET FUNCTION AND COAGULATION
SUNDAY
Lisa Jennings*, Jayaprakash Kotha*, Juan Cardenas, Michael Herr, Vinay Bhal, Mason
PO164-TUE IN VITRO FACTOR VIII ACTIVITY AFTER RECONSTITUTION WITH DILU- Dixon, Melanie White, Sophie Combe, Edmond Godfroid (United States)
ENT FLUID FOR CONTINUOUS INFUSION
Kun Soo Lee*, Ji Yoon Kim, Jin Kyung Seo, Uk Hyun Kim, Ji Hye Lee, Ye-Jee Shim, PO175-TUE BLOOD GROUP, BLEEDING PHENOTYPE AND POST-PARTUM HAEMOR-
Hwi-Joong Yoon, Shin Young Hyun, Sae Yun Baik (Korea, Republic Of) RHAGE IN FACTOR XI-DEFICIENT WOMEN
Bethan Myers*, Rebecca Neal, Nicola Curry, Rezan Kadir, Sue Pavord (United King-
PO165-TUE APPLICATION OF CLOT WAVEFORM ANALYSIS ON HEMOSTATIC MON- dom)
ITORING FOR FACTOR (F)VIII MIMICKING ANTI-FIXA/FX BISPECIFIC
SATURDAY
ANTIBODY (ACE910) PO176-TUE IDENTIFICATION OF THREE NOVEL FACTOR XII MUTATIONS ASSOCIATED
Tomoko Matsumoto*, Keiji Nogami, Koji Yada, Takehisa Kitazawa, Kunihiro Hattori, WITH CONGENITAL FACTOR XII DEFICIENCY
Midori Shima (Japan) Peipei Jin*, Wenli Jiang, Hui Yan, Lanbo Liu, Song Gu, Xuefeng Wang, Lisong Shen, Xi
Mo (China)
Contact pathway
PO177-TUE FXI-INDEPENDENT CEREBRAL HEMOSTASIS IN EXPERIMENTAL TRAU-
MATIC BRAIN INJURY
PO166-TUE EFFICACY OF A NOVEL CONTACT PATHWAY INHIBITOR, IR-CPI, IN AN Christina Lorentz*, Suzanne Schwarzmaier, Ciaran de Chaumont, Matilde Balbi,
EXTRACORPOREAL MEMBRANE OXYGENATOR MODEL Nicole Terpolilli, Erik Tucker, Owen McCarty, Christoph Kleinschnitz, Andras Gruber,
Sophie Combe*, Yves Fromes, Chantal Krezel, Pierre Gueret, Jean Amiral, Michel Nikolaus Plesnila (United States)
232 Guyaux, Edmond Godfroid (France, Belgium) 233
PO178-TUE ACTIVATION OF FACTOR XII BY PLASMIN LEADS TO BRADYKININ FOR- PO188-TUE UPREGULATION OF MATRIX METALLOPROTEINASE-2 EXPRESSION BY
THURSDSAY
MATION IN HEREDITARY ANGIOEDEMA ACTIVATED PROTEIN C IN HUMAN UMBILICAL VEIN ENDOTHELIAL
Steven De Maat*, Jenny Bjrkqvist, Chiara Suffritti, Philip de Groot, Marco Cicardi, CELLS REQUIRES ENDOTHELIAL PROTEIN C RECEPTOR AND ACTIVA-
Thomas Renn, Coen Maas (The Netherlands) TION OF PROTEASE-ACTIVATED RECEPTORS-1 AND -3
Helena Liang*, Meilang Xue, Chris Jackson (Australia)
PO179-TUE UNEXPECTED HEPATOCYTE GROWTH FACTOR ACTIVATOR (HGFA) ACTIV-
ITY ALLOWS A POSSIBLE CROSSTALK BETWEEN ACTIVATED FACTOR XII PO189-TUE BIOMARKERS OF ENDOTHELIAL DAMAGE AND INFLAMMATORY PRO-
AND THE HGF/C-MET PATHWAY IN HUMAN PLASMA CESS IN PATIENTS WITH ALZHEIMER DISEASE OR WITH MILD COGNI-
Benedito Prezoto*, Guacyara Motta, Mariana Viana, Catarina Teixeira, Priscila Araujo, TIVE IMPAIRMENT.
Douglas Mariano, Daniel Pimenta (Brazil)
WEDNESDAY
Melina B. Pinheiro, Marcos Vincius Silva, Gisele Gonalves, Mayara Faria, Edgar Mo-
raes, Maria Aparecida Bicalho, Luci Maria Dusse, Maria das Graas Carvalho* (Brazil)
PO180-TUE FXI AND FXII ACTIVITY LEVELS IN YOUNG PATIENTS WITH CRYPTOGEN-
IC ISCHEMIC STROKE PO190-TUE ACTIVATION OF THE ENDOTHELIUM MAY BE INVOLVED IN THE HEMO-

TUESDAY
Cristina Duboscq*, Jose Ceresetto, German Stemmelin, Claudia Shanley, Oscar Rabi- STATIC ALTERATIONS INDUCED BY MICRURUS TENER TENER VENOM
novich, Silvina Palmer, Eduardo Bullorsky (Argentina) IN C57BL/6 MICE
Emelyn Salazar*, Ana Salazar, Karin Perez, Izaskun Urdanibia, Alexis Rodriguez-Acos-
PO181-TUE ANTITHROMBOTIC EFFECTS OF IR-CPI IN AN ARTERIO-VENOUS SHUNT ta, Peter Taylor, Belsy Guerrero (Venezuela, Bolivarian Republic Of)
MODEL IN THE RABBIT
Michel Guyaux*, Pierre Gueret, Francois Becher, Jean Amiral, Stephanie Simon, PO191-TUE INCREASED ENDOCAN LEVELS AND ITS ASSOCIATION WITH SEVERITY
TUESDAY
Edmond Godfroid (Belgium) IN STEVENS JOHNSON SYNDROME AND TOXIC EPIDERMAL NECROLY-
POSTERS
SIS.
PO182-TUE SURFACE PLASMON RESONANCE: SENSIQ PIONEER AS A MEANS TO
Daneyal Syed*, Omer Iqbal, Charles Bouchard, Michael Mosier, Debra Hoppensteadt,
SCREEN DRUG DISCOVERY FRAGMENTS FOR HITS Jawed Fareed (United States)
Clare Wishart*, Lewis Hardy, Amy Cilia La Corte, Emma Hethershaw, Charlotte Revill,
Colin Fishwick, Richard Foster, Robert Ariens, Helen Philippou (United Kingdom) PO192-TUE ENDOTHELIAL PATHOGENESIS RESULTS IN THE GENERATION OF A
PROTEOGLYCAN ENDOCAN IN VARIOUS DISEASES
PO183-TUE MODELLING OF SURFACE-DEPENDENT ACTIVATION OF CONTACT ACTI-
Debra Hoppensteadt*, Amanda Walborn, Omer Iqbal, Daneyal Syed, Vinod Bansal,
VATION FACTOR XII IN A BUFFER SOLUTION Michael Mosier, Charles Bouchard, Nil Guler, Jawed Fareed (United States)
MONDAY
Vladislava Terenteva*, Mikhail Panteleev (Russian Federation)
PO193-TUE UPREGULATION OF CHEMOKINE EXPRESSION BY STREPTOCOCCUS
PO184-TUE EFFECT OF A PLANT INHIBITOR OF THE CONTACT SYSTEM ON A MOUSE MUTANS BEARING COLLAGEN-BINDING PROTEIN IN CULTURED BRAIN
THROMBOSIS MODEL ENDOTHELIAL CELLS
Maria Luiza Oliva*, Marlon Brito, Bruno Salu, Jos Walber Cruz, Alexander Wlodawer,
Yuji Matsumoto*, Kazuya Hokamura, Kazuo Umemura (Japan)
Francisco Maffei (Brazil)
Fibrinogen/fibrin/D-dimer I
Endothelium and vessel wall II
PO185-TUE ENDOTHELIAL CELL INCREASES ITS RIGIDITY DURING INFLAMMATION SUNDAY PO194-TUE TWO NOVEL DIFFERENT SUBSTITUTIONS OF FIBRINOGEN AALPHA 98
Roman Kotln*, Zuzana Reicheltova-Riedelova, Elika Ceznerov, Jana tikarov,
THROUGH MODIFICATION OF THE GAP JUNCTION Ondrej Pastva, Jir Suttnar, Peter Salaj, Jan Dyr (Czech Republic)
Takayuki Okamoto*, Eiji Kawamoto, Nobuyuki Akita, Tatsuya Hayashi, Koji Suzuki,
Motomu Shimaoka (Japan) PO195-TUE CLINICAL FEATURES AND MOLECULAR BASIS OF 102 CHINESE
PATIENTS WITH CONGENITAL DYSFIBRINOGENEMIA
PO186-TUE ANALYSIS OF THE EXPRESSION AND LOCALIZATION OF RNASE AND
Jingyi Zhou*, Qiulan Ding, Yaopeng Chen, Qi Ouyang, Linlin Jiang, Jing Dai, Yeling Lu,
SATURDAY
RNASE INHIBITOR IN BLOOD CELLS AND VASCULAR ENDOTHELIAL Xi Wu, Qian Liang, Hongli Wang, Xuefeng Wang (China)
CELLS INVOLVED IN HOMEOSTASIS IN THE VASCULAR SYSTEM
Ayaka Ohashi*, Yuichiro Cho, Shizuko Ichinose, Osamu Hoshi, Takatoshi Koyama PO196-TUE COEXISTENCE OF CONGENITAL FIBRINOGEN DEFICIENCY AND
(Japan) HEREDITARY PROTEIN C DEFICIENCY IN AN INFANT PRESENTING WITH
PURPURA FULMINANS
PO187-TUE CHANGES IN THE ENDOTHELIAL EXPRESSION OF GENES RELATED TO
zcan Br*, Zeynep zdemir, Ayse Turhan (Turkey)
INFLAMMATION AND ATHEROTHROMBOSIS IN RESPONSE TO UREMIA
Susana Martin-Rodriguez, Manel Vera, Enrique Mir, Marcelina Prrizas, Aleix Cases, PO197-TUE INTERNATIONAL STUDY TO ASSESS THE PERFORMANCES OF A NEW
Josep Cruzado, Gins Escolar, Maribel Diaz-Ricart* (Spain)
LIQUID ASSAY FOR DETERMINATION OF FIBRINOGEN
Neil Harris*, Jacqueline Valadier, Sophie Testa (United States)
234 235
PO198-TUE PHARMACOKINETIC (PK) COMPARISON OF TWO FIBRINOGEN CONCEN- PO208-TUE IMMUNOGENICITY ASSESSMENT OF THE FIRST EXTENDED HALF-LIFE
THURSDSAY
TRATES FOR THE TREATMENT OF CONGENITAL FIBRINOGEN DEFICIENCY FACTOR VIII PRODUCT, RECOMBINANT FACTOR VIII FC FUSION PRO-
Bruce Schwartz*, Savita Rangarajan, Mehran Karimi, Sigurd knaub, Flora Peyvandi TEIN (RFVIIIFC), IN HUMANS
(United States) Darshana Jani, Jason Pennucci, Jaya Goyal, Jenny Dumont, Geoffrey Allen, Glenn
Pierce, Jurg M. Sommer* (United States)
PO199-TUE FIBRINOGEN AND FACTOR XIII ARE MODIFIED BY N-HOMOCYSTEINYLA-
TION REACTIONS PO209-TUE A STUDY OF DEPRESSION IN FAMILY MEMBERS OF HEMOPHILIAC
Valeria Genoud, Ana Maria Lauricella, Lucia Kordich, Irene Quintana* (Argentina) PATIENTS
Mi Kyung Kim*, Jiwon Park, Tae Hyeong Kim, Sunah Lee (Korea, Republic Of)
PO200-TUE A CASE OF THROMBOSIS IN CONGENITAL AFIBRINOGENEMIA PATIENT:
WEDNESDAY
A PHYSIOPATHOLOGIC AND MANAGEMENT DILEMMA PO210-TUE HAEMTRACK: UK PATIENT HOME THERAPY REPORTING SYSTEM
Cristina Santoro*, Fulvio Massaro, Vera Capria, Salvatore Venosi, Erminia Baldacci, Rob Hollingsworth*, Hua Xiang, Gerry Dolan, Charles Hay* (United Kingdom)
Roberta Abbruzzese, Francesco Barone, Raffaele Bochicchio, Federico De Angelis,
Paola Volpicelli, Maria Gabriella Mazzucconi (Italy) PO211-TUE JOINT LAVAGE FOLLOWED BY VISCOSUPLEMENTATION AND TRIAM-
TUESDAY
CINOLONE IN PATIENTS WITH SEVERE HEMOPHILIC ARTHROPATHY.
PO201-TUE CTEPH-ASSOCIATED DYSFIBRINOGENEMIA WITH ENHANCED ACCESSI- OBJECTIVE FUNCTIONAL RESULTS.
BILITY ON FIBRIN OF LIGANDS FOR VE-CADHERIN Thiago Pasqualin*, Marcia Rezende, Felix Andrusaitis, Gustavo Campos, Renato Fruc-
Benjamin Planquette*, Peter Chiles, James Marsh, Olivier Sanchez, Guy Meyer, Timo- chi, Alexandre Pailo, Erica Okazaki, Paula Villaa (Brazil)
thy Morris (France, United States)
TUESDAY
PO212-TUE ENDOVASCULAR ABDOMINAL AORTIC ANEURYSM REPAIR IN A PATIENT
PO202-TUE NON-ENZYMATIC FIBRINOGEN SELF-ASSEMBLY UNVEILED WITH MILD HEMOPHILIA A ON DABIGATRAN FOR ATRIAL FIBRILLATION
POSTERS
Dennis Galanakis*, Liu Zhang, Miriam Rafailovich, Brendan Case (United States) Beatriz Delgado*, Manuela Carvalho, Luciana Gonalves, Susana Fernandes, Carla
Monteiro, Joel Sousa, Dalila Rolim, Sergio Sampaio, Fernando Arajo (Portugal)
PO203-TUE ASSESSMENT OF A TEST FOR FUNCTIONAL FIBRINOGEN IN WHOLE
BLOOD USING ULTRASOUND TECHNOLOGY COMPARED TO CLAUSS PO213-TUE ANALYSIS OF MODERATE PHENOTYPE OF HEMOPHILIA A WITH NOVEL
FIBRINOGEN IN PLASMA MISSENSE MUTATION, W2229R IN C2 DOMAIN, OF WHICH FVIII HAS
Kiev Blasier*, Elisa Ferrante, Jennifer Terrasi, Timothy Fischer, Francesco Viola (United NO RESPONSIVENESS WITH DDAVP.
States) Takashi Suzuki*, Keiko Shinozawa, Hiroshi Inaba, Ikuo Seita, Takashi Muramatsu,
MONDAY
Kagehiro Amano, Katsuyuki Fukutake (Japan)
Hemophilia clinical II PO214-TUE RUSSIAN NATIONAL REGISTRY OF INHIBITOR HEMOPHILIA PATIENTS:

FIRST CUT-OFF ANALYSIS
Nadezhda Zozulya*, Tatiana Andreeva, Vladimir Vdovin, Farida Perina, Elena Parovich-
PO204-TUE HAEMOPHILIA PRESENTATIONS.LET ME COUNT THE WAYS. nicova (Russian Federation)
Vaughan Williams*, Samantha Reardon (Australia)
PO215-TUE SEPTIC ARTHRITIS IN HEMOPHILIC TARGET JOINTS A NOT UNCOMMON
PO205-TUE INTRACRANIAL HEMORRHAGE IN EARLY NEONATES WITH HEMOPHILIA COMPLICATION AWARENESS IS THE MAIN DIAGNOSTIC FEATURE
SUNDAY
IN JAPAN Peter Staritz*, Rainer Zimmermann, Angela Huth-Kuehne (Germany)
Masashi Taki*, Midori Shima (Japan)
PO216-TUE MANAGING MODERN MAJOR ORTHOPAEDIC SURGERY WITH PLASMA
PO206-TUE A PHASE III, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE PHAR- DERIVED FVIII CONCENTRATE (FANHDI) IN SEVERE HAEMOPHILIA A
MACOKINETICS OF A PLASMA-DERIVED VON WILLEBRAND FACTOR/ PATIENTS WITH ADVANCED ARTHROPATHY
FACTOR VIII (VWF/FVIII) CONCENTRATE IN PEDIATRIC SUBJECTS WITH Pu-Lin Luo*, Steve Austin, Ruth Pink, Savita Rangarajan (United Kingdom)
HAEMOPHILIA A (SWIFTLY-HA STUDY).
PO217-TUE THROMBOELASTOGRAM FOR INTRA-OPERATIVE MONITORING OF
SATURDAY
Maria Teresa Pompa, Genadi Iosava, Claudia Khayat, Irina Romashevskaya, Olga
Aleinikova, Oleksandra Stasyshyn, Liudmyla Vashchenko, Marta Julia Lopez, Wilfried HEMOPHILIA PATIENTS DURING CORONARY ARTERY BYPASS GRAFT
Seifert* (Germany) SURGERY
Mudi Misgav*, Gili Kenet, Tal Mandelbaum, Yigal Kassif, Yariv Fruchtman, Ilia Tamarin
PO207-TUE NATIONAL INHIBITOR SURVEY IN HAEMOPHILIA PATIENTS (NISH) (Israel)
FROM INDIA
Shrimati Shetty*, Patricia Pinto, Tejashree Shelar, Vidhya Nawadkar, Darshana Mirgal, PO218-TUE FACTORS INFLUENCING RISK OF BLEEDING AFTER DENTAL EX-
Alfiya Mukaddam, Kanjaksha Ghosh (India) TRACTION IN HEMOPHILIA PATIENTS
Predrag Miljic*, Jelena Bodroic, Ivo Elezovic, Milan Juriic, Boidar Brkovic, Darko
Antic, Danijela Lekovic, Mirjana Mitrovic (Serbia)
236 237
PO219-TUE FACTORS INFLUENCING THE OUTCOME OF IMMUNE TOLERANCE IN- PO229-TUE OBSERVATIONAL IMMUNE TOLERANCE INDUCTION RESEARCH PRO-
THURSDSAY
DUCTION IN PATIENTS WITH HAEMOPHILIA A AND INHIBITORS GRAM (OBSITI) A MULTIFACETED APPROACH TO EXPLORE IMMUNE
Natascha Marquardt*, Bernhard Bailer, Georg Goldmann, Silvia Horneff, Anna Pavlova, TOLERANCE INDUCTION
Hans-Hermann Brackmann, Johannes Oldenburg (Germany) Carmen Escuriola Ettingshausen*, Erik Berntorp, Yesim Dargaud, Zeynep Gutowski,
Sbastien Lacroix-Desmazes, Claude Ngrier, Johannes Oldenburg, Anna Pavlova,
PO220-TUE INDIVIDUALISED TREATMENT IN HAEMOPHILIA A VARIABILITY IN Wolfhart Kreuz (Germany)
FACTOR VIII ACTIVITY MEASUREMENT FOR PHARMACOKINETIC DOSING
Jane Needham*, Helen Lewis, Niamh McIndoe, Sarah Mangles, Savita Rangarajan PO230-TUE DEFINING ADHERENCE TO PROPHYLAXIS IN HAEMOPHILIA: RESULTS
(United Kingdom) OF A DELPHI CONSENSUS PROCEDURE
Liesbeth Schrijvers*, Marjon Cnossen, Marlene Beijlevelt - van der Zande, Marjolein
WEDNESDAY
PO221-TUE CYCLOPHOSPHAMIDE EFFICACY AND TOXICITIES IN THE FIRST LINE Peters, Marieke Schuurmans, Kathelijn Fischer (The Netherlands)
TREATMENT OF ACQUIRED HEMOPHILIA
John Chapin*, Sarah Rutherford, Maria DeSancho (United States) PO231-TUE UTILIZATION PREDICTABILITY FOR BAX 855 VS. BIIB031: A DESCRIP-
TIVE COMPARISON FROM PIVOTAL TRIALS
TUESDAY
PO222-TUE TWO YEAR USE OF SHARED GUIDELINES AND A DEDICATED WEB SITE Elizabeth L. Schwartz*, Yan Xiong, Joshua Epstein, Andrea Hafeman, Leonard Valenti-
TO IMPROVE MANAGEMENT OF INHERITED BLEEDING DISORDERS IN no (United States)
THE EMERGENCY DEPARTMENT
Annarita Tagliaferri*, Caterina Di Perna, Gianna Franca Rivolta, Chiara Biasoli, Gabri- PO232-TUE ORIGIN OF MUTATION AND MOSAICISM IN FAMILIES WITH SPORADIC
ele Quintavalle, Laura Benedettini, Gianfranco Cervellin, Corrado Pattacini (Italy) CASES OF HEMOPHILIA A IN SWEDEN
TUESDAY
Annika Mrtensson*, Stina Ivarsson, Rolf Ljung (Sweden)
PO223-TUE EVIDENCE OF APCC MODE OF ACTION IN A CLINICAL STUDY TREATING
POSTERS
HEMOPHILIA A INHIBITOR PATIENTS WITH PROPHYLAXIS THERAPY PO233-TUE DIFFERENCES IN THE TROUGH LEVELS OF FACTOR VIII DEPENDING ON
Katalin Varadi, Srilatha Tangada*, Gerald Schrenk, Jennifer Doralt, Bruce Ewenstein, BLOOD GROUPS
Peter Turecek (United States) Tomoko Ashikaga*, Atsuki Yamashita, Chiai Nagae, Mika Mori, Masashi Taki (Japan)
PO224-TUE A CASE OF MODERATE HEMOPHILIA A WITH P.R1800H MUTATION COM- PO234-TUE CONTINUOUS INFUSION OF FVIII IN OBESE PATIENTS WITH SEVERE
PLICATED WITH JUVENILE IDIOPATHIC ARTHRITIS HAEMOPHILIA A: IS WEIGHT-BASED DOSE-ADJUSTMENT REQUIRED?
Yasuaki Shida*, Yuka Kondo, Tomoaki Ishikawa, Koji Yada, Masahiro Takeyama, Keiji Ana Boban*, Severine Henrard, Catherine Lambert, Cedric Hermans (Belgium)
MONDAY
Nogami, Midori Shima (Japan)
PO235-TUE USE OF APCC IN COMBINATION WITH TRANEXAMIC ACID: A SINGLE
PO225-TUE LONG TERM FOLLOW-UP IN THE USE OF DIFFERENT TYPES OF CENTRE EXPERIENCE
CENTRAL VENOUS CATHETERS IN CHILDREN WITH HEMOPHILIA ON Jerzy Windyga*, Beata Baran, Edyta Odnoczko, Ewa Stefanska-Windyga (Poland)
PROPHYLAXIS OR IMMUNE-TOLERANCE REGIMEN
Marta Milan*, Guendalina Mognato, Piergiorgio Gamba, Bertilla Ranzato, Ezio Zanon PO236-TUE NON-NEUTRALIZING ANTIBODIES MODULATE FACTOR VIII PHARMACO-
(Italy) KINETIC IN PATIENTS WITH HEMOPHILIA A WITHOUT FVIII INHIBITORS
Christoph J. Hofbauer*, Sylvia Kepa, Michael Schemper, Peter Quehenberger, Sylvia
PO226-TUE SUCCESSFUL MULTI-VESSEL PERCUTANEOUS CORONARY INTERVEN- Reitter-Pfoertner, Christine Mannhalter, Birgit Reipert, Ingrid Pabinger (Austria)
SUNDAY
TION FOR ACUTE CORONARY SYNDROME IN A SEVERE TAIWANESE HE-
MOPHILIAC WITH HIV INFECTION UNDER HARRT: THE FIRST REPORTED PO237-TUE IPAQ SCORING AND CAROTID INTIMA MEDIA THICKNESS IN PATIENTS
CASE IN CHINESE POPULATION WITH HAEMOPHILIA
Chia-Yau Chang*, Chun-Yao Huang, Chen-Hua Tsai, Ming-Ching Shen, Yeu-Chin Chen, Fahri Sahin*, Miray Bozgul Kilincer, Ugur Turk, Kaan Kavakli, Guray Saydam (Turkey)
Jia-Ruey Tsai, Geng-Chang Yeh, Yen-Lin Liu (Taiwan)
PO238-TUE LEFT VENTRICLE DIASTOLIC FUNCTIONS AND PHYSICAL ACTIVITY
PO227-TUE RELATIONSHIP BETWEEN QUALITY OF LIFE AND COAGULATION FAC- SCORE IN ADULT HEMOPHILIA PATIENTS: AEGEAN HAEMOPHILIA CEN-
TOR LEVEL IN HEMOPHILIA CARRIERS: PRELIMINARY RESULTS TER EXPERIENCE
SATURDAY
Jane Young*, Julie Grabell, Natalia Rydz, Wilma Hopman, David Good, Johnny Mahlan- Fahri Sahin*, Miray Bozgul Kilincer, Ugur Turk, Kaan Kavakli, Guray Saydam (Turkey)
gu, Paula James (Canada)
PO239-TUE REGIONAL DATA SUPPORTS NEED FOR UNIFORM APPROACH TO EX-
PO228-TUE DOES QUALITY OF TREATMENT INFLUENCE GLOBAL HEMOSTASIS TENDED HALF-LIFE (EHL) PRODUCT TRANSITION
IRRESPECTIVELY OF FVIII LEVELS IN PATIENTS WITH HEMOPHILIA A? Stacy E. Croteau*, Chris Holmes, Joanne Porter, Aric Parnes, Ellis Neufeld (United
Maria Berndtsson*, Eva Zetterberg, Margareta Holmstrm, Nida Mahmoud Hourani States)
Soutari, Danijela Mikovic, Ivo Elezovic, Jovan Antovic (Sweden)
238 239
PO240-TUE DDAVP-INDUCED RISE IN PRE-INFUSION VON WILLEBRAND FACTOR PO249-TUE IMMUNE TOLERANCE INDUCTION IN HEMOPHILIA A AND B WITH
THURSDSAY
LEVELS MAY SLIGHTLY AFFECT THE PHARMACOKINETICS OF PLAS- INHIBITOR. SINGLE CENTRE EXPERIENCE.
MA-DERIVED FACTOR VIII CONCENTRATE IN SEVERE HEMOPHILIA A Angelika Batorova*, Eva Bubanska, Denisa Jankovicova, Anna Morongova, Tatiana
PATIENTS Prigancova, Erika Balazova (Slovakia)
Eva Stokhuijzen*, Janneke Loomans, Marjolein Peters, Karin Fijnvandraat (The Nether-
lands) PO250-TUE PUPS WITH SEVERE HAEMOPHILIA A - A GCP STUDY EVALUATING THE
IMMUNOGENICITY, EFFICACY AND SAFETY OF HUMAN-CL RHFVIII
PO241-TUE POPULATION PHARMACOKINETIC MODEL OF RECOMBINANT SIN- Raina Liesner, Martina Jansen*, Natalya Kavardakova, Marina Abashidze, Sigurd
GLE-CHAIN FACTOR VIII (RVIII SINGLECHAIN) IN PATIENTS WITH HEMO- Knaub (Austria)
PHILIA A
WEDNESDAY
Ying Zhang*, Tharin Limsakun, Debra Bensen-Kennedy, Alex Veldman, Jagdev Sidhu
PO251-TUE POPULATION PHARMACOKINETICS IN HEMOPHILIA A: TOWARDS INDI-
(United States) VIDUALIZATION OF PERIOPERATIVE REPLACEMENT THERAPY
Hendrika C. Hazendonk*, Karin Fijnvandaat, Maritte Driessens, Felix van der Meer,
PO242-TUE DISCREPANCY BETWEEN THE FACTOR VIII LEVELS AND SEVERITY Karina Meijer, Marieke Kruip, Britta Laros-van Gorkom, Marjolein Peters, Saskia de
TUESDAY
OF HEMOPHILIA A IN TWO MATERNAL COUSINS PATIENTS Wildt, Frank Leebeek, Marjon Cnossen, Ron Matht (The Netherlands)
Hadjira Ahmidatou*, Meriem Bensadok, Karima Chennoukh, Amar Arour, Nadia Zidani,
Mohamed Ramaoun, Meriem Belhani, Salim Nekkal (Algeria)
PO252-TUE PRENATAL DIAGNOSIS FOR HAEMOPHILIA: UMBILICAL CORD BLOOD
SAMPLE USED
PO243-TUE THE AHEAD STUDY: EFFECTIVENESS INTERIM RESULTS AFTER ONE Jing Zhong*, Jing Dai, Xuefeng Wang (China)
TUESDAY
YEAR OF OBSERVATION, AN ANALYSIS OF THE EUROPEAN PATIENTS
COHORT PO253-TUE BLEEDING AFFECTS HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN
POSTERS
Johannes Oldenburg*, Dimitrios Tsakiris, Cedric Hermans, Ri Liesner, Maria Mazzuc-
PEOPLE WITH HAEMOPHILIA PATIENTS (PWH) EVEN A SINGLE BLEED
coni, Rafael Parra, Katharina Steinitz, Lydia Abad-Franch, Alexandra Loew-Baselli MATTERS
(Germany) Sylvia von Mackensen*, Hermann Eichler, Katharina Holstein, Kate Khair, Wolfgang
Schramm (Georgia)
PO244-TUE THE AHEAD STUDY: SAFETY REAL WORLD DATA AFTER 1 YEAR OF OB-
SERVATION, AN ANALYSIS OF THE EUROPEAN COHORT OF PATIENTS PO254-TUE INTRACRANIAL HEMORRHAGE AND MANAGEMENT IN HEREDITARY
Johannes Oldenburg*, Dimitrios Tsakiris, Cedric Hermans, Ri Liesner, Maria Mazzuc- BLEEDING DISORDERS: THE EXPERIENCE OF CUKUROVA UNIVERSITY,
MONDAY
coni, Rafael Parra, Katharina Steinitz, Alexandra Loew-Baselli, Lydia Abad-Franch ADANA, TURKEY
(Germany) Ilgen Sasmaz*, Bulent Antmen, Barbaros Karagun, Dervis Yilmaz, Gokdel Leblebisatan,
Yurdanur Kilinc (Turkey)
PO245-TUE A CORE SET OF OUTCOME MEASUREMENT TOOLS IN PATIENTS WITH
HEMOPHILIA: A SYSTEMATIC REVIEW OF THE MEASUREMENT PROPER- PO255-TUE EXPLORING COST EFFECTIVENESS OF VARIOUS PROPHYLACTIC TREAT-
TIES MENT STRATEGIES FOR SEVERE HAEMOPHILIA USING A COMPUTER
Victor Blanchette, Alok Srivastava, Samantha Gouw*, Brian Feldman, Pamela Hilliard, SIMULATION MODEL
Audrey Abad, Andrea Doria, Kathelijn Fischer (The Netherlands) Kathelijn Fischer*, Mart Janssen (The Netherlands)
SUNDAY
PO246-TUE CLINICAL SIGNIFICANCE OF TYPE 1, TYPE 2 T CELLS, TH17 AND TREG PO256-TUE ULTRASOUND EVALUATION OF HAEMOPHILIC JOINTS BY HAEMOPHILIA
IN THE DEVELOPMENT OF FVIII INHIBITOR IN PEDIATRIC HEMOPHILIA PHYSICIANS: A RELIABILITY STUDY
A PATIENTS. Kathelijn Fischer*, Johannes Oldenburg, Jan Astermark, Gerald Dolan, Massimo Morfi-
Zhenping Chen, Runhui Wu*, Qiqi Wei, Gang Li, Ling Tang, Yingzi Zhen, Xinyi Wu (Chi- ni, Natascha Marquardt, Carlo Martinoli (The Netherlands)
na)
PO257-TUE DOSING OF RVIIA-FP IN CLINICAL STUDIES IN HEMOPHILIA WITH IN-
PO247-TUE EVALUATE THE QUALITY OF LIFE IN THE ELDERLY WITH HAEMOPHILIA HIBITORS AND FACTOR VII DEFICIENCY
Mohammad Reza Shaverdi Niasari*, Gholamreza Toogeh, Samin Roostaei, Jayran Ze- Britta Laros-van Gorkom*, Pal Holme, Waander van Heerde, Johnny Mahlangu,
SATURDAY
bardast, Elham Ale booye, Shadi Shaverdi, Alireza Rahimi, Hossein Eftekhar Ardebili, Faraizah Dato Abd Karim, Pratima Chowdary, Debbie Bensen Kennedy, Alex Veldman,
Fariba Zarrabi (Iran, Islamic Republic Of) Regina Clementi, Claude Negrier (The Netherlands)
PO248-TUE RESULTS OF ANKLE PROSTHESIS IN PATIENTS WITH SEVERE HAEMO- PO258-TUE EFFICACY AND SAFETY OF RVIII-SINGLECHAIN IN SURGICAL PROPHY-
PHILIC ARTHROPATHY FOLLOW UP LAXIS
Manuela Krause, Daniele Pillitteri*, Markus Preis, Carl Kirchmaier, Ute Scholz, Roger Claudia Djambas Khayat*, Johnny Mahlangu, Cindy Leisinger, Stephanie Png, Elena
Scholz (Germany) Santagostino, Fernanda Lopez Fernandez, Debbie Bensen Kennedy, Alex Veldman,
Clementi Regina, Ingrid Pabinger (Lebanon)
240 241
PO259-TUE INHIBITORS IN HEMOPHILIA (HA): EXPERIENCE OF A SINGLE CENTER PO269-TUE HEPARIN-INDUCED THROMBOCYTOPENIA AND CALIBRATED THROMBIN
THURSDSAY
IN THE LAST 22 YEARS. GENERATION ASSAY.
Cristina Santoro*, Erminia Baldacci, Maura Acquila, Maria Patrizia Bicocchi, Maria Valentine Minet, Charlotte Bouckaert*, Jean-Michel Dogn, Franois Mullier (Belgium)
Basso, Federico De Angelis, Ferrara Grazia, Laura Parlanti, Paola Volpicelli, Roberta
Abbruzzese, Francesco Barone, Maria Gabriella Mazzucconi (Italy)
Immune thrombocytopenia (ITP) II
PO260-TUE SYSTEMATIC LITERATURE REVIEW OF ECONOMICS ANALYSES COM-
PARING APCC AND RFVIIA ACROSS ON-DEMAND, PROPHYLAXIS AND
SURGERY PO270-TUE THE ROLE OF CELLULAR IMMUNITY IN CHILDREN WITH IDIOPATHIC
Darshan Mehta*, Joel Hay (United States)
WEDNESDAY
THROMBOCYTOPENIC PURPURA
Erol Erduran*, Fulya Celikturk, Gokce Pinar Reis, Aysenur Bahadir (Turkey)
PO261-TUE ADDRESSING THE GAP IN TREATMENT ADHERENCE:DEVELOPMENT OF
THE HEMOPHILIA JOINT VISUALIZER TOOL PO271-TUE DIAGNOSIS OF VENOUS THROMBOEMBOLISM DURING ELTROMBOPAG

TUESDAY
Hiruyeki Takedani*, Luigi Solimeno, Kapil Saxena, Prasad Mathew (Japan) THERAPY FOR IMMUNE THROMBOCYTOPENIA AND SUCCESSFUL RE-
PLACEMENT WITH ROMIPLOSTIM.
PO262-TUE RVIII-SINGLECHAIN PHARMACOKINETICS IN ADULTS, ADOLESCENTS Odelia Amit*, Ilya Kirgner, Irit Avivi (Israel)
AND CHILDREN
Johnny Mahlangu*, Lynda Lepatan, Kateryna Vilchevska, Johannes Oldenburg, Olek- PO272-TUE RE-EVALUATION OF NEED FOR BONE MARROW EXAMINATION IN PA-
sandra Stasyshyn, Kathelijn Fischer, Genadi Iosava, Claudia Djambas Khayat, Mindy TIENTS WITH ISOLATED THROMBOCYTOPENIA TREATED WITH STE-
TUESDAY
Simpson. Michael Wang, Debbie Bensen Kennedy, Nicolas France, Katie St.Ledger,
ROIDS AS FIRST LINE THERAPY
Tharin Limsakun, Ingrid Pabinger (South Africa)
POSTERS
Mukul Aggarwal*, Abhishek Purohit, Pravas Mishra, Tulika Seth, Seema Tyagi, Man-
oranjan Mahapatra, Hara Pati, Renu Saxena (India)
Heparin-induced thrombocytopenia (HIT) I
PO273-TUE GLYCOPROTEIN IBA CLUSTERING INDUCES MACROPHAGE-MEDIATED
PO263-TUE ARGATROBAN IN THE MANAGEMENT OF HEPARIN-INDUCED THROMBO- PLATELET CLEARANCE IN THE LIVER
CYTOPENIA TYPE II: AN OPEN-LABEL, MULTICENTER CLINICAL TRIAL Rong Yan, Mengxing Chen, Kesheng Dai* (China)
IN FRANCE PO274-TUE EXTENDED PLATELET PARAMETERS AS A MEANS TO DIFFERENTIATE
MONDAY
Brigitte Tardy*, Philippe Nguyen, Jean-Claude Thiranos, Pierre-Emmanuel Morange,
IMMUNE THROMBOCYTOPENIA FROM HYPOPROLIFERATIVE THROMBO-
Christine Biron Andrani, Yves Gruel, Jerome Morel, Alain Wynckel, Lelia Grunebaum,
Judith Villacorta-Torres, Sandrine Grosjean, Emmanuel De Maistre (France)
CYTOPENIAS
Hrvoje Melinscak*, Tahir Mirzoyev, Mala Varma (United States)
PO264-TUE CASE REPORT: DABIGATRAN USE IN A POSTOPERATIVE ORTHOPEDIC
PATIENT WITH HEPARIN INDUCED THROMBOCYTOPENIA PO275-TUE TREATMENT OF ATRAUMATIC SPLENIC RUPTURE IN AN ADOLESCENT
Luciana Goncalves*, Ana Leite, Helena Gomes, Ana Freixo, Luisa Fonseca, Manuela
WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AND AUTOIMMUNE
Carvalho, Paulo Bettencourt, Fernando Araujo (Portugal) CYTOPENIAS: A CASE REPORT
Rungrote Natesirinilkul*, Pimlak Charoenkwan, Wattana Chartapisak, Sanit Ruangron-
SUNDAY
PO265-TUE RIVAROXABAN FOR TREATMENT OF HEPARIN INDUCED THROMBOCYTO- grat, Sauwalak Opastirakul, Trichak Sandhu, Prapan Jutavijittum (Thailand)
PENIA
Nikhil Mukhi*, FNU Kirti, Hana Lim, Olcay Batuman (United States)
PO276-TUE CD70 MOLECULE INVOLVED IN THE DENDRITIC CELLS DYSFUNTION IN
PATIENTS WITH IMMUNE THROMBOCYTOPENIA
PO266-TUE THE INCIDENCE OF HEPARIN-INDUCED THROMBOCYTOPENIA IN CRITI- Zhang Xian*, Zhou Zeping, Hao Yating, Zhang Donglei, Li Huiyuan, Yang Renchi (China)
CALLY ILL MEDICAL PATIENTS
Rattaporn Vichitratchaneekorn, Benjaporn Akkawat, Ponlapat Rojnuckarin, Noppacharn
PO277-TUE MEGAKARYOCYTES AND MACROPHAGE -LYMPHOCYTE INTERACTIONS
Uaprasert* (Thailand) IN VITRO IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA
SATURDAY
Tamar Saralidze*, Tinatin Shvelidze, Bela Metreveli, Tinatin Saralidze (Georgia)

PO267-TUE EVALUATING EFFICACY, SAFETY AND COMPLIANCE OF ARGATROBAN
DOSING NOMOGRAM AT CANADIAN TEACHING HOSPITAL PO278-TUE THE INVOLVEMENT OF NEUROPILIN-1 IN PRIMARY IMMUNE THROMBO-
Harsimran Saini*, Gary Wong, Jin-Hyeun Huh, Bill Brien, Laura Murphy, Amita Woods CYTOPENIA
(Canada) Hu Zhou*, Jingyi Yang, Yongping Song (China)
PO268-TUE RAPID FUNCTIONAL ASSAY FOR HEPARIN-INDUCED THROMBOCYTOPE- PO279-TUE SUCCESSFUL TREATMENT OF REFRACTORY ITP WITH CYCLOSPORINE
NIA USING A PRACTICAL FLOW CYTOMETRY APPROACH A, TWO CASE REPORTS
Michal Cipok*, Sigi Kay, Shoshana Bar On, Ilya Kirgner, Aaron Tomer, Varda Antonin Hlusi*, Tomas Szotkowski (Czech Republic)
Deutsch (Israel)
242 243
PO280-TUE EFFICACY AND PROGNOSIS OF SHORT TERM AND VERY LOW-DOSE IVIG PO291-TUE HIGH-FAT DIET IS ASSOCIATED WITH INCREASED VON WILLEBRAND
THURSDSAY
THERAPY (200 MG/KG/D) FOR NEWLY DIAGNOSED ACUTE IMMUNE FACTOR-RELATED PROCOAGULANT ACTIVITY IN HUMAN AND MURINE
THROMBOCYTOPENIC PURPURA IN CHILDREN MODELS
Kun Soo Lee*, Jung Eun Kim, Uk Hyun Kim, Ye-Jee Shim, Ji Yoon Kim (Korea, Alison Michels*, Laura Swystun, Silvia Albnez, Jeffrey Mewburn, KateSponagle, David
Republic Of) Lillicrap (Canada)
PO292-TUE INFLAMMATORY AND ENDOTHELIAL MARKERS AND THEIR RELATIONS

Inflammation II TO THE HAEMOSTATIC POTENTIAL DURING THE MENSTRUAL CYCLE.
Roza Chaireti*, Tomas Lindahl, Katarina Bremme, Anders Larsson (Sweden)
WEDNESDAY
PO281-TUE A SYNTHETIC PEPTIDE, CORRESPONDING TO THE NONCANONICAL PO293-TUE CIGARETTE SMOKING SIGNIFICANTLY REDUCES GEN- AND PROTEIN
PAR1- TETHERED LIGAND, MIMICS THE APC-INDUCED STIMULATION EXPRESSION OF THE PRO-INFLAMMATORY CYTOKINE IL-12
OF WOUND HEALING IN VITRO Trine Baur Opstad*, Harald Arnesen, Alf-ge Pettersen, Ingebjrg Seljeflot (Norway)
Ekaterina Kiseleva*, Lyubov Gorbacheva, Svetlana Strukova, Maria Sidorova (Russian
TUESDAY
Federation) PO294-TUE THE INTERACTION BETWEEN EXPRESSION OF COXSACKIE-ADENOVI-
RUS RECEPTOR ON THE SURFACE OF PLATELETS AND CARDIOMYO-
PO282-TUE DIFFERENTIAL IN VIVO ACTIVATION OF MONOCYTE SUBSETS DURING
CYTES, INFLAMMATION AND VIRUS PERSISTENCE INSIDE CELLS
EXPERIMENTAL ENDOTOXEMIA IN HUMANS
Elena Gupalo*, Liudmila Buryachkovskaya, Petr Chumachenko, Natalia Mironova
Barbara Thaler*, Philipp Hohensinner, Konstantin Krychtiuk, Lorenz Koller, Mira (Russian Federation)
TUESDAY
Brekalo, Gerald Maurer, Bernd Jilma, Johann Wojta, Walter Speidl (Austria)
PO295-TUE THE ROLE OF INFLAMMATION IN PREGNANCY-RELATED VENOUS
POSTERS
PO283-TUE REGULATION OF IL-10 AND HIGH MOBILITY GROUP BOX 1 (HMGB1) EX-
THROMBOSIS
PRESSION IN HUMAN MONOCYTES BY PLATELETS AND NEUTROPHILS
Hilde Skuterud Wik*, Anne Jacobsen, Per Sandset (Norway)
Bjarne sterud*, Jan Ole Olsen (Norway)
PO296-TUE THE EXTRACELLULAR FIBRINOGEN-BINDING PROTEIN (EFB) SECRETED
PO284-TUE EFFECT OF LIPOPOLYSACCHARIDE AND VARIOUS CYTOKINES ON PRO-
BY STAPHYLOCOCCUS AUREUS BINDS P-SELECTIN AND COMPETI-
TEIN C INHIBITOR PRODUCTION BY HEPG2 CELLS
TIVELY INHIBITS ITS INTERACTION WITH P-SELECTIN GLYCOPROTEIN
Tatsuya Hayashi*, Nobuyuki Akita, Takayuki Okamoto, Junji Nishioka, Koji Suzuki
LIGAND-1 (PSGL-1)
MONDAY
(Japan)
Giordano Pula*, Stefan Bagby, Mareike Posner, Abhishek Upadhyay (United Kingdom)
PO285-TUE DOES THE COAGULATION CASCADE PLAY A ROLE IN RETINAL PATHOLO-
GIES?
Innate and acquired Immunity
Tami Livnat*, Alon Zahavi, Ruth Axer-Siegel, Ayelet Dreznik, Elinor Megiddo, Mor
Dachbash, Yael Nisgav, Gili Kenet, Dov Weinberger, Rita Ehrlich (Israel)
PO297-TUE CRITICAL BEHAVIOR OF SUBCELLULAR DENSITY ORGANIZATION
PO286-TUE CLINICAL PRESENTATION OF THROMBOEMBOLIC EVENTS IN INFLAM- DURING NEUTROPHIL ACTIVATION AND MIGRATION
MATORY BOWEL DISEASE Sandra Baker-Groberg*, Kevin Phillips, Laura Healy, Asako Itakura, Juliana Porter, Paul
SUNDAY
Lize Bollen*, Niels Vande Casteele, Vera Ballet, Sverine Vermeire, Ann Gils (Belgium) Newton, Owen McCarty (United States)
PO287-TUE LOSS OF PAR-4 RECEPTOR AFFECTS RENAL ISCHEMIA REPERFUSION PO298-TUE NATURALLY OCCURRING ANTIBODIES TO OXIDATION-SPECIFIC EPI-
IN MICE TOPES IN PATIENTS WITH VENOUS THROMBOEMBOLISM
Marcel P. B. Jansen*, Sandrine Florquin, Joris Roelofs (The Netherlands) Sabine Eichinger*, Paul Kyrle, Michael Kammer, Maria Ozsvar Kozma, Lisbeth Eischer,
Christoph Binder (Austria)
PO288-TUE TIPE2 IS INDUCED BY SIMULATED MICROGRAVITY IN MONOCYTES
Shilong Xiong*, Zhi Wei Wang, Xiao Yan Li (China) PO299-TUE C. CANIMORSUS AFFECTS COAGULATION BY PROTEOLYTIC CLEAVAGE
SATURDAY
OF FACTOR X
PO289-TUE MOUSE MACROPHAGES UPREGULATE PODOPLANIN UNDER INFLAMMA- Katrin Hack*, Jonathan Douxfils, Jean-Michel Dogn, Guy Cornelis (Belgium)
TORY AND APOPTOTIC CONDITIONS
Julie Rayes*, Samantha Montague, Stephanie Watson, Steve Watson (United Kingdom) PO300-TUE POLYPHOSPHATE ACTS AS A COFACTOR FOR C1-INHIBITOR-MEDIATED
REGULATION OF THE CLASSICAL PATHWAY OF COMPLEMENT
PO290-TUE ANTI-INFLAMMATORY EFFECT OF NON-CANONICAL PEPTIDE-AGONIST Emilie Lameignere*, Lakshmi Wijeyewickrema, Alice OByrne, Linnette Ocariza, Toshi-
OF PAR-1 ON RAT MAST CELLS RESEMBLES ACTIVATED PROTEIN C kazu Shiba, Stephanie Smith, James Morrissey, Robert Pike, Edward Conway (Canada)
ACTION
Irina Babkina*, Maria Sidorova, Lyubov Gorbacheva, Svetlana Strukova (Russian Feder-
ation)
244 245
PO301-TUE HUMAN MONOCYTE SUBSETS DIFFERENTLY EXPRESS TISSUE FACTOR PO311-TUE IN VITRO OPTIMIZATION OF AN INNOVATIVE BIOLOGICAL GLUE COMPO-
THURSDSAY
Konstantin Krychtiuk*, Barbara Thaler, Philipp Hohensinner, Max Lenz, Kurt Huber, SITION
Gerald Maurer, Johann Wojta, Gottfried Heinz, Walter Speidl (Austria) Jean-Luc Plantier*, Vronique Duretz, Sami Chtourou, Philippe Mondon (France)
PO302-TUE MHC CLASS I ANTIGEN PRESENTATION BY MEGAKARYOCYTES. PO312-TUE 4F-PCC (BERIPLEX P/N) IS SUPERIOR TO 3F-PCC FOR REVERSAL OF
nne Zufferey*, Edwin Speck, Li Guo, Rukhsana Aslam, Rick Kapur, John Semple
A COUMARIN ANTICOAGULATION IN A RAT BLEEDING MODEL
(Canada) Eva Herzog*, Franz Kaspereit, Wilfried Krege, Peter Niebl, Gerhard Dickneite (Germany)
PO313-TUE EVALUATION OF THE PERFORMANCE OF EIGHT SCORES FOR PREDIC-

PO303-TUE PROTHROMBIN MUTANTS REVEAL A NEW MECHANISM OF MASP-1 TION OF BLEEDING RISK IN BRAZILIAN HEART DISEASE OUTPATIENTS
WEDNESDAY
MEDIATED CLOTTING TREATED WITH WARFARIN
Lorenz Jenny, Jzsef Dob, Pter Gl, Verena Schroeder* (Switzerland) Joao Oliveira, Antonio Ribeiro, Daniel D. Ribeiro*, Vandack Nobre Junior, Manoel
Rocha, Maria Martins (Brazil)
PO304-TUE COMPLEMENT AND TISSUE-FACTOR INDUCED THROMBIN GENERATION
TUESDAY
IN THE PATHOGENESIS OF VENOUS THROMBOEMBOLISM PO314-TUE IDARUCIZUMAB SPECIFICALLY REVERSES DABIGATRAN ANTICOAGULA-
Ina Isabella Hiland*, Robin Liang, Erin Hald, Nadezhda Latysheva, Cathrine Ram- TION BUT DOES NOT INDUCE A PROCOAGULANT STATE IN A PORCINE
berg, Vladimir Tichelaar, Tom Eirik Mollnes, John-Bjarne Hansen (Norway) TRAUMA MODEL WITH DABIGATRAN ANTICOAGULATION
Markus Honickel, Joanne van Ryn, Johanna Schurer, Rolf Rossaint, Oliver Grottke*
PO305-TUE UNIQUE GENETIC VARIATION IN AN INVASIVE SEROTYPE M23ND STRAIN (Germany)
TUESDAY
OF STREPTOCOCCUS PYOGENES INFLUENCES BACTERIUMHOST CELL
INTERACTIONS AND COMPLEMENT-MEDIATED OPSONIZATION PO315-TUE WHOLE BLOOD THROMBOELASTOMETRY PROFILES IN PATIENTS UN-
POSTERS
Garima Agrahari*, Zhong Liang, Dustin Higashi, Shaun Lee, Victoria Ploplis, Francis DERGOING MAJOR ORTHOPAEDIC SURGERY.
Castellino (United States) Luca Spiezia*, Francesco Vasques, Astrid Behr, Elena Campello, Sara Maggiolo, Mari-
angela Fadin, Paolo Simioni (Italy)
PO306-TUE CD44 ANTIBODIES CAN DIRECTLY INHIBIT MURINE MACROPHAGE
FC-GAMMA RECEPTOR AND COMPLEMENT RECEPTOR 3 MEDIATED PO317-TUE A MULTICENTER OBSERVATIONAL STUDY OF THE EFFECTIVENESS OF
PHAGOCYTOSIS PROTHROMBIN COMPLEX CONCENTRATE FOR TREATMENT OF BLEEDING
Alaa Amash*, Yawen Wang, Lin Wang, Alan Lazarus (Canada) IN THE PERIOPERATIVE AND INTENSIVE CARE SETTING: PROBE STUDY
MONDAY
Pratima Chowdary*, Augustine Tang, Dale Watson, Martin Besser, Peter Collins,
PO307-TUE EXOGENOUS AND ENDOGENOUS TOLL-LIKE RECEPTOR LIGANDS Michael Creagh, Hafiz Qureshi, Margaret Rokicka, Tim Nokes, Paul Diprose, Surekha
INDUCE THE FORMATION OF PLATELET-NEUTROPHIL AND PLATE- Frith, Ravi Gill (United Kingdom)
LET-MONOCYTE COMPLEXES IN HUMAN WHOLE BLOOD
Julia Seyfert*, Christoph Bode, Daniel Duerschmied, Ingo Ahrens (Germany) PO318-TUE BLEEDING COMPLICATIONS AFTER INVASIVE DENTAL PROCEDURES IN
PATIENTS UNDER VITAMIN K ANTAGONISTS
PO308-TUE COMPLEMENT ACTIVATION AND THROMBIN GENERATION IN HEALTHY Ana Spinola, Maria Coutinho, Fernanda Leite, Sara Morais*, Rui Moreira, Eva Pacheco,
INDIVIDUALS SUBJECTED TO MILD ISOBARIC HYPOXIA AND VENOUS Norival Pinho, Nilsa Seidi, Eugenia Cruz, Manuel Campos (Portugal)
STASIS
SUNDAY
Ina Isabella Hiland*, Robin Liang, Erin Hald, Trond B;rvik, Nadezhda Latysheva, PO319-TUE AN ANALYSIS OF MANAGEMENT STRATEGIES AND OUTCOMES IN NVAF
Cathrine Ramberg, Tom Mollnes, John Bjarne Hansen (Norway) PATIENTS TREATED WITH DABIGATRAN: A MULTI-CENTER RETROSPEC-
TIVE COHORT OF PATIENTS WITH MAJOR BLEEDING EVENTS
Truman J. Milling, Jr*, Michael Ganetsky, Carol Duffy, Heather Paden, Adam Singer
Management of bleeding I (United States)
PO320-TUE USE OF PROTHROMBIN COMPLEX CONCENTRATE AND ACTIVATED PRO-

PO309-TUE RETROSPECTIVE EVALUATION OF THE USE OF RECOMBINANT FAC- THROMBIN COMPLEX CONCENTRATE FOR REVERSAL OF DIRECT ORAL
SATURDAY
TOR VIIA BEFORE AND AFTER THE IMPLEMENTATION OF A PHARMA- ANTICOAGULANT ASSOCIATED BLEEDING
CIST-LED FACTOR STEWARDSHIP PROGRAM Lana A. Castellucci*, Joseph Shaw, Gregoire Le Gal, Melanie Tokessy, Nancy Cober,
Taylor White*, Lindsey Amerine, Sheh Li Chen (United States) Elianna Saidenberg, Marc Carrier (Canada)
PO310-TUE USE OF A 4 FACTOR PROTHROMBIN COMPLEX CONCENTRATE IN A PO321-TUE TREATMENT APPROACHES IN SPONTANEOUS RECTUS SHEATH HEMA-
UNITED STATES COMMUNITY HOSPITAL SYSTEM TOMAS IN CLINICAL PRACTICE. A SINGLE-CENTER EXPERIENCE
Linda R. Kelly*, Bente Garcia (United States) Veronica Pons*, Josep M Suriach, Laura Lopez-Andreoni, Jose Loureiro, Pavel Olivera,
Antonieta Guliana Molero, Ana Marin, Francesc Bosch, Amparo Santamaria (Spain)
246 247
Microparticles II Natural anticoagulants
THURSDSAY
PO322-TUE SYNTHESIS AND IN VITRO STUDIES OF NANOXIDES AS HEMOSTATIC PO333-TUE A GAIN-OF-FUNCTION VARIANT OF PROTEIN C MANIFESTS ITSELF AS
AGENTS FOR THE BLOOD COAGULATION ACCELERATION TYPE II PROTEIN C DEFICIENCY IN A HEALTHY SUBJECT
Juliana Bergamasco*, Gabriel Zazeri, Tnia Da Rocha, lbio DAmico, Moacir De Qiulan Ding*, Likui Yang, Peyman Dinarvand, Xuefeng Wang, Alireza Rezaie (China)
Godoy, Jos Geraldo Nery (Brazil)
PO334-TUE EVALUATION OF PROTEIN C LEVELS IN SICKLE CELL DISEASE SUB-
PO323-TUE COMPOSITION-DEPENDENT EFFECTS OF NANOPARTICLES ON COAGU- JECTS SEEN AT THE UNIVERSITY OF BENIN TEACHING HOSPITAL,
LATION
WEDNESDAY
BENIN CITY, NIGERIA.
Kamran Bakhtiari*, Joost Meijers, Sophie Laurent, Svetlana Mintova, Eng-Poh Ng, Obinna Iheanacho*, Benedict Nwogoh (Nigeria)
Hussein Awala, Somayyeh Mirsadeghi, Morteza Mahmoudi, Farhad Rezaee (The Neth-
erlands) PO335-TUE POSSIBLE MECHANISM OF ACTIVATED PROTEIN C-INDUCED INHIBI-
TUESDAY
TION OF OSTEOCLAST DIFFERENTIATION
PO324-TUE PLATELET ACTIVATION RELEASES MATURE MIR-494 IN MICROPARTI-
Nobuyuki Akita*, Kakunoshin Yoshida, Takayuki Okamoto, Kunihiro Asanuma, Junji
CLES Nishioka, Koji Suzuki, Tatsuya Hayashi (Japan)
Jasmine Tay*, Jessica Jorritsma, Quintin Hughes, Ross Baker (Australia)
PO336-TUE PHARMACOKINETIC STUDY OF THE NOVEL ANTICOAGULANT PEPTIDE
PO325-TUE CHARACTERISTICS AND ROLE OF EXTRACELLULAR VESICLES IN THE VARIEGIN USING LC-MS/MS, CHROMOGENIC SUBSTRATE AND MODI-
TUESDAY
PATHOPHYSIOLOGY OF TRANSFUSION DEPENDENT B-THALASSEMIA FIED THROMBIN TIME ASSAYS
Carina Levin*, Annie Sabbah, Benjamin Brenner, Anat Aharon (Israel)
POSTERS
Norrapat Shih*, R. Manjunatha Kini (Singapore)
PO326-TUE MICROPARTICLES : WHATS PLASMA MADE OF ? PO337-TUE THROMBOMODULIN INHIBITS TISSUE FACTOR MEDIATED THROMBIN
lain R. Brisson*, Nicolas Arraud, Celine Gounou, Romain Linares, Sisareuth Tan
A GENERATION IN BLOOD AND PROTHROMBIN COMPLEX CONCENTRATES
(France)
Jawed Fareed*, Debra Hoppensteadt, Daneyal Syed, Daniel Kahn, Michael Mosier,
Inder Kaul (United States)
PO327-TUE COAGULATION ACTIVITY OF MICROPARTICLES FROM DIFFERENT CEL-
LULAR SOURCES. INVOLVEMENT OF ACTIVE TISSUE FACTOR. PO338-TUE HEPARANASE ACTIVATES ANTITHROMBIN THROUGH THE BINDING TO
MONDAY
Alexey Mazurov*, Svetlana Khaspekova, Olga Antonova, Olga Shustova, Nina Golubeva, ITS HEPARIN BINDING SITE
Vladimir Yakushkin, Anatoly Dobrovolsky (Russian Federation)
Nataliya Bohdan, Salvador Espn, Sonia guila, Ral Teruel-Montoya, Javier Corral,
Vicente Vicente, Irene Martnez-Martnez* (Spain)
PO328-TUE IMPACT OF VARIOUS ANTICOAGULANTS AND STORAGE TIME ON PLAS-
MA CONCENTRATION AND SIZE DISTRIBUTION OF EXTRACELLULAR PO339-TUE ANTITHROMBIN BINDS TO AND ENHANCES THE BARRIER FUNCTION
VESICLES OF HUVECS INDEPENDENTLY OF CELL-SURFACE HEPARAN SULFATE
Simin Jamaly*, Vladimir Tichelaar, Randi Olsen, Erin Hald, Cathrine Ramberg, Nadezh- PROTEOGLYCANS
da Latysheva, John-Bjarne Hansen (Norway)
Franois Saller*, Stphane Pautus, Yasmine Bourti, Allan De Carvalho, Toufik Abache,
SUNDAY
Elsa Bianchini, Jean-Luc Plantier, Delphine Borgel (France)
PO329-TUE PLASMA CONCENTRATION AND SIZE DISTRIBUTION OF EXTRACELLU-
LAR VESICLES IN HEALTHY INDIVIDUALS SUBJECTED TO MILD ISOBAR PO340-TUE TETRAMETHYLPYRAZINE DECREASES RECEPTOR FOR ADVANCED
HYPOXIA AND VENOUS STASIS GLYCATION END-PRODUCTS (RAGE) VIA SUPPRESSION OF FOXA2 AND
Trond Brvik*, Ina Hiland, Erin Mathiesen Hald, Cathrine Ramberg, Nadezhda Laty- INDUCTION OF NOS IN HEPG2 CELLS
sheva, John-Bjarne Hansen (Norway)
Junling Li*, Wenhui Zhu, Ping Zhou (China)
PO330-TUE NEW TECHNIQUE TO STUDY CELL-DERIVED MICROPARTICLES
PO341-TUE QUANTITATIVE TRANSCRIPTOME AND PROTEOME ANALYSIS OF DERMA-
sa Thulin*, Junhong Yan, Masood Kamali-Moghaddam, Agneta Siegbahn (Sweden)
SATURDAY
CENTOR RETICULATUS SALIVARY GLANDS FOR THE IDENTIFICATION OF

PO331-TUE MICROPARTICLE LEVEL AND ORIGIN DURING PROGRESSION OF NOR- NOVEL ANTICOAGULANTS AND IMMUNOMODULATORY PROTEINS
MAL PREGNANCY: A LONGITUDINAL STUDY IN HEALTHY WOMEN. Janaki Iyer*, Mirko Slovak, Ivo Francischetti, Jose Ribeiro, Manjunatha Kini (Singapore)
Elena Campello*, Claudia Radu, Luca Spiezia, Sonila Dhima, Silvia Visetin, Sabrina
Gavasso, Barry Woodhams, Erich Cosmi, Paolo Simioni (Italy)
PO342-TUE SIMILAR RESPONSES OF PHOSPHATIDYLSERINE AND PHOSPHATIDY-
LETHANOLAMINE TOWARDS COFACTOR ACTIVITY OF HUMAN PROTEIN
PO332-TUE CIRCULATING MICROPARTICLES IN CORD BLOOD OF NORMAL PREG- Z, A NATURAL ANTICOAGULANT
NANCY AND OF PREGNANCY WITH PREECLAMPSIA (PET). Tanusree Sengupta*, N Manoj (India)
Elena Campello*, Luca Spiezia, Claudia Radu, Sonila Dhima, Silvia Visetin, Sabrina
Gavasso, Barry Woodhams, Erich Cosmi, Paolo Simioni (Italy)
248 249
PO343-TUE THE EFFECT OF AGE ON GLYCAN MICROHETEROGENEITY OF HUMAN PO353-TUE CLINICAL PRESENTATION, IMPACT AND COURSE OF MAJOR BLEEDING
THURSDSAY
ALPHA-2-MACROGLOBULIN EVENTS WITH APIXABAN AND WARFARIN
Laura S. Calvert*, Helen Atkinson, Leslie Berry, Anthony Chan (Canada) Suzanne M. Bleker*, Alexander Cohen, Harry Bller, Giancarlo Agnelli, Alexander
Gallus, Gary Raskob, Jeffrey Weitz, Madelyn Curto, Melanie Sisson, Saskia Middeldorp
PO344-TUE QUANTITATIVE IMMUNOASSAY FOR THE MEASUREMENT OF ACTIVATED (The Netherlands)
PROTEIN C COMPLEXES WITH ALFA-2-MACROGLOBULIN (APC:A2M)
Francisco Espaa*, Silvia Navarro, Laura Martos, Luis Ramn, Elena Bonet, Pilar PO354-TUE DABIGATRAN PREVENTS THROMBOSIS WITH ENHANCEMENT OF SEC-
Medina (Spain) ONDARY FIBRINOLYSIS IN A MOUSE VENOUS THROMBOSIS MODEL
Asuka Sakata*, Tsukasa Ohmori, Kinya Seo, Satoshi Nishimura (Japan)
PO345-TUE IDENTIFICATION OF A NOVEL MUTATION P.K234EFS*24 IN THE PROC
WEDNESDAY
GENE AND A PHENOTYPE-GENOTYPE CHARACTERISTICS OF THAI PO355-TUE DABIGATRAN AND RIVAROXABAN ADHERENCE STUDY- REAL WORLD
PATIENTS DIAGNOSED WITH HEREDITARY PROTEIN C DEFICIENCY AND EXPERIENCE IN DIFFERENT CLINICS AND EXTENDED FOLLOW UP
SYMPTOMATIC THROMBOEMBOLISM (DARIVA STUDY)

TUESDAY
Bundarika Suwanawiboon*, Wanna Thongnoppakhun, Chanin Limwongse (Thailand) Deepa Suryanarayan*, Faris Al-Khalili, Ammar Majeed, Sam Schulman (Canada)
PO346-TUE THE PDI INHIBITOR ISOQUERCETIN REDUCES THROMBIN GENERATION PO356-TUE A QUALITATIVE POINT OF CARE TEST TO ASSESS ANTICOAGULANT AC-
IN HEALTHY ADULTS AND IN PATIENTS WITH ELEVATED ANTIPHOSPHO- TIVITY IN URINE SAMPLES OF PATIENTS TREATED WITH NON-VITAMIN
LIPID ANTIBODIES K ANTAGONIST ORAL ANTICOAGULANTS A GERMAN CONSENSUS
Jack D. Stopa*, Bruce Furie, Robert Flaumenhaft, Jeffrey Zwicker (United States) Job Harenberg*, Ingo Ahrens, Rupert Bauersachs, Sylvia Haas, Jrgen Koscielny, Ro-
TUESDAY
land Krmer, Edelgard Lindhoff-Last, Jrgen Prochaska, Sebastian Schellong, Michael
PO347-TUE INVESTIGATION OF PROTEIN S DEFICIENCY INDUCED PURPURA FULMI- Spannagl, Philipp Wild, Jan Beyer-Westendorf (Germany)
POSTERS
NANS
Raja Prince*, Sara Calzavarini, Franois Saller, Luca Bologna, Federica Bisignani,
PO357-TUE PARADOXICAL ENHANCEMENT OF THE INTRINSIC PATHWAY-INDUCED
Anne Angelillo-Sherrer (Switzerland) THROMBIN GENERATION IN HUMAN PLASMA BY MELAGATRAN, A
DIRECT THROMBIN INHIBITOR, BUT NOT EDOXABAN, A DIRECT FACTOR
PO348-TUE QUANTITATIVE PLATELET TFPI-ALPHA RELEASE IS NOT INFLUENCED XA INHIBITOR
BY SEX AND ORAL CONTRACEPTIVE USE. Taketoshi Furugohri*, Yoshiyuki Morishima (Japan)
Kristien Winckers, Stella Thomassen, Hugo ten Cate, Tilman Hackeng* (The Nether-
MONDAY
lands) PO358-TUE EVALUATION OF ANTICOAGULATION WITH RIVAROXABAN BY ANTI-XA
ACTIVITY, THROMBIN GENERATION AND COMPLEX THROMBIN AN-
PO349-TUE ROLE OF TISSUE FACTOR PATHWAY INHIBITOR-ALPHA IN PLATELET-DE- TI-THROMBIN LEVELS IN PATIENTS WITH NEW ONSET NON VALVULAR
PENDENT FIBRIN FORMATION UNDER FLOW ATRIAL FIBRILLATION.
Stella Thomassen*, Tom Mastenbroek, Kristien Winckers, Marion Feijge, Judith Cose- Victor M. Neira Vidal*, Ramn Corbalan Herreros, Jaime Pereira Garcs, Olga Panes
mans, Tilman Hackeng, Johan Heemskerk (The Netherlands) Becerra, Bernardita Garayar Pulgar, Andrs Aizman Sevilla, Silvana LLevaneras
Madariaga, Luis Villarroel del Pino (Chile)
Non-vitamin K antagonist oral anticoagulants II PO359-TUE LOW DOSE RIVAROXABAN FOR SECONDARY PROPHYLAXIS AFTER FULL
SUNDAY
ANTICOAGULATION IN PATIENTS WITH VENOUS THROMBOEMBOLISM
PO350-TUE ASSOCIATION RATE CONSTANTS RATIONALIZE THE SENSITIVITY OF Alan Zhou*, Anthony Chan, Keith Lau, Howard Chan (Canada)
PROTHROMBIN TIME AND THROMBIN GENERATION ASSAY TO APIX-
PO360-TUE INTRA-INDIVIDUAL VARIABILITY IN TROUGH AND PEAK DABIGATRAN
ABAN AND RIVAROXABAN
LEVELS IN REAL-LIFE ATRIAL FIBRILLATION PATIENTS
Georges Jourdi*, Virginie Siguret, Anne-Cline Martin, Jean-Louis Golmard, Anne
Godier, Charles-Marc Samama, Pascale Gaussem, Isabelle Gouin-Thibault, Bernard Le Nina Vene*, Petra inigoj, Rickard Malmstrm, Yuko Rnquist-Nii, Mojca Boi-Mijovs-
Bonniec (France) ki, Anton Pohanka, Jovan Antovi, Alenka Mavri (Slovenia)
SATURDAY
PO351-TUE INTERACTION OF ANDEXANET ALFA, A UNIVERSAL ANTIDOTE TO FXA PO361-TUE DIRECT-ACTING ORAL ANTICOAGULANTS IN THE REAL WORLD: IN-
INHIBITORS, WITH TISSUE FACTOR PATHWAY INHIBITOR ENHANCES SIGHTS INTO HEALTH CARE PROVIDERS UNDERSTANDING OF MEDICA-
REVERSAL OF FXA INHIBITOR-INDUCED ANTICOAGULATION TION DOSING AND USE
Genmin Lu*, Joyce Lin, Gregory Coffey, John Curnutte, Pamela Conley (United States) Menaka Pai*, Mary Salib, Jennifer Delaney, Mohamed Panju, Sam Schulman (Canada)
PO352-TUE DIRECT ORAL ANTICOAGULANTS: OUR EXPERIENCE PO362-TUE DIRECT ORAL ANTICOAGULANTS IN CLINICAL PRACTICE - REAL WORLD
Rita Santoro*, Roberto Minici, Piergiorgio Iannaccaro, Sergio Morgione (Italy) AUDIT DATA
Sarah Bond,* Sue Rhodes (United Kingdom)
250 251
PO363-TUE NUANCES OF NOACS IN A DEVELOPING COUNTRY - A SINGLE CENTER PO374-TUE TREATMENT OPTIONS FOR MAJOR HAEMORRHAGE AND URGENT IN-
THURSDSAY
EXPERIENCE TERVENTION IN PATIENTS ON A NOAC - INTERIM RESULTS FROM THE
Shamanna Iyengar*, Roopa Ravibabu, Sumithra Lakshman, Anand Shenoy, Sridhar G, ANTICOAGULATION REVERSAL AND EVENTS STUDY (ARES) COLLABO-
Mukul Fulmali, Subash Chandra V (India) RATIVE
Ross Baker*, Alex Gallus, Timothy Brighton, Paul Harper, Laura Young, Joanna Joseph,
PO364-TUE RIVAROXABAN PHARMACOKINETICS BEFORE AND AFTER BARIATRIC Amanda Hugman, Krys Hiscock, Scott McGregor, Jennifer Curnow (Australia)
SURGERY: A CASE AND DISCUSSION
George Dresser*, Markus Gulilat, Richard Kim (Canada) PO375-TUE PROTHROMBINASE INDUCED CLOTTING TIME (PICT) FOR MEASUR-
ING THE ACTIVITY OF DIRECT FACTOR XA INHIBITORS IN CLINICAL
PO365-TUE RENAL FUNCTION COURSE IN PATIENTS TREATED WITH NEW ORAL SETTING.
WEDNESDAY
ANTICOAGULANTS. Pvel E. Olivera*, Vicente Cortina, Vernica Pons, Brayan Merchn, Laura Lpez-An-
Elisa Grifoni, Rossella Marcucci, Daniela Poli, Raffaella Priora, Maddalena Pazzi, dreoni, Gonzalo Artaza, Eva Menino, Ana Marn, Francesc Bosch, Amparo Santamara
Alessia Fabbri, Cinzia Fatini, Lucia Mannini, Anna Maria Gori*, Rosanna Abbate, Gian (Spain)
Franco Gensini (Italy)
TUESDAY
PO376-TUE AN OPEN-LABEL STUDY OF DABIGATRAN PHARMACOKINETICS AND
PO366-TUE THE EFFECTS OF DIRECT ORAL ANTICOAGULANTS APIXABAN AND PHARMACODYNAMICS IN PATIENTS WITH MODERATE RENAL IMPAIR-
RIVAROXABAN ON HAEMOSTASIS TESTS: RESULTS FROM A COMPRE- MENT UNDERGOING PRIMARY UNILATERAL ELECTIVE TOTAL KNEE OR
HENSIVE CROSS-LABORATORY EXERCISE. HIP REPLACEMENT SURGERY
Roslyn A. Bonar*, Emmanuel Favaloro, Katherine Marsden, John Sioufi (Australia) Bengt Eriksson*, Zsolt Mikuska, Martin Feuring, Jean Amiral, Sebastian Haertter,
TUESDAY
Joachim Stangier, Gerhard Nehmiz, Maximilian Lobmeyer, Jeffrey Weitz (Sweden)
PO367-TUE EFFECT OF NEW ORAL ANTICOAGULANTS ON PROTEIN C SYSTEM.
POSTERS
Irina Geltcer*, Olga Golovina, Olga Smirnova, Olesya Matvienko, Ludmila Papayan PO377-TUE QUALITATIVE FOLLLOW UP OF EMERGENCY DEPARTMENT (ED)
(Russian Federation) PATIENTS DISCHARGED ON RIVAROXABAN FOR LOW RISK VENOUS
THROMBOEMBOLISM
PO368-TUE A STUDY OF DOAC AWARENESS INDICATING INADEQUATE RECOGNI-
Kristen E. Nordenholz*, Elaina Thompson, Toby Trujillo, Gregory Misky (United States)
TION WITH POTENTIAL FOR PATIENT HARM
Henry Watson*, Adetomilola Olaiya, Blair Watt, Brenda Lurie, Lyn McDonald (United PO378-TUE NET CLINICAL BENEFIT OF DABIGATRAN VERSUS WARFARIN IN PRE-
Kingdom)
VENTION OF RECURRENT VENOUS THROMBOEMBOLISM: A POOLED
MONDAY
PO369-TUE CIRCULATING CONCENTRATION OF RIVAROXABAN OR DABIGATRAN ANALYSIS OF RE-COVER AND RE-COVER II
ANTICOAGULANTS IN CLINICALLY SELECTED PATIENTS Sam Schulman*, Henry Eriksson, Ajay Kakkar, Clive Kearon, Sebastian Schellong,
Martin Feuring, Stefan Hantel, Joerg Kreutzer, Samuel Goldhaber (Canada)
Jane Needham*, Helen Lewis, Amanda McMullen, Tamara Everington, Savita Rangara-
jan, Sarah Mangles (United Kingdom)
PO379-TUE IDENTIFICATION OF POSSIBLE DRUG RELATED PROBLEMS IN PATIENTS
PO370-TUE COMPARING REVERSAL EFFECT OF FACTOR X CONCENTRATE AND ON ORAL ANTICOAGULANTS. A SYSTEMATIC REVIEW OF MEDICATION
BY-PASSING AGENTS ON RIVAROXABAN IN AN EX VIVO SPIKING STUDY CHARTS BY PHARMACIST.
WITH ROTEM Anne Fjrkenstad*, Eva-Marie Jacobsen, Liv Mathiesen, Espen Molden (Norway)
SUNDAY
Anja Drebes*, Anne Riddell (United Kingdom)
PO380-TUE INFLUENCE OF DOACS ON THROMBIN GENERATION ASSAY
PO371-TUE MANAGEMENT OF BLEEDING AND EMERGENCY SITUATIONS FOR PA- Kazuo Kawasugi*, Tadashi Yamamoto, Naoki Shirafuji (Japan)
TIENTS TREATED WITH DABIGATRAN- SINGLE CENTRE EXPERIENCE.
Tatiana Prigancova*, Angelika Batorova, Denisa Jankovicova (Slovakia) Platelet activation/adhesion/aggregation II
PO372-TUE BLEEDING AND TREATMENT FAILURE IN PATIENTS TAKING DIRECT
ORAL ANTICOAGULANTS REFERRED TO EMERGENCY DEPARTMENT: A PO381-TUE NEW FACTOR OF PLATELET HEMOSTASIS PATHOLOGY RISK MARKER IN
SATURDAY
COHORT MANAGEMENT STUDY POPULATION OF NENETS AUTONOMOUS DISTRICT

Caterina Compostella, Foscarina Della Rocca, Seena Padayattil Jose, Giacomo Zoppel- Nadezda Vorobyeva*, Natalia Belova (Russian Federation)
laro, Gentian Denas, Alessia Bracco, Gianna Vettore, Vittorio Pengo* (Italy)
PO382-TUE THE EFFECT OF IGG OF ISCHEMIC STROKE PATIENTS ON PLATELET
PO373-TUE PERFORMANCES OF A NEW COMMERCIAL CHROMOGENIC ASSAY FOR PROTEINS SECRETION
THE MEASUREMENT OF APIXABAN CONCENTRATION IN PLASMA Tetiana B. Katrii*, Olexiy Savchuk, Ludmila Ostapcenko (Ukraine)
Jean-Marc Minon*, Myriam Vasbien, Thierry Gougnard, Hlne Appeltans, Philippe
Borgoens (Belgium)
252 253
PO383-TUE MEAL-INDUCED PLATELET ACTIVATION DIFFERS BETWEEN PATIENTS PO393-TUE GPVI AND THE CLEC-2/PODOPLANIN AXIS AS POTENTIAL BIOMARKERS
THURSDSAY
WITH TYPE 1 AND TYPE 2 DIABETES AND IS RELATED TO INSULIN OF PLATELET ACTIVATION IN INFLAMMATORY CONDITIONS
SECRETION Samantha J. Montague*, Robert Dinsdale, Eelo Gitz, Elizabeth Gardiner, Robert An-
Galia Spectre*, Ragnhild Stlesen, Claes-Gran stenson, Paul Hjemdahl (Israel, drews, Peter Hampson, Christopher Wearn, Christopher Buckley, Gerard Nash, Naiem
Sweden) Moiemen, Paul Harrison, Steve Watson (United Kingdom)
PO384-TUE INFLUENCE OF PLATELET COUNT IN PLATELET RICH PLASMA FOR PO394-TUE NOVEL WHOLE BLOOD MODEL OF THROMBOCYTOPENIA WITH PRE-
ADENOSINE TRIPHOSPHATE RELEASE ASSAY SERVED PLATELET FUNCTION
Sylvie Mulliez*, Katrien Devreese (Belgium) Mette T. Skipper*, Peter Rubak, Ole Larsen, Anne-Mette Hvas (Denmark)
WEDNESDAY
PO385-TUE ACTIVATION OF HUMAN PLATELETS BY STAPHYLOCOCCUS AUREUS PO395-TUE LOCAL ANAESTHETICS INHIBIT ACTIVATION OF PROTEIN DISULFIDE
SECRETED PROTEASE STAPHOPAIN A ISOMERASE (PDI).
Amie K. Waller*, Katie Birch, Pratik Vikhe, Graeme Cottrell, Jon Gibbins, Simon Clarke Christopher Stavermann, Anne Bertling, Mayken Visser, Martin Brodde, Wiebke Gogar-
ten, Beate E. Kehrel* (Germany)
TUESDAY
(United Kingdom)
PO386-TUE LOW PLATELET REACTIVITY IS ASSOCIATED WITH MORE SEVERE PO396-TUE PROSPECTIVE ANALYSIS OF PLATELET ACTIVATION MARKERS TO PRE-
ATHEROSCLEROSIS AND INCREASED REVASCULARIZATION DURING DICT SEVERE INFECTION AND MORTALITY IN INTENSIVE CARE UNITS.
FOLLOW UP. Celine Delierneux*, Nathalie Layios, Alexandre Hego, Justine Huart, Arnaud Joly, Pierre
Tesse Leunissen*, Crystel Gijsberts, Peter Paul Wisman, Folkert Asselbergs, Imo Geurts, Pierre Damas, Christelle Lecut, Andr Gothot, Ccile Oury (Belgium)
TUESDAY
Hoefer, Gerard Pasterkamp, Gert Jan de Borst, Frans Moll, Mark Roest (The Nether-
lands) PO397-TUE STAPHYLOCOCCUS AUREUS LIPOPROTEINS INHIBIT PLATELET ACTIVA-
POSTERS
TION.
PO387-TUE EVALUATION OF MULTIPLATE WHOLE BLOOD IMPEDANCE AG- Pratik Vikhe*, Amie Waller, Jonathan Gibbins, Simon Clarke (United Kingdom)
GREGOMETRY IN ROUTINE INVESTIGATION OF BLEEDING DISORDERS
Joanne E. Joseph*, Joyce Low, Susan Jarvis (Australia) PO398-TUE COMPARATIVE IMPACTS OF ANTIRETROVIRAL HIV THERAPIES ON
PLATELET FUNCTION
PO388-TUE ANALYSIS OF PROCOAGULANT PS-EXPOSING PLATELETS BY IMAGING Erica Smyth*, Mark Nelson, Michael Emerson (United Kingdom)
FLOW CYTOMETRY
MONDAY
Emily C. Reddy*, Hong Wang, Hilary Christensen, Sara Israels, Annie Bang, Margaret PO399-TUE ANALYZING IN VITRO PLATELET THROMBUS FORMATION OF PATIENTS
Rand (Canada) WITH ESSENTIAL THROMBOCYTHEMIA UNDER BLOOD FLOW CONDI-
TIONS
PO389-TUE THE POTENTIAL OF THE NEW PLATELET ACTIVATION IN UNPROCESSED Takashi Ito*, Tomoka Nagasato, Takahiro Nakashima, Hitomi Yamashita, Hideki Mat-
BLOOD (PACT-UB)- TEST suoka, Kazuya Hosokawa, Ikuro Maruyama (Japan)
Tesse Leunissen*, Peter Paul Wisman, Thijs Van Holten, Philip de Groot, Jasper Remi-
jn, Frans Moll, Gert Jan de Borst, Martin Teraa, Marianne Verhaar, Rolf Urbanus, Mark PO400-TUE GENERATION OF PROCOAGULANT COAT PLATELETS IN STORED PLATE-
Roest (The Netherlands) LET-CONCENTRATE UNITS DERIVED FROM BUFFY-COAT PREPARATIONS
Debora Bertaggia Calderara*, David Crettaz, Stefano Barelli, Jean-Daniel Tissot, Niels
SUNDAY
PO390-TUE DETERMINATION OF THRESHOLD AGONIST CONCENTRATIONS FOR Lion, Michel Prudent, Lorenzo Alberio (Switzerland)
WHOLE BLOOD AGGREGATION USING THE MULTIPLATE ANALYZER
Sara J. Israels*, Eileen McMillan-Ward, Hong Wang, Victor Blanchette, Margaret Rand PO401-TUE OPIATES MAY ATTENUATE PLATELET ACTIVATION
(Canada) alumeh Bastami, Nahreen Tynngard, Ankit S. Macwan*, Tomas Lindahl, Srinivas
S
Uppugunduri (Sweden)
PO391-TUE ASSESSMENT OF TIME-RELATED PREANALYTICAL INFLUENCES ON
PLATELET FUNCTION: COMPARISON OF THE MULTIPLATE, THE PFA- PO402-TUE IN VIVO AND PROTEASE-ACTIVATED RECEPTOR 1-MEDIATED PLATELET
100 AND THE VERIFY NOW ACTIVATION IN PATIENTS PRESENTING FOR CARDIAC CATHETERIZA-
SATURDAY
Petra Jilma*, Franz Ratzinger, Christian Schrgenhofer, Bernd Jilma, Peter Quehen- TION
berger (Austria) Thomas Gremmel*, Alan Michelson, Andrew Frelinger (Austria, United States)
PO392-TUE DYNAMICS OF CALCIUM SPIKING, MITOCHONDRIAL COLLAPSE AND PO403-TUE PLATELET FACTOR-3 (PF-3) AVAILABILITY AND PLATELET COUNT OF
PHOSPHATIDYLSERINE EXPOSURE IN SINGLE PLATELETS DURING PREGNANT WOMEN IN IRRUA, EDO STATE.
ACTIVATION Rose A. Anyanwu*, Bridget Omaivboje, Eidangbe Adesuwa (Nigeria)
Sergei I. Obydennyi*, Anastasia Sveshnikova, Fazoil Ataullakhanov, Mikhail Panteleev
(Russian Federation)
254 255
PO404-TUE FLOW CYTOMETRY BASED EVALUATION OF PLATELET-NEUTROPHIL PO414-TUE CHARACTERISING CELL-TYPE INTERACTIONS FOLLOWING PLATELET
THURSDSAY
COMPLEX FORMATION IN HUMAN AND MURINE WHOLE BLOOD: A ACTIVATION IN A NOVEL LOW VOLUME WHOLE BLOOD ASSAY
DETAILED ANALYSIS OF EX VIVO SAMPLE PREPARATION, CYTOMETER Paul C. Armstrong*, Timothy Warner (United Kingdom)
SETTINGS AND MOLECULAR BASICS
Maximilian Mauler*, Julia Seyfert, David Haenel, Hannah Seeba, Janine Guenther, PO415-TUE CHARACTERISATION OF PROCOAGULANT PLATELETS IN WHOLE BLOOD
Christoph Bode, Ingo Ahrens, Daniel Duerschmied (Germany) USING A NOVEL CELL DEATH MARKER
Leonardo Pasalic*, Heather Campbell, Philip Hogg, Vivien Chen (Australia)
PO405-TUE T2MR PLATELET ANALYSIS CORRELATES WITH LTA AND REVEALS
UNIQUE DETAILS OF ADP-MEDIATED PLATELET ACTIVATION IN WHOLE
Platelet disorders II
WEDNESDAY
BLOOD
Adam Cuker, Tatiana Lebedeva, Holleh Husseinzadeh, Walt Massefski, Joseph Martura-
no, Thomas Lowery*, Charles Abrams, Doug Cines (United States)
PO416-TUE NATURAL HISTORY OF ACQUIRED GLANZMANN THROMBASTHENIA : A
CASE REPORT
TUESDAY
PO406-TUE NEW APPROACH FOR EVALUATION OF PLATELET FUNCTION IN THROM-
BOCYTOPENIA USING IMPEDANCE AGGREGOMETRY Marie Tuffigo, Chlo James, Estibaliz Lazaro, Jean-Franois Viallard, Mathieu Fiore*
(France)
Mette T. Skipper*, Peter Rubak, Jesper Stentoft, Anne-Mette Hvas, Ole Larsen (Den-
mark)
PO417-TUE HOT-WATER EXTRACTS OF THE MUSHROOM, AGARICUS BRASILIENSIS,
PO407-TUE DEVELOPMENT AND VALIDATION OF A FLOW CYTOMETRY ASSAY FOR INHIBITS PLATELET ACTIVATION VIA P2Y1 RECEPTOR.
TUESDAY
ASSESSING CYCLOOXYGENASE-1 AND 2 IN PLATELETS Kaneo Satoh*, Katsuyuki Akahane, Masato Ohta, Yukio Ozaki (Japan)
POSTERS
Peter Rubak*, Steen Kristensen, Anne-Mette Hvas (Denmark)
PO418-TUE A REDUCED RESPONSE TO TRAP-6 IN PLATELET AGGREGATION STUD-
PO408-TUE PLATELET AGGREGATION AND BIOLOGICAL RESPONSE MODIFIERS IES IS NOT USUALLY DUE TO A PAR-1 RECEPTOR DEFECT.
RELEASE BY COMBINATIONS OF STREPTOCOCCUS SANGUINIS AND Michael Mitchell*, Aine McCormick, James Maloney, Gary Moore, Steve Austin (United
Kingdom)
PORPHYROMONAS GINGIVALIS
Archie McNicol*, Sara Israels, Hind Hamzeh-Cognasse, Fabrice Cognasse (Canada) PO419-TUE DIFFERENTIAL REGULATION OF THE PLATELET PROTEOME IN
GLANZMANN THROMBASTHENIA TYPE I
PO409-TUE INCREASE IN IONIC STRENGTH INHIBITS PLATELET AGGREGATION
MONDAY
Kerstin Jurk*, Stefan Loroch, Cora Reiss, Kathrin Schwierczek, Wolfgang Behnisch,
IRRESPECTIVE OF SOLUTE TYPE IN VITRO
Barbara Zieger, Rene Zahedi, Ulrich Walter (Germany)
Gordon Ogweno* (Kenya)
PO420-TUE GRANULES SECRETION IN PATIENTS WITH GLANZMANNS THROMBAS-
PO410-TUE A NEW APPROACH TO MEASURING PLATELET AGGREGATION AND
THENIA
PLATELET-LEUCOCYTE CONJUGATE FORMATION IN A SMALL VOLUME
Ann-Kathrin Pilgrimm-Thorp, Manuela Krause, Daniele Pillitteri*, Tanja Behrendt, Carl
OF FIXED WHOLE BLOOD Kirchmaier (Germany)
Mohammad Algahtani*, Natalia Dovlatova, Jane May, Stan Heptinstall, Sue Fox (Unit-
ed Kingdom) PO421-TUE THE GFI1B C.503G>T MUTATION IN THE FIRST ZINC FINGER DO-
SUNDAY
MAIN PREDICTS A MILDER BLEEDING PHENOTYPE THAN THE GFI1B
PO411-TUE THE AUTOMATION OF ROUTINE LIGHT TRANSMISSION PLATELET AG-
C.880-881INSC MUTATION
GREGATION ON SYSMEX CS-2000I
David Rabbolini*, Marie-Christine Morel-Kopp, Qiang Chen, Sara Gabrielli, Lindsay
Katsushi Kobayashi, Pierre Gueret, Maxime Sansot, Fabienne Nedelec Gac, Jean Dunlop, Christopher Ward, William Stevenson (Australia)
Amiral (France)
PO422-TUE ABNORMAL PROPLATELET FORMATION AND EMPERIPOLESIS IN
PO412-TUE EFFECTS OF PH AND CONCENTRATION OF SODIUM CITRATE ANTICOAG-
CULTURED MEGAKARYOCYTES FORM GRAY PLATELET SYNDROME
ULANT ON PLATELET AGGREGATION MEASURED BY LIGHT TRANSMIS-
PATIENTS
SATURDAY
SION AGGREGOMETRY INDUCED BY ADENOSINE DIPHOSPHATE

Erica De Candia*, Christian Di Buduo, Maria Adele Alberelli, Ana Glembostky, Gi-
Ksenia Germanovich, Eti A. Femia, Chun Yan Cheng*, Natalia Dovlatova, Marco Catta- anmarco Podda, Marco Cattaneo, Raffaele Landolfi, Paula Heller, Alessandra Balduini
neo (Italy) (Italy)
PO413-TUE ANTI-PROTAMINE/HEPARIN ANTIBODIES INDUCED PLATELET ACTIVA- PO423-TUE MULTIPLEX PHOSPHOSPECIFIC FLOW CYTOMETRY FOR THE SCREEN-
TION IN THE PRESENCE OF NPH-INSULIN IN HEPARIN DEPENDENT ING OF PLATELET SIGNALING DISORDERS
MANNER Marie Levade*, Cdric Garcia, Sarah Cadot, Jennifer Series, Pierre Si, Bernard Payra-
Tamam Bakchoul*, Heike Zllner, Rabie Jouni, Lars Janzen, Jan Wesche, Jessica stre (France)
Fuhrmann, Andreas Greinacher (Germany)
256 257
PO424-TUE THIOREDOXIN REDUCTASE PROTECTS PLATELETS FROM CELL DEATH PO434-TUE DETERMINING THE USABILITY OF THE PEDIATRIC THROMBOSIS EDU-
THURSDSAY
Matthew T. Harper* (United Kingdom) CATIONAL TOOL (P-TET) IN CHILDREN RECEIVING ANTICOAGULATION
THERAPY
PO425-TUE A NOVEL MUTATION IN NBEAL2 GENE CAUSING GRAY PLATELET SYN- Madeline I. Montoya*, Leonardo Brando, Frederica Cassis, Jennifer Stinson, Jorge
DROME Carneiro (Canada)
Lijuan Cao*, Zhaoyue Wang, Xia Bai, Jiaming Li, Lijun Xia, Changgeng Ruan (China)
PO435-TUE RARE LABORATORY PRESENTATION OF TYPE IIB VON WILLEBRANDS
DISEASE IN A 6 YEAR OLD BOY.
Pediatric thrombosis and hemostasis II Irene E. Regan*, Marie Lyons, Michelle ORourke, Brian Philbin, Vince Jenkins,
Beatrice Nolan (Ireland)
WEDNESDAY
PO426-TUE VALIDATION OF THE SELF-PBQ (SELF-ADMINISTERED PEDIATRIC PO436-TUE SYNERGISTIC EFFECT OF ELEVATED LIPOPROTEIN (A) LEVELS WITH
BLEEDING QUESTIONNAIRE) AS A SCREENING TOOL FOR A NEW DIAG- INHERITED THROMBOPHILIA RISK FACTORS IN CHILDREN WITH ARTE-
NOSIS OF VON WILLEBRAND DISEASE (VWD) RIAL ISCHEMIC STROKE
TUESDAY
Angie Tuttle*, Julie Grabell, Steven Bae, Paul Moorehead, Victor Blanchette, John Desiree Coen Herak*, Jasna Lenicek Krleza, Renata Zrinski Topic, Margareta Radic
Wu, MacGregor Steele, Robert Klaassen, Mariana Silva, Margaret Rand, Paula James Antolic, Ivana Horvat, Marija Milos, Vlasta Djuranovic, Renata Zadrio (Croatia)
(Canada)
PO437-TUE THE ROLE OF FVR2 POLYMORPHISM IN CHILDREN CARRIERS OF FV-
PO427-TUE FAMILY HISTORY OF VENOUS THROMBOEMBOLISM IN THE PAEDIATRIC
LEIDEN
POPULATION: THE NEED FOR A STANDARDIZED DEFINITION
TUESDAY
Zoey Kapsimali*, Helen Pergantou, Anna Komitopoulou, Helen Platokouki (Greece)
Anna Hau, Eric Wegener*, Paul Monagle, Shoshana Revel-Vilk, Vera Ignjatovic (Austra-
POSTERS
lia) PO438-TUE WHOLE BLOOD THROMBOELASTOMETRY (ROTEM) PROFILES IN CHIL-
DREN WITH CYANOTIC CONGENITAL HEART DISEASES UNDERGOING
PO428-TUE INITIAL DOSE OF ENOXAPARIN IN NEONATES WITH THROMBOSIS
CARDIAC SURGERY
Mirta Hepner*, Gabriela Sciuccati, Carolina Cervio, Graciela Pieroni, Silvina Annetta,
Diana Faria, Juan Frontroth, Lilian Diaz, Aurora Feliu Torres, Mariana Bonduel (Argen- Luca Spiezia*, Vladimiro Vida, Giacomo Bortolussi, Marta Marchetti, Elena Campello,
tina) Demetrio Pittarello, Guido Di Gregorio, Giovanni Stellin, Paolo Simioni (Italy)
PO429-TUE SKIN NECROSIS AND PURPURA FULMINANS IN CHILDREN WITH AND PO439-TUE THE INCIDENCE OF DEEP VEIN THROMBOSIS IN CHILDREN WITH
MONDAY
WITHOUT THROMBOPHILIA - A TERTIARY CENTERS EXPERIENCE PERIPHERALLY INSERTED CENTRAL CATHETERS VERSUS TUNNELED
Yariv Fruchtman*, Tzipora Strauss, Marina Rubinstein, Miriam Ben Harosh, Shoshana CENTRALLY INSERTED CATHETERS IN PEDIATRIC PATIENTS: A PRO-
Revel-Vilk, Joseph Kapelushmik, Gideon Paret, Gili Kenet (Israel) SPECTIVE COHORT STUDY
Julie Jaffray*, Kaitlyn Dang, Brian Vasquez, Jano Boghossian, Chadi Zeinati, Jemily
PO430-TUE INCIDENCE RATE AND RISK FACTORS OF VENOUS THROMBOEMBOLISM Malvar, Guy Young (United States)
IN ASIAN PEDIATRIC ONCOLOGY PATIENTS.
Wai Ming Mendy Ong*, Koon Mian Foo, Joyce Ching Mei Lam, Mei Yi Loke (Singapore) PO440-TUE BENIGN JOINT HYPERMOBILITY SYNDROME IS PREVALENT IN CHIL-
DREN WITH UNDEFINED BLEEDING DISORDERS
PO431-TUE CLINICAL FEATURES, RISK FACTORS AND OUTCOME OF PULMONARY
SUNDAY
MacGregor Steele*, Sheri VanGunst, Leah Odiaman, Man-Chiu Poon, Shannon Jackson
EMBOLISM IN CHILDREN ADMITTED TO A SINGLE ACADEMIC CENTER (Canada)
IN SO PAULO BRAZIL: LOTS TO LEARN OR READY TO TEACH?
PO441-TUE THROMBOEMBOLIC COMPLICATION IN CHILDHOOD WITH NEPHROTIC
Jorge D. A. Carneiro*, Daniele Celeste, Fernanda Sequeira, Vicente Odone-Filho (Brazil)
SYNDROME: EXPERIENCE IN THREE PEDIATRIC HOSPITALS IN ARGEN-
PO432-TUE AN INTERNATIONAL SURVEY REGARDING MANAGEMENT OF COAGU- TINA.
LOPATHY IN CHILDREN UNDERGOING LIVER BIOPSY. Monica S. Martinez*, Daniela Morell, Guillermo Arbesu, Carina Calvo, Alejandra Costa,
Maria Magnusson*, Bjrn Fischler, Winita Hardikar, Paul Monagle (Sweden) E Hiratmasu, Vanesa Gimenez, Roberto Navarro (Argentina)
SATURDAY
PO433-TUE EVALUATION OF THROMBOPHILIA IN CHILDREN BEFORE RENAL PO442-TUE ACQUIRED VON WILLEBRAND SYNDROME (AVWS) - AN UNDERDIAG-
TRANSPLANT AND OUTCOME OF PROPHYLACTIC ANTICOAGULATION NOSED COMPLICATION IN SEVERELY ILL PEDIATRIC PATIENTS WITH
POST-TRANSPLANT BLEEDING COMPLICATIONS
Jorge D. A. Carneiro*, Andreia Watanabe, Vera Koch, Benita Schvartsman, Marlene Ivonne Wieland*, Karl-Walter Sykora (Germany)
Garanito, Gustavo Messi, William Nahas, Elbio DAmico (Brazil)
PO443-TUE THE IMPACT OF SERUM BILE ACID LEVELS ON THE MRNA EXPRESSION
OF PRO-AND ANTICOAGULANT PROTEINS IN LIVER TISSUE.
Maria Magnusson*, Cecilia Glman, Bjrn Fischler, Eva Beijer, Henrik Arnell, Antal
Nmeth, Gsta Eggertsen (Sweden)
258 259
PO444-TUE THROMBOMODULIN GENE ANALYSIS IN A CASE OF ATYPICAL HEMOLYT- PO454-TUE IMPROVEMENT IN THROMBIN GENERATION BY THE ANTI-TFPI ANTI-
THURSDSAY
IC-UREMIC SYNDROME BODY, CONCIZUMAB, IN PLASMA FROM INDIVIDUALS WITH HAEMO-
Vilalta Noelia*, Tirado Isabel, Mateo Jose, Coll Immaculada, Cuevas Biel, Lpez-Pardo PHILIA A WITH OR WITHOUT INHIBITORS OR HAEMOPHILIA B, IS NOT
Jordi, Fraga Gloria, Bri Sonia, Souto Juan Carlos, Martinez-Snchez Elisabet, Fontcu- AFFECTED BY THE PRESENCE OF CORN TRYPSIN INHIBITOR
berta Jordi (Spain) Emily K. Waters*, Ida Hilden, Supreet Dhillon, Catherine Rea, Brit Srensen (Denmark)
PO445-TUE CLINICAL CHARACTERIZATION OF VENOUS THROMBOEMBOLISM IN PO455-TUE CHARACTERIZATION OF PRO-COAGULANT ANTIBODIES BINDING TO
CHILDHOOD AT A TERTIARY LEVEL HOSPITAL KUNITZ DOMAIN-1 OF TFPI
Laura L. Andreoni*, Vernica Pons, Pavel Olivera, Carlos Chavez, Vicente Cortina, Ana Helle Heibroch Petersen*, Cecilia Augustsson, Berit Olsen Krogh, Jens Breinholt, Jes
Marin, Francesc Bosch, Amparo Santamara (Spain)
WEDNESDAY
Thorn Clausen, Birgitte Kjr, Ida Hilden, Lars Christian Petersen (Denmark)
PO446-TUE LETS CUT TO THE BONE: RISK FACTORS OF VENOUS THROMBOEMBO- PO456-TUE THE EFFECT OF ULTRA HIGH LEVELS OF C-REACTIVE PROTEIN (CRP)
LISM IN CHILDREN WITH MUSCULOSKELETAL INFECTIONS ON THE COAGULATION SYSTEM
Rungrote Natesirinilkul*, Suzan Williams, Upton Allen, Leonardo Brandao (Canada)
TUESDAY
Ramin Artang*, Daniel Anderson, Jrn Dalsgaard Nielsen (United States)
PO447-TUE FEASIBILITY AND SAFETY OF ENOXAPARIN WHOLE MILLIGRAM DOSING PO457-TUE ASSESSMENT OF THE EFFECT OF INTER-ALPHA TRYPSIN INHIBITOR BY
IN PREMATURE AND TERM NEONATES THROMBIN GENERATION ASSAY
Rebecca Goldsmith*, Anthony Chan, Mihir Bhatt (Canada) Jean-Luc Plantier*, Vronique Devos, Sami Chtourou, Sylvie Jorieux (France)
TUESDAY
Platelets and cancer PO458-TUE PROLONGATION OF CLOT LYSIS TIME BY A DIRECT THROMBIN INHIBI-
TOR: INVOLVEMENT OF THROMBIN GENERATION ENHANCEMENT AND
POSTERS
PO448-TUE IMMUNOPHENOTYPIC EXPRESSION OF PLATELETS IN MYELODYSPLAS- THROMBIN-ACTIVATABLE FIBRINOLYSIS INHIBITOR
TIC SYNDROME Yoshiyuki Morishima*, Chikako Kamisato (Japan)
Yi-Feng Wu*, Chao-Zong Liu (Taiwan)
PO459-TUE ORAL FACTOR XA ANTICOAGULANTS, RIVAROXABAN AND APIXABAN,
PO449-TUE RECURSIVE PARTITIONING WITH AMALGAMATION ANALYSIS OF CAN- ENHANCE CLOT DISSOLUTION IN PLASMA
CER SPECIFIC BIOMARKERS IN THE PREDICTION OF CANCER ASSOCI- Rolinda L. Carter*, Kimberley Talbot, Tyler Smith, Agnes Lee, Edward Pryzdial (Canada)
MONDAY
ATED THROMBOSIS. PO460-TUE ULTRASONIC MONITORING OF FIBRIN CLOT FORMATION AND FIBRINO-
Alfonso Tafur*, George Dale, Aaron Mansfield, Mohamad Cherry, Philip Comp, Suman
LYSIS IN FLOWING BLOOD
Rathbun, Julie Stoner (United States)
Konstantin G. Guria*, Shakhla Dzhumaeva, Dmitriy Ivlev, Svetlana Uzlova, Georgy
PO450-TUE CANCER CELLS INDUCE THE RELEASE OF MICROPARTICLES FROM Guria (Russian Federation)
HUMAN PLATELETS PO461-TUE A NOVEL APPROACH FOR HEMOPHILIA THERAPY THROUGH ANTIBODY
Gianni F. Guidetti*, Ilaria Canobbio, Daria Manganaro, Marta Zar, Caterina Visconte,
TARGETED TFPI
Mauro Torti (Italy)
Sumin Lee*, Kisu Kim, Dong-Sik Kim, Heechun Kwak, Mijung Lee, Jae Chan Park,
SUNDAY
PO451-TUE THE EFFECTS OF INTERFERON-2B ON THE DEFECTIVE BONE MARROW Young Seoub Park, Hyung-Kwon Lim, SungHo Hwang (Korea, Republic Of)
MESENCHYMAL STEM CELLS IN PATIENTS WITH ESSENTIAL THROMBO- PO462-TUE FUNCTIONAL COMPONENTS OF JAPANESE TRADITIONAL SOYBEAN
CYTHEMIA FOOD NATTONATTOKINASE, VITAMIN K2 AND POLYAMIN
Tiantian Sun*, Cuicui Lv, Donglei Zhang, Xian Zhang, Rongfeng Fu, Mingen Lv, Wenjie
Hiroyuki Sumi*, Tadanori Ohsugi, Sawa Naito, Chieko Yatagai (Japan)
Liu, Yang Li, Yating Hao, Huiyuan Li, Renchi Yang, Lei Zhang (China)
PO463-TUE FIBRINOLYTIC ACTIVITY PRODUCED BY FERMENTED SWEET CORN WITH
PO452-TUE SUNITINIB IS TAKEN UP BY PLATELETS AND INHIBITS PLATELET ACTI-
BACILLUS SUBTILIS NATTO
VATION AND THROMBUS FORMATION IN CANCER PATIENTS

SATURDAY
Hiroyuki Sumi*, Sawa Naito, Chieko Yatagai (Japan)

Siamack Sabrkhany, Sharo Pineda, Linda Sanders, Maureen Aarts, Johan Heemskerk,
Arjan Griffioen, Mirjam oude Egbrink, Marijke J. Kuijpers* (The Netherlands)
PO464-TUE INHIBITION OF FIBRINOLYSIS BY HEPARIN, LOW MOLECULAR WEIGHT
HEPARIN AND A NOVEL ANTICOAGULANT, ANTITHROMBIN-HEPARIN
Regulation of coagulation and fibrinolysis I COVALENT COMPLEX (ATH)
Gabriela Chang*, Helen Atkinson, Leslie Berry, Anthony Chan (Canada)
PO453-TUE ALLELIC VARIANTS WITHIN ANXA5 DIFFERENTIALLY IMPACT ON THE PO465-TUE COMPLEMENT C3 AND HYPOFIBRINOLYSIS: A POTENTIAL ROLE FOR
CONTROL OF GENE EXPRESSION PROTEIN GLYCATION
Giovanni Tiscia*, Per Morten Sandset, Elisabeth Drum, Christiane Myklebust, Elvira Katharina Schuett, Rhodri King*, Fladia Phoenix, Kerrie Smith, Sebastian Maxeiner,
Grandone, Grethe Skretting (Italy) Katharina Lysaja, Vera Jankowski, Nikolaus Marx, Ramzi Ajjan (Germany)
260 261
PO466-TUE THE ARTERIOVENOUS DIFFERENCE OF HEMOSTASIS PARAMETERS IN PO476-TUE MATERNAL DEATH AND VENOUS THROMBOEMBOLISM (VTE) IN PA-
THURSDSAY
CRITICALLY ILL PATIENTS WITH DIFFERENT TYPE OF HYPOERGOSIS TIENTS ADMITTED IN A MATERNITY OF HIGH RISK: RESULTS PRE AND
Sergei Sinkov*, Igor Zabolotskikh, Denis Velichko, Sergei Grigoriev (Russian Federation) POST APPLICATION OF A RISK SCORE.
Roberta Santos*, Venina Barros, Ana Igai, Rossana Francisco, Marcelo Zugaib (Brazil)
PO467-TUE EFFECTS OF AN ACIDIC ENVIRONMENT ON COAGULATION DYNAMICS
Matthew Gissel*, Thomas Orfeo, Saulius Butenas, Anthony Pusateri, Kathleen Brum- PO477-TUE A COMMON GENETIC BACKGROUND SHARED BY WOMEN WITH HIS-
mel-Ziedins, Kenneth Mann (United States) TORY OF ADVERSE PREGNANCY OUTCOMES AND CARDIOVASCULAR
DISEASE: A WINDOW TO FUTURE CARDIOVASCULAR RISK.
PO468-TUE EXERCISE-INDUCED CORE BODY TEMPERATURE ELEVATIONS SHIFT Ilaria Romagnuolo*, Elena Sticchi, Elisa Grifoni, Maddalena Pazzi, Agatina Alessan-
HEMOSTASIS TO A PROTHROMBOTIC STATE
WEDNESDAY
drello Liotta, Raffaella Priora, Monica Attanasio, Rosanna Abbate, Cinzia Fatini (Italy)
Waander Van Heerde*, Matthijs Veltmeijer, Wideke Barteling, Kitty Verbeek-Knobbe,
Thijs Eijsvogels, Maria Hopman (The Netherlands) PO478-TUE POLYMORPHISMS IN TUMOR NECROSIS FACTOR-ALPHA (-863C>A,
-857C>T AND +488G>A) ARE ASSOCIATED WITH IDIOPATHIC RECUR-
PO469-TUE IN VITRO INTERACTIONS OF SUGAMMADEX WITH VARIOUS ANTICOAGU-
TUESDAY
RENT PREGNANCY LOSS IN KOREAN WOMEN
LANTS Hui Jeong An*, Jung O Kim, Hyo Geun Jang, Gun Ho Choi, Ki Han Ko, Ji Hyang Kim,
Annelieke C. Kruithof*, Cornelis Kluft, Pieter-Jan de Kam, Ria Laterveer, Matthijs Nam Keun Kim (Korea, Republic Of)
Moerland, Jacobus Burggraaf (The Netherlands)
PO479-TUE THE IMPACT OF MODE OF DELIVERY AND POSTPARTUM THROMBO-
PO470-TUE COAGULOPATHY AND OSMOLAR GAP IN CRITICALLY ILL PATIENTS: AN PROPHYLAXIS ON ROTATIONAL THROMBOELASTOMETRY (ROTEM) IN
TUESDAY
INTIMATE RELATIONSHIP PREGNANT WOMEN WITH A HIGH RISK OF POSTPARTUM VENOUS
Vladimir Sukhanov*, Olga Petrova, Alexander Levit (Russian Federation)
POSTERS
THROMBOEMBOLISM.
PO471-TUE NET AND NEUTROPHIL INDUCED THROMBIN GENERATION Boriana Guimicheva*, Lara Roberts, Jignesh Patel, Devi Subramanaian, Roopen Arya
(United Kingdom)
Jaewoo Song*, Eun-Young Lee, Rojin Park, Ye-Jin Song, Yun A Jo, Jongha Yoo (Korea,
Republic Of)
PO480-TUE RETROSPECTIVE STUDY OF PATIENTS WHO WERE TREATED WITH
FONDAPARINUX PRE-, PERI- AND/OR POSTPARTUM FOR PROPHYLAXIS
Reproductive issues II OR TREATMENT OF VENOUS THROMBOEMBOLISM (FONDAPPP)
Carl-Erik Dempfle*, Juergen Koscielny, Edelgard Lindhoff-Last, Johannes Oldenburg,
MONDAY
Hartmut Pollmann, Guenther Kappert, Ute Scholz, Stefan Kropff, Sonja Eberle, An-
PO472-TUE EARLY ANTICOAGULATION AND PREGNANCY OUTCOMES IN PATIENTS dreas Heinken (Germany)
REFERRED TO A SERVICE OF THROMBOSIS AND THROMBOPHILIA IN
PREGNANCY PO481-TUE ROTATIONAL THROMBOELASTOMETRY IN PREGNANCY AND ITS ROLE
Tain Rocha, Venina Barros*, Roberta Santos, Fernanda Baptista, Rossana Franscisco IN ASSESSMENT OF HAEMOSTASIS IN WOMEN WITH FACTOR XI DEFI-
(Brazil) CIENCY
Joanna Davies*, Rezan Kadir (United Kingdom)
PO473-TUE IMPACT OF HORMONE TREATMENT IN INFERTILE WOMEN UNDERGO-
ING ARTIFICIAL REPRODUCTIVE TECHNIQUES (ART) ON THROMBIN PO482-TUE THROMBIN GENERATION IN WOMEN UNDERGOING IVF TREATMENT IS
SUNDAY
GENERATION, TISSUE FACTOR, THROMBOMODULIN AND PROCOAGU- PROLONGED, BUT NOT ENHANCED COMPARED TO CONTROLS.
LANT PHOSPHOLIPID ACTIVITIES. Roza Chaireti*, Katarina Bremme (Sweden)
Patrick Van Dreden*, Emmanuelle Mathieu dArgent, Marjorie Comtet, Hela Ketatni,
Matthieu Grusse, Vassiliki Galea, Eleftheria Lefkou, Ismail Elalamy, Grigoris Gerotzi- PO483-TUE LOW-MOLECULAR WEIGHT HEPARIN IN PREGNANCIES AFTER ART -A
afast (France) RANDOMIZED STUDY-
Corrado Lodigiani*, Paola Ferrazzi, Luca Libr, Elena Banfi, Luca Cafaro, Manuela
PO474-TUE NEW THROMBOPHILIC RISK FACTORS IN PATIENTS WITH VASCULAR Morenghi, Monica Demarco, Ilaria Quaglia, Paolo Levi-Setti (Italy)
PLACENTAL COMPLICATIONS (VPC) AND PREGNANCY OR HORMONAL
SATURDAY
THERAPY - RELATED THROMBOSIS AND MANAGEMENT IN THE CLINI- PO484-TUE EFFECTS OF SILDENAFIL CITRATE ON COAGULATION PROCESS DURING
CAL PRACTICE. RESULTS FROM THE INTERNATIONAL TEAM PROJECT. PREGNANCY: A PROMISING THERAPEUTIC APPROACH IN COMBINATION
Amparo Santamaria*, Carmen Medina, Artur Oliver, Edel Marti, Daniella Mussio, Ana WITH LOW MOLECULAR WEIGHT HEPARIN FOR RECURRENT PREGNAN-
Redondo Izal, Ceciilia Stevenazzi, Isabel De Diego, A. Rodriguez-Huerta (Spain) CY LOSS
Rayana Luna*, Christina Peixoto, Anne Croy, Maha Othman (Brazil, Canada)
PO475-TUE ASSOCIATION BETWEEN POLYMORPHISMS IN VASCULAR ENDOTHELIAL
GROWTH FACTOR (VEGF) GENE AND REPEATED IMPLANTATION FAIL-
URE (RIF)
Jung O Kim*, Hyo Geun Jang, Gun Ho Choi, Ki Han Ko, Hui Jeong An, Youngsok Choi,
Woo Sik Lee, Nam Keun Kim (Korea, Republic Of)
262 263
PO493-TUE IMPACT OF INHERITED RISK FACTORS OF VENOUS THROMBOEMBO-
Risk factors in venous thrombosis II
THURSDSAY
LISM (VTE) ON THE ASSOCIATIONS BETWEEN RED CELL DISTRIBUTION
WIDTH AND RISK OF VTE.
PO485-TUE A RISK SCORE FOR PREDICTION OF RECURRENCE IN PATIENTS WITH Trygve Ellingsen*, Jostein Lappegrd, Erin Smith, Tom Wilsgaard, Sigrid Brkkan,
UNPROVOKED VENOUS THROMBOEMBOLISM (DAMOVES) Terry Solomon, Kelly Frazer, John-Bjarne Hansen (Norway)
Ana Isabel Franco Moreno*, Mara Jos Garca Navarro, Judith Ortiz Snchez, Rosa
Mara Martn Daz, Elena Madroal Cerezo, Cristina Luca de Ancos Aracil, Victoria PO494-TUE IMPACT OF INHERITED RISK FACTORS OF VENOUS THROMBOSIS ON
Martnez Daz, Alejandra Gimeno Garca, Carmen Montero Hernndez, Sari Arponen, RISK OF STROKE AND VTE IN ATRIAL FIBRILLATION
Noem Cabello Clotet, Jos Manuel Ruiz Giardn (Spain) Ina Rye-Holmboe*, Erin Smith, Erin Hald, Anders Vik, Ellen Brodin, Sigrid Brkkan,
Terry Solomon, Tom Wilsgaard, Frits Rosendaal, Kelly Frazer, John Bjarne Hansen
WEDNESDAY
PO486-TUE ANALYSIS OF PROTHROMBIN MUTANTS IN NA+ BINDING DOMAIN AS A (Norway)
POTENTIAL CANDIDATE CONVEYING ANTITHROMBIN RESISTANCE
Moe Murata*, Naoki Mizutani, Yuki Takagi, Ryo Hasebe, Toshihiro Kozuka, Yukiko PO495-TUE IMPACT OF THE FIBRINOGEN GAMMA GENE RS2066865 VARIANT ON
THE RISK OF VENOUS THROMBOSIS IN CANCER PATIENTS
TUESDAY
Nakata, Akira Takagi, Tetsuhito Kojima (Japan)
Olga Dziewiecka*, Erin Smith, Sigrid Brkkan, Hilde Jensvoll, Kristine Blix, Terry
PO487-TUE ORAL ANTICOAGULANT THERAPY FOR THE PREVENTION OF RECUR- Solomon, Tom Wilsgaard, Frits Rosendaal, Kelly Frazer, John-Bjarne Hansen (Norway)
RENT THROMBOSIS IN PATIENTS WITH POLYCYTHEMIA VERA OR
ESSENTIAL THROMBOCYTHEMIA PO496-TUE CHARACTERISTICS OF HOSPITAL-ASSOCIATED THROMBOSIS ATTRIBUT-
Eduardo Arellano-Rodrigo*, JC Hernndez-Boluda, F Cervantes, A Alvarez- Larrn, M ED TO THROMBOPROPHYLAXIS FAILURE
TUESDAY
Gmez, P Barba, MI Mata, JR Gonzlez-Porras, F Ferrer-Marn, V Garca-Gutirrez, E Lara Roberts, Emma Gee*, Gayle Mulla, Cara Doyle, Melanie Ferreira, Jig Patel, Raj
Patel, Roopen Arya (United Kingdom)
POSTERS
Magro, M Moreno, A Kerguelen, M Prez-Encinas, N Estrada, R Ayala, C Besses, A
Pereira (Spain)
PO497-TUE ANTI-VIMENTIN ANTIBODIES INCREASE THROMBUS FORMATION AT VE-
PO488-TUE ACSF2 EXPRESSION AND RISK OF RECURRENCE AFTER A FIRST UN- NOUS SHEAR RATES IN VITRO AND IN VIVO: IMPLICATION FOR VENOUS
PROVOKED DEEP VENOUS THROMBOSIS EVENT. RESULTS FROM THE THROMBOEMBOLISM IN AUTOIMMUNE DISEASES
RETRO STUDY Qi Da, Rolando Rumbaut, Miguel Cruz* (United States)
Ramn Lecumberri*, Ramn Montes, Elisabeth Guruceaga, Jos Gonzlez-Porras, Joan
Reverter, Pascual Marco, Elena Pina, Javier Trujillo, ngel Bernardo, Pilar Llamas, PO498-TUE SWITCHING TYPE OF ORAL CONTRACEPTIVE AND RISK OF VENOUS
MONDAY
Alicia Lorenzo, Carmen Fernndez-Capitn, David Jimnez, Ana Alfonso, Jos Pramo, THROMBOEMBOLISM: A CASE-CROSSOVER STUDY
Jos Hermida (Spain) Luuk Scheres*, Willem Lijfering, Astrid van Hylckama Vlieg, Saskia Middeldorp, Su-
zanne Cannegieter (The Netherlands)
PO489-TUE PROSPECTIVE OBSERVATIONAL STUDY ON INCIDENCE OF VENOUS
THROMBOEMBOLISM IN MEDICALLY-ILL HOSPITALIZED ELDERLY PA- PO499-TUE FORGOTTEN NO MORE A CASE OF A 54 YEAR OLD FEMALE WITH
TIENTS LEMIERRES SYNDROME
Jeong-Ok Lee*, Jin Won Kim, Se Hyun Kim, Yu Jung Kim, Keun-Wook Lee, Jee Hyun Edward Gacrama* (Philippines)
Kim, Hwi-Joong Yoon, Soo-Mee Bang (Korea, Republic Of)
PO500-TUE PREAVELANCE OF RISK FACTORS PREDISPOSING TO THROMBOSIS IN
SUNDAY
PO490-TUE INHERITED PROTHROMBOTIC RISK FACTORS IN CHILDREN WITH IN- PATIENTS WITH CENTRAL RETINAL VEIN OCCLUSION
TRACRANIAL VENOUS THROMBOSIS: SINGLE CENTER EXPERIENCE IN Jerzy Dropinski*, Agnieszka Kubicka-Trzaska, Teresa Domagala, Marek Sanak, Teresa
TURKEY Iwaniec, Jacek Musial (Poland)
Turkan Patiroglu*, Gonca Koc, Mehmet Canpolat, Ekrem Unal, Selim Doganay, Musa
Karakukcu, Mehmet Ozdemir (Turkey) PO501-TUE NO DIFFERENCES IN THROMBIN GENERATION BETWEEN PATIENTS
WITH AND WITHOUT PORTAL VEIN THROMBOSIS IN END-STAGE LIVER
PO491-TUE THROMBOPROPHYLAXIS SKIPPED DOSES IN HOSPITALIZED PATIENTS. DISEASE
CAN WE RECOGNIZE WHICH ARE THE CAUSES OR FACTORS? Dana R. Tomescu*, Mihai Popescu, Carmen Orban, Lavinia Jipa, Irinel Popescu (Ro-
SATURDAY
Alicia Beatriz Vilaseca*, Rubn Barbera, Jimena Bonadeo, Nadia Kujta, Adriana Lopez mania)
(Argentina)
PO502-TUE ENDOGENOUS SEX HORMONE LEVELS IN MEN WITH UNPROVOKED
PO492-TUE IDENTIFICATION OF A NOVEL HOMOZYGOUS MUTATION RESPONSIBLE DEEP VEIN THROMBOSIS
FOR TYPE II (P.S169F) ANTITHROMBIN DEFICIENCY Nicola Mumoli*, Marco Cei, Barbara Brondi, Matteo Giorgi Pierfranceschi, Jos Vitale,
Ying Y. Wu*, Liang Tang, Wei Zeng, Yu Hu (China) Francesco Dentali (Italy)
264 265
PO503-TUE A-FIBRINOGEN THR312ALA POLYMORPHISM IS AN INDEPENDENT PO511-TUE PHOSPHATIDYLINOSITOL-3,4,5-TRISPHOSPHATE STIMULATES CA2+
THURSDSAY
GENETIC RISK FACTOR FOR VENOUS THROMBOEMBOLISM IN THE ELEVATION AND AKT PHOSPHORYLATION TO CONSTITUTE A MAJOR
POPULATION OF NORTH-WESTERN RUSSIA MECHANISM OF THROMBOXANE A2 FORMATION IN HUMAN PLATELETS.
Sergey Kapustin*, Anna Demyanenko, Veronika Shmeleva, Vitaly Soldatenkov, Pavel Kalwant S. Authi*, Nick Kassouf, Archana Ambily, Stephanie Watson, Sheila Hassock,
Chechulov, Viktor Kargin, Lyudmila Papayan (Russian Federation) Harmeet Authi, Steve Watson (United Kingdom)
PO504-TUE VENOUS THROMBOEMBOLISM (VTE) IN HOSPITALISED NON-SURGICAL PO512-TUE A SYSTEMS BIOLOGY MODEL FOR THE COAGULATION NETWORK
CANCER PATIENTS AND ITS BURDEN ON HEALTHCARE IN AN ASIAN DESCRIBES BIOMARKER CHANGES OBSERVED IN A CLINICAL STUDY
TERTIARY HOSPITAL WITH FVIIA VARIANT

WEDNESDAY
Lai Heng Lee*, Arul Earnest, Jeffrey Hui, Yong Yang (Singapore) Dooyoung Lee, Satryaprakash Nayak, Steven Arkin, Steven Martin, Anne Heather-
ington, Paolo Vicini, Fei Hua* (United States)
PO505-TUE A NOVEL MICROFLUIDIC DEVICE DEVELOPMENT FOR VENOUS THROM-
BUS UNDERSTANDING PO513-TUE IMPORTANCE OF TRANSFORMING GROWTH FACTOR ETA-INDUCED
SIGNALING FOR CHRONIC POSTTHROMBOTIC VASCULAR REMODELING
TUESDAY
Naoko Sugita*, Hideo Hirakata, Kyo Inoue, Kazuya Tatsumi, Kaoru Koike, Toshiya
Murai (Japan) PROCESSES
Katrin Schfer, Magdalena L. Bochenek*, Nico Rosinus, Eva Schtz, Mareike Lankeit,
PO506-TUE ANTICOAGULANTS FOR PREVENTION OF THROMBOTIC COMPLICATIONS Markus Bosmann, Eckard Mayer, Thomas Mnzel, Stavros Konstantinides (Germany)
IN PATIENTS ON PARENTERAL NUTRITION: A SYSTEMATIC REVIEW.
Stefano L. Barco*, Jasper Atema, Michiel Coppens, Mireille Serlie, Saskia Middeldorp PO514-TUE ROLE OF P110ALPHA ISOFORM OF CLASS I PI3-KINASES IN PLATELET
TUESDAY
(The Netherlands) ACTIVATION AND FUNCTIONS

POSTERS
Pierre-Alexandre Laurent, Sonia Sverin, Batrice Hechler, Gatan Chicanne,
PO507-TUE LONG-TERM PARENTERAL NUTRITION-ASSOCIATED THROMBOEMBOLIC Anne-Dominique Terrisse, Gachet Christian, Bart Vanhaesebroeck, Bernard Payrastre,
AND HEMORRHAGIC COMPLICATIONS IN 236 SINGLE-CENTER OUTPA- Marie-Pierre Gratacap* (France)
TIENTS.
Stefano L. Barco*, Michiel Coppens, Caroline Heuschen, Bram Salman, Marjolein
Brekelmans, Mireille Serlie, Saskia Middeldorp (The Netherlands) Stroke
PO508-TUE ROLE OF BODY COMPOSITION MEASUREMENTS IN PREDICTING CAN-
MONDAY
PO515-TUE EVALUATION OF THE THERAPEUTIC EFFECT OF NOVEL STROKE DRUG
CER ASSOCIATED THROMBOSIS
SMTP-7 ON EMBOLIC STROKE IN MONKEYS
Omer Iftikhar, Federico Silva, Aaron Mansfield, Mohammad Cherry, Alfonso Tafur*
(United States) Eriko Suzuki*, Yudai Kunikiyo, Naoki Matsumoto, Hironobu Sawada, Naoko Nishimura,
Keiko Hasegawa, Keiji Hasumi (Japan)
PO508.1-TUE
A NOVEL RS2232710 SINGLE NUCLEOTIDE VARIANT IN THE PROTEIN
PO516-TUE THE ASSOCIATION OF FACTOR VIII AND VON WILLEBRAND FACTOR
Z-DEPENDENT PROTEASE INHIBITOR (ZPI, SERPINA10) GENE AND A
LEVELS AND THE OUTCOME OF THROMBOLYSIS IN ISCHEMIC STROKE
RISK OF DEEP VEIN THROMBOSIS
Marcin M. Gorski*, Luca A. Lotta, Hugoline de Haan, Astrid van Hylckama Vlieg, Sere- PATIENTS
na Passamonti, Paolo Bucciarelli, Emanuela Pappalardo, Marco Boscarino, Richard A. Noemi Klara Toth*, Edina Szkely, Katalin Kovcs, Lszl Csiba, Lszl Muszbek,
SUNDAY
Gibbs, Ida Martinelli, Frits Rosendaal, Flora Peyvandi (Italy) Zsuzsa Bagoly (Hungary)
PO517-TUE ADAMTS13 DESTABILIZES THROMBI IN A MOUSE MODEL OF THROM-

Signal transduction BOTIC FOCAL CEREBRAL ISCHEMIA
Frederik Denorme*, Friederike Langhauser, Hanspeter Rottensteiner, Barbara Plaim-
auer, Friedrich Scheiflinger, Christoph Kleinschnitz, Karen Vanhoorelbeke, Simon De
PO509-TUE UROKINASE PLASMINOGEN ACTIVATOR PROTECTS CARDIAC MYOCYTES Meyer (Belgium)
FROM OXIDATIVE DAMAGE AND APOPTOSIS VIA OGG1
SATURDAY
Philipp Hohensinner*, Nikol Takacs, Christoph Kaun, Stefan Pfaffenberger, Konstantin PO518-TUE REMOTE PLATELET FUNCTION TESTING USING MEASUREMENTS OF
Krychtiuk, Arezu Aliabadi, Andreas Zuckermann, Gerald Maurer, Kurt Huber, Johann P-SELECTIN IN PATIENTS WITH ACUTE STROKE OR TIA ALREADY RE-
Wojta (Austria) CEIVING TREATMENT WITH ANTIPLATELET AGENTS
Stan Heptinstall*, Natalia Dovlatova, Jane May, Katie Robson, Philip Bath (United
PO510-TUE FACTOR VII ACTIVATING PROTEASE (FSAP) EXPRESSION IS NEGATIVELY Kingdom)
REGULATED BY TRANSFORMING GROWTH FACTOR-BETA (TGF-) IN THE
LIVER. PO519-TUE INHIBITION OF TAFI AND PAI-1 IS PROTECTIVE IN A MOUSE MODEL OF
Sebastian Seidl*, Silke Leiting, Lars Muhl, Sandip Kanse (Norway) CEREBRAL ISCHEMIA/REPERFUSION INJURY
Frederik Denorme*, Tine Wyseure, Miet Peeters, Ann Gils, Paul Declerck, Simon De
Meyer (Belgium)
266 267
PO520-TUE A FACTOR XA VARIANT IMPROVES HEMOSTASIS MODELS OF INTRACE- PO529-TUE ANTITHROMBIN LEVELS IN ADULT STROKE PATIENTS AT THE UNIVER-
THURSDSAY
REBRAL HEMORRHAGE SITY OF BENIN TEACHING HOSPITAL
Reema Jasuja, Rodney Camire, Steven Arkin, Debra Pittman* (United States) Omolade A. Awodu*, Oluomachi Nnachi (Nigeria)
PO521-TUE GENETIC ABLATION OF EXTRA DOMAIN A OF CELLULAR FIBRONECTIN PO530-TUE CLOPIDOGREL RESISTANCE AFTER MINOR ISCHEMIC STROKE OR TIA
PROTECTS HYPERCHOLESTEROLEMIC MICE FROM ACUTE STROKE BY IS ASSOCIATED TO PRE-DIABETES, HYPERTENSION AND CEREBRAL
REDUCING THROMBO-INFLAMMATION MICROANGIOPATHY
Nirav Dhanesha, Ajmal Ahmad, Prem Prakash, Prakash Doddapattar, Steven Lentz, Annika Lundstrm*, Ann Charlotte Laska, Bruna Gigante, Magnus von Arbin, Gun
Anil Chauhan* (United States) Jrneskog, Evaldas Laurencikas, Karin Heg Dembrower, Hkan Walln (Sweden)
WEDNESDAY
PO522-TUE EFFECTS OF THE MAIN ACTIVE COMPONENT COMBINATION BETWEEN PO531-TUE ASSOCIATION BETWEEN POLYMORPHISMS IN MICRORNA MACHINERY
ASTRAGALUS AND PANAX NOTOGINSENG ON INFLAMMATION AND GENES (DICER1, DROSHA, RAN, AND XPO5) AND ISCHEMIC STROKE
APOPTOSIS OF NERVE CELL AFTER CEREBRAL ISCHEMIA-REPERFU- Hui Jeong An*, Jung O Kim, Hyo Geun Jang, Gun Ho Choi, Ki Han Ko, Ok Joon Kim,
TUESDAY
SION Nam Keun Kim (Korea, Republic Of)
Chang-Qing Deng*, Xiao-Ping Huang, Huang Ding, Jin-Dong Lu, Ying-Hong Tang, Bing-
Xiang Deng (China) PO532-TUE THROMBOLYSIS USING N-ACETYLCYSTEINE IN ACUTE ISCHEMIC
STROKE
PO523-TUE THE ANGIOTENSIN-CONVERTING ENZYME GENE INSERTION/DELETION Maxime Gauberti*, Sara Martinez de Lizarrondo, Clment Gakuba, Denis Vivien
POLYMORPHISM IS ASSOCIATED WITH INCREASED RISK FOR ISCHEMIC (France)
TUESDAY
STROKE BUT NOT FOR MYOCARDIAL INFARCTION IN YOUNG MEXICAN
PO533-TUE MULTIPLE MENINGIOMAS DOES NOT INCREASE THE RISK OF INTRA-
POSTERS
POPULATION
Irma Isordia-Salas*, Rosa Mara Jimnez-Alvarado, Lorena Mendoza-Valdz, Jos
CRANIAL HEMORRHAGE AFTER INTRAVENOUS THROMBOLYSIS FOR
Antonio Alvarado-Moreno, David Santiago-Germn, Mara Valades-Meja, Jess Hernn- ACUTE ISCHEMIC STROKE
dez-Jurez, Abraham Majluf-Cruz (Mexico) Navdeep Lail*, Ashkan Mowla, Karanbir Singh, Sandhya Mehla, Peyman Shirani (Unit-
ed States)
PO524-TUE THROMBOELASTOMETRY (ROTEM) PROFILES IN PATIENTS UNDERGO-
ING THROMBOLYTIC THERAPY FOR ACUTE ISCHEMIC STROKE. PO534-TUE PATENT FORAMEN OVALE IN PATIENTS WITH PREVIOUS CEREBRAL
Elena Campello*, Filippo Farina, Luca Spiezia, Anna Palmieri, Sara Maggiolo, Letizia ISCHEMIC EVENTS:ECHOCARDIOGRAPHIC FEATURES AND RELATION-
MONDAY
Banzato, Fabio Dalla Valle, Claudio Baracchini, Paolo Simioni (Italy) SHIPS WITH TRANSCRANIAL DOPPLER
Paola Ieran, Antonella Tufano*, Roberta Esposito, Ciro Santoro, Francesco De Stefa-
PO525-TUE SEVERE OBESITY IS A RISK FACTOR FOR CEREBRAL VENOUS THROM- no, Anna Maria Cerbone, Giovanni Di Minno, Giovanni de Simone, Maurizio Galderisi
BOSIS: A CASE-CONTROL STUDY (Italy)
Jonathan M. Coutinho*, Susanna Zuurbier, Anne Broeg-Morvay, Mirjam Heldner, Frits
Rosendaal, Jan Stam, Marcel Arnold, Saskia Middeldorp, Suzanne Cannegieter (The PO535-TUE HEMORHEOLOGY AND HEMOSTASIS IN ISCHEMIC STROKE PATIENTS
Netherlands) TREATED WITH I.V.THROMBOLYSIS
Marina Gafarova*, Maxim Domashenko, Marina Maximova, Mark Loskutnikov, Daria
PO526-TUE LIGHT-SHEET FLUORESCENCE MICROSCOPY OF THE ACUTELY ISCH- Korobkova, Alla Shabalina, Marina Kostyreva, Rodion Konovalov (Russian Federation)
SUNDAY
EMIC BRAIN REVEALS DRAMATICALLY REDUCED THROMBOTIC ACTIVI-
TY IN T-CELL DEFICIENT MICE PO536-TUE ALTERED FIBRIN CLOT STRUCTURE/FUNCTION IN PATIENTS WITH
David Stegner*, Mari Gorelashvili, Judith van Eeuwijk, Oguzhan Angay, Jrgen Pin- CEREBRAL SINUS VENOUS THROMBOSIS AND THE RISK OF RECUR-
necker, Michael Schuhmann, Mike Friedrich, Guido Stoll, Katrin Heinze, Bernhard RENCE.
Nieswandt (Germany) Jakub Siudut*, Micha Zabczyk, Anetta Undas (Poland)
PO527-TUE THE ALTERATION OF IRON TRANSMEMBRANE PROTEINS EXPRESSION PO537-TUE THE NOVEL BIASED AGONIST FOR PAR-1 PROTECTS BRAIN CELLS
IN THE RAT HIPPOCAMPUS FOLLOWING FOCAL CEREBRAL ISCHEMIA FROM TOXICITY SIMILAR TO ACTIVATED PROTEIN C
SATURDAY
Jun Liao*, Shaowu Cheng, Jinwen Ge (China) Liubov Gorbacheva*, Irina Savinkova, Svetlana Strukova (Russian Federation)
PO528-TUE NONCLINICAL AND CLINICAL DEVELOPMENT OF TMS-007, A MEMBER

OF THE ANTI-INFLAMMATORY SMALL-MOLECULE THROMBOLYTIC Thrombophilia II
SMTPS
Keiji Hasumi*, Naoko Nishimura, Keiko Hasegawa, Hironobu Sawada, Eriko Suzuki
(Japan) PO538-TUE ROLE OF GENETIC POLYMORPHISMS OF HAEMOSTASISS SYSTEM IN
CASE OF HABITUAL MISCARRIAGE
Nadezda Vorobyeva, Diana Gamirkina (Russian Federation)
268 269
PO539-TUE INDIVIDUAL ABSOLUTE AND RELATIVE RISK (RR) OF PULMONARY PO551-TUE A 28-YEARS-OLD WOMAN WITH FACTOR VII DEFICIENCY REVEALED
THURSDSAY
EMBOLISM (PE) IN PREGNANCY AND PUERPERIUM IN PRESENCE OF AFTER TWO SEVERE POSTOPERATIVE BLEEDING EPISODES
HEREDITARY THROMBOPHILIC RISK FACTORS Evangelia Papapetrou*, Muriel Giansily-Blaizot, Haralambos Harissis, Georgios
Rainer B. Zotz*, Ruediger Scharf, Andrea Gerhardt (Germany) Vartholomatos, Nikolaos Kolaitis, Jean Francois Schved (Greece)
PO540-TUE R147W IN PROC GENE AND THE RISK OF THROMBOEMBOLISM IN THAI PO552-TUE TISSUE FACTOR / FVIIA TRANSACTIVATES THE IGF-1R IN PROSTATE
CHILDREN CANCER CELLS VIA INHIBITION OF CAVEOLIN-1
Nongnuch Sirachainan*, Ampaiwan Chuansumrit, Werasak Sasanakul, Lalita Ma- Mikael berg*, Agneta Siegbahn (Sweden)
haklan, Jarin Vaewpanich, Pimlak Charoenkwan, Somjai Kanjanapongkul, Pakawan
Wongwerawattanakoon, Pimpun Kitpoka (Thailand) PO553-TUE THE LRP1 RECEPTOR PROMOTES THE IN VIVO CLEARANCE OF ACTIVAT-
WEDNESDAY
ED FACTOR VII (FVIIA) IN COMPLEX WITH ANTITHROMBIN
PO541-TUE ACUTE SUPERIOR MESENTERIC VEIN THROMBOSIS IN A NON-CIR- Judicael G. Fazavana*, Nikolett Wohner, Olivier Christophe, Ccile Denis, Peter Lenting
RHOTIC PATIENT WITH HETEROZYGOUS G20210A PROTHROMBIN (France)
GENE MUTATION: A CASE REPORT
TUESDAY
Sagger Mawri*, David Paje (United States) PO554-TUE HIGH PLASMA CONCENTRATION OF ACTIVATED FACTOR VII-ANTI-
THROMBIN COMPLEX IS ASSOCIATED WITH AN ENHANCED THROMBIN
PO542-TUE THROMBIN GENERATION TEST AT R2 POLYMORPHISM OF FACTOR V GENERATION
Jana Prochazkova*, Ludek Slavik, Martin Prochazka, Jana Ulehlova (Czech Republic) Marcello Baroni*, Alessio Branchini, Patrizia Guarini, Federica Tosi, Filippo Sartori,
Matteo Campioni, Francesco Puzzo, Barry Woodhams, Domenico Girelli, Oliviero Oliv-
TUESDAY
PO543-TUE FACTOR V LEIDEN IN THE ABSENCE OF APC RESISTANCE IN A PATIENT ieri, Francesco Bernardi, Nicola Martinelli (Italy)
AFTER LIVER TRANSPLANTATION
POSTERS
Edyta Odnoczko, Ksenia Bykowska, Beata Baran, Jerzy Windyga* (Poland) PO555-TUE TISSUE FACTOR AND FACTOR VII GENE POLYMORPHISMS INFLUENC-
ING FVIIA-AT PLASMA CONCENTRATION ARE NOT UNIFORMLY ASSOCI-
PO544-TUE VENOUS THROMBOEMBOLISM ASSOCIATED WITH FIRST PREGNANCY ATED WITH MORTALITY IN PATIENTS WITH STABLE CORONARY ARTERY
IN 80 WOMEN WITH HEREDITARY ANTITHROMBIN DEFICIENCY. DISEASE.
Marie Helene Horellou*, Narymane Benmiloud, Jacqueline Conard, Claire Flaujac, Filippo Sartori*, Federica Tosi, Barbara Lunghi, Patrizia Guarini, Marcello Baroni, Ales-
Jacques Lepercq, Martine Alhenc-Gelas, Genevive Plu-Bureau (France) sio Branchini, Barry Woodhams, Domenico Girelli, Oliviero Olivieri, Francesco Bernardi,
Nicola Martinelli (Italy)
MONDAY
PO545-TUE MOLECULAR MODELING OF A NOVEL MUTATION IN THE SERPINC1
GENE ASSOCIATED WITH TYPE 1 ANTITHROMBIN DEFICIENCY PO556-TUE THE ROLE OF FACTOR VII MUTATIONS IN ENDOPLASMIC RETICULUM
Tzu-Fei Wang*, Jennifer Dawson, Julie Forman-Kay, Walter Kahr, Suzan Williams, STRESS
Anthony Chan, Riten Kumar (United States) Elisabeth Drum*, Maria Eugenia Chollet, Mirko Pinotti, Francesco Bernardi, Per
Morten Sandset, Grethe Skretting (Norway)
PO546-TUE ANTIPHOSPHOLIPID ANTIBODIES AS EMBOLIC RISK MARKER OF IN-
FECTIVE ENDOCARDITIS. PO557-TUE FVII DEFICIENCY: UNVEILING THE CELLULAR AND MOLECULAR
Jean Devignes*, Charles-Henry Maigrat, Franois Goehringer, Carine Thivillier, Yves MECHANISMS UNDERLYING THREE MODEL ALTERATIONS (MISSENSE,
Juillre, Thomas Lecompte, Thanh Doco-Lecompte, Christine Selton-Suty (France) DELETION, EXTENSION) OF THE FVII CATALYTIC DOMAIN
SUNDAY
Maria Eugenia Chollet Dugarte*, Elisabeth Drum, Ellen Skarpen, Christian Koehler,
PO547-TUE HEREDITARY AND ACQIRED THROMBOPHILIAS AND WOMEN Bernd Thiede, Jens Preben Morth, Christiane F. Myklebust, Mirko Pinotti, Francesco
Ivo Elezovic*, Darko Antic, Mirjana Mitrovic (Serbia) Bernardi, Per Morten Sandset, Grethe Skretting (Norway)
PO548-TUE CHARACTERIZATION OF A NEW HEREDITARY PROTHROMBIN VARIANT PO558-TUE MICRORNAS MODULATE HUMAN TISSUE FACTOR PATHWAY INHIBI-
ASSOCIATED WITH INCREASED RISK OF VENOUS THROMBOEMBOLISM TOR-A (TFPIA) EXPRESSION IN RESPONSE TO ANDROGENS IN ENDO-
Cristiana Bulato*, Claudia Radu, Elena Campello, Sabrina Gavasso, Daniela Tormene, THELIAL CELLS
Paolo Simioni (Italy) Ana Beln Arroyo Rodrguez*, Salam Salloum-Asfar, Carlos Prez-Snchez, Raul
SATURDAY
Teruel-Montoya, Nuria Garca-Barber, Gins Luengo-Gil, Silvia Navarro, Pilar Medina,

PO549-TUE ARTERIOVENOUS THROMBOSIS IN END STAGE RENAL DISEASE PATIENTS Chary Lpez-Pedrera, Vicente Vicente, Constantino Martnez, Roco Gonzalez-Conejero
Munira Borhany*, Naveena Fatima, Asif Hussain, Tahir Shamsi (Pakistan) (Spain)
PO559-TUE SINGLE CENTRE EXPERIENCE OF FACTOR VII DEFICIENCY

Tissue factor and factor VII - II Bella Madan*, Gulnaz Shah, Theodora Vatopoulou, Mike Mitchell, Jacqueline Cutler
(United Kingdom)
PO550-TUE EFFECT OF A CARBOXY-TERMINAL PEPTIDE ON FACTOR VIIA ACTIVITY
Dougald M. Monroe*, Lior Binder, Malka Hoffman, Gili Hart, Maureane Hoffman (Unit-
ed States)
270 271
PO560-TUE THROMBIN GENERATION IN PATIENTS WITH MILD FACTOR VII DEFI- PO569-TUE AUTOANTIBODY INDUCED THROMBOTIC THROMBOCYTOPENIC PUR-
THURSDSAY
CIENCY MEASURED IN THE PRESENCE OF THROMBOPLASTINS OF PURA (TTP) IN A YOUNG PATIENT WITH METASTASIZING CANCER OF
DIFFERENT ORIGIN UNKNOWN PRIMARY (CUP) SYNDROME
Roza Chaireti, Kerstin Arbring, Egon Persson, Tomas Lindahl* (Sweden) Charis Von Auer*, Heidi Rossmann, Bernhard Lmmle (Germany)
PO561-TUE MUTATIONS IN THE F7 GENE IN SWEDISH PATIENTS WITH DISCREPANT PO570-TUE SEVERE MATERNAL MORBIDITY AND FETAL DEATH IN A PREGNANT
FACTOR VII ACTIVITY IN THE PRESENCE OF THROMBOPLASTINS OF WOMAN WITH RECURRENT ACQUIRED THROMBOTIC THROMBOCYTO-
DIFFERENT ORIGIN PENIC PURPURA (TTP)
Roza Chaireti, Kerstin Arbring*, Ole Olsen, Egon Persson, Tomas Lindahl (Sweden) Charis Von Auer*, Tanja Falter, Heidi Rossmann, Antje Lebrecht, Dana Marandiuc, Inge
WEDNESDAY
Scharrer, Bernhard Lmmle (Germany)
PO562-TUE FVII DEFICIENCY AND THROMBOSIS, COINCIDENCE OR NEW MECHA-
NISM OF THROMBOPHILIA PO571-TUE OBESITY AS A RISK FACTOR FOR THE DEVELOPMENT OF THROMBOTIC
Yacine Larfi*, I Bachiri, W Zazoua, N Fenni, M Giancily-Blaizot, Jean-Franois THROMBOCYTOPENIC PURPURA IN ADAMTS13 DEFICIENT MICE
TUESDAY
Schved(Algeria) Lotte Geys, Elien Roose*, Ilse Scroyen, Claudia Tersteeg, Hanspeter Rottensteiner,
Simon De Meyer, H Roger Lijnen, Karen Vanhoorelbeke (Belgium)
TTP/thrombotic microangiopathies II PO572-TUE A MULTICENTER, RANDOMIZED STUDY OF CYCLOSPORINE OR COR-

TICOSTEROIDS AS AN ADJUNCT TO PLASMA EXCHANGE IN INITIAL
THERAPY OF THROMBOTIC THROMBOCYTOPENIC PURPURA
PO563-TUE USE OF A PLASMA DERIVED FVIII PRODUCT FOR PRIMARY PROPHYLAC-
TUESDAY
Spero R. Cataland*, Shangbin Yang, Susan Geyer, Haifeng Wu (United States)
TIC THERAPY IN AN INFANT WITH CONGENITAL THROMBOTIC THROM-
POSTERS
BOCYTOPENIC PURPURA PO573-TUE COMPARING PERFORMANCES OF COMPLEMENT ACTIVATION BIOMARK-
MacGregor Steele*, Sheri VanGunst, Michael Leaker (Canada) ERS BETWEEN RESPONDERS AND NON-RESPONDERS TO ECULIZUMAB
THERAPY
PO564-TUE ANTI-IDIOTYPIC DARPINS RESTORE ADAMTS13 ACTIVITY IN BABOONS
Spero R. Cataland*, Shangbin Yang, Haiwa Wu, Haifeng Wu (United States)
CHALLENGED WITH HUMAN MONOCLONAL ANTIBODIES: FIRST STEP
TOWARDS AN ANIMAL MODEL FOR HUMAN ACQUIRED TTP PO574-TUE EVALUATION OF LONG TERM NEUROLOGICAL SEQUELAE AFTER A
Monica Schaller*, Magdalena Skowronska, Monique Vogel, Deborah Stearns-Kurosawa, FIRST EPISODE OF THROMBOTIC THROMBOCYTOPENIC PURPURA.
MONDAY
Shinichiro Kurosawa, Johanna Kremer Hovinga (Switzerland) Barbara Ferrari, Alberto Maino, Andrea Artoni, Silvia Riva, Lucia Scirpa,
Paola Santalucia*, Gabriella Pravettoni, Antonella Costa, Flora Peyvandi (Italy)
PO565-TUE THE LABORATORY PROFILE THAT PREDICTS FAVORABLE OUTCOME
AFTER ECULIZUMAB THERAPY IN PATIENTS WITH CLINICAL FEATURES
COMPATIBLE WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME Venous thromboembolism - diagnosis II
Hira Mian*, Anthony Chan, Keith Lau, Howard Chan (Canada)
PO566-TUE THE CLINICAL ANALYSIS OF 58 THROMBOTIC THROMBOCYTOPENIC PO576-TUE INCORPORATION OF RIGHT VENTRICULAR DYSFUNCTION INTO THE
PURPURA PATIENTS SIMPLIFIED PULMONARY EMBOLISM SEVERITY INDEX AS A PREDICTOR
SUNDAY
Lv Cuicui*, Sun Tiantian, Ju Mankai, Fu Rongfeng, Lv Mingen, Xue Feng, Liu Xiaofan, OF COMPLICATED CLINICAL COURSE IN LOW-RISK PATIENTS PRESENT-
Li Huiyuan, Zhang Donglei, Zhang Xian, Liu Wenjie, Li Yang, Hao Yating, Zhang Lei, ING WITH ACUTE SYMPTOMATIC PULMONARY EMBOLISM
Yang Renchi (China) David Jimenez*, Jose Luis Lobo, Ana Portillo, Covadonga Fernandez-Golfin, Remedios
Otero, Roger Yusen (Spain)
PO567-TUE RITUXIMAB THERAPY AS PROPHYLAXIS AGAINST THROMBOTIC THROM-
BOCYTOPENIC PURPURA: COMPARISON OF STANDARD AND REDUCED PO577-TUE RADIATION AND BREAST CANCER RISK IN WOMEN DIAGNOSED WITH
DOSE REGIMENS PULMONARY EMBOLISM: CT PULMONARY ANGIOGRAPHY VERSUS VEN-
John-Paul Westwood*, Debra Ellis, Siobhan Mc Guckin, Marie Scully (United Kingdom) TILATION-PERFUSION SCANNING
SATURDAY
Vicky Tagalakis*, Mark Tulchinsky, Alejandro Lazo-Langner, Samy Suissa, Gregoire Le

PO568-TUE CLINICAL AND BIOCHEMICAL STUDIES OF A PATIENT WITH ACUTE Gal (Canada)
THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) TREATED WITH
N-ACETYLCYSTEINE (NAC) PO578-TUE RISK-ASSESSMENT MODEL OF RECURRENCE WITHIN 3 MONTHS
Junmei Chen*, Tahsin Ozpolat, Colette Norby, Jennie Le, Minhua Ling, Shelby Cate, AFTER A FIRST EPISODE OF ACUTE VENOUS THROMBOEMBOLISM:
Dominic Chung, Xiaoyun Fu, Barbara Konkle, Jos Lpez (United States) WORCESTER VENOUS THROMBOEMBOLISM STUDY
Wei Huang*, Robert Goldberg, Frederick Anderson, Frederick Spencer (United States)
272 273
PO579-TUE PERFORMANCE OF PULMONARY EMBOLISM RULE-OUT CRITERIA
Venous thromboembolism - epidemiology II
THURSDSAY
(PERC) COMBINED WITH LOW GESTALT CLINICAL PROBABILITY IN
EUROPEAN CHEST PAIN POPULATION
Emilie Friou* , Vanessa Richard-Jourjon, Thomas Moumneh, Betty Mazet, Jacques PO589-TUE PREVALENCE OF VENOUS THROMBOEMBOLISM & RELATED MORBIDITY
Choukroun, Thibault Schotte, Andrea Penaloza, Pierre-Marie Roy (France) AND MORTALITY AMONG HOSPITALIZED PATIENTS IN SAUDI ARABIA
(SAVTE STUDY)
PO580-TUE AN ELECTRONIC TOOL AND RECORD FOR DEEP VEIN THROMBOSIS
Essam Aboelnazar* (Saudi Arabia)
(DVT) ASSESSMENT, DIAGNOSIS, TREATMENT AND FOLLOW UP.
Jane Strong, Victoria Frimpong, Jo Eggleston*, Deborah Thornton, Helen Briggs, Tamy- PO590-TUE BELOW KNEE DEEP VEIN THROMBOSIS (BKDVT): A BENIGN ENTITY OR
ka Stewart, Rachel Clarke-Drury, Karen Coultas, Alistair Stewart, George Kitching, Syd
WEDNESDAY
NOT?
Stewart (United Kingdom)
Prahlad Ho*, Hui Yin Lim, Chyn Chua, Matthew Sleeman, Lachlan Hayes (Australia)
PO581-TUE VALIDATION OF THE USE OF AGE ADJUSTED D DIMER CUT OFF VALUES
PO591-TUE ETIOLOGY OF PORTAL VENOUS THROMBOSIS AND BUDD-CHIARI SYN-
TO REDUCE THE COMPRESSION VENOUS ULTRASOUND RATES IN AN
TUESDAY
DROME IN ADULTS
ACUTE AMBULATORY DVT SERVICE
Anil Tombak*, Gizem Isguzar, Enver Ucbilek, Serkan Yaras, Aydan Akdeniz, Mehmet
Jane Strong*, Jo Eggleston, Victoria Frimpong, Deborah Thornton, Helen Briggs, Tamy- Ucar, Emel Gurkan, Eyup Tiftik, Mehmet Sungur (Turkey)
ka Stewart, Rachel Clarke-Drury, Karen Coultas (United Kingdom)
PO592-TUE INCIDENCE OF CATHETER-RELATED VENOUS THROMBOEMBOLISM
PO582-TUE THE USE OF AN AGE-ADJUSTED CUT-OFF FOR D-DIMER IN SCREEN-
EVENTS IN ACUTE LEUKEMIA PATIENTS; A RETROSPECTIVE STUDY OF
TUESDAY
ING PATIENTS FOR SUSPECTED DVT IN THE COMMUNITY CAN SAFELY
THE SAFETY OF PERIPHERALLY-INSERTED CENTRAL CATHETER.
DECREASE THE NEED FOR COMPRESSION ULTRASONOGRAPHY.
POSTERS
Mohammad Refaei*, Bruna Fernandes, Joseph Brandwein, Cynthia Wu (Canada)
Andrew S. Hughes*, Benjamin Hall, Kate Jennings, Victoria Webb, Georgia Page,
Christine Smith, Florence Charova (United Kingdom) PO593-TUE EPIDEMIOLOGY OF VENOUS THROMBOEMBOLISM IN THE FRAMING-
PO583-TUE DIAGNOSTIC PREDICTION MODEL VERSUS GESTALT IN THE DIAGNOSIS HAM HEART STUDY
Marja K. Puurunen*, Philimon Gona, Joanne Murabito, Jared Magnani, Christopher
OF PULMONARY EMBOLISM IN PRIMARY CARE
ODonnell (United States)
Janneke Hendriksen*, Geert-Jan Geersing, Wim Lucassen, Petra Erkens, Ruud Oudega,
Karel Moons (The Netherlands) PO594-TUE IMPACT OF INCIDENT STROKE ON FUTURE RISK OF VENOUS THROM-
MONDAY
BOEMBOLISM
PO584-TUE CLINICAL PREDICTION RULES PLUS D-DIMER TESTING DO NOT EN-
Ludvig B. Rinde*, Birgit Smbrekke, Caroline Lind, Inger Njlstad, Ellisiv Mathiesen,
ABLE A SAFE EXCLUSION OF DEEP VEIN THROMBOSIS OR PULMONARY
Erin Hald, Sigrid Brkkan, John-Bjarne Hansen (Norway)
EMBOLISM IN ELDERLY PATIENTS RESIDING IN NURSING HOMES OR
HOMES FOR THE ELDERLY. PO595-TUE EVALUATING THE ACCURACY OF INTERNATIONAL CLASSIFICATION OF
Geert-Jan Geersing*, Henrike Schouten, Ruud Oudega, Hans van Delden, Karel Moons, DISEASES 10TH REVISION CODES FOR VENOUS THROMBOEMBOLISM
Dineke Koek (The Netherlands) (VTE) AND MAJOR BLEEDING (MB) IN EMERGENCY ROOM (ER) DIS-
CHARGES
PO585-TUE COMBINED ASSESSMENT OF THROMBOTIC AND HAEMORRHAGIC RISK
SUNDAY
Fatimah Al-Ani*, Salimah Shariff, Lenicio Siqueira, Alejandro Lazo-Langner (Canada)
IN ACUTE MEDICAL PATIENTS
Micaela La Regina, Francesco Orlandini, francesca Marchini, Antonio Marinaro, Rosan- PO596-TUE ASYMPTOMATIC CENTRAL VENOUS LINE - RELATED THROMBOSIS IN
na Bonacci, Paola Bonanni, Francesca Corsini, Francesco Dentali* (Italy)
CHILDREN: FEASIBILITY OF CONDUCTING A CLINICAL STUDY
PO586-TUE PREDICTION OF SEPSIS DEVELOPMENT IN PUERPERAS WITH SYSTEM- Sophie E. Jones*, Fiona Newall, Warwick Butt, Paul Monagle (Australia)
IC INFLAMMATORY RESPONSE SYNDROME
PO597-TUE CEREBRAL VENOUS THROMBOSIS: A LONGITUDINAL FOLLOW UP
Sergei Sinkov*, Igor Zabolotskikh, Grigoriy Penjoyan, Valeriy Muzychenko, Irina Prok-
Maria Teresa Desancho*, Mohini Aras (United States)
horova (Russian Federation)
SATURDAY
PO598-TUE PULMONARY EMBOLISM: DOES THE SEASONAL EFFECT DEPEND ON

PO587-TUE PROSPECTIVE VALIDATION OF THE SIMPLIFIED REVISED GENEVA SCORE
AGE? A 10 YEARS NATIONWIDE ANALYSIS OF HOSPITALIZATION AND
Gregoire Le Gal*, Khaled Mostaguir, Marcel Hovens, Meissa Kare, Arnaud Perrier,
Franck Verschuren, Philippe Girard, Menno Huisman, Hlia Robert-Ebadi, Fars Mous- MORTALITY
tafa, Pieter Kamphuisen, Harry Buller, Marc Righini (France, Canada) Valerie Olie*, Christophe Bonaldi (France)
PO588-TUE REVIEW OF EMERGENCY DEPARTMENT INVESTIGATED DVT PO599-TUE IMPLICATIONS OF CYTOGENETICS FOR VENOUS THROMBOEMBOLISM
Gary Benson, Rosemary Lavery*, Hilary Speers, Mark Worthington (United Kingdom) IN ACUTE MYELOID LEUKEMIA
Yun-Gyoo Lee*, Inho Kim, Ji-Hyun Kwon, Sung Soo Yoon, Seongyang Park, Jae-Ho
Yoon, Seung-Hwan Shin, Woo-Sung Min, Hee-Je Kim (Korea, Republic Of)
274 275
PO600-TUE LONG-TERM HEALTH-RELATED QUALITY OF LIFE AFTER DEEP VEIN PO610-TUE LOW-RISK PULMONARY EMBOLISM AND LENGTH OF HOSPITAL-STAY:
THURSDSAY
THROMBOSIS IS IMPAIRED COMPARED TO CONTROLS. THE LORPELHS STUDY
Kristin Utne*, Waleed Ghanima, Per Sandset, Hilde Wik, Lars-Petter Jelsness-Jr- Marco P. Donadini*, Marco Castellaneta, Paola Gnerre, Micaela La Regina, Fulvio
gensen (Norway) Pomero, Roberta Re, Andrea Gallo, Francesco Dentali, Walter Ageno, Alessandro Squiz-
zato (Italy)
PO601-TUE LONG-HAUL TRAVEL AND THE RISK OF RECURRENT VENOUS THROM-
BOSIS PO611-TUE ANTITHROMBOTIC TREATMENT AND OUTCOMES OF NON-MALIGNANT
Jasmijn Timp*, Saskia le Cessie, Astrid van Hylckama Vlieg, Frits Rosendaal, Suzanne NON-CIRRHOTIC SPLANCHNIC VEIN THROMBOSIS: A SUB-ANALYSIS
Cannegieter (The Netherlands) FROM THE ISTH REGISTRY
Nicoletta Riva*, Walter Ageno, Sam Schulman, Jan Beyer-Westendorf, Elvira Grandone,
WEDNESDAY
PO602-TUE RECENT DISCHARGE CONFERS RISK FOR VENOUS THROMBOEMBO- Matteo Nicola Dario Di Minno, Maria Teresa Sartori, Alessandra Malato, Ida Martinelli,
LISM Elbio Antonio Damico, Eugenio Bucherini, Valerio De Stefano, Marcello Di Nisio,
Hiren Shah*, Nicholas Christensen (United States) Renzo Poggio, Barbara Nardo, Asher Winder, Dominique Farge-Bancel, Silvia Betti,
Francesco Dentali, IRSVT study investigators (Italy)
TUESDAY
Venous thromboembolism - therapy II PO613-TUE A GLOBAL PROSPECTIVE COHORT STUDY OF DABIGATRAN FOR THE
TREATMENT OF VENOUS THROMBOEMBOLISM (RE-COVERY)
Samuel Z. Goldhaber*, Walter Ageno, Ivan Casella, Chee Kok Han, Gary Raskob, Sebas-
PO603-TUE A DRUG-DRUG INTERACTION STUDY OF DS-1040 AND ASPIRIN IN tian Schellong, Daniel Singer, Dalia Shash, Marc Desch, Sam Schulman (United States)
HEALTHY SUBJECTS
TUESDAY
James Dow, Adeep Puri, Penny McPhillips, Yasushi Orihashi, Victor Dishy, Jin Zhou*
POSTERS
(United States) Vitamin K antagonists II
PO604-TUE FEASIBILITY OF COMPARING INTERMITTENT PNEUMATIC COMPRES-

SION VS. A NOVEL DEVICE FOR PREVENTION OF VENOUS THROMBOEM- PO614-TUE INFLUENCE OF VKA-POTENTIATING DRUGS ON OVER-ANTICOAGULA-
BOLISM IN TRAUMA PATIENTS WITH CONTRAINDICATION TO ANTICO- TION IN ATRIAL FIBRILLATION
AGULATION Stijn P. van Vugt*, Jeroen Jaspers Focks, Robert Joustra, Marjo Albers-Akkers, Lucie
Vinai Bhagirath*, Nayef Al Onazi, Sam Schulman, Mark Crowther (Canada) Bloem-de Vries, Freek Verheugt, Marc Brouwer (The Netherlands)
MONDAY
PO605-TUE PREDICTION OF THE BLEEDING RISK DURING ANTICOAGULATION PO615-TUE AGREEMENT OF POINT-OF-CARE INR TEST WITH STANDARD VENOUS
TREATMENT FOR PULMONARY THROMBOEMBOLISM SAMPLING ASSAY AT HIGHER EXTREME RANGES
Zhenguo Zhai*, Zhu Zhang, Yuanhua Yang, Chen Wang (China) Yi Feng Lai*, Ming Chai Kong, Fiona Seet Ling Chan, Heng Joo Ng (Singapore)
PO606-TUE RECURRENCES AFTER STOPPING ANTICOAGULANT THERAPY IN THAI PO616-TUE IN ANTICOAGULATION TREATMENT WITH VITAMIN K ANTAGONISTS
PATIENTS WITH NON CANCER-RELATED VENOUS THROMBOEMBOLISM (AVKS): WHICH IS THE BEST MONITORING TEST?
Pitiphong Kijrattanakul*, Paphatsaphan Thippayanuruksakul, Benjaporn Akkawat, Gustavo L. Vidmar*, Claudio DAntonio, Cecilia Capmany, Jimena Bonadeo, Nadia
Ponlapat Rojnuckarin (Thailand) Kujta, Ruben Barbera, Elizabeth Velasquez, Lorena Meza (Argentina)
PO607-TUE XALIA, A NON-INTERVENTIONAL STUDY COMPARING RIVAROXABAN

WITH STANDARD ANTICOAGULATION FOR INITIAL AND LONG-TERM
SUNDAY PO617-TUE COMPARISON OF RISK FACTORS FOR WARFARIN-ASSOCIATED BLEEDING
Meric Ozgenel, Elif Umit, Nesrin Turan, Muzaffer Demir* (Turkey)
THERAPY IN DEEP VEIN THROMBOSIS: BASELINE DEMOGRAPHICS AND
HOSPITALIZATION RATES PO618-TUE EXPANDING TELEMEDICINE TO MEDICAL HOMES FOR COMPREHEN-
Alexander G. Turpie*, Lorenzo Mantovani, Sylvia Haas, Reinhold Kreutz, Danja Monje, SIVE CARE DELIVERY FOR PERSONS WITH HEMOSTATIC DISORDERS:
Jonas Schneider, Walter Ageno (Canada) A PILOT STUDY OF THE AMERICAN THROMBOSIS AND HEMOSTASIS
NETWORK (ATHN)/NATIONAL HEMOPHILIA PROGRAM COORDINATING
SATURDAY
PO608-TUE APIXABAN FOR TREATMENT OF VENOUS THROMBOEMBOLISM IN CENTER (NHPCC).

PATIENTS FROM STUDY CENTRES IN ASIA; A SUBGROUP ANALYSIS OF Roshni Kulkarni*, Rebecca Malouin, Colleen Vallad-Hix, Laura Carlson, Marcia Bird,
THE AMPLIFY TRIAL Diane Aschman, Ann Forsberg, Zachary Trost, Robert Greenhoe (United States)
Alexander S. Gallus*, Giancarlo Agnelli, Harry Buller, Alexander Cohen, Theodore Lee,
Raphael Pak, Gary Raskob, Harry Shi, Jeffrey Weitz (Australia) PO619-TUE ANTICOAGULATION REVERSAL IN WARFARIN-ASSOCIATED INTRACERE-
BRAL HEMORRHAGE: A SYSTEMATIC REVIEW
PO609-TUE SHOULD WE USE VENOUS THROMBOEMBOLISM PROPHYLAXIS IN Darae Ko*, Zayd Razouki, Elaine Hylek (United States)
PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES RECEIVING CHEMO-
THERAPY?
Adam Wiszniewski*, Piotr Szopinski, Krzysztof Warzocha (Poland)
276 277
PO620-TUE THE QUA-VKA STUDY TO IDENTIFY NEW RISK FACTORS FOR BLEEDING PO629-TUE A PHASE III OPEN-LABEL, MULTI-CENTER STUDY WITH A PLASMA-DE-
THURSDSAY
DURING TREATMENT WITH VITAMIN K ANTAGONISTS: OBJECTIVES RIVED VON WILLEBRAND FACTOR/FACTOR VIII CONCENTRATE TO AS-
AND DESIGN SESS THE PHARMACOKINETICS, EFFICACY, AND SAFETY IN PEDIATRIC
Nienke Van Rein*, Mettine Bos, Willem Lijfering, Felix van der Meer, Pieter Reitsma SUBJECTS WITH VON WILLEBRAND DISEASE (SWIFTLY-VWD STUDY)
(The Netherlands) Guenter Auerswald, Claudia Khayat, Olexandra Stasyshyn, Genadi Iosova, Irina Ra-
masheuskaya, Marta Julia Lopez Ruano, Wilfried Seifert* (Germany)
PO621-TUE ASSESSMENT OF THE TIME IN THERAPEUTIC RANGE IN PATIENTS
WITH ATRIAL FIBRILLATION TREATED WITH VITAMIN K ANTAGONISTS PO630-TUE VON WILLEBRAND DISEASE AND MENORRHAGIA: MULTIPLE TREAT-
BY SPECIALISTS IN HAEMOSTASIS IN ARGENTINA. THE TERRA REGIS- MENT OPTIONS FOR DIFFERENT PATIENTS
TRY.
WEDNESDAY
Kaan Kavakli*, Can Balkan, Deniz Karapinar (Turkey)
Jose Manuel Ceresetto*, Federico Bottaro, Marcelo Casey, Alejandra Marti, Carlos Tajer
(Argentina) PO631-TUE UNEXPECTED FINDING OF LOW VON WILLEBRAND FACTOR LEVELS OR
VON WILLEBRAND DISEASE IN PEDIATRIC PATIENTS WITH SCOLIOSIS
PO622-TUE RESULTS FROM THE PROSPECTIVE FARMAMICO STUDY: INR VARI-
TUESDAY
Brian Castillo*, S. Kate Hartman, Michael Gorena, Jamie Wingate, Shiu-Ki Hui, Jun
ATIONS IN WARFARIN-TREATED PATIENTS UNDERGOING ANALGESIC Teruya (United States)
AND ANTI-INFLAMMATORY THERAPIES
Anna Falanga*, Viola Milesi, Giuliana Martini, Daria Bettoni, Laura Russo, Federica PO632-TUE PERCENTAGE OF PLATELET AGGREGATES AND MACROPLATELETS:
Gualandris, Federica Brognoli (Italy) A POTENTIAL USEFUL LABORATORY PARAMETER FOR PREDICTING
BLEEDING IN VON WILLEBRAND DISEASE TYPE 2B (VWD2B) WITH THE
TUESDAY
PO623-TUE USE OF PROTON PUMP INHIBITORS AMONG ANTICOAGULATED PA- P.VAL1361MET MUTATION
TIENTS: THE MICHIGAN ANTICOAGULATION QUALITY IMPROVEMENT
POSTERS
Hugo Guglielmone*, Salvador Minoldo, Gustavo Jarchum, Tara Adams, Jorge DiPaola
INITIATIVE (MAQI2) EXPERIENCE (Argentina)
Geoffrey D. Barnes*, Jacob Kurlander, Xiaokui Gu, Keely Haymart, Eva Kline-Rogers,
Steve Almany, Jay Kozlowski, Gregory Krol, Scott Kaatz, Sameer Saini, James Froehlich PO633-TUE DEVELOPMENT OF APLASTIC ANEMIA IN A PATIENT WITH ACQUIRED
(United States) VON WILLEBRANDS SYNDROME AND AUTOIMMUNE PREPONDERANCE
Arief Gunawan*, Gary Moore, Bella Madan (United Kingdom)
PO624-TUE WHAT BLEEDINGS PREDICT HAS-BLED AND HEMORR2HAGES SCALES
IN PATIENTS ON LONG-TERM WARFARIN THERAPY? PO634-TUE RELATIONSHIP BETWEEN BLEEDING TENDENCY AND THE AFFECTED
MONDAY
Olga Moreva*, Ekaterina Kropacheva, Oksana Zemlyanskaya, Elena Titaeva, Anatoliy DOMAIN WITH MUTATIONS RESPONSIBLE OF VWD2M PHENOTYPE
Dobrovolsky, Elizaveta Panchenko (Russian Federation) Adriana I. Woods*, Ana Kempfer, Juvenal Paiva, Alicia Blanco, Roberto Chuit, Maria
Casinelli, Analia Sanchez-Luceros, Maria Lazzari (Argentina)
PO625-TUE VITAMIN K ANTAGONISTS FAVORABLY MODULATE FIBRIN CLOT PROP-
ERTIES IN PATIENTS WITH ATRIAL FIBRILLATION AS EARLY AS AFTER PO635-TUE CHARACTERIZATION OF VON WILLEBRAND DISEASE SUBTYPES IN 303
3 DAYS OF TREATMENT: RELATION TO COAGULATION FACTORS AND PATIENTS - A SINGLE CENTRE STUDY OVER THE PAST 10 YEARS
THROMBIN GENERATION Anil Pathare*, Karima Al Falahi, Badriya Al-Belushi, Shoaib Al Zadjali, Salam Alkindi
Micha Zabczyk*, Jacek Majewski, Grzegorz Karkowski, Anetta Undas (Poland) (Oman)
SUNDAY
PO626-TUE PREVALENCE OF ANEMIA IN PATIENTS UNDER TREATMENT WITH VITA- PO636-TUE VWD2B PHENOTYPE: ITS PREVALENCE WITHIN FAMILIES AND BLEED-
MIN K ANTAGONISTS ING TENDENCY IN AFFECTED MEMBERS
Marco Sampaio, Maria Faria*, Lurdes Moreira, Ana Spinola, Fernanda Leite, Eugenia Adriana I. Woods*, Ana Kempfer, Juvenal Paiva, Emilse Bermejo, Alicia Blanco, Rober-
Cruz, Manuel Campos (Portugal) to Chuit, Analia Sanchez-Luceros, Maria Lazzari (Argentina)
PO637-TUE VON WILLEBRAND DISEASE (VWD), EXPERIENCE OF ALGERIA IN BENI

Von Willebrand disease II MESSOUS CENTER IN ALGIERS
Meriem Bensadok*, Karima Chennoukh, Chahyra Aboura, Mylad Aribi, Nadia Zidani,
SATURDAY
Meriem Belhani, Mohamed Salim Nekkal (Algeria)

PO627-TUE GENETIC VARIATIONS IN EXON 28 OF VON WILLEBRANDS FACTOR
GENE IN NIGERIAN POPULATION PO638-TUE TWO UNUSUAL CASES OF TYPE 2N VON WILLEBRAND DISEASE.
Eyiuche D. Ezigbo*, Ernest Ukaejiofo, Theresa Nwagha (Nigeria) Patricia Bignell*, Nicola Curry, Pamela Wright, James Beavis, Shirley Henderson, Anna
Schuh (United Kingdom)
PO628-TUE CLINICAL FEATURES AND TYPES OF VON WILLEBRAND DISEASE IN
WOMEN WITH MENORRHAGIA REFERRED TO HEMATOLOGY CLINIC OF
KERMANSHAH
Mehrdad Payandeh* (Iran, Islamic Republic Of)
278 279
PO639-TUE HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND HEALTH-ECONOM- PO649-TUE IDENTIFICATION OF NOVEL VWF GENE MUTATIONS IN THE TURKISH
THURSDSAY
IC ASSESSMENT IN PATIENTS WITH VON WILLEBRAND DISEASE IN TYPE 2 VWD PATIENT POPULATION
FRANCE: THE WISH-QOL STUDY Ergul Berber*, Yesim Oymak, Oguzhan Baltaci, Reyhan Diz-Kckkaya, Bulent Zu-
Annie Borel-Derlon*, Jenny Goudemand, Catherine Boyer-Neumann, Edith Fressinaud, lfikar, Kaan Kavakli (Turkey)
Catherine Ternisien, Marc Trossaert, Agns Veyradier, WiSH-QoL Study Group, Caroline
Martinez, Catherine Chatelanaz, Sylvia Von Mackensen (France) PO650-TUE CANCERS IN PATIENTS WITH VON WILLEBRAND DISEASE: A SURVEY
FROM THE ITALIAN ASSOCIATION OF HEMOPHILIA CENTRES
PO640-TUE POOR RESPONSE TO 1-DESAMINO-8-D ARGININE VASOPRESSIN Annarita Tagliaferri, Giancarlo Castaman*, Caterina Di Perna, Cristina Santoro, Simona
(DDAVP) TEST IN A PATIENT WITH VON WILLEBRAND DISEASE TYPE 2M Maria Siboni, Ezio Zanon, Silvia Linari, Paolo Gresele, Samantha Pasca, Antonio Cop-
(VWD2M) WITH P.GLU1549LYS MUTATION pola, Rita Santoro, Ranalli Paola, Mariasanta Napolitano, Massimo Franchini (Italy)
WEDNESDAY
Hugo Guglielmone*, Juan Frontroh, Salvador Minoldo, Mirta Hepner, Marcela Sabagh,
Gustavo Jarchum (Argentina) PO651-TUE MODIFICATIONS OF HEMOSTATIC THERAPY FOR PATIENTS WITH VON
WILLEBRAND DISEASE BASED ON COMORBIDITY
PO641-TUE ALLELE-SPECIFIC SILENCING OF THE VON WILLEBRAND FACTOR GENE Nadezhda Zozulya*, Elena Likhacheva, Olga Yastrubinetskaya (Russian Federation)
TUESDAY
TO AMELIORATE THE VON WILLEBRAND DISEASE PHENOTYPE
Annika de Jong*, Richard Dirven, Jeroen Eikenboom (The Netherlands) PO652-TUE ACQUIRED VON WILLEBRAND SYNDROME (AVWS) WITH A TYPE 2B
PHENOTYPE SECONDARY TO AN IGA AUTOANTIBODY WITH ANTI-VON
PO642-TUE EVALUATION OF A NEW AUTOMATED RISTOCETIN COFACTOR ASSAY ON WILLEBRAND FACTOR ACTIVITY.
THE STA-R EVOLUTION ANALYZER Maria Alberto, Emilse Bermejo, Susana Meschengieser, Maria Romero, Adriana Woods,
TUESDAY
Heleen Eising*, Lisan te Roller, Michelle Visser-Koldenhof, Bertil Wildeboer, Jasper Ana Kempfer, Juvenal Paiva, Marcos Pizzolato, Maria Lazzari, Analia Sanchez-Luceros*
Remijn (The Netherlands) (Argentina)
POSTERS
PO643-TUE HOW WELL CAN LABORATORIES DIAGNOSE TYPE 2N VWD? DATA FROM PO653-TUE ACCUIRED VON WILLEBRAND SYNDROME IN PATIENTS TREATED WITH
A UK NEQAS (BLOOD COAGULATION) EXERCISE. LEFT VENTRICULAR ASSIST DEVICES
Ian Jennings*, Steve Kitchen, Dianne Kitchen, Timothy Woods, Mike Makris, Isobel Kenki Saito*, Ko Sakatsume, Ryutaro Shirakawa, Tomohiro Kimura, Masatoshi Akiya-
Walker (United Kingdom) ma, Yoshikatsu Saiki, Hisanori Horiuchi (Japan)
PO644-TUE POSTOPERATIVE BLEEDING AND OTHER OUTCOMES IN CHILDREN PO654-TUE DENTAL INVASIVE PROCEDURES IN VON WILLEBRAND DISEASE (VWD)
MONDAY
WITH VON WILLEBRAND DISEASE OR LOW VON WILLEBRAND FACTOR OUTPATIENTS TREATED WITH HIGH PURITY VWF/FVIII COMPLEX CON-
UNDERGOING ADENOTONSILLECTOMY CENTRATE: EXPERIENCE OF A SINGLE CENTER.
Rosa Diaz*, Donald Mahoney JR, MaryFrances Musso, Donald Yee (United States) Valeria De Padua*, Cristina Santoro, Domenico Gaglioti, Francesco Riva, Erminia
Baldacci, Caterina Mercanti, Maria Gabriella Mazzucconi (Italy)
PO645-TUE WILLEBRAND DISEASE MOLECULAR DIAGNOSIS BY HIGH THROUGH-
PUT SEQUENCING: WHATS ABOUT THE HIGHLY HOMOLOGOUS PO655-TUE RECOGNITION AND CORRELATION OF A RANDOM PATIENT-SPECIFIC
PSEUDOGENE ? ERROR OF THE AUTOMATED VON WILLEBRAND FACTOR ACTIVITY LATEX
Mathilde Giraud*, Solenne Dumont, Pierre Boisseau, Patricia Talarmain, Marie Annick IMMUNOASSAY
Gourlaouen, Jessy Hary, Catherine Ternisien, Edith Fressinaud, Jenny Goudemand, Julie I. Tange*, Rachel Leger, Diane Grill, Rajiv Pruthi, Dong Chen (United States)
SUNDAY
Agnes Veyradier, Stephane Bezieau (France)
PO646-TUE CLINICAL AND LABORATORY DETECTION OF TRANSIENT NEUTRALIZING Von Willebrand factor II
ANTIBODIES IN SEVERE VON WILLEBRAND DISEASE ON LONG TERM
PROPHYLAXIS
PO656-TUE LONG TERM EXERCISE SIGNIFICANTLY DECREASES VON WILLEBRAND
Anala Snchez-Luceros*, Maria Alberto, Ana Kempfer, Adriana Woods, Alicia Blanco,
FACTOR ANTIGEN LEVELS IN ABDOMINALLY OBESE ADULTS
Silvia Grosso, Maria Romero, Maria Lazzari, Emilse Bermejo, Susana Meschengieser
(Argentina) Cynthia Pruss*, Robert Ross, Michael Adams (Canada)
SATURDAY
PO647-TUE VON WILLEBRAND DISEASE: THE PHENOTYPIC CHARACTERIZATION IN PO657-TUE DEVELOPMENT OF A VWF PROPEPTIDE ASSAY
THAILAND Muriel Meiring* (South Africa)
Theera Ruchutrakool*, Bundarika Suwanawiboon, Yupa Nakkinkun, Pimlak Charoenk-
PO658-TUE CROSS-SPECIES INHIBITION OF HUMAN AND MURINE VON WILLE-
wan, Weerasak Nawarawong, Werasak Sasanakul, Ampaiwan Chuansumrit (Thailand)
BRAND FACTOR BY A SINGLE DOMAIN VHH-ANTIBODY
PO648-TUE ACQUIRED VON WILLEBRAND SYNDROME IN PATIENTS WITH ESSEN- Ibrahim Habib*, Paulette Legendre, Amine Bazaa, Ccile Denis, Peter Lenting,
TIAL THROMBOCYTHEMIA Valrie Proulle, Olivier Christophe (France)
Ksenia Bykowska, Ewa Mendek-Czajkowska, Beata Sokoowska, Adam Wiszniewski*,
Beata Baran, Jerzy Windyga (Poland)
280 281
PO659-TUE HIGH ACTIVITY OF VON WILLEBRAND FACTOR AND LEVELS OF PO669-TUE THE VON WILLEBRAND FACTOR A2 DOMAIN DISULFIDE BOND EXISTS
THURSDSAY
VWF-CLEAVING PROTEASE (ADAMTS-13) IN TERM AND PRETERM NEO- IN OXIDIZED AND REDUCED STATES IN THE CIRCULATION AND REGU-
NATES LATES FUNCTION
Tzipora Strauss*, Naama Elisha, Bruria Ravid, Ariela Zivelin, Ahron Lubetsky, Iris Philip Hogg*, Diego Butera, Robert Andrews, Elizabeth Gardiner, Amanda Davis, Deir-
Morag, Gili Kenet (Israel) dre Murphy, Ross Baker, Jim Thom, Vivien Chen, Brenda Luken, Jason Wong, Camilo
Aponte-Santamara, Agnieszka Bronowska, Carsten Baldauf, Frauke Graeter (Australia)
PO660-TUE ANGIOGENIC CHARACTERISTICS OF BLOOD OUTGROWTH ENDOTHELIAL
CELLS FROM PATIENTS WITH VON WILLEBRAND DISEASE PO670-TUE MODIFICATION OF ABO(H) BLOOD GROUP ANTIGENS ON HUMAN VWF
Dafna Groeneveld*, Tamara van Bekkum, Richard Dirven, Jiongwei Wang, Jan WITH PLASMA GLYCOSYLTRANSFERASE
Voorberg, Pieter Reitsma, Jeroen Eikenboom (The Netherlands) Taiki Kano*, Fumio Matsushita, Jiharu Hamako, Yoshihiro Fujimura, Kazunao Kondo,
WEDNESDAY
Taei Matsui (Japan)
PO661-TUE REGULATION OF VWF-GPIB INTERACTION WITH MODIFIED RECOMBI-
NANT BOTROCETIN PO671-TUE REFERENCE VALUE OF VON WILLEBRAND FACTOR ACTIVITY BY IM-
MUNO-TURBIDIMETRY METHOD
TUESDAY
Taei Matsui*, Arisa Hori, Jiharu Hamako, Fumio Matsushita, Namiho Takagishi, Kazu-
nao Kondo, Taiki Kano, Masaki Hayakawa, Masanori Matsumoto, Yoshihiro Fujimura Rahajuningsih Dharma*, Yona Mimanda (Indonesia)
(Japan)
PO672-TUE ANALYSIS OF PLASMA VON WILLEBRAND FACTOR AND COMPLEMENT
PO662-TUE VON WILLEBRAND FACTOR TO MONITOR PERCUTANEOUS AORTIC FACTOR H POLYMORPHISMS IN PATIENTS WITH AGE-RELATED MACU-
VALVE INTERVENTIONS LAR DEGENERATION
TUESDAY
Antoine Rauch*, Eric Van Belle, Andr Vincentelli, Emmanuelle Jeanpierre, Paulette Mariko Yamashita*, Masanori Matsumoto, Ayami Isonishi, Yoko Yoshida, Masaki Haya-
Legendre, Francis Juthier, Natacha Rousse, Carlo Banfi, Anne Godier, Claudine Caron, kawa, Yoshihiro Fujimura, Nahoko Ogata (Japan)
POSTERS
Dupont Annabelle, Christophe Zawadski, Delphine Corseaux, Frederic Mouquet, Cdric
Delhaye, Bart Staels, Jenny Goudemand, Brigitte Jude, Peter Lenting, Sophie Susen PO673-TUE IMPROVED RESOLUTION OF HIGH MOLECULAR WEIGHT MULTIMERS OF
(France) RECOMBINANT VON WILLEBRAND FACTORALBUMIN FUSION PRODUCT
BY AGAROSE ELECTROPHORESIS/WESTERN BLOTTING
PO663-TUE PLATELET AND ENDOTHELIAL FUNCTION EVALUATION IN PEDIATRIC
Jeffrey Hey*, Thomas Barnes, Matthias Zimmermann, Bianca Yarwood, Christophe
CHRONIC KIDNEY DISEASE Pical, Holger Lind (Australia)
Luci M. S. Dusse*, Rivia Silva, Leticia Sousa, Fernanda Nunes, Rejane Diniz, Marcos
MONDAY
Silva, Cristina Loures, Maria Carvalho, Ana Silva (Brazil) PO674-TUE ANALYSIS OF OXALIPLATIN-BASED CHEMOTHERAPY INDUCED LIVER
INJURY IN PATIENTS WITH ADVANCED COLORECTAL CANCER WITH
PO664-TUE FUNCTIONAL STUDY OF TWO NEW MUTATIONS IN THE C4 DOMAIN OF
SPECIAL REFERENCES TO VON WILLEBRAND FACTOR
VON WILLEBRAND FACTOR
Naoto Nishigori*, Masanori Matsumoto, Fumikazu Koyama, Masaki Hayakawa, Kinta
Paulette Legendre*, Maxime Delrue, Pierre Boisseau, Catherine Ternisien, Edith Fres-
Hatakeyama, Yoshihiro Fujimura, Yoshiyuki Nakajima (Japan)
sinaud, Agns Veyradier, Cecile Denis, Peter Lenting, Olivier Christophe (France)
PO675-TUE DESMOPRESSIN TREATMENT IMPROVES PLATELET FUNCTION UNDER
PO665-TUE POSTOPERATIVE CHANGES IN VON WILLEBRAND FACTOR (VWF) AFTER
FLOW IN PATIENTS WITH POSTOPERATIVE BLEEDING
ORTHOPAEDIC SURGERY IN HAEMOSTATICALLY HEALTHY PATIENTS
Frauke Swieringa, Marcus Lance, Birte Fuchs, Marion Feijge, Barbara Solecka, Lieke
SUNDAY
Mario von Depka*, Carsten Detering, Cornelia Wermes, Birgit Nawroth, Emilie von
Verheijen, Kevin Hughes, Hans Deckmyn, Christoph Kannicht, Johan Heemskerk, Paola
Depka, Mahnaz Ekhlasi-Hundrieser (Germany)
Van Der Meijden* (The Netherlands)
PO666-TUE GENERATION OF REFERENCE INTERVALS FOR TWO AUTOMATED, PO676-TUE O TO AVOID MYOCARDIAL INFARCTION.
NEW-GENERATION VON WILLEBRAND FACTOR ACTIVITY ASSAYS ON A Eimear Dunne*, James ODonnell, Dermot Kenny (Ireland)
LARGE DONOR POPULATION.
Katarzyna Mayger*, Gary Moore, Jan Jacques Michiels, Inge Vangenechten, Alain PO677-TUE ON WILLEBRAND FACTORS SHEAR-AND-TIME DEPENDENT DEGRADA-
V
Gadisseur (United Kingdom) TION UNDER PULSATILE SHEAR THROUGH A CAPILLARY SHEAR SYSTEM
SATURDAY
Shuo Yang, Jawaad Sherif, Danny Bluestein, Vincent Turitto* (United States)
PO667-TUE EXPOSURE OF VON WILLEBRAND FACTOR (VWF) TO VORTEX SHEAR
SIGNIFICANTLY ENHANCES ITS PROTEOLYSIS BY PLASMIN PO678-TUE LONGITUDINAL ANALYSIS OF VON WILLEBRAND FACTOR (VWF) LEVELS
Teresa M. Brophy*, James ODonnell (Ireland) IN THE PHASE 3 A-LONG STUDY OF RECOMBINANT FACTOR VIII FC FU-
SION PROTEIN (RFVIIIFC) IN SUBJECTS WITH HEMOPHILIA A DEMON-
PO668-TUE BELGIAN MULTICENTER STUDY INTO VON WILLEBRAND DISEASE
STRATES DIFFERENT MAGNITUDES OF TEMPORAL VARIABILITY
(B-WILL STUDY): FIRST RESULTS
David Lillicrap*, Roshni Kulkarni, Shuanglian Li, Elisa Tsao, Alison Long, Glenn
Inge Vangenechten*, Kristin Jochmans, Katrien Devreese, Serge Motte, Alain Gadis-
Pierce, Jennifer Dumont (Canada)
seur (Belgium)
282 283
SCIENTIFIC PROGRAM
PO679-TUE EVALUATION OF AGE AND GLYCAN-RELATED CHANGES ON VON WILLE-
THURSDSAY
BRAND FACTOR (VWF) CLEARANCE IN A VWF DEFICIENT MOUSE MODEL
Silvia Albnez*, Laura Swystun, Kate Sponagle, Julie Grabell, Christine Brown, Paula
James, David Lillicrap (Canada)
PO680-TUE ANNEXIN A2 SNP REGULATES PLASMA VON WILLEBRAND FACTOR LEV-

ELS AND IS ENRICHED IN PATIENTS WITH VON WILLEBRAND DISEASE Scientific Program
Waander Van Heerde*, Iris Kloots, Jelmer van Puffelen, Clint van Duren, Selene Schoo-
rmans, Paul Brons, Britta Laros-van Gorkom, Lambertus Kiemeney (The Netherlands)
Wednesday, June 24
WEDNESDAY

Trainee Tracks (oral sessions only):
Platelets track
TUESDAY
MONDAY
SUNDAY
SATURDAY
284 285
08:15 08:30 RETROSPECTIVE ANALYSIS OF RITUXIMAB THERAPY IN CHILDHOOD
Wednesday, June 24, 2015
THURSDSAY
OR262 CHRONIC AND REFRACTORY IMMUNE THROMBOCYTOPENIC PURPURA
ilmaz Ay*, Tuba Hilkay Karapinar, Yesim Oymak, Ersin Toret, Bengu Demirag, Dilek
Y
ORAL COMMUNICATIONS 5 08:00-09:15 Ince, Esin Ozcan, Nergial Moueminoglou, Sultan Aydn Koker, Canan Vergin (Turkey)
WEDNESDAY
08:30 08:45 OCCURRENCE OF METHEMOGLOBINEMIA IN IMMUNE
Venous thromboembolism therapy I Room 718 OR263 THROMBOCYTOPENIA PATIENTS TREATED WITH DAPSONE
Moderators: Sabine Eichinger (Austria), Dimitrios Scarvelis (Canada) Marina P. Colella*, Fernanda Orsi, Joyce Annichino-Bizzacchi, Erich de Paula (Brazil)
08:45 09:00 EFFECT OF CD72 ON B CELLS IN CHRONIC PRIMARY IMMUNE
WEDNESDAY
08:00 08:15
RESIDUAL VEIN THROMBOSIS AND THE INCIDENCE OF SUBSEQUENT
OR264 THROMBOCYTOPENIA
OR256 SERIOUS COMPLICATIONS IN PATIENTS TREATED WITH CONVENTIONAL
Hao Yating*, Lyu Mingen, Li Yang, Fu Rongfeng, Liu Wenjie, Zhang Donglei, Zhang
ANTICOAGULATION Xian, lyu Cuicui, Sun Tiantian, Li Huiyuan, Yang Renchi (China)
Paolo Prandoni*, Anthonie Lensing, Martin Prins, Sabina Villalta, Franco Noventa
ORALS
(Italy) 09:00 09:15 THE EFFECT OF DANAZOL AND A NEW TREATMENT STRATEGY IN
OR265 PRIMARY IMMUNE THROMBOCYTOPENIA AN ANALYSIS OF 412 CASES
08:15 08:30 EFFICACY AND SAFETY OF OUTPATIENT TREATMENT BASED ON THE
FROM A SINGLE CENTER IN CHINA
OR257 HESTIA CLINICAL DECISION RULE WITH OR WITHOUT NT-PROBNP
enjie Liu*, Xuping Gu, Yang Li, Mingen Lv, Tiantian Sun, Cuicui Lv, Renchi Yang
W
TESTING IN PATIENTS WITH ACUTE PULMONARY EMBOLISM: (China)
TUESDAY
A RANDOMIZED TRIAL
Paul L. den Exter*, Wendy Zondag, Frederikus Klok, Rolf Brouwer, Anneke Dolsma,
Michiel Eijsvogel, Laura Faber, Marco Grootenboers, Roxane Heller-Baan, Marcel Risk factors for venous thrombosis II Room 801
Hovens, Ge Jonkers, Klaas van Kralingen, Ronne Mairuhu, Christian Melissant, Henny
Peltenburg, Judith Post, Marcel van de Ree, Tom Vlasveld, Marielle de Vreede, Menno Moderators: William Geerts (Canada), Scott Kaatz (United States)
Huisman (The Netherlands)
08:30 08:45 COMPARISON OF ULTRASOUND ASSISTED CATHETER-DIRECTED 08:00 08:15 META-ANALYSIS OF 65,734 INDIVIDUALS IDENTIFIES TSPAN15 AND
OR258 THROMBOLYSIS (CDT) AND CDT ALONE FOR TREATMENT OF PROXIMAL OR266 SLC44A2 AS TWO NEW SUSCEPTIBILITY LOCI FOR VENOUS
MONDAY
DEEP VEIN THROMBOSIS THROMBOEMBOLISM
ladimir Tichelaar*, Ellen Brodin, Anders Vik, Trond Isaksen, Finn-Egil Skjeldestad,
V Pierre-Emmanuel Morange*, Marine Germain, Weihong Tang, Christopher Kabrhel,
Kulbir Singh, John-Bjarne Hansen (Norway) Pieter Reitsma, John Heit, Daniel Chasman, David Tregouet, Frits Rosendaal, Nicholas
Smith (France)
08:45 09:00 LONG-TERM ANTICOAGULATION WITH RIVAROXABAN FOR THE
OR259 PREVENTION OF RECURRENT DEEP VENOUS THROMBOSIS AND 08:15 08:30 ASSOCIATIONS BETWEEN ATRIAL FIBRILLATION AND CAUSE-SPECIFIC
PULMONARY EMBOLISM: A BENEFITRISK ANALYSIS ON THE EINSTEIN OR267 RISKS OF PULMONARY EMBOLISM AND STROKE
EXTENSION TRIAL Ina Rye-Holmboe*, Erin Hald, Anders Vik, Ellisiv Mathiesen, Inger Njlstad, Maja-Lisa
hilip S. Wells*, Martin Prins, Bennett Levitan, Zhong Yuan, Eva Katz, Jan Beyer-West-
P Lchen, Sigrid Brkkan, John Bjarne Hansen (Norway)
SUNDAY
endorf, Timothy Brighton, Henri Bounameaux, Alexander Cohen, Bruce Davidson, Gary
Raskob, Anthonie Lensing (Canada) 08:30 08:45 GLUCOCORTICOID RECEPTOR GENE AND RISK OF VENOUS
OR268 THROMBOEMBOLISM
09:00 09:15 A NETWORK META-ANALYSIS COMPARING THE EFFICACY AND SAFETY Laura Elbers*, Bregje van Zaane, Victor Gerdes, Olaf Dekkers, Astrid van Hylckama
OR260 OF ANTICOAGULANTS FOR THE TREATMENT OF VENOUS Vlieg, Suzanne Cannegieter (The Netherlands)
THROMBOEMBOLISM IN CANCER PATIENTS
lorian Posch*, Oliver Koenigsbruegge, Christoph Zielinski, Ingrid Pabinger, Cihan Ay
F 08:45 09:00 F11 IS ASSOCIATED WITH RECURRENT EVENT OF VTE IN WOMEN:
(Austria) OR269 A PROSPECTIVE COHORT STUDY
SATURDAY
aria Bruzelius*, Maria Ljungqvist, Matteo Bottai, Annica Bergendal, Rona Straw-
M
bridge, Angela Silveira, Helle Kieler, Anders Hamsten, Gerd Lrfars, Jacob Odeberg
ITP Clinical Room 701 (Sweden)
Moderators: Donald Arnold (Canada), John Freedman (Canada) 09:00 09:15 ROLE OF APOLIPOPROTEIN(A) KRINGLE-IV TYPE 2 COPY NUMBER
OR270 VARIATION IN VENOUS THROMBOEMBOLISM
08:00 08:15 ALL-TRANS RETINOIC ACID (ATRA) CORRECTS THE IMBALANCE OF Elena Sticchi*, Betti Giusti, Alberto Magi, Pia Kamstrup, Domenico Prisco, Ida Marti-
OR261 MACROPHAGE POLARIZATION IN PATIENTS WITH IMMUNE nelli, Pier Mannucci, Rosanna Abbate (Italy)
THROMBOCYTOPENIA
Qi Feng*, Miao Xu, Yu Hou, Yingyi Yu, Xin Li, Yuanxin Sun, Jun Peng (China)
286 287
Platelets II Room 713 09:00 09:15 AADACL1 REGULATION OF PKC-DEPENDENT SECRETION IN HUMAN
THURSDSAY
OR280 PLATELETS
Moderators: Christian Gachet (France), Heyu Ni (Canada) Stephen Holly*, Putianqi Wang, Rinku Majumder, Davia Blake, Leslie Parise (United
States)
08:00 08:15 THE DIRECT DENGUE VIRUS-PLATELET INTERACTION: GENERATION
WEDNESDAY
OR271 OF INFECTIOUS PROGENY
Non-vitamin K oral anticoagulants and surgery Room 714
Michael R. Sutherland*, Ayo Simon, Edward Pryzdial (Canada)
Moderators: Lama Castellucci (Canada), Marc Samama (France)
08:15 08:30 THE PH-DOMAIN ADAPTOR BAM32/DAPP1 RESTRAINS GPVI-MEDIATED
WEDNESDAY
OR272 PLATELET ACTIVATION AND THROMBUS FORMATION 08:00 08:15 IMPACT OF ORAL ANTICOAGULATION ON TIME TO PROCEDURE IN
James L. Hutchinson*, Tom Durrant, Samantha Moore, Ingeborg Hers (United Kingdom) OR281 PATIENTS ADMITTED FOR HIP FRACTURE.
08:30 08:45 IMPAIRED PLATELET ACTIVATION BUT INTACT HEMOSTASIS IN MICE homas Tran*, Carine de Wit, Aurelien Delluc, William Petrcich, Gregoire Le Gal, Marc
T
Carrier (Canada)
OR273 EXPRESSING LOW LEVELS OF THE RAP-GEF, CALDAG-GEFI
ORALS
Raymond Piatt*, Brian Cooley, Dale Cowley, Wolfgang Bergmeier (United States) 08:15 08:30 PERIOPERATIVE MANAGEMENT OF DABIGATRAN: A PROSPECTIVE
OR282 COHORT STUDY
08:45 09:00
THE CALCIUM-BINDING PROTEIN S100A1 NEGATIVELY REGULATES
Sam Schulman*, Marc Carrier, Agnes Lee, Sudeep Shivakumar, Mark Blostein, Fred-
OR274 COLLAGEN-DEPENDENT PLATELET ACTIVATION AND THROMBOSIS IN erick Spencer, Susan Solymoss, Rebecca Barty, Grace Wang, Nancy Heddle, James
MICE Douketis (Canada)
TUESDAY
Yacine Boulaftali*, David Paul, Raymond Piatt, Dengmin Feng, Brian Cooley, Patrick
Most, Wolfgang Bergmeier (France, United States) 08:30 08:45 AN OBSERVATIONAL COHORT STUDY TO EVALUATE THE SAFETY AND
OR283 EFFICACY OF DABIGATRAN ETEXILATE IN PATIENTS WITH MODERATE
09:00 09:15 DISSECTING ROLES FOR THE SNARE-ASSOCIATED PROTEIN, SNAP29, RENAL IMPAIRMENT UNDERGOING ELECTIVE TOTAL HIP OR KNEE
OR275 IN MOUSE PLATELETS REPLACEMENT SURGERY
Christopher Williams*, Joshua Savage, Matthew Harper, Samantha Moore, Ingeborg imon P. Frostick*, Nadia Rosencher, Eva Kleine, Martin Feuring, Martina Brueck-
S
Hers, Alastair Poole (United Kingdom) mann, Andreas Clemens, Jenny Gullberg, Charles-Marc Samama (United Kingdom)
MONDAY
08:45 09:00 EFFICACY OF RIVAROXABAN FOR PREVENTION OF VENOUS
Platelets kinases II Room 716
OR284 THROMBOEMBOLISM AFTER KNEE ARTHROSCOPY: A RANDOMIZED
Moderators: Joel Bennett (United States), Alexandra Mazharian (United Kingdom) DOUBLE-BLIND TRIAL (ERIKA STUDY)
Giuseppe Camporese*, Enrico Bernardi, Franco Noventa (Italy)
08:00 08:15
A COMPARISON OF BTK/TEC KINASES IN PLATELETS USING IBRUTINIB
OR276 AND KNOCKOUT MICE 09:00 09:15 ASSAYS TO MEASURE DIRECT ORAL ANTICOAGULANTS (DOAC) :
Craig E. Hughes*, Monique Laudat, Michael Tomlinson, Wilfried Ellmeier, Steve Wat- OR285 DATA FROM UK NEQAS MULTICENTRE STUDIES.
son (United Kingdom) Ian Jennings*, Steve Kitchen, Dianne Kitchen, Shelene Munroe-Peart, Robert Jones,
Anna Lowe, Timothy Woods, Isobel Walker (United Kingdom)
SUNDAY
08:15 08:30 PP1C ALPHA NEGATIVELY REGULATES PLATELET THROMBUS
OR277 FORMATION VIA MAPK P38
Contact system I Room 715
Subhashree Pradhan, Qi Da, Tanvir Khatlani, K. Vinod Vijayan* (United States)
Moderators: Ronit Mor-Cohen (Israel), David Gailani (United States)
08:30 08:45
DUSP3 PHOSPHATASE DEFICIENCY OR INHIBITION LIMIT PLATELET
OR278 ACTIVATION AND ARTERIAL THROMBOSIS 08:00 08:15 ARTERIAL THROMBOSIS IS ACCELERATED IN HISTIDINE-RICH
Souad Rahmouni*, Lucia Musumeci, Marijke Kuijpers, Karen Gilio, Hego Alexandre, OR286 GLYCOPROTEIN DEFICIENT MICE
Emilie Thtre, Yotis Senis, Johan Heemskerk, Marc Thiry, Lutz Tautz, Ccile Oury
SATURDAY
(Belgium)
Trang T. Vu*, Ji Zhou, Beverly Leslie, Alan Stafford, James Fredenburgh, Ran Ni,
Shengjun Qiao, Nima Vaezzadeh, Willi Jahnen-Dechent, Brett Monia, Peter Gross,
Jeffrey Weitz (Canada)
08:45 09:00
CLASS III PI3K POSITIVELY REGULATES PLATELET ACTIVATION AND
OR279 THROMBUS FORMATION VIA PTDINS3P DIRECTED FUNCTION OF THE 08:15 08:30 PHOSPHATE POLYMERS AND FACTOR XI ACTIVATION.
NADPH OXIDASE OR287 nton Matafonov*, Ivan Ivanov, Mao-fu Sun, Vladimir Serebrov, David Gailani (Russian
A
Hu Hu*, Dongjiao Luo, Yang Yang, Ming Yue, Mengjiao Hu, Shuai Wang, Qian Huang, Federation, United States)
Zhongzhou Yang (China)
08:30 08:45 FACTOR XII ACTIVATION BY ACTIVATED FACTOR XI
OR288 Ivan Ivanov*, Anton Matafonov, Mao-fu Sun, Dave Gailani (United States)
288 289
08:45 09:00 AN ALLOSTERIC DISULFIDE BOND IS INVOLVED IN ENHANCED 08:15 08:30 SUPPRESSION OF LEAKY NONSENSE MUTATIONS BY RIBOSOME
THURSDSAY
OR289 ACTIVATION OF FACTOR XI BY PROTEIN DISULFIDE ISOMERASE OR297 READTHROUGH ACCOUNTS FOR RESIDUAL FACTOR IX LEVELS IN
Ronit Mor-Cohen*, Adva Yeheskel, Uri Seligsohn, Michal Zucker (Israel) HAEMOPHILIA B PATIENTS
Alessio Branchini*, Mattia Ferrarese, Marcello Baroni, Matteo Campioni, Francesco
09:00 09:15 DNA AND RNA ACTIVATE THE CONTACT PATHWAY OF COAGULATION BY Burini, Federica Nicolosi, Giancarlo Castaman, Paolo Radossi, Francesco Bernardi,
WEDNESDAY
OR290 PROMOTING RECIPROCAL ACTIVATION OF FACTOR XII AND Mirko Pinotti (Italy)
PREKALLIKREIN
Jagmanpreet S. Dang*, Trang Vu, Beverly Leslie, Alan Stafford, James Fredenburgh, 08:30 08:45 F8 AND F9 GENE VARIANTS, CADD SCORES, AND HEMOPHILIA
Jeffrey Weitz (Canada) OR298 SEVERITY IN THE MY LIFE, OUR FUTURE GENOTYPING PROJECT

WEDNESDAY
Jill Johnsen*, Shelley Fletcher, Haley Huston, Martin Kircher, Diane Aschman, Val
Bias, Sally McAlister, Jay Shendure, Barbara Konkle (United States)
Cancer and thrombosis clinical III Room 717
08:45 09:00 CB-FIX: AN IMPROVED SECOND GENERATION FIX DRUG CANDIDATE
Moderators: Marc Carrier (Canada), Alok Khorana (United States) OR299 Edwin Madison*, Christopher Thanos, Grant Blouse, Mark Fox, Russell Overbeck, Hoa
ORALS
Ly, Kerryn McCluskie, David Sloane (United States)
08:00 08:15
THROMBOTIC BURDEN AND THE RISK OF SUBSEQUENT MANIFEST
OR291 CANCER 09:00 09:15 CORRECTION OF ABERRANT SPLICING CAUSING HAEMOPHILIA B
Paolo Prandoni*, Sabina Villalta, Anthonie Lensing, Martin Prins, Franco Noventa, OR300 THROUGH THE COMBINATION OF COMPENSATORY U1SNRNAS AND
Andrea Piccioli (Italy) ANTISENSE OLIGONUCLEOTIDES
TUESDAY
Daniela Scalet*, Dario Balestra, Elena Barbon, Nicola Cavallari, Daniela Perrone,
08:15 08:30 RECURRENT VENOUS THROMBOEMBOLISM AND MORTALITY IN Francesco Bernardi, Mirko Pinotti (Italy)
OR292 CANCER PATIENTS WITH UPPER EXTREMITY DEEP VEIN THROMBOSIS
uzanne Bleker*, Nick van Es, Ankie Kleinjan, Harry Bller, Pieter Kamphuisen, Anita
S Blood coagulation tests I Room 707
Aggarwal, Jan Beyer-Westendorf, Giuseppe Camporese, Benilde Cosmi, Thomas Gary,
Angelo Ghirarduzzi, Karin Kaasjager, Teresa Lerede, Peter Marschang, Karina Meijer, Moderators: Augusto Federici (Italy), Ran Ni (Canada)
Hans-Martin Otten, Ettore Porreca, Marc Righini, Peter Verhamme, Sanne van Wissen,
Marcello Di Nisio (The Netherlands) 08:00 08:15 SIMULTANEOUS MEASUREMENT OF THROMBIN GENERATION AND
OR301 FIBRIN FORMATION IN WHOLE BLOOD APPLYING CONTINUOUS FLOW
08:30 08:45 INTERRELATION BETWEEN CANCER AND MYOCARDIAL INFARCTION IN
MONDAY
IS INDICATIVE FOR THE AMOUNT OF BLOOD LOSS DURING/AFTER
OR293 THE GENERAL POPULATION CARDIOTHORACIC SURGERY
udvig B. Rinde*, Birgit Smbrekke, Hilde Jensvoll, Kristine Blix, Inger Njlstad,
L eonie Pelkmans*, Hilde Kelchtermans, Anne Bouwhuis, Evelien Schurgers, Theo Lind-
L
Ellisiv Mathiesen, Anders Vik, Sigrid Brkkan, John-Bjarne Hansen (Norway) hout, Dana Huskens, Coenraad Hemker, Marcus Lanc, Bas de Laat (The Netherlands)
08:45 09:00 EPIDEMIOLOGY OF FIRST VENOUS THROMBOEMBOLISM IN PATIENTS 08:15 08:30 A NOVEL SUBSTRATE FOR USE IN A POINT OF CARE THROMBIN
OR294 WITH ACTIVE CANCER OR302 GENERATION ASSAY
lexander Cohen*, Anja Katholing, Stephan Rietbrock, Carlos Martinez (United King-
A Shengjun Qiao, Paul Kim, Ran Ni, Jeffrey Weitz, Peter Gross* (Canada)
dom)
SUNDAY
08:30 08:45 FACTOR XIA AND TISSUE FACTOR ACTIVITY IN TRAUMA PATIENTS
09:00 09:15 THE RISKS AND BENEFITS OF THROMBOPROPHYLAXIS (TP) AMONG OR303 Saulius Butenas, Matthew Gissel, Myung Park (United States)
OR295 HOSPITALIZED MEDICALLY ILL CANCER PATIENTS.
arc Carrier*, Cynthia Wu, Erica Peterson, Carine de Wit, Mabel Ma, Julia Tien, Gina
M 08:45 09:00 DRVVT AS SIMPLE METHOD FOR MONITORING PATIENTS WITH FXA
Polley, Agnes Lee (Canada) OR304 INHIBITORS
Annelie Siegemund*, Ute Scholz, Thomas Siegemund (Germany)
Factor VIII and IX Room 705 09:00 09:15 EFFICACY AND MECHANISM OF CLOT CONTRACTION ARE DETERMINED
SATURDAY
Moderators: Jill Johnsen (United States), Rebecca Kruse-James (United States) OR305 BY BLOOD COMPOSITION
alerie Tutwiler*, Rustem Litvinov, Andrey Lozhkin, Alina Peshkova, Tatiana Lebedeva,
V
08:00 08:15 A UNIQUE EXON SPECIFIC U1SNRNA RESCUES DIFFERENT Fazoil Ataullakhanov, Douglas Cines, John Weisel (United States)
OR296 HAEMOPHILIA B -CAUSING SPLICING-DEFECTIVE FACTOR IX VARIANTS
IN MICE.
ario Balestra*, Daniela Scalet, Franco Pagani, Francesco Bernardi, Mirko Pinotti
D
(Italy)
290 291
09:00 09:15 DETECTION OF PROCOAGULANT AND PROFIBRINOLYTIC
Heparin and heparinoids Room 709
THURSDSAY
OR315 EPCAM-POSITIVE MICROPARTICLES IN PLEURAL FLUID: A NEW
Moderators: Andreas Greinacher (Germany), Thomas Lindahl (Sweden) APPROACH FOR THE DIAGNOSIS OF THE TUMORAL ORIGIN OF
PLEURAL EFFUSIONS
08:00 08:15 IN VIVO CHARACTERIZATION OF ANTI-THROMBOTIC AND lisa Roca, Romaric Lacroix*, Coralie Judicone, Sophie Laroumagne, Stephane Robert,
E
WEDNESDAY
OR306 ANTI-INFLAMMATORY PROPERTIES OF NEW SYNTHETIC, Sylvie Cointe, Alexandre Muller, Elise Kaspi, Patrice Roll, Alain Brisson, Claudio Tan-
PROTAMINE-REVERSIBLE LOW MOLECULAR WEIGHT HEPARIN tucci, Philippe Astoul, Franoise Dignat-George (France)
asemsiri Chandarajoti, Erica Sparkenbaugh*, Nigel Key, Yongmei Xu, Brian Cooley,
K
Jian Liu, Rafal Pawlinski (United States)
Late breaking abstract session - Bleeding disorders, TTP Plenary Hall F&G
WEDNESDAY
08:15 08:30 PARTIALLY DESULFATED HEPARIN MODULATES THE INTERACTIONS Moderators: Beverly Hunt (United Kingdom), Miguel Escobar (United States)
OR307 BETWEEN ANTI-PROTAMINE/HEPARIN ANTIBODIES AND PLATELETS
Rabie Jouni*, Heike Zllner, Ahmad Khadour, Jan Wesche, Jessica Fuhrmann, Anne 08:00 08:15 ADDITIONAL DATA FROM THE TITAN TRIAL WITH THE ANTI-VWF
Grotevendt, Krystin Krauel, Andreas Greinacher, Tamam Bakchoul (Germany)
ORALS
LB006 NANOBODY CAPLACIZUMAB IN THE TREATMENT OF ACQUIRED TTP
08:30 08:45 THERMAL STABILITY OF PLATELET FACTOR 4 AND ITS COMPLEXES lora Peyvandi*, Marie Scully, Paul Knbl, Johanna A. Kremer Hovinga, Haifeng Wu,
F
Spero Cataland, Dominique Tersago (Italy)
OR308 WITH HEPARINS STUDIED BY DIFFERENTIAL SCANNING CALORIMETRY
Mihaela Delcea*, Martin Kreimann, Andreas Greinacher (Germany) 08:15 08:30 TIMING OF PLASMA TRANSFUSION AND MATERNAL MORTALITY AND
LB007 SEVERE MATERNAL MORBIDITY IN WOMEN WITH PERSISTENT
TUESDAY
08:45 09:00 COMPARISON OF BLEEDING COMPLICATIONS BETWEEN ANTI-XA AND
POSTPARTUM HAEMORRHAGE: THE TEMPOH-1 STUDY
OR309 APTT MONITORING IN PATIENTS RECEIVING UNFRACTIONATED HEPARIN
Dacia D. Henriquez*, Kitty Bloemenkamp, Saskia le Cessie, Joost Zwart, Jos van
Kathy W. Belk*, Michael Laposata, Christopher Craver (United States) Roosmalen, Jeroen Eikenboom, Cynthia So-Osman, Leo van de Watering, Jaap Jan
Zwaginga, Johanna van der Bom (Netherlands)
09:00 09:15
PROPHYLACTIC ENOXAPARIN IN CRITICALLY ILL PATIENTS WITH
OR310 SEVERE RENAL INSUFFICIENCY 08:30 08:45 RVIII-SINGLECHAIN, RESULTS OF THE PIVOTAL PHASE I/III PK,
Lana A. Castellucci*, Joseph Shaw, Shelley Acres, Rebecca Porteous, Brigitte Gomes, LB008 EFFICACY AND SAFETY CLINICAL TRIAL IN ADULTS AND ADOLESCENTS
Irene Watpool, Cedric Edwards, Antonio Giulivi, Marc Carrier, Rakesh Patel (Canada) WITH SEVERE HEMOPHILIA A
MONDAY
J ohnny Mahlangu*, Kazimierz Kuliczkowski, Oleksandra Stasyshyn, Aleksander
Skotricki, Marina Kasinova, Debbie Bensen Kennedy, Nicolas France, Katie St.Ledger,
Microparticles II Room 711
Ingrid Pabinger (South Africa)
Moderators: Patrick Provost (Canada), Romaric Lacroix (France)
08:45 09:00 SAFETY, EFFICACY AND PHARMACOKINETICS OF RECOMBINANT
08:00 08:15 LEUCOCYTES MPS PROMOTE CLOT DISSOLUTION IN A UPA/UPAR LB009 FACTOR IX FC FUSION PROTEIN IN CHILDREN WITH HAEMOPHILIA B
OR311 DEPENDENT MANNER (KIDS B-LONG)
Sylvie Cointe*, Romaric Lacroix, Stephane Robert, Coralie Judicone, Laurence Pani- Kathelijn Fischer*, Roshni Kulkarni, Beatrice Nolan, Johnny Mahlangu, Savita Rang-
cot-Dubois, Christophe Dubois, Franoise Dignat-George (France) arajan, Giulia Gambino, Lei Diao, Lynda Cristiano, Glenn Pierce, Geoffrey Allen (The
SUNDAY
Netherlands)
08:15 08:30 THE CHANGE OF THE AMOUNT OF CIRCULATING MICROPARTICLES AND
09:00 09:15 UPDATE ON A PHASE 1/2 OPEN-LABEL TRIAL OF BAX335, AN
OR312 THEIR ASSOCIATION TO THE GENERAL ATHEROSCLEROTIC BURDEN
LB010 ADENO-ASSOCIATED VIRUS 8 (AAV8) VECTOR-BASED GENE THERAPY
AFTER ACUTE CORONARY SYNDROME.
PROGRAM FOR HEMOPHILIA B
Christina Christersson, Birgitta Jonelid, sa Thulin*, Agneta Siegbahn (Sweden)
aul Monahan*, Christopher Walsh, Jerry Powell, Barbara Konkle, Neil Josephson,
P
08:30 08:45 DECREASED MICROPARTICLE-ASSOCIATED TISSUE FACTOR ACTIVITY IN Miguel Escobar, Scott McPhee, Boyan Litchev, Michael Cecerle, Bruce Ewenstein,
Hanspeter Rottensteiner, Maurus De la Rosa, Birgit Reipert, Richard Samulski, John
OR313 MORBID OBESE PATIENTS AFTER BARIATRIC SURGERY
SATURDAY
Orloff, Friedrich Scheiflinger (United States)

J ohannes Thaler*, Leyla Ay, Johanna Brix, Gerit Schernthaner, Cihan Ay, Guntram
Schernthaner, Ingrid Pabinger (Austria)
08:45 09:00 PROTEOLYTIC ACTIVITY OF CIRCULATING MICROPARTICLES FROM

OR314 ISCHEMIC STROKE PATIENTS REVEALED BY SINGLE PARTICLE LASER
SCANNING CONFOCAL MICROSCOPY
Sara Martinez De Lizarrondo*, Aurlien Briens, Jrme Parcq, Joan Montaner, Denis
Vivien, Maxime Gauberti (France)
292 293
Coffee break time in the exhibition (Level 800) Small thrombosis a big deal? Room 701
THURSDSAY
From 09:15 to 09:45
Moderators: Philip S. Wells (Canada); Gary E. Raskob (United States)

Wednesday, June 24, 2015 10:45 - 11:15 Superficial vein thrombosis
WEDNESDAY
Herv Decousus (France)
11:15 - 11:45 Cerebral vein thrombosis
Jonathan M. Coutinho (The Netherlands)
WEDNESDAY
Michael E. Nesheim Plenary Lecture Hall F&G
Moderator: Nigel Key (United States) Controversies in antiplatelet therapy for patients with coronary artery disease Room 801
THE ART
Moderator: Andrew Frelinger (United States)
STATE OFPOSTERS
09:45 -10.30 Genetics of thrombosis: from mice to humans
David Ginsburg (United States)
10:45 - 11:05 Antiplatelet drugs: what are the best targets for which treatments?
Christian Gachet (France)
11:05 - 11:25 Proteomic signatures of antiplatelet drugs: new approaches to exploring

drug effects
TUESDAY
Desmond Fitzgerald (Ireland)
11:25 - 11:45 Triple therapy for PCI in atrial fibrillation: standard of care, or a nightmare
soon to end?
Freek Verheugt (The Netherlands)
Platelets and Inflammation Room 714
MONDAY
Michael E. Nesheim, 1945-2011
Moderator: Peter M. Newman ((United States)
10:45 - 11:05 The role of platelets in tissue regeneration following acute coronary syn-
Wednesday, June 24, 2015 drome and stroke
David Varon (Israel)
STATE-OF-THE-ART LECTURES 10:45-11:45
11:05 - 11:25 Reincarnation of ancient links between coagulation and complement
Ed Conway (Canada)
SUNDAY
Trauma-induced coagulopathy Room 718
11:25 - 11:45 The role of circulating platelet transcripts
Moderator: Graham Pineo (Canada) Jane G. Freedman (United States)
10:45 - 11:05 Molecular and clinical mechanisms of traumatic coagulopathy

Mitchell Cohen (United States) Innovations and technology Room 716
11:05 - 11:25 Safer than blood: Tranexamic acid in acute severe bleeding Moderators: Bjorn Dahlbck (Sweden); Pieter H. Reitsma (The Netherlands)
Ian Roberts (United Kingdom)
SATURDAY
10:45 - 11:05 Global assays for assessing coagulation: enough data for clinical utility?
11:25 - 11:45 The challenge of coagulopathy in trauma: Trans-Agency Consortium for Claude Ngrier (France)
Trauma-Induced Coagulopathy (TACTIC)
Ken Mann (United States) 11:05 - 11:25 Use of genetic data to guide therapy in arterial disease
Guillaume Par (Canada)
11:25 - 11:45 Warfarin pharmacogenomics current best evidence

Steve Kimmel (United States)
294 295
Treatment of anticoagulant-associated bleeding Plenary Hall F&G 14:30 14:45 ANDEXANET ALFA BUT NOT FOUR-FACTOR PROTHROMBIN COMPLEX
THURSDSAY
OR318 CONCENTRATE REVERSES RIVAROXABAN-INDUCED ANTICOAGULATION
Moderators: Saskia Middeldorp (The Netherlands); Alex C. Spyropoulos (United States) AS MEASURED BY REDUCTION IN BLOOD LOSS IN A RABBIT LIVER
LACERATION MODEL
10:45 - 11:15 New strategies to treat bleeding in patients on anticoagulants: More effec- Polly Pine*, Stanley Hollenbach, Francis DeGuzman, Siusze Tan, John Malinowsky,
WEDNESDAY
tive treatment Pratikhya Pratikhya, Genmin Lu, John Curnutte, Pamela Conley (United States)
Ravi Sarode (United States)
14:45 15:00 REVERSAL OF TARGETED ANTICOAGULANTS BY COMPLEXES OF
11:15 - 11:45 Reversal of oral factor Xa inhibitors by prothrombin complex concentrates: a OR319 ALPHA-2-MACROGLOBULIN WITH THROMBIN AND FACTOR XA.
WEDNESDAY
re-appraisal Dougald M. Monroe*, Jen-Yea Chang (United States)
Sunny Dzik (United States)
15:00 15:15 IDARUCIZUMAB DOES NOT HAVE PROTHROMBOTIC EFFECTS:
OR320 ASSESSMENT OF COAGULATION MARKERS IN HEALTHY VOLUNTEERS
Transplantation medicine in childhood Room 713 Joachim Stangier*, Michael Schmohl, Stephan Glund, Akiko Harada, Susumu Imazu,
ORALS
Marina De Smet, Viktoria Moschetti, Steven Ramael, Ippei Ikushima, Fredrick Gruen-
Moderators: Suzan Williams (Canada); Christophe Male (Austria) enfelder, Paul Reilly (Germany)
10:45 - 11:15 Preventing thrombosis

Jeremy Robertson (Australia) Venous thromboembolism epidemiology III Room 718
TUESDAY
11:15 - 11:45 Managing bleeds Moderators: Paul Kyrle (Austria), John-Bjarne Hansen (Norway)
Leslie Raffini (United States)
14:00 14:15 PROGNOSTIC SIGNIFICANCE OF ASYMPTOMATIC DEEP VEIN
OR321 THROMBOSIS IN PATIENTS PRESENTING WITH ACUTE SYMPTOMATIC
Lunch in the exhibition (Level 800) PULMONARY EMBOLISM
avid Jimenez*, Borja Castejon, Jose Luis Lobo, Ana Portillo, Rosa Nieto, Roger Yusen
D
From 11:45 to 12:15 (Spain)
MONDAY
Lunch Symposia 14:15 14:30 THE INCREASED RISK OF ARTERIAL CARDIOVASCULAR DISEASE IN
OR322 PATIENTS WITH PRIOR VENOUS THROMBOSIS IS NOT EXPLAINED
From 12:15 to 13:45 THROUGH ELEVATED LEVELS OF PROCOAGULANT FACTORS.
Eng Soo Yap*, Jasmijn Timp, Astrid van Hylckama Vlieg, Frits Rosendaal, Suzanne
Lunch Symposia Programs are available in the Show Guide. Please consult the different options to Cannegieter, Willem Lijfering (Singapore)
attend the symposium of your choice.
14:30 14:45 INCIDENCE OF VENOUS THROMBOEMBOLISM IN WESTERN FRANCE:
OR323 COMPARISON BETWEEN 1998 AND 2013
Wednesday, June 24, 2015 urelien Delluc*, Ccile Tromeur, Emmanuelle Le Moigne, Francis Couturaud, Grgoire
A
SUNDAY
ORAL COMMUNICATIONS 6 14:00-15:15 Le Gal, Luc Bressollette, Maelenn Gouillou, Karine Lacut, Dominique Mottier (France)
14:45 15:00 RISK FACTORS FOR VENOUS THROMBOEMBOLISM IN WOMEN UNDER

Non-vitamin K oral anticoagulants and reversal Plenary Hall F&G OR324 COMBINED ORAL CONTRACEPTIVE: THE PILL GENETIC RISK
MONITORING (PILGRIM) STUDY
Moderators: Dougald Monroe (United States), Alexander Graham Turpie (Canada) Pierre Suchon*, Fadi Al Frouh, Agathe Henneuse, Manal Ibrahim, Dominique Brunet,
Marie-Christine Barthet, Marie-Franoise Aillaud, Marie-Christine Alessi, David
14:00 14:15
THROMBOTIC SAFETY OF A FOUR-FACTOR PROTHROMBIN COMPLEX Tregout, Pierre-Emmanuel Morange (France)
SATURDAY
OR316 CONCENTRATE (BERIPLEX P/N) FOR EDOXABAN REVERSAL IN A RABBIT

MODEL 15:00 15:15 SPLENECTOMY AND RISK OF VENOUS THROMBOSIS IN PATIENTS WITH
Eva Herzog*, Franz Kaspereit, Wilfried Krege, Baerbel Doerr, Yoshiyuki Morishima, OR325 AUTOIMMUNE HEMOLYTIC ANEMIA (AIHA)
Gerhard Dickneite (Germany) Ted Wun*, Ann Brunson, Aaron Rosenberg, Richard White (United States)
14:15 14:30 REVERSING THE EFFECT OF RIVAROXABAN -AN IN-VITRO STUDY

OR317 Nina Schultz*, Hoa Thi Tuyet Tran, Carola Henriksson, Marissa LeBlanc, Stine Bjoern-
sen, Per Morten Sandset, Pl Andre Holme (Norway)
296 297
14:45 15:00 ROLE OF CALCIUM IN REGULATING THE INTRA- AND EXTRA- CELLULAR
Post-thrombotic syndrome, thrombophilia Room 701
THURSDSAY
OR334 CLEAVAGE OF VON WILLEBRAND FACTOR BY THE METALLOPROTEASE
Moderators: Marc Rodger (Canada), Paolo Prandoni (Italy) ADAMTS13
Sriram Neelamegham*, Shobhit Gogia, Kannayakanahalli Dayananda, Anju Kelkar
14:00 14:15 POST THROMBOTIC SYNDROME IN PATIENTS TREATED WITH (United States)
WEDNESDAY
OR326 RIVAROXABAN OR ENOXAPARIN/VITAMIN K ANTAGONISTS FOR ACUTE
DEEP VEIN THROMBOSIS 15:00 15:15 ROLE OF PROTEIN DISULFIDE ISOMERASE PDI IN VON WILLEBRAND
Whitney Cheung*, Saskia Middeldorp, Martin Prins, Akos Pap, Anthonie Lensing, Arina OR335 FACTOR DIMERIZATION
Hoek-ten Cate, Marta Milan, Paolo Prandoni (The Netherlands) aria Alexandra Brehm*, Svenja Lippok, Katra Kolek, Dennis Eggert, Tobias Obser,
M
Reinhard Schneppenheim, Frauke Grter, Carsten Baldauf, Joachim Rdler (Germany)
WEDNESDAY
14:15 14:30 IMPACT OF PRIMARY VENOUS INSUFFICIENCY ON THE PREVALENCE
OR327 AND RISK OF POST-THROMBOTIC SYNDROME
Jean-Philippe Galanaud*, Thierry Ducruet, Susan Kahn (France) Platelet disorders bleeding Room 714
ORALS
Moderators: Sara Israels (Canada), Paolo Gresele (Italy)
14:30 14:45 A SIMPLE PEDIATRIC POST-THROMBOTIC SYNDROME CLASSIFICATION
OR328 ALGORITHM FOR THE GENERAL PRACTITIONER
14:00 14:15 DEFECTIVE ALPHAIIBETA3 ACTIVATION CAUSES PLATELET
Laura Avila*, Leonardo Brandao, Suzan Williams, Alex Kiss, Jennifer Stinson, Madeline
Montoya, Brian Feldman (Canada)
OR336 DYSFUNCTION IN VON WILLEBRAND DISEASE PLATELET-TYPE (PT-VWD)
Loredana Bury*, Emanuela Falcinelli, Anna Maria Mezzasoma, Paolo Gresele (Italy)
TUESDAY
14:45 15:00 HEREDITARY RISK FACTORS OF THROMBOPHILIA AND THE INDIVIDUAL
14:15 14:30 COMPREHENSIVE EVALUATION OF MECHANISMS ASSOCIATED WITH
OR329 PROBABILITY OF FIRST VENOUS THROMBOEMBOLISM (VTE) IN
PREGNANCY AND PUERPERIUM OR337 HYPER-RESPONSIVE PLATELET GPIBA AND THE ROLE OF PROTEIN
INHIBITION IN SECURING HEMOSTASIS
Andrea Gerhardt*, Ruediger Scharf, Rainer Zotz (Germany)
Harmanpreet Kaur*, Kathryn Corscadden, Maha Othman (Canada)
15:00 15:15 CLINICAL AND GENETIC FEATURES OF ANTITHROMBIN DEFICIENCY IN
14:30 14:45 OXIDATIVE STRESS ACCELERATES PLATELET RECEPTOR
OR330 13 TAIWANESE PATIENTS PATIENTS
OR338 GLYCOPROTEIN GPIBA AND GPVI SHEDDING DURING NON-SURGICAL
Yeu-Chin Chen*, Jyh-Pyng Gau, Tsu-Yi Chao (Taiwan)
BLEEDING IN HEART FAILURE PATIENTS SUPPORTED BY
MONDAY
CONTINUOUS-FLOW LEFT VENTRICULAR ASSIST DEVICE
Von Willebrand factor I Room 801 Nandan Mondal*, Erik Sorensen, Mark Slaughter, Si Pham, Bartley Griffith, Zhongjun
Wu (United States)
Moderators: Ccile Denis (France), Daniel Hampshire (United Kingdom)
14:45 15:00 METHODS FOR IDENTIFYING RARE GENETIC VARIANTS AFFECTING THE
14:00 14:15
PHAGE DISPLAY AND NEXT GENERATION DNA SEQUENCING ENABLES OR339 FORMATION AND FUNCTION OF PLATELETS
OR331 HIGH RESOLUTION MAPPING OF VWF FUNCTIONAL DOMAINS AND Ernest Turro*, Daniel Greene (United Kingdom)
ALLOANTIBODY EPITOPES
15:00 15:15 SEVERE BLEEDING TENDENCY AND IMPAIRED PLATELET FUNCTION IN
SUNDAY
Andrew Yee*, Manhong Dai, Steven Pipe, Jordan Shavit, Fan Meng, David Ginsburg
(United States) OR340 A PATIENT WITH CALDAG-GEFI DEFICIENCY.
Hisashi Kato*, Yozo Nakazawa, Hirokazu Kashiwagi, Seiji Tadokoro, Yoichiro Morikawa,
14:15 14:30 SCAVENGER RECEPTOR CLASS A MEMBER 5 (SCARA5) BINDS AND Daisuke Morita, Yumi Kurokawa, Yuzuru Kanakura, Yoshiaki Tomiyama (Japan)
OR332 INTERNALIZES VWF IN VITRO: A NOVEL CANDIDATE VWF CLEARANCE
RECEPTOR. Platelets and cancer Room 716
Kenichi Ogiwara*, Laura Swystun, Christine Brown, Colleen Notley, Juha Ojala, Karl
Tryggvason, David Lillicrap (Canada) Moderators: Issaka Yougbare (Canada), Maha Othman (Canada)
SATURDAY
14:30 14:45 NEW IN VITRO AND IN VIVO STRATEGIES TO MODULATE VON 14:00 14:15 15(S)-HETE IS A PRO-ANGIOGENIC FACTOR PRODUCED BY PLATELETS
OR333 WILLEBRAND FACTOR GENE MUTATIONS WITH DOMINANT-NEGATIVE OR341 THROUGH COX-1
EFFECT Francesca Rauzi*, Nicholas Kirkby, Matthew Edin, Darryl Zeldin, James Whiteford,
Caterina Casari*, Matteo Campioni, Paulette Legendre, Ccile Loubire, Barbara Lung- Jane Mitchell, Timothy Warner (United Kingdom)
hi, Mirko Pinotti, Olivier Christophe, Peter Lenting, Ccile Denis, Francesco Bernardi
(France) 14:15 14:30 PLATELETS ENGINEERED TO STORE INTERLEUKIN-24 INHIBITED
OR342 MELANOMA GROWTH IN MICE
Juan Fang, Ming Yao, Weiqing Jing, Beicheng Sun, Bryon Johnson, David A. Wilcox*
(United States)
298 299
14:30 14:45 CLEC-2 FACILITATES HEMATOGENOUS TUMOR METASTASIS AND IN 15:00 15:15 POPULATION PHARMACOKINETICS (PK) OF RECOMBINANT FUSION
THURSDSAY
OR343 VITRO TUMOR GROWTH, BUT NOT IN VIVO TUMOR GROWTH OR350 PROTEIN LINKING COAGULATION FACTOR IX WITH RECOMBINANT
Toshiaki Shirai*, Osamu Inoue, Kazuyoshi Hirayama, Hiroshi Endo, Hitomi Sato-Utida, ALBUMIN (RIX-FP) IN ADULT AND PEDIATRIC PATIENTS WITH SEVERE
Hideki Fujii, Katsue Suzuki-Inoue, Yukio Ozaki (Japan) HEMOPHILIA B
harin Limsakun, Ying Zhang, Jagdev Sidhu, Debra Bensen-Kennedy*, Annette Feuss-
T
WEDNESDAY
14:45 15:00 IDENTIFICATION OF A NOVEL C-TYPE LECTIN-LIKE RECEPTOR 2 ner, Christine Voigt, Iris Jacobs, Elena Santagostino, Morfini Massimo (United States)
OR344 INHIBITOR THAT SUPPRESSES PODOPLANIN-INDUCED PLATELET
AGGREGATION AND CANCER METASTASIS
Yao-Wen Chang*, Pei-Wen Hsieh, Ju-Chien Cheng, Ching-Ping Tseng (Taiwan) Contact system II Room 715
WEDNESDAY
15:00 15:15 SURVIVAL AFTER CANCER-ASSOCIATED VENOUS THROMBOSIS: Moderators: Jim Morrissey (United States), Rodney Camire (United States)
OR345 RESULTS FROM THE SCANDINAVIAN THROMBOSIS AND CANCER (STAC)
STUDY 14:00 14:15 ROLE OF FXIIA, FXIA, AND PLATELET-DERIVED POLYPHOSPHATE IN
Monique Crobach, Hilde Jensvoll, Marianne Severinsen, Jens Hammerstrom, Sigrid OR351 THROMBIN GENERATION USING HUMAN WHOLE BLOOD PERFUSED
ORALS
Braekkan, Kristine Blix*, Soren Kristensen, Anne Tjonneland, Frits Rosendaal, Kim OVER A COLLAGEN/TISSUE FACTOR SURFACE
Overvad, John-Bjarne Hansen, Inger Naess, Suzanne Cannegieter (The Netherlands) Shu Zhu*, Richard Travers, James Morrissey, Scott Diamond (United States)
14:15 14:30 ANTITHROMBOTIC EFFECT OF ONO-8610539, A NEW, POTENT AND

Hemophilia B Room 713 OR352 SELECTIVE SMALL MOLECULE FACTOR XIA INHIBITOR, IN A MONKEY
TUESDAY
MODEL OF ARTERIOVENOUS SHUNT
Moderators: Man-Chiu Poon (Canada), Gili Kenet (Israel) Masaru Sakai*, Tetsuya Hagio, Sho Koyama, Masashi Gohda, Keizo Suzuki, Takehiro
Ono, Takashi Kondo, Taihei Nishiyama, Kenji Tanaka, Hidekazu Matsuya, Akira Imaga-
14:00 14:15 EFFICACY, PHARMACOKINETICS (PK) AND SAFETY RESULTS OF A wa, Yasushi Hirota, Kazuhito Kawabata (Japan)
OR346 PHASE 3 CLINICAL STUDY OF RECOMBINANT FUSION PROTEIN
LINKING COAGULATION FACTOR IX WITH ALBUMIN (RIX-FP) IN 14:30 14:45 PLATELET POLYPHOSPHATE ACCELERATES THE INHIBITION OF TFPI BY
PREVIOUSLY TREATED CHILDREN WITH HEMOPHILIA B OR353 FACTOR XIA.
ili Kenet*, Herve Chambost, Christoph Male, Thierry Lambert, Mara lvarez-Romn,
G Cristina Puy*, Erik Tucker, Andrs Gruber, David Gailani, Stephanie Smith, Sharon
Susan Halimeh, Anthony Chan, Chris Barnes, Tatiana Chernova, Jan Blatny, Maria Elisa Choi, James Morrissey, Owen McCarty (United States)
MONDAY
Mancuso, Sandrine Meunier, Vladimir Komrska, Hans-Juergen Laws, Massimo Morfini,
Julie Curtain, Bohumir Blazek, Christine Voigt, Iris Jacobs, Elena Santagostino (Israel) 14:45 15:00 BINDING OF POLYPHOSPHATE TO CONTACT PATHWAY ENZYMES IS
OR354 DEPENDENT ON TRANSITION METALS
14:15 14:30 EFFICACY AND SAFETY RESULTS OF A PHASE 3 PIVOTAL CLINICAL Stephanie A. Smith*, Julie Collins, Brent Ito, James Morrissey (United States)
OR347 STUDY OF RECOMBINANT FUSION PROTEIN LINKING COAGULATION
FACTOR IX WITH ALBUMIN (RIX-FP) IN PREVIOUSLY TREATED PATIENTS 15:00 15:15 COAGULATION FACTOR XII BINDING TO APOPTOTIC CELLS INITIATES
WITH HEMOPHILIA B OR355 THROMBIN GENERATION
Elena Santagostino*, Uri Martinowitz, Toshko Lissitchkov, Brigitte Pan-Petesch, Hideji Aizhen Yang*, Robert Colman, Yi Wu (China)
Hanabusa, Johannes Oldenburg, Lisa Boggio, Claude Negrier, Ingrid Pabinger-Fas-
SUNDAY
ching, Mario von Depka Prondzinski, Carmen Altisent, Giancarlo Castaman, Koji
Yamamoto, Mara lvarez-Romn, Christine Voigt, Iris Jacobs (Italy) Cancer and thrombosis basic I Room 717
14:30 14:45 PERIOPERATIVE HEMOSTATIC MANAGEMENT OF MAJOR SURGERY IN Moderators: Ingrid Pabinger (Austria), Yona Nadir (Israel)
OR348 HEMOPHILIA B WITH LONG-ACTING RECOMBINANT GLYCOPEGYLATED
FACTOR IX: RESULTS FROM THE PARADIGM3 CLINICAL TRIAL 14:00 14:15 SYNERGISTIC ANTI-TUMOR EFFECTS WITH DABIGATRAN ETEXILATE
iguel Escobar*, Torben Colberg, Faraizah Karim, Umran Caliskan, Pratima Chowdary,
M OR356 AND CISPLATIN IN A MURINE OVARIAN CANCER MODEL
Paul Giangrande, Adam Giermasz, Maria Mancuso, Margit Serban, Woei Tsay, Marek ric Alexander, Candace Hayes, Allyson Minton, Khushboo Jain, Ashley Goss, Joanne
E
SATURDAY
Zak, Johnny Mahlangu (United States) Van Ryn, Susan Gilmour* (United States)
14:45 15:00 IMPROVED HEALTH-RELATED QUALITY OF LIFE (QOL) OF HAEMOPHILIA 14:15 14:30 PODOPLANIN EXPRESSION AND INTRAVASCULAR PLATELET
OR349 B PATIENTS TREATED WITH A WEEKLY 40 IU/KG DOSE OF A NEW OR357 AGGREGATES: THE MISSING LINK BETWEEN CANCER AND
LONG-ACTING RECOMBINANT FACTOR IX (FIX) PRODUCT, NONACOG THROMBOSIS IN PRIMARY MALIGNANT BRAIN TUMORS
BETA PEGOL Julia Riedl*, Matthias Preusser, Florian Posch, Christine Marosi, Peter Birner, Jo-
Pratima Chowdary*, Susan Kearney, Donald Yee, Juliette Meunier, Ulla Slothuus, hannes Thaler, Johannes Hainfellner, Ingrid Pabinger, Cihan Ay (Austria)
Christina Hoxer (United Kingdom)
300 301
14:30 14:45 THE GENE ENCODING VITAMINE K-DEPENDENT ANTICOAGULANT 14:15 14:30 AVATHRIN: A NOVEL FAST AND TIGHT BINDING COMPETITIVE
THURSDSAY
OR358 PROTEIN S: A POSITIVE REGULATOR OF LUNG CANCER CELL OR367 INHIBITOR OF THROMBIN FROM AMBLYOMMA VARIEGATUM
MIGRATION AND INVASION. Janaki Iyer*, Maria Kazimirova, Jobichen Chako, Patricia Nuttall, Swaminathan
Lutfi Suleiman* (France) Kunchithapadam, Manjunatha Kini (Singapore)
WEDNESDAY
14:45 15:00 ANTI-TUMOR ROLE OF ANTITHROMBIN BY INHIBITION OF 14:30 14:45 INCREASED HALF-LIFE AND SELECTIVE FUNCTION OF A
OR359 ENTEROPEPTIDASE THROUGH A NOVEL MECHANISM OR368 GLYCOENGINEERED ANTITHROMBIN VARIANT
Sonia guila, Gins Luengo-Gil, Ester Martn-Villar, Nataliya Bohdan, Miguel Quintanil- onia Aguila*, Irene Martinez-Martinez, Nataliya Bohdan, Nuria Garcia-Barbera, Vicen-
S
la, Ana I. Antn, Salvador Espn, Francisco Ayala, Vicente Vicente, Javier Corral, Irene te Vicente, Jose Rivera, Javier Corral (Spain)
WEDNESDAY
Martnez-Martnez* (Spain)
14:45 15:00 AMINO ACID RESIDUES IN THE LAMININ G DOMAINS OF PROTEIN S
15:00 15:15 EXPRESSION OF COAGULATION PROTEASES FROM THE APC PATHWAY OR369 INVOLVED IN TISSUE FACTOR PATHWAY INHIBITOR INTERACTION
OR360 IN TUMOURS FROM GYNAECOLOGICAL CANCER PATIENTS WITH AND Sofia Somajo, Josefin Ahnstrm*, Magdalena Gierula, Juan Fernandez-Recio, Bruno
WITHOUT VENOUS THROMBOSIS Villoutreix, Bjrn Dahlbck (United Kingdom)
ORALS
iona Martin, Sharon OToole, Jessica Long, John OLeary, Noreen Gleeson, Feras Abu
F
Saadeh, Lucy Norris* (Ireland) 15:00 15:15 SPLICING MUTATIONS ON ANTITHROMBIN DEFICIENCY. DIAGNOSTIC
OR370 RELEVANCE AND UNEXPECTED CONSEQUENCES.
Maria Eugenia De La Morena-Barrio*, Irene Martnez-Martnez, Susana Asenjo, Teresa
ADAMTS13 Room 705 Sevivas, Jos Padilla, Antonia Miano, Mara Toderici, Raquel Lpez-Glvez, Jos
TUESDAY
Navarro-Fernndez, Vicente Vicente, Javier Corral (Spain)
Moderators: Dave Motto (United States), Frank Leebeek (The Netherlands)
14:00 14:15 EXOSITE INTERACTIONS UNCOVER A BROAD SUBSTRATE RECOGNITION

Fibrinogen and fibrin I Room 709
OR361 PROFILE FOR ADAMTS13
Colin A. Kretz*, Krt Tomberg, Andrew Yee, David Ginsburg (United States) Moderators: Helen Philippou (United Kingdom), Kelly Njine Mouapi (United States)
14:15 14:30 TIMELY FORMATION OF ULVWF MULTIMERS AND REDUCTION OF

OR362 ADAMTS13 ACTIVITY PRECEDE CLINICAL EVENTS OF TTP RELAPSE 14:00 14:15 INTERACTION OF FIBRIN WITH THE VLDL RECEPTOR ON ENDOTHELIAL

MONDAY
Haiwa Wu, Shangbin Yang, Benjamin Witkoff, Ming Jin, Spero Cataland, Haifeng M. OR371 CELLS: LOCALIZATION OF THE FIBRIN-BINDING SITE AND
Wu* (United States) IDENTIFICATION OF ITS INHIBITORS
14:30 14:45 THE PREDICTIVE VALUE OF ADAMTS13 ACTIVITY FOR TREATMENT Leonid Medved*, Sergiy Yakovlev (United States)
OR363 MONITORING OF PATIENTS WITH ACQUIRED TTP: DATA FROM THE 14:15 14:30 CHARACTERIZING REACTIVE GLUTAMINES IN FIBRINOGEN ALPHA C
PHASE II TITAN TRIAL WITH CAPLACIZUMAB OR372 (233-425) AND PROBING FACTOR XIII SUBSTRATE SPECIFICITY
Filip Callewaert*, Hans Ulrichts, Johanna A. Kremer Hovinga, Katelijne De Swert, Kelly Njine Mouapi*, Jacob Bell, Kerrie Smith, Robert Arins, Helen Philippou, Muriel
Dominique Tersago (Belgium) Maurer (United States)
SUNDAY
14:45 15:00 LOW ADAMTS13 ACTIVITY AND THE RISK OF CORONARY HEART 14:30 14:45 DEVELOPMENT AND VALIDATION OF A JAVA-BASED COMPUTER
OR364 DISEASE: A PROSPECTIVE COHORT STUDY THE ROTTERDAM STUDY OR373 PROGRAM FOR IMAGE ANALYSIS OF FIBRIN ULTRASTRUCTURE
Michelle A. H. Sonneveld*, Maryam Kavousi, Mohammed Ikram, Fritz Scheiflinger, rancis Chan*, Jorell Gantioqui, Ivan Stevic, Celia Kwan, Keith Lau, Anthony Chan,
F
Albert Hofman, Frank Leebeek, Oscar Franco, Moniek de Maat (The Netherlands) Howard Chan (Canada)
15:00 15:15 EVOLUTIONARY VARIATION IN THE ALLOSTERIC PROPERTIES OF 14:45 15:00 EFFECT OF FIBRINOGEN GAMMA PEPTIDE ON FACTOR XI ACTIVATION
OR365 ADAMTS13 OR374 BY THROMBIN
Joshua Muia*, Jian Zhu, Garima Gupta, Lisa A. Westfield, Suellen Greco, Louis De- Farida Omarova*, Shirley Uitte de Willige, Robert Arins, Rogier Bertina, Jan Rosing,
SATURDAY
forche, Karen Vanhoorelbeke, J. Evan Sadler (United States) Elisabetta Castoldi (The Netherlands)
15:00 15:15 FIBRIN(OGEN) ENGAGEMENT OF INTEGRIN MAC-1 (ALPHA-M BETA-2)

Natural anticoagulants Room 707 OR375 LIMITS CHRONIC LIVER FIBROSIS INDUCED BY A BILE DUCT TOXICANT
Moderators: Paolo Simioni (Italy), Janaki Iyer (Singapore) IN MICE
ikita Joshi*, Anna Kopec, Holly Fedewa, Matthew Flick, James Luyendyk (United
N
14:00 14:15
DEVELOPMENT OF A NOVEL PROTEIN S-BASED ANTITHROMBOTIC States)
OR366 AGENT
Rinku Majumder*, Anze Testen, Howard Fried, Paulo Simioni (United States)
302 303
16:35 16:55 SWAPPING C-DOMAINS BETWEEN FACTOR VIII AND V REVEALS A
Fibrinolytic system I Room 711
THURSDSAY
AS121 DIFFERENTIAL ROLE OF THE TWO FACTOR VIII C-DOMAINS IN VON
Moderators: Nicola Mutch (United Kingdom), Roger Lijnen (Belgium) WILLEBRAND FACTOR BINDING AND INTRACELLULAR TRAFFICKING TO
WEIBEL-PALADE BODIES IN ENDOTHELIAL CELLS
14:00 14:15 NANOPARTICLE-BASED, MOLECULAR CONTROL OF THE PLASMIN Eduard H. Ebberink*, Eveline Bouwens, Maritte Boon-Spijker, Esther Bloem, Maartje
WEDNESDAY
OR376 ACTIVE SITE TO ACHIEVE DIRECT FIBRINOLYSIS IN A NOVEL IN-VITRO Van den Biggelaar, Jan Voorberg, Alexander Meijer, Koen Mertens (The Netherlands)
SYSTEM OF PULMONARY EMBOLISM
Jeffrey A. Kline*, Nathan Alves, Aditya Shah, Daren Beam (United States) 16:55 17:15 A POPULATION APPROACH TO HEMOPHILIA PHARMACOKINETICS.
AS122 WAPPS: A WEB-SERVICE FOR BAYESIAN POST HOC ESTIMATION

WEDNESDAY
14:15 14:30 EFFECT OF QUEBEC PLATELET DISORDER ON LEUKOCYTE UROKINASE Alfonso Iorio*, Victor Blanchette, Jan Blatny, Peter Collins, Stacy Croteau, Amy Dunn,
OR377 PLASMINOGEN ACTIVATOR (UPA) LEVELS. Kathleen Fischer, Cedric Hermans, Kaan Kavakli, Shannon Jackson, Paula James,
Subia Tasneem*, Asim Soomro, Georges-tienne Rivard, John Waye, Catherine Hay- Sunil Mammen, Massimo Morfini, Tamara Navarro-Ruan, Ellis Neufeld, Margarete Oze-
ward (Canada) lo, Paolo Radossi, Savita Rangarajan, Arlette Ruiz-Sez, Jerry Teitel, Lehana Thabane,
SYMPOSIA
Guy Young, Mengchen Xi (Canada)
14:30 14:45 ASSESSMENT OF FIBRINOLYTIC PARAMETERS IN PATIENTS WITH
OR378 HEMOPHILIA A Platelet activation Room 713
Marija Milos*, Desiree Coen Herak, Silva Zupancic-Salek, Renata Zadro (Croatia)
Moderators: Alaistair Poole (United Kingdom), Vincenzo Leo (United Kingdom)
14:45 15:00
DEFIBROTIDE IMPROVES FIBRINOLYSIS EFFICIENCY IN TPA-RESISTANT
TUESDAY
OR379 ARTERIAL THROMBOSIS 15:45-16:15 REGULATION OF PLATELET MEMBRANE TRAFFICKING
Sara Martinez De Lizarrondo*, Sophie Guettier, Marina Rubio, Clement Gakuba, Em- AS123 Sidney Wally Whiteheart (United States)
manuel Touz, Denis Vivien, Maxime Gauberti (France)
16:15 16:35 IMPAIRED NUCLEAR ACCUMULATION AND DNA BINDING OF TWO FLI1
15:00 15:15
VALPROIC ACID SELECTIVELY INCREASES ENDOTHELIAL, BUT NOT AS124 VARIANTS RESULTS IN ABNORMALLY LARGE PLATELET ALPHA
OR380 BRAIN, T-PA PRODUCTION AND REDUCES THROMBUS FORMATION IN GRANULES AND A REDUCTION IN PLATELET DENSE GRANULE
MOUSE NUMBER
Pia Larsson, Imala Alwis*, Beeri Niego, Maithili Sashindranath, Emma Lu, Maria Vincenzo C. Leo*, Bart Wagner, Lucinda Nicholson-Goult, Michael Makris, Steve
Daglas, Amanda Au, Niklas Bergh, Shaun Jackson, Robert Medcalf, Sverker Jern (Aus- Watson, Martina Daly (United Kingdom)
MONDAY
tralia)
16:35 16:55 DYSREGULATION OF PLDN (PALLIDIN) AS A MECHANISM FOR PLATELET
Coffee break time in the exhibition (Level 800) AS125 DENSE GRANULE DEFICIENCY IN RUNX1 HAPLODEFICIENCY
From 15:15 to 15:45 Guangfen Mao, Chengxiang Fan, Gauthami Jalagadugula, Robert Freishtat, A. Koneti
Rao* (United States)
16:55 17:15 GRANUPHILIN (SYNAPTOTAGMIN-LIKE PROTEIN 4, SLP4) REGULATES

Wednesday, June 24, 2015 AS126 PLATELET DENSE GRANULE SECRETION AND AGGREGATION
SUNDAY
ABSTRACT SYMPOSIA 15:45-17:15 Ewelina M. Golebiewska*, Christopher Williams, Tetsuro Izumi, Alastair Poole (Japan)
Platelet function testing assays Room 801

Factor VIII Room 701
Moderators: Paul Harrison (United Kingdom), Owen McCarty (United States)
Moderators: Peter Lenting (France), Bob Montgomery (United States)

15:45-16:15
REGULATION OF FACTOR VIII CLEARANCE: A MULTIFACTORIAL
15:45-16:15 CAN PLATELET FUNCTION TESTING TELL WHETHER YOUR PATIENT
SATURDAY
AS119 PROCESS
AS127 WILL BLEED OR THROMBOSE?
David Lillicrap (Canada)
Marie Lordkipanidz (Canada)
16:15 16:35
ENHANCED FACTOR VIII GENE THERAPY FOR HEMOPHILIA A DOGS
16:15 16:35 UNCOVERING GENETIC NETWORKS UNDERLYING PLATELET RESPONSE
AS120 WITH A NOVEL FURIN-EVADING FACTOR VIII VARIANT
AS128 TO THIENOPYRIDINES BY EXOME SEQUENCING OF
Joshua Siner, Ben Samelson-Jones*, Julie Crudele, Shanzhen Zhou, Elizabeth Mer-
CLOPIDOGREL-TREATED PATIENTS EXHIBITING EXTREME PLATELET
ricks, Timothy Nichols, Rodney Camire, Valder Arruda (United States)
REACTIVITY
Jean-Luc Reny*, Brian Stevenson, Mark Ibberson, Youssef Daali, Mylne Docquier,
Ioannis Xenarios, Pierre Fontana (Switzerland)
304 305
16:35 16:55 DEVELOPMENT OF A SMALL VOLUME, WHOLE BLOOD, PLATELET 16:45 17:00 STATIN USE AND RISK OF RECURRENT VENOUS THROMBOSIS:
THURSDSAY
AS129 FUNCTION ASSAY TO ASSESS NEONATAL PLATELET ADHESION, AS138 RESULTS FROM THE MEGA FOLLOW-UP STUDY
ACTIVATION, AND AGGREGATION illem Lijfering*, Sigrid Braekkan, Camilla Caram-Deeelder, Bob Siegerink, Astrid van
W
andra Baker-Groberg*, Kristina Haley, Natalia Dovlatova, Michael Recht, Owen McCa-
S Hylckama Vlieg, Saskia le Cessie, Frits Rosendaal, Suzanne Cannegieter (The Nether-
rty (United States) lands)
WEDNESDAY
16:55 17:15 PLATELET AGGREGATION ASSAYS DO NOT RELIABLY DIAGNOSE 17:00 17:15 LONG -TERM FOLLOW-UP OF A PROSPECTIVE COHORT OF
AS130 PLATELET STORAGE POOL DEFICIENCY AS139 UNPROVOKED VENOUS THROMBOEMBOLISM (VTE) PATIENTS OFF
Lorene Yoxtheimer*, Mary Smith, William Gunning (United States) ANTICOAGULANTS- RISK STRATIFICATION EVALUATION (REVERSE)
Marc A. Rodger*, Michael Kovacs, Gregoire Le Gal, Dimitri Scarvelis, Susan Kahn,
WEDNESDAY
David Anderson (Canada)
Assay challenges Room 709
Moderators: Pall nundarson (Iceland), Sandra Haberichter (United States)
SYMPOSIA
Membrane scrambling Room 711
15:45-16:15 LABORATORY DIAGNOSIS OF VON WILLEBRAND DISEASE Moderators: Ejaife Agbani (United Kingdom), Julia Anderson (Scotland)
AS131 Veronica Flood (United States)
15:45-16:15 SCRAMBLING THE MEMBRANE: A REGULATORY MECHANISM FOR
16:15 16:35 VALIDATION OF A NEXT GENERATION DNA SEQUENCING PANEL FOR AS140 PLATELET FUNCTION
AS132 HAEMOSTATIC AND PLATELET DISORDERS
TUESDAY
Johan Heemskerk (The Netherlands)
Anne Goodeve*, Nicholas Beauchamp (United Kingdom)
16:15 16:35 PLATELETS MAXIMISE MEMBRANE SURFACE AREA THROUGH
16:35 16:55
COMPARATIVE ANALYSIS OF STANDARD AND NEW VON WILLEBRAND AS141 COORDINATED BALLOONING AND PROCOAGULANT SPREADING TO
AS133 ASSAYS IN A WELL TYPED COHORT OF PATIENTS WITH VON AMPLIFY LOCALISED THROMBIN GENERATION
WILLEBRAND DISEASE Ejaife Agbani*, Ed Brown, Marion Van Den Bosch, Christopher Williams, Nadine Mat-
Inge Vangenechten*, Katarzyna Mayger, Petr Smejkal, O Zapletal, Jan Jacques theij, Judith Cosemans, Peter Collin, Johan Heemskerk, Ingeborg Hers, Alastair Poole
Michiels, Gary Moore, Alain Gadisseur (Belgium) (United Kingdom)
16:55 17:15 ELISA-BASED ASSESSMENT OF EXCESSIVE VON WILLEBRAND FACTOR 16:35 16:55 HYSTERESIS-LIKE BINDING OF COAGULATION FACTOR X/XA TO LIPIDS
MONDAY
AS134 PROTEOLYSIS AS142 PROTECTS FROM BLOOD FLOW
Antoine Rauch*, Claudine Caron, Emmanuelle Jeanpierre, Sylvie Hermoire, Edith Nadezhda Podoplelova, Anastasia Sveshnikova, James Kurasawa, Andrey Sarafanov,
Fressinaud, Pierre Boisseau, Agns Veyradier, Alexandre Ung, Eric Van Belle, Andr Fazly Ataullakhanov, Mikhail Panteleev* (Russian Federation)
Vincentelli, Catherine Ternisien, Jenny Goudemand, Sophie Susen (France)
16:55 17:15 NOVEL PEPTIDE AND PEPTIDOMIMETIC INHIBITORS OF
AS143 PROTHROMBINASE ASSEMBLY ON PHOSPHATIDYLSERINE INHIBIT
Therapeutic management of venous thrombosis Plenary Hall F&G THROMBIN GENERATION AND FIBRIN FORMATION
Noah Kastelowitz*, Abimbola Jarvis, Ormacinda White, Peter Brown, Gary Brodsky, Ryo
SUNDAY
Moderators: Susan Kahn (Canada), Ammar Majeed (Sweden) Tamura, Jorge Di Paola, Hang Yin (United States)
15:45-16:15 IVC FILTERS: CLEAR AND NOT SO CLEAR INDICATIONS

AS135 Patrick Mismetti (France) Modulators of fibrinolytic activity Room 705
Moderators: Jim Fredenburg (Canada), Jonathan Foley (United Kingdom)
16:15 16:30
ADDITIONAL CATHETER-DIRECTED THROMBOLYSIS FOR HIGH
AS136 PROXIMAL DEEP VEIN THROMBOSIS; 5 YEAR RESULTS OF A
15:45-16:15 NOVEL APPROACHES TO MODULATING FIBRINOLYTIC ACTIVITY
RANDOMIZED CONTROLLED TRIAL (THE CAVENT STUDY)
SATURDAY
AS144 Paul Declerck (Belgium)

Ylva Haig*, Tone Enden, Ole Grtta, Nils-Einar Klw, Carl Erik Slagsvold, Waleed Ghan-
ima, Pl Andre Holme, Per Morten Sandset (Norway)
16:15 16:35 EFFECT OF DS-1040 ON ENDOGENOUS FIBRINOLYSIS AND IMPACT ON
16:30 16:45
ANTICOAGULANT THERAPY FOR SYMPTOMATIC DISTAL DEEP VEIN AS145 BLEEDING TIME IN RATS
AS137 THROMBOSIS: THE CACTUS RANDOMIZED PLACEBO-CONTROLLED Kengo Noguchi*, Naoko Edo, Yusuke Ito, Kyoji Yamaguchi (Japan)
TRIAL
16:35 16:55 A NOVEL METHOD TO DEVELOP PLASMINOGEN ACTIVATOR
Marc Righini*, Jean-Philippe Galanaud, Herv Guenneguez, Dominique Brisot, Antoine
AS146 INHIBITOR-1 ANTAGONIST AS THROMBOLYTIC AGENT
Diard, Pascale Faisse, Marie-Thrse Barrelier, Claudine Hamel Desnos, Christine
Jurus, Olivier Pichot, Myriam Martin, LUCIA Mazzolai, Clarisse Choquenet, Sandrine Lihu Gong, Valerie Proulle, Zebin Hong, Zhonghui Lin, Min Liu, Cai Yuan, Lin Lin,
Accassat, Marc Carrier, Grgoire Le Gal, Bernadette Mermillod, Jean-Pierre Laroche, Barbara Furie, Robert Flaumenhaft, Peter Andreasen, Bruce Furie, Mingdong Huang*
Henri Bounameaux, Arnaud Perrier, Susan Kahn, Isabelle Qur (Switzerland) (China, United States)
306 307
16:55 17:15 INHIBITION OF PAI-1 ACCELERATES VENOUS THROMBOSIS Prevention of thrombosis in children Room 718
THURSDSAY
AS147 RESOLUTION IN TYPE II DIABETIC MICE.
Rong Li*, Xin Deng, Meiping Ren, Ni Chen, Mao Luo, Kai Yan, Min Zeng, Jianbo Wu Moderators: Tina Biss (United Kingdom), Guy Young (United States)
(China)
15:45-16:15 WHY DO WE NEED DVT PROPHYLAXIS IN CHILDREN?
WEDNESDAY
AS157 Suzan Williams (Canada)
Factor V and regulation Room 716
16:15 16:30 BLOOD GROUP, AGE AND TYPE OF CANCER ARE INDEPENDENTLY
Moderators: Alan Mast (United States), Josefin Ahnstrm (United Kingdom)
AS158 ASSOCIATED WITH SYMPTOMATIC VENOUS THROMBOTIC EVENTS IN
WEDNESDAY
15:45-16:15
FACTOR V AND TISSUE FACTOR PATHWAY INHIBITOR (TFPI) PEDIATRIC CANCER PATIENTS: A POPULATION BASED STUDY FROM
AS148 INTERACTIONS MARITIMES, CANADA
Rodney Camire (United States)
Ketan Kulkarni*, Tamara MacDonald, Victoria Price, Pamala Cox, Conrad Fernandez,
Mark Bernstein, Margaret Yhap (Canada)
SYMPOSIA
16:15 16:35
FV ENHANCES PROTEIN S COFACTOR FUNCTION FOR TFPI IN THE
16:30 16:45 VENOUS THROMBOEMBOLISM OCCURRING DURING ADOLESCENCE:
AS149 INHIBITION OF FXA
AS159 IS IT PREVENTABLE?
Natalia Reglinska-Matveyev, James Crawley, Rodney Camire, David Lane, Josefin Ahn-
strm* (United Kingdom)
Tina Biss*, Raza Alikhan, Jeanette Payne, Jayanthi Alamelu, Michael WIlliams, Mi-
chael Richards, Mary Mathias, Oliver Tunstall, Elizabeth Chalmers (United Kingdom)
16:35 16:55
EAST TEXAS FV-SHORT/TFPI INTERACTION IN INHIBITION OF FXA- AND
TUESDAY
16:45 17:00 VENOUS THROMBO-EMBOLISM (VTE) IN CHILDREN WITH SICKLE CELL
AS150 TF-INITIATED THROMBIN GENERATION
AS160 DISEASE (SCD): AN INSTITUTIONAL EXPERIENCE
Ruzica Livaja-Koshiar*, Rodney Camire, Michelle Ho, Bjrn Dahlbck (Sweden)
Gary Woods*, Ruchika Sharma, Susan Creary, Amy Dunn, Kan Hor, Jeniffer Young,
Cody Young, Riten Kumar (United States)
16:55 17:15 DEVELOPMENT AND CHARACTERIZATION OF AN RNA APTAMER
AS151 TARGETING FV/FVA 17:00 17:15 HOSPITAL-ASSOCIATED VENOUS THROMBOEMBOLISM (HA-VTE) IN
Erin Soule*, Sriram Krishnaswamy, Bruce Sullenger (United States) AS161 PEDIATRICS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF RISK
FACTORS AND RISK ASSESSMENT MODELS
rash Mahajerin, Brian R. Branchford*, Ernest Amankwah, Leslie Raffini, Elizabeth
A
MONDAY
Determinants of thrombus structure and susceptibility to lysis Room 707
Chalmers, Heleen van Ommen, Neil Goldenberg (United States)
Moderators: Robert Arins (United Kingdom), Marie-Christine Alessi (France)
Pregnancy related bleeding complications Room 715
15:45-16:15 CELLULAR AND MECHANICAL MODULATORS OF FIBRIN STRUCTURE
AS152 Krasimir Kolev (Hungary) Moderators: Menaka Pai (Canada), Claire McLintok (New Zealand)
16:15 16:30 FACTOR XIIIA CROSSLINKING OF FIBRIN A-CHAINS MEDIATES RED 15:45-16:15 MANAGEMENT OF REPRODUCTIVE HEMORRHAGIC COMPLICATIONS
AS153 BLOOD CELL RETENTION IN CLOTS AS162 Andra James (United States)
SUNDAY
J ames R. Byrnes*, Cdric Duval, Yiming Wang, Micah Mooberry, Susan Lord, Joost
Meijers, Heyu Ni, Robert Arins, Alisa Wolberg (United States) 16:15 16:30 TRANSFUSION PROTOCOL IN SEVERE POSTPARTUM HEMORRHAGE
AS163 Giuseppe Colucci*, Karin Helsing, Franziska Demarmels, Luigi Raio, Balthasar Eberle,
16:30 16:45 ZN2+ ACCELERATES CLOT FORMATION, MODIFIES CLOT STRUCTURE, Daniel Surbek, Bernhard Lmmle, Lorenzo Alberio (Switzerland)
AS154 AND PROMOTES CLOT STABILITY
ara J. Henderson*, Jing Xia, Alan Stafford, Beverly Leslie, James Fredenburgh, David
S 16:30 16:45 MANAGEMENT OF 40 DELIVERIES IN 28 WOMEN WITH TYPE 1 AND
Weitz, Jeffrey Weitz (Canada) AS164 TYPE 2 VON WILLEBRAND DISEASE
atoumata Tall*, Valrie Roussel-Robert, Sophie Combe, Claire Flaujac, Nadra Ounno-
F
SATURDAY
16:45 17:00
THROMBIN AND FIBRINOGEN GAMMA REGULATE PROTOFIBRIL ughene, Firas Ibrahim, Marie-Hlne Horellou, Natalie Stieltjes(France)
AS155 PACKING WITHIN THE FIBRIN FIBER LEADING TO CHANGES IN CLOT
STRUCTURE AND STRENGTH 16:45 17:00 POSTPARTUM BLEEDING AND NEUROAXIAL ANESTHESIA IN PATIENTS
Marco Domingues*, Cedric Duval, Helen McPherson, Ramzi Ajjan, Victoria Ridger, AS165 WITH FACTOR XI DEFICIENCY
Simon Connell, Helen Philippou, Robert Ariens (United Kingdom) Kelsey Klute*, John Chapin, Paul Christos, Maria DeSancho (United States)
17:00 17:15 THE ROLE OF BLOOD MICROPARTICLES IN THE FORMATION, 17:00 17:15 ENDOTHELIUM DRIVES A PRE-DIC STATE IN ENDOTOXEMIA WITH
AS156 STRUCTURE, AND PROPERTIES OF FIBRIN CLOTS AS166 ENHANCED THROMBOSIS AND PROLONGED BLEEDING SECONDARY TO
Rustem I. Litvinov*, Rosa Nabiullina, Ilshat Mustafin, John Weisel, Laily Zubairova IMPAIRED TIE2 FUNCTION
(Russian Federation, United States) Karen De Ceunynck*, Jennifer Fitch-Tewfik, Sarah Higgins, Samir Parikh, Robert Flau-
menhaft (United States)
308 309
Platelet structure and function Room 714 Poster with refreshments
THURSDSAY
From 17:15 18:30 in the Exhibition on Level 800
Moderators: Bernard Nieswandt (Germany), Emily Catherine Reddy (Canada)
15:45-16:15 THE ROLE OF GAP JUNCTIONS IN PLATELET ACTIVATION

WEDNESDAY
AS167 Jonathan Gibbins (United Kingdom)
16:15 16:30 INTEGRIN PSI DOMAIN HAS ENDOGENOUS THIOL ISOMERASE POSTER SESSION 17:15-18:30
AS168 FUNCTION AND IS A NOVEL TARGET FOR ANTI-THROMBOTIC THERAPY
WEDNESDAY
aadiya Carrim*, Guangheng Zhu, Emily Reddy, Miao Xu, Xiaohong Xu, Yiming Wang,
N
Yan Hou, Li Ma, Christopher Lavalle, Yan Li, Min Rui, Tania Petruzziello, Xi Lei, Adili Posters will be presented on different days during the Congress and are accessible at the same times as the
Reheman, Pingguo Chen, John Wilkins, Richard Hynes, John Freedman, Heyu Ni exhibition opening hours. The official poster sessions with refreshments will take place as follows:
(Canada) Monday, June 22, 2015, from 17.15-18.30
POSTERS
Tuesday, June 23, 2015, from 18.00-19.30
16:30 16:45 THE WAVE COMPLEX MEMBER HEM1 IS A CRITICAL REGULATOR OF Wednesday, June 24, 2015, from 17.15-18.30
AS169 PLATELET SIZE AND FUNCTION IN MICE
ebastian Dtting*, Simon Stritt, Sarah Schiel, Georg Krohne, Theresia Stradal,
S The Poster Area is located inside the Exhibition on Level 800.
Bernhard Nieswandt (Germany)
Poster setup times are as follows:
TUESDAY
16:45 17:00 VAMP-7 LINKS GRANULE EXOCYTOSIS TO PLATELET SPREADING Monday, June 22, 2015, from 07.30 - 09.15
AS170 ecil Koseoglu, Jennifer Fitch-Tewfik, Christian Peters, Omozuanvbo Aisiku, Lydia
S Tuesday, June 23, 2015, from 07.30 - 09.15
Danglot, Thierry Galli, Robert Flaumenhaft* (United States) Wednesday, June 24, 2015, from 07.30 - 09.15
17:00 17:15 SHEAR-INDUCED GPIB-IX SIGNALING VIA UNFOLDING OF ITS Monday, June 22, 2015, from 18.30 - 19.00
Tuesday, June 23, 2015, from 19.30 - 20.00
AS171 JUXTAMEMBRANE MECHANOSENSORY DOMAIN
Wei Deng*, Anum Syed, Xin Liang, Franois Lanza, Renhao Li (United States)
Posters not taken down after the dismantling time will be discarded.
MONDAY
Vascular remodeling Room 717 If you have sent your poster to the poster printing service, kindly note that you will be able to pick it up at the
Poster Booth located in the Swing Space on Level 800.
Moderators: Stefania Momi (Italy), Giannoula Klement (United States)
15:45-16:15 CONTROL OF VASCULAR PATTERNING Monday, June 22, 2015, from 07.30 - 19.00
AS172 Anne Eichmann (United States) Tuesday, June 23, 2015, from 19.30 - 20.00
16:15 16:30 EXTRACELLULAR HISTONES EXERT A DIFFERENTIAL CYTOTOXIC AND
AS173 ANTIANGIOGENIC EFFECT IN PROGENITOR AND MATURE ENDOTHELIAL Pins are provided on the poster boards directly
SUNDAY
CELLS
Hebe A. Mena*, Agostina Carestia, Mirta Schattner, Soledad Negrotto (Argentina) Acquired coagulation disorders/inhibitors
16:30 16:45 BLOOD CELLS-DERIVED MATRIX METALLOPROTEINASE (MMP)-2

AS174 CONTRIBUTES TO ABDOMINAL AORTIC ANEURYSM (AAA) PO001-WED ACQUIRED HAEMOSTATIC DISORDERS BY ORTHOTOPIC LIVER TRANS-
DEVELOPMENT IN A MOUSE MODEL OF PLANTATION
HYPERTENSION/HYPERCHOLESTEROLEMIA. Dorit Blickstein*, Marius Braun, Eytan Cohen, Eytan Mor (Israel)
Stefania Momi*, Emanuela Falcinelli, Paolo Gresele (Italy)
SATURDAY
PO002-WED CORRELATION BETWEEN ACTIVATED PROTEIN C (APC) RESISTANCE

16:45 17:00 MECHANISM OF REGULATION OF VEGF-A BY JUNCTIONAL ADHESION AND STNFR2 IN ALZHEIMER DISEASE PATIENTS CARRYING EPSILON4
AS175 MOLECULE-A, AN ENDOGENOUS SUPPRESSOR OF ANGIOGENESIS ALLELE OF THE APOLIPOPROTEIN E
Meghna Naik*, Ulhas Naik (United States) Priscila Moreira*, Maria das Gracas Carvalho, Gisele Goncalves, Danyelle Rios, Edgar
Moraes, Maria Aparecida Bicalho, Luci Maria Dusse, Mayara Faria, Marcos Vincius
17:00 17:15 PLATELET ENDOTHELIAL AGGREGATION RECEPTOR -1: A NOVEL Silva, Ana Paula Fernandes, Maria Christella Thomassen, Tilman Hackeng (Brazil)
AS176 MODIFIER OF NEOANGIOGENESIS
PO003-WED PERSISTENT INTERNATIONAL NORMALIZED RATIO (INR) ELEVATION
Christophe Vandenbriele*, Alexandre Kauskot, Ine Vandersmissen, Maarten Criel, Sander
Craps, Aernout Luttun, Stefan Janssens, Peter Verhamme, Marc Hoylaerts (Belgium)
ASSOCIATED WITH OLMESARTAN-INDUCED ENTEROPATHY IN A PA-
TIENT RECEIVING WARFARIN
Alexandra McGrath, Jennifer Lowerison*, Elizabeth MacKay (Canada)
310 311
PO004-WED DIFFERENTIATION BETWEEN PRO- AND ANTICOAGULANT ACTIVITY PO015-WED COMPARISON OF DIFFERENT COAGULATION ASSAYS FOR THE MANAGE-
THURSDSAY
DEMONSTRATES REBALANCED THROMBIN GENERATION IN LIVER CIR- MENT OF ACQUIRED HEMOPHILIA
RHOSIS Miguel Escobar*, Elizabeth Donnachie (United States)
Romy Kremers*, Marie-Claire Kleinegris, Hugo ten Cate, Rob Wagenvoord, Coenraad
Hemker (The Netherlands) PO016-WED FVIII/VWF:AG RATIO IS A POWERFULL TOOL TO EARLY PREDICT RE-
WEDNESDAY
LAPSE IN ACQUIRED HAEMOPHILIA A
PO005-WED HEMOSTATIC EFFECTS OF REGENERATIVE THERAPY IN PATIENTS WITH Maxime Halliez, Sophie Voisin, Marc Trossaert*, Marianne Sigaud, Marc Fouassier,
ALCOHOLIC CIRRHOSIS-A DEVELOPING COUNTRY EXPERIENCE. Catherine Ternisien, Antoine Neel, Mohamed Hamidou, Julie Graveleau (France)
Priyanka Saxena*, Chhagan Bihari, Pratibha Dhiman, Archana Rastogi, S.K. Sarin
(India) PO017-WED ASSESSMENT OF PROTHROMBIN TIME PROLONGATION BY THROM-
WEDNESDAY
BOELASTOMETRY AND THROMBELASTOGRAPHY DURING LIVER TRANS-
PO006-WED TWO JAPANESE CASES OF ACQUIRED FACTOR V INHIBITOR WHICH PLANTATION
WERE INITIALLY DIAGONOSED WITH CONGENITAL FACTOR V DEFICIENCY Shu Lu, Tetsuro Sakai, Ezeldeen Abuelkasem, Raymond Planinsic, Kenichi Tanaka*
POSTERS
Masato Bingo*, Keiko Shinozawa, Takeshi Hagiwara, Hiroshi Inaba, Takashi Suzuki, (United States)
Kagehiro Amano, Katsuyuki Fukutake (Japan)
PO018-WED A NOVEL DIAGNOSTIC SYSTEM OF ACQUIRED COAGULATION FACTOR
PO007-WED TREATMENT OF AQUIRED FACTOR V INHIBITORS RESULTING IN DIS- INHIBITORS USING COMPREHENSIVE COAGULATION ASSAYS
SEMINATED INTRAVASCULAR COAGULATION Tomoko Matsumoto*, Keiji Nogami, Midori Shima (Japan)
Julie Tarrant*, Christopher Hughes, Laura Malins, Martin Howard, Elizabeth Horn
TUESDAY
(United Kingdom) PO019-WED INHIBITOR OF FACTOR VIII IN THE NEWBORN. CASE REPORT.
avel Svirin*, Ekaterina Shiller, Vladimir Vdovin, Viktor Petrov, Artiom Bullih, Igor
P
PO008-WED LUPUS ANTICOAGULANT - HYPOPROTHROMBINEMIA SYNDROME IN A Donin, Liubov Larina (Russian Federation)
7-YEAR OLD GIRL: A CASE REPORT
Turkan Patiroglu*, Ebru Yilmaz, Ekrem Unal, Musa Karakukcu, Mehmet Ozdemir (Tur- PO020-WED USEFULNESS OF VARIOUS SCORING METHODS WITH CROSS-MIXING
key) TEST FOR DETECTION OF LUPUS ANTICOAGULANT
Sumiyoshi Naito*, Masahiro Ieko, Osamu Kumano, Mika Yoshida, Nobuhiko Takahashi,
PO009-WED ACHIEVING HAEMOSTATIC CONTROL IN ACQUIRED HAEMOPHILIA A Takeshi Suzuki, Akihide Ito, Nobutaka Wakamiya (Japan)
WITH PLASMA DERIVED FVIII INFUSIONS
MONDAY
Pu-Lin Luo*, Steve Austin, Sangeeta Atwal, Sarah Mangles, Karan Rangarajan, Savita PO021-WED DEFINING COAGULATION DYSFUNCTION IN PATIENTS WITH LEPTOSPI-
Ranagarajan (United Kingdom) ROSIS
Lallindra Gooneratne*, Rasa Threeswaran, Shiroma Handunetti, Senaka Rajapakse,
PO011-WED ACQUIRED HAEMOPHILIA A IN POLAND A REPORT FROM AHA-POL Roopen Arya (Sri Lanka)
REGISTRY
Jerzy Windyga*, Joanna Zdziarska, Krzysztof Chojnowski, Magdalena Letowska, Krysty- PO022-WED ACQUIRED VON WILLEBRAND SYNDROME DIAGNOSIS AND MANAGE-
na Zawilska (Poland) MENT.
Angelika Batorova*, Tatiana Prigancova, Denisa Jankovicova, Anna Morongova, Erika
PO012-WED SUCCESSFUL THERAPY WITH BORTEZOMIB FOR ERADICATION OF Balazova (Slovakia)
SUNDAY
INHIBITOR IN A PATIENT WITH MULTIPLE MYELOMA AND ACQUIRED
HEMOPHILIA A PO023-WED ACQUIRED ACTIVATED PROTEIN C RESISTANCE IN ELDERLY PEOPLE
Susana Nobre Fernandes, Manuela Carvalho*, Manuela Lopes, Ricardo Pinto, Rui WITH AND WITHOUT COGNITIVE IMPAIRMENT
Bergantim, Jos Eduardo Guimares, Fernando Arajo (Portugal) Maria Das Graas Carvalho*, Gisele Gonalves, Danyelle Rios, Edgar Moraes, Maria
Aparecida Bicalho, Marcos Bastos, Luci Maria Dusse, Elisabetta Castoldi, Jan Rosing,
PO013-WED CRITICAL INSIGHTS INTO ACQUIRED HAEMOPHILIA A AND RISK-BEN- Maria Christella Thomassen, Tilman Hackeng (Brazil)
EFIT ASPECTS WITH REGARD TO CLINICAL COMPLICATIONS - A CASE
REPORT PO024-WED SINGLE-CENTER EXPERIENCE WITH RITUXIMAB IN THE TREATMENT OF
SATURDAY
Bernhard Stephan, H. Lauer, J. Gro, Andreas Link, Joachim F. Schenk* (Germany) INHIBITOR-ASSOCIATED HEMOSTATIC DISORDERS
Danielle Hammond*, Eliana Saidenberg, Alan Tinmouth (Canada)
PO014-WED CLINICAL UTILITY OF HEAT INACTIVATED NIJMEGEN MODIFIED
BETHESDA ASSAYS IN FVIII DEFICIENCY A 4 YEAR SINGLE CENTRE PO025-WED LUPUS ANTICOAGULANT (LA) TESTING OF A PREGNANT PATIENT RE-
EXPERIENCE VEALING AN ACQUIRED FACTOR XI AUTOANTIBODY
Tejas Gandhi*, Pura Lawler, Pratima Chowdary, Anja Drebes, Anne Riddell (United Geoffrey D. Wool*, Tammy Utset, Jonathan Miller (United States)
Kingdom)
312 313
PO026-WED ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) IN PA- PO035-WED PROSPECTIVE VALIDATION OF CLINI-BIOLOGICAL PARAMETERS IN-
THURSDSAY
TIENT WITH HETEROZYGOUS MTHFR C677T MUTATION AND HYPER- CLUDING INITIAL HEMOSTASIS, WHICH IMPROVE THE PREDICTION OF
HOMOCYSTEINEMIA - A CASE REPORT DEATH AT 1 MONTH AMONG PATIENTS WITH SEPTIC SHOCK: SEPSICO-
Bernadeta Ceglarek, Ksenia Bykowska, Adam Wiszniewski*, Jerzy Windyga (Poland) AG STUDY
Geraldine Lavigne-Lissalde*, Jean-Yves Lefrant, Samir Jaber, Christel Castelli, Jean-mi-
WEDNESDAY
PO027-WED ACQUIRED INHIBITORS TO FACTOR VIII AND IX, A CASE REPORT chel Constantin, Jacques Albanes, Marc Leone, Jean-Christophe Forban, Jerme Morel,
Saa Anej Doma, Irena Zupan*, Tadej Pajic, Duan Andoljek, Peter Cernelc (Slovenia) Gilles Seni, Loubna Elotmani, Jean-Christophe Gris (France)
PO028-WED ANTITROMBIN FUNCTION IN INFECTION DEVELOPMENT IN PATIENTS ADAMTS13 II

WITH SEVERE BURNS
WEDNESDAY
Marina Presnyakova*, Viktoria Kuznetsova, Artem Borisevich, Irina Strelkova (Russian
PO036-WED THE IMPORTANCE OF CONFORMATIONAL ACTIVATION OF ADAMTS13
Federation)
FOR CONTROL OF PLATELET DEPOSITION UNDER FLOW

POSTERS
PO029-WED EFFICACY OF FVIII IN THE TREATMENT OF PATIENTS WITH ACQUIRED Kieron South*, Isabelle Salles-Crawley, James Crawley, David Lane (United Kingdom)
HAEMOPHILIA A AND VASCULAR DISEASES
PO037-WED THE IMPACT OF TIMELY ADAMTS13 RESULTS ON CLINICAL DIAGNOSIS
Samantha Pasca, Claudia Battello, Giovanni Barillari* (Italy)
AND MANAGEMENT OF PATIENTS WITH SUSPECTED THROMBOTIC
PO030-WED CORRELATION BETWEEN INDICES OF HEMOSTASIS SYSTEM AND MICROANGIOPATHY (TMA): MAYO CLINICS EXPERIENCE
BIOCHEMICAL BLOOD METABOLITES IN PATIENTS WITH DIABETIC FOOT Mohamed Alsammak, Tahir Mehmood*, Michelle Taylor, Rajiv Pruthi, Jeffrey Winters,
TUESDAY
SYNDROME Dong Chen (United States)
Marina Presnyakova*, Vctoria Kuznetsova, Michail Bobrov, Maksim Kudykin, Irina
PO038-WED ADAMTS13: VON WILLEBRAND FACTOR CLEAVING PROTEASE GROWTH
Strelkova, Olga Kostina (Russian Federation)
FACTOR?
PO031-WED NEUTRALIZING AUTOANTIBODY AGAINST FACTOR XIII A SUBUNIT WITH Justin M. Keener*, Courtney Hoyt, George Rodgers (United States)
MULTIPLE INHIBITORY EFFECT ON FACTOR XIII ACTIVATION/ACTIVITY
PO039-WED DETECTION OF ADAMTS13 ACTIVITY USING THE NATIVE VWF91 PEP-
RESULTED IN SEVERE BLEEDING WITH FATAL OUTCOME
TIDE
Krisztina Pnzes*, Anna Selmeczi, va Katona, Zsuzsanna Bereczky, Adrienne Kernyi,
va Molnr, Hajnalka Gulys, gota Schlammadinger, Zoltn Boda, Lszl Muszbek Xia Bai*, Jian Su, Lijuan Cao, Ziqiang Yu, Zhaoyue Wang, Changgeng Ruan (China)
MONDAY
(Hungary)
PO040-WED CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH UP-
PO032-WED THE ACQUIRED DEFICIENCY OF FACTORS II, VII, IX, X IN THE COURSE SHAW-SCHULMAN SYNDROME RECEIVING MAINTENANCE HEMODIALY-
OF THE INTOXICATION OF SECOND GENERATION ANTICOAGULANT RO- SIS DUE TO CHRONIC RENAL FAILURE
DENTICIDES IN FEMALE PATIENT SUFFERING WITH SEVERE DIATHE- Masanori Matsumoto*, Ayami Isonishi, Koichi Kokame, Masaki Hayakawa, Hideo Yagi,
SIS HAEMORRHAGICA - A CASE REPORT Toshiyuki Miyata, Yoshihiro Fujimura (Japan)
Bernadeta Ceglarek, Ksenia Bykowska, Anna Sikorska, Beata Baran, Adam Wiszniews-
PO041-WED THE COURSE OF ADAMTS13-PROPERTIES DURING PREGNANCY IN-
ki*, Jerzy Windyga (Poland)
DUCED THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP)
SUNDAY
PO033-WED PREDICTION OF BLEEDING COMPLICATIONS AFTER RENAL BIOPSY IN Rita Dittmer* (Germany)
POST-RENAL TRANSPLANT PATIENTS WITH UREMIA
PO042-WED ANTI-ADAMTS13 ANTIBODY FEATURES (IG ISOTYPE TITERS, FUNCTION-
Gerhardus J. A. J. M. Kuiper, Monique Mullens, Paul Verhezen, Karly Hamulyak,
Maarten Christiaans, Hugo ten Cate, Yvonne Henskens* (The Netherlands) AL ADAMTS13 INHIBITOR AND CIRCULATING IMMUNE COMPLEXES
(CIC)) IN PATIENTS WITH ACQUIRED THROMBOSIS THROMBOCYTOPE-
PO034-WED ANALYSIS OF THE PROFILE OF IMMUNE CELLS, CYTOKINES AND NIC PURPURA (ATTP) AT FIRST CONSULTATION IN OUR INSTITUTION.
CHEMOKINES IN PREVIOUSLY UNTREATED PATIENTS WITH Ana Kempfer, Juvenal Paiva*, Anala Sanchez-Luceros, Fabiana Alberto, Adriana
HEMOPHILIA Woods, Mara Casinelli, Mara Lazzari (Argentina)
SATURDAY
Leticia Jardim*, Daniel Chaves, Monica Cerqueira, Alessandra Prezoti, Claudia Loren-
zato, Marcio Portugal, Suely Rezende (Brazil) PO043-WED ADAMTS13 GENE EXPRESSION IS INCRESEAD IN KIDNEY AND LIVER IN
TYPE 1 DIABETES MELLITUS ANIMAL MODEL
Michelle T. Alve*, Guilherme Reis, Adriana Bosco, Brbara Quirino, Caroline
Domingueti, Ana Fernandes, Karina Gomes (Brazil)
PO044-WED AN ACTIVITY-BASED APPROACH TO ANTI-ADAMTS 13 ANTIBODIES

Annelie Siegemund*, Ute Scholz, Thomas Siegemund (Germany)
314 315
PO045-WED DETECTION OF PLASMA ADAMTS13 ACTIVITY USING E. COLI DERIVED PO054-WED EFFECT OF A RECOMBINANT PLANT ELASTASE INHIBITOR WITH AN-
THURSDSAY
VWF-A2 SUBSTRATES AND MICROSPHERE-CYTOMETRY ASSAYS TI-INFLAMMATORY ACTION - RBBCI (BAUHINIA BAUHINIOIDES CRUZAIN/
Sriram Neelamegham*, Shobhit Gogia, Chi Lo (United States) CRUZIPAIN INHIBITOR) ON A RAT MODEL OF VENOUS THROMBOSIS
Maria Luiza Oliva, Cleide Oliveira, Mayara Valois, Tatiana Ottaiano, Marcelo Lima,
Animal models III Antonio Miranda, Misako Sampaio, Francisco H. Maffei* (Brazil)
WEDNESDAY
PO046-WED THE EFFECT OF PEPTIDE-NOOTROPICS ON PLATELET AGGREGATION Antiphospholipid syndrome II
INDUCED BY EPINEPHRINE
Maria Golubeva* (Russian Federation)
WEDNESDAY
PO055-WED EVALUATION OF THE IMPORTANCE OF MIXING PATIENT PLASMA WITH
PO047-WED EVALUATION OF THE BLEEDING TENDENCY IN MURINE MODELS OF A POOL OF NORMAL PLASMAS WHEN DIAGNOSING LUPUS ANTICOAGU-
HEMOPHILIA AND HEPARIN THERAPY USING THE THROMBODYNAMICS LANT
ASSAY
POSTERS
Ana Mara Lena*, Datevig Attarian, Nora Mota, Sebastian De Los Santos, Gabriela
Vladimir Kolyadko*, Stepan Surov, Semen Buvaliy, Vladislav Kuznetcov, Tatiana Vuimo, Domnguez, Ana Otero (Uruguay)
Fazoil Ataullakhanov, Mikhail Panteleev (Russian Federation)
PO056-WED THE TAIPAN SNAKE VENOM TIME COULD BE A RELIABLE ASSAY FOR
PO048-WED ASSESSMENT OF MOD-5014, A LONG ACTING FVIIA, PHARMACOKINET- THE DETECTION OF LUPUS ANTICOAGULANT IN PATIENT RECEIVING
IC, PHARMACODYNAMICS AND CORRECTION OF HEMOPHILIC COAG- RIVAROXABAN.
TUESDAY
ULOPATHY IN DOGS WITH HEMOPHILIA A AS PART OF THE PREPARA- Clment Berthomet, Bndicte Delahousse, Yves Gruel*, Claire Pouplard (France)
TION FOR FIRST IN HUMAN STUDY
Gili Hart*, Elizabeth Merricks, Natalie Rigsbee, Robin Raymer, Ahuva Bar-Ilan, Lior PO057-WED NEW MIXING TEST INDEX TO DISCRIMINATE BETWEEN LUPUS ANTICO-
Binder, Michal Jaron-Mendelson, Malka Hoffman, Timothy Nichols (Israel) AGULANT AND COAGULATION INHIBITOR
Osamu Kumano*, Masahiro Ieko, Sumiyoshi Naito, Mika Yoshida, Nobuhiko Takahashi,
PO049-WED SAFETY EVALUATION OF CHRONIC ANTITHROMBIN SILENCING IN Takeshi Suzuki, Takashi Aoki (Japan)
NON-HUMAN PRIMATE AND EXPANDED THERAPEUTIC INDEX IN A
HEMOPHILIA A MOUSE MODEL PO058-WED PREDICTIVE MARKERS FOR THROMBOTIC EVENTS IN AUTOIMMUNE
Scott Barros*, Kun Qian, June Qin, Brian Bettencourt, Alfica Sehgal, Akin Akinc (Unit- DISEASES: COMPARISON OF ANTIPHOSPHOLIPID SCORE (APL-S) AND
MONDAY
ed States) GLOBAL ANTI-PHOSPHOLIPID SYNDROME SCORE (GAPSS)
Kenji Oku*, Olga Amengual, Ryo Hisada, Kazumasa Oomura, Ikuma Nakagawa, Toshi-
PO050-WED AN ANTIBODY PRETREATMENT STRATEGY FOR IMPROVING CELL- yuki Watanabe, Toshiyuki Bohgaki, Tetsuya Horita, Shinsuke Yasuda, Tatsuya Atsumi
BASED THERAPY IN A MOUSE MODEL OF HEMOPHILIA B (Japan)
Yu-Chen Hsu*, Meng-Ni Fan, Yu-Jen Huang, Shu-Jhu Yang, I-Shing Yu, Yao-Ming Wu,
Shu-Wha Lin (Taiwan) PO059-WED DETECTION OF ANTIPHOSPHOLIPID ANTIBODIES IN NORMAL PREG-
NANT WOMEN AND IN PREGNANT WOMEN AT THE TIME OF PRE-
PO051-WED EFFECTS OF ANKAFERD BLOOD STOPPER ON CUTANEOUS WOUND ECLAMPSIA ONSET
HEALING: EXPERIMENTAL STUDY Beatriz Grand*, Andrea Avigliano, Monica Gonzalez Alcantara, Liliana Voto (Argentina)
SUNDAY
Duzgun Ozatli*, Osman Kelahmetoglu, Ayhan Bozkurt, Volkan Tayfur, Sirri Bilge, Piltan
Buyukkaya, Levent Yildiz, Tunc Fisgin (Turkey) PO060-WED HIGH AVIDITY AUTO-ANTIBODIES AGAINST TISSUE FACTOR PATHWAY
INHIBITOR ARE FREQUENTLY OBSERVED IN THROMBOTIC ANTIPHOS-
PO052-WED ASSESSMENT OF KNEE JOINT BLEEDING IN HEMOPHILIA B MICE BY PHOLIPID SYNDROME PATIENTS
FLUORESCENCE MOLECULAR TOMOGRAPHY Maria Efthymiou, Andrew Lawrie, Deepa Jayakody Arachchillage, Samuel Machin,
Elizabeth Chappell*, Junjiang Sun, Paul Monahan, Rupa Appa, Bo Wiinberg, Maureane Hannah Cohen, Ian Mackie* (United Kingdom)
Hoffman, Dougald Monroe (United States)
PO061-WED PREGNANCY IN WOMEN WITH ANTIPHOSPHOLIPID SYNDROME.
SATURDAY
PO053-WED SERUM ENDOCAN LEVELS AS A POTENTIAL NON-INVASIVE BIOMARKER Denisa Jankovicova*, Angelika Batorova, Tatiana Prigancova, Miroslav Korbel (Slovakia)
FOR DIAGNOSING DIFFERENT HEPATIC DISEASES
Rachel Palumbo*, Susan Uprichard, Scott Cotler, Thomas Layden, Jawed Fareed, PO062-WED ANTIPHOSPHOLIPID ANTIBODIES IN CEREBRAL VASCULAR EVENTS
Debra Hoppensteadt (United States) Hla Baccouche, Sonia Mahjoub, Montaha Ben Jemaa, Samia Ben Sassi,
Meriam Sellami*, Neila Ben Romdhane (Tunisia)
PO063-WED ANTIPHOSPHOLIPID ANTIBODIES AND THE RISK OF STROKE IN TANZA-

NIA: RESULTS FROM A COMMUNITY-BASED CASE-CONTROL STUDY
J.E. Molhoek*, Q. de Mast, Ph.G. de Groot, A.J. van der Ven, W.K. Gray, A. Jusabani,
M. Swai, F. Mugusi, R.T. Urbanus, R. Walker (The Netherlands)
316 317
PO064-WED ANTIPHOSPHOLIPID SYNDROME ALLIANCE FOR CLINICAL TRIALS PO073-WED ANTIPLATELET EFFECTS OF GLYPROLINE PEPTIDES BY EXPERIMENTAL
THURSDSAY
AND INTERNATIONAL NETWORKING (APS ACTION) CORE LABORATORY METABOLIC SYNDROM
VALIDATION EXERCISE: AN INTERNATIONAL PERFORMANCE ASSESS- Marina Grigorjeva*, Ludmila Lyapina (Russian Federation)
MENT OF LUPUS ANTICOAGULANT (LA) TESTS USING STANDARDISED
METHODS AND REAGENTS PO074-WED PLATELET TRANSFUSION REVERSES BLEEDING EVOKED BY TRIPLE
WEDNESDAY
Ian J. Mackie*, Vittorio Pengo, Elaine Gray, Danieli Andrade, Steven Krilis, Rohan ANTI-PLATELET THERAPY INCLUDING VORAPAXAR, A NOVEL PLATELET
Willis, Doruk Erkan, Hannah Cohen (United Kingdom) THROMBIN RECEPTOR ANTAGONIST
Tian-Quan Cai*, Alexandra Wickham, Gary Sitko, Maria Michener, Richard Raubertas,
PO065-WED BENEFICIAL EFFECT OF PRAVASTATIN IN FOUR PREGNANT WOMEN Larry Handt, Madhu Chintala, Deitmar Seiffert, Michael Forrest (United States)
WEDNESDAY
WITH ANTIPHOSPHOLIPID SYNDROME AND ISCHAEMIC PLACENTAL
DISEASE PO075-WED THE ANTIPSYCHOTIC CLOZAPINE IS A POTENT ANTIPLATELET AGENT
Eleftheria Lefkou*, Apostolos Mamopoulos, Themistoklis Dagklis, Christos Vosnakis, Karl Egan*, Jogin Thakore, Ana Lopez Alonso, Eimear Dunne, Niamh Cooke, Nicolas
Gerorgios Mavromatidis, Efthimios Nounopolos, David Rousso, Guillermina Girardi Ramperti, Dermot Kenny (Ireland)
POSTERS
(Greece)
PO076-WED AN IN VITRO TRANSFUSION MODEL FOR THE ASSESSMENT OF PLATE-
PO066-WED INCREASED LEVELS OF TISSUE FACTOR IN ANTIPHOSPHOLIPID SYN- LET FUNCTION RECOVERY FOLLOWING EXPOSURE TO TRIPLE AN-
DROME ARE ASSOCIATED WITH THE DIAGNOSIS OF SYSTEMIC LUPUS TI-PLATELET AGENTS
ERYTHEMATOUS AND MAY HAVE NO IMPACT ON DISEASE PROGNOSIS Lisa K. Jennings*, Vinay Bhal, Michael Herr, Mason Dixon, Steven Akins, Edward Hord,
Bruna Mazzeto, Kiara Zapponi, Isadora Custdio, Sabrina Saraiva, Marina Collela, Er- Dietmar Seiffert, Jayaprakash Kotha (United States)
TUESDAY
ich de Paula, Simone Appenzeller, Joyce Annichino-Bizzacchi, Fernanda Orsi* (Brazil)
PO077-WED EFFECTS OF SINGLE COMPARED TO DUAL ANTI-PLATELET THERAPY ON
PO067-WED DISTINCT RISK FACTORS FOR ARTERIAL AND VENOUS THROMBOSIS IN HEMOSTATIC SYSTEM ACTIVATION A PROSPECTIVE, RANDOMIZED,
ANTIPHOSPHOLIPID SYNDROME DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL IN HEALTHY VOLUN-
Isadora Custdio, Bruna Mazzeto, Sabrina Saraiva, Marina Collela, Erich de Paula, TEERS
Simone Appenzeller, Joyce Annichino-Bizzacchi, Fernanda Orsi* (Brazil) Ludwig Traby*, Alexandra Kaider, Marietta Kollars, Sabine Eichinger, Michael Wolzt,
Paul Kyrle (Austria)
PO068-WED CLINICAL RELEVANCE OF THE GLOBAL ANTIPHOSPHOLIPID SYNDROME
SCORE (GAPSS) IN DIFFERENTIATING BETWEEN TRANSIENT ISCHEMIC PO078-WED DEVELOPMENT OF A RECEPTOR OCCUPANCY ASSAY FOR ANFIBATIDE, A
MONDAY
ATTACK AND STROKE IN PATIENTS WITH ANTIPHOSPHOLIPID ANTIBOD- NOVEL GPIB ANTAGONIST
IES. Alysia Cox*, Dermot Cox, Marian Brennan (Ireland)
Savino Sciascia*, Giovanni Sanna, Veronica Murru, Dario Roccatello, Munther
Khamashta, Maria Bertolaccini (United Kingdom) PO079-WED PEGYLATED DISINTEGRIN EXHIBITS MORE POTENT ANTITHROMBOTIC
ACTIVITY IN VIVO
PO069-WED EVALUATION OF 2-GLYCOPROTEIN I LEVELS IN PATIENTS WITH ANTI- Chun-Chieh Hsu*, Woei-Jer Chuang, Tur-Fu Huang (Taiwan)
PHOSPHOLIPID SYNDROME.
Teresa Iwaniec*, Magdalena Celinska-Lwenhoff, Marcin Kaczor, Jacek Musia (Poland) PO080-WED RESISTANCE TO ASPIRIN IN MYELOPROLIFERATIVE NEOPLASMS. IS IT
A REALITY?
SUNDAY
PO070-WED THE ASSOCIATION OF 3 STAT4 SINGLE NUCLEOTIDE POLYMORPHISMS Nadine Ajzenberg*, Dorothe Faille, Marie-Genevive Huisse, Anh Cungh, Lamia Lam-
AND ANTIPHOSPHOLIPID SYNDROME rani, Nicolas Dumontier, Martine Jandrot-Perrus, Bruno Cassinat, Christine Chomienne,
Magdalena M. Celinska-Lwenhoff*, Teresa Iwaniec, Sylwia Dziedzina, Marcin Kaczor, Christine Dosquet (France)
Marek Sanak, Jacek Musial (Poland)
PO081-WED PHARMACOKINETICS AND PHARMACODYNAMICS OF APAC, A DUAL
PO071-WED LABORATORY INTERPRETATION OF LA TEST RESULTS IN THE ERA OF NOVEL ANTICOAGULANT AND ANTIPLATELET HEPARIN COMPLEX
TARGET SPECIFIC ORAL ANTICOAGULANTS Annukka Jouppila*, Marie-Claude Benoit, Charles-E. Laurent, Dany Salvail, Riitta
Lassila (Finland)
SATURDAY
Bo Hyun Kim*, Seongsoo Jang, Mi Hyun Bae, Young-Uk Cho, Chan-Jeoung Park (Ko-
rea, Republic Of)
PO082-WED INHIBITION OF THROMBIN GENERATION BY APIXABAN OR RIVAROX-
ABAN, IN A CELL-BASED MODEL OF COAGULATION PRIMED BY PLATE-
Antiplatelet agents III LETS
Irene Lopez-Vilchez*, Lluis Pujadas-Mestres, Nerea Rincon-Tome, Eduardo Arella-
no-Rodrigo, Ana Galan, Maribel Diaz-Ricart, Gines Escolar (Spain)
PO072-WED PRODUCTION AND PURIFICATION OF VERSATILE ENZYMES FOR POTEN-
TIAL ANTIPLATELET APPLICATIONS
Bat-Erdene Jugder*, Altantsetseg Buyanbat, Tseren Purev (Mongolia)
318 319
PO083-WED HOW SHOULD WE MEASURE THE EFFECT OF PERSANTINE USING PO092-WED INCREASED CLOT FORMATION IN THE ABSENCE OF INCREASED
THURSDSAY
THROMBOELASTOGRAPHY? CORRELATION AND AGREEMENT BETWEEN THROMBIN GENERATION IN PATIENTS WITH PERIPHERAL ARTERIAL
PERCENT ADP INHIBITION AND ADP NET G DISEASE
Patti Massicotte, Jennifer Conway, Lindsay May, Holger Buchholz, Clara Lo, Aisha Marie-Claire Kleinegris, Joke Konings, Jan-Willem Daemen, Yvonne Henskens, Bas de
Bruce, Tiffany Tesoro, David Rosenthal, Christopher Almond (Canada) Laat, Henri Spronk, Arina ten Cate - Hoek, Hugo ten Cate* (The Netherlands)
WEDNESDAY
PO084-WED NSAIDS IN VIVO TREATMENT AND MRP4 EXPRESSION IN HUMAN PO094-WED MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH ACUTE
PLATELETS CORONARY SYNDROME UNDERGOING CORONARY ANGIOPLASTY: ROLE
Flavia Temperilli*, Isabella Massimi, Maria Luisa Guarino, Laura Alemanno, Maria OF NADPH OXIDASE P22PHOX GENE POLYMORPHISMS
Paola Guzzo, Cristina Iannuccelli, Manuela Di Franco, Fabio M. Pulcinelli* (Italy)
WEDNESDAY
Betti Giusti*, Claudia Saracini, Silvia Galora, Rossella Marcucci, Anna Maria Gori,
Renato Valenti, Guido Parodi, Gian Franco Gensini, David Antoniucci, Francesco Violi,
PO085-WED THE EFFECTIVENESS OF P2Y12 RECEPTOR BLOCKADE IS STRONGLY Rosanna Abbate (Italy)
DETERMINED BY THE PRESENCE OF ENDOTHELIAL MEDIATORS PROS-
PO095-WED THROMBOGENICITY ACCORDING TO THE VASCULAR SITE OF ATHERO-
POSTERS
TACYCLIN AND NITRIC OXIDE
Rebecca B. Knowles*, Melissa Chan, Paul Armstrong, Chih-Chin Shih, Melissa Hay- SCLEROSIS DISEASE
man, Ivana Vojnovic, Arthur Tucker, Adam Timmis, Timothy Warner (United Kingdom) Daniela Calderaro*, Adriana Pastana, Tania Rubia Rocha, Fernanda Justo, Danielle
Gualandro, Pai Yu, Mariana Matheus, Elbio DÀmico, Bruno Caramelli (Brazil)
PO086-WED COMPARISON OF THE BIOCYTEX AND THE VASPFIX ASSAYS OF VASP
PHOSPHORYLATION IN CORONARY-ARTERY DISEASE PATIENTS TREAT- PO096-WED THE ROLES OF TRANSGLUTAMINASE 2 AND FXIII-A IN ABDOMINAL
TUESDAY
ED WITH CLOPIDOGREL PLUS ASPIRIN AORTIC ANEURYSM DEVELOPMENT
Ksenia Germanovich, Eti A. Femia, Mariangela Scavone, Vera Caroppo, Marco Catta- Kathryn Griffin, Kingsley R. Simpson*, Nadira Yuldasheva, Robert Graham, Peter
neo* (Italy) Grant, Julian Scott, Chris Jackson, Richard Pease (United Kingdom)
PO097-WED FACTOR XIA AND THROMBIN GENERATION ARE ELEVATED IN ACUTE

Arterial vascular disorders - clinical III CORONARY SYNDROME AND ARE PREDICTORS OF RECURRENT CAR-
DIOVASCULAR EVENTS.
Rinske Loeffen*, Rene van Oerle, Mathie Leers, Harry Crijns, Henri Spronk, Hugo ten
PO087-WED LOCAL PARAMETERS OF HEMOSTASIS ACTIVATION IN THE FIBRILLAT- Cate (The Netherlands)
MONDAY
ING ATRIUM
Noemi Klara Toth*, Zsuzsa Bagoly, Zoltn Csandi, Alexandra Kiss, Edina Nagy-Bal,
Kitti Kovcs, Lszl Muszbek, Zsuzsanna Bereczky, Lszl Csiba (Hungary) Atherosclerosis III
PO088-WED THE ASSESMENT OF ENDOTHELIAL PROGENITOR CELLS IN PATIENTS

WITH ST ELEVATION MYOCARDIAL INFARCTION UNDER FIBRINOLYTIC PO098-WED TWO PEPTIDE EPITOPES DERIVED FROM HUMAN AND MYCOBAC-
THERAPY OR PRIMARY PERCUTANEOUS CORONARY INTERVENTION TERIUM, RESPECTIVELY, REDUCE ATHEROSCLEROTIC LESION IN
Mehmet Sonmez* Safiye Tuba Kaplan (Turkey) B6;129S-LDLR(TM1HER)APOB(TM2SGY)/J MICE
Min Xia, Daxin Chen, Valeria Endresz, Ildiko Lantos, Andrea Szabo, Lakshmi Mundkur,
SUNDAY
PO089-WED rhADAMTS13 TREATMENT AMELIORATES CARDIAC LONG-TERM REMOD- Vijay Kakkar, Xinjie Lu* (United Kingdom)
ELING AFTER ISCHEMIA-REPERFUSION INJURY
Thilo Witsch*, Kimberly Martinod, Katlynn Gwilt, Denisa Wagner (United States) PO099-WED THE GUT MICROBIOTA IMPACTS PLASMATIC COAGULATION FACTORS
AND AUGMENTS ARTERIAL THROMBUS FORMATION.
PO090-WED RISK FACTORS FOR CORONARY ARTERY DISEASE IN YOUNG IRANIAN: Avinash Khandagale*, Eivor Wilms, Sven Jckel, Karl Lackner, Ulrich Walter, Christoph
RESULTS FROM THE MILANO-IRAN (MIRAN) STUDY Reinhardt (Germany)
Alberto Maino*, Seyed Hesameddin Abbasi, Saeed Sadeghian, Mohammadali Borou-
mand, Masoumeh Lotfi-Tokaldany, Frits Rosendaal, Flora Peyvandi (Italy) PO100-WED THE ROLE OF CLOTTING FACTOR IX IN THE DEVELOPMENT OF ATHERO-
SATURDAY
SCLEROSIS
PO091-WED BLOCKING HETEROMERIZATION OF PLATELET CHEMOKINES CCL5 AND Las De Paula*, Devanira Costa, Aline Urban, Joyce Annichino-Bizzacchi (Brazil)
CXCL4 REDUCES INFLAMMATION AND PRESERVES HEART FUNCTION
AFTER MYOCARDIAL INFARCTION PO101-WED PHOSPHORYLATION OF PLATELET ACETYL-COA CARBOXYLASE IS IN-
Rory Koenen, Isabella Werner, Tanja Vajen*, Delia Projahn, Mareike Staudt, Adelina CREASED IN HUMAN AND MICE ATHEROSCLEROSIS AND COULD BE AN
Curaj, Taha Snmez, Sakine Simsekyilmaz, Tilman Hackeng, Philipp von Hundelshau- INDICATOR OF PERSISTENT THROMBIN GENERATION.
sen, Christian Weber, Elisa Liehn (The Netherlands) Sophie Lepropre*, Shakeel Kautbally, Marie-Blanche Onselaer, David Vancraeynest,
Nicolas Barrile, Luc Bertrand, Jean-Louis Vanoverschelde, Christophe Beauloye, San-
drine Horman (Belgium)
320 321
PO102-WED DIFFERENTIAL EFFECTS OF LEPTIN SIGNALING IN ENDOTHELIAL OR PO112-WED EFFECT OF RECOMBINANT LUBRICIN ON COAGULATION PARAMETERS
THURSDSAY
SMOOTH MUSCLE CELLS ON NEOINTIMA FORMATION FOLLOWING IN HUMAN BLOOD
VASCULAR INJURY IN MICE Jawed Fareed*, Debra Hoppensteadt, Omer Iqbal, Schuharazad Abro, Patrick Swei-
Katrin Schfer, Astrid Hubert*, Magdalena Bochenek, Marco Schroeter, Thomas Mn- gert, Ed Truitt, Gregory Jay, William Hopkinson (United States)
zel (Germany)
PO113-WED CHARACTERISTICS OF COAGULATION DYNAMICS IN ACUTE PHASE OF
WEDNESDAY
PO103-WED BINDING OF COAGULATION FACTOR XIII TO ACTIVATED PLATELET SUB- KAWASAKI DISEASE
POPULATIONS Hiroyuki Yoshizawa*, Keiji Nogami, Tomoko Matsumoto, Tamaki Hayashi, Midori Shima
Yana Kotova*, Nadezhda Podoplelova, Alexandra Demyanova, Herve Chambost, Marie (Japan)
Christine Alessi, Mikhail Panteleev (Russian Federation)
WEDNESDAY
PO114-WED ABILITY OF THROMBOELASTOGRAPHY TO DISTINGUISH THE SEVERITY
PO104-WED EFFECT OF DABIGATRAN ETEXILATE AND WARFARIN ON ATHEROSCLE- OF PHENOTYPE IN PATIENTS WITH SEVERE HEMOPHILIA
ROTIC PLAQUE CALCIFICATION IN APOE-/- MICE. Maria Elisa Mancuso*, Veena Chantarangkul, Marigrazia Clerici, Maria Fasulo, Lidia
POSTERS
Leon J. Schurgers*, Rick van Gorp, Brecht Willems, Henri Spronk, Chris Reuteling- Padovan, Erica Scalambrino, Flora Peyvandi, Armando Tripodi, Elena Santagostino (Italy)
sperger (The Netherlands)
PO115-WED WHOLE BLOOD COAGULATION ANALYSES ARE DEPENDENT ON THE
PO105-WED HYPERGLYCAEMIC APOLIPOPROTEIN-E DEFICIENT MICE HAVE ACCEL- TEMPERATURE THEY ARE PERFORMED AT
ERATED ATHEROSCLEROSIS AND ABERRANT VASA VASORUM NEOVAS- Anni N. Jeppesen*, Hans Kirkegaard, Susanne Ilkjaer, Anne-Mette Hvas (Denmark)
CULARIZATION
TUESDAY
Heidi Stoute*, Daniel Venegas-Pino, Kaley Veerman, Peter Shi, Geoff Werstuck (Canada) PO116-WED CORRELATION OF PEAK THROMBIN CONCENTRATIONS WITH ONE-
STAGE ACTIVITY ASSAY LEVELS INDICATES THAT THROMBIN GENER-
ATION ASSAYS CORRELATE WITH FACTOR VIII ACTIVITY IN CLINICAL
Blood coagulation tests III HEMOPHILIA A PLASMA SAMPLES.
Sunita Patel-Hett*, Julie Lee, Swapnil Rakhe, Steven Arkin, Francois Huard, Debra
Pittman, John Murphy, Fei Hua (United States)
PO106-WED THE EFFECT OF HOMOCYSTEINE ON THE RESULTS OF THROMBODY-
NAMICS TEST PO117-WED HEPARIN INTERFERENCE IN ANTI-XA ASSAYS FOR RIVAROXABAN AND
Nadezda Vorobyeva*, Yulia Pavlovskaia (Russian Federation) APIXABAN
MONDAY
Gwyn A. Cutsforth*, Kathleen Finnegan (United States)
PO107-WED EVALUATION OF A NEW HOMOGENEOUS IMMUNOASSAY FOR QUANTIFI-
CATION OF PROTHROMBIN FRAGMENT 1+2 (F1+2) IN HUMAN PLASMA PO118-WED USE OF LYOPHILIZED PHOSPHOLIPID VESICLES IN THROMBODYNAM-
SAMPLES* ICS ASSAY
Matthias Ehm*, Doris Kraul, Achim Stangl, Martina Pfeiff, Lisa Feddersen, Verena Natalia Korotina*, Lubov Sokolova, Elena Ponomareva, Natalia Dashkevich, Fazoil
Smith, Christa Duwe, Uwe Kuhn, Olivia Pohlack-Marsch, Petra Vesper, Elfriede Bouc- Ataullakhanov (Russian Federation)
sein-Mueller, Norbert Zander (Germany)
PO119-WED DOES ANTITHROMBOTIC THERAPY INFLUENCE RESULTS OBTAINED BY
PO108-WED IDENTIFYING FACTOR DEFICIENCIES BY USING THE SECOND DERIVA- THROMBOELASTOMETRY?
SUNDAY
TIVE CURVE OF APTT ON AN ACL-TOP COAGULATION ANALYZER Mia Hammer Holck*, Thomas Decker Christensen, Anne-Mette Hvas (Denmark)
Tokunaga Naoki*, Inoue Chihiro, Sakata Toshiyuki, Kagawa Kumiko, Abe Masahiro,
Nakao Takayuki, Takamatsu Norimichi, Doi Toshio (Japan) PO120-WED SCREENING METHOD USING TWO DIFFERENT ACTIVATED PARTIAL
THROMBOPLASTIN TIME (APTT) REAGENTS FOR SPECIMENS WITH
PO109-WED A RARE COMBINATION: CONGENITAL FACTOR VII DEFICIENCY WITH PROLONGED APTT
CHIARI MALFORMATION Emi Takeo*, Etsuji Suehisa, Masayuki Toku, Tomio Kawasaki, You Hidaka (Japan)
Ali Bay, Elif Aktekin, Ibrahim Erkutlu (Turkey)
PO121-WED TROMBIN GENERATION; ESTABLISHMENT OF A REFERENCE INTERVAL
SATURDAY
PO110-WED CAN COMPARING THE VALUE OF THE PROTHROMBIN TIME RATIO AND AND THE EFFECT OF ASPIRIN
THE ACTIVATED PARTIAL THROMBOPLASTIN TIME RATIO HELP DIAG- Vivi Bo Mogensen*, Mai Therkelsen, Ss Nedergaard-Petersen, Ivy Modrau, Anne-Mette
NOSE THE CAUSE OF COAGULOPATHY? Hvas (Denmark)
Yingyong Chinthammitr*, Phasakorn Putchakarn (Thailand)
PO122-WED A NEW ASSAY FOR MEASUREMENT OF THE IN-VIVO THROMBIN AC-
PO111-WED THROMBIN GENERATION TEST FOR MONITORING OF CONVENTIONAL TIVITY IN COMPARISON TO THE IN-VITRO THROMBIN GENERATION
HAEMOPHILIA TREATMENT POTENTIAL IN PATIENTS WITH HYPER- AND HYPOCOAGULABLE STATE
Olga Smirnova*, Vera Kobilyanskaya, Vitaliy Soldatenkov, Vyacheslav Burakov, Ludmila Silvia M. Koder*, Oliver Koenigsbruegge, Julia Riedl, Simon Panzer, Ingrid Pabinger,
Papayan (Russian Federation) Cihan Ay (Austria)
322 323
PO123-WED INFLUENCE OF PRE-ANALYTICAL HEPARIN ON T-PA INDUCED FIBRINO- PO135-WED DETERMINATION OF INSUFFICIENT ANTICOAGULANT EFFECT IN PA-
THURSDSAY
LYSIS DETERMINED BY THROMBOELASTOGRAPHY DESPITE THE USE TIENTS WITH ATRIAL FIBRILLATION USING THROMBODYNAMICS ASSAY
OF DISCARD TUBES Nikolay N. Topalov*, Irina Zotova, Dmitriy Zateyshchikov, Fazoil Ataullakhanov, Ilya
Floor Moenen*, Inge Verheijen, Ron Straat, Rick Wetzels, Erik Beckers, Yvonne Hen- Serebriyskiy (Russian Federation)
skens (The Netherlands)
WEDNESDAY
PO136-WED NEW LIQUID RECOMBINANT THROMBOPLASTIN (DG PT RECOMBILIQ,
PO124-WED EFFECT OF FRESH FROZEN PLASMA IN CRITICALLY ILL PATIENTS DIAGNOSTIC GRIFOLS) SUITABLE FOR ROUTINE USE
Emil Vibede*, Christine Hvas, Else Toennesen, Anne-Mette Hvas (Denmark) Anita Woolley*, Stephen Kitchen (United Kingdom)
PO125-WED A DRVVT-BASED ASSAY TO ESTIMATE THE INTENSITY OF ANTICOAGULA- PO137-WED EVALUATION OF A NEW, HIGHLY SENSITIVE LOCI D-DIMER METHOD
WEDNESDAY
TION IN PATIENTS TREATED WITH NOACS FOR THE DETECTION OF VERY LOW CONCENTRATIONS IN HUMAN
Anne-Laure Sennesael*, Jonathan Douxfils, Tom Exner, Bernard Chatelain, Anne-So- CITRATED PLASMA*
phie Larock, Jean-Michel Dogn, Anne Spinewine, Franois Mullier (Belgium) Matthias Ehm*, Doris Kraul, Achim Stangl, Uwe Kuhn, Olivia Pohlack-Marsch, Petra
POSTERS
Vesper, Melanie Preis, Elfriede Boucsein-Mueller, Udo Krupka (Germany)
PO126-WED PRE-ANALYTICAL SAMPLE CHECK IN HAEMOSTASIS: EVALUATION OF
THE NEW COAGULOMETER ACL TOP 750 CTS SYSTEM PO138-WED SILICA CLOTTING TIME (SCT) VS DILUTE VENOM RUSSELL VIPER
Chiara Novelli*, Benedetto Morelli, Maria Gabriella Cozzi, Maria Luisa Duca, Elisa (DVRV) AND ACTIVATED PARTIAL THROMBOPLASTIN TIME (APTT) IN
Garghetti, Franca Rampinini (Italy) THE DIAGNOSIS OF ANTIPHOSPHOLIPID ANTIBODIES SYNDROME.
Evelyn Cortina de la Rosa*, Mara Nuez Toscano, Omar Coronel Ayala, Alejandra
TUESDAY
PO127-WED THROMBIN GENERATION IN PATIENTS UNDERGOING MAJOR ORTHO- Navarrete Villarruel, Raul Izaguirre vila (Mexico)
PAEDIC SURGERY
Luca Spiezia*, Francesco Vasques, Astrid Behr, Fabio Dalla Valle, Barry Woodhams, PO139-WED DISCORDANCE BETWEEN ACTIVATED PARTIAL THROMBOPLASTIN TIME
Sabrina Gavasso, Paolo Simioni (Italy) AND HEPARIN LEVEL MEASURED WITH ANTI-XA ASSAY IN ANTITHROM-
BIN-DEFICIENT PLASMA
PO128-WED EVALUATION OF THE AUTOMATED COAGULATION ANALYSER SYSMEX Alice Kun Yi*, Ivan Stevic, Jorell Gantioqui, Keith Lau, Robin Roberts, Anthony Chan,
CS-5100 (SIEMENS) Howard Chan (Canada)
Isabelle Martin Toutain*, Karim Maloum, Lionel Jobic, Tessy Mancic, Alexandre Bris-
sard, Annick Ankri (France) PO140-WED MULTICENTER STUDY OF TWO NEW COAGULATION ANALYZERS IN
MONDAY
COMPARISON TO A PREDICATE DEVICE ALREADY IN THE US-MARKET,
PO129-WED IMPACT OF ASSAY, PRODUCT, AND PATIENT VARIABILITY ON PRECISION USING SIEMENS HEALTHCARE REAGENTS
DOSING FOR FACTOR VIII PROPHYLAXIS Michael R. Weik*, Ingvild Birschmann, Charles Eby, Kemkes-Matthes Bettina, Stephen
Leonard A. Valentino*, Peter Turecek, Kenneth Mann (United States) Manzella, Ellinor Peerschke, Steven Pipe (Germany)
PO130-WED EVALUATION OF WAVEFORM ANALYSIS ON THE DESTINY MAX COAGULA- PO141-WED EVALUATION OF THE NEW QSMART FROM GRIFOLS IN COMPARISON TO
TION ANALYSER THE QHEMOSTASIS ANALYZER
Jane Needham*, Helen Lewis, Nina Harrison, Savita Rangarajan (United Kingdom) Anita Woolley*, Stephen Kitchen (United Kingdom)
SUNDAY
PO131-WED FOUR-FACTOR PROTHROMBIN COMPLEX CONCENTRATE SHOWS ANTI- PO142-WED HEMOCOMPATIBILITY OF ESTETROL AND ESTRADIOL COUPLED TO
COAGULANT EFFECT WHEN USED FOR IN VITRO EXPERIMENTS CYCLODEXTRINES
Emilie Sandgaard Pedersen*, Christine Lodberg Hvas, Signe Voigt Lauridsen, Anne- Julie Laloy*, Claudio Palazzo, Lutfiye Alpan, Jean-Michel Foidart, Graldine Piel,
Mette Hvas (Denmark) Jean-Michel Dogn (Belgium)
PO132-WED EVALUATION OF A NEW, INNOVATIVE, INTERMEDIATE THROUGHPUT PO143-WED EVALUATION OF PROLONGED PT / APTT TESTS IN PRESURGICAL PLAS-
COAGULATION ANALYSER MA SAMPLES
Philip J. Lane, Irfan Patel*, Ian Mackie, Sam Machin (United Kingdom)
SATURDAY
Zhre Kaya*, Turkiz Gursel (Turkey)
PO133-WED HAEMOPHILIA A CARRIER DETECTION IN SUDANESE FAMILIES: DNA PO144-WED VALIDATION OF NEW AUTOMATED LATEX-IMMUNOTURBIDIMETRIC
LINKAGE ANALYSIS APPROACHES ASSAY FOR MEASURING VWF ACTIVITY
Rayan Elsheikh, Maria Satti, Eltahir Khalil (Sudan) Vladimira Rimac, Sanela Simic Vojak, Desiree Coen Herak*, Renata Zadro (Croatia)
PO134-WED IMPACT OF SILVER NANOPARTICLES ON HEMOLYSIS, PLATELET FUNC- PO145-WED LABORATORY EVALUATION OF PATIENTS WITH UNDIAGNOSED BLEED-
TION, COMPLEMENT SYSTEM AND COAGULATION ING DISORDERS
Julie Laloy*, Valentine Minet, Lutfiye Alpan, Franois Mullier, Sonja Beken, Olivier Fernanda D. S. Bassora*, Graziela Alves, Susan Quaino, Silmara Montalvo, Erich de
Toussaint, Stphane Lucas, Jean-Michel Dogn (Belgium) Paula, Fernanda Orsi, Joyce Annichino-Bizzacchi (Brazil)
324 325
PO146-WED COMPARISON OF METHODS OF MEASUREMENT OF FACTOR VIII INHIBI- PO156-WED FRACTAL DIMENSION (DF) AS A MARKER OF HYPERCOAGULABILITY,
THURSDSAY
TORS IN A NEW HAEMOPHILIA CARE CENTER CLOT STRUCTURE AND 12 MONTH SURVIVAL IN LUNG CANCER
Mirta Arias, Emanuel Sueldo, Marcela Avalos, Patricia Do Nascimento*, Gabriela Nia Davies, Nicholas Harrison, Simon Noble*, Matthew Lawrence, Vanessa Evans,
Guerrero, Alejandra Baques (Argentina) Roger Morris, Karl Hawkins, Phylip Williams, Philip Evans (United Kingdom)
PO147-WED THE NORMAL RANGE OF THE THROMBODYNAMICS VALUES FOR AP- PO157-WED PREDICTION OF CANCER ASSOCIATED THROMBOSIS. PROSPECTIVE
WEDNESDAY
PARENTLY HEALTHY PREGNANT WOMEN BIOMARKER STUDY
Tatiana A. Vuimo*, Olga Baskova, Olga Gerasimova, Ruzanna Ovsepyan, Stepan Surov, Alfonso Tafur*, Aaron Mansfield, Mohammad Cherry, Philip Comp, Suman Rathbun,
Anastasya Mogilevets, Oleg Brusov, Ekaterina Voroshilina (Russian Federation) Julie Stoner (United States)
WEDNESDAY
PO148-WED FACTOR VIII INHIBITOR TESTING, INTERPRETATION AND STANDARDIZA- PO159-WED FACTOR V LEIDEN MUTATION AND HIGH FVIII ARE ASSOCIATED WITH
TION ITS COMPLICATED AN INCREASED RISK OF VTE IN WOMEN WITH BREAST CANCER
Thomas Siegemund*, Annelie Siegemund, Ute Scholz, Zaverio Ruggeri (Germany) DURING ADJUVANT TAMOXIFEN - RESULTS FROM A PROSPECTIVE,
POSTERS
SINGLE CENTER, CASE CONTROL STUDY
PO149-WED CAN THE OVERALL HAEMOSTATIC POTENTIAL ASSAY PREDICT BLEED- Mirjana Kovac*, Zeljko Kovac, Zorica Tomasevic, Slavko Vucicevic, Valentina Djordje-
ING AND THROMBOSIS RISK IN WARFARINISED PATIENTS? vic, Iva Pruner, Dragica Radojkovic (Serbia)
Caroline J. Reddel*, Kate Burbury, Ray Dauer, Sue Wilson, David Westerman, Bernhard
Riedel, Jennifer Curnow (Australia) PO161-WED INCREASING PLATELETS AND OTHER MEASURES ENHANCING HE-
MOSTASIS ARE BOTH IMPORTANT TO PREVENT BLEEDING EPISODES
TUESDAY
PO150-WED DETECTION OF HYPERCOAGULATION IN HIP ARTHROPLASTY PATIENTS. WHEN THROMBOCYTOPENIC PATIENTS REQUIRING ANTITHROMBOTIC
Leonid A. Parunov*, Irina Taranenko, Andrey Momot, Fazoil Ataullakhanov, Ilya Sere- THERAPY A REVIEW OF THE MEDICAL LITERATURE
briyskiy (Russian Federation)
Linda Chow*, Mohammed Almakadi, Keith Lau, Anthony Chan, Howard Chan (Canada)
PO151-WED HEPARIN AND PROTAMINE CONFOUND FACTOR ACTIVITY AND INHIBI- PO162-WED PANCREATIC CANCER PATIENTS EXPRESS ELEVATED FVIII LEVELS AND
TOR TESTING WHILE ON CARDIOPULMONARY BYPASS METASTASIS-ASSOCIATED FIBRIN TURNOVER PRIOR TO THEIR DIAGNO-
Michelle Sholzberg*, Chai Phua, Hubert Tsui, Hilde Vandenberghe, Georges Rivard,
SIS
Hina Chaudhry, Jerome Teitel (Canada)
Nora Varkila*, Caj Haglund, Hanna Seppnen, Riitta Lassila (Finland)
MONDAY
PO152-WED HEMOSTASIS ALTERATIONS ASSOCIATED TO COMPLICATIONS IN SICK-
PO163-WED VARIATIONS OF PLASMA LEVELS OF TFPI AND ACTIVATED FVII-ANTI-
LE CELL SYNDROME
THROMBIN COMPLEX IN CANCER PATIENTS: THE INCREASE OF TFPI AS
Diego Higuera*, Martha Bravo, Guerrero Belsy, Emelyn Salazar, Karin Perez (Venezuela,
Bolivarian Republic Of)
A MAJOR DETERMINANT OF THROMBIN GENERATION.
Patrick Van Dreden, Hlne Doubre, Dominique Franois, Mariette Adam, Matthieu
PO153-WED ACTIVATED PARTIAL THROMBOPLASTIN TIME (APTT) CLOT WAVEFORM Grusse, Marc Vasse* (France)
ANALYSIS (CWA) ON SYSMEX CS 2000 HELPS DIFFERENTIATE MILDER
PO164-WED PROTEIN C LEVELS ARE ASSOCIATED WITH MORTALITY IN PATIENTS
FROM SEVERE PHENOTYPE IN PATIENTS WITH SEVERE HEMOPHILIA A.
WITH ADVANCED CANCER
Sukesh C. Nair,* Ramya Vijay, Helen Margaret, Aby Abraham, Auro Vishwabandya,
SUNDAY
Abraham Sundarsingh, Kavitha ML, Arai Nobuo, Parag Tavkar, Kurono Hiroshi, Alok
Dorienke Wilts*, Barbara Hutten, Joost Meijers, C. Arnold Spek, Harry Bller, Pieter
Willem Kamphuisen (The Netherlands)
Srivastava (India)
PO154-WED BLOOD COAGULATION TESTS: REVIEW OF VALIDATION REQUIREMENTS PO165-WED L-ASPARAGINASE LOWERS PLASMA ANTITHROMBIN AND MAN-
FOR FDA CLEARANCE NAN-BINDING-LECTIN LEVELS: IMPACT ON THROMBOTIC AND INFEC-
Iwona Fijalkowska*, Claudia Dollins (United States)
TIOUS EVENTS IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA
Clmence Merlen, Arnaud Bonnefoy*, Eric Wagner, Anik Cormier, Laurence Dedeken,
Jean-Marie Leclerc, Caroline Laverdire, Georges-Etienne Rivard (Canada)
SATURDAY
Cancer and thrombosis/hemostasis III

PO166-WED LONGITUDINAL ANALYSIS OF HEMOSTATIC BIOMARKERS IN CANCER
PATIENTS DURING ANTI-TUMOR TREATMENT
PO155-WED SP-SELECTIN AS A MARKER OF PLATELET ACTIVATION IN AFRICANS Ingrid Pabinger, Alexandra Kaider, Cihan Ay, Christoph Zielinski, Peter Quehenberger,
WITH PROSTATE CANCER. Christine Marosi, Eva-Maria Reitter* (Austria)
Hannah Omunakwe*, Onyeanunam Ekeke, Christopher Obiorah, Oseikhuemen Ejele
(Nigeria) PO167-WED MICROVESICLES ARE A POTENTIAL BIOMARKER FOR THROMBOSIS
AND DIC IN LEUKEMIC PATIENTS: A CROSS-SECTIONAL STUDY
Damien Gheldof*, Jean-Michel Dogn, Carlos Graux, Fabienne George, Anne Sonet,
Bernard Chatelain, Franois Mullier, Christian Chatelain (Belgium)
326 327
PO168-WED GENETIC VARIANTS IN 3-UTRS OF METHYLENETETRAHYDROFOLATE PO178-WED INCREASED ACTIVATED PROTEIN C RESISTANCE AND D-DIMER IN
THURSDSAY
REDUCTASE (MTHFR) PREDICT COLORECTAL CANCER SUSCEPTIBILITY BREAST CANCER: PHENOTYPIC AND GENOTYPIC DETERMINANTS AND
IN KOREANS ASSOCIATION WITH TUMOR CHARACTERISTICS
Jung O Kim*, Hyo Geun Jang, Gun Ho Choi, Ki Han Ko, Hui Jeong An, Young Joo Jeon, Mari Tinholt*, Hans Kristian Vollan, ystein Garred, Marie-Christine Mowinckel,
Doyeun Oh, Hwi Joong Yoon, Nam Keun Kim (Korea, Republic Of) Kristine Sahlberg, Marit Sletten, Anne-Lise Brresen-Dale, Vessela Kristensen, Rolf
WEDNESDAY
Kresen, Ellen Schlichting, Grethe Skretting, Per Sandset, Nina Iversen (Norway)
PO169-WED SIGNIFICANCE OF HAEMOSTATIC PARAMETERS IN PATIENTS WITH
URINARY CANCER PO179-WED THROMBIN GENERATION (TG) IS DOWNREGULATED BY LOW MOLEC-
Aristeidis Alevizopoulos, Paraskevi Kotsi*, Joanna Anastasopoulou, Sofia Gkotsi, Maria ULAR WEIGHT HEPARIN (LMWH) IN CANCER PATIENTS WITH VENOUS
Gavalaki, Olga Katsarou (Greece) THROMBOEMBOLISM (VTE)
WEDNESDAY
Anna Falanga*, Carmen Tartari, Marina Marchetti, Laura Russo, Kim Lambregts,
PO170-WED EVALUATION OF THROMBOELASTOMETRY PARAMETERS AS PREDICTIVE Davide Resta, Andrea DAlessio (Italy)
MARKERS FOR SINUSOIDAL OBSTRUCTION SYNDROME IN PATIENTS
PO180-WED HYPERCOAGULABILITY: AN ADDED SIDE EFFECT FOR ANDROGEN
POSTERS
UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE
LEUKEMIA DEPRIVATION THERAPY IN PROSTATE CANCER PATIENTS
Joanna Rupa-Matysek*, Lidia Gil, Ewelina Wojtasiska, Zuzanna Kandua, Mieczysaw Harmanpreet Kaur*, Spencer Barr, Angela Black, Sylvia Robb, Robert Siemens, Maha
Komarnicki (Poland) Othman (Canada)
PO171-WED CANCER INDUCING NETOSIS PROMOTES WIDESPREAD ARTERIAL
TUESDAY
THROMBOSIS PRESENTING AS ISCHEMIC STROKE WITH TROPONIN Coagulation factor V, X, II, XIII - III
ELEVATION
Charlotte Thlin*, Melanie Demers, Bo Blomgren, Ann Charlotte Laska, Magnus von
PO181-WED IDENTIFICATION OF TWO NOVEL MISSENSE MUTATIONS CAUSING
Arbin, Hkan Walln, Denisa Wagner, Sara Aspberg (Sweden)
SEVERE FACTOR XIII DEFICIENCY
PO172-WED RELEVANCE OF D-DIMER AND IL-6 LEVELS AMONG PATIENTS WITH Munira Borhany*, Helena Handrkova, Verena Schroeder Schroeder, Naveena Fatima,
CANCER AND INCIDENTAL PULMONARY EMBOLISM Asif Hussain, Tahir Shamsi, Hans Peter Kohler (Pakistan)
Casey Oconnell*, Diana Hanna, Denice Tsao-Wei, Scott Tagawa, Caroline Piatek, David
PO182-WED FIRST GROUNDING FOR COMPLETE STRUCTURAL CHARACTERIZATION
Quinn, Ilene Weitz, Howard Liebman (United States)
MONDAY
OF FXIII HETEROTETRAMER: SUCCESSFUL DISULFIDES!
PO173-WED DIAGNOSTIC APPROACH TO RARE LOCALISATION TROMBOSIS IN CAN- Sneha Gupta*, Christoph Reinhart, Christoph Krettler, Mohammad Akhter, Vytautus
CER PATIENTS Ivaskevicius, Hartmut Micheal, Johannes Oldenburg, Arijit Biswas (Germany)
Alexander Vorobev, Alexander Makatsaria* (Russian Federation)
PO183-WED REVISITING THE MECHANISM OF COAGULATION FACTOR XIII ACTIVA-
PO174-WED CLINICAL SIGNIFICANCE OF CIRCULATING TISSUE FACTOR (TF) IN TION IN PLASMA
WOMEN WITH SUSPECTED OVARIAN CANCER Sneha Gupta*, Christoph Reinhart, Christoph Krettler, Mohhamad Akhter, Johannes
Dodt, Hartmut Micheal, Johannes Oldenburg, Arijit Biswas (Germany)
Carlota Claussen, Alma Rausch, Brigitte Spath, Susanne Lezius, Ali Amirkhosravi,
Monica Davila, John Francis, Carsten Bokemeyer, Fritz Jnicke, Sven Mahner, Florian
SUNDAY
PO184-WED MUTATING CORE STRUCTURAL DISULFIDES OF THE FXIII B SUBUNIT
Langer* (Germany)
AS A MEANS TO UNCOVER THE FUNCTIONAL ROLES OF INDIVIDUAL
PO175-WED RIVAROXABAN IN PATIENTS WITH VTE AND CANCER: A SINGLE CENTER FXIIIB SUBUNIT SUSHI DOMAINS
EXPERIENCE Mohammad S. Akhter*, Sneha Gupta, Hamideh Yadegari, Vytautus Ivaskevicius,
Samantha Pasca, Ugo Venturelli, Giovanni Barillari* (Italy) Johannes Dodt, Johannes Oldenburg, Arijit Biswas (Germany)
PO176-WED D-DIMER PLASMA LEVELS AS A MARKER OF PULMONARY EMBOLISM PO185-WED THE ACTIVATION PEPTIDE OF COAGULATION FACTOR XIII IS VITAL FOR
IN PATIENTS UNDERGOING SURGERY FOR TUMORS OF THE CENTRAL ITS EXPRESSION AND STABILITY
SATURDAY
NERVOUS SYSTEM Helena Handrkova, Verena Schroeder*, Hans Kohler (Switzerland)

Andrea Artoni*, Paolo Bucciarelli, Serena Passamonti, Giorgio Carrabba, Valeria Conte,
PO186-WED THE B-SUBUNIT OF COAGULATION FACTOR XIII DOES NOT SPECIFICAL-
Massimo Castellani, Erica Scalambrino, Ida Martinelli (Italy)
LY INTERACT WITH COMPLEMENT FACTORS
PO177-WED TISSUE FACTOR PATHWAY INHIBITOR (TFPI) IS A MARKER OF TUMOR Lorenz Jenny, Zhuoer Lin, Daniel Ricklin, Hans Kohler, Verena Schroeder* (Switzer-
PROGRESSION AND PROGNOSIS IN BREAST CANCER land)
Mari Tinholt*, Hans Kristian Vollan, Kristine Sahlberg, Rolf Kresen, Torill Sauer,
Vessela Kristensen, Anne-Lise Brresen-Dale, Per Sandset, Nina Iversen (Norway)
328 329
PO187-WED THE EFFECT OF FACTOR XIII B SUBUNIT POLYMORPHISMS ON FAC- PO197-WED WHOLE-EXOME SEQUENCING APPROACH TO STUDY INHIBITOR DEVEL-
THURSDSAY
TOR XIII LEVELS AND ON THE RISK OF CORONARY ARTERY DISEASE; OPMENT IN ITALIAN SEVERE HEMOPHILIA A PATIENTS.
INTERACTION WITH FIBRINOGEN LEVEL AND FACTOR XIII A SUBUNIT Marcin M. Gorski*, Kevin Blighe, Isabella Garagiola, Sabrina Seregni, Maria Elisa
P.VAL34LEU POLYMORPHISM Mancuso, Elena Santagostino, Luca A. Lotta, Flora Peyvandi (Italy)
Lszl Muszbek*, Zoltn Mezei, Zsuzsanna Bereczky, va Katona, Rka Gindele, Szil-
PO198-WED MINIGENE APPROACH TO CHARACTERIZE A NOVEL SPLICE SITE MUTA-
WEDNESDAY
via Fiatal, Lszl Balogh, Istvn Czuriga, Rza dny, Istvn des (Hungary)
TION IN HUMAN F8 GENE CAUSING SEVERE HAEMOPHILIA A
PO188-WED FXIII-A V34L AFFECTS THROMBUS CROSS-LINKING, BUT NOT SIZE, IN Yohann Jourdy, Christophe Nougier*, Dominique Bozon, Mathilde Fretigny, Claude
A MURINE THROMBOSIS MODEL Ngrier, Christine Vinciguerra (France)

WEDNESDAY
Cedric Duval*, Majid Ali, Waleed Chaudhry, Victoria Ridger, Helen Philippou, Robert
Ariens (United Kingdom) PO199-WED CLEARANCE RECEPTOR INTERACTION AND HALF-LIFE PROLONGATION
OF PEGYLATED RECOMBINANT FULL-LENGTH FACTOR VIII IN MICE
PO189-WED PLATELET FACTOR XIII-A TRANSLOCATES FROM THE ACTIVATED PLATE- Gerald Schrenk, Alexandra Schiviz, Sabine Knappe, Alexander Bauer, Herbert Gritsch,
POSTERS
LET SURFACE ONTO ADJACENT FIBRIN FIBRES Manfred Billwein, Schaedler Michaela, Peter Turecek, Michael Dockal*, Marietta Putz,
Joanne L. Mitchell*, Nicola Mutch (United Kingdom) Werner Hoellriegl, Friedrich Scheiflinger (Austria)
PO190-WED RESIDENT TISSUE MACROPHAGES ARE THE PROBABLE SOURCE OF PO200-WED SAFETY OF PEG, PEG CONJUGATES AND PEGYLATED RECOMBINANT
PLASMA CLOTTING FACTOR XIII-A HUMAN FULL-LENGTH COAGULATION FACTOR VIII (BAX 855)
Kingsley R. Simpson*, Cora Beckers, Kathryn Griffin, Jane Brown, Paul Cordell, Kerrie Reinhard Stidl, Sabine Fuchs, Mary Bossard, Juergen Siekmann, Marietta Putz*, Peter
TUESDAY
Smith, Esther Cooke, Mark Kearney, Jean Vacher, Warren Alexander, Richard Pease, Turecek (Austria)
Peter Grant (United Kingdom)
PO201-WED FUNCTIONAL CHARACTERIZATION OF DIFFERENT FACTOR VIII MOLE-
CULES WITH FOCUS ON PHOSPHOLIPID AND PLATELET BINDING
Coagulation factor VIII and IX - III Susanne Till, Sylvia Tippl, Michael Palige, Ernst Boehm, Gerald Schrenk, Jadranka
Koehn, Herbert Gritsch, Sabine Knappe, Rudolf Hartmann, Friedrich Scheiflinger,
Michael Dockal* (Austria)
PO191-WED EFFECT OF STABLE GABARAP KNOCKOUT ON THE FVIII SECRETION
Heike Singer*, Behnaz Pezeshkpoor, Nicole Nuesgen, Ursula Schreck, Judith Junen, PO202-WED MOLECULAR SIGNATURE OF LSECS: A F8 SECRETING ENDOTHELIAL
MONDAY
Johannes Oldenburg, Osman El-Maarri (Germany) CELLS
Osman El-Maarri*, Ahmer Jamil, Nicole Nuesgen, Amit Sharma, Behnaz Pezeshkpoor,
PO192-WED DIMERIC ORGANIZATION OF MEMBRANE-BOUND FACTOR VIII ON LIPID Andrea Hofmann, Per Hoffmann, Stefanie Heilmann, Markus Noethen, Holger Froeh-
NANOTUBES lich, Johannes Oldenburg (Germany)
Svetla Stoilova-Mcphie*, Daniela Dalm, Jesus Galaz-Montoya, Kirill Grushin, Jaimy
Miller (United States) PO203-WED ANCESTRAL RECONSTRUCTION OF COAGULATION FACTOR VIII
Philip M. Zakas*, Kristopher Knight, H. Trent Spencer, Eric Gaucher, Christopher
PO193-WED IMPACT OF INHIBITORS TO EPITOPES OF FACTOR VIII ON THROMBIN Doering (United States)
GENERATION
SUNDAY
Amina Rafique*, Candace Enockson, Mindy Simpson (United States) PO204-WED A SYNONYMOUS MUTATION IN THE F8 GENE, C.120C>A; P.(L40=), MAY
CAUSE MILD HEMOPHILIA A
PO194-WED MOLAR SPECIFIC ACTIVITY OF FACTOR VIII CONCENTRATES Hiroshi Inaba*, Keiko Shinozawa, Kagehiro Amano, Katsuyuki Fukutake (Japan)
Carsten Horn, Stephanie Steede, Stefan Schmidbauer, Hubert J. Metzner* (Germany)
PO205-WED LONG-TERM PHENOTYPIC CORRECTION OF HEMOPHILIA A MICE BY
PO195-WED HIGH-PURITY, PLASMA-DERIVED, PASTEURISED FACTOR VIII CON- NON-VIRAL PIGGYBAC TRANSPOSON VECTOR
CENTRATE IN THE TREATMENT OF PATIENTS WITH HAEMOPHILIA A: Hideto Matsui*, Masahi Noda, Midori Shima, Akitsu Hotta, Mitsuhiko Sugimoto (Japan)
UPDATE OF A LONG-TERM OBSERVATIONAL STUDY
SATURDAY
Robert Klamroth*, Claudia Niekrens, Susanne Holzhauer, Ronald Fischer, Christine PO206-WED DISCORDANT IN VITRO AND IN VIVO ACTIVITY OF FACTOR VIII MUTANTS
Heller, Patrick Sommerer, Karin Kurnik (Germany) mine Bazaa*, Vincent Muczynski, Ccile loubire, Amlie Harel, Tom Knudsen, Olivi-
A
er D. Christophe, Ccile V. Denis, Peter J. Lenting (France)
PO196-WED EXPRESSION, PURIFICATION AND CHARACTERIZATION OF CODON OPTI-
MIZED COAGULATION FACTOR VIII PO207-WED BENEFICIAL EFFECT OF VWF IN FVIII RECOVERY OF DIFFERENT FVIII
Svetlana Shestopal, James Kurasawa, Elena Karnaukhova, John McVey, Timothy Lee, CONCENTRATES IN A MOUSE MODEL OF SEVERE HEMOPHILIA WITH
Andrey G. Sarafanov* (United States) HIGH INHIBITOR TITERS
Maria Isabel Bravo*, Montserrat Costa, Salvador Grancha, Juan Ignacio Jorquera
(Spain)
330 331
PO208-WED VARIATION IN FACTOR VIII MEASUREMENT AND CLASSIFICATION OF PO218-WED QUANTITATION OF MISFOLDED PROTEINS AND QUANTITATION AND
THURSDSAY
HAEMOPHILIA A SEVERITY IN THE ECAT EXTERNAL QUALITY ASSESS- VISUALISATION OF NANOSIZE PROTEIN AGGREGATES IN RFVIII AND
MENT PROGRAMME PDVIII CONCENTRATES
Iris van Moort*, Piet Meijer, Bert Verbruggen, Marjon H. Cnossen, Moniek P.M. de Maat Martin Brodde*, Martin Wiemann, Mayken Visser, Lisa Smits, Anja Mller, Beate
(The Netherlands) Kehrel (Germany)
WEDNESDAY
PO209-WED PRO-HEMOSTATIC ACTIVITY OF TFPI INHIBITION IN HEMOPHILIA IS PO219-WED HEPAROSAN GLYCO-CONJUGATES OF FVIII AND FIX SHOWS PRO-
WELL REGULATED BY TISSUE FACTOR AND FACTOR VIII LONGED CIRCULATING HALF-LIFE IN HAEMOPHILIA MOUSE MODELS
Rudolf Hartmann, Erwin Panholzer, Willibald Kammlander, Friedrich Scheiflinger, Carsten Behrens, Jens Buchardt, Mie Broberg, Ditte Karpf, Mette Loftager, Mette Jen-
WEDNESDAY
Michael Dockal* (Austria) sen, Heidi Bagger, Matthas Thrlfsson, Maria Dainiak, Johan Karlsson, Ernst Hansen,
Janus Krarup, Henrik Rahbek-Nielsen, Marianne Kjalke, Paul DeAngelis, F. Michael
PO210-WED RARE ALTERNATE PRESENTATIONS OF THE F8 INTRON 22 INVERSION Haller, Jesper Haaning* (Denmark)
MUTATION COMPLICATE DETECTION AND MAY LEAD TO MISDIAGNOSIS.
PO220-WED SUPPRESSION OF INHIBITOR FORMATION IN HEMOPHILIA BY LAP+
POSTERS
Jacky Cutler*, Gillian McGaffin, Anne White, Mike Mitchell (United Kingdom)
TREG INDUCED BY PLANT-BASED ORAL TOLERANCE
PO211-WED CHARACTERIZATION OF IGA TYPE FVIII INHIBITOR IN AN ADULT PA- Xiaomei Wang*, Jin Su, Alexandra Sherman, Henry Daniell, Roland Herzog (United
TIENT WITH CONGENITAL MODERATE HEMOPHILIA A SHOWING ABNOR- States)
MALLY LARGE SUBCUTANEOUS HEMATOMA SIMILAR TO BLEEDING IN
PATIENTS WITH ACQUIRED HEMOPHILIA PO221-WED LOW-DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN 1 EXPRES-
TUESDAY
Atsuki Yamashita*, Chiai Nagae, Mika Mori, Tomoko Ashikaga, Mieko Akita, Noriko
SION IN LIVER IS ASSOCIATED WITH PLASMA FACTOR VIII LEVELS
Suzuki, Satoshi Yamazaki, Shigenobu Takayama, Masashi Taki (Japan) Luis F. Bittar*, Adriana Duarte, Erich De Paula, Joyce Annichino-Bizzacchi (Brazil)
PO212-WED RECOMBINANT FACTOR VIII INCREASES HEMOPHILIA A CLOT PO222-WED THE IMMUNOGENICITY OF PLATELETS CONTAINING FVIII IN HEMO-
STRENGTH THROUGH ALTERATIONS IN CLOT STRUCTURE AND COMPO- PHILIA A MICE WITH OR WITHOUT PRE-EXISTING ANTI-FVIII IMMUNITY
SITION Yingyu Chen, Jocelyn Schroeder, Xiaofeng Luo, Juan Chen, Christina Baumgartner,
Robert Montgomery, Jianda Hu, Qizhen Shi* (United States)
Lilley Leong*, Irina Chernysh, Yifan Xu, Derek Sim, Chandrasekaran Nagaswami, Zelda
de Lange, Sofia Kosolapova, Adam Cuker, Katalin Kauser, John Weisel (United States)
PO223-WED ELEVATED FACTOR VIII LEVELS AND ALL-CAUSE MORTALITY: RESULTS
MONDAY
PO213-WED ADDING MULTIPLE POLYETHYLENE GLYCOL (PEG) MOIETIES FURTHER FROM THE MEGA FOLLOW-UP STUDY
REDUCES PEG-FACTOR VIII CONJUGATE (PEG-FVIII) CLEARANCE BY HE- Eng Soo Yap*, Jasmijn Timp, Linda Flinterman, Astrid van Hylckama Vlieg, Frits
Rosendaal, Suzanne Cannegieter, Willem Lijfering (Singapore)
PATOCYTES IN VITRO, BUT MINIMALLY IMPACTS PEG-FVIII CLEARANCE
OR HALF-LIFE IN VIVO. PO224-WED NOVEL MUTATIONS ASSOCIATED WITH A DISCREPANCY BETWEEN ONE-
Eric Blasko*, Elena Ho, James Wu, Derek Sim, Liang Tang, Lilley Leong, Katalin Kaus-
STAGE AND CHROMOGENIC FVIII ACTIVITY ASSAY
er, Babu Subramanyam (United States)
Dana Provaznikova*, Katerina Houskova, Alena Radovska, Ingrid Hrachovinova (Czech
Republic)
PO214-WED DISTRIBUTION OF 14C-LABELED PEG (60 KDA) IN RATS
SUNDAY
Andreas Baumann*, Thomas Schwarz, Dietrich Seidel, Wolfram Steinke, Klaus Bueh-
PO225-WED HEMOPHILIA A CAUSED BY RETROTRANSPOSITION OF LONG INTER-
ner (Germany)
SPERSED ELEMENT-1 (LINE-1) INTO THE FVIII GENE
PO215-WED SINGLE CENTER EXPERIENCE EVALUATING ACTIVITY OF N8-GP WITH Rima Dardik*, Ariella Zivelin, Yariv Fruchtman, Tami Livnat, Einat Avishai, Shirley
Azar-Avivi, Gili Kenet, Nurit Rosenberg (Israel)
ONE-STAGE CLOTTING ASSAY
Brigitte Cornelia Brand-Staufer*, Karin Koch, Stefan Balabanov, Wan Hui Ong Clausen,
PO226-WED COMPLEMENT MODULATES THE IMMUNE RESPONSE AGAINST THERA-
Mirella Ezban (Switzerland)
PEUTIC FACTOR VIII IN HEMOPHILIA A
PO216-WED INTERNATIONAL STUDY TO ASSESS THE PERFORMANCE OF IMMUNO- Julie Rays, Mathieu Ing*, Ivan Peyron, Jordan Dimitrov, Sandrine Delignat, David
SATURDAY
Fritzinger, Carl-Wilhelm Vogel, Vronique Fremeaux-Bacchi, Srinivas Kaveri, Lubka

DEPLETED PLASMAS FOR DETERMINATION OF FACTORS VIII AND IX
Roumenina, Sbastien Lacroix-Desmazes (France)
ACTIVITY
Chris Watson, Siegmund Gehrisch, Stefan Tiefenbacher, Alberto Tosetto*, Maria Di PO227-WED SURFACE BOUND VON WILLEBRAND FACTOR MODULATES FACTOR VIII
Paolo, Dorothy Adcock (United Kingdom)
PEPTIDE PRESENTATION BY DENDRITIC CELLS
PO217-WED GENETIC DETERMINANTS FOR FACTOR VIII LEVELS: GENOME-WIDE Robin B. Hartholt*, Nicoletta Sorvillo, Magdalena Sedek, Anja ten Brinke, Carmen van
der Zwaan, Floris van Alphen, Alexander Meijer, Jan Voorberg (The Netherlands)
LINKAGE AND ASSOCIATION ANALYSES FROM THE GAIT PROJECT
Sonia Lpez*, Andrey Ziyatdinov, Noelia Vilalta, Jordi Fontcuberta, Juan Carlos Souto,
Jose Manuel Soria (Spain)
332 333
PO228-WED ROLE OF MEMBRANE-INTERACTING RESIDUES WITHIN FACTOR VIII C2 PO237-WED RELATIONSHIP BETWEEN OXIDATIVE STRESS AND BLOOD COAGULA-
THURSDSAY
DOMAIN IN IMMUNOGENICITY OF THERAPEUTIC FACTOR VIII. TION IN PAEDIATRIC CHRONIC KIDNEY DISEASE (CKD)
Bagirath Gangadharan*, Mathieu Ing, Sandrine Delignaut, Ivan Peyron, Olivier Christo- Luci M. S. Dusse*, Leticia Sousa, Rivia Silva, Maria Carvalho, Rita Duarte, Cristina
phe, Srinivas Kaveri, Sebastien Lacroix-Desmazes (France) Loures, Marcos Silva, Rejane Diniz, Sergio Pinheiro, Ana Silva (Brazil)
PO229-WED FVIII ACTIVITY ASSAY VARIABILITY OF THE PEGLYLATED FORM OF RFVIII PO238-WED INFLUENCE OF OXIDATIVE STRESS ONTO FIBRIN NET FORMATION,
WEDNESDAY
ADVATE (BAX 855) IN CLINICAL HEMOSTASIS LABORATORIES: INTERIM ARCHITECTURE AND LYSIS
RESULTS FROM A WORLD-WIDE FIELD STUDY. Jana Stikarova*, Roman Kotlin, Jiri Suttnar, Tomas Riedel, Pavel Sacha, Pavel Majek,
Peter L. Turecek*, Herbert Gritsch, Claudia Apostol, Stefan Romeder-Finger, Alexander Leona Chrastinova, Alzbeta Hlavackova, Jan Dyr (Czech Republic)
Bauer, Divan Burger, Andrea Hunt (Austria)
WEDNESDAY
PO239-WED CD44 LOCATED IN THE SURFACE OF SICKLE RED BLOOD CELL (SRBC)
PO230-WED SIGNIFICANCE OF ENDOGENOUS VON WILLEBRAND FACTOR IN DEVEL- CORRELATES WITH REDUCED BLOOD HBF LEVELS AND INCREASED
OPMENT OF FACTOR VIII IMMUNE RESPONSES IN SEVERE EXPERIMEN- SRBC ADHESION TO FIBRIN
POSTERS
TAL HEMOPHILIA A Luciana W. Serro*, Maria Clara Silva, Andrea Soares, Daniela Beghini, Russolina
Bagirath Gangadharan*, Mathieu Ing, Sandrine Delignaut, Olivier Christophe, Srinivas Zingali (Brazil)
Kaveri, Sebastien Lacroix-Desmazes (France)
PO240-WED FREE FATTY ACIDS MODULATE THROMBIN ACTIVITY ON FIBRINOGEN
PO231-WED COMPARISON OF METHODS FOR THE DOSAGE OF FVIII IN A NEW HAE- AND DESTABILISE FIBRIN CLOTS
MOPHILIA CENTER CARE Anna Tanka-Salamon*, Erzsbet Komorowicz, Lszl Szab, Raymund Machovich,
TUESDAY
Emanuel Sueldo, Mirta Arias, Beatriz Erramouspe, Rodrigo Porsella, Patricia Do Nasci- Kraszimir Kolev (Hungary)
mento, Gabriela Guerrero, Alejandra Baques* (Argentina)
PO241-WED TEMPORAL EVOLUTION OF FIBRIN NANOSTRUCTURE DURING CLOT-
PO232-WED CRITICAL QUALITY ATTRIBUTES OF RECOMBINANT FVIII PRODUCTS TING AND FIBRINOLYSIS
PROTEIN AGGREGATES AND SUBVISIBLE PARTICLES Carhel Dassi*, Emmanuelle Bigo, Landry Seyve, Raphal Marlu, Benot Polack,
Mantas Malisauskas*, Christian Lubich, Thomas Prenninger, Peter Matthiessen, Peter Franois Caton, Genevive Contant (France)
Turecek, Friedrich Scheiflinger, Birgit Reipert (Austria)
PO242-WED FIBRINOGEN LEVELS DURING THE LAST STAGE OF PREGNANCY IN
PO233-WED FVIII OS/CS RATIOS FOR SELECT NOVEL RECOMBINANT FVIII REPLACE- MEXICAN WOMEN
MONDAY
MENT PRODUCTS MEASURED IN FOUR FDA APPROVED FVIII ONE- Jesus Hernandez*, Hugo Espejo, Nidia Espinoza, Manuel Moreno, Jose Alvarado, Maria
STAGE CLOT ASSAY SYSTEMS AND ONE CHROMOGENIC ASSAY Gomez, Abraham Majluf (Mexico)
Stefan Tiefenbacher*, Mary Robinson, Erika Ross, Patrick Williams, Caroline Cogswell,
Tyrelle Wham, Geoff Chow, Dorothy Adcock (United States) PO243-WED UNDERSTANDING FIBRIN PROTOFIBRILS AT THE MOLECULAR LEVEL:
FORMATION AND FLEXIBILITY THROUGH A NEW COARSE-GRAINED
PO234-WED PLASMA DERIVED FVIII (PDFVIII) CONCENTRATES ENHANCE SYNOVIAL PROTEIN MODELLING APPROACH
CELL PROLIFERATION AND MIGRATION BY BINDING OF MISFOLDED Albert Solernou*, Sarah Harris, Oliver Harlen, Daniel Read, Kerrie Smith, Stephen
PROTEINS TO ADAM15 Muench (United Kingdom)
Martin Brodde*, Martin Wiemann, Robert Klamroth, Mayken Visser, Lisa Smits, Beate
SUNDAY
Kehrel (Germany) PO244-WED IMPACT OF MATERNAL D-DIMER LEVELS IN NEWBORN OF PREECLAMP-
TIC MOTHERS
PO235-WED ARE DIFFERENT PLASMA DERIVED FVIII CONCENTRATES EQUALLY Melina Pinheiro, Sandra Armond, Maria das Graas Carvalho, Lara Godoi, Patrcia
EFFICIENT IN TERTIARY PROPHYLAXIS? Alpoim, Karina Borges, Luci Dusse* (Brazil)
Jelena Bodrozic*, Ivo Elezovic, Darko Antic, Predrag Miljic (Serbia)
PO245-WED
IBRIN CLOT STRUCTURE IS AFFECTED BY LEVELS OF PARTICULATE
F
AIR POLLUTION EXPOSURE IN PATIENTS WITH VENOUS THROMBOSIS
Fibrinogen/fibrin/D-dimer III
Xiaoxi Pan*, Yunyun Gong, Ida Martinelli, Pier Mannucci, Michael Routledge, Robert
SATURDAY
Arins (United Kingdom)
PO236-WED CHANGES OF COAGULATION PARAMETERS DURING HIGH ALTITUDE PO246-WED INCREASED PLASMA CLOT PERMEABILITY AND SUSCEPTIBILITY TO
EXPEDITION. LYSIS ARE ASSOCIATED WITH HEAVY MENSTRUAL BLEEDING OF UN-
Susana Der Parsehian*, Miriam Pereiro, Alvaro Ortiz Nareto, Sebastian Donato, Cristina KNOWN CAUSE
Artana (Argentina) Piotr Szczepaniak, Micha Zabczyk, Anetta Undas* (Poland)
334 335
PO247-WED SEVERE THROMBOSIS IN PREGNANCY IN PATIENT WITH CONGENITAL PO255-WED LOW ANNUALIZED BLEEDING RATES (ABRS) WITH RECOMBINANT
THURSDSAY
DYSFIBRINOGENEMIA FACTOR VIII FC FUSION PROTEIN (RFVIIIFC) ACROSS DEMOGRAPHIC
Vera Geierova*, Ingrid Hrachovinova, Roman Kotlin, Peter Salaj (Czech Republic) SUBGROUPS OF PREVIOUSLY TREATED PEDIATRIC SUBJECTS WITH
SEVERE HEMOPHILIA A
Guy Young*, Roshni Kulkarni, Margaret Ragni, Simon Brown, Irena Wozni-
WEDNESDAY
Hemophilia clinical III ca-Karczmarz, John Puetz, Rienk Tamminga, Giulia Gambino, Glenn Pierce, Geoffrey
Allen (United States)

PO248-WED ARTERIOVENOUS FISTULAS FOR REPLACEMENT THERAPY IN ADULTS PO256-WED CHILDREN WITH HEMOPHILIA IN THE US THE HEMOPHILIA ASSOCI-
WITH HEMOPHILIA ATED CAREGIVER BURDEN SCALE (HEMOCABTM)
WEDNESDAY
Jerry Teitel*, Michelle Sholzberg, Vernon Campbell, Rachel He, Georgina Floros (Cana- Sylvia von Mackensen*, Tami Wisniewski, John Urgo, Lisa Boggio (Germany)
da)
PO257-WED DEVELOPING A MEASURE OF HEMOPHILIA CAREGIVER IMPACT
PO249-WED A PHASE III, OPEN-LABEL, MULTICENTRE STUDY TO EVALUATE EFFICA-
POSTERS
Carolyn Schwartz*, Adi Eldar-Lissai (United States)
CY AND SAFETY OF A PLASMA-DERIVED VON WILLEBRAND FACTOR/FAC-
TOR VIII CONCENTRATE IN PEDIATRIC SUBJECTS WITH HEMOPHILIA A PO258-WED VENEPUNCTURE VERSUS LABORATORY SAMPLE TIMING DISCREPAN-
(SWIFTLY-HA STUDY) CIES: IMPLICATIONS FOR PHARMACOKINETIC PREDICTION OF PROPHY-
Maria Teresa Pompa, Genadi Iosava, Claudia Khayat, Irina Romashevskaya, Olga LAXIS DOSING IN SEVERE HEMOPHILIA A: UK-PK PILOT STUDY
Aleinikova, Oleksandra Stasyshyn, Liudmyla Vashchenko, Marta Julia Lopez, Wilfried Paul Batty*, Mike Spencer Chapman, Sean Platton, Daniel Hart (United Kingdom)
TUESDAY
Seifert* (Germany)
PO259-WED A NOVEL MISSENSE MUTATION, P.PHE360CYS, IN F9 GENE RESULTS
PO250-WED JOINT LAVAGE FOLLOWED BY VISCOSUPLEMENTATION AND TRIAN- IN HEMOPHILIA B IN FEMALE PATIENT
CINOLONE IN PATIENTS WITH SEVERE HEMOPHILIC ARTHROPATHY. Ziqiang Yu*, Chunchen Yang, Wei Zhang, Lijuan Cao, Xia Bai, Changgeng Ruan (China)
SUBJECTIVE PAIN, FUNCTION AND QUALITY OF LIFE RESULTS.
Thiago Pasqualin*, Marcia Rezende, Gustavo Campos, Thiago Rosa, Renato Frucchi, PO260-WED INHIBITORS IN PREVIOUSLY UNTREATED PATIENTS (PUPS) WITH SE-
Alexandre Pailo, Erica Okazaki, Paula Villaa (Brazil) VERE HEMOPHILIA A: A FOLLOW-UP COHORT STUDY.
Maria Elisa Mancuso*, H. Marijke van den Berg (Italy)
PO251-WED INTERIM RESULTS FROM A LARGE MULTINATIONAL EXTENSION TRIAL
MONDAY
(GUARDIAN TM2) USING TUROCTOCOG ALFA FOR PROPHYLAXIS AND PO261-WED SATISFACTION PATIENT SURVEY: A KEY TOOL TO IMPROVE PATIENT
TREATMENT OF BLEEDING IN PATIENTS WITH SEVERE HAEMOPHILIA A DELIVERY OF CARE AT A PORTUGUESE COMPREHENSIVE HEMOPHILIA
Steven Lentz*, Christine Kempton, Dragana Janic, Aleksandar Savic, Monica Cerque- CENTRE
ira, Margareth Ozelo, Michael Recht, Johannes Oldenburg, Andreas Tiede, Takashi Manuela Carvalho*, Joo Martins, Beatriz Delgado, Susana Fernandes, Manuela Reis,
Suzuki, Irina Matytsina, Niels Zeuthen, Elena Santagostino (United States) Fernando Arajo (Portugal)
PO252-WED VALIDATION OF THE INTERNATIONAL SOCIETY ON THROMBOSIS AND PO262-WED NUMERICAL MODELS OF THROMBIN GENERATION APPLICABLE TO
HAEMOSTASIS BLEEDING ASSESSMENT TOOL (ISTH-BAT) IN HEMO- HEMOPHILIA
PHILIA CARRIERS
SUNDAY
Pierre Chelle, Michel Cournil, Michle Piot, Aurlie Montmartin, Emilie Presles, Claire
Paula James*, Christoph Bidlingmaier, Maria Eva Mingot-Castellano, Meera Chitlur, Morin, Stphane Avril, Patrick Mismetti, Bernard Tardy, Brigitte Tardy* (France)
Patrick Fogarty, Julie Grabell, Prasad Mathew, Johnny Mahlangu (Canada)
PO263-WED THE EFFECT OF NORDIC WALKING ON JOINT STATUS, QUALITY OF LIFE,
PO253-WED EFFICACY AND SAFETY OF RECOMBINANT FUSION PROTEIN LINKING PHYSICAL ABILITY, EXERCISE CAPACITY AND PAIN IN OLDER MEN WITH
COAGULATION FACTOR IX WITH ALBUMIN (RIX-FP) IN PREVIOUSLY HEMOPHILIA
TREATED PATIENTS WITH HEMOPHILIA B UNDERGOING A SURGICAL Maryem Salim*, Yvonne Spls-Abrahamsson, Erik Berntorp, Elistabeth Brodin, Eva
PROCEDURE Zetterberg (Sweden)
Claude Ngrier*, Lynda Mae Lepatan, Aaron Lubetsky, Faraizah Abd Karim, Brigitte
SATURDAY
Pan-Petesch, Annarita Tagliaferri, Carmen Altisent, Julie Curtin, Christoph Male, Anne PO264-WED PERIOPERATIVE MANAGEMENT AND OUTCOME OF URGENT APPENDEC-
Lienhart, Denise Wolko, Christine Voigt, Iris Jacobs, Elena Santagostino (France) TOMY IN A PATIENT WITH SEVERE HEMOPHILIA
Murat Sker, Hikmet Zeytun, Sevda Sker, Cahit Sahin (Turkey)
PO254-WED COMPARISON OF ANNUAL BLEEDING RATES IN SUBJECTS WITH
SEVERE HEMOPHILIA A RECEIVING PROPHYLAXIS TREATMENT WITH PO265-WED PREVALENCE, SEVERITY AND CORRELATION FACTORS OF HEMOPHILIC
RECOMBINANT FACTOR VIII OR PEGYLATED RECOMBINANT FACTOR VIII ARTHROPATHY AMONG TAIWANESE HEMOPHILIACS
(BAX 855). Chia-Yau Chang*, Tsung-Ying Li, Shin-Nan Cheng, Ru-Yu Pan, Hung-Jung Wang, Shi-Yi
Werner Engl, Birgitt Abbuehl*, Martin Wolfsegger, Borislava Pavlova, Bruce Ewenstein Lin, Yeu-Chin Chen (Taiwan)
(Austria)
336 337
PO266-WED SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF PF- PO275-WED MOLECULAR GENETICS AND INHIBITOR DEVELOPMENT IN PATIENTS
THURSDSAY
05280602 (RECOMBINANT FVIIA VARIANT): PRELIMINARY RESULTS WITH HEMOPHILIA B
FROM A SINGLE ASCENDING DOSE PHASE I STUDY IN HEMOPHILIA A Ampaiwan Chuansumrit*, Werasak Sasanakul, Nongnuch Sirachainan, Praguywan
AND B SUBJECTS Kadegasem, Pakawan Wongwerawattanakoon (Thailand)
Ralph Gruppo,* Daniel Malan, Judit Kapocsi, Charles Hay, Lisa Boggio, Pratima Chow-
PO276-WED HAEMOPHILIA WITH INHIBITORS,UPDATE FROM ALGIERS EXPERIENCE,
WEDNESDAY
dary, Giuseppe Tagariello, Annette von Drygalski, Fei Hua, Matthew Scaramozza, Harry
Shi, Steven Arkin (United States) ABOUT ONE CENTER
Meriem Bensadok*, Wafia Karima Chennoukh, Chahira Aboura, Mylade Aribi, Nadia
PO267-WED SEVERE HEMOPHILIA A PATIENTS WHO DONT BLEED WHILE ON Zidani, Samira Boutiba, Meriem Fadila Belhani, Salim Nekkal (Algeria)
PROPHYLAXIS: INVESTIGATION INTO POSSIBLE FACTORS INFLUENCING
WEDNESDAY
THE OUTCOME PO277-WED PREVALENCE AND RISK FACTORS ASSOCIATED WITH HYPERTENSION
Johannes Oldenburg*, Elena Santagostino, Steven Lentz, Irina Matytsina, Niels Zeu- IN HEMOPHILIA
then (Germany) Craig D. Seaman*, Mariya Apostolova, Diane Comer, Jonathan Yabes, Margaret Ragni
POSTERS
(United States)
PO268-WED QUALITY OF LIFE AMONG HAEMOPHILIA IN THAILAND
Yingyong Chinthammitr*, Ploy Pengchata, Bundarika Suwannawiboon, Bunchoo Pong- PO278-WED A CASE OF ACUTE CEREBRAL INFARCTION IN A PATIENT WITH HEMO-
tanakul, Yupa Nakkinkun, Tasneem Binhama, Theera Ruchutrakool (Thailand) PHILIA B
Sunah Lee*, Mi-Kyung Kim (Korea, Republic Of)
PO269-WED IMPACT OF TRANSITION ON CLINICAL OUTCOMES IN HEMOPHILIA: 10
TUESDAY
YEARS OF EXPERIENCE AT A MAJOR CANADIAN TREATMENT CENTER PO279-WED THE USE OF SECONDARY PROPHYLAXIS IN THE HAEMOPHILIA A PA-
Celina Woo*, Erica Crilly, Deborah Gue, Kam McIntosh, Lawren De Marchi, Sandra TIENTS
Squire, Alexia Silva, Ming Yang, John Wu, Shannon Jackson (Canada) Gonul Aydogan*, Hulya Sen, Zafer Salcioglu, Ferhan Akici, Deniz Tugcu, Ali Aycicek,
Muge Gokce, Cengiz Bayram, Gonca Keskindemirci, Nuray Ayaz (Turkey)
PO270-WED PRO- AND ANTICOAGULANT FACTORS BALANCE THROMBIN GENERA-
TION INDUCED BY APCC PO280-WED COMPARATIVE STUDY OF THE PREVALENCE OF CLOTTING FACTOR
Katalin Varadi, Srilatha Tangada, Gerald Schrenk, Jennifer Doralt, Peter Turecek* DEFICIENCY IN CARRIERS OF HEMOPHILIA A AND B
(Austria) Ana Boban*, Nathalie Lannoy, Catherine Lambert, Cedric Hermans (Belgium)
MONDAY
PO271-WED MUSCLE STRENGTH IN LOAD-BEARING JOINTS IN HAEMOPHILIC PA- PO281-WED PREVALENCE AND INCIDENCE OF HEMOPHILIA IN THE NORTH OF
TIENTS: COMPARATIVE VALUES WITH THE GENERAL POPULATION. TUNISIA
Santiago Bonanad-Boix*, Sofia Perez-Alenda, Juan J. Carrasco, Jos Casaa-Granell, Melliti Mariem*, El Mahmoudi Hajer, Achour Mariem, Zahra Kaouther, Meddeb Balkis,
Yasser Alakhdar-Mohamara, Daniel Alonso-Roca, Felipe Querol (Spain) Gouider Emna (Tunisia)
PO272-WED PERSONALIZED PROPHYLAXIS WITH HUMAN-CL RHFVIII IN HEMOPHILIA PO282-WED EFFECTS OF MODERATE-INTENSITY PHYSICAL EXERCISE ON PHARMA-
A PATIENTS COKINETICS OF FACTOR VIII AND VON WILLEBRAND FACTOR IN YOUNG
Robert Klamroth*, Toscho Lissitchkov, L Rusen, Olaf Walter, Sigurd Knaub, Johann ADULTS WITH SEVERE HAEMOPHILIA A.
Bichler, John Pasi, Andreas Tiede (Germany) Nichan Zourikian*, Clmence Merlen, Arnaud Bonnefoy, Jean St-Louis, Georges-Eti-
SUNDAY
enne Rivard (Canada)
PO273-WED THROMBOPROPHYLAXIS FOR MAJOR ORTHOPEDIC SURGERY IN HE-
MOPHILIA: OUTCOMES OF AN EXPERT OPINION SURVEY ON CLINICAL PO283-WED PROSPECTIVE STUDY ON THE RISK, INCIDENCE AND MANAGEMENT OF
PRACTICE AND APPLICABILITY OF ACCP GUIDELINES BY THE ADVANCE CARDIOVASCULAR DISEASE IN OLDER PATIENTS WITH HAEMOPHILIA:
WORKING GROUP THE ADVANCE STUDY
Cdric Hermans*, Ingrid Pabinger, Maria Elisa Mancuso, Claude Ngrier, Pl Andr Robert Campbell Tait*, Pl Andr Holme, Christophe Combescure, Philippe de Mo-
Holme (Belgium) erloose, Erik Berntop, Roger Schutgens, Robert Klamroth, Cedric Hermans, Stephan
Rauchensteiner, Gerard Dolan (United Kingdom)
SATURDAY
PO274-WED AGE AND TREATMENT RELATED INFLUENCES ON ANNUAL BLEED

RATES (ABR) IN PATIENTS WITH HEMOPHILIA A (PWHA): OBSERVA- PO284-WED LONGEVITY OF NON-PATHOGENIC ANTIBODIES AGAINST HUMAN RE-
TIONAL STUDY DATA OF PATIENTS TREATED WITH RECOMBINANT FVIII COMBINANT PROTEINS IN HEALTHY INDIVIDUALS
FORMULATED WITH SUCROSE (RFVIII-FS) IN A GLOBAL SETTING Frank Horling*, Christoph Hofbauer, Peter Allacher, Susanne Till, Brigitt Abbuehl,
Gili Kenet*, Arlette Ruiz-Sez, Ming-Ching Shen, Stephan Rauchensteiner, Claudia Friedrich Scheiflinger, Birgit Reipert (Austria)
Tueckmantel, Elke Kellermann, Jose Cabre Marquez, Steve Liang, Monika Brunn, Karin
Achilles, Robert Klamroth (Israel)
338 339
PO285-WED PLASMA PROTEIN ABUNDANCES OF PROTEINS INVOLVED IN COAGULA- PO294-WED EXPANDING COMMUNICATIONS ON HEMOPHILIA A OUTCOMES (ECHO)
THURSDSAY
TION AND BONE/CARTILAGE TURNOVER ARE ALTERED AFTER HAEMO- STUDY: A LONGITUDINAL, OBSERVATIONAL DISEASE REGISTRY OF
PHILIC JOINT BLEED PATIENT-REPORTED AND CLINICAL OUTCOMES IN PATIENTS WITH
Ileana Rodrguez Len*, Mari Enoksson, Lise Nikolic Nielsen, Kirstine Roepstorff, HEMOPHILIA A
Mads Kjelgaard-Hansen, Eva Norling Olsen, Brian Vandahl (Denmark) Charles R. M. Hay*, Nikki Church, Shurjeel Choudhri, Craig Kessler (United Kingdom)
WEDNESDAY
PO286-WED IMMUNE TOLERANCE INDUCTION EXPERIENCE WITH ADVATE: FINAL PO295-WED EFFECTIVE RADYOACTIVE SYNOVECTOMY IN HEMOPHILIA WITH INHIBI-
RESULTS OF AN INTERNATIONAL PROSPECTIVE ITI REGISTRY (PAIR) TORS
Amy Shapiro*, Kate Khair, Jerry Teitell, Iliana Leony-Lasso, Katharina Steinitz, Ales- Bulent Zulfikar*, Cuneyt Turkmen, Onder Kilicoglu, Basak Koc, Ata Can Atalar, Fikret
WEDNESDAY
sandro Gringeri, Gerald Spotts (United States) Bezgal, Hanife Ozcan (Turkey, Turkey)
PO287-WED FREQUENCY OF BLEEDING EVENTS IN PATIENTS WITH HEMOPHILIA ON PO296-WED IMPROVING HEMOPHILIA CARE IN BRAZIL: AVAILABILITY OF FACTOR
PROPHYLAXIS BASED ON A COMMERCIAL INSURANCE CLAIMS DATA- CONCENTRATES AND BEYOND RESULTS OF LEVANTH SURVEY
POSTERS
BASE Samuel S. Medin*, Andrea Sambo, Margareth Ozelo (Brazil)
Katharine Batt*, Anshu Shrestha, Adi Eldar-Lissai, Yanyu Wu, Sangeeta Krishnan,
Darius Lakdawalla (United States) PO297-WED PREVALENCE, DESCRIPTION, AND MANAGEMENT OF PAIN IN ADULT
PEOPLE WITH HEMOPHILIA (PWH): INITIAL LESSONS FROM THE PAIN
PO288-WED IMPROVEMENT OF THE QUALITY OF HEALTH CARE FOR CHILDREN FUNCTIONAL IMPAIRMENT AND QUALITY OF LIFE (P-FIQ) STUDY
WITH SEVERE HAEMOPHILIA A USING PROPHYLAXIS AND TREATMENT Tyler Buckner*, Michelle Witkop, Michael Wang, Michael Recht, Katharine Batt, David
TUESDAY
OF BLEEDING EPISODES WITH RECOMBINANT FACTOR VIII Cooper, Christine Kempton (United States)
Sofijanka Glamocanin*, Zorica Trajkova-Antevska, Biljana Coneska (Macedonia, The
Former Yugoslav Republic Of) PO298-WED IMPACT OF PAIN AND FUNCTIONAL IMPAIRMENT IN US ADULT PEOPLE
WITH HEMOPHILIA (PWH): RESULTS FROM RETEST POPULATION IN
PO289-WED INHIBITOR DEVELOPMENT AS SWITCHING FULL-LENGTH RECOMBI- THE PAIN FUNCTIONAL IMPAIRMENT AND QUALITY OF LIFE (P-FIQ)
NANT FVIII TO B-DOMAIN DELETED RECOMBINANT FVIII IN PREVIOUS- STUDY
LY TREATED PATIENTS WITH HEMOPHILIA A: TAIWANS EXPERIENCE Christine Kempton*, Michael Recht, Anne Neff, Michael Wang, Tyler Buckner, Diane
Chia-Yau Chang*, Shu-Huey Chen, Geng-Chang Yeh, Chen-Hua Tsai, Jia-Ruey Tsai, Nugent, Doris Quon, Michelle Witkop, Lisa Boggio, David Cooper (United States)
Yen-Lin Liu (Taiwan)
MONDAY
PO299-WED A RETROSPECTIVE STUDY OF THE CURRENT TREATMENT PRACTICE OF
PO290-WED ULTRASONOGRAPHY OF JOINTS AND CORRELATION WITH FUNCTION IN HAEMOPHILIA A AND B IN THE UNITED KINGDOM
HAEMOPHILIC ARTHROPATHY - RESULTS OF A CLINICAL PILOT TRIAL Charles Hay, Gerry Dolan, Erik Berntorp, Christopher Ludlam, Karl-Johan Myrn, Lisa
(HMARTHROSONOPILOT) AND POTENTIAL IMPORTANCE OF JOINT-UL- Osterling Koskinen, Stefan Lethagen* (Sweden, Denmark)
TRASOUND FOR AN INDIVIDUALIZED PROPHYLAXIS
Michael Sigl-Kraetzig*, Axel Seuser (Germany) PO300-WED IMMUNE TOLERANCE INDUCTION IN PATIENTS WITH SEVERE HEMO-
PHILIA A WITH INHIBITORS IN KOREA
PO291-WED COMPARING CARDIOVASCULAR DISEASE IN PATIENTS WITH HEMO- Young Shil Park*, Hwi-Joong Yoon (Korea, Republic Of)
PHILIA WITH DATA IN THE GENERAL POPULATION: METHODOLOGICAL
SUNDAY
CONSIDERATIONS PO301-WED THE USAGE OF RECOMBINANT ACTIVATED FACTOR VII (RFVIIA) DURING
Karin Berger, Gordon Lowe, Dorothee Schopohl, Campbell Tait, Pl-Andre Holme, MAJOR AND MINOR SURGERIES IN SEVERE HEMOPHILIA PATIENTS
Stephan Rauchensteiner, Robert Klamroth* (Germany) WITH INHIBITOR
Bulent A. Antmen*, Ilgen Sasmaz, Barbaros Karagun, Goksel Leblebisatan, Yurdanur
PO292-WED BLEEDING EVENTS IN CHINESE CHILDREN WITH SEVERE HEMOPHILIA Kilinc, Atilla Aridogan, Iffet Yazicioglu, Cenk Ozkan (Turkey)
A RECEIVING STANDARD PROPHYLAXIS VS ON-DEMAND TREATMENT
WITH BAYERS SUCROSE-FORMULATED RECOMBINANT FACTOR VIII PO302-WED INTRACRANIAL HEMORRHAGE AND MANAGEMENT IN HEREDITARY
SATURDAY
Yongqiang Zhao, Juan Xiao, Renchi Yang, Runhui Wu, Yu Hu, Horst Beckmann, Junde BLEEDING DISORDERS: THE EXPERIENCE OF CUKUROVA UNIVERSITY,
Wu, Denny Hou, Jing Sun* (China) ADANA, TURKEY
Ilgen Sasmaz*, Bulent Antmen, Barbaros Karagun, Goksel Leblebisatan, Dervis Yilmaz,
PO293-WED PROPHYLACTIC EFFICACY OF TWICE-WEEKLY VERSUS 3-TIMES-WEEKLY Yurdanur Kilinc (Turkey)
BAY 81-8973 IN SEVERE HEMOPHILIA A: RESULTS OF THE LEOPOLD I
AND II CLINICAL TRIALS PO303-WED A PROSPECTIVE ITALIAN SURVEY ON INTRACRANIAL HEMORRHAGE IN
Johnny N. Mahlangu*, Kaan Kavakli, L. Hvitfeldt Poulsen, Despina Tseneklidou-Stoet- HEMOPHILIA PATIENTS: CHANGES OVER TIME
er, Horst Beckmann, Monika Maas Enriquez, Luminita Rusen (South Africa) Ezio Zanon*, Marta Milan, Chiara Biasoli, Isabella Cantori, Giancarlo Castaman, Anto-
nio Coppola, Matteo Luciani, Claudio Molinari, Piercarla Schinco, Gianluca Sottilotta,
Annarita Tagliaferri, Antonino Cannav, Elena Santagostino (Italy)
340 341
PO304-WED COMBINATION OF BIOMARKERS FOR ASSESSMENT OF HEMOPHILIC PO314-WED IMMUNOLOGICAL ASSAYS FOR DIAGNOSIS OF HEPARIN-INDUCED
THURSDSAY
ARTHROPATHY THROMBOCYTOPENIA: A SYSTEMATIC REVIEW AND META-ANALYSIS
Cheng Shin-Nan, Luke Yang, Tsung-Yi Li, Pan Ru-Yu, Hu Shu-Hsia, Yeu-Chin Chen* Michael Nagler*, Lucas Bachmann, Hugo ten Cate, Arina ten Cate (Switzerland, Neth-
(Taiwan) erlands)
PO305-WED HOW HAEMOPHILIA PATIENTS IN GERMANY PERCEIVE THEIR ACTUAL
WEDNESDAY
PO315-WED IMPACT OF OVERDIAGNOSIS OF HIT IN A LARGE COMMUNITY HOSPITAL
TREATMENT AND WHAT THEY EXPECT FOR FUTURE TREATMENT WITH J acqueline King, Davide Ventura, Jason Hodge, Austin Satterthwaite, John Francis*
NEW LONG-LASTING PRODUCTS (United States)
Sylvia Von Mackensen*, Heinrich Struck, Werner Kalnins (Georgia)
PO316-WED NEW PLATELET FUNCTIONAL METHOD TO IDENTIFY PATHOGENIC ANTI-
WEDNESDAY
PO306-WED CHALLENGES IN THE DIAGNOSIS AND MANAGEMENT OF HAEMOPHILIA BODIES IN HIT PATIENTS
Sitalakshmi Subramanian, Cecil Ross, Shanthala Devi, Vanamala Alwar (India) Maria Luisa Guarino, Isabella Massimi, Flavia Temperilli, Alessandra Zicari, Fabio M.
Pulcinelli* (Italy)
PO307-WED FACTOR XI DEFICIENCY AND BLEEDING RISK ON ANTICOAGULATION
POSTERS
John Chapin*, Kelsey Klute, Paul Christos, Maria DeSancho (United States) PO317-WED LOW MOLECULAR WEIGHT HEPARIN TREATMENT FOR SUPERFICIAL
VEIN THROMBOSIS AND THE RISK OF HEPARIN-INDUCED THROMBOCY-
PO308-WED THE EFFECT OF ADVANCING AGE ON THE RESPONSE TO DDAVP IN TOPENIA
RE-EXPOSED NONSEVERE HEMOPHILIA A PATIENTS Michelangelo Sartori*, Ludovica Migliaccio, Elisabetta Favaretto, Cristina Legnani,
Janneke I. Loomans*, Alice Van Velzen, Marjolein Peters, Christoph Knigs, Anne Lelia Valdr, Giuliana Guazzaloca, Gualtiero Palareti, Benilde Cosmi (Italy)
TUESDAY
Mkipernaa, Helena Platokouki, Evelien Mauser-Bunschoten, Christoph Male, Britta
Laros-van Gorkom, Saturnino Haya, Marjon Cnossen, Johanna Van der Bom, Karin PO318-WED AUDIT OF TEST RESULTS FOLLOWING THE INTRODUCTION OF A TEST-
Fijnvandraat (The Netherlands) ING ALGORITHM FOR HEPARIN INDUCED THROMBOCYTOPENIA (HIT) IN
A REFERRAL LABORATORY
PO309-WED FOLLOW UP OF FACTOR VIII INHIBITOR KINETICS IN HEMOPHILIA Mary B. Byrne*, Fiona Holden, Caroline Gannon, Barry White, James ODonnell, Kevin
PATIENTS Ryan, Niamh OConnell (Ireland)
Jaewoo Song*, Ji Houn Yoon, Jung Woo Han, Rojin Park, Yun A Jo, Jongha Yoo, Moon-
hee Oh (Korea, Republic Of)
Immune thrombocytopenia (ITP) III
MONDAY
PO310-WED THE POTENTIAL CORRELATION BETWEEN PATIENT-REPORTED SYMP-
TOMS AND THE NEED FOR ADDITIONAL HEMOSTATIC MEDICATION; A
POST HOC EXPLORATORY ANALYSIS BASED ON RFVIIA DATA FROM THE PO319-WED CLINICAL SIGNIFICANCE OF ANTINUCLEAR ANTIBODY TEST AND RISK
ADEPTTM2 TRIAL FACTOR PREDICTORS OF CHILDHOOD CHRONIC IMMUNE THROMBOCY-
Steven Lentz*, Savita Rangarajan, Faraizah Karim, Philip Andersen, Per Arkhammar, TOPENIA
Gabriela Rosu, Johnny Mahlangu (United States) Bunchoo Pongtanakul*, Suchawadee Horsuwan (Thailand)
PO320-WED CLINICAL SIGNIFICANCE OF IPF% OR RP% MEASUREMENT IN DISTIN-

Heparin-induced thrombocytopenia (HIT) II GUISHING PRIMARY IMMUNE THROMBOCYTOPENIA FROM APLASTIC
SUNDAY
THROMBOCYTOPENIC DISORDERS
Mikiko Sakuragi, Satoru Hayashi, Miho Maruyama, Osamu Kabutomori, Tomoko
PO311-WED EFFICACY ASSESSMENT OF FONDAPARINUX TREATMENT OF PATIENTS Kiyokawa, Keisuke Nagamine, Hisashi Kato, Hirokazu Kashiwagi, Yuzuru Kanakura,
WITH HEPARIN INDUCED THROMBOCYTOPENIA (HIT) Yoshiaki Tomiyama* (Japan)
Franciszek Grzegorczyk*, Pawe Kuca, Magorzta Dybowska, Janusz Burakowski, Cezary
Czajka, Barbara Kazanecka, Agnieszka Wrbel, Witold Tomkowski (Poland) PO321-WED INTRAVENOUS IMMUNOGLOBULIN TREATMENT OF CHILDREN IMMUNE
THROMBOCYTOPENIA META ANALYSIS OF EFFICACY AND SAFETY IN
PO312-WED SAFETY AND EFFICACY OF STARTING WARFARIN AFTER TWO CONSECU- CHINA
SATURDAY
TIVE PLATELET RISES IN PATIENTS WITH HEPARIN-INDUCED THROM- Zhixu He*, Tao Li, Liping Shu (China)
BOCYTOPENIA
Lydia D. Chen*, William Dager, A. Josh Roberts (United States) PO322-WED VARIATIONS OF MEAN PLATELET VOLUME OF IMMUNE THROMBOCYTO-
PENIA
PO313-WED RAPID FUNCTIONAL HEPARIN INDUCED THROMBOCYTOPENIA (HIT) Kenji Yokoyama*, Tomoki Ueda (Japan)
ASSAY USING MULTIPLATE: COMPARISON WITH HEPARIN INDUCED
PLATELET ACTIVATION (HIPA) ASSAY AND ACL ACUSTAR ANTIGEN AS- PO323-WED THE POLYMORPHISMS OF TUMOR NECROSIS FACTOR-INDUCED PRO-
SAY TEIN 3 GENE MAY CONTRIBUTE TO THE SUSCEPTIBILITY OF CHRONIC
Kevin Horner*, Joost Van Veen, Rhona Maclean, Steve Kitchen (United Kingdom) PRIMARY IMMUNE THROMBOCYTOPENIA IN CHINESE POPULATION
Jingyi Yang*, Hu Zhou, Yongping Song, Renchi Yang (China)
342 343
PO324-WED ANTI-PLATELET ANTIBODIES PRESENT IN BREAST MILK OF AN PO333-WED BARETTIN: A NATURAL MARINE COMPOUND WITH POTENT ANTICOAG-
THURSDSAY
IMMUNE THROMBOCYTOPENIC MOTHER INCREASE AN APOPTOTIC ULANT AND ANTI-INFLAMMATORY PROPERTIES
MARKER IN NORMAL PLATELETS Karianne F Lind, Jan Ole Olsen, Bjarne sterud* (Norway)
Hagit Hauschner* Uri Seligsohn, Nechama Sharon, Nurit Rosenberg (Israel)
PO334-WED PROTECTION EFFECTS OF 4AAQB ISOLATED FROM ANTRODIA CINNA-
WEDNESDAY
PO325-WED CLINICAL OBSERVATION OF 10 CASES OF NEWLY DIAGNOSED ITP MOMEA ON LPSINDUCED SEPSIS MODEL.
PATIENTS RECEIVING LOW-DOSE RITUXIMAB COMBINED WITH HIGH- Chien-Hsin Chang, Ching-Hu Chung* (Taiwan)
DOSE DEXAMETHASONE
Ke Feng* (China) PO335-WED COAGULATION ACTIVITY INCREASES WITH DISEASE SEVERITY IN PA-
TIENTS WITH ASTHMA
WEDNESDAY
PO326-WED ANTI-GPIBALPHA ANTIBODIES INDUCE IMMUNE THROMBOCYTOPENIA Marlous Sneeboer, Christof Majoor, Anne de Kievit, Joost Meijers, Rene Lutter, Tom
IN DISTINCT PATHWAYS: FC-DEPENDENT VS. FC-INDEPENDENT van der Poll, Pieter-Willem Kamphuisen*, Peter Sterk, Elisabeth Bel (The Netherlands)
Miao Xu*, Naadiya Carrim, Guangheng Zhu, Pingguo Chen, Heyu Ni (Canada)
PO336-WED ANTI-POLYPHOSPHATE ANTIBODIES AS ANTI-INFLAMMATORY/ANTICO-
POSTERS
PO327-WED COMPARISON OF RELAPSE RATES OF IMMUNE THROMBOCYTOPENIA AGULANT THERAPEUTICS
IN PATIENTS WHO RECEIVED INITIAL TREATMENT WITH STEROIDS VER- Richard J. Travers*, Catherine Baker, Rachel Breitenfeld, Michael Drake, Xiaomei
SUS ANTI-RH(D) WITH OR WITHOUT STEROIDS Zhang, Naomi Esmon, Charles Esmon, James Morrissey (United States)
Mala Varma* (United States)
PO337-WED CHLAMYDIA INFECTION IN VENOUS INSUFFICIENCY AND VENOUS
TUESDAY
PO328-WED PATHOGENESIS OF ANTI-INTEGRIN ALPHAIIB-MEDIATED FETAL AND ULCERS
NEONATAL ALLOIMMUNE THROMBOCYTOPENIA: ESTABLISHMENT OF Tamar Saralidze*, Giorgi Kavtaradze, Bela Metreveli, Tinatin Shvelidze (Georgia)
NOVEL MURINE MODELS IN ALPHAIIB DEFICIENT AND HUMAN AL-
PO338-WED EARLY MEASUREMENT OF THROMBIN ACTIVATABLE FIBRINOLYSIS
PHAIIB TRANSGENIC MICE
INHIBITOR (TAFI) AND ACTIVATED TAFI (TAFIA) PREDICT OUTCOME IN
Brian Vadasz, Darko Zdravic*, Pingguo Chen, Issaka Yougbare, Guangheng Zhu, Jona-
than Frampton, Mortimer Poncz, John Freedman, Heyu Ni (Canada)
PATIENTS WITH SEVERE SEPSIS OR SEPTIC SHOCK
Fabrizio Semeraro*, Serge Masson, Pietro Caironi, Concetta Ammollo, Nicola Semer-
aro, Mauro Panigada, Caterina Fanizza, Gianni Tognoni, Luciano Gattinoni, Roberto
Latini, Mario Colucci (Italy)
Inflammation III
MONDAY
PO339-WED INFLAMMATORY CYTOKINE UP REGULATION MAY BE AN EARLY MARK-
PO329-WED ASSOCIATION BETWEEN A PRO-INFLAMMATORY AXIS COMPRISED BY ER OF THROMBOSIS IN PATIENTS WITH IMPLANTED LVADS
TSP1-TGFB-CTGF WITH THREE MICRO-RNAS, MIR-19A, 122, AND 133A Walter Jeske*, Daneyal Syed, Erin Coglianese, Jeffrey Schwartz, Mamdouh Bakhos,
IN THE PATHOPHYSIOLOGY OF DIABETIC RETINOPATHY: A THERAPEU- Jeanine Walenga (United States)
TIC NOVEL MODALITY
PO340-WED ANNEXIN A1 CONCENTRATION IS INCREASED IN PATIENTS WITH PRE-
Raul Dela Cadena*, Melissa Lester, Alina Shevchenko, John St. Angelo III, Philippe
ECLAMPSIA
Alvarez DeLa Cadena, Fabiola Del Carpio-Cano, William Foster (United States)
Luiza Perucci, Fernanda Carneiro, Cludia Ferreira, Frederico Soriani, Gustavo Martins,
SUNDAY
PO330-WED FIBRINOGEN IN SEPSIS: CROSSTALK BETWEEN COAGULATION AND Ktia Lima, Flvia Guimares, Antnio Teixeira, Luci Dusse*, Karina Borges, Lirlndia
Sousa (Brazil)
INFLAMMATION
Mirjam Bachler*, Dietmar Fries, Christian Niederwanger, Caroline Linhart, Bettina PO342-WED COMBINED HIGH LEVELS OF IL-18 AND IL-12 ARE ASSOCIATED WITH
Schenk (Austria)
NEW CLINICAL EVENTS IN CAD PATIENTS.
PO331-WED INCREASED BIOMARKERS OF METABOLIC SYNDROME IN TOTAL JOINT Trine Baur Opstad*, Harald Arnesen, Alf-ge Pettersen, Ingebjrg Seljeflot (Norway)
ARTHOPLASTY PATIENTS
PO343-WED DETERMINATION OF HEPARIN LEVEL IN BLOOD PLASMA SENSITIVITY
SATURDAY
Andrew Banos*, William Hopkinson, Harold Rees, Daneyal Syed, Schuharazad Abro,
AND SPECIFICITY AS A MARKER FOR IDENTIFICATION OF SYSTEMIC
Debra Hoppensteadt, Omer Iqbal (United States)
MAST CELL ACTIVATION DISEASE
PO332-WED END-STAGE RENAL DISEASE ASSOCIATED WITH METABOLIC SYN- Hans-Joerg Hertfelder*, Milda Vysniauskaite, Iris Haussels, Sandra Ohlenforst, Heiko
DROME: A STUDY OF BIOMARKERS RELEVANT TO CARDIOVASCULAR Ruehl, Anne Selbitz, Susanne Unkrig, Peter Dreen, Stefan Brettner, Juergen Homann,
Franz-Josef Dumoulin, Johannes Oldenburg, Gerhard Molderings (Germany)
RISK
Vinod Bansal*, Jennifer Saluk, Debra Hoppensteadt, Daneyal Syed, Schuharazad Abro,
Nil Guler, Rakesh Wahi, Jawed Fareed (United States)
344 345
PO344-WED CYTOKINE-MEDIATED TRIGGERING OF THROMBIN GENERATION AND PO352-WED THROMBO(ELASTO)GRAPHIC EVALUATION OF THE INFLUENCE OF
THURSDSAY
INFLAMMATION IN PATIENTS WITH STEVENS- JOHNSON SYNDROME/ ANTICOAGULANT CONSTITUENTS ON THE PROHEMOSTATIC POTENTIAL
TOXIC EPIDERMAL NECROLYSIS. OF PROTHROMBIN COMPLEX CONCENTRATE AND FACTOR IX CONCEN-
Omer Iqbal*, Daneyal Syed, Debra Hoppensteadt, Michael Mosier, Fareed Jawed, TRATE
Charles Bouchard (United States) Herm Jan M. Brinkman*, Sanne Patiwael, Shrijana Tripathi, Alexander Meijer, Joost
WEDNESDAY
Meijers (The Netherlands)
Management of bleeding II PO353-WED PROTHROMBIN COMPLEX CONCENTRATE CAN INCREASE THROMBIN

GENERATION IN THE PRESENCE OF LOW PLATELET NUMBER

WEDNESDAY
Colleen Hamid*, John McVey, Anne Riddell, Keith Gomez, David Slatter, Pratima
PO345-WED NONCLINICAL EVALUATION OF CATIONICALLY MODIFIED POLYSACCHA- Chowdary (United Kingdom)
RIDE ANTIDOTES FOR UNFRACTIONATED HEPARIN
Bartlomiej Kalaska*, Kamil Kaminski, Emilia Sokolowska, Monika Kujdowicz, Krzysztof PO354-WED EVALUATION OF ACTIVATED PROTHROMBIN COMPLEX CONCENTRATE
POSTERS
Szczubialka, Dariusz Pawlak, Maria Nowakowska, Andrzej Mogielnicki (Poland) USE AND ITS ROLE IN THE REVERSAL OF NOVEL ORAL ANTICOAGU-
LANTS
PO346-WED SCREENING TOOL FOR BLEEDING DISORDERS IN WOMEN WITH HEAVY
Sarah Sienko*, Michael Vasovski, Mona Ali (United States)
MENSTRUAL BLEEDING
Sophie Wiewel-Verschueren*, H. Marieke Knol, Y.I.G. Vladimir Tichelaar, Andr Mulder, PO355-WED THE COST-EFFECTIVENESS OF PD-APCC VERSUS RFVIIA IN PEDIATRIC
Ellen Klinkert, Hanneke Kluin-Nelemans, Ate G. van der Zee, Karina Meijer (The Neth- PATIENTS WITH HAEMOPHILIA A AND INHIBITORS WITH MILD TO MOD-
TUESDAY
erlands)
ERATE JOINT BLEEDING IN MEXICO.
PO347-WED THE IMPACT OF RED BLOOD CELLS ON HEMOSTASIS UNDER WHOLE Janet Soto*, Lourdes Gonzlez, Amalia Bravo, Adolfina Bergs, Teresa Pompa, Maricar-
men Rodrguez, Silva Salvador, Rogelio Paredes, Mark Lamotte (Mexico)
BLOOD FLOW CONDITIONS
Hiroaki Yaoi*, Yasuaki Shida, Keiji Nogami, Tomoko Matsumoto, Kenich Ogiwara, PO356-WED PLATELET ADP REACTIVITY AND BLEEDING RISK IN LONG-TERM
Kazuya Hosokawa, Midori Shima (Japan)
DOUBLE ANTIPLATELET THERAPY PATIENTS WITH CORONARY ARTERY
PO348-WED REVERSAL OF DABIGATRAN COULD BE ACHIEVED BY HEMODIALYSIS DISEASE
WITH OR WITHOUT OTHER HEMOSTATIC AGENTS Ekaterina Guskova*, Andrey Komarov, Anatoly Dobrovolsky, Alexander Deev, Anatoly
Samko, Elizaveta Panchenko (Russian Federation)
MONDAY
Rachelle Li*, Francis Chan, Keith Lau, Anthony Chan, Howard Chan (Canada)
PO357-WED THROMBIN ACTIVATED FIBRINOLYSIS INHIBITOR IS A SIGNIFICANT
PO349-WED INCREASED COAGULATION AND FIBRINOLYTIC POTENTIAL OF SOL-
RISK FACTOR OF RECURRENT BLEEDINGS IN PATIENTS ON LONG-
VENT-DETERGENT PLASMA: AN OBSERVATIONAL STUDY BETWEEN
TERM WARFARIN THERAPY.
SD-TREATED POOLED PLASMA AND FRESH FROZEN QUARANTINE
Olga Moreva*, Ekaterina Kropacheva, Oksana Zemlyanskaya, Elena Titaeva, Anatoliy
PLASMA
Dobrovolskiy, Elizaveta Panchenko (Russian Federation)
Joyce van Beers, Lieve van Egmond, Rick Wetzels, Paul Verhezen, Erik Beckers, Rene
van Oerle, Henri Spronk, Ron Straat, Yvonne Henskens* (The Netherlands) PO358-WED LOW DOSE FEIBA AND HEMODIALYSIS FOR MANAGING MAJOR BLEED-
ING ON DABIGATRAN
SUNDAY
PO350-WED PROSPECTIVE HEMOSTASIS REGISTRY OF PATIENTS IN CARDIAC
William E. Dager*, Aaron Roberts, Robert Gosselin, Richard White (United States)
SURGERY (HEROES-CS): EVALUATION OF THE INTRODUCTION OF A
THROMBOELASTOGRAPHY BASED TRANSFUSION PROTOCOL IN CARDI- PO359-WED EFFECTIVE USE OF LOW DOSE ACTIVATED PROTHROMBIN COMPLEX
AC SURGERY. CONCENTRATES IN MANAGING MAJOR GI BLEEDING ON RIVAROXABAN
Yvonne Henskens*, Lieve van Egmond, Rick Wetzels, Maurice Theunissen, Wouter van William E. Dager*, Aaron Roberts, Robert Gosselin, Richard White (United States)
Willigem, Geert-Jan Kuiper, Marcus Lanc (The Netherlands)
PO351-WED SIDE EFFECTS OF AND RESPONSE TO DDAVP DO NOT CORRELATE WITH

Management of bleeding III
SATURDAY
OVERWEIGHT IN PATIENTS WITH HEMOPHILIA A OR VON WILLEBRAND

DISEASE
Lisette M. Schutte*, Sara C.M. Stoof, Marjon Cnossen, Frank W.G. Leebeek, Marieke PO360-WED THE COST-EFFECTIVENESS OF PD-APCC VERSUS RFVIIA IN PEDIATRIC
J.H.A. Kruip (The Netherlands) PATIENTS WITH HAEMOPHILIA TYPE A AND INHIBITORS WITH MILD TO
MODERATE JOINT BLEEDING IN COLOMBIA
Carlos A. Portilla*, Andres Felipe Gonzalez, Javier Mauricio Corts, Angel Castro,
Sandra Patricia Sterling, Mafalda Ramos (Colombia)
346 347
PO361-WED IMPROVING EDUCATION AND ADVOCACY FOR YOUNG WOMEN WITH PO372-WED EFFECTS OF HEMOSTATIC GAUZE WITH SELF-PROPELLING THROMBIN
THURSDSAY
MENORRHAGIA THROUGH USE OF INNOVATIVE TECHNOLOGY PARTICLES ON SURVIVAL AND BLOOD LOSS IN A SWINE MODEL OF
Lakshmi Srivaths (United States) LETHAL ARTERIAL HEMORRHAGE
Alex St. John*, James Baylis, Xu Wang, Esther Lim, Diana Chien, Susan Stern, Chris-
PO362-WED REDUCED HEMOSTATIC CAPACITY AFTER CARDIOPULMONARY BYPASS tian Kastrup, Nathan White (United States)
WEDNESDAY
Lakshmi Srivaths*, Shu He, Margareta Blombck, Anders Jeppsson, Stefan Grass*
(Sweden) PO373-WED CLINICAL MANAGEMENT AND OUTCOME OF MAJOR BLEEDING IN
PATIENTS ON TREATMENT WITH VITAMIN K ANTAGONISTS: RESULTS
PO363-WED A FIXED DOSE PROTOCOL FOR PROTHROMBIN COMPLEX CONCENTRATE FROM THE CLIMBING STUDY.
DOES NOT LEAD TO QUICKER AND RELIABLE INR REDUCTION IN VITA-
WEDNESDAY
Laura Franco*, Cecilia Becattini, Luca Masotti, Cinzia Nitti, Sergio Cattinelli, Roberto
MIN K ANTAGONIST RELATED INTRACRANIAL HEMORRHAGE Cappelli, Giorgia Manina, Rodolfo Sbrojavacca, Fulvio Pomero, Giancarlo Agnelli (Italy)
Rahat Abdoellakhan*, Ishita Miah, Nakisa Khorsand, Korn Jellema, Karina Meijer
(The Netherlands) PO374-WED COMPARATIVE STUDIES ON A BRANDED RECOMBINANT FACTOR VIIA
POSTERS
AND ITS GENERIC VERSION TO DEMONSTRATE EQUIVALENCE.
PO364-WED RISKS AND PREDICTORS OF ISCHEMIC/BLEEDING COMPLICATIONS IN Nasir Sadeghi, Paul OMalley*, Massimo Iacobelli, Behrouz Vaziri, Daneyal Syed,
CARDIAC PATIENTS UNDERGOING ELECTIVE NON-CARDIAC SURGERY Daniel Kahn, Debra Hoppensteadt, Nil Guler, Jawed Fareed (United States)
AN ANALYSIS OF THE PRAGUE-14 STUDY
Zuzana Motovska*, Ladislav Dusek, Martina Ondrakova, Jiri Knot, Lukas Havluj, Robert PO375-WED SELF-PROPELLING PARTICLES THAT TRANSPORT THROMBIN TO MAN-
Gurlich, Radek Bartoska, Valer Dzupa, Lukas Bittner, Petr Widimsky (Czech Republic) AGE HEMORRHAGE
TUESDAY
James Baylis*, Ju Hun Yeon, Max Thomson, Amir Kazerooni, Xu Wang, Alex St. John,
PO365-WED THE PHARMACOKINETICS AND IMMUNE RESPONSE OF NEW CATIONIC Esther Lim, Diana Chien, Anna Lee, Jesse Zhang, James Piret, Lindsay Machan, Thom-
DEXTRAN ANTIDOTES OF HEPARIN as Burke, Nathan White, Christian Kastrup (Canada)
Bartlomiej Kalaska*, Kamil Kaminski, Dominik Czaplicki, Agnieszka Blazejczyk, Emilia
Sokolowska, Monika Kujdowicz, Krystyna Stalinska, Krzysztof Szczubialka, Joanna
Wietrzyk, Joanna Bereta, Dariusz Pawlak, Maria Nowakowska, Andrzej Mogielnicki Megakaryocytes and thrombopoiesis
(Poland)
PO366-WED GENDER AND BLEEDING IN ATRIAL FIBRILLATION: A REAL-WORLD PO376-WED A MICROFLUIDIC CHAMBER FOR ELONGATING MEGAKARYOCYTES AND
MONDAY
PROSPECTIVE COHORT STUDY PRODUCING FUNCTIONAL PLATELETS
Jeroen Jaspers Focks*, Jaap Seelig, Stijn van Vugt, Alexander Sern, Lucie Bloem-de Antoine Blin, Anne Le Goff, Sonia Poirault-Chassac, Geraldine Sicot, Bruno Teste,
Vries, Marjo Albers-Akkers, Freek Verheugt, Marc Brouwer (The Netherlands) Aurelie Magniez, Mathilde Reyssat, Dominique Baruch* (France)
PO367-WED LOW-DOSE 4-FACTOR PCC FOR URGENT WARFARIN REVERSAL PO377-WED NOVEL ROLES OF THE DUAL-SPECIFICITY PHOSPHATASES 1 AND 6 IN
esley Zemrak*, Kathryn Smith, Stephen Rolfe, Timothy Hayes, Robert Trowbridge,
W MEGAKARYOPOIESIS AND PROPLATELET FORMATION
David Seder (United States) Alexandra Mazharian*, Yotis Senis (United Kingdom)
PO368-WED DEVELOPMENT AND VALIDATION OF AN ASSAY FOR INTRA-SURGICAL PO378-WED FUNCTIONALLY ACTIVE TISSUE FACTOR IS EXPRESSED DURING MEGA-
SUNDAY
(OR PERI-OPERATIVE) MANAGEMENT OF BLEEDING KARYOCYTE MATURATION AND IS TRANSFERRED TO A SUBSET OF
Elisa A. Ferrante*, Kiev Blasier, Timothy Fischer, Francesco Viola (United States) PLATELETS
Marta Brambilla, Laura Facchinetti, Paola Canzano, Laura Rossetti, Nicola Ferri, Ales-
PO369-WED APTT SCREENING TEST IN THE COHORT OF ADULT PATIENTS UN- sandra Balduini, Vittorio Abbonante, Daniela Boselli, Luigi De Marco, Matteo Di Minno,
DERGOING SURGICAL PROCEDURES: INSIGHTS FOR CLINICAL DAILY Vincenzo Toschi, Alberto Corsini, Elena Tremoli, Marina Camera* (Italy)
PRACTICE
Paolo Radossi, Lorena Zardo, Roberta Salviato, Silvia Chiappin, Federica Pierobon, PO379-WED FUNCTIONAL ANALYSIS OF NBEAL2 IN HUMAN MEGAKARYOCYTES VIA
Antonino Floridia, Gianpaolo Piaserico, Giuseppe Tagariello* (Italy) COLOCALIZATION WITH SUBCELLULAR COMPARTMENTS
SATURDAY
Richard W. Lo*, Fred Pluthero, Ling Li, Walter Kahr (Canada)

PO370-WED INTRAVENTRICULAR FIBRINOLYSIS RESTORES GLYMPHATIC CIRCULA-
TION AFTER SUBARACHNOID HEMORRHAGE. PO380-WED CCL5 RELEASED FROM PLATELETS DRIVES INCREASED MEGAKARYO-
Maxime Gauberti*, Thomas Gaberel, Clment Gakuba, Sara Martinez de Lizarrondo, CYTE MATURATION AND PROPLATELET FORMATION
Denis Vivien (France) Kellie R. Machlus*, Kelly Johnson, Rajesh Kulenthirarajan, Saleh El-Husayni, Joseph
Italiano, Elisabeth Battinelli (United States)
PO371-WED EVALUATING THE INTER-OBSERVER RELIABILITY OF POTENTIAL PRE-
DICTOR VARIABLES TO DEVELOP A MORE ACCURATE PREDICTION TOOL
FOR BLEEDING FOR PATIENTS ON ORAL ANTICOAGULANT
Parvaneh Fallah*, Philip S. Wells, Melissa A Forgie (Canada)
348 349
PO381-WED ANTI-GPIIB ANTIBODY INHIBITS PLATELET PRODUCTION FROM MEGA- PO390-WED EFFECT OF ACETYLSALICYLIC ACID ON THE CONCENTRATION OF
THURSDSAY
KARYOCYTES, BUT NOT MEGAKARYOCYTE MATURATION, ANALYZED IN MONOCYTE MICROPARTICLES COEXPRESSING TISSUE FACTOR IN PA-
A MURINE MODEL OF IMMUNE THROMBOCYTOPENIA. TIENTS WITH DIABETES MELLITUS TYPE 2
Yukinori Kozuma*, Hiroshi kojima, Haruhiko Ninomiya (Japan) Marcelo Luide Goncalves*, Lilian Goncalves, Fernanda Nunes, William Pedrosa, Maria
Carvalho, Silvana Santos (Brazil)
WEDNESDAY
PO382-WED PLANT FOOD CYANIDIN-3-O--GLUCOSIDE PROMOTED MEGAKARYO-
POIESIS BY REGULATION OF THE APOPTOTIC PATHWAY IN DAMI AND PO391-WED LOW MICROPARTICLE-ASSOCIATED TISSUE FACTOR ACTIVITY IN PA-
MEG-01 CELL LINES IN VITRO TIENTS WITH PERSISTENT LUPUS ANTICOAGULANT AND A HISTORY OF
Yan Yang*, Jing Ren, Fuli Ya, Xiujuan Deng, Yanyan Wang, Wenhua Ling (China) THROMBOSIS

WEDNESDAY
Lena Hell*, Cihan Ay, Florian Posch, Silvia Koder, Johanna Gebhart, Ingrid Pabinger,
PO383-WED MEGAKARYOCYTES AND PLATELETS EXPRESS NICOTINIC ACETYLCHO- Johannes Thaler (Austria)
LINE RECEPTORS BUT NICOTINE DOES NOT AFFECT MEGAKARYPOIE-
SIS OR PLATELET FUNCTION PO392-WED MEAL INTAKE INCREASES CIRCULATING PROCOAGULANT MICROPARTI-
POSTERS
Peter Bugert*, Angelika Schedel, Kerstin Kaiser, Stefanie Uhlig, Florian Lorenz, Anip CLES IN PATIENTS WITH DIABETES MELLITUS
Sarin, Julian Starigk, Dennis Hassmann, Karen Bieback (Germany) Galia Spectre*, Fariborz Mobarrez, Ragnhild Stlesen, Hkan Walln, Claes-Gran
stenson, Paul Hjemdahl (Israel, Sweden)
PO384-WED NOVEL REGULATORS OF MEGAKARYOPOIESIS BY RIBOSOME-PROTECT-
ED RNA SEQUENCING PO393-WED ATRA MODULATES THE EMISSION OF EXTRACELLULAR VESICLES IM-
Sjoert B. G. Jansen*, Romina Petersen, Myrto Kostadima, Maria Colzani, Mattia PLICATIONS FOR INTERCELLULAR COMMUNICATION BETWEEN ACUTE
TUESDAY
Frontini, Daniel Greene, Ilenia Simeoni, Ernest Turro, Jose Guerrero, Willem Ouwehand PROMYELOCYTIC LEUKEMIA AND ENDOTHELIAL CELLS
(United Kingdom) Yi Fang*, Delphine Garnier, Tae Hoon Lee, Esterina DAsti, Laura Montermini, Brian
Meehan, Janusz Rak (Canada, China)
PO385-WED GENE EXPRESSION PROFILE IN MEGAKARYOCYTES FROM TYPE 2 DIA-
BETIC MICE EMPHASIZES INCREASE IN STEFINA EXPRESSION LEVELS PO394-WED CLINICAL SIGNIFICANCE OF CIRCULATING MICROPARTICLES IN PH-
Anna Mezzapesa, Marjorie Poggi, Vronique Baccini, Patricia Ancel, Delphine Bas- MYELOPROLIFERATIVE NEOPLASMS (MPN)
telica, Dorsaf Ghalloussi, Franck Peiretti, Jean-Franois Landrier, Matthias Canault*, Han Yue*, Wu Depei, Zhang Wenjuan, Qi Jiaqian, Zhao Shixiang, Wang Zhaoyue, Ruan
Marie-Chrisitne Alessi (France) Changgeng (China)
MONDAY
PO386-WED IDENTIFICATION OF MEGAKARYOCYTIC PROGENITOR CELLS AMONG PO395-WED PLATELET MICROVESICLES IN VASCULAR INFLAMMATION
SUBCUTANEOUS PRE-ADIPOCYTES anja Vajen*, Elena Vasina, Leon Schurgers, Christian Weber, Tilman Hackeng, Johan
T
Keiichi Tozawa*, Yukako Ono-Uruga, Tadashi Horiuchi, Shinichiro Okamoto, Mitruru Heemskerk, Rory Koenen (The Netherlands)
Murata, Yasuo Ikeda, Toshio Suda, Yumiko Matsubara (Japan)
PO396-WED IMPACT OF A FAT-TOLERANCE TEST ON PLASMA CONCENTRATION AND
PO387-WED PLATELET FACTOR XIII: THE RESCUE IN THE FACTOR FXIII DEFICIENCY. SIZE DISTRIBUTION OF EXTRACELLULAR VESICLES ASSESSED BY
Claudia Maria Radu*, Cristiana Bulato, Elena Campello, Francesca Sartorello, Sabrina NANOPARTICLE TRACKING ANALYSIS
Gavasso, Mariangela Fadin, Paolo Simioni (Italy) Cathrine Ramberg*, Simin Jamaly, Nadezhda Latysheva, Erin Mathiesen Hald, Vladi-
mir Tichelaar, John-Bjarne Hansen (Norway)
Microparticles III SUNDAY PO397-WED DYNAMICS OF INTERACTIONS AMONG PLATELET MICROPARTICLES,

AND INFLAMMATORY, HEMOSTATIC AND OXIDATIVE BIOMARKERS IN
ELDERLY INDIVIDUALS WITH AND WITHOUT COGNITIVE IMPAIRMENT.
PO388-WED RAC1 REGULATES PLATELET MICROPARTICLES FORMATION AND RHEU-
Walter B. Cicarini*, Gisele Gonalves, Rita Duarte, Fernanda Campos, Lirlndia Souza,
MATOID ARTHRITIS DETERIORATION Mayara Faria, Olindo Filho, Maria Bicalho, Josianne Silveira, Maria Carvalho (Brazil)
Xue Chen*, Kemin Wang, Xiaoping Du, Junling Liu (China)
SATURDAY
PO389-WED ALTERATIONS IN THE EXTRACELLULAR VESICLES PROPERTIES INDI- Non-vitamin K antagonist oral anticoagulants III
CATE HYPERCOAGULABLE STATE IN PATIENTS WITH ACUTE MYELOID
LEUKEMIA
Inna Tzoran-Rosenthal*, Annie Rebibo-Sabbah, Benjamin Brenner, Anat Aharon (Israel) PO398-WED PERFORMANCE OF THREE FUNCTIONAL ASSAYS FOR THE MEASURE-
MENT OF DABIGATRAN PLASMA CONCENTRATIONS
Genevieve Freyburger*, David Girard, Anne-Laure Vervaeke, Marine Rousset, Sylvie
Labrouche (France)
350 351
PO399-WED DIRECT ORAL ANTICOAGULANTS (DOAS) PLASMA LEVELS IN PATIENTS PO410-WED INTERFERENCE STUDY OF DIRECT THROMBIN INHIBITORS AND
THURSDSAY
FOLLOWED BY A SINGLE CENTER ANTI-XA INHIBITORS ON HEMOSTASIS ASSAYS ON A COBAS T 411
Rita Santoro*, Roberto Minici, Piergiorgio Iannaccaro, Sergio Morgione (Italy) SYSTEM
An K. Stroobants*, Willem van Dam, Bianca Bakker, Erik-Jan van den Dool, Marion
PO400-WED DIRECT ORAL ANTICOAGULANTS AND SURGERY: OUR EXPERIENCE Heckman (The Netherlands)
WEDNESDAY
Rita Santoro*, Roberto Minici, Piergiorgio Iannaccaro, Sergio Morgione (Italy)
PO411-WED NEUTRALIZATION OF BLEEDING INDUCED BY NON-VITAMIN K ORAL
PO401-WED DILUTE RUSSELL VIPER VENOM TIME, A PARTIAL SOLUTION FOR ANTICOAGULANTS BY PROTHROMBIN COMPLEX CONCENTRATES
SCREENING AND CONCENTRATION DETERMINATION OF DIRECT ORAL ALONE AND IN COMBINATION WITH ANTIFIBRINOLYTIC AGENTS
ANTICOAGULANTS
WEDNESDAY
Walter Jeske*, Vicki Escalante, Elizabeth Mcgeehan, Jeanine Walenga, Rakesh Wahi,
An K. Stroobants*, Erik-Jan van den Dool, Marion Heckman, Michiel Coppens, Auguste Jawed Fareed, Mamdouh Bakhos (United States)
Sturk (The Netherlands)
PO412-WED THE DILUTE FIIX PROTHROMBIN TIME (DFIIX-PT) FOR ASSESSMENT
PO402-WED DRUG INTERACTIONS OF NEWER ORAL ANTICOAGULANTS DABIGA-
POSTERS
OF DABIGATRAN, RIVAROXABAN AND WARFARIN EFFECT IN PATIENT
TRAN, RIVAROXABAN, AND APIXABAN WITH ROUTINELY USED NONAN- SAMPLES
TICOAGULANT/ANTIPLATELET DRUGS Loic Letertre*, Brynja Gudmundsdottir, Mika Skeppholm, Rickard Malmstrm, Charles
Shermin Sayani*, Omer Iqbal, Debra Hoppensteadt, Jawed Fareed (United States) Francis, Pall nundarson (Iceland)
PO403-WED UNEXPECTEDLY STABLE DABIGATRAN LEVELS IN ANTICOAGULATION PO413-WED EVALUATION OF APPROPRIATENESS OF RIVAROXABAN PRESCRIPTION
TUESDAY
CLINIC PATIENTS IN A TERTIARY CARE HOSPITAL IN SINGAPORE
David L. Mcglasson*, George Fritsma (United States) Su Ching Tan*, Yashi Saw, Nicholas Seah, Edgar Tay, Eng Soo Yap (Singapore)
PO404-WED SUCCESSFUL USE OF HEMODIALYSIS IN A DABIGATRAN OVERDOSE PO414-WED IDARUCIZUMAB ANTAGONIZES DABIGATRAN-INDUCED ALTERATIONS
Ana Freixo, Alcina Ferreira, Luciana Gonalves, Lurdes Santos, Manuela Carvalho, ON PLATELET AND FIBRIN DEPOSITION IN AN IN VITRO THROMBOSIS
Antonio Sarmento, Fernando Araujo* (Portugal) MODEL WITH CIRCULATING HUMAN BLOOD
Eduardo Arellano-Rodrigo*, Irene Lopez-Vilchez, Patricia Molina, Marcos Pino, Maribel
PO405-WED CLINICAL IMPACT OF BLEEDING COMPLICATIONS WITH DIRECT ORAL Diaz-Ricart, Joanne van Ryn, Gines Escolar (Spain)
ANTICOAGULANTS FOR THE PREVENTION OF VENOUS THROMBO-
MONDAY
EMBOLISM IN ORTHOPAEDIC SURGERY: A SYSTEMATIC REVIEW AND PO415-WED DIRECT FACTOR XA INHIBITORS PARADOXICALLY PROLONG THE HALF
META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS LIFE OF ACTIVE FACTOR XA IN PLASMA
Eleonora Tamborini Permunian*, Walter Ageno, Francesco Dentali, Nicoletta Riva (Italy) Nabil Thalji*, Sriram Krishnaswamy, Rodney Camire (United States)
PO406-WED ROLE OF ANTICOAGULANT CLINICS IN THE MANAGEMENT OF PATIENTS PO416-WED DETECTING RELEVANT RIVAROXABAN OR DABIGATRAN LEVELS IN
ON NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS (NOACS) AT CLINICAL CARE BY ROUTINE COAGULATION TESTS OR THROMBOELAS-
CORK UNIVERSITY HOSPITAL (CUH) TOGRAPHY IN PATIENTS WITH ATRIAL FIBRILLATION.
Catriona Oleary*, Virginia Silvari, Muhammad Khan, Susan OShea (Ireland) Yvonne Henskens*, Rene van Oerle, Rick Wetzels, Henri Spronk, Simon Schalla, Harry
SUNDAY
Crijns, Hugo ten Cate, Arina ten Cate-Hoek (The Netherlands)
PO407-WED ARE NON-VKA ORAL ANTICOAGULANTS (NOACS) PLASMA CONCENTRA-
TIONS ASSOCIATED WITH THE RISK OF POSTOPERATIVE BLEEDING? PO417-WED CORRELATION OF CHROMOGENIC RIVAROXABAN ANTI-XA AND DAB-
PRELIMINARY RESULTS FROM THE REAL LIFE COHORT. IGATRAN ANTI-IIA ACTIVITY WITH ROUTINE PROTHROMBIN TIME AND
Pvel E. Olivera*, Vernica Pons, Vicente Cortina, Laura Lpez-Andreoni, Gonzalo ACTIVATED PARTIAL THROMBOPLASTIN TIME
Artaza, Ana Marn, Francesc Bosch, Amparo Santamara (Spain) Jane Needham*, Helen Lewis, Amanda McMullen, Tamara Everington, Savita Rangara-
jan (United Kingdom)
PO408-WED A NOVEL APPROACH TO EVALUATING ORAL ANTICOAGULANTS
PO418-WED FOUR-FACTOR PROTHROMBIN COMPLEX CONCENTRATE (4F-PCC)
SATURDAY
Jeremy B. Chang*, Ronald Realubit, Charles Karan, Jacob Rand, Nicholas Tatonetti
(United States) REVERSES BLEEDING ASSOCIATED WITH NEW ORAL ANTICOAGULANTS
(NOAC) DABIGATRAN, RIVAROXABAN, EDOXABAN AND APIXABAN IN A
PO409-WED CLINICAL PRESENTATION AND EXTENT OF CLINICAL CARE OF CLINI- RABBIT MODEL OF ACUTE BLEEDING
CALLY RELEVANT NON-MAJOR BLEEDING EVENTS WITH APIXABAN AND Eva Herzog*, Franz Kaspereit, Wilfired Krege, Jochen Mueller-Cohrs, Baerbel Doerr,
WARFARIN Peter Niebl, Dickneite Gerhard (Germany)
Suzanne M. Bleker,* Alexander Cohen, Harry Bller, Giancarlo Agnelli, Alexander
Gallus, Gary Raskob, Jeffrey Weitz, Madelyn Curto, Melanie Sisson, Saskia Middeldorp
(The Netherlands)
352 353
PO419-WED STABILITY OF RENAL FUNCTION IN PATIENTS WITH ATRIAL FIBRILLA- Platelet activation/adhesion/aggregation III
THURSDSAY
TION SWITCHED FROM WARFARIN TO TARGET-SPECIFIC ORAL ANTICO-
AGULANTS
Anum Minhas*, Qingmei Jiang, Xiaokui Gu, Keely Haymart, Eva Kline-Rogers, Steve PO428-WED INTRAVITAL THREE-DIMENSIONAL VISUALIZATION AND QUANTIFICA-
Almany, Jay Kozlowski, Gregory Krol, Scott Kaatz, James Froehlich, Geoffrey Barnes TION OF THROMBUS FORMATION BASED ON NON-LINEAR MICROSCOPE
WEDNESDAY
(United States) Satoshi Nishimura*, Asuka Sakata, Kinya Seo, Tsukasa Ohmori, Koji Eto (Japan)
PO420-WED BLEEDING ON NOVEL ORAL ANTICOAGULATION - OUR EXPERIENCE IN PO429-WED C-CBL REGULATES GPVI-INDUCED THROMBOXANE A2 GENERATION
THE NORTHERN REGION, UNITED KINGDOM: PRESENTING FEATURES INDEPENDENTLY OF THE SYK-PLC GAMMA 2 PATHWAY THROUGH Y737
AND MANAGEMENT OF BLEEDING IN INDIVIDUALS TREATED WITH A
WEDNESDAY
PHOSPHORYLATION
NOVEL ORAL ANTICOAGULANT (NOAC):RESULTS OF AN OBSERVATION- Carol Dangelmaier*, Soochung Kim, Bhanu Kanth Manne, Jianuo Jin, Mauro Torti,
AL COHORT STUDY Wallace Langdon, Steven McKenzie, Archana Sanjay, James Daniel, Satya Kunapuli
Shikha Chattree*, Adil Iqbal, Janice Robertson, Andrew Mcgregor, Tina Biss (United (United States)
POSTERS
Kingdom)
PO430-WED THROMBIN-STIMULATED PHOSPHORYLATION OF DISABLED-2 REG-
PO421-WED DRUG USE EVALUATION OF RIVAROXABAN IN TAN TOCK SENG HOSPI- ULATES ITS INTERACTION WITH CIN85 DURING HUMAN PLATELET
TAL: A REVIEW OF UTILIZATION TRENDS AMONG ASIAN POPULATION ACTIVATION
Lee Hwei Khien*, Choo Theresa (Singapore) Hui-Ju Tsai*, Hung-Pin Chiu, Chien-Sheng Chou, Man-Leng Kao, Yao-Wen Chang, Ju-
Chien Cheng, Ching-Ping Tseng (Taiwan)
TUESDAY
PO422-WED IN VITRO ASSESSMENT OF DIRECT ORAL ANTICOAGULANTS HEMOR-
RHAGIC OR THROMBOTIC RISK BY FIBRIN CLOT NANOSTRUCTURE PO431-WED INTEGRIN ALPHA IIB BETA 3-MEDIATED C-SRC ACTIVATION:
PROFILES DIFFERENTIAL BINDING TO INACTIVE AND ACTIVE C-SRC
Carhel Dassi*, Olivier Mathieu, Emmanuelle Bigo, Landry Seyve, Raphal Marlu, Beno- Joel Bennett*, Lisa Span, Patrik Nygren, Yibing Wu, Hua Zhu, David Moore, Hong
t Polack, Franois Caton, Genevive Contant (France) Chen, Heinrich Roder, William DeGrado (United States)
PO423-WED USE OF NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS FOR PO432-WED ORALLY ADMINISTERED TETRAHYDROBIOPTERIN (BH4) SUPPRESSES
NON-VALVULAR ATRIAL FIBRILLATION IN REAL-LIFE: COMPARISON PLATELET AGGREGATION VIA INTRAPLATELET PRODUCTION OF NITRIC
WITH PHASE III TRIALS OXIDE
MONDAY
Maria Cristina Vedovati*, Michela Giustozzi, Cecilia Becattini, Serenella Conti, Paolo Yui Suganuma*, Taiki Kano, Kazuhisa Ikemoto, Chiho Ichinose, Takahide Nomura,
Verdecchia, Federica Cianella, Emanuela Marchesini, Melina Verso, Esmeralda Filip- Kazunao Kondo (Japan)
pucci, Giancarlo Agnelli (Italy)
PO433-WED DROSPIRENONE ENHANCES GPIB-IX-V MEDIATED PLATELET
PO424-WED COMPARISON IN ASSESSMENT OF THE KINETICS OF NOACS (DABIGA- ACTIVATION
TRAN, RIVAROXABAN, APIXABAN) BETWEEN TARGET SPECIFIC ASSAYS Xuemei Fan, Xue Chen, Conghui Wang, Jing Dai, Yeling Lu, Yizhu Chen, Kemin Wang,
AND COMMON COAGULATION TESTS ASSAYS Junling Liu, Junfeng Zhang, Xiaolin Wu* (China)
Ramin Artang*, Jorn Dalsgaard Nielsen, Claire Dunois, Cedric Amiral, Jean Amiral
PO434-WED A PARADOXICAL HAEMORRHAGIC STATE CAUSED BY DELETION OF THE
SUNDAY
(United States)
SRC KINASE INHIBITOR CSK IS PARTIALLY RESCUED BY DELETION OF
PO425-WED ANTICOAGULATION PHARMACOKINETICS DURING DABIGATRAN CD148
THERAPY Jun Mori*, Alexandra Mazharian, Luke Boothman, Silke Heising, Louise Tee, Alexander
Thomas Orfeo*, Matthew Gissel, Kenneth Mann (United States) Tarakhovsky, Arthur Weiss, Steve Watson, Yotis Senis (United Kingdom)
PO426-WED EFFICACY OF PROTHROMBIN TIME AND ACTIVATED PARTIAL THROMBO- PO435-WED EFFECT OF HOMOCYSTEINE AND FOLIC ACID IN CA2+ HOMEOSTASIS
PLASTIN TIME AS A GAUGE FOR SPECIFIC FACTOR INHIBITION AND ROS PRODUCTION IN PLATELETS FROM BILE-DUCT LIGATION
SATURDAY
Catherine Keller*, Jasmine Dennis, Dougald Monroe, Richard Tidwell, Frank Church RATS.
(United States) Paola Romecin*, Noem Marn, David Iyu, Jose Milln, Faustino Garca, Clara Ortz,
Esther Garca, Joaqun Garca-Esta (Spain)
PO427-WED TARGET SPECIFIC ORAL ANTICOAGULANTS CAN CAUSE FALSE-POSITIV-
ITY OF CONFIRMATORY LUPUS ANTICOAGULANT TESTING, ESPECIALLY PO436-WED COMPUTATIONAL MODEL OF MICROVASCULAR THROMBUS FORMATION:
IN DRVVT TESTING THE IMPACT OF DAMAGED AREA SIZE ON THROMBUS DYNAMICS
Bo Hyun Kim*, Seongsoo Jang, Mi Hyun Bae, Young-Uk Cho, Chan-Jeoung Park (Ko- Dmitry Nechipurenko*, Mikhail Panteleev, Fazoil Ataullakhanov (Russian Federation)
rea, Republic Of)
354 355
PO437-WED SPHINGOSINE KINASE DEFICIENCY MODULATES PLATELET ACTIVATION PO448-WED MODULATION OF ACTIN CYTOSKELETON ON SHEAR-DEPENDENT
THURSDSAY
Benoit Decouture*, Boubacar Mariko, Salom Gazit, Patrice Thrond, Ludovic Couty, FIBRILLOGENESIS OF FIBRONECTIN
Blandine Dizier, Jessica Ransinan, Pascale Gaussem, Christilla Bachelot-Loza, Eric Huong T. T. Nguyen*, Khon Huynh, Rudiger Scharf, Volker Stoldt (Germany)
Camerer (France)
PO449-WED JANUS KINASE 3 (JAK3) DEPENDENT SIGNALING IS CRITICAL TO
PO438-WED MOLECULAR CHARACTERIZATION OF GAP JUNCTION MEDIATED INTER-
WEDNESDAY
CA2+-DEPENDENT PLATELET ACTIVATION AND THROMBUS FORMATION
CELLULAR COMMUNICATION IN PLATELETS Patrick Mnzer*, Britta Walker, Anna Fotinos, Roland Tegtmeyer, Florian Lang, Meinrad
Sakthivel Vaiyapuri, Alexander Bye, Michael Benn, Yumiko Sakurai, Wilbur Lam, Gawaz, Oliver Borst (Germany)
Jonathan M. Gibbins* (United Kingdom)
PO450-WED THE IDENTIFICATION AND CHARACTERIZATION OF CINNAMALDEHYDE
WEDNESDAY
PO439-WED IMPAIRED PLATELET RESPONSES TO THROMBOXANE A2 AND THROM- ANALOGS, AS NOVEL SMALL MOLECULE INHIBITORS OF PLATE-
BIN IN MICE LACKING RECEPTOR-INTERACTING PROTEIN KINASE 3 LET-SURFACE ERP57
Yiwen Zhang, Jian Zhang, Kesheng Dai* (China) Lisa-Marie Holbrook*, Elizabeth Brunt, Kayleigh Mitchell, Megan Ooms, Christine
POSTERS
Galinski, Amanda Unsworth, Jonathan Gibbins, Daniel Kennedy (United Kingdom)
PO440-WED LYSINE ACETYLTRANSFER SUPPORTS PLATELET FUNCTION
J oseph E. Aslan*, Rachel Rigg, Sandra Baker, Jiaqing Pang, Larry David, Owen McCa- PO451-WED POLYPHOSPHATE DECAY IN SERUM IS CHEMICAL, NOT ENZYMATIC
rty (United States) Carleigh F. Hebbard*, Stephanie Smith, Rachel Breitenfeld, Mark Klein, James Mor-
rissey (United States)
PO441-WED GLYCOPROTEIN VI (GPVI) IS INTERNALIZED IN PLATELETS ACTIVATED
BY SOLUBLE GPVI-SPECIFIC AGONISTS
TUESDAY
PO452-WED EFFECT OF PAR-4 TETHERED-LIGAND PEPTIDE ANALOGS ON HUMAN
Stephanie M. Jung*, Elizabeth Gardiner, Robert Andrews, Hiroyuki Shimizu, Kenji Soe- PLATELET ACTIVATION
jima, Tomohiro Nakagaki, Dominique Bihan, Richard Farndale, Masaaki Moroi (United Iraklis Moschonas, Tahsin Kellici, Vasiliki Magafa, Thomas Mavromoustakos, Andreas
Kingdom) Tzakos, Alexandros Tselepis* (Greece)
PO442-WED RELEASE OF EXTRA CELLULAR DNA CONTRIBUTES TO RENAL ISCH- PO453-WED PLATELET HSP70 REGULATES INTEGRIN ALPHAIIBBETA3 ACTIVATION
EMIA REPERFUSION INJURY THROUGH PLATELET ACTIVATION AND AND PLATELET AGGREGATION
FORMATION OF NEUTROPHIL EXTRACELLULAR TRAPS Rachel A. Rigg*, Joseph Aslan, Jiaqing Pang, Marie Nowak, Owen McCarty (United
Marcel P. B. Jansen*, Diba Emal, Gwen Teske, Sandrine Florquin, Joris Roelofs (The States)
MONDAY
Netherlands)
PO454-WED INFLUENCE OF PRO-MMP-9 ON PLATELET AGGREGATION AND ADHE-
PO443-WED TRACTOPODS: NOVEL INTEGRIN ALPHA(IIB) BETA(3) DEPENDENT SION TO FIBRINOGEN
PLATELET MEMBRANE ANCHORS PROMOTING PLATELET-ENDOTHELIAL Aneta Wrzyszcz*, Joanna Urbaniak, Mieczyslaw Wozniak (Poland)
INTERACTIONS AND THROMBO-INFLAMMATION
James Mcfadyen*, Warwick Nesbitt, Imala Alwis, Zane Kaplan, Simone Schoenwaelder, PO455-WED THE DEFECTIVE CD36 GENE MUTATIONS CAUSE A MOLECULAR
Yuping Yuan, Shaun Jackson (Australia) EXPRESSION DIVERSITY ON PLATELETS AND MONOCYTES EVEN IN
NON-DEFICIENT PHENOTYPE POPULATION
PO444-WED SPECIFIC REGULATION OF MOUSE PLATELET ADP SECRETION BY SAR- Yuya Masuda, Shogo Tamura*, Kazuhiko Matsuno, Koji Hayasaka, Chikara Shimizu,
SUNDAY
CO-ENDOPLASMIC RETICULUM CALCIUM ATPASE TYPE 3 Takanori Moriyama (Japan)
Ziane Elaib*, Frdric Adam, Eliane Berrou, Rgis Bobe, Marijke Bryckaert, Jean-
Philippe Rosa (France) PO456-WED SHEAR-INDUCED FIBRILLAR-LIKE SUPRAMOLECULE OF PLASMA FI-
BRONECTIN: A NEW FORM OF FIBRONECTIN WITH ENHANCED ACTIVITY
PO445-WED CD32 ANTIBODIES PROTECT FCGR2A MICE FROM IGG MEDIATED HY- IN PLATELET ADHESION AND AGGREGATION
PERSENSITIVITY REACTIONS AND THROMBOSIS Khon Huynh*, Huong Nguyen, Volker Stoldt, Thi-Hiep Nguyen, Rudiger Scharf (Viet
Ali Amirkhosravi*, Todd Meyer, Liza Robles-Carrillo, Monica Davila, Meghan Brodie,
Nam, Germany)
Hina Desai, Mildred Rivera-Amaya, John Francis (United States)
SATURDAY
PO457-WED ELASTIN-DERIVED PEPTIDES REGULATE LEUKOCYTE-PLATELET AGGRE-

PO446-WED CONVERGING ROLES OF PLATELETS AND CD32A IN IGG-MEDIATED
GATES
HYPERSENSITIVITY REACTIONS
Valrie Creuza, Charlotte Kawecki, Marie-Christine Mulpas, Laurent Duca, Sbastien
Ali Amirkhosravi*, Todd Meyer, Monica Davila, Liza Robles-Carrillo, John Francis (Unit-
Blaise, Batrice Romier, Laurent Debelle, Philippe Nguyen*, Nathalie Hzard, Pascal
ed States)
Maurice (France)
PO447-WED PLANT FOOD CYANIDIN-3-GLUCOSIDE INDUCES HUMAN ACTIVATED
PLATELET APOPTOSIS VIA BCL-2/BCL-XL INTRINSIC PATHWAY
Yan Yang*, Jinju Tian, Liyi Chen, Like Zhang, Wenhua Ling (China)
356 357
PO458-WED PLATELET DENSE GRANULE SECRETION DEFECTS MAY OBSCURE OUR PO469-WED EFFECT OF CARDIOPULMONARY BYPASS PUMP ON THE PLATELET
THURSDSAY
UNDERSTANDING OF A-GRANULE SECRETION MECHANISMS: EVI- FUNCTION USING PLATELET FUNCTION ANALYZER (PFA-100) PRE AND
DENCE FROM MUNC13-4-DEFICIENT PLATELETS POSTOPERATIVE CARDIAC SURGERY OPERATION
Matthew T. Harper*, Marion van den Bosch, Ingeborg Hers, Alastair Poole (United Rashed B. Albakr* (Saudi Arabia)
Kingdom)
WEDNESDAY
PO470-WED DECREASED PLATELET REACTIVITY IN WOMEN WITH HEAVY MENSTRU-
PO459-WED THE INOSITOL(1,4,5)TRISPHOSPHATE RECEPTOR TYPE 2 IS IMPORT- AL BLEEDING: A NOVEL APPROACH IN THE GYNAECOLOGY CLINIC TO
ANT IN THROMBIN INDUCED PLATELET ACTIVATION AND IS REQUIRED DIAGNOSE THROMBOPATHY USING A NOVEL PLATELET FUNCTION
FOR THROMBUS FORMATION IN VIVO. TEST.

WEDNESDAY
Kalwant S. Authi*, Harmeet Authi, Claire Sand, Fulye Argunhan, Manasi Nandi (United Heleen Eising*, Mark Roest, Philip de Groot, Jasper Remijn (The Netherlands)
Kingdom)
PO471-WED DIAGNOSTIC ACCURACY OF FLOW CYTOMETRY ANALYSIS OF PLATELET
PO460-WED TRANSCRIPTION OF EXOGENOUS RNA IN HUMAN PLATELETS LEUKOCYTE AGGREGATES IN ACUTE CORONARY SYNDROME PATIENTS
POSTERS
Vivienne Wai Tung Chan*, Stefanie Novakowski, Simon Law, Christian Kastrup (Canada) VERSUS NORMAL VOLUNTEERS
Najib Dally*, Elizabeth Eshel, Tatyana Levinas, Inna Rozenfeld, Adi Sharabi-Nov, Yifat
PO461-WED THE PI(3,4,5)P3-BINDING PROTEIN RASA3 NEGATIVELY REGULATES Zivony, Majdi Halabi (Israel)
RAP1B AND INTEGRIN AIIB3-MEDIATED SPREADING
Anthony M. Battram*, Tom Durrant, Ejaife Agbani, Samantha Moore, Alastair Poole, PO472-WED A STEP FORWARD IN THE EVALUATION OF PLATELET FUNCTION TEST-
Ingeborg Hers (United Kingdom) ING: ROUTINE, SIMULTANEOUS MEASUREMENT OF PLATELET AGGRE-
TUESDAY
GATION, SEROTONIN (5-HT) CONTENT AND SECRETION BY HPLC-ELEC-
PO462-WED DEXTRAN SULFATE TRIGGERS PLATELET AGGREGATION VIA PEAR1,
TROCHEMICAL DETECTION IN HEMOSTASIS LABORATORIES.
INDEPENDENT FROM SYK
Eduardo Aranda, Pablo Riquelme, Viviana Romero, Jaime Pereira, Teresa Quiroga,
Christophe Vandenbriele*, Yi Sun, Maarten Criel, Benedetta Izzi, Peter Verhamme,
Oslando Padilla, Olga Panes, Diego Mezzano* (Chile)
Marc Hoylaerts (Belgium)
PO473-WED OUTCOMES OF 65 PREGNANCIES IN 34 WOMEN WITH 5 DIFFERENT
PO464-WED IDENTIFICATION OF LOW MOLECULAR WEIGHT FACTORS RELEASED
FORMS OF INHERITED PLATELET FUNCTION DISORDERS ENROLLED IN
FROM PLATELETS THAT INDUCE PROCR IN MONOCYTES
A RETROSPECTIVE AND MULTICENTRIC STUDY, ON BEHALF OF EHA-
Robert E. Turnbull*, Jatinderpal Sandhu, Leong Ng, Donald Jones, Alison Goodall
SWG ON THROMBOCYTOPENIAS AND PLATELET FUNCTION DISORDERS
MONDAY
(United Kingdom)
Patrizia Noris*, Elisa Civaschi, Catherine Klersy, Federica Melazzini, Nuria Pu-
PO465-WED CELL SURFACE EXPRESSION OF CHEMERIN RECEPTORS ON HUMAN jol-Moix, Cristina Santoro, Marco Cattaneo, Ccile Lavenu-Bombled, Loredana Bury,
Pietro Minuz, Paquita Nurden, Ana Rosa Cid-Haro, Adam Cuker, Vronique Lat-
PLATELETS UPON CELL ACTIVATION
ger-Cannard, Remi Favier, Ilaria Nichele, Carlo Balduini (Italy)
Zhifei Shao, John Morser*, Lawrence Leung (United States)
PO474-WED THE VALUE OF IMPEDANCE AGGREGOMETRY IN ACUTE LEUKEMIA
PO466-WED GPIB ACTIVATION MEDIATES PLATELET TISSUE FACTOR (TF) PHOS-
PATIENTS
PHORYLATION, TRANSFER TO LIPID RAFTS (LR) AND ACTIVITY. TFPI
Andra Costache*, Silvana Angelescu, Doina Barbu, Delia Mut, Anca Lupu (Romania)
AND PROTEIN S, RELEASED BY OTHER AGONISTS, WOULD ASSEMBLE
SUNDAY
THE INHIBITORY COMPLEX (TF/FVIIA/TFPI/PS) IN LR, DAMPENING FXA PO475-WED A NATIONAL REGISTRY OF PATIENTS WITH INHERITED PLATELET DIS-
ACTIVITY ORDERS: BLEEDING SCORE IS ASSOCIATED WITH TIME OF FOLLOW-UP
Olga Panes, Viviana Romero, Csar Gonzlez, Gustavo Soto, Jaime Pereira, Diego Shoshana Revel-Vilk*, Tal Ben Ami, Chana Richter, Joanne Yacobovich, Shraga Aviner,
Mezzano* (Chile) Ayelet Ben-Barak, Amir Kuperman, Shira Ben-Barak, Chaim Kaplinsky, Hannah Tam-
ary, Gili Kenet (Israel)
PO467-WED THE IMPACT OF CIRCULATING HISTONES ON PLATELET ACTIVATION
AND THROMBUS FORMATION IN VIVO PO476-WED PLASMA MARKERS OF FIBRINOLYSIS, THROMBIN GENERATION AND
Timothy J. Stalker*, Jie Wu, Lawrence Brass (United States) PLATELET ACTIVITY IN MYELOPROLIFERATIVE NEOPLASMS
SATURDAY
Hung Chang*, Po-Nan Wang, Po Dunn, Alan Michelson, Andrew Frelinger (Taiwan)
Platelet disorders III PO477-WED COMPARISON OF A NOVEL AUTOMATED MICROCHIP FLOW-CHAMBER

SYSTEM AND CONVENTIONAL PLATELET FUNCTION TESTS IN PATIENTS
WITH ISCHEMIC CEREBROVASCULAR DISEASES
PO468-WED EVALUATION OF ISTH-BLEEDING ASSESSMENT TOOL IN INDIVIDUALS
Masako Yamazaki*, Tomoko Ohnishi, Kazuya Hosokawa, Kouji Yamaguchi, Taku
WITH SUSPECTED INHERITED PLATELET FUNCTION DISORDER RE-
Yoneyama, Akitsugu Kawashima, Yoshikazu Okada, Kazuo Kitagawa, Shinichiro Uchiya-
FERRED TO TERTIARY HEALTH CARE FACILITY IN PAKISTAN ma (Japan)
Anila Rashid, Bushra Moiz*, Bushra Rizvi, Humaira Perveen (Pakistan)
358 359
PO478-WED GENETIC AND NON-GENETIC DETERMINANTS OF MPV DIFFER IN PO487-WED NICOTINIC ACETYLCHOLINE RECEPTOR FUNCTION IN PLATELETS FROM
THURSDSAY
MALES AND FEMALES RESULTS FROM THE GUTENBERG HEALTH ALZHEIMER DISEASE PATIENTS
STUDY Peter Bugert*, Angelika Schedel, Lucrezia Hausner, Isabella Wiest, Tim Wiemers, Anip
Marina Panova-Noeva*, Vera Grossmann, Iris Hermanns, Andreas Schulz, Johanna Sarin, Dennis Hassmann, Sabrina Besenfelder, Lutz Frlich (Germany)
Mazur, Stefan Blankenberg, Tanja Zeller, Thomas Mnzel, Karl Lackner, Hugo ten Cate,
PO488-WED HEMODIAFILTRATION ELICITS AN ATTENUATED DEGREE OF PLATELET
WEDNESDAY
Philipp Wild (Germany)
ACTIVATION COMPARED TO HEMODIALYSIS
PO479-WED EVALUATION OF PLATELETS COUNT AND ACTIVATION DURING MEN- Jnos Kappelmayer*, Gergely Becs, Renta Hudk, Ildik Debreceni, Harjit Bhattoa,
STRUAL CYCLE IN YOUNG WOMEN IN ORAL CONTRACEPTIVE USE Jzsef Balla (Hungary)
Luci M. S. Dusse*, Leticia Freitas, Cristina Loures, Marcos Silva, Fernanda Nunes,
WEDNESDAY
Maria Carvalho (Brazil) PO489-WED TWICE-DAILY DOSING OF ASA OVERCOMES REDUCED PLATELET
RESPONSE TO ONCE-DAILY ASA AFTER CORONARY ARTERY BYPASS
PO480-WED REVISITING THE HEMOSTATIC DISORDER OF UREMIA : PATIENTS ON GRAFT SURGERY: A RANDOMIZED CONTROLLED TRIAL
PERITONEAL DIALYSIS (CRF-PD) HAVE NORMAL PLATELET AGGREGA-
POSTERS
Jeremy S. Paikin*, Jack Hirsh, Jeff Ginsberg, Jeff Weitz, Noel Chan, Richard Whitlock,
TION AND SECRETION BUT INCREASED PLATELET TISSUE FACTOR AC- Guillaume Pare, John Eikelboom (Canada)
TIVITY (TF-PCA), PROBABLY THE CAUSE OF INTRAVASCULAR CLOTTING
ACTIVATION. PO490-WED INCREASED MITOCHONDRIAL ELECTRON TRANSPORT ASSOCIATED
Olga Panes*, Csar Gonzlez, M. Macarena Ruiz, Camila Sandoval, Marcela Cayuleo, WITH APOPTOSIS IN HYPER-REACTIVE PLATELETS OF PATIENTS WITH
Alejandro Rojas, Mariana Soto, Melan Peralta, Jaime Pereira, Mireya Ortiz, Diego ACUTE PULMONARY EMBOLISM
TUESDAY
Mezzano (Chile) Samin Rezania*, Michael Puskarich, Scott Mercer, Jeffrey Kline (United States)
PO481-WED TREATMENT OF INHERITED PLATELET FUNCTION DISORDERS IN CHIL- PO491-WED ANTENATAL GENETIC ANALYSIS OF A JAPANESE TYPE I CD36-DEFI-
DREN AND ADOLESCENTS INTERDISCIPLINARY GUIDELINE OF THE CIENT WOMAN IN THE PREGNANCY
GERMAN SOCIETY OF THROMBOSIS AND HAEMOSTASIS RESEARCH Naomi Sanda*, Hiroko Endo, Chiaki Kato, Shigeo Nakamura, Tadashi Matsushita
(GTH). (Japan)
Ralf Knfler*, Wolfgang Eberl, Werner Streif (Germany)
PO492-WED A RELIABLE AND SIMPLE DIAGNOSTIC APPROACH TO DETECT PLATE-
PO482-WED CHANGES IN THE EXPRESSION OF PLASMA AND PLATELET MICRORNAS LET SECRETION DEFECTS IN SUBJECTS WITH MUCOCUTANEOUS
MONDAY
IN TYPE 2 DIABETES MELLITUS AND OBESITY BLEEDING
Zsolt Fejes*, Szilrd Pliska, Andrs Penyige, Mikls Kplr, Ildik Debreceni, Jnos Natalia Dovlatova*, Marie Lordkipanidz, Gillian Lowe, Ban Dawood, Jane May, Stan
Kappelmayer, Bla Nagy Jr (Hungary) Heptinstall, Steve Watson, Sue Fox (United Kingdom)
PO483-WED THROMBIN ACTIVATED FACTOR XI-DRIVEN PLATELET THROMBIN GEN- PO493-WED PLATELET CD40L CONTROLS BLEEDING DURING P2Y12 BLOCKERS
ERATION: A NEW SENSITIVE MARKER FOR HYPERCOAGULABILITY IN TREATMENT
STABLE CORONARY ARTERY DISEASE Charlotte Grosdidier, Pierre Deharo, Denis Bernot, Pierre Morange, Kelly Daryll Blanz,
Karoline Rosenplnter, Mareike Dhrmann, Kathrin Schwierczek, Ulrich Walter, Tom- Daniel Duerschmied, Dennis Wolf, Jacques Quilici, Jean-Louis Bonnet, Thomas Cui-
sset, Matthias Canault*, Marie-Chrisitne Alessi (France)
SUNDAY
maso Gori, Boris Schnorbus, Kerstin Jurk* (Germany)
PO484-WED CLINICAL AND LABORATORY FEATURES OF PATIENTS WITH PLATELET PO494-WED CLINICAL AND GENETIC PREDICTORS OF POOR PLATELET RESPONSE
DENSE GRANULE DEFICIENCY: A SINGLE INSTITUTION EXPERIENCE TO CLOPIDOGREL IN PATIENTS WHO UNDERWENT PERCUTANEOUS
Deepti Warad*, Laynalee Cardel, Cindy Uhl, Rong He, Rajiv Pruthi, Dong Chen (United CORONARY INTERVENTION
States) Ayse A. Timur*, Gurunathan Murugesan, John Barnard, Sanjay Gandhi, Deepak Bhatt,
Kandice Kottke-Marchant (United States)
PO485-WED SUCCESSFUL USE OF LOCAL PLATELET PELLET FOR CHILDREN WITH
SEVERE EPISTAXIS PO495-WED NO INCREASE IN PLATELET AGGREGATION IN HEALTHY WOMEN START-
SATURDAY
Davut Albayrak*, Canan Albayrak (Turkey) ING COMBINED ORAL CONTRACEPTIVES

Julie Brogaard Larsen*, Mustafa Vakur Bor, Anne-Mette Hvas (Denmark)
PO486-WED ELEVATED SOLUBLE PLATELET GLYCOPROTEIN VI LEVELS IN PATIENTS
AFTER LIVING DONOR LIVER TRANSPLANTATION PO496-WED THE PLATELETS CHARACTERISTICS IN TYPE 2 DIABETES MELLITUS
Takeshi Matsumoto*, Naoki Takahashi, Masanobu Usui, Katsuki Naitoh, Hideo Wada, (T2DM)
Kohshi Ohishi, Naoyuki Katayama, Shuji Isaji (Japan) Liudmila I. Buryachkovskaya*, Irina Uchitel, Alexander Sumarokov, Ula Docenko (Rus-
sian Federation)
360 361
PO497-WED STUDY OF PLATELET FUNCTION IN HEMOPHILIA A IN THE REGION OF PO508-WED NOVEL HOMOZYGOUS MUTATION IN MCFD2 AND HETEROZYGOUS
THURSDSAY
MURCIA SMALL DELETION IN LMAN1 GENES CAUSING COMBINED FACTOR V
Antonia Melero-Amor*, Faustino Garcia-Candel, Noemi Marn Atucha, Paola Romecin, AND VIII DEFICIENCY
David Garca Bernal, David Iyu, Jos Eduardo Milln, Jos Mara Moraleda (Spain) Mualla Cetin*, Sule Unal, Turan Bayhan, Johannes Oldenburg, Fatma Gumruk (Turkey)
WEDNESDAY
PO498-WED REDUCED PLATELET ACTIVITY UNDER INDUCED OXIDATIVE STRESS PO509-WED TREATMENT OF PEDIATRIC THROMBOSIS WITH DALTEPARIN SODIUM.
CONDITIONS IN GILBERTS SYNDROME avel Svirin*, Libov Larina, Alena Kazankova, Viktor Petrov, Artiom Bullih (Russian
P
Avinash Reddy Kundur*, Abishek Santhakumar, Andrew Bulmer, Indu Singh (Australia) Federation)
PO510-WED NEONATAL AND ADULT PLATELETS REVEAL A DISTINCT PROTEIN EX-
WEDNESDAY
Pediatric thrombosis and hemostasis III PRESSION PROFILE?
Eva Stokhuijzen*, Floris van Alphen, Maartje van den Biggelaar, Annemarie Koornneef,
Carmen van der Zwaan, Carlijn Kuijk, Koen Mertens, Karin Fijnvandraat, Alexander
PO499-WED CEREBRAL VENOUS THROMBOSIS OCCURRING DURING OXYMETHO-
POSTERS
Meijer (The Netherlands)
LONE THERAPY IN A PATIENT WITH FANCONI APLASTIC ANEMIA
Gokce Pinar Reis, Aysenur Bahadir, Erol Erduran* (Turkey) PO511-WED THE INFLUENCE OF CHILDHOOD IMMUNIZATIONS ON WARFARIN EF-
FECT
PO500-WED MANAGEMENT OF ORAL ANTICOAGULANT THERAPY INTERRUPTION IN Mary Bauman, Patti Massicotte, Suzanne Siddons, Aisha Bruce* (Canada)
CHILDREN
TUESDAY
Fiona Newall*, Varun Kommidi, Paul Monagle (Australia) PO512-WED NIACIN HAS LIMITED EFFECTIVENESS IN REDUCTION OF ELEVATED
LIPOPROTEIN(A) IN CHILDREN WITH OR AT RISK OF THROMBOSIS OR
PO501-WED THROMBOSIS IN CHILDREN WITH SYSTEMIC LUPUS ERYTHEMATOSUS: STROKE
ENDOGENOUS AND EXOGENOUS RISK FACTORS Kavita Patel*, Rachel Swerdlin, Robert Sidonio (United States)
O.V. Shpitonkova* , N.S. Podchernyaeva, Y.O. Kostina, M.K. Osminina, E.U. Afonina
(Russian Federation) PO513-WED HEMOSTASIS PROFILE IN CALVES RECEIVING THE CARMAT BIOPROS-
THETIC ARTIFICIAL HEART
PO502-WED EVALUATION OF AGE-DEPENDENT DOSING RECOMMENDATIONS FOR David Smadja*, Sophie Susen, Antoine Rauch, Bernard Cholley, Christian Latremouille,
THE ADMINISTRATION OF TINZAPARIN IN THE TREATMENT OF PAEDI- Daniel Duveau, Luca Zilberstein, Eric Vanbelle, Antoine Capel, Pascale Gaussem, Piet
MONDAY
ATRIC THROMBOSIS Jansen, Alain Carpentier (France)
Kat Webber, Paul Murphy, Kate Talks, John Hanley, Tina Biss* (United Kingdom)
PO514-WED PEDIATRIC STROKE OCCURRENCE IN ONE CHILDREN HOSPITAL IN
PO503-WED USING A FUNCTIONAL PLATELET ACTIVITY ANALYSIS IN CHILDREN CORDOBA, ARGENTINA
WITH UNEXPLAINED BLEEDING. FIRST RESULTS FROM RUSSIA Maria Morell*, Elizabeth Hiramatsu, Roberto Navarro (Argentina)
Pavel A. Zharkov*, Irina Demina, Aleksey Pshonkin, Galina Novichkova, Mikhail Pan-
teleev, Aleksey Maschan (Russian Federation) PO515-WED DOSE REQUIREMENTS OF ACENOCOUMAROL IN PAEDIATRIC PATIENTS
INITIATION OF THERAPY
PO504-WED FOUR YOUNG CHILDREN WITH THROMBOTIC COMPLICATIONS AS A Evelina Doncheva*, Ivanka Paskaleva (Bulgaria)
SUNDAY
RESULT OF ANTITHROMBIN HEPARIN-BINDING DEFECTS.
Michael Mitchell*, Jacky Cutler, Ruth Wheeler, Jayanthi Alamelu (United Kingdom) PO516-WED DIRECT THROMBIN INHIBITOR FOR ANTICOAGULATION: ROLE OF
ARGATROBAN IN PEDIATRIC POST LIVER TRANSPLANT PATIENTS WITH
PO505-WED RISK OF THROMBOSIS IN A COHORT OF PEDIATRIC ACUTE LYMPHO- HEPATIC ARTERY THROMBOSIS
BLASTIC LEUKEMIA PATIENTS Mukta Sharma*, Richard Hendrickson, Ryan Fischer, James Daniel, Rachel Cisernos,
Sule Unal*, Fatma Gumruk, Turan Bayhan, Selin Aytac, Betul Tavil, Baris Kuskonmaz, Megan Davis, Walter Andrews, Brian Wicklund (United States)
Mualla Cetin (Turkey)
SATURDAY
PO506-WED COMPARISON OF THE IMPACT OF SERPINC1, PROC AND PROS1 MUTA- Rare bleeding disorders II
TIONS ON THROMBOTIC PHENOTYPES IN CHILDREN AND ADULTS: AN
OBSERVATIONAL MULTICENTER COHORT STUDY
PO517-WED CHARACTERIZATION OF SIX ALTERATIONS IN ITGA2B AND ITGB3 ASSO-
Verena Limperger*, Gili Kenet, Christine Heller, Melchior Lauten, Karin Kurnik, Ulrich
Klostermeier, Rolf Mesters, Neil Goldenberg, Guy Young, Ulrike Nowak-Gttl (Germany) CIATED WITH GLANZMANNS THROMBASTHENIA
Essa Sabi*, Vincenzo Leo, Areej Al-Musbahi, Asmaa Al-Marwani, Michael Makris,
PO507-WED ACQUIRED VON WILLEBRAND DISEASE IN A PATIENT WITH UNDERLY- Martina Daly (United Kingdom)
ING BECKWITH-WIEDEMANN SYNDROME
Fatma Gumruk*, Sule Unal, Turan Bayhan, Mualla Cetin (Turkey)
362 363
PO518-WED TWO FAMILIES FROM ARGENTINA WITH FX DEFICIENCY DUE TO TWO PO528-WED CHARACTERIZATION OF PATIENTS WITH A MILD TO MODERATE BLEED-
THURSDSAY
DIFFERENT MUTATIONS (P.CYS241GLY AND P.GLN138ARG). ING PHENOTYPE: RESULTS OF THE VIENNA BLEEDING BIOBANK (VIBB)
Hugo Guglielmone*, Luisa Sambado, Maria Molina, Salvador Minoldo, Laura Lopez Stefanie Hofer*, Johanna Gebhart, Sylvia Kepa, Cihan Ay, Paul Knbl, Sabine
Galetti, Antonio Girolami (Argentina) Eichinger, Paul Kyrle, Peter Quehenberger, Simon Panzer, Ingrid Pabinger (Austria)
PO529-WED CLINICOHEMATOLOGICAL PROFILE OF RARE INHERITED COAGULATION
WEDNESDAY
PO519-WED PLATELET TYPE - VON WILLEBRAND DISEASE (PT-VWD): A DIAGNOSTIC
AND THERAPEUTIC DILEMMA IN CHILDREN DISORDERS.
Shilpa Shukla*, Harmanpreet Kaur, Maha Othman, Suchitra Acharya (United States) Somasundaram Venkatesan*, Mukul Aggarwal, Ankur Ahuja, Manoranjan Mahapatra,
Renu Saxena (India)
PO520-WED RARE BLEEDING DISORDERS: 17 YEARS OF DIAGNOSIS IN THE HE-
WEDNESDAY
MOSTASIS LABORATORY OF THE HEMATOLOGY DEPARTMENT OF THE PO530-WED CLINICAL PRESENTATION AND MANAGEMENT OF RARE FACTOR DEFI-
UNIVERSITY HOSPITAL OF BENI MESSOUS, ALGIERS, ALGERIA CIENCIES:CASE STUDY
Karima W. Chennoukh*, Meriem Bensadok, Mylade Aribi, Nadia Zidani, Mohamed Bulent A. Antmen*, Ilgen Sasmaz, Barbaros Karagn, Goksel Leblebisatan, Yurdanur
POSTERS
Ramaoun, Meriem Belhani, Salim Nekkal (Algeria) Kilinc (Turkey)
PO521-WED FACTOR XIII DEFICIENCY: PRELIMINARY RESULTS OF THE PRO-RBDD PO531-WED SPECTRUM OF RARE BLEEDING DISORDERS
PROJECT Sitalakshmi Subramanian*, Cecil Ross, Fulton Dsouza, Anand Prakash, Parimala
Flora Peyvandi*, Roberta Palla, Marzia Menegatti, Simona Siboni, Marco Boscarino, Puttaiah, Latha Shaju (India)
Britta Lachmann, Susan Halimeh, Naveena Fatima, Munira Borhany, Nihal Ozdemir,
PO532-WED CONGENITAL FXI DEFICIENCY: A REPORT OF NINE FAMILIES FROM
TUESDAY
Marko Saracevic, Danijela Mikovic, Andrew Harvey, Andrew Mumford, Fraustina Hsu,
John Chapin, Helen Pergantou, Helen Platokouki, Ay Yilmaz, Adrianna Williamson, GERMANY AND LITHUANIA
Amy Shapiro, Alessandro Casini, Philippe de Moerloose, Jeanette Payne, Laszlo Musz- Vytautas Ivaskevicius*, Georg Goldmann, Lina Kryzauskaite, Giedre Rutkauskiene,
bek (Italy) Silvia Horneff, Natascha Marquardt, Anna Pavlova, Johannes Oldenburg (Germany)
PO522-WED EFFECTS OF FACTOR XIII DEFICIENCY ON THROMBOELASTOGRAPHY. PO533-WED TWO FEMALE CASES OF A1- ANTITRYPSIN PITTSBURGH
BASAL THROMBELASTOGRAPH AND LYSIS BY ADDITION OF STREPTO- Lijuan Cao*, Zhaoyue Wang, Ziqiang Yu, Jian Su, Wei Zhang, Changgeng Ruan (China)
KINASE ARE MORE AFFECTED THAN SOLUBILITY TESTS
Marta Martinuzzo*, Luis Barrera, Diana Altuna, Maria Tisi Baa, Quillen Amigo, Mara PO534-WED CONGENITAL FXI DEFICIENCY: PRELIMINARY RESULTS OF PHENOTYPIC
MONDAY
DÀdamo, Marina Lpez, Juan Otaso (Argentina) (CLINICAL AND LABORATORY) AND GENOTYPIC CHARACTERIZATION OF
A CASE SERIES FROM A SINGLE CENTER.
PO523-WED HIGH MOLECULAR WEIGHT KININOGEN DEFICIENCY: A REPORT OF Cristina Santoro*, Roberta Di Mauro, Maria Patrizia Bicocchi, Maura Acquila, Erminia
ELEVEN VENEZUELAN CASES Baldacci, Roberta Abbruzzese, Maria Basso, Francesco Barone, Raffaele Bochicchio,
Marion Echenagucia*, AApsara Boadas, Tibisay Jimnez, Maria Hernndez, Carlos Grazia Ferrara, Paola Volpicelli, Maria Gabriella Mazzucconi (Italy)
Acosta, Maria Dos Santos, Arlette Ruiz-Sez (Venezuela, Bolivarian Republic Of)
PO535-WED FACTOR VII DEFICIENCY AND PROPHYLAXIS DUE TO INTERVENTIONS
PO524-WED DIAGNOSIS OF FXIII DEFICIENCY: DATA FROM MULTICENTRE STUDIES Violeta Dejanova-Ilijevska*, Emilija Velkova, Violeta Neceva, Slobodan Drakulevski
AMONGST UK NEQAS AND PRO-RBDD PROJECT LABORATORIES. (Macedonia, The Former Yugoslav Republic Of)
SUNDAY
Ian Jennings*, Flora Peyvandi, Steve Kitchen, Marzia Menegatti, Roberta Palla, Isobel
Walker, Mike Makris (United Kingdom) PO536-WED COURSE OF PREGNANCY, LABOUR AND PERIOPERATIVE MANAGEMENT
OF TWO PATIENTS WITH BERNARD-SOULIER SYNDROME CASE RE-
PO525-WED THE CLINICAL FINDINGS OF CHILDREN WITH FACTOR X DEFICIENCY AT PORTS AND LITERATURE REVIEW
A SINGLE CENTER IN THE MIDDLE EAST OF TURKEY Anna Sikorska*, Justyna M Teliga-Czajkowska, Ksenia Bykowska, Bernadeta Ceglarek,
Gulen Tuysuz, Funda Tayfun*, Nihal Ozdemir (Turkey) Wieslaw Schubert, Ewa Dmoch-Gajzlerska, Krzysztof Czajkowski, Jerzy Windyga (Po-
land)
PO526-WED LUPUS ANTICOAGULANT - HYPOPROTHROMBINEMIA SYNDROME IN
SATURDAY
PATIENT - A CASE REPORT. PO537-WED INHERITED FXIII DEFICIENCY IN THE NORTHERN REGION OF TURKEY
Bernadeta Ceglarek, Ksenia Bykowska, Anna Sikorska, Beata Baran, Edyta Odnoczko, Davut Albayrak*, Canan Albayrak (Turkey)
Adam Wiszniewski*, Jerzy Windyga (Poland)
PO538-WED VON WILLEBRAND DISEASE: BE OR NOT TO BE, THAT IS THE QUESTION
PO527-WED INHERITED FXI DEFICIENCY IS NOT A RARE DISEASE IN THE NORTH- Ana Azevedo*, Isabel Freire, Teresa Fidalgo, Teresa Gago (Portugal)
ERN REGION OF TURKEY
Davut Albayrak*, Canan Albayrak (Turkey)
364 365
PO549-WED INDIRECT REGULATION OF HEMOSTATIC PROTEINS BY MIR24 AND
Regulation of coagulation and fibrinolysis II
THURSDSAY
MIR34A THROUGH HEPATIC NUCLEAR FACTOR 4 ALPHA (HNF4A)
Salam Salloum-Asfar*, Ana Belen Arroyo, Nuria Garcia-Barbera, Amarjit Chaudhry, Erin
PO539-WED IDENTIFICATION OF COAGULATION GENE 3UTR VARIANTS THAT ARE Schuetz, Vicente Vicente, Roco Gonzlez-Conejero, Constantino Martnez (Spain)
POTENTIALLY REGULATED BY MIRNAS
PO550-WED INVESTIGATION OF MODE OF ACTION OF SUGAMMADEX EFFECTS ON
WEDNESDAY
Astrid van Hylckama Vlieg*, Constantino Martnez, Carla Vossen, Salam Salloum-Asfar,
Hugoline de Haan, Ral Teruel-Montoya, Javier Corral, Pieter Reitsma, Frits Rosendaal COAGULATION
(The Netherlands) Annelieke C. Kruithof*, Cornelis Kluft, Pieter-Jan de Kam, Ria Laterveer, Matthijs
Moerland, Jacobus Burggraaf (The Netherlands)
PO540-WED IDENTIFICATION OF OESTROGEN RESPONSIVE MIRNAS ASSOCIAT-
WEDNESDAY
ED WITH THE REGULATION OF COAGULATION AND THE INCREASED PO551-WED IDENTIFYING SUBSTRATES OF PROTEIN DISULFIDE ISOMERASE USING
THROMBOTIC RISK IN PREGNANT WOMEN ENZYME VARIANTS WITH ALTERED REDOX POTENTIAL
Jasmine Tay*, Ian James, Quintin Hughes, Ross Baker (Australia) Jack D. Stopa*, Barbara Furie, Bruce Furie (United States)
POSTERS
PO541-WED STRUCTURAL AND FUNCTIONAL STUDIES OF MONOCLONAL HIGH AF- PO552-WED INHIBITORY EFFECT OF VITAMIN D INTAKE IN PLASMA FACTOR VIII
FINITY ANTIBODIES (MABS) AGAINST THE HUMAN TFPI KUNITZ-TYPE ACTIVITY AND TISSUE FACTOR EXPRESSION IN MONOCYTIC CELLS
PROTEASE INHIBITOR DOMAIN 1 Raul Teruel-Montoya*, Jesus Lozano, Antonia Miano, Ana Belen Arroyo, MJ Hernn-
Anders Svensson*, Birgitte Kjr, Jes Clausen, Berit Krogh, Peder Nrby, Jens Brein- dez, V Gmez, Salam Salloum-Asfar, Vanessa Roldn, Begoa Muia, Javier Corral,
holt, Helle Petersen (Denmark) Maria Teresa Herranz, Vicente Vicente, Rocio Gonzlez-Conejero , Constantino Martnez
TUESDAY
(Spain)
PO542-WED ORM1: A NOVEL REGULATOR OF THROMBIN GENERATION AND POTEN-
PO553-WED A NOVEL ANTI-TISSUE FACTOR PATHWAY INHIBITOR ANTIBODY, BAY
TIAL CARDIOVASCULAR RISK FACTOR
1093884, PREVENTS BLEEDING IN HEMOPHILIA A MICE
Mohammed A. Alsahli*, Matthew Denniff, Unni Krishnan, Ravi Singh, Joy Wright,
Nilesh Samani, Alison Goodall (Saudi Arabia, United Kingdom) Maria Kllnberger, Perry Liu, Derek Sim* (Germany)
PO543-WED ROLE OF COAGULATION FACTOR XI IN PROMOTING DISTAL PLATELET PO554-WED A NOVEL ANTI-TISSUE FACTOR PATHWAY INHIBITOR ANTIBODY, BAY
AGGREGATION AND THROMBUS FORMATION IN WHOLE BLOOD UNDER 1093884, RESTORES HEMOSTASIS IN INDUCED HEMOPHILIA A RAB-
FLOW BITS WITH REDUCED THROMBOGENIC POTENTIAL
MONDAY
Jevgenia Zilberman-Rudenko*, Asako Itakura, Erik Tucker, David Gailani, Stephanie Maria Kllnberger, Axel Trabandt, Volker Laux* (Germany)
Smith, Sharon Choi, James Morrissey, Andrs Gruber, Owen McCarty (United States)
PO555-WED ANTIBODIES TO INVESTIGATE THE ANTITHROMBOTIC ROLE OF ANTI-
PO544-WED NUCLEIC ACIDS AND POLYPHOSPHATE AS MODULATORS OF COAGULA- THROMBIN IIIBETA
TION Ye Jin, Subramanian Yegneswaran*, Philip Ramsey, Jian-Ming Gu, Chandra Patel,
Joshua M. Gajsiewicz*, Richard Travers, Stephanie Smith, James Morrissey (United Frank Dittmer, Uwe Gritzan, Michael Sherath, Lars Linden, Peter Bringmann, Volker
States) Laux, Katalin Kauser, Terry Hermiston (United States)
PO545-WED SELECTIVE NEUTRALIZATION OF THE SERPIN PROTEASE NEXIN-1 BY A PO556-WED POLYSTAT: A SYNTHETIC POLYMER HEMOSTAT FOR USE IN COMBINA-
SUNDAY
SPECIFIC MONOCLONAL ANTIBODY TION WITH FACTOR REPLACEMENT THERAPIES FOR HEMOPHILIA A
Marie-Christine Bouton*, Dborah Franois, Laurence Venisse, Els Brouwers, Vronique Leslie Chan*, Carol Miao, Nathan White, Suzie Pun (United States)
Arocas, Paul Declerck (France)
PO546-WED IN SILICO PREDICTION OF MICRORNA BINDING SITES IN HAEMOSTATIC Risk factors for venous thrombosis III
FACTORS
Jessica Jorritsma, Jasmine Tay*, Quintin Hughes, Ross Baker (Australia) PO557-WED THE ASSOCIATION OF ENDOGENOUS STEROID HORMONE, SHBG, AND
SATURDAY
PRECURSOR STEROID LEVELS WITH HEMOSTATIC FACTOR LEVELS IN

PO547-WED ANALYSIS OF THE MECHANISM OF SPECIES DIFFERENCES REGARDING
RECOMBINANT HUMAN SOLUBLE THROMBOMODULIN ON PROTEIN C POSTMENOPAUSAL WOMEN
ACTIVATION IN HUMAN AND MOUSE Laura B. Harrington*, Brett Marck, Kerri Wiggins, Barbara McKnight, Susan Heckbert,
Nancy Woods, Andrea LaCroix, Marc Blondon, Bruce Psaty, Frits Rosendaal, Alvin
Takashi Arioka*, Shunsuke Tawara, Takumi Sakai (Japan) Matsumoto, Nicholas Smith (United States)
PO548-WED THE IMMEDIATE AND LATE EFFECTS OF THYROID HORMONE (TRIIODO- PO558-WED OBSTRUCTIVE SLEEP APNOEA DOES NOT ENHANCE HYPERCOAGULABILI-
THYRONINE) ON MURINE COAGULATION GENE TRANSCRIPTION TY AS MEASURED BY THROMBIN GENERATION IN THE MORBIDLY OBESE
Salam Salloum-Asfar*, Anita Boelen, Pieter H. Reitsma, Bart J. M. van Vlijmen (Neth- Paradzai Chitongo*, Lara Roberts, Lyall Rebecca, Raj Patel, Simon Aylwin, Roopen
erlands, Spain) Arya (United Kingdom)
366 367
PO559-WED VEREMA - AN AFFINITY PROTEOMICS STUDY TO IDENTIFY AND TRANS- PO569-WED ASSOCIATION BETWEEN THROMBOMODULIN C.1418C>T AND VENOUS
THURSDSAY
LATE PLASMA BIOMARKERS FOR VENOUS THROMBOEMBOLISM THROMBOSIS: A META-ANALYSIS
Maria Bruzelius*, Maria Jesus Iglesias, Mun-Gwan Hong, David Trgout, Juan Carles Bei Hu*, Liang Tang, Yu Hu (China)
Souto, Margareta Holmstrm, Mattias Frnberg, Rona Strawbridge, Maria Sabater-Lle-
al, Bengt Sennblad, Angela Silveira, Jos Manuel Soria, Pierre Morange, Lynn Butler, PO570-WED NEUTROPHILS AND FACTOR XII, UNLIKE PLATELETS, ARE NOT CRU-
WEDNESDAY
Jochen Schwenk, Anders Hamsten, Jacob Odeberg (Sweden) CIAL FOR DEVELOPMENT OF EXPERIMENTAL SPONTANEOUS VENOUS
THROMBOSIS
PO560-WED ANALYSIS OF PROTHROMBIN MISSENSE MUTANTS AT 596ARG BY SIN- Marco Heestermans*, Salam Salloum-Asfar, El Houari Laghmani, Gerry Wagenaar,
GLE NUCLEOTIDE SUBSTITUTION FOR ANTICOAGULANT SYSTEM Brenda Luken, Pieter Reitsma, Bart van Vlijmen (The Netherlands)
Yuki Takagi*, Moe Murata, Yuki Nakamura, Toshihiro Kozuka, Yukiko Nakata, Ryo
WEDNESDAY
Hasebe, Akira Takagi, Tetsuhito Kojima (Japan) PO571-WED ENDOGENOUS THROMBIN POTENTIAL IS DIRECTLY CORRELATED WITH
PROTEINURIA SEVERITY AND HYPOALBUMINEMIA IN NEPHROTIC SYN-
PO561-WED RED CELL DISTRIBUTION WIDTH AND FUTURE RISK OF VENOUS DROME PATIENTS
THROMBOSIS, MYOCARDIAL INFARCTION, STROKE AND CANCER A
POSTERS
Amanda P. Waller*, Brad Rovin, Samir Parikh, William Smoyer, Marvin Nieman, Mat-
CAUSE SPECIFIC ANALYSIS. thias Kretzler, Bryce Kerlin (United States)
Trygve Ellingsen*, Jostein Lappegrd, Tove Skjelbakken, Ellisiv Mathiesen, Inger Njls-
tad, Sigrid Brkkan, John-Bjarne Hansen (Norway) PO572-WED DIFFERENTIAL EXPRESSION OF MIRNAS IN PLASMA AND PERIPHER-
AL BLOOD MONONUCLEAR CELLS COLLECTED FROM PATIENTS WITH
PO562-WED RISK OF VENOUS THROMBOSIS IN PERSONS WITH INCREASED BODY UNPROVOKED VENOUS THTOMBOEMBOLISM AND HEALTHY CONTROL
TUESDAY
MASS INDEX AND INTERACTIONS WITH OTHER GENETIC AND AC- INDIVIDUALS
QUIRED RISK FACTORS: A CASE-CONTROL STUDY Irina Starikova*, Simin Jamaly, Antonio Sorrentino, Thorarinn Blondal, Nadezhda
Daniel Ribeiro*, Willem Lijfering, Frits Rosendaal, Suzanne Cannegieter (Brazil, Neth- Latysheva, Cathrine Ramberg, Mikhail Sovershaev, John-Bjarne Hansen (Norway)
erlands)
PO573-WED THE RISK OF RECURRENT VENOUS THROMBOSIS IN PATIENTS WITH
PO563-WED DEHYDRATION AS A POSSIBLE CAUSE OF SEASONAL VARIATIONS IN (LOWER) LEG CAST IMMOBILISATION.
THE INCIDENCE OF VENOUS THROMBOEMBOLISM Banne Nemeth*, Jasmijn Timp, Frits Rosendaal, Suzanne Cannegieter (The Nether-
Elias Saad*, Ron Hoffman, Benjamin Brenner, Gleb Saharov, Yona Nadir (Israel) lands)
MONDAY
PO564-WED AN AFFINITY PROTEOMICS STUDY FOR PLASMA BIOMARKER CANDI- PO574-WED THE PREVALENCE OF CONGENITAL TROMBOPHILIA IN CHILDREN
DATES OF CARDIOVASCULAR DISEASE IN VENOUS THROMBOEMBOLISM TREATED FOR ACUTE LYMPHOBLASTIC LEUKEMIA WITH THROMBOSIS
Maria Jesus Iglesias*, Maria Bruzelius, Mun-Gwan Hong, David Trgout, Ljubica Anna Klukowska*, Katarzyna Smalisz-Skrzypczyk, Katarzyna Pawelec, Michal Matysiak
Perisic, Mattias Frnberg, Paolo Parini, Andrea Ganna, Erik Ingelsson, Peter Nilsson, (Poland)
Ulf Hedin, Mathias Uhln, Angela Silveira, Pierre Morange, Anders Hamsten, Jochen
Schwenk, Jacob Odeberg (Sweden) PO575-WED THE ASSESSMENT OF RISK FACTORS FOR THROMBOSIS IN CHILDREN
TREATED FOR NON- HODGKIN LYMPHOMA
PO565-WED LUNG DISORDERS IN ELDERLY PEOPLE ARE ASSOCIATED WITH PULMO-
Anna Klukowska*, Katarzyna Smalisz-Skrzypczyk, Iwona Malinowska, Agata Sobocins-
NARY EMBOLISM AND NOT WITH DEEP VEIN THROMBOSIS ka-Mirska, Micha Romiszewski, Micha Matysiak (Poland)
SUNDAY
Alev Karasu*, Adeleid C. Jorissen, Marissa J. Engbers, Mary Cushman, Frits R.
Rosendaal, Astrid van Hylckama Vlieg (The Netherlands) PO576-WED GENETIC AND ACQUIRED RISK FACTORS OF VENOUS THROMBOEMBO-
LISM IN YOUNG PATIENTS IN THE NORTH-WEST REGION OF RUSSIA
PO566-WED ASSESSMENT OF RISK FACTORS IN ESTABLISHED CASES OF DEEP
Anna Demyanenko*, Sergey Kapustin, Vladimir Soroka, Pavel Chechulov (Russian
VEIN THROMBOSIS (DVT) AND GREAT SAPHENOUS VEIN THROMBOSIS Federation)
(GSVT) IN INDIAN PATIENTS
Chithra Barvadheesh (India) PO577-WED LIPID LEVELS AND RISK OF RECURRENT VENOUS THROMBOSIS: RE-
SULTS FROM THE MEGA FOLLOW-UP STUDY
SATURDAY
PO567-WED JOINT EFFECT HOMOZYGOUS CARRIERS OF A RISK ALLELE IN THE Vnia Morelli*, Willem Lijfering, Frits Rosendaal, Suzanne Cannegieter (Brazil, Neth-
FIBRINOGEN GAMMA CHAIN AND OVERWEIGHT ON RISK OF VENOUS erlands)
THROMBOEMBOLISM.
Tine Lnneberg*, Erin Smith, Sigrid Brkkan, Lars Horvei, Terry Solomon, Tom Wils-
gaard, Frits Rosendaal, Kelly Frazer, John-Bjarne Hansen (Norway) Thrombophilia III
PO568-WED IMPACT OF THE ABO RS8176719 SINGLE NUCLEOTIDE POLYMOR-

PHISM ON CANCER-RELATED VENOUS THROMBOEMBOLISM PO578-WED SECONDARY THROMBOPROPHYLAXIS WITH RIVAROXABAN IN MAJOR
Olga Dziewiecka*, Erin Smith, Sigrid Brkkan, Hilde Jensvoll, Kristine Blix, Terry INHERITED THROMBOPHILIAS
Solomon, Tom Wilsgaard, Frits Rosendaal, Kelly Frazer, John-Bjarne Hansen (Norway) Karen Schreiber*, Savino Sciascia, Alexander Cohen, Beverley Hunt (Denmark, United
Kingdom)
368 369
PO579-WED MONITORING DRUG ACTIVITY OF DABIGATRAN AND RIVAROXABAN PO589-WED LMWH IN PROPHYLAXIS OF THE REPEATED PREGNANCY COMPLICA-
THURSDSAY
BY THROMBIN GENERATION USING THE CALIBRATED AUTOMATED TIONS IN WOMEN WITH THROMBOPHILIA AND MULTIPLE PREGNACY
THROMBINOSCOPE. AFTER IVF
Andrs Moret, Noelia Cabrera, Yolanda Mira, Fernando Ferrando, Saturnino Haya, Ana Natalya Makatsariya*, Nadezhda Stuleva, Jamilya Khizroeva (Russian Federation)
R Cid, Elena Mesa, Rafael Hernani, Virtudes Vila, Santiago Bonanad* (Spain)
WEDNESDAY
PO580-WED DIFFERENT PATTERNS OF THROMBOPHILIA MARKERS IN PREGNANCY Tissue factor and factor VII - III
COMPLICATIONS
Gabriella Gamba*, Lorenzo Gervaso, Chiara Ambaglio, Nicola Ghidelli, Federica Zane,
PO590-WED ANTIBODIES TO THE K2 AND K3 DOMAINS OF TISSUE FACTOR PATH-
WEDNESDAY
Fausta Beneventi (Italy)
WAY INHIBITOR (TFPI) DIFFER IN BIODISTRIBUTION AND EFFECT ON
PO581-WED BETA2-GLYCOPROTEIN I DEFICIENCY WITH VENOUS THROMBOSIS: PLASMA TFPI CONCENTRATION
IDENTIFICATION AND IN VITRO EXPRESSION STUDY OF A MISSENSE Kasper Almholt*, Brian Lauritzen, Torben Elm, Lars Holten-Andersen, Bill Vestergaard,
POSTERS
MUTATION P.LYS38GLU IN APOH GENE Mette Loftager, Lene Hansen (Denmark)
Wei Zeng*, Yu Hu (China)
PO591-WED EXPLOITING THE BIOLOGY OF TISSUE FACTOR PATHWAY INHIBITOR:
PO582-WED TOWARDS IDENTIFICATION OF GENETIC RISK FACTORS IN TWO DUTCH PROSPECT FOR FUTURE THERAPEUTIC TARGETS.
FAMILIES WITH UNEXPLAINED HEREDITARY VENOUS THROMBOEMBO- Samuel Abegunde (Nigeria)
LISM
TUESDAY
Marisa Cunha*, Pieter Reitsma, Frits Rosendaal, Joost Meijers, Saskia Middeldorp (The PO592-WED POPULATION PHARMACOKINETIC/PHARMACODYNAMIC MODELING OF
Netherlands) A NEW RECOMBINANT HUMAN FACTOR VIIA (LR769) TO DERIVE THE
DOSE TO BE STUDIED IN PHASE 3
PO583-WED RECURRENT VENOUS THROMBOEMBOLISM DURING PREGNANCY IN Johan Frieling*, Jasper Stevens, Joannes Reijers, Mattthijs Moerland, Jacobus Burg-
WOMEN WITH QUANTITATIVE ANTITHROMBIN DEFICIENCY WITH OR graaf, Kees van Leuven, Cornelis Kluft, Jean-Franois Schved (United States)
WITHOUT ANTITHROMBOTIC PROPHYLAXIS
Serena Maria Passamonti*, Andrea Artoni, Paolo Bucciarelli, Francesca Gianniello, Ida PO593-WED PRODUCTION OF HIGHLY ACTIVE RECOMBINANT HUMAN TISSUE FAC-
Martinelli (Italy) TOR PATHWAY INHIBITOR
Mathieu Castellan, Raphal Marlu, Benoit Polack*, Marie-Claire Dagher (France)
MONDAY
PO584-WED MOLECULAR ANALYSIS OF PROTEIN S DEFICIENCY IN THAILAND
Ponlapat Rojnuckarin*, Rung Settapiboon, Benjaporn Akkawat, Noppacharn Uaprasert PO594-WED COMPREHENSIVE ASSESSMENT OF THE SAFETY AND EFFICACY OF
(Thailand) FACTOR VIIA-CTP SUPPORTING PHASE 2A STUDY
Ahuva Bar-Ilan, Lior Binder, Malka Hoffman, Gili Hart* (Israel)
PO585-WED INHERITED THROMBOPHILIA AS A HIGH RISK FACTOR OF RECURRENT
PREGNANCY LOSS IN GEORGIAN POPULATION PO595-WED FACTOR VIIA-CTP, A LONG-ACTING COAGULATION FACTOR PROPOSING
Nino Pirtskhelani*, Nino Kochiashvili, Levan Makhaldiani, Nugzar Pargalava, Ketevan A NOVEL SUBCUTANEOUS (SC) ROUTE OF ADMINISTRATION FOR PRO-
Kartvelishvili, Mamuka Bokuchava (Georgia) PHYLACTIC TREATMENT EFFICACY AND SAFETY IN PREPARATION FOR
FIRST IN HUMAN STUDY.
SUNDAY
PO586-WED DO ENDOTHELIUM-RELATED GENES AND INHERITED THROMBOPHILIA Lior Binder, Malka Hoffman, Miri Zakar, Ahuva Bar-Ilan, Gili Hart* (Israel)
INTERACT IN INCREASING PREGNANCY LOSS RISK?
Ilaria Romagnuolo*, Elena Sticchi, Angela Rogolino, Agatina Alessandrello Liotta, Anna PO596-WED THE RECOMBINANT FUSION PROTEIN LINKING ACTIVATED FACTOR
Paola Cellai, Niccol Maggini, Rosanna Abbate, Cinzia Fatini (Italy) VIIA TO HUMAN ALBUMIN (RVIIA-FP) PROVIDES SUPERIOR BLEEDING
PROTECTION COMPARED TO RECOMBINANT FVIIA (RFVIIA) IN A NOVEL
PO587-WED RIVAROXABAN IN LONG-TERM SECONDARY PREVENTION OF VTE IN
MONKEY MODEL OF ACQUIRED FACTOR VIII INHIBITORS
PATIENTS WITH HEREDITARY OR ACQUIRED THROMBOPHILIA IS AS
Eva Herzog*, Elmar Raquet, Hendrik Peil, Baerbel Doerr, Alex Veldman, Stefan Schul-
EFFECTIVE AND SAFE AS STANDARD TREATMENT WITH VITAMIN K
SATURDAY
te, Sabine Zollner (Germany)

ANTAGONISTS
Grigoris T. Gerotziafas*, Eleftheria Lefkou, Vassiliki Gkalea, Anastasia Spanoudaki, PO597-WED PF-05280602, A FACTOR VIIA VARIANT WITH ENHANCED IN VITRO
Hela Ketatni, Ilias Evnorfiadis, Ismail Elalamy (France) POTENCY COMPARED TO WILD-TYPE FACTOR VIIA IN HEMOPHILIC HE-
MOSTASIS ASSAYS.
Sunita Patel-Hett*, Swapnil Rakhe, Michelle Zhao, Edwin Madison, Steven Arkin, John
PO588-WED OBSTETRIC HISTORY, COURSE OF PREGNANCY AND LABOUR OF Murphy, Debra Pittman (United States)
PATIENTS WITH MTHFR MUTATION CASE REPORT AND LITERATURE
REVIEW PO598-WED MATHEMATICAL MODELLING OF MEMBRANE-DEPENDENT FACTOR X
Justyna M Teliga-Czajkowska*, Anna Sikorska, Ksenia Bykowska, Bernadeta Ceglarek, ACTIVATION BY EXTRINSIC TENASE
Ewa Dmoch-Gajzlerska, Jerzy Windyga, Krzysztof Czajkowski (Poland) Tatiana Kovalenko (Russian Federation)
370 371
PO599-WED IN VITRO MECHANISM OF BAY 1093884 INHIBITION OF TISSUE FAC- PO609-WED MONITORING PLATELET TRANSFUSION IN THROMBOCYTOPENIC PA-
THURSDSAY
TOR PATHWAY INHIBITOR TIENTS WITH HEMATOLOGIC MALIGNANCIES MEASURED BY THROM-
Subramanian Yegneswaran*, Maria Kllnberger, Vincent Evans, Chandra Patel (United BOELASTOMETRY: A PILOT STUDY.
States) Floor Moenen*, Inge Verheijen, Ron Straat, Rick Wetzels, Erik Beckers, Yvonne Hen-
skens (The Netherlands)
PO600-WED EVALUATION OF ARYOSEVEN SAFETY (RECOMBINANT ACTIVATED FAC-
WEDNESDAY
TOR VII) IN PATIENTS WITH BLEEDING DISORDERS (AN OBSERVATION- PO610-WED CHARACTERIZATION AND EVALUATION OF THE HEMOSTATIC ACTION OF
AL POST-MARKETING SURVEILLANCE, STUDY) CRYOPRESERVED PLATELETS
Alireza Abdolahi, Gholamreza Toogeh, Mohamad Reza Managhchi, Mohammad Reza Irene Lopez-Vilchez*, Patricia Molina, Miquel Lozano, Nerea Rincon-Tome, Joan Cid,
Shaverdi*, Katayon Rahimi, Samin Roostaei, Hassan Abolghasemi, Peyman Eshghi, Ana Galan, Maribel Diaz-Ricart, Gines Escolar (Spain)
WEDNESDAY
Jayran Zebardast, Akram Sarbayani, Fatemeh Sori (Iran, Islamic Republic Of)
PO611-WED THROMBIN GENERATION POTENTIAL OF A NEW TREHALOSE-STABI-
LIZED PLATELET-DERIVED HEMOSTATIC AGENT
Transfusion II
POSTERS
Arthur Bode, Narendra Tandon*, Evgenia Matveeva, Michael Fitzpatrick (United States)
PO612-WED ASPHYXIA BY DROWNING INDUCES MASSIVE BLEEDING DUE TO HY-

PO601-WED DOSE-RELATED PULMONARY COMPLICATION RATES AFTER FRESH PERFIBRINOLYTIC DISSEMINATED INTRAVASCULAR COAGULATION
FROZEN PLASMA ADMINISTRATION FOR WARFARIN REVERSAL Michael Schwameis*, Andreas Schober, Christian Schrgenhofer, Wolfgang Sperr,
Ariela Marshall*, Michael Levine, Melissa Howell, Yuchiao Chang, Eric Riklin, Blair Herbert Schchl, Karin Janata-Schwatczek, Erol Kuerkciyan, Fritz Sterz, Bernd Jilma
TUESDAY
Parry, Ryan Callahan, Ikenna Okechukwu, Alison Ayres, Brian Nahed, Walter Dzik, (Austria)
Joshua Goldstein (United States)
PO613-WED THE STABILITY OF FVIII:C, VON WILLEBRAND FACTOR AND FIBRINOGEN
PO603-WED ANALYSIS OF MEMBRANE MICROPARTICLES AND THROMBIN GENERA- IN FFP AND CRYOPRECIPITATE IN THAI BLOOD DONORS
TION ACTIVITY OF DMSO CRYOPRESERVED PLATELETS Theera Ruchutrakool*, Songsri Gledkruemas, Tasneem Binhama, Yupa Nakkinkun,
Tseday Tegegn, Silvia De Paoli, Martina Orecna, Oumsalama Elhelu, Samuel Woodle, Waraporn Meesmat, Usanee Siriboonrit, Parichart Permpikul (Thailand)
Ivan Tarandovskiy, Mikhail Ovanesov, Jan Simak* (United States)
PO614-WED INFUSION OF CRYOPRESERVED POOLED PLATELETS IN PATIENTS
PO604-WED PHOSPHATIDYLINOSITOL-3-KINASE IS IMPAIRED FOLLOWING AMO- WITH ACUTE LEUKEMIA: PRELIMINARY RESULTS OF A CLINICAL TRIAL
MONDAY
TOSALEN AND ULTRAVIOLET A LIGHT TREATMENT OF PLATELETS IN (NCT02032134)
CONCENTRATES FOR TRANSFUSION Mariasanta Napolitano*, Stefania Arf, Lucio Lococo, Giorgia Saccullo, Giovanni De
Hendrik B. Feys*, Britt Van Aelst, Rosalie Devloo, Philippe Vandekerckhove, Veerle Francisci, Amalia Reina, Laura Orlando, Diana Diliberto, Salvatrice Mancuso, Giuseppe
Compernolle (Belgium) Tarantino, Simona Raso, Rosalia Agliastro, Francesco Dieli, Sergio Siragusa (Italy)
PO605-WED INACTIVATION OF EMERGING VIRUSES BY PASTEURIZATION IN PLAS- PO615-WED MASSIVE HAEMORRHAGE MANAGEMENT: FROM CHAOS TO ORDER.
MA-DERIVED MEDICINAL PRODUCTS LEGNANO HOSPITALS EXPERIENCE.
Nathan J. Roth, Wolfram Schfer, Thomas Nowak, Birgit Popp*, Josephine Schlosser, Ivo Beverina, Chiara Novelli*, Matteo Lucchelli, Erika Borotto, Alessandro Aloni, Bruno
Martin Eiden, M Groschup, Albrecht Grner (United States) Brando (Italy)
SUNDAY
PO606-WED PLATELETS ARE DISPENSABLE DURING THE INITIAL STEPS OF IMMU- PO616-WED INTERVENTIONS TO REDUCE BLOOD LOSS FROM LABORATORY TEST-
NOLOGICAL TRANSFUSION RELATED ACUTE LUNG INJURY (TRALI) ING IN CRITICALLY ILL PATIENTS AND IMPACT ON TRANSFUSION: A
Beatrice Hechler*, Blandine Matre, Stphanie Magnenat, Vronique Heim, Marie-Belle SYSTEMATIC REVIEW
El Mdawar, Christian Gachet, Henri de la Salle (France) Neal Manning*, Nancy Heddle, Donald Arnold, Mark Crowther, Deborah Siegal (Canada)
PO607-WED VOLUME OF FLUID RESUSCITATION IN WOMEN WITH PERSISTENT PO617-WED COMPARISON OF THE EFFECT OF FRESH FROZEN PLASMA PRE- AND
POSTPARTUM HAEMORRHAGE AND TOTAL BLOOD LOSS, MATERNAL POST-TRANSFUSION IN ITU PATIENTS ON STANDARD AND GLOBAL
SATURDAY
MORTALITY AND SEVERE MATERNAL MORBIDITY COAGULATION ASSAYS

Dacia D. Henriquez*, Kitty Bloemenkamp, Jaap Jan Zwaginga, Johanna van der Bom Emma L. Fosbury*, Jonathan Manguiat, Anne Riddell, Pratima Chowdary (United
(Netherlands) Kingdom)
PO608-WED RAPID ASSESSMENT OF PLATELET FUNCTION UNDER FLOW FOLLOW-
ING TRAUMA & RECAPITULATION OF TRAUMA-INDUCED COAGULOPA-
THY IN WHOLE BLOOD MICROFLUIDIC ASSAYS
Ruizhi Li*, Hanna Elmongy, Carrie Sims, Scott Diamond (United States)
372 373
PO628-WED CURRENT PRACTICES IN LUNG SCINTIGRAPHY FOR PULMONARY EM-
Venous thromboembolism - diagnosis III
THURSDSAY
BOLISM (PE) DIAGNOSIS: AN INTERNATIONAL SURVEY IN AUSTRALIA,
CANADA AND FRANCE
PO618-WED SERUM ALBUMIN AND S PROTEIN ARE BETTER PREDICTORS THAN Pierre-Yves Le Roux*, Matthieu Pelletier-Galarneau, Romain De Laroche, Michael
CLINICAL SCORES IN THE DIAGNOSIS OF DEEP VENOUS THROMBOSIS Hofman, Lionel Zuckier, Paul Roach, Jean-Philippe Vuillez, Rod Hicks, Grgoire Le
WEDNESDAY
IN PATIENTS WITH SEVERAL COMORBIDITIES Gal, Pierre-Yves Salaun (France)
Antonella Maria Cardella*, Giovanni Tripepi, Antonio DAssoro, Giuseppe Puccia (Italy)
PO619-WED DERIVATION OF A NEW SCORE TO PREDICT CHRONIC THROMBOEMBOL- Venous thromboembolism - epidemiology III
WEDNESDAY
IC PULMONARY HYPERTENSION AFTER ACUTE PULMONARY EMBOLISM
Frederikus A. Klok*, Olga Dzikowska-Diduch, Maciej Kostrubiec, Hubert Vliegen, Piotr PO629-WED COMPARISON OF RISK FACTORS AND OUTCOMES ASSOCIATED WITH
Pruszczyk, Gerd Hasenfu, Menno Huisman, Stavros Konstantinides, Mareike Lankeit
COMMUNITY (CAT) VERSUS HOSPITAL ACQUIRED THROMBOSIS (HAT).
(Germany, Netherlands)

POSTERS
Huw Rowswell*, Tim Nokes (United Kingdom)
PO620-WED THE PREVALENCE OF DEEP VEIN THROMBOSIS IN HOSPITALIZED
PO630-WED ASSOCIATION BETWEEN VENOUS THROMBOEMBOLISM (VTE) MINOR
PATIENTS WITH SUSPECTED PULMONARY EMBOLISM RULED OUT BY
RISK FACTORS AND THE RISK OF RECURRENCE AFTER A FIRST UN-
MULTISLICE CT ANGIOGRAPHY
PROVOKED EPISODE
Fernando Vazquez*, Maria Lourdes Posadas-Martinez, Bruno Boietti, Alejandra Rome-
ro, Fernan Gonzalez Bernaldo de Quiros, Diego Giunta, Esteban Gndara (Argentina) Luana Farren-Dai*, Grgoire Le Gal, Marc Carrier, Marc Rodger, Michael J Kovacs
TUESDAY
(Canada)
PO621-WED CEREBRAL AND SPLANCHNIC VEIN THROMBOSIS : WHAT MOLECULAR
PO631-WED DO PATIENTS WHO EXPERIENCED VENOUS THROMBOEMBOLISM DE-
GENETICS RISK FACTORS ?
SPITE THROMBOPROPHYLAXIS DURING A MEDICAL IMMOBILIZATION
Pascaline Etancelin, Aude Bagan-Triquenot, Odile Goria, Jeanne-Yvonne Borg, Chris-
tian Bastard, Vronique Lecam Duchez* (France) HAVE A WORSE OUTCOME ?
Adel Merah, Laurent Bertoletti*, Mouzayan Ginzarly, David Zeltser, Manuel Barrn,
PO622-WED A PROSPECTIVE EVALUATION OF VENOUS THROMBOEMBOLISM IN Ramon Lecumberri, Paola Ferrazzi, Pablo Csar Malfante, Maria Guil, Manuel Monreal
SPINE SURGERY: INCIDENCE, COST-EFFECTIVENESS OF PROPHYLAXIS (France)
AND BLEEDING COMPLICATIONS
MONDAY
PO632-WED DISCREPANCIES IN SEVERE RI SCREENING IN THE ELDERLY WITH
Kerry Hitos*, David Young, John Fletcher (Australia)
COCKCROFT-GAULT AND MDRD FORMULAS: 20% OF PATIENTS ARE
PO623-WED THROMBOEMBOLIC DISEASE FOLLOWING PANCREATICODUODENECTO- MISEVALUATED.
MY FOR BENIGN OR CONFIRMED MALIGNANCY: EFFICACY OF PROPHY- Nicolas Janus*, Isabelle Mah, Ismail Elalamy, Jean-Jacques Boffa, Vincent
Launay-Vacher (France)
LACTIC MEASURES AND ASSOCIATED BLEEDING COMPLICATIONS
Kerry Hitos*, John Fletcher, Lawrence Yuen, Emma Johnston, Tony Pang, Vincent Lam, PO633-WED ASSOCIATION BETWEEN RED CELL DISTRIBUTION WIDTH AND RISK OF
Michael Hollands, Arthur Richardson, Henry Pleass (Australia)
VENOUS THROMBOEMBOLISM
PO624-WED PERFORMANCE OF A DIAGNOSTIC STRATEGY USING A CLINICAL DE- Paolo Bucciarelli*, Alberto Maino, Irene Felicetta, Maria Abbattista, Serena Passamon-
SUNDAY
ti, Andrea Artoni, Ida Martinelli (Italy)
CISION RULE AND D-DIMER TESTING TO EXCLUDE UPPER EXTREMITY
DEEP VEIN THROMBOSIS IN CLINICALLY IMPORTANT SUBGROUPS PO634-WED PATIENT AND DOCTOR ENGAGEMENT: THE MISSING LINK IN PREVENT-
Nick van Es*, Suzanne Bleker, Marcello di Nisio, Ankie Kleinjan, Jan Beyer-Westen- ING VENOUS THROMBOEMBOLISM
dorf, Giuseppe Camporese, Pieter Kamphuisen, Hans-Martin Otten, Sebastian Werth,
Kerry Hitos*, Travis Stephenson, Tony Poulton, John Fletcher (Australia)
Ettore Porreca, Chiara Tonello, Harry Bller, Patrick Bossuyt (The Netherlands)
PO635-WED EPIDEMIOLOGY OF THROMBOEMBOLIC DISEASE IN PATIENTS UNDER-
PO625-WED PREDICTION OF VENOUS THROMBOSIS RISK AFTER ARTHROSCOPY OF
GOING HEPATECTOMY
THE KNEE.
SATURDAY
Kerry Hitos*, John Fletcher, Lawrence Yuen, Emma Johnston, Tony Pang, Vincent Lam,
Banne Nemeth*, Raymond van Adrichem, Saskia le Cessie, Astrid van Hylckama Vlieg,
Michael Hollands, Arthur Richardson, Henry Pleass (Australia)
Trevor Baglin, Frits Rosendaal, Suzanne Cannegieter (The Netherlands)
PO636-WED IMPACT OF WEIGHT CHANGE ON RISK OF VENOUS THROMBOEMBO-
PO627-WED RELATIONSHIP OF PATIENT AFFECT TO CLINICIAN-DERIVED PRETEST
LISM: THE TROMS STUDY
PROBABILITY ASSESSMENT FOR PULMONARY EMBOLISM
Lars Daae Horvei*, Tine Lnneberg, Sigrid Brkkan, John-Bjarne Hansen (Norway)
Jeffrey A. Kline*, Dawn Neumann (United States)
374 375
PO637-WED DEVELOPING A CASE DEFINITION FOR VENOUS THROMBOEMBO- PO647-WED MULTICENTER PROSPECTIVE STUDY OF TREATMENT AND RISK FAC-
THURSDSAY
LISM-RELATED DEATHS USING DEATH CERTIFICATES TORS FOR UNUSUAL SITE THROMBOSIS: TRUST REGISTRY
Ashley Sword-Buster*, Aaron Wendelboe, Janis Campbell, Michele Beckman, Nimia Kim Ma*, Phillip Wells, Charlotte Guzman, David Anderson, Mark Blostein, Andrew
Reyes, Gary Raskob (United States) Hirsch, Michael Kovacs, Alejandro Lazo-Langner, Marc Rodger, Vicky Tagalakis, Susan
Kahn (Canada)
PO638-WED CASE-FATALITY AFTER PULMONARY EMBOLISM AND STROKE IN SUB-
WEDNESDAY
JECTS WITH ATRIAL FIBRILLATION PO648-WED THE WITHIN PATIENT EFFECT OF STATIN USE ON COAGULATION IN
Ina Rye-Holmboe*, Erin Hald, Anders Vik, Ellisiv Mathiesen, Inger Njlstad, Maja-Lisa VITAMIN K ANTAGONIST USERS: A CROSSOVER STUDY
Lchen, Sigrid Brkkan, John Bjarne Hansen (Norway) Nienke Van Rein*, Joseph Biedermann, Stacey Bonafacio, Marieke Kruip, Willem
Lijfering, Felix van der Meer (The Netherlands)
WEDNESDAY
PO639-WED HOSPITAL ACQUIRED THROMBOSIS (HAT) IN AN IRISH TERTIARY RE-
FERRAL HOSPITAL. PO649-WED RIVAROXABAN VERSUS VITAMIN K ANTAGONIST IN PROVOKED DEEP
Muhammad I. Khan*, Joe Eustace, Susan OShea (Ireland) VENOUS THROMBOSIS - WHICH TREATMENT IS BETTER FOR THE PA-
TIENT ?
POSTERS
PO640-WED PREVALENCE AND RISK FACTORS FOR PULMONARY EMBOLISM IN Emma Groarke*, William Courtney, Jane Conway, Elaine Conway, Deborah Bourke, Jean
PATIENTS WITH ACUTE EXACERBATION OF COPD: RESULTS OF A LARGE Saunders, Michael Watts, Denis OKeeffe (Ireland)
COLLABORATIVE STUDY.
Francesco Dentali*, Dimitriy Arioli, Fulvio Pomero, Nicola Mumoli, Jos Vitale, Filippo PO650-WED WARFARIN DOSING AND TIME TO THERAPUTIC INTERNATIONAL NOR-
Pieralli, Paola Gnerre, Micaela La Regina (Italy) MALIZED RATIO IN PATIENTS WITH HYPERCOAGULABILITY SYNDROMES
TUESDAY
Pushpinderdeep S. Kahlon*, Shahzaib Nabi, Haythem Ali (United States)
PO641-WED RISK OF FIRST AND RECURRENT VENOUS THROMBOSIS IN INDIVIDU-
ALS TREATED WITH ANTIBIOTICS PO651-WED SAFETY OF STOPPING ANTICOAGULANT TREATMENT FOR CANCER-AS-
Jasmijn F. Timp*, Suzanne Cannegieter, Vladimir Tichelaar, Sigrid Braekkan, Frits SOCIATED VENOUS THROMBOEMBOLISM AFTER REACHING COMPLETE
Rosendaal, Saskia le Cessie, Willem Lijfering (The Netherlands) REMISSION FROM CANCER
Tom Van Der Hulle*, Paul den Exter, Pim van den Hoven, Jacobus van der Hoeven, Felix
PO642-WED INHOSPITAL MORTALITY AMONG CLINICAL AND SURGICAL INPATIENTS van der Meer, Jeroen Eikenboom, Menno Huisman, Frederikus Klok (The Netherlands)
RECENTLY DIAGNOSED WITH VENOUS THROMBOEMBOLIC DISEASE
Fernando Vazquez*, Maria Posadas-Martinez, Maria Grande-Ratti, Jimena Vicens, PO652-WED PROLONGED USE OF LMWH DURING PREGNANCY AND BONE SAFETY
MONDAY
Bruno Boietti, Paloma Rojas-Saunero, Gabriel Waisman, Fernan Quiros, Diego Giunta Pivi J. Galambosi*, Risto Kaaja (Finland)
(Argentina)
PO653-WED PRACTICE VARIATION IN THE MANAGEMENT OF DISTAL DVT BETWEEN
PO643-WED LOW PREVALENCE OF SYMPTOMATIC VENOUS THROMBOEMBOLISM GPS AND VASCULAR MEDICINE PHYSICIANS: A FRENCH SURVEY OF
AFTER HIP AND KNEE ARTHROPLASTY AT SIRIRAJ HOSPITAL PHYSICIAN PRACTICES
Chompunut Wongprasert*, Theera Ruchutrakool, Bundarika Suwannawiboon, Keerati Jean-Philippe Galanaud*, Jennifer Almosni, Arthur Meusy, Pierre Frances, Isabelle
Chareancholvanich, Pacharapol Udomkiat, Yupa Nakkinkun, Tasneem Binhama, Quere (France)
Yingyong Chinthammitr (Thailand)
PO654-WED IMPROVING EVIDENCE-BASED DECISIONS IN VTE TREATMENT: SIMU-
SUNDAY
PO644-WED THE PREVALENCE AND DIAGNOSTIC CHARACTERISTICS OF PATIENTS LATION IN CONTINUING EDUCATION
WITH ANTIPHOSHOLIPID ANTIBODIES IN CHRONIC THROMBOEMBOLIC Jelena Spyropoulos*, Alex Spyropoulos (United States)
PULMONARY HYPERTENSION
Timothy Fernandes, Timothy Morris, William Auger* (United States) PO655-WED RISK OF RECURRENT VENOUS THROMBOEMBOLISM IN PATIENTS
WITH A FIRST EPISODE OF UNPROVOKED PULMONARY EMBOLISM: A
PO645-WED PREDICTORS OF VENOUS THROMBOEMBOLISM RECURRENCE, PRE-SPECIFIED SUBGROUP ANALYSIS FROM THE PADIS PE RANDOM-
ADJUSTED FOR TREATMENTS AND INTERIM EXPOSURES: A POPULA- IZED TRIAL
TION-BASED CASE-COHORT STUDY Francis Couturaud*, Olivier Sanchez, Gilles Pernod, Patrick Mismetti, Patrick Jego,
SATURDAY
John Heit, Brian Lahr, Aneel A. Ashrani*, Tanya Petterson, Kent Bailey (United States) Elisabeth Duhamel, Karine Provost, Claire Bal dit Sollier, Emilie Presles, Philippe Cas-
tellant, Florence Parent, Pierre Yves Salaun, Luc Bressollette, Michel Nonent, Philippe
Lorillon, Philippe Girard, Karine Lacut, Marie Gugan, Jean Luc Bosson, Silvy Laporte,
Venous thromboembolism - therapy III Christophe Leroyer, Herv Dcousus, Guy Meyer, Dominique Mottier (France)
PO656-WED NEW ORAL ANTICOAGULANTS (NOACS) IN VTE TREATMENT: WILL MON-

PO646-WED DABIGATRAN OR WARFARIN IN THE TREATMENT OF ACUTE VENOUS ITORING DIMINISH THEIR COST-EFFECTIVENESS?
THROMBOEMBOLISM IN ANTIPHOSPHOLIPID SYNDROME Carla Vossen*, Katya Sion, Andreas Karabis (The Netherlands)
Sam Schulman*, Samuel Goldhaber, Clive Kearon, Ajay Kakkar, Sebastian Schellong,
Henry Eriksson, Elke Schueler, Martin Feuring, Jrg Kreutzer (Canada)
376 377
PO657-WED COMMUNITY HOSPITALS ARE USING NOVEL ORAL ANTICOAGULANTS PO666-WED MULTI-DOSE DRUG DISPENSING AS A TOOL TO IMPROVE MEDICATION
THURSDSAY
AND MORE ASPIRIN AS VENOUS THROMBOEMBOLISM (VTE) PROPHY- ADHERENCE: A CROSSOVER STUDY
LAXIS FOLLOWING TOTAL HIP AND KNEE REPLACEMENT Nienke van Rein*, Kristel de Geus, Suzanne Cannegieter, Pieter Reitsma, Felix van der
Darae Ko*, Alok Kapoor, Adam Rose, Amresh Hanchate, Donald Miller, Michael Winter, Meer, Willem Lijfering (The Netherlands)
Joseph Palmisano, Zhaoyang Teng, Lori Henault, Yorghos Tripodis, Anita Karcz, Elaine
WEDNESDAY
Hylek (United States) PO667-WED CYP2C9 POLYMORPHISM CONTROLS PHENPROCOUMON METABOLISM
RESULTING IN SEVERE BLEEDING EVENTS
PO658-WED GLOBAL ADHERENCE TO AMERICAN COLLEGE OF CHEST PHYSICIANS Gesa Wiegand*, Ralf Rauch, Vanya Icheva, Elke Schffeler, Michael Hofbeck, Matthias
GUIDELINES FOR THROMBOPROPHYLAXIS AFTER MAJOR ORTHOPEDIC Schwab (Germany)
SURGERY. HAVE WE IMPROVED? A SYSTEMATIC REVIEW OF THE LITER-
WEDNESDAY
ATURE PO668-WED INCREASED RISK FOR MAJOR BLEEDS AFTER MINOR BLEEDS IS DE-
Maria P Bautista, Miguel Farfan*, Guillermo Bonilla, Adolfo Llinas (Colombia, Colombia) TERMINED BY UNKNOWN PERSISTENT COMMON RISK FACTORS
Nienke Van Rein*, Willem Lijfering, Isabelle van Vliet, Felix van der Meer, Saskia le
POSTERS
PO659-WED INCIDENCE OF THROMBOEMBOLISM IN KOREAN MULTIPLE MYELOMA Cessie, Suzanne Cannegieter, Pieter Reitsma (The Netherlands)
PATIENTS WITH THALIDOMIDE INDUCTION CHEMOTHERAPY; COMPARI-
SON PREVIOUS DATA IN KOREA. PO669-WED ACCURACY OF A WARFARIN MAINTENANCE DOSE PREDICTOR AFTER
Hyerim Ha*, Jeonghwan youk, Hyunkyung Park, Jeong-Ok Lee, Soo-Mee Bang, Ki-
COMPLETION OF THE 10 MG INITIATION NOMOGRAM
Hwan Kim, Jin-Hyun Park, Youngil Koh, Inho Kim, Sung-Soo Yoon, Seonyang Park Parvaneh Fallah*, Philip S. Wells, Melissa A Forgie, Lisa Duffett (Canada)
(Korea, Republic Of)
TUESDAY
PO670-WED A NATIONAL ANTICOAGULANT MANAGEMENT SERVICE PROVIDED BY
PO660-WED THROMBOPROPHYLAXIS IN A PATIENT WITH MORBID OBESITY COMMUNITY PHARMACIES IN NEW ZEALAND ACHIEVES A HIGH LEVEL
Saket Badle*, Simon Coppack, Peter MacCallum (United Kingdom) OF ANTICOAGULANT CONTROL WHICH IS SAFE AND CONVENIENT FOR
PATIENTS.
PO661-WED COAGULATION TESTS FOR DETECTION OF VKA THERAPY INSUFFICIEN- Paul L. Harper*, Ian McMichael, Dale Griffiths, Claire Hill (New Zealand)
CY IN PATIENTS WITH ACUTE DEEP VEIN THROMBOSIS
Faina Verkholomova*, Aleksey Krylov, Aleksander Shulutko, Fazly Ataullakhanov, Ilya PO671-WED RECURRENT THROMBOTIC EVENTS AFTER DISCONTINUATION OF VITA-
Serebriyskiy (Russian Federation) MIN K ANTAGONIST TREATMENT FOR SPLANCHNIC VEIN THROMBOSIS:
A MULTICENTER RETROSPECTIVE COHORT STUDY
MONDAY
PO662-WED BIOMARKERS FOR PREDICTION OF REOCCURRENCE OF VENOUS Nicoletta Riva*, Walter Ageno, Daniela Poli, Sophie Testa, Simona Pedrini, Lucia
THROMBOEMBOLISM Marigo, Piera Sivera, Samantha Pasca, Giuseppe Malcangi, Cavallero Giobatta, Pietro
Abimbola Jarvis*, Elizabeth Villalobos-menuey, Linda Jacobson, Julie Smith, Marilyn Falco, Lucia Ruocco, Carmelo Paparo, Eugenio Bucherini, Luciano Suriano, Luigi Ria,
Manco-Johnson (United States) Alberto Tosetto (Italy)
PO672-WED PATIENTS WITH VITAMIN K ANTAGONIST (VKA) RESISTANCE: DOES

Vitamin K antagonists III THE IDENTIFICATION OF VKORC1 MUTATIONS HELP PREDICTING THE
MAINTENANCE DOSAGE?
Isabelle Gouin-Thibault*, Emeline Gillet, Julie Frchaud, Alain Stpanian, Emmanuel
SUNDAY
PO663-WED MEDICATION ADHERENCE OF NOVEL ORAL ANTICOAGULANT VERSUS de Maistre, Cline Narjoz, Jean-Louis Golmard, Pascale Gaussem, Anne-Marie Fischer,
WARFARIN Katell Peoch, Marie-Anne Loriot, Virginie Siguret (France)
Yi Feng Lai*, Jun Kai Neo, Mcvin Hua Heng Cheen, Ming Chai Kong, Heng Joo Ng
(Singapore) PO673-WED SIMILAR PERFORMANCE OF HASBLED, CHADS2 AND CHA2DS2VASC
SCORES IN BLEEDING RISK PREDICTION: DO WE NEED A BLEEDING
PO664-WED RISK OF MAJOR BLEEDING IN PATIENTS TREATED WITH VITAMIN K AN- SCORE?
TAGONISTS OR ASPIRIN. A SYSTEMATIC REVIEW AND META-ANALYSIS Daniela Poli*, Emilia Antonucci (Italy)
Fernando Vazquez*, Joaquin Gonzalez, Marc Carrier, Gregoire Le Gal, Esteban Gandara
SATURDAY
(Argentina) PO674-WED LOW INCIDENCE OF BLEEDING EVENTS IN A REAL WORLD, VITAMIN

K ANTAGONIST-TREATED PATIENT POPULATION: RESULTS FROM THE
PO665-WED IMPACT OF POINT-OF-CARE INR MONITORING ON ANTICOAGULANT START-REGISTER
CONTROL DURING TREATMENT WITH VITAMIN K ANTAGONISTS IN Emilia Antonucci, Daniela Poli, Alberto Tosetto, Vittorio Pengo*, Armando Tripodi,
PATIENTS MONITORED BY A SPECIALIZED ANTICOAGULATION CLINIC: A Nicola Magrini, Francesco Marongiu, Gualtiero Palareti (Italy)
POPULATION BASED COHORT STUDY
Joseph Biedermann*, Nienke van Rein, Peter Buhre, Moniek de Maat, Felix van der
Meer, Frank Leebeek, Marieke Kruip (The Netherlands)
378 379
SCIENTIFIC PROGRAM
PO675-WED THE START-REGISTER (SURVEY ON ANTICOAGULATED PATIENTS REG-
THURSDSAY
ISTER): FOCUS ON PATIENTS TREATED FOR NON-VALVULAR ATRIAL
FIBRILLATION
Emilia Antonucci, Daniela Poli, Alberto Tosetto, Vittorio Pengo*, Armando Tripodi,
Nicola Magrini, Francesco Marongiu, Gualtiero Palareti (Italy)
PO676-WED EAHAD-DB: A COMBINED COAGULATION FACTOR VARIANT DATABASES Scientific Program

RESOURCE FOR THE CLINICAL AND SCIENTIFIC COMMUNITIES
Daniel J. Hampshire*, Andrea Cairo, Gerard Dolan, Muriel Giansily-Blaizot, Keith
Gomez, Anne Goodeve, Geoffrey Kemball-Cook, Christopher Ludlam, John McVey,
Thursday, June 25
WEDNESDAY
Johannes Oldenburg, Stephen Perkins, Flora Peyvandi, Pavithra Rallapalli (United
Kingdom)
PO677-WED POLYHEDROCYTES IN WHOLE BLOOD CLOTS OF PATIENTS WITH VE-

NOUS THROMBOEMBOLISM TAKING VITAMIN K ANTAGONISTS: A ROLE
OF THE QUALITY OF ANTICOAGULATION
Micha Zabczyk*, Jakub Siudut, Anetta Undas (Poland) Trainee Tracks (oral sessions only):
Platelets track
TUESDAY
MONDAY
SUNDAY
SATURDAY
380 381
THURSDSAY
08:15 08:30 PERIOPERATIVE TREATMENT OF HEMOPHILIA A PATIENTS: BLOOD
Thursday, June 24, 2015
THURSDSAY
OR387 GROUP O PATIENTS ARE AT RISK OF BLEEDING COMPLICATIONS
endrika C. Hazendonk*, Janske Lock, Ron Matht, Karina Meijer, Marjolein Peters,
H
ORAL COMMUNICATIONS 7 08:00-09:15 Britta Laros-van Gorkom, Felix van der Meer, Maritte Driessens, Karin Fijnvandaat,
Frank Leebeek, Marjon Cnossen (The Netherlands)
Venous thromboembolism therapy II Plenary Hall F&G 08:30 08:45 SPINART 3-YEAR ANALYSES: PATIENT- AND JOINT-LEVEL CHANGES
ORALS
OR388 IN COLORADO ADULT JOINT ASSESSMENT SCALE AND MAGNETIC
Moderators: Michael Kovacs (Canada), Carl-Erik Dempfle (Germany)
RESONANCE IMAGING SCORES WITH BAYERS SUCROSE-FORMULATED
RECOMBINANT FACTOR VIII IN ADOLESCENTS AND ADULTS
WEDNESDAY
08:00 08:15 PATIENTS WITH CANCER ASSOCIATED THROMBOSIS: LONG-TERM VTE
OR381 RECURRENCES AND BLEEDINGS ACCORDING TO CANCER SITE; Sharon Funk*, Bjrn Lundin, Walter Hong (United States)
DATA FROM THE RIETE REGISTRY 08:45 09:00 BLEEDING PHENOTYPE AND BASELINE FVIII LEVEL IN PATIENTS WITH
Isabelle Mah*, Laurent Bertoletti, Jean Chidiac, Javier Trujillo-Santos, Fares Mousta-
OR389 NONSEVERE HEMOPHILIA A: RESULTS FROM THE INSIGHT STUDY
fa, Henri Bounameaux, Lloren Font, Maria Dolores Adarraga, Pablo Javier Marchena,
Manuel Monreal (France) amantha C. Gouw*, Eva Stokhuijzen, Alice van Velzen, Corien de Groot-Eckhardt,
S
Charles Hay, Jan Astermark, Frans Smiers, Cedric Hermans, Ri Liesner, Massimo Morfi-
08:15 08:30 DURATION OF ANTICOAGULATION FOLLOWING ACUTE VENOUS ni, Marjolein Peters, Johanna van der Bom, Karin Fijnvandraat (The Netherlands)
OR382 THROMBOEMBOLISM IN ROUTINE CARE IN ENGLAND: 09:00 09:15 NOVEL IMAGING TECHNIQUE FOR ASSESSMENT OF EARLY CARTILAGE
AN OBSERVATIONAL STUDY USING CPRD-HES DATABASES
TUESDAY
OR390 CHANGES IN HAEMOPHILIC KNEES AND ANKLES
aure Lacoin, Essra Ridha*, Cinira Lefevre, Vidya Moorthy, Mridula Vasudev, Steven
L
umayun Ahmed*, Johnny Wang, Afsaneh Amirabadi, Marshall Sussman, Carina
H
Lister, Alex Bird, Ian Minns, Ameet Bakhai, Raza Alikhan (United Kingdom)
Man, Victor Blanchette, Andrea Doria (Canada)
08:30 08:45 NO BENEFICIAL EFFECT OF STATINS IN REDUCING RECURRENT
OR383 DISEASE IN A META-ANALYSIS OF 21,587 PATIENTS WITH ACUTE Risk factors for venous thrombosis - III Room 701
SYMPTOMATIC VENOUS THROMBOEMBOLISM TREATED IN PHASE 3
TRIALS COMPARING DIRECT ORAL ANTICOAGULANTS WITH VITAMIN K Moderators: Leslie Zypchen (Canada), Jacob Odeberg (Sweden)
ANTAGONISTS
08:00 08:15 AGEING OF THE VENOUS VALVES AS A NEW RISK FACTOR FOR VENOUS
MONDAY
Mandy N. Lauw*, Sam Schulman, Martin Gebel, George Zhang, Min Lin, Michael
Grosso, Harry Buller (The Netherlands) OR391 THROMBOSIS IN THE ELDERLY THE BATAVIA STUDY
lev Karasu*, Alexandr Sramek, Frits R. Rosendaal, Astrid van Hylckama Vlieg (The
A
08:45 09:00
NET CLINICAL BENEFIT OF HOSPITALIZATION VERSUS OUTPATIENT Netherlands)
OR384 MANAGEMENT OF PATIENTS WITH ACUTE PULMONARY EMBOLISM
08:15 08:30 IMPACT OF INHERITED RISK FACTORS OF VENOUS THROMBOSIS
Pierre-Marie Roy*, Daniel Corsi, Antony Theogene, Carine de Wit, Carole Dennie,
Grgoire Le Gal, Marc Rodger, Phillip Wells, Marc Carrier, Esteban Gandara (France) OR392 ON THE ASSOCIATIONS BETWEEN FAMILY HISTORY OF MYOCARDIAL
INFARCTION AND RISKS OF MYOCARDIAL INFARCTION AND VENOUS
09:00 09:15 EXTENDED DURATIONS OF ANTICOAGULATION AND MORTALITY THROMBOEMBOLISM
SUNDAY
OR385 FOLLOWING INCIDENT VENOUS THROMBOEMBOLISM IN THE Q-VTE Birgit Smbrekke*, Caroline Lind, Ludvig Rinde, Erin Smith, Terry Solomon, Tom Wils-
COHORT gaard, Inger Njlstad, Ellisiv Mathiesen, Frits Rosendaal, Sigrid Brkkan, Kelly Frazer,
Adi Klil-Drori*, Janie Coulombe, Samy Suissa, Vicky Tagalakis (Canada) John-Bjarne Hansen (Norway)
08:30 08:45 IMPACT OF VARIANTS IN THE FACTOR 5 GENE ON THE RISK OF

Hemophilia joint disease and clinical Room 718 OR393 VENOUS THROMBOEMBOLISM IN CANCER
Olga Dziewiecka*, Erin Smith, Sigrid Brkkan, Hilde Jensvoll, Kristine Blix, Terry
Moderators: Jenny Goudemand (France), Marilyn Manco-Johnson (United States) Solomon, Tom Wilsgaard, Frits Rosendaal, Kelly Frazer, John-Bjarne Hansen (Norway)
SATURDAY
08:00 08:15 INTRACRANIAL HAEMORRHAGE IN CHILDREN WITH INHERITED 08:45 09:00 IDENTIFICATION OF NEW GENETIC RISK FACTORS FOR VENOUS
OR386 BLEEDING DISORDERS IN THE UK 2003-2013. OR394 THROMBOSIS BY TARGETED SEQUENCING: RESULTS OF THE MILES
lizabeth Chalmers*, Jayanthi Alamelu, Peter Collins, Mary Mathias, Jeanette Payne,
E STUDY
Mike Richards, Oliver Tunstall, Mike Williams, Ben Palmer, Andrew Mumford (United Hugoline G. de Haan*, Astrid van Hylckama Vlieg, Luca Lotta, Marcin Gorski, Paolo
Kingdom) Bucciarelli, Ida Martinelli, Trevor Baglin, Flora Peyvandi, Frits Rosendaal (The Nether-
lands)
382 383
THURSDSAY
09:00 09:15 OCCURENCE AND PREDICTORS OF RECURRENCE WITHIN 3 YEARS 08:30 08:45 PROOF OF PRINCIPLE FOR EFFICIENCY IN THROMBOSIS OF
THURSDSAY
OR395 AFTER A FIRST EPISODE OF ACUTE VENOUS THROMBOEMBOLISM: OR403 SHEAR-GENERATED PLATELETS FROM CULTURED MEGAKARYOCYTES
WORCESTER VENOUS THROMBOEMBOLISM STUDY udrey Pietrzyk-Nivau, Sonia Poirault-Chassac, Alexandre Kauskot, Ccile Denis,
A
Wei Huang*, Robert Goldberg, Frederick Anderson, Frederick Spencer (United States) Dominique Baruch* (France)
08:45 09:00 A NOVEL FUNCTION OF CLEC-2 IN MEGAKARYOPOIESIS: CLEC-2/PDPN

Anti-platelet agents clinical Room 801 OR404 MICROENVIRONMENT FACILITATES EXPANSION AND MATURATION OF
ORALS
Moderators: Marco Cattaneo (Italy), Alan Michelson (United States)
MEGAKARYOCYTES
Shogo Tamura*, Katsue Suzuki-Inoue, Nagaharu Tsukiji, Toshiaki Shirai, Tomoyuki
WEDNESDAY
Sasaki, Makoto Osada, Kaneo Satoh, Yukio Ozaki (Japan)
08:00 08:15 PLATELET FUNCTION AS A PREDICTOR OF ISCHEMIC AND BLEEDING
OR396 EVENTS IN PAD PATIENTS UNDERGOING PTA: RESULTS FROM TRAIANO 09:00 09:15 THE DENSE BLOOD VESSEL NETWORK IN THE MURINE BONE MARROW
STUDY. OR405 SPATIALLY LIMITS MEGAKARYOCYTE MIGRATION
Rossella Marcucci, Anna Maria Gori*, Renato Valenti, Rita Paniccia, Stefania Basili, J udith M. M. Van Eeuwijk*, David Stegner, Ouzhan Angay, Jrgen Pinnecker, Mike
Elisa Grifoni, Giulia Naldini, Guido Parodi, Laura Napoleone, David Antoniucci, Fran- Friedrich, Christian Brede, Andreas Beilhack, Bernhard Nieswandt, Katrin Heinze
cesco Violi, Rosanna Abbate (Italy) (Germany)
08:15 08:30 IDENTIFICATION OF CANDIDATE GENE MODULATING PLATELET

OR397 REACTIVITY IN ASPIRIN-TREATED PATIENTS USING A NOVEL Von Willebrand factor II Room 716
NETWORK-BASED APPROACH
TUESDAY
Moderators: Mackenzie Bowman (Canada), Scott Diamond (United States)
nne Zufferey, Mark Ibberson, Jean-Luc Reny, Sverine Nolli, Mylne Docquier, Ioan-
A
nis Xenarios, Jean-Charles Sanchez, Pierre Fontana* (Switzerland)
08:00 08:15 SINGLE NUCLEOTIDE VARIANTS C.2365A>G AND C.2385T>C ARE
08:30 08:45 PRASUGREL MONOTHERAPY PROVIDES MOST EFFECTIVE PLATELET OR406 ASSOCIATED WITH INCREASED VWF PLASMA LEVELS THROUGH AN
OR398 INHIBITION WITHOUT AFFECTING FIBRIN CLOT DYNAMICS IN EFFECT ON MRNA HALF-LIFE
INDIVIDUALS WITH DIABETES Ahmad Mufti*, Anne Goodeve, Ian Peake, Daniel Hampshire (United Kingdom)
obert Storey, Penny rice, Natalie Oxley, Fladia Phoenix, Zeyad Kurdee, Rhodri King,
R
08:30 08:45 PATHOLOGICAL VWF FIBERS RESIST TPA AND ADAMTS13 WHILE
Michal Zabczyk, Peter Grant, Ramzi Ajjan* (United Kingdom)
OR408 FACILITATING THE CONTACT PATHWAY AND SHEAR-INDUCED PLATELET
MONDAY
08:45 09:00 GENERATION AND CHARACTERIZATION OF A PANEL OF NANOBODIES ACTIVATION
OR399 TOWARDS HUMAN MMP-2: APPLICATION TO THE STUDY OF MMP-2 IN Bradley A. Herbig*, Scott Diamond (United States)
CARDIOVASCULAR PATHOPHYSIOLOGY
08:45 09:00 THE SCAVENGER RECEPTOR STABILIN-2 (STAB-2) MEDIATES
Alessandro Marturano*, Maarten Hendrickx, Loredana Bury, Emanuela Falcinelli,
Giorgia Manni, Marco Malvestiti, Gholamreza Hassanzadeh-Ghassabeh, Serge Muyl- OR409 CLEARANCE OF HUMAN VON WILLEBRAND FACTOR AND FACTOR VIII
dermans, Paul Declerck, Paolo Gresele (Italy) BY LIVER SINUSOIDAL ENDOTHELIAL CELLS
aura L. Swystun*, Colleen Notley, Ilinca Georgescu, Kate Sponagle, Kai Schledzews-
L
09:00 09:15 HIGH ON ASPIRIN PLATELET REACTIVITY PREDICTS CARDIAC DEATH ki, Cyrill Graud, Sergij Goerdt, Paula James, David Lillicrap (Canada)
SUNDAY
OR400 IN ACUTE CORONARY SYNDROME PATIENTS UNDERGOING PCI
(RECLOSE2-ACS STUDY) 09:00 09:15 VON WILLEBRAND FACTOR DEFICIENCY CAUSES INCREASED
ossella Marcucci*, Anna Maria Gori*, Rita Paniccia, Elisa Grifoni, Betti Giusti, Re-
R OR410 ANGIOGENESIS FOLLOWING ISCHEMIC TISSUE DAMAGE
nato Valenti, Guido Parodi, Angela Migliorini, David Antoniucci, Gian Franco Gensini, ichard D. Starke*, Omary Chillo, Koval Smith, Elisabeth Deindl, Anna Randi (United
R
Rosanna Abbate (Italy) Kingdom)
Factor VIII III Room 713

Megakaryocytes and thrombopoiesis III Room 714
SATURDAY
Moderators: Margareth Ozelo (Brazil), Elisa Mancuso (Italy)

Moderators: Dominique Baruch (France), Pudur Jagadeeswaran (United States)
08:00 08:15 CELL-SPECIFIC FVIII EXPRESSION IN HEMOPHILIA A GENE THERAPY TO

08:00 08:15 MICE LACKING THE INHIBITORY COLLAGEN RECEPTOR LAIR1 EXHIBIT
OR411 OVERCOME IMMUNOLOGICAL RESPONSES
OR401 A MILD THROMBOCYTOSIS AND HYPERACTIVE PLATELETS
Simone Merlin*, Elvira Cannizzo, Valentina Bruscaggin, Kevin Bellofatto, Antonia
lexandra Mazharian*, Steven Thomas, Marie Lordkipanidz, Danai Bem, Silke
A
Follenzi (Italy)
Heising, Linde Meyaard, Yotis Senis, Steve Watson (United Kingdom)
08:15 08:30 IDENTIFICATION OF HOX GENES CONTROLLING THROMBOPOIESIS IN

OR402 ZEBRAFISH
Pudur Jagadeeswaran*, Hemalatha Sundaramoorthi (United States)
384 385
THURSDSAY
08:15 08:30 INFLUENCE OF VWF-FVIII BINDING ON ARTERIAL THROMBUS Regulation of coagulation and fibrinolysis Room 717
THURSDSAY
OR412 FORMATION AND STABILITY IN A MURINE MODEL OF SEVERE TYPE 2N
VWD Moderators: William Sheffield (Canada), Maureane Hoffman (United States)
Laura L. Swystun*, Ilinca Georgescu, Jeff Mewburn, Kate Sponagle, Colleen Notley,
David Lillicrap (Canada) 08:00 08:15 PLASMINOGEN ACTIVATOR INHIBITOR-1 PARTIALLY PROTECTS MICE
OR421 AGAINST CARDIAC FIBROSIS BY INHIBITING UROKINASE-TYPE
08:30 08:45 A FVIII/VWF CHIMERIC PROTEIN WITH VWF INDEPENDENT
ORALS
PLASMINOGEN ACTIVATOR-MEDIATED PLASMINOGEN ACTIVATION
OR413 PHARMACOKINETIC PROPERTIES Kamlesh K. Gupta*, Deborah Donahue, Mayra Sandoval-Cooper, Donna Emge, Francis
usannah Patarroyo-White*, Douglas Drager, Tongyao Liu, Ayman Ismail, Jiayun Liu,
S Castellino, Victoria Ploplis (United States)
WEDNESDAY
Amy Holthaus, Ekta Chhabra, John Kulman, Volker Schellenberger, Robert Peters
(United States) 08:15 08:30 PROTECTIVE ROLE OF PROTEASE NEXIN-1 AGAINST LUNG FIBROSIS IN
OR422 BLEOMYCIN-TREATED MICE
08:45 09:00 FVIII-VWF INTERACTION ASSESSED BY HYDROGEN-DEUTERIUM Dborah Franois*, Marie-Christine Bouton, Laurence Venisse, Martine Jandrot-Perrus,
OR414 EXCHANGE MASS SPECTROMETRY AND BINDING AFFINITY Vronique Arocas (France)
J ohan H. Faber*, Kasper Lamberth, Jens Hansen, Ole Hvilsted Olsen, Martin Heit-
mann, Gert Bolt, Thomas Nylandsted Krogh, Frederik Rode, Marianne Kjalke, Jesper 08:30 08:45 AN ANTI-STAPHYLOCOAGULASE MONOCLONAL ANTIBODY INHIBITS
Haaning, Lars Thim (Denmark) OR423 PROTHROMBIN ACTIVATION AND PROLONGS SURVIVAL IN MICE
FOLLOWING STAPHYLOCOCCUS AUREUS INFECTION.
09:00 09:15 IMPROVED PHARMACOKINETICS AND IN VIVO EFFICACY OF
aitlyn Begins*, William Church, Ashoka Maddur, Peter Panizzi, Paul Bock (United
K
TUESDAY
OR415 PLATELET-TARGETED FACTOR VIIA-XTEN IN HUMAN ALPHA IIB States)
TRANSGENIC / HEMOPHILIA A MICE
Arjan Van Der Flier*, Joe Salas, Zhan Liu, Tamera Ashworth, Elena Kistanova, Sarah 08:45 09:00 PROTEIN DISULFIDE ISOMERASE RELEASED DURING THROMBUS
Smith, Kai Chen, Deana Rabinovich, Siyuan Tan, Volker Schellenberger, David Light, OR424 FORMATION CLEAVES A DISULFIDE BOND IN PLASMA VITRONECTIN
Robert Peters (United States) AND ENABLES ITS BINDING TO ALPHAVBETA3 INTEGRIN.
Sheryl R. Bowley*, Barbara Furie, Bruce Furie (United States)
Platelets III Room 715
09:00 09:15 IDENTIFICATION OF ALPHA-1 PROTEINASE INHIBITOR VARIANTS WITH
Moderators: Kesheng Dai (China), Viola Lorenz (Germany) OR425 ENHANCED SPECIFICITY FOR ACTIVATED FACTOR XI OVER THROMBIN
MONDAY
VIA COMBINED PHAGE DISPLAY AND BACTERIAL LYSATE SCREENING
08:00 08:15 TARGETED DOWNREGULATION OF CLEC-2 OCCURS THROUGH SRC Varsha Bhakta, William Sheffield* (Canada)
OR416 FAMILY KINASE DEPENDENT INTERNALIZATION IN MOUSE PLATELETS
iola Lorenz*, David Stegner, Simon Stritt, Timo Vgtle, Friedemann Kiefer, Walter
V
Witke, Steve Watson, Barbara Walzog, Bernhard Nieswandt (Germany) Blood coagulation tests II Room 705
Moderators: Aida Inbal (Israel), Cedric Carter (Canada)
08:15 08:30 PROTEIN DISULFIDE ISOMERASE DENITROSYLASE ACTIVITY IN
OR417 PLATELET ACTIVATION
08:00 08:15 ANALYSIS OF FACTOR XIA, FACTOR IXA AND TISSUE FACTOR ACTIVITY
SUNDAY
oelof Bekendam*, Srila Gopal, Pavan Bendapudi, Kristina Cook, James Dilks, Lin
R
Lin, Sheryl Bowley, Jack Stopa, Mingdong Huang, Kevin Croce, Bruce Furie, Phil Hogg,
OR426 IN BURN PATIENTS
Robert Flaumenhaft (United States) Saulius Butenas*, Daniel Jo, Lauren Moffatt, Jeffrey Shupp (United States)
08:30 08:45 PEAR1: A NOVEL LINK BETWEEN IGE-MEDIATED ALLERGY AND 08:15 08:30 THE WHOLE BLOOD THROMBIN GENERATION TEST PREDICTS
OR418 CARDIOVASCULAR DISEASE OR427 BLEEDING RISK IN PATIENTS TAKING VITAMIN K ANTAGONISTS
i Sun, Christophe Vandenbriele*, Alexandre Kauskot, Peter Verhamme, Marc Hoy-
Y Saartje Bloemen*, Arina ten Cate-Hoek, Hugo ten Cate, Bas de Laat (The Netherlands)
laerts, Gavin Wright (Belgium)
08:30 08:45 COMPARATIVE IN VITRO EVALUATION OF THROMBIN GENERATION
SATURDAY
08:45 09:00
CHARACTERIZATION OF A NOVEL INTEGRIN BINDING PROTEIN THAT IS OR428 ASSAY (TGA) AFTER SPIKING FRESH FROZEN PLASMA (FFP) OR
OR419 ESSENTIAL FOR ALPHAIIBBETA3 OUTSIDE-IN SIGNALING AND PROTHROMBIN COMPLEX CONCENTRATE (PCC) TO SAMPLES FROM
HEMOSTASIS PATIENTS UNDERGOING ORTHOTOPIC LIVER TRANSPLANTATION (OLT)
Binggang Xiang*, Guoying Zhang, Shaojing Ye, Cai Huang, Jun Liu, Min Tao, Chang- Mikael Perin, Laurent Ardillon, Benedicte Delahousse, Ephrem Salam, Yves Gruel*
geng Ruan, Susan Smyth, Sidney Whiteheart, Zhenyu Li (United States) (France)
09:00 09:15 GPVI INTERACTION WITH POLYMERIZED FIBRIN BOOSTS THROMBIN 08:45 09:00 EFFECTS OF APIXABAN ON PT AND APTT AS DETERMINED WITH A FULL
OR420 GENERATION AND THROMBUS GROWTH OR429 RANGE OF REAGENTS: RESULTS OF A UK NEQAS EXERCISE
Pierre Mangin*, Elmina Mammadova-Bach, Bndicte Dumont, Stphane Loyau, tephen Kitchen, Ian Jennings*, Anna Lowe, Dianne Kitchen, Tim Woods, Isobel Walk-
S
Christian Gachet, Vronique Ollivier, Martine Jandrot-Perrus (France) er (United Kingdom)
386 387
THURSDSAY
09:00 09:15 PROTHROMBOTIC MECHANISMS IN A SETTING OF PERI-OPERATIVE 08:45 09:00 INHIBITION OF MICROPARTICLE INDUCED TUMOR CELL MIGRATION BY
THURSDSAY
OR430 BRIDGING WITH LOW MOLECULAR WEIGHT HEPARINS IN PATIENTS OR439 LMWH TINZAPARIN
UNDERGOING SURGERY Frank Gieseler*, Hans Gamperl, Corinna Plattfaut, Rike Theophil, Tabea Quecke (Ger-
ieter Eijgenraam, Hugo ten Cate, Yvonne Henskens, Ren van den Ham, Arina ten
P many)
Cate-Hoek* (The Netherlands)
09:00 09:15 NOVEL REGULATION OF TFPI EXPRESSION BY OESTROGENS IN BREAST
OR440 CANCER CELLS THROUGH MICRORNAS
ORALS
Fibrinogen and fibrin II Room 707
uda O. Ali*, Ana Arroyo, Roco Conejero, Benedicte Stavik, Nina Iversen, Per Morten
H
Moderators: Michael Nagler (The Netherlands), Nicola Mutch (United Kingdom) Sandset, Constantino Martnez, Grethe Skretting (Norway)
WEDNESDAY
08:00 08:15 SEQUENCING OF FGA, FGB AND FGG REVEALS BOTH NOVEL AND Fibrinolytic system II Room 711
OR431 PREVIOUSLY DESCRIBED MUTATIONS IN PATIENTS WITH CONGENITAL
FIBRINOGEN DEFICIENCIES Moderators: Tom Plug (The Netherlands), Colin Longstaff (United Kingdom)
Natalie Smith*, Leila Noetzli, Tara Adams, Salvador Minoldo, Hugo Guglielmone,
Marilyn Manco-Johnson, Jorge Di Paola (United States) 08:00 08:15 THROMBIN-ACTIVATABLE FIBRINOLYSIS INHIBITOR (TAFI) PEPTIDES
OR441 SELECTIVELY MODULATE TAFI ACTIVATION BY THROMBIN OR THE
08:15 08:30 HEREDITARY AFIBRINOGENEMIA LONG-TERM OBSERVATION OF A THROMBIN-THROMBOMODULIN COMPLEX
OR432 HIGHLY THROMBOGENIC CONDITION AND ITS MANAGEMENT Tom Plug*, Arnoud Marquart, Pauline Marx, Joost Meijers (The Netherlands)
ichael Nagler*, Johanna Kremer Hovinga, Lorenzo Alberio, Kristiina Peter-Salonen,
M
TUESDAY
Hendrik von Tengg-Kobligk, Daniel Lottaz, Bernhard Lmmle (Switzerland, Nether- 08:15 08:30 LYSINE RESIDUES 42, 43, AND 44 OF THROMBIN ACTIVABLE
lands) OR442 FIBRINOLYSIS INHIBITOR CONTRIBUTE TO ITS ACTIVATION BY THE
THROMBIN-THROMBOMODULIN COMPLEX IN A COOPERATIVE FASHION
08:30 08:45 ELEVATED FIBRINOGEN BUT NOT FIBRINOGEN GAMMA PRIME IN
hengliang Wu*, Ann Gils, Paul Declerck, James Fredenburgh, Jeffrey Weitz, Paul Kim
C
OR433 ABDOMINAL AORTIC ANEURYSMAL DISEASE
(Canada)
raser Macrae*, Tittu Thomas, Anne Johnson, Katherine Bridge, Helen Philippou, D
F
Scott, Robert Ariens (United Kingdom) 08:30 08:45 ELUCIDATION OF THE MOLECULAR MECHANISMS OF TWO
OR443 NANOBODIES THAT INHIBIT TAFI ACTIVATION AND TAFIA ACTIVITY
08:45 09:00 ROLE OF FIBRIN(OGEN) IN HEPATOCYTE PROLIFERATION AFTER
MONDAY
iaohua Zhou*, Stephen Weeks, Sergei Strelkov, Nico Callewaert, Paul Declerck (Bel-
X
OR434 ACETAMINOPHEN OVERDOSE
gium)
Anna Kopec*, Nikita Joshi, Keara Towery, Holly Cline-Fedewa, Matthew Flick, James
Luyendyk (United States) 08:45 09:00 THE ROLE OF THROMBIN-ACTIVATABLE FIBRINOLYSIS INHIBITOR IN
OR444 HUMAN ABDOMINAL AORTIC ANEURYSMS
09:00 09:15 PROTHROMBOTIC PROPERTIES OF FIBRIN CLOTS IN PATIENTS WITH
atherine I. Bridge*, Mark Hesketh, Lize Bollen, Fraser Macrae, Anne Johnson, Helen
K
OR435 NON-ALCOHOLIC FATTY LIVER DISEASE
Philippou, Julian Scott, Ann Gils, Robert Arins (United Kingdom)
ilma Potze, Mohammad Siddiqui, Sherry Boyett, Jelle Adelmeijer, Kalyani Daita,
W
Arun Sanyal, Ton Lisman* (The Netherlands) 09:00 09:15 MECHANISTIC STUDIES AND FIBRIN SPECIFICITY OF STREPTOKINASE
SUNDAY
OR445 FROM STREPTOCOCCUS PYOGENES
Cancer and thrombosis basic II Room 709 Craig Thelwell*, Sian Huish-Williams, Colin Longstaff (United Kingdom)
Moderators: Ali Al-Hashimi (Canada), Cihan Ay (Austria)
08:00 08:15 ANTI-TUMORIGENIC EFFECTS ARE EXERTED BY EXOSOMES DERIVED

Coffee break time in the Foyers (Levels 700 and 800)
OR436 FROM HEPARIN TREATED HUMAN BREAST CANCER CELLS AND From 09:15 to 09:30
PERSIST EVEN AFTER HEPARIN TREATMENT HAS BEEN DISCONTINUED
SATURDAY
Yunliang Chen*, Michael Scully, Christopher Goodwin, Ajay Kakkar (United Kingdom)
08:15 08:30 CONTRIBUTION OF ANTI-GRP78 AUTOANTIBODIES TO PROSTATE

OR437 CANCER PROGRESSION THROUGH TISSUE FACTOR PROCOAGULANT
ACTIVITY
Ali Al-Hashimi* (Canada)
08:30 08:45 CANCER CELLS BXPC3 AND MCF7 DIFFERENTIALLY REVERSE THE
OR438 INHIBITION OF THROMBIN GENERATION BY APIXABAN, FONDAPARINUX
AND ENOXAPARIN
388 Aurlie Rousseau, Patrick Van Dreden, Ismail Elalamy, Grigoris Gerotziafas* (France) 389
THURSDSAY
11:32 - 11:45 VON WILLEBRAND FACTOR, ADAMTS13 AND THE RISK OF MORTALITY:
Thursday, June 25, 2015
THURSDSAY
AS181 THE ROTTERDAM STUDY
ichelle A. H. Sonneveld*, Mohammed Ikram, Maryam Kavousi, Albert Hofman, Oscar
M
PLENARY SESSION 09:30-10:15 Franco, Frank Leebeek, Moniek de Maat (The Netherlands)
SYMPOSIA
Louis B. Jaques Plenary Lecture Novel anti-platelet agents Plenary Hall F&G
Moderator: Geoff Werstuck (Canada) Moderators: Paul Jurasz (Canada), Jean-Franois Schved (France)
WEDNESDAY
09:30 - 10:15 Non-coding RNAs: novel therapeutic targets in cardiovascular disease 10:30-11:00 CHEMOPROTEOMIC DISCOVERY OF NOVEL ANTI-PLATELET TARGETS
Stefanie Dimmeler (Germany) AS182 Leslie Parise (United States)
11:00 11:15 A SMALL MOLECULE INHIBITOR OF ASK1 PROTECTS MICE FROM

AS183 THROMBOSIS WITH MINIMAL EFFECT ON HEMOSTASIS
Meghna Naik*, Brendan Bachman, David Maloney, Ulhas Naik (United States)
11:15 - 11:30 SITE SPECIFIC INHIBITION OF THROMBUS FORMATION USING SHEAR

AS184 SENSITIVE ANTI-THROMBOTIC NANOPARTICLES
TUESDAY
Erik Westein*, Christopher Molloy, Joy Yao, Karlheinz Peter (Australia)
11:30 - 11:45 MODULATING PLATELET REACTIVITY THROUGH REGULATED CONTROL

AS185 OF FREE RGS18 LEVELS
Peisong Ma*, Andrew Sinnamon, Kristy Ou, Lawrence Brass (United States)
Louis B. Jaques, 1911-1997

Glycobiology Room 711

MONDAY
Moderators: Gilbert White (United States), Silvia Giannini (United States)
10:30-11:00
PLATELET GLYCOBIOLOGY: THE POWERS OF POSTTRANSLATIONAL
ABSTRACT SYMPOSIA 10:30-11:45
AS186 MODIFICATIONS
Karin Hoffmeister (United States)
ADAMTS13 Room 717
11:00 11:15 RECESSIVE AND TRANSIENT ANTITHROMBIN DEFICIENCY CAUSED
Moderators: Johanna Kremmer Hovinga (Switzerland), Andrew Yee (United States) AS187 BY A WIDE SPECTRUM OF CONGENITAL DISORDERS OF
SUNDAY
N-GLYCOSYLATION WITH UNUSUAL CLINICAL FEATURES.
10:30-10:50 ADAMTS13: DYNAMIC INTERACTIONS WITH VON WILLEBRAND FACTOR IDENTIFICATION OF A NEW THROMBOPHILIC DISORDER
AS177 David Lane (United Kingdom) Maria Eugenia De La Morena-Barrio*, Irene Martnez-Martnez, Mara Toderici, Carmen
De Cos, Teresa Sevivas, Antonia Miano, Jos Padilla, Dirk Lefeber, Jaak Jaeken,
10:50 - 11:04 ADAMTS13-INDUCED UNFOLDING OF THE VON WILLEBRAND FACTOR Vicente Vicente, Javier Corral (Spain)
AS178 A2 DOMAIN
11:15 - 11:30 MECHANISM OF N-LINKED GLYCAN STABILISATION OF THE VON
ouis Deforche*, Hendrik Feys, Karen De Ceunynck, Aline Vandenbulcke, Nele Van-
L
deputte, Elien Roose, Yoshihiro Fujimura, Kenji Soejima, David A. Lane, Brenda Luken, AS188 WILLEBRAND FACTOR A2 DOMAIN
SATURDAY
J. Evan Sadler, Hans Deckmyn, Simon De Meyer, Karen Vanhoorelbeke (Belgium) Christopher J. Lynch*, David Lane (United Kingdom)
11:04 - 11:18 N-LINKED GLYCOSYLATION IS A MODULATOR OF ADAMTS13 11:30 - 11:45 PEPTIDE ANTAGONISTS FOR P-SELECTIN DISCRIMINATE BETWEEN
AS179 EXPRESSION, STRUCTURE AND FUNCTION. AS189 SULFATIDE-DEPENDENT PLATELET AGGREGATION AND
Agata A. Nowak*, Rens de Groot, Mike Laffan, Thomas McKinnon (United Kingdom) PSGL-1-MEDIATED CELL ADHESION
Suzanne J. Korporaal*, Tom Molenaar, Bianca Lutters, Illiana Meurs, Sandra Verhoef,
11:18 - 11:32 ADAMTS13 DEFICIENCY WORSENS MURINE COLITIS AND TREATMENT Martin Ijsseldijk, Johan Kuiper, Theo Van Berkel, Jan-Willem Akkerman, Erik Biessen
AS180 OF WILD TYPE COLITIC MICE WITH RHADAMTS13 LEADS TO (The Netherlands)
IMPROVEMENT
Naamah L. Zitomersky*, Melanie Demers, Kimberly Martinod, Maureen Gallant, Denisa
Wagner (United States)
390 391
THURSDSAY
Unusual site venous thrombosis Room 718 11:32 - 11:45 IDENTIFICATION OF CARDIOVASCULAR DISEASE SPECIFIC GENES AND
THURSDSAY
AS202 THEIR REGULATING MIRNAS
Moderators: Alejandro Lazo-Langner (Canada), Walter Ageno (Italy) Vrushali Deshpande*, Madan Ghatge, Lakshmi Mundkur, Vijay Kakkar (India)
10:30-11:00 MANAGEMENT OF MESENTERIC VEIN THROMBOSIS

AS194 Fibrinolysis in health and disease Room 707
SYMPOSIA
Geoffrey Nguyen (Canada)
Moderators: Francis Castellino (United States), Thijs van Mens (The Netherlands)
11:00 11:15 ANTITHROMBOTIC TREATMENT AND OUTCOMES OF CIRRHOTIC
AS195 PATIENTS WITH SPLANCHNIC VEIN THROMBOSIS: A SUB-STUDY FROM
10:30-11:00
ROLE OF PLASMINOGEN RECEPTOR KT (PLG-RKT) IN HEALTH AND
WEDNESDAY
THE ISTH REGISTRY
AS203 DISEASE
Nicoletta Riva*, Walter Ageno, Marco Senzolo, Sam Schulman, Jan Beyer-Westendorf,
Lindsey Miles (United States)
Rita Duce, Rita Santoro, Pieter Kamphuisen, Doyeun Oh, Cecilia Becattini, Kryssia
Rodriguez, Giovanni Barillari, Serena Maria Passamonti, Maria Anna Guardascione,
11:00 11:15 PLASMINOGEN LOCALIZES TO DISTINCT CAPS ON
Gianpaolo Vidili, Antonella Vaccarino, Francesco Dentali, IRSVT study investigators
(Italy) AS204 PHOSPHATIDYLSERINE-EXPOSING PLATELETS AND PROMOTES
THROMBUS LYSIS UNDER FLOW
11:15 - 11:30 NEXT-GENERATION DNA SEQUENCING APPROACH TO IDENTIFY NOVEL Claire S. Whyte, Frauke Swieringa, Tom Mastenbroek, Ausra Lionikiene, Marcus Lance,
AS196 GENETIC RISK FACTORS UNDERLYING CEREBRAL VEIN THROMBOSIS. Paola van der Meijden, Johan Heemskerk, Nicola Mutch* (United Kingdom)
arcin M. Gorski*, Hugoline de Haan, Astrid van Hylckama Vlieg, Luca A. Lotta, Paolo
M
11:15 - 11:30 INHIBITION OF TAFI AFFECTS AAA FORMATION AND RUPTURE IN THE
TUESDAY
Bucciarelli, Serena Passamonti, Ida Martinelli, Frits Rosendaal, Flora Peyvandi (Italy)
AS205 ANGIOTENSIN II MODEL OF ABDOMINAL AORTIC ANEURYSM
11:30 - 11:45 THE CURRENT MANAGEMENT STRATEGIES AND CLINICAL OUTCOME OF atherine I. Bridge*, Charlotte Revill, Marc Bailey, Nadira Yuldasheva, Stephen
K
AS197 UPPER EXTREMITY DEEP VEIN THROMBOSIS Wheatcroft, Roger Butlin, Richard Foster, Julian Scott, Ann Gils, Robert Ariens (United
uzanne Bleker*, Nick van Es, Ankie Kleinjan, Harry Bller, Pieter Kamphuisen, Anita
S Kingdom)
Aggarwal, Jan Beyer-Westendorf, Giuseppe Camporese, Benilde Cosmi, Thomas Gary,
Angelo Ghirarduzzi, Karin Kaasjager, Teresa Lerede, Peter Marschang, Karina Meijer, 11:30 - 11:45 ROLE OF DNA METHYLATION IN CANDIDATE GENES REGIONS ON
Hans-Martin Otten, Ettore Porreca, Marc Righini, Peter Verhamme, Sanne van Wissen, AS206 TISSUE PLASMINOGEN ACTIVATOR LEVELS
Marcello Di Nisio (The Netherlands) Nora Zwingerman*, Irfahan Kassam, Vinh Truong, Dylan Assi, Jessica Dennis, Michael
MONDAY
Wilson, Phil Wells, Pierre-Emmanuel Morange, David-Alexandre Trgout, France
Gagnon (Canada)
Atherosclerosis: progression and development Room 709
Moderators: Hugo Ten Cate (The Netherlands), Tilman Hackeng (The Netherlands) Protein C and sepsis Room 714
10:30-10:50
ENDOTHELIAL DYSFUNCTION, INFLAMMATION AND THE INITIATION OF Moderators: Laura Pepler (Canada), Kamlesh Gupta (United States)
AS198 ATHEROSCLEROSIS
Myron Cybulsky (Canada) 10:30-11:00 PROTEIN C (APC) FUNCTIONS IN INFLAMMATORY DISEASES
AS207 Charles Chuck Esmon (United States)
SUNDAY
10:50 - 11:04 PLATELET-DERIVED MATRIX METALLOPROTEINASE (MMP)-2
AS199 CONTRIBUTES TO ATHEROSCLEROSIS PROGRESSION IN 11:00 11:15 SILENCING ANTITHROMBIN AND PROTEIN C IN APOE KNOCKOUT MICE
HYPERCHOLESTEROLEMIC MICE AS208 CAUSES SEVERE COAGULOPATHY BUT NOT ATHEROTHROMBOSIS
Stefania Momi*, Emanuela Falcinelli, Giorgia Manni, Paolo Gresele (Italy) Amber B. Ouweneel*, Marco Heestermans, Bart Van Vlijmen, Miranda Van Eck (The
Netherlands)
11:04 - 11:18
11:15 - 11:30 E-WE THROMBIN ACTIVATES PROTEIN C ON THE PLATELET SURFACE
AS200 MACROPHAGE M2 DIFFERENTIATION INDUCES PAI-1 EXPRESSION VIA
AS209 AND RAPIDLY INTERRUPTS EXPERIMENTAL THROMBUS PROGRESSION
SATURDAY
A STAT6 DEPENDENT PATHWAY

IN PRIMATES
hilipp Hohensinner*, Barbara Thaler, Christoph Kaun, Benjamin Ebenbauer, Michael
P
Fischer, Gerald Maurer, Kurt Huber, Walter Speidl, Johann Wojta (Austria) Erik Tucker*, Michael Wallisch, Norah Verbout, Brandon Markway, Owen McCarty,
Andras Gruber (United States)
11:18 - 11:32
M1 AND M2 MACROPHAGE PROTEOLYTIC AND ANGIOGENIC PROFILES
AS201 ANALYSIS IN ATHEROSCLEROTIC PATIENTS REVEALS A DISTINCTIVE 11:30 - 11:45 IMPACT OF THE ENDOTHELIAL PROTEIN C RECEPTOR IN
PROFILE IN TYPE 2 DIABETES AS210 COAGULATION, INFLAMMATION AND HEMATOPOIESIS
Charlotte Roma, Madjid Tagzirt, Christophe Zawadzki, Rodrigo Lorenzi, Andr Vincen- Laura Pepler*, Pei Yu, Dhruva Dwivedi, Bernardo Trigatti, Patricia Liaw (Canada)
telli, Stephan Haulon, Francis Juthier, Bart Staels, Brigitte Jude, Eric Van Belle, Giulia
Chinetti-Gbaguidi, Sophie Susen, Annabelle Dupont* (France)
392 393
THURSDSAY
Chronic kidney disease and coagulation Room 705 Inhibitors - clinical Room 801
THURSDSAY
Moderators: Joanne van Ryn (Germany), Rita Selby (Canada) Moderators: Roshni Kulkarni (United States), Amy Dunn (United States)
10:30-11:00 CHRONIC KIDNEY DISEASE AS A RISK FACTOR FOR THROMBOTIC AND 10:30-10:50 FACTOR VIII INHIBITORS IN PATIENTS WITH NON-SEVERE
AS211 BLEEDING EVENTS AS220 HEMOPHILIA A
SYMPOSIA
Manish Sood (Canada) Christine Kempton (Canada)
11:00 11:15 GRP78 INJECTION AMELIORATES HAEMOLYTIC URAEMIC SYNDROME 10:50 - 11:04 STATE-OF-THE-ART ANALYSIS OF FVIII-BINDING ANTIBODIES REVEALS
WEDNESDAY
AS212 (HUS) PHENOTYPE IN A SUBAB TOXIN INDUCED MOUSE MODEL AS221 IGA AS A PROGNOSTIC BIOMARKER FOR POOR TREATMENT OUTCOMES
Sarah Kamel*, Susanna Freddi, Carly Selan, Anushka Samudra, Anup Sharma, Peter IN ACQUIRED HEMOPHILIA A
Cowan, Harshal Nandurkar (Australia) hristoph J. Hofbauer*, Sonja Werwitzke, Paul Knoebl, Saskia Gottstein, Ruediger
C
Scharf, Juergen Heinz, Juergen Gross, Katharina Holstein, Christiane Dobbelstein,
11:15 - 11:30 TUMOR NECROSIS FACTOR SUPPRESSES THE GLOMERULAR Friedrich Scheiflinger, Birgit Reipert, Andreas Tiede (Austria)
AS213 ENDOTHELIAL CELL SURFACE PROTEIN CD141 (THROMBOMODULIN)
AND STIMULATES EXPRESSION OF C3 AND FACTOR B: IMPLICATIONS 11:04 - 11:18 PREDICTORS OF SUCCESS OF IMMUNE TOLERANCE INDUCTION IN
FOR RENAL INJURY AND THROMBOSIS IN THE ATYPICAL HEMOLYTIC AS222 HEMOPHILIA A PATIENTS WITH HIGH-RESPONDING INHIBITORS.
UREMIC SYNDROME A PROGNOSTIC SCORE FROM THE ITALIAN PROFIT REGISTRY
Sarah Sartain*, Nancy Turner, Joel Moake (United States) ntonio Coppola*, Maurizio Margaglione, Angiola Rocino, Maria Elisa Mancuso, An-
A
TUESDAY
narita Tagliaferri, Ezio Zanon, Rita Santoro, Piercarla Schinco, Silvia Linari, Giancarlo
11:30 -11:45 LONG-TERM TINZAPARIN VERSUS WARFARIN FOR TREATMENT OF Castaman, Maria Messina, Dorina Cultrera, Cristina Santoro, Chiara Biasoli, Elena
AS214 VENOUS THROMBOEMBOLISM (VTE) IN CANCER PATIENTS ANALYSIS Santagostino, Giovanni Di Minno (Italy)
OF RENAL IMPAIRMENT (RI) IN THE CATCH STUDY
11:18 - 11:32 RISK FOR INHIBITOR DEVELOPMENT IN SEVERE HEMOPHILIA A PUPS
Rupert Bauersachs*, Agnes Y.Y. Lee, Pieter W. Kamphuisen, Guy Meyer, Mette S.
Janas, Mikala F. Jarner, Alok A. Khorana (Germany)
AS223 IS NOT ASSOCIATED WITH CLASS OF FVIII CONCENTRATES NOR BY
HIGH VON-WILLEBRAND FACTOR OR BY TYPE OF VIRAL INACTIVATION
PROCEDURE
Endothelial cell-VTE models Room 715 SM Hashemi*, J Oldenburg, H Platokouki, R Liesner, HM van den Berg (The Nether-
MONDAY
lands)
Moderators: Iqbal Jaffer (Canada), Anthony Chan (Canada)
11:32 - 11:45 MUTATION ANALYSIS OF SWEDISH HEMOPHILIA B FAMILIES - HIGH
AS224 FREQUENCY OF UNIQUE MUTATIONS
10:30-10:50 THE ROLE OF GAS6 AND INFLAMMATION IN THE PATHOPHYSIOLOGY OF Annika Mrtensson*, Anna Letelier, Rolf Ljung (Sweden)
AS215 VENOUS THROMBOEMBOLISM
Mark Blostein (Canada)
Stroke Room 713
10:50 - 11:04
CORRELATION BETWEEN DEEP VEIN THROMBOSIS AND PULMONARY
SUNDAY
Moderators: Paul Ockelford (New Zealand), Pieter Kamphuisen (The Netherlands)
AS216 EMBOLISM USING AN IN VIVO MOUSE MODEL OF VENOUS
THROMBOEMBOLISM: EFFECT OF THROMBIN INHIBITION
10:30-11:00 WHAT IS THE OPTIMAL ANTITHROMBOTIC THERAPY FOR
Shana A. Shaya*, Lisa Saldanha, Nima Vaezzadeh, Ran Ni, Ji Zhou, Peter Gross (Canada)
AS225 NON-CARDIOEMBOLIC STROKE?
11:04 - 11:18 INHIBITION OF PLATELET FUNCTION WITH THE NOVEL 12-LOX Martin ODonnell (Ireland)
AS217 INHIBITOR ML355 IMPAIRS THROMBUS GROWTH, STABILITY AND
11:00 11:15 PRE-EVENT CHA2DS2-VASC SCORE AND SEVERITY OF ACUTE STROKE
VESSEL OCCLUSION IN VIVO
AS226 IN PATIENTS WITH ATRIAL FIBRILLATION: FINDINGS FROM THE RAF
SATURDAY
Reheman Adili*, Jennifer Yeung, Theodore Holman, Michael Holinstat* (United States)
STUDY
11:18 - 11:32 TISSUE FACTOR PATHWAY INHIBITOR (TFPI): AN ENDOGENOUS Maurizio Paciaroni*, Cecilia Becattini, Giancarlo Agnelli, Monica Acciarresi (Italy)
AS218 SUBSTRATE FOR FACTOR VII ACTIVATING PROTEASE (FSAP) IN VIVO
11:15 - 11:30 EARLY RECURRENCE AND CEREBRAL BLEEDING IN PATIENTS WITH
Saravanan Subramaniam*, Ina Thielmann, Martina Morowski, Ingo Pragst, Per Sand-
set, Bernhard Nieswandt, Michael Etscheid, Sandip Kanse (Germany)
AS227 ACUTE ISCHEMIC STROKE AND ATRIAL FIBRILLATION: EFFECT OF
ANTICOAGULATION AND ITS TIMING. THE (RAF) STUDY
11:32 - 11:45 INTRINSIC AND EXTRINSIC COAGULATION PATHWAYS BOTH Maurizio Paciaroni*, Cecilia Becattini, Giancarlo Agnelli (Italy)
AS219 CONTRIBUTE TO LIGATION-INDUCED DEEP VEIN THROMBOSIS IN RATS
J i Zhou*, Peng Liao, Beverly Leslie, Trang Vu, Ran Ni, Alan Stafford, James Freden-
burgh, Brett Monia, Peter Gross, Jeffrey Weitz (Canada)
394 395
THURSDSAY
11:20 11:30 MAGNESIUM TRANSPORTER MAGT1 PLAYS A CRITICAL ROLE IN 11:18 - 11:32 IMPACT OF INITIAL CANCER STAGE ON THE RISK OF VENOUS
THURSDSAY
AS228 THROMBO-INFLAMMATORY DISEASES AND HEMOSTASIS IN MICE AS083 THROMBOEMBOLISM: THE SCANDINAVIAN THROMBOSIS AND CANCER
anjeev Kiran Gotru*, Karen Wolf, Timo Vgtle, Peter Kraft, Simon Stritt, Guido Stoll,
S (STAC) STUDY
Bernhard Nieswandt, Attila Braun (Germany) Inger LIse Gade*, Sigrid Brkkan, Inger Anne Nss, John-Bjarne Hansen, Frits
Rosendaal, Suzanne Cannegieter, Kim Overvad, Hilde Jensvoll, Jens Hammerstrm,
Kristine Blix, Anne Tjnneland, Sren Risom Kristensen, Marianne Severinsen (Den-
SYMPOSIA
Atherosclerosis, inflammation and cancer Room 701 mark)
Moderators: Angela Silveira (Sweden), Josune Orbe (Spain)
11:32 - 11:45 RISK OF RECURRENT VENOUS THROMBOEMBOLISM IN PATIENTS WITH
AS084 ACTIVE CANCER
WEDNESDAY
10:30 11:00 RECEPTORS FOR PLASMINOGEN ACTIVATORS: ROLE IN
lexander Cohen*, Stephan Rietbrock, Anja Katholing, Carlos Martinez (United King-
A
AS229 INFLAMMATION, ATHEROSCLEROSIS, AND CANCER dom)
Stevens Gonias (United States)
11:00 11:15 CM-352, A NEW MATRIX METALLOPROTEINASE INHIBITOR, IS A

AS230 POTENT AND SAFE ANTIFIBRINOLYTIC AGENT FOR THE PREVENTION Highlights of ISTH - Victor Marder Symposium 12:00 - 13:00
AND TREATMENT OF HEMORRHAGE
J osune Orbe*, Jose Rodriguez, Juan Sanchez, Agustina Salicio, Miriam Belzunce, Ana Moderators: Sam Schulman (Canada), Johannes Oldenburg (Germany)
Ugarte, Haisul Chang, Obdulia Rabal, Julen Oyarzabal, Jose Paramo (Spain)
TUESDAY
12:00 - 12:30 Highlights of the basic science at ISTH 2015
11:15 - 11:30 INHIBITION OF COMPLEMENT C3 AND FIBRINOGEN INTERACTION:
AS231 A POTENTIAL NOVEL THERAPEUTIC TARGET TO REDUCE Peter Gross (Canada)
FIBRIN-RELATED THROMBOSIS RISK 12:30 - 13:00 Highlights of the clinical research at ISTH 2015
hodri King*, Christian Tiede, Katie Simmons, Colin Fishwick, Katharina Schuett,
R
Wendy Lim (Canada)
Katherine Kearney, Darren Tomlinson, Ramzi Ajjan (United Kingdom)
11:30 - 11:45 MODULATION OF RECOMBINANT ANTIGENIC CONSTRUCTS
MONDAY
AS232 CONTAINING MULTI-EPITOPES TOWARDS EFFECTIVE REDUCTION OF
ATHEROSCLEROTIC LESION IN B6;129S-LDLR(TM1HER)APOB
(TM2SGY)/J MICE
in Xia, Valeria Endresz, Daxin Chen, Ildiko Lantos, Andrea Szabo, Lakshmi Mundkur,
M
Vijay Kakkar, Xinjie Lu* (United Kingdom)
Cancer and thrombosis clinical Room 716
SUNDAY
Moderators: Agnes Lee (Canada), Aurelien Delluc (France)
10:30 10:50 CONTROVERSIES IN CANCER-ASSOCIATED THROMBOSIS

AS080 Marc Carrier (Canada)
10:50 - 11:04 TISSUE FACTOR (TF) AS PREDICTOR OF RECURRENT VENOUS

AS081 THROMBOEMBOLISM (VTE): RISK FACTOR AND BIOMARKER ANALYSIS
FROM THE CATCH TRIAL OF TREATMENT OF CANCER-ASSOCIATED VTE
SATURDAY
WITH TINZAPARIN OR WARFARIN

lok A. Khorana*, Pieter W. Kamphuisen, Guy Meyer, Rupert Bauersachs, Mette S.
A
Janas, Mikala F. Jarner, Agnes Y.Y. Lee (United States)
11:04 - 11:18 EXTENSIVE SCREENING BASED ON 18F-FDG PET/CT FOR OCCULT

AS082 MALIGNANT DISEASE IN UNPROVOKED VENOUS THROMBOEMBOLISM:
A PROSPECTIVE RANDOMIZED CLINICAL TRIAL
Philippe Robin*, Pierre-Yves Le Roux, Olivier Sanchez, Sandrine Accassat, Pierre-Ma-
rie Roy, Francis Couturaud, Nadia Ghazzar, Nathalie Prevot, Olivier Couturier, Aurlien
Delluc, Guy Meyer, Bernard Tardy, Grgoire Le Gal, Pierre-Yves Salaun (France)
396 397
Notes
Exhibition Floor Plan
398 399
Exhibition Floor Plan Exhibition Floor Plan
Metro Toronto Convention Centre

South Meeting Room Level 800
NETWORKING
AREA
400 401
Exhibitor List Exhibitor List
Company Name Booth Number Company Name Booth Number
3i - Intelligent Imaging Innovations 640 HYPHEN BioMed 1702

Accriva Diagnostics 1015 Immucor 648
Affinity Biologicals, Inc. 737 Instrumentation Laboratory 410
Aniara Diagnostica & CoaChrom Diagnostica 424 International Initiative on Thrombosis
Answering T.T.P. (Thrombotic Thrombocytopenic and Cancer (ITAC-CME) 1810
Purpura) Foundation 1804 International Society on Thrombosis
Aspen Pharma 512 and Haemostasis (ISTH) 1036
Baxalta 1602 ISTH 2017 - Berlin, Germany 1036
Bayer HealthCare 1722 + 702 + 502 ISTH SSC 2016 - Montpellier, France 1036
Bio Products Laboratory USA, Inc. 1017 Journal of Thrombosis and Haemostasis 1036
Biogen and Sobi 922 Kedrion Biopharma 428
bioMerieux 741 LABTEK Science and Development Co., Ltd. 1828
Biotest AG 1739 LFB BIOMEDICAMENTS 1546
Boehringer Ingelheim GmbH 1638+1639 MediRox 1709
Canadian Hemophilia Society (CHS) 1814 Novo Nordisk Haemophilia Foundation (NNHF) 1018
CEDARLANE 1711 Novo Nordisk Health Care AG 1010
Chrono-log Corp. 638 Octapharma AG 1301
Covidien 1840 Pfizer 736
CSL Behring GmbH 1522 Pfizer Canada Inc./Bristol-Myers Squibb Canada 522
Daiichi Sankyo, Inc. 422 Portola Pharmaceuticals, Inc. 1713
Diapharma Group 1016 Precision BioLogic 1610
DSM Nutritional Products Ltd Branch Pentapharm 521 Roche Diagnostics International Ltd 1728
Schattauer Publishers 1822
Enzyme Research / r2 Diagnostics 1616
Sekisui Diagnostics 1800
European and Mediterranean League against
Thrombotic Disorders (EMLTD) 1542 Siemens Healthcare 436
Ferrer inCode 1802 STAGO 1122
Foundation for Women & Girls with Sysmex Corporation 436
Blood Disorders (FWGBD) 1808 TECHNOCLONE 1538
George King Bio-Medical, Inc. 642 Thrombosis.TV 1826
GRIFOLS 1336 Wiley 1614
Haematologic Technologies, Inc. 1612 World Federation of Hemophilia 1812
Hemostasis Reference Laboratory Inc. 739 World Thrombosis Day (WTD) - 13 October 1036
402 403
Reversal of old and
newer anticoagulants: Congress Information
evolving evidence
from trials
A lunchtime satellite symposium
Programme
Co-chairs: Jerrold Levy (USA), Edelgard Lindhoff-Last (Germany)
12:15 Chairs welcome
Emergency reversal of warfarin: lessons from randomised
controlled trials
Ravi Sarode (USA)
Reversal of apixaban anticoagulation with 4-factor prothrombin
complex concentrates: a healthy volunteer study
Charles Frost (USA)
4F-PCC reverses edoxaban-associated bleeding: data from
a healthy volunteer study
Hamim Zahir (USA)
The role of prothrombin complex concentrate in patients
with major bleeding while using NOACs
Pieter Kamphuisen (The Netherlands)
Closing remarks
13:45 Close of symposium
522
t booth 1
isit us a
Please v
Tuesday 23 June 2015, 12:1513:45

Room 714, Metro Toronto Convention Centre (MTCC), Toronto, Canada
CSL Behring-sponsored satellite symposium at the
XXV Congress of the International Society on Thrombosis and Haemostasis (ISTH)
Pre-register to receive your post-symposium

digital newsletter!
Scan the QR code or visit
404 www.POBnews.info to register your interest. 405
The information presented in the symposium will not necessarily reflect the content of the approved Canadian product monograph.
Venue Plan Congress Information
Abstracts Business Center

The ISTH 2015 abstracts are available on MTCC Toronto has its own Business Center
USB sticks which will be distributed at the that provides the following services:
ISTH Booth (# 1036). Abstracts will also be - Printing (including posters and business
available as an online supplement (only) to cards)
JTH as an open-access publication on the Con- - Copying
gress app and on the Congress website. - Faxing Scanning
- Laminating
- Binding
Accommodation
Participants who have booked their accom- Furthermore, the Business Center sells a wide
modation in advance via MCI can visit the range of office and ICT supplies. You can also
Registration Help Desk counter located in the ship small packages there.
Registration Area for any questions related to The Business Center is located between the 2
their hotel booking. The staff at this counter Exhibition entrance doors on Level 800.
will also help you to find and book rooms, if
required and pending availabilities.
Certificates of Attendance
Certificates of attendance will be distributed
Badges
to all registered participants inside the con-
Participants will receive their name badges gress bags.
when collecting their meeting documents on
site. You are required to wear your name badge
during all meeting events, including the All Charging StationsStay Plugged In
Congress Party (if you have purchased tick- Conveniently located in the exhibition hall,
ets). Please note that admission to scientific 10 charging stations for mobile phones are
sessions and the exhibition is restricted to par- provided for attendees to charge their mobile
ticipants wearing their badges. devices.
Please note:
Cloakroom and Luggage
- Accompanying persons and exhibitors will
not be admitted to the scientific sessions. The cloakroom (free of charge) is located near
- Accompanying persons will not be admit- the Registration Area, Level 600.
ted to the Exhibition Area and the Poster
area except for the Welcome Reception on Saturday, June 20 07:30-18:00
Sunday, June 21 Sunday, June 21 07:30-20:00
Monday, June 22 07:30-20:00
The charge for the replacement of a lost badge Tuesday, June23 07:30-19:30
is CAD 105. Wednesday, June 24 07:30-18:30
Thursday, June 25 07:30-13:00
Automatic Teller Machines (ATM)

CME
In the MTCC Congress venue, ATM machines
are located in the North wing inside the main Royal College MOC credit, AMA PRA credit,
entrance from Front Street; in the South wing ECMEC credit
on Level 600 in the Registration Area and on This activity is an Accredited Group Learning
Level 800 at the corner of the Plenary Hall and Activity (Section 1) as defined by the Main-
the Exhibition Hall. tenance of Certification program of The Royal
College of Physicians and Surgeons of Canada
and approved by McMaster University, Con-
tinuing Health Sciences Education Program
for up to 26 MOC Section 1 hours.
406 407
Congress Information
Transfuse
Through an agreement between the Royal Col- Conference Capture
lege of Physicians and Surgeons of Canada
Plenary and State-of-the-Art lectures of ISTH
and the American Medical Association, physi-
2015 will be captured and be available online
cians may convert Royal College MOC credits
for meeting attendees and ISTH members in
to AMA PRA Category 1 Credits. Informa-
the weeks after the meeting.
tion on the process to convert Royal College
MOC credit to AMA credit can be found at
www.ama-assn.org/go/internationalcme. Congress E-daily
The ISTH 2015 Congress will publish its offi-
Live educational activities, occurring in Can-
cial e-Daily from Monday, June 22 to Wednes-
ada, recognized by the Royal College of Phy-
day, June 24 and a post-congress issue two
sicians and Surgeons of Canada as Accredit-
weeks following the meeting. The e-Daily will
Transplant
ed Group Learning Activities (Section 1) are
be sent via email to all congress registrants,
deemed by the European Union of Medical
can be accessed via the Congress App and di-
Specialists (UEMS) eligible for ECMEC.
rectly at www.isthcongressdaily.org.
Each attendee should only claim the hours
they attended. Congress Mobile App
Transform a life
Use your mobile device to navigate the ISTH
Please note that the Royal College MOC will 2015 Congress. Download the Congress App
send your certificate after the Congress. In or- from your respective app store! The ISTH
der to receive this, please go to the designated 2015 Mobile App is free for meeting partic-
computer stations near the Registration Area ipants and ISTH members. It conveniently
on Level 600. You will be able to update your provides iPhone/iPad, BlackBerry, Windows,
profile to your personal e-mail. This can be Android and other smartphone and tablet us-
done as of Monday, June 22, 14:00. ers with on-the-go access to the ISTH 2015s
Immucor is the leading provider of transfusion and transplantation diagnostic most exciting, informational and interactive
EHA Accreditation features, such as program overviews, speaker
products worldwide. In addition, Immucor also delivers a unique portfolio to and abstract information, general meeting
The European Hematology Association (EHA)
assist with the identification of deficiencies in clotting factors and detection has accredited ISTH 2015 in Toronto, Canada
and exhibitor information, venue and city
maps and tips.
of antibodies involved in thrombosis and thrombocytopenia, providing (June 20 25, 2015) with 35 credit points.
All participants may print a European Hema-
support for the diagnosis of Heparin-Induced Thrombocytopenia (HIT), Von tology Association CME System approved CME Corporate Symposia and Technical
Willebrand Disease (VWD) and Thrombotic Thrombocytopenic Purpura (TTP). certificate indicating the number of EHA-CME
Sessions
Credit Points awarded, directly from the sys-
tem on the CME section of the EHA website at Corporate Sympsia and Technical Sessions will
www.ehaweb.org. All participants will receive take place during the following times:
Visit us at Booth #648 PF4 Family of Products the relevant information by e-mail after the
meeting. Special Industry Symposia
to learn more about: ATS-13 Activity Assay*
Sunday, June 21
VWF & Propeptide Assay**
15:30 17:30
Factor VIII Antibody Screen Congress Bag
The Congress bag including all delegate ma- Lunch Symposia
terial will be distributed to registered partici- Monday, June 22 - Wednesday, June 24
pants at the Congress bag desk in the Regis- 12:15 13:45
tration Area. Please note that no replacements
for lost bags are available. Technical Sessions
Monday, June 22
Computers / Cyber Caf 18:30 20:00
If you need access to a computer while at ISTH
For more details and the program of each of
2015, youre in luck! A Cyber Caf is locat-
these symposia and sessions, please refer to the
ed for attendees to use in the ISTH booth (#
Show Guide. For the Lunch Symposia, lunch-
www.immucor.com or call 855.IMMUCOR 1036) located in the Exhibition area on Level
boxes will be served near the session rooms.
800.
408 409
* For Research Use Only ** For Research Use Only Immucor, Inc. 2015
Not for use in diagnostic procedures Not for diagnostic use in US and Canada
Congress Information Congress Information
Duplicating/Recording Lost and Found Opening Hours

Any form of duplication (recording, audio tap- Found articles may be brought to the lost
ing, photography and video) of sessions is pro- items collected from the Registration Desk on Date Friday Saturday Sunday Monday Tuesday Wednesday Thursday
hibited without expressed written consent of Level 600.
the author and Congress organizer. Speaker 15:30-20:00 07:30-18:00 07:30-18:00 07:30-18:30 07:30-18:30 07:30-18:30 07:30-13:00
Lunches and Coffee Breaks Ready Room,
Exhibition Hours Lunch is provided during the duration of the
Level 600
The ISTH 2015 Industry Exhibition is located Congress. Lunch tickets will be provided as part
in Ballroom D and E on Level 800 of the Met- of the registration package. The tickets are valid Registration 15:30-20:00 07:30-18:00 06:30-20:00 06:30-20:00 06:30-19:30 06:30-18:30 07:30-13:00
ro Toronto Convention Center (MTCC), South from Saturday, June 20 to Wednesday, June 24. Registration Area,
Building. Level 600
From Monday, June 22 to Wednesday, June
Sunday, June 21 24, lunch and coffee will be available in the
19:30 - 22:00 (Welcome Reception Exhibition 19:30-22:00 09:00-18:30 09:00-19:30 09:00-18:30
Exhibition Area (Level 800). There will be
in the Exhibition Hall) Exhibition Area,
continuous complimentary coffee stations
Level 800
Monday, June 22 throughout the opening times of the Exhibition
09:00 - 18:30 during those days, too. Lunches will also be
available in front of the meeting rooms of the Poster Pick Up Booth 19:30-22:00 07:30-19:00 07:30-20:00 07:30-19:00
Tuesday, June 23 lunch time symposia. Exhibition Area,
09:00 - 19:30 Level 800
Wednesday, June 24 On Saturday and Sunday, June 20 - 21 as well
09:00 - 18:30 as on Thursday June 25, lunch and coffee will
be available in the foyers of the session rooms. Press Room 08:00-17:00 08:00-17:00 08:00-17:00
Registration Area,
Internet Level 600
WIFI is available throughout the MTCC. Mobile Telephones
Wireless Network: ISTH 2015 As a courtesy to speakers and other partici-
Cloak Room 12:30-20:00 07:30-18:00 07:30-20:00 07:30-20:00 07:30-19:30 07:30-18:30 07:30-13:00
Password: biogensobi pants, all mobile phones and pagers must be
Registration Area,
muted when attending sessions or symposia.
The Cyber Caf, located in the ISTH booth Level 600
(#1036) in the Exhibition Hall, will be for the
Notepads and Pens
exclusive use of meeting attendees.
A notepad and pen are included in the Con-
Overflow
Insurance and Liability gress bag.
Be advised that there is an Overflow room in the Exhibition, next to the Poster area. Should any
It is recommended that participants obtain session be full, the Overflow will be activated.
adequate insurance coverage for travel, health
Nurses Program
and accidents before they depart from their The Nurses Program takes place Sunday and
Monday, June 21-22, 2015, during the Con- Passport Program to the ISTH 2015 Exhibition
countries of residence. ISTH and MCI as or-
ganizers cannot accept responsibility for per- gress. On the morning of the second day (Mon- Participate in the ISTH 2015 Passport Program, learn more about our exhibitors and sponsors
sonal injuries, or loss of, or damage to private day, June 22), there is a scientific session with and enter to win valuable prizes. Scan the code below or go to: http://bycell.co/cjzp to use this
property belonging to the conference partici- oral presentation of peer-reviewed abstracts. web-based application.
pants and accompanying persons.
Visit the booths of the participating ISTH 2015 exhibitors, answer questions and enter into a
Official Carrier Network drawing of valuable prizes.
ISTH 2015 Presidents Room Star Alliance is the official carrier network for
The ISTH 2015 Presidents Room is located in ISTH 2015 Participants may complete their passport program between 09:00 on Monday, June 22 and 12
room 401 on Level 400. noon on Wednesday, June 24.
All entries need to submitted by 13:00 on Wednesday, June 24. Prize winners
ISTH Secretariat will be announced at the ISTH booth (# 1036) between 15:15 and 15:45 on
The ISTH secretariat is located in room 501 Online Disclosures Wednesday, June 24.
on Level 500. As part of the CME accreditation procedures,
all speakers are obliged to provide disclosure Make sure you participate!
Language of potential conflicts of interest. On the first
The official language of the meeting is En- slide of every presentation, these disclosures Photo Policy
glish. There is no simultaneous translation must be presented. The Speaker Ready Room We kindly ask that attendees DO NOT photograph, tape record, film, or use a cellphone to capture
service provided. can assist you with drafting this slide. images of presentations at any time during the meeting as well as on the exhibit floors.
410 411
Congress Information
SickKids Handbook
of Pediatric Thrombosis
Pocket Program Wednesday, June 24, 2015
from 07:30 - 09:15
A pocket program will be provided to partici-
pants upon registration. It is an at-a-glance
Pins are provided on the poster boards
reference. It contains a program-at a-glance,
directly
and Hemostasis
venue information and map, information about
Toronto and other useful tips.
Poster Printing Service & Pick Up Monday, June 22, 2015

Booth from 18:30 - 19:00
If you have opted to take advantage of the Tuesday, June 23, 2015
ISTH 2015 poster printing service, kindly note from 19:30 - 20:00
that you will be able to pick up your poster(s)
at the Poster Booth located in the Swing Space
from 18:30 - 19:00
Editors: Contents
on Level 800. Victor S. Blanchette (Toronto, Ont.) Pediatric Thrombosis and Hemostasis:
Posters not taken down after the dismantling
time will be discarded.
Vicky R. Breakey (Hamilton, Ont.) A Historical Perspective
Shoshana Revel-Vilk (Jerusalem) Primary and Secondary Hemostasis, Regulators of
Sunday, June 21, 2015
from 19:30 - 22:00 Coagulation, and Fibrinolysis: Understanding the
Prayer Room
An all-denomination prayer room is located in
Basics
from 07:30 - 19:00
room 830 on Level 800. An Approach to the Bleeding Child
from 07:30 - 20:00
Bleeding in the Neonate
Press Room Platelet Disorders in Children
Wednesday, June 24, 2015 ISTH 2015 will feature both a press lounge
from 07:30 - 19:00 available for journalists attending the Congress
Managing Hemophilia in Children and Adolescents
to use and ISTH 2015 exhibitors as well as a von Willebrand Disease in Children
Poster Sessions press briefing room that will hold press brief- Rare Congenital Factor Deficiencies in Childhood
Posters will be presented on different days ings from 8:00 through 17:00 beginning Mon-
during the Congress and are accessible at the day, June 22 through Wednesday, June 24.
Acquired Bleeding Disorders in Children
same times as the exhibition opening hours. A Diagnostic Approach to a Child with Thrombosis
The official poster sessions with refreshments To use the press lounge, media credentials
must be presented. Public relations and com-
Venous Thrombosis
will take place as follows:
pany representatives may enter the room to Arterial Thrombosis
drop off materials to share with the media;
however, we ask that they do not stay. All me-
Thromboembolic Events at Specific Organ Sites
from 17:15-18:30
dia are asked to follow the media policy in its XVIII + 254 p., 23 fig., 9 in color, Pediatric Stroke
Tuesday, June 23, 2015 entirety.
from 18:00-19:30
9 algorithms, 59 tab., soft cover, 2013 Bleeding and Clotting in Children with Cardiac Disease
CHF 98. / EUR 82. / USD 155.00
Wednesday, June 24, 2015 For a full schedule of media briefings, see the Prices subject to change
Antithrombotic Therapy in Children
from 17:15-18:30 board in front of the Press Briefing Room or EUR price for Germany, Reference Ranges for Common Tests of
stop by the press lounge for the schedule. The
press lounge is located near the Registration
USD price for USA and Bleeding and Clotting
The Poster Area is located inside the Exhibi- Latain America only
tion on Level 800. Area on Level 600.
ISBN 9783318021974
Common Products Used to Manage Bleeding
and Clotting
Poster setup times are as follows: Program Changes
Program changes will be made public via the
Monday, June 22, 2015 official ISTH 2015 mobile app and the web-
from 07:30 - 09:15 site.
KI15371
from 07:30 - 09:15
412 413
Congress Information Congress Information
Ramadan - Special Considerations materials, of the Congress in general, provided State-of-the-Art Book and Abstracts Transportation
that:
Taken The ISTH 2015 State-of-the-Art manuscripts No transportation is provided during the Con-
The month of Ramadan will fall during the and abstracts are available on USB sticks gress since the conference venue is very cen-
1) Copyright law is observed; 2) verbatim infor-
ISTH 2015 Congress in June 2015. For those which will be distributed at the ISTH Booth (# trally located and all official hotels are within
mation is limited to a few quotes, and; 3) the
of you who are observing Ramadan, we will 1036). Both the State-of-the-Art manuscripts walking distance. If you need additional infor-
author or speaker is referenced and cited ap-
have boxed meals available for you at the and abstracts will also be available as online mation on public transportation, please see:
propriately. To get the latest updates through-
Registration Area on Level 600 to take back supplements (only) to JTH as open-access page 421.
out the Congress, follow ISTH online via the
to your rooms in the late afternoon each day publications.
following links.
of the Congress. Travel Grants
Abstracts are also available via the Congress
Congress hashtag via Facebook and Twitter: Travel Grant recepients can go to the specific
app and on the Congress website.
Registration Hours #isth2015. Travel Grant desk at the Registration Area
Registration will start Friday, June 19 in the (Level 600) to receive their grant. Grants will
F
acebook: https://www.facebook.com/ Toronto Information Desk be distributed between Monday, June 22,
afternoon. The Registration Area, located on internationalsocietythrombosisand
Level 600 at the MTCC in Toronto will be open For city and restaurant information, please vis- 10.00 and Thursday, June 25, 12 noon.
haemostasis it the Toronto Information Desk located near
during the following hours:
the Registration Area on Level 600.
Twitter: https://twitter.com/isth
Friday, June 19 15:30-20:00
Saturday, June 20 07:30-18:00 Saturday, June 20 10:00 17:00
LinkedIn: https://www.linkedin.com/ Sunday, June 21 09:30 18:00
Sunday, June 21 06:30-20:00 company/international-society-on-
Monday, June 22 06:30-20:00 Monday, June 22 09:00 16:00
thrombosis-and-haemostasis-isth- Tuesday, June 23 09:00 16:00
Tuesday, June 23 06:30-19:30
Wednesday, June 24 06:30-18:30 Wednesday, June 24 09:00 16:00
Instagram: http://www.instagram.com/
Thursday, June 25 07:30-13:00 isthofficeteam
Useful Telephone Numbers
Show Guide Speaker Ready Room Name Location Telephone
The ISTH 2015 Show Guide to Corporate Sym- Speakers were contacted in advance to upload ISTH Executive Office Room 401, Level 400 001 416-585-3823
posia and the Industry Exhibition is distribut- their presentations but should still report to Hotel Information Desk Registration Area, Level 600 001 416-585-3824
ed to all participants as part of the delegate the Speaker Ready Room at least two hours in Registration Desk Registration Area, Level 600 001 416-585-3825
materials as well as on-site in literature racks advance of their presentation to ensure proper
in the registration area and the exhibition
hall. It provides an overview and the detailed
viewing. All conference rooms feature state-of- Venue
the-art technical equipment. Audiovisual ma- MTCC - South Building - 222
programs of the corporate symposia (Special terial will be available for your presentation:
Symposia, Satellite Symposia and Technical Bremner Boulevard, Toronto,
The use of your own laptop during your presen- Ontario M5V 2W6, Canada
Sessions) as well as trade show floor plan, ex- tation is prohibited.
hibitor and sponsor profiles. Please note that the numbering of the floor levels increases as you go down.
The Speaker Ready Room is located on Level
Smoking 600 near the Registration Area. The opening Water Stations
Please note that this is a non-smoking meet- hours of the Speaker Ready Room are as Keeping hydrated is always important, particularly during a busy day at ISTH 2015.
ing. Smoking is neither permitted in or outside follows: 15 distinct water stations are located in the exhibition hall for the convenience of our
the meeting halls nor in the Exhibition Area. attendees.
Friday, June 19 15:30-20:00
Saturday, June 20 07:30-18:00
Social Media Sunday, June 21 07:30-20:00
ISTH 2015 encourages the use of social me- Monday, June 22 07:30-20:00
Website
dia, such as Twitter, Facebook, LinkedIn, In- Tuesday, June 23 07:30-19:30 Up-to-date information regarding the Congress program, including all abstracts, is available on
stagram and other social media platforms at Wednesday, June 24 07:30-18:30 the website www.isth2015.org
the conference as a way to summarize, high- Thursday, June 25 07:30-13:00
light, excerpt, review or promote the presented
414 415
Social Program
THROMBOSIS RESEARCH
Opening Ceremony and
Welcome Reception
Sunday, June 21, 2015
Time: 18:00 22:00
Venue: MTCC Metro Toronto
Convention Center
About Price: included in registration fee
Thrombosis Research is an international journal with a goal of rapid The opening ceremony takes place in
dissemination of new information on thrombosis, hemostasis, the Plenary Hall (Level 800) in the
and vascular biology to advance science and clinical care. Congress Center from 18:00 19:30. Please go to the Registration Desk if
The ISTH Grant Medal will be awarded you still want to buy tickets onsite.
The journal publishes peer-reviewed original research, along with during this ceremony. Besides official
Buses for the All Congress Party will
reviews, editorials, and opinions and critics. Both basic and clinical opening speeches, all participants are
leave in front of the Congress Center
invited to enjoy a selection of typical
studies are published. Canadian entertainment and perfor- South Entrance starting 18:30 until
mances. 19:30 at the latest.
Publication of research which will lead to novel approaches in
diagnosis, therapy, prognosis and prevention of thrombotic and The welcome reception will take place MUZIK: 15 Saskatchewan Rd,
hemorrhagic diseases is given high priority. in the adjacent exhibition hall from Toronto, ON, M6K 3C3
19:30 22:00.
Notes:
Your benefit of publishing in Thrombosis Research:
None of the listed events are industry
Editors in Chief Unrivalled article visibility via inclusion in Scopus, the worlds All Congress Party supported
Per Morten Sandset largest abstract and citation database Wednesday, June 24, 2015
Oslo University Hospital, Time: 19:30 01:00 Social events are only open to
Oslo, Norway Article Usage Alert service: a combination of an email and a Venue: MUZIK individuals who are registered
Price per person: CAD 100 (including accompanying persons)
dashboard that shows usage data of your article, downloads with a ticket.
& article views, social media mentions and from which countries The All Congress Party is always the
talk of the town, and you really dont
Follw us on Online submission which is fast, efficient and provides step- want to miss out! We have something ISTH 5K Fun Run
Facebook: by-step instructions on how to submit your article special planned for you in Toronto a Tuesday, June 23, 2015
smashing evening on the penultimate Time: 20:00 - 21:00
www.facebook.com/ Advance notification of the publication of your article via day of the Congress at the nightclub Venue: Budapest Park, Toronto
ELShematology ScienceDirects online alerting service MUZIK, which has developed a rep-
utation for style and unsurpassed Ticketed event, late registration fee
Twitter: The option to enrich your article with graphical abstracts, service. Relaxing in a 1907 building CAD 45
@ELShematology research highlights, AudioSlides and video content under a 60 foot-high classical glass
dome is an experience that one could Register at http://www.isth.org/
describe as a Canadian in Paris. page/2015FunRun
The highlight of the night will be the Buses will leave in front of the
VISIT THE JOURNAL rock band Barenaked Ladies with
their performance and entertainment.
Congress Center South Entrance
starting 18:30 until 19:30 at the
HOMEPAGE FOR DETAILS: latest.
www.thrombosisresearch.com
416 417
Toronto & Canada Information Toronto & Canada Information
Banks, Banking Services and Shopping in Toronto Tipping Etiquette in Canada Dining Out in Toronto and Tipping
Automatic Teller Machines (ATM) Shoppers delight in trendy Queen Street West, Restaurants: It is customary to tip approxi- Restaurants usually open at 18:00, with bus-
Yorkvilles designer boutiques, fabulous malls mately 15% on the total bill before tax, 20% iest time between 20:00 and 22:00. Booking
The official currency in Canada is the Cana-
like the Toronto Eaton Center and Vaughan for exceptional service. Many restaurants is recommended, particularly on Thursday, Fri-
dian Dollar (CAD) which is divided into 100
Mills and the PATH, which features more than charge an automatic gratuity of 15% or more day and Saturday nights.
cents. For denominations under five dollars,
1,200 shops in over 16 miles of underground for larger groups typically 8 or more persons.
coins are used.
concourses. If youre happy with the service you receive, a
Hotels: It is customary to tip the valet service 15-20% tip on the pre-tax bill is a standard
Only major banks exchange foreign currency.
Visit http://www.toronto.ca/ for more informa- and the staff that brings the baggage to a expression of appreciation when dining out
Credit Cards and Travelers checks are accept-
tion. guest room as well as the chambermaids. in the city. Note that some restaurants auto-
ed at most (but not all) major retailers. Travel-
matically add this gratuity when serving large
ers checks should be issued in Canadian dol-
Taxi drivers, hairdressers, manicurists, aesthe- groups, so be sure to check your bill. For more
lars for maximum convenience. Banking hours Taxes ticians etc: 10% is the common minimum. information and to find the right restaurant
are Monday to Friday 9 AM to 5 PM. Currency The Harmonized Sales Tax (HST) is a 13% tax please visit www.dine.to/
exchange is also available at the airport. that is applied to most purchases of taxable Overall, servers/wait staff are not paid well in
supplies of goods and services in the Province Canada. However, when you see a tip jar on
ATMs are widespread and found in most of Ontario. The HST consists of a 5% federal a counter in a bar, cafeteria etc. it is NOT nec-
banks, hotels and shopping centers. In the portion and an 8% retail sales tax portion. essary to tip.
MTCC Congress venue, ATM machines are
located in the North wing inside the main en- Visitors to Canada may qualify for a refund
trance from Front Street; in the South wing of some of the Goods and Services Tax/Har- Toronto City Guide App
on Level 600 in the Registration Area and on monized Sales Tax (GST/HST) they have paid To learn more about Toronto, download Tour-
Level 800 at the corner of the Plenary Hall and during their visit in Canada. ism Torontos new See Toronto App. Available
the Exhibition Hall. for iPhone, Android, Blackberry and Windows
Please visit the Canada Revenue Agency Phone, it provides tips on things to see and
Climate website for more information. including easy-to-search event, dining, attrac-
tions and shopping listings.
Toronto has a humid continental climate.
http://www.cra-arc.gc.ca/tx/bsnss/tpcs/gst-tps/
Summers are usually warm and humid. The
rbts/vstrs/fctp-eng.html Learn more about Toronto online at
average temperature in June is 80 degrees F
www.seetorontonow.com
(27 degrees C) for a high and 65 degrees F (18
degrees C) for a low. Time
Standard time zone: UTC/GMT -5 hours
Electricity Daylight Savings Time: +1 hour
Toronto is on EST (Eastern Standard Time)
110-120 volts, 60 Hz. Plugs are mainly the
two, flat-pin type, although three-pin plugs are
also widely used. Appliances without dual volt-
age capabilities will require an adapter, which
can be purchased in most major airports.
Emergency Phone Numbers

Dial 911 for all emergencies (police, fire, med-
ical). Callers will then be placed through to the
appropriate emergency service. Calls are free
from pay phones.
418 419
Transportation in Toronto
Public Transport Ticket Bloor-Danthforth Line: When travelling

west or east, you will need to transfer to the
The Toronto public transit system is the Toron-
Yonge-University-Spadina Subway Line at ei-
to Transit Commission (TTC), and it includes
ther Bloor-Yonge Station, St. George Station
subways, buses and streetcars.
or Spadina Station. Then continue until you
reach Union Station.
GO Transit is Ontarios inter-regional bus and
train service. It links Toronto with outlying ar-
Scarborough RT Line: Travel west to Kennedy
eas of the Greater Toronto region and beyond.
Station. From Kennedy Station transfer to the
Bloor-Yonge Line. Continue on the Bloor-Yonge
To learn more about Torontos parking, taxi
Line until your reach Union Station.
and bike resources, visit the Tourism Toronto
website.
Sheppard Line: Travel west to the Shep-
pard-Yonge Station and transfer to the
Maps and Guides
Yonge-University Spadina Line. Travel south
There are many visitor guides, pedestrian
until you reach Union Station.
Visit us on
maps and more available via Tourism Toronto.
These cover areas such as downtown Toronto
Facebook
as well as the Greater Toronto region. Car Parking
The MTCC Toronto has dedicated parking both
How to Reach the MTCC Toronto? for the North and the South building and can
accommodate up to 1,700 vehicles.
From the Airport
Thrombosis and Haemostasis The Union Pearson (UP) Express train takes
The following rates apply: (incl. 13% tax)
International Journal for you directly from the airport to the Union
Station in downtown Toronto in less than 25
Vascular Biology and Medicine Each Day of the Week (7am 7pm)
minutes. Union Station is only a few blocks
Volumes 113 and 114 in 2015 1/2 hr or less: CAD 4.00
away from the Congress center (Metro Toronto
1/2 hr to 1 hr: CAD 8.00
6 issues per volume | ISSN 0340-6245 Convention Centre) and most of the Congress
1 hr to 1.5 hrs: CAD 12.00
hotels.
1.5 hrs to 2 hrs: CAD 16.00
Visit our homepage and register for eTOC today at: 2 hrs to 2.5 hrs: CAD 20.00
The adult regular fare is $27.50, with reduced
www.thrombosis-online.com Day max (< 2.5 hrs): CAD 23.00
fares for seniors, children and families. Tickets
can be purchased online, in-station, or at the
Evenings (5pm 7am)
ticket vending machines and counters.
1/2 hr or less: CAD 4.00
1/2 to 1 hr: CAD 8.00
By Train
Thrombosis and Haemostasis The MTCC is located next to the Union Station
1 hr to 1.5 hrs:
1.5 hrs to 2 hrs:
CAD
CAD
12.00
16.00
Toronto. From Union station you can proceed
2 hrs to 2.5 hrs: CAD 20.00
publishes original contributions of basic Electronic Table of Contents register online west on Front Street to the North Building,
Eve. Max (< 2.5 hrs): CAD 23.00
where you can access the Skywalk to enter
and original research and clinical studies in today! | online submission and TH First: epub the South Building. You can, in case of rainy
Day Max + 1/2 hr: CAD 27.00
Day Max + 1 hr: CAD 28.00
weather, walk the entire way from Union Train
vascular biology and medicine, serving as an ahead of print | a broad scope covering expand- 24 hr Max: CAD 28.00
Station to the MTCC indoors and through cov-
international platform for the dissemination ed areas of interest (Blood coagulation, fibrinoly- ered skywalks.
There are also more than 10,000 alternate
and debate of scientific information. sis and cellular haemostasis | Platelets and blood Please visit www.gotransit.com to plan your
spaces within walking distance to the Metro
Toronto Convention Center.
Subscribers to and readers of Thrombosis and cells | Endothelium and vascular development trip and find your most convenient connection.
Haemostasis enjoy a reliable publication platform | Wound healing and inflammation/infection | By Subway
Yonge-University-Spadina Line: Exit at Union
in vascular biology and medicine | renowned Cardiovascular biology and cell signalling etc.) station and proceed west on Front Street to
authors leaders in their field of research | the North Building, where you can access the
Skywalk to enter the South Building.
420 421
Future ISTH Meetings and Congresses
Publish your next research article in
Thrombosis Journal
Editors-in-Chief:
Yukio Ozaki (Japan), Hugo ten Cate (Netherlands) Meetings and Congresses President Date Location
62nd Annual SSC Meeting Jean-Franois Schved May 25-28, 2016 Montpellier, France
XXVI ISTH Congress with 63rd Annual SSC Meeting Johannes Oldenburg July 8 - 13, 2017 Berlin, Germany
64th Annual SSC Meeting to be confirmed to be confirmed to be confirmed
XXVII ISTH Congress with 65th Annual SSC Meeting Robert Medcalf 2019 Melbourne, Australia
Learn more at www.isth.org
Hidenori Suzuki, Nippon Medical School, Japan
Reasons to publish in Thrombosis Journal

Internationally renowned Editorial Board
Publishes various article types
Supports research in the developing world
Free color images
THROMBOSIS
JOURNAL
www.thrombosisjournal.com www.biomedcentral.com
422 423
Notes
Impactful. Influential.
4,122 total citations More than 3.1 million
and top-ranked articles influencing future
among 65 Peripheral research downloaded by
Vascular Disease and 12,200 subscribers and
68 Hematology users at 12,400 institutions
journals.* with access.
Flexible.
Fast and Reliable. The ATVB iPad app has
Rapid publication been downloaded more
online within 5 to than 4,662 times.
10 days of acceptance.
Life is why. Submit Your Manuscript Join the AHA/ASA

Science is how.
http://atvb-submit.aha-journals.org Call: 1-800-787-8984 (United States)
The American Heart Association The forum for publication of basic, translational, +1-301-223-2307 (Rest of World)
Professional Membership is where clinical, and population research in the area my.americanheart.org/membership
youll find the richest source of of arteriosclerosis, thrombosis, and vascular
cardiovascular science and news. biology.
Subscribe
Enhance your knowledge, ATVB is top-ranked for total cites, Impact
experience, and networking Factor, 5-Year Impact Factor, Article Influence Call: 1-800-638-3030 (United States)
with a membership today. Score, and Eigenfactor Score among journals in +44 (0) 20-7981-0525 (Europe)
the Peripheral Vascular Disease and Hematology +1-301-223-2300 (Rest of World)
Visit my.americanheart.org/ subject categories.* www.ahajournals.org/site/subscriptions
membership.
Learn how ATVB impacts the caliber of scientific
publishing at www.ahajournals.org/site/metrics
atvb.ahajournals.org
4242013
*
Journal Citation Reports
As of December 31, 2014.

(Thomson Reuters, 2014). Apple and iPad are trademarks of Apple Inc., registered in the
U. S. and other countries. App Store is a service mark of Apple Inc.
425
Authors Index
Participate in the ISTH Academy!

Your Personal Resource for Education
2015 Webinar Series Covering

Laboratory and Clinical Science
Webcasts from Congress and SSC

Meeting Presentations
Education Courses - Access the

ISTH Course on Venous Thrombosis
The Academy is the online education arm of the
International Society of Thrombosis and
Haemostasis (ISTH). As part of the Societys mission to
advance the understanding, prevention, diagnosis and
treatment of thrombotic and bleeding disorders, the
ISTH Academy promotes advanced learning
opportunities, networking and the opportunity to build
an understanding of a desired topic without managing
travel budgets or flight plans.
The ISTH Academy includes a comprehensive webinar
series, educational webcasts and online course
modules for scientists, physicians and allied health
academy.isth.org professionals with notable speakers and presenters on
a variety of topics related to bleeding and clotting. All
accessible from a computer and location of your
choice, let the ISTH Academy provide you with the
knowledge needed to advance science and patient care
to improve the health outcomes for patients around the
world.
Join Us! For more information on upcoming
426
Visit us at Booth 1036 programming, visit academy.isth.org. 427
Authors Index Authors Index
AUTHORS INDEX
Aarts M., PO452-TUE Abro S., PO182-MON, PO293- Agnelli G., AS226, AS227, Akinc A., OR177, OR213, PO154- Alberto F., PO004-MON, PO629- Almany S., PO623-TUE, PO419-
Abache T., PO131-TUE, MON, PO305-MON, PO334-MON, OR074, OR119, PO370-MON, TUE, PO049-WED MON, PO042-WED WED
PO339-TUE PO112-WED, PO331-WED, PO626-MON, PO353-TUE, Akins S., PO076-WED Alberto M., PO646-TUE, PO652- Al-Marwani A., PO517-WED
Abad A., PO245-TUE PO332-WED PO608-TUE, PO373-WED, Akinshina S., PO008-MON TUE Almholt K., PO590-WED
Abad-Franch L., PO243-TUE, Abshire T., PO659-MON PO409-WED, PO423-WED Akita M., PO211-WED Albisetti M., PO174-MON Almond C., PO457-MON, PO083-
PO244-TUE Abu Saadeh F., OR360 Agnoli A., PO084-TUE Akita N., PO185-TUE, PO284- Ale Booye E., PO247-TUE WED
Abajas Y., PO166-MON Abubakar A.-Z., PO025-TUE Agrahari G., PO305-TUE TUE, PO335-TUE Aledort L., OR105, PO270-MON Almosni J., PO653-WED
Abalkhail H., PO085-MON, Abuelkasem E., PO017-WED gren A., PO297-MON, PO368- Akiyama M., PO599-MON Alef T., PO669-MON Al-Musbahi A., PO517-WED
PO148-TUE Accassat S., AS082, AS137 MON, PO661-MON Akiyama M., PO653-TUE Aleidan F., OR052, PO307-MON Aloni A., PO615-WED
Abashidze M., PO250-TUE Accetta G., OR096, OR119 Agten S., PO037-TUE Akkawat B., PO266-TUE, PO606- Aleinikova O., PO206-TUE, Alonso-Roca D., PO271-WED
Abbas M., AS039 Acciarresi M., AS226 Aguila S., OR368 TUE, PO584-WED PO249-WED Alotaibi G., AS023
Abbasi S. H., PO090-WED Acharya S., PO519-WED guila S., OR076, OR359, Akkerman J.-W., AS189 Alekseeva P., PO023-MON Alpan L., PO134-WED, PO142-
Abbate R., OR253, OR270, Achilles K., PO274-WED PO338-TUE Akolekar R., OR033 Alemanno L., PO084-WED WED
OR396, OR400, PO067-MON, Acker J., PO570-MON Aguilar C., PO047-TUE Akpinar F., PO143-TUE Alessandrello Liotta A., PO365- Alpoim P., PO566-MON, PO244-
PO086-MON, PO226-MON, Acosta C., PO523-WED Aharon A., OR171, PO335-MON, Akpotuzor J., PO386-MON MON, PO366-MON, PO071-TUE, WED
PO365-MON, PO366-MON, PO325-TUE, PO389-WED PO477-TUE, PO586-WED Alrokan S., PO307-MON
Acquila M., PO259-TUE, PO534- kra S., PO042-TUE
PO020-TUE, PO039-TUE, WED Ahluwalia J., PO200-MON Alessi M. C., PO103-WED Alsahli M., PO542-WED
PO071-TUE, PO076-TUE, Akrour M., OR055, PO107-TUE
Acres S., OR310 Ahmad A., PO521-TUE Alessi M.-C., AS014, PO441- Alsammak M., PO037-WED
PO365-TUE, PO477-TUE, Aktekin E., PO109-WED
Adam F., OR003, OR205, OR234, Ahmad M., PO369-MON MON, PO443-MON, PO385-WED, Alshehri O., PO415-MON
PO094-WED, PO586-WED Al Asmi A., PO009-TUE
PO444-WED Ahmad O., PO400-MON PO493-WED Alt K., PO014-TUE
Abbattista M., PO633-WED Al Dieri R., PO089-MON, PO143-
Adam M., OR047, PO163-WED Ahmad S., OR047 MON, PO290-MON Alessi M.-C., OR324, PO416- Althawadi H., PO117-MON,
Abbonante V., PO378-WED Ahmad-Nejad P., PO669-MON MON, PO436-MON, PO440-MON
Abbott T., OR073 Adamczuk Y., PO079-TUE Al Falahi K., PO009-TUE, PO635- PO119-MON
Adamczyk-Wojciechowska P., Ahmed H., OR390 TUE Alevizopoulos A., PO169-WED Altisent C., OR347, PO056-TUE,
Abbruzzese R., PO200-TUE, Ahmed Y., PO365-MON, PO076- Alexander E., OR356
PO259-TUE, PO534-WED PO549-MON Al Frouh F., OR324 PO253-WED
Adams G., AS059 TUE Al Khalili F., OR061 Alexander W., PO190-WED Altuna D., PO522-WED
Abbuehl B., PO254-WED Ahmidatou H., PO242-TUE Alexandre H., OR278
Abbuehl B., PO281-MON Adams M., PO656-TUE Al Onazi N., PO604-TUE Alvarado J., PO242-WED
Adams T., OR431, PO632-TUE Ahnstrm J., AS149, OR369, Al Zadjali S., PO635-TUE Alfarsi H., PO119-MON Alvarado-Moreno J. A., PO020-
Abbuehl B., PO284-WED PO139-MON Alfarsi H., PO117-MON
Adamson L., OR031 Alakhdar-Mohamara Y., PO271- MON, PO073-MON, PO523-TUE
Abbuehl B., OR215, PO242-MON, Ahrens I., PO307-TUE, PO356- Alfonso A., PO516-MON, PO116-
PO260-MON dny R., PO187-WED WED Alvarez Dela Cadena P., PO329-
TUE, PO404-TUE TUE, PO488-TUE WED
Abd El Ghani H., PO243-MON Adarraga M. D., OR381 Al-Allaf A., PO085-MON
Ahuja A., PO529-WED Algahtani M., PO410-TUE Alvarez- Larrn A., PO487-TUE
Abdallah N., PO243-MON Adcock D., PO216-WED Al-Allaf F., PO085-MON, PO148-
Aillaud M.-F., OR324 TUE Algra A., OR255 Alvarez-Larrn A., PO435-MON
Abdel-Azeim S., PO582-MON Adcock D., PO173-MON, PO161-
TUE, PO233-WED Aisiku O., AS170 Alamelu J., OR104 Alhamdi Y., OR004, OR168 lvarez-Romn M., OR346,
Abdoellakhan R., PO363-WED Aisiku O., AS091 Al-Hashimi A., OR437 OR347
Abdolahi A., PO600-WED Adelman M., OR233 Alamelu J., AS159, OR145,
Adelmeijer J., OR070, OR435, Aisina R., PO213-MON OR386, PO239-MON, PO504- Alhenc-Gelas M., OR055, PO527- Alves G., PO145-WED
Abdul S., PO665-MON Aisina R., PO113-MON WED MON, PO544-TUE Alves M., PO043-WED
PO002-MON
Abdul S., PO209-MON Assi D., AS045, AS206 Al-Ani F., PO595-TUE Al-Horani R., PO306-MON Alves N., OR376
Adesuwa E., PO403-TUE
Abduljaleel Z., PO085-MON, Ait Aissa K., PO031-TUE Alarcon M., PO010-TUE Ali H., PO650-WED Alwar V., PO306-WED
PO148-TUE Adeyemi O., PO567-MON
Adiguzel C., PO305-MON Atchafa Tadlaoui D., PO375-MON Alarcn M., AS116 Ali H., PO118-MON Alwis I., OR380, PO443-WED
Abdulla M., PO148-TUE Aizman Sevilla A., PO358-TUE Ali H., OR440, PO123-MON
Adili R., AS217 Alashwal A., PO085-MON Amadio P., PO005-TUE
Abdulrehman A., PO410-MON Ajjan R., AS231, OR398, PO465- Ali M., PO180-MON, PO188-WED
Aernouts J., PO219-MON Alatri A., PO614-MON Amankwah E., AS161
Abe J.-I., PO032-TUE TUE Ali M., PO506-MON
Afonina E., PO501-WED Alayash A., OR174 Amano K., PO161-MON, PO213-
Abegunde S., PO591-WED Ajjan R., OR016 Ali M., PO354-WED TUE, PO006-WED, PO204-WED
Afrasiabi A., PO490-MON Albakr R., PO469-WED
berg M., PO552-TUE Ajjan R., AS155 Aliabadi A., PO509-TUE Amash A., PO306-TUE
Afshar H., PO077-TUE, PO084- Albanes J., PO035-WED
Abergel A., PO075-TUE Ajzenberg N., PO080-WED Alikhan R., AS159, OR130, Ambaglio C., OR030, PO483-
TUE Albnez S., PO678-MON, PO291-
Abeynaike L., OR185, PO404- Akahane K., PO417-TUE TUE, PO679-TUE OR382, PO638-MON, PO083- MON, PO580-WED
MON Agbani E., AS141
Agbani E., PO461-WED Akbayram H., PO310-MON Albayrak C., PO485-WED, PO527- TUE Ambily A., PO511-TUE
Abibatou S., PO542-MON Akbayram S., PO310-MON WED, PO537-WED Al-Khalili F., PO368-MON, Ambrose A., AS041
Aboelnazar E., PO589-TUE Ageno W., PO610-TUE, AS195,
OR195, PO511-MON, PO613- Akcay A., PO315-MON Albayrak D., PO485-WED, PO527- PO355-TUE Amengual O., PO058-WED
Abohelaika S., OR099 MON, PO614-MON, PO639- Akdeniz A., PO591-TUE WED, PO537-WED Alkindi S., PO635-TUE Ameri A., PO248-MON
Abolghasemi H., PO600-WED MON, PO115-TUE, PO607-TUE, Akhter M., PO182-WED, PO184- Al-Belushi B., PO009-TUE, Alkozai E., PO002-MON Amerine L., PO309-TUE
Abomansoor I., PO085-MON PO611-TUE, PO613-TUE, WED PO635-TUE Allacher P., PO249-MON, PO284- Amigo Q., PO522-WED
Aboura C., PO276-WED PO405-WED, PO671-WED Akhter M., PO183-WED Alber K., PO397-MON WED Amirabadi A., OR390
Aboura C., PO637-TUE Aggarwal A., AS197, OR292 Akici F., PO265-MON, PO459- Alberelli M. A., PO422-TUE Allen G., PO237-MON, PO239- Amiral C., PO424-WED
Abraham A., PO153-WED Aggarwal M., PO316-MON, MON, PO279-WED Alberio L., AS163, OR432, MON, PO208-TUE, PO255-WED
Amiral J., PO352-MON, PO166-
Abrams C., PO405-TUE PO272-TUE, PO529-WED Akc F., PO313-MON PO400-TUE Allen G., PO235-MON TUE, PO181-TUE, PO376-TUE,
Abrams S., OR004, OR168 Agliastro R., PO614-WED Akin M., PO158-TUE Albers-Akkers M., PO614-TUE Allen U., PO446-TUE PO411-TUE, PO424-WED
Albers-Akkers M., PO366-WED Allorto N., PO483-MON
Almakadi M., PO161-WED
428 429
AUTHORS INDEX
Amirkhosravi A., PO174-WED, Antic D., PO121-TUE, PO235- Ardissino G., PO589-MON Artemenko E., OR245 Attarian D., PO042-MON, PO055- Ayombil F., PO133-TUE
PO445-WED, PO446-WED WED Arellano-Rodrigo E., PO435- Artemov A., PO496-MON WED Ayres A., PO601-WED
Amit O., PO271-TUE Antic D., PO547-TUE MON, PO487-TUE, PO082-WED, Artoni A., OR005, PO592-MON, Attinasi F., PO071-TUE Aytac S., PO505-WED
Ammollo C., OR065, PO338-WED Anti D., PO218-TUE PO414-WED PO574-TUE, PO176-WED, Atwal S., PO009-WED Azar-Avivi S., PO225-WED
An H. J., PO475-TUE, PO478- Antmen B., PO254-TUE Arf S., PO614-WED PO583-WED, PO633-WED Au A., OR380 Azevedo A., PO163-TUE, PO538-
TUE, PO531-TUE, PO168-WED Antmen B., PO301-WED, PO302- Argunhan F., PO459-WED Artzer D., PO188-MON Aubas P., PO535-MON WED
Anastasopoulou J., PO169-WED WED, PO530-WED Arias M., PO092-TUE, PO146- Arvind P., PO081-MON Auerswald G., PO643-MON, Azhar Z., PO085-MON
Ancel P., PO385-WED Antn A. I., OR359 WED, PO231-WED Arya R., AS047, NUR008, PO629-TUE Azimzadeh A., PO306-MON
Andersen M., PO509-MON Antoniucci D., OR396, OR400, Aribi M., PO637-TUE OR033, OR063, OR073, PO347- Auger C., AS039 Azizi M., OR196
Andersen P., PO310-WED PO094-WED Aribi M., PO494-MON, PO276- MON, PO098-TUE, PO479-TUE, Auger W., PO644-WED B;Rvik T., PO308-TUE
Anderson D., PO456-TUE Antonova O., PO327-TUE WED, PO520-WED PO496-TUE, PO021-WED, Augustsson C., PO455-TUE
PO558-WED Baars J., PO103-TUE
Anderson D., AS077, AS139, Antonucci E., PO226-MON, Ariceta G., PO589-MON Aujesky D., OR193 Babinchak T., PO168-MON,
PO647-WED PO639-MON, PO640-MON, Aridogan A., PO301-WED Arza B., PO198-MON
Austin S., OR213, PO247-MON, PO169-MON, PO312-MON
Anderson F., OR395, PO578-TUE PO024-TUE, PO673-WED, Ariela Z., PO659-TUE Asada Y., PO552-MON PO502-MON, PO216-TUE, Babkina I., PO290-TUE
Andoljek D., PO027-WED PO674-WED, PO675-WED Ariens R., AS205, OR433, Asanuma K., PO335-TUE PO009-WED Babu B., PO154-MON
Andoskin P., PO444-MON Antovic A., OR187 OR444, PO182-TUE, PO188- Aschman D., PO285-MON, Austin S., PO418-TUE
PO618-TUE Baccini V., AS014, PO416-MON,
Andrade D., PO064-WED Antovic J., PO080-TUE, PO228- WED, PO245-WED Autar A., PO078-MON PO443-MON, PO385-WED
TUE Ariens R., AS155 Aschman D., OR298 Authi H., PO511-TUE, PO459-
Andre P., PO073-TUE Baccouche H., PO528-MON,
Antovic J., OR187, PO195-MON Arins R., OR372, OR374 Asenjo S., OR076, OR370 WED PO062-WED
Andr M.-H., PO501-MON
Antovi J., PO360-TUE Arins R., PO466-MON Ashfaq A., OR082 Authi K., PO511-TUE, PO459- Bachelot-Loza C., PO016-TUE,
Andreasen J., PO343-MON
Anyanwu R., PO403-TUE Arins R., AS153 Ashikaga T., PO233-TUE, PO211- WED PO018-TUE, PO038-TUE,
Andreasen P., AS146 WED
Anej Doma S., PO027-WED Arioka T., PO547-WED Avagyan A., PO573-MON PO437-WED
Andreeva E., PO054-MON Ashrani A., OR128, PO645-WED
Aoki T., PO041-MON, PO057- Arioli D., OR197, PO640-WED Avalos M., PO146-WED Bachler M., PO330-WED
Andreeva T., PO214-TUE WED Ashtiani M., PO186-MON
Andreoni L., PO445-TUE Arkhammar P., PO310-WED Avc E., PO230-MON Bachman B., AS183
Aoki T., PO434-MON Arkin S., PO512-TUE, PO520- Ashworth T., OR415 Avery P., OR099 Bachmann L., PO314-WED
Andresen M., PO118-MON Apartsin K., PO054-MON Aslam R., OR139, PO302-TUE
TUE, PO116-WED, PO266-WED, Avigliano A., PO059-WED Badimon L., PO017-MON,
Andrews R., PO497-MON, PO669- Aponte-Santamara C., PO669- PO597-WED Aslan J., PO068-MON
TUE Avila M., OR105, OR159, OR328, PO019-MON
TUE Armand-Perroux A., OR192 Aslan J., PO432-MON, PO440- PO270-MON, PO475-MON Badle S., PO660-WED
Andrews R., PO431-MON Apostol C., PO229-WED WED
Armond S., PO244-WED Avila M. L., PO479-MON Badolia R., OR111, OR184
Andrews W., PO516-WED Apostolova M., OR090, PO277- Aslan J., PO453-WED
Armstrong P., PO414-TUE, Aviner S., PO475-WED Badowska W., PO650-MON
Andrews R., PO393-TUE, PO441- WED PO085-WED Aspberg S., PO171-WED
WED Avishai E., PO225-WED Bae M. H., PO071-WED, PO427-
Appa R., OR110, PO052-WED Arnau M. A., PO536-MON Asplund A., OR046 Avivi I., PO335-MON, PO271-TUE WED
Andrusaitis F., PO211-TUE Appel I., OR225 Arndt B., OR054 Assalia M., PO126-MON Avorn J., PO232-MON Bae O.-N., PO115-MON
Ang S. K., PO012-TUE Appeltans H., PO373-TUE Arnell H., PO443-TUE Asselbergs F., PO386-TUE Avril S., PO262-WED Bae S., PO426-TUE
Angay O., OR405, PO526-TUE Appenzeller S., OR094, PO066- Arnesen H., OR251, PO079- Astermark J., OR389, PO256-TUE Avruscio G., PO385-MON Baeriswyl V., PO101-MON
Angchaisuksiri P., OR096, OR119 WED, PO067-WED MON, PO030-TUE, PO042-TUE, Astoul P., OR315 Awa Oumar T., PO542-MON Bagan-Triquenot A., PO621-WED
Angela L., OR167 Apte S., PO164-MON PO293-TUE, PO342-WED Ataga K., PO331-MON Awala H., PO323-TUE Bagby S., PO296-TUE
Angelescu S., PO474-WED Arabia F., OR216 Arnold D., PO616-WED Atalar A. C., PO295-WED Awodu O., PO529-TUE Bagger H., PO219-WED
Angelillo-Scherrer A., PO101- Arai R., PO106-MON Arnold D., AS110
MON, PO489-MON Ataullakhanov F., AS142, OR245, Axelman E., AS096, PO126-MON Bagger H., PO153-TUE
Aranda E., PO472-WED Arnold M., PO525-TUE PO661-WED Baghaei F., OR029
Angls-Cano E., PO187-MON Axer-Siegel R., PO285-TUE
Aras M., PO597-TUE Arocas V., OR422, PO545-WED Ataullakhanov F., PO462-MON, Baghaipour M. R., PO149-TUE
Angoulvant D., PO064-MON Ay C., AS034, OR227, OR260,
Araujo F., PO286-MON Arour A., PO242-TUE PO047-WED, PO118-WED, OR313, OR357, PO096-MON, Baglin T., OR135, PO625-WED
Anguela X., PO172-MON Araujo F., PO264-TUE, PO404- Arponen S., PO485-TUE PO150-WED, PO436-WED
Ankri A., PO128-WED PO559-MON, PO122-WED, Baglin T., OR148, OR394
WED Arraud N., PO326-TUE Ataullakhanov F., OR305, PO067- PO166-WED, PO391-WED,
Annabelle D., OR219, PO662- TUE, PO392-TUE, PO135-WED Bagnard D., AS095
Araujo P., PO179-TUE Arroyo A., OR440 PO528-WED
TUE Ataullakhanov F., PO097-MON Bagoly Z., PO516-TUE, PO087-
Arajo F., PO212-TUE, PO012- Arroyo A. B., PO549-WED, Ay L., OR313 WED
Anne A.-S., PO347-TUE WED, PO261-WED PO552-WED Atema J., PO506-TUE Ay Y., OR262, PO590-MON Bahadir A., PO270-TUE, PO499-
Annetta E., OR160 Arajo H., PO231-MON, PO333- Arroyo Rodrguez A. B., PO558- Athale U., PO463-MON, PO118- Ayadurai T., PO541-MON WED
Annetta S., PO644-MON, PO428- MON TUE TUE
TUE Ayala F., OR359 Ba-Hammam F., PO085-MON,
Aravind P., PO082-MON Arruda V., PO155-MON Athar M., PO085-MON Ayala R., PO487-TUE PO148-TUE
Annichino-Bizzacchi J., OR094, Arbasi M., PO264-MON Arruda V., AS120, PO160-MON Athar M., PO148-TUE
PO066-WED, PO067-WED, Ayaz N., PO279-WED Bahl B., OR198
Arbesu G., PO441-TUE Arshad N., PO609-MON, PO612- Atiee G., PO621-MON Aycicek A., PO459-MON, PO279- Bai X., PO011-MON, PO425-TUE,
PO100-WED
Arbring K., PO367-MON, PO560- MON Atkinson H., PO159-MON WED PO039-WED, PO259-WED
Annichino-Bizzacchi J., OR263 TUE, PO561-TUE Artana C., PO236-WED Atkinson H., PO343-TUE Aydn Koker S., OR262 Bai Y., PO011-MON
Annichino-Bizzacchi J., PO190- Arderiu G., PO017-MON, PO019-
MON, PO422-MON, PO531-MON, Artang R., PO352-MON, PO456- Atkinson H., PO464-TUE Aydogan G., PO265-MON, PO313- Baik S. Y., PO164-TUE
MON TUE, PO424-WED Atsumi T., PO058-WED MON, PO315-MON, PO459-MON,
PO145-WED, PO221-WED Bailer B., PO219-TUE
Ardeshiri R., PO490-MON Artaza G., PO538-MON, PO375- Attanasio M., OR253, PO076- PO279-WED
Antal-Szalms P., PO124-MON Bailey K., OR128, PO645-WED
Ardillon L., OR428 TUE, PO407-WED TUE, PO477-TUE Aylwin S., AS047, PO558-WED Bailey M., AS205
430 431
AUTHORS INDEX
Bajaj S. P., PO165-MON Baques A., PO092-TUE, PO146- Barteling W., PO468-TUE Bayhan T., PO505-WED, PO507- Belhani M. F., PO276-WED Bercovitz R., OR058
Bakchoul T., OR307, AS106, WED, PO231-WED Barthet M.-C., OR324 WED, PO508-WED Belik S., PO096-MON Bereczky Z., PO550-MON,
PO413-TUE Bar -Ilan A., PO062-TUE Barthez-Toullec M., PO484-MON, Baylis J., PO375-WED Belk K., OR309 PO031-WED, PO087-WED,
Baker C., PO336-WED Bar On S., PO268-TUE PO488-MON Baylis J., PO372-WED Bell J., OR372 PO187-WED
Baker J., PO238-MON Baracchini C., PO524-TUE Bartholomew C., NUR005 Bayliss S., PO019-TUE Bell R., PO004-TUE Beregi J.-P., PO035-MON
Baker J., PO507-MON Baracco E., PO385-MON Bartoska R., PO364-WED Bayram C., PO313-MON, PO459- Belleville T., PO018-TUE Bereta J., PO365-WED
Baker R., PO374-TUE, PO669- Baran B., PO278-MON, PO049- Barty R., OR282 MON, PO279-WED Bellire J., AS117 Brziat O., PO337-MON
TUE TUE, PO235-TUE, PO543-TUE, Baruch D., OR205, OR234, Baytan B., PO268-MON, PO156- Bellinger D. A., OR178 Bereznikova A., PO197-MON
Baker R., PO098-MON, PO324- PO648-TUE, PO032-WED, OR403, PO376-WED TUE Bellissimo D., OR086 Berg J. P., PO561-MON
TUE, PO540-WED, PO546-WED PO526-WED Barutcuoglu B., PO266-MON Bazaa A., PO658-TUE Bellissimo D., OR089 Bergamasco J., PO322-TUE
Baker S., PO440-WED Barat N., PO045-TUE Barvadheesh C., PO566-WED Bazaa A., AS062, OR246, Bellofatto K., OR411 Bergantim R., PO012-WED
Baker-Groberg S., AS129, PO010- Barba P., PO487-TUE Bas D. L., PO072-TUE PO206-WED Bergendal A., OR269
Bellon A., PO488-MON
MON, PO297-TUE Barbanti C., PO018-TUE Basay O., PO143-TUE, PO158- Bazzan M., PO614-MON Berger K., PO291-WED
Bellosillo B., PO435-MON
Bakhai A., OR382 Barbara A., OR144 TUE Beam D., OR376, PO033-MON Bergs A., PO355-WED
Belova N., PO381-TUE
Bakhos M., OR173, PO291-MON, Barbay V., PO520-MON Basili S., OR396 Beauchamp N., AS132 Bergh N., OR380
Belsy G., PO152-WED
PO339-WED, PO411-WED Barbera R., PO616-TUE Basilio J., PO559-MON Beauloye C., PO101-WED Bergmann F., OR054
Beltramello G., OR132
Bakhtiari K., PO323-TUE Barbera R., PO491-TUE Baskova O., PO147-WED Beavis J., PO638-TUE Bergmeier W., AS070, OR273,
Beltran J., PO045-TUE
Bakker B., PO410-WED Barbieri S., PO005-TUE Baslar Z., PO265-MON Becattini C., AS226, AS227, OR274, PO423-MON, PO003-
AS195, OR074, PO370-MON, Belzunce M., AS230
Bal Dit Solier C., OR149 Barbon E., OR179, OR300, Basol G., PO266-MON TUE
PO626-MON, PO373-WED, Bem D., AS054, AS011, OR401
Bal Dit Sollier C., PO655-WED PO158-MON Bassand J.-P., OR119 Beriault D., OR007
PO423-WED Ben Ami T., PO475-WED
Balabanov S., PO215-WED Barbu D., PO474-WED Basso G., PO456-MON Berlin G., PO571-MON
Becher F., PO181-TUE Ben Dov I., PO474-MON
Balakhonova T., PO199-MON Barchielli A., OR253, PO020-TUE Basso M., OR202, PO007-MON, Bermejo E., PO646-TUE, PO652-
Beckers C., PO190-WED Ben Harosh M., PO429-TUE TUE
Balandina A., PO097-MON Barco S., PO372-MON, PO537- PO259-TUE, PO534-WED
MON, PO506-TUE, PO507-TUE Beckers C., AS003 Ben Jemaa M., PO528-MON, Bermejo E., PO039-MON, PO636-
Balantac Z., PO138-TUE Bassora F., PO145-WED PO062-WED
Balazova E., PO249-TUE, PO022- Bardakchyan S., PO573-MON Beckers E., PO645-MON TUE
Bastami S., PO401-TUE Ben Romdhane N., PO528-MON,
WED Brdos H., PO550-MON Beckers E., PO349-WED Bernardi E., OR284
Bastard C., PO621-WED PO062-WED
Balbi M., PO177-TUE Barelli S., PO400-TUE Beckers E., OR015, PO123-WED, Bernardi F., OR050, OR080,
Bastelica D., PO385-WED PO609-WED Ben Sassi S., PO528-MON,
Baldacci E., PO200-TUE, PO259- Bar-Ilan A., PO048-WED, PO594- OR179, OR296, OR297, OR300,
Bastos M., PO023-WED Becker-Scheidemann B., PO094- PO062-WED OR333, PO554-TUE, PO555-
TUE, PO654-TUE, PO534-WED WED, PO595-WED Bateman T., PO032-MON Benamer S., PO344-MON
Baldauf C., OR335, PO669-TUE Barillari G., AS195, PO358-MON, MON TUE, PO556-TUE, PO557-TUE
Bath P., PO518-TUE Beckman M., PO637-WED Ben-Barak A., PO475-WED Bernardo ., PO488-TUE
Balduini A., PO422-TUE, PO378- PO029-WED, PO175-WED
Batlle J., PO010-WED Beckmann H., OR214, PO292- Ben-Barak S., PO475-WED Berndt M., PO395-MON
WED Bark Jr D., PO332-MON
Batorova A., PO249-TUE, PO371- WED, PO293-WED Bendapudi P., OR417 Berndtsson M., OR187, PO080-
Balduini C., PO438-MON, PO473- Barnard J., PO494-WED TUE, PO022-WED, PO061-WED
WED Becs G., PO530-MON, PO488- Bender M., OR232 TUE, PO228-TUE
Barnard S., PO214-MON Batt K., PO287-WED, PO297-
Balestra D., OR296, OR300 WED Benedettini L., PO222-TUE Bernot D., AS014, PO493-WED
Barnes C., OR346 WED
Balkan C., PO630-TUE Bedarida T., PO038-TUE Beneventi F., PO580-WED Bernstein M., AS158
Barnes G., PO623-TUE, PO419- Battello C., PO029-WED
Balkis M., PO281-WED WED Beenen L., PO597-MON Benipal P., PO306-MON Berntop E., PO283-WED
Battinelli E., PO380-WED Beer J., PO027-MON Benmiloud N., PO544-TUE Berntorp E., PO240-MON, PO271-
Balla J., PO530-MON, PO488- Barnes T., PO673-TUE Battistelli S., OR132
WED Baron S., PO038-TUE Beghini D., PO239-WED Benn M., AS167, PO438-WED MON, PO080-TUE, PO229-TUE,
Battram A., PO461-WED Begins K., OR423 Bennett J., PO431-WED PO263-WED, PO299-WED
Ballet V., PO286-TUE Baronciani L., PO663-MON Batty P., OR108, PO284-MON, Behnisch W., PO419-TUE Bennett M., PO601-MON Berny-Lang M., PO411-MON,
Balogh L., PO224-MON, PO187- Barone F., PO200-TUE, PO259- PO258-WED
WED Behr A., PO061-MON, PO315- Bennett P., NUR014 PO096-TUE
TUE, PO534-WED Batuman O., PO265-TUE
Baltaci O., PO649-TUE TUE, PO127-WED Benoit M.-C., PO081-WED Berra C., PO107-MON
Baroni M., OR050, OR297, Baudar J., PO092-MON, PO063-
Balzi D., OR253, PO020-TUE PO554-TUE, PO555-TUE Behrendt T., PO420-TUE Bensadok M., PO494-MON, Berrou E., OR003, OR234,
TUE Behrens C., PO219-WED PO242-TUE, PO637-TUE, PO444-WED
Banfi C., OR219, PO662-TUE Barr S., PO180-WED Bauer A., PO249-MON, PO199- Beijer E., PO443-TUE PO276-WED, PO520-WED Berruyer M., PO448-MON
Banfi C., PO005-TUE Barrelier M.-T., AS137 WED, PO229-WED
Beijlevelt - Van Der Zande M., Bensen Kennedy D., PO089- Berry L., PO087-MON
Banfi E., PO483-TUE Barrera L., PO068-TUE, PO522- Bauer B., OR123
WED NUR004, PO230-TUE TUE, PO257-TUE, PO258-TUE, Berry L., PO343-TUE
Bang A., PO388-TUE Bauersachs J., PO058-MON, PO262-TUE
Barrett D., PO429-MON, PO565- Beilhack A., OR405 Berry L., PO159-MON, PO464-
Bang S.-M., PO614-MON, PO035- PO013-TUE Bensen-Kennedy D., OR350, TUE
TUE, PO119-TUE, PO489-TUE, MON Beishuizen A., OR225
Bauersachs R., AS081, AS214, PO241-TUE Berta G., AS088
PO659-WED Barrett J., PO273-MON OR199, OR228, PO356-TUE Beken S., PO134-WED
Bekendam R., OR417 Ben-Shlomo Y., OR209 Bertaggia Calderara D., PO400-
Bannish B., PO207-MON Barrile N., PO101-WED Bauman M., PO455-MON,
Bel E., PO611-MON, PO335-WED Benson D. W., OR058 TUE
Banos A., PO212-MON, PO331- Barrn M., PO631-WED PO460-MON, PO511-WED
WED Bla S., PO333-MON Benson G., PO481-MON, PO588- Berthomet C., PO056-WED
Barros S., OR213, PO049-WED Baumann A., PO214-WED TUE
Bansal V., PO192-TUE, PO332- Belanger A., PO374-MON Bertil S., AS086
Barros V., PO472-TUE Baumgartner C., PO222-WED Beranger T., PO568-MON, PO575-
WED Belen F. B., PO309-MON Bertin F.-R., OR167
Barros V., PO508-MON, PO476- Baunsgaard D., PO153-TUE MON
Banzato L., PO524-TUE TUE Belhani M., PO494-MON, PO242- Bertina R., OR374
Bautista M. P., PO658-WED Berber E., PO649-TUE Bertling A., PO015-TUE, PO157-
Baptista F., PO472-TUE Barsela G., OR171 Bay A., PO109-WED TUE, PO637-TUE, PO520-WED
Berbert L., PO158-WED TUE, PO395-TUE
432 433
AUTHORS INDEX
Bertolaccini M., PO068-WED Bidlingmaier C., PO252-WED Blades T., PO103-MON Blondon M., OR034, OR133, Bologna L., PO489-MON Boroumand M., PO090-WED
Bertoletti L., OR381, PO608- Bieback K., PO383-WED Blair T., PO428-MON PO557-WED Bolt G., OR414 Brresen-Dale A.-L., PO177-WED,
MON, PO103-TUE, PO107-TUE, Biedermann J., PO623-MON, Blair T., OR112 Blostein M., OR282, AS215, Bolt J., NUR011 PO178-WED
PO631-WED PO665-WED Blaise F., PO542-MON PO647-WED Bolton-Maggs P., AS054 Borst O., OR114, PO412-MON,
Bertone A., PO358-MON Biedermann J., PO648-WED Blaise S., PO457-WED Blostein M., OR167 Bolton-Maggs P., PO495-MON PO449-WED
Bertrand A., PO501-MON Biel C., PO444-TUE Blake D., OR280 Blouse G., OR299 Bonacci R., PO585-TUE Bortolussi G., PO438-TUE
Bertrand L., PO101-WED Biemond B., PO294-MON Blanchard A., OR196 Bluestein D., PO677-TUE Bonadeo J., PO616-TUE, PO491- Brtz A., PO382-MON
Besbes S., PO117-MON Bierings R., AS118 Blanchette V., AS122, OR105, Blunt D., PO633-MON TUE Brvik T., PO329-TUE
Besenfelder S., PO487-WED Biessen E., AS189 OR390, PO262-MON, PO245- Bluteau O., OR082 Bonafacio S., PO648-WED Bos M., PO522-MON
Besser M., PO317-TUE Bignell P., PO653-MON, PO638- TUE, PO426-TUE Bo Z., PO129-MON Bonaldi C., PO598-TUE Bos M., AS056, OR147, PO144-
Besses C., PO487-TUE TUE Blanchette V., AS078 Bo Mogensen V., PO121-WED Bonanad S., PO093-MON, MON, PO562-MON, PO616-MON
Beswick A., OR209 Bigo E., PO241-WED, PO422- Blanchette V., PO390-TUE Boadas A., PO523-WED PO534-MON, PO536-MON, Bos M., PO620-TUE
Bettella M., PO385-MON WED Blanco A., PO004-MON, PO629- Boban A., PO234-TUE, PO280- PO579-WED Boscarino M., OR083, PO502-
Bettencourt B., PO049-WED Biguzzi E., OR026, PO503-MON, MON, PO634-TUE, PO636-TUE, WED Bonanad-Boix S., PO271-WED MON, PO521-WED
Bettencourt P., PO264-TUE PO656-MON, PO663-MON, PO646-TUE Bobe R., PO444-WED Bonanni P., PO585-TUE Bosch F., PO538-MON, PO056-
PO090-TUE, PO091-TUE Blanco A., PO039-MON Bobrov M., PO030-WED Bonar R., PO366-TUE TUE, PO321-TUE, PO375-TUE,
Betti S., PO611-TUE PO445-TUE, PO407-WED
Bettin C., PO084-TUE Bihan D., AS065, PO441-WED Blanco J. E., OR221 Bochenek M., PO513-TUE, Bond S., PO362-TUE
Bihari C., PO540-MON, PO005- Blankenberg S., PO478-WED PO102-WED Bonduel M., OR160, PO644- Bosch Y., PO290-MON
Bettina K.-M., PO140-WED Bosco A., PO043-WED
WED Blanty J., PO502-MON Bochicchio R., PO200-TUE, MON, PO428-TUE
Bettoni D., PO622-TUE Boscolo Anzoletti M., PO164-MON
Biino G., PO438-MON Blanz K., OR252 PO534-WED Bonet E., PO093-MON, PO344-
Bevan D. H., OR213 Boselli D., PO378-WED
Bilge S., PO051-WED Blasier K., PO203-TUE Bock F., PO129-TUE TUE
Beverina I., PO615-WED Bosmann M., PO513-TUE
Bilir S. P., PO312-MON Blasier K., PO368-WED Bock P., OR423 Bonhomme F., PO011-TUE
Beyer - Westendorf J., PO103-TUE Bosmans J., PO218-MON
Biller E., PO587-MON Blasko E., PO213-WED Boda Z., OR199, PO031-WED Bonilla G., PO658-WED
Beyer-Westendorf J., AS022, Bossard M., PO200-WED
AS098, AS099, AS195, AS197, Billwein M., PO199-WED Blatny J., PO655-MON Bode A., PO611-WED Bonnard T., PO014-TUE
OR259, OR292, PO477-MON, Binard S., PO440-MON Blatny J., AS122, OR346, Bode C., OR252, PO307-TUE, Bonneau D., OR003 Bosson J. L., PO655-WED
PO614-MON, PO636-MON, Binder C., PO298-TUE PO262-MON PO404-TUE Bonneau J., NUR013 Bosson J.-L., PO095-TUE
PO356-TUE, PO611-TUE, Binder L., PO062-TUE, PO550- Blazejczyk A., PO365-WED Bodrozic J., PO235-WED Bonnefoy A., OR217, PO006- Bossuyt P., PO596-MON, PO624-
PO624-WED TUE, PO048-WED, PO594-WED, Blazek B., OR346 Bodroi J., PO218-TUE MON, PO165-WED, PO282-WED WED
Bez J., PO340-MON PO595-WED Bledzka K., PO194-MON Boef A., PO532-MON Bonner L., NUR008 Bossuyt P., PO597-MON
Bez J., PO337-MON Bingo M., PO161-MON, PO006- Bleker S., AS197, OR292 Boehlen F., OR034 Bonnet D., AS086 Bottai M., OR269
Bezgal F., PO295-WED WED Boehm E., PO201-WED Bonnet J.-L., PO493-WED Bottaro F., PO621-TUE
Bleker S., OR199, PO624-WED
Beziau S., OR025 Binhama T., PO675-MON, PO268- Boelen A., PO548-WED Bonvini R., PO011-TUE Bottenus R., PO360-MON,
WED, PO613-WED, PO643-WED Bleker S., PO103-TUE, PO353-
Beziaud M., OR192 TUE, PO409-WED Boender J., PO665-MON Bonzini M., PO613-MON PO374-MON, PO054-TUE
Bezie Y., PO033-TUE Birch K., PO385-TUE Boender J., AS079, OR021, Bookhart B., PO625-MON Bttger C., PO256-MON
Blickstein D., PO001-WED
Bezieau S., PO645-TUE Bird A., OR382, PO638-MON OR203 Boon-Spijker M., AS121 Bouazzaoui A., PO085-MON,
Bliden K., PO076-MON, PO099-
Bhagirath V., PO570-MON, Bird M., PO618-TUE MON, PO041-TUE Boffa J.-J., PO632-WED Boonyawat K., OR068 PO148-TUE
PO604-TUE Birner P., OR357 Blighe K., PO197-WED Bogdanov V., AS028, OR047 Booth S., PO635-MON Bouchard B., PO145-MON
Bhakta V., OR425 Biron Andrani C., PO263-TUE Blin A., PO376-WED Bogdanov V., PO017-MON Boothman L., OR183, PO434- Bouchard B., PO576-MON
Bhal V., PO174-TUE, PO076-WED Birschmann I., PO140-WED Blinc A., AS101 Boggio L., OR347, PO256-WED, WED Bouchard B., AS050
Bhatt D., PO494-WED Bischoff J., AS087 Blix K., AS083, OR129, OR293, PO266-WED, PO298-WED Bor M. V., PO495-WED Bouchard C., PO191-TUE,
Bhatt M., PO447-TUE Biselli C., PO018-TUE OR345, OR393, PO526-MON, Boghossian J., PO439-TUE Br ., PO196-TUE PO192-TUE, PO344-WED
Bhattoa H., PO488-WED Biss T., AS054, AS159, OR104, PO104-TUE, PO111-TUE, Bohdan N., OR076, OR359, Boraso S., PO084-TUE Bouckaert C., PO172-TUE,
OR145, PO420-WED, PO502- PO112-TUE, PO495-TUE, OR368, PO336-MON, PO338- PO269-TUE
Bhavanasi D., OR184 Borchert A., PO094-MON
WED PO568-WED TUE Boucsein-Mueller E., PO107-WED,
Bialkowska K., PO194-MON Borel-Derlon A., OR025, PO650- PO137-WED
Biss T., PO447-MON Bloch Mnster A.-M., PO130- Bohgaki T., PO058-WED MON, PO639-TUE
Bianchi F., PO568-MON, PO575- Boulaftali Y., AS070, OR274,
MON Bisset A., PO346-MON MON Bohn R., PO232-MON Borg J.-Y., PO501-MON, PO520-
Biswas A., OR248, PO498-MON, Bloch-Mnster A.-M., PO051-TUE Boietti B., PO620-WED PO222-MON, PO423-MON
Bianchini E., PO339-TUE MON, PO621-WED
PO637-MON, PO674-MON, Bloem E., AS121 Boietti B., PO642-WED Bouman A., PO466-MON, PO471-
Bias V., OR298 Borgel D., PO018-TUE, PO339- MON
PO182-WED, PO183-WED, Bloem-De Vries L., PO614-TUE, Bing A., PO342-MON TUE
Biasoli C., AS222, PO264-MON, PO184-WED Bouman A., PO470-MON
PO222-TUE, PO303-WED PO366-WED Boisseau P., AS134, OR024, Borges K., PO340-WED
Bito S., OR051 Bloemen S., OR427, PO143- OR025, PO645-TUE, PO664-TUE Bounameaux H., AS099, AS137,
Bicalho M., PO397-WED Borges K., PO244-WED OR259, OR381
Bitsadze V., PO008-MON MON, PO290-MON, PO546-MON, Boisson-Vidal C., PO014-MON
Bicalho M. A., PO189-TUE, Borges K., PO566-MON Bourdon C., PO131-TUE
Bitsadze V., PO548-MON PO072-TUE Bojenov E., OR043
PO023-WED Borgoens P., PO373-TUE Bourgeois C., OR028
Bittar L., PO221-WED Bloemenkamp K., PO607-WED Bokemeyer C., PO251-MON,
Bicalho M. A., PO002-WED Borhany M., PO502-MON, PO134- Bourhim M., PO122-MON
Bittner L., PO364-WED Blombck M., PO255-MON, PO174-WED TUE, PO549-TUE, PO181-WED,
Bichler J., PO272-WED PO368-MON, PO661-MON, Bouriche T., PO337-MON, PO340-
Bjoernsen S., OR317 Bokuchava M., PO585-WED PO521-WED
Bicker M., PO382-MON PO362-WED MON
Bjrkqvist J., PO178-TUE Bollen L., OR444, PO215-MON, Borisevich A., PO028-WED
Bicocchi M. P., PO259-TUE, Blomgren B., PO171-WED Bourke D., PO649-WED
PO534-WED Black A., PO180-WED PO286-TUE Borotto E., PO615-WED
Blackshear P., OR085 Blondal T., PO572-WED Bours V., AS006
434 435
AUTHORS INDEX
Bourti Y., PO339-TUE Brando L., PO434-TUE Brionne-Franois M., PO448-MON Brusov O., PO147-WED Burleson D., PO211-MON, Calderaro D., PO034-TUE,
Bouskill V., AS078 Brando L., PO479-MON Brioschi M., PO005-TUE Bruzelius M., OR269, PO559- PO212-MON PO095-WED
Boutiba S., PO276-WED Brando B., PO615-WED Brisot D., AS137 WED, PO564-WED Burra P., PO114-TUE Caliskan U., OR348
Bouton M.-C., OR422, PO545- Brand-Staufer B. C., PO215-WED Brissard A., PO128-WED Bryckaert M., OR003, OR205, Burthem J., PO495-MON Callahan R., PO601-WED
WED Brandt S., AS008, PO298-MON Brisson A., OR315 OR234, PO444-WED Bury L., OR208, OR336, OR399, Callewaert F., OR363
Bouvier S., OR095, OR188, Brandtzaeg P., PO561-MON Brisson A., PO326-TUE Brzoska T., AS030 PO473-WED Callewaert N., OR443
OR190, PO035-MON Brandwein J., PO592-TUE Brito M., PO184-TUE Bubanska E., PO249-TUE Buryachkovskaya L., PO294-TUE Calmette L., PO016-TUE
Bouwens E., AS121 Brass L., AS185 Britta Laros-Van Gorkom B., Bucciarelli P., AS196, OR083, Buryachkovskaya L., PO496-WED Calvert L., PO343-TUE
Bouwhuis A., OR301 Brass L., OR038, OR207 PO257-TUE OR394, PO656-MON, PO663- Buscema M., PO066-MON Calvez T., OR143
Bova C., OR132 Brix J., OR313 MON, PO176-WED, PO583-WED, Bushueva N., PO204-MON Calvo A., PO585-MON
Brass L., PO467-WED PO633-WED
Bovolenta M., OR179 Bratset V., PO079-MON Brizuela M., PO079-TUE Bussel J., PO311-MON Calvo C., PO441-TUE
Bowley S., OR417, PO425-MON Buchardt J., PO219-WED Busstra M., PO282-MON
Braun A., AS068, AS228, OR081 Brkovi B., PO218-TUE Calzavarini S., PO101-MON,
Bowley S., OR424 Bucherelli S., PO067-MON Butenas S., OR303, OR426, PO489-MON
Braun M., PO001-WED Broberg M., PO219-WED
Bowman M., OR023 Bucherini E., OR132, OR195, PO248-MON, PO168-TUE, Camera M., PO378-WED
Braunreiter C., AS103 Brodde M., PO163-MON, PO218- PO611-TUE, PO671-WED
Boyd J., NUR006 WED, PO234-WED PO467-TUE Camerer E., PO437-WED
Bravo A., PO355-WED Buchholz H., PO455-MON,
Boyd S., PO487-MON Brodde M., PO157-TUE Butera D., PO669-TUE Cameron A., PO004-TUE
Bravo M. C., PO371-MON PO083-WED
Boyer-Neumann C., PO639-TUE Brodde M., PO395-TUE Butler L., PO559-WED Cameron S., OR241
Bravo M. I., PO207-WED Buckley C., AS092
Boyett S., OR435 Brodie M., PO445-WED Butlin R., AS205 Cameron S., PO032-TUE
Bravo M., PO152-WED Buckley C., PO393-TUE
Bozgul Kilincer M., PO266-MON, Brodin E., PO263-WED Butt W., PO607-MON, PO596- Camire R., AS149, PO520-TUE
Brayne M., PO053-TUE Buckner T., PO297-WED, PO298- TUE
PO237-TUE, PO238-TUE Brede C., OR405 Brodin E., OR258, PO472-MON WED Camire R., AS120, AS150,
Bozic-Mijovski M., PO082-TUE Brodin E., OR075 Butter L., OR124 PO144-MON, PO160-MON,
Breen K., PO045-MON, PO603- Budde U., PO649-MON, PO667- Buvaliy S., PO047-WED
Boi-Mijovski M., PO360-TUE MON Brodin E., PO494-TUE MON, PO676-MON PO632-MON, PO415-WED
Bozkurt A., PO051-WED Brodsky G., AS143 Buyanbat A., PO072-WED Camire R., AS148
Brehm M. A., OR335 Budnik I., PO396-MON
Bozon D., PO198-WED Broeg-Morvay A., PO525-TUE Buyukkaya P., PO051-WED Camm J., OR096, OR119
Breinholt J., PO455-TUE Buehner K., PO214-WED
Bracco A., PO024-TUE, PO372- Brognoli F., PO622-TUE Buzdin A., PO496-MON Campbell H., PO075-MON,
Breinholt J., PO541-WED Buevich E., PO643-MON
TUE Brondi B., PO502-TUE Buzzi J.-C., PO620-MON PO415-TUE
Breitenfeld R., PO451-WED Bugert P., PO383-WED, PO487-
Bracken T., AS114 Bronowska A., PO669-TUE WED Byams V., PO285-MON Campbell J., PO637-WED
Breitenfeld R., PO336-WED
Brackmann H.-H., OR103, Brons P., AS079, PO502-MON, Bugger H., OR252 Bye A., AS167, PO438-WED Campbell R., OR085, PO423-
Brekalo M., PO282-TUE MON
PO219-TUE PO680-TUE Buhre P., PO665-WED Bykov K., PO232-MON
Brekelmans M., PO507-TUE Campbell V., PO248-WED
Braekkan S., AS138, OR075, Brophy D., PO273-MON Bulato C., OR078, OR172, Bykowska K., PO278-MON,
OR120, OR134, OR345, PO524- Brekelmans M., OR199 PO549-MON, PO543-TUE, Campello E., AS042, OR078,
Bremme K., PO292-TUE, PO482- Brophy T., PO667-TUE PO193-MON, PO341-MON,
MON, PO525-MON, PO610- PO548-TUE, PO387-WED PO648-TUE, PO026-WED, OR172, PO061-MON, PO341-
MON, PO111-TUE, PO112-TUE, TUE Brousse V., AS086 PO032-WED, PO526-WED, MON, PO456-MON, PO114-TUE,
PO567-WED Brener S., PO253-MON Brouwer M., PO366-WED Bulder I., PO326-MON PO536-WED, PO588-WED PO315-TUE, PO331-TUE, PO332-
Braekkan S., AS083, PO519- Brennan M., PO078-WED Brouwer M., PO614-TUE Buller H., OR383, PO587-TUE, Byrkjeland R., PO079-MON, TUE, PO438-TUE, PO524-TUE,
MON, PO641-WED Brouwer R., OR257 PO608-TUE PO042-TUE PO548-TUE, PO387-WED
Brenner B., OR171, PO126-
Brkkan S., AS046, OR129, MON, PO325-TUE, PO389-WED, Brouwers E., PO545-WED Bller H., OR199, PO596-MON, Byrne M., PO318-WED Campioni M., OR297, OR333,
OR267, OR393, PO526-MON, PO563-WED PO409-WED, PO624-WED PO554-TUE
Brown A., NUR008, PO347-MON Byrne R., NUR008, PO347-MON
PO104-TUE, PO494-TUE, Brenner M., OR058 Bller H., AS197, OR191, Camporese G., AS197, OR195,
Brown C., OR332, PO679-TUE Byrnes J., AS153
PO495-TUE, PO568-WED, OR292, PO100-TUE, PO103- OR284, OR292, PO624-WED
Bressollette L., OR149, OR323, Brown E., AS141 Byun T., OR247
PO636-WED, PO638-WED TUE, PO353-TUE, PO164-WED Campos F., PO397-WED
PO655-WED Brown J., PO190-WED Byzova T. V., AS093
Brkkan S., OR071, OR254, Bullih A., PO019-WED, PO509- Campos F., OR116
Brettner S., PO343-WED Brown J., AS003 C. Jorissen A., PO565-WED
OR293, OR392, PO609-MON, WED
Bridey F., PO488-MON Brown P., AS143 Caballero J., PO010-TUE Campos G., PO211-TUE, PO250-
PO612-MON, PO493-TUE, Bullorsky E., PO180-TUE WED
Bridey F., PO484-MON, PO650- Brown S., PO255-WED Cabello Clotet N., PO485-TUE
PO594-TUE, PO561-WED Bulmer A., PO498-WED Campos M., PO442-MON, PO318-
MON Brown S., NUR013
Braggio E., PO128-MON Bungard T., NUR011 Cabre Marquez J., PO274-WED TUE, PO626-TUE
Bridge K., OR433 Brox J., AS046, OR120
Brailly-Tabard S., PO527-MON Burakov V., PO111-WED Cabrera N., PO579-WED Campos-Nunes F., PO333-MON
Bridge K., AS205, OR444 Bruce A., PO455-MON, PO460-
Braley H., AS016 Burakowski J., PO311-WED Cabrera V., PO051-MON Canault M., AS014, PO416-MON,
Brien B., PO267-TUE MON, PO083-WED, PO511-WED
Brambilla M., PO378-WED Burbury K., PO149-WED Cacco L., PO385-MON PO441-MON, PO443-MON,
Brien W., AS078 Brueckmann M., OR283, PO362-
Branchford B., AS161, OR156 Burdorf L., PO306-MON Cadot S., PO423-TUE PO385-WED, PO493-WED
Briens A., OR314 MON
Branchini A., OR179, OR297, Burger D., PO229-WED Cafaro L., PO483-TUE Canbolat Ayhan A., PO230-MON
Briggs H., PO580-TUE, PO581- Brummel-Ziedins K., PO467-TUE
PO554-TUE, PO555-TUE Burggraaf J., PO469-TUE, PO550- Cai T.-Q., PO074-WED Cannav A., PO090-TUE, PO091-
TUE Brunel H., PO543-MON
Brand B., OR213, PO242-MON WED, PO592-WED Caiani V., PO656-MON TUE, PO303-WED
Brighton T., PO468-MON, PO618- Brunet D., OR324
Brandao L., PO465-MON, PO118- MON Burghaus R., AS104 Cain T., PO449-MON Cannav A., PO503-MON
TUE Brunn M., PO274-WED Burgiss J., PO578-MON Cairo A., PO580-MON, PO582- Cannegieter S., AS138, OR035,
Brighton T., PO374-TUE Brunson A., OR325
Brandao L., AS078 Burini F., OR297 MON, PO592-MON, PO676-WED OR131, OR135, OR268, OR345,
Brighton T., AS099, OR259 Brunt E., PO450-WED
Brandao L., OR159, OR328, Burk O., PO412-MON Caironi P., PO338-WED PO522-MON, PO623-MON
Brill A., OR121, PO325-MON Bruria R., PO659-TUE
PO475-MON, PO446-TUE Burke T., PO375-WED Cajfinger F., PO624-MON
Bringmann P., PO555-WED Bruscaggin V., OR106, OR411
Brando B., PO158-WED Burkhart J., PO499-MON
Brinkman H. J., PO352-WED
436 437
AUTHORS INDEX
Cannegieter S., AS083, OR134, Carreras L., PO484-MON, PO488- Castaman G., AS222, OR015, Ceresetto J., PO180-TUE Chan M., PO085-WED Chaudhry A., PO549-WED
OR150, OR322, PO532-MON, MON OR088, OR144, OR297, OR347, Ceresetto J. M., PO621-TUE Chan N., PO489-WED Chaudhry H., PO151-WED
PO616-MON, PO601-TUE, Carrier M., AS137, OR053, PO649-MON, PO162-TUE, Ceriello A., PO608-MON Chan S., PO606-MON Chaudhry H., PO150-MON
PO223-WED, PO562-WED, OR281, OR282, OR295, OR310, PO650-TUE, PO303-WED Cermakova Z., OR152 Chan V., PO421-MON Chaudhry W., PO188-WED
PO573-WED, PO577-WED, OR384, AS080, PO467-MON, Castejon B., OR074, OR321
PO625-WED, PO641-WED ernel P., PO181-MON, PO027- Chan V. W. T., PO460-WED Chauhan A., PO521-TUE
PO473-MON, PO100-TUE, Castellan M., PO593-WED WED
Cannegieter S., OR098, OR118, PO101-TUE, PO320-TUE, Chandarajoti K., AS049, OR306 Chauleur C., OR095, OR188
Castellaneta M., PO610-TUE Cerqueira M., PO034-WED, Chandra S., PO288-MON Chaves D., PO231-MON, PO253-
OR129, PO514-MON, PO104- PO630-WED, PO664-WED Castellani M., PO176-WED
TUE, PO111-TUE, PO112-TUE, PO251-WED Chandrakumaran K., PO344-MON MON, PO333-MON, PO135-TUE
Carrim N., AS168, PO326-WED Castellant P., OR146, OR149,
PO498-TUE, PO525-TUE, Cerrone G., PO323-MON Chandrasekaran S., PO110-MON Chaves D., PO034-WED
Carrizo C., PO042-MON PO655-WED
PO666-WED, PO668-WED Cervantes F., PO487-TUE Chang C.-Y., PO226-TUE, PO265- Chavez C., PO445-TUE
Carter R., PO459-TUE Castelli C., PO035-WED
Cannizzo E., OR411 Cervantes F., PO435-MON WED, PO289-WED Chvez-Gonzlez M. A., PO020-
Cartier D., OR122 Castellino F., AS112, OR421,
Canobbio I., OR115, OR183, Cervellin G., PO222-TUE Chang C.-H., PO059-MON, MON
Cartwright A., AS064, PO667- PO305-TUE
PO450-TUE MON, PO676-MON Cervio C., OR160, PO644-MON, PO334-WED Chawanasuntorapoj R., PO675-
Canonico M., PO527-MON Castellucci L., OR198, PO641- PO428-TUE Chang G., PO464-TUE MON
Cartwright E., OR168 MON
Canpolat M., PO490-TUE Csar Malfante P., PO631-WED Chang H., AS230 Che S., AS060
Caruso F., PO014-TUE Castellucci L., OR310, PO320-
Cantori I., OR027, PO303-WED Cesarman E., PO128-MON Chang H., PO476-WED Chechulov P., PO503-TUE,
Caruso V., PO629-MON TUE PO576-WED
Canzano P., PO378-WED Cesarman-Maus G., PO128-MON Chang J.-Y., OR319
Carvalho M., PO212-TUE, PO264- Castet S., OR024 Cheen M. H. H., PO663-WED
Cao L., PO425-TUE, PO039-WED, TUE, PO012-WED, PO261-WED, Cetin M., PO505-WED, PO507- Chang J., PO408-WED
Castillo B., PO631-TUE WED, PO508-WED Chelghoum N., AS014
PO259-WED, PO533-WED PO404-WED Chang L., PO409-MON
Castillo J., OR116 Ceznerov E., PO194-TUE Chelle P., PO262-WED
Cao Z., PO360-MON, PO374- Carvalho M., PO390-WED Chang S.-K., PO031-MON
MON, PO054-TUE Castillo O., PO187-MON Chagnon I., AS077 Chen C.-Y., PO029-MON
Carvalho M., PO663-TUE Castilloux J.-F., OR217 Chang S.-P., PO245-MON
Caparrs-Prez E., OR221, Carvalho M., PO237-WED, Chai-Adisaksopha C., OR068 Chang S. S., AS031 Chen I.-S., PO328-MON
PO497-MON Castoldi E., OR248, OR374, Chaikitpinyo A., PO461-MON Chen C., PO238-MON
PO479-WED PO470-MON, PO023-WED Chang W., PO008-TUE
Capel A., PO513-WED Carvalho M., PO397-WED Chaireti R., PO292-TUE, PO482- Chang Y.-W., OR344, PO430-WED Chen D., AS232, PO098-WED
Capmany C., PO616-TUE Castro A., PO056-TUE TUE, PO560-TUE, PO561-TUE
Carvalho M. D. G., PO023-WED Chang Y., PO601-WED Chen D., PO648-MON, PO655-
Cappelli R., PO373-WED Castro A., PO360-WED Chako J., OR367 TUE, PO037-WED, PO484-WED
Carvalho M. D. G., PO002-WED Casuccio A., PO117-TUE Changgeng R., PO113-TUE,
Cappucci F., PO513-MON Carvalho M. D. G., PO566-MON, Chakrabarti E., PO032-TUE PO394-WED Chen G., PO076-MON
Capria V., PO200-TUE Cataland S., OR362, PO587- Chakroun E., PO528-MON Chen H., PO431-WED
PO189-TUE, PO244-WED MON, PO588-MON, PO572-TUE, Chantarangkul V., PO091-MON,
Caram-Deeelder C., AS138 Casa L., PO677-MON PO573-TUE Challande P., PO031-TUE PO059-TUE, PO114-WED Chen J., OR407
Caramelli B., PO034-TUE, Casagran O., PO516-MON Cate S., PO568-TUE Chalmers E., AS159, AS161, Chao T.-Y., OR330 Chen J.-J., PO327-MON
PO095-WED Casais P., PO323-MON OR104, OR145, OR386, PO239- Chapelle C., OR012, OR055, Chen J., PO222-WED
Caton F., PO223-MON, PO340- MON
Carcao M., OR141 Casale C., PO568-MON, PO575- MON, PO241-WED, PO422-WED PO107-TUE Chen J., PO568-TUE
Carcao M., OR013, PO270-MON MON Chambost H., OR346, PO103- Chapin J., AS165, PO502-MON, Chen K., OR415
Cattaneo M., OR019, PO066- WED
Carcao M., AS078 Casali A., OR197 MON, PO412-TUE, PO422-TUE, PO575-TUE, PO307-WED, Chen L., AS100, OR062
Cardel L., PO484-WED PO086-WED, PO473-WED Chambost H., OR012, OR143 PO521-WED Chen L., PO409-MON
Casaa-Granell J., PO271-WED
Cardella A. M., PO618-WED Cattepoel S., AS016 Champier G., AS108 Chapman M., OR088 Chen L., PO447-WED
Casanegra A., PO523-MON
Cardenas J., PO174-TUE Cattinelli S., PO373-WED Chan A., AS104, OR346, PO087- Chappell E., OR239, PO153- Chen L., PO312-WED
Casari C., AS070, OR205, MON, PO463-MON, PO118-TUE,
Carestia A., AS173, PO323-MON OR234, OR333, PO423-MON Cavalcanti F., PO038-MON MON, PO052-WED Chen M., PO273-TUE
PO447-TUE Chareancholvanich K., PO643-
Carlson L., PO618-TUE Casazza F., PO626-MON Cavallari I., PO024-TUE Chen M., PO245-MON
Chan A., PO446-MON WED
Carneiro F., PO340-WED Case B., PO202-TUE Cavallari N., OR300 Chen N., AS147, OR249, PO070-
Chan A., PO276-MON, PO595- Charilaou P., PO615-MON
Carneiro J., PO431-TUE, PO433- Casella I., PO613-TUE Cavallo L., PO582-MON MON, PO161-WED MON, PO205-MON
TUE Charoenkwan P., PO275-TUE, Chen P., AS168, OR031, PO326-
Casella M., OR197 Cayuleo M., OR220, PO480-WED Chan A., PO343-TUE, PO545- PO540-TUE, PO647-TUE
Carneiro J., PO434-TUE Cases A., PO184-MON, PO187- Ceglarek B., PO278-MON, PO549- TUE WED, PO328-WED
Caroff E., PO022-TUE Charova F., PO600-MON, PO582- Chen Q., OR002, PO433-MON,
TUE MON, PO026-WED, PO032-WED, Chan A., PO159-MON, PO464- TUE
Caron C., AS134, OR024, OR025, Casey L., OR023 PO526-WED, PO536-WED, TUE PO421-TUE
OR219, PO650-MON, PO662- PO588-WED Charpidou A., PO102-TUE Chen S. L., PO309-TUE
Casey M., PO621-TUE Chan A., OR373, PO350-MON, Chartapisak W., PO275-TUE
TUE Casinelli M., PO634-TUE Cei M., PO502-TUE PO359-TUE, PO565-TUE, Chen S.-H., PO289-WED
Caron K., PO423-MON Celarier T., PO107-TUE Chasman D., OR266 Chen V., OR185, PO075-MON,
Casinelli M., PO003-MON, PO139-WED, PO348-WED
Caroppo V., OR019, PO086-WED Celeste D., PO431-TUE Chatelain B., PO092-MON, PO404-MON, PO415-TUE,
PO004-MON, PO042-WED Chan F. S. L., PO615-TUE PO063-TUE, PO125-WED,
Carpentier A., PO513-WED Casini A., PO217-MON, PO485- Celikturk F., PO270-TUE Chan F., OR373, PO348-WED PO669-TUE
PO167-WED Chen W., AS068
Carr M., PO257-MON MON, PO502-MON, PO521-WED Celinska-Lowenhoff M., PO070- Chan H., NUR007 Chatelain C., OR126, PO167-WED Chen X., OR113, OR210, PO388-
Carrabba G., PO176-WED Casoli G., PO592-MON WED Chan H., PO595-MON, PO161- Chatelanaz C., PO639-TUE WED, PO433-WED
Carraro P., PO077-TUE, PO084- Casper C., PO604-MON Celiska-Lwenhoff M., PO048- WED
TUE MON, PO069-WED Chatterjee M., OR114 Chen Y., PO195-TUE
Cassinat B., PO080-WED Chan H., OR373, PO350-MON, Chatterjee N., PO259-MON
Carrasco J. J., PO271-WED Cassis F., PO434-TUE Cellai A., PO226-MON PO355-MON, PO359-TUE, Chen Y.-C., OR330, PO226-TUE,
Carrasco P., PO336-MON Cellai A. P., PO586-WED PO565-TUE, PO139-WED, Chattree S., PO420-WED PO265-WED, PO304-WED
Carreras E., PO189-MON, PO191- Cenci C., PO226-MON PO348-WED Chaturvedi P., OR213 Chen Y., PO172-MON
MON Cerbone A. M., PO534-TUE Chan L., PO556-WED Chaudhary R., PO099-MON Chen Y., PO222-WED
438 439
AUTHORS INDEX
Chen Y., PO433-WED Chitongo P., AS047, OR063, Chu Z., OR047 Clausen W. H. O., PO215-WED Collier M., OR175, PO555-MON, Cooley B., OR273, OR274,
Chen Y., AS055 PO558-WED Chua C., PO605-MON, PO590- Claushuis T., AS007 PO556-MON, PO557-MON, OR306
Chen Y., OR436, PO301-MON Chitongo P., PO347-MON TUE Claussen C., PO174-WED PO558-MON Cools F., OR119
Chen Z., OR140, PO317-MON, Chiu H.-P., PO430-WED Chuang W.-J., PO079-WED Clemens A., OR283 Collier M., PO553-MON Cooper C., AS114
PO246-TUE Cho Y.-U., PO071-WED, PO427- Chuansumrit A., PO540-TUE, Clement K., AS043 Collin P., AS141 Cooper D., PO277-MON, PO297-
Chenet C., PO568-MON, PO575- WED PO647-TUE, PO275-WED Clementi R., PO257-TUE Collins J., OR354 WED, PO298-WED
MON Cho Y., PO186-TUE Chubanov V., AS068, OR081 Clerici M., PO091-MON, PO114- Collins P., AS054, AS011, Cooper D., PO306-MON
Cheng C. Y., PO412-TUE Choi G. H., PO475-TUE, PO478- Chudzinski-Tavassi A. M., PO107- WED AS122, OR104, OR145, OR386, Coppack S., PO660-WED
Cheng J., PO261-MON TUE, PO531-TUE, PO168-WED MON Cleuren A., AS090 PO149-MON, PO262-MON Coppens M., PO372-MON,
Cheng J., PO673-MON Choi S. I., PO119-TUE Chuit R., PO634-TUE, PO636- Cline-Fedewa H., OR434 Collins P., PO317-TUE PO537-MON, PO506-TUE,
Cheng J.-C., OR344, PO430-WED Choi S., OR353, PO543-WED TUE Cloutier S., OR217 Collins P., PO499-MON PO507-TUE, PO401-WED
Cheng S., PO527-TUE Choi W.-I., PO628-MON Chumachenko P., PO294-TUE Clozel M., OR020 Colman R., OR355 Coppola A., AS222, PO650-TUE,
Cheng S.-N., PO265-WED Choi Y., PO475-TUE Chun E. J., PO119-TUE Colomer D., PO435-MON PO303-WED
Cnossen M., AS079, NUR004,
Cheng X., PO306-MON Choi Y., OR199 Chung C.-H., PO059-MON, OR021, OR203, OR225, PO658- Colucci G., AS163 Corbalan R., OR096
Cheng Z., PO132-TUE Chojnowski K., PO260-MON, PO334-WED MON, PO230-TUE Colucci M., OR065, PO503-MON, Corbalan Herreros R., PO358-TUE
Chennoukh K., PO242-TUE, PO011-WED Chung D., PO568-TUE Cnossen M., PO351-WED PO338-WED Corbau R., PO172-MON
PO637-TUE Chollet M. E., PO556-TUE Chung J.-H., PO115-MON Cnossen M., OR387, PO267- Colzani M., PO384-WED Cordell P., AS003, PO190-WED
Chennoukh K., PO494-MON, Chollet Dugarte M. E., PO557- Chung S., NUR009, PO390-MON, MON, PO251-TUE, PO308-WED Combe S., AS164, PO166-TUE, Cormier A., PO165-WED
PO520-WED TUE PO393-MON Cnossen M. H., PO651-MON, PO174-TUE Cornelis G., PO299-TUE
Chennoukh W. K., PO276-WED Cholley B., PO513-WED Chunilal S., PO468-MON, PO618- PO208-WED Combescure C., PO271-MON, Cornelissen L., PO584-MON
Cherel G., OR246 Chomienne C., PO080-WED MON Cober N., PO320-TUE PO283-WED Coronel Ayala O., PO138-WED
Chermak E., PO582-MON Chong K., PO288-MON Church F., PO426-WED Cocchi V., OR197 Comer D., OR090, OR201, Corral J., AS187, OR076, OR359,
Choquenet C., AS137 Church N., PO294-WED Cockhill C., NUR007, PO355- PO277-WED OR368, OR370, PO336-MON,
Chernova T., OR346
Chou C.-S., PO430-WED Church W., AS051, OR423 MON Comi G., OR005 PO338-TUE, PO539-WED,
Chernysh I., PO212-WED
Chou S.-C., PO031-MON Ciais J.-F., PO107-TUE Coen Herak D., OR378, PO436- Comp P., PO449-TUE, PO157- PO552-WED
Chernysh I., PO026-MON WED
Choudhri S., PO294-WED Ciammaichella M., OR132 TUE, PO144-WED Corrales I., PO543-MON
Cherry M., PO449-TUE Compernolle V., PO604-WED
Choukroun J., PO579-TUE Cianella F., PO370-MON, PO423- Coffey G., PO351-TUE Correia J., OR183
Cherry M., PO508-TUE, PO157- Compostella C., PO372-TUE
WED Chow G., PO161-TUE, PO233- WED Coglianese E., OR173, PO339- Corrocher R., OR080
WED Ciantar E., PO614-MON WED Comtet M., PO473-TUE Corscadden K., OR337
Cheung K. L., AS056, OR147
Chow L., PO161-WED Cicardi M., PO178-TUE Cognasse F., PO410-MON, Comuth W., PO051-TUE Corseaux D., OR219, PO662-TUE
Cheung W., OR326, PO470-MON
Chowdary P., OR028, OR212, Cicarini W., PO397-WED PO408-TUE Conard J., OR032, PO544-TUE Corsi D., AS077, OR384
Cheung Y., PO466-MON
OR348, OR349, PO235-MON, Cid A., PO534-MON Cogswell C., PO173-MON, PO161- Conejero R., OR440 Corsini A., PO378-WED
Cheung Y., PO372-MON TUE, PO233-WED
PO260-MON, PO295-MON, Cid A. R., PO093-MON, PO579- Coneska B., PO287-MON, PO288- Corsini F., PO585-TUE
Chew D., PO606-MON Cohen A., AS084, OR294, WED
PO486-MON, PO257-TUE, WED Corts J. M., PO360-WED
Chhabra E., OR413 PO317-TUE, PO014-WED, PO124-TUE, PO353-TUE, Conley P., OR318, PO351-TUE
Cid J., PO610-WED Cortina V., PO056-TUE, PO375-
Chia J., AS016 PO266-WED, PO353-WED, PO608-TUE, PO409-WED Connell S., AS155
Cid-Haro A. R., PO473-WED TUE, PO445-TUE, PO407-WED
Chiappin S., PO369-WED PO617-WED Cohen A., AS099, OR074, OR259 Connolly S., PO362-MON
Cilia La Corte A., PO182-TUE Cortina De La Rosa E., PO138-
Chiappino D., PO086-MON, Chrastinova L., PO238-WED Cohen A., OR199 Connor D., PO075-MON WED
PO039-TUE Cines D., PO405-TUE
Christensen H., OR235, PO388- Cines D., OR305 Cohen D., PO589-MON Constans J., PO103-TUE Cosemans J., AS141, AS140
Chicanne G., PO416-MON, TUE Cohen E., PO099-MON
PO514-TUE Cini M., PO050-MON Constantin J.-M., PO035-WED Cosemans J., PO499-MON
Christensen N., PO602-TUE Cohen E., PO001-WED Contant G., PO340-MON Cosemans J., PO411-MON,
Chidiac J., PO117-MON Cipok M., PO268-TUE
Christensen T. D., PO119-WED Cohen H., PO044-MON, PO046- Contant G., PO223-MON, PO241- PO349-TUE
Chidiac J., OR381, PO620-MON Cipolla L., OR115
Christersson C., OR312 MON, PO060-WED, PO064-WED WED, PO422-WED Cosmi B., AS197, OR292,
Chien D., PO372-WED, PO375- Cisernos R., PO516-WED
Christiaans M., PO033-WED Cohen A., PO578-WED Conte V., PO176-WED PO050-MON, PO602-MON,
WED Ciucciarelli L., PO226-MON
Christian G., PO514-TUE Cohn D., PO510-MON Conti S., PO072-MON, PO370- PO627-MON, PO317-WED
Chihiro I., PO108-WED Civaschi E., PO438-MON, PO473-
Christophe O., PO553-TUE, WED Cointe S., OR311, OR315, MON, PO027-TUE, PO423-WED Cosmi E., PO331-TUE, PO332-
Chiles P., PO201-TUE PO658-TUE, PO228-WED, PO340-MON TUE
Claes J., AS009, AS113 Conway E., PO021-MON, PO001-
Chiles P., PO476-MON PO230-WED Colaizzo D., PO511-MON, PO513- TUE Costa A., PO441-TUE
Chillo O., OR410 Christophe O., OR333, PO664- Claessen N., OR124 MON, PO614-MON Conway E., PO300-TUE Costa A., PO574-TUE
Chinetti-Gbaguidi G., AS201 TUE Claesson K., PO406-MON Colangelo D., AS088 Conway E., PO649-WED Costa D., PO100-WED
Chinni E., PO513-MON Christophe O., OR205, OR246 Claeyssens S., PO501-MON Colberg T., OR348, PO149-MON Conway J., PO649-WED Costa M., PO207-WED
Chintala M., PO074-WED Christophe O. D., AS062, OR234, Clark D., AS078 Cole R., OR058 Conway J., PO455-MON, PO083- Costa S.-D., PO518-MON
Chinthammitr Y., PO040-MON, PO206-WED Clarke G., PO086-TUE Colella M., OR263 WED Costache A., PO474-WED
PO110-WED, PO268-WED, Christopherson P., PO659-MON Clarke S., PO397-TUE Colin E., OR003 Cook K., OR417 Costa-Pinto J., PO010-WED
PO643-WED Christopherson P., OR089, OR204 Clarke S., PO385-TUE Collaud F., PO158-MON Cooke B., PO285-MON Cotler S., PO053-WED
Chiswell K., OR119 Christos P., AS165, PO307-WED Clarke-Drury R., PO601-MON, Collela M., OR094, PO531-MON,
PO580-TUE, PO581-TUE Cooke E., AS003, PO190-WED Cottart C.-H., PO038-TUE
Chitlur M., PO252-WED Chtourou S., PO311-TUE, PO457- PO066-WED, PO067-WED
Clausen J., OR110, PO541-WED Cooke N., PO075-WED Cottrell G., PO385-TUE
Chitolie A., OR154, PO046-MON TUE Collet M., PO512-MON
Clausen W. H., OR212 Cooke S., PO392-MON Coulombe J., OR385
Chu L., PO028-MON
440 441
AUTHORS INDEX
Coultas K., PO580-TUE, PO581- Crowther M., PO616-WED Czogalla K., PO631-MON Dangelmaier C., OR111, PO429- De Cos C., AS187, OR076 De Meyer S., AS178, OR087,
TUE Croy A., PO484-TUE Czuprynska J., NUR008, OR063, WED De Cristofaro R., OR202, PO007- OR151, OR153, PO517-TUE,
Couperus C., PO145-MON Crudele J., AS120 PO347-MON Dangelo L., OR022 MON, PO582-MON PO519-TUE, PO571-TUE
Coupry I., OR003 Cruz J. W., PO184-TUE Czuriga I., PO224-MON, PO187- DAngelo A., OR093 De Diego I., PO474-TUE De Meyer S. F., OR155
Cournil M., PO262-WED Cruz C., PO125-MON WED Danglot L., AS170 De Francisci G., PO614-WED De Moerloose P., PO217-MON,
Courtney W., PO649-WED Cruz E., PO318-TUE, PO626-TUE Czwalinna A., OR054 Daniel J., PO429-WED De Geus K., PO666-WED PO271-MON, PO484-MON,
Courtois D., PO045-TUE DÀdamo M., PO068-TUE, Daniel J., PO516-WED De Godoy M., PO322-TUE PO485-MON, PO488-MON,
Cruz M. S., PO662-MON
PO522-WED PO502-MON, PO283-WED,
Coutinho J., OR118, PO525-TUE Cruz M., PO497-TUE Daniell H., PO220-WED De Groot P., AS035, PO063-WED
DÀmico E., PO034-TUE, PO095- PO521-WED
Coutinho M., PO442-MON, Cruzado J., PO184-MON, PO187- Danielsson-Rnby M., PO367- De Groot P., PO389-TUE, PO470-
WED De Montalembert M., AS086
PO318-TUE TUE MON WED
DAntonio C., PO616-TUE De Natale M., PO626-MON
Couto L., PO172-MON Csandi Z., PO087-WED Danielyan S., PO573-MON De Groot P., PO178-TUE
DAsti E., PO393-WED De Padua V., PO654-TUE
Couturaud F., AS082, OR146, Csap J., PO530-MON Darbari D., PO381-MON De Groot P., PO405-MON, PO672-
OR149, OR323, PO103-TUE, Da Q., OR277, PO497-TUE MON De Paoli S., OR174, PO603-WED
Csiba L., PO516-TUE, PO087- Darbousset R., PO322-MON,
PO655-WED Da X.-W., PO426-MON PO022-TUE De Groot R., AS179, PO586-MON De Paula E., OR263
WED
Couturier O., AS082 Da Rocha T., PO322-TUE Dardik R., PO192-MON, PO225- De Groot-Eckhardt C., OR389, De Paula E., OR094, PO066-
Cuadrado M., OR092
Couty L., PO437-WED Daali Y., AS128 WED WED, PO067-WED, PO145-WED
Cui J., PO001-TUE De Haan H., AS196, OR083
Covens K., PO186-MON Dachbash M., PO285-TUE Dargaud Y., OR012, PO156-MON, De Paula E., PO422-MON,
Cui J., PO014-TUE De Haan H., OR148, OR394, PO531-MON, PO221-WED
Covill S., PO361-MON Cuicui L., PO566-TUE Daemen J.-W., PO092-WED PO157-MON, PO229-TUE PO539-WED
Daryll Blanz K., PO493-WED De Paula L., PO100-WED
Cowan P., AS212 Cuicui L., AS075, OR264 Dager W., PO312-WED, PO358- De Jong A., PO641-TUE
WED, PO359-WED Dashkevich N., PO118-WED De Perrot M., PO619-MON
Cowley D., OR273 Cuisset T., PO493-WED De Jong P., AS021
Dagher M.-C., PO131-TUE, Dashkevich N., PO067-TUE De Queiroz Monteiro R., PO131-
Cowley D., PO423-MON Cuker A., PO405-TUE, PO212- De Kam P.-J., PO469-TUE,
PO593-WED MON
Cox A., PO078-WED WED, PO473-WED Dasi M. A., PO414-MON PO550-WED
Dagklis T., PO065-WED De Sancho M. T., PO614-MON
Cox D., PO078-WED Culhane A., PO037-MON Dassi C., PO223-MON, PO340- De Kievit A., PO335-WED
Daglas M., OR380 MON, PO241-WED, PO422-WED De Santis A., PO158-WED
Cox P., AS158 Cultrera D., AS222 De Kleijn P., PO241-MON
Daher G., PO538-MON DAssoro A., PO618-WED De Simone G., PO534-TUE
Coxon C., PO065-MON Cumming A., PO495-MON De Kleijn P., OR102
Dahlbck B., AS040, AS150, DAsti E., PO094-TUE De Smet M., OR320
Cozzi M. G., PO126-WED Cummins P., OR043 De Koning M.-S., PO272-MON
OR369 Dato Abd Karim F., PO257-TUE De Stefano F., PO534-TUE
Crain E., PO349-MON Cungh A., PO080-WED De La Morena-Barrio M., OR076
Dahm A. E. A., PO109-MON Dauer R., PO149-WED De Stefano V., PO611-TUE
Crampe C., PO159-TUE Cunha M., PO582-WED De La Morena-Barrio M. E.,
Dai J., PO228-MON David L., PO440-WED AS187, OR370 De Stoppelaar S., AS007
Craps S., AS176 Cuppini S., OR132
Dai J., OR113, OR210, PO492- Davidson B., OR259 De La Salle H., PO606-WED De Swert K., OR363
Craver C., OR309 Curaj A., PO091-WED MON, PO195-TUE, PO252-TUE, Davidson R., OR165 De Laat B., OR224, OR301, De Vega S., PO079-TUE
Crawley J., PO586-MON Curis E., AS086 PO433-WED
Davies J., PO481-TUE OR427, PO025-MON, PO089- De Vreede M., OR257
Crawley J., PO069-MON Curnow J., PO374-TUE, PO149- Dai K., PO273-TUE, PO439-WED
Davies N., PO156-WED MON, PO143-MON, PO272-MON, De Wildt S., PO251-TUE
Crawley J., AS149 WED Dai M., OR331
Davila M., PO174-WED, PO445- PO546-MON, PO672-MON, De Wit C., OR295, OR384
Crawley J., OR044, PO036-WED Curnutte J., OR318, PO351-TUE Dainiak M., PO219-WED PO092-WED
WED, PO446-WED Deangelis P., PO219-WED
Crawley J. T., PO139-MON Curry N., AS054, PO653-MON, Daita K., OR435 De Laat M., PO546-MON
Davis A., PO101-TUE Debank P., PO016-MON
Crea R., OR029 PO175-TUE, PO638-TUE
Dale B., PO130-TUE Davis A., PO669-TUE De Lange Z., PO026-MON, Debelle L., PO457-WED
Creagh D., OR213 Curtain J., OR346 PO210-MON, PO212-WED
Dale G., PO449-TUE Davis M., PO516-WED Debili N., OR082
Creagh M., PO317-TUE Curtin J., PO253-WED De Laroche R., PO628-WED
DAlessio A., PO179-WED Daw C., PO037-MON Debourdeau P., PO624-MON
Creary S., AS160 Curto M., PO353-TUE, PO409- De Lisa E., PO042-MON
WED Dalibard V., OR143 Dawood B., AS054, AS011, Debreceni I., PO488-WED
Crescente M., PO506-MON Dalla Valle F., OR078, PO524- De Los Santos S., PO055-WED
Cushman M., OR133, PO565- PO492-WED Debreceni I., PO077-MON,
Crespo J., PO017-MON TUE, PO127-WED De Los Santos S., PO042-MON PO124-MON, PO482-WED
WED Dawson J., PO545-TUE
Crettaz D., PO400-TUE Dallas K., PO577-MON De Maat M., PO078-MON, Decherf C., PO107-TUE
Custdio I., OR094, PO066-WED, Dayananda K., OR334
Creuza V., PO457-WED Dally N., PO471-WED PO665-WED Deckmyn H., AS178, OR087,
PO067-WED De Ancos Aracil C. L., PO485-TUE
Criel M., AS009, AS176, PO462- Dalm D., PO192-WED De Maat M., AS181, OR364 OR153, OR155, PO401-MON,
WED Cutler J., PO210-WED De Angelis F., PO200-TUE,
Dalsgaard Nielsen J., PO352- PO259-TUE De Maat M. P., PO208-WED PO675-TUE
Crijns H., PO348-MON, PO097- Cutler J., PO504-WED
MON, PO456-TUE, PO424-WED De Boer I., OR133 De Maat S., PO178-TUE Declerck P., OR399, OR442,
WED, PO416-WED Cutler J., PO559-TUE
Daly M., AS054, AS011 De Maistre E., OR055, PO345- OR443, PO545-WED
Crilly E., PO269-WED Cutsforth G., PO117-WED De Borst G. J., PO386-TUE,
Daly M., AS124, PO517-WED PO389-TUE MON, PO263-TUE, PO672-WED Declerck P., OR153, AS144,
Crispel Y., AS096 Cvrin G., PO464-MON PO519-TUE
Damas P., PO396-TUE De Broucker D., PO107-TUE De Marchi L., PO269-WED
Crobach M., OR345 Cwikla J., PO279-MON Dcousus H., OR146, OR149,
Dambrine S., OR192 De Candia E., PO422-TUE De Marco L., PO378-WED
Croce K., OR417 Cybulsky M., AS198 PO655-WED
DAmico E., PO433-TUE De Cario R., PO086-MON De Martin R., PO559-MON
Crosby J., OR049 Czajka C., PO311-WED Decouture B., PO437-WED
DAmico ., PO322-TUE De Carvalho A., PO339-TUE De Mast Q., PO063-WED
Croteau S., AS122 Czajkowski K., PO536-WED, Dedeken L., PO165-WED
DAmico E. A., PO611-TUE De Carvalho Bittencourt M., De Meis E., PO158-WED
Croteau S., OR022 PO588-WED Deev A., PO356-WED
Dang J., OR290 AS036 De Meis J., PO158-WED
Croteau S., PO458-MON, PO239- Czaplicki D., PO365-WED Deforche L., AS178, OR153,
Dang K., PO439-TUE De Ceunyck K., AS091 De Mel S., PO606-MON
TUE Czer L., OR216 OR365
Dang V., OR007 De Ceunynck K., AS166, AS178 De Meris J., AS079
Crowther M., OR068, PO619- Czogalla K., PO498-MON, PO637- Deforest M., PO646-MON
MON De Chaumont C., PO177-TUE De Meyer S., PO401-MON
MON, PO604-TUE
442 443
AUTHORS INDEX
Degen J., PO021-MON Dempfle C.-E., PO669-MON, Detering C., PO654-MON, PO665- Dietrich J., PO361-WED Dob J., PO303-TUE Dopsaj V., PO252-MON
Degrado W., PO431-WED PO480-TUE TUE Dietrich J., PO567-MON Dobrovolskiy A., PO357-WED Doralt J., OR029, PO223-TUE,
Deguchi H., PO093-MON Demulder A., PO081-TUE Deutsch V., PO268-TUE Dietrich K., PO465-MON Dobrovolsky A., PO624-TUE PO270-WED
Deguzman F., OR318 Demyanenko A., PO503-TUE, Devi S., PO306-WED Dignat-George F., OR311, PO322- Dobrovolsky A., PO199-MON, Doria A., PO245-TUE
Deharo P., PO493-WED PO576-WED Devignes J., PO546-TUE MON PO327-TUE, PO356-WED Doria A., OR390
Deindl E., OR410 Demyanets S., PO559-MON Devloo R., PO604-WED Dignat-George F., OR315, AS085 Dobrovolsky A., PO069-TUE Dornbach A., PO669-MON
Deitelzweig S., PO625-MON Demyanova A., PO103-WED Devos T., OR231 Diliberto D., PO614-WED Docenko U., PO496-WED Dorner L., OR252
Dejanova Ilijevska V., PO287-MON Den Exter P., PO596-MON Devos V., PO457-TUE Dilks J., OR417 Dockal M., PO150-TUE, PO151- Dors N., OR021
Dejanova-Ilijevska V., PO535-WED Den Exter P., OR191, OR257, Devreese K., PO384-TUE, PO668- Dilks J., AS091 TUE, PO152-TUE, PO199-WED, Drum E., PO123-MON, PO453-
Dekkers O., OR098 PO597-MON, PO100-TUE, TUE Dillard P., PO416-MON PO201-WED, PO209-WED TUE, PO556-TUE, PO557-TUE
PO651-WED Dewarrat N., PO489-MON Dillon A., OR218 Dockendorff C., AS091 Dos Santos M., PO523-WED
Dekkers O., OR268
Den Hertog J., OR183 Dewit C., OR281 Dillon R., PO120-MON, PO121- Dockrell D., OR016 Dosquet C., PO080-WED
Del Bianco T., PO092-MON,
PO063-TUE Denas G., PO077-TUE, PO372- Dezetter A.-S., PO131-TUE MON Doco-Lecompte T., PO546-TUE Doubleday M., PO078-TUE
TUE Dhanesha N., PO521-TUE Dimitrov J., PO226-WED Docquier M., AS128, OR397 Doubre H., PO163-WED
Del Carpio-Cano F., PO329-WED
Deng B.-X., PO522-TUE Dharma R., PO141-MON, PO671- Dinarvand P., PO333-TUE Doddapattar P., PO521-TUE Douketis J., OR195, PO362-MON
Del Toro L., PO198-MON
Deng C.-Q., PO522-TUE TUE Ding H., OR018 Dodt J., PO183-WED, PO184- Douketis J., OR282
Dela Cadena R., PO329-WED
Deng J., PO177-MON, PO179- Dhillon S., PO454-TUE Ding H., PO522-TUE WED Douma R., PO598-MON
Delaat B., AS105 MON
Delahousse B., OR428 Dhima S., PO331-TUE, PO332- Ding Q., OR164, PO228-MON, Doering C., PO203-WED Douma R., PO597-MON
Deng W., AS171 TUE PO492-MON, PO195-TUE, Doerr B., OR316, PO418-WED,
Delahousse B., PO056-WED Douma R., PO596-MON
Deng X., AS147, OR249, PO070- Dhiman P., PO540-MON, PO005- PO333-TUE PO596-WED
Delaney J., NUR010, PO361-TUE MON, PO205-MON Douma R., OR191
WED Ding Z., PO409-MON Doerr B., PO152-MON Douxfils J., OR126, PO092-
Delavenne X., OR196 Deng X., PO382-WED Di Buduo C., PO422-TUE Diniz R., PO663-TUE, PO237- Doerschuk C., PO331-MON MON, PO063-TUE, PO299-TUE,
Delbes C., PO134-TUE Denis C., PO553-TUE Di Franco M., PO084-WED WED Doganay S., PO490-TUE PO125-WED
Delcea M., AS008, OR308, Denis C., PO664-TUE
PO298-MON Di Gregorio G., PO438-TUE Dinsdale R., PO325-MON Dogn J.-M., OR126, PO092- Dovlatova N., AS129, PO057-
Denis C., PO322-MON, PO658- Di Mauro R., PO534-WED Dinsdale R., OR121, PO393-TUE MON, PO063-TUE, PO172-TUE, MON, PO026-TUE, PO410-TUE,
Delerue M., PO107-TUE TUE PO269-TUE, PO299-TUE,
Di Micco P., PO608-MON Dioun Broyles A., OR022 PO412-TUE, PO518-TUE,
Delesen H., OR011 Denis C., OR333, OR403 PO125-WED, PO134-WED, PO492-WED
Deleuze J.-F., OR148 Di Minno G., AS222, PO534-TUE Dipaola J., PO632-TUE
Denis C., OR205, OR246 PO142-WED, PO167-WED Dow J., PO603-TUE
Delgado B., PO212-TUE, PO261- Di Minno M., PO378-WED Dipietro M., PO172-MON
Denis C. V., AS062, OR234, Dhrmann M., PO427-MON, Dowlatshahi D., OR200
WED Di Minno M. N. D., PO611-TUE Diprose P., PO317-TUE PO483-WED
PO206-WED Doyle C., PO378-MON, PO496-
Delhaye C., PO662-TUE Di Nisio M., AS099, AS197, Dirks M., PO546-MON DOiron R., OR143
Denk G., PO236-MON OR292, PO103-TUE, PO611- TUE
Delierneux C., AS006, PO396- Dirksen C., PO471-MON Dolan G., PO256-TUE
Dennie C., OR384 TUE, PO624-WED Doyle M., PO050-TUE
TUE Dirven R., PO641-TUE, PO660- Dolan G., PO283-WED, PO676-
Denniff M., PO542-WED Di Paola J., OR431, PO660-MON TUE Doyle M., PO088-MON
Delierneux C., PO407-MON Dennis J., PO426-WED WED
Di Paola J., AS143 Dishy V., PO621-MON, PO603- Doyon K., OR217
Delignat S., PO226-WED Dennis J., AS045, AS206 Dolan G., PO210-TUE, PO299-
Di Paolo M., PO216-WED TUE Dragani A., OR202
Delignaut S., PO228-WED, Denorme F., PO517-TUE, PO519- WED
PO230-WED Di Perna C., PO264-MON, PO222- Distasio K., PO088-MON Drager D., AS192, OR413
TUE Dollins C., PO154-WED
Della Latta D., PO086-MON, TUE, PO650-TUE Dittmer F., PO555-WED Drake M., PO336-WED
Dentali F., PO610-TUE, AS195, Dolsma A., OR257
PO039-TUE Diab Y., PO381-MON Dittmer R., PO041-WED Drake S., AS054, AS011
PO511-MON, PO613-MON, Domagala T., PO074-MON,
Della Riva D., PO066-MON Diacovo A., OR407 Dixon M., PO174-TUE, PO076- PO500-TUE Drakulevski S., PO535-WED
PO614-MON, PO640-MON,
Della Rocca F., PO372-TUE PO115-TUE, PO502-TUE, Diacovo T., OR407 WED Domashenko M., PO535-TUE Draxler D., OR123
Della Valle P., OR093 PO585-TUE, PO611-TUE, Diamond S., OR351 Dizier B., PO014-MON, PO437- Domenech P., PO354-MON Dreano E., PO038-TUE
Dellanoce C., OR065 PO405-WED, PO640-WED Diamond S., OR038, OR207, WED Drebes A., OR028, PO370-TUE,
Domingues M., AS155
Delluc A., OR281, OR323, Depasse F., PO045-TUE OR408, PO608-WED Diz-Kckkaya R., PO649-TUE PO014-WED
Domingues V., OR189
PO512-MON Depei W., PO113-TUE, PO394- Diard A., AS137 Djambas Khayat C., PO484- Dreen P., PO343-WED
MON, PO488-MON, PO258-TUE, Domingueti C., PO043-WED
Delluc A., AS082 WED Diaz J. A., PO030-MON Dresser G., PO364-TUE
PO262-TUE Dominguez Z., PO187-MON
Delrue M., PO664-TUE Depooter N., PO448-MON Diaz L., PO428-TUE Dretzke J., PO019-TUE
Djordjevic V., PO547-MON, Domnguez G., PO042-MON,
Delva Y.-L., PO463-MON Deppermann C., AS092, OR169 Diaz R., PO644-TUE PO055-WED Dreznik A., PO285-TUE
Diaz-Ricart M., PO184-MON, PO159-WED Driessen M., PO532-MON
Demarco M., PO483-TUE Der Parsehian S., PO236-WED Donadini M., PO610-TUE
PO191-MON, PO187-TUE, Djunic I., PO252-MON Driessens M., OR387, PO251-
Demarmels F., AS163 Derdabi S., PO081-TUE Donahue D., OR421
PO082-WED, PO414-WED, Djuranovic V., PO436-TUE TUE
Demers C., OR217 Desai H., PO445-WED Donato S., PO236-WED
PO610-WED Djurasinovic V., PO121-TUE Drobic B., PO168-MON, PO169-
Demers M., AS180, PO329-MON, Desai U., PO306-MON Doncheva E., PO515-WED
Daz-Ricart M., AS044, PO189- Dmitrieva J., PO407-MON MON
PO171-WED Desancho M., AS165, PO221- MON Donga P., PO312-MON
TUE, PO307-WED Dmoch-Gajzlerska E., PO536- Dropinski J., PO074-MON,
Demiguel V., OR143 Dicke C., PO251-MON WED, PO588-WED Donglei Z., OR264, PO320-MON,
Desancho M. T., PO597-TUE PO500-TUE
Demina I., PO496-MON Dickneite G., OR316, PO152- Do Nascimento P., PO092-TUE, PO276-TUE, PO566-TUE
Desch M., PO613-TUE DSilva L., PO083-TUE
Demina I., PO503-WED MON, PO312-TUE PO146-WED, PO231-WED Donin I., PO019-WED
Deschmann E., OR232 Dsouza M., PO676-MON
Demir M., PO617-TUE Dieli F., PO614-WED Dobbelstein C., AS221 Donnachie E., PO015-WED
Desguerre I., AS086 DSouza F., PO531-WED
Demirag B., OR262 Diesen J., PO674-MON Dobesh P., OR059 Donnan G., PO048-TUE
Deshpande V., AS202, OR008 Du X., PO388-WED
Demkova O., PO054-MON Dpke S., PO654-MON
444 445
AUTHORS INDEX
Duan Q., PO137-MON Dtting S., AS169, OR017 Eichler H., PO253-TUE El-Maarri O., PO191-WED, Esch V., PO065-TUE Ezekowitz M., PO362-MON
Duarte A., PO221-WED Duval C., AS155, PO188-WED Eichmann A., AS172 PO202-WED Escobar M., OR348, PO288-MON, Ezigbo E., PO627-TUE
Duarte E., PO107-MON Duval C., AS153 Eickholz P., PO657-MON Elmongy H., PO608-WED PO015-WED Faaborg L., PO051-TUE
Duarte R., PO397-WED Duveau D., PO513-WED Eiden M., PO605-WED El-Noueam K., PO243-MON Escolar G., PO082-WED, PO414- Fabbri A., PO067-MON, PO020-
Duarte R., PO237-WED Duwe C., PO107-WED Eijgenraam P., OR430 Elotmani L., PO035-WED WED, PO610-WED TUE, PO365-TUE
Dubois C., OR311, PO322-MON, Duzan J., PO457-MON, PO458- Eijsvogel M., OR257 Elsheikh R., PO133-WED Escolar G., AS044, PO184-MON, Faber J., OR414
PO022-TUE MON Eijsvogels T., PO468-TUE Elsherif L., PO331-MON PO189-MON, PO191-MON, Faber L., OR257
Duboscq C., PO180-TUE Dvorak T., PO242-MON Elson A., OR183 PO187-TUE Facchinetti L., PO378-WED
Eikelboom J., OR096, PO570-
Duca L., PO457-WED Dwivedi D., AS210, PO127-MON, MON, PO130-TUE Emal D., OR124, PO442-WED Escuriola Ettingshausen C., Fadin M., PO315-TUE, PO387-
PO220-MON, PO324-MON PO229-TUE WED
Duca M. L., PO126-WED Eikelboom J., PO489-WED Emanuele M., PO334-MON
Dybowska M., PO311-WED Escuriola-Ettingshausen C., Faella A., OR178
Duce R., AS195 Eikenboom H., PO665-MON Emed J., NUR009, PO390-MON, PO259-MON
Ducros E., PO119-MON Dyr J., PO238-WED Eikenboom J., OR021, OR203, PO393-MON Faille D., PO080-WED
Eshel E., PO471-WED
Ducruet T., OR327 Dyr J., PO194-TUE PO649-MON, PO658-MON, Emelyanov A., PO444-MON Faisse P., AS137
PO641-TUE, PO660-TUE, Eshghi P., PO164-MON, PO649-
Dudley B., PO285-MON Dzhumaeva S., PO460-TUE Emerson M., PO400-MON, MON, PO600-WED Falaise C., AS014, PO443-MON
Duerschmied D., OR252, PO307- Dziedzina S., PO070-WED PO651-WED PO398-TUE Falanga A., OR027, PO339-
Eintrei J., PO195-MON Esmailian F., OR216
TUE, PO404-TUE, PO493-WED Dziewiecka O., OR129, OR393, Emge D., OR421 MON, PO103-TUE, PO622-TUE,
Eischer L., OR226, PO298-TUE Esmon C., AS207, PO336-WED PO179-WED
Duffett L., PO669-WED PO526-MON, PO104-TUE, Emmi G., PO226-MON
PO111-TUE, PO112-TUE, Eising H., PO642-TUE, PO470- Esmon N., PO336-WED Falasca M., OR115
Duffett L., OR053 Emmi L., PO226-MON
PO495-TUE, PO568-WED WED Espaa F., PO093-MON, PO534- Falcinelli E., AS174, AS199,
Duffy C., PO319-TUE Emna G., PO281-WED MON, PO536-MON, PO344-TUE
Duhamel E., OR146, OR149, Dzik W., PO601-WED Ejele O., PO450-MON, PO155- Empson V., OR215 OR336, OR399
Dzikowska-Diduch O., PO619- WED Espejo H., PO023-TUE, PO242- Falco P., PO671-WED
PO655-WED Emsley J., OR407 WED
Dumont B., OR420 WED Ek Olsson H., PO240-MON Falcone L., PO515-MON
Enden T., AS136 Espn S., OR359, PO336-MON,
Dumont J., PO678-TUE Dzupa V., PO364-WED Ekeke O., PO155-WED Falet H., PO506-MON
Endo H., PO491-WED PO338-TUE
Dumont J., PO208-TUE Earnest A., PO504-TUE Ekhlasi-Hundrieser M., PO654- Falet H., OR235, AS186
Endo H., OR343 Espinosa S., PO017-MON,
Ebberink E., AS121 MON, PO665-TUE Fallah P., AS077, PO371-WED,
Dumont S., PO645-TUE Endresz V., AS025, AS232, PO019-MON
Ebenbauer B., AS200 Eksteen P., PO210-MON PO669-WED
Dumontier N., PO080-WED OR006, PO098-WED Espinoza N., PO242-WED
Eberl W., PO481-WED El Khorassani M., PO484-MON, Fallarino F., PO162-TUE
Dumoulin F.-J., PO343-WED Engelen S., OR101 Esposito F., PO515-MON
Eberle B., AS163 PO488-MON Falter T., PO593-MON, PO570-
Dunhill J., OR216 Engl W., OR215, PO260-MON, Esposito R., PO534-TUE
Eberle S., PO480-TUE El Mdawar M.-B., PO606-WED TUE
Dunlop L., PO421-TUE PO254-WED Estrada N., PO487-TUE
Eby C., PO140-WED Elaib Z., PO444-WED Fan C., AS125
Dunn A., AS122, AS160, OR157, Engle E., OR042 Etancelin P., PO621-WED
Echenagucia M., PO523-WED Elalamy I., OR438, PO116- Fan M.-N., PO031-MON, PO050-
PO262-MON Enhrenforth S., OR212 Eto K., OR084, PO428-WED
Eckes B., PO505-MON MON, PO292-MON, PO102- WED
Dunn P., PO476-WED TUE, PO105-TUE, PO473-TUE, Enjolras N., PO156-MON, PO157- Etscheid M., AS218
Eckhardt C., PO283-MON MON Fan X., OR113, OR210, PO433-
Dunne E., PO437-MON, PO676- PO587-WED, PO632-WED Ettelaie C., OR175, PO553-MON, WED
TUE, PO075-WED Eckly A., PO572-MON Elalamy I., OR055 Enockson C., PO193-WED PO555-MON, PO556-MON,
Edn D., PO563-MON Enoksson M., PO285-WED Fanciullacci C., PO365-MON,
Dunnington J., PO202-MON El-Alfy M., PO164-MON PO557-MON, PO558-MON PO366-MON
Dunois C., PO424-WED des I., PO077-MON, PO224- Elashoff D., PO507-MON Ensor J., PO019-TUE Etulain J., PO012-MON
MON, PO187-WED Fang J., OR342
Dupont A., AS201 Elbers L., OR035, OR268, Eppel W., PO185-MON, PO559- Eustace J., PO639-WED
Edin M., OR341 MON Fang Y., PO393-WED
Durcan L., PO437-MON PO028-TUE Evans D., PO638-MON Fanizza C., PO338-WED
Duretz V., PO311-TUE Edo N., AS145, PO203-MON El-Beshlawy A., PO164-MON Epstein J., OR014, PO281-MON Evans P., PO156-WED
Edwards C., OR310 Epstein J., OR211 Fareed J., PO182-MON, PO211-
Durian M., PO598-MON Eldar-Lissai A., PO257-WED, Evans P., PO083-TUE MON, PO212-MON, PO291-MON,
Durieux P., OR192 Eelde A., PO255-MON PO287-WED Epstein J., PO108-TUE Evans V., PO156-WED PO292-MON, PO293-MON,
Durkin M., OR073 Eftekhar Ardebili H., PO247-TUE Elezovic I., PO252-MON, PO080- Epstein J., PO231-TUE Evans V., PO599-WED PO303-MON, PO305-MON,
Duron C., PO075-TUE Efthymiou M., PO044-MON, TUE, PO228-TUE, PO547-TUE, Erduran E., PO270-TUE, PO499- Everington T., PO344-MON, PO334-MON, PO346-MON,
Durot E., PO440-MON PO046-MON, PO060-WED PO235-WED WED PO369-TUE, PO417-WED PO053-TUE, PO191-TUE,
Durrant T., PO461-WED Egan K., OR218, PO075-WED Elezovi I., PO218-TUE Eriksson B., PO376-TUE Everret L., OR180 PO192-TUE, PO337-TUE,
Eggert D., OR335 El-Gendy W., PO243-MON Eriksson H., PO378-TUE, PO646- Evmorfiadis I., PO102-TUE PO053-WED, PO112-WED,
Durrant T., OR272 PO332-WED, PO374-WED,
Eggertsen G., PO443-TUE Elhelu O., OR174, PO603-WED WED Evnorfiadis I., PO587-WED
Dusek L., PO364-WED PO402-WED, PO411-WED
Eggleston J., PO580-TUE, PO581- El-Husayni S., PO380-WED Eriksson J., OR069 Ewenstein B., OR088, OR211,
Dusse L., PO340-WED Farfan M., PO658-WED
TUE Elisabet M.-S., PO444-TUE Eriksson O., OR046 OR215, PO281-MON, PO223-
Dusse L., PO663-TUE, PO237- Farge-Bancel D., PO624-MON,
WED, PO479-WED Ehammer-Rosenkranz A., PO453- Elisha N., PO659-TUE Eriksson P.-O., PO294-MON TUE, PO254-WED
MON PO611-TUE
Dusse L., PO244-WED Elkeeb A., PO557-MON Erkan D., PO064-WED Ewenstein B., PO232-MON
Ehm M., PO107-WED, PO137- Faria M., PO626-TUE
Dusse L., PO566-MON Elli E., PO614-MON Erkens P., PO583-TUE Eweputanna L., PO450-MON
WED Faria M., PO189-TUE, PO002-
Dusse L. M., PO189-TUE Ellingsen T., PO493-TUE, PO561- Erkens P., PO598-MON Exner T., PO125-WED
Ehrlich R., PO285-TUE WED, PO397-WED
Dusse L. M., PO002-WED, WED Erkutlu I., PO109-WED Eyster M., PO260-MON
Ehrlicher A., OR232 Farid T., PO196-MON
PO023-WED Ellingsen T., OR120 Ermolina O., PO199-MON Ezban M., AS019, PO146-MON,
Eicher J., OR209 Faridah A., PO541-MON
Dutrillaux F., OR012 Ellis D., PO567-TUE Erramouspe B., PO092-TUE, PO147-MON, PO153-MON,
Eichinger S., OR226, PO298- PO147-TUE, PO153-TUE, Farin H., OR028
Dutt T., PO369-MON, PO578- Ellmeier W., OR111, OR276 PO231-WED
TUE, PO077-WED, PO528-WED PO215-WED Farina F., PO524-TUE
MON Elm T., PO147-MON, PO590-WED Escalante V., OR173, PO411-WED
446 447
AUTHORS INDEX
Faria D., PO428-TUE Ferguson K., AS065 Fijnvandraat K., AS079, OR013, Flierl U., PO058-MON, PO013- Fox-Robichaud A., PO324-MON Frelinger A., PO021-TUE, PO402-
Farkas . Z., AS004 Fernandes A., PO043-WED OR015, OR021, OR203, OR389, TUE Fraessdorf M., PO362-MON TUE, PO476-WED
Farm M., PO195-MON Fernandes A. P., PO002-WED PO283-MON, PO658-MON, Flinterman L., PO223-WED Frampton J., AS092, PO415-MON Fremeaux-Bacchi V., PO589-MON
Farndale R., PO441-WED Fernandes B., PO592-TUE PO240-TUE, PO308-WED, Flood V., PO659-MON Fremeaux-Bacchi V., PO226-WED
Frampton J., PO328-WED
PO510-WED
Farndale R., AS065 Fernandes S., PO212-TUE, Flood V., OR089, OR204 Frnberg M., PO559-WED, Freson K., OR231
PO261-WED Filbet M., PO107-TUE
Farquharson R., PO045-MON Flood V., AS131 PO564-WED Fressinaud E., AS134, OR024,
Fernandes T., PO476-MON, Filho O., PO397-WED OR025, PO639-TUE, PO645-
Farren-Dai L., PO630-WED Flores-Nascimento M., PO190- France N., PO262-TUE
PO644-WED Filippi L., OR132 MON, PO422-MON, PO531-MON TUE, PO664-TUE
Farris D., PO030-MON Frances P., PO653-WED
Fernandez C., AS158 Filippucci E., PO370-MON, Floridia A., PO369-WED Fretigny M., PO198-WED
Fasulo M., PO091-MON, PO114- Franchi F., OR026, PO663-MON
Fernndez M., PO010-WED PO423-WED Freund M., AS095
WED Floros G., PO274-MON, PO248- Franchini M., PO650-TUE
Fernndez Ponce N., OR160 Finazzi G., PO339-MON WED Freyburger G., PO398-WED
Fasulo M. R., PO090-TUE, Francis C., PO412-WED
PO091-TUE Fernndez-Capitn C., PO488-TUE Finley C., PO619-MON Florou V., PO615-MON Freyburger G., PO345-MON
Francis J., PO315-WED
Fatemi M., PO165-MON Fernandez-Golfin C., PO576-TUE Finn J., PO160-MON Florquin S., OR124, PO287-TUE, Freynhofer M., PO030-TUE
Francis J., PO174-WED
Fatima N., PO502-MON, PO134- Fernndez-Mosteirin N., OR076 Finnegan K., PO117-WED PO442-WED Fried H., OR366, PO155-MON
Francis J., PO445-WED, PO446-
TUE, PO549-TUE, PO181-WED, Fernandez-Recio J., OR369 Finney B., AS092 Fogarty P., PO252-WED Friedman K., OR152, PO361-
WED
PO521-WED Fernandez-Ruiz R., AS044 Fiore M., PO416-TUE Foidart J.-M., PO142-WED MON
Francis P., PO449-MON
Fatini C., PO365-TUE, PO477- Ferrando F., PO534-MON, PO536- Fischer A.-M., PO014-MON, Foley J., PO021-MON Friedman K., OR089, OR204
Francischetti I., PO068-MON,
TUE, PO586-WED MON, PO579-WED PO672-WED Foley K., PO021-MON Friedman M., PO579-MON
PO341-TUE
Fatou Samba N., PO542-MON Ferrante E., PO203-TUE, PO368- Fischer K., OR141 Follenzi A., AS088, OR106, Friedrich M., OR405, PO526-TUE
Francisco R., PO476-TUE
Faure G., AS036 WED Fischer K., OR144 OR161, OR411 Frieling J., PO592-WED
Franco L., PO373-WED
Favaloro E., PO366-TUE Ferrara G., PO534-WED Fischer K., NUR004, OR102, Fong S. C., AS100, OR062 Fries D., PO330-WED
Franco O., AS181, OR364
Favaretto E., PO602-MON, Ferrarese M., OR297, PO158- PO246-MON, PO272-MON, Fonseca K., PO004-TUE Franco Moreno A. I., PO485-TUE Frigo A., OR132
PO627-MON, PO317-WED MON PO230-TUE, PO245-TUE,
Fonseca L., PO264-TUE Franois B., PO337-MON Frimpong V., PO580-TUE, PO581-
Favier M., AS014 PO255-TUE, PO256-TUE,
Ferrari B., PO580-MON, PO592- PO262-TUE Fonseca R., PO128-MON Franois D., OR422, PO545-WED TUE
Favier R., PO473-WED MON, PO574-TUE Font L., PO469-MON Friou E., PO579-TUE
Fischer K., AS122, PO262-MON Franois D., PO163-WED
Faxlv L., PO406-MON Ferrazzi P., PO483-TUE, PO631- Font L., OR381 Frith S., PO317-TUE
Fischer M., AS200 Franois S., PO347-TUE
Fazavana J., PO553-TUE WED Fontaine S., PO223-MON Fritsch S., OR088
Fischer R., PO195-WED Franks Z., OR243
Featherby S., PO556-MON Ferre N., PO568-MON, PO575- Fontana P., AS128, OR055, Fritsma G., PO403-WED
MON Fischer R., PO516-WED Franscisco R., PO472-TUE
Featherby S., PO558-MON OR397, PO011-TUE Fritzinger D., PO226-WED
Ferreira A., PO404-WED Fischer T., PO368-WED Frasson S., PO608-MON
Feddersen L., PO107-WED Fontayne A., PO131-TUE Froehlich H., PO202-WED
Ferreira C., PO286-MON Fischer T., PO203-TUE Frati L., PO060-MON
Feder S., PO169-TUE Fontcuberta J., PO217-WED Froehlich J., PO623-TUE, PO419-
Ferreira C., PO340-WED Fischetti L., PO513-MON Frazer K., OR392, PO524-MON,
Federica B., PO347-TUE Foo K. M., PO430-TUE PO525-MON, PO493-TUE, WED
Ferreira M., PO496-TUE Fischler B., PO432-TUE, PO443-
Federici A., OR027 TUE Foppen W., OR102 PO567-WED Frlich L., PO487-WED
Federici A. B., PO649-MON Ferreira R., PO422-MON, PO531- Forban J.-C., PO035-WED Fromes Y., PO166-TUE
Fisgin T., PO051-WED Frazer K., PO519-MON
Fedewa H., OR375 MON
Fish R., AS002 Forbes P., PO457-MON Frazer K., OR393, PO526-MON, Frontini M., PO384-WED
Feese W., PO202-MON Ferreira Filho L. I., PO286-MON
Fisher M., PO521-MON Ford J., OR222 PO494-TUE, PO495-TUE, Frontroh J., PO640-TUE
Feijge M., PO349-TUE, PO675- Ferrer-Marin F., PO497-MON PO568-WED
Fishwick C., AS231, PO182-TUE Forestier E., PO337-MON Frontroth J., OR160
TUE Ferrer-Marn F., PO487-TUE Frchaud J., PO672-WED
Fitch-Tewfik J., AS091, AS166 Forgie M. A., PO371-WED, Frontroth J., PO644-MON,
Fejes Z., PO077-MON, PO482- Ferrer-Marn F., OR221 PO669-WED Frechtel G., PO323-MON PO428-TUE
WED Ferri N., PO378-WED Fitch-Tewfik J., AS170
Forman-Kay J., PO545-TUE Freddi S., AS212 Frostick S., OR283
Feldman B., OR328, PO475- Ferro A., PO516-MON Fitzgerald D., PO063-MON
Fornari T., PO422-MON, PO531- Fredenburgh J., AS154, AS219, Frucchi R., PO211-TUE, PO250-
MON, PO245-TUE Feuring M., OR283, PO376-TUE, Fitzmaurice D., PO019-TUE
MON OR286, OR290, PO138-MON, WED
Felicetta I., PO633-WED PO378-TUE, PO646-WED Fitzmaurice D., OR096, OR119 PO403-MON, PO130-TUE,
Forrest M., PO074-WED Fruchtman Y., PO217-TUE
Feliu Torres A., OR160, PO428- Feussner A., OR350, PO089-TUE Fitzpatrick M., PO611-WED PO170-TUE
Forsberg A., PO618-TUE Fruchtman Y., PO429-TUE,
TUE Feyen B., PO221-MON Fitzsimmons P., PO578-MON Fredenburgh J., OR442 PO225-WED
Fortes-Mayer G., PO098-TUE
Feliu-Torres A., PO644-MON Feys H., AS178, PO604-WED Fjrkenstad A., PO379-TUE Fredenburgh J., OR057 Frymire E., OR200
Fortunato F., OR005
Femia E. A., OR019, PO066- Fiatal S., PO187-WED Flament G., PO081-TUE Frederick M., AS059 Fu A.-C., PO521-MON
Fortunato T., PO016-MON
MON, PO412-TUE, PO086-WED Fidalgo T., PO538-WED Flaujac C., AS164, OR032, Frdrick R., PO172-TUE Fu R., OR001, PO451-TUE
Fosbury E., PO295-MON, PO617-
Feng D., OR274 Field D., OR241 PO544-TUE Freedman J., AS168, OR031,
WED Fu X., PO568-TUE
Feng K., PO318-MON, PO325- Field D., OR166, PO032-TUE Flaumenhaft R., AS091, AS166, PO328-WED
Foster G., PO463-MON Fu X., PO635-MON
WED Field M., PO139-TUE AS170, AS146, OR417, PO425- Freeman K., PO168-TUE
MON, PO346-TUE Foster R., AS205, PO182-TUE Fuchs B., PO675-TUE
Feng Q., AS074, OR138, OR261, Fields L., PO521-MON Freire I., PO163-TUE, PO538-
Fletcher J., PO622-WED, PO623- Foster W., PO329-WED Fuchs S., PO200-WED
PO319-MON Fierro T., PO024-TUE WED
WED, PO634-WED, PO635-WED Fotinos A., OR114, PO449-WED Fuchs T., OR193
Feng X., AS075, OR136, PO566- Fijalkowska I., PO154-WED Freishtat R., AS125
TUE Fletcher S., AS054, AS011 Fouassier M., PO016-WED Fuchs T., PO583-MON
Fijnheer R., PO584-MON Fox M., OR247, OR299 Freitag M., OR243 Fuentes E., AS116, PO010-TUE
Fennen M., PO157-TUE Fletcher S., OR298
Fijnvandaat K., OR387, PO251- Fox S., PO057-MON, PO026-TUE, Freitas L., PO479-WED Fuerlinger M., PO242-MON
Fenoglio L., PO613-MON Flick M., OR434, PO125-MON
TUE PO410-TUE, PO492-WED Freixo A., PO264-TUE, PO404- Fuhrmann J., OR307, PO413-TUE
Fergelot P., OR003 Flick M., OR375 WED
Fijnvandraat K., PO665-MON Fox-Robichaud A., PO389-MON Fuiman J., PO167-MON
448 449
AUTHORS INDEX
Fujii H., OR343 Gajsiewicz J., PO544-WED Ganna A., PO564-WED Gavasso S., AS042, OR078, Gershkovich K.B. K., PO113- Gill J., OR089
Fujii S., PO183-MON Gakuba C., OR379 Gannon C., PO318-WED OR172, PO341-MON, PO114- MON Gill J., OR204, PO659-MON
Fujii T., OR011, PO233-MON, Gakuba C., PO532-TUE, PO370- Gantioqui J., OR373, PO350- TUE, PO331-TUE, PO332-TUE, Gerstenbauer G., PO150-TUE Gill R., PO317-TUE
PO377-MON WED MON, PO139-WED PO548-TUE, PO127-WED, Gertz J., PO145-MON Gillespie S., PO677-MON
Fujii T., PO233-MON, PO377- Gl G., PO124-MON Gao C., OR140 PO387-WED Gervaso L., PO580-WED Gillet E., PO672-WED
MON Gl P., PO303-TUE Gao X., OR060 Gawaz M., OR114, PO412-MON, Gesheff M., PO041-TUE
PO449-WED Gilman E., OR144
Fujimura Y., AS178, OR152, Galambosi P., PO652-WED Garabet L., PO311-MON Geske F. J., PO150-MON Gilmour S., OR356
PO661-TUE, PO670-TUE, Gay V., PO484-MON
Galan A., PO082-WED, PO610- Garagiola I., PO164-MON, Gessner J. E., OR017 Gils A., AS205, OR153, OR442,
PO672-TUE, PO674-TUE, WED PO197-WED Gazit S., PO437-WED
Getz T., PO003-TUE OR444, PO215-MON, PO286-
PO040-WED Galanakis D., PO202-TUE Garanito M., PO433-TUE Ge J., PO527-TUE TUE, PO519-TUE
Getz T., AS070
Fujioka A., PO351-MON Galanaud J.-P., AS137, OR095, Garayar Pulgar B., PO358-TUE Ge X., AS031 Gimenez V., PO441-TUE
Geurts P., PO396-TUE
Fujita K., PO173-TUE OR188, OR190, OR327, PO467- Garcia B., PO310-TUE Gebel M., AS022, OR097, OR383 Gimeno Garca A., PO485-TUE
Geyer S., PO587-MON, PO572-
Fukazawa N., AS017 MON, PO473-MON, PO535-MON, Garcia C., PO423-TUE Gebhart J., AS034, PO391-WED, TUE Gindele R., PO550-MON, PO187-
Fukuda N., PO173-TUE PO653-WED PO528-WED WED
Garca E., PO435-WED Geys L., PO571-TUE
Fukutake K., AS017, PO161- Galaz-Montoya J., PO192-WED Geddis A., PO239-MON Ginsberg J., PO489-WED
Garca F., PO435-WED Ghalloussi D., AS014, PO416-
MON, PO213-TUE, PO006-WED, Galderisi M., PO534-TUE Gee E., NUR008, PO378-MON, MON, PO441-MON, PO443-MON, Ginsburg D., AS090, OR180,
PO204-WED Garca Bernal D., PO497-WED PO496-TUE
Galea V., PO473-TUE Garca Navarro M. J., PO485-TUE PO385-WED OR331, OR361
Fulmali M., PO363-TUE Galinski C., PO450-WED Geer M., AS069 Ghanima W., AS136, OR072, Ginzarly M., PO631-WED
Funck-Brentano C., OR196 Garca-Andreo A., PO336-MON Geersing G.-J., PO583-TUE,
Gallant M., AS180, PO321-MON, Garcia-Barbera N., OR368, PO311-MON, PO600-TUE Giobatta C., PO671-WED
Fung F. Y., PO012-TUE PO329-MON PO584-TUE Ghatge M., AS202
PO549-WED Giorgi Pierfranceschi M., PO502-
Fung M., PO576-MON Galli T., AS170 Gehrisch S., PO216-WED Ghatge M., OR010 TUE
Garca-Barber N., PO558-TUE Geierova V., PO247-WED
Funk S., OR101, OR388 Gallistl S., PO453-MON, PO464- Ghatge M., OR009, PO084-MON, Giorni C., PO018-TUE
Garcia-Candel F., PO497-WED Geltcer I., PO367-TUE
Furie B., AS146 MON PO040-TUE Giozos G., PO102-TUE
Garca-Candel F., PO229-MON Gen S., PO315-MON
Furie B., OR424, PO635-MON, Gallo A., PO610-TUE Ghazzar N., AS082 Girard D., PO398-WED
PO551-WED Garca-Esta J., PO435-WED Genoud V., PO199-TUE
Galloway G., PO352-MON Gheldof D., PO167-WED Girard J., PO156-MON, PO157-
Furie B., AS146, OR417, OR424, Garca-Gutirrez V., PO487-TUE Gensini G. F., OR253, OR400,
Gallus A., OR199, PO374-TUE Ghidelli N., PO483-MON, PO580- MON
PO425-MON, PO635-MON, Garca-Mouriz A., PO116-TUE PO086-MON, PO020-TUE,
Gallus A., PO608-TUE WED Girard P., OR146, OR149,
PO346-TUE, PO551-WED Gardiner E., PO497-MON, PO669- PO024-TUE, PO039-TUE,
Gallus A., PO353-TUE, PO409- TUE Ghirarduzzi A., AS197, OR195, OR192, PO587-TUE, PO655-WED
Furugohri T., PO353-MON, WED PO076-TUE, PO365-TUE, OR292, PO602-MON
Gardiner E., PO393-TUE, PO441- PO094-WED Girardi G., PO065-WED
PO357-TUE Glman C., PO443-TUE Ghosh K., PO207-TUE
WED Genty C., PO095-TUE Giraud M., PO645-TUE
Furukawa S., PO244-MON, Galora S., PO086-MON, PO094- Ghysdael J., AS014
PO652-MON, PO145-TUE Gardiner E., PO431-MON Georg Geissler G., PO015-TUE Girelli D., OR050, OR080,
WED Gianellini S., PO005-TUE PO554-TUE, PO555-TUE
Fuset M. P., PO062-MON Gareus R., AS069 George D., NUR002
Galvin R., PO457-MON Giangrande P., OR212, OR348, Girolami A., PO518-WED
Fustulo-Gunnink S., AS091 Garg P., OR213 George F., PO167-WED
Galvin Z., OR218 PO653-MON Gissel M., OR303, PO371-MON,
Ftterer J., AS054 Gargaro M., PO162-TUE George F., PO337-MON
Galy-Fauroux I., PO014-MON Gianniello F., PO583-WED PO576-MON, PO467-TUE,
G S., PO363-TUE Garghetti E., PO126-WED George J., OR152 PO425-WED
Gamba G., OR027, OR030, Giannini S., OR233, OR235,
Gaberel T., PO370-WED PO483-MON, PO580-WED Garipardic M., PO310-MON Georges M., PO407-MON AS186 Gissen P., AS054
Gabilondo M., PO354-MON Gamba P., PO225-TUE Garnier D., PO393-WED Georgescu I., OR409, OR412 Giansily-Blaizot M., PO502-MON, Gitz E., PO393-TUE
Gable B., OR192 Gamba S., PO339-MON Garraud O., PO575-MON Georgescu M., AS192 PO551-TUE, PO676-WED Giuffrida G., OR027
Gabrielli S., OR002, PO433-MON, Gambino G., PO239-MON, Garred ., PO178-WED Georgescu V., PO535-MON Giansily-Blaizot M. G.-, PO134- Giulivi A., OR200, OR310
PO421-TUE PO255-WED Gary T., AS197, OR292 Georgiev P., OR213 TUE Giunta D., PO620-WED
Gachet C., PO079.1-MON, Gamble-Williams N., NUR001 Gasteyger C., PO589-MON Gerasimova O., PO147-WED Gibbins J., PO385-TUE Giunta D., PO642-WED
AS095, OR420, PO572-MON, Gamirkina D., PO538-TUE Gattinoni L., PO338-WED Graud C., OR409 Gibbins J., PO397-TUE, PO450-
PO606-WED Giusti B., OR270, OR400,
Gamperl H., OR439 Gau J.-P., OR330 Gerdabi J., PO490-MON WED PO086-MON, PO020-TUE,
Gacrama E., PO499-TUE Gauberti M., AS032, AS117, Gerdes V., OR035 Gibbins J., AS167, PO398-MON, PO039-TUE, PO094-WED
Gamst A., PO476-MON
Gade I. L., AS083 OR314, OR379, PO532-TUE, Gerdes V., OR268, PO028-TUE PO506-MON, PO438-WED Giustozzi M., PO370-MON,
Gandara E., OR384, PO467-MON,
Gadisseur A., AS133, PO655- PO473-MON, PO641-MON, PO370-WED Gerhard D., PO418-WED Gibbs H., OR119 PO423-WED
MON, PO666-TUE, PO668-TUE PO664-WED Gaucher E., PO203-WED Gibbs R. A., OR083 Gkalea V., PO116-MON
Gerhardt A., OR077, OR329,
Gaertner F., OR206 Gndara E., OR053, PO620-WED Gaultier J.-B., PO107-TUE PO539-TUE Giermasz A., OR348 Gkalea V., PO587-WED
Gafarova M., PO535-TUE Gandhi P., OR237 Gaussem P., AS086, AS087, Germain M., OR148, OR266 Gierula M., OR369, PO139-MON Gkotsi S., PO169-WED
Gagliardi G., PO084-TUE Gandhi S., PO494-WED OR196, PO016-TUE, PO038- Germanovich K., PO412-TUE, Gieseler F., OR439 Glamocanin S., PO287-MON,
Gaglioti D., PO654-TUE TUE, PO350-TUE, PO437-WED, PO086-WED Gigante B., PO530-TUE PO288-WED
Gandhi T., PO014-WED PO513-WED, PO672-WED
Gagnon F., AS045, AS206 Gando S., PO178-MON Gerotziafas G., PO116-MON Giglioli C., PO020-TUE, PO076- Glaros E., PO404-MON
Gago T., PO163-TUE, PO538- Gautam M., PO369-MON TUE
Ganesh S., AS090 Gerotziafas G., OR438, PO108- Glaves R., PO603-MON
WED Gavalaki M., PO169-WED MON, PO102-TUE Gijsberts C., PO386-TUE
Ganetsky M., PO319-TUE Glazebrook D., PO235-MON
Gaida A., AS016 Gerotziafas G., PO587-WED Gil L., PO125-TUE, PO170-WED Glazebrook D., PO237-MON
Gangadharan B., PO228-WED,
Gailani D., OR288 PO230-WED Gerotziafast G., PO292-MON, Gil-Bazo I., PO116-TUE Gledkruemas S., PO613-WED
Gailani D., OR287, OR353, Gangemi M., PO515-MON PO473-TUE Gilio K., OR278 Gleeson E., OR182
PO543-WED Gill J., OR088
450 451
AUTHORS INDEX
Gleeson N., OR360 Gomez M., PO242-WED Gorelashvili M., PO526-TUE Grand F., PO448-MON Grigoriev S., PO466-TUE Grusse M., PO102-TUE, PO473-
Glembostky A., PO422-TUE Gmez M., PO487-TUE Gorena M., PO631-TUE Grande-Ratti M., PO642-WED Grigorjeva M., PO073-WED TUE, PO163-WED
Gloria F., PO444-TUE Gmez V., PO552-WED Gori A. M., OR396, OR400, Grandone E., PO511-MON, Grill D., PO655-TUE Grzegorczyk F., PO311-WED
Glund S., OR320 Gmez Del Castillo M. D. C., PO067-MON, PO020-TUE, PO513-MON, PO453-TUE, Grimm J., PO256-MON Gu J.-M., AS018, PO555-WED
Gnerre P., PO610-TUE, PO640- PO451-MON PO039-TUE, PO365-TUE, PO611-TUE Grimwade D., PO120-MON, Gu S., PO176-TUE
WED Gmez-Del-Castillo M. D. C., PO094-WED Grangl G., PO464-MON PO121-MON Gu X., PO623-TUE, PO419-WED
Gobbato S., PO027-MON PO010-WED Gori A., OR253 Granoski D., PO460-MON Gringeri A., OR014, OR029, Gu X., OR265
Goddijn M., AS021 Gomez-Rodriguez V., PO342-MON Gori A.-S., PO407-MON Grant P., OR398 PO259-MON, PO286-WED Gualandris F., PO622-TUE
Godfroid E., PO166-TUE, PO174- Gomis R., AS044 Gori L., PO071-TUE Grant P., PO096-WED, PO190- Grinspon A., PO373-MON Gualandro D., PO034-TUE,
TUE, PO181-TUE Gomperts E., PO168-MON, Gori T., PO483-WED WED Gris J.-C., OR095, OR188, PO095-WED
Godier A., OR219, PO016-TUE, PO169-MON Goria O., PO621-WED Grant P., AS003 OR190, PO035-MON Guardascione M. A., AS195
PO350-TUE, PO662-TUE Gona P., PO593-TUE Gorski M., OR394 Granzen B., AS079 Gris J.-C., PO035-WED Guarini P., OR050, PO554-TUE,
Godoi L., PO566-MON, PO244- Goncalves G., PO002-WED Gorski M., PO580-MON Grass S., PO362-WED Griskevicius L., PO242-MON, PO555-TUE
WED Goncalves L., PO390-WED Gorski M. M., AS196, OR083, Gratacap M.-P., PO514-TUE PO260-MON Guarino M. L., PO060-MON,
Goehringer F., PO546-TUE Goncalves L., PO264-TUE PO197-WED Grter F., OR335 Grissom C., PO604-MON PO084-WED, PO316-WED
Goekoop R., PO596-MON Goncalves M. L., PO390-WED Goruppi M., PO376-MON Gratsiansky N., PO069-TUE Gritsch H., PO199-WED, PO201- Guazzaloca G., PO317-WED
Goerdt S., OR409 Gonalves G., PO189-TUE, Gosain R., PO041-TUE Gratz M., PO079.1-MON WED, PO229-WED Gubensek M., AS101
Goerge T., OR170 PO023-WED, PO397-WED Goss A., OR356 Graux C., OR126, PO167-WED Gritzan U., PO555-WED Gudermann T., AS068, OR081
Goetze J. P., PO482-MON Gonalves L., PO212-TUE, Gosselin R., PO358-WED, PO359- Graveleau J., PO016-WED Groarke E., PO649-WED Gudmundsdottir B., PO412-WED
Gogarten W., PO395-TUE PO404-WED WED Gray E., PO294-MON, PO064- Groeneveld D., OR070, PO002- Gue D., PO269-WED
Goggs R., OR244 Gong L., AS146 Gothot A., PO396-TUE WED MON, PO660-TUE Guechi Z., PO375-MON
Gogia S., OR334, PO045-WED Gong Y., PO245-WED Goto S., OR096, OR119 Gray W., PO063-WED Grner A., PO605-WED Gugan M., OR146, OR149,
Gohda M., OR352, PO351-MON Gonias S., AS229 Goto T., PO173-TUE Grazia F., PO259-TUE Grning A., OR054 PO655-WED
Gohlke H., PO418-MON Gonzalez A. F., PO360-WED Gotru S., AS068, OR081 Greaves M., PO225-MON Grootenboers M., OR257 Gueguen P., PO440-MON
Goizet C., OR003 Gonzalez C., PO323-MON Gotru S. K., AS228 Greblikas F., PO242-MON Gros A., OR170, PO330-MON Guelcher C., PO381-MON
Gokce M., PO313-MON, PO315- Gonzlez A., PO010-MON Gottstein S., AS221 Greco S., OR365 Groschup M., PO605-WED Guenneguez H., AS137
MON, PO459-MON, PO279-WED Gonzlez C., OR220, PO466- Goudemand J., AS134, OR024, Greenbaum L., PO589-MON Grosdidier C., PO493-WED Guenther J., PO404-TUE
Goldberg R., OR395, PO578-TUE WED, PO480-WED OR025, OR143, OR144, OR219, Greene D., OR339, PO384-WED Grosjean S., PO263-TUE Gueret P., PO166-TUE, PO181-
Goldenberg N., PO506-WED Gonzlez L., PO355-WED PO639-TUE, PO645-TUE, Greene L., PO632-MON Gro J., PO013-WED TUE, PO411-TUE
Goldenberg N., AS161, OR156 Gonzlez V., PO051-MON PO662-TUE Gross J., AS221 Guerra L., OR078
Greene L., OR165
Goldfine A., PO329-MON Gonzalez J., PO664-WED Goufman E., PO113-MON Gross P., AS216, AS219, OR286, Guerrera M., PO381-MON
Greenhoe R., PO618-TUE
Goldford M., PO346-MON Gonzalez Alcantara M., PO059- Gougnard T., PO373-TUE OR302 Guerrero B., PO190-TUE
Greenman J., PO558-MON
Goldhaber S., PO646-WED WED Gouider E., PO650-MON Grosse S., OR134 Guerrero F., PO440-MON
Greenspan E., PO096-TUE
Goldhaber S., OR096, OR119, Gonzalez Bernaldo De Quiros F., Gouillou M., OR323 Grossi E., PO066-MON Guerrero G., PO092-TUE, PO146-
Gregersen H., PO130-MON
PO378-TUE, PO613-TUE PO620-WED Gouin-Thibault I., OR196, Grossmann V., PO478-WED WED, PO231-WED
PO345-MON, PO016-TUE, Gregory-Miller K., AS110
Goldman B., PO149-MON Gonzalez-Conejero R., PO558-TUE Grosso M., OR199, OR383 Guerrero J., PO384-WED
PO350-TUE, PO672-WED Greinacher A., AS008, OR055,
Goldman L., PO532-MON Gonzlez-Conejero R., PO549- OR307, OR308, PO298-MON, Grosso S., PO629-MON Guettier S., OR379
WED Gould T., PO220-MON Grosso S., PO646-TUE Gugiu G., PO476-MON
Goldmann G., OR103, PO219- PO413-TUE
TUE, PO532-WED Gonzlez-Conejero R., PO552- Goult B., PO553-MON Grosso S., PO039-MON Guglielmone H., OR431, PO632-
Greisel J., OR049
Goldsmith R., PO447-TUE WED Gounou C., PO326-TUE Grotevendt A., OR307 TUE, PO640-TUE, PO518-WED
Greist A., OR028
Goldstein J., PO601-WED Gonzlez-Porras J., PO488-TUE Gourlaouen M. A., PO645-TUE Grtta O., AS136 Guidetti G., OR115
Gremmel T., PO021-TUE, PO402-
Golebiewska E., AS126 Gonzlez-Porras J., PO487-TUE Gouw S., PO245-TUE TUE Grottke O., OR067, PO078-TUE, Guidetti G., PO450-TUE
Golightly L., PO622-MON Good D., PO227-TUE Gouw S., OR389 Grenier D., PO131-TUE PO314-TUE Guidez F., AS014
Golmard J.-L., PO345-MON, Goodall A., AS041, PO429-MON, Gouw S., OR141 Gresele P., AS174, AS199, Grozovsky R., AS186 Guil M., PO631-WED
PO350-TUE, PO672-WED PO553-MON, PO565-MON, Govers-Riemslag J., PO546-MON OR208, OR336, OR399, PO024- Gruber A., AS049, AS209, Guillemin F., OR186
PO464-WED, PO542-WED Goy J., AS110 TUE, PO650-TUE PO177-TUE
Golovina O., PO057-TUE, PO367- Guillen K., PO516-MON
TUE Goodemand J., PO649-MON Goyal J., PO208-TUE Griesmacher A., PO096-MON Gruber A., OR049, OR353, Guillonneau F., PO572-MON
Golubeva M., PO046-WED Goodeve A., AS132, OR406, Grabell J., PO646-MON, PO678- Griffin J. H., PO093-MON PO543-WED
PO649-MON Guillot A., PO107-TUE
Golubeva N., PO327-TUE MON, PO227-TUE, PO426-TUE, Griffin K., PO096-WED, PO190- Gruel Y., AS108, OR143, OR428, Guillot O., PO134-TUE
Goodeve A., AS064, OR086, PO679-TUE, PO252-WED WED PO064-MON, PO345-MON,
Gomas J.-M., PO107-TUE PO667-MON, PO676-MON, Guimares F., PO340-WED
Gomes B., OR310 Grace R., PO458-MON Griffioen A., PO452-TUE PO501-MON, PO263-TUE,
PO676-WED PO056-WED Guimares J. E., PO012-WED
Gomes H., PO264-TUE Gracheva M., PO462-MON Griffith B., OR338
Goodwin C., OR436, PO301-MON Gruenenfelder F., OR320 Guimicheva B., PO479-TUE
Gomes K., PO043-WED Graeter F., PO669-TUE Griffiths D., PO670-WED
Gooneratne L., PO021-WED Gruenheid S., PO135-MON Guiochon-Mantel A., PO527-MON
Gomes T., PO068-MON Graham R., PO096-WED Grifoni E., OR396, OR400,
Gopal S., OR417, PO425-MON Grunebaum L., PO263-TUE Guirimand F., PO107-TUE
Gomes T., PO131-MON Grammel N., PO144-TUE PO067-MON, PO366-MON,
Gorbacheva L., PO537-TUE Gruppo R., PO242-MON, PO260- Gujjar A., PO009-TUE
Gomes T., PO158-WED Grammel N., PO146-TUE PO076-TUE, PO365-TUE,
Gorbacheva L., PO281-TUE, PO477-TUE MON, PO266-WED Guler N., PO211-MON, PO212-
Gomez K., PO486-MON, PO353- Grancha S., PO207-WED MON, PO192-TUE, PO332-WED,
PO290-TUE Griggio N., PO385-MON Grushin K., PO192-WED
WED, PO676-WED Grand B., PO059-WED PO374-WED
Gordanpour A., OR159
452 453
AUTHORS INDEX
Gulilat M., PO364-TUE Haertter S., PO376-TUE Hampshire D., AS064, OR086, Harenberg J., PO346-MON, Hasumi K., PO515-TUE, PO528- He Y., AS072, OR137
Gulin D., PO113-MON Hafeman A., PO231-TUE PO667-MON, PO676-MON, PO356-TUE TUE He Z., PO321-WED
Gullberg J., OR283 Hagan M., OR064 PO676-WED Harissis H., PO551-TUE Hatakeyama K., PO674-TUE Healey F., OR073
Gullerud R., OR128 Hagedorn I., AS094 Hampson P., OR121, PO393-TUE Harlen O., PO243-WED Hatmi M., PO116-MON Healey J., PO362-MON
Gulys H., PO031-WED Hagemeyer C., PO014-TUE Hamsten A., OR269, PO559- Harling H., OR230 Hato T., PO055-MON Healy L., PO297-TUE
Gumruk F., PO505-WED, PO507- Hgerling R., AS092 WED, PO564-WED Harney K., PO457-MON Hattori K., PO491-MON, PO165- Heatherington A., PO512-TUE
WED, PO508-WED Haghpanah S., PO490-MON Hamulyak K., PO033-WED Harney K., PO458-MON TUE Hebbard C., PO451-WED
Gunawan A., PO633-TUE Hagio T., OR352, PO351-MON Hamzeh-Cognasse H., PO410- Harper A., OR045 Hau A., PO427-TUE Hebert K., AS192
Gunawan S., PO014-TUE MON, PO408-TUE Hauck B., PO172-MON
Hagiwara N., PO399-MON Harper M., PO065-MON Hechler B., PO572-MON, PO606-
Gundert E., PO469-MON Han C. K., PO613-TUE Haulon S., AS201
Hagiwara T., PO161-MON, Harper M., OR244, OR275, WED
Gunning W., AS130 PO006-WED Han J. W., PO309-WED PO424-TUE, PO458-WED Hauschner H., PO171-TUE, Hechler B., PO514-TUE
Guo L., OR139, PO302-TUE Haglund C., PO162-WED Hanabusa H., AS017, OR212, Harper P., PO374-TUE PO324-WED Heckbert S., PO557-WED
OR347, PO149-MON Hausfater P., OR192
Guo Z., OR140 Haguet H., OR126 Harper P., AS100, OR062, Hecker A., PO094-MON
Hanagavadi S., PO164-MON PO670-WED Hausner L., PO487-WED
Gupalo E., PO294-TUE Haidl H., PO453-MON, PO464- Heckman M., PO401-WED,
MON Hanchate A., PO657-WED Harrington L., OR034 Haussels I., PO343-WED
Gupta G., OR365 PO410-WED
Haig Y., AS136 Handrkova H., PO181-WED, Harrington L., PO557-WED Havelick J., PO050-TUE
Gupta K., OR421 Heddle N., OR282, PO570-MON
PO185-WED
Gupta S., PO182-WED, PO183- Hainfellner J., OR357 Harris D., PO306-MON Havluj L., PO364-WED Heddle N., PO616-WED
Handt L., PO074-WED
WED, PO184-WED Haining E., OR181 Harris N., PO197-TUE Hawke L., PO670-MON Heddle N., PO276-MON
Handunetti S., PO021-WED
Gurbel P., PO076-MON, PO099- Hajer E. M., PO281-WED Harris P. J., OR127 Hawkins B., PO523-MON Hedengran K., PO509-MON
MON Hanley J., PO502-WED
Hajjar K., AS089 Harris S., PO243-WED Hawkins K., PO156-WED Hedge G., OR046
Gurbel P., PO041-TUE Hanna D., PO172-WED
Hakobyan L., PO573-MON Harrison M., PO408-MON Hawley A., PO030-MON Hedin U., PO564-WED
Gureasko J., OR247 Hanna W., PO619-MON
Halabi M., PO471-WED Harrison N., PO156-WED Hay C., OR213, PO210-TUE, Heemskerk J., AS141, OR278,
Guria G., PO460-TUE Hanna W., PO032-MON PO266-WED, PO299-WED
Hald E., OR071, OR254, Harrison N., PO064-TUE, PO130- AS140, PO452-TUE, PO675-TUE
Guria K., PO460-TUE OR267, PO304-TUE, PO328- Hansen A., OR036 WED Hay C., PO294-WED Heemskerk J., PO395-WED
Gurkan E., PO591-TUE TUE, PO494-TUE, PO594-TUE, Hansen E., PO219-WED Harrison S., OR157 Hay C., OR389, PO495-MON Heemskerk J., AS204, PO411-
Gurlich R., PO364-WED PO638-WED Hansen H., OR230 Harrison P., AS054, OR121, Hay J., PO260-TUE MON, PO499-MON, PO672-MON,
Gursel T., PO143-WED Hald E., PO308-TUE Hansen J., OR414 PO325-MON, PO393-TUE Haya S., PO093-MON, PO308- PO155-TUE, PO349-TUE
Guruceaga E., PO488-TUE Haley K., AS129 Hansen J. B., OR267, PO308- Hart D., OR108, PO284-MON, WED, PO579-WED Heestermans M., AS208, PO570-
Halilovic S., PO094-MON, TUE, PO494-TUE, PO638-WED PO258-WED Hayakawa M., PO661-TUE, WED
Guskova E., PO356-WED
PO066-TUE Hansen J.-B., AS046, AS028, Hart G., PO062-TUE, PO550- PO672-TUE, PO674-TUE, Heggermont W., PO002-TUE
Gussoni G., PO608-MON AS083, OR071, OR075, OR120,
Halimeh S., OR346, PO256- TUE, PO048-WED, PO594-WED, PO040-WED Hego A., AS006, PO396-TUE
Gutowski Z., PO229-TUE OR129, OR134, OR254, OR258, PO595-WED
MON, PO502-MON, PO647-MON, Hayakawa M., PO178-MON Heibroch Petersen H., PO455-TUE
Guyaux M., PO166-TUE, PO181- PO521-WED OR293, OR345, OR392, OR393, Hartholt R., PO227-WED
TUE Hayasaka K., PO455-WED Heide-Jrgensen U., OR098
Hall B., PO600-MON, PO601- PO338-MON, PO472-MON,
Hartman S. K., PO631-TUE Hayashi S., PO320-WED Heilmann S., PO202-WED
Guzman C., PO647-WED MON, PO582-TUE PO519-MON, PO524-MON,
PO525-MON, PO526-MON, Hartmann R., PO151-TUE, Hayashi T., PO113-WED Heim V., PO606-WED
Guzzo M. P., PO084-WED Hall C., PO168-MON, PO169- PO152-TUE, PO201-WED,
Gvozdenov M., PO547-MON PO609-MON, PO610-MON, Hayashi T., PO185-TUE, PO284- Heinis C., PO101-MON
MON PO612-MON, PO104-TUE, PO209-WED TUE, PO335-TUE
Gwilt K., PO089-WED Heinken A., PO480-TUE
Haller F. M., PO219-WED PO111-TUE, PO112-TUE, Hartwick J., NUR013 Hayashida K., OR142
Gwynn S., PO098-TUE Heinz G., OR123, PO301-TUE
Halliez M., PO016-WED PO304-TUE, PO328-TUE, Hartwig J., OR232 Hayes C., OR356
Gyenes M., PO413-MON, PO417- PO329-TUE, PO493-TUE, Heinz J., AS221
Halton J., PO465-MON Harudova M., PO128-TUE Hayes L., PO605-MON, PO590-
MON PO495-TUE, PO594-TUE, Heinze K., OR405, PO526-TUE
Hamaia S., AS065 Harutyunyan L., PO573-MON TUE
H. Reitsma P., PO548-WED PO396-WED, PO561-WED, Heising S., AS069, OR183,
Hamako J., PO661-TUE, PO670- Harvey A., PO502-MON, PO521- Hayes T., PO367-WED
Ha H., PO659-WED PO567-WED, PO568-WED, OR401, PO434-WED
TUE WED Hayman M., PO085-WED
Haaning J., OR110, OR414, PO572-WED, PO636-WED Heit J., OR266
Hamasaki T., AS107 Hary J., PO645-TUE Haymart K., PO623-TUE, PO419-
PO147-MON, PO219-WED Hansen L., PO590-WED Heit J., OR128, PO645-WED
Hamedani N., OR248 Hasebe R., PO151-MON, PO486- WED
Haas S., OR096, OR119, PO356- Hansen M., PO147-TUE TUE, PO560-WED Heitmann M., OR414
Hamel Desnos C., AS137 Haynes L., PO371-MON
TUE, PO607-TUE Hanslik A., PO302-MON Hasegawa K., PO515-TUE, Heldner M., PO525-TUE
Hamid C., PO295-MON, PO353- Haynes L., PO140-MON, PO133-
Haberichter S., PO361-MON, WED Hantel S., PO378-TUE PO528-TUE Helfer H., PO620-MON
PO659-MON, PO667-MON TUE
Hamidou M., PO016-WED Hanzu F., AS044 Hasenfu G., PO619-WED Helin T., PO363-MON
Haberichter S., OR089, OR204 Hayward C., OR377
Hammelburger J., PO054-TUE Hao Y., OR001, PO451-TUE Hashemi S., AS223, OR141 Hell L., PO559-MON, PO391-
Habib I., PO658-TUE Hazeldine J., OR121 WED
Hammerschmidt S., AS008 Harada A., OR320 Hashimoto A., PO351-MON
Hack K., PO299-TUE Hazendonk H., OR387, PO251- Heller C., PO195-WED, PO506-
Hammerstrom J., OR345 Harada K., PO351-MON Hassab H., PO243-MON TUE
Hackeng T., PO617-MON, PO037- Haramura G., PO550-MON WED
Hammerstrm J., AS083, OR129, Hassanzadeh-Ghassabeh G., Hazendonk H. C., PO651-MON
TUE, PO348-TUE, PO002-WED, Hardikar W., PO432-TUE OR399 Heller P., PO422-TUE
PO023-WED PO104-TUE, PO111-TUE, He A.-D., PO426-MON
PO112-TUE Hardt R., PO591-MON Hassell K., PO356-MON Heller-Baan R., OR257
Hackeng T., PO411-MON, PO518- He R., PO248-WED Helley D., PO014-MON
Hammond D., PO024-WED Hardy L., PO100-MON, PO182- Hassenpflug W., PO174-MON He R., PO484-WED
MON, PO349-TUE, PO091-WED, Hellum M., PO561-MON
Hampshire D., OR406 TUE Hassmann D., PO383-WED,
PO395-WED He S., PO255-MON, PO368-
Harel A., AS062, OR246, PO206- PO487-WED Helm C., AS008
Haenel D., PO404-TUE MON, PO362-WED
WED Hassock S., PO511-TUE Helseth R., OR251, PO030-TUE
454 455
AUTHORS INDEX
Helsing K., AS163 Hernandez J., PO023-TUE Hines P., OR060 Hogg P., OR417 Hoorfar H., PO649-MON Hou Y., AS074, OR138, OR261,
Hemker C., OR224, OR301, Hernndez M., PO523-WED Hirakata H., PO505-TUE Hogg P., OR185, PO075-MON, Hoorntje J., PO056-MON PO319-MON
PO025-MON, PO089-MON, Hernndez M., PO552-WED Hiramatsu E., PO514-WED PO404-MON, PO415-TUE, Hooton L., PO601-MON Hough C., AS191, AS192, OR122
PO290-MON, PO004-WED Hernndez Herrera H., PO533- Hiratmasu E., PO441-TUE PO669-TUE Hopkinson W., PO211-MON, Houlahan K., PO458-MON
Hemker C., PO672-MON MON Hirayama K., OR343 Hogwood J., PO294-MON PO212-MON, PO112-WED, Houppert B., PO031-TUE
Hemker H., PO143-MON Hernndez-Boluda J., PO487-TUE Hiroshi K., PO153-WED Hohensinner P., AS200, PO002- PO331-WED Houskova K., PO224-WED
Hemker H., PO527-MON Hernndez-Jurez J., PO020- Hirota Y., OR352, PO351-MON TUE, PO282-TUE, PO301-TUE, Hopman M., PO468-TUE Hovens M., PO587-TUE
Hemmeryckx B., PO002-TUE MON, PO073-MON, PO523-TUE PO509-TUE Hopman W., PO646-MON, Hovens M., OR257
Hirsch A., PO647-WED
Henault L., PO657-WED Hernandez-Lpez J. R., PO020- Hohensinner P., OR123 PO227-TUE Howard L., OR074
Hirsh J., PO130-TUE, PO489-
Henderson S., AS154, PO403- MON WED Hiland I., PO329-TUE Hoppensteadt D., PO182-MON, Howard M., PO007-WED
MON Hernani R., PO579-WED Hisada R., PO058-WED Hiland I. I., PO304-TUE, PO308- PO211-MON, PO212-MON, Howard Leong-Poi H. X., OR031
Henderson S., PO653-MON, Herold S., PO593-MON TUE PO291-MON, PO293-MON,
Hiscock K., PO374-TUE PO303-MON, PO305-MON, Howell M., PO601-WED
PO638-TUE Heroux A., OR173 Hokamura K., PO193-TUE
Hitos K., PO622-WED, PO623- PO334-MON, PO346-MON, Hoxer C., OR349, PO138-TUE,
Hendrickson R., PO516-WED Herr M., PO174-TUE, PO076- WED, PO634-WED, PO635-WED Holbrook A., OR200 PO139-TUE
Holbrook L.-M., PO506-MON, PO053-TUE, PO191-TUE, PO192-
Hendrickx M., OR399 WED Hitzler W., AS052 TUE, PO337-TUE, PO053-WED, Hoylaerts M., AS009, AS176,
Hendriks D., PO218-MON, Herranz M. T., PO552-WED PO450-WED PO462-WED
Hjemdahl P., PO363-MON, PO112-WED, PO331-WED,
PO219-MON, PO221-MON Herrera M. D. L., PO373-MON PO661-MON, PO383-TUE, Holck M. H., PO119-WED PO332-WED, PO344-WED, Hoylaerts M., AS113
Hendriksen J., PO583-TUE Herrero B., PO010-WED PO392-WED Holden F., PO318-WED PO374-WED, PO402-WED Hoylaerts M., OR418
Henkel-Klene A., PO654-MON Hers I., AS141, OR112, OR272, Hlavackova A., PO238-WED Holinstat M., AS217 Hor K., AS160 Hoyt C., PO038-WED
Henkens Y., PO143-MON OR275, PO428-MON, PO458- Hlusi A., PO060-TUE, PO279- Hollands M., PO623-WED, Hord E., PO076-WED Hrachovinova I., OR152, PO224-
Hennessey C., PO381-MON WED, PO461-WED TUE PO635-WED Hord J., PO238-MON WED, PO247-WED
Henneuse A., OR324 Hertfelder H.-J., PO343-WED Ho E., AS018, PO213-WED Hollenbach S., OR318 Horellou M.-H., AS164 Hsieh H.-W., PO031-MON
Henniphof T., OR225 Herv T., PO045-TUE Ho M., AS150 Hollenberg M., AS057 Horellou M. H., PO544-TUE Hsieh P.-W., OR344
Henrard S., PO234-TUE Herzog E., AS016, OR316, Ho P., PO605-MON, PO048-TUE, Hollingdrake O., PO391-MON Horellou M.-H., OR032, OR055 Hsu Y.-C., PO029-MON
Henriet C., PO484-MON, PO650- PO152-MON, PO312-TUE, PO590-TUE Hollingsworth R., PO210-TUE Horemans H., PO267-MON Hsu C.-C., PO059-MON, PO017-
MON PO418-WED, PO596-WED Ho Tin Noe B., PO222-MON Holly S., OR280 TUE, PO079-WED
Hori A., PO661-TUE
Henriksen A., PO153-TUE Herzog R., OR107 Hodge J., PO315-WED Holly S., AS182 Hsu F., PO502-MON, PO521-WED
Horita T., PO058-WED
Henriksen L., PO051-TUE Herzog R., PO220-WED Hodgins D., PO267-MON Holm P., PO046-TUE Hsu Y.-C., PO050-WED
Horiuchi H., PO653-TUE
Henriksson C., OR317, PO561- Hesketh M., OR444 Hodgkinson J., PO019-TUE Holman T., AS217 Hu B., PO162-MON, PO132-TUE,
Horiuchi T., PO386-WED
MON Hess P., OR020 Hoefer I., PO386-TUE Holme P., PO257-TUE PO569-WED
Horling F., PO249-MON, PO284-
Henriquez D., PO607-WED Hethershaw E., PO100-MON, Hoefer T., PO431-MON Holme P. A., AS136, OR317, WED Hu G., PO166-MON
Henskens Y., PO056-MON, PO182-TUE Heg Dembrower K., PO530-TUE PO271-MON Hu H., OR279
Horman S., PO101-WED
PO645-MON Hettinger J., OR177 Hoekstra M., PO405-MON Holme P. A., PO283-WED Hu J., PO222-WED
Hrmann N., PO397-MON
Henskens Y., OR430, PO348- Heuschen C., PO507-TUE Hoek-Ten Cate A., OR326 Holme P. A., PO273-WED Hu L., PO409-MON
Horn C., PO089-TUE, PO194-
MON, PO092-WED, PO349-WED, Hey J., PO673-TUE Hoellriegl W., PO151-TUE, Holme P.-A., PO291-WED WED Hu M., OR279
PO350-WED, PO416-WED Heying R., AS113 PO199-WED Holmer E., PO294-MON Horn E., PO007-WED Hu S., AS026
Henskens Y., PO033-WED Heylen E., PO142-TUE Hofbauer C., PO284-WED Holmes C., PO239-TUE Horneff S., PO219-TUE, PO532- Hu Y., PO111-MON, PO132-
Henskens Y., PO123-WED, Heylen O., OR079 Hofbauer C., AS221, PO236-TUE Holmstrm M., PO297-MON, WED MON, PO162-MON, PO177-MON,
PO609-WED Heymann D., PO032-MON PO661-MON, PO080-TUE, PO179-MON, PO132-TUE,
Hofbeck M., PO667-WED Horner K., PO313-WED
Hepner M., OR160, PO644-MON, Heymonet M., AS036 PO228-TUE, PO559-WED PO132-TUE, PO492-TUE,
PO428-TUE, PO640-TUE Hofer S., PO528-WED Hornung V., PO631-MON, PO637-
Hzard N., PO457-WED Hoffman M., PO062-TUE, PO550- Holnthoner W., PO559-MON MON PO292-WED, PO569-WED,
Heptinstall S., PO057-MON, Hezemans R., PO598-MON Holstein K., AS221, PO251-MON, PO581-WED
PO026-TUE, PO410-TUE, TUE, PO048-WED, PO594-WED, Horsuwan S., PO319-WED
Hiatt W., PO029-TUE PO595-WED PO253-TUE Horvat I., PO436-TUE Hu Z., OR039
PO518-TUE, PO492-WED Holten-Andersen L., PO590-WED Hua F., PO512-TUE, PO116-WED,
Herbig B., OR408 Hickey K., PO058-TUE Hoffman M., OR239, PO104- Horvei L., PO524-MON, PO525-
Hicks R., PO628-WED MON, PO153-MON, PO273-MON, Holthaus A., OR413 MON, PO567-WED PO266-WED
Herbreteau D., PO064-MON PO550-TUE, PO052-WED Holzhauer S., PO647-MON, Hua M., OR185
Hermanns H., AS068 Hickson N., PO667-MON Horvei L. D., AS046, PO636-WED
Hidaka Y., PO120-WED Hoffman R., PO563-WED PO195-WED Hoshi O., PO186-TUE Hua Y., PO168-MON, PO169-
Hermanns I., PO478-WED Hoffman S., AS103 Homann J., PO343-WED MON
Hermans C., AS122, OR389, Higashi D., PO305-TUE Hosokawa K., PO661-MON
Hoffmann P., PO202-WED Homeyer N., PO418-MON Huang C.-Y., PO226-TUE
PO262-MON, PO234-TUE, Higgins S., AS166 Hosokawa K., PO666-MON,
Hoffmann R., PO094-MON Hong M.-G., PO559-WED, PO564- PO668-MON, PO399-TUE, Huang Y.-J., PO050-WED
PO243-TUE, PO244-TUE, High K., OR178, PO172-MON
Hoffmeister K., OR233, AS186 WED PO347-WED, PO477-WED Huang T.-F., PO059-MON
PO280-WED, PO283-WED Higuera D., PO152-WED
Hoffmeister K., OR235 Hong W., OR101, OR388 Hostinska E., PO564-MON Huang A., PO094-TUE
Hermans C., PO273-WED Hilden I., AS019, PO454-TUE,
PO455-TUE Hofman A., AS181, OR364 Hong Z., AS146 Ho-Tin-No B., OR170, PO330- Huang C., OR419
Hermida J., PO116-TUE, PO488-
TUE Hill C., PO670-WED Hofman M., PO628-WED Hongjie W., PO129-TUE MON Huang J., OR018
Hermiston T., PO555-WED Hilliard P., PO245-TUE Hofmann A., PO202-WED Honickel M., OR067, PO314-TUE Hotta A., PO205-WED Huang L., AS087
Hermoire S., AS134 Hillis C., OR068 Hogan C., PO622-MON Hning K., PO631-MON, PO637- Hou D., PO292-WED Huang L., PO022-MON
Hogg K., OR194, OR198, PO641- MON Hou M., AS074, OR138 Huang M., AS146, OR417,
Hernandez J., PO023-TUE, Hindawi S., PO089-MON
PO242-WED MON Hood K., OR130 Hou Y., AS168, OR041 PO425-MON
Hinds M., OR049
456 457
AUTHORS INDEX
Huang Q., OR279 Huskens D., OR301, PO089- Ijsseldijk M., AS189 Isenberg D., PO044-MON, Izzi B., PO462-WED Janas M. S., AS214
Huang T.-F., PO017-TUE, PO079- MON, PO143-MON, PO072-TUE Ikeda K., OR051 PO046-MON J. Engbers M., PO565-WED Janas M. S., AS081, OR228
WED Hussain A., PO549-TUE, PO181- Ikeda Y., PO386-WED Isermann B., PO129-TUE J. M. Van Vlijmen B., PO548-WED Janata-Schwatczek K., PO612-
Huang W., OR395, PO578-TUE WED Ikemoto K., PO432-WED Isguzar G., PO591-TUE Jaax M., AS008 WED
Huang X.-P., PO522-TUE Husseinzadeh H., PO405-TUE Ikesaka R., PO467-MON, PO473- Ishigaki K., PO399-MON Jaber S., PO035-WED Jandrot-Perrus M., PO079.1-MON,
Huang Z., PO009-MON, PO013- Husted S., PO051-TUE MON Ishikawa T., PO224-TUE Jckel S., PO397-MON, PO099- OR170, OR420, OR422, PO222-
MON, PO015-MON Huston H., OR298 Ikram M., AS181, OR364 Ishola T., PO445-MON WED MON, PO330-MON, PO080-WED
Huard F., PO116-WED Hutabarat R., OR213 Ikuma Y., PO173-TUE Isik Balci Y., PO143-TUE, PO158- Jackowski M., PO035-MON Jang H. G., PO475-TUE, PO531-
Huarng M., OR039 Hutchinson J., OR272 Ikushima I., OR320 TUE Jackson C., PO099-TUE TUE, PO168-WED
Huart J., PO396-TUE Huth-Kuehne A., PO215-TUE Ilardi M., PO004-TUE Ismail A., OR413 Jackson C., PO188-TUE, PO096- Jang S., PO071-WED, PO427-
Huber K., AS200, OR123, Hutten B., PO611-MON Isola H., PO572-MON WED WED
Ilkjaer S., PO115-WED
PO185-MON, PO559-MON, Hutten B., AS021, PO164-WED Isonishi A., PO672-TUE, PO040- Jackson E., PO410-MON Jani D., PO208-TUE
Illi M., AS016
PO030-TUE, PO301-TUE, Huveneers S., AS118 WED Jackson S., AS122, OR013, Janic D., PO251-WED
Imagawa A., OR352, PO351-MON
PO509-TUE Huynh K., PO456-WED Isordia I., PO023-TUE PO235-MON, PO262-MON, Jnicke F., PO174-WED
Imai M., PO216-MON
Hubert A., PO102-WED Huynh K., PO394-MON, PO448- Isordia-Salas I., PO020-MON, PO440-TUE, PO269-WED Jankovicova D., PO249-TUE,
Imamura M., OR142 PO371-TUE, PO022-WED,
Hubler F., PO022-TUE WED PO073-MON, PO523-TUE Jackson S., AS055, OR380,
Imazu S., OR320 PO061-WED
Hudk R., PO124-MON, PO488- Hvas A.-M., PO090-MON, PO394- Israel-Biet D., AS087 PO443-WED
WED Immaculada C., PO444-TUE Jankowski V., PO465-TUE
TUE, PO406-TUE, PO407-TUE, Israels S., PO410-MON, PO408- Jackson S., OR037, PO332-MON
Hugenholtz G., OR070 Inaba H., PO161-MON, PO213- Jansen M., OR124, PO287-TUE,
PO115-WED, PO119-WED, TUE, PO006-WED, PO204-WED TUE Jacobi P., PO361-MON, PO667-
Hughes A., PO600-MON, PO601- PO121-WED, PO124-WED, Israels S., PO388-TUE MON PO442-WED
MON, PO582-TUE PO131-WED, PO495-WED Incampo F., OR065, PO503-MON Jansen M., PO258-MON, PO250-
Israels S., OR223, PO390-TUE Jacobs I., OR346, OR347,
Hughes C., PO007-WED Hvas C., PO124-WED Ince D., OR262 OR350, PO253-WED TUE
Indalecio A., PO156-MON, Israels S., PO465-MON
Hughes C., OR276, PO415-MON Hvilsted Olsen O., OR414 Jacobsen A., PO478-MON, Jansen P., PO513-WED
PO157-MON Itakura A., PO297-TUE, PO543-
Hughes C., OR183 Hwa J., PO673-MON WED PO295-TUE Jansen S., PO384-WED
Ing M., PO226-WED, PO228- Jacobsen E.-M., PO379-TUE Janssen M., PO255-TUE
Hughes K., PO675-TUE Hwang H. G., PO628-MON WED, PO230-WED Italiano J., OR085, OR232,
Hughes Q., PO324-TUE, PO540- Hwang S., PO461-TUE PO380-WED Jacobsen S., PO045-MON Janssens S., AS176
Ingelsson E., PO564-WED Janus N., PO632-WED
WED, PO546-WED Hwei Khien L., PO421-WED Ito A., PO020-WED Jacobson B., OR096, OR119
Ingratti M., PO629-MON Janzen L., PO413-TUE
Hugman A., PO374-TUE Hylek E., PO657-WED Ito B., OR354 Jacobson L., PO103-MON,
Ingratti M., PO039-MON PO662-WED Jarchum G., PO632-TUE, PO640-
Hugon-Rodin J., OR032, PO527- Hylek E., PO619-TUE Ito T., PO399-TUE
MON Inoue K., PO505-TUE Jacquemin M., PO186-MON, TUE
Hynes R., AS168 Inoue O., OR242, OR343, Ito Y., AS145, PO203-MON
Huh J.-H., PO267-TUE Hyun S. Y., PO164-TUE Ivanov I., OR288 PO364-MON, PO142-TUE Jardim L., PO034-WED
PO419-MON Jaeken J., AS187 Jrnberg I., PO195-MON
Huhtala H., PO304-MON Iacobelli M., PO374-WED Ivanov I., OR287
Intharapetch P., PO001-MON, Jaffer I., OR057 Jarner M. F., AS081, AS214
Hui D., PO172-MON Iannaccaro P., PO352-TUE, PO080-MON Ivanova A., PO496-MON
Hui J., PO529-MON, PO504-TUE PO399-WED, PO400-WED Ivanova E., PO213-MON Jaffray J., OR156, PO439-TUE Jarner M. F., OR228
Iori I., OR197
Hui S.-K., OR056, PO631-TUE Iannuccelli C., PO084-WED Ivarsson S., PO232-TUE Jagadeeswaran P., OR236, Jaron-Mendelson M., PO048-WED
Iorio A., AS122, OR144, PO170- OR402, PO034-MON
Hui Z., PO102-MON Ibarra G., PO585-MON MON, PO171-MON, PO261-MON, Ivaskevicius V., PO674-MON, Jarvis A., AS143, PO662-WED
Huish-Williams S., OR445 Ibberson M., AS128, OR397 PO262-MON, PO276-MON, PO532-WED Jahnen-Dechent W., OR286 Jarvis S., PO387-TUE
Huisman A., PO272-MON Ibrahim M., OR324 PO662-MON, PO138-TUE, Ivaskevicius V., PO182-WED, Jaimes Albornoz D., PO439-MON Jaspers Focks J., PO614-TUE,
Huisman M., PO596-MON, Ibrahim F., AS164 PO162-TUE PO184-WED Jain D., PO389-MON PO366-WED
PO587-TUE, PO619-WED Icheva V., PO667-WED Iosava G., PO206-TUE, PO262- Iversen N., OR440, PO109-MON, Jain K., OR356 Jasuja R., PO520-TUE
Huisman M., OR191, OR257, Ichinose A., OR250 TUE, PO249-WED PO118-MON, PO123-MON, Jain S., PO200-MON Jawed F., PO344-WED
PO597-MON, PO100-TUE, Ichinose C., PO432-WED Iosova G., PO629-TUE PO177-WED, PO178-WED Jakubowski J., PO015-TUE Jay G., PO112-WED
PO651-WED Iosub D., PO103-TUE Ivlev D., PO460-TUE Jalagadugula G., AS125 Jayakody Arachchillage D.,
Ichinose S., PO186-TUE
Huisse M.-G., PO080-WED Iotti M., PO602-MON Ivy S. P., OR127 Jalagadugula G., AS067 PO044-MON, PO046-MON,
Ieko M., PO041-MON, PO357- PO060-WED
Huiyuan L., AS075, OR136, MON, PO020-WED, PO057-WED Ippel H., PO037-TUE Iwaki S., PO183-MON Jallu V., PO568-MON, PO575-
OR264, PO320-MON, PO276- Iqbal A., PO420-WED Iwakiri T., PO552-MON MON Jeannette S., PO299-MON
TUE, PO566-TUE Ieraci A., PO005-TUE
Iqbal O., PO293-MON, PO303- Iwaniec T., PO048-MON, PO074- Jamaly S., PO338-MON, PO328- Jeannine Q., PO575-MON
Huk I., PO559-MON Ieran P., PO534-TUE
MON, PO053-TUE, PO191-TUE, MON, PO500-TUE, PO069-WED, TUE, PO396-WED, PO572-WED Jeanpierre E., AS134, OR219,
Hunker K., AS090 Ieven M., PO221-MON PO662-TUE
PO192-TUE, PO112-WED, PO070-WED James A., AS162
Hunt A., PO229-WED Iftikhar O., PO508-TUE PO331-WED, PO344-WED, Jego P., OR146, OR149, PO655-
Iwase H., PO306-MON James C., PO416-TUE
Hunt B., OR092, PO120-MON, Igai A., PO508-MON, PO476-TUE PO402-WED WED
Iwata M., PO173-TUE James I., PO540-WED
PO121-MON, PO603-MON Iglesias M. J., PO559-WED, Irsvt Study Investigators , AS195, Jellema K., PO363-WED
PO564-WED Iyengar S., PO363-TUE James P., AS122, OR023, OR086,
Hunt B., PO046-MON PO614-MON, PO611-TUE Iyer J., OR367, PO341-TUE AS076, PO262-MON, PO670- Jelsness-Jrgensen L.-P., PO600-
Hunt B., PO045-MON, PO578- Iglesias T., PO010-WED Irwin J., PO380-MON MON, PO678-MON, PO227-TUE, TUE
Ignatova A., PO569-MON Iyu D., PO435-WED, PO497-WED
WED Isabel T., PO444-TUE Izaguirre vila R., PO138-WED PO679-TUE, PO252-WED Jenkins V., PO280-MON
Hunter E., AS065 Ignjatovic V., AS105, OR224, Isaji S., PO486-WED James P., OR409, PO646-MON, Jenkins V., PO435-TUE
PO087-MON, PO449-MON, Izsvak Z., OR155
Hunter R., NUR014 Isaksen T., OR258, PO472-MON, PO426-TUE Jennemann-Watzka I., PO094-
PO427-TUE Izsvk Z., OR087
Hurjk B., PO530-MON PO609-MON, PO610-MON, Jamil A., PO202-WED MON
Iheanacho O., PO334-TUE PO612-MON Izumi T., AS126
Jan H. G., PO478-TUE
458 459
AUTHORS INDEX
Jennings I., OR285, OR429, Jin Y., PO555-WED Joustra R., PO614-TUE Kahr W., OR235 Kanjanapongkul S., PO540-TUE Karpova O., PO569-MON
PO095-MON, PO500-MON, Jing W., OR342 Joutsi-Korhonen L., PO363-MON Kahr W., PO545-TUE Kannicht C., PO675-TUE Karroum A., PO116-MON
PO087-TUE, PO643-TUE, Jipa L., PO501-TUE Jowett S., PO019-TUE Kahr W., AS010 Kanno N., PO061-TUE Kartvelishvili K., PO585-WED
PO524-WED Jirungda S., PO080-MON Ju A., OR037 Kaider A., PO077-WED, PO166- Kano T., PO661-TUE, PO670- Karuturi R., PO306-MON
Jennings K., PO600-MON, Jo D., OR426 Ju L., AS055 WED TUE, PO432-WED
PO582-TUE Kashiwagi H., OR340, PO320-
Jo Y. A., PO471-TUE, PO309- Juan Carlos S., PO444-TUE Kaiser K., PO383-WED Kanse S., PO109-MON, PO510- WED
Jennings L., PO174-TUE, PO076- WED TUE
WED Jude B., AS201, OR219, PO662- Kajornkijaroen A., PO675-MON Kaspereit F., OR316, PO312-TUE,
Jobic L., PO128-WED TUE Kakkar A., PO301-MON Kanse S., AS218 PO418-WED
Jennings M., PO145-MON
Jochmans K., OR079, PO668- Judge H., OR016 Kakkar A., OR436, PO378-TUE Kao M.-L., PO430-WED Kaspi E., OR315
Jenny L., PO303-TUE, PO186- TUE
WED Judicone C., OR311, OR315, Kakkar A., OR096, OR119, Kaouther Z., PO281-WED Kassam I., AS045, AS206
Johansen P., PO147-MON PO337-MON PO646-WED Kapelushmik J., PO429-TUE Kassif Y., PO217-TUE
Jenny N., OR133
Johnsen J., OR298 Juffermans N., OR124 Kakkar V., AS025, AS232, Kaplan D., PO604-MON Kassim N., PO196-MON
Jensen M., PO219-WED
Johnson A., OR200 Jugder B.-E., PO072-WED AS202, OR006, PO098-WED Kaplan S. T., PO088-WED Kassouf N., PO511-TUE
Jensvoll H., AS083, OR129,
OR293, OR345, OR393, PO526- Johnson A., OR209 Juillre Y., PO546-TUE Kakkar V., AS027, OR008, Kaplan Z., PO443-WED Kastelowitz N., AS143
MON, PO104-TUE, PO111-TUE, Johnson A., OR433, OR444 Junen J., PO191-WED OR010, PO082-MON, PO083- Kplr M., PO482-WED Kastl S., PO185-MON
PO112-TUE, PO495-TUE, Johnson B., AS054, AS011 Jung S., PO441-WED MON Kaplinsky C., PO475-WED Kastrup C., PO421-MON, PO460-
PO568-WED Johnson B., OR342 Jurak Begonja A., OR233 Kalaska B., PO300-MON, PO345- Kapocsi J., PO266-WED WED
Jeon Y. J., PO168-WED Johnson K., PO380-WED Jurii M., PO218-TUE WED, PO365-WED Kastrup C., PO372-WED
Kapoor A., PO657-WED
Jeppesen A., PO115-WED Johnson S., PO589-MON Jurk K., PO397-MON, PO427- Kalayci T., PO265-MON Kastrup C., PO375-WED
Kappelmayer J., PO077-MON,
Jeppesen A., PO090-MON Johnston E., PO623-WED, MON, PO419-TUE, PO483-WED Kalff A., OR229 PO124-MON, PO482-WED, Katayama N., PO486-WED
Jeppsson A., PO362-WED PO635-WED Jurus C., AS137 Kalina U., PO089-TUE PO488-WED Katholing A., AS084, OR294,
Jerjes-Sanchez C., OR119 Jokela V., PO234-MON Jusabani A., PO063-WED Kallner A., PO195-MON Kappert G., PO480-TUE PO124-TUE
Jern S., OR380 Joly A., PO396-TUE Justo F., PO034-TUE, PO095- Kalnins W., PO269-MON, PO305- Kapsimali Z., PO437-TUE Kato C., PO491-WED
Joly B., PO520-MON WED WED Kapubagli N., PO158-TUE Kato H., PO173-TUE
Jesel L., AS039
Jonassen C., PO311-MON Jutavijittum P., PO275-TUE Kamali F., OR099 Kapur R., OR139, PO302-TUE Kato H., OR340, PO320-WED
Jeske W., OR173, PO291-MON,
PO303-MON, PO305-MON, Jonelid B., OR312 Juthier F., AS201, OR219, Kamali-Moghaddam M., PO330- Kapustin S., PO503-TUE, PO576- Katona ., PO224-MON, PO530-
PO334-MON, PO346-MON, PO662-TUE TUE WED MON, PO031-WED, PO187-WED
Jones C., PO398-MON
PO339-WED, PO411-WED Kaaja R., PO652-WED Kamei M., OR051 Kara A., PO197-MON Katrii T., PO382-TUE
Jones D., PO464-WED
Jesmin S., PO178-MON Kaandorp S., AS021 Kamel S., AS212 Karabis A., PO656-WED Katrukha A., PO197-MON
Jones R., PO087-TUE
Jessup P., AS051 Kaasjager K., AS197, OR292 Kaminski K., PO300-MON, Karagn B., PO530-WED Katsarou O., PO169-WED
Jones R., OR285 PO345-WED, PO365-WED
Jesus J., PO158-WED Jones S., PO607-MON, PO596- Kaasjager K., PO597-MON Karagun B., PO254-TUE, PO301- Katz E., OR259
Jetsrisuparb A., PO120-TUE Kaatz S., AS077, PO623-TUE, Kaminsky P., OR186 WED, PO302-WED
TUE Katz T., PO335-MON
Jiang H., AS192, OR107 PO419-WED Kamisato C., PO353-MON, Karakukcu M., PO490-TUE,
Jonkers G., OR257 PO458-TUE Kaul I., PO337-TUE
Jiang H., OR018 Joore M., PO471-MON Kablaoui N., PO004-TUE PO008-WED Kaun C., AS200, OR123, PO185-
Kabrhel C., OR266 Kamiya N., PO088-TUE Karaman K., PO310-MON
Jiang H., AS090 Jordana Sanchez M. D. M., OR197 MON, PO559-MON, PO509-TUE
Kabukcu Basay B., PO143-TUE Kammer M., OR226, PO298-TUE Karan C., PO408-WED
Jiang L., PO195-TUE Jordi F., PO444-TUE Kaur H., OR337, PO180-WED,
Kabukcu Basay B., PO158-TUE Kammlander W., PO209-WED Karapinar D., PO630-TUE PO519-WED
Jiang M., OR117 Jordi L.-P., PO444-TUE
Kabutomori O., PO320-WED Kamphuisen P., AS195, OR195, Karapinar T., PO590-MON Kaur H., PO074-TUE
Jiang Q., PO419-WED Jorgensen L., OR230 PO626-MON
Jiang W., PO176-TUE Jorieux S., PO457-TUE Kaczor M., PO069-WED, PO070- Karapinar T. H., OR262 Kauser K., PO026-MON, PO212-
WED Kamphuisen P., PO596-MON, WED, PO213-WED, PO555-WED
Jiang Z., OR164 Jrneskog G., PO530-TUE PO587-TUE, PO624-WED Karasu A., OR391, PO565-WED
Jiaqian Q., PO394-WED Jorquera J. I., PO207-WED Kaczor M., PO048-MON Karcz A., PO657-WED Kauskot A., AS176, OR205,
Kamphuisen P., AS197, OR191, OR234, OR403, OR418
Jie W., PO113-TUE Jorritsma J., PO324-TUE, PO546- Kadegasem P., PO275-WED OR292, PO100-TUE Kare M., PO587-TUE
Jilma B., PO282-TUE, PO391- WED Kadir R., PO175-TUE Kresen R., PO177-WED, PO178- Kautbally S., PO101-WED
Kamphuisen P., PO597-MON,
TUE, PO612-WED Jose M., PO444-TUE Kadir R., PO481-TUE PO598-MON WED Kavakli K., AS122, PO257-MON,
Jilma P., PO391-TUE Kagami Y., PO434-MON Kargin V., PO503-TUE PO262-MON, PO266-MON,
Jose S. P., PO077-TUE Kamphuisen P. W., AS081, PO237-TUE, PO238-TUE,
Jimenez D., OR074, OR321, Joseph J., PO374-TUE Kagdi H., PO486-MON AS214, OR228 Karim F., OR348, PO310-WED
PO630-TUE, PO649-TUE,
PO469-MON, PO576-TUE Joseph J., PO387-TUE Kahlon P., PO650-WED Kamphuisen P. W., PO164-WED Karim F., PO541-MON PO293-WED
Jimnez D., PO488-TUE Josephson C., AS051 Kahn C. R., PO329-MON Kamphuisen P.-W., PO611-MON, Karim F. A., PO253-WED Kavakli K., OR144
Jimnez T., PO523-WED Josephson N., PO248-MON Kahn D., PO293-MON, PO303- PO335-WED Karim F. A., PO149-MON Kavardakova N., PO250-TUE
Jimnez-Alczar M., OR193, Joshi N., OR375, OR434 MON, PO337-TUE, PO374-WED Kampmann P., PO482-MON Karimi M., PO164-MON, PO490- Kaveri S., PO228-WED, PO230-
PO583-MON Kahn M., OR111 Kamstrup P., OR270 MON, PO649-MON, PO198-TUE WED
Joshi R., PO026-TUE
Jimnez-Alvarado R. M., PO073- Kahn S., AS077, AS137, OR072, Kanakura Y., OR340, PO320-WED Karkowski G., PO625-TUE Kaveri S., PO226-WED
Joung J. K., OR039
MON, PO523-TUE OR327, PO467-MON, PO473- Kanaumi Y., AS107 Karlsson J., PO219-WED
Jouni R., OR307, PO413-TUE MON, PO647-WED Kavousi M., AS181, OR364
Jimnez-Yuste V., PO250-MON Kandua Z., PO170-WED Karnaukhova E., PO196-WED
Jouppila A., PO234-MON, PO081- Kahn S., AS139 Kavtaradze G., PO337-WED
Jin J., PO429-WED Kaneko M., PO061-TUE Karner P., PO170-MON, PO171-
WED Kawabata K., OR352, PO351-
Jin M., OR362, PO588-MON Kahr W., OR159 Kanematsu T., PO434-MON MON
Jourdi G., PO350-TUE MON
Jin P., PO176-TUE Kahr W., AS078, PO403-MON, Kang S., PO115-MON Karpf D., PO219-WED
Jourdy Y., PO198-WED PO506-MON, PO379-WED Kawaguchi M., PO671-MON
Jin X., PO545-MON Kang S.-B., PO119-TUE Karpha I., PO578-MON Kawai T., AS107
460 461
AUTHORS INDEX
Kawamoto E., PO185-TUE Kempton C., OR101, AS220, Khizroeva J., PO052-MON, King M., PO098-TUE Klamroth R., OR013, PO259- Knyazev A., PO069-TUE
Kawamura S., AS107 PO251-WED PO589-WED King M., PO110-MON MON, PO195-WED, PO234-WED, Ko D., PO619-TUE, PO657-WED
Kawasaki T., PO120-WED Kenet G., OR141 Khorana A. A., AS081, AS214, King R., AS231, OR398, PO465- PO272-WED, PO274-WED, Ko K. H., PO475-TUE, PO478-
Kawashima A., PO477-WED Kenet G., AS104, OR346, PO062- OR228 TUE PO283-WED, PO291-WED TUE, PO531-TUE, PO168-WED
Kawasugi K., PO380-TUE TUE, PO217-TUE, PO285-TUE, Khorsand N., PO363-WED Kini M., OR367, PO341-TUE Klein M., PO451-WED Kobayashi K., PO411-TUE
Kawecki C., PO457-WED PO429-TUE, PO659-TUE, Kicken C., PO546-MON Kini M., OR147 Kleine E., OR283 Kobilyanskaya V., PO111-WED
PO225-WED, PO274-WED, Kiefer F., AS092, OR416 Kleinegris M.-C., PO004-WED,
Kay S., PO268-TUE PO475-WED, PO506-WED Kini R. M., PO336-TUE Koc B., PO275-MON, PO295-
Kieler H., OR269 Kiouptsi K., PO397-MON PO092-WED WED
Kaya Z., PO143-WED Kennedy D., PO450-WED Kiemeney L., OR203, PO680-TUE Kircher M., OR298 Kleinjan A., AS197, OR292, Koc G., PO490-TUE
Kayani G., OR096, OR119 Kenny D., PO676-TUE, PO075- Kieper-Rupp I., PO066-TUE PO103-TUE, PO624-WED Kocak U., PO309-MON
Kay-Jones C., PO578-MON WED Kirchhofer D., OR048
Kijrattanakul P., PO606-TUE Kleinschnitz C., OR114, PO177- Koch D., PO066-TUE
Kazanc E., PO143-TUE Kepa S., PO236-TUE, PO528- Kirchmaier C., PO248-TUE, TUE, PO517-TUE
Kazanecka B., PO311-WED WED Kilicoglu O., PO295-WED PO420-TUE Koch K., PO215-WED
Klem P., PO356-MON, PO622-
Kazankova A., PO509-WED Kernyi A., PO077-MON, PO031- Kilinc Y., PO254-TUE, PO301- Kirgner I., PO268-TUE, PO271- Koch V., PO433-TUE
MON
Kazerooni A., PO375-WED WED WED, PO302-WED, PO530-WED TUE Kochan J., PO621-MON
Klersy C., PO483-MON, PO473-
Kazimer D., PO392-MON Kerguelen A., PO487-TUE Kim B. H., PO071-WED, PO427- Kirienko A., PO199-MON Kochiashvili N., PO585-WED
WED
WED Kirk S., PO445-MON Koda T., PO351-MON
Kazimirova M., OR367 Kerlin B., OR157 Klil-Drori A., OR385
Kim D.-S., PO461-TUE Kirkby N., OR341 Kodama M., AS107
Kearney K., AS231 Kerlin B., PO571-WED Kline J., PO227-MON
Kim D.-W., PO119-TUE Kirkegaard H., PO090-MON, Koder S., AS034, PO391-WED
Kearney M., PO190-WED Kerlin B., PO237-MON Kline J., OR194, PO202-MON,
Kim H.-J., PO599-TUE PO115-WED Koder S., PO122-WED
Kearney S., OR349 Kerr B., AS093 PO490-WED
Kim H. K., PO036-MON Kirti F., PO585-MON, PO265-TUE Koehler C., PO557-TUE
Kearon C., AS077, PO378-TUE, Kerrigan S., OR043 Kline J., PO033-MON
PO646-WED Kim I., PO115-MON, PO035-TUE, Kiseleva E., PO281-TUE Koehler-Vajta K., PO236-MON
Kerrigan S., AS005 Kline J., OR376, PO627-WED
PO599-TUE, PO659-WED Kishi K., OR051
Kechele D., PO423-MON Keskindemirci G., PO315-MON, Kline J., PO469-MON Koehn J., PO152-TUE, PO201-
Kim J. H., PO119-TUE, PO489- Kishimoto M., PO434-MON WED
Kedia N., PO098-TUE PO279-WED TUE Kline-Rogers E., PO623-TUE,
Keeling D., AS077, PO653-MON Keskndemirci G., PO313-MON Kishor K., PO480-MON PO419-WED Koek D., PO584-TUE
Kim J. H., PO478-TUE Kiss A., OR328, PO475-MON
Keenan C., PO280-MON Kessler C., PO248-MON, PO277- Klinkert E., PO346-WED Koellnberger M., AS018
Kim J. Y., PO164-TUE, PO280- Kiss A., PO087-WED
Keenan R., OR013 MON, PO664-MON TUE Klok F., PO596-MON Koenen R., PO037-TUE
Keener J. M., PO038-WED Kessler C., PO294-WED Kistanova E., OR415 Klok F., OR191, OR257, PO619- Koenen R., PO091-WED, PO395-
Kim J. W., PO119-TUE, PO489-
Keeney M., PO006-MON Kessler P., PO128-TUE TUE Kitagawa K., PO477-WED WED, PO651-WED WED
Kehrel B., PO163-MON, PO218- Kestenbaum B., OR133 Kim J.-W., PO035-TUE Kitazawa J.-I., PO151-MON Kloots I., OR203, PO680-TUE Koenigsbruegge O., OR260,
WED, PO234-WED Ketatni H., PO473-TUE, PO587- Kitazawa T., PO491-MON, PO165- Klostermeier U., PO506-WED PO122-WED
Kim J. E., PO280-TUE
Kehrel B., PO157-TUE WED TUE Klw N.-E., AS136 Koentges C., OR252
Kim J. O., PO475-TUE, PO478-
Kehrel B., PO015-TUE, PO395- Kevane B., OR218 TUE, PO531-TUE, PO168-WED Kitchen D., OR429, PO087-TUE Kluft C., PO070-TUE, PO469- Kogan A., PO197-MON
TUE Key N., PO248-MON Kim K., PO115-MON Kitchen D., OR285, PO643-TUE TUE, PO550-WED, PO592-WED Kogan I., AS096
Keil R., OR047 Key N., AS049, OR306 Kim K. H., PO035-TUE Kitchen D., PO095-MON Kluin-Nelemans H., OR100, Koh H. L., PO012-TUE
Keith H., AS050 Khachatryan A., PO642-MON Kitchen S., OR429, PO087-TUE, PO346-WED Koh S.-H., PO115-MON
Kim K.-H., PO659-WED
Keith H., PO576-MON Khadour A., OR307 PO136-WED, PO141-WED Klukowska A., PO258-MON, Koh Y., PO035-TUE, PO659-WED
Kim K., PO461-TUE
Kelahmetoglu O., PO051-WED Khadwal A., PO200-MON Kitchen S., OR285, PO095- PO279-MON, PO643-MON, Kohler H., PO185-WED, PO186-
Kim M. K., PO209-TUE MON, PO201-MON, PO500- PO650-MON, PO574-WED,
Kelchtermans H., AS105, OR301, Khair K., PO662-MON, PO253- WED
Kim M.-K., PO278-WED MON, PO058-TUE, PO085-TUE, PO575-WED
PO025-MON, PO672-MON, TUE, PO286-WED Kohler H. P., PO181-WED
Kim M. S., PO628-MON PO643-TUE, PO313-WED, Klute K., AS165, PO307-WED
PO072-TUE Khalil E., PO133-WED Khler E., PO583-MON
Kim N. K., PO475-TUE, PO478- PO524-WED Knappe S., PO150-TUE, PO199-
Kelkar A., PO176-MON Khamashta M., OR092, PO046- TUE, PO531-TUE, PO168-WED Koike K., PO505-TUE
Kitching G., PO580-TUE WED, PO201-WED
Kelkar A., AS063, OR334 MON, PO068-WED Kim O. J., PO531-TUE Kojima H., PO381-WED
Kitpoka P., PO540-TUE Knaub S., PO258-MON, PO662-
Keller C., PO426-WED Khan A., PO088-MON Kim P., OR302, PO130-TUE Kojima T., PO151-MON, PO486-
Kittelson J., OR222, PO103-MON MON, PO664-MON, PO198-TUE,
Kellermann E., PO274-WED Khan M., PO324-MON TUE, PO560-WED
Kim P., OR442 Kittoe K., NUR008 PO250-TUE, PO272-WED
Kellici T., PO452-WED Khan M., PO406-WED Kokame K., OR152, PO599-MON,
Kim R., PO364-TUE Kiyoi H., PO434-MON Knight K., PO203-WED
Kelly L., PO310-TUE Khan M., PO639-WED PO040-WED
Kim S. H., PO489-TUE Kiyokawa T., PO320-WED Knbl P., PO528-WED
Kelly M., PO432-MON Khan N., PO174-MON Kokiet S., PO098-TUE
Kim S., OR115, OR184 Kizlik-Masson C., AS108 Knbl P., OR152
Kelsch R., PO015-TUE Khan S., PO384-MON Kola J., PO053-TUE
Kim S., PO429-WED Kjr B., PO455-TUE, PO541- Knoebl P., AS221
Kemball-Cook G., PO676-WED Khandagale A., PO099-WED Kolaitis N., PO551-TUE
Kim T. H., PO209-TUE WED Knofl F., PO150-TUE, PO151-TUE
Kemkes-Matthes B., PO647-MON Khandekar G., OR236, PO034- Kolbe-Scheu K., PO065-TUE
Kim U. H., PO164-TUE, PO280- Kjalke M., OR110, OR414, Knfler R., PO263-MON, PO481-
Kempe K., PO014-TUE MON Kolev K., AS004, AS152, PO207-
TUE PO147-TUE, PO219-WED WED
Khartechi A., PO292-MON MON
Kempfer A., PO003-MON, PO004- Kim Y. J., PO119-TUE, PO489- Kjelgaard-Hansen M., PO141- Knol H. M., PO346-WED
MON, PO005-MON, PO634- Khaspekova S., PO327-TUE Kolev K., PO240-WED
TUE TUE, PO285-WED Knot J., PO364-WED
TUE, PO636-TUE, PO646-TUE, Khaterchi A., PO116-MON Kollars M., PO077-WED
Kimpton M., PO101-TUE Klaassen I., OR158 Knowles R., PO085-WED
PO652-TUE, PO042-WED Khatlani T., OR277 Koller L., OR123, PO282-TUE
Kimura T., PO653-TUE Klaassen R., PO426-TUE Knuchel N., PO650-MON
Kempton C., PO248-MON, Khayat C., PO206-TUE, PO629- Kllnberger M., PO553-WED,
PO277-MON, PO297-WED, Kindzelski A., PO096-TUE Knudsen T., AS062, PO147-MON, PO554-WED, PO599-WED
TUE, PO249-WED King J., PO315-WED PO206-WED
PO298-WED Kolm A., PO151-TUE
462 463
AUTHORS INDEX
Kolek K., OR335 Koscielny J., PO356-TUE Kreimann M., OR308, PO298- Krychtiuk K., OR123, PO185- Kundur A. R., PO498-WED Lador F., PO217-MON
Kolyadko V., PO047-WED Koseoglu S., AS170 MON MON, PO559-MON, PO282-TUE, Kung C., PO374-MON Lafeber F., PO241-MON
Komanasin N., PO001-MON, Koshkina E., PO197-MON Krekeler S., PO657-MON PO301-TUE, PO509-TUE Kunikiyo Y., PO515-TUE Laffan M., AS179
PO080-MON Kosolapova S., PO026-MON, Kremer Hovinga J., PO583-MON Krylov A., PO661-WED Kunishima S., PO309-MON, Laghmani E. H., PO570-WED
Komarnicki M., PO125-TUE, PO212-WED Kremer Hovinga J., OR152, Kryzauskaite L., PO532-WED PO434-MON Lagrange J., PO031-TUE
PO170-WED Kossorotoff M., AS086 PO581-MON, PO564-TUE Ku D., PO677-MON Kupelian V., PO589-MON Laguna P., PO258-MON, PO279-
Komromi I., PO550-MON Kostadima M., PO384-WED Kremer Hovinga J., OR432 Kubicek-Hofmann C., OR144 Kuperman A., PO475-WED MON
Komarov A., PO356-WED Kostina Y., PO501-WED Kremer Hovinga J. A., OR363 Kubicka-Trzaska A., PO074-MON, Kurasawa J., AS142 Lahr B., PO645-WED
Kombrinck K., AS059 Kostina O., PO030-WED Kremers R., OR224, PO089- PO500-TUE Kurasawa J., OR163, PO196-WED Lai J., AS191, OR122
Komitopoulou A., PO437-TUE Kostousov V., OR056 MON, PO290-MON, PO072-TUE, Kubitza D., AS104 Kurata M., PO078-MON Lai Y. F., PO615-TUE, PO663-
Kommidi V., PO500-WED Kostrubiec M., PO619-WED PO004-WED Kubota C., OR051 WED
Kurdee Z., OR398
Komodikis G., PO615-MON Kostyreva M., PO535-TUE Krettler C., PO182-WED, PO183- Kuca P., PO311-WED Lail N., PO533-TUE
WED Kuriakose P., PO277-MON
Komorowicz E., AS004, PO240- Kotha J., PO174-TUE, PO076- Kudykin M., PO030-WED Kurlander J., PO623-TUE Laitinen M., PO106-TUE
WED WED Kretz C., OR361 Kuerkciyan E., PO612-WED Kurnik K., OR141 Lakdawalla D., PO287-WED
Komrska V., OR346, PO258-MON, Kotlin R., PO238-WED, PO247- Kretzler M., PO571-WED Kuhn J., PO273-MON Kurnik K., PO259-MON, PO195- Lakshman S., PO363-TUE
PO260-MON WED Kreutz R., PO607-TUE Kuhn P., PO110-MON WED, PO506-WED Lalezari S., OR011
Komvilaisak P., PO461-MON, Kotln R., PO194-TUE Kreutzer J., PO378-TUE Kuhn U., PO107-WED, PO137- Kurokawa Y., OR340 Laloy J., PO134-WED, PO142-
PO120-TUE Kotova Y., PO103-WED Kreutzer J., PO646-WED WED WED
Kurosawa S., PO564-TUE
Kondo K., PO661-TUE, PO670- Kotsi P., PO169-WED Kreuz W., PO229-TUE Kuhnt V., PO518-MON Lam J. C. M., PO430-TUE
TUE, PO432-WED Kurowski S., PO028-MON
Kottke-Marchant K., PO494-WED Krezel C., PO166-TUE Kuijk C., PO510-WED Lam L., OR216
Kondo T., OR352, PO351-MON Kurz J., PO066-TUE
Kou H., PO177-MON, PO179- Kriek N., PO398-MON Kuijpers M., OR278 Lam P., AS022
Kondo Y., PO224-TUE Kuskonmaz B., PO505-WED
MON Krilis S., PO064-WED Kuijpers M., PO155-TUE, PO452- Lam V., PO623-WED, PO635-WED
Kong F., PO009-MON Kuzminova J., PO097-MON
Kouides P., OR088 Krishnamoorthy G., PO546-MON TUE Lam W., AS167, PO438-WED
Kong M. C., PO615-TUE, PO663- Kuznetcov V., PO047-WED
Kovac M., PO547-MON Krishnan R., OR008 Kuiper G.-J., PO350-WED Lamas M., PO079-TUE
WED Kuznetsova V., PO030-WED
Kovac M., PO159-WED Krishnan U., PO542-WED Kuiper G., PO033-WED Lamb D., NUR011
Konieczny S., PO125-MON Kuznetsova V., PO028-WED
Kovac Z., PO159-WED Krishnan S., PO170-MON, Kuiper J., AS189 Lambeir A.-M., PO218-MON,
Konig S., PO131-MON PO171-MON, PO287-WED Kwak H., PO461-TUE
Kovacs M., AS139 Kuitunen A., PO304-MON Kwan C., OR373 PO219-MON, PO221-MON
Knigs C., PO308-WED Kovacs M., AS077, PO647-WED Krishnaswamy S., AS151, PO415- Kujdowicz M., PO345-WED, Kwon J.-H., PO599-TUE Lambert C., PO234-TUE, PO280-
Knigsbrgge O., PO096-MON Kovacs M. J., PO630-WED WED PO365-WED WED
Konings J., PO143-MON, PO546- Kristensen S., OR345 Kwong Y., OR011
Kovcs K., PO516-TUE Kujta N., PO616-TUE, PO491- Lambert M., OR186
MON, PO072-TUE, PO092-WED Kristensen S., OR076, OR129, TUE Kyrle P., OR135, PO298-TUE,
Kovcs K., PO087-WED PO528-WED Lambert T., OR105, OR144,
Konkle B., OR298, PO238-MON, PO104-TUE Kukongviriyapan U., PO001-MON OR346, PO488-MON, PO501-
PO568-TUE Kovalenko T., PO598-WED Kyrle P., OR226, PO077-WED
Kristensen S., PO111-TUE, Kukongwiriyapan U., PO080-MON MON
Konkle B., OR162 Koyama F., PO674-TUE PO112-TUE La Corte A., PO100-MON
Koyama S., OR352, PO351-MON Kulawig R., PO505-MON Lamberth K., OR414
Konkle B., PO260-MON Kristensen S. R., AS083, PO343- La Marca S., OR005
Koyama T., PO106-MON, PO186- Kulenthirarajan R., PO380-WED Lamblin A., PO624-MON, PO105-
Konovalov R., PO535-TUE MON La Regina M., PO610-TUE, TUE
TUE Kuliczkowski K., PO643-MON PO585-TUE, PO640-WED
Konstantinides S., PO626-MON, Kristensen S., PO407-TUE Lamblin G., PO075-TUE
Kozlowski J., PO623-TUE, Kulkarni K., AS158 Labarque V., AS078
PO513-TUE, PO619-WED Kristensen V., PO177-WED, Lamboux-Matthieu C., OR186
PO419-WED PO178-WED Kulkarni R., OR162, PO238- Labrouche S., PO398-WED
Kooistra H., OR097, OR100 MON, PO277-MON, PO618-TUE, Lambregts K., PO179-WED
Kozuka T., PO151-MON, PO486- Krogh B., PO541-WED Lacasa D., AS043
Kool M., PO094-TUE TUE, PO560-WED PO678-TUE, PO255-WED Lameignere E., PO300-TUE
Kool R., AS021 Krohne G., AS169 Kulman J., OR413 Lachmann B., PO382-MON,
Kozuma Y., PO381-WED PO502-MON, PO521-WED Lamers M., PO155-TUE
Koornneef A., PO510-WED Krokstad S., OR134 Kumano O., PO037-MON, PO041-
Kraft P., AS068, AS094, AS228, Lackner K., PO593-MON, PO099- Lammertyn L., PO071-MON
Kopec A., OR434 OR169 Krol G., PO623-TUE, PO419-WED MON, PO357-MON, PO020-WED,
WED Lmmle B., AS163, OR152,
Kopec A., OR375 Kraiss L., PO604-MON Kropacheva E., PO624-TUE, PO057-WED OR193, OR432, PO583-MON,
Korbel M., PO061-WED PO357-WED Kumar E., OR173, PO293-MON, Lackner K., PO478-WED
Kraiss L., OR243 PO593-MON, PO569-TUE,
Kordich L., PO199-TUE Kropff S., PO480-TUE PO303-MON Lacoin L., OR382, PO638-MON PO570-TUE
Krmer L., OR103 Lacolley P., OR091, PO122-MON,
Kordich L., PO533-MON Krougliak V., PO374-MON Kumar E., PO291-MON Lamotte M., PO355-WED
Krmer R., PO356-TUE PO031-TUE, PO033-TUE
Kormann J., OR235 Kruger H. S., PO210-MON Kumar R., AS160, OR157, Lamrani L., OR170, PO080-WED
Krarup J., PO219-WED Lacroix A., PO557-WED
Korobkova D., PO535-TUE Kruip M., PO623-MON, PO665- PO545-TUE Lamuraglia M., PO620-MON
Krauel K., AS008, OR125, WED Lacroix R., AS086, OR311,
Korotina N., PO118-WED OR307 Kumar S., OR066 Lamy M. T., PO107-MON
Kruip M., PO251-TUE Kumar N., PO200-MON OR315, PO337-MON, PO340-
Korporaal S., AS189, PO405- Kraul D., PO107-WED, PO137- MON Lance M., PO645-MON
MON WED Kruip M., OR013, PO267-MON, Kumari S., PO200-MON Lance M., PO143-MON, PO675-
PO282-MON, PO648-WED Lacroix-Desmazes S., PO228-
Korshunov A., PO094-TUE Krause M., PO647-MON, PO248- Kumiko K., PO108-WED WED, PO230-WED TUE
Korth-Bradley J., PO167-MON TUE, PO420-TUE Kruip M. J., PO351-WED Kumskova M., PO496-MON Lance M., AS204
Kruithof A., PO469-TUE, PO550- Lacroix-Desmazes S., PO229-TUE,
Korubo K., PO450-MON Krcova V., PO060-TUE Kun M. C., PO012-TUE PO226-WED Lanc M., PO546-MON, PO350-
WED Kunapuli S. P., OR111 WED
Korver C., PO510-MON Krege W., PO418-WED Lacut K., OR146, OR149,
Krumpholz B., PO065-TUE Kunapuli S., OR115, PO429-WED Lanc M., OR301
Koryakina L., PO054-MON Krege W., OR316, PO312-TUE OR323, PO512-MON, PO655-
Krupka U., PO137-WED Kunchithapadam S., OR367 WED
Koscielny J., PO480-TUE
Krus K., PO030-MON
464 465
AUTHORS INDEX
Lancellotti P., AS006, PO407- Lassila R., PO234-MON, PO363- Laws H.-J., OR346 Lecut C., AS006, PO407-MON, Lefkou E., PO473-TUE, PO065- Lepatan L., PO262-TUE
MON MON, PO106-TUE, PO081-WED, Layden T., PO053-WED PO396-TUE WED, PO587-WED Lepatan L. M., PO253-WED
Lancellotti S., OR202, PO007- PO162-WED Layios N., PO396-TUE Leduc M., PO572-MON Lefrant J.-Y., PO035-WED Lepercq J., PO544-TUE
MON, PO582-MON Lastrapes K., PO273-MON Lazaro E., PO416-TUE Lee A. Y., AS214 Legal G., OR055 Lepropre S., PO101-WED
Landolfi R., PO422-TUE Laterveer R., PO469-TUE, PO550- Lazarus A., PO306-TUE Lee A., OR295 Legendre P., OR205, OR219, Lequier L., PO460-MON
Landrier J.-F., PO385-WED WED Lazo-Langner A., PO577-TUE, Lee A., PO459-TUE OR333, PO658-TUE, PO662- Lerede T., AS197, OR292
Lane D., AS149, AS188, OR044, Latger-Cannard V., PO473-WED PO595-TUE, PO647-WED Lee A., OR282 TUE, PO664-TUE Leroux P. Y., OR146
AS177, PO036-WED Latini R., PO338-WED Lazzareschi I., PO582-MON Lee A. Y., AS081, OR228 Leger R., PO648-MON, PO655- Leroyer C., OR146, OR149,
Lane D., PO069-MON Latorre A., PO062-MON, PO414- Lazzari M., PO629-MON Lee A., PO375-WED TUE PO655-WED
Lane D. A., AS178, PO139-MON MON Lazzari M., PO039-MON, PO634- Lee B., PO172-MON Legnani C., PO050-MON, PO317- Leschnik B., PO453-MON
Lane P., PO132-WED Latremouille C., PO513-WED TUE, PO636-TUE, PO646-TUE, WED
Lee D., PO512-TUE Leslie B., PO138-MON, PO130-
Lang F., OR114, PO412-MON, Latysheva N., PO338-MON, PO652-TUE Leguina A., AS116 TUE
Lee E., PO119-TUE
PO449-WED PO304-TUE, PO308-TUE, Lazzari M., PO003-MON, PO004- Lehmann M., PO660-MON Leslie B., AS154, AS219, OR286,
PO328-TUE, PO329-TUE, Lee E.-Y., PO471-TUE
Lang K., OR063, PO347-MON MON, PO005-MON, PO042-WED Lei D., PO022-MON OR290, PO170-TUE
PO396-WED, PO572-WED Lee F., PO005-TUE
Langdon W., PO429-WED Le J., PO568-TUE Lei V., PO021-MON Lessiani G., PO602-MON
Lau A., PO032-MON Lee F., PO350-MON
Lange L., OR238 Le Bonniec B., PO016-TUE, Lei X., AS168, OR041 Lessire S., PO092-MON, PO063-
Lau C., PO442-MON Lee J.-O., PO035-TUE, PO119-
Lange S., PO296-MON PO350-TUE TUE, PO489-TUE, PO659-WED Lei Z., AS075, PO566-TUE TUE
Langer F., PO251-MON, PO259- Lau K., OR373, PO359-TUE, Le Cam-Duchez V., PO520-MON Leinoe E., PO482-MON Lester M., PO329-WED
PO565-TUE, PO139-WED, Lee J., OR037
MON, PO174-WED Le Cam-Duchez V., PO440-MON Lee J. H., PO164-TUE Leisinger C., PO258-TUE Letelier A., AS224
PO161-WED, PO348-WED
Langhauser F., OR114, PO517- Le Cessie S., AS138, PO601- Lee J. S., PO119-TUE Leissinger C., PO248-MON Letertre L., PO412-WED
TUE Laudat M., OR276 TUE, PO625-WED, PO641-WED,
Lee J., PO116-WED Leissinger C., PO270-MON Lethagen S., PO170-MON,
Lankeit M., PO626-MON, PO513- Lauer H., PO013-WED PO668-WED
Lee J., PO035-TUE Leite A., PO264-TUE PO171-MON, PO299-WED
TUE, PO619-WED Launay-Vacher V., PO632-WED Le Gal G., AS082, AS137,
Lee K.-W., PO119-TUE, PO489- Leite F., PO318-TUE, PO626-TUE Letourneur D., PO079.1-MON
Lannoy N., PO280-WED Laurance S., OR167 OR053, OR323, OR384, PO100-
TUE Leitgeb A., PO294-MON Letowska M., PO011-WED
Lantos I., AS025, AS232, OR006, Laurencikas E., PO530-TUE TUE, PO628-WED, PO630-WED
Lee K. S., PO164-TUE, PO280- Leiting S., PO510-TUE Leung A., PO237-MON
PO098-WED Laurent C.-E., PO081-WED Le Gal G., AS139, OR281,
PO467-MON, PO473-MON, TUE Lejniece S., PO250-MON Leung L., AS031, PO465-WED
Lanza F., AS171, PO443-MON Laurent P.-A., PO514-TUE
PO101-TUE, PO320-TUE, Lee L. H., PO529-MON, PO012- Lekovi D., PO218-TUE Leung R., OR235
Laohathai P., PO026-TUE Laurent S., PO323-TUE
PO577-TUE, PO587-TUE, TUE, PO504-TUE Lemarie C., OR167 Leunissen T., PO386-TUE,
Laporte S., OR146, OR149, Lauricella A. M., PO199-TUE PO389-TUE
PO664-WED Lee M., PO461-TUE Lembo G., PO366-MON, PO084-
PO107-TUE, PO655-WED Lauricella A. M., PO533-MON TUE Levade M., PO423-TUE
Le Goff A., PO376-WED Lee S., PO305-TUE
Laposata M., OR309 Lauritzen B., PO590-WED Lemponen M., PO363-MON Levin C., PO325-TUE
Le Moigne E., OR323, PO512- Lee S., PO311-MON
Lappegrd J., OR120, PO493- Lauten M., PO506-WED MON Lena A., PO042-MON Levinas T., PO471-WED
TUE, PO561-WED Lee S., PO461-TUE
Lautmann K., OR033 Le Moual H., PO135-MON Lena A. M., PO055-WED Levine M., PO601-WED
Lara Corrales I., PO475-MON Lee S., PO209-TUE, PO278-WED
Lauw M., OR158, OR383 Le Quellec S., PO156-MON, Lenicek Krleza J., PO436-TUE Levi-Setti P., PO483-TUE
Lrfars G., OR269 Lee T. H., PO393-WED
Laux V., PO554-WED, PO555- PO157-MON Lensing A., AS022 Levit A., PO470-TUE
Larfi Y., PO562-TUE WED Lee T., PO476-MON
Le Roux P.-Y., AS082, PO628- Lee T., PO608-TUE Lensing A., OR097, OR326 Levitan B., OR259
Larina L., PO509-WED Lauzin D., PO158-WED WED
Lee T., OR163, PO560-MON, Lensing A., AS104, AS099, Levy M., AS087
Larina L., PO019-WED Lavalle C., AS168 Leaker M., PO563-TUE OR256, OR259, OR291
PO196-WED Lewis H., PO064-TUE, PO220-
Laroche J.-P., AS137 LavendHomme R., PO186-MON Leal A. C., PO133-MON Lentaigne C., AS012 TUE, PO369-TUE, PO130-WED,
Lee W. S., PO475-TUE
Larock A.-S., PO125-WED Lavenu-Blombed C., OR025 Lebedeva T., OR305, PO405-TUE Lenting P., OR205, OR219, PO417-WED
Lee Y.-G., PO599-TUE
Laros-Van Gorkom B., OR387, Lavenu-Bombled C., PO473-WED Leblanc M., OR317 PO322-MON, PO658-TUE, Lewis M., PO291-MON
PO251-TUE, PO308-WED Leebeek F., AS079, OR021,
Laverdiere C., PO463-MON Leblebisatan G., PO254-TUE OR088, OR203, PO078-MON, PO662-TUE Lewis S., NUR014
Laros-Van Gorkom B., OR021, Laverdire C., PO165-WED Leblebisatan G., PO301-WED, PO658-MON, PO665-WED Lenting P., OR333, PO664-TUE Ley C., PO147-MON
OR203, PO502-MON, PO680- Lavery R., PO481-MON, PO588- PO302-WED, PO530-WED Lenting P., OR246, PO553-TUE
TUE Leebeek F., OR212, OR387, Lezius S., PO174-WED
TUE Lebrecht A., PO570-TUE PO069-MON, PO209-MON, Lenting P. J., AS062, OR234, Li D., PO454-MON
Laroumagne S., OR315 Lavigne G., OR095, OR188, PO267-MON, PO282-MON, PO206-WED
Lebret M., OR003 Li G., PO246-TUE
Larsen J., PO136-TUE OR190, PO035-MON PO251-TUE Lentz S., PO251-WED, PO267-
Lebreton A., PO075-TUE Li H., AS109, AS073, OR001,
Larsen J. B., PO495-WED Lavigne-Lissalde G., PO035-WED Leebeek F., AS181, OR364 WED, PO310-WED
Lebreton A., PO217-MON PO451-TUE
Larsen O., PO154-TUE Lavoie E., PO371-MON Leebeek F. W., PO651-MON, Lentz S., PO521-TUE
Lecam Duchez V., PO621-WED Li J., PO523-MON
Larsen O., PO394-TUE, PO406- Lavoie E., PO576-MON PO351-WED Lentz S., OR212
TUE Lecchi A., OR005 Li J., PO425-TUE
Lavoie E., AS050 Lecessie S., PO069-MON Leebeek F., PO665-MON Lenz M., OR123, PO301-TUE Li J., PO340-TUE
Larsson A., PO292-TUE Law L., PO014-TUE Leemans J., OR124 Leo V., AS054
Larsson K., PO141-TUE Leclerc J.-M., PO165-WED Li L., OR018
Law S., PO421-MON, PO460- Lecompte T., OR055, PO546-TUE Leenaerts D., PO218-MON, Leo V., AS124, PO517-WED Li L., PO506-MON, PO379-WED
Larsson P., OR380 WED PO219-MON, PO221-MON Leone M., PO035-WED
Laska A. C., PO530-TUE, PO171- Lecumberri R., PO516-MON, Li N., PO009-MON, PO013-MON,
Lawler P., PO014-WED PO631-WED Leers M., PO097-WED Leong L., PO026-MON PO015-MON
WED Lawrence M., PO083-TUE Lefeber D., AS187
Lecumberri R., PO116-TUE, Leong L., PO212-WED, PO213- Li R., PO348-WED
Lasne D., AS086, OR055, PO448- Lawrence M., PO156-WED Lefevre C., OR382, PO638-MON WED
MON, PO018-TUE PO488-TUE Li R., AS051, AS171
Lawrie A., PO060-WED Leony-Lasso I., PO286-WED Li R., PO006-TUE
Lasom S., PO001-MON
466 467
AUTHORS INDEX
Li R., AS147, PO070-MON, Lijfering W., OR098, PO498- Lindgren M., PO294-MON Livaja-Koshiar R., AS150 Lopez V., PO018-TUE Loures C., PO237-WED, PO479-
PO205-MON TUE, PO620-TUE, PO648-WED, Lindhoff-Last E., PO356-TUE, Livingston E., PO032-MON Lpez J., PO568-TUE WED
Li R., PO608-WED PO666-WED, PO668-WED PO480-TUE Livnat T., PO062-TUE Lpez M., PO068-TUE, PO522- Loven D., OR171
Li S., PO678-TUE Lijnen H. R., PO571-TUE Lindhout T., OR301, PO546- Livnat T., PO285-TUE, PO225- WED Lvgren K., OR040, PO141-TUE
Li T., PO321-WED Lijnen H., PO002-TUE MON, PO672-MON WED Lpez S., PO217-WED Low J., PO387-TUE
Li T.-Y., PO304-WED Likhacheva E., PO651-TUE Lindstrm C., OR061 Ljung R., AS224, AS193, PO232- Lpez L., PO538-MON Lowe A., OR285, OR429
Li T.-Y., PO265-WED Lillich M., PO397-MON Ling G., PO486-MON TUE Lopez Alonso A., PO075-WED Lowe G., AS011
Li X., PO012-TUE Lillicrap D., AS191, AS192, Ling M., PO568-TUE Ljungqvist M., PO080-TUE Lpez Andreoni L., PO056-TUE Lowe G., AS054
Li X., PO235-MON OR122, OR332, OR409, OR412, Ling W., PO382-WED, PO447- Ljungqvist M., OR269 Lopez Fernandez F., PO258-TUE Lowe G., PO492-WED
Li X., PO288-TUE AS119, PO248-MON, PO678- WED Llamas P., OR076, PO488-TUE Lopez Fernandez M. F., PO242- Lowe G., PO291-WED
MON, PO291-TUE, PO678-TUE, Linhart C., PO330-WED Llevaneras Madariaga S., PO358- MON
Li X., OR261 PO679-TUE Lowe G., PO069-MON
Li Y., AS168 Link A., PO013-WED TUE Lopez Galetti L., PO518-WED Lowe K., AS092
Lillo-Lelouet A., OR055 Linkins L.-A., PO619-MON Llinas A., PO658-WED
Li Y., OR265, PO320-MON, Lopez Ruano M. J., PO629-TUE Lowerison J., NUR011, PO003-
Lim E., PO372-WED Linn Y. C., PO012-TUE, PO074- Lliso G., OR092
PO451-TUE Lopez-Andreoni L., PO321-TUE WED
Lim E., PO375-WED TUE Lloyd J., PO504-MON
Li Y., OR249 Lpez-Andreoni L., PO375-TUE, Lowery T., PO073-TUE, PO405-
Lim G.-I., PO628-MON Lion N., PO400-TUE Lo C., PO045-WED PO407-WED TUE
Li Z., PO122-MON
Lim H., PO265-TUE Lionikiene A., PO225-MON Lo C., PO083-WED Lpez-Fernndez M. F., PO010- Lox M., AS009
Li Z., OR419
Lim H. Y., PO605-MON, PO590- Lionikiene A., AS204 Lo R., PO506-MON, PO379-WED WED Loyau S., OR170, OR420,
Liang H., PO188-TUE TUE
Liang M.-L., PO426-MON Lip G., PO325-MON, PO029-TUE Lo R., OR235 Lpez-Glvez R., OR370 PO222-MON
Lim H.-K., PO461-TUE Lip G., PO359-MON Lpez-Pedrera C., PO558-TUE Lozano J., PO552-WED
Liang Q., OR164, PO195-TUE Lobmeyer M., PO376-TUE
Lim K.-M., PO115-MON Liphardt K., PO631-MON Lpez-Picazo J., PO116-TUE Lozano M. L., PO439-MON,
Liang R., PO304-TUE, PO308- Lobo J. L., OR321, PO576-TUE
Lim W., OR068 Lippok S., OR335 Lopez-Vilchez I., PO082-WED, PO497-MON
TUE Lchen M.-L., OR267, PO638-
Lima K., PO340-WED Lis M., PO049-TUE WED PO414-WED, PO610-WED Lozano M., PO610-WED
Liang S., PO274-WED
Lima M., PO291-MON, PO054- Lisman T., OR070, OR435, Lock J., NUR004, OR387 Lorcerie B., OR186 Lozhkin A., OR305
Liang X., AS051, AS171 WED
Liang Y., PO008-TUE PO002-MON Lococo L., PO614-WED Lord J., OR121 Lozier J., OR028
Limacher A., OR193 Lissens W., OR079 Lord S., AS153 Lu E., OR380
Liang Z., AS112, PO305-TUE Lodberg Hvas C., PO131-WED
Limozin L., PO416-MON Lissitchkov T., OR144 Lordkipanidze M., AS127, PO019- Lu G., OR318, PO351-TUE
Liao H. R., PO327-MON Lodigiani C., PO483-TUE
Limperger V., PO506-WED Lissitchkov T., PO272-WED TUE Lu J.-D., PO522-TUE
Liao H.-R., PO328-MON Loeffen R., PO097-WED
Limsakun T., OR350, PO241- Lissitchkov T., OR347, PO643- Lordkipanidz M., AS054, AS011, Lu J., PO673-MON
Liao J., PO527-TUE TUE, PO262-TUE Loew-Baselli A., PO243-TUE,
MON PO244-TUE OR401, PO408-MON, PO492- Lu S., PO017-WED
Liao P., AS219 Limwongse C., PO345-TUE WED
Liaw P., PO389-MON, PO570- Lister S., OR382, PO638-MON Loewenthal R., PO192-MON Lu X., AS025, AS027, AS232,
Lin C.-Y., PO245-MON Little G., PO312-MON Lorente M., PO469-MON OR006, OR008, PO098-WED
MON Loftager M., OR110, PO219-WED,
Lin C.-H., PO327-MON Litvinov R., OR305, PO424-MON PO590-WED Lorentz C., PO177-TUE Lu Y., PO492-MON
Liaw P., AS210, PO127-MON, Lin H.-F., PO050-TUE
PO220-MON, PO324-MON Litvinov R., AS156 Loftis L., OR056 Lorenz F., PO383-WED Lu Y., OR210, PO228-MON,
Lin J., PO351-TUE Liu J., PO433-WED Loh J. L. M., PO606-MON Lorenz V., OR017, OR416 PO195-TUE, PO433-WED
Libr L., PO483-TUE
Lin L., AS146, OR417, PO425- Liu Y.-L., PO226-TUE Lohse J., PO263-MON Lorenzato C., PO034-WED Luan Y., PO009-MON
Licht C., PO589-MON MON
Lichte A., PO094-MON, PO065- Liu C.-Z., PO448-TUE Lokajczyk A., PO014-MON Lorenzato C., PO286-MON Lubetsky A., PO253-WED
Lin M., OR383 Lorenzi R., AS201 Lubetsky A., PO659-TUE
TUE, PO066-TUE Liu F., PO076-MON Loke M. Y., PO430-TUE
Lin S.-Y., PO265-WED Lorenzo A., PO608-MON, PO488- Lubich C., PO249-MON, PO160-
Lidya P., PO208-MON Liu F., PO205-MON Lombard S., PO408-MON
Lin S.-W., PO029-MON, PO031- TUE TUE, PO232-WED
Liebman H., PO311-MON, MON, PO050-WED Liu H., PO162-MON, PO132-TUE Lombardo A., AS088
PO172-WED Liu J., OR306, PO298-MON Long A., PO678-TUE Lorillon P., PO655-WED Luboshitz J., PO474-MON
Lin S.-Y., PO245-MON Loriot M.-A., OR196, PO672-WED Luca B., PO347-TUE
Liehn E., PO091-WED Liu J., OR413 Long J., OR360
Lin Z., AS146 Loroch S., PO419-TUE Lucas S., PO134-WED
Lienhart A., OR012, PO253-WED Liu J., OR018 Long Z., OR018
Lin Z., PO186-WED Loskutnikov M., PO535-TUE Lucassen W., PO583-TUE
Liesenborghs L., AS009, AS113 Liu J., OR419 Longstaff C., AS004, OR445,
Linares R., PO326-TUE Lotfi-Tokaldany M., PO090-WED Lucca P., PO441-MON
Liesner R., AS223, OR141 Liu J., OR113, OR210, PO388- PO207-MON
Linari M., PO323-MON Lotta L., OR394 Lucchelli M., PO615-WED
Liesner R., PO250-TUE WED Longue A., PO131-TUE
Linari S., AS222, PO650-TUE Lotta L., PO069-MON Luciani M., PO303-WED
Liesner R., OR389, PO243-TUE, Liu L., PO176-TUE Lnneberg T., PO525-MON,
PO244-TUE Lind C., OR071, OR392, PO594- PO567-WED Lotta L. A., AS196, OR083, Ludlam C., PO299-WED
TUE Liu L., PO318-MON
Lifshits G., PO054-MON Liu M., AS146 Lnneberg T., PO524-MON, PO197-WED Ludlam C., PO676-WED
Lind H., PO673-TUE PO636-WED Lottaz D., OR432
Light D., OR415 Liu P., PO553-WED Luengo-Gil G., OR359, PO558-
Lind K. F., PO333-WED Loomans J., OR013, OR015, Lotti L. V., PO060-MON TUE
Lijfering W., AS138, OR131, Liu Q., PO465-MON
OR135, PO522-MON, PO623- Lindahl T., PO401-TUE PO283-MON, PO308-WED Lou M., PO238-MON Luettgen J., PO349-MON
Lindahl T., PO294-MON, PO367- Liu T., AS192, OR413
MON Liu W., OR265, PO451-TUE Loomans J., PO240-TUE Loubire C., OR205, OR246, Luken B., AS178, PO669-TUE
Lijfering W., OR150, OR322, MON, PO292-TUE, PO560-TUE, Loots D. T., PO214-MON OR333, PO206-WEDLouis H.,
PO561-TUE Liu X., PO136-MON, PO137-MON Luken B., PO326-MON, PO570-
PO223-WED, PO562-WED, Lopes M., PO012-WED PO122-MON, PO031-TUE WED
PO577-WED, PO641-WED Lindahl T., PO406-MON Liu X., AS074, OR138 Loureiro J., PO321-TUE
Liu Y., OR039 Lopez A., PO491-TUE Lukowski S., PO485-MON
Lindeman R., OR185 Loures C., PO663-TUE
Liu Y.-L., PO289-WED Lopez M. J., PO206-TUE, PO249- Lukowski S., AS002
Linden L., PO555-WED WED
Liu Z., OR415 Lumelsky G., PO079-TUE
468 469
AUTHORS INDEX
Luna R., PO484-TUE Macek B., PO412-MON Magy-Bertrand N., OR186 Malfliet J., PO665-MON Mann K., PO248-MON, PO576- Marcucci R., OR253, OR396,
Lundberg A., PO588-MON Machado E., PO158-WED Mahajerin A., AS161, OR156 Malfliet J., PO209-MON MON, PO467-TUE, PO425-WED OR400, PO067-MON, PO365-
Lunde K., OR251 Machan L., PO375-WED Mahaklan L., PO540-TUE Malhotra P., PO200-MON Mann K., AS050 MON, PO366-MON, PO020-
Lundin B., OR388 Machin S., PO132-WED Mahan C., PO521-MON Malinowska I., PO575-WED Manne B. K., PO429-WED TUE, PO024-TUE, PO039-TUE,
Manne B., OR111 PO071-TUE, PO076-TUE,
Lundstrm A., PO530-TUE Machin S., OR154, PO044-MON, Mahapatra M., OR066, PO316- Malinowsky J., OR318 PO365-TUE, PO094-WED
Lunghi B., OR050, OR333, PO046-MON MON, PO480-MON, PO272-TUE, Malins L., PO007-WED Mannens E., PO290-MON
PO529-WED Mars P., OR095, OR188, OR190
PO555-TUE Machin S., PO060-WED Malisauskas M., PO160-TUE, Mannhalter C., PO236-TUE
Mah I., OR381, PO620-MON, Margaglione M., AS222, PO511-
Luo C., OR018 Machlus K., OR085 PO232-WED Mannherz H., PO583-MON MON, PO513-MON
Luo D., OR279 Machlus K., PO380-WED PO103-TUE, PO105-TUE, Malmstrom R., PO412-WED Manni G., AS199, OR208, OR399
PO632-WED Margaret H., PO153-WED
Luo M., AS147, PO070-MON, Machovich R., PO240-WED Malmstrm R., PO368-MON, Manning C., PO168-TUE Margaritis P., OR178
PO205-MON Machuca M., PO579-MON Mahjoub S., PO528-MON, PO360-TUE Manning N., PO616-WED
PO062-WED Margolis J., PO625-MON
Luo P.-L., PO247-MON, PO216- Mackay E., PO003-WED Maloney D., AS183 Mannini L., PO071-TUE, PO365-
TUE, PO009-WED Mahlangu J., OR348, PO239- Marhic G., OR146
Mackie I., PO044-MON, PO046- Maloney J., PO418-TUE TUE
Luo X., PO222-WED MON, PO248-MON, PO227- Mariani A., PO066-MON
MON TUE, PO257-TUE, PO258-TUE, Malouin R., PO618-TUE Mannucci P., PO245-WED
Lupu A., PO474-WED Mariano D., PO179-TUE
Mackie I., OR154, PO060-WED, PO262-TUE, PO252-WED, Maloum K., PO128-WED Mannucci P., OR270
Lurie B., PO368-TUE PO064-WED, PO132-WED Mariem A., PO281-WED
PO310-WED Maltese T., PO060-MON Mannucci P. M., PO649-MON
Lurz E., PO485-MON Mackman N., AS049, OR047, Mariem M., PO281-WED
Mahlangu J., PO293-WED Malvar J., PO439-TUE Mannucci P. M., PO164-MON
Lscher T., PO027-MON OR239, PO322-MON Marigo L., PO671-WED
Mahmoud Hourani Soutari N., Malvestiti M., OR399 Manoj N., PO342-TUE
Lushchekina S., PO496-MON Maclean R., PO313-WED Mariko B., PO437-WED
PO228-TUE Maly R., PO469-MON Mansfield A., OR127, PO449-
Lusher J., PO248-MON Macmullan P., PO437-MON TUE, PO508-TUE, PO157-WED Marin A., PO321-TUE, PO445-
Mahmoudi M., PO323-TUE Mammadova-Bach E., PO079.1- TUE
Lusty D., PO344-MON Macoura G., PO542-MON Mahner S., PO174-WED MON, AS095, OR420 Mansouri M., OR152
Macrae F., OR433, OR444 Marn A., PO056-TUE, PO375-
Lutter R., PO335-WED Mahoney Jr D., PO644-TUE Mammen S., AS122, PO262-MON Mant T., OR213 TUE, PO407-WED
Lutters B., AS189 Macri F., PO035-MON Mahuad C., PO373-MON Mamopoulos A., PO065-WED Mantiero M., PO115-TUE Marn N., PO435-WED
Luttun A., AS176 Macwan A., PO401-TUE Maigrat C.-H., PO546-TUE Man C., OR390 Mantovani L., OR119, PO607- Marn Atucha N., PO497-WED
Lutz P., OR143 Madan B., PO559-TUE, PO633- Maino A., OR255, PO069-MON, Managhchi M. R., PO600-WED TUE
TUE Marinaro A., PO585-TUE
Luyendyk J., OR434, PO125-MON PO574-TUE, PO090-WED, Manai Z., PO528-MON Manzella S., PO140-WED
Maddur A., OR423 Marn-Atucha N., PO229-MON
Luyendyk J., OR375 PO633-WED Mancic T., PO128-WED Mao G., AS125
Maden M., PO043-TUE Markova I., PO057-TUE
Lv C., OR265, PO451-TUE Mairuhu R., OR257 Mancini I., PO580-MON, PO592- Mao P., PO432-MON
Madigan A., PO437-MON Marks R., OR128
Lv M., OR001, OR265, PO451- Matre B., PO606-WED MON Maragoni G., PO072-MON,
Madison E., OR247, OR299 PO027-TUE Markusic D., OR107, PO148-MON
TUE Majeed A., OR061, OR069, Manco-Johnson M., OR431,
Madison E., PO597-WED PO297-MON, PO355-TUE PO662-WED Marandiuc D., PO570-TUE Markway B., AS209
Ly H., OR299
Madlener K., PO296-MON Majek P., PO238-WED Manco-Johnson M., OR222, Maraveyas A., OR175, PO553- Marlu R., PO131-TUE
Lyapina L., PO206-MON, PO073-
WED Madrid I., PO062-MON Majewski J., PO625-TUE PO103-MON, PO285-MON MON, PO555-MON, PO556-MON, Marlu R., PO223-MON, PO159-
Manco-Johnson M., PO260-MON PO557-MON, PO558-MON, TUE, PO241-WED, PO422-WED,
Lyle M., OR109 Madridano O., PO608-MON Majluf A., PO023-TUE, PO242- PO593-WED
Lynam C., OR213 Madroal Cerezo E., PO485-TUE WED Mancuso E., PO164-MON PO110-TUE, PO127-TUE
Marchais S., PO033-TUE Marongiu F., PO674-WED, PO675-
Lynch C., AS188 Madsen D. E., PO046-TUE Majluf-Cruz A., PO020-MON, Mancuso M., OR013, OR108, WED
Lyons C., OR042 Madsen J., OR237 PO073-MON, PO523-TUE OR348 Marchena P. J., OR381
Marchesini E., PO370-MON, Marosi C., OR357, PO166-WED
Lyons M., PO435-TUE Maeda T., AS107 Majoor C., PO611-MON, PO335- Mancuso M. E., AS222, OR214,
WED OR346, PO091-MON, PO090- PO423-WED Marquardt N., OR103, PO674-
Lysaja K., PO465-TUE Maejima T., PO203-MON MON, PO219-TUE, PO256-TUE,
Majumder R., OR280, OR366, TUE, PO091-TUE, PO114-WED, Marchetti G., OR050, OR080
Lysov Z., PO127-MON, PO324- Maekawa K., PO178-MON PO197-WED, PO260-WED, PO532-WED
AS182, PO155-MON Marchetti M., PO339-MON,
MON Maes P., PO650-MON PO273-WED Marquart A., OR441
Makatsaria A., PO548-MON, PO179-WED
Ma D., PO068-MON Maffei F., PO184-TUE, PO054- Mancuso S., PO117-TUE, PO614- Marques A. P., PO286-MON
PO122-TUE, PO173-WED Marchetti M., PO438-TUE
Ma J., PO319-MON WED WED Marques-Verdier A., PO075-TUE
Makatsaria A., PO008-MON Marchewka M., PO549-MON
Ma J., OR140, PO317-MON Magafa V., PO452-WED Mandelbaum T., PO217-TUE Marschang P., AS197, OR292
Makatsariya N., PO052-MON, Marchi R., PO187-MON
Ma K., PO647-WED Magdelaine A., PO045-TUE PO589-WED Maneyro A., PO043-MON Marsden K., PO366-TUE
Marchini F., PO585-TUE
Ma L., AS168 Maggini N., PO586-WED Makhaldiani L., PO585-WED Manganaro D., OR115, PO450- Marsh J., PO201-TUE
Marchula B., PO152-TUE
Ma M., OR295 Maggiolo S., PO061-MON, Makhoul S., OR091 TUE Marsh J., PO476-MON
PO456-MON, PO315-TUE, Marck B., PO557-WED
Ma P., AS185 Mkipernaa A., PO308-WED Mangin P., PO079.1-MON, Marshall A., OR031
PO524-TUE Marco A., PO051-MON
Ma T., PO036-TUE Makris M., AS124, OR144, AS095, OR420 Marshall A., PO601-WED
Magi A., OR270 Marco P., PO051-MON, PO488-
Maas A., PO221-MON PO517-WED Manglani M. V., PO164-MON TUE Marsman G., PO326-MON
Maas C., OR153, PO178-TUE Magnani J., PO593-TUE Mangles S., PO220-TUE, PO369- Martageix C., PO568-MON,
Makris M., AS054, PO500-MON, Marcone S., PO063-MON
Maas Enriquez M., OR011, Magnenat S., PO606-WED PO643-TUE, PO524-WED TUE, PO009-WED PO575-MON
Magniez A., PO376-WED Marcos-Contreras O., AS032
OR214, PO293-WED Malan D., PO266-WED Manguiat J., PO617-WED Marten S., AS098, PO636-MON
Magnusson M., PO432-TUE, Marcos-Contreras O. A., OR178
Macbeth F., OR130 Malato A., PO611-TUE Manina G., PO373-WED Mrtensson A., AS224, PO232-
PO443-TUE Marcucci M., PO261-MON
Maccallum P., PO660-WED Malcangi G., PO671-WED Mankai J., PO566-TUE TUE
Macchi S., PO264-MON Magrini N., PO674-WED, PO675- Mankowski J., OR042 Marti A., PO621-TUE
Male C., AS104, OR346, PO253-
Macdonald D., AS054 WED Mann K., PO371-MON, PO129- Marti E., PO474-TUE
WED, PO308-WED
Macdonald T., AS158 Magro E., PO487-TUE WED
470 471
AUTHORS INDEX
Martin A.-C., PO016-TUE, PO350- Marx N., PO465-TUE Matsumoto M., OR152, PO661- May F., PO152-MON, PO411- Mcgeehan E., PO411-WED Meijer K., AS197, OR015,
TUE Marx P., OR441 TUE, PO672-TUE, PO674-TUE, MON Mcglasson D., PO403-WED OR021, OR097, OR100, OR203,
Martin E., PO273-MON Masahiro A., PO108-WED PO040-WED May J., PO057-MON, PO026- Mcgregor A., PO420-WED OR292, OR387, PO651-MON,
Martin F., OR360 Matsumoto N., PO515-TUE TUE, PO410-TUE, PO518-TUE, Mcgregor C., NUR001, PO376- PO658-MON, PO251-TUE,
Maschan A., PO503-WED PO346-WED, PO363-WED
Martin K., PO673-MON Matsumoto T., PO486-WED PO492-WED MON
Maschan A., PO496-MON Meijer P., PO208-WED
Martin M., AS137 Matsumoto T., PO652-MON, May L., PO083-WED Mcgregor S., PO374-TUE
Mason J., PO653-MON Meijers J., AS035
Martin S., PO512-TUE PO666-MON, PO668-MON, Mayer E., PO513-TUE Mcgregor S., PO098-MON
Masotti L., PO626-MON, PO373- Meijers J., OR441, PO522-MON,
Martn Daz R. M., PO485-TUE WED PO165-TUE, PO018-WED, Mayeur D., PO105-TUE Mcindoe N., PO220-TUE
PO113-WED, PO347-WED Mayfield J., AS112 PO335-WED, PO582-WED
Martin Toutain I., PO128-WED Massaro F., PO200-TUE Mcintosh K., PO269-WED
Matsumoto Y., PO193-TUE Mayger K., AS133, PO666-TUE Meijers J., PO294-MON, PO510-
Martinelli I., AS022, AS196, Massefski W., PO405-TUE Mckenzie S., AS108, PO429-WED MON, PO352-WED
OR083, OR270, OR394, PO611- Matsumura N., PO351-MON Mayo K., PO037-TUE Mckinnon T., AS179
Massicotte P., AS104, PO455- Meijers J., AS153
TUE, PO176-WED, PO245-WED, MON, PO460-MON, PO083-WED, Matsunari Y., PO671-MON Mazepa M., OR162 Mcknight B., PO557-WED
PO583-WED, PO633-WED Matsuno K., PO455-WED Mazet B., PO579-TUE Meijers J., PO323-TUE, PO164-
PO511-WED Mcloughlin A., OR043 WED
Martinelli N., OR050, OR080, Massimi I., PO060-MON, PO084- Matsuoka H., PO399-TUE Mazetto B., PO190-MON, PO422- Mcmaster J., PO676-MON
PO554-TUE, PO555-TUE Matsushita F., PO661-TUE, MON, PO531-MON Mein C., PO284-MON
WED, PO316-WED Mcmichael I., PO670-WED
Martinelli P., PO513-MON PO670-TUE Mazharian A., AS069, OR401, Meiring M., PO657-TUE
Massimo M., OR350 Mcmillan-Ward E., OR223,
Martinez C., AS084, OR294, Matsushita K., PO173-TUE PO377-WED, PO434-WED Meister A., PO144-TUE
Masson S., PO338-WED PO390-TUE
PO124-TUE Matsushita M., AS068 Mazoyer E., PO440-MON Mekkaoui C., PO035-MON
Mastbergen S., PO241-MON Mcmullen A., PO369-TUE,
Martinez C., PO639-TUE Matsushita T., AS017, PO434- Mazur J., PO478-WED Mlac S., OR146, OR149
Mastenbroek T., AS204, PO349- PO417-WED
Martinez M., PO441-TUE TUE MON, PO491-WED Mazurov A., PO327-TUE Melazzini F., PO473-WED
Mcnicol A., OR223, PO410-MON,
Martnez C., OR221, OR440, Mastrangelo S., PO582-MON Matsuura Y., PO552-MON Mazutis L., OR232 PO408-TUE Melazzini F., PO438-MON
PO558-TUE, PO539-WED, Masuda Y., PO455-WED Matsuya H., OR352, PO351-MON Mazzeto B., OR094, PO066-WED, Mcphelim J., PO098-TUE Meldau J., PO381-MON
PO549-WED, PO552-WED Mata M., PO487-TUE Mattheij N., AS141, AS140 PO067-WED Mcpherson H., PO466-MON Melero-Amor A., PO229-MON,
Martinez De Lizarrondo S., AS032, Mattheij N., PO411-MON, PO499- Mazzolai L., AS137 PO497-WED
Matafonov A., OR287, OR288 Mcpherson H., AS155
AS117, OR314, OR379, PO532- MON Mazzucconi M., PO283-MON Melinscak H., PO274-TUE
TUE, PO370-WED Matheus M., PO034-TUE, PO095- Mcphillips P., PO603-TUE
WED Matthew P., OR144 Mazzucconi M., PO243-TUE, Melissant C., OR257
Martnez Daz V., PO485-TUE Mcrae S., OR013, PO468-MON,
Mathew J., PO374-MON Matthews D., PO248-MON PO244-TUE PO618-MON, PO633-MON Melton L., OR213
Martnez Martnez I., PO497-MON Matthiessen P., PO232-WED Mazzucconi M., OR027 Men S., PO604-MON
Mathew P., PO261-TUE, PO252- Mcredmond K., PO248-MON
Martinez-Martinez I., OR368 WED Mattsson E., PO297-MON Mazzucconi M. G., PO200-TUE, Mena A., PO012-MON
Mcvey J., PO196-WED, PO353-
Martnez-Martnez I., AS187, Mathias M., AS159, OR104, Matveeva E., PO611-WED PO259-TUE, PO654-TUE, WED Mena H., AS173
OR076, OR359, OR370, PO336- OR145, OR386 Matvienko O., PO367-TUE PO534-WED Menapace B., OR173
MON, PO338-TUE Mcvey J., PO676-WED
Mathiesen E., AS046, OR120, Matysiak M., PO279-MON, Mbemba E., PO116-MON, Man M., OR193 Mendek-Czajkowska E., PO648-
Martinez-Perez A., PO543-MON OR254, PO561-WED PO574-WED PO292-MON TUE
Martin-Fernandez L., PO543-MON Medcalf R., OR380
Mathiesen E., OR075 Matysiak M., PO575-WED Mc Grath A., PO003-WED Mendoza-Valdz L., PO523-TUE
Martini G., PO622-TUE Meddeb B., PO650-MON
Mathiesen E., OR267, PO638- Matytsina I., PO251-WED, Mc Guckin S., PO567-TUE Mendoza-Valz L., PO073-MON
Martinod K., AS180, PO321- Medina C., PO474-TUE
WED PO267-WED Mcalister S., OR298 Menegatti M., OR039, PO500-
MON, PO329-MON, PO089-WED Medina P., OR076, PO093-MON,
Mathiesen E., OR071, OR293, Matzdorff A., PO110-TUE Mccarthy G., PO437-MON PO534-MON, PO536-MON, MON, PO502-MON, PO503-MON,
Martinoli C., PO256-TUE OR392, PO594-TUE Mauler M., OR252, PO404-TUE Mccarty O., AS209, PO010-MON, PO521-WED, PO524-WED
PO344-TUE, PO558-TUE
Martinowitz U., OR347 Mathiesen L., PO379-TUE Maurer G., AS200, OR123, PO297-TUE Meng F., OR331
Medina S., PO286-MON
Martin-Rodriguez S., PO184-MON, Mathiesen Hald E., PO329-TUE, PO185-MON, PO282-TUE, Mccarty O., PO411-MON Menino E., PO375-TUE
PO187-TUE Medina S., PO296-WED
PO396-WED PO301-TUE, PO509-TUE Mccarty O., PO110-MON Medved L., OR371 Menown I., PO638-MON
Martins G., PO340-WED Mathieu O., PO223-MON, PO340- Maurer M., OR372 Mccarty O., OR049, PO432- Mensink D., PO078-MON
Martins J., PO261-WED Meehan B., PO393-WED
MON, PO422-WED Maurice P., PO457-WED MON, PO440-WED, PO453-WED, Merah A., PO107-TUE, PO631-
Martins M., PO313-TUE PO543-WED Meeks S., AS190
Mathieu DArgent E., PO473-TUE Mauser-Bunschoten E., PO665- WED
Martins-Filho O., PO231-MON, Mccarty O., AS129, OR353, Meesmat W., PO613-WED
Mathot R., PO372-MON MON Meral Gune A., PO156-TUE
PO333-MON, PO135-TUE PO177-TUE Mege J.-L., PO322-MON
Matht R., OR387, PO251-TUE Mauser-Bunschoten E., AS079, Meral Gne A., PO268-MON
Martinuzzo M., PO068-TUE, OR021, OR102, OR203, PO658- Mccleary R., OR147 Megiddo E., PO285-TUE
Matilla S., PO038-MON Mercanti C., PO654-TUE
PO522-WED MON Mccluskie K., OR247, OR299 Mehla S., PO533-TUE
Matino D., PO162-TUE Mercer S., PO490-WED
Martn-Villar E., OR359, PO336- Mauser-Bunschoten E., PO283- Mccormick A., PO418-TUE Mehmood T., PO037-WED
Matos R., PO442-MON Merchn B., PO375-TUE
MON MON Mccormick N., PO170-MON, Mehta A., PO306-MON
Matsubara J., PO001-TUE Mercier E., OR095, OR188,
Martlew V., PO578-MON Mauser-Bunschoten E., PO308- PO171-MON Mehta D., PO260-TUE OR190, PO035-MON
Matsubara Y., PO386-WED
Martos L., PO093-MON, PO534- WED Mccrae K., AS049 Mei H., PO177-MON, PO179- Mercier G., PO535-MON
MON, PO536-MON, PO344-TUE Matsuda S., PO552-MON MON
Mavri A., AS101, PO360-TUE Mcdonald E., NUR007, PO355- Mercuri M., OR199
Marturano A., OR399 Matsui H., PO671-MON, PO205- Meijer A., PO352-WED
WED Mavromatidis G., PO065-WED MON, PO389-MON, PO392-MON Mergemeier K., PO015-TUE
Marturano J., PO405-TUE Mavromoustakos T., PO452-WED Mcdonald L., PO368-TUE Meijer A., AS058, AS121,
Matsui T., PO661-TUE, PO670- PO510-WED Merlen C., PO165-WED, PO282-
Maruotti G., PO513-MON TUE Mawri S., PO541-TUE Mcdonald V., PO603-MON WED
Maruyama I., PO399-TUE Maxeiner S., PO465-TUE Mcdonnell C., OR043 Meijer A., PO227-WED
Matsumoto A., PO557-WED Merlin S., AS088, OR106,
Maruyama K., PO599-MON Maximova M., PO535-TUE Mcfadyen J., OR229, PO443-WED Meijer K., PO665-MON OR161, OR411
Maruyama M., PO320-WED Mcgaffin G., PO210-WED Mermillod B., AS137
472 473
AUTHORS INDEX
Merricks E., AS120, OR178, Michaela S., PO199-WED Miano A., AS187, OR076, Mitra S., PO446-MON Molinari A. C., AS104 Moons K., PO583-TUE, PO584-
PO048-WED Michalski F., AS098, PO636-MON OR370, PO552-WED Mitrovic M., PO218-TUE, PO547- Molinari C., PO303-WED TUE
Merricks E., PO046-TUE Micheal H., PO182-WED, PO183- Minet V., PO269-TUE, PO134- TUE Moll F., PO386-TUE, PO389-TUE Moore D., PO019-TUE
Merriman E., PO468-MON, WED WED Mitrugno A., PO110-MON Molle R., PO072-MON, PO027- Moore D., PO431-WED
PO618-MON Micheau M., OR143 Ming Z.-Y., PO426-MON Mittler K., PO457-MON TUE Moore G., AS133
Mertens K., AS058, AS121, Michels A., PO291-TUE Mingen L., PO566-TUE Miyakoshi Y., PO377-MON Mollnes T., PO308-TUE Moore G., PO037-MON, PO418-
PO510-WED Michelson A., PO457-MON, Mingen L., AS075, OR264 Miyamoto D., PO178-MON Mollnes T. E., PO304-TUE TUE, PO633-TUE
Merz M., PO296-MON PO458-MON, PO021-TUE, Mingot Castelano M. E., OR144 Miyata S., AS107, OR051 Molloy C., AS184 Moore G., PO666-TUE
Mesa E., PO579-WED PO402-TUE, PO476-WED Mingot-Castellano M. E., PO252- Miyata T., PO599-MON, PO040- Molnr ., PO530-MON, PO031- Moore J., AS114
Meschengieser S., PO646-TUE, Michener M., PO074-WED WED WED WED Moore R., PO476-MON
PO652-TUE Michiels J. J., AS133, PO655- Mingozzi F., PO158-MON Mizote H., PO216-MON Moloney E., PO019-TUE Moore S., OR112, OR275,
Meschengieser S., PO039-MON MON, PO666-TUE Minhas A., PO419-WED Mizrahi T., OR217 Momi S., AS174, AS199 PO428-MON, PO461-WED
Meschengieser S. S., PO629-MON Michos E., OR133 Minici R., PO352-TUE, PO399- Mizugaki A., PO178-MON Momot A., PO150-WED Moore S., OR272
Meshksar A., PO490-MON Mickelsen D., PO032-TUE WED, PO400-WED Mizurini D., PO068-MON Monagle P., AS104, AS105, Moorehead P., AS191, PO426-
Messaoudi K., OR082 Micovic D., PO080-TUE Minns I., OR382 Mizurini D., PO133-MON OR224, PO087-MON, PO449- TUE
Messas N., AS039 Middeldorp S., AS021, OR035, Minoldo S., OR431, PO632-TUE, Mizutani N., PO151-MON, MON, PO607-MON, PO427- Moorlag M., PO025-MON
Messer A., PO165-MON OR118, OR199, OR326, PO045- PO640-TUE, PO518-WED PO486-TUE TUE, PO432-TUE, PO596-TUE, Moorthy V., OR382
Messi G., PO433-TUE MON, PO372-MON, PO510-MON, Minon J.-M., PO373-TUE Ml K., PO153-WED PO500-WED Mor E., PO001-WED
Messina M., AS088, AS222 PO514-MON, PO537-MON, Minton A., OR356 Monahan P., PO166-MON Moraes E., PO189-TUE, PO002-
Mlakar U., PO181-MON
PO353-TUE, PO498-TUE, PO506- Mintova S., PO323-TUE Monahan P., PO032-MON, WED, PO023-WED
Mesters R., PO506-WED TUE, PO507-TUE, PO525-TUE, Mo M., OR028
Minuz P., PO473-WED PO052-WED Moraes L., PO398-MON
Metcalf Pate K., OR042 PO409-WED, PO582-WED Mo X., AS051, PO176-TUE
Miolo M., PO077-TUE Monahan P., OR162 Morag I., PO659-TUE
Metcalfe C., PO065-MON Miesbach W., PO269-MON, Moake J., AS213
Mir E., PO184-MON, PO189- Mondal N., OR338 Morais K., PO107-MON
Metharom P., PO395-MON PO657-MON Mobarrez F., PO392-WED
MON, PO191-MON, PO187-TUE Mondon P., PO311-TUE Morais S., PO442-MON, PO318-
Metreveli B., PO277-TUE, PO337- Migita K., OR051 Modjeski K., OR241
WED Mira Y., PO536-MON, PO579- Mondoro T., PO096-TUE TUE
Migliaccio L., PO602-MON, Modjeski K., PO032-TUE
Metzner H., PO089-TUE WED Monia B., AS059 Moraleda J. M., PO497-WED
PO627-MON, PO317-WED Modrau I., PO121-WED
Metzner H., PO146-TUE, PO194- Miranda A., PO054-WED Monia B., AS219, OR049, OR286 Morandin S., PO385-MON
Migliorini A., OR400 Moenen F., PO123-WED, PO609-
WED Mirgal D., PO207-TUE WED Monje D., PO607-TUE Morange P.-E., AS045
Migliorini M., PO493-MON
Meunier J., OR349 Mironova N., PO294-TUE Moerland M., PO469-TUE, Monkman J., OR044 Morange P., OR012
Mihaljevic B., PO121-TUE
Meunier S., OR346 Mirsadeghi S., PO323-TUE PO550-WED Monreal M., OR074, OR381, Morange P., AS014, PO441-MON,
Miklosz J., PO300-MON
Meurs I., AS189 Mirshahi S., PO117-MON, Moerland M., PO592-WED PO469-MON, PO608-MON, PO443-MON, PO493-WED,
Mikovic D., PO502-MON, PO228- PO631-WED
Meusy A., PO653-WED PO119-MON Moffatt L., OR426 PO559-WED, PO564-WED
TUE, PO521-WED
Mirshahi M., PO117-MON, Monroe D., PO426-WED Morange P.-E., AS206, OR266,
Mewburn J., OR412 Mikrut K., PO049-MON Mogielnicki A., PO300-MON,
PO119-MON, PO299-MON PO345-WED, PO365-WED Monroe D., OR239, OR319, OR324, PO263-TUE
Mewburn J., PO291-TUE Mikuska Z., PO376-TUE PO153-MON, PO273-MON,
Mirshahi S., PO299-MON Mogilevets A., PO147-WED Mor-Cohen R., OR289
Meyaard L., OR401 Milan M., OR027, OR030, PO550-TUE, PO052-WED
Mirzoyev T., PO579-MON, PO274- Mognato G., PO225-TUE Moreira L., PO626-TUE
Meyer G., AS214 OR326, PO225-TUE, PO303-WED Montague S., PO415-MON,
TUE Moreira M., PO333-MON
Meyer G., AS081, AS082, OR146, Miles L., AS203 Mohamadi A., PO014-MON, PO289-TUE
OR149, OR192, OR228, PO103- Misgav M., PO217-TUE PO122-MON, PO031-TUE Moreira P., PO002-WED
Milesi V., PO622-TUE Montague S., PO393-TUE
TUE, PO201-TUE, PO655-WED Mishra P., OR066, PO480-MON, Mohamed A., PO089-MON Moreira R., PO318-TUE
Milic N., PO121-TUE PO272-TUE Montalvo S., PO145-WED
Meyer T., PO445-WED, PO446- Mohamed S., OR186 Morel J., PO263-TUE
Miljic P., PO252-MON, PO547- Misky G., PO377-TUE Montalvo S. A., PO286-MON
WED MON, PO235-WED Mohammed B., PO273-MON Morel J., PO035-WED
Mismetti P., OR012, OR146, Montaner J., OR314 Morel O., AS039
Meza L., PO616-TUE Milji P., PO218-TUE Mohammed N., PO099-MON
OR149, OR196, PO262-WED, Montani N., OR030 Morel-Kopp M.-C., OR002,
Mezei Z., PO224-MON Milln J., PO435-WED Mohand-Oumoussa B., AS014
PO655-WED Monteiro C., PO212-TUE PO433-MON, PO421-TUE
Mezei Z., PO187-WED Milln J. E., PO497-WED Moharir M., PO118-TUE
Misselwitz F., OR119 Monteiro R., PO068-MON Morell D., PO441-TUE
Mezouar S., PO322-MON Miller D., PO657-WED Mohr F., PO169-TUE
Missiakas D., AS113 Monteiro R., PO133-MON Morell M., PO514-WED
Mezzano D., AS116, OR220, Miller J., PO192-WED Moiemen N., OR121, PO393-
PO466-WED, PO472-WED, Mistretta C., PO656-MON, Montermini L., PO393-WED Morelli B., OR093, PO126-WED
Miller J., PO049-MON, PO025- PO090-TUE, PO091-TUE TUE
PO480-WED Montero Hernndez C., PO485- Morelli V., PO577-WED
WED Miszta A., PO672-MON Moiz B., PO384-MON, PO539- TUE
Mezzapesa A., AS014, PO385- Miller M., AS110 MON, PO468-WED Morelli V., OR150
WED Mitchell J., OR341 Montes R., PO488-TUE
Miller W., AS059 Mokhtari D., PO563-MON Morenghi M., PO483-TUE
Mezzasoma A. M., OR336 Mitchell J., PO189-WED Montgomery R., PO222-WED
Milling, Jr T., PO319-TUE Molden E., PO379-TUE Moreno M., PO487-TUE
Miah I., PO363-WED Mitchell K., PO450-WED Montgomery R., OR089, OR204,
Mills R., PO521-MON Molderings G., PO343-WED Moreno M., PO023-TUE, PO242-
Mian H., PO565-TUE Mitchell L., PO454-MON, PO465- PO659-MON WED
Milos M., OR378, PO436-TUE MON Molenaar T., AS189 Montmartin A., OR055, PO262-
Mian O., NUR007, PO355-MON Molero A. G., PO321-TUE Moret A., PO579-WED
Mimanda Y., PO671-TUE Mitchell M., OR058, PO418-TUE, WED
Miao C., PO556-WED Molhoek J., AS035, PO063-WED Morettini A., PO067-MON
Min W.-S., PO599-TUE PO504-WED Montoya M., OR328, PO475-MON
Miao C., OR109 Molina M., PO518-WED Moreva O., PO624-TUE, PO357-
Minami H., PO244-MON, PO491- Mitchell M., PO559-TUE, PO210- Montoya M., PO434-TUE
Miao X., PO009-MON, PO013- Molina P., PO414-WED, PO610- WED
MON, PO652-MON WED Montoya M., PO479-MON
MON, PO015-MON WED
Minamizaki T., OR051 Mithoowani S., AS110 Mooberry M., AS153
474 475
AUTHORS INDEX
Morfini M., AS122, OR346, Motovska Z., PO364-WED Mundell S., AS054, PO065-MON Muzychenko V., PO586-TUE Nakkinkun Y., PO675-MON, Neff A., PO277-MON, PO298-
OR389, PO262-MON, PO256- Motta G., PO179-TUE Munder M., PO591-MON Mwirigi A., PO603-MON PO647-TUE, PO268-WED, WED
TUE Motte S., PO598-MON, PO668- Mundkur L., AS025, AS027, Myers B., OR064, PO175-TUE PO613-WED, PO643-WED Negrier C., OR029, OR347,
Morgan N., AS054 TUE AS232, AS202, OR006, OR008, Myers D., PO030-MON Naldini G., OR396 PO149-MON, PO156-MON,
Morgan N., AS011 Mottier D., OR146, OR149, PO083-MON, PO098-WED Myers O., OR064 Naldini L., AS088 PO157-MON, PO488-MON,
Mrgelin M., AS040 OR323, PO512-MON, PO655- Muoz A., PO126-TUE Nalin F., PO385-MON PO067-TUE, PO198-WED,
Myklebust C., PO118-MON PO253-WED
Morgione S., PO352-TUE, PO399- WED Munoz Martn A., PO103-TUE Namestnikov Y., PO057-TUE
Myklebust C. F., PO557-TUE Ngrier C., PO484-MON, PO501-
WED, PO400-WED Motwani J., AS054, AS011 Munroe-Peart S., OR285, PO095- Nandi M., PO459-WED
Myklebust C., PO123-MON, MON, PO229-TUE, PO273-WED
Mori J., OR183, PO434-WED Mouapi K. N., OR372 MON PO453-TUE Nandurkar H., AS212
Mori M., PO173-TUE Moueminoglou N., OR262 Muntean W., PO453-MON, Negrotto S., AS173, PO012-MON
Myrn K.-J., PO170-MON, Nante G., OR132, PO077-TUE
Mori M., PO233-TUE, PO211- Moumneh T., PO579-TUE PO464-MON Nehmiz G., PO376-TUE
PO171-MON, PO299-WED Naoki T., PO108-WED
WED Mouquet F., PO662-TUE Mnzel T., PO513-TUE, PO102- Neira Vidal V., PO358-TUE
Nabi S., PO650-WED Napirei M., PO583-MON
Mori T., OR051 Moussa S., PO542-MON WED, PO478-WED Nekkal M. S., PO637-TUE
Nabiullina R., AS156 Napoleone L., OR396
Moriguchi J., OR216 Moustafa F., OR381 Mnzer P., OR114, PO412-MON, Nekkal S., PO494-MON, PO242-
PO449-WED Nader H., PO291-MON Napolitano M., PO117-TUE, TUE, PO276-WED, PO520-WED
Moriguchi-Goto S., PO552-MON Moustafa F., PO587-TUE Nadir Y., AS096, PO126-MON, PO650-TUE, PO614-WED
Morikawa Y., OR340 Muoio A., OR197 Nelemans P., PO645-MON
Mowinckel M.-C., PO311-MON, PO563-WED Narata A. P., PO064-MON
Morin C., PO262-WED PO178-WED Murabito J., PO593-TUE Nelissen R., PO532-MON
Naess I., OR345 Nardelli G. B., PO515-MON
Morishima Y., OR316, PO353- Mowla A., PO533-TUE Murai T., PO505-TUE Nelson A., PO097-TUE, PO109-
Nss I. A., AS083, OR129, Nardo B., PO611-TUE TUE
MON, PO357-TUE, PO458-TUE Muazzam I. A., PO127-TUE Murakami A., PO377-MON OR134, PO104-TUE, PO111- Narjoz C., PO672-WED Nelson M., PO398-TUE
Morishita E., PO599-MON Muczynski V., AS062, OR246, Muramatsu T., PO213-TUE TUE, PO112-TUE Nash G., PO393-TUE Nemes L., OR212
Morita D., OR340 PO206-WED Murasaki K., PO399-MON Nagae C., PO233-TUE, PO211- Natesirinilkul R., PO275-TUE, Nemeth B., PO573-WED, PO625-
Moriyama T., PO455-WED Mueller J., PO066-TUE Murata M., PO386-WED WED PO446-TUE
Murata M., PO151-MON, PO486- Nagamine K., PO320-WED WED
Mrk M., PO343-MON Mueller K., AS099 Navani S., OR046
TUE, PO560-WED Nagasato T., PO399-TUE Nmeth A., PO443-TUE
Moroi M., PO441-WED Mueller-Cohrs J., PO418-WED Navarrete Villarruel A., PO138-
Muresan A., PO099-MON Nagaswami C., PO026-MON, Neo J. K., PO663-WED
Morongova A., PO249-TUE, Muench S., PO243-WED WED
PO022-WED Murphy C. L., PO437-MON PO212-WED Negrier C., PO257-TUE
Mufti A., OR406 Navarro R., PO441-TUE, PO514-
Morowski M., AS218 Murphy D., PO669-TUE Nagler M., OR432, PO314-WED WED Nery J. G., PO322-TUE
Mugusi F., PO063-WED
Morrell C., OR166, OR241 Murphy J., PO116-WED, PO597- Nagy Jr B., PO077-MON, PO482- Navarro S., PO093-MON, PO534- Nesbitt W., PO443-WED
Muhl L., PO510-TUE
Morrell C., OR042, PO032-TUE WED WED MON, PO536-MON, PO344-TUE, Neto-Neves E., PO033-MON
Muia J., OR365
Morris R., PO156-WED Murphy L., PO267-TUE Nagy-Bal E., PO087-WED PO558-TUE Neufeld E., AS122, OR022,
Muia B., PO439-MON, PO552-
Murphy P., PO502-WED Nahas W., PO433-TUE Navarro-Fernndez J., OR076, PO262-MON, PO239-TUE
Morris T., PO201-TUE, PO644- WED
WED Murray J., PO457-MON Nahed B., PO601-WED OR370 Neufeld E., PO457-MON, PO458-
Muir I., AS016
Murray S., OR049 Nahirniak S., PO455-MON Navarro-Ruan T., AS122, PO262- MON
Morris T., PO476-MON Mukaddam A., PO207-TUE
Murru V., PO068-WED Naik M., AS175, AS183 MON Neumann D., PO627-WED
Morrison H., OR073 Mukhametova L., PO113-MON
Murugesan G., PO494-WED Naik U., AS175, AS183 Nawadkar V., PO207-TUE Neumayer C., PO559-MON
Morrison K., OR020 Mukhametova L., PO213-MON
Musa F., OR045 Nair J., OR010, PO082-MON Nawarawong W., PO647-TUE Neunziger R., PO094-MON
Morrissey J., OR351 Mukharyamova K., PO197-MON
Musgrave K., PO447-MON Nair S., PO153-WED Nawroth B., PO665-TUE Neven B., PO440-MON
Morrissey J., OR353, OR354, Mukhi N., PO265-TUE
PO001-TUE, PO451-WED, Musial J., PO074-MON, PO500- Naito S., PO462-TUE, PO463- Nayak D., PO164-MON Newall F., PO449-MON, PO607-
Mulder A., PO346-WED MON, PO596-TUE, PO500-WED
PO543-WED, PO544-WED TUE, PO070-WED TUE Nayak S., PO512-TUE
Mulders G., PO282-MON Newman D., OR058
Morrissey J., PO300-TUE, PO336- Musia J., PO048-MON, PO069- Naito S., PO041-MON, PO357- Nayiager T., PO463-MON
Mulla G., PO496-TUE Newton P., PO297-TUE
WED WED MON, PO020-WED, PO057-WED Neal R., PO175-TUE
Mullens M., PO033-WED Newton P., PO110-MON
Morser J., AS031, AS029, Mussio D., PO474-TUE Naitoh K., PO486-WED Neary E., OR218
PO465-WED Muller A., OR315 Ng C., PO660-MON
Musso M., PO644-TUE Najarro K., OR042 Neceva V., PO544-MON, PO535-
Morth J. P., PO557-TUE Muller D., PO075-MON Ng E.-P., PO323-TUE
Mustafin I., AS156 Najmi N., PO384-MON WED
Mos I., PO596-MON Muller S., PO440-MON Ng H. S., PO529-MON
Musumeci L., AS006, OR278 Nakagaki T., PO441-WED Nechipurenko D., PO436-WED
Mos I., OR191, PO597-MON Mller A., PO163-MON, PO218- Ng H. J., PO012-TUE, PO074-
Muszbek L., PO521-WED Nakagawa I., PO058-WED Nedelec Gac F., PO411-TUE
WED TUE, PO615-TUE, PO663-WED
Moscardo A., PO414-MON Muszbek L., PO224-MON, PO530- Nakahara S., OR051 Nedergaard-Petersen S., PO121-
Mullier F., OR055, OR126, Ng L., PO464-WED
Moscard A., PO062-MON MON, PO550-MON, PO516-TUE, Nakajima Y., PO674-TUE WED
PO092-MON, PO063-TUE,
Moschetti V., OR320 PO031-WED, PO087-WED, Nakamura M., OR051 Needham J., PO064-TUE, PO220- Nguyen G., OR165
PO269-TUE, PO125-WED,
Moschonas I., PO452-WED PO134-WED, PO167-WED PO187-WED TUE, PO369-TUE, PO130-WED, Nguyen H., PO456-WED
Nakamura S., PO491-WED
Mosier M., PO182-MON, PO191- Mut D., PO474-WED PO417-WED Nguyen H., PO394-MON, PO448-
Mulliez S., PO384-TUE Nakamura Y., PO151-MON,
TUE, PO192-TUE, PO337-TUE, Mutch N., PO225-MON PO560-WED Neel A., PO016-WED WED
Mulpas M.-C., PO457-WED
PO344-WED Mutch N., AS204, PO189-WED Nakano H., OR142 Neelamegham S., AS063, OR334, Nguyen J.-P., OR192
Mumford A., AS054, OR386,
Most P., OR274 Muth M., PO094-MON PO430-MON, PO045-WED Nguyen P., OR055, PO263-TUE,
PO502-MON, PO521-WED Nakashima T., PO399-TUE
Mostaguir K., PO587-TUE Muthard R., OR207 Neerman-Arbez M., AS002, PO457-WED
Muminoglu N., PO590-MON Nakata Y., PO151-MON, PO486-
Mota N., PO042-MON, PO055- Muttucumaru N., PO601-MON PO217-MON, PO485-MON Nguyen P. N., AS039
Mumoli N., PO502-TUE, PO640- TUE, PO560-WED
WED Muttucumaru T., PO601-MON Neeves K., PO660-MON Nguyen T.-H., PO456-WED
WED Nakazawa Y., OR340
Motokawa S., OR051 Muyldermans S., OR399 Neeves K., PO188-MON Nguyen T.-H., PO298-MON
Munakata J., PO312-MON Nakazono E., PO545-MON
Nguyen T., OR056
476 477
AUTHORS INDEX
Ni H., AS153 Nitti C., PO626-MON, PO373- Nouvellon E., OR095, OR188, Ocariza L., PO001-TUE, PO300- Okoye H., PO450-MON Ono T., OR352, PO351-MON
Ni H., AS168, OR031, OR139, WED OR190, PO035-MON TUE Okpokam D., PO386-MON Ono Y., PO178-MON
PO326-WED, PO328-WED Nivet-Antoine V., PO038-TUE Novack A., OR028, OR029, Oconnell C., PO172-WED Okpokam O., PO386-MON Ono-Uruga Y., PO386-WED
Ni R., AS216, AS219, OR286, Njerve I. U., PO042-TUE PO108-TUE OConnell N., PO318-WED Oku K., PO058-WED Onselaer M.-B., PO101-WED
OR302, PO403-MON Njlstad I., AS046, OR071, Novk M., PO564-MON Odeberg J., OR269, PO559-WED, Oladapo A., PO108-TUE Onundarson P., PO412-WED
Ni Ainle F., OR218 OR075, OR120, OR254, OR267, Novakowski S., PO421-MON, PO564-WED Olh Z., PO550-MON Ooms M., PO450-WED
Nicham F., PO045-TUE OR293, OR392, PO594-TUE, PO460-WED Odiaman L., PO440-TUE
PO561-WED, PO638-WED Olaiya A., PO368-TUE Oomura K., PO058-WED
Nichele I., PO473-WED Novelli C., OR093, PO126-WED, Odnoczko E., PO278-MON,
Nnachi O., PO529-TUE PO615-WED Oldenburg J., AS223 Opastirakul S., PO275-TUE
Nichol M., PO238-MON PO049-TUE, PO235-TUE, Oldenburg J., OR103, OR212, Opstad T., OR251, PO030-TUE
Nichols T., AS120, PO048-WED Noble S., NUR014, OR130, Noventa A., PO385-MON PO543-TUE, PO526-WED
PO097-TUE, PO109-TUE, OR248, OR347, PO256-MON, Opstad T. B., PO293-TUE,
Nichols T., OR178, PO046-TUE Noventa F., OR256, OR284, Odone-Filho V., PO431-TUE PO498-MON, PO631-MON,
PO110-TUE, PO156-WED OR291 PO342-WED
Nicholson-Goult L., AS124 ODonnell C., PO593-TUE PO637-MON, PO674-MON, Orban C., PO501-TUE
Nobre Fernandes S., PO012-WED Novichkova G., PO496-MON ODonnell J., PO676-TUE, PO219-TUE, PO229-TUE,
Nickles K., PO657-MON Orbe J., AS230, OR116, PO342-
Nobre Junior V., PO313-TUE Novichkova G., PO503-WED PO318-WED PO243-TUE, PO244-TUE,
Nicolas P., PO512-MON MON
Nobuo A., PO153-WED Novkovic A., PO252-MON ODonnell J., PO667-TUE PO256-TUE, PO262-TUE,
Nicolosi F., OR297 Orecna M., OR174, PO603-WED
Noda M., PO205-WED Nowak A., AS179 ODonnell J., OR182 PO480-TUE, PO182-WED,
Niebl P., PO312-TUE, PO418- PO183-WED, PO184-WED, Orfeo T., AS050, PO576-MON,
WED Noelia V., PO444-TUE Nowak J., PO136-TUE ODonnell J., PO019-TUE
PO191-WED, PO202-WED, PO467-TUE, PO425-WED
Niebler R., OR058 Noethen M., PO202-WED Nowak M., PO453-WED Offenberg H., PO136-TUE PO251-WED, PO267-WED, Orfeo T., PO371-MON
Niederwanger C., PO330-WED Noetzli L., OR431 Nowak T., PO605-WED Offermanns S., OR244 PO343-WED, PO508-WED, Orihashi Y., PO621-MON, PO603-
Niego B., OR380 Noga T., PO455-MON Nowak-Goettl U., AS104 OGara F., PO395-MON PO532-WED, PO676-WED TUE
Niekrens C., PO195-WED Nogami K., AS017, PO244-MON, Nowak-Gttl U., PO506-WED Ogasawara M., PO183-MON Oldgren J., PO362-MON Orlandini F., PO585-TUE
PO491-MON, PO652-MON, Nowakowska M., PO300-MON, Ogata N., PO672-TUE
Nielsen A., PO140-TUE PO666-MON, PO668-MON, OLeary C., PO406-WED Orlando C., OR079
Nielsen L., OR036 PO345-WED, PO365-WED Ogawa M., PO589-MON OLeary J., OR360 Orlando L., PO614-WED
PO088-TUE, PO145-TUE, PO165- Noya L., PO043-MON
Nielsen P., PO140-TUE TUE, PO224-TUE, PO018-WED, Ogawa M., PO434-MON Olgasi C., AS088 Orosz A., PO224-MON
Nielsen T., PO130-MON PO113-WED, PO347-WED Nuesgen N., PO191-WED, Ogiwara K., PO347-WED Olie R., PO056-MON Orsi F., PO066-WED, PO067-WED
PO202-WED Ogiwara K., OR332, PO244-MON,
Nieman M., PO571-WED Noguchi K., AS145, PO203-MON Olie V., PO598-TUE Orsi F., OR263
Nugent D., PO298-WED PO652-MON, PO678-MON,
Niessner A., OR123 Noguchi K., PO545-MON Oliva M. L., PO184-TUE, PO054- Orsi F., OR094, PO145-WED
Nunes F., PO663-TUE, PO479- PO145-TUE WED
Nieswandt B., AS068, AS092, Noh J.-Y., PO115-MON WED Orsi F., PO422-MON, PO531-MON
AS094, AS169, AS218, AS228, Nokes T., PO317-TUE Ogweno G., PO409-TUE Oliva R., PO582-MON Orsi F., PO190-MON
OR017, OR081, OR169, OR170, Nunes F., PO390-WED Oh D., AS195, OR199, PO168-
Nokes T., PO629-WED Oliveira J., PO313-TUE Ortiz M., OR220, PO480-WED
OR181, OR405, OR416, PO436- Nuez Toscano M., PO138-WED WED
Nolan B., PO237-MON, PO280- Oliveira L., PO286-MON Ortz C., PO435-WED
MON, PO505-MON, PO129-TUE, Nunn M., OR154 Oh H.-K., PO119-TUE
MON, PO435-TUE Oliveira C., PO054-WED Ortiz Nareto A., PO236-WED
PO526-TUE Nurden A., PO436-MON Oh M., PO309-WED
Nolli S., OR397 Oliver A., PO474-TUE Ortiz Snchez J., PO485-TUE
Nieto R., OR321 Nurden A., AS014, PO416-MON Ohashi A., PO106-MON, PO186-
Nolte M., PO152-MON, PO411- Olivera P., PO538-MON, PO056- Ortiz-Costa S., PO133-MON
Nieuwland R., AS038, PO342- MON Nurden P., AS014, OR003, TUE TUE, PO321-TUE, PO445-TUE
MON OR081, OR169, PO436-MON, Ohashi Y., OR142 Osada M., OR404
Nolte M., PO273-MON PO473-WED Olivera P., PO375-TUE, PO407- Osaki T., OR250
Nijdam A., OR102 Ohishi K., PO486-WED WED
Nomura T., PO432-WED Nuttall P., OR367 OShea S., PO406-WED, PO639-
Nijziel M., OR013 Ohlenforst S., PO343-WED Olivieri O., OR050, OR080,
Nonent M., OR146, PO655-WED Nwagha T., PO627-TUE WED
Nikolic Nielsen L., PO285-WED Ohlman P., AS039 PO554-TUE, PO555-TUE
Norberg E.-M., OR187 Nwogoh B., PO334-TUE Osim E., PO386-MON
Nikolovski S., PO121-TUE Ohlmann P., PO572-MON Ollivier V., PO079.1-MON
Norby C., PO568-TUE Nygren P., PO431-WED Osman A., AS052
Nilsson G., PO013-MON Ohmori T., OR084, PO354-TUE, Ollivier V., OR170, OR420,
Nrby P., PO541-WED Nylandsted Krogh T., OR414 Osminina M., PO501-WED
Nilsson P., PO564-WED PO428-WED PO330-MON
Nordenholz K., PO377-TUE O Connell N., PO280-MON Ostapcenko L., PO382-TUE
Nimbargi R., PO176-MON Ohnishi T., PO477-WED Olsen J. O., PO283-TUE, PO333-
Nordholm-Carstensen A., OR230 O Donnell J., PO280-MON stenson C.-G., PO383-TUE
Ninet J., OR186 Ohsugi T., PO462-TUE WED
Norimichi T., PO108-WED OByrne A., PO300-TUE stenson C.-G., PO392-WED
Ning S., PO595-MON Ohta M., PO417-TUE Olsen O., OR237, PO561-TUE
Noris P., PO438-MON, PO473- ORourke M., PO435-TUE stergaard H., OR237
Ninivaggi M., PO272-MON, WED Ojala J., OR332 Olsen R., PO328-TUE
PO546-MON, PO072-TUE Oakley E., PO449-MON Okada Y., PO477-WED Olsen Krogh B., PO455-TUE Osterling Koskinen L., PO299-
Norling Olsen E., PO285-WED WED
Ninomiya H., PO381-WED Oakley M., PO285-MON Okafor I., PO386-MON Olson N., OR238
Norman D., PO126-MON sterud B., PO283-TUE, PO333-
Nisal A., PO176-MON Oberbach A., PO169-TUE Okamoto S., PO386-WED Olson W., PO625-MON
Norman K., PO180-MON WED
Nisgav Y., PO285-TUE Obergan T., PO308-MON Okamoto T., PO185-TUE, PO284- Omaivboje B., PO403-TUE
Noronha C., PO037-MON Ota S., OR051
Nishigori N., PO674-TUE Obergan T., PO206-MON TUE, PO335-TUE OMalley P., PO374-WED
Noroozi N., AS110 Otaso J., PO068-TUE, PO522-
Nishimura N., PO515-TUE, Obermann-Slupetzky O., OR088 Okazaki E., PO211-TUE, PO250- Omarova F., OR374 WED
PO528-TUE Norris L., OR360 WED
Obiorah C., PO155-WED Omunakwe H., PO155-WED Otero A., PO042-MON, PO055-
Nishimura S., OR084, PO354- Norton M., PO504-MON Okazaki H., AS107
OBrien S., PO454-MON Ondrakova M., PO364-WED WED
TUE, PO428-WED Notley C., OR332, OR409, Okechukwu I., PO601-WED
OR412 Obser T., OR335 ONeil K., PO457-MON Otero R., PO576-TUE
Nishioka J., PO284-TUE, PO335- Obydennyi S., PO392-TUE OKeeffe D., PO649-WED Onelv L., PO195-MON
TUE Nougier C., PO159-TUE, PO198- Othman M., OR337, PO484-TUE,
WED OByrne A., PO021-MON Okigaki M., OR115 Oner A., PO310-MON PO180-WED, PO519-WED
Nishiyama T., OR352 OByrne A., PO001-TUE Okoroh E., OR134
Nounopolos E., PO065-WED Ong W. M. M., PO430-TUE Othman N., OR060
478 479
AUTHORS INDEX
OToole S., OR360 P N., PO200-MON Palomo M., PO191-MON Pappalardo E., OR083, PO580- Paskaleva I., PO515-WED Pavlova B., OR088
Ottaiano T., PO054-WED PNg S., PO258-TUE Palomo De Udaeta M., AS044, MON Pasquali J.-L., OR186 Pavlovskaia Y., PO044-TUE,
Otteby K., AS040 Pabinger I., AS034, OR227, PO189-MON Paramo J., AS230, OR116 Pasqualin T., PO211-TUE, PO106-WED
Otten H.-M., AS197, OR292, OR260, OR313, OR357, PO096- Palumbo J., AS059, PO125-MON Paramo J., PO516-MON PO250-WED Pavord S., AS054, OR064,
PO624-WED MON, PO235-MON, PO236- Palumbo R., PO053-WED Paramo J. A., PO342-MON Pasqualoto K., PO107-MON PO175-TUE
Ou K., AS185 TUE, PO258-TUE, PO262-TUE, Pamuk G., PO043-TUE Pramo J., PO116-TUE, PO488- Passam F., PO425-MON Pawelec K., PO574-WED
Oude Egbrink M., PO452-TUE PO122-WED, PO166-WED, Pamuk O., PO043-TUE TUE Passamonti S., AS196, OR083, Pawlak D., PO300-MON, PO345-
PO273-WED, PO391-WED, Paraskevi B., PO102-TUE PO633-WED WED, PO365-WED
Oudega R., PO583-TUE, PO584- PO528-WED Pan R.-Y., PO265-WED
TUE Pan T. Y., PO017-TUE Parcq J., OR314 Passamonti S., PO176-WED Pawlinski R., AS049, OR048,
Pabinger-Fasching I., OR347 OR306
Ounnoughene N., AS164 Pan X., PO245-WED Pare G., PO489-WED Passamonti S. M., AS195,
Pacheco E., PO318-TUE PO583-WED Payandeh M., PO628-TUE
Oury C., AS006, OR278, PO407- Panchenko E., PO199-MON, Paredes R., PO355-WED
MON, PO396-TUE Pacheco M., PO107-MON Pastana A., PO034-TUE, PO095- Payne J., AS159, OR104, OR145,
PO624-TUE, PO356-WED, Parent F., OR146, OR149,
Outteridge S., OR016 Pachlinger R., PO150-TUE, PO357-WED OR192, PO655-WED WED OR386, PO521-WED
PO151-TUE Pasterkamp G., PO386-TUE Payrastre B., PO416-MON,
Ouvia S., PO043-MON Panda R., PO583-MON Paret G., PO429-TUE
Paciaroni M., AS226, AS227 Pastore A., PO115-TUE PO423-TUE, PO514-TUE
Ouwehand W., PO436-MON Pandya S., PO041-TUE Pareyn I., OR087, OR155
Padayattil Jose S., PO372-TUE Pastori D., PO359-MON, PO029- Pazzi M., PO067-MON, PO366-
Ouwehand W., PO384-WED Panes O., OR220, PO466-WED, Pargalava N., PO585-WED
Paden H., PO319-TUE TUE MON, PO365-TUE, PO477-TUE
Ouweneel A., AS208 PO472-WED, PO480-WED Parikh S., AS166, PO571-WED
Padilla J., AS187, OR076, Pastva O., PO194-TUE Pc J., PO009-TUE
Ouyang Q., PO195-TUE Panes Becerra O., PO358-TUE Parini P., PO564-WED
OR370, PO497-MON Patarroyo-White S., AS192, Peake I., OR406
Ovanesov M., PO560-MON, Pang J., PO440-WED, PO453- Parise L., OR280, AS182
Padilla O., PO472-WED WED OR413 Peake I., AS064, OR086, PO649-
PO008-TUE Parise L., PO331-MON
Padovan L., PO091-MON, PO059- Patel A., PO579-MON MON, PO667-MON, PO676-MON
Ovanesov M., OR174, PO603- Pang N., OR249 Park C.-J., PO071-WED, PO427-
TUE, PO114-WED Patel C., AS018, PO555-WED, Pease R., PO190-WED
WED Pang T., PO623-WED, PO635- WED
Paes B., PO446-MON WED PO599-WED Pease R., AS003, PO096-WED
Overbeck R., OR299 Park H., PO035-TUE, PO659-
Pagan B., PO469-MON Panholzer E., PO150-TUE, Patel H., PO374-MON Pedersen L., OR098
Overgaard M., OR237 WED
Pagani F., OR296 PO151-TUE, PO152-TUE, Patel H., NUR009, PO390-MON, Pedersen S., PO130-MON,
Overvad K., AS083, OR076, Park J. C., PO461-TUE
Pagani G., PO418-MON PO209-WED PO393-MON PO343-MON
OR129, OR345, PO104-TUE, Park J.-H., PO659-WED
PO111-TUE, PO112-TUE Pagano M., PO079-TUE Paniccia R., OR253, OR396, Patel I., PO132-WED Pedrazzi P., PO264-MON
Park J., PO209-TUE
Ovsepyan R., PO147-WED Page G., PO600-MON, PO582- OR400, PO067-MON, PO365- Patel I., PO432-MON Pedrini S., PO671-WED
TUE MON, PO366-MON, PO020- Park M., OR303
Ovstebo R., PO561-MON Patel J., PO496-TUE Pedrosa W., PO390-WED
Pagliari M. T., PO582-MON TUE, PO071-TUE, PO076-TUE, Park R., PO471-TUE, PO309-
Owaidah M. T., PO164-MON WED Patel J., NUR008, OR063, Peerlinck K., PO186-MON
Pai M., NUR010, PO361-TUE PO084-TUE PO347-MON, PO479-TUE Peerlinck K., OR013, OR144,
Owaidah T., PO148-TUE Panicot-Dubois L., OR311, Park S., PO599-TUE
Paikin J., PO489-WED Patel K., PO512-WED OR231, PO364-MON, PO142-
Own R., PO085-MON PO322-MON, PO022-TUE Park S., PO035-TUE, PO659-WED
Pailo A., PO211-TUE, PO250- Patel R., AS047, OR063, PO558- TUE
Oxley N., OR398 Panigada M., PO338-WED Park Y. S., PO461-TUE
WED WED Peerschke E., PO140-WED
Oyarzabal J., AS230, OR116 Panizo E., PO116-TUE Park Y. S., PO300-WED
Paiva J., PO003-MON, PO004- Patel R., NUR008, PO347-MON, Peetermans M., AS009, AS113,
Oymak Y., OR262, PO590-MON, MON, PO005-MON, PO634- Panizzi P., OR423 Parker A., AS023 PO364-MON
PO496-TUE
PO649-TUE TUE, PO636-TUE, PO652-TUE, Panju M., NUR010, PO361-TUE Parlanti L., PO259-TUE Patel R., OR310 Peeters M., PO215-MON, PO519-
Ozaki Y., OR242, OR343, OR404, PO042-WED Pannier B., PO033-TUE Parmar K., PO120-MON, PO121- TUE
PO402-MON, PO419-MON, Patel-Hett S., PO116-WED,
Paje D., PO541-TUE Panova-Noeva M., PO478-WED MON PO597-WED Peil H., PO596-WED
PO417-TUE Parmer R., AS203
Paji T., PO181-MON, PO027- Pan-Petesch B., OR024, OR347, Paternoga I., PO477-MON Peine S., PO583-MON
Ozatli D., PO051-WED WED Parnes A., PO239-TUE
PO512-MON, PO253-WED Pathare A., PO009-TUE, PO635- Peiretti F., AS014, PO385-WED
Ozcan E., OR262 Pak R., PO608-TUE Parodi G., OR396, OR400,
Panteleev M., AS142, OR245, TUE Peixoto C., PO484-TUE
Ozcan H., PO295-WED Palareti G., PO050-MON, PO627- PO496-MON, PO569-MON, PO094-WED Pati H., PO272-TUE Peixoto S., PO253-MON
Ozdemir M., PO490-TUE, PO008- MON, PO639-MON, PO640- PO183-TUE, PO047-WED, Parovichnicova E., PO214-TUE
WED Patiroglu T., PO490-TUE, PO008- Peled E., PO126-MON
MON, PO024-TUE, PO317-WED, PO103-WED, PO436-WED Parra R., OR144 WED
Ozdemir N., OR144 PO674-WED, PO675-WED Pelkey G., OR056
Panteleev M., PO067-TUE, Parra R., PO056-TUE, PO243- Patiwael S., PO352-WED
Ozdemir N., PO275-MON, PO502- Palazzo A., OR082 PO392-TUE Pelkmans L., AS105, OR301,
TUE, PO244-TUE Patrone L., PO242-MON, PO260- PO089-MON, PO672-MON
MON, PO521-WED, PO525-WED Palazzo C., PO142-WED Panteleev M., PO503-WED Prrizas M., PO187-TUE MON Pellegrinelli V., AS043
zdemir Z., PO196-TUE Palige M., PO201-WED Panzer S., PO122-WED, PO528- Parrott M., PO423-MON Pattacini C., PO222-TUE Pelletier-Galarneau M., PO628-
Ozelo M., PO286-MON, PO251- Palla A., OR132 WED Parry B., PO601-WED
WED, PO296-WED Patti G., PO024-TUE WED
Palla R., PO500-MON, PO502- Paola R., PO650-TUE Parunov L., PO150-WED
Ozelo M., AS122, PO262-MON Patzke J., PO094-MON Peltenburg H., OR257
MON, PO521-WED, PO524-WED Paoletti O., OR065 Pasalic L., PO075-MON, PO404-
Ozgenel M., PO617-TUE Paul D., OR274 Pelzing M., PO144-TUE
Palmer B., OR386 Pap A., OR326 MON, PO415-TUE
Ozgurler Akpinar F., PO158-TUE Paul D., AS070, PO423-MON Pena E., PO017-MON, PO019-
Palmer L., PO043-MON Papapetrou E., PO551-TUE Pasca S., PO358-MON, PO614- MON
Ozkan C., PO301-WED Pautus S., PO339-TUE
Palmer S., PO180-TUE Paparo C., PO671-WED MON, PO650-TUE, PO029-WED, Penaloza A., OR192, OR194,
Ozpolat T., PO568-TUE PO175-WED, PO671-WED Pav J., PO621-MON
Palmerini T., PO066-MON Papayan L., PO057-TUE, PO367- PO598-MON, PO579-TUE
Ozsvar Kozma M., PO298-TUE TUE, PO111-WED Pascreau T., PO018-TUE Pavani G., OR178
Palmieri A., PO524-TUE Pendleton R., PO604-MON
Ozturk O., PO143-TUE Papayan L., PO503-TUE Pasi J., PO098-TUE, PO272-WED Pavlova A., OR248, PO219-TUE,
Palmisano J., PO657-WED PO229-TUE, PO532-WED Peng C.-T., PO452-MON
ztrk ., PO158-TUE Palomo I., AS116, PO010-TUE Papkov V., PO073-TUE Pasi K. J., OR213
Pavlova B., PO254-WED
480 481
AUTHORS INDEX
Peng J., AS074, OR138, OR261, Persson E., PO146-MON, PO560- Pezeshkpoor B., OR248, PO191- Pillois X., PO443-MON Plesnila N., PO177-TUE Pompa M. T., PO206-TUE,
PO319-MON TUE, PO561-TUE WED, PO202-WED Pimenta D., PO179-TUE Plo I., OR082 PO249-WED
Pengchata P., PO268-WED Perucci L., PO340-WED Pfaffenberger S., PO509-TUE Pina E., PO354-MON, PO488- Plomann M., OR235 Pompa T., PO355-WED
Pengo V., AS037, PO024-TUE, Perveen H., PO539-MON, PO468- Pfeiff M., PO107-WED TUE Ploplis V., AS112, OR421, Pompili M., PO007-MON
PO077-TUE, PO372-TUE, WED Pfister S., PO094-TUE Pine P., OR318 PO305-TUE Poncelet P., PO337-MON, PO340-
PO064-WED, PO674-WED, Pesavento R., OR132 Pham S., OR338 Pineda S., PO452-TUE Plow E., PO194-MON MON
PO675-WED Peshkova A., OR305 Phan M., PO523-MON Poncet A., PO011-TUE
Pinheiro M., PO244-WED Plu-Bureau G., OR032, PO527-
Penigalapati D., PO615-MON Pessar S., PO196-MON Philbin B., PO435-TUE MON, PO544-TUE Poncz M., PO328-WED
Pinheiro M., PO566-MON,
Penjoyan G., PO586-TUE Peter K., AS184, PO431-MON, Philip S., AS027, OR008 PO189-TUE Plug T., OR441 Pongtanakul B., PO268-WED,
Penka M., PO655-MON PO014-TUE Philippe S., PO568-MON, PO575- Pinheiro S., PO237-WED Pluskota E., PO194-MON PO319-WED
Pennucci J., PO208-TUE Petermann R., PO568-MON, MON Pinho N., PO318-TUE Pluthero F., PO403-MON, PO506- Ponnusamy T., AS027, OR008,
Penyige A., PO482-WED PO575-MON Philippou H., AS155, OR372, Pink R., PO247-MON, PO216- MON, PO379-WED PO083-MON
Pnzes K., PO031-WED Peters C., AS091 OR433, OR444, PO100-MON, TUE Pluthero F., OR235 Ponomareva E., PO118-WED
Pnzes-Daku K., PO530-MON Peters C., AS170 PO180-MON, PO182-TUE, Pinnecker J., OR405, PO526-TUE Pocard M., PO117-MON, PO119- Ponomaryov T., PO325-MON
Peoch K., PO672-WED Peters L., PO423-MON PO188-WED Pino M., PO414-WED MON Pons E., PO042-MON
Pepe C., PO644-MON Peters L., AS070 Phillips K., PO110-MON, PO297- Pinotti G., PO115-TUE Pocard M., PO299-MON Pons S., PO373-MON
Pepler L., AS210 Peters M., NUR004, NUR004, TUE Pochet L., PO172-TUE Pons V., PO321-TUE
Pinotti M., OR179, OR296,
Peralta M., OR220, PO480-WED OR013, OR015, OR387, Phillips M., PO165-MON OR297, OR300, OR333, PO158- Podchernyaeva N., PO501-WED Pons V., PO538-MON, PO056-
Perceau E., PO107-TUE OR389, PO283-MON, PO230- Phoenix F., OR016, OR398, MON, PO556-TUE, PO557-TUE Podda G. M., PO066-MON TUE, PO375-TUE, PO445-TUE,
Pereira A., PO487-TUE TUE, PO240-TUE, PO251-TUE, PO465-TUE Pinto P., PO207-TUE PO407-WED
PO308-WED Podda G., PO422-TUE
Pereira A. C., PO158-WED Phua C., PO151-WED Pinto R., PO012-WED Pontal D., PO535-MON
Peters R., OR413, OR415, Podgornik H., PO181-MON
Pereira F., PO035-MON Piana A., PO614-MON Piot M., OR055 Poole A., AS141
PO248-MON Podoplelova N., AS142, PO103-
Pereira J., AS116, OR220, Piaserico G., PO369-WED Piot M., OR012, PO262-WED WED Poole A., OR244, OR275, PO458-
Peters T., PO546-MON Piatek C., PO172-WED WED, PO461-WED
PO466-WED, PO472-WED, Pipe S., OR331 Poggi M., AS014, PO441-MON,
PO480-WED Peter-Salonen K., OR432 Piatt R., AS070, OR273, OR274, Poole A., AS126
Pipe S., PO140-WED PO385-WED
Pereira M., PO442-MON Petersen H., PO541-WED PO003-TUE Poon M.-C., PO440-TUE
Piret J., PO375-WED Poggio R., PO611-TUE
Pereira Garcs J., PO358-TUE Petersen L. C., PO455-TUE Pical C., PO673-TUE Popescu I., PO501-TUE
Pirtskhelani N., PO585-WED Pohanka A., PO360-TUE
Pereira-Flores K., AS116 Petersen M., OR036 Picard S., PO107-TUE Popescu M., PO501-TUE
Pisa G., PO110-TUE Pohar Perme M., AS101
Pereiro M., PO236-WED Petersen R., PO384-WED Piccioli A., OR291 Popp B., PO605-WED
Piselli E., OR208 Pohlack-Marsch O., PO107-WED,
Perez K., PO190-TUE, PO152- Peterson E., OR295 Pich S., PO516-MON PO137-WED Popp M., OR017
Petlura C., OR007 Pitoc G., PO104-MON
WED Pichot O., AS137 Poirault-Chassac S., OR234, Porreca E., AS197, OR292,
Petrcich W., OR281 Pittarello D., PO438-TUE
Perez-Alenda S., PO271-WED Pichugin A., OR245 OR403, PO376-WED PO103-TUE, PO624-WED
Petrini P., OR015, PO255-MON Pittman D., PO520-TUE
Perez-Alvarez S., PO198-MON Pickering W., PO147-TUE Polack B., PO340-MON, PO131- Porro F., OR132
Petris M., PO456-MON Pittman D., PO116-WED, PO597-
Prez-Encinas M., PO487-TUE Piel G., PO142-WED WED TUE, PO593-WED Porsella R., PO092-TUE, PO231-
Prez-Rodrguez A., PO010-WED Petrov V., PO019-WED, PO509- Pieralli F., PO640-WED Polack B., PO241-WED WED
WED Pitukhina N., PO023-MON
Prez-Snchez C., PO558-TUE Pierce G., PO248-MON Pizzini A., OR197 Polack B., PO223-MON, PO422- Porte R., OR070, PO002-MON
Pergantou H., PO502-MON, Petrova O., PO470-TUE Pierce G., PO208-TUE, PO678- WED Porteous R., OR310
Petruccelli T., PO511-MON Pizzini A., PO264-MON
PO437-TUE, PO521-WED TUE Polk P., PO564-MON Porter J., PO239-TUE
Petrucci G., OR202 Pizzolato M., PO652-TUE
Periago A., PO439-MON Pierce G., PO237-MON, PO239- Polaski S., PO048-MON Porter J., PO297-TUE
Petruzzelli F., PO511-MON MON, PO255-WED Plaimauer B., OR151, PO517-
Perin M., OR428 TUE Polat A., PO143-TUE, PO158- Portier I., OR087
Perina F., PO214-TUE Petruzziello T., AS168 Pierobon F., PO369-WED TUE Portilla C., PO360-WED
Planche V., OR003
Peris J., PO354-MON Pettersen A.-., PO293-TUE, Pieroni G., OR160, PO644-MON, Polat M., PO309-MON Portillo A., OR321, PO576-TUE
PO342-WED PO428-TUE Planinsic R., PO017-WED
Perisic L., PO564-WED Poletaev A., PO097-MON Portugal M., PO034-WED
Petterson T., OR128, PO645-WED Piersma-Wichers M., OR100 Planquette B., PO100-TUE,
Perkins S., PO676-WED PO201-TUE Poletaev A., PO462-MON Posadas-Martinez M., PO642-WED
Perkmann T., AS034 Pettil V., PO304-MON Pierson R., PO306-MON Polgar J., PO050-TUE Posadas-Martinez M. L., PO620-
Plantier J.-L., PO131-TUE,
Permpikul P., PO613-WED Peyron I., PO226-WED, PO228- Pieters M., PO071-MON, PO210- PO311-TUE, PO339-TUE, Poli D., PO365-MON, PO366- WED
WED MON, PO214-MON PO457-TUE MON, PO614-MON, PO639-MON, Posch F., AS034, OR227, OR260,
Pernod G., OR146, OR149,
Peyvandi F., AS196, OR005, Pieters R., OR158 Platokouki H., AS223, OR141 PO640-MON, PO071-TUE, OR357, PO391-WED
PO095-TUE, PO105-TUE, OR026, OR039, OR083, OR108,
PO655-WED Pietrzyk-Nivau A., OR234, OR403 PO365-TUE, PO671-WED, Posner M., PO296-TUE
OR255, OR394, PO069-MON, Platokouki H., PO502-MON, PO673-WED, PO674-WED,
Pernow J., PO013-MON PO091-MON, PO164-MON, Pignani S., OR179 PO650-MON, PO437-TUE, Post J., OR257
Pignatelli P., PO359-MON, PO675-WED
Perot E., PO156-MON, PO157- PO500-MON, PO502-MON, PO521-WED Potze W., OR435
PO503-MON, PO580-MON, PO029-TUE Pliska S., PO482-WED
MON Platokouki H., PO308-WED Pou R., PO042-MON
PO582-MON, PO592-MON, Pike G., PO495-MON Polley G., OR295
Perozziello A., PO620-MON Platt C., OR022 Pouard P., PO018-TUE
PO649-MON, PO656-MON, Pike R., PO300-TUE Pollitt A., PO408-MON
Perrier A., AS137, OR074, PO663-MON, PO059-TUE, Plattfaut C., OR439 Poul H., PO128-TUE
PO587-TUE Pilgrim S., PO065-TUE Pollmann H., PO480-TUE
PO090-TUE, PO091-TUE, Platton S., PO258-WED Poulsen L. H., PO293-WED
Perroche S., PO045-TUE Pilgrimm-Thorp A.-K., PO420-TUE Pollock D., OR062, PO388-MON
PO198-TUE, PO574-TUE, Pleass H., PO623-WED, PO635- Poulsen L., OR212
Perrone D., OR300 PO090-WED, PO114-WED, Pillitteri D., PO248-TUE, PO420- WED Pombo M., PO007-TUE
Pomero F., PO610-TUE, PO613- Poulton T., PO634-WED
Perry D., PO235-MON PO197-WED, PO521-WED, TUE Plebani M., PO077-TUE
PO524-WED, PO676-WED MON, PO373-WED, PO640-WED
482 483
AUTHORS INDEX
Pouplard C., AS108, OR055, Prochazkova J., PO060-TUE, Qi X., OR047 Radu C., AS042, OR172, PO341- Rana H., PO615-MON Rauzi F., OR341, PO400-MON
PO056-WED PO542-TUE Qian K., OR177, PO154-TUE, MON, PO331-TUE, PO332-TUE, Ranagarajan S., PO009-WED Ravanat C., PO572-MON
Pouymayou C., PO440-MON, Prochzkov J., PO564-MON PO049-WED PO548-TUE Ranaldo G., AS088 Ravibabu R., PO363-TUE
PO441-MON, PO443-MON Prohaska K., PO150-TUE Qiao S., OR286, OR302 Radu C. M., PO193-MON, PO387- Ranalli P., OR202 Raviv G., PO099-MON
Pouymayou K., OR024 Projahn D., PO091-WED Qiao Z., AS109 WED Rnby M., PO367-MON Raya A., AS088
Prabhala H., PO154-TUE Prokhorova I., PO586-TUE Qin J., PO194-MON Rafailovich M., PO202-TUE Rancan E., PO614-MON Rayes J., PO289-TUE
Pradella P., OR093 Protti A., OR005 Qin J., PO049-WED Rafeedheen R., PO099-MON, Rance J., NUR014 Rays J., PO226-WED
Pradhan S., OR277 PO041-TUE
Proulle V., AS146 Qu D., OR031 Rancon F., PO107-TUE Raymer R., PO048-WED
Praet S., PO267-MON Raffini L., AS161
Proulle V., PO658-TUE Qu G., PO172-MON Rand J., AS033, PO408-WED Raynard S., PO102-MON
Pragst I., AS218 Rafique A., PO193-WED
Prout H., PO097-TUE, PO109- Qu L., OR117 Rand J., AS037 Razouki Z., PO619-TUE
Prakash A., PO531-WED TUE Rafowicz A., OR141
Quaglia I., PO483-TUE Rand M., AS078, PO426-TUE Re R., PO610-TUE
Prakash G., PO200-MON Provaznikova D., PO224-WED Ragni M., OR088, OR090,
Quaino S., PO145-WED OR201, PO255-WED Rand M., PO388-TUE, PO390- Rea C., PO454-TUE
Prakash P., PO521-TUE Provost K., OR146, OR149, Quan M., PO349-MON TUE Read D., PO243-WED
PO655-WED Ragni M., PO277-WED
Prandoni P., OR132, OR195, Quarroz C., PO101-MON Randi A., AS061 Realubit R., PO408-WED
OR256, OR291, OR326, PO608- Provost P., AS052 Ragoonanan V., PO379-MON,
Quartey P., PO502-MON PO383-MON Randi A., OR410 Reardon S., PO204-TUE
MON Prudent M., PO400-TUE Quecke T., OR439 Rangarajan K., PO009-WED
Rahbek-Nielsen H., PO219-WED Rebecca L., AS047, PO558-WED
Prasad J., PO493-MON Pruner I., PO547-MON, PO159- Queen S., OR042 Rangarajan S., AS122, OR015,
Rahimi A., PO247-TUE Rebello R., PO595-MON
Prat A., PO324-MON WED Quehenberger P., AS034, PO096- OR213, PO237-MON, PO247-
Rahimi K., PO600-WED Rebibo-Sabbah A., PO389-WED
Prat M., OR161 Pruss C., PO656-TUE MON, PO236-TUE, PO391-TUE, MON, PO262-MON, PO064-TUE,
Rahmouni S., AS006, OR278 Recht M., AS129, PO239-MON,
Pratikhya P., OR318 Pruszczyk P., PO626-MON, PO166-WED, PO528-WED PO198-TUE, PO216-TUE, PO220- PO285-MON, PO251-WED,
Pratt K., PO248-MON PO619-WED Raichand S., PO019-TUE TUE, PO369-TUE, PO130-WED,
Quere I., PO535-MON, PO653- PO297-WED, PO298-WED
Pravettoni G., PO574-TUE Pruthi R., PO484-WED WED Rainey J., PO030-MON PO310-WED, PO417-WED
Reddel C., PO149-WED
Preis M., PO248-TUE Pruthi R., PO648-MON, PO655- Qur I., AS137, OR095, OR188, Rainger G., PO408-MON Ransinan J., PO437-WED
Reddy E., AS168
Preis M., PO137-WED TUE OR190 Raio L., AS163 Ranzato B., PO225-TUE
Reddy E. C., PO388-TUE
Premjani V., PO135-MON Pruthi R., PO037-WED Querol F., PO271-WED Raja P., PO347-TUE Rao A. K., AS067, AS125
Reding M., PO277-MON
Prenninger T., PO249-MON, Pryzdial E., AS111 Quesne J., PO568-MON Rajapakse S., PO021-WED Rao L. N., OR008
Reding M., OR101
PO160-TUE, PO232-WED Pryzdial E., OR271 Quilici J., PO493-WED Rak J., PO094-TUE, PO393-WED Rao T. L. N., AS027
Redondo Izal A., PO474-TUE
Prentice D., OR194 Pryzdial E., PO459-TUE Quinn D., PO172-WED Rak J., OR047 Raquet E., PO596-WED
Rees H., PO211-MON, PO212-
Presch I., OR088 Psaty B., PO557-WED Quintana I., PO533-MON, PO199- Rakhe S., PO116-WED, PO597- Rashid A., PO539-MON, PO468- MON, PO331-WED
Presles E., OR146, OR149, Pshonkin A., PO503-WED TUE WED WED
Reeves B., OR048
PO262-WED, PO655-WED Puccia G., PO618-WED Quintanilla M., OR359, PO336- Rakic L., PO387-MON Raskob G., PO613-TUE
Refaei M., PO592-TUE
Presnyakova M., PO028-WED, Puetz J., PO255-WED MON Rallapalli P., PO676-WED Raskob G., OR199, OR259,
PO608-TUE, PO637-WED Regan I., PO435-TUE
PO030-WED Puget H., PO620-MON Quintavalle G., PO264-MON, Ramael S., OR320
Raskob G., PO353-TUE, PO409- Regan L., PO045-MON
Preston R., OR182 Puig J., PO038-MON PO222-TUE Ramanan Madatha V., PO164-
MON WED Regar E., PO078-MON
Pretzell I., PO591-MON Pujadas-Mestres L., PO082-WED Quirino B., PO043-WED
Ramanjappa M., PO083-MON Raslova H., AS014, OR082 Regina C., PO258-TUE
Preusser M., OR357 Pujol-Moix N., PO473-WED Quiroga T., PO472-WED
Ramaoun M., PO494-MON, Rasmussen C., PO136-TUE Reglinska-Matveyev N., AS149
Prevot N., AS082 Pula G., PO065-MON Quiros F., PO642-WED
PO242-TUE, PO520-WED Rasmussen L., PO343-MON Regnault V., OR186
Prezoti A., PO034-WED Pula G., PO016-MON, PO296- Quon D., PO235-MON, PO298-
WED Ramasheuskaya I., PO629-TUE Rasmussen M., OR230 Regnault V., OR091, PO122-
Prezoto B., PO179-TUE TUE MON, PO031-TUE, PO033-TUE
Prezotti A., PO286-MON Pulcinelli F. M., PO084-WED, Qureshi H., PO317-TUE Ramasubramoni A., PO065-MON Raso S., PO117-TUE, PO614-
Ramberg C., PO338-MON WED Reheman A., AS168
Price M., PO019-TUE PO316-WED R N., PO009-TUE
Ramberg C., PO304-TUE, PO308- Rastogi A., PO540-MON, PO005- Reich H., OR216
Price V., AS158 Pulcinelli F. M., PO060-MON R. Rosendaal F., PO565-WED
TUE, PO328-TUE, PO329-TUE, WED Reichel J., PO128-MON
Prigancova T., PO249-TUE, Pulcinelli R., PO508-MON Raake W., PO291-MON
PO396-WED, PO572-WED Rat A.-C., OR186 Reicheltova-Riedelova Z., PO194-
PO371-TUE, PO022-WED, Pulskens W., OR124 Rabal O., AS230
Rameau P., OR082 Ratasvuori M., PO106-TUE TUE
PO061-WED Pun S., PO556-WED Rabbolini D., OR002, PO433-
Ramirez L., PO454-MON Rathbun S., PO449-TUE, PO157- Reijers J., PO592-WED
Prince R., PO489-MON Purev T., PO072-WED MON, PO421-TUE
Ramrez L., PO543-MON WED Reilly P., OR320, PO362-MON
Pringle J., AS041 Puri A., PO603-TUE Rabinovich D., OR415
Ramon L. A., PO093-MON, Ratzinger F., PO391-TUE Reina A., PO614-WED
Prins M., AS022, AS099, OR256, Purohit A., PO272-TUE Rabinovich O., PO180-TUE
PO536-MON Raubertas R., PO074-WED Reiner A., OR238
OR259, OR291 Pusateri A., PO467-TUE Radhakrishnan A., PO057-MON,
PO026-TUE Ramn L., PO344-TUE Rauch A., AS134, OR219, Reiner M., PO027-MON
Prins M., OR326 Puskarich M., PO490-WED
Radic Antolic M., PO436-TUE Ramn L., PO534-MON PO662-TUE, PO513-WED Reinhardt C., PO397-MON,
Priora R., OR253, PO365-MON, Putchakarn P., PO110-WED Ramos M., PO360-WED Rauch R., PO667-WED PO099-WED
PO366-MON, PO071-TUE, Puttaiah P., PO531-WED Rdler J., OR335
PO076-TUE, PO365-TUE, Ramperti N., PO075-WED Rauchensteiner S., PO271-MON, Reinhart C., PO182-WED, PO183-
Putti M., PO456-MON Radojkovic D., PO547-MON,
PO477-TUE Rampinini F., PO126-WED PO274-WED, PO283-WED, WED
PO159-WED
Prisco D., OR132, OR270, Putz M., PO199-WED, PO200- Ramsey P., PO555-WED PO291-WED Reininger A., OR014
WED Radossi P., AS122, OR297,
PO226-MON, PO084-TUE PO262-MON, PO369-WED Ramstrm S., PO294-MON, Rausch A., PO174-WED Reipert B., AS191, PO152-TUE,
Prochaska J., PO356-TUE Puurunen M., PO593-TUE PO571-MON Rauscher S., PO559-MON PO160-TUE, PO232-WED,
Radovska A., PO224-WED
Puy C., OR353 Raut M., PO625-MON PO284-WED
Prochazka M., PO564-MON, Ramzy D., OR216
PO542-TUE Puzzo F., PO554-TUE Rauter I., PO259-MON Reipert B., AS221, PO236-TUE
484 485
AUTHORS INDEX
Reipert B., PO249-MON Rezaie A., PO333-TUE Rincon-Tome N., PO082-WED, Robson S., PO306-MON Rolland M., PO118-TUE Rosendaal F., AS083, OR148,
Reis G. P., PO270-TUE, PO499- Rezania S., PO490-WED PO610-WED Roca E., OR315 Rollin J., AS108 OR150, OR322, OR394, PO532-
WED Rezende M., PO211-TUE, PO250- Rinde L., OR071, OR254, Rocca B., OR202 Roma C., AS201 MON, PO616-MON, PO525-TUE,
Reis G., PO043-WED WED OR293, OR392, PO594-TUE Roccatello D., PO068-WED Romagnoli E., OR197 PO601-TUE, PO223-WED,
Reis M., PO261-WED Rezende S., PO522-MON Rios D., PO023-WED PO539-WED, PO562-WED,
Rocha M., PO313-TUE Romagnuolo I., PO477-TUE, PO573-WED, PO577-WED,
Reiss C., PO397-MON, PO419- Rezende S., PO034-WED Rios D., PO002-WED Rocha T., PO472-TUE PO586-WED PO625-WED, PO641-WED
TUE Rezende S. M., PO614-MON Riquelme P., PO472-WED Rocha T. R., PO034-TUE, PO095- Romanov V., OR144, PO261-MON Rosendaal F., OR129, OR393,
Reitsma P., OR266, PO623-MON, Rhodes S., PO362-TUE Risom Kristensen S. R. K., WED Romashevskaya I., PO206-TUE, PO164-MON, PO514-MON,
PO660-TUE, PO582-WED Ria L., PO671-WED PO130-MON Rochael N., PO133-MON PO249-WED PO526-MON, PO104-TUE,
Reitsma P., AS056, OR147, Ribeiro A., PO313-TUE Ritterhaus C., PO073-TUE Roche-Nagle G., PO467-MON, Rome E., OR059 PO111-TUE, PO112-TUE,
PO144-MON, PO562-MON, Ribeiro D., PO562-WED Riva F., PO654-TUE PO473-MON Romecin P., PO435-WED, PO497- PO494-TUE, PO495-TUE,
PO616-MON, PO539-WED, Riva N., AS195, OR195, PO614- Rocino A., AS222 WED PO557-WED, PO568-WED
PO570-WED Ribeiro D., PO313-TUE
Ribeiro J., PO341-TUE MON, PO611-TUE, PO405-WED, Rode F., OR110, OR414 Romecn P., PO229-MON Rosendaal F. R., OR391
Reitsma P., PO620-TUE, PO666- PO671-WED Romeder-Finger S., PO229-WED Rosenfeldt L., AS059
WED, PO668-WED Ribeiro T., AS039 Roder H., PO431-WED
Riva S., PO574-TUE Rodger M., AS077, OR053, Romera M., PO497-MON Rosenplnter K., PO483-WED
Reitter E.-M., OR227, PO166- Ricao-Ponce I., PO580-MON
Rivard G.-., OR377 OR384, PO467-MON, PO473- Romero A., PO620-WED Rosenthal D., PO083-WED
WED Riccardi F., PO264-MON
Rivard G., OR141 MON, PO630-WED, PO647-WED Romero M., PO646-TUE, PO652- Roshal M., PO128-MON
Reitter-Pfoertner S., PO236-TUE Riccardi L., PO007-MON
Rivard G., PO670-MON Rodger M., AS139 TUE Rosholm A., PO250-MON
Reitter-Pfoertner S., PO283-MON Rice P., OR398
Rivard G., PO151-WED Rodgers R., OR104 Romero V., PO466-WED, PO472- Rosing J., OR374, PO023-WED
Remijn J., PO389-TUE, PO642- Richard-Jourjon V., PO579-TUE
Rivard G.-E., OR217, PO165- Rodgers G., PO038-WED WED Rosinus N., PO513-TUE
TUE, PO470-WED Richards M., AS159 WED, PO282-WED Rodorigo G., PO264-MON, Romier B., PO457-WED Ross C., PO164-MON, PO306-
Remijn J., PO072-TUE Richards M., OR104, OR145, Rivera J., OR368, PO184-MON
OR386 PO627-MON Romiszewski M., PO575-WED WED, PO531-WED
Remotti L., PO039-MON, PO629- Rivera J., AS011, OR221, PO439-
MON Richardson A., PO623-WED, Rodriguez J., AS230, OR116 Roncal C., PO342-MON Ross E., PO173-MON, PO161-
MON, PO497-MON Rodriguez K., AS195 Rondina M., PO227-MON TUE, PO233-WED
Ren J., PO382-WED PO635-WED
Rivera-Amaya M., PO445-WED Rodriguez M., PO068-TUE Rondina M., OR243 Ross R., PO656-TUE
Ren M., AS147, OR249, PO070- Riches W., PO641-MON
Rivolta G., OR144 Rodriguez R., AS077 Rondina M., PO604-MON Rossaint R., OR067, PO314-TUE
MON Richter C., OR039
Rivolta G. F., PO264-MON, Rodriguez V., PO454-MON Rongfeng F., OR264, PO320- Rossell E., PO354-MON
Renchi Y., AS075, OR136, Richter C., PO475-WED PO222-TUE
OR264, PO320-MON, PO276- Ricklin D., PO186-WED Rodrguez M., PO355-WED MON, PO566-TUE Rossetti L., PO378-WED
TUE, PO566-TUE Rizvi B., PO539-MON, PO468- Rodrguez Len I., PO285-WED Rnnekleiv O., PO432-MON Rossi E., AS087
Riddell A., PO295-MON, PO370- WED
Rendina A., PO349-MON TUE, PO014-WED, PO353-WED, Rodriguez-Acosta A., PO190-TUE Rnquist-Nii Y., PO363-MON, Rossmann H., PO593-MON,
Rizzo M. A., PO355-MON PO360-TUE PO569-TUE, PO570-TUE
Rendo P., PO167-MON, PO257- PO617-WED Rodriguez-Castro K., PO193-MON,
MON Rizzo M., NUR007 PO114-TUE Ronzitti G., PO158-MON Rosu G., PO310-WED
Ridger V., PO188-WED
Rene O., PO440-MON Roach G., PO507-MON Rodriguez-Huerta A., PO474-TUE Roose E., AS178, PO571-TUE Roth N. J., PO605-WED
Ridger V., AS155
Renn T., AS008, OR193, Roach P., PO628-WED Roelofs J., OR124, PO287-TUE, Roosendaal G., PO241-MON Rothaus Srensen K., OR036
Ridha E., OR382, PO638-MON
PO178-TUE Roach R., OR135 PO442-WED Roosendaal G., OR102 Rothschild C., OR025, OR143,
Riedel T., PO238-WED
Renn T., PO583-MON Robb S., PO180-WED Roepstorff K., OR036, OR110, Roostaei S., PO247-TUE, PO600- PO501-MON
Riedel B., PO149-WED
Rentz A., PO138-TUE Robbel L., PO146-TUE PO285-WED WED Rottensteiner H., PO517-TUE
Riederer M., OR020, PO022-TUE
Reny J.-L., AS128, OR397, Robbins A., OR130 Roest M., PO143-MON, PO246- Roques C., PO079.1-MON Rottensteiner H., OR151, OR153,
Riedl J., OR227, OR357, PO122-
PO011-TUE WED Robert S., OR311, OR315 MON, PO584-MON, PO072- Rosa J.-P., OR003, OR205, OR155, PO571-TUE
Reperant C., OR205 Robert-Ebadi H., OR034 TUE, PO386-TUE, PO389-TUE, OR234, PO444-WED Rotz H., OR159
Riera-Mestre A., AS099 PO470-WED
Repping S., PO510-MON Rietbrock S., AS084, OR294, Robert-Ebadi H., PO587-TUE Rosa T., PO250-WED Rouault C., AS043
Resta D., PO179-WED Roberts A. J., PO312-WED Rogers G., PO148-MON Rose A., PO657-WED Rouillon C., OR091
PO124-TUE
Reutelingsperger C., PO104-WED Roberts A., PO358-WED, PO359- Rogers G., OR107 Rosn P., PO146-MON Roumenina L., PO226-WED
Rietveld I., PO562-MON, PO616-
Reuveny R., PO474-MON MON WED Rogolino A., PO586-WED Rosn S., PO146-MON Rousse N., OR219, PO662-TUE
Revel-Vilk S., PO427-TUE, Rieubland C., PO485-MON Roberts L., AS047, OR063, Rogozina A., PO630-MON Rosenberg A., OR325 Rousseau A., PO116-MON
PO429-TUE, PO475-WED Rigano J., PO048-TUE OR073, PO479-TUE, PO496- Rojas A., OR220, PO480-WED Rosenberg N., PO192-MON, Rousseau A., OR438, PO108-
Revenko A., AS059 TUE, PO558-WED Rojas H., PO187-MON PO171-TUE, PO225-WED, MON, PO102-TUE
Rigg R., PO440-WED, PO453-
Reverter J., PO488-TUE WED Roberts L., NUR008, PO347- Rojas-Fernandez C., NUR013 PO324-WED Rousseau F., PO134-TUE
MON Rojas-Saunero P., PO642-WED Rosencher N., OR283
Reverter J.-C., PO435-MON Righini M., AS137, AS197, Roussel-Robert V., AS164,
OR034, OR195, OR292, PO100- Roberts R., PO139-WED Rojnuckarin P., PO266-TUE, Rosendaal F., AS138, AS196, OR144
Revill C., AS205, PO182-TUE
TUE, PO587-TUE Robertson J., PO420-WED PO606-TUE, PO584-WED OR083, OR131, OR135, OR266, Rousset M., PO398-WED
Rewerts C., PO125-MON
Rigsbee N., PO048-WED Robertson J., PO118-TUE Rokicka M., PO317-TUE OR345, OR392, PO522-MON, Rousso D., PO065-WED
Rey J.-B., PO105-TUE PO524-MON, PO525-MON,
Rijken D., PO665-MON Robin P., AS082 Rokni Zadeh H., PO186-MON Routledge M., PO245-WED
Rey M., OR020 PO617-MON, PO567-WED,
Rijken D. C., PO209-MON Robinson M., PO173-MON, Roldn V., PO552-WED Rovin B., PO571-WED
Reyes N., PO637-WED PO161-TUE, PO233-WED PO582-WED
Reyon D., OR039 Rijken D., PO214-MON Rolfe S., PO367-WED Rovira M., PO189-MON, PO191-
Robledo R., AS070 Rosendaal F., OR255, PO069-
Reyssat M., PO376-WED Riklin E., PO601-WED Rolim D., PO212-TUE MON, PO090-WED MON
Riley R., PO019-TUE Robles-Carrillo L., PO445-WED, Roll P., OR315 Rowley J., OR243
Rezaee F., PO323-TUE PO446-WED
Rezaie A., PO560-MON Rimac V., PO144-WED Rolland C., PO095-TUE Rowswell H., PO629-WED
Robson K., PO518-TUE
486 487
AUTHORS INDEX
Roy P.-M., AS082, OR192, Sabbah A., PO325-TUE Salazar E., PO190-TUE, PO152- Sanchez Luceros A., PO039-MON, Santoro C., AS222, OR015, Sato T., AS017
OR194, OR384, PO579-TUE Sabi E., PO517-WED WED PO629-MON PO162-TUE, PO200-TUE, PO259- Sato T., OR051
Royer B., PO440-MON Sabraa A., PO083-TUE Salcioglu Z., PO265-MON, Sanchez-Luceros A., PO634-TUE, TUE, PO650-TUE, PO654-TUE, Sato Y., PO167-TUE
Rozen L., PO081-TUE Sabrkhany S., PO452-TUE PO459-MON, PO279-WED PO636-TUE, PO652-TUE PO473-WED, PO534-WED Sato Y., PO552-MON
Rozenfeld I., PO471-WED Sabroe I., OR016 Salcoglu Z., PO313-MON Sanchez-Luceros A., PO003-MON, Santoro R., AS222, AS195, Satoh K., OR242, OR404,
Ruan C., OR117, OR419, PO425- Saldanha L., AS216 PO004-MON, PO005-MON, PO352-TUE, PO650-TUE, PO402-MON, PO417-TUE
Saccullo G., PO117-TUE, PO614- PO399-WED, PO400-WED
TUE, PO039-WED, PO259-WED, WED Sales M., PO198-MON PO042-WED Sato-Utida H., OR343
PO533-WED Salib M., NUR010, PO361-TUE Snchez-Luceros A., PO646-TUE Santos L., PO404-WED
Sacha P., PO238-WED Satterthwaite A., PO315-WED
Ruan Z., OR018 Salicio A., AS230 Snchez-Mndez J. V., PO497- Santos M., PO062-MON, PO414-
Sadeghi N., PO374-WED MON Satti M., PO133-WED
Ruangrongrat S., PO275-TUE Salim M., PO263-WED MON
Sadeghian S., PO090-WED Santos R., PO508-MON, PO476- Sauer T., PO177-WED
Rubak P., PO394-TUE, PO406- Saliou D., PO542-MON Sand C., PO459-WED
Sadeghi-Khomami A., PO102- TUE Saunders J., PO649-WED
TUE, PO407-TUE MON, PO150-MON Saller F., PO489-MON Sanda N., PO491-WED
Santos R., PO472-TUE Saut N., AS014, PO436-MON,
Rubinstein M., PO429-TUE Sadler J. E., AS178, OR365 Saller F., PO339-TUE Sander K., PO429-MON, PO565- PO441-MON, PO443-MON
Rubio M., OR379 MON Santos S., PO390-WED
Sez C., AS116 Salles-Crawley I., OR044 Santos X., PO567-MON Savage J., OR275
Ruchutrakool T., PO643-WED Sanders L., PO452-TUE
Safarpour M. M., PO490-MON Salles-Crawley I., PO036-WED Sanyal A., OR435 Savchuk O., PO382-TUE
Ruchutrakool T., PO647-TUE, Sanders Y., AS079, OR021,
Safaryan L., PO573-MON Salles-Crawley I. I., PO139-MON OR203 Sap J., OR183 Savic A., PO251-WED
PO268-WED, PO613-WED Sage T., PO398-MON Salloum-Asfar S., PO558-TUE, Savigny S., PO047-TUE
Ruckert M., PO231-MON Sanders Y. V., PO651-MON Sapharikas E., PO014-MON
Saggiorato G., OR030, PO193- PO539-WED, PO548-WED, Savinkova I., PO537-TUE
Rudianto R., PO141-MON PO549-WED, PO552-WED, Sandgaard Pedersen E., PO131- Sapin A.-F., PO075-TUE
MON WED Savion N., PO396-MON
Rueda J., PO536-MON PO570-WED Sara C., PO347-TUE
Sagheer S., PO633-MON Sandhu J., PO464-WED Saw Y., PO413-WED
Ruehl H., PO343-WED Salman B., PO537-MON, PO507- Saracevic M., PO502-MON,
Saharov G., PO563-WED Sandhu T., PO275-TUE PO521-WED Sawada H., PO515-TUE, PO528-
Ruf W., PO397-MON Sahin F., PO266-MON, PO237- TUE TUE
Ruggeri Z., PO148-WED Salomon O., PO192-MON Sandoval C., OR220, PO480-WED Saracini C., PO086-MON, PO094-
TUE, PO238-TUE WED Sawamura A., PO178-MON
Ruhittel S., OR123 Salomon T., PO253-MON Sandoval Gonzalez A. C., PO164-
Sahin K., OR097 MON Saraeva N., PO054-MON Saxena K., PO261-TUE
Rui M., AS168 ahin C., PO264-WED Salu B., PO184-TUE Saxena P., PO540-MON, PO005-
Saluk J., PO212-MON, PO332- Sandoval-Cooper M., OR421 Sarafanov A., AS142, PO493-
Ruiz M. M., OR220, PO480-WED Sahlberg K., PO177-WED, MON WED
WED Sandset P., AS218, OR072,
Ruiz Giardn J. M., PO485-TUE PO178-WED PO478-MON, PO295-TUE, Sarafanov A., OR163, PO196- Saxena R., PO316-MON, PO480-
Ruiz-Sez A., PO274-WED, Said H., OR159 Salvador S., PO355-WED MON, PO272-TUE, PO529-WED
PO600-TUE, PO177-WED, WED
PO523-WED Saidenberg E., PO024-WED Salvail D., PO081-WED PO178-WED Sayani S., PO402-WED
Saraiva E., PO133-MON
Ruiz-Sez A., AS122, PO262- Saidenberg E., PO320-TUE Salviato R., PO369-WED Sandset P. M., AS136, OR317, Saydam G., PO266-MON, PO237-
Saraiva S., OR094, PO066-WED,
MON Saiki Y., PO653-TUE Samama C.-M., OR283, PO350- OR440, PO109-MON, PO118- PO067-WED TUE, PO238-TUE
Rumbaut R., PO497-TUE Sainati L., PO456-MON TUE MON, PO123-MON, PO311- Sayilan Sen H., PO265-MON,
Saralidze T., PO277-TUE, PO337-
Rumyantsev S., PO569-MON Saini H., PO267-TUE Samani N., PO542-WED MON, PO453-TUE, PO556-TUE, WED PO459-MON
Ruocco L., PO671-WED Samba C., PO542-MON PO557-TUE Saralidze T., PO277-TUE Sayles M. J., PO392-MON
Saini S., PO623-TUE
Rupa-Matysek J., PO125-TUE, Sambado L., PO518-WED Sanhes L., PO501-MON Sarbayani A., PO600-WED Sbrojavacca R., PO373-WED
Saito K., PO653-TUE
PO170-WED Sambo A., PO296-WED Sanjay A., PO429-WED Sardo L., NUR012 Scalambrino E., PO091-MON,
Saito S., PO233-MON
Rusen L., PO272-WED Samelson-Jones B., AS120, Sanna G., PO068-WED Sargsyan L., PO573-MON PO059-TUE, PO114-WED,
Sakai M., OR352, PO351-MON
Rusen L., PO293-WED PO160-MON Sano H., AS030 PO176-WED
Sakai R., PO167-TUE Sarin A., PO383-WED, PO487-
Russo A., PO412-MON Sameshima N., PO552-MON Sansot M., PO411-TUE WED Scalet D., OR050, OR296,
Sakai T., PO547-WED OR300
Russo L., PO339-MON, PO622- Samis J., PO135-MON Santagostino E., AS222, OR015, Sarin S., PO005-WED
Sakai T., PO017-WED Scarabin P.-Y., OR032, PO527-
TUE, PO179-WED Samko A., PO356-WED OR108, OR212, OR346, OR347, Sarin S., PO540-MON
Sakata A., OR084, PO354-TUE, OR350, PO091-MON, PO164- MON
Russo M., PO483-MON PO428-WED Sampaio M., PO626-TUE Sarmento A., PO404-WED
Rutherford S., PO221-TUE Sampaio M., PO054-WED MON, PO235-MON, PO250-MON, Scaramozza M., PO266-WED
Sakatsume K., PO653-TUE PO090-TUE, PO091-TUE, PO258- Sarr D., AS114 Scarpazza O., PO385-MON
Rutkauskiene G., PO532-WED Sakimoto S., PO351-MON Sampaio S., PO212-TUE Sartain S., AS213
TUE, PO114-WED, PO197-WED, Scarvelis D., AS139, PO641-MON
Ru-Yu P., PO304-WED Sakuma I., PO357-MON Sampol J., PO337-MON PO251-WED, PO253-WED, Sartorello F., OR078, PO387-WED
Ryan K., PO280-MON, PO318- Samson A., OR037 Scavone M., OR019, PO086-WED
Sakuragi M., PO320-WED PO267-WED, PO303-WED Sartori F., OR050, OR080,
WED Samudra A., AS212 Scazziota A., PO373-MON
Sakurai Y., AS167, PO438-WED Santalucia P., PO574-TUE PO554-TUE, PO555-TUE
Rydz N., PO227-TUE Sanak M., PO074-MON, PO500- Scekic M., PO052-TUE
Salaj P., PO194-TUE, PO247- Santamaria A., PO321-TUE, Sartori M., PO456-MON
Rye-Holmboe I., OR267, PO494- TUE, PO070-WED PO474-TUE Schaefer F., PO589-MON
WED Sartori M. T., PO611-TUE
TUE, PO638-WED Sanchez J.-C., OR397 Santamara A., PO538-MON, Schfer A., PO058-MON, PO013-
Salam E., OR428 Sartori M., PO602-MON, PO627- TUE
Ryerson L., PO460-MON Sanchez J., AS230 PO056-TUE, PO375-TUE, MON, PO317-WED
Salas E., PO516-MON Schfer K., PO513-TUE, PO102-
Rthlisberger B., PO635-MON Sanchez O., AS082, OR146, PO445-TUE, PO407-WED Sasaki T., OR242, OR404,
Salas J., OR415 WED
Saad E., PO563-WED OR149, OR192, PO201-TUE, Santana M., PO135-TUE PO402-MON
Salas Q., PO354-MON PO655-WED Schfer W., PO605-WED
Saadin K., PO099-MON Santhakumar A., PO498-WED Sasanakul W., PO540-TUE,
Salas S., PO107-TUE Snchez Guiu M. I., PO439-MON, Schffeler E., PO667-WED
Sabagh M., PO640-TUE Santiago-Germn D., PO073- PO647-TUE, PO275-WED
Salaun P. Y., OR146, OR149, PO497-MON MON, PO523-TUE Schalla S., PO348-MON, PO416-
Sabater-Lleal M., PO559-WED PO655-WED Sashindranath M., OR380
Sabatier F., AS085 Snchez Gui I., AS054, AS011 Santoro C., PO534-TUE WED
Salaun P.-Y., AS082, PO628-WED Sasmaz I., PO254-TUE, PO301-
Sabatino D., OR165 WED, PO302-WED, PO530-WED Schaller M., PO412-MON
Salazar A., PO190-TUE
488 489
AUTHORS INDEX
Schaller M., PO581-MON, Schlichting E., PO178-WED Schuetz E., PO549-WED Schwenk J., PO559-WED, PO564- Selbitz A., PO343-WED Serra S., PO172-TUE
PO564-TUE Schlosser J., PO605-WED Schuh A., PO653-MON, PO638- WED Seligsohn U., OR289, PO171- Serro L., PO239-WED
Scharf R., PO394-MON, PO448- Schmid E., PO412-MON TUE Schwertz H., OR243 TUE, PO324-WED Serrato T., PO033-TUE
WED, PO456-WED Schmidbauer S., PO146-TUE, Schuhmacher J., AS018 Schwertz H., OR125 Seljeflot I., OR251, PO079- Seth T., OR066, PO164-MON,
Scharf R. E., PO413-MON, PO194-WED Schuhmann M., PO526-TUE Schwierczek K., PO427-MON, MON, PO030-TUE, PO042-TUE, PO480-MON, PO272-TUE
PO420-MON Schmidt E.-M., PO412-MON Schulman J., PO297-MON PO419-TUE, PO483-WED PO293-TUE, PO342-WED Settapiboon R., PO584-WED
Scharf R. E., PO418-MON Schmidt M., PO107-MON Schulman S., AS077, AS195, Schwocho L., OR199 Sellami M., PO062-WED Settasatian C., PO001-MON,
Scharf R. E., PO417-MON Schmidt S., PO094-MON NUR010, NUR012, OR061, Sciani J., PO107-MON Selmeczi A., PO550-MON, PO080-MON
Scharf R., AS221 OR069, OR200, OR282, OR383, Sciascia S., OR092, PO045-MON, PO031-WED Settasatian N., PO001-MON,
Schmitt V., PO593-MON
Scharf R., OR077, OR329, AS097, PO297-MON, PO614- PO068-WED, PO578-WED Selton-Suty C., PO546-TUE PO080-MON
Schmitz C., AS068
PO539-TUE MON, PO355-TUE, PO361-TUE, Scirpa L., PO574-TUE Selvam S., OR023 Seuser A., PO290-WED
Schmohl M., OR320 PO378-TUE, PO604-TUE,
Scharrer I., PO591-MON, PO593- Sciuccati G., OR160, PO644- Semeniak D., PO505-MON Sverin S., PO514-TUE
Schneewind O., AS113 PO611-TUE, PO613-TUE,
MON, PO570-TUE MON, PO428-TUE Semeraro F., OR065, PO338-WED Severinsen M., OR345
Schneider H., OR042 PO646-WED
Schattner M., AS173, PO012- Scott D., OR433 Semeraro N., PO503-MON, Severinsen M., OR129, PO104-
MON Schneider J., AS099, PO607-TUE Schulman S., PO635-MON
Scott D., PO008-TUE PO338-WED TUE
Schattner M., PO323-MON Schneider L., PO619-MON Schulte S., PO146-TUE, PO596-
Scott J., OR058 Semple J., AS071 Severinsen M., AS083, PO111-
Schedel A., PO383-WED, PO487- Schneppenheim R., OR086, WED
Scott J., AS205, OR444, PO096- Semple J., OR139, PO302-TUE TUE, PO112-TUE
WED OR152, OR335, PO174-MON, Schultz N., OR317
PO649-MON WED Sen H., PO279-WED Sevestre M., PO095-TUE
Scheidler A., PO094-MON Schulz A., PO478-WED
Schnorbus B., PO483-WED Scroyen I., PO571-TUE Sener S., PO221-MON Sevivas T., AS187, OR076
Scheiflinger F., AS221, OR151, Schulz M., PO256-MON
Schnurr T., PO392-MON Scudeller L., PO483-MON Sengupta T., PO342-TUE Sevivas T., OR370
PO249-MON, PO150-TUE, Schulze H., OR081, PO505-MON
Schober A., PO612-WED Scully M., PO586-MON, PO567- Seni G., PO035-WED Seyfert J., PO307-TUE, PO404-
PO151-TUE, PO152-TUE, PO160- Schumacher A., OR125 TUE TUE
TUE, PO517-TUE, PO199-WED, Schobess R., PO093-TUE Senis Y., OR278
Schurer J., PO314-TUE Scully M.-F., PO487-MON Seynabou F., PO542-MON
PO201-WED, PO209-WED, Schchl H., PO612-WED Senis Y., AS069, OR401, AS066,
Schurgers E., OR301, PO025- Scully M., OR436, PO301-MON PO377-WED, PO434-WED Seyve L., PO223-MON, PO241-
PO232-WED, PO284-WED Schoenegger E., PO152-TUE MON, PO072-TUE
Scheiflinger F., OR364 Seabra M. C., PO412-MON Senis Y., OR183 WED, PO422-WED
Schoenwaelder S., PO443-WED Schurgers L., PO395-WED
Schein J., PO625-MON Seah N., PO413-WED Sennblad B., PO559-WED Sezgin Evim M., PO268-MON,
Schoenwaelder S., OR037 Schurgers L., PO104-WED PO156-TUE
Schellenberger V., OR413, OR415 Seaman C., OR201 Sennesael A.-L., PO125-WED
Schoergenhofer C., PO391-TUE Schuster M., PO151-TUE Shabalina A., PO535-TUE
Schellong S., PO356-TUE, Seaman C., OR090, PO277-WED Senthong V., PO001-MON,
Schoeters J., PO364-MON, Schutgens R., PO241-MON Shah A., OR376
PO378-TUE, PO613-TUE, Sebastian P., PO146-TUE PO080-MON
PO142-TUE Schutgens R., OR102, PO658-
PO646-WED Sebastian S., PO584-MON Senzolo M., AS195, PO193-MON, Shah A., OR011
Scholz R., PO248-TUE MON, PO283-WED
Schemper M., PO236-TUE Sedek M., PO227-WED PO114-TUE Shah G., PO559-TUE
Scholz U., OR304, PO517- Schutgens R., PO272-MON
Schenk A., OR059 Seder D., PO367-WED Seo J.-W., PO035-TUE Shah H., PO602-TUE
MON, PO093-TUE, PO248-TUE, Schutgens R. E., PO246-MON
Schenk B., PO330-WED PO480-TUE, PO044-WED, Seeba H., PO404-TUE Seo J. K., PO164-TUE Shah M., PO445-MON
Schutte A., PO071-MON Seo K., OR084, PO354-TUE, Shah V., PO579-MON
Schenk J. F., PO013-WED PO148-WED Seeger J., PO232-MON
Schutte L., PO351-WED PO428-WED Shah V., AS077
Schenk M., PO398-MON, PO506- Schoormans S., OR021, OR203, Seelig J., PO366-WED
PO680-TUE Schutte R., PO071-MON Sepoyan A., PO097-MON Shahani T., PO186-MON
MON Segal M., PO474-MON
Schopohl D., PO291-WED Schtz E., PO513-TUE Sepoyan H., PO462-MON Shahzad K., PO129-TUE
Schenk S., PO152-MON Seger C., PO096-MON
Schrgenhofer C., PO612-WED Schuurmans M., NUR004, Seppnen H., PO162-WED Shaju L., PO531-WED
Scheres L., PO514-MON, PO498- PO230-TUE Seguchi S., AS107
TUE Schotte T., PO579-TUE Sehgal A., OR177, OR213, Sequeira F., PO431-TUE Shaker J., OR010
Schvartsman B., PO433-TUE Serban M., OR348, PO664-MON
Schernthaner G., OR313 Schouten H., PO584-TUE PO154-TUE, PO049-WED Shamsi T., PO134-TUE, PO549-
Schved J. F., PO502-MON, Serdaroglu E., PO590-MON TUE, PO181-WED
Schernthaner G., OR313 Schramm W., PO253-TUE PO551-TUE Seidah N., PO324-MON
Schieman C., PO619-MON Schreck U., PO191-WED Seidel D., PO214-WED Serebriyskiy I., PO150-WED, Shanker J., PO082-MON
Schved J.-F., PO592-WED PO661-WED
Schiel S., AS094, AS169 Schreiber K., PO045-MON, Seidi N., PO318-TUE Shanley C., PO180-TUE
Schwaab R., PO283-MON Serebriyskiy I., PO135-WED
Schillemans M., AS118 PO578-WED Seidl S., PO109-MON, PO510- Shantsila E., PO325-MON
Schwab M., PO412-MON, PO667- Serebrov V., OR287
Schimmel M., PO326-MON Schrenk G., PO223-TUE, PO199- WED TUE Shao Y., PO492-MON
Schinco P., AS088, AS222, WED, PO201-WED, PO270-WED Seifert W., PO643-MON, PO206- Seregina E., PO462-MON Shao Z., PO465-WED
Schwabe J., PO565-MON
PO303-WED Schreuder M., AS056 TUE, PO629-TUE, PO249-WED Seregina E., PO097-MON Shapira I., PO579-MON
Schwameis M., PO612-WED
Schini-Kerth V., AS039 Schrijvers L., PO230-TUE Seiffert D., PO074-WED Seregni S., PO197-WED Shapiro A., PO523-MON
Schwartz B., PO198-TUE
Schipper I., PO532-MON Schrijvers M., NUR004 Seiffert D., PO028-MON, PO349- Sereni A., PO086-MON, PO039- Shapiro A., OR028, PO235-MON,
Schwartz B., PO664-MON TUE
Schiviz A., OR151, PO199-WED Schroeder J., PO222-WED MON, PO076-WED PO277-MON, PO502-MON,
Schwartz C., PO257-WED Series J., PO423-TUE PO286-WED, PO521-WED
Schlagenhauf A., PO453-MON, Schroeder V., PO303-TUE, Seigal D., NUR007
PO185-WED, PO186-WED Schwartz E., OR014, OR211, Serino M. L., PO264-MON Shapiro S., PO603-MON
PO464-MON PO281-MON Seignovert C., PO159-TUE
Schlammadinger ., PO550-MON, Schroeder V. S., PO181-WED Seita I., PO161-MON, PO213- Serlie M., PO372-MON, PO537- Sharabi-Nov A., PO471-WED
Schwartz E., PO231-TUE MON, PO506-TUE, PO507-TUE
PO031-WED Schroeter M., PO102-WED TUE Sharda A., PO425-MON
Schwartz J., OR173, PO339-WED Sermsathanasawadi N., PO594-
Schledzewski K., OR409 Schrum J., PO174-MON ekir U., PO268-MON Shargall Y., PO619-MON
Schwarz T., AS018, PO214-WED MON
Schlegel N., PO436-MON, Schubert W., PO536-WED Sekiya A., PO599-MON Shariff S., PO595-TUE
PO440-MON Schwarzmaier S., PO177-TUE Sern A., PO366-WED
Schueler E., PO646-WED Seksarn P., PO254-MON Sharma A., PO202-WED
Schleifer M., PO065-TUE Schuett K., AS231, PO465-TUE Selan C., AS212 Serra J., PO038-MON
490 491
AUTHORS INDEX
Sharma A., OR009, PO084-MON, Shim Y.-J., PO164-TUE, PO280- Siddons S., PO511-WED Silveira J., PO397-WED Siriboonrit U., PO613-WED Smith E., OR392, OR393,
PO040-TUE TUE Sidhu J., OR350, PO241-TUE Silver R. M., AS020 Sirotkina O., PO444-MON PO519-MON, PO524-MON,
Sharma A., AS212 Shima M., AS017, AS015, Sidhu M., OR167 Silvestri E., PO226-MON Sisson M., PO353-TUE PO525-MON, PO526-MON,
Sharma M., PO516-WED PO151-MON, PO244-MON, Sidonio R., PO512-WED Sim D., PO026-MON, PO212- Sisson M., PO409-WED PO493-TUE, PO494-TUE,
Sharma R., AS160 PO491-MON, PO652-MON, WED, PO213-WED, PO553-WED PO495-TUE, PO567-WED,
Sidorova M., PO281-TUE, PO290- Sitko G., PO074-WED PO568-WED
Sharon N., PO324-WED PO666-MON, PO668-MON, TUE Sim E., PO628-MON
PO088-TUE, PO145-TUE, PO165- Siudut J., PO105-MON, PO536- Smith G., OR127
Shash D., PO613-TUE TUE, PO205-TUE, PO224-TUE, Sie P., PO440-MON Sim Y., PO218-MON, PO219- TUE, PO677-WED
MON, PO221-MON Smith H., OR028
Shaverdi M. R., PO600-WED PO018-WED, PO113-WED, Si P., PO345-MON, PO501- Sivera P., PO671-WED
MON, PO423-TUE Simak J., OR174, PO603-WED Smith J., PO662-WED
Shaverdi S., PO247-TUE PO205-WED, PO347-WED Sjouke B., PO028-TUE
Siebert M., PO382-MON Simeoni I., OR176, PO384-WED Smith J. M., PO201-MON
Shaverdi Niasari M. R., PO247- Shimaoka M., PO185-TUE Skarpen E., PO557-TUE
TUE Siegal D., PO355-MON, PO616- Simic Vojak S., PO144-WED Smith K., PO367-WED
Shimizu C., PO455-WED Skelton S., OR108
Shavit J., OR039 WED Simioni P., AS042, OR078, Smith K., OR372, PO465-TUE
Shimizu H., PO441-WED Skeppholm M., OR187, PO368-
Shavit J., OR331 Siegbahn A., OR046, OR312, OR172, PO061-MON, PO193- MON, PO412-WED Smith K., AS003, PO190-WED,
Shimizu I., PO173-TUE PO243-WED
Shaw J., OR310, PO641-MON, PO563-MON, PO330-TUE, MON, PO341-MON, PO456-MON, Skipper M., PO394-TUE, PO406-
Shimizu M., OR051 PO552-TUE PO515-MON, PO114-TUE, Smith K., OR410
PO320-TUE Shin S.-H., PO599-TUE TUE
Shawkat S., PO196-MON Siegemund A., OR304, PO517- PO315-TUE, PO331-TUE, Skjelbakken T., OR120, PO561- Smith L., PO167-MON, PO257-
Shin S., PO115-MON MON, PO093-TUE, PO169-TUE, PO332-TUE, PO438-TUE, MON
Shaya S., AS216 WED
Shin-Nan C., PO304-WED PO044-WED, PO148-WED PO524-TUE, PO548-TUE, Smith M., AS130
Sheehan J., PO175-MON PO127-WED, PO387-WED Skjeldestad F. E., PO472-MON
Shinohara K., OR051 Siegemund T., OR304, PO517- Smith N., OR431
Sheffield W., OR425 Simioni P., OR366 Skjeldestad F.-E., OR134, OR258
Shinozawa K., PO161-MON, MON, PO093-TUE, PO169-TUE, Smith N., NUR005
Shelar T., PO207-TUE PO213-TUE, PO006-WED, PO044-WED, PO148-WED Simmons K., AS231 Skov S., OR036, OR040
Skowronska M., PO581-MON, Smith N., OR034, OR133, OR266
Shelke P., PO176-MON PO204-WED Siegerink B., OR255, PO069- Simon A., OR213
PO564-TUE Smith N., PO557-WED
Shen J., PO331-MON Shintome M., PO173-TUE MON Simon A., OR271
Skretting G., OR440, PO109- Smith O., OR182
Shen L., PO176-TUE Shiota N., OR051 Siegerink B., AS138 Simon S., PO181-TUE MON, PO118-MON, PO123- Smith R., PO073-TUE
Shen M.-C., PO245-MON, PO226- Shirafuji N., PO380-TUE Siegert G., PO263-MON Simpson C., OR200
TUE, PO274-WED MON, PO453-TUE, PO556-TUE, Smith S., OR415
Shirahata A., OR142 Siegmund B., PO283-MON Simpson K., PO096-WED, PO190- PO557-TUE, PO178-WED Smith S., OR178
Shen W., OR137 Shirai T., OR242, OR343, OR404, Siekmann J., PO200-WED WED Slade J., NUR003 Smith S., PO300-TUE
Shendure J., OR298 PO402-MON Siekmann J., PO249-MON Simpson K., AS003 Slagsvold C. E., AS136 Smith S., OR353, PO001-TUE,
Shenkman B., PO396-MON, Shirakawa R., PO653-TUE Siemens R., PO180-WED Simpson M., AS054, AS011
PO055-TUE, PO062-TUE Slatter D., PO353-WED PO451-WED, PO543-WED,
Shirani P., PO533-TUE Sienko S., PO354-WED Simpson M., PO193-WED Slaughter M., OR338 PO544-WED
Shenoy A., PO363-TUE Shivakumar S., OR282 Sigaud M., PO016-WED Simpson M., PO262-TUE Slavik L., PO564-MON, PO060- Smith S., OR354
Shenoy V., PO424-MON Shixiang Z., PO394-WED Sigh J., AS019 Sims C., PO608-WED TUE, PO542-TUE Smith T., PO459-TUE
Shepherd A., OR108 Shmeleva V., PO503-TUE Sigl-Kraetzig M., PO256-MON, Simsekyilmaz S., PO091-WED Sled J., OR031 Smith V., PO107-WED
Shepherd L., OR200 Sholzberg M., PO150-MON, PO290-WED Sinegre T., PO075-TUE Sleeman M., PO605-MON, Smith W., PO071-MON
Sherath M., PO555-WED PO274-MON, PO151-WED, Siguret V., OR196, PO350-TUE, Siner J., AS120 PO590-TUE Smits L., PO157-TUE, PO218-
Sherif J., PO677-TUE PO248-WED PO672-WED Singer A., PO319-TUE Sletten M., PO178-WED WED, PO234-WED
Sherman A., OR107, PO220-WED Shpitonkova O., PO501-WED Sikorska A., PO278-MON, PO549- Singer D., PO613-TUE Sloane D., OR247, OR299 Smoyer W., PO571-WED
Shestopal S., OR163, PO196- Shrestha A., PO287-WED MON, PO032-WED, PO526-WED, Singer H., PO191-WED Slothuus U., OR349, PO139-TUE Smyth E., PO400-MON, PO398-
WED Shresthna A., PO591-MON PO536-WED, PO588-WED TUE
Singh I., PO498-WED Slovak M., PO341-TUE
Shetty S., PO207-TUE Shu L., PO321-WED Silva A., PO269-WED Smyth S., OR419
Singh K., PO533-TUE Smbrekke B., OR071, OR254,
Shevchenko A., PO329-WED Shubina T., PO206-MON, PO308- Silva A., PO663-TUE, PO237- OR293, OR392, PO594-TUE Sneeboer M., PO611-MON,
WED Singh K., OR041
Shi H., PO608-TUE, PO266-WED MON Smadja D., AS087, PO513-WED PO335-WED
Silva F., PO523-MON, PO508- Singh K., OR258, PO472-MON
Shi P., OR210 Shu-Hsia H., PO304-WED Smadja D., AS086 Snoeren I., PO405-MON
TUE Singh R., PO542-WED
Shi P., PO105-WED Shukla S., PO519-WED Smalisz-Skrzypczyk K., PO574- Soares A., PO239-WED
Silva M., PO663-TUE, PO237- Singla A., PO041-TUE
Shi Q., PO222-WED Shulutko A., PO661-WED WED, PO575-WED Sobociska-Mirska A., PO575-
WED, PO479-WED Sinha R., PO577-MON
Shi W., PO132-MON Shupp J., OR426 Smejkal P., AS133, PO655-MON WED
Silva M. V., PO189-TUE, PO002- inigoj P., PO360-TUE
Shi X., OR018 Shustova O., PO327-TUE Smetanina N., PO097-MON Sobrino T., OR116
WED Sinkov S., PO466-TUE, PO586-
Shi Y., OR007 Shvelidze T., PO277-TUE, PO337- TUE Smiers F., AS079 Sdergren A., PO571-MON
WED Silva M., PO426-TUE
Shiba T., PO300-TUE Sinnamon A., AS185 Smiers F., OR389 Soejima K., AS178, PO441-WED
Siboni S., OR026, PO502-MON, Silva R., PO663-TUE, PO237-
Shibata Y., OR051 WED Sion K., PO656-WED Smirnova O., PO057-TUE, PO367- Soendergaard H., OR040
Shibeko A., PO560-MON PO663-MON, PO090-TUE, TUE, PO111-WED Sofi F., PO086-MON, PO039-TUE
PO091-TUE, PO521-WED Silva G. C., AS039 Sioufi J., PO366-TUE
Shida Y., PO652-MON, PO666- Silva M. C., PO239-WED Siqueira L., PO595-TUE Smith B., OR109 Sohn D.-W., PO035-TUE
MON, PO668-MON, PO224-TUE, Siboni S. M., PO656-MON,
PO650-TUE Silvari V., PO406-WED Siqueira L. H., PO422-MON, Smith C., PO048-TUE Sker M., PO264-WED
PO347-WED Smith C., AS114 Sker S., PO264-WED
Sibrowski W., PO015-TUE Silveira A., PO231-MON, PO333- PO531-MON
Shih A., PO570-MON Smith C., PO600-MON, PO582- Sokollik C., PO485-MON
Sickmann A., PO499-MON MON, PO135-TUE Sirachainan N., PO540-TUE,
Shih C.-C., PO085-WED PO275-WED TUE Sokolova L., PO118-WED
Sicot G., PO376-WED Silveira A., OR269, PO559-WED,
Shih N., PO336-TUE PO564-WED Siragusa S., OR027, PO117-TUE, Smith D., PO625-MON Sokolowska E., PO300-MON,
Shiller E., PO019-WED Siddiqui A., PO195-MON
Silveira J., PO145-MON PO614-WED PO345-WED, PO365-WED
Siddiqui M., OR435
492 493
AUTHORS INDEX
Sokoowska B., PO648-TUE Sottilotta G., PO303-WED Spronk H., PO056-MON Staudt M., PO091-WED Stivala S., PO027-MON Stufano F., PO663-MON
Solari F., PO499-MON Soucie M., OR162 Spronk H., OR067, OR225, Stausholm-Mller A. K., PO130- St-Louis J., OR028, OR217, Stuleva N., PO052-MON, PO589-
Sola-Visner M., OR232 Soule E., AS151 PO348-MON, PO097-WED, MON PO282-WED WED
Soldatenkov V., PO111-WED Souri M., OR250 PO104-WED, PO349-WED, Stavermann C., PO395-TUE Stoilova-Mcphie S., PO192-WED Stumpo D., OR085
Soldatenkov V., PO503-TUE Sousa J., PO212-TUE PO416-WED Stavik B., OR440, PO109-MON, Stojkovic S., PO185-MON, Stunnenberg M., PO326-MON
Solecka B., PO675-TUE Sousa L., PO237-WED Spronk H., PO092-WED PO118-MON, PO123-MON PO559-MON Sturgeon S., OR037
Soler M., PO439-MON Sousa L., PO663-TUE Spronk H., PO470-MON Stearns-Kurosawa D., PO564-TUE Stokhuijzen E., OR389, PO240- Sturk A., PO401-WED
Spronk H., PO143-MON Steede S., PO194-WED TUE, PO510-WED Sturm R., OR047
Solernou A., PO243-WED Sousa L., PO340-WED
Spyropoulos A., PO362-MON, Steele M., PO426-TUE, PO440- Stokol T., AS060, PO112-MON Stuth E., OR058
Solheim S., OR251, PO079-MON, South K., PO036-WED
PO030-TUE, PO042-TUE PO654-WED TUE, PO563-TUE Stoldt V., PO394-MON, PO448- Su J., PO039-WED, PO533-WED
Souto J., OR076 WED, PO456-WED
Solimeno L., PO261-TUE Spyropoulos A., PO521-MON Stefanini L., AS070, PO423-MON Su J., PO220-WED
Souto J. C., PO559-WED Stoldt V. R., PO413-MON, PO417-
Solomon T., OR392, OR393, Spyropoulos J., PO654-WED Stefanska-Windyga E., PO049- Subramanaian D., PO479-TUE
Souto J. C., PO543-MON, PO126- TUE, PO235-TUE MON, PO418-MON, PO420-MON
PO519-MON, PO524-MON, TUE, PO217-WED Squatrito D., PO226-MON Subramaniam S., AS218
PO525-MON, PO526-MON, Squire S., PO269-WED Steggewentz B., OR054 Stoll G., AS068, AS094, AS228,
Souza L., PO397-WED OR169, PO526-TUE Subramanian S., PO306-WED,
PO493-TUE, PO494-TUE, Squizzato A., PO610-TUE, Stegner D., AS094, OR017, PO531-WED
Sovershaev M., AS028, PO572- OR169, OR181, OR405, OR416, Stoner J., PO523-MON, PO449-
PO495-TUE, PO567-WED, WED PO613-MON, PO028-TUE Subramanyam B., PO213-WED
PO568-WED Sramek A., OR391 PO505-MON, PO526-TUE TUE, PO157-WED
Sovershaev T., AS028, OR047 Stoof S., PO267-MON, PO282- Subramanyan B., AS018
Solymoss S., AS077, OR282 Sripraya P., PO120-TUE Steiner B., OR020
Spls-Abrahamsson Y., PO263- MON Such G., PO014-TUE
Somajo S., OR369 Srivastava A., PO664-MON, Steinitz K., AS191, PO243-TUE,
WED PO244-TUE, PO286-WED Stoof S. C., PO351-WED Suchon P., OR324
Sommer J., PO208-TUE Span L., PO431-WED PO245-TUE, PO153-WED
Steinke W., PO214-WED Stopa J., OR417, PO425-MON Suda T., PO386-WED
Sommerer P., PO647-MON, Spannagl M., PO356-TUE Srivaths L., PO445-MON, PO567-
Stellin G., PO438-TUE Stopa J., PO346-TUE, PO551- Suehisa E., PO120-WED
PO195-WED MON
Spanoudaki A., PO102-TUE, Stemmelin G., PO180-TUE WED Sueldo E., PO092-TUE, PO146-
Sommerville L., PO104-MON PO587-WED St. Angelo Iii J., PO329-WED
Storey R., OR398 WED, PO231-WED
Sonet A., PO167-WED St. John A., PO372-WED Stender S., PO509-MON
Sparkenbaugh E., AS049, OR306 Storey R., OR016 Suffritti C., PO178-TUE
Song J., PO471-TUE, PO309- St. John A., PO375-WED Stennicke H., OR237
Spath B., PO251-MON, PO174- Stoute H., PO105-WED Suganuma Y., PO432-WED
WED WED St.Ledger K., PO089-TUE, Stensballe J., PO482-MON
Stowers A., PO089-TUE Sugi T., PO167-TUE
Song Y.-J., PO471-TUE Spavor M., PO465-MON PO262-TUE Stentoft J., PO406-TUE
Straat R., PO349-WED Sugimoto M., PO671-MON,
Song Y., PO278-TUE, PO323- Speck E., OR139, PO302-TUE Stchele J., PO263-MON Stpanian A., PO672-WED
Straat R., PO123-WED, PO609- PO205-WED
WED Staels B., AS201, OR219, Stephan B., PO013-WED
Spectre G., PO383-TUE, PO392- WED Sugita N., PO505-TUE
Songnuy R., PO254-MON WED PO662-TUE Stephenson J., PO521-MON
Stradal T., AS169 Suidan G., PO004-TUE
Sonia B., PO444-TUE Speers H., PO481-MON, PO588- Stafford A., PO138-MON Stephenson T., PO634-WED
Strader M., OR174 Suissa S., OR385, PO577-TUE
Sonmez M., PO088-WED TUE Stafford A., AS154, AS219, Sterk P., PO335-WED
OR057, OR286, OR290, PO403- Strahs A., OR213 Sukarova Stefanovska E., PO287-
Snmez T., PO091-WED Speidl W., AS200, PO282-TUE Sterling S. P., PO360-WED
MON, PO170-TUE Strauss T., PO429-TUE, PO659- MON
Sonneveld M., AS181, OR364 Speidl W., OR123, PO185-MON, Stern J., PO006-TUE
Stain A. M., AS078 TUE Sukhanov V., PO470-TUE
Sood M., AS211 PO301-TUE Stern S., PO372-WED
Stlesen R., PO383-TUE, PO392- Strawbridge R., OR269, PO559- Suleiman L., OR358
Soomro A., OR377 Spek C. A., PO164-WED Sterz F., PO612-WED
WED WED Sullenger B., PO104-MON
Sorensen A., OR237 Speker M., PO550-MON Stevano A., OR161
Stalinska K., PO365-WED Strayhorn D., PO331-MON Sullenger B., AS151
Sorensen B., OR177, OR213, Spencer A., OR229 Stevenazzi C., PO474-TUE
Stalker T., OR038, OR207 Streif W., PO481-WED Sullivan A., PO088-MON
PO154-TUE Spencer F., OR395, PO578-TUE Stevens J., PO592-WED
Stalker T., PO467-WED Strelkov S., OR443 Sumarokov A., PO496-WED
Sorensen E., OR338 Spencer F., OR282 Stevenson B., AS128
Stallmann D., OR252 Strelkova I., PO028-WED, Sumi H., PO216-MON, PO462-
Srensen B., PO454-TUE Spencer H. T., PO203-WED Stevenson W., OR002, PO433-
Stam J., OR118, PO525-TUE PO030-WED TUE, PO463-TUE
Srensen H., OR098 Spencer Chapman M., PO258- MON, PO421-TUE
Stampfuss J., AS104 Strickland D., PO493-MON Sun B., OR342
Sori F., PO600-WED WED Stevic I., OR373, PO350-MON,
Stanek J., OR157 Strike K., PO380-MON Sun H., OR249
Soria J., PO117-MON, PO119- Sperr W., PO612-WED PO139-WED
Stanford S., PO083-TUE Stritt S., AS068, AS169, AS228, Sun J., PO292-WED
MON Spiezia L., AS042, OR078, Stewart A., PO580-TUE
Stang L., PO086-TUE OR081, OR416, PO436-MON Sun J., PO032-MON, PO166-
Soria J., PO516-MON OR172, PO061-MON, PO341- Stewart S., OR218 Strong J., PO601-MON, PO580- MON, PO052-WED
Soria J. M., PO126-TUE, PO217- MON, PO456-MON, PO114- Stangier J., OR320, PO376-TUE Stewart S., PO580-TUE TUE, PO581-TUE Sun M.-F., OR287, OR288
WED TUE, PO315-TUE, PO331-TUE, Stangl A., PO107-WED, PO137- Stewart T., PO580-TUE, PO581-
PO332-TUE, PO438-TUE, WED Stroobants A., PO401-WED, Sun T., OR265, PO451-TUE
Soria J. M., PO543-MON, PO559- TUE PO410-WED
WED PO524-TUE, PO127-WED Starigk J., PO383-WED Sun Y., OR418, PO462-WED
Sticchi E., OR270, PO477-TUE, Struble E., PO008-TUE Sun Y., OR261
Soriani F., PO340-WED Spinewine A., PO125-WED Starikova I., PO338-MON, PO572- PO586-WED
Spinola A., PO318-TUE, PO626- WED Struck H., PO305-WED Sundaramoorthi H., OR402,
Soroka V., PO576-WED Stidl R., PO200-WED
TUE Staritz P., PO215-TUE Strukov A., PO620-MON PO034-MON
Sorrentino A., PO572-WED Stiell I., OR198
Spnola A., PO442-MON Starke R., OR410 Strukova S., PO281-TUE, PO290- Sundarsingh A., PO153-WED
Sorvillo N., PO227-WED Stieltjes N., AS164, PO501-MON TUE, PO537-TUE
Spirig R., AS016 Stasyshn O., PO260-MON Sung L., PO454-MON
Sosothikul D., PO254-MON Stikarova J., PO238-WED Strulovitch C., NUR009, PO390-
Sponagle K., AS191, AS192, Stasyshyn O., OR215, PO206- Sungur M., PO591-TUE
Soto G., PO466-WED tikarov J., PO194-TUE MON, PO393-MON
OR409, OR412, PO291-TUE, TUE, PO262-TUE, PO249-WED Suntsova M., PO496-MON
Soto J., PO355-WED Stinson J., OR328, PO475-MON, Stubblefield W., PO227-MON
PO679-TUE Stasyshyn O., PO643-MON, Surbek D., AS163
Soto M., OR220, PO480-WED PO434-TUE Study Group W.-Q., PO639-TUE
Spotts G., PO286-WED PO629-TUE Suri V., PO200-MON
494 495
AUTHORS INDEX
Suriano L., PO671-WED Syed D., PO182-MON, PO293- Takagi Y., PO151-MON, PO486- Tange J., PO648-MON, PO655- Temperilli F., PO060-MON, Thaler J., OR313, OR357,
Suriach J. M., PO321-TUE MON, PO305-MON, PO334-MON, TUE, PO560-WED TUE PO084-WED, PO316-WED PO391-WED
Surov S., PO047-WED PO346-MON, PO191-TUE, Takagishi N., PO661-TUE Tanka-Salamon A., PO240-WED Ten Brinke A., PO227-WED Thlin C., PO171-WED
Surov S., PO147-WED PO192-TUE, PO337-TUE, PO331- Takahashi H., AS017 Tantanate C., PO040-MON Ten Cate A., PO314-WED Thalji N., PO415-WED
WED, PO332-WED, PO339-WED, Takahashi N., PO486-WED
Suryanarayan D., OR061 Tantry U., PO076-MON, PO099- Ten Cate H., PO056-MON, Thalji N., PO632-MON
PO344-WED, PO374-WED
Suryanarayan D., PO355-TUE Takahashi N., PO041-MON, MON, PO041-TUE PO645-MON Thanos C., OR247, OR299
Sykora K.-W., PO442-TUE PO357-MON, PO020-WED,
Susanna L., PO240-MON Tantucci C., OR315 Ten Cate H., OR067, OR096, Thati M., PO129-TUE
Sylman J., PO188-MON PO057-WED OR119, OR427, OR430, AS024,
Susen S., AS134, AS201, OR024, Tao M.-H., PO029-MON Thaweekhot T., PO040-MON
Syrigos K., PO102-TUE Takayama S., PO211-WED PO143-MON, PO348-MON,
OR025, OR219, PO345-MON, Tao M., OR419 Thtre E., OR278, PO407-MON
PO662-TUE, PO513-WED Syvannarath V., OR170, PO330- Takayuki N., PO108-WED PO466-MON, PO470-MON,
Tao Y., AS051 Thelwell C., OR445
MON Takedani H., PO261-TUE PO348-TUE, PO004-WED,
Sussman M., OR390 Tarakhovsky A., PO434-WED PO033-WED, PO092-WED, Theogene A., OR384
Szabo A., AS025, AS232, OR006, Takeo E., PO120-WED
Sutherland M., OR271 PO098-WED Tarandovskiy I., OR174, PO603- PO097-WED, PO314-WED, Theophil R., OR439
Suttnar J., PO238-WED Takeyama M., PO666-MON, WED PO416-WED, PO478-WED Theophilus B., OR086
Szab L., AS004, PO240-WED PO668-MON, PO224-TUE
Suttnar J., PO194-TUE Taranenko I., PO150-WED Ten Cate - Hoek A., PO092-WED Theresa C., PO421-WED
Szafarczyk D., OR077 Taki M., AS017, PO205-TUE,
Suvajdzic-Vukovic N., PO252- Tarantino E., PO005-TUE Ten Cate-Hoek A., PO056-MON Therkelsen M., PO121-WED
Szczepaniak P., PO246-WED PO233-TUE, PO211-WED
MON Tarantino G., PO614-WED Ten Cate-Hoek A., OR427, Thrond P., PO437-WED
Szczubialka K., PO300-MON, Talarmain P., PO645-TUE
Suwanawiboon B., PO675-MON, PO345-WED, PO365-WED Tardy B., AS082, OR012, OR055, OR430, PO348-MON, PO416- Therwath A., PO117-MON,
PO345-TUE, PO647-TUE Talavera E., OR092 PO107-TUE, PO262-WED WED
Szecsi P., PO509-MON PO119-MON
Suwannawiboon B., PO268-WED, Talbot K., PO459-TUE Tardy B., OR012, OR055, PO263- Ten Cate-Hoek A., PO466-MON,
Szkely E., PO516-TUE Theunissen M., PO350-WED
PO643-WED Talbot T., PO098-TUE TUE, PO262-WED PO471-MON
Szkotak A., PO086-TUE Thiede B., PO557-TUE
Suylen D., PO037-TUE Taliaferro J., OR207 Tarrant J., PO007-WED Ten Cate-Hoek A., PO470-MON
Szollosi R., PO098-MON Thiele B., PO669-MON
Suylen D., PO411-MON Talks K., PO502-WED Tartaglione R., OR202 Ten Wolde M., PO466-MON,
Szopiski P., PO609-TUE Thielmann I., AS094, AS218,
Suzuki E., PO515-TUE, PO528- Talks K., AS054 Tartari C., PO179-WED PO470-MON PO129-TUE
TUE Szotkowski T., PO279-TUE Tall F., AS164 Teng Z., PO657-WED
Tartari C., PO339-MON Thim L., OR414
Suzuki K., OR352 Szk T., PO077-MON Talmon M., AS088 Tenna A., PO447-MON
Tasneem S., OR377 Thippayanuruksakul P., PO606-
Suzuki K., PO185-TUE, PO284- Tablin F., PO006-TUE, PO007- Tamamyan G., PO573-MON Teraa M., PO389-TUE
Tatonetti N., PO408-WED TUE
TUE, PO335-TUE TUE
Tamara S., PO208-MON Tatour M., AS096 Terenteva V., PO183-TUE Thiranos J.-C., PO263-TUE
Suzuki K., PO173-TUE Taboukouyout A., PO375-MON
Tamarin I., PO217-TUE Tatsumi K., PO505-TUE Ternisien C., AS134, OR024, Thiry M., OR278
Suzuki N., PO434-MON Tabuchi Y., PO085-TUE OR025, PO639-TUE, PO645-
Tamary H., PO475-WED Tautz L., OR278 Thivillier C., PO546-TUE
Suzuki N., PO211-WED Tadokoro S., OR340 TUE, PO664-TUE, PO016-WED
Tamborini Permunian E., PO405- Tavil B., PO505-WED Thom J., PO669-TUE
Suzuki T., PO161-MON, PO213- Tafur A., PO449-TUE, PO508- WED Ternissien A., PO535-MON
TUE, PO157-WED Tavkar P., PO153-WED Thom K. E., PO302-MON
TUE, PO006-WED, PO251-WED Tamminga R., AS079, PO255- Terpolilli N., PO177-TUE
Tafur A., PO523-MON Tawara S., PO547-WED Thomas A., OR104
Suzuki T., PO041-MON, PO357- WED Terrasi J., PO203-TUE
Tafur A., OR127 Tay J., PO324-TUE, PO540-WED, Thomas J., OR056
MON, PO020-WED, PO057-WED Tamura R., AS143 Terrisse A.-D., PO514-TUE
PO546-WED Thomas M., PO586-MON
Suzuki Y., AS030 Tafuro E., PO071-TUE Tamura S., OR242, OR404, Tersago D., OR363
Tay J., PO101-TUE Thomas M., OR016
Suzuki-Inoue K., OR242, OR343, Taga S., PO173-TUE PO402-MON, PO455-WED Tersteeg C., OR151, OR153,
Tay E., PO413-WED Thomas S., PO404-MON
OR404, PO402-MON, PO419- Tagalakis V., OR385, PO577-TUE, Tan C. W., PO012-TUE, PO074- PO401-MON, PO571-TUE
MON PO647-WED Tayfun F., PO525-WED Thomas S., OR401
TUE Teruel-Montoya R., PO558-TUE,
Svensson A., OR237, PO541-WED Tagariello G., PO266-WED, Tayfur V., PO051-WED Thomas T., OR433
Tan S., PO326-TUE PO552-WED
Sveshnikova A., AS142 PO369-WED Taylor M., PO037-WED Thomassen M., PO518-MON
Tan S., OR318 Teruel-Montoya R., OR221,
Sveshnikova A., PO392-TUE Tagawa S., PO172-WED Taylor P., PO190-TUE Thomassen M. C., PO002-WED,
Tan S., OR415, PO248-MON PO497-MON, PO338-TUE,
Svirin P., PO019-WED, PO509- Tagliaferri A., AS222, OR144, Tchaikovski S., PO518-MON PO539-WED PO023-WED
Tan S. C., PO413-WED
WED PO264-MON, PO283-MON, Tcherniantchouk O., OR216 Teruya J., OR056, PO631-TUE Thomassen S., PO617-MON,
PO222-TUE, PO650-TUE, Tanaka K., PO017-WED
Swai M., PO063-WED Te Roller L., PO642-TUE Teske G., PO442-WED PO348-TUE, PO349-TUE
PO253-WED, PO303-WED Tanaka K., OR352, PO351-MON
Swartz D., AS063 Tee L., AS069, PO434-WED Tesoro T., PO083-WED Thompson A., PO248-MON
Tagzirt M., AS201 Tanaka M., PO351-MON
Sweigert P., PO112-WED Tegegn T., OR174, PO603-WED Testa S., OR065, PO639-MON, Thompson E., PO377-TUE
Taher M., PO085-MON Tanck M., OR015
Swerdlin R., PO512-WED Tegtmeyer R., PO449-WED PO640-MON, PO059-TUE, Thomson M., PO375-WED
Taher M., PO148-TUE Tandakha D., PO542-MON
Swieringa F., AS204, PO411- Teitel J., PO151-WED PO197-TUE, PO671-WED Thon J., OR232
Tahtakesen T., PO313-MON Tandon N., PO611-WED
MON, PO499-MON, PO155-TUE, Teitel J., AS122, PO150-MON, Teste B., PO376-WED Thongnoppakhun W., PO345-TUE
PO675-TUE Tai W.-S., OR031 Tang A., PO317-TUE PO262-MON, PO274-MON, Testen A., OR366 Thorack U., OR125
Swinnen M., PO002-TUE Tait C., PO291-WED Tang C., AS026, PO022-MON PO248-WED Texter K., OR157 Thorn Clausen J., PO455-TUE
Sword-Buster A., PO637-WED Tait R., OR135 Tang L., PO162-MON, PO132- Teitell J., PO286-WED Thabane L., AS122, PO261-MON, Thornton D., PO580-TUE, PO581-
Tait R., PO271-MON TUE, PO492-TUE, PO213-WED, Teixeira A., PO340-WED
Swystun L., OR332, PO679-TUE PO262-MON, PO463-MON TUE
PO569-WED
Swystun L., OR412, PO291-TUE Tait R. C., PO283-WED Teixeira C., PO179-TUE Thacil J., AS054 Thrlfsson M., PO219-WED
Tang L., PO246-TUE
Swystun L., OR409 Tajer C., PO621-TUE Teixeira-Carvalho A., PO333-MON Thakore J., PO075-WED Thorsson O., PO240-MON
Tang W., OR266
Syed A., AS171 Takach Lapner S., AS023 Teliga-Czajkowska J. M., PO536- Thaler B., AS200, PO282-TUE, Threeswaran R., PO021-WED
Tang Y.-H., PO522-TUE WED, PO588-WED
Syed A., AS051 Takacs N., PO509-TUE PO301-TUE Thulin A., OR312
Tangada S., PO223-TUE, PO270- Tellier Z., PO501-MON
Takagi A., PO151-MON, PO486- WED Thulin ., OR046, PO330-TUE
TUE, PO560-WED Tian J., PO447-WED
496 497
AUTHORS INDEX
Tiantian S., AS075, OR264, Tomberg K., OR361 Tran H., OR229, PO468-MON, Tsai J.-R., PO226-TUE, PO289- Tutwiler V., OR305, PO424-MON Urbanus R., PO584-MON, PO389-
PO566-TUE Tomczyk M., AS030 PO618-MON WED Tuysuz G., PO525-WED TUE
Tichelaar V., OR258, PO338- Tomer A., OR055, PO268-TUE Tran K., AS018 Tsai W., PO245-MON Tweddell J., OR058 Urbanus R., PO072-TUE
MON, PO472-MON, PO304-TUE, Tomescu D., PO501-TUE Tran L., PO033-TUE Tsakiris D., PO243-TUE, PO244- Tyagi S., PO272-TUE Urbanus R. T., PO246-MON
PO328-TUE, PO396-WED Tomi B., PO547-MON Tran O., PO625-MON TUE Urdanibia I., PO190-TUE
Tynngard N., PO401-TUE
Tichelaar V., PO641-WED Tomin D., PO252-MON Tran S., AS040 Tsao E., PO237-MON, PO678- Urgo J., PO256-WED
Tynngrd N., PO571-MON
Tichelaar Y. V., PO346-WED Tomiyama Y., OR340, PO320- Tran T., OR281 TUE Usanga E., PO386-MON
Tzakos A., PO452-WED
Tidwell R., PO426-WED WED Tranholm M., PO147-MON Tsao-Wei D., PO172-WED Usui M., PO486-WED
Tzoran-Rosenthal I., PO389-WED
Tiede A., AS221, PO256-MON, Tomkowski W., PO311-WED Traore A., PO276-MON Tsay W., OR348 Utne K., OR072, PO600-TUE
PO259-MON, PO251-WED, Uaprasert N., PO266-TUE,
Tomlinson D., AS231 Tratar G., AS101 Tselepis A., PO452-WED PO584-WED Utset T., PO025-WED
PO272-WED Tseneklidou-Stoeter D., PO293-
Tomlinson M., OR276 Travers R., OR351 Ucar M., PO591-TUE Uyanik M., PO043-TUE
Tiede C., AS231 WED
Tomokiyo K., OR142 Travers R., PO336-WED, PO544- Ucbilek E., PO591-TUE Uzlova S., PO460-TUE
Tiefenbacher S., PO173-MON, WED Tseng C.-P., OR344, PO430-WED
PO161-TUE, PO216-WED, Tonai T., OR051 Uchitel I., PO496-WED V S. C., PO363-TUE
Tonello C., OR195, PO385-MON, Treffon J., PO157-TUE Tseng T.-C., PO328-MON Uchiyama S., PO477-WED Vaara S., PO304-MON
PO233-WED
PO624-WED Tregouet D.-A., PO441-MON Tsuda H., PO545-MON Udomkiat P., PO643-WED Vaccarino A., AS195
Tien J., OR295
Toogeh G., PO247-TUE, PO600- Tregouet D., OR266 Tsuda T., PO545-MON Udvari ., PO550-MON Vacher J., PO190-WED
Tientadakul P., PO040-MON
WED Tregouet D.-A., AS014 Tsui H., PO151-WED Ueda T., PO322-WED Vadasz B., OR031, PO328-WED
Tiftik E., PO591-TUE
Topalov N., PO135-WED Tregout D., OR324 Tsukamoto K., PO351-MON Ugarte A., AS230 Vadivel K., PO165-MON
Tijssen M., OR231
Toret E., OR262 Trgout D., PO559-WED, PO564- Tsukiji N., OR242, OR404, Uhl C., PO484-WED Vaewpanich J., PO540-TUE
Tikhonova N., PO113-MON PO402-MON, PO419-MON
Tormene D., OR078, OR172, WED Uhln M., PO564-WED Vaezzadeh N., AS216, OR286,
Till S., PO201-WED, PO284-WED PO341-MON, PO515-MON, Tsunaka M., PO106-MON
Trgout D.-A., AS045, AS206, Uhlig S., PO383-WED PO403-MON
Tilley D., PO135-MON PO548-TUE OR148 Tu Q., AS036
Timmis A., PO085-WED Uitte De Willige S., PO665-MON Vainchenker W., OR082
Torramad S., AS044 Tremoli E., PO005-TUE, PO378- Tucker A., PO085-WED
Timp J., PO601-TUE Uitte De Willige S., OR374, Vaishnaw A., OR213
Torregrosa J. M., OR221 WED Tucker E., AS209
Timp J., OR322, PO223-WED, PO209-MON Vaiyapuri S., AS167, PO506-
Torres R., PO038-MON Trenor C., PO458-MON Tucker E., OR049, OR353, MON, PO438-WED
PO573-WED, PO641-WED Ukaejiofo E., PO627-TUE
Torri V., PO579-MON Trepat X., PO010-MON PO543-WED Vajen T., PO091-WED, PO395-
Timur A., PO494-WED Ulaga B., PO082-TUE
Tortella B., PO257-MON Trevarrow B., OR059 Tucker E., PO177-TUE WED
Timur C., PO230-MON Ulehlova J., PO060-TUE, PO542-
Torti M., OR115, OR183, PO450- Trichet C., PO440-MON Tckmantel C., OR011 TUE Valades-Meja M., PO523-TUE
Tinholt M., PO177-WED, PO178- TUE, PO429-WED Tricker A., PO648-MON Tueckmantel C., PO274-WED
WED lehlov J., PO564-MON Valades-Meja M. G., PO073-MON
Toschi V., PO378-WED Trigatti B., AS210 Tufano A., PO534-TUE Valadier J., PO197-TUE
Tinmouth A., PO024-WED Ullman M., PO238-MON
Tosetto A., PO639-MON, PO649- Trillot N., PO440-MON Tuffigo M., PO416-TUE Valcarce I., PO538-MON
Tippl S., PO201-WED MON, PO216-WED, PO671-WED, Ullrich N., PO150-TUE, PO151-
Tripathi S., PO352-WED Tugcu D., PO265-MON, PO313- TUE Valdr L., PO264-MON, PO317-
Tiscia G., PO453-TUE PO674-WED, PO675-WED MON, PO315-MON, PO459-MON,
Tripepi G., PO618-WED Ulrichts H., OR363 WED
Tiscia G., PO511-MON, PO513- Toshio D., PO108-WED PO279-WED
MON Tripkovic N., PO250-MON Ulusoy A., PO230-MON Valente G., OR161
Toshiyuki S., PO108-WED Tripodi A., PO091-MON, PO059- Tulchinsky M., PO577-TUE
Tisi Baa M., PO522-WED Umemura K., PO193-TUE Valente S., OR253, PO020-TUE,
Tosi F., OR050, OR080, PO554- TUE, PO114-WED, PO674-WED, Tuncbilek O. F., PO143-TUE PO024-TUE
Tissot J.-D., PO400-TUE TUE, PO555-TUE Umit E., PO617-TUE
PO675-WED Tunstall O., AS159, OR104, Valenti R., OR396, OR400,
Titaeva E., PO199-MON, PO624- Toso R., PO172-MON OR145, OR386 Unal E., PO490-TUE, PO008-
Tripodis Y., PO657-WED WED PO094-WED
TUE, PO357-WED Toth N. K., PO516-TUE, PO087- Turan N., PO617-TUE
Triscott M., PO088-MON, PO360- Unal S., PO505-WED, PO507- Valentino L., OR211, PO231-TUE
Tittl L., AS098, PO477-MON, WED MON, PO050-TUE, PO054-TUE Ture S., OR166, OR241
PO636-MON WED, PO508-WED Valentino L., PO129-WED
Toti F., AS039 Tromeur C., OR146, OR323 Ture S., PO032-TUE
Tjonneland A., OR345 Undas A., PO105-MON, PO536- Valeri F., AS088
Toulon P., PO448-MON Troseid A. M. S., PO561-MON Turecek P., PO200-WED
Tjnneland A., AS083, OR129, TUE, PO625-TUE, PO246-WED, Valgimigli M., PO078-MON
Toussaint O., PO134-WED Trossaert M., OR025, PO639- Turecek P., PO129-WED, PO229- PO677-WED
PO104-TUE, PO111-TUE, Vallad-Hix C., PO618-TUE
Toussaint-Hacquard M., OR055 TUE, PO016-WED WED Ung A., AS134
PO112-TUE Valles J., PO062-MON, PO414-
Touz E., OR379 Trost Z., PO618-TUE Turecek P., PO223-TUE, PO199- Unkrig S., PO343-WED MON
Toda M., PO173-TUE
Towery K., OR434 Trowbridge R., PO367-WED WED, PO232-WED, PO270-WED Unlu B., PO554-MON Valois M., PO054-WED
Toderici M., AS187, OR370
Tozawa K., PO386-WED Truitt E., PO112-WED Turhan A., PO196-TUE Unruh D., AS028, OR047 Van Adrichem R., PO625-WED
Todesco A., PO456-MON
Trabandt A., PO554-WED Trujillo J., PO488-TUE Turitto V., PO677-TUE Unsworth A., PO450-WED Van Adrichem R., PO532-MON
Toelen J., PO364-MON, PO142-
TUE Traby L., PO077-WED Trujillo T., PO356-MON, PO622- Turk U., PO266-MON, PO237- Unsworth A., PO398-MON Van Aelst B., PO604-WED
Tracy P., PO145-MON MON, PO377-TUE TUE, PO238-TUE
Toennesen E., PO124-WED Untiveros P., PO225-MON Van Alphen F., PO227-WED
Tracy P., PO140-MON, PO133- Trujillo-Santos J., OR074, OR381, Turkmen C., PO295-WED
Tognoni G., PO338-WED Upadhyay A., PO296-TUE Van Alphen F., AS058, PO510-
TUE PO608-MON Turnbull R., PO429-MON, PO565- WED
Toh C., PO578-MON MON, PO464-WED Uppugunduri S., PO401-TUE
Tracy R., OR238 Truong V., AS045, AS206 Van Beers J., PO349-WED
Toh C.-H., OR004, OR168 Turner N., AS213 Uprichard J., NUR002
Trahtman P., PO569-MON Tryggvason K., OR332 Van Bekkum T., PO660-TUE
Tokessy M., PO320-TUE Turpie A., OR096, OR119, Uprichard S., PO053-WED
Trajanovic M., AS022 Tsai C.-H., PO226-TUE, PO289- Van Belle E., AS134, AS201,
Toku M., PO120-WED WED PO607-TUE Urano T., AS030
Trajkova Antevska Z., PO287-MON OR219, PO662-TUE
Tolen N., PO532-MON Tsai H.-J., PO430-WED Turro E., OR339, PO436-MON, Urban A., PO100-WED
Trajkova-Antevska Z., PO288-WED Van Berkel T., AS189
Tomasevic Z., PO159-WED Tsai J., OR134 PO384-WED Urbaniak J., PO454-WED
Tran H. T. T., OR317 Van Beusekom H., PO078-MON
Tombak A., PO591-TUE Tuttle A., PO426-TUE Urbanus R., AS035, PO063-WED
498 499
AUTHORS INDEX
Van Bladel E. R., PO246-MON Van Eck-Smit B., PO598-MON Van Vlijmen B., PO570-WED Vasina E., PO395-WED Vergura P., PO511-MON Vignoli A., PO339-MON
Van Breevoort D., AS118 Van Eeuwijk J., OR405 Van Vlijmen B., AS208 Vasovski M., PO354-WED Verhaar M., PO389-TUE Vijay R., PO153-WED
Van Dam W., PO410-WED Van Eeuwijk J., PO526-TUE Van Vugt S., PO614-TUE Vasques F., PO061-MON, PO315- Verhagen A., AS016 Vijayan K. V., OR277
Van De Ree M., OR257 Van Egmond L., PO349-WED, Van Vugt S., PO366-WED TUE, PO127-WED Verhamme P., AS009, AS113, Vik A., OR075, OR254, OR258,
Van De Wetering M., OR158 PO350-WED Van Vulpen L., PO241-MON Vasquez B., PO439-TUE AS176, AS197, OR195, OR292, OR267, OR293, PO472-MON,
Van Delden H., PO584-TUE Van Eickels M., OR119 Van Willigem W., PO350-WED Vassal P., PO107-TUE OR418, PO364-MON, PO614- PO494-TUE, PO638-WED
Van Den Abeelen L., PO591-MON Van Es J., OR191, PO596-MON, Van Wissen S., AS197, OR292 Vasse M., PO163-WED MON, PO462-WED Vikhe P., PO397-TUE
Van Den Berg H. M., PO260-WED PO597-MON, PO598-MON, Van Zaane B., OR268 Vasudev M., OR382 Verheijen I., PO123-WED, PO609- Vikhe P., PO385-TUE
Van Den Berg H., AS193 PO100-TUE Vanassche T., AS009, AS113 Vatopoulou T., PO559-TUE WED Vila V., PO579-WED
Van Den Berg H., AS223, OR141 Van Es N., AS197, OR191, Vanbelle E., PO513-WED Vavilova T., PO444-MON Verheijen L., PO675-TUE Vilalta N., PO217-WED
OR292, PO596-MON, PO103- Verhenne S., OR087, OR155 Vilaseca A. B., PO491-TUE
Van Den Besselaar A., PO634- TUE, PO624-WED Vancraeynest D., PO101-WED Vaziri B., PO374-WED
MON Vandahl B., PO285-WED Vazquez F., PO620-WED, PO642- Verheugt F., PO614-TUE Vilchevska K., PO262-TUE
Van Galen K., OR102, PO658- Verheugt F., OR119, PO366-WED
Van Den Biggelaar M., AS058, MON Vande Casteele N., PO215-MON, WED, PO664-WED Villaa P., PO286-MON, PO211-
AS118, AS121, PO510-WED PO286-TUE Vazquez F., PO467-MON, PO473- Verhezen P., PO349-WED TUE, PO250-WED
Van Geet C., OR231 Verhezen P., PO033-WED
Van Den Bosch M., AS141 Vande Walle J., PO589-MON MON Villacorta-Torres J., PO263-TUE
Van Geet C., PO650-MON Verhoef D., AS056, OR147,
Van Den Bosch M., PO458-WED Vandekerckhove P., PO604-WED Vdovin V., PO258-MON, PO214- Villalobos-Menuey E., PO103-
Van Gorp R., PO104-WED TUE, PO019-WED PO144-MON MON, PO662-WED
Van Den Dool E.-J., PO401-WED, Vandenberghe H., PO151-WED
PO410-WED Van Heerde W., OR011, OR021, Veca V., PO007-MON Verhoef S., AS189 Villalta S., OR132, OR256,
OR203, PO257-TUE, PO468- Vandenbriele C., AS009, AS176,
Van Den Eshof B., AS058 OR418, PO462-WED Vedovati M., PO626-MON Verkholomova F., PO661-WED OR291
TUE, PO680-TUE
Van Den Ham R., OR430 Vandenbulcke A., AS178 Vedovati M. C., AS099, PO072- Verma S., OR041 Villani M., PO511-MON, PO513-
Van Holten T., PO389-TUE MON
Van Den Hoven P., PO651-WED Vandeputte N., AS178, OR155 MON, PO370-MON, PO027-TUE, Vermeersch E., PO401-MON
Van Hylckama Vlieg A., AS138, PO423-WED Villarroel Del Pino L., PO358-TUE
Van Der Bom J., AS079, OR021, AS196, OR083, OR148, OR268, Vandereyken M., AS006 Vermeire S., PO215-MON,
OR203 OR322, OR391, OR394, PO617- Vandergouwe L., PO086-TUE Veeger N., OR100 PO286-TUE Villoutreix B., OR369
Van Der Bom J., OR013, OR015, MON, PO498-TUE, PO601-TUE, Vanderslice N., PO165-MON Veenstra L., PO056-MON Verschuren F., OR194, PO587- Vincelli J., PO479-MON
PO283-MON, PO308-WED PO223-WED, PO539-WED, Veerman H. C., PO651-MON TUE Vincenot A., PO440-MON
Vandersmissen I., AS176
Van Der Bom J., OR389, PO607- PO565-WED, PO625-WED Veerman K., PO105-WED Verso M., PO370-MON, PO423- Vincentelli A., AS134, AS201,
Vangala R. K., OR009, PO084- WED
WED Van Kralingen K., OR257 MON, PO040-TUE Vehamme P., PO469-MON OR219, PO662-TUE
Van Der Flier A., OR415 Van Lent M., PO502-MON Velander W., PO165-MON Versteeg H., PO554-MON Vinciguerra C., OR143, PO198-
Vangenechten I., AS133, PO655-
Van Der Hoeven J., PO651-WED Van Leuven C., PO070-TUE MON, PO666-TUE, PO668-TUE Velasquez E., PO616-TUE Versteeg H., OR047 WED
Van Der Hulle T., OR191, PO596- Van Leuven K., PO592-WED Vangunst S., PO440-TUE, PO563- Veldman A., PO241-TUE, PO257- Vervaeke A.-L., PO398-WED Vindt Holm M., PO110-TUE
MON, PO651-WED Van Loon L., PO546-MON TUE TUE, PO258-TUE, PO596-WED Vesley S., OR152 Viola F., PO203-TUE, PO368-WED
Van Der Meer F., PO623-MON, Van Meel R., PO072-TUE Vanhaesebroeck B., PO514-TUE Velic A., PO412-MON Vesper P., PO107-WED, PO137- Viola M., PO079-TUE
PO665-WED Van Mens T., PO510-MON Vanhoorelbeke K., AS178, OR087, Velichko D., PO466-TUE WED Violeta D., PO544-MON
Van Der Meer F., PO634-MON Van Moort I., PO208-WED OR151, OR153, OR155, OR365, Velkova E., PO535-WED Vestergaard B., PO590-WED Violi F., OR396, PO359-MON,
Van Der Meer F., OR387, PO251- Van Oerle C., PO645-MON PO401-MON, PO517-TUE, Veltmeijer M., PO468-TUE Vettore G., PO372-TUE PO029-TUE, PO094-WED
TUE, PO620-TUE, PO648-WED, PO571-TUE Vene N., AS101, PO360-TUE Veyradier A., PO645-TUE Vischjager M., PO532-MON
PO651-WED, PO666-WED, Van Oerle R., OR225, PO097-
WED, PO349-WED, PO416-WED Vanni S., PO626-MON Venegas-Pino D., PO105-WED Veyradier A., AS134, OR024, Visconte C., PO450-TUE
PO668-WED Vanoverschelde J.-L., PO101-WED OR025, PO639-TUE, PO664-TUE Visetin S., PO331-TUE, PO332-
Van Der Meijden P., PO056-MON Van Oerle R., PO348-MON Venemans-Jellema A., OR035
Van Ommen C., AS161 Varadarajan R., PO164-MON Venisse L., OR422, PO545-WED Veyrie N., AS043 TUE
Van Der Meijden P., PO411-MON, Varadi K., PO223-TUE, PO270- Viallard J.-F., PO416-TUE Vishwabandya A., PO153-WED
PO675-TUE Van Ommen C. H., OR158 Venkatachala S., PO083-MON
Van Ommen H., AS102 WED Venkatesan S., PO529-WED Viana M., PO179-TUE Vison A., OR132
Van Der Meijden P., AS204, Varfolomeyev S., PO213-MON Vibede E., PO124-WED Visser M., PO157-TUE, PO395-
PO155-TUE Van Puffelen J., OR203, PO680- Venosi S., PO200-TUE
TUE Varga-Szab V. J., AS004 Vibert F., PO038-TUE TUE, PO218-WED, PO234-WED
Van Der Poll T., AS007, PO335- Ventura D., PO315-WED
Van Rein N., OR098, OR131, Varj I., AS004 Vicens J., PO642-WED Visser-Koldenhof M., PO642-TUE
WED Ventura Pereira J., PO418-MON
PO532-MON, PO620-TUE, Varkila N., PO162-WED Vicente C., PO133-MON Vitale J., PO502-TUE, PO640-
Van Der Sluijs C., AS056 Venturelli U., PO358-MON, WED
Van Der Sluis I., OR158 PO648-WED, PO665-WED, Varma M., PO314-MON, PO551- PO175-WED Vicente V., AS187, OR076,
PO666-WED, PO668-WED MON, PO579-MON, PO274-TUE, OR221, OR359, OR368, OR370, Viviana A., PO068-TUE
Van Der Stoep M., PO405-MON Vera M., PO184-MON, PO187-
Van Roermund P., PO241-MON PO327-WED TUE PO336-MON, PO439-MON, Vivien D., AS032, AS117, OR314,
Van Der Veken P., PO218-MON Varma S., PO200-MON PO497-MON, PO338-TUE, OR379, PO532-TUE, PO370-WED
Van Ryn J., OR067, OR356, Vera Morandini M., PO039-MON
Van Der Ven A., PO063-WED PO364-MON, PO078-TUE, Varma N., PO200-MON PO558-TUE, PO549-WED, Vizintin Cuderman T., AS101
Van Der Zee A. G., PO346-WED Vera Morandini M. P., PO629- PO552-WED
PO314-TUE, PO414-WED Varnado S., OR059 Vlasveld T., OR257
Van Der Zwaan C., PO227-WED, MON Vichitratchaneekorn R., PO266-
Van T Veer C., AS007 Varon D., OR183 Vliegen H., PO619-WED
PO510-WED Verbeek-Knobbe K., PO468-TUE TUE
Van Veen J., PO313-WED Vartholomatos G., PO551-TUE Vodolazkaia A., PO142-TUE
Van Dreden P., OR047, OR438, Verbout N., AS209 Vicini P., PO512-TUE
Van Velzen A., OR122 Vasbien M., PO373-TUE Vogel C.-W., PO226-WED
PO108-MON, PO116-MON, Verbruggen B., PO208-WED Vida V., PO438-TUE
PO292-MON, PO102-TUE, Van Velzen A., OR013, OR015, Vashchenko L., PO206-TUE, Vogel M., PO564-TUE
Verdecchia P., PO370-MON, Vidal F., PO543-MON
PO473-TUE, PO163-WED OR389, PO283-MON, PO308- PO249-WED Vogely C., PO658-MON
PO423-WED Vidili G., AS195
WED Vashi V., PO621-MON Vogely H., PO241-MON
Van Duren C., PO680-TUE Vergin C., OR262 Vidmar G., PO616-TUE
Van Vliet I., PO668-WED Vasiliev S., PO496-MON Vgtle T., AS228, OR416
Van Eck M., AS208, PO405-MON Vergin C., PO590-MON Vigan F., PO515-MON
500 501
AUTHORS INDEX
Voigt C., OR346, OR347, OR350, Vulih D., OR127 Walton B., PO021-MON Wang Z., PO288-TUE Wei D., PO129-TUE Westfield L. A., OR365
PO253-WED Vybivantseva A., PO054-MON Waltz D., AS059 Warad D., PO484-WED Wei H., PO113-TUE Westmark P., PO175-MON
Voigt K., PO445-MON Vysniauskaite M., PO343-WED Walzog B., OR416 Ward C., OR002, PO433-MON, Wei Q., PO246-TUE Weston-Davies W., OR154
Voigt Lauridsen S., PO131-WED Wada H., PO486-WED Wan Q., PO205-MON PO421-TUE Wei S., PO129-MON Westwood J.-P., PO567-TUE
Voigtlnder M., PO251-MON Wada T., PO178-MON Wang K., PO433-WED Ward L., PO475-MON Weickert L., PO657-MON Wettstein M., PO236-MON
Voisin S., OR029, PO016-WED Wagenaar G., PO570-WED Wang A., PO136-MON, PO137- Ward R., PO389-MON Weigel G., PO096-MON Wetzels R., PO645-MON
Vojnovic I., PO085-WED Wagenvoord R., OR224, PO290- MON Wareing A., NUR002 Weik M., PO140-WED Wetzels R., PO348-MON, PO349-
Volf I., PO427-MON MON, PO004-WED Wang C., PO449-MON Warkentin M., NUR013 Weinberger D., PO285-TUE WED, PO350-WED, PO416-WED
Vollan H. K., PO177-WED, Wagenvoord R., PO143-MON Wang C., PO605-TUE Warner M., OR217 Weisel J., OR305, PO026-MON, Wetzels R., PO123-WED, PO609-
PO178-WED Wagner B., AS124 Wang C., OR113, OR210, PO433- Warner T., OR341 PO424-MON, PO212-WED WED
Volot F., OR012, OR024 Wagner D., PO171-WED WED Warner T., PO414-TUE Weisel J., AS156 Wexler R., PO349-MON
Volpicelli P., PO200-TUE, PO259- Wagner D., PO321-MON, PO089- Wang G., OR282 Warner T., PO085-WED Weiss A., PO434-WED Weyer V., PO593-MON
TUE, PO534-WED WED Wang G., PO022-MON Warren V., PO621-MON Weiss N., AS098, PO477-MON, Weyrich A., OR085, PO423-MON,
Von Arbin M., PO530-TUE, Wagner D., AS180, PO329-MON Wang G., OR004, OR168 Warzocha K., PO609-TUE PO636-MON PO604-MON
PO171-WED Wagner E., PO165-WED Wang H., PO424-MON Wasilewski R., PO278-MON Weiss T., PO030-TUE Weyrich A., OR243
Von Auer C., PO591-MON, Wahedi M., AS118 Wang H., PO388-TUE, PO390- Watanabe A., PO433-TUE Weitz D., AS154 Wham T., PO173-MON, PO161-
PO593-MON, PO569-TUE, Wahi R., PO334-MON, PO332- TUE Watanabe T., PO058-WED Weitz I., PO172-WED TUE, PO233-WED
PO570-TUE WED, PO411-WED Wang H., PO492-MON, PO195- Weitz J., PO489-WED Wheatcroft S., AS205
Waters E., PO046-TUE
Von Depka E., PO654-MON, Wahl D., AS036, OR091, OR186, TUE Weitz J., PO135-MON, PO376- Wheeler R., PO504-WED
PO665-TUE Waters E., AS019, PO454-TUE
OR189, PO031-TUE Wang H., PO179-MON, PO132- Watpool I., OR310 TUE White A., PO210-WED
Von Depka M., PO654-MON, Wahlgren M., PO294-MON TUE Weitz J., AS154, AS219, OR286, White B., PO280-MON, PO318-
PO665-TUE Watras M., PO347-MON
Waisman G., PO642-WED Wang H.-J., PO265-WED OR290, OR302, PO138-MON, WED
Von Depka Prondzinski M., OR347 Watson C., PO349-MON
Wakamiya N., PO020-WED Wang J.-D., PO137-TUE PO220-MON, PO403-MON, White M., PO174-TUE
Von Drygalski A., PO266-WED Watson C., PO216-WED PO130-TUE, PO170-TUE,
Wakefield C., AS078 Wang J., PO660-TUE White N., PO372-WED, PO556-
Von Hundelshausen P., PO091- Watson D., PO317-TUE PO608-TUE WED
Wakefield T., PO030-MON Wang J., OR390 Watson H., PO225-MON, PO368-
WED Weitz J., OR057, OR442, PO353- White N., PO375-WED
Walborn A., PO182-MON, PO192- Wang K., OR113, OR210, PO388- TUE
Von Krogh A. S., OR152 WED TUE, PO409-WED White O., AS143
TUE Watson P., PO565-MON
Von Mackensen S., PO253-TUE, Wang L., PO306-TUE Weldingh K., OR040, PO141-TUE White R., OR325, PO358-WED,
PO639-TUE, PO256-WED, Walenga J., PO291-MON, PO292- Watson S., PO289-TUE, PO511-
MON Wang M., PO177-MON, PO179- Wells P., AS077, AS206 PO359-WED
PO305-WED TUE Wells P., AS045, PO641-MON
Walenga J., OR173, PO305-MON, MON White T., PO309-TUE
Von Tengg-Kobligk H., OR432 Watson S., AS054, AS011, Wells P., AS099, OR200, OR259
PO339-WED, PO411-WED Wang M., PO237-MON, PO277- AS092, PO511-TUE Whiteford J., OR341
Voorberg J., AS118, AS121, MON, PO262-TUE, PO297-WED, Wells P. S., PO371-WED, PO669- Whiteheart S., OR419
PO660-TUE, PO227-WED Walker B., OR114, PO412-MON, Watson S., AS069, AS124,
PO449-WED PO298-WED WED Whiteheart S. ., AS123
Vorobev A., PO122-TUE, PO123- OR276, OR401, PO408-MON,
Walker D., OR101 Wang P.-N., PO476-WED PO415-MON, PO393-TUE, Wells P., OR384, PO647-WED Whiteman M., PO400-MON
TUE, PO173-WED Welsh J., OR038
Walker I., PO276-MON Wang P., AS182 PO434-WED, PO492-WED Whitlock R., OR057, PO489-WED
Vorobyeva N., PO204-MON, Welsh J., OR207
PO630-MON, PO044-TUE, Walker I., OR429, PO095-MON, Wang P., OR280 Watson S., PO289-TUE Whyte C., AS204
PO381-TUE, PO538-TUE, PO087-TUE Wang Q., PO162-MON, PO132- Watson S., OR416 Welters I., OR004, OR168 Wiangnon S., PO120-TUE
PO106-WED Walker I., OR285, PO500-MON, TUE Watson S. P., PO497-MON Wen Y., OR018 Wickham A., PO074-WED
Vorobyeva N., PO199-MON PO643-TUE, PO524-WED Wang R., PO036-TUE Watt B., PO368-TUE Wendelboe A., PO637-WED Wicklund B., PO516-WED
Voroshilina E., PO147-WED Walker R., PO063-WED Wang S., OR048 Watts M., PO649-WED Weng T.-F., PO452-MON Widimsky P., PO364-WED
Vos H., OR147 Walln H., PO368-MON, PO530- Wang S., OR279 Watts R., PO248-MON Wenjie L., AS075, OR136, Wiegand G., PO667-WED
Voskanyan A., PO573-MON TUE, PO171-WED, PO392-WED Wang T.-F., PO545-TUE Watzka M., PO498-MON, PO631- OR264, PO566-TUE Wieland I., PO647-MON, PO442-
Vosnakis C., PO065-WED Wallentin L., PO362-MON Wang X., PO220-WED MON, PO637-MON Wenjuan Z., PO394-WED TUE
Vossen C., PO656-WED Waller A., PO571-WED Wang X., PO014-TUE Waye J., OR377 Wermes C., PO259-MON, PO647- Wielders S., PO470-MON
Waller A., PO397-TUE Wang X., PO028-MON Wearn C., OR121 MON, PO665-TUE Wiemann M., PO163-MON,
Vossen C., PO539-WED
Waller A., PO385-TUE Wang X., PO372-WED, PO375- Wearn C., PO393-TUE Wernek C., PO133-MON PO218-WED, PO234-WED
Voto L., PO059-WED
Wallisch M., AS209, OR049 WED Webb V., PO600-MON, PO582- Werner I., PO091-WED Wiemers T., PO487-WED
Voutsis M., PO285-MON
Wallstedt M., PO367-MON Wang X., OR164, OR210, PO228- TUE Werner S., PO662-MON, PO664- Wiest I., PO487-WED
Vries M., PO056-MON, PO645- MON
MON Wallvik N., OR069 MON, PO492-MON, PO176- Webber K., PO502-WED Wietrzyk J., PO365-WED
Walsh C., PO248-MON TUE, PO195-TUE, PO252-TUE, Weber C., PO037-TUE, PO091- Werstuck G., PO105-WED Wiewel-Verschueren S., PO346-
Vries M., PO143-MON PO333-TUE
Walsh C., PO149-MON WED, PO395-WED Werstuck G., OR007 WED
Vu T., AS219, OR286, OR290, Wang Y., PO329-MON
PO220-MON, PO170-TUE Walsh T., OR244 Weber E., OR020 Werth S., AS098, PO477-MON, Wiggins K., PO557-WED
Waltenberger J., PO015-TUE Wang Y., PO382-WED Webster S., PO667-MON, PO676- PO636-MON, PO103-TUE, Wiinberg B., OR036, OR040,
Vucicevic S., PO159-WED PO624-WED
Walter O., PO272-WED Wang Y., PO132-MON MON PO046-TUE, PO141-TUE,
Vukovi B., OR131 Werwitzke S., AS221
Walter U., PO397-MON, PO427- Wang Y., PO306-TUE Webster S., AS064, OR086 PO052-WED
Vuillez J.-P., PO628-WED Wesche J., OR307, PO413-TUE
MON, PO419-TUE, PO099-WED, Wang Y., PO588-MON Wecht B., PO094-MON Wijeyewickrema L., PO300-TUE
Vuimo T., PO047-WED Westein E., AS184, PO431-MON
PO483-WED Wang Y., AS168, AS153 Weeks S., OR443 Wijgaerts A., AS013, OR231
Vuimo T., PO147-WED Westerman D., PO149-WED
Walters H., OR060 Wang Z., PO011-MON, PO425- Wegener E., PO427-TUE Wijmenga C., PO580-MON
Vukovic V., PO121-TUE TUE, PO039-WED, PO533-WED
502 503
AUTHORS INDEX
Wik H., OR072, PO600-TUE Wisman P. P., PO386-TUE, Woods A., PO267-TUE Wu Y., PO132-TUE Yakovlev S., OR371 Yao J., AS184
Wik H. S., PO478-MON, PO295- PO389-TUE Woods G., AS160, OR157 Wu Z., OR338 Yakovlev V.N. V., PO113-MON Yao M., OR342
TUE Wismer M., PO028-MON Woods N., PO557-WED Wu Y., PO287-WED Yakushkin V., PO327-TUE Yao Y., PO303-MON
Wilcox D., OR342 Wisniewski T., PO256-WED Woods R., OR058 Wulff Nielsen A. K., PO090-MON Yamada S., OR051 Yaoi H., PO652-MON, PO347-
Wild P., PO356-TUE Wiszniewski A., PO278-MON, Woods T., OR429, PO095-MON, Wun T., OR325 Yamaguchi K., PO477-WED WED
Wild P., PO478-WED PO549-MON, PO609-TUE, PO087-TUE Wutzelhofer L., OR123 Yamaguchi K., AS145, PO203- Yap E. S., OR322, PO606-MON,
Wilde J., AS054 PO648-TUE, PO026-WED, Woods T., OR285, PO643-TUE Wynckel A., PO263-TUE MON PO223-WED, PO413-WED
Wildeboer B., PO642-TUE PO032-WED, PO526-WED Wool G., PO049-MON, PO025- Yamaguchi Y., AS031 Yaras S., PO591-TUE
Wynn T., PO242-MON, PO260-
Wilkens M., PO094-MON Witke W., OR416 WED MON Yamamoto K., OR347 Yarwood B., PO673-TUE
Wilkins J., AS168 Witkoff B., OR362 Woolley A., PO085-TUE, PO136- Wynne H., OR099 Yamamoto T., PO380-TUE Yastrubinetskaya O., PO651-TUE
Willems B., PO104-WED Witkop M., PO277-MON, PO297- WED, PO141-WED Wyseure T., PO519-TUE Yamanouchi J., PO055-MON Yasuda S., PO058-WED
WED, PO298-WED Worthington M., PO588-TUE Yasui Y., PO465-MON
Williams C., AS141, OR275 Xenarios I., AS128, OR397 Yamasaki N., PO233-MON
Witsch T., OR252, PO089-WED Wozniak E., PO284-MON Yasukawa M., PO055-MON
Williams C., OR244 Xi M., AS122, PO262-MON Yamashita A., PO233-TUE,
Witter L., PO112-MON Wozniak M., PO454-WED PO211-WED Yatagai C., PO462-TUE, PO463-
Williams C., AS126 Xi X., OR018, PO492-MON
Wittevrongel M.-C., OR231 Woznica-Karczmarz I., PO255- Yamashita A., PO552-MON TUE
Williams C., PO110-MON Xia J., AS154
Witzel R., PO146-TUE WED Yamashita H., PO399-TUE Yating H., AS075, OR264,
Williams M., AS159 Xia L., PO425-TUE
Wlodawer A., PO184-TUE Wright F., PO172-MON Yamashita M., PO672-TUE PO276-TUE, PO566-TUE
Williams M., AS054, OR104, Xia M., AS025, AS232, OR006,
OR145, OR386 Wohner N., PO553-TUE Wright G., OR418 PO098-WED Yamaura Y., PO351-MON Yatomi Y., PO061-TUE
Williams P., PO173-MON, PO161- Wojta J., AS200, OR123, PO185- Wright G., PO021-TUE Xian Z., OR136, OR264, PO320- Yamazaki M., PO477-WED Yau J., OR041
TUE, PO233-WED MON, PO559-MON, PO002- Wright J., PO542-WED MON, PO276-TUE, PO566-TUE Yavelov I., PO069-TUE
TUE, PO282-TUE, PO301-TUE, Yamazaki S., PO211-WED
Williams P., PO156-WED Wright P., PO653-MON, PO638- Xiang B., OR419 Yan H., PO176-TUE Yazicioglu I., PO301-WED
PO509-TUE TUE
Williams R., PO083-TUE Xiang H., PO210-TUE Yan J., PO330-TUE Ye S., OR419
Wojtasiska E., PO170-WED Wrbel A., PO311-WED
Williams S., OR159, OR328, Xiang Y., PO673-MON Yan K., AS147, PO070-MON Yee A., AS090, OR331, OR361
Wolberg A., PO021-MON, PO046- Wrobleski S., PO030-MON
AS157, PO475-MON, PO118- TUE Xiao B., OR018 Yan R., PO273-TUE Yee D., OR349
TUE, PO446-TUE, PO545-TUE Wrzyszcz A., PO454-WED Xiao J., PO292-WED Yanachkov I., PO021-TUE Yee D., PO644-TUE
Wolberg A., AS153
Williams V., PO204-TUE Wu C., OR442 Xiao N., OR249 Yanagida Y., PO178-MON Yee T., OR015
Wolf D., PO493-WED
Williamson A., PO502-MON, Wu C., AS023, OR295, PO592- Xiao X., PO432-MON Yang A., OR355 Yegneswaran S., PO555-WED,
PO521-WED Wolf K., AS068, AS228, OR169 TUE Xiaofan L., AS075, PO566-TUE Yang C., PO259-WED PO599-WED
Willis R., PO064-WED Wolfsegger M., PO254-WED Wu H., PO592-MON, PO572-TUE Xie F., PO432-MON Yang F., AS026 Yeh C., PO138-MON, PO130-TUE
Wilms E., PO099-WED Wolfson T., PO476-MON Wu H., OR362, PO587-MON, Xie W., PO426-MON Yang J., OR018 Yeh G.-C., PO226-TUE, PO289-
Wilsgaard T., AS046, OR075, Wolgast L., AS037 PO588-MON, PO573-TUE WED
Wolko D., PO253-WED Xiong S., PO288-TUE Yang J., PO278-TUE, PO323-WED
OR120, OR254, OR392, OR393, Wu H., OR362, PO587-MON, Yeheskel A., OR289
PO519-MON, PO524-MON, Wolzt M., PO077-WED PO588-MON, PO573-TUE Xiong Y., OR014, OR211, PO642- Yang L., AS075, OR264, PO566-
MON, PO108-TUE, PO231-TUE TUE Yen C.-T., PO031-MON
PO525-MON, PO526-MON, Wong G., PO267-TUE Wu J., PO213-WED Yeon J. H., PO375-WED
PO493-TUE, PO494-TUE, Wong J., PO669-TUE Xu M., AS074, AS168, OR138, Yang L., PO333-TUE
Wu J., AS147, OR249, PO070- OR261, PO319-MON, PO326- Yerov O., PO073-TUE
PO495-TUE, PO567-WED, Wong K. L., PO606-MON MON, PO205-MON Yang L., PO304-WED
PO568-WED WED Yang M., PO269-WED Yeung J., AS217
Wong M., PO622-MON Wu J., PO467-WED Xu W., PO165-MON Yhap M., AS158
Wilson E., PO288-MON Wong P., PO349-MON Wu J., PO136-MON, PO137-MON Yang R., AS109, AS073, OR001,
Wilson M., AS045, AS206 Xu X., AS168 OR265, PO451-TUE, PO292- Yi A. K., PO139-WED
Wong S. L., PO329-MON Wu J., PO426-TUE Xu Y., OR200, PO646-MON Yildiz L., PO051-WED
Wilson S., PO149-WED WED, PO323-WED
Wong W. H., PO012-TUE, PO074- Wu J., PO269-WED Xu Y., PO026-MON, PO212-WED Yilmaz A., PO521-WED
Wilts D., PO100-TUE, PO164- TUE Yang S., OR362, PO587-MON,
Wu J., PO292-WED Xu Y., OR306 PO588-MON, PO572-TUE, Yilmaz D., PO254-TUE, PO302-
WED Wongprasert C., PO643-WED Wu K.-H. W., PO452-MON Xue F., AS109 PO573-TUE WED
Winburn I., PO256-MON Wongswadiwat Y., PO461-MON Wu Q., AS072 Xue L., OR209 Yang S.-F., PO029-MON Yilmaz E., PO008-WED
Winckers K., PO617-MON, Wongwerawattanakoon P., PO540-
PO348-TUE, PO349-TUE Wu R., OR140, PO317-MON, Xue M., PO188-TUE Yang S.-J., PO029-MON, PO050- Yin H., AS143
TUE, PO275-WED PO246-TUE, PO292-WED WED
Winder A., PO611-TUE Xue Yan C., PO109-MON Yin O., PO621-MON
Woo C., PO269-WED Wu S., OR232 Yang S., PO677-TUE
Windyga J., OR088, OR144, Ya F., PO382-WED Ylmaz A., PO502-MON
Wood M., PO400-MON Wu S., OR085 Yang X., AS056
PO278-MON, PO549-MON, Yabes J., OR201 Ylnen A., PO304-MON
PO049-TUE, PO235-TUE, Woodhams B., AS042, OR050, Wu W., PO028-MON Yang Y., OR249, PO205-MON,
OR172, PO341-MON, PO114- Yabes J., OR090, PO277-WED Yoder M. C., PO020-MON
PO543-TUE, PO648-TUE, Wu X., OR164, PO195-TUE PO382-WED, PO447-WED Yoe J., PO579-MON
TUE, PO331-TUE, PO332-TUE, Yacobovich J., PO475-WED
PO011-WED, PO026-WED, Wu X., AS037 Yang Y., OR279 Yokoyama K., PO322-WED
PO032-WED, PO526-WED, PO554-TUE, PO555-TUE, Yada K., PO652-MON, PO666-
PO127-WED Wu X., OR113, OR210, PO433- MON, PO668-MON, PO088-TUE, Yang Y., PO125-MON Yones H., PO347-MON
PO536-WED, PO588-WED WED Yang Y., OR045
Woodhams B., OR047 PO165-TUE, PO224-TUE Yoneyama K., AS017
Wingate J., PO631-TUE Wu X., PO246-TUE Yang Y., PO529-MON, PO504-
Woodhouse G., PO356-MON Yadav M., PO200-MON Yoneyama T., PO477-WED
Wing-Lun E., PO075-MON Wu Y.-M., PO050-WED TUE
Woodle S., PO603-WED Yadegari H., PO184-WED Yoo J., PO471-TUE, PO309-WED
Winter M., PO657-WED Wu Y., OR355 Yang Y., PO605-TUE
Woods A., PO634-TUE, PO636- Yadegari Baharanchi H., PO674- Yoon H. J., PO168-WED
Winters J., PO037-WED Wu Y., PO431-WED MON Yang Y.-L., PO031-MON
TUE, PO646-TUE, PO652-TUE Yoon H.-J., PO164-TUE, PO489-
Wiseman A., PO487-MON Wu Y.-F., PO448-TUE Yagi H., PO040-WED Yang Z., OR279
Woods A., PO003-MON, PO004- TUE, PO300-WED
Wishart C., PO182-TUE MON, PO005-MON, PO042-WED Wu Y., PO492-TUE Yakimenko A., OR245 Yao G.-Q., PO426-MON Yoon J.-H., PO599-TUE
504 505
AUTHORS INDEX
Yoon J. H., PO309-WED Zadro R., OR378, PO144-WED Zeng W., PO132-TUE, PO492- Zhou H., PO318-MON, PO278- Zide R., AS077 Zourikian N., PO282-WED
Yoon S. S., PO599-TUE Zaffaroni M., OR161 TUE, PO581-WED TUE, PO323-WED Zieger B., PO419-TUE Zozulya N., PO214-TUE, PO651-
Yoon S.-S., PO035-TUE, PO659- Zaharyan E., PO213-MON Zeping Z., PO276-TUE Zhou J., AS216, AS219, OR286, Zielinski C., OR260, PO166-WED TUE
WED Zahavi A., PO285-TUE Zerbinati P., PO193-MON PO403-MON, PO170-TUE Zierler S., AS068 Zrinski Topic R., PO436-TUE
Yoruk A., PO230-MON Zahedi R., AS068, PO419-TUE Zerdiew A., PO079-TUE Zhou J., PO621-MON, PO603- Zijlstra F., PO078-MON Zubairova L., AS156
Yoshida H., AS017 Zahedi R., PO499-MON Zetterberg E., PO240-MON, TUE Zilberman-Rudenko J., PO543- Zucker M., OR289, PO171-TUE
Yoshida K., PO335-TUE Zak M., OR348 PO080-TUE, PO228-TUE, Zhou J., PO195-TUE WED Zuckerman L., PO346-MON
Yoshida M., PO041-MON, PO357- Zakar M., PO595-WED PO263-WED Zhou P., PO340-TUE Zilberstein L., PO513-WED Zuckermann A., PO185-MON,
MON, PO020-WED, PO057-WED Zakas P., PO203-WED Zeuthen N., PO267-WED Zhou S., OR178 Zimmerman G., PO604-MON PO509-TUE
Yoshida Y., PO672-TUE Zalvidea D., PO010-MON Zeuthen N., PO251-WED Zhou S., AS120 Zimmerman G., OR243 Zuckier L., PO628-WED
Yoshizawa H., PO113-WED Zaman F., PO099-MON, PO078- Zeytun H., PO264-WED Zhou W., PO298-MON Zimmermann M., PO673-TUE Zufferey A., OR397, PO302-TUE
You C., OR212 TUE Zhai Z., PO605-TUE Zhou X., OR443 Zimmermann R., PO215-TUE Zugaib M., PO508-MON, PO476-
You M., PO638-MON Zamora C., PO621-MON Zhang B., OR180 Zhou X., PO028-MON Zingali R., PO239-WED TUE
Yougbare I., OR031, PO328-WED Zander N., PO107-WED Zhang B., PO111-MON, PO132- Zhou Z., AS109 Zitomersky N., AS180 Zuily S., AS036, OR186, OR189
Youk J., PO659-WED Zandstra J., PO584-MON MON Zhu W., PO340-TUE Zulfikar B., PO275-MON, PO295-
Zivelin A., PO225-WED
Young C., AS160 Zane F., PO483-MON, PO580- Zhang C., AS063, PO430-MON Zhu C., AS055 WED
Zivony Y., PO471-WED
Young D., OR104, PO622-WED WED Zhang D., AS073, OR136, Zhu G., AS168, OR031, PO326- Zulfikar B., PO649-TUE
Ziyatdinov A., PO126-TUE,
Young G., AS104, AS122, Zanetto A., PO114-TUE PO451-TUE WED, PO328-WED Zulian P., PO385-MON
PO217-WED
OR156, PO164-MON, PO237- Zaninetti C., PO438-MON Zhang G., OR383 Zhu H., PO431-WED Zuo B., AS072
Zoghlami C., AS034
MON, PO239-MON, PO262- Zanolini D., OR106, OR161 Zhang G., OR419 Zhu J., OR365 Zupan I., PO181-MON, PO027-
Zohrabyan D., PO573-MON
MON, PO439-TUE, PO255-WED, Zanon E., AS222, OR027, Zhang J., PO375-WED Zhu K., OR018 WED
Zollner S., AS016, PO596-WED
PO506-WED OR030, OR144, PO225-TUE, Zhang J., PO439-WED Zhu L., AS026, PO022-MON Zupancic-Salek S., OR378
Zllner H., OR307, PO413-TUE
Young J., PO227-TUE PO650-TUE, PO303-WED Zhang J., PO433-WED Zhu M., OR180 Zuurbier S., OR118, PO525-TUE
Zondag M., NUR012
Young J., AS160 Zapletal O., AS133, PO655-MON Zhang L., OR001, PO451-TUE Zhu S., OR351 Zwaginga J. J., PO607-WED
Zondag W., OR257
Young J., PO603-MON Zapletal O., PO502-MON Zhang L., PO447-WED Zhuravleva E., PO008-MON, Zwicker J., PO346-TUE
Zoppellaro G., PO077-TUE,
Young L., PO374-TUE Zapponi K., PO066-WED Zhang L., PO202-TUE PO548-MON Zwingerman N., AS045, AS206
PO372-TUE
Young P., PO493-MON Zapponi K., PO422-MON Zhang L., OR001 Zi M., OR168 Zorio E., PO536-MON
Yoxtheimer L., AS130 Zar M., PO450-TUE Zhang N., OR018 Zicari A., PO316-WED Zotova I., PO135-WED
Yu H., PO129-MON Zardo L., PO369-WED Zhang S., PO409-MON Zidani N., PO494-MON, PO242- Zotz R., OR077, OR329, PO539-
Yu I.-S., PO029-MON, PO031- Zarfati M., PO335-MON Zhang W., PO015-MON, PO259- TUE, PO637-TUE, PO276-WED, TUE
MON, PO050-WED Zarrabi F., PO247-TUE WED, PO533-WED PO520-WED
Yu L. X., OR031 Zarrin A., NUR013 Zhang X., AS109, PO451-TUE
Yu P., PO034-TUE, PO095-WED Zarrineh P., PO186-MON Zhang X. Z., PO529-MON
Yu P., AS210 Zateyshchikov D., PO135-WED Zhang X., PO336-WED
Yu Y., AS074, OR138, OR261, Zavrelova J., PO655-MON Zhang Y., PO409-MON
PO319-MON Zhang Y., OR350, PO241-TUE
Zawadski C., OR219, PO662-TUE
Yu Z., PO039-WED, PO259-WED, Zhang Y., PO439-WED
PO533-WED Zawadzki C., AS201, OR024
Zawilska K., PO614-MON, Zhang Z., PO605-TUE
Yuan C., AS146 Zhao L., AS031
PO011-WED
Yuan Y., PO332-MON, PO443- Zhao M., PO597-WED
WED Zazeri G., PO322-TUE
Zbikowski P., PO279-MON Zhao X.-Y., AS018
Yuan Z., OR259
Zdravic D., OR031, PO328-WED Zhao Y., PO012-TUE
Yue H., PO113-TUE, PO394-WED
Zdziarska J., PO011-WED Zhao Y., OR117
Yue M., OR279
Zebardast J., PO247-TUE, Zhao Y., PO292-WED
Yuen L., PO623-WED, PO635-
WED PO600-WED Zhao Y., AS072
Yuldasheva N., AS205, PO096- Zebari R., PO356-MON Zhaoyue W., PO113-TUE, PO394-
WED Zeerleder S., PO326-MON WED
Yusa S.-I., PO300-MON Zeinati C., PO439-TUE Zharkov P., PO462-MON
Yusen R., OR074, OR321, Zeissink B., PO391-MON Zharkov P., PO503-WED
PO576-TUE Zeldin D., OR341 Zhen Y., PO246-TUE
Yusuf S., PO362-MON Zeller T., PO478-WED Zheng C., OR180
Zabczyk M., OR398, PO368-MON Zeltser D., PO631-WED Zheng G.-Y., PO029-MON
Zbczyk M., PO105-MON, PO536- Zemlyanskaya O., PO624-TUE, Zheng S., PO409-MON
TUE, PO625-TUE, PO246-WED, PO357-WED Zheng X. L., OR407
PO677-WED Zemrak W., PO367-WED Zheng Y., AS115
Zabolotskikh I., PO466-TUE, Zenclussen A., PO518-MON Zhong J., PO252-TUE
PO586-TUE Zeng M., AS147, PO070-MON Zhou A., PO359-TUE
Zadrio R., PO436-TUE Zeng M., PO205-MON Zhou H., OR407
506 507
Save the date for the next ISTH Scientific
and Standardization Committee (SSC)
meeting in Montpellier, France, from
May 25 28, 2016.
The 62nd Annual SSC Meeting of the ISTH
will be devoted to the discussion of diagnostic
May 25-28, 2016 standards, disease nomenclature and
classification, and the latest research on
62nd Annual SSC Meeting bleeding and thrombotic disorders. SSC 2016
Montpellier, France will continue the tradition of offering
Jean-Franois Schved, President dedicated education and plenary sessions to
complement the in-depth presentations of the
www.ssc2016.org work in progress by the SSC subcommittees

and working groups. A must- attend event in
Join the Conversation Using #SSC2016 the field of thrombosis and hemostasis, you
are welcome to participate and get involved!
The program will include the following topics:

Animal, Cellular, and Molecular Models;
Please visit us at Booth 1036! Biorheology; Control of Anticoagulation;
Disseminated Intravascular Coagulation;
Factor VIII, Factor IX and Rare Coagulation
THE LARGEST
Disorders; Factor XI and the Contact System;
Factor XIII and Fibrinogen; Fibrinolysis;
Genomics in Thrombosis and Hemostasis;
INTERNATIONAL Hemostasis & Malignancy; Lupus

Anticoagulant/Phospholipid- Dependent
MEETING FOR Antibodies; Pediatric/Neonatal Hemostasis

and Thrombosis; Plasma Coagulation
THE GLOBAL
Inhibitors; Platelet Immunology; Platelet
Physiology; Perioperative Thrombosis and
Hemostasis; Predictive and Diagnostic
BLEEDING DISORDERS Variables in Thrombotic Disease; Vascular
COMMUNITY
Biology; Von Willebrand Factor; and, Womens
Health Issues in Thrombosis and Hemostasis.
Mark your calendars to

join us for SSC 2016!
Sign up for the newsletter at www.wfh.org/congress
Hosted by / En colaboracin con: Organized by / Organizado por:
FEDERACIN MUNDIAL
DE HEMOFILIA
508 2016 CONGRESO MUNDIAL 509
24-28 DE JULIO
TRANSCENDING
SCIENTIFIC BOUNDARIES
BERLIN, GERMANY
Save the Date

for ISTH 2017!
You are invited to attend the XXVIth Congress
of the International Society on Thrombosis
and Haemostasis (ISTH). Held in Berlin,
Germany, from July 8 13, 2017, the ISTH
2017 Congress will be the foremost meeting in
thrombosis, hemostasis and vascular biology
and will be attended by thousands of the
worlds experts.
Join us in Transcending Scientific
Boundaries at ISTH 2017!
510
www.isth2017.org
Visit the ISTH at Booth 1036!

Isth2015 Book Complete Jun 0

Transféré par

Informations du document

Copyright

Formats disponibles

Partager ce document

Partager ou intégrer le document

Options de partage

Avez-vous trouvé ce document utile ?

Ce contenu est-il inapproprié ?

Droits d'auteur :

Formats disponibles

Isth2015 Book Complete Jun 0

Transféré par

Droits d'auteur :

Formats disponibles

In Memoriam:

June 20 25, 2015

Contacts Membership Questions or any

the global conversation about Lisa Astorga c/o MCI Suisse SA

Marketing and Media:

Visit us at Booth 1036 T: +1 919 929-3807

The scientific congress is composed of a variety of sessions five plenary lectures by

Practical Clinical and

Please accept my best wishes for an informative and memorable congress.

The Rt. Hon. Stephen Harper, P.C., M.P.

OTTAWA Kathleen Wynne

Managing Hemophilia for Life Managing Hemophilia for Life

Toronto Waterfront Royal Ontario Museum

13:30 Panel discussion 13:25 Panel discussion

Local Organizing Committee Scientific and Standardization Scientific Program

Educational Program Margaret Rand, Canada, Chair

Vascular Biology Inflammation and Immunology

Ed Conway, Canada, Chair John Semple, Canada, Chair

Atherothrombosis Pediatric Hemostasis and

John Eikelboom, Canada, Chair

How to manage labour & delivery in VWD

Management of surgeries in VWD: final results

Canadian experience with 1:1 VWF/FVIII concentrate

Lunch will be served

ISTH 2015 Awards opinion of their peers, have made significant

ISTH Reach-the-World Fellowship Program

Join the conversation online!

Munira Borhany, Pakistan Lyu Mingen, China

Monday 22 June Monday 22 June

Real-world experiences Sharing real-world

Come and visit us at Booth 922 to hear more about the

Date of preparation April 2015

From Baxters BioScience

Visit the Baxalta booth #1602 to learn more.

Baxalta is a trademark of Baxalta Incorporated

Master Classes Master Classes

Nurse Forum 08:00 - 16:30

Nurse Forum 09:00 - 18:00

Exhibition 09:00 - 18:30

Exhibition 9:00 - 18:30

Exhibition 09:00 - 19:30

Presidents All Congress

From Monday, June 22 Wednesday, June 24 On Thursday, June 25

Program Day by Day

Womens Issues in Predictive and diagnostic Factor VIII, IX and Rare

Coffee Break Coffee Break

Coffee Break Coffee Break

Working Factor XI and Control of Factor VIII and Platelet

Special Special Special Special

Coffee Break 09:15 - 09:45 Coffee Break 09:15 - 09:45

Coffee Break 15:15 - 15:45 Coffee Break 15:15 - 15:45

Technical Technical Technical Technical Technical

Coffee Break 09:15 - 09:45 Coffee Break 09:15 - 09:45

Lunch 11:45 - 12:15 Lunch 11:45 - 12:15

Coffee Break 15:15 - 15:45 Coffee Break 15:15 - 15:45

Lunch 11:45 - 12:15 Lunch Lunch 11:45 - 12:15

Coffee Break 15:15 - 15:45 Coffee Break 15:15 - 15:45

Coffee Break 09:15 - 09:30 Coffee Break 09:15 - 09:30

Coffee Break 11:45 - 12:00 Coffee Break 11:45 - 12:00

SSC and Educational Program

Factor VIII and IX, part 1 Room 718

Lupus anticoagulant/Phospholipid-dependent antibodies Room 716

10:45 - 11:00 Discussion

AUTOIMMUNE AND DRUG-INDUCED ITP Vascular biology Room 714

10:00 - 10:20 Platelets and the inflamed vasculature 09:05 - 09:20

UPDATES ON REGISTRIES AND PROJECTS 12:20 - 12:30

18:25-18:30 Conclusion 18:15-18:30

VWF-MEDIATED MECHANISMS IN COMPLEX AND PATHOLOGICAL FLOWS 15:50 - 16:10

SUBCOMMITTEE SESSION 2 16:10 - 16:15

18:10 - 18:20 Comparative schemes for thrombophilia testing by region-country: India

14:00 14:15 Review of VWD guidelines/compare/contrast/diagnostic